<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Psychological therapies for people with borderline personality disorder - Storebø, OJ - 2020 | Cochrane Library</title> <meta content="Psychological therapies for people with borderline personality disorder - Storebø, OJ - 2020 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012955.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Psychological therapies for people with borderline personality disorder - Storebø, OJ - 2020 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012955.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD012955.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Psychological therapies for people with borderline personality disorder" name="citation_title"/> <meta content="Ole Jakob Storebø&lt;sup&gt;a&lt;/sup&gt;" name="citation_author"/> <meta content="ojst@regionsjaelland.dk" name="citation_author_email"/> <meta content="Jutta M Stoffers-Winterling&lt;sup&gt;a&lt;/sup&gt;" name="citation_author"/> <meta content="University Medical Center Mainz" name="citation_author_institution"/> <meta content="Birgit A Völlm" name="citation_author"/> <meta content="University Rostock" name="citation_author_institution"/> <meta content="Mickey T Kongerslev" name="citation_author"/> <meta content="Jessica T Mattivi" name="citation_author"/> <meta content="University Medical Center Mainz" name="citation_author_institution"/> <meta content="Mie S Jørgensen" name="citation_author"/> <meta content="Region Zealand Psychiatry" name="citation_author_institution"/> <meta content="Erlend Faltinsen" name="citation_author"/> <meta content="Region Zealand Psychiatry" name="citation_author_institution"/> <meta content="Adnan Todorovac" name="citation_author"/> <meta content="Region Zealand Psychiatry" name="citation_author_institution"/> <meta content="Christian P Sales" name="citation_author"/> <meta content="Henriette E Callesen" name="citation_author"/> <meta content="Psychiatry of Region Zealand" name="citation_author_institution"/> <meta content="Klaus Lieb&lt;sup&gt;a&lt;/sup&gt;" name="citation_author"/> <meta content="Leibniz Institute for Resilience Research (LIR)" name="citation_author_institution"/> <meta content="Erik Simonsen&lt;sup&gt;a&lt;/sup&gt;" name="citation_author"/> <meta content="Region Zealand Psychiatry" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="5" name="citation_issue"/> <meta content="10.1002/14651858.CD012955.pub2" name="citation_doi"/> <meta content="2020" name="citation_date"/> <meta content="2020/05/04" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012955.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012955.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012955.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Borderline Personality Disorder [*therapy]; Depression [therapy]; Dialectical Behavior Therapy [statistics &amp; numerical data]; Mentalization; Patient Dropouts [statistics &amp; numerical data]; Psychotherapy [*methods, statistics &amp; numerical data]; Randomized Controlled Trials as Topic; Self-Injurious Behavior [therapy]; Suicide Prevention; Treatment Outcome; Waiting Lists" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012955.pub2&amp;doi=10.1002/14651858.CD012955.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012955.pub2&amp;doi=10.1002/14651858.CD012955.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012955.pub2&amp;doi=10.1002/14651858.CD012955.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012955.pub2&amp;doi=10.1002/14651858.CD012955.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012955.pub2&amp;doi=10.1002/14651858.CD012955.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012955.pub2&amp;doi=10.1002/14651858.CD012955.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012955.pub2&amp;doi=10.1002/14651858.CD012955.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012955.pub2&amp;doi=10.1002/14651858.CD012955.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012955.pub2&amp;doi=10.1002/14651858.CD012955.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012955.pub2&amp;doi=10.1002/14651858.CD012955.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012955.pub2&amp;doi=10.1002/14651858.CD012955.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012955.pub2&amp;doi=10.1002/14651858.CD012955.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012955.pub2&amp;doi=10.1002/14651858.CD012955.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012955.pub2&amp;doi=10.1002/14651858.CD012955.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012955.pub2&amp;doi=10.1002/14651858.CD012955.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012955.pub2&amp;doi=10.1002/14651858.CD012955.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012955.pub2&amp;doi=10.1002/14651858.CD012955.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012955.pub2&amp;doi=10.1002/14651858.CD012955.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012955.pub2&amp;doi=10.1002/14651858.CD012955.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012955.pub2&amp;doi=10.1002/14651858.CD012955.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012955.pub2&amp;doi=10.1002/14651858.CD012955.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012955.pub2&amp;doi=10.1002/14651858.CD012955.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012955.pub2&amp;doi=10.1002/14651858.CD012955.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="IYhCEbRn";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD012955\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD012955\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012955\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012955\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","zh_HANT","ko","pt","ms","ja","hr","fa","pl","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD012955.pub2",title:"Psychological therapies for people with borderline personality disorder",firstPublishedDate:"May 4, 2020 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Developmental, Psychosocial and Learning Problems Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=IYhCEbRn&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012955.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012955.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD012955.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD012955.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012955.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD012955.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;comments&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Comments&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD012955.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD012955.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD012955.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD012955.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>40618 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD012955.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012955.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012955.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012955.pub2/full#CD012955-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012955.pub2/full#CD012955-sec-0544"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012955.pub2/full#CD012955-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012955.pub2/full#CD012955-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012955.pub2/full#CD012955-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012955.pub2/full#CD012955-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012955.pub2/full#CD012955-sec-0044"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012955.pub2/full#CD012955-sec-0529"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012955.pub2/appendices#CD012955-sec-0549"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/supinfo/CD012955StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/supinfo/CD012955StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012955.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012955.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012955.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012955.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012955.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD012955.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2020 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Psychological therapies for people with borderline personality disorder</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author custom-tooltip" title="Shared 1st authorship."><a href="/cdsr/doi/10.1002/14651858.CD012955.pub2/information#CD012955-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Ole Jakob Storebø</a><sup>a</sup></li> <li class="author custom-tooltip" title="Shared 1st authorship."><a href="/cdsr/doi/10.1002/14651858.CD012955.pub2/information#CD012955-cr-0005">Jutta M Stoffers-Winterling</a><sup>a</sup></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012955.pub2/information#CD012955-cr-0006">Birgit A Völlm</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012955.pub2/information#CD012955-cr-0007">Mickey T Kongerslev</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012955.pub2/information#CD012955-cr-0008">Jessica T Mattivi</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012955.pub2/information#CD012955-cr-0009">Mie S Jørgensen</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012955.pub2/information#CD012955-cr-0010">Erlend Faltinsen</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012955.pub2/information#CD012955-cr-0011">Adnan Todorovac</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012955.pub2/information#CD012955-cr-0012">Christian P Sales</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012955.pub2/information#CD012955-cr-0013">Henriette E Callesen</a></li> <li class="author custom-tooltip" title="Shared last authorship."><a href="/cdsr/doi/10.1002/14651858.CD012955.pub2/information#CD012955-cr-0014">Klaus Lieb</a><sup>a</sup></li> <li class="author custom-tooltip" title="Shared last authorship."><a href="/cdsr/doi/10.1002/14651858.CD012955.pub2/information#CD012955-cr-0015">Erik Simonsen</a><sup>a</sup></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/information/en#CD012955-sec-0619">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 04 May 2020 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD012955.pub2">https://doi.org/10.1002/14651858.CD012955.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD012955-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012955-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012955-abs-0017">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012955-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012955-abs-0015">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD012955-abs-0006">한국어</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012955-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD012955-abs-0001" lang="en"> <section id="CD012955-sec-0001"> <h3 class="title" id="CD012955-sec-0001">Background</h3> <p>Over the decades, a variety of psychological interventions for borderline personality disorder (BPD) have been developed. This review updates and replaces an earlier review (Stoffers‐Winterling 2012). </p> </section> <section id="CD012955-sec-0002"> <h3 class="title" id="CD012955-sec-0002">Objectives</h3> <p>To assess the beneficial and harmful effects of psychological therapies for people with BPD. </p> </section> <section id="CD012955-sec-0003"> <h3 class="title" id="CD012955-sec-0003">Search methods</h3> <p>In March 2019, we searched CENTRAL, MEDLINE, Embase, 14 other databases and four trials registers. We contacted researchers working in the field to ask for additional data from published and unpublished trials, and handsearched relevant journals. We did not restrict the search by year of publication, language or type of publication. </p> </section> <section id="CD012955-sec-0004"> <h3 class="title" id="CD012955-sec-0004">Selection criteria</h3> <p>Randomised controlled trials comparing different psychotherapeutic interventions with treatment‐as‐usual (TAU; which included various kinds of psychotherapy), waiting list, no treatment or active treatments in samples of all ages, in any setting, with a formal diagnosis of BPD. The primary outcomes were BPD symptom severity, self‐harm, suicide‐related outcomes, and psychosocial functioning. There were 11 secondary outcomes, including individual BPD symptoms, as well as attrition and adverse effects. </p> </section> <section id="CD012955-sec-0005"> <h3 class="title" id="CD012955-sec-0005">Data collection and analysis</h3> <p>At least two review authors independently selected trials, extracted data, assessed risk of bias using Cochrane's 'Risk of bias' tool and assessed the certainty of the evidence using the GRADE approach. We performed data analysis using Review Manager 5 and quantified the statistical reliability of the data using Trial Sequential Analysis. </p> </section> <section id="CD012955-sec-0006"> <h3 class="title" id="CD012955-sec-0006">Main results</h3> <p>We included 75 randomised controlled trials (4507 participants), predominantly involving females with mean ages ranging from 14.8 to 45.7 years. More than 16 different kinds of psychotherapy were included, mostly dialectical behaviour therapy (DBT) and mentalisation‐based treatment (MBT). The comparator interventions included treatment‐as‐usual (TAU), waiting list, and other active treatments. Treatment duration ranged from one to 36 months. </p> <p><b>Psychotherapy versus TAU</b> </p> <p>Psychotherapy reduced BPD symptom severity, compared to TAU; standardised mean difference (SMD) −0.52, 95% confidence interval (CI) −0.70 to −0.33; 22 trials, 1244 participants; moderate‐quality evidence. This corresponds to a mean difference (MD) of −3.6 (95% CI −4.4 to −2.08) on the Zanarini Rating Scale for BPD (range 0 to 36), a clinically relevant reduction in BPD symptom severity (minimal clinical relevant difference (MIREDIF) on this scale is −3.0 points). </p> <p>Psychotherapy may be more effective at reducing self‐harm compared to TAU (SMD −0.32, 95% CI −0.49 to −0.14; 13 trials, 616 participants; low‐quality evidence), corresponding to a MD of −0.82 (95% CI −1.25 to 0.35) on the Deliberate Self‐Harm Inventory Scale (range 0 to 34). The MIREDIF of −1.25 points was not reached. </p> <p>Suicide‐related outcomes improved compared to TAU (SMD −0.34, 95% CI −0.57 to −0.11; 13 trials, 666 participants; low‐quality evidence), corresponding to a MD of −0.11 (95% CI −0.19 to −0.034) on the Suicidal Attempt Self Injury Interview. The MIREDIF of −0.17 points was not reached. </p> <p>Compared to TAU, psychotherapy may result in an improvement in psychosocial functioning (SMD −0.45, 95% CI −0.68 to −0.22; 22 trials, 1314 participants; low‐quality evidence), corresponding to a MD of −2.8 (95% CI −4.25 to −1.38), on the Global Assessment of Functioning Scale (range 0 to 100). The MIREDIF of −4.0 points was not reached. </p> <p>Our additional Trial Sequential Analysis on all primary outcomes reaching significance found that the required information size was reached in all cases. </p> <p>A subgroup analysis comparing the different types of psychotherapy compared to TAU showed no clear evidence of a difference for BPD severity and psychosocial functioning. </p> <p>Psychotherapy may reduce depressive symptoms compared to TAU but the evidence is very uncertain (SMD −0.39, 95% CI −0.61 to −0.17; 22 trials, 1568 participants; very low‐quality evidence), corresponding to a MD of −2.45 points on the Hamilton Depression Scale (range 0 to 50). The MIREDIF of −3.0 points was not reached. </p> <p>BPD‐specific psychotherapy did not reduce attrition compared with TAU. Adverse effects were unclear due to too few data. </p> <p><b>Psychotherapy versus waiting list or no treatment</b> </p> <p>Greater improvements in BPD symptom severity (SMD −0.49, 95% CI −0.93 to −0.05; 3 trials, 161 participants), psychosocial functioning (SMD −0.56, 95% CI −1.01 to −0.11; 5 trials, 219 participants), and depression (SMD −1.28, 95% CI −2.21 to −0.34, 6 trials, 239 participants) were observed in participants receiving psychotherapy versus waiting list or no treatment (all low‐quality evidence). No evidence of a difference was found for self‐harm and suicide‐related outcomes. </p> <p><b>Individual treatment approaches</b> </p> <p>DBT and MBT have the highest numbers of primary trials, with DBT as subject of one‐third of all included trials, followed by MBT with seven RCTs. </p> <p>Compared to TAU, DBT was more effective at reducing BPD severity (SMD −0.60, 95% CI −1.05 to −0.14; 3 trials, 149 participants), self‐harm (SMD −0.28, 95% CI −0.48 to −0.07; 7 trials, 376 participants) and improving psychosocial functioning (SMD −0.36, 95% CI −0.69 to −0.03; 6 trials, 225 participants). MBT appears to be more effective than TAU at reducing self‐harm (RR 0.62, 95% CI 0.49 to 0.80; 3 trials, 252 participants), suicidality (RR 0.10, 95% CI 0.04, 0.30, 3 trials, 218 participants) and depression (SMD −0.58, 95% CI −1.22 to 0.05, 4 trials, 333 participants). All findings are based on low‐quality evidence. For secondary outcomes see review text. </p> </section> <section id="CD012955-sec-0007"> <h3 class="title" id="CD012955-sec-0007">Authors' conclusions</h3> <p>Our assessments showed beneficial effects on all primary outcomes in favour of BPD‐tailored psychotherapy compared with TAU. However, only the outcome of BPD severity reached the MIREDIF‐defined cut‐off for a clinically meaningful improvement. Subgroup analyses found no evidence of a difference in effect estimates between the different types of therapies (compared to TAU) . </p> <p>The pooled analysis of psychotherapy versus waiting list or no treatment found significant improvement on BPD severity, psychosocial functioning and depression at end of treatment, but these findings were based on low‐quality evidence, and the true magnitude of these effects is uncertain. No clear evidence of difference was found for self‐harm and suicide‐related outcomes. </p> <p>However, compared to TAU, we observed effects in favour of DBT for BPD severity, self‐harm and psychosocial functioning and, for MBT, on self‐harm and suicidality at end of treatment, but these were all based on low‐quality evidence. Therefore, we are unsure whether these effects would alter with the addition of more data. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD012955-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012955-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012955-abs-0018">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012955-abs-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012955-abs-0016">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD012955-abs-0011">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ja#CD012955-abs-0010">日本語</a> </li> <li class="section-language"> <a class="" href="full/ko#CD012955-abs-0007">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD012955-abs-0009">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD012955-abs-0014">Polski</a> </li> <li class="section-language"> <a class="" href="full/pt#CD012955-abs-0008">Português</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012955-abs-0004">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD012955-abs-0005">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD012955-abs-0002" lang="en"> <h3>Psychological therapies for people with borderline personality disorder</h3> <p><b>Background</b> </p> <p>People affected by borderline personality disorder (BPD) often have difficulties with controlling their impulses and emotions. They may have a poor self‐image, experience rapid changes in mood, harm themselves and find it hard to engage in harmonious interpersonal relationships. Different types of psychological treatments ('talking treatments') have been developed to help people with BPD. The effects of these treatments must be investigated to decide how well they work and if they can be harmful. </p> <p><b>Objective</b> </p> <p>This review summarises what we currently know about the effect of psychotherapy in people with BPD. </p> <p><b>Methods</b> </p> <p>We compared the effects of psychological treatments on people affected by BPD who did not receive treatment or who continued their usual treatment, were on a waiting list or received active treatment. </p> <p><b>Findings</b> </p> <p>We searched for relevant research articles, and found 75 trials (4507 participants, mostly female, mean age ranging from 14.8 to 45.7 years). The trials examined a wide variety of psychological treatments (over 16 different types). They were mostly conducted in outpatient settings, and lasted between one and 36 months. Dialectical behaviour Therapy (DBT) and Mentalisation‐Based Treatment (MBT) were the therapies most studied. </p> <p><i>Psychotherapy compared with usual treatment</i> </p> <p>Psychotherapy reduced the severity of BPD symptoms and suicidality and may reduce self‐harm and depression whilst also improving psychological functioning compared to usual treatment. DBT may be better than usual treatment at reducing BPD severity, self‐harm and improving psychosocial functioning. Similarly, MBT appears to be more effective than usual treatment at reducing self‐harm, suicidality and depression. However, these findings were all based on low‐quality evidence and therefore we are uncertain whether or not these results would change if we added more trials. Most trials did not report adverse effects, and those that did, found no obvious unwanted reactions following psychological treatment. The majority of trials (64 out of 75) were funded by grants from universities, authorities or research foundations. Four trials reported that no funding was received. For the remaining trials (7), funding was not specified. </p> <p><i>Psychotherapy versus waiting list or no treatment</i> </p> <p>Psychotherapy was more effective than waiting list at improving BPD symptoms, psychosocial functioning, and depression, but there was no clear difference between psychotherapy, and waiting list for outcomes of self‐harm, and suicide‐related outcomes. </p> <p><b>Conclusions</b> </p> <p>In general, psychotherapy may be more effective than usual treatment in reducing BPD symptom severity, self‐harm, suicide‐related outcomes and depression, whilst also improving psychosocial functioning. However, only the decrease in BPD symptom severity was found to be at a clinically important level. DBT appears to be better at reducing BPD severity, self‐harm, and improving psychosocial functioning compared to usual treatment and MBT appears more effective than usual treatment at reducing self‐harm and suicidality. However, we are still uncertain about these findings as the quality of the evidence is low. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD012955-sec-0544" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD012955-sec-0544"></div> <h3 class="title" id="CD012955-sec-0545">Implications for practice</h3> <section id="CD012955-sec-0545"> <p>The interventions included in this review represent a broad spectrum of therapies, covering cognitive‐behavioural therapy (CBT), dialectical behavioural therapy (DBT), DBT skills group, eclectic therapy, psychodynamic therapy, systems training for emotional predictability and problem‐solving (STEPPS), schema‐focused therapy (SFT), interpersonal psychotherapy and mentalisation‐based therapy. </p> <p>Analyses showed beneficial effects of psychotherapy compared to TAU for all primary outcomes. However, only the improvement in BPD severity reached the level of a clinically important improvement compared to the MIREDIF; we considered this to be moderate‐quality evidence, meaning that additional research could impact our confidence in the effect estimate and may change the estimate. All trials had a high risk of bias and, for most outcomes, we considered the data to be of low quality due to imprecision, small sample sizes and inconsistency. </p> <p>We found no unequivocal, high‐quality evidence to support one BPD‐specific therapy over another in the treatment of BPD; our subgroup analyses showed no differences in effect estimates between the different types of therapies. However, compared to TAU, we observed significant effects in favour of DBT for the primary outcomes of BPD severity, self‐harm and psychosocial functioning, and in favour of MBT for self‐harm, suicidality and depression. We rated the quality of the evidence for these outcomes as low, meaning that the true magnitude of these effects is uncertain. </p> <p>In relation to implications for practice, low‐certainty evidence shows that that BPD‐tailored therapies (like DBT, MBT, CBT, SFT, TFP and ACT) may be more effective than usual treatments. We must await ongoing and new trials that can compare more validly the different treatment effects for the various types of treatment for BPD, including head‐to‐head comparisons. Current evidence indicates that psychotherapy, especially BPD‐tailored approaches, have beneficial effects on a variety of outcomes. However, only the decrease in BPD symptom severity was found to be clinically important. In order to help people affected by BPD decide on treatment according to their preferences and values, they should be informed about the variety of treatments available, working models, treatment durations and related information. </p> <p>Though a subgroup analysis indicated that adolescents may benefit less from psychotherapy compared to adults regarding overall BPD severity, this finding is based on low‐quality evidence only and very few observations (only two RCTs of adolescents included; <a href="./references#CD012955-fig-0217" title="">Analysis 27.1</a>.1), so the true effect remains uncertain. In practice, many adolescents often present with BPD symptoms on a subthreshold level, not yet reaching the full diagnostic threshold for BPD. Subthreshold BPD symptoms (even with only one BPD feature present) have been shown to be clinically important and correlated with the presence of mental state disorders, reduced social functioning and suicidal behaviour (<a href="./references#CD012955-bbs2-0409" title="ThompsonKN , JacksonH , CaveltiM , BettsJ , McCutcheonL , JovevM , et al. The clinical significance of subthreshold borderline personality disorder features in outpatient youth. Journal of Personality Disorders2019;33(1):71-81. [DOI: 10.1521/pedi_2018_32_330] [PMID: 30036169]">Thomson 2019</a>). Therefore, RCTs on early intervention for BPD in adolescence often include participants with subthreshold BPD. We have not included such participants in this review despite accumulating research findings that support the conduct of early interventions (<a href="./references#CD012955-bbs2-0269" title="ChanenAM , BerkM , ThompsonK . Integrating early intervention for borderline personality disorder and mood disorders. Harvard Review of Psychiatry2016;24(5):330–41. [DOI: https://doi.org/10.1097/HRP.0000000000000105]">Chanen 2016</a>; <a href="./references#CD012955-bbs2-0271" title="ChanenAM , ThompsonKN . Early intervention for personality disorder. Current Opinion in Psychology2018;21:132-5. [DOI: https://doi.org/10.1016/j.copsyc.2018.02.012]">Chanen 2018</a>). </p> </section> <h3 class="title" id="CD012955-sec-0546">Implications for research</h3> <section id="CD012955-sec-0546"> <p>In order to thoroughly investigate the efficacy of the treatments described in this review, there is a need for further high‐quality RCTs with larger patient groups. Here, it is essential that individual researchers are not involved in the delivery or the development of the treatment being investigated. Additionally, to assess the efficacy of psychotherapeutic treatments in BPD, there is a need for a greater consensus on what constitutes the core outcomes of BPD. Here, the selection of outcomes should be based on what people with BPD and their caregivers consider to be of value. Besides the core symptoms of BPD, which are still included in the DSM‐5 (<a href="./references#CD012955-bbs2-0232" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-5). 5th edition. Washington (DC): American Psychiatric Association, 2013. [ISBN 978-0-89042-554-1]">APA 2013</a>) and will be retained in ICD‐11 (<a href="./references#CD012955-bbs2-0423" title="World Health Organization. ICD-11 for mortality and morbidity statistics. icd.who.int/browse11/l-m/en (accessed 06 December 2019).">WHO 2018</a>), the dimensional outcome domains of personality disorders should also be considered, as this would foster the applicability of BPD research to non‐BPD personality disorders. Furthermore, assessment of outcomes should be based on validated, universal scales that enable a comparison of treatment effects between trials. Fortunately, BPD‐specific measures have been developed and used more often during the past decade. Yet for some important BPD‐specific outcomes (like 'avoidance of abandonment', 'feeling of emptiness'), assessment still relies on single items of questionnaires (like the Zan‐BPD (<a href="./references#CD012955-bbs2-0433" title="ZanariniMC , VujanovicAA , ParachiniEA , BoulangerJL , FrankenburgFR , HennenJ . Zanarini Rating Scale for Borderline Personality Disorder (Zan-BPD): a continuous measure of DSM-IV borderline psychopathology. Journal of Personality Disorders2003;17(3):233-42. [DOI: 10.1521/pedi.17.3.233.22147] [PMID: 12839102]">Zanarini 2003a</a>) or BPDSI‐IV (<a href="./references#CD012955-bbs2-0233" title="ArntzA , Van den HoornM , CornelisJ , VerheulR , Van den BoschW , De BieAJ . Reliability and validity of the borderline personality disorder severity index. Journal of Personality Disorders2003;17(1):45-59. [PMID: 12659546]">Arntz 2003</a>)). The development of validated assessments tools would be helpful. </p> <p>Future trials should include standardised control interventions that are carefully considered and reported fully in order to get a clear picture of what the psychological therapies are being compared to. More research is needed, when it comes to understanding the effects of interventions in certain groups of people, especially adolescents and the elderly, but also in men who are still under‐represented in BPD research. Long‐term trials should be conducted in order to understand which treatment effects are maintained and which diminish over time. </p> <p>Our findings that different BPD‐specific treatments are helpful is certainly in line with all‐day experiences of clinicians. There are some interventions beyond the prominent paradigms for which we found encouraging results and that deserve further attention. These especially include add‐on therapies such as STEPPS and ERGT. Though the different treatment approaches are theoretically divergent and postulate different mechanisms of change (<a href="./references#CD012955-bbs2-0309" title="GundersonJG , FruzzettiA , UnruhB , Choi-KainL . Competing theories of borderline personality disorder. Journal of Personality Disorders2018;32(2):148-67. [DOI: 10.1521/pedi.2018.32.2.148] [PMID: 29561723]">Gunderson 2018</a>), analyses of the technical aspects reveal many commonalities in terms of structure, focus and interventions, including general factors across therapies such as a structured treatment framework, consistent focus on the therapeutic relationship, active therapists and therapist support (<a href="./references#CD012955-bbs2-0245" title="BatemanAW , GundersonJ , MulderR . Treatment of personality disorder. Lancet2015;385(9969):735-43. [DOI: 10.1016/S0140-6736(14)61394-5]">Bateman 2015</a>; <a href="./references#CD012955-bbs2-0286" title="De GrootER , VerheulR , TrijsburgRW . An integrative perspective on psychotherapeutic treatments for borderline personality disorders. Journal of Personality Disorders2008;22(4):332-52. [DOI: 10.1521/pedi.2008.22.4.332] [PMID: 18684048]">De Groot 2008</a>; <a href="./references#CD012955-bbs2-0340" title="KongerslevMT , ChanenAM , SimonsenE . Personality disorder in childhood and adolescence comes of age: a review of the current evidence and prospects for future research. Scandinavian Journal of Child and Adolescent Psychiatry and Psychology2015;3(1):31-48. [DOI: 10.21307/sjcapp-2015-004]">Kongerslev 2015</a>; <a href="./references#CD012955-bbs2-0420" title="WeinbergI , RonningstamE , GoldblattMJ , SchechterM , MaltsbergerJT . Common factors in empirically supported treatments of borderline personality disorder. Current Psychiatry Reports2011;13(1):60-8. [DOI: 10.1007/s11920-010-0167-x] [PMID: 21057901]">Weinberg 2011</a>). However, more research is needed to understand the shared mechanisms of these specialist treatments, and how they contribute to change in BPD symptomatology (<a href="./references#CD012955-bbs2-0333" title="KarterudS , KongerslevMT . Psychotherapy of personality disorders needs an integrative theory of personality. Journal of Psychotherapy Integration 2020 Mar 2 [Epub ahead of print]. [DOI: 10.1037/int0000196]">Karterud 2020</a>). Future RCTs should consider incorporating measurements of diverse mechanisms of change that are known to be generally effective across therapies and diagnoses (e.g. focusing on the working alliance). This would allow for investigating the role of general mechanisms of change across different treatments in terms of outcome (<a href="./references#CD012955-bbs2-0272" title="ChatoorI , KrupnickJ . The role of non-speciifc factors in treatment outcome of psychotherapy studies. European Child &amp; Adolescent Psychiatry2001;10:19-25. [DOI: 10.1007/s007870170004]">Chatoor 2001</a>; <a href="./references#CD012955-bbs2-0335" title="KazdinAE . Understanding how and why psychotherapy leads to change. Psychotherapy Research2009;19(4-5):418-28. [DOI: 10.1080/10503300802448899]">Kazdin 2009</a>). </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD012955-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD012955-sec-0008"></div> <div class="table" id="CD012955-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Psychotherapy versus treatment‐as‐usual</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Psychotherapy versus treatment‐as‐usual</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> borderline personality disorder </p> <p><b>Settings:</b> inpatient and outpatient </p> <p><b>Intervention:</b> psychotherapy </p> <p><b>Comparison:</b> treatment‐as‐usual (TAU) </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Number of participants</b> </p> <p><b>(RCTs)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Quality of the evidence</b> </p> <p><b>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="center" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="center" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>TAU</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Psychotherapy</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>BPD symptom severity</b> </p> <p>Measured by: clinicians and self‐rated</p> <p>Timing of outcome assessment: end of treatment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean score in the intervention groups was <b>0.52 SD lower</b> (0.70 lower to 0.33 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1244 </p> <p>(22 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>Moderate<sup>a</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The SMD of −0.52 corresponds to −3.6 on the Zanarini BPD scale. The MIREDIF on this scale is 3.0 points </p> <p>TSA adjusted Cl = −5.49 to −1.90 on the Zanarini BPD scale</p> <p>TSA RIS = 901</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Self‐harm (frequency)</b> </p> <p>Measured by: clinicians and self‐rated</p> <p>Timing of outcome assessment: end of treatment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean score in the intervention groups was <b>0.32 SD lower</b> (0.49 lower to 0.14 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>616</p> <p>(13 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low<sup>a,b</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The SMD of −0. 32 corresponds to −0.82 on the DSHI. The MIREDIF on this scale is −1.25 points (½ SD) </p> <p>TSA adjusted CI = −0.59 to −0.08 on the DSHI</p> <p>TSA RIS = 97</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Suicide‐related outcomes (suicidality)</b> </p> <p>Measured by: clinicians and self‐rated</p> <p>Timing of outcome assessment: end of treatment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean score in the intervention groups was <b>0.34 SD lower</b> (0.57 lower to 0.11 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>666</p> <p>(13 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low<sup>a,b</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The SMD of −0. 34 corresponds to −0.11 on the SASII. The MIREDIF on this scale is −0.17 points (½ SD) </p> <p>TSA adjusted CI = −0.18 to −0.04 on the SASII</p> <p>TSA RIS = 253</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Psychosocial functioning</b> </p> <p>Measured by: clinicians and self‐rated</p> <p>Timing of outcome assessment: end of treatment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean score in the intervention groups was <b>0.45 SD lower</b> (0.68 lower to 0.22 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1314</p> <p>(22 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low<sup>a,c</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The SMD of −0.45 corresponds to −2.8 on the GAF. The MIREDIF on this scale is −4.0 points </p> <p>TSA adjusted CI = −3.97 to −1.94 on the GAF</p> <p>TSA RIS = 947</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Depression</b> </p> <p>Measured by: clinicians and self‐rated</p> <p>Timing of outcome assessment: end of treatment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean score in the intervention groups was <b>0.39 SD lower</b> (0.61 lower to 0.17 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1568</p> <p>(22 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very</b> <b>low<sup>a,b,c</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The SMD of ‐0.45 corresponds to −2.45 on the Hamilton Depression Scale. The MIREDIF on this scale is 3.0 points </p> <p>TSA adjusted CI = −3.34 to −1.72 on the Hamilton Depression Scale</p> <p>TSA RIS = 2274</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Attrition</b> </p> <p>Timing of outcome assessment: end of treatment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>328 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>328 per 1000</b> (95% CI 56 fewer to 66 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.00 (95% CI 0.83 to 1.20)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2225</p> <p>(32 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low<sup>a,b</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects</b> </p> <p>Timing of outcome assessment: end of treatment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>74 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>6 per 1000</b> (95% CI 41 fewer to 65 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.92 (95% CI 0.45 to 1.88)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>381</p> <p>(2 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low<sup>a,b</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> Confidence interval; <b>DSHI:</b> Deliberate Self‐Harm Inventory; <b>GAF:</b> Global Assessment of Functioning scale; <b>MIREDIF:</b> Minimum relevant difference; <b>RCTs:</b> Randomised controlled trials; <b>RIS:</b> Required information size; <b>RR:</b> Risk Ratio; <b>SASII:</b> Suicide Attempt Self‐Injury Interview; <b>SD:</b> Standard deviation; <b>SMD:</b> Standardised mean difference; <b>TAU:</b> treatment‐as‐usual; <b>TSA:</b> Trial Sequential Analysis </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect<br/><b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate<br/><b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate<br/><b>Very low quality:</b> we are very uncertain about the estimate </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>We downgraded the quality of this evidence by one level due to risk of bias (other bias).<br/><sup>b</sup>We downgraded the quality of this evidence by one level due to imprecision.<br/><sup>c</sup>We downgraded the quality of this evidence by one level due to high heterogeneity. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012955-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Psychotherapy versus waiting list or no treatment</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Psychotherapy versus waiting list or no treatment</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> borderline personality disorder </p> <p><b>Settings:</b> inpatient and outpatient </p> <p><b>Intervention:</b> psychotherapy </p> <p><b>Comparison:</b> waiting list or no treatment </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Number of participants</b> </p> <p><b>(RCTs)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Quality of the evidence</b> </p> <p><b>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="center" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="center" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Waiting list or no treatment</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Psychotherapy</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>BPD symptom severity</b> </p> <p>Measured by: clinicians and self‐rated</p> <p>Timing of outcome assessment: end of treatment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean score in the intervention groups was <b>0.49 SD lower</b> (0.93 lower to 0.05 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>161</p> <p>(3 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low<sup>a,b</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>An SMD of 0.49 represents a moderate effect.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Self‐harm</b> </p> <p>Measured by: clinicians and self‐rated</p> <p>Timing of outcome assessment: end of treatment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean score in the intervention groups was<b>0.17 SD lower</b> (0.52 lower to 0.18 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>128</p> <p>(2 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low<sup>a,b</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>An SMD of 0.17 represents a small effect.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Suicide‐related outcomes</b> </p> <p>Measured by: self‐rated</p> <p>Timing of outcome assessment: end of treatment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean score in the intervention groups was <b>5.62 SD lower</b> (16.39 lower to 5.16 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>108</p> <p>(2 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very</b> <b>low<sup>a,b,c</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>An SMD of 5.62 represents a large effect.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Psychosocial functioning</b> </p> <p>Measured by: clinicians and self‐rated</p> <p>Timing of outcome assessment: end of treatment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean score in the intervention groups was <b>0.56 SD lower</b> (1.01 lower to 0.11 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>219</p> <p>(5 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low<sup>a,b</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>An SMD of 0.56 represents a moderate effect.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Depression</b> </p> <p>Measured by: clinicians and self‐rated</p> <p>Timing of outcome assessment: end of treatment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean score in the intervention groups was <b>1.28 SD lower</b> (2.21 lower to 0.34 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>239</p> <p>(6 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low<sup>a,b</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>An effect size of 1.28 represents a large effect.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Attrition</b> </p> <p>Timing of outcome assessment: end of treatment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>81 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>147 per 1000</b> (95% CI 118 fewer to 74 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.55 (95% CI 0.20 to 1.50)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>144</p> <p>(3 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very</b> <b>low<sup>a,b,c</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects (not measured</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comments</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comments</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies were found that assessed this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> Confidence interval; <b>RCTs:</b> Randomised controlled trials; <b>RR:</b> Risk ratio; <b>SMD:</b> Standardized mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect<br/><b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate<br/><b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate<br/><b>Very low quality:</b> we are very uncertain about the estimate </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>We downgraded the quality of this evidence by one level due to risk of bias.<br/><sup>b</sup>We downgraded the quality of this evidence by one level due to imprecision (there was a wide CI).<br/><sup>c</sup>We downgraded the quality of this evidence by one level due to inconsistency. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012955-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Dialectical behavioural therapy or mentalisation‐based therapy versus treatment‐as‐usual</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Dialectical behavioural therapy or mentalisation‐based therapy versus treatment‐as‐usual</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> borderline personality disorder </p> <p><b>Settings:</b> inpatient and outpatient </p> <p><b>Intervention:</b> dialectical behavioural therapy (DBT) or mentalisation‐based therapy (MBT) </p> <p><b>Comparison:</b> treatment‐as‐usual (TAU) </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Number of participants</b> </p> <p><b>(RCTs)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Quality of the evidence</b> </p> <p><b>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="center" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="center" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>TAU</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>DBT or MBT</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell" colspan="7" rowspan="1" scope="col" valign=""> <p><b><i>DBT</i> </b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>BPD severity</b> </p> <p>Measured by: clinicians</p> <p>Timing of outcome assessment: end of treatment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean score in the intervention groups was <b>0.60 SD lower</b> (1.05 lower to 0.14 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>149</p> <p>(3 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low<sup>a,b</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>An SMD of 0.60 represents a moderate effect.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Self‐harm</b> </p> <p>Measured by: clinicians</p> <p>Timing of outcome assessment: end of treatment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean score in the intervention groups was<br/><b>0.28 SD lower</b> (0.48 lower to 0.07 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>376</p> <p>(7 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low<sup>a,b</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>An SMD of 0.28 represents a small effect.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Psychosocial functioning</b> </p> <p>Measured by: clinicians and self‐rated</p> <p>Timing of outcome assessment: end of treatment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean score in the intervention groups was <b>0.36 SD lower</b> (0.69 lower to 0.03 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>225</p> <p>(6 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low<sup>a,b,</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>An SMD of 0.36 represents a small effect.</p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="7" rowspan="1" scope="col" valign=""> <p><b><i><b>MBT</b> </i> </b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Self‐harm</b> </p> <p>Measured by: clinicians</p> <p>Timing of outcome assessment: end of treatment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>631 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>240 per 1000</b> (95% CI 334 fewer to 126 fewer) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.62 (95% CI 0.49 to 0.80)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>252</p> <p>(3 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low<sup>a,b</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Suicide‐related outcomes</b> </p> <p>Measured by: clinicians</p> <p>Timing of outcome assessment: end of treatment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>298 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>268 per 1000</b> (95% CI 286 fewer to 209 fewer) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.10 (95% CI 0.04 to 0.30)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>218</p> <p>(3 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low<sup>a,b</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> Confidence interval; <b>DBT:</b> Dialectical behavioural therapy; <b>MBT:</b> Mentalisation‐based therapy; <b>RCTs:</b> Randomised controlled trials; <b>RR:</b> Risk ratio; <b>SMD:</b> Standardized mean difference; <b>TAU:</b> Treatment‐as‐usual </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect<br/><b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate<br/><b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate<br/><b>Very low quality:</b> we are very uncertain about the estimate </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>We downgraded the quality of this evidence by one level due to risk of bias.<br/><sup>b</sup>We downgraded the quality of this evidence by one level due to imprecision (there was a wide CI). </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD012955-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD012955-sec-0009"></div> <section id="CD012955-sec-0010"> <h3 class="title" id="CD012955-sec-0010">Description of the condition</h3> <p>Borderline personality disorder (BPD) is a condition first formally described in the 20th century (<a href="./references#CD012955-bbs2-0306" title="GundersonJG . Borderline personality disorder: ontogeny of a diagnosis. American Journal of Psychiatry2009;166(5):530-9. [DOI: 10.1176/appi.ajp.2009.08121825] [NIHMS313194] [PMC3145201]">Gunderson 2009</a>). Historically, the term BPD was coined by Adolph Stern to describe a condition in the 'borderland' between psychosis and neurosis (<a href="./references#CD012955-bbs2-0401" title="SternA . Psychoanalytic investigation of and therapy in the borderline group of neuroses. Psychoanalytic Quarterly1938;7:467-89.">Stern 1938</a>). Subsequent psychoanalytic contributions (especially that of <a href="./references#CD012955-bbs2-0336" title="KernbergOF . Borderline Conditions and Pathological Narcissism. New York (NY): Aronson, 1975.">Kernberg 1975</a>) have reaffirmed this distinction, emphasising that the capacity to test reality remains grossly intact but is subject to subtle distortions, especially under stress. The current evidence supports a biopsychological model of the aetiological factors in BPD, all of which may contribute. It is assumed that there is an interaction between the experience of adverse effects during childhood (like neglect, emotional or sexual abuse), and genetic or biological factors. Relevant biological factors include neurobiological structures, such as reduced aymgdala volume, increased volume of the pituitary gland, reduced grey matter volume in the anterior cingulate gyrus, posterior cingulate gyrus or hippocampus, and reduction in size of the right parietal cortex (<a href="./references#CD012955-bbs2-0342" title="LeichsenringF , LeibingE , KruseJ , NewAS , LewekeF . Borderline personality disorder.. Lancet2011;377(9759):74-84.">Leichsenring 2011</a>; <a href="./references#CD012955-bbs2-0346" title="LiebK , ZanariniMC , SchmahlC , LinehanMM , BohusM . Borderline personality disorder. Lancet2004;364(9432):453-61. [DOI: dx.doi.org/10.1016/S0140-6736(04)16770-6] [PMID: 15288745]">Lieb 2004</a>), and neurobiological dysfunctions (especially of the serotonergic system). In combination with psychosocial factors, personality traits (e.g. neuroticisms), personality functioning (self and interpersonal) and proneness to react highly emotionally may contribute to the core components of BPD, like affective and behavioural dysregulation, and disturbed relatedness (<a href="./references#CD012955-bbs2-0342" title="LeichsenringF , LeibingE , KruseJ , NewAS , LewekeF . Borderline personality disorder.. Lancet2011;377(9759):74-84.">Leichsenring 2011</a>; <a href="./references#CD012955-bbs2-0346" title="LiebK , ZanariniMC , SchmahlC , LinehanMM , BohusM . Borderline personality disorder. Lancet2004;364(9432):453-61. [DOI: dx.doi.org/10.1016/S0140-6736(04)16770-6] [PMID: 15288745]">Lieb 2004</a>). </p> <p>According to current diagnostic criteria, BPD is characterised by a pervasive pattern of instability in affect regulation, impulse control, interpersonal relationships and self‐image (<a href="./references#CD012955-bbs2-0232" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-5). 5th edition. Washington (DC): American Psychiatric Association, 2013. [ISBN 978-0-89042-554-1]">APA 2013</a>; <a href="./references#CD012955-bbs2-0422" title="World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders: Diagnostic Criteria for Research. Geneva (CH): World Health Organization, 1993.">WHO 1993</a>). Clinical hallmarks include, amongst other things, emotional dysregulation, impulsivity, anger, repeated self‐injury and chronic suicidal tendencies, together with inner emptiness and fear of abandonment (<a href="./references#CD012955-bbs2-0288" title="DimaggioG , SemerariA , CarcioneA , NicolòG , ProcacciM . Psychotherapy of Personality Disorders: Metacognition, States of Mind and Interpersonal Cycles. London (UK): Routledge, 2007.">Dimaggio 2007</a>; <a href="./references#CD012955-bbs2-0297" title="FonagyP , LuytenP . A developmental, mentalization-based approach to the understanding and treatment of borderline personality disorder. Development and Psychopathology2009;21(4):1355-81. [DOI: 10.1017/S0954579409990198] [PMID: 19825272]">Fonagy 2009</a>; <a href="./references#CD012955-bbs2-0309" title="GundersonJG , FruzzettiA , UnruhB , Choi-KainL . Competing theories of borderline personality disorder. Journal of Personality Disorders2018;32(2):148-67. [DOI: 10.1521/pedi.2018.32.2.148] [PMID: 29561723]">Gunderson 2018</a>; <a href="./references#CD012955-bbs2-0332" title="KarterudSW , KongerslevMT . A temperament-attachment-mentalization-based (TAM) theory of personality and its disorders. Frontiers in Psychology2019;10:518. [DOI: 10.3389/fpsyg.2019.00518] [PMCID: PMC6439347] [PMID: 30967807]">Karterud 2019</a>; <a href="./references#CD012955-bbs2-0346" title="LiebK , ZanariniMC , SchmahlC , LinehanMM , BohusM . Borderline personality disorder. Lancet2004;364(9432):453-61. [DOI: dx.doi.org/10.1016/S0140-6736(04)16770-6] [PMID: 15288745]">Lieb 2004</a>). Despite the difficulties and controversies in defining and delimiting the condition, BPD is being vigorously researched still, not only in adults but also in childhood and adolescence (<a href="./references#CD012955-bbs2-0270" title="ChanenA , SharpC , HoffmanP , Global Alliance for the Prevention and Early Intervention for Borderline Personality Disorder. Prevention and early intervention for borderline personality disorder: a novel public health priority. World Psychiatry2017;16(2):215-6. [DOI: 10.1002/wps.20429] [PMCID: PMC5428197] [PMID: 28498598]">Chanen 2017</a>), and is the only specific personality disorder to be carried over to the new, eleventh edition of the <i>International Classification of Diseases</i> (ICD‐11) (<a href="./references#CD012955-bbs2-0238" title="BachB , First MB . Application of the ICD-11 classification of personality disorders. BMC Psychiatry2018;18:351. [DOI: 10.1186/s12888-018-1908-3] [PMCID: PMC6206910] [PMID: 30373564]">Bach 2018</a>; <a href="./references#CD012955-bbs2-0423" title="World Health Organization. ICD-11 for mortality and morbidity statistics. icd.who.int/browse11/l-m/en (accessed 06 December 2019).">WHO 2018</a>). The importance of effective treatments for BPD stems from the considerable psychological suffering of the persons concerned (<a href="./references#CD012955-bbs2-0403" title="StiglmayrCE , GrathwolT , LinehanMM , IhorstG , FahrenbergJ , BohusM . Aversive tension in patients with borderline personality disorder: a computer-based controlled field study. Acta Psychiatrica Scandinavica2005;111(5):372-9. [DOI: 10.1111/j.1600-0447.2004.00466.x] [PMID: 15819731]">Stiglmayr 2005</a>; <a href="./references#CD012955-bbs2-0432" title="ZanariniMC , FrankenburgFR , DeLucaCJ , HennenJ , KheraGS , GundersonJG . The pain of being borderline: dysphoric states specific to borderline personality disorder. Harvard Review of Psychiatry1998;6(4):201-7. [DOI: 10.3109/10673229809000330] [PMID: 10370445]">Zanarini 1998</a>), the burden incurred on their families and significant others (<a href="./references#CD012955-bbs2-0239" title="BaileyRC , GrenyerBF . Supporting a person with personality disorder: a study of carer burden and well-being. Journal of Personality Disorders2014;28(6):796-809. [DOI: 10.1521/pedi_2014_28_136] [PMID: 24689763]">Bailey 2014</a>; <a href="./references#CD012955-bbs2-0248" title="BatemanA , Fonagy P. A randomized controlled trial of a mentalization-based intervention (MBT-FACTS) for families of people with borderline personality disorder. Personality Disorders2019;10(1):70-9. [DOI: 10.1037/per0000298] [PMID: 29999394]">Bateman 2019a</a>), the significant impact on mental health services (<a href="./references#CD012955-bbs2-0263" title="CailholL , ThalamasC , GarridoC , BirmesP , Lapeyre-MestreM . Mental health service utilization among borderline personality disorder patients inpatient [Utilisation des services de soin par les patients hospitalisés, présentant un trouble de personnalité borderline en Midi-Pyrénées]. L'Encéphale2015;41(2):115-22. [DOI: 10.1016/j.encep.2014.10.008] [PMID: 25526809]">Cailhol 2015</a>; <a href="./references#CD012955-bbs2-0328" title="HörzS , ZanariniMC , FrankenburgFR , ReichDB , FitzmauriceG . Ten-year use of mental health services by patients with borderline personality disorder and with other axis II disorders. Psychiatric Services2010;61(6):612-6. [DOI: 10.1176/ps.2010.61.6.612] [PMC3889171] [PMID: 20513685]">Hörz 2010</a>; <a href="./references#CD012955-bbs2-0395" title="SoetemanDI , Hakkaart-van RoijenL , VerheulR , BusschbachJJV . The economic burden of personality disorders in mental health care. Journal of Clinical Psychiatry2008;69(2):259–65. [PMID: 18363454]">Soeteman 2008a</a>; <a href="./references#CD012955-bbs2-0415" title="TyrerP , ReedGM , CrawfordMJ . Classification, assessment, prevalence, and effect of personality disorders. Lancet2015;385(9969):717-26. [DOI: 10.1016/S0140-6736(14)61995-4]">Tyrer 2015</a>; <a href="./references#CD012955-bbs2-0435" title="ZanariniMC , FrankenburgFR , HennenJ , SilkKR . Mental health service utilization by borderline personality disorder patients and Axis II comparison subjects followed prospectively for 6 years. Journal of Clinical Psychiatry2004;65(1):28-36. [PMID: 14744165]">Zanarini 2004</a>; <a href="./references#CD012955-bbs2-0439" title="ZanariniMC , FrankenburgFR , ReichB , FitzmauriceG . Attainment and stability of sustained symptomatic remission and recovery among patients with borderline personality disorder and axis II comparison subjects: a 16-year prospective follow-up study. American Journal of Psychiatry2012;169(5):476-83. [DOI: 10.1176/appi.ajp.2011.11101550] [PMC3509999] [PMID: 22737693]">Zanarini 2012</a>), and not least the association of BPD with debilitating functional impairments and premature death (<a href="./references#CD012955-bbs2-0296" title="FokML , HayesRD , ChangCK , StewartR , CallardFJ , MoranP . Life expectancy at birth and all-cause mortality among people with personality disorder. Journal of Psychosomatic Research2012;73(2):104-7. [DOI: 10.1016/j.jpsychores.2012.05.001] [PMID: 22789412]">Fok 2012</a>; <a href="./references#CD012955-bbs2-0307" title="GundersonJG . Borderline personality disorder. New England Journal of Medicine2011;364(21):2037-42. [DOI: doi.org/10.1056/NEJMcp1007358]">Gunderson 2011a</a>; <a href="./references#CD012955-bbs2-0308" title="GundersonJG , StoutRL , McGlashanTH , SheaMT , MoreyLC , GriloCM , et al. Ten-year course of borderline personality disorder: psychopathology and function from the Collaborative Longitudinal Personality Disorders study. Archives of General Psychiatry2011;68(8):827-37. [DOI: doi.org/10.1001/archgenpsychiatry.2011.37] [PMC3158489] [PMID: 21464343]">Gunderson 2011b</a>; <a href="./references#CD012955-bbs2-0337" title="KjærJNR , BiskinR , VestergaardC , Munk-JørgensenP . All-cause mortality of hospital-treated borderline personality disorder: a nationwide cohort study. Journal of Personality Disorders2018;11:1-13. [DOI: 10.1521/pedi_2018_32_403] [PMID: 30307824]">Kjær 2018</a>; <a href="./references#CD012955-bbs2-0371" title="NiestenIJ , KaranE , FrankenburgFR , FitzmauriceGM , ZanariniMC . Description and prediction of the income status of borderline patients over 10   years of prospective follow-up. Personality and Mental Health2016;10(4):285-92. [DOI: 10.1002/pmh.1331] [PMID: 26864557]">Niesten 2016</a>; <a href="./references#CD012955-bbs2-0394" title="SkodolAE , GundersonJG , McGlashanTH , DyckIR , StoutRL , BenderDS , et al. Functional impairment in patients with schizotypal, borderline, avoidant, or obsessive-compulsive personality disorder. American Journal of Psychiatry2002;159(2):276-83. [DOI: 10.1176/appi.ajp.159.2.276] [PMID: 11823271]">Skodol 2002</a>; <a href="./references#CD012955-bbs2-0396" title="SoetemanDI , VerheulR , BusschbachJJV . The burden of disease in personality disorders: diagnosis-specific quality of life. Journal of Personality Disorders2008;22(3):259-68. [DOI: doi.org/10.1521/pedi.2008.22.3.259] [PMID: 18540798]">Soeteman 2008b</a>). </p> <p>The definition of BPD in the <i>Diagnostic and Statistical Manual of Mental Disorders</i> (DSM), Fifth Edition (DSM‐5; <a href="./references#CD012955-bbs2-0232" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-5). 5th edition. Washington (DC): American Psychiatric Association, 2013. [ISBN 978-0-89042-554-1]">APA 2013</a>), Fourth Edition (DMS‐IV; <a href="./references#CD012955-bbs2-0230" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). 4th edition. Washington (DC): American Psychiatric Association, 1994. [ISBN 978-0-89042-0610]">APA 1994</a>) and Fourth Edition Text Revision (DSM‐IV‐TR; <a href="./references#CD012955-bbs2-0231" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR), 4th edition, text revision. Washington (DC): American Psychiatric Association, 2000. [ISBN 978-0-89042-0256]">APA 2000</a>) comprises nine criteria that cover the features mentioned above. At least five criteria should be met for a definitive, categorical diagnosis of BPD to be made, and four criteria for a probable diagnosis (see <a href="./appendices#CD012955-sec-0550">Appendix 1</a>). In the alternative diagnostic classification system of the World Health Organization (WHO), the <i>ICD</i>, which is currently in its tenth edition (ICD‐10; <a href="./references#CD012955-bbs2-0422" title="World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders: Diagnostic Criteria for Research. Geneva (CH): World Health Organization, 1993.">WHO 1993</a>), the relating condition is referred to as "Emotionally unstable personality disorder (F60.3)", of which there is an impulsive type (F60.30) and a borderline type (F60.31; see <a href="./appendices#CD012955-sec-0551">Appendix 2</a>). The latter essentially overlaps with the DSM‐IV definition and DSM‐5 criteria (<a href="./references#CD012955-bbs2-0375" title="OttossonH , EkseliusL , GrannM , KullgrenG . Cross-system concordance of personality disorder diagnoses of DSM-IV and diagnostic criteria for research of ICD-10. Journal of Personality Disorders2002;16(3):283-92. [DOI: 10.1521/pedi.16.3.283.22537] [PMID: 12136684]">Ottosen 2002</a>). </p> <p>In addition to categorical classification systems, the DSM‐5 also includes an alternative model for personality disorders (Section III: "Emerging Measures and Models"). This hybrid model is made up of two dimensions: 1) the severity of impairment in personality (self and interpersonal); and 2) the domains of personality traits (i.e. negative affectivity, detachment, antagonism, disinhibition, psychoticism; <a href="./references#CD012955-bbs2-0232" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-5). 5th edition. Washington (DC): American Psychiatric Association, 2013. [ISBN 978-0-89042-554-1]">APA 2013</a>, Section III). The ICD‐11 (which will be in effect from 2022; <a href="./references#CD012955-bbs2-0423" title="World Health Organization. ICD-11 for mortality and morbidity statistics. icd.who.int/browse11/l-m/en (accessed 06 December 2019).">WHO 2018</a>) is also moving towards a dimensional approach, where the different types of personality disorders are being replaced with a model that focuses on the severity of core personality functioning instead. However, a specifier relating to a "Borderline pattern" will be retained. Preliminary studies have found that there is a substantial overlap between the current categorical and alternative models found in the DSM‐5 (<a href="./references#CD012955-bbs2-0237" title="BachB , SellbomM . Continuity between DSM-5 categorial criteria and traits criteria for borderline personality disorder. Canadian Journal of Psychiatry2016;61(8):489-94. [DOI: 10.1177/0706743716640756] [PMC4959646] [PMID: 27310232]">Bach 2016</a>; <a href="./references#CD012955-bbs2-0238" title="BachB , First MB . Application of the ICD-11 classification of personality disorders. BMC Psychiatry2018;18:351. [DOI: 10.1186/s12888-018-1908-3] [PMCID: PMC6206910] [PMID: 30373564]">Bach 2018</a>; <a href="./references#CD012955-bbs2-0392" title="SellbomM , SansoneRA , SongerDA , AndersonJL . Convergence between DSM-5 Section II and Section III diagnostic criteria for borderline personality disorder. Australian &amp; New Zealand Journal of Psychiatry2014;48(4):325-32. [DOI: 10.1177/0004867413511997] [PMID: 24253360]">Sellbom 2014</a>), as well as overlap between the dimensional models of the DSM‐5 and ICD‐11 (<a href="./references#CD012955-bbs2-0238" title="BachB , First MB . Application of the ICD-11 classification of personality disorders. BMC Psychiatry2018;18:351. [DOI: 10.1186/s12888-018-1908-3] [PMCID: PMC6206910] [PMID: 30373564]">Bach 2018</a>). Therefore, sufficient continuity between current categorical and upcoming dimensional models is warranted. The findings of this review will be applicable also to populations diagnosed with the DSM‐5 Section III Hybrid BPD type and ICD‐11 Borderline pattern qualifier. </p> <p>The prevalence of BPD in the general population is estimated to be 1.8 % (95% CI 1.2% to 2.5%) (<a href="./references#CD012955-bbs2-0424" title="WinsperC , BilginA , ThompsonA , MarwahaS , ChanenAM , SinghS , et al. The prevalence of personality disorders in the community: a global systematic review and meta-analysis.. British Journal of Psychiatry2020;216(2):69-78. [DOI: 10.1192/bjp.2019.166]">Winsper 2020</a>). In clinical populations, BPD occurs frequently (<a href="./references#CD012955-bbs2-0365" title="Munk-JørgensenP , Najarraq LundM , BertelsenA . Use of ICD-10 diagnoses in Danish psychiatric hospital-based services in 2001-2007. World Psychiatry2010;9(3):183-4. [ PMC2948730] [PMID: 20975866]">Munk‐Jørgensen 2010</a>), with trials reporting a prevalence ranging from 9.3% to 46.3% and a mean point prevalence across studies of 28.5% (<a href="./references#CD012955-bbs2-0413" title="TorgersenS . Epidemiology. In: WidigerTA , editors(s). The Oxford Handbook of Personality Disorders. New York (NY): Oxford University Press, 2012:186-205. [DOI: 10.1093/oxfordhb/9780199735013.013.0009] [ISBN 978-0-19-973501-3]">Torgersen 2012</a>). BPD usually has its onset in childhood and adolescence, and younger people are affected as much as or even more often than adults (<a href="./references#CD012955-bbs2-0367" title="NeacsiuAD , EberleJW , KengSL , FangCM , RosenthalZ . Understanding borderline personality disorder across sociocultural groups: findings, issues, and future directions. Current Psychiatry Reviews2017;13(3):188-223. [DOI: 10.2174/1573400513666170612122034]">Neacsiu 2017</a>). BPD has been found to peak around 14 to 17 years of age with a linearly decline into adulthood; however, it continues throughout the lifespan and can also be found in older people (<a href="./references#CD012955-bbs2-0265" title="ChanenAM , McCutcheonLK , JovevM , JacksonHJ , McGorryPD . Prevention and early intervention for borderline personality disorder. Medical Journal of Australia2007;187(7):S18-21. [DOI: 10.5694/j.1326-5377.2007.tb01330.x]">Chanen 2007</a>; <a href="./references#CD012955-bbs2-0368" title="Newton-HowesG , ClarkLA , ChanenA . Personality disorder across the life course. Lancet2015;385(9969):727-34. [DOI: 10.1016/S0140-6736(14)61283-6] [PMID: 25706218]">Newton‐Howes 2015</a>; <a href="./references#CD012955-bbs2-0393" title="SharpC , WallK . Personality pathology grows up: adolescence as a sensitive period. Current Opinion in Psychology2018;21:111-6. [DOI: 10.1016/j.copsyc.2017.11.010] [PMID: 29227834]">Sharp 2018</a>; <a href="./references#CD012955-bbs2-0418" title="VidelerAC , HutsebautJ , SchulkensJEM , SobczakS , Van AlphenSPJ . A life span perspective on borderline personality disorder. Current Psychiatry Reports2019;21(7):51. [10.1007/s11920-019-1040-1] [31161404] [PMC6546651]">Videler 2019</a>). Though BPD is predominantly diagnosed in women (75%; <a href="./references#CD012955-bbs2-0231" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR), 4th edition, text revision. Washington (DC): American Psychiatric Association, 2000. [ISBN 978-0-89042-0256]">APA 2000</a>; <a href="./references#CD012955-bbs2-0232" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-5). 5th edition. Washington (DC): American Psychiatric Association, 2013. [ISBN 978-0-89042-554-1]">APA 2013</a>), it is estimated to be almost equally frequent in men in epidemiological studies (<a href="./references#CD012955-bbs2-0343" title="LenzenwegerMF , WillettJB . Predicting individual change in personality disorder features by simultaneous individual change in personality dimensions linked to neurobehavioral systems: the longitudinal study of personality disorders. Journal of Abnormal Psychology2007;116(4):684–700. [DOI: 10.1037/0021-843X.116.4.684] [PMID: 18020716]">Lenzenweger 2007</a>; <a href="./references#CD012955-bbs2-0406" title="Ten HaveM , VerheulR , KaasenbroodA , Van DorsselaerS , TuithofM , KleinjanM , et al. Prevalence rates of borderline personality disorder symptoms: a study based on the Netherlands Mental Health Survey and Incidence Study-2. BMC Psychiatry2016;16:249. [DOI: doi.org/10.1186/s12888-016-0939-x] [PMC4949762] [PMID: 27435813]">Ten Have 2016</a>; <a href="./references#CD012955-bbs2-0412" title="TorgersenS , KringlenE , CramerV . The prevalence of personality disorders in a community sample. Archives of General Psychiatry2001;58(6):590–6. [PMID: 11386989]">Torgersen 2001</a>; <a href="./references#CD012955-bbs2-0413" title="TorgersenS . Epidemiology. In: WidigerTA , editors(s). The Oxford Handbook of Personality Disorders. New York (NY): Oxford University Press, 2012:186-205. [DOI: 10.1093/oxfordhb/9780199735013.013.0009] [ISBN 978-0-19-973501-3]">Torgersen 2012</a>). Moreover, BPD commonly co‐occurs with mood disorders, substance use disorder, eating disorders, post‐traumatic stress disorder (PTSD), attention‐deficit hyperactivity disorder (ADHD), and other specific personality disorders (<a href="./references#CD012955-bbs2-0277" title="CoidJ , YangM , TyrerP , RobertsA , UllrichS . Prevalence and correlates of personality disorder in Great Britain. British Journal of Psychiatry2006;188:423-31. [DOI: 10.1192/bjp.188.5.423] [PMID: 16648528]">Coid 2006</a>; <a href="./references#CD012955-bbs2-0343" title="LenzenwegerMF , WillettJB . Predicting individual change in personality disorder features by simultaneous individual change in personality dimensions linked to neurobehavioral systems: the longitudinal study of personality disorders. Journal of Abnormal Psychology2007;116(4):684–700. [DOI: 10.1037/0021-843X.116.4.684] [PMID: 18020716]">Lenzenweger 2007</a>; <a href="./references#CD012955-bbs2-0400" title="SteppSD . Development of borderline personality disorder in adolescence and young adulthood: introduction to the special section. Journal of Abnormal Child Psychology2012;40(1):1-5. [DOI: 10.1007/s10802-011-9594-3] [ PMC3865353] [PMID: 22116635]">Stepp 2012</a>; <a href="./references#CD012955-bbs2-0404" title="StorebøOJ , SimonsenE . Is ADHD an early stage in the development of borderline personality disorder?Nordic Journal of Psychiatry2014;68(5):289-95. [DOI: 10.3109/08039488.2013.841992] [PMID: 24117059]">Storebø 2014</a>; <a href="./references#CD012955-bbs2-0411" title="TomkoRL , TrullTJ , WoodPK , SherKJ . Characteristics of borderline personality disorder in a community sample: comorbidity, treatment utilization, and general functioning. Journal of Personality Disorders2014;28(5):734-50. [DOI: doi.org/10.1521/pedi_2012_26_093] [PMC3864176] [PMID: 25248122]">Tomko 2014</a>). Suicidal behaviour is reported to occur in up to 84% of people diagnosed with BPD (<a href="./references#CD012955-bbs2-0300" title="GoodmanM , RoiffT , OakesAH , ParisJ . Suicidal risk and management in borderline personality disorder. Current Psychiatry Reports2012;14(1):79-85. [DOI: doi.org/10.1007/s11920-011-0249-4] [PMID: 22113831]">Goodman 2012</a>; <a href="./references#CD012955-bbs2-0397" title="SoloffPH , LynchKG , KellyTM . Childhood abuse as a risk factor for suicidal behavior in borderline personality disorder. Journal of Personality Disorders2002;16(3):201-14. [PMID: 12136678]">Soloff 2002</a>), and it is estimated that up to 10% of those affected by BPD will die from suicide (<a href="./references#CD012955-bbs2-0379" title="ParisJ . Suicidality in borderline personality disorder. Medicina2019;55(6):E223. [DOI: 10.3390/medicina55060223] [PMCID: PMC6632023] [PMID: 31142033]">Paris 2019</a>). Comorbid mood disorders or substance use disorders are the most common risk factors associated with successful suicide attempts (<a href="./references#CD012955-bbs2-0256" title="BlackDW , BlumN , PfohlB , HaleN . Suicidal behavior in borderline personality disorder: prevalence, risk factors, prediction, and prevention. Journal of Personality Disorders2004;18(3):226-39. [DOI: 10.1521/pedi.18.3.226.35445] [PMID: 15237043]">Black 2004</a>; <a href="./references#CD012955-bbs2-0290" title="DoyleM , WhileD , MokPL , WindfuhrK , Ashcroft, DM, KontopantelisE , et al. Suicide risk in primary care patients diagnosed with a personality disorder: a nested case control study. BMC Family Practice2016;17:106. [DOI: 10.1186/s12875-016-0479-y] [PMC4974738] [PMID: 27495284]">Doyle 2016</a>; <a href="./references#CD012955-bbs2-0426" title="YenS , SheaMT , SanislowCA , GriloCM , SkodolAE , GundersonJG , et al. Borderline personality disorder criteria associated with prospectively observed suicidal behavior. American Journal of Psychiatry2004;161(7):1296-8. [DOI: doi.org/10.1176/appi.ajp.161.7.1296] [PMID: 15229066]">Yen 2004</a>). </p> <p>Although the short‐ to medium‐term social functioning of people with BPD is poor, diagnostic remission is around 85% within 10 years (<a href="./references#CD012955-bbs2-0308" title="GundersonJG , StoutRL , McGlashanTH , SheaMT , MoreyLC , GriloCM , et al. Ten-year course of borderline personality disorder: psychopathology and function from the Collaborative Longitudinal Personality Disorders study. Archives of General Psychiatry2011;68(8):827-37. [DOI: doi.org/10.1001/archgenpsychiatry.2011.37] [PMC3158489] [PMID: 21464343]">Gunderson 2011b</a>; <a href="./references#CD012955-bbs2-0437" title="ZanariniMC , FrankenburgFR , ReichDB , SilkKR , HudsonJI , McSweeneyLB . The subsyndromal phenomenology of borderline personality disorder: a 10-year follow-up study. American Journal of Psychiatry2007;164(6):929-35. [DOI: 10.1176/ajp.2007.164.6.929] [PMID: 17541053]">Zanarini 2007</a>). Here, however, remission only means that diagnostic criteria are not fulfilled; it does not indicate the absence of any symptoms. Indeed, whereas acute symptoms — such as self‐mutilation, help‐seeking suicide threats or attempts and impulsivity — decrease with time in most cases, affective symptoms reflecting areas of chronic dysphoria, such as chronic feelings of emptiness, intense anger or profound feelings of abandonment, largely remain (<a href="./references#CD012955-bbs2-0437" title="ZanariniMC , FrankenburgFR , ReichDB , SilkKR , HudsonJI , McSweeneyLB . The subsyndromal phenomenology of borderline personality disorder: a 10-year follow-up study. American Journal of Psychiatry2007;164(6):929-35. [DOI: 10.1176/ajp.2007.164.6.929] [PMID: 17541053]">Zanarini 2007</a>). Therefore, the majority of people with BPD still have significant levels of symptoms and experience severe and persistent impairment in social functioning over time (<a href="./references#CD012955-bbs2-0340" title="KongerslevMT , ChanenAM , SimonsenE . Personality disorder in childhood and adolescence comes of age: a review of the current evidence and prospects for future research. Scandinavian Journal of Child and Adolescent Psychiatry and Psychology2015;3(1):31-48. [DOI: 10.21307/sjcapp-2015-004]">Kongerslev 2015</a>; <a href="./references#CD012955-bbs2-0369" title="NgFY , BourkeME , GrenyerBFS . Recovery from borderline personality disorder: a systematic review of the perspectives of consumers, clinicians, family and carers. PLOS One2016;11(8):e0160515. [DOI: 10.1371/journal.pone.0160515] [PMC4978398] [PMID: 27504634]">Ng 2016</a>). Risk factors for poor, long‐term outcomes are comorbid substance use disorders, PTSD, and anxiety cluster disorders (<a href="./references#CD012955-bbs2-0436" title="ZanariniMC , FrankenburgFR , HennenJ , ReichDB , SilkKR . The McLean Study of Adult Development (MSAD): overview and implications of the first six years of prospective follow-up. Journal of Personality Disorders2005;19(5):505-23. [DOI: 10.1521/pedi.2005.19.5.505] [PMID: 16274279]">Zanarini 2005</a>; <a href="./references#CD012955-bbs2-0437" title="ZanariniMC , FrankenburgFR , ReichDB , SilkKR , HudsonJI , McSweeneyLB . The subsyndromal phenomenology of borderline personality disorder: a 10-year follow-up study. American Journal of Psychiatry2007;164(6):929-35. [DOI: 10.1176/ajp.2007.164.6.929] [PMID: 17541053]">Zanarini 2007</a>), as well as a family history of psychiatric disorder (especially mood disorders and substance use disorders), demographic issues such as older age, longer treatment history, pathological childhood experiences, temperament issues and adult psychosocial functioning (<a href="./references#CD012955-bbs2-0266" title="ChanenAM , KaessM . Developmental pathways to borderline personality disorder. Current Psychiatry Reports2012;14(1):45-53. [DOI: 10.1007/s11920-011-0242-y] [PMID: 22009682]">Chanen 2012</a>; <a href="./references#CD012955-bbs2-0285" title="De FruytF , De ClercqB . Antecedents of personality disorder in childhood and adolescence: towards an integrative developmental model. Annual Review of Clinical Psychology2014;10:449-76. [DOI: 10.1146/annurev-clinpsy-032813-15364] [PMID: 24471374]">De Fruyt 2014</a>; <a href="./references#CD012955-bbs2-0340" title="KongerslevMT , ChanenAM , SimonsenE . Personality disorder in childhood and adolescence comes of age: a review of the current evidence and prospects for future research. Scandinavian Journal of Child and Adolescent Psychiatry and Psychology2015;3(1):31-48. [DOI: 10.21307/sjcapp-2015-004]">Kongerslev 2015</a>; <a href="./references#CD012955-bbs2-0437" title="ZanariniMC , FrankenburgFR , ReichDB , SilkKR , HudsonJI , McSweeneyLB . The subsyndromal phenomenology of borderline personality disorder: a 10-year follow-up study. American Journal of Psychiatry2007;164(6):929-35. [DOI: 10.1176/ajp.2007.164.6.929] [PMID: 17541053]">Zanarini 2007</a>). </p> <p>People with BPD have severe difficulties in achieving and maintaining vocational and social functioning over time (<a href="./references#CD012955-bbs2-0321" title="HastrupLH , KongerslevMT , SimonsenE . Low vocational outcome among people diagnosed with borderline personality disorder during first admission to mental health services in Denmark: a nationwide 9-year register-based study. Journal of Personality Disorders2019;33(3):326-40. [DOI: 10.1521/pedi_2018_32_344] [PMID: 29505387]">Hastrup 2019a</a>; <a href="./references#CD012955-bbs2-0378" title="ParisJ . The relevance of social capital for the treatment of personality disorders. Personality and Mental Health2014;8(1):24-9. [DOI: 10.1002/pmh.1238]">Paris 2014</a>; <a href="./references#CD012955-bbs2-0438" title="ZanariniMC , FrankenburgFR , ReichDB , FitzmauriceG . The 10-year course of psychosocial functioning among patients with borderline personality disorder and axis II comparison subjects. Acta Psychiatrica Scandinavica2010;122(2):103-9. [DOI: doi:10.1111/j.1600-0447.2010.01543.x] [PMC3876887] [PMID: 20199493]">Zanarini 2010</a>). Furthermore, treatment‐seeking people with personality disorders, such as BPD, pose a high economic burden on society (<a href="./references#CD012955-bbs2-0322" title="HastrupLH , JennumP , IbsenR , KjellbergJ , SimonsenE . Societal costs of borderline personality disorders: a matched-controlled nationwide study of patients and spouses. Acta Psychiatrica Scandinavica2019;140(5):458-67. [DOI: 10.1111/acps.13094] [PMID: 31483859]">Hastrup 2019b</a>; <a href="./references#CD012955-bbs2-0416" title="Van AsseltAD , DirksenCD , ArntzA , SeverensJL . The cost of borderline personality disorder: societal cost of illness in BPD-patients. European Psychiatry2007;22(6):354-61. [DOI: 10.1016/j.eurpsy.2007.04.001] [PMID: 17544636]">Van Asselt 2007</a>). Effective treatments could potentially decrease the high costs associated with the condition (<a href="./references#CD012955-bbs2-0395" title="SoetemanDI , Hakkaart-van RoijenL , VerheulR , BusschbachJJV . The economic burden of personality disorders in mental health care. Journal of Clinical Psychiatry2008;69(2):259–65. [PMID: 18363454]">Soeteman 2008a</a>). The problem of deliberate self‐harm is also a particular issue within this group (<a href="./references#CD012955-bbs2-0236" title="AyodejiE , GreenJ , RobertsC , TrainorG , RothwellJ , WoodhamA , et al. The influence of personality disorder on outcome in adolescent self-harm. British Journal of Psychiatry2015;207(4):313-9. [DOI: 10.1192/bjp.bp.113.138941] [PMID: 26250743]">Ayodeji 2015</a>; <a href="./references#CD012955-bbs2-0340" title="KongerslevMT , ChanenAM , SimonsenE . Personality disorder in childhood and adolescence comes of age: a review of the current evidence and prospects for future research. Scandinavian Journal of Child and Adolescent Psychiatry and Psychology2015;3(1):31-48. [DOI: 10.21307/sjcapp-2015-004]">Kongerslev 2015</a>; <a href="./references#CD012955-bbs2-0350" title="LinehanMM . Behavioral treatments of suicidal behaviors. Definitional obfuscation and treatment outcomes. Annals of the New York Academy of Sciences1997;836:302-28. [DOI: 10.1111/j.1749-6632.1997.tb52367.x] [PMID: 9616806]">Linehan 1997</a>; <a href="./references#CD012955-bbs2-0062" title="ISRCTN95266816. The emergence of personality disorder traits in adolescents who deliberately self harm and the potential for using a mentalisation based treatment approach as an early intervention for such individuals: a randomised controlled trial. www.isrctn.com/ISRCTN95266816 (first received 29 October 2007). RossouwT . Mentalisation based treatment for adolescents with self harm: an RCT. European Child &amp; Adolescent Psychiatry2015;24(1 Suppl):S113. [DOI: 10.1007%2Fs00787-015-0714-4.pdf] [W1-02-02]RossouwT . Self harm in adolescence, is MBT the answer?: an RCT. Adolescent Psychiatry2012;2(1):102. [DOI: 10.2174/2210676611202010077]RossouwTI , FonagyP . Mentalization-based treatment for self-harm in adolescents: a randomized controlled trial. Journal of the American Academy of Child and Adolescent Psychiatry2012;51(12):1304-13.e3. [DOI: 10.1016/j.jaac.2012.09.018] [PMID: 23200287]">Rossouw 2012b</a>). In medical settings, people diagnosed with BPD often present after self‐harming behaviour or in suicidal crisis and are treated in emergency settings, often involving repeated psychiatric hospitalisations (<a href="./references#CD012955-bbs2-0263" title="CailholL , ThalamasC , GarridoC , BirmesP , Lapeyre-MestreM . Mental health service utilization among borderline personality disorder patients inpatient [Utilisation des services de soin par les patients hospitalisés, présentant un trouble de personnalité borderline en Midi-Pyrénées]. L'Encéphale2015;41(2):115-22. [DOI: 10.1016/j.encep.2014.10.008] [PMID: 25526809]">Cailhol 2015</a>). </p> <p>In summary, BPD is a condition that has been studied extensively. It has a major impact on health facilities as those affected often present in crisis. Recovery from symptoms or functional impairment (or both) was previously considered likely for only a small percentage of people diagnosed with BPD. However, the long‐term course, in terms of symptomatic recovery, is favourable (<a href="./references#CD012955-bbs2-0308" title="GundersonJG , StoutRL , McGlashanTH , SheaMT , MoreyLC , GriloCM , et al. Ten-year course of borderline personality disorder: psychopathology and function from the Collaborative Longitudinal Personality Disorders study. Archives of General Psychiatry2011;68(8):827-37. [DOI: doi.org/10.1001/archgenpsychiatry.2011.37] [PMC3158489] [PMID: 21464343]">Gunderson 2011b</a>; <a href="./references#CD012955-bbs2-0437" title="ZanariniMC , FrankenburgFR , ReichDB , SilkKR , HudsonJI , McSweeneyLB . The subsyndromal phenomenology of borderline personality disorder: a 10-year follow-up study. American Journal of Psychiatry2007;164(6):929-35. [DOI: 10.1176/ajp.2007.164.6.929] [PMID: 17541053]">Zanarini 2007</a>; <a href="./references#CD012955-bbs2-0439" title="ZanariniMC , FrankenburgFR , ReichB , FitzmauriceG . Attainment and stability of sustained symptomatic remission and recovery among patients with borderline personality disorder and axis II comparison subjects: a 16-year prospective follow-up study. American Journal of Psychiatry2012;169(5):476-83. [DOI: 10.1176/appi.ajp.2011.11101550] [PMC3509999] [PMID: 22737693]">Zanarini 2012</a>). Nonetheless, people diagnosed with BPD continue to have considerable interpersonal and functional problems, and sustainable recovery appears difficult to attain (<a href="./references#CD012955-bbs2-0255" title="BiskinRS . The lifetime course of borderline personality disorder. Canadian Journal of Psychiatry2015;60(7):303-8. [DOI: 10.1177/070674371506000702] [PMC4500179] [PMID: 26175388]">Biskin 2015</a>; <a href="./references#CD012955-bbs2-0340" title="KongerslevMT , ChanenAM , SimonsenE . Personality disorder in childhood and adolescence comes of age: a review of the current evidence and prospects for future research. Scandinavian Journal of Child and Adolescent Psychiatry and Psychology2015;3(1):31-48. [DOI: 10.21307/sjcapp-2015-004]">Kongerslev 2015</a>; <a href="./references#CD012955-bbs2-0062" title="ISRCTN95266816. The emergence of personality disorder traits in adolescents who deliberately self harm and the potential for using a mentalisation based treatment approach as an early intervention for such individuals: a randomised controlled trial. www.isrctn.com/ISRCTN95266816 (first received 29 October 2007). RossouwT . Mentalisation based treatment for adolescents with self harm: an RCT. European Child &amp; Adolescent Psychiatry2015;24(1 Suppl):S113. [DOI: 10.1007%2Fs00787-015-0714-4.pdf] [W1-02-02]RossouwT . Self harm in adolescence, is MBT the answer?: an RCT. Adolescent Psychiatry2012;2(1):102. [DOI: 10.2174/2210676611202010077]RossouwTI , FonagyP . Mentalization-based treatment for self-harm in adolescents: a randomized controlled trial. Journal of the American Academy of Child and Adolescent Psychiatry2012;51(12):1304-13.e3. [DOI: 10.1016/j.jaac.2012.09.018] [PMID: 23200287]">Rossouw 2012b</a>). </p> </section> <section id="CD012955-sec-0011"> <h3 class="title" id="CD012955-sec-0011">Description of the intervention</h3> <p>About three‐quarters of people with BPD present to mental healthcare professionals (<a href="./references#CD012955-bbs2-0411" title="TomkoRL , TrullTJ , WoodPK , SherKJ . Characteristics of borderline personality disorder in a community sample: comorbidity, treatment utilization, and general functioning. Journal of Personality Disorders2014;28(5):734-50. [DOI: doi.org/10.1521/pedi_2012_26_093] [PMC3864176] [PMID: 25248122]">Tomko 2014</a>), and they are even more likely to do so than people with mood, anxiety, or other personality disorders (<a href="./references#CD012955-bbs2-0227" title="AnsellEB , SanislowCA , McGlashanTH , GriloCM . Psychosocial impairment and treatment utilization by patients with borderline personality disorder, other personality disorders, mood and anxiety disorders, and a healthy comparison group. Comprehensive Psychiatry2007;48(4):329-36. [DOI: 10.1016/j.comppsych.2007.02.001] [PMID: 17560953]">Ansell 2007</a>). Most will receive psychological interventions, because drugs are not effective for the BPD core symptoms (<a href="./references#CD012955-bbs2-0299" title="GoodmanM , PatilU , SteffelL , AvedonJ , SassoS , TriebwasserJ , et al. Treatment utilization by gender in patients with borderline personality disorder. Journal of Psychiatric Practice2010;16(3):155-63. [DOI: 10.1097/01.pra.0000375711.47337.27] [PMID: 20485103]">Goodman 2010</a>; <a href="./references#CD012955-bbs2-0411" title="TomkoRL , TrullTJ , WoodPK , SherKJ . Characteristics of borderline personality disorder in a community sample: comorbidity, treatment utilization, and general functioning. Journal of Personality Disorders2014;28(5):734-50. [DOI: doi.org/10.1521/pedi_2012_26_093] [PMC3864176] [PMID: 25248122]">Tomko 2014</a>), and these psychosocial interventions will often be provided for a relatively long periods of time (e.g. for a period of one year or longer) (<a href="./references#CD012955-bbs2-0227" title="AnsellEB , SanislowCA , McGlashanTH , GriloCM . Psychosocial impairment and treatment utilization by patients with borderline personality disorder, other personality disorders, mood and anxiety disorders, and a healthy comparison group. Comprehensive Psychiatry2007;48(4):329-36. [DOI: 10.1016/j.comppsych.2007.02.001] [PMID: 17560953]">Ansell 2007</a>; <a href="./references#CD012955-bbs2-0440" title="ZanariniMC , FrankenburgFR , ReichDB , ConkeyLC , FitzmauriceGM . Rates of psychiatric treatment reported by patients with borderline personality disorder and other personality disorders over 16 years of prospective follow-up. Psychiatric Services2015;66(1):15-20. [DOI: 10.1176/appi.ps.201400055] [NIHMS597508] [PMC4283568] [PMID: 25270039]">Zanarini 2015</a>). </p> <p>A broad range of psychotherapies exist for BPD. The therapy can be delivered in individual or group formats, or a combination of these two treatment modalities. As for most other mental disorders, psychological interventions can be based on the traditional, major psychotherapeutic schools such as psychodynamic psychotherapy, cognitive behaviour therapy (CBT) or client‐centred/humanistic therapy. In addition, several specific treatment approaches have been developed within recent decades to meet the particular challenges of treating BPD. These disorder‐specific approaches are usually precisely structured and manualised (<a href="./references#CD012955-bbs2-0286" title="De GrootER , VerheulR , TrijsburgRW . An integrative perspective on psychotherapeutic treatments for borderline personality disorders. Journal of Personality Disorders2008;22(4):332-52. [DOI: 10.1521/pedi.2008.22.4.332] [PMID: 18684048]">De Groot 2008</a>; <a href="./references#CD012955-bbs2-0345" title="LevyKN , ClarkinJF , YeomansFE . The mechanisms of change In the treatment of borderline personality disorder with transference focused psychotherapy. Journal of Clinical Psychology2006;62(4):481-501. [DOI: https://doi.org/10.1002/jclp.20239.]">Levy 2006</a>; <a href="./references#CD012955-bbs2-0420" title="WeinbergI , RonningstamE , GoldblattMJ , SchechterM , MaltsbergerJT . Common factors in empirically supported treatments of borderline personality disorder. Current Psychiatry Reports2011;13(1):60-8. [DOI: 10.1007/s11920-010-0167-x] [PMID: 21057901]">Weinberg 2011</a>). Strategies are provided for addressing interpersonal challenges, such as emotional dysregulation and impulsivity, which are core problems for people diagnosed with BPD and could lead to difficulties in forming a therapeutic alliance. Most BPD‐specific psychological interventions involve multimodal therapy, treatment contracts, actively taking measures to minimise premature non‐completion of treatment, providing a crisis intervention protocol and encouraging the affected one's sense of agency (<a href="./references#CD012955-bbs2-0247" title="BatemanA , CampbellC , LuytenP , FonagyP . A mentalization-based approach to common factors in the treatment of borderline personality disorder. Current Opinion in Psychology2018;21:44-49. [DOI: doi:10.1016/j.copsyc.2017.09.005]">Bateman 2018</a>; <a href="./references#CD012955-bbs2-0274" title="ClarkinJF . An integrated approach to psychotherapy techniques for patients with personality disorder. Journal of Personality Disorders2012;26(1):43-62. [DOI: 10.1521/pedi.2012.26.1.43] [PMID: 22369166]">Clarkin 2012</a>; <a href="./references#CD012955-bbs2-0286" title="De GrootER , VerheulR , TrijsburgRW . An integrative perspective on psychotherapeutic treatments for borderline personality disorders. Journal of Personality Disorders2008;22(4):332-52. [DOI: 10.1521/pedi.2008.22.4.332] [PMID: 18684048]">De Groot 2008</a>; <a href="./references#CD012955-bbs2-0340" title="KongerslevMT , ChanenAM , SimonsenE . Personality disorder in childhood and adolescence comes of age: a review of the current evidence and prospects for future research. Scandinavian Journal of Child and Adolescent Psychiatry and Psychology2015;3(1):31-48. [DOI: 10.21307/sjcapp-2015-004]">Kongerslev 2015</a>; <a href="./references#CD012955-bbs2-0355" title="LivesleyWJ . Moving beyond specialized therapies for borderline personality disorder: the importance of integrated domain-focused treatment. Psychodynamic Psychiatry2012;40(1):47-74. [DOI: 10.1521/pdps.2012.40.1.4] [PMID: 23006029]">Livesley 2012</a>; <a href="./references#CD012955-bbs2-0420" title="WeinbergI , RonningstamE , GoldblattMJ , SchechterM , MaltsbergerJT . Common factors in empirically supported treatments of borderline personality disorder. Current Psychiatry Reports2011;13(1):60-8. [DOI: 10.1007/s11920-010-0167-x] [PMID: 21057901]">Weinberg 2011</a>). They are typically highly focused on affect and the therapeutic relationship, with a relatively active therapist implementing interventions within a supportive and validating atmosphere (<a href="./references#CD012955-bbs2-0247" title="BatemanA , CampbellC , LuytenP , FonagyP . A mentalization-based approach to common factors in the treatment of borderline personality disorder. Current Opinion in Psychology2018;21:44-49. [DOI: doi:10.1016/j.copsyc.2017.09.005]">Bateman 2018</a>; <a href="./references#CD012955-bbs2-0274" title="ClarkinJF . An integrated approach to psychotherapy techniques for patients with personality disorder. Journal of Personality Disorders2012;26(1):43-62. [DOI: 10.1521/pedi.2012.26.1.43] [PMID: 22369166]">Clarkin 2012</a>; <a href="./references#CD012955-bbs2-0286" title="De GrootER , VerheulR , TrijsburgRW . An integrative perspective on psychotherapeutic treatments for borderline personality disorders. Journal of Personality Disorders2008;22(4):332-52. [DOI: 10.1521/pedi.2008.22.4.332] [PMID: 18684048]">De Groot 2008</a>; <a href="./references#CD012955-bbs2-0340" title="KongerslevMT , ChanenAM , SimonsenE . Personality disorder in childhood and adolescence comes of age: a review of the current evidence and prospects for future research. Scandinavian Journal of Child and Adolescent Psychiatry and Psychology2015;3(1):31-48. [DOI: 10.21307/sjcapp-2015-004]">Kongerslev 2015</a>; <a href="./references#CD012955-bbs2-0355" title="LivesleyWJ . Moving beyond specialized therapies for borderline personality disorder: the importance of integrated domain-focused treatment. Psychodynamic Psychiatry2012;40(1):47-74. [DOI: 10.1521/pdps.2012.40.1.4] [PMID: 23006029]">Livesley 2012</a>; <a href="./references#CD012955-bbs2-0420" title="WeinbergI , RonningstamE , GoldblattMJ , SchechterM , MaltsbergerJT . Common factors in empirically supported treatments of borderline personality disorder. Current Psychiatry Reports2011;13(1):60-8. [DOI: 10.1007/s11920-010-0167-x] [PMID: 21057901]">Weinberg 2011</a>). Eclectic therapy is an open, integrative form of psychotherapy, which adapts to the unique needs of each specific client, depending on the problem, the treatment goals and the person’s expectations and motivation (<a href="./references#CD012955-bbs2-0387" title="SansoneR , LevittJ . Personality Disorders and Eating Disorders. New York: Routledge, 2006. [DOI: https://doi.org/10.4324/9780203957097]">Sansone 2006</a>). Eclectic therapies integrate elements from different forms of psychotherapy. </p> <p>Among the specific psychological interventions for people diagnosed with BPD, the most commonly used are: transference‐focused therapy (<a href="./references#CD012955-bbs2-0273" title="ClarkinJF , YeomansFE , KernbergOF . Psychotherapy for Borderline Personality. New York (NY): John Wiley &amp; Sons, Inc., 1999.">Clarkin 1999</a>; <a href="./references#CD012955-bbs2-0427" title="YeomansFE , ClarkinJF , KernbergOF . Transference-Focused Psychotherapy for Borderline Personality Disorder: A Clinical Guide. Arlington (VA): American Psychiatric Publishing, 2015. [ISBN 978-1-58562-437-9]">Yeomans 2015</a>); mentalisation‐based treatment (<a href="./references#CD012955-bbs2-0243" title="BatemanA , FonagyP . Psychotherapy for Borderline Personality Disorder: Mentalisation Based Treatment. Oxford (UK): Oxford University Press, 2004. [ISBN 978-0-19-852766-4]">Bateman 2004</a>; <a href="./references#CD012955-bbs2-0244" title="BatemanA , FonagyP . Mentalization-Based Treatment for Borderline Personality Disorders: A Practical Guide. Oxford (UK): Oxford University Press, 2006. [ISBN 978-0-19-857090-5]">Bateman 2006</a>; <a href="./references#CD012955-bbs2-0246" title="BatemanA , FonagyP . Mentalization-Based Treatment for Personality Disorders: A Practical Guide. Oxford (UK): Oxford University Press, 2016. [ISBN 019968037X]">Bateman 2016</a>); dialectical behaviour therapy (<a href="./references#CD012955-bbs2-0348" title="LinehanMM . Cognitive-Behavioral Treatment of Borderline Personality Disorder. New York (NY): Guilford Press, 1993. [ISBN 0-89862-183-6]">Linehan 1993a</a>; <a href="./references#CD012955-bbs2-0351" title="LinehanMM . DBT® Skills Training Manual. 2nd edition. New York (NY): Guilford Press, 2015. [ISBN 978-1-4625-1699-5]">Linehan 2015b</a>); cognitive analytic therapy (<a href="./references#CD012955-bbs2-0268" title="ChanenAM , McCutcheonL , KerrIB . HYPE: a cognitive analytic therapy-based prevention and early intervention programme for borderline personality disorder. In: SharpC , TackettJL , editors(s). Handbook of Borderline Personality Disorder in Children and Adolescents. New York (NY): Springer, 2014:361-83. [ISBN 978-1-4939-0590-4]">Chanen 2014</a>; <a href="./references#CD012955-bbs2-0386" title="RyleA . Cognitive Analytic Therapy and Borderline Personality Disorder: The Model and the Method. Chichester (UK): John Wiley &amp; Sons, Inc., 1997. [ISBN-13: 978-0471976189]">Ryle 1997</a>); schema‐focused therapy (<a href="./references#CD012955-bbs2-0234" title="ArntzA , Van GenderenH . Schema Therapy for Borderline Personality Disorder. Chichester (UK): Wiley-Blackwell, 2009. [ISBN 978-0-470-51080-3]">Arntz 2009</a>; <a href="./references#CD012955-bbs2-0428" title="YoungJE , KloskoJS , WeishaarME . Schema Therapy: A Practitioner's Guide. New York (NY): Guilford Press, 2003.">Young 2003</a>); and the systems training for emotional predictability and problem‐solving (STEPPS) (<a href="./references#CD012955-bbs2-0257" title="BlackDW , BlumN , St JohnD . STEPPS: a practical, evidence-based way to treat borderline personality disorder. Current Psychiatry2009;8:31-7.">Black 2009</a>). Most of these treatments are designed as outpatient treatments of six to 24 months duration, with once or twice weekly individual sessions. Some also include additional group therapy sessions, inpatient or day‐hospital therapeutic community treatment and psychoeducation. Other potential therapies for BPD include the likes of CBT (<a href="./references#CD012955-bbs2-0251" title="BeckAT , FreemanA . Cognitive Therapy of Personality Disorder. New York (NY): Guilford Press, 2003.">Beck 2003</a>), acceptance and commitment therapy (ACT; <a href="./references#CD012955-bbs2-0026" title="Gratz KL. Important: question regarding your BPD trial for systematic review in Cochrane Collaboration [personal communication]. Email to: J Stoffers-Winterling 11 December 2010. GratzKL , GundersonJG . Preliminary data on an acceptance-based emotion regulation group intervention for deliberate self-harm among women with borderline personality disorder. Behavior Therapy2006;37(1):25-35. [DOI: 10.1016/j.beth.2005.03.002] [PMID: 16942958]">Gratz 2006</a>), interpersonal psychotherapy (IPT; <a href="./references#CD012955-bbs2-0360" title="MarkowitzJC , SkodolAE , BleibergK . Interpersonal psychotherapy for borderline personality disorder: possible mechanisms of change. Journal of Clinical Psychology2006;62(4):431-44. [DOI: 10.1002/jclp.20242] [PMID: 16470711]">Markowitz 2006</a>), and psychodynamic psychotherapy (e.g. psychoanalytic‐interactional therapy; <a href="./references#CD012955-bbs2-0405" title="StreeckU , LeichsenringF . Handbuch Psychoanalytisch-Interaktionelle Therapie. Zur Behandlung von Patienten mit Strukturellen Störungen und Schweren Persönlichkeitsstörungen. Göttingen (NI): Vandenhoeck &amp; Ruprecht, 2009.">Streeck 2009</a>). Broadly speaking, psychodynamic therapies aim to help people understand and reflect on their inner mental processes and make links between their past and current difficulties. Treatments based on CBT place emphasis on self‐directed learning processes: people are encouraged to identify their core beliefs; evaluate and modify their behaviour accordingly; and gain new experiences. Psychotherapy is defined as the "treatment of mental illness or emotional disturbances primarily by verbal or nonverbal communication" (quote; <a href="./references#CD012955-bbs2-0372" title="US National Library of Medicine. Medical Subject Headings (MeSH Browser). meshb.nlm.nih.gov/search (accessed 31 March 2009).">NLM 2009</a>). </p> <p><b>Dialectical behavioural therapy</b> (DBT; <a href="./references#CD012955-bbs2-0348" title="LinehanMM . Cognitive-Behavioral Treatment of Borderline Personality Disorder. New York (NY): Guilford Press, 1993. [ISBN 0-89862-183-6]">Linehan 1993a</a>) is a highly structured and complex psychological therapy that was developed using some of the principles of CBT in combination with mindfulness‐based and Zen‐Buddhistic and dialectical thinking strategies. It aims to change behaviour and enhance the ability to tolerate difficult or painful feelings by focusing on improving skills in stress tolerance, emotion regulation, interpersonal behaviour, and mindfulness. </p> <p><b>Mentalisation‐based therapy</b> (<a href="./references#CD012955-bbs2-0243" title="BatemanA , FonagyP . Psychotherapy for Borderline Personality Disorder: Mentalisation Based Treatment. Oxford (UK): Oxford University Press, 2004. [ISBN 978-0-19-852766-4]">Bateman 2004</a>; <a href="./references#CD012955-bbs2-0246" title="BatemanA , FonagyP . Mentalization-Based Treatment for Personality Disorders: A Practical Guide. Oxford (UK): Oxford University Press, 2016. [ISBN 019968037X]">Bateman 2016</a>) is a complex psychodynamic and attachment‐based psychological therapy programme that aims to increase the reflective functioning or mentalising capacity of the individual, helping the person to understand and recognise the feelings they evoke in others and the feelings they experience themselves, as well as improving the capacity for emotion regulation in interpersonal relations. </p> <p><b>Schema‐focused therapy</b> (SFT; <a href="./references#CD012955-bbs2-0428" title="YoungJE , KloskoJS , WeishaarME . Schema Therapy: A Practitioner's Guide. New York (NY): Guilford Press, 2003.">Young 2003</a>) draws from both cognitive‐behavioural and psychoanalytic theories and helps people with BPD to identify their self‐defeating core themes arising from unmet emotional needs in childhood and presenting as maladaptive coping styles in adulthood. The goal of SFT is to aid people affected by BPD in getting their needs met in adaptive ways. </p> <p><b>Transference‐focused psychotherapy</b> (TFP; <a href="./references#CD012955-bbs2-0273" title="ClarkinJF , YeomansFE , KernbergOF . Psychotherapy for Borderline Personality. New York (NY): John Wiley &amp; Sons, Inc., 1999.">Clarkin 1999</a>) strives to achieve integrated representations of self and others, modification of primitive defence operations, and resolution of identity diffusion by analysis of the transference within the therapeutic relationship. Primitive object relations, which can be polarised and split, may be transformed to advanced or mature object relations characterised by more integrated object relations. TFP relies on techniques of clarification, confrontation and transference interpretation within the relationship between patient and therapist. </p> <p><b>Cognitive analytic therapy</b> (CAT; <a href="./references#CD012955-bbs2-0386" title="RyleA . Cognitive Analytic Therapy and Borderline Personality Disorder: The Model and the Method. Chichester (UK): John Wiley &amp; Sons, Inc., 1997. [ISBN-13: 978-0471976189]">Ryle 1997</a>) assumes that people with BPD typically experience rapid switching from one self‐state to another in a dissociate manner. The aim is to work with the patient cognitively, to identify procedural sequences, chains of events, emotions, thoughts and motivations, in order to understand how a target problem (like self‐harm) is established and maintained, and to identify reciprocal roles (i.e. how early experiences are replayed later in life). </p> <p><b>Systems training for emotional predictability and problem‐solving</b> (STEPPS; <a href="./references#CD012955-bbs2-0257" title="BlackDW , BlumN , St JohnD . STEPPS: a practical, evidence-based way to treat borderline personality disorder. Current Psychiatry2009;8:31-7.">Black 2009</a>) combines group‐based psychoeducation with skills training, and targets biased social cognition driven by cognitive filters or schemas. </p> <p><b>Dynamic deconstructive psychotherapy (DDP)</b> is a manualised, 12‐ to 18‐month treatment for adults diagnosed with BPD and other complex co‐occurring disorders such as substance use disorders, additional personality disorders or eating disorders (<a href="./references#CD012955-bbs2-0303" title="GregoryRJ , RemenAL . A manual-based psychodynamic therapy for treatment-resistant borderline personality disorder. Psychotherapy: Theory, Research, Practice, Training2008;45:15-27.">Gregory 2008</a>; <a href="./references#CD012955-bbs2-0304" title="GregoryRJ , DeLucia-DeranjaE , MogleJA . Dynamic deconstructive psychotherapy versus optimized community care for borderline personality disorder co-occurring with alcohol use disorders: a 30-month follow-up.. Journal of Nervous and Mental Disease2010;198(4):292-8. [DOI: doi:10.1097/NMD.0b013e3181d6172d]">Gregory 2010</a>). The DDP model of BPD pathology draws on and combines elements of translational neuroscience, object relations theory, and the philosophy of deconstruction. The aim of DDP is to help people with BPD to connect with and verbalise their experience better, as well as to foster better interpersonal relations and self‐acceptance. DDP was used in a randomised controlled trial (RCT) conducted by its developer (<a href="./references#CD012955-bbs2-0303" title="GregoryRJ , RemenAL . A manual-based psychodynamic therapy for treatment-resistant borderline personality disorder. Psychotherapy: Theory, Research, Practice, Training2008;45:15-27.">Gregory 2008</a>). </p> <p><b>Relaxation techniques</b> and <b>patient education programmes</b> will be considered their own intervention class (i.e. not CBT or psychoanalytically based), as long as they are not explicitly grounded in or taken from a specific treatment approach (such as psychoeducation according to the DBT approach, CBT, or the SFT approach, etc.). </p> </section> <section id="CD012955-sec-0012"> <h3 class="title" id="CD012955-sec-0012">How the intervention might work</h3> <p>Evidence‐based psychological therapies are based on assumptions about causality, core symptoms, and maintenance of the disorder (<a href="./references#CD012955-bbs2-0334" title="KazdinAE . Psychotherapy for children and adolescents. In: LambertMJ , editors(s). Bergin and Garfield's Handbook of Psychotherapy and Behavior Change. 5th edition. New York (NY): John Wiley &amp; Sons, Inc., 2004:543-89. [ISBN 0-471-37755-4]">Kazdin 2004</a>; <a href="./references#CD012955-bbs2-0353" title="LivesleyWJ . Practical Management of Personality Disorder. New York (NY): Guilford Press, 2003. [ISBN 1-57230-889-3]">Livesley 2003</a>; <a href="./references#CD012955-bbs2-0354" title="LivesleyWJ . Changing ideas about the treatment of borderline personality disorder. Journal of Contemporary Psychotherapy2004;34(3):185-92. [DOI: 10.1023/B:JOCP.0000036697.03467.27]">Livesley 2004</a>). The various psychotherapeutic approaches to BPD claim different mechanisms of action according to their respective models of causation (<a href="./references#CD012955-bbs2-0309" title="GundersonJG , FruzzettiA , UnruhB , Choi-KainL . Competing theories of borderline personality disorder. Journal of Personality Disorders2018;32(2):148-67. [DOI: 10.1521/pedi.2018.32.2.148] [PMID: 29561723]">Gunderson 2018</a>; <a href="./references#CD012955-bbs2-0329" title="HuprichSK . Personality Disorders: Toward Theoretical and Empirical Integration in Diagnosis and Assessment. Washington (DC): American Psychological Association, 2015. [ISBN 978-1-4228-1846-2]">Huprich 2015</a>; <a href="./references#CD012955-bbs2-0354" title="LivesleyWJ . Changing ideas about the treatment of borderline personality disorder. Journal of Contemporary Psychotherapy2004;34(3):185-92. [DOI: 10.1023/B:JOCP.0000036697.03467.27]">Livesley 2004</a>; <a href="./references#CD012955-bbs2-0356" title="LivesleyWJ , DimaggioG , ClarkinJF , editor(s). Integrated Treatment for Personality Disorder: A Modular Approach. New York (NY): Guilford Press, 2016. [ISBN 978-1-4625-2288-0]">Livesley 2016</a>). However, they also contain a number of common elements that can account for why a number of seemingly different approaches appear to be effective in ameliorating BPD symptoms (<a href="./references#CD012955-bbs2-0245" title="BatemanAW , GundersonJ , MulderR . Treatment of personality disorder. Lancet2015;385(9969):735-43. [DOI: 10.1016/S0140-6736(14)61394-5]">Bateman 2015</a>; <a href="./references#CD012955-bbs2-0298" title="FonagyP , AllisonE . The role of mentalizing and epistemic trust in the therapeutic relationship. Psychotherapy2014;51(3):372-80. [DOI: 10.1037/a0036505] [PMID: 24773092]">Fonagy 2014</a>; <a href="./references#CD012955-bbs2-0340" title="KongerslevMT , ChanenAM , SimonsenE . Personality disorder in childhood and adolescence comes of age: a review of the current evidence and prospects for future research. Scandinavian Journal of Child and Adolescent Psychiatry and Psychology2015;3(1):31-48. [DOI: 10.21307/sjcapp-2015-004]">Kongerslev 2015</a>; <a href="./references#CD012955-bbs2-0420" title="WeinbergI , RonningstamE , GoldblattMJ , SchechterM , MaltsbergerJT . Common factors in empirically supported treatments of borderline personality disorder. Current Psychiatry Reports2011;13(1):60-8. [DOI: 10.1007/s11920-010-0167-x] [PMID: 21057901]">Weinberg 2011</a>), including: a clear and highly structured treatment framework; an explicit model of BPD symptomatology; a consistent focus on the therapeutic relationship, affect regulation, tolerance of emotional states, and biases in social cognition; a high priority given to self‐harm and suicidal behaviour; active therapists who deliver both support and validation as well as explorative and change‐oriented interventions; mix of treatment formats (e.g. includes both individual and group therapy); and therapist support in the form of supervision and regular meetings. The symptoms of BPD are addressed using the following therapeutic approaches. Following <a href="./references#CD012955-bbs2-0420" title="WeinbergI , RonningstamE , GoldblattMJ , SchechterM , MaltsbergerJT . Common factors in empirically supported treatments of borderline personality disorder. Current Psychiatry Reports2011;13(1):60-8. [DOI: 10.1007/s11920-010-0167-x] [PMID: 21057901]">Weinberg 2011</a>: </p> <p> <ol id="CD012955-list-0001"> <li> <p>'emotional dysregulation' (e.g. intense anger and affective instability) is addressed through attention to affect, including raising awareness of emotional states, their triggers, and enhancing tolerance and regulative strategies; </p> </li> <li> <p>'behavioural dysregulation' (e.g. impulsivity, self‐harm and suicidal behaviours) is addressed through change‐oriented interventions, including, for example, challenging negative thoughts, skills training, behavioural experiments, praise, and limit setting; and </p> </li> <li> <p>'interpersonal dysfunction' (e.g. unstable relationships and stress‐related paranoid ideation) is treated using interventions that enhance the social‐cognitive (or mentalising) capacities of the BPD patient, through making basic and often negatively biased automatic assumptions explicit and more realistic or adaptive, and through paying attention to the establishment and maintenance of a safe and sound working alliance within the therapy sessions. </p> </li> </ol> </p> <p>There is a risk that psychological therapies might not be helpful for all people affected by BPD, either due to the interventions delivered or through factors in the therapeutic relationship (<a href="./references#CD012955-bbs2-0340" title="KongerslevMT , ChanenAM , SimonsenE . Personality disorder in childhood and adolescence comes of age: a review of the current evidence and prospects for future research. Scandinavian Journal of Child and Adolescent Psychiatry and Psychology2015;3(1):31-48. [DOI: 10.21307/sjcapp-2015-004]">Kongerslev 2015</a>; <a href="./references#CD012955-bbs2-0347" title="LilienfeldSO . Psychological treatments that cause harm. Perspectives on Psychology Science2007;2(1):53-70. [DOI: doi: 10.1111/j.1745-6916.2007.00029.x] [PMID: 26151919]">Lilienfeld 2007</a>; <a href="./references#CD012955-bbs2-0380" title="ParryGD , CrawfordMJ , DugganC . Iatrogenic harm from psychological therapies - time to move on. British Journal of Psychiatry2016;208(3):210-2. [DOI: 10.1192/bjp.bp.115.163618] [PMID: 26932481]">Parry 2016</a>), and very little research has been done on this in people with BPD. The effectiveness of the therapy depends on the skills of the therapist to create the possibility for change with each patient. There is, therefore, the added complexity that the relationship or working alliance between the therapist and the patient itself is an ‘active ingredient’ of the therapy and that the quality of this relationship is an important predictor of outcome (<a href="./references#CD012955-bbs2-0327" title="HorvathAO , Del ReAC , FlückigerC , SymondsD . Alliance in individual psychotherapy. Psychotherapy2011;48(1):9-16. [DOI: 10.1037/a0022186] [PMID: 21401269]">Horvath 2011</a>; <a href="./references#CD012955-bbs2-0373" title="NorcrossJC , editor(s). Psychotherapy Relationships That Work: Evidence-Based Responsiveness. 2nd edition. New York (NY): Oxford University Press, Inc., 2011. [ISBN 978-0-19-973720-8]">Norcross 2011</a>). There is no guarantee that the therapy will deliver what was specified in the manual or what was investigated in a randomised clinical trial (<a href="./references#CD012955-bbs2-0380" title="ParryGD , CrawfordMJ , DugganC . Iatrogenic harm from psychological therapies - time to move on. British Journal of Psychiatry2016;208(3):210-2. [DOI: 10.1192/bjp.bp.115.163618] [PMID: 26932481]">Parry 2016</a>). </p> </section> <section id="CD012955-sec-0013"> <h3 class="title" id="CD012955-sec-0013">Why it is important to do this review</h3> <p>People with BPD and their family and friends experience high levels of psychological suffering. BPD is associated with considerable social costs in terms of service use (e.g. presentation to emergency clinics due to self‐harm or suicidal crises and repeated hospitalisations) and poor psychosocial functioning (e.g. inability to complete education or get/maintain a job). Consequently, identification of effective psychological therapies for BPD is important (<a href="./references#CD012955-bbs2-0442" title="Stoffers-WinterlingJM , VöllmBA , RückerG , TimmerA , HubandN , LiebK . Psychological therapies for people with borderline personality disorder. Cochrane Database of Systematic Reviews2012, Issue 8. Art. No: CD005652. [DOI: 10.1002/14651858.CD005652.pub2]">Stoffers‐Winterling 2012</a>). </p> <p>Our review aims to provide a systematic summary of the evidence from randomised controlled trials (RCTs) in order to help people with BPD, their family and friends, mental healthcare workers, and policy and decision managers in general, to make informed decisions about evidence‐based treatment for BPD. </p> <p>This review is an update of two previous Cochrane Reviews on psychological therapies for BPD (<a href="./references#CD012955-bbs2-0441" title="BinksC , FentonM , McCarthyL , LeeT , AdamsCE , DugganC . Psychological therapies for people with borderline personality disorder. Cochrane Database of Systematic Reviews2006, Issue 1. Art. No: CD005652. [DOI: 10.1002/14651858.CD005652]">Binks 2006</a>; <a href="./references#CD012955-bbs2-0442" title="Stoffers-WinterlingJM , VöllmBA , RückerG , TimmerA , HubandN , LiebK . Psychological therapies for people with borderline personality disorder. Cochrane Database of Systematic Reviews2012, Issue 8. Art. No: CD005652. [DOI: 10.1002/14651858.CD005652.pub2]">Stoffers‐Winterling 2012</a>). In addition to updating the two former Cochrane Reviews, our study also seeks to address some of the methodological limitations of both past and current reviews (<a href="./references#CD012955-bbs2-0245" title="BatemanAW , GundersonJ , MulderR . Treatment of personality disorder. Lancet2015;385(9969):735-43. [DOI: 10.1016/S0140-6736(14)61394-5]">Bateman 2015</a>; <a href="./references#CD012955-bbs2-0280" title="CristeaIA , GentiliC , CotetCD , PalombaD , BarbuiC , CuijpersP . Efficacy of psychotherapies for borderline personality disorder: a systematic review and meta-analysis. JAMA Psychiatry2017;74(4):319-28. [DOI: doi:10.1001/jamapsychiatry.2016.4287] [PMID: 28249086]">Cristea 2017</a>; <a href="./references#CD012955-bbs2-0339" title="KliemS , KrögerC , KosfelderJ . Dialectical behavior therapy for borderline personality disorder: a meta-analysis using mixed-effects modeling. Journal of Consulting and Clinical Psychology2010;78(6):936-51. [DOI: 10.1037/a0021015] [PMID: 21114345]">Kliem 2010</a>), by using updated methods, including a more comprehensive search strategy. We also had a new protocol published prior to conducting this review (<a href="./references#CD012955-bbs2-0443" title="StorebøOJ , Stoffers-WinterlingJM , VöllmBA , KongerslevMT , MattiviJT , KielsholmML , et al. Psychological therapies for people with borderline personality disorder. Cochrane Database of Systematic Reviews2018, Issue 2. Art. No: CD012955. [DOI: 10.1002/14651858.CD012955]">Storebø 2018</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD012955-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD012955-sec-0014"></div> <p>To assess the beneficial and harmful effects of psychological therapies for people with BPD. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD012955-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD012955-sec-0015"></div> <section id="CD012955-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD012955-sec-0017"> <h4 class="title">Types of studies</h4> <p>Randomised controlled trials (RCTs).</p> </section> <section id="CD012955-sec-0018"> <h4 class="title">Types of participants</h4> <p>Persons of all ages, in any setting, with a formal, categorical diagnosis of BPD according to the <i>Diagnostic and Statistical Manual of Mental Disorders</i> (DSM) Third Edition (DSM‐III; <a href="./references#CD012955-bbs2-0228" title="American Psychiatric Asssociation. Diagnostic and Statistical Manual of Mental Disorders (DSM-III). 3rd edition. Washington (DC): American Psychiatric Association, 1980. [ISBN 978-0-89042-0416]">APA 1980</a>), Third Edition Revised (DSM‐III‐R; <a href="./references#CD012955-bbs2-0229" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-III-R). 3rd edition. Washington (DC): American Psychiatric Association, 1987. [ISBN 978-0-89042-0195]">APA 1987</a>), Fourth Edition (DSM‐IV; <a href="./references#CD012955-bbs2-0230" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). 4th edition. Washington (DC): American Psychiatric Association, 1994. [ISBN 978-0-89042-0610]">APA 1994</a>), Fourth Edition Text Revision (DSM‐IV‐TR; <a href="./references#CD012955-bbs2-0231" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR), 4th edition, text revision. Washington (DC): American Psychiatric Association, 2000. [ISBN 978-0-89042-0256]">APA 2000</a>), and Fifth Edition (DSM‐5; <a href="./references#CD012955-bbs2-0232" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-5). 5th edition. Washington (DC): American Psychiatric Association, 2013. [ISBN 978-0-89042-554-1]">APA 2013</a>), and the International Classification of Diseases and Related Health Problems (ICD) 10th version (<a href="./references#CD012955-bbs2-0422" title="World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders: Diagnostic Criteria for Research. Geneva (CH): World Health Organization, 1993.">WHO 1993</a>), with or without comorbid conditions. </p> <p>To meet our inclusion criteria, at least 70% of participants of a respective trial had to have a formal diagnosis of BPD. We included trials involving subsamples of people with BPD when data on those with BPD were provided separately (we asked for separate data from trials including less than 70% BPD participants). We did not include trials that focused on people with mental impairment, organic brain disorder, dementia or other severe neurologic/neurodevelopmental diseases. </p> </section> <section id="CD012955-sec-0019"> <h4 class="title">Types of interventions</h4> <p>Any defined psychological intervention regardless of theoretical orientation (e.g. psychodynamic therapy, CBT, systemic therapy or eclectic therapies designed for BPD treatment), in any kind of treatment setting (e.g. inpatient, outpatient or day clinic), compared to: </p> <p> <ol id="CD012955-list-0002"> <li> <p>control interventions, such as standard care, treatment‐as‐usual (TAU), waiting list or no treatment; and </p> </li> <li> <p>specific psychotherapeutic interventions (that were well defined and theory driven).</p> </li> </ol> </p> <p>We divided control interventions into two categories: The first category was “waiting list/no treatment”: participants did not receive any treatment or support from the study centre (like, e.g. clinical management, regular medical review, or support/encouragement to find a therapist outside the study centre). The second category, “TAU” included any other kinds of controls: participants were either free to use any treatment except from the respective experiential treatment (optional TAU), or they received usual community treatment, or standardised usual care (obligatory TAU). </p> <p>We pooled the different types of TAU into one comparison in our main analyses, and compared the effects between the two types of TAU as well as the effect observed by comparison to TAU controls to the effects of comparisons to waiting‐list/no treatment controls (see <a href="#CD012955-sec-0040">Subgroup analysis and investigation of heterogeneity</a>). </p> <p>We allowed concomitant treatments provided they were applied to both treatment conditions.</p> <p>We accepted trials with active controls, including relaxation techniques such as autogenic training or meditation regimens, or patient education programmes such as self‐management and community‐based education programmes. </p> </section> <section id="CD012955-sec-0020"> <h4 class="title">Types of outcome measures</h4> <p>Outcomes were either self‐rated by the persons with BPD or observer‐rated by clinicians, with clinician‐rated outcomes being preferred. We included only adequately validated measures (plus spontaneous reporting of adverse effects). </p> <p>We analysed all outcomes at post‐treatment and at six months follow‐up or longer.</p> <section id="CD012955-sec-0021"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD012955-list-0003"> <li> <p>BPD symptom severity, assessed by, for example, the Zanarini Rating Scale for Borderline Personality Disorder (Zan‐BPD; <a href="./references#CD012955-bbs2-0433" title="ZanariniMC , VujanovicAA , ParachiniEA , BoulangerJL , FrankenburgFR , HennenJ . Zanarini Rating Scale for Borderline Personality Disorder (Zan-BPD): a continuous measure of DSM-IV borderline psychopathology. Journal of Personality Disorders2003;17(3):233-42. [DOI: 10.1521/pedi.17.3.233.22147] [PMID: 12839102]">Zanarini 2003a</a>); the Borderline Personality Disorder Severity Index, Fourth version (BPDSI‐IV; <a href="./references#CD012955-bbs2-0233" title="ArntzA , Van den HoornM , CornelisJ , VerheulR , Van den BoschW , De BieAJ . Reliability and validity of the borderline personality disorder severity index. Journal of Personality Disorders2003;17(1):45-59. [PMID: 12659546]">Arntz 2003</a>) or the Clinical Global Impression Scale for people with Borderline Personality Disorder (CGI‐BPD; <a href="./references#CD012955-bbs2-0381" title="PerezV , BarrachinaJ , SolerJ , PascualJC , CampinsMJ , PuigdemontD , et al. The clinical global impression scale for borderline personality disorder patients (CGI-BPD): a scale sensible to detect changes [Impresión clinica global para pacientes con trastorno límite de la personalidad (ICG-TLP): una escala sensible al cambio]. Actas Espanolas de Psiquiatria2007;35(4):229-35. [PMID: 17592784]">Perez 2007</a>). </p> </li> <li> <p>Self‐harm, in terms of the proportion of participants with self‐harming behaviour, or assessed by, for example, the Deliberate Self‐harm Inventory (DSHI; <a href="./references#CD012955-bbs2-0301" title="GratzKL . Measurement of deliberate self-harm: preliminary data on the Deliberate Self-Harm Inventory. Journal of Psychopathology and Behavioral Assessment2001;23(4):253-63. [DOI: 10.1023/A:1012779403943.pdf]">Gratz 2001</a>) or the Self‐harm behaviour Questionnaire (SHBQ; <a href="./references#CD012955-bbs2-0310" title="GuttierezPM , OsmanA , BarriosFX , KopperBA . Development and initial validation of the Self-Harm Behavior Questionnaire. Journal of Personality Assessment2001;77(3):475-90. [DOI: 10.1207/S15327752JPA7703_08] [PMID: 11781034]">Guttierez 2001</a>). </p> </li> <li> <p>Suicide‐related outcomes, assessed by, for example, the Suicidal Behaviours Questionnaire (SBQ; <a href="./references#CD012955-bbs2-0374" title="OsmanA , BaggeCL , GutierrezPM , KonickLC , KopperBA , BarriosFX . The Suicidal Behaviors Questionnaire-Revised (SBQ-R): validation with clinical and nonclinical samples. Assessment2001;8(4):443-54. [DOI: dx.doi.org/10.1177/107319110100800409] [PMID: 11785588]">Osman 2001</a>) or the Beck Scale for Suicidal Ideation (BSSI; <a href="./references#CD012955-bbs2-0250" title="BeckAT , KovacsM , WeissmanA . Assessment of suicidal intention: the Scale for Suicide Ideation. Journal of Consulting and Clinical Psychology1979;47(2):343-52. [PMID: 469082]">Beck 1979</a>), or in terms of the proportion of participants with suicidal acts. </p> </li> <li> <p>Psychosocial functioning, assessed by, for example, the Global Assessment Scale (GAS; <a href="./references#CD012955-bbs2-0291" title="EndicottJ , SpitzerRL , FleissJL , CohenJ . The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance. Archives of General Psychiatry1976;33(6):766-71. [PMID: 938196]">Endicott 1976</a>), the Global Assessment of Functioning Scale (GAF; <a href="./references#CD012955-bbs2-0229" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-III-R). 3rd edition. Washington (DC): American Psychiatric Association, 1987. [ISBN 978-0-89042-0195]">APA 1987</a>) or the Social Functioning Questionnaire (SFQ; <a href="./references#CD012955-bbs2-0414" title="TyrerP , NurU , CrawfordM , KarlsenS , McLeanC , RaoB , et al. The Social Functioning Questionnaire: a rapid and robust measure of perceived functioning. International Journal of Social Psychiatry2005;51(3):265-75. [PMID: 16252794]">Tyrer 2005</a>). </p> </li> </ol> </p> </section> <section id="CD012955-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD012955-list-0004"> <li> <p>Anger, assessed by, for example, the Hostility subscale of the Symptom Checklist ‐ 90 ‐ Revised (SCL‐90‐R; <a href="./references#CD012955-bbs2-0287" title="DerogatisLR , LazarusL . SCL-90-R, Brief Symptom Inventory, and matching clinical rating scales. In: MaruishME , editors(s). The Use of Psychological Testing for Treatment Planning and Outcomes Assessment. Hillsdale (NJ): Lawrence Erlbaum Associates, Inc., 1994:217-48.">Derogatis 1994</a>) or the State‐Trait Anger Expression Inventory (STAXI; <a href="./references#CD012955-bbs2-0398" title="SpielbergerCD . Manual for the State-Trait Anger Expression Inventory. Odessa (FL): Psychological Assessment Resources, 1988.">Spielberger 1988</a>). </p> </li> <li> <p>Affective instability, assessed by, for example, the relevant item or subscale on the Zan‐BPD (<a href="./references#CD012955-bbs2-0433" title="ZanariniMC , VujanovicAA , ParachiniEA , BoulangerJL , FrankenburgFR , HennenJ . Zanarini Rating Scale for Borderline Personality Disorder (Zan-BPD): a continuous measure of DSM-IV borderline psychopathology. Journal of Personality Disorders2003;17(3):233-42. [DOI: 10.1521/pedi.17.3.233.22147] [PMID: 12839102]">Zanarini 2003a</a>), CGI‐BPD (<a href="./references#CD012955-bbs2-0381" title="PerezV , BarrachinaJ , SolerJ , PascualJC , CampinsMJ , PuigdemontD , et al. The clinical global impression scale for borderline personality disorder patients (CGI-BPD): a scale sensible to detect changes [Impresión clinica global para pacientes con trastorno límite de la personalidad (ICG-TLP): una escala sensible al cambio]. Actas Espanolas de Psiquiatria2007;35(4):229-35. [PMID: 17592784]">Perez 2007</a>) or BPDSI‐IV (<a href="./references#CD012955-bbs2-0233" title="ArntzA , Van den HoornM , CornelisJ , VerheulR , Van den BoschW , De BieAJ . Reliability and validity of the borderline personality disorder severity index. Journal of Personality Disorders2003;17(1):45-59. [PMID: 12659546]">Arntz 2003</a>). </p> </li> <li> <p>Chronic feelings of emptiness, assessed by, for example, the relevant item or subscale on the Zan‐BPD (<a href="./references#CD012955-bbs2-0433" title="ZanariniMC , VujanovicAA , ParachiniEA , BoulangerJL , FrankenburgFR , HennenJ . Zanarini Rating Scale for Borderline Personality Disorder (Zan-BPD): a continuous measure of DSM-IV borderline psychopathology. Journal of Personality Disorders2003;17(3):233-42. [DOI: 10.1521/pedi.17.3.233.22147] [PMID: 12839102]">Zanarini 2003a</a>), CGI‐BPD (<a href="./references#CD012955-bbs2-0381" title="PerezV , BarrachinaJ , SolerJ , PascualJC , CampinsMJ , PuigdemontD , et al. The clinical global impression scale for borderline personality disorder patients (CGI-BPD): a scale sensible to detect changes [Impresión clinica global para pacientes con trastorno límite de la personalidad (ICG-TLP): una escala sensible al cambio]. Actas Espanolas de Psiquiatria2007;35(4):229-35. [PMID: 17592784]">Perez 2007</a>) or BPDSI‐IV (<a href="./references#CD012955-bbs2-0233" title="ArntzA , Van den HoornM , CornelisJ , VerheulR , Van den BoschW , De BieAJ . Reliability and validity of the borderline personality disorder severity index. Journal of Personality Disorders2003;17(1):45-59. [PMID: 12659546]">Arntz 2003</a>). </p> </li> <li> <p>Impulsivity, assessed by, for example, the Barrett Impulsiveness Scale (BIS; <a href="./references#CD012955-bbs2-0241" title="BarrettES , StanfordMS . Impulsiveness. In: CostelloCG , editors(s). Personality Characteristics of the Personality Disordered. New York (NY): Wiley, 1995:91-118. [ISBN 978-0-471-01529-1]">Barrett 1995</a>), or the Anger, Irritability and Assault Questionnaire (AIAQ; <a href="./references#CD012955-bbs2-0275" title="CoccaroEF , HarveyPD , Kupsaw-LawrenceE , HerbertJL , BernsteinDP . Development of neuropharmacologically-based behavioral assessments of impulsive aggressive behavior. Journal of Neuropsychiatry and Clinical Neurosciences1991;3(2):S44-S51. [PMID: 1821222]">Coccaro 1991</a>). </p> </li> <li> <p>Interpersonal problems, assessed by, for example, the Inventory of Interpersonal Problems (IIP; <a href="./references#CD012955-bbs2-0326" title="HorowitzLM , RosenbergSE , BaerBA , UreñoG , VillaseñorVS . Inventory of interpersonal problems: psychometric properties and clinical applications. Journal of Consulting and Clinical Psychology1988;56(6):885-92. [PMID: 3204198]">Horowitz 1988</a>), or the relevant item or subscale on the Zan‐BPD (<a href="./references#CD012955-bbs2-0433" title="ZanariniMC , VujanovicAA , ParachiniEA , BoulangerJL , FrankenburgFR , HennenJ . Zanarini Rating Scale for Borderline Personality Disorder (Zan-BPD): a continuous measure of DSM-IV borderline psychopathology. Journal of Personality Disorders2003;17(3):233-42. [DOI: 10.1521/pedi.17.3.233.22147] [PMID: 12839102]">Zanarini 2003a</a>), CGI‐BPD (<a href="./references#CD012955-bbs2-0381" title="PerezV , BarrachinaJ , SolerJ , PascualJC , CampinsMJ , PuigdemontD , et al. The clinical global impression scale for borderline personality disorder patients (CGI-BPD): a scale sensible to detect changes [Impresión clinica global para pacientes con trastorno límite de la personalidad (ICG-TLP): una escala sensible al cambio]. Actas Espanolas de Psiquiatria2007;35(4):229-35. [PMID: 17592784]">Perez 2007</a>), BPDSI‐IV (<a href="./references#CD012955-bbs2-0233" title="ArntzA , Van den HoornM , CornelisJ , VerheulR , Van den BoschW , De BieAJ . Reliability and validity of the borderline personality disorder severity index. Journal of Personality Disorders2003;17(1):45-59. [PMID: 12659546]">Arntz 2003</a>), or SCL‐90‐R (<a href="./references#CD012955-bbs2-0287" title="DerogatisLR , LazarusL . SCL-90-R, Brief Symptom Inventory, and matching clinical rating scales. In: MaruishME , editors(s). The Use of Psychological Testing for Treatment Planning and Outcomes Assessment. Hillsdale (NJ): Lawrence Erlbaum Associates, Inc., 1994:217-48.">Derogatis 1994</a>). </p> </li> <li> <p>Abandonment, assessed by, for example, the relevant item or subscale on the Zan‐BPD (<a href="./references#CD012955-bbs2-0433" title="ZanariniMC , VujanovicAA , ParachiniEA , BoulangerJL , FrankenburgFR , HennenJ . Zanarini Rating Scale for Borderline Personality Disorder (Zan-BPD): a continuous measure of DSM-IV borderline psychopathology. Journal of Personality Disorders2003;17(3):233-42. [DOI: 10.1521/pedi.17.3.233.22147] [PMID: 12839102]">Zanarini 2003a</a>), CGI‐BPD (<a href="./references#CD012955-bbs2-0381" title="PerezV , BarrachinaJ , SolerJ , PascualJC , CampinsMJ , PuigdemontD , et al. The clinical global impression scale for borderline personality disorder patients (CGI-BPD): a scale sensible to detect changes [Impresión clinica global para pacientes con trastorno límite de la personalidad (ICG-TLP): una escala sensible al cambio]. Actas Espanolas de Psiquiatria2007;35(4):229-35. [PMID: 17592784]">Perez 2007</a>) or BPDSI‐IV (<a href="./references#CD012955-bbs2-0233" title="ArntzA , Van den HoornM , CornelisJ , VerheulR , Van den BoschW , De BieAJ . Reliability and validity of the borderline personality disorder severity index. Journal of Personality Disorders2003;17(1):45-59. [PMID: 12659546]">Arntz 2003</a>). </p> </li> <li> <p>Identity disturbance, assessed by, for example, the relevant item or subscale on the Zan‐BPD (<a href="./references#CD012955-bbs2-0433" title="ZanariniMC , VujanovicAA , ParachiniEA , BoulangerJL , FrankenburgFR , HennenJ . Zanarini Rating Scale for Borderline Personality Disorder (Zan-BPD): a continuous measure of DSM-IV borderline psychopathology. Journal of Personality Disorders2003;17(3):233-42. [DOI: 10.1521/pedi.17.3.233.22147] [PMID: 12839102]">Zanarini 2003a</a>), CGI‐BPD (<a href="./references#CD012955-bbs2-0381" title="PerezV , BarrachinaJ , SolerJ , PascualJC , CampinsMJ , PuigdemontD , et al. The clinical global impression scale for borderline personality disorder patients (CGI-BPD): a scale sensible to detect changes [Impresión clinica global para pacientes con trastorno límite de la personalidad (ICG-TLP): una escala sensible al cambio]. Actas Espanolas de Psiquiatria2007;35(4):229-35. [PMID: 17592784]">Perez 2007</a>) or BPDSI‐IV (<a href="./references#CD012955-bbs2-0233" title="ArntzA , Van den HoornM , CornelisJ , VerheulR , Van den BoschW , De BieAJ . Reliability and validity of the borderline personality disorder severity index. Journal of Personality Disorders2003;17(1):45-59. [PMID: 12659546]">Arntz 2003</a>). </p> </li> <li> <p>Dissociation and psychotic‐like symptoms, assessed by, for example, the Dissociative Experience Scale (DES; <a href="./references#CD012955-bbs2-0254" title="BernsteinEM , PutnamFW . Development, reliability, and validity of a dissociation scale. Journal of Nervous and Mental Disease1986;174(12):727-35. [PMID: 3783140]">Bernstein 1986</a>), or the Brief Psychiatric Rating Scale (BPRS; <a href="./references#CD012955-bbs2-0377" title="OverallJE , GorhamDR . The Brief Psychiatric Rating Scale. Psychological Reports1962;10(3):799-812. [DOI: 10.2466/pr0.1962.10.3.799]">Overall 1962</a>). </p> </li> <li> <p>Depression, assessed by, for example, the Beck Depression Inventory (BDI; <a href="./references#CD012955-bbs2-0249" title="BeckAT , WardCH , MendelsonM , MockJ , ErbaughJ . An inventory for measuring depression. Archives of General Psychiatry1961;4:561-71. [PMID: 13688369]">Beck 1961</a>) or the Montgomery Åsberg Depression Rating Scale (MADRS; <a href="./references#CD012955-bbs2-0363" title="MontgomerySA , AsbergM . A new depression scale designed to be sensitive to change. British Journal of Psychiatry1979;134:382-9. [PMID: 444788]">Montgomery 1979</a>). </p> </li> <li> <p>Attrition, in terms of participants lost after randomisation in each group.</p> </li> <li> <p>Adverse effects, measured by the use of standardised psychometric rating scales, such as the Systematic Assessment for Treatment Emergent Events (SAFTEE; <a href="./references#CD012955-bbs2-0344" title="LevineJ , SchoolerNR . SAFTEE: a technique for the systematic assessment of side effects in clinical trials. Psychopharmacology Bulletin1986;22(2):343-81. [PMID: 3774930]">Levine 1986</a>), or by laboratory values or spontaneous reporting. We defined adverse effects as unfavourable outcomes that occurred during or after psychotherapy but that were not necessarily caused by it (see Chapter 19 in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i>; <a href="./references#CD012955-bbs2-0382" title="PeryerG , GolderS , JunqueiraD , VohraS , LokeYK . Chapter 19: Adverse effects. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019), Cochrane 2019. Available from www.training.cochrane.org/handbook.">Peryer 2019</a>. We divided any reported adverse effects into severe and non‐severe, according to the International Committee of Harmonization guidelines (<a href="./references#CD012955-bbs2-0330" title="International Council for Harmonisation Expert Working Group. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline. Guideline for good clinical practice E6(R1). www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6/E6_R1_Guideline.pdf (accessed 6 May 2011).">ICH 1996</a>). We defined serious adverse effects as any event that led to death, was life‐threatening, required inpatient hospitalisation or prolongation of existing hospitalisation, resulted in persistent or significant disability, or any important medical event that may have jeopardised the participant’s health or required intervention to prevent one of the aforementioned outcomes occurring. We considered all other adverse effects to be non‐serious. </p> </li> </ol> </p> </section> </section> </section> <section id="CD012955-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD012955-sec-0024"> <h4 class="title">Electronic searches</h4> <p>We searched the electronic databases and trials registers listed below up to March 2019. </p> <p> <ol id="CD012955-list-0005"> <li> <p>Cochrane Central Register of Controlled trials (CENTRAL; 2019, Issue 3), in the Cochrane Library, which includes the Cochrane Developmental, Psychosocial and Learning Problems Specialised Register (searched 20 March 2019). </p> </li> <li> <p>MEDLINE Ovid (1948 to 20 March 2019).</p> </li> <li> <p>Embase Ovid (1980 to 20 March 2019).</p> </li> <li> <p>CINAHL EBSCOhost (Cumulative Index to Nursing and Allied Health Literature; 1980 to 20 March 2019). </p> </li> <li> <p>PsycINFO Ovid (1806 to 20 March 2019).</p> </li> <li> <p>ERIC EBSCOhost (Education Resources Information Center; 1966 to 20 March 2019).</p> </li> <li> <p>BIOSIS Previews Web of Science Clarivate Analytics (1969 to 20 March 2019).</p> </li> <li> <p>Web of Science Core Collection Clarivate Analytics (1900 to 20 March 2019).</p> </li> <li> <p>Sociological Abstracts ProQuest (1952 to 20 March 2019).</p> </li> <li> <p>LILACS (Latin American and Caribbean Health Science Information database; <a href="http://lilacs.bvsalud.org/en/" target="_blank">lilacs.bvsalud.org/en</a>; searched 20 August 2019). </p> </li> <li> <p>OpenGrey (<a href="http://www.opengrey.eu/" target="_blank">www.opengrey.eu</a>; searched 20 August 2019). </p> </li> <li> <p>Library Hub Discover,previously COPAC (<a href="http://discover.libraryhub.jisc.ac.uk/" target="_blank">Library Hub Discover</a>; searched 20 August 2019). </p> </li> <li> <p>ProQuest Dissertations and Theses A&amp;I (1743 to 20 March 2019).</p> </li> <li> <p>DART Europe E‐Theses Portal (<a href="http://www.dart-europe.eu/basic-search.php" target="_blank">www.dart-europe.eu/basic-search.php</a>; searched 20 August 2019). </p> </li> <li> <p>Networked Digital Library of Theses and Dissertations (NDLTD; <a href="http://www.ndltd.org/" target="_blank">www.ndltd.org</a>; searched 20 August 2019). </p> </li> <li> <p>Australian New Zealand Clinical trials Registry (ANZCTR; <a href="http://www.anzctr.org.au/BasicSearch.aspx" target="_blank">www.anzctr.org.au/BasicSearch.aspx</a>; searched 20 August 2019). </p> </li> <li> <p>Clinicaltrials.gov (<a href="https://clinicaltrials.gov/" target="_blank">clinicaltrials.gov</a>; searched 20 March 2019). </p> </li> <li> <p>EU Clinical trials Register (<a href="https://www.clinicaltrialsregister.eu/ctr-search/search" target="_blank">www.clinicaltrialsregister.eu/ctr-search/search</a>; searched 20 August 2019). </p> </li> <li> <p>ISRCTN Registry (<a href="https://www.isrctn.com/" target="_blank">www.isrctn.com</a>; searched 20 August 2019). </p> </li> <li> <p>Be Part of research (<a href="https://www.ukctg.nihr.ac.uk/#popoverSearchDivId" target="_blank">www.ukctg.nihr.ac.uk/#popoverSearchDivId</a>; searched 20 August 2019). </p> </li> <li> <p>WHO International Clinical trials Registry Platform (ICTRP; <a href="http://who.int/ictrp/en/" target="_blank">who.int/ictrp/en</a>; searched 20 March 2019). </p> </li> </ol> </p> <p>The search strategies for all databases can be found in <a href="./appendices#CD012955-sec-0552">Appendix 3</a>. We did not limit our searches by language, year of publication, or type of publication. We sought translation of the relevant sections of non‐English language articles. </p> </section> <section id="CD012955-sec-0025"> <h4 class="title">Searching other resources</h4> <p>We handsearched relevant journals, including: Journal of Personality Disorders; American Journal of Psychiatry; JAMA Psychiatry; British Journal of Psychiatry; ACTA Psychiatrica Scandinavica; Journal of the American Academy of Child and Adolescent Psychiatry; Personality Disorders: Theory, Research and Treatment; and Journal of Clinical Psychiatry. Additionally, we emailed researchers working in the field, to ask for unpublished data. We also checked abstracts of key conferences for BPD (congresses of the European and the International Society for the Study of Personality Disorders; ESSPD and ISSPD, respectively) and asked for any relevant unpublished data<i>.</i> We traced cross‐references from relevant literature. On 13 December 2019, we ran searches to make sure that none of our included trials had been retracted due to error or fraud. In the next update of this review, we will handsearch additional journal titles for relevant trials, (see <a href="#CD012955-sec-0623">Differences between protocol and review</a>). </p> </section> </section> <section id="CD012955-sec-0026"> <h3 class="title" id="CD012955-sec-0026">Data collection and analysis</h3> <p>We conducted this review in accordance with the guidelines set out in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012955-bbs2-0325" title="HigginsJPT , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al (editors). Cochrane Handbook for Systematic Reviews of Interventions. 2nd edition. Chichester (UK): John Wiley &amp; Sons, 2019. [Available from: www.training.cochrane.org/handbook]">Higgins 2019</a>), and performed analyses using the latest version of Review Manager 5 (RevMan 5), Cochrane's statistical software (<a href="./references#CD012955-bbs2-0385" title="Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">Review Manager 2014</a>). </p> <p>We report only the methods used in successive sections below. Planned but unused methods can be found in the protocol, <a href="./references#CD012955-bbs2-0443" title="StorebøOJ , Stoffers-WinterlingJM , VöllmBA , KongerslevMT , MattiviJT , KielsholmML , et al. Psychological therapies for people with borderline personality disorder. Cochrane Database of Systematic Reviews2018, Issue 2. Art. No: CD012955. [DOI: 10.1002/14651858.CD012955]">Storebø 2018</a>, and additional <a href="#CD012955-tbl-0004">Table 1</a>. </p> <div class="table" id="CD012955-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Unused methods</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Section</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Protocol (</b><a href="./references#CD012955-bbs2-0443" title="StorebøOJ , Stoffers-WinterlingJM , VöllmBA , KongerslevMT , MattiviJT , KielsholmML , et al. Psychological therapies for people with borderline personality disorder. Cochrane Database of Systematic Reviews2018, Issue 2. Art. No: CD012955. [DOI: 10.1002/14651858.CD012955]">Storebø 2018</a><b>)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Review</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Unit of analysis issues</b><br/> <br/>  </p> <p> <br/>  </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cross‐over trials</b> </p> <p>We would have included cross‐over trials. We planned to include data up to the point of first cross‐over (first period only; <a href="./references#CD012955-bbs2-0282" title="CurtinF , ElbourneD , AltmanDG . Meta-analysis combining parallel and cross-over clinical trials. III: the issue of carry-over. Statistics in Medicine2002;21(15):2161-73. [DOI: 10.1002/sim.1207] [PMID: 12210631]">Curtin 2002</a>). We did not intend to use data from subsequent periods due to the likelihood of carry‐over effects from the preceding treatment(s). We planned not to combine repeated participant interventions in one meta‐analysis. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We did not include any cross‐over trial. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cluster‐randomised trials</b> </p> <p>Had trials used cluster randomisation, we would have anticipated that investigators would have presented their results after appropriately controlling for clustering effects (robust standard errors or hierarchical linear models). If it had been unclear whether a cluster‐randomised trial had used appropriate controls for clustering, we would have contacted the investigators for further information. We would have requested and re‐analysed individual patient data using multilevel models that controlled for clustering, if appropriate controls had not been used. Following this, we would have analysed effect sizes and standard errors in RevMan 5 (<a href="./references#CD012955-bbs2-0385" title="Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">Review Manager 2014</a>), using the generic inverse method (<a href="./references#CD012955-bbs2-0324" title="HigginsJPT , DeeksJJ , AltmanDG , editor(s), Cochrane Statistical Methods Group. Chapter 16: Special topics in statistics. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011</a>). If there had been insufficient information to control for clustering, we would have entered outcome data using individuals as the units of analysis, and then conducted a sensitivity analysis to assess the potential biasing effects of inadequately controlled cluster‐randomised trials (<a href="./references#CD012955-bbs2-0289" title="DonnerA , KlarN . Issues in the meta-analysis of cluster-randomized trials. Statistics in Medicine2002;21(9):2971-80. [DOI: 10.1002/sim.1301] [PMID: 12325113]">Donner 2002</a>). If individual participant data had not been available, we would have looked for information on intra‐class correlation coefficients to adjust for the potential clustering effects.   </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We did not include any cluster‐randomised trial.<br/>  </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adjustment for multiplicity</b> </p> <p>We planned to adjust the P values and CIs for multiplicity due to the many secondary outcome comparisons following the method described by <a href="./references#CD012955-bbs2-0331" title="JakobsenJC , WetterslevJ , WinkelP , LangeT , GluudC . Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods. BMC Medical Research Methodology2014;14:120. [DOI: 10.1186/1471-2288-14-120] [PMCID: PMC4251848] [PMID: 25416419]">Jakobsen 2014</a>. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>We only adjusted the primary outcomes and one secondary outcomes for multiplicity, i.e. those outcomes presented in the SoF table. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Dealing with missing data</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Had dichotomous data not been presented on the basis of ITT data, we would have added the number of participants lost in each group to the participants with unfavourable results, acting on the assumption that most people with BPD do not get lost at random. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We were unable to perform this analysis due to insufficient information</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Subgroup analysis and investigation of heterogeneity</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We intended to conduct subgroup analyses to make hypotheses about the subgroups mentioned below. </p> <p> <ol id="CD012955-list-0006"> <li> <p>Sex (male versus female)</p> </li> <li> <p>Comorbidity (people with comorbidity versus people without comorbidity)</p> </li> <li> <p>Treatment intensity (once a week compared to more than once a week</p> </li> <li> <p>Concurrent‐drug interventions (trials with concurrent‐drug interventions compared to those without) </p> </li> </ol> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We did not conduct these preplanned analyses because of lack of data.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sensitivity analysis</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We intended to assess the impact of heterogeneity on the overall pooled effect estimate by removing studies ('outliers') that contributed to heterogeneity. We intended to remove outliers one by one and assess the impact on the overall outcome. </p> <p> <ol id="CD012955-list-0007"> <li> <p>Decisions made during the review process (our assessment of the level of clinical heterogeneity) </p> </li> <li> <p>Impact of bias (studies with low and high risk of bias)</p> </li> <li> <p>Type of data collection (for example, different ways to measure depression)</p> </li> <li> <p>Imputed data (comparing analyses with available outcome data with those using an ITT approach) </p> </li> </ol> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We were not able to perform these analyses, due to a lack of sufficient data.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>TSA</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We intended to calculate post hoc, low bias, risk diversity‐adjusted required information size TSA analyses for the primary outcomes. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We were not able to perform these analyses with low risk of bias trials.</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>BPD:</b> borderline personality disorder; <b>CI:</b> confidence interval;<b>ITT:</b> intention to treat; <b>TAU:</b> treatment‐as‐usual </p> </div> </div> <section id="CD012955-sec-0027"> <h4 class="title">Selection of studies</h4> <p>Twelve review authors (OJS, JMSW, BAV, JTM, HEC, AT, CPS, MTK, SSN, MLK, MSJ, EF) worked in six pairs and independently screened titles and abstracts of all records retrieved by the searches. For any record that could have been an eligible RCT, we obtained the full‐text report and assessed it for eligibility against the inclusion criteria (see <a href="#CD012955-sec-0016">Criteria for considering studies for this review</a>). During all stages of study selection, we resolved uncertainty or disagreement by consensus. When agreement could not be reached, the review authors discussed disagreements and consulted a third review author (KL, OJS, JMSW or ES). </p> <p>We list apparently relevant RCTs that did not fulfil the inclusion criteria, along with reasons for their exclusion, in the <a href="./references#CD012955-sec-0638" title="">Characteristics of excluded studies</a> tables. We used <a href="https://www.covidence.org" target="_blank">Covidence software</a> to keep track of appraised trials and decisions. To ensure transparency of study selection, we provided flow charts according to the QUOROM statement, showing how many records have been excluded for a certain reason (<a href="./references#CD012955-bbs2-0362" title="MoherD , CookDJ , EastwoodS , OlkinI , RennieD , StroupDF . Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of reporting of meta-analyses. Lancet1999;354(9193):1896-900. [PMID: 10584742]">Moher 1999</a>). </p> </section> <section id="CD012955-sec-0028"> <h4 class="title">Data extraction and management</h4> <p>We developed data extraction forms to facilitate standardisation of data extraction. The form was piloted by OJS, SSN, MTK. </p> <p>Working in pairs, all review authors extracted data independently using the data collection form to ensure accuracy. We resolved disagreements by discussion or by using an arbiter (ES), if required. </p> <p>OJS, HEC, AT, EF, and JMSW entered data into RevMan 5 (<a href="./references#CD012955-bbs2-0385" title="Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">Review Manager 2014</a>). After all data had been entered, another reviewer (JMSW, OJS) re‐checked the data for completeness and accuracy, to make sure the data were complete, correct and appropriately categorised. Any entered data were verified against the original publication, and we updated the list of outcomes (<a href="./appendices#CD012955-sec-0574">Appendix 4</a>), if necessary. </p> </section> <section id="CD012955-sec-0029"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Using Cochrane's tool for assessing risk of bias (<a href="./references#CD012955-bbs2-0324" title="HigginsJPT , DeeksJJ , AltmanDG , editor(s), Cochrane Statistical Methods Group. Chapter 16: Special topics in statistics. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011</a>), all review authors assessed the risk of bias in each included trial across the following domains: random sequence generation; allocation concealment; blinding of outcome assessment; incomplete outcome data, selective outcome reporting; and other potential sources of bias. Data extractors independently assigned each trial to one of three categories (low risk of bias, unclear (uncertain) risk of bias or high risk of bias), according to guidelines provided in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012955-bbs2-0324" title="HigginsJPT , DeeksJJ , AltmanDG , editor(s), Cochrane Statistical Methods Group. Chapter 16: Special topics in statistics. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011</a>), using the criteria set out in <a href="./appendices#CD012955-sec-0591">Appendix 5</a>. We called upon a third review author (ES) to resolve any ongoing disagreements, when needed. </p> <p>Considering bias due to a lack of blinding is undoubtedly of importance, but it remains unclear how best to deal with this issue in research practice (<a href="./references#CD012955-bbs2-0259" title="BoutronI , MoherD , AltmanDG , SchulzK , RavaudP , CONSORT Group. Extending the CONSORT statement to randomised trials of nonpharmacologic treatment: explanation and elaboration. Annals of Internal Medicine2008;148(4):295-309. [PMID: 18283207]">Boutron 2008</a>). We decided not to judge the likelihood of detection bias due to inadequate blinding of participants and personnel, as it is almost impossible to blind therapists and people receiving treatment in psychological therapy outcome research. However, we assessed the likelihood of detection bias due to inadequate blinding of outcome assessors. </p> <p>In accordance with Cochrane’s guidelines (<a href="./references#CD012955-bbs2-0324" title="HigginsJPT , DeeksJJ , AltmanDG , editor(s), Cochrane Statistical Methods Group. Chapter 16: Special topics in statistics. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011</a>), we also included other potential sources of bias as a final bias component. Here, we included: the likelihood of performance bias due to inadequate treatment adherence; the likelihood of bias due to different amounts of attention given to the treatment groups (attention bias); and other potential sources of bias, such as allegiance bias. We defined allegiance bias as a therapist’s personal belief both in the superiority and the efficacy of a particular treatment. This belief can be based on an education in that particular treatment. This bias is especially strong if the inventor of a treatment is investigating the effects of the particular treatment he/she has invented. </p> <p>We considered trials with one or more unclear or high risk of bias domains as trials at high risk of bias overall, due to the risk of overestimating beneficial effects and underestimating harmful effects in RCTs with unclear or inadequate methodological quality (<a href="./references#CD012955-bbs2-0338" title="KjaergardLL , VillumsenJ , GluudC . Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Annals of Internal Medicine2001;135(11):982-9. [PMID: 11730399]">Kjaergard 2001</a>; <a href="./references#CD012955-bbs2-0359" title="LundhA , SismondoS , LexchinJ , BusuiocOA , BeroL . Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews2012, Issue 12. Art. No: MR000033. [DOI: 10.1002/14651858.MR000033.pub2]">Lundh 2012</a>; <a href="./references#CD012955-bbs2-0361" title="MoherD , PhamB , JonesA , CookDJ , JadadAR , MoherM , et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analysis?Lancet1998;352(9128):609-13. [DOI: 10.1016/S0140-6736(98)01085-X] [PMID: 9746022]">Moher 1998</a>; <a href="./references#CD012955-bbs2-0389" title="SavovićJ , JonesH , AltmanD , HarrisR , JüniP , PildalJ , et al. Influence of reported study design characteristics on intervention effect estimates from randomised controlled trials: combined analysis of meta-epidemiological studies. Health Technology Assessment2012;16(35):1-82. [DOI: 10.3310/hta16350] [PMID: 22989478]">Savović 2012a</a>; <a href="./references#CD012955-bbs2-0390" title="SavovićJ , JonesHE , AltmanDG , HarrisRJ , JüniP , PildalJ , et al. Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Annals of Internal Medicine2012;157(6):429-38. [DOI: 10.7326/0003-4819-157-6-201209180-00537] [PMID: 22945832]">Savović 2012b</a>; <a href="./references#CD012955-bbs2-0391" title="SchulzKF , ChalmersI , HayesRJ , AltmanDG . Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA1995;273(5):408-12. [PMID: 7823387]">Schulz 1995</a>; <a href="./references#CD012955-bbs2-0425" title="WoodL , EggerM , GluudLL , SchulzKF , JüniP , AltmanDG , et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ2008;336(7644):601-5. [DOI: 10.1136/bmj.39465.451748.AD] [PMC2267990] [PMID: 18316340]">Wood 2008</a>). We defined trials with a low risk of bias in all domains to be at low risk of bias overall. </p> </section> <section id="CD012955-sec-0030"> <h4 class="title">Measures of treatment effect</h4> <section id="CD012955-sec-0031"> <h5 class="title">Continuous data</h5> <p>For continuous data, we compared the mean score between the two groups to give a mean difference (MD) and presented this with 95% confidence intervals (CIs). We used the overall MD, where possible, to combine the same outcome measures from trials. If two or more different instruments were used to measure the same construct, we reported the effect sizes as standardised mean differences (SMD) in the meta‐analysis. We calculated SMDs on the basis of post‐treatment results and, in separate analyses, follow‐up data. We grouped follow‐up data in six‐month intervals (zero to six months, six to 12 months and 12 months and over). Where the direction of a scale was opposite to most of the other scales, we multiplied the corresponding mean values by −1 to ensure adjusted values. If the trials did not report means and standard deviations (SDs) but reported other values like t‐tests and P values, we tried to transform these into SDs. </p> <p>To identify the minimum relevant clinical difference (MIREDIF), we transformed the SMD to MD, using the scale with the best validity and reliability for the given outcome. For the analyses of the four primary outcomes in the comparison of psychotherapy versus TAU, we transformed SMDs into MDs on the following scales, to assess whether results exceeded the MIREDIF: ZAN‐BPD Scale, Delibarate Self‐Harm Inventory (DSHI), Suicidal Attempt Self Injury Interview (SASII), Global Assessment of Functioning (GAF), and the Hamilton Depression scale. We identified a MIREDIF of −3.0 points on the ZAN‐BPD, ranging from 0 to 36 points, based on a trial by <a href="./references#CD012955-bbs2-0279" title="CrawfordMJ ,  SanatiniaR ,  BarrettB , CunninghamG , DaleO ,  GanguliP , et al. The clinical effectiveness and cost-effectiveness of lamotrigine in borderline personality disorder: a randomized placebo-controlled trial. American Journal of Psychiatry2018;175(8):756-64. [DOI: 10.1176/appi.ajp.2018.17091006] [PMID: 29621901]">Crawford 2018a</a>; a MIREDIF of −1.25 points on the DSHI, ranging from 0 to 34 points, which corresponds to ½ SD based on a trial by <a href="./references#CD012955-bbs2-0293" title="FarivarSS , LiuH ,  HaysRD . Half standard deviation estimate of the minimally important difference in HRQOL scores?Expert Review of Pharmacoeconomics &amp; Outcomes Research2004;4(5):515-23. [DOI: 10.1586/14737167.4.5.515] [PMID: 19807545]">Farivar 2004</a>; a MIREDIF of −0.17 points on the Suicidal Attempt Self Injury Interview, ranging from 0 to 4 points, which corresponds to ½ SD based on a trial by <a href="./references#CD012955-bbs2-0293" title="FarivarSS , LiuH ,  HaysRD . Half standard deviation estimate of the minimally important difference in HRQOL scores?Expert Review of Pharmacoeconomics &amp; Outcomes Research2004;4(5):515-23. [DOI: 10.1586/14737167.4.5.515] [PMID: 19807545]">Farivar 2004</a>; and a MIREDIF of −4.0 on the GAF scale, ranging from 0 to 100, based on a trial by <a href="./references#CD012955-bbs2-0224" title="AmriA , MillierM , ToumiM . Minimum clinically important difference in the global assessment functioning in patients with schizophrenia. Value in Health2014;17(7):A765-6. [DOI: 10.1016/j.jval.2014.08.285] [Abstract #PMH2] [PMID: 27202809]">Amri 2014</a>. The MIREDIF of the Hamilton Depression scale is 3.0 points (<a href="./references#CD012955-bbs2-0370" title="National Institute for Health and Care Excellence. Depression in adults: recognition and management. Cinical guideline (CG90). www.nice.org.uk/guidance/cg90 (accessed prior to 16 March 2020).">NICE CG90</a>). For other outcomes, we provided an interpretation of the effect size using Cohen's D, considering 0.2 as a small effect, 0.5 as a medium effect size, and 0.8 as a large effect size (<a href="./references#CD012955-bbs2-0276" title="CohenJ . Statistical Power Analysis for the Behavioral Sciences. 2nd edition. Hillsdale (NJ): Lawrence Erlbaum Associates, 1988.">Cohen 1988</a>). </p> </section> <section id="CD012955-sec-0032"> <h5 class="title">Dichotomous data</h5> <p>We summarised dichotomous data as risk ratios (RRs) with 95% CIs. The RR is the ratio of the risk of an event in the two groups. We decided to use the RR as it may be easier to interpret than odds ratios (ORs). </p> </section> </section> <section id="CD012955-sec-0033"> <h4 class="title">Unit of analysis issues</h4> <section id="CD012955-sec-0034"> <h5 class="title">Repeated observations</h5> <p>We calculated trial estimates on the basis of post‐treatment group results. We conducted separate analyses for data from different points of measurement (i.e. post‐treatment, follow‐up data of 0‐ to 6‐month, 6‐ to 12‐month, and above 12‐month intervals, where we used the last measurement within these intervals). If a trial reported data at both 7‐month and 11‐month follow‐up periods, we included both; however, we categorised cases like the 11‐month follow‐up as above 12‐month follow‐up. We did not use interim observations (<a href="./references#CD012955-bbs2-0407" title="ThalheimerW , CookS . How to calculate effect sizes from published research: a simplified methodology. www.bwgriffin.com/gsu/courses/edur9131/content/Effect_Sizes_pdf5.pdf (accessed 9 August 2019).">Thalheimer 2002</a>). </p> </section> <section id="CD012955-sec-0035"> <h5 class="title">Adjustment for multiplicity</h5> <p>Multiplicity reflects the concern that performing multiple comparisons increases the risk of falsely rejecting the null hypothesis. Multiplicity, therefore, may affect the results found within a systematic review and, as a result, needs to be adjusted for. We adjusted the P values and CIs of the primary outcomes and one secondary outcome (depression) for multiplicity using the method described by (<a href="./references#CD012955-bbs2-0331" title="JakobsenJC , WetterslevJ , WinkelP , LangeT , GluudC . Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods. BMC Medical Research Methodology2014;14:120. [DOI: 10.1186/1471-2288-14-120] [PMCID: PMC4251848] [PMID: 25416419]">Jakobsen 2014</a>). </p> </section> </section> <section id="CD012955-sec-0036"> <h4 class="title">Dealing with missing data</h4> <p>We tried to obtain any missing data, including incomplete outcome data, by contacting trial authors. We report this information in the 'Risk of bias' tables. </p> <p>We evaluated the methods used to handle the missing data in the publications and to what extent it was likely that the missing data had influenced the results of outcomes of interest. We calculated effect sizes on the basis of intention‐to‐treat data, if that was possible. If only available case analysis data were reported, we calculated effect sizes on this basis. </p> <p>We consulted a statistician if data were not reported in an immediately usable way and if data required processing before being analysed. We assessed results derived from statistically processed data in sensitivity analyses. See <a href="#CD012955-sec-0042">Sensitivity analysis</a>. </p> </section> <section id="CD012955-sec-0037"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed trials for clinical homogeneity with respect to type of therapy, therapy setting and control group. We evaluated methodological heterogeneity by comparing the designs of trials. For any trials judged as homogeneous and adequate for pooling, we investigated statistical heterogeneity by both visual inspection of the graphs and the I<sup>2</sup> statistic (<a href="./references#CD012955-bbs2-0323" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta-analyses. BMJ2003;327(7414):557-60. [DOI: https://doi.org/10.1136/bmj.327.7414.557] [PMC192859] [PMID: 12958120]">Higgins 2003</a>). We considered I<sup>2</sup> values between 0% and 40% as indication of little heterogeneity, between 30% and 60% as indication of moderate heterogeneity, between 50% and 90% as indication of substantial heterogeneity, and between 75% and 100% as indication of considerable heterogeneity (<a href="./references#CD012955-bbs2-0325" title="HigginsJPT , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al (editors). Cochrane Handbook for Systematic Reviews of Interventions. 2nd edition. Chichester (UK): John Wiley &amp; Sons, 2019. [Available from: www.training.cochrane.org/handbook]">Higgins 2019</a>). Along with the size of the I<sup>2</sup> scores, we also took into account the P value, CI and the overall number of included trials in the respective analysis when interpreting the values (<a href="./references#CD012955-bbs2-0284" title="DeeksJJ , HigginsJPT , Altman DG editor(s). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane 2019. Available from www.training.cochrane.org/handbook.">Deeks 2019</a>). </p> </section> <section id="CD012955-sec-0038"> <h4 class="title">Assessment of reporting biases</h4> <p>We drew funnel plots (estimated differences in treatment effects against their standard error) and performed Egger's statistical test for small‐study effects for the primary outcomes; asymmetry in the funnel plot could be due to publication bias or could indicate genuine heterogeneity between small and large trials (<a href="./references#CD012955-bbs2-0325" title="HigginsJPT , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al (editors). Cochrane Handbook for Systematic Reviews of Interventions. 2nd edition. Chichester (UK): John Wiley &amp; Sons, 2019. [Available from: www.training.cochrane.org/handbook]">Higgins 2019</a>). It is important to assess the funnel axis in the funnel plot as a significant Egger's test could also indicate publication bias or be due to genuine small treatment effects. We did not visually inspect the funnel plot if fewer than 10 trials were included in the meta‐analysis, in accordance with the recommendations of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012955-bbs2-0325" title="HigginsJPT , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al (editors). Cochrane Handbook for Systematic Reviews of Interventions. 2nd edition. Chichester (UK): John Wiley &amp; Sons, 2019. [Available from: www.training.cochrane.org/handbook]">Higgins 2019</a>; <a href="http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD012069/full#CD012069-bbs2-0030" target="_blank">Egger 1997</a>; <a href="./references#CD012955-bbs2-0402" title="SterneJAC , EggerM , MoherD , BoutronI , editor(s). Chapter 10: Addressing reporting biases. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017). Cochrane, 2017. Available from www.training.cochrane.org/handbook.">Sterne 2017</a>). </p> </section> <section id="CD012955-sec-0039"> <h4 class="title">Data synthesis</h4> <p>We performed the statistical analyses in accordance with the recommendations in the latest version of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012955-bbs2-0325" title="HigginsJPT , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al (editors). Cochrane Handbook for Systematic Reviews of Interventions. 2nd edition. Chichester (UK): John Wiley &amp; Sons, 2019. [Available from: www.training.cochrane.org/handbook]">Higgins 2019</a>). </p> <p>In carrying out meta‐analyses, we used the inverse‐variance method, to give more weight to more precise estimates from trials with less variance (mostly larger trials). This minimises the imprecision of the pooled effect estimate, and is a common and simple approach to conducting meta‐analyses (<a href="./references#CD012955-bbs2-0325" title="HigginsJPT , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al (editors). Cochrane Handbook for Systematic Reviews of Interventions. 2nd edition. Chichester (UK): John Wiley &amp; Sons, 2019. [Available from: www.training.cochrane.org/handbook]">Higgins 2019</a>). We used the random‐effects model for our meta‐analyses, since we expected some degree of clinical heterogeneity to be present in most cases, though not too substantial to prevent pooling in principle. Where only one trial was included in an analysis, we used the fixed‐effect model, and where different models led to different results (<a href="#CD012955-sec-0042">Sensitivity analysis</a>), we reported the results of both models. </p> <p>For trials with a high level of statistical heterogeneity, and where the amount of clinical heterogeneity made it inappropriate to use these trials in meta‐analyses, we provide a narrative description of the trial results. If data pooling seemed feasible, we pooled the primary trials' effects and calculated their 95% CIs. </p> <p>If a trial reported data for a particular outcome using two or more assessment instruments (e.g. several questionnaires for the assessment of depression), we selected the one used most often in the whole pool of included trials for effect size calculation, in order to minimise heterogeneity of outcomes in form and content. If a trial reported data of two assessment instruments that were equally frequently used, two review authors discussed the issue and chose the one that was, in its content, the most appropriate for the assessment of people affected by BPD.  </p> <p>We divided the doses and the controls into the different comparisons, ensuring that the treatment comparisons were comparable and homogeneous. </p> <p>We have two main overarching comparisons. In the first comparison, we pooled all of the different types of psychotherapy together and compared them with the different types of TAU pooled together. In the second comparison, we pooled all of the different types of psychotherapy and compared them with waiting list or no treatment. Within in each comparison, we broke down the interventions by therapeutic category compared with different types of TAU, waiting list, no treatment or with another psychotherapy (active control). </p> </section> <section id="CD012955-sec-0040"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We conducted the following prespecified subgroup analyses for two primary outcomes (BPD symptom severity and psychosocial functioning), where data were sufficient, in order to make hypotheses. </p> <p> <ol id="CD012955-list-0008"> <li> <p>Therapeutic approaches: specific therapies versus each other (only analyses with two or more trials were included in this subgroup) </p> </li> <li> <p>Age: mean age of 15 to 18 years versus older than 18 years</p> </li> <li> <p>Duration: less than six months versus six to 12 months versus over 12 months</p> </li> <li> <p>Mode of therapy: individual therapy versus group therapy and with the combination of individual and group therapy </p> </li> <li> <p>Setting: inpatient versus outpatient and the combination of inpatient and outpatient</p> </li> </ol> </p> <p>In addition, we added the following four subgroup analyses post hoc, for the primary outcomes of BPD symptom severity and psychosocial functioning. </p> <p> <ol id="CD012955-list-0009"> <li> <p>Type of raters: self‐rated versus clinician‐rated</p> </li> <li> <p>Types of TAU: obligatory TAU versus unspecified TAU</p> </li> <li> <p>Type of comparison group: trials comparing psychotherapy plus TAU versus trials comparing psychotherapy with waiting list or no treatment </p> </li> <li> <p>Types of scales: different measuring scales versus each other</p> </li> </ol> </p> <section id="CD012955-sec-0041"> <h5 class="title">Trial Sequential Analysis</h5> <p>Trial Sequential Analysis (TSA) is a methodology that combines a required information size (RIS) calculation for a meta‐analysis with the threshold for statistical significance (<a href="./references#CD012955-bbs2-0260" title="BrokJ , ThorlundK , GluudC , WetterslevJ . Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses. Journal of Clinical Epidemiology2008;61(8):763-9. [DOI: 10.1016/j.jclinepi.2007.10.007] [PMID: 18411040]">Brok 2008</a>; <a href="./references#CD012955-bbs2-0261" title="BrokJ , ThorlundK , WetterslevJ , GluudC . Apparently conclusive meta-analysis may be inconclusive -- trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta-analyses. International Journal of Epidemiology2009;38(1):287-98. [DOI: 10.1093/ije/dyn188] [PMID: 18824466]">Brok 2009</a>; <a href="./references#CD012955-bbs2-0410" title="ThorlundK , DevereauxPJ , WetterslevJ , GuyattG , IoannidisJP , ThabaneL , et al. Can trial sequential monitoring boundaries reduce spurious inferences from meta-analysis?International Journal of Epidemiology2009;38(1):276-86. [DOI: 10.1093/ije/dyn179] [PMID: 18824467]">Thorlund 2009</a>; <a href="./references#CD012955-bbs2-0421" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. Journal of Clinical Epidemiology2008;61(1):64-75. [DOI: 10.1016/j.jclinepi.2007.03.013] [PMID: 18083463]">Wetterslev 2008</a>). TSA is a tool for quantifying the statistical reliability of the data in a cumulative meta‐analysis, adjusting P values for sparse data and for repetitive testing on accumulating data (<a href="./references#CD012955-bbs2-0260" title="BrokJ , ThorlundK , GluudC , WetterslevJ . Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses. Journal of Clinical Epidemiology2008;61(8):763-9. [DOI: 10.1016/j.jclinepi.2007.10.007] [PMID: 18411040]">Brok 2008</a>; <a href="./references#CD012955-bbs2-0261" title="BrokJ , ThorlundK , WetterslevJ , GluudC . Apparently conclusive meta-analysis may be inconclusive -- trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta-analyses. International Journal of Epidemiology2009;38(1):287-98. [DOI: 10.1093/ije/dyn188] [PMID: 18824466]">Brok 2009</a>; <a href="./references#CD012955-bbs2-0410" title="ThorlundK , DevereauxPJ , WetterslevJ , GuyattG , IoannidisJP , ThabaneL , et al. Can trial sequential monitoring boundaries reduce spurious inferences from meta-analysis?International Journal of Epidemiology2009;38(1):276-86. [DOI: 10.1093/ije/dyn179] [PMID: 18824467]">Thorlund 2009</a>; <a href="./references#CD012955-bbs2-0421" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. Journal of Clinical Epidemiology2008;61(1):64-75. [DOI: 10.1016/j.jclinepi.2007.03.013] [PMID: 18083463]">Wetterslev 2008</a>). </p> <p>Comparable to the a priori sample size estimation in a single randomised trial, a meta‐analysis should include an RIS calculation at least as large as the sample size of an adequately powered single trial to reduce the risk of random error. TSA calculates the RIS in a meta‐analysis and provides an alpha‐spending boundary to adjust the significance level for sparse data and repetitive testing on accumulating data (<a href="./references#CD012955-bbs2-0281" title="Copenhagen Trial Unit. TSA - Trial Sequential Analysis. www.ctu.dk/tsa (accessed 12 December 2016).">CTU 2011</a>; <a href="./references#CD012955-bbs2-0421" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. Journal of Clinical Epidemiology2008;61(1):64-75. [DOI: 10.1016/j.jclinepi.2007.03.013] [PMID: 18083463]">Wetterslev 2008</a>); hence, the risk of random error can be assessed. Multiple analyses of accumulating data when new trials emerge leads to repeated significant testing and introduces multiplicity. Thus, use of a conventional P value is prone to exacerbate the risk of random error (<a href="./references#CD012955-bbs2-0253" title="BerkeyCS , MostellerF , LauJ , AntmanEM . Uncertainty of the time of first significance in random effects cumulative meta-analysis. Controlled Clinical Trials1996;17(5):357-71. [PMID: 8932970]">Berkey 1996</a>; <a href="./references#CD012955-bbs2-0341" title="LauJ , SchmidCH , ChalmersTC . Cumulative meta-analysis of clinical trials builds evidence for exemplary medical care. Journal of Clinical Epidemiology1995;48(1):45-57. [PMID: 7853047]">Lau 1995</a>). Meta‐analyses not reaching the RIS are analysed with trial sequential alpha‐spending monitoring boundaries analogous to interim monitoring boundaries in a single trial (<a href="./references#CD012955-bbs2-0421" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. Journal of Clinical Epidemiology2008;61(1):64-75. [DOI: 10.1016/j.jclinepi.2007.03.013] [PMID: 18083463]">Wetterslev 2008</a>). This approach will be crucial in coming updates of the review. </p> <p>If a TSA does not reveal significant findings (no crossing of the alpha‐spending boundary and no crossing of the conventional boundary of P = 0.05) before the RIS has been reached, then the conclusion should either be that more trials are needed to reject or accept an intervention effect that was used for calculation of the required sample size or — in case the cumulated Z‐curve enters the futility area — the anticipated effect can be rejected. </p> <p>We used a MIREDIF from studies defining this or, where we could not find this, we used an assumption that the minimal relevant clinical intervention effect was approximately ½ SD on the used scale, which can be used as a MIREDIF (<a href="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008223.pub3/references#CD008223-bbs2-0162" target="_blank">Norman 2003</a>). </p> <p>We calculated the diversity‐adjusted required information size (DARIS; that is the number of participants required to detect or reject a specific intervention effect in a meta‐analysis), and performed a TSA for the primary outcomes at the end of treatment for the main comparison versus TAU, based on the following a priori assumptions: </p> <p> <ol id="CD012955-list-0010"> <li> <p>the SD of the primary outcomes;</p> </li> <li> <p>an anticipated MIREDIF defined in a trial reporting on this or we used a ½ SD on the used scale; </p> </li> <li> <p>a maximum type I error of 2.0% (due to four primary outcomes; <a href="./references#CD012955-bbs2-0331" title="JakobsenJC , WetterslevJ , WinkelP , LangeT , GluudC . Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods. BMC Medical Research Methodology2014;14:120. [DOI: 10.1186/1471-2288-14-120] [PMCID: PMC4251848] [PMID: 25416419]">Jakobsen 2014</a>); </p> </li> <li> <p>a maximum type II error of 10% (minimum 90% power; <a href="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008223.pub3/references#CD008223-bbs2-0086" target="_blank">Castellini 2018</a>); and </p> </li> <li> <p>the diversity observed in the meta‐analysis.</p> </li> </ol> </p> <p>We furthermore performed a TSA for the three secondary outcomes (for the main comparison versus TAU) not closely connected to the BPD core symptoms (depression, attrition and adverse effects) based on the following priori assumptions: </p> <p> <ol id="CD012955-list-0011"> <li> <p>the SD of the primary outcomes;</p> </li> <li> <p>an anticipated MIREDIF defined in a trial reporting on this or we used a ½ SD on the used scale; </p> </li> <li> <p>a maximum type I error of 0.8% (due to 11 secondary outcomes; <a href="./references#CD012955-bbs2-0331" title="JakobsenJC , WetterslevJ , WinkelP , LangeT , GluudC . Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods. BMC Medical Research Methodology2014;14:120. [DOI: 10.1186/1471-2288-14-120] [PMCID: PMC4251848] [PMID: 25416419]">Jakobsen 2014</a>); </p> </li> <li> <p>a maximum type II error of 10% (minimum 90% power; <a href="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008223.pub3/references#CD008223-bbs2-0086" target="_blank">Castellini 2018</a>); and </p> </li> <li> <p>the diversity observed in the meta‐analysis.</p> </li> </ol> </p> <p>We only performed a TSA for depression as this was the only significant finding.</p> </section> </section> <section id="CD012955-sec-0042"> <h4 class="title">Sensitivity analysis</h4> <p>We conducted sensitivity analyses to determine whether findings were sensitive to:</p> <p> <ol id="CD012955-list-0012"> <li> <p>imprecision, as assessed by GRADE, by conducting TSA analyses on all primary outcomes and for the three secondary outcomes (for the main comparison versus TAU) not closely connected to the BPD core symptoms (depression, attrition and adverse effects) with significant findings. </p> </li> <li> <p>random‐effects or fixed‐effect models.</p> </li> </ol> </p> </section> <section id="CD012955-sec-0043"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We used the GRADE approach to construct 'Summary of findings' tables in which to document the results of review outcomes. Two reviewers (HEC and JSW) , working independently, assessed the quality of the evidence. Any conflicts were resolved by consulting a third author (OJS). The GRADE approach appraises the quality of a body of evidence based on the extent to which one can be confident that an estimate of effect or association reflects the item being assessed. Considerations are due to: within‐trial risk of bias; directness of the evidence; heterogeneity of the data; precision of effect estimates; and risk of publication bias (<a href="./references#CD012955-bbs2-0225" title="AndrewsJ , GuyattG , OxmanAD , AldersonP , DahmP , Falck-YtterY , et al. GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations. Journal of Clinical Epidemiology2013;66(7):719–25. [DOI: 10.1016/j.jclinepi.2012.03.013] [PMID: 23312392]">Andrews 2013a</a>; <a href="./references#CD012955-bbs2-0226" title="AndrewsJC , SchünemannHJ , OxmanAD , PottieK , MeerpohlJJ , CoelloPA , et al. GRADE guidelines: 15. Going from evidence to recommendation - determinants of a recommendation’s direction and strength. Journal of Clinical Epidemiology2013;66(7):726–35. [DOI: 10.1016/j.jclinepi.2013.02.003] [PMID: 23570745]">Andrews 2013b</a>; <a href="./references#CD012955-bbs2-0240" title="BalshemH , HelfandM , SchünemannHJ , OxmanAD , KunzR , BrozekJ , et al. GRADE guidelines: 3. Rating the quality of evidence. Journal of Clinical Epidemiology2011;64(4):401–6. [DOI: 10.1016/j.jclinepi.2010.07.015] [PMID: 21208779]">Balshem 2011</a>; <a href="./references#CD012955-bbs2-0262" title="BrunettiM , ShemiltI , PregnoS , ValeL , OxmanAD , LordJ , et al. GRADE guidelines: 10. Considering resource use and rating the quality of economic evidence. Journal of Clinical Epidemiology2013;66(2):140–50. [DOI: 10.1016/j.jclinepi.2012.04.012] [PMID: 22863410]">Brunetti 2013</a>; <a href="./references#CD012955-bbs2-0311" title="GuyattG , OxmanAD , AklEA , KunzR , VistG , BrozekJ , et al. GRADE guidelines: 1. Introduction - GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology2011;64(4):383–94. [DOI: 10.1016/j.jclinepi.2010.04.026] [PMID: 21195583]">Guyatt 2011a</a>; <a href="./references#CD012955-bbs2-0312" title="GuyattGH , OxmanAD , KunzR , AtkinsD , BrozekJ , VistG , et al. GRADE guidelines: 2. Framing the question and deciding on important outcomes. Journal of Clinical Epidemiology2011;64(4):395–400. [DOI: 10.1016/j.jclinepi.2010.09.012] [PMID: 21194891]">Guyatt 2011b</a>; <a href="./references#CD012955-bbs2-0313" title="GuyattGH , OxmanAD , VistG , KunzR , BrozekJ , Alonso-CoelloP , et al. GRADE guidelines: 4. Rating the quality of evidence - study limitations (risk of bias). Journal of Clinical Epidemiology2011;64(4):407–15. [DOI: 10.1016/j.jclinepi.2010.07.017] [PMID: 21247734]">Guyatt 2011c</a>; <a href="./references#CD012955-bbs2-0314" title="GuyattGH , OxmanAD , MontoriV , VistG , KunzR , BrozekJ , et al. GRADE guidelines: 5. Rating the quality of evidence - publication bias. Journal of Clinical Epidemiology2011;64(12):1277–82. [DOI: 10.1016/j.jclinepi.2011.01.011] [PMID: 21802904]">Guyatt 2011d</a>; <a href="./references#CD012955-bbs2-0315" title="GuyattGH , OxmanAD , KunzR , BrozekJ , Alonso-CoelloP , RindD , et al. GRADE guidelines 6. Rating the quality of evidence - imprecision. Journal of Clinical Epidemiology2011;64(12):1283–93. [DOI: 10.1016/j.jclinepi.2011.01.012] [PMID: 21839614]">Guyatt 2011e</a>; <a href="./references#CD012955-bbs2-0316" title="GuyattGH , OxmanAD , KunzR , WoodcockJ , BrozekJ , HelfandM , et al. GRADE guidelines: 7. Rating the quality of evidence - inconsistency. Journal of Clinical Epidemiology2011;64(12):1294–302. [DOI: 10.1016/j.jclinepi.2011.03.017] [PMID: 21803546]">Guyatt 2011f</a>; <a href="./references#CD012955-bbs2-0317" title="GuyattGH , OxmanAD , KunzR , WoodcockJ , BrozekJ , HelfandM , et al. GRADE guidelines: 8. Rating the quality of evidence - indirectness. Journal of Clinical Epidemiology2011;64(12):1303–10. [DOI: 10.1016/j.jclinepi.2011.04.014] [PMID: 21802903]">Guyatt 2011g</a>; <a href="./references#CD012955-bbs2-0318" title="GuyattG , OxmanAD , SultanS , BrozekJ , GlasziouP , Alonso-CoelloP , et al. GRADE guidelines: 11. Making an overall rating of confidence in effect estimates for a single outcome and for all outcomes. Journal of Clinical Epidemiology2013;66(2):151–7. [DOI: 10.1016/j.jclinepi.2012.01.006] [PMID: 22542023]">Guyatt 2013a</a>; <a href="./references#CD012955-bbs2-0319" title="GuyattGH , OxmanAD , SantessoN , HelfandM , VistG , KunzR , et al. GRADE guidelines: 12. Preparing summary of findings tables - binary outcomes. Journal of Clinical Epidemiology2013;66(2):158–72. [DOI: 10.1016/j.jclinepi.2012.01.012] [PMID: 22609141]">Guyatt 2013b</a>; <a href="./references#CD012955-bbs2-0320" title="GuyattGH , ThorlundK , OxmanAD , WalterSD , PatrickD , FurukawaTA , et al. GRADE guidelines: 13. Preparing summary of findings tables and evidence profiles - continuous outcomes. Journal of Clinical Epidemiology2013;66(2):173–83. [DOI: 10.1016/j.jclinepi.2012.08.001] [PMID: 23116689]">Guyatt 2013c</a>; <a href="./references#CD012955-bbs2-0366" title="MustafaRA , SantessoN , BrozekJ , AklEA , WalterSD , NormanG , et al. The GRADE approach is reproducible in assessing the quality of evidence of quantitative evidence syntheses. Journal of Clinical Epidemiology2013;66(7):736-42. [DOI: 10.1016/j.jclinepi.2013.02.004] [PMID: 23623694]">Mustafa 2013</a>). When possible, we reported the MD or the RR, and we used TSA to rate imprecision (<a href="./references#CD012955-bbs2-0331" title="JakobsenJC , WetterslevJ , WinkelP , LangeT , GluudC . Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods. BMC Medical Research Methodology2014;14:120. [DOI: 10.1186/1471-2288-14-120] [PMCID: PMC4251848] [PMID: 25416419]">Jakobsen 2014</a>). TSA can be used as a secondary analysis in Cochrane Reviews, to provide an additional interpretation of the data from a specific perspective, and can be used for testing imprecision (<a href="./references#CD012955-bbs2-0408" title="ThomasJ , AskieLM , BerlinJA , ElliottJH , GhersiD , SimmondsM , et al. Chapter 22: Prospective approaches to accumulating evidence. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019. Available from www.training.cochrane.org/handbook.">Thomas 2019</a>). </p> <p>We report the four primary outcomes (BPD severity, self‐harm, suicide‐related outcomes and psychosocial functioning) and three secondary outcomes not closely connected to the BPD core symptoms (depression, attrition and adverse effects) in 'Summary of findings' tables for our two main comparisons (<a href="./references#CD012955-bbs2-0235" title="AtkinsD , BestD , BrissPA , EcclesM , Falck-YtterY , FlottorpS , et al. Grading quality of evidence and strength of recommendations. BMJ2004;328(7454):1490-9. [DOI: doi.org/10.1136/bmj.328.7454.1490] [PMC428525] [PMID: 15205295]">Atkins 2004</a>): psychotherapy versus treatment‐as‐usual (<a href="./full#CD012955-tbl-0001">summary of findings Table 1</a>); and psychotherapy versus waiting list or no treatment (<a href="./full#CD012955-tbl-0002">summary of findings Table 2</a>). We also created a third 'Summary of findings' table in which we report data from the DBT and MBT treatments with the highest numbers of primary trials, with DBT being the subject of roughly one‐third of all included trials, followed by MBT with seven RCTs. In this table, we report only the primary outcomes (see <a href="./full#CD012955-tbl-0003">summary of findings Table 3</a>). </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD012955-sec-0044" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD012955-sec-0044"></div> <section id="CD012955-sec-0045"> <h3 class="title">Description of studies</h3> <p>See <a href="./references#CD012955-sec-0637" title="">Characteristics of included studies</a>, <a href="./references#CD012955-sec-0638" title="">Characteristics of excluded studies</a>, <a href="./references#CD012955-sec-0639" title="">Characteristics of studies awaiting classification</a> and <a href="./references#CD012955-sec-0640" title="">Characteristics of ongoing studies</a> tables. </p> <section id="CD012955-sec-0046"> <h4 class="title">Results of the search</h4> <p>All electronic databases and search periods are listed in the Methods section (see <a href="#CD012955-sec-0024">Electronic searches</a>). There were no language, date or document format restrictions. This current review is part of a series of reviews on interventions for BPD. Therefore, we used a very comprehensive search strategy, covering all psychotherapeutic or pharmacological treatment (or both) of BPD. </p> <p>Altogether, the searches generated 22,078 records, of which 3477 were duplicates. Following screening of titles and abstracts, 400 citations merited closer inspection. An assessment of full texts for possible inclusion into this review led to the exclusion of 118 reports. This left 282 reports included. Of these, 50 reports referred to 33 different ongoing trials (see <a href="./references#CD012955-bbs1-0004" title="">Ongoing studies</a>). Another 12 reports related to 11 different trials that we were unable to classify definitively as included or excluded at this point of time, despite our best efforts to retrieve further information from the trial authors (see <a href="./references#CD012955-bbs1-0003" title="">Studies awaiting classification</a>). This finally left 220 reports relating to 75 different included trials (see <a href="./references#CD012955-bbs1-0001" title="">Included studies</a>, and <a href="#CD012955-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD012955-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram" data-id="CD012955-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> </div> </section> <section id="CD012955-sec-0047"> <h4 class="title">Included studies</h4> <p>Below, we summarise the key characteristics of the included trials. For information about which trials correspond to which characteristics for certain categories below, please see <a href="#CD012955-tbl-0005">Table 2</a>. Further detail can also be found in the <a href="./references#CD012955-sec-0637" title="">Characteristics of included studies</a> tables.   </p> <div class="table" id="CD012955-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Key demographic characteristics of the included studies</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Category</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study frequency</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="3" rowspan="1" scope="col" valign="bottom"> <p><b><i>Sample size</i> </b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sample size above 100 participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012955-bbs2-0002" title='AndreoliA , BurnandY , CochennecMF , MarieD , Di ClementeT , OhlendorfP . Psychoanalytic psychotherapy and venlafaxine among acutely suicidal borderline patients: a randomized clinical study. European Psychiatry2009;24(Suppl 1):S93. [DOI: 10.1016/S0924-9338(09)70326-8] [S18-03]AndreoliA , BurnandY , CochennecMF , OhlendorfP , FrambatiL , Gaudry-MaireD , et al. Disappointed love and suicide: a randomized controlled trial of "abandonment psychotherapy" among borderline patients. Journal of Personality Disorders2016;30(2):271-87. [DOI: 10.1521/pedi_2015_29_196] [PMID: 26111250]AndreoliA , BurnandY , FrambatiL , ManningD , FrancesA . Abandonment psychotherapy and psychosocial functioning among suicidal patients with borderline personality disorder: a 3-year naturalistic follow-up. Journal of Personality Disorders 2019 Feb 20 [Epub ahead of print]. [DOI: 10.1521/pedi_2019_33_423] [PMID: 30785852]AndreoliA . Re: your study in BPD - Cochrane Collaboration review [personal communication]. Email to: J Stoffers-Winterling 5 June 2018. '>Andreoli 2016</a>; <a href="./references#CD012955-bbs2-0003" title="AntonsenBT , JohansenMS , RøFG , KvarsteinEH , WilbergT . Is reflective functioning associated with clinical symptoms and long-term course in patients with personality disorders?Comprehensive Psychiatry2016;64:46-58. [DOI: 10.1016/j.comppsych.2015.05.016] [PMID: 26104432]AntonsenBT , KlungsøyrO , KampsA , HummelenB , JohansenMS , PedersenG , et al. Step-down versus outpatient psychotherapeutic treatment for personality disorders: 6-year follow-up of the Ullevål personality project. BMC Psychiatry2014;14:119. [DOI: 10.1186/1471-244X-14-119] [PMC4000615] [PMID: 24758722]AntonsenBT , KvarsteinEH , Urnes Ø, HummelenB , KarterudS , WilbergT . Favourable outcome of long-term combined psychotherapy for patients with borderline personality disorder: six-year follow-up of a randomized study. Psychotherapy Research2017;27(1):51-63. [DOI: 10.1080/10503307.2015.1072283] [PMID: 26261865]ArnevikE , WilbergT , Urnes Ø, JohansenM , MonsenJT , KarterudS . Psychotherapy for personality disorders: short-term day hospital psychotherapy versus outpatient individual therapy - a randomized controlled study. European Psychiatry2009;24(2):71-8. [DOI: 10.1016/j.eurpsy.2008.09.004] [PMID: 19097870]GullestadFS , JohansenMS , HøglendP , KarterudS , WilbergT . Mentalization as a moderator of treatment effects: findings from a randomized clinical trial for personality disorders. Psychotherapy Research2013;23(6):674-89. [DOI: 10.1080/10503307.2012.684103] [PMID: 22612470]GullestadFS . Re: questions regarding your trial on day hospital step-down program [personal communication]. Email to: E Faltinsen 4 December 2017. KvarsteinEH , ArnevikE , HalsteinliV , RøFG , KarterudS , WilbergT . Health service costs and clinical gains of psychotherapy for personality disorders: a randomized controlled trial of day-hospital-based step-down treatment versus outpatient treatment at a specialist practice. BMC Psychiatry2013;13:315. [DOI: 10.1186/1471-244X-13-315] [PMC4222503] [PMID: 24268099]">Antonsen 2017</a>; <a href="./references#CD012955-bbs2-0047" title="BedicsJD , AtkinsDC , ComtoisKA , LinehanMM . Treatment differences in the therapeutic relationship and introject during a 2-year randomized controlled trial of dialectical behavior therapy versus nonbehavioral psychotherapy experts for borderline personality disorder. Journal of Consulting and Clinical Psychology2012;80(1):66-77. [DOI: 10.1037/a0026113] [PMC3265694] [PMID: 22061867]BedicsJD , AtkinsDC , ComtoisKA , LinehanMM . Weekly therapist ratings of the therapeutic relationship and patient introject furing the course of dialectical behavioral therapy for the treatment of borderline personality disorder. Psychotherapy2012;49(2):231-40. [DOI: 10.1037/a0028254] [PMID: 22642526]BedicsJD , AtkinsDC , HarnedMS , LinehanMM . The therapeutic alliance as a predictor of outcome in dialectical behavior therapy versus nonbehavioral psychotherapy by experts for borderline personality disorder. Psychotherapy2015;52(1):67-77. [DOI: 10.1037/a0038457] [PMID: 25751116]BrownMZ , LinehanMM , ComtoisKA , MurrayA , ChapmanAL . Shame as a prospective predictor of self-inflicted injury in borderline personality disorder: a multi-modal analysis. Behaviour Research and Therapy2009;47(10):815-22. [DOI: 10.1016/j.brat.2009.06.008] [PMC2761705] [PMID: 19596223 ]CoyleTN , ShaverJA , LinehanMM . On the potential for iatrogenic effects of psychiatric crisis services: the example of dialectical behavior therapy for adult women with borderline personality disorder. Journal of Consulting and Clinical Psychology2018;86(2):116-24. [DOI: 10.1037/ccp0000275] [PMID: 29369662]HarnedMS , ChapmanAL , Dexter-MazzaET , MurrayA , ComtoisKA , LinehanMM . Treating co-occurring Axis I disorders in recurrently suicidal women with borderline personality disorder: a 2-year randomized trial of dialectical behavior therapy versus community treatment by experts. Journal of Consulting and Clinical Psychology2008;76(6):1068-75. [DOI: 10.1037/a0014044] [PMID: 19045974]HarnedMS , ChapmanAL , Dexter-MazzaET , MurrayA , ComtoisKA , LinehanMM . Treating co-occurring Axis I disorders in recurrently suicidal women with borderline personality disorder: a 2-year randomized trial of dialectical behavior therapy versus community treatment by experts. Personality Disorders: Theory, Research, and Treatment2009;S(1):35-45. [DOI: 10.1037/1949-2715.S.1.35]HarnedMS , JacksonSC , ComtoisKA , LinehanMM . Dialectical behavior therapy as a precursor to PTSD treatment for suicidal and/or self-injuring women with bordreline personality disorder. Journal of Traumatic Stress2010;23(4):421-9. [DOI: 10.1002/jts.20553] [PMID: 20648564]LindenboimN , ComtoisKA , LinehanMM . Skills practice in dialectical behavior therapy for suicidal women meeting criteria for borderline personality disorder. Cognitive and Behavioral Practice2007;14(2):147-56. [DOI: 10.1016/j.cbpra.2006.10.004]LinehanMM , ComtoisKA , MurrayAM , BrownMZ , GallopRJ , HeardHL , et al. Two-year randomized controlled trial and follow-up of dialectical behavior therapy vs therapy by experts for suicidal behaviors and borderline personality disorder. Archives of General Psychiatry2006;63(7):757-66. [DOI: 10.1001/archpsyc.63.7.757] [PMID: 16818865]LinehanMM . Error in table in: two-year randomized controlled trial and follow-up of dialectical behavior therapy vs therapy by experts for suicidal behaviors and borderline personality disorder. Archives of General Psychiatry2007;64(12):1401. Erratum for: Archives of General Psychiatry 2007;64(12):1401. McMainS . Dialectic behaviour therapy reduces suicide attempts compared with non-behavioural psychotherapy in women with borderline personality disorder. Evidence-Based Mental Health2007;10(1):18. [DOI: 10.1136/ebmh.10.1.18] [PMID: 17255387]NeacsiuAD , LunguA , HarnedMS , RizviSL , LinehanMM . Impact of dialectical behavior therapy versus community treatment by experts on emotional experience, expression, and acceptance in borderline personality disorder. Behaviour Research and Therapy2014;53:47-54. [DOI: 10.1016/j.brat.2013.12.004] [PMC3955205] [PMID: 24418652]NeacsiuAD , RizviSL , LinehanMM . Dialectical behavior therapy skills use as a mediator and outcome of treatment for borderline personality disorder. Behaviour Research and Therapy2010;48(9):832-9. [DOI: 10.1016/j.brat.2010.05.017] [PMC2914145] [PMID: 20579633]SecristCD . The Role of Executive Functioning in the Treatment of Borderline Personality Disorder [PhD thesis]. Washington (DC): University of Washington, 2014. ">Linehan 2006</a>; <a href="./references#CD012955-bbs2-0049" title="CaseBG . Letter to the editor on 'McMain SF, Links PS, Gnam WH, Guimond T, Cardish RJ, Korman L, et al. A randomized trial of dialectical behavior therapy versus general psychiatric management for borderline personality disorder. American Journal of Psychiatry 2009;166(12):1365-74. DOI: 10.1176/appi.ajp.2009.09010039'. American Journal of Psychiatry2010;167(4):475. [DOI: 10.1176/appi.ajp.2009.09101532] [PMID: 20360332 ]ISRCTN02634417. Hope for chronically suicidal patient: evaluating the clinical and health services impact of dialectical behaviour therapy (DBT) in individuals with borderline personality disorder [Evaluating the clinical and health services impact of dialectical behaviour therapy (DBT) in individuals with borderline personality disorder: a randomised controlled trial]. www.isrctn.com/ISRCTN02634417 (first received 16 November 2005). [DOI: 10.1186/ISRCTN02634417]McMainSF , FitzpatrickS , BoritzT , BarnhartR , LinksP , StreinerDL . Outcome trajectories and prognostic factors for suicide and self-harm behaviors in patients with borderline personaliy disorder following one year of outpatient psychotherapy. Journal of Personality Disorders2018;32(4):497-512. [DOI: 10.1521/pedi_2017_31_309] [PMID: 28910214]McMainSF , LinksPS , GnamWH , GuimondT , CardishRJ , KormanL , et al. A randomized trial of dialectical behavior therapy versus general psychiatric management for borderline personality disorder. American Journal of Psychiatry2009;166(12):1365-74. [DOI: 10.1176/appi.ajp.2009.09010039] [PMID: 19755574]McMainSF . Dr McMain replies to letter to the editor on 'McMain SF, Links PS, Gnam WH, Guimond T, Cardish RJ, Korman L, et al. A randomized trial of dialectical behavior therapy versus general psychiatric management for borderline personality disorder. American Journal of Psychiatry 2009;166(12):1365-74. DOI: 10.1176/appi.ajp.2009.09010039'. American Journal of Psychiatry2010;167(4):475-6. [DOI: 10.1176/appi.ajp.2009.09101532r)]NCT00154154. Hope for the chronically suicidal patient [Hope for the chronically suicidal patient: evaluating the clinical and health services impact of dialectical behaviour therapy in individuals with borderline personality disorder]. www.clinicaltrials.gov/ct2/show/NCT00154154 (first received 7 September 2005). ">McMain 2009</a>; <a href="./references#CD012955-bbs2-0051" title="McMurranM , CrawfordMJ , ReillyJ , DelportJ , McCroneP , WhithamD , et al. Psychoeducation with problem-solving (PEPS) therapy for adults with personality disorder: a pragmatic randomised controlled trial to determine the clinical effectiveness and cost-effectiveness of a manualised intervention to improve social functioning. Health Technology Assessment2016;20(52):1-282. [DOI: 10.3310/hta20520]McMurranM . RE: Cochrane Collaboration review - PEPS study [personal communication]. Email to: J Stoffers-Winterling 5 July 2018. McMurranM . Request for data on BPD subjects in the PEPS rcp-study for use a new Cochrane review [personal communication]. Email to: M Kongerslev 7 March 2017. ">McMurran 2016</a> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="3" rowspan="1" scope="col" valign="bottom"> <p><b><i>Setting</i> </b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Studies with inpatient settings</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Jahangard-2012" target="_blank">Jahangard 2012</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Leichsenring-2016" target="_blank">Leichsenring 2016</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Mohamadizadeh-2017" target="_blank">Mohamadizadeh 2017</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Schilling-2018" target="_blank">Schilling 2018</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Stanley-2017" target="_blank">Stanley 2017</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Studies with both inpatient and outpatient settings</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Antonsen-2017" target="_blank">Antonsen 2017</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Bateman-1999" target="_blank">Bateman 1999</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Davidson-2014" target="_blank">Davidson 2014</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Gleeson-2012" target="_blank">Gleeson 2012</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Kredlow-2017b" target="_blank">Kredlow 2017b</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Laurenssen-2018" target="_blank">Laurenssen 2018</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Smith-2012" target="_blank">Smith 2012</a> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="3" rowspan="1" scope="col" valign="bottom"> <p><b><i>Gender</i> </b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Only females included</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Carter-2010" target="_blank">Carter 2010</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Doering-2010" target="_blank">Doering 2010</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Farrell-2009" target="_blank">Farrell 2009</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Gratz-2006" target="_blank">Gratz 2006</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Gratz-2014" target="_blank">Gratz 2014</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Harned-2014" target="_blank">Harned 2014</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Koons-2001a" target="_blank">Koons 2001a</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Linehan-1991" target="_blank">Linehan 1991</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Linehan-1994" target="_blank">Linehan 1994</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Linehan-2006" target="_blank">Linehan 2006</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Linehan-2015a" target="_blank">Linehan 2015a</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Mohamadizadeh-2017" target="_blank">Mohamadizadeh 2017</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Smith-2012" target="_blank">Smith 2012</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Van-den-Bosch-2005" target="_blank">Van den Bosch 2005</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Weinberg-2006" target="_blank">Weinberg 2006</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Zanarini-2008" target="_blank">Zanarini 2008</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Zanarini-2018" target="_blank">Zanarini 2018</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Only males included</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Bianchini-2019" target="_blank">Bianchini 2019</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Kamalabadi-2012" target="_blank">Kamalabadi 2012</a> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="3" rowspan="1" scope="col" valign="bottom"> <p><b><i>Diagnostic classification</i> </b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DSM‐III diagnosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Linehan-1991" target="_blank">Linehan 1991</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DSM‐III‐R diagnosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Bateman-1999" target="_blank">Bateman 1999</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Koons-2001a" target="_blank">Koons 2001a</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Linehan-1994" target="_blank">Linehan 1994</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Turner-2000" target="_blank">Turner 2000</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DSM‐IV diagnosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Borschmann-2013" target="_blank">Borschmann 2013</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-McMurran-2016" target="_blank">McMurran 2016</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Mohamadizadeh-2017" target="_blank">Mohamadizadeh 2017</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Priebe-2012" target="_blank">Priebe 2012</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Rossouw-2012b" target="_blank">Rossouw 2012b</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Schilling-2018" target="_blank">Schilling 2018</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DSM‐IV‐TR diagnosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Andreoli-2016" target="_blank">Andreoli 2016</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Antonsen-2017" target="_blank">Antonsen 2017</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Bateman-2009" target="_blank">Bateman 2009</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Bellino-2006" target="_blank">Bellino 2006</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Bellino-2007" target="_blank">Bellino 2007</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Bellino-2010" target="_blank">Bellino 2010</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Blum-2008" target="_blank">Blum 2008</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Bos-2010" target="_blank">Bos 2010</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Carter-2010" target="_blank">Carter 2010</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Cottraux-2009" target="_blank">Cottraux 2009</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Davidson-2006" target="_blank">Davidson 2006</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Davidson-2014" target="_blank">Davidson 2014</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Doering-2010" target="_blank">Doering 2010</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Elices-2016" target="_blank">Elices 2016</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Feigenbaum-2012" target="_blank">Feigenbaum 2012</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Feliu_x002d_Soler-2017" target="_blank">Feliu-Soler 2017</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Giesen_x002d_Bloo-2006" target="_blank">Giesen-Bloo 2006</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Gleeson-2012" target="_blank">Gleeson 2012</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Gratz-2006" target="_blank">Gratz 2006</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Gratz-2014" target="_blank">Gratz 2014</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Gregory-2008b" target="_blank">Gregory 2008b</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Haeyen-2018" target="_blank">Haeyen 2018</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Harned-2014" target="_blank">Harned 2014</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Jahangard-2012" target="_blank">Jahangard 2012</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Jochems-2015" target="_blank">Jochems 2015</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-J_x00f8_rgensen-2013" target="_blank">Jørgensen 2013</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Kamalabadi-2012" target="_blank">Kamalabadi 2012</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Kramer-2011" target="_blank">Kramer 2011</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Kramer-2014" target="_blank">Kramer 2014</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Kramer-2016" target="_blank">Kramer 2016</a>: <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Kredlow-2017a" target="_blank">Kredlow 2017a</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Kredlow-2017b" target="_blank">Kredlow 2017b</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Laurenssen-2018" target="_blank">Laurenssen 2018</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Lepp_x00e4_nen-2016" target="_blank">Leppänen 2016</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Lin-2019" target="_blank">Lin 2019</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Linehan-2006" target="_blank">Linehan 2006</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-McMain-2009" target="_blank">McMain 2009</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-McMain-2017" target="_blank">McMain 2017</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Morey-2010" target="_blank">Morey 2010</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Morton-2012" target="_blank">Morton 2012</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Nadort-2009" target="_blank">Nadort 2009</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Pascual-2015" target="_blank">Pascual 2015</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Philips-2018" target="_blank">Philips 2018</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Reneses-2013" target="_blank">Reneses 2013</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Robinson-2016" target="_blank">Robinson 2016</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Santisteban-2015" target="_blank">Santisteban 2015</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Schilling-2018" target="_blank">Schilling 2018</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Sinnaeve-2018" target="_blank">Sinnaeve 2018</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Soler-2009" target="_blank">Soler 2009</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Smith-2012" target="_blank">Smith 2012</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Van-den-Bosch-2005" target="_blank">Van den Bosch 2005</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Weinberg-2006" target="_blank">Weinberg 2006</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Zanarini-2008" target="_blank">Zanarini 2008</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Zanarini-2018" target="_blank">Zanarini 2018</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ICD‐10 diagnosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Leichsenring-2016" target="_blank">Leichsenring 2016</a> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="3" rowspan="1" scope="col" valign="bottom"> <p><b><i>Diagnostic assessment</i> </b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BPDSI‐IV (<a href="./references#CD012955-bbs2-0233" title="ArntzA , Van den HoornM , CornelisJ , VerheulR , Van den BoschW , De BieAJ . Reliability and validity of the borderline personality disorder severity index. Journal of Personality Disorders2003;17(1):45-59. [PMID: 12659546]">Arntz 2003</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Kamalabadi-2012" target="_blank">Kamalabadi 2012</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CI‐BPD (<a href="./references#CD012955-bbs2-0434" title="ZanariniMC . The Childhood Interview for DSM-IV Borderline Personality Disorder (CI-BPD). Belmont (MA): McLean Hospital and Harvard Medical School, 2003.">Zanarini 2003b</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Rossouw-2012b" target="_blank">Rossouw 2012b</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DIB (<a href="./references#CD012955-bbs2-0305" title="GundersonJG , KolbJE , AustinV . The diagnostic interview for borderline patients. American Journal of Psychiatry1981;138(7):896-903. [DOI: 10.1176/ajp.138.7.896] [PMID: 7258348]">Gunderson 1981</a>) or DIB‐R (<a href="./references#CD012955-bbs2-0430" title="ZanariniMC , GundersonJG , FrankenburgFR , ChaunceyDL . The revised Diagnostic Interview for Borderlines: discriminating BPD from other Axis II disorders. Journal of Personality Disorders1989;3(1):10-8. [DOI: 10.1521/pedi.1989.3.1.10]">Zanarini 1989</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Cottraux-2009" target="_blank">Cottraux 2009</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Feliu_x002d_Soler-2017" target="_blank">Feliu-Soler 2017</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Linehan-1991" target="_blank">Linehan 1991</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Zanarini-2008" target="_blank">Zanarini 2008</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DIB‐R (<a href="./references#CD012955-bbs2-0430" title="ZanariniMC , GundersonJG , FrankenburgFR , ChaunceyDL . The revised Diagnostic Interview for Borderlines: discriminating BPD from other Axis II disorders. Journal of Personality Disorders1989;3(1):10-8. [DOI: 10.1521/pedi.1989.3.1.10]">Zanarini 1989</a>) and the BSI (<a href="./references#CD012955-bbs2-0278" title="ConteHR , PlutchikR , KarasuTB , JerretI . A self-report borderline scale. Discriminative validity and preliminary norms. Journal of Nervous and Mental Disease1980;168(7):428-35. [DOI: 10.1097/00005053-198007000-00007] [PMID: 7400793]">Conte 1980</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Farrell-2009" target="_blank">Farrell 2009</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DIB‐R (<a href="./references#CD012955-bbs2-0430" title="ZanariniMC , GundersonJG , FrankenburgFR , ChaunceyDL . The revised Diagnostic Interview for Borderlines: discriminating BPD from other Axis II disorders. Journal of Personality Disorders1989;3(1):10-8. [DOI: 10.1521/pedi.1989.3.1.10]">Zanarini 1989</a>) plus any other DSM‐oriented diagnostic interview SCID‐II (<a href="./references#CD012955-bbs2-0295" title="FirstMB , GibbonM , SpitzerRL , WilliamsJBW , BenjaminLS . Structured Clinical Interview for DSM-IV Axis II Personality Disorders (SCID-II). Washington (DC): American Psychiatric Press, 1997.">First 1997</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Bateman-1999" target="_blank">Bateman 1999</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DIPD‐IV (<a href="./references#CD012955-bbs2-0429" title="ZanariniMC , FrankenburgFR , ChaunceyDL , GundersonJG . The Diagnostic Interview for Personality Disorders: interrater and test-retest reliability. Comprehensive Psychiatry1987;28(6):467-80. [DOI: 10.1016/0010-440x(87)90012-5] [PMID: 3691072]">Zanarini 1987</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Gratz-2006" target="_blank">Gratz 2006</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Gratz-2014" target="_blank">Gratz 2014</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Morey-2010" target="_blank">Morey 2010</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IPDE (<a href="./references#CD012955-bbs2-0358" title="LorangerAW , JancaA , SartoriusN , editor(s). Assessment and Diagnosis of Personality Disorders. The ICD-10 International Personality Disorder Examination (IPDE). Cambridge (Camb): Cambridge University Press, 1995. [WHO IRIS: apps.who.int/iris/handle/10665/41912]">Loranger 1995</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Andreoli-2016" target="_blank">Andreoli 2016</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Harned-2014" target="_blank">Harned 2014</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-McMain-2017" target="_blank">McMain 2017</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-McMurran-2016" target="_blank">McMurran 2016</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IPDE‐self‐rating screening and questionnaire, with the preliminary findings confirmed in clinical interviews by a psychiatrist </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Carter-2010" target="_blank">Carter 2010</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Millon Clinical Multiaxial Inventory, 3rd Edition (MCMI‐III)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Jahangard-2012" target="_blank">Jahangard 2012</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PDE (<a href="./references#CD012955-bbs2-0357" title="LorangerAW . Personality Disorder Examination (PDE) Manual. Yonkers (NY): DV Communications, 1988.">Loranger 1988</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Turner-2000" target="_blank">Turner 2000</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SCID‐II (<a href="./references#CD012955-bbs2-0295" title="FirstMB , GibbonM , SpitzerRL , WilliamsJBW , BenjaminLS . Structured Clinical Interview for DSM-IV Axis II Personality Disorders (SCID-II). Washington (DC): American Psychiatric Press, 1997.">First 1997</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Amianto-2011" target="_blank">Amianto 2011</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Antonsen-2017" target="_blank">Antonsen 2017</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Bateman-1999" target="_blank">Bateman 1999</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Bateman-2009" target="_blank">Bateman 2009</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Bellino-2006" target="_blank">Bellino 2006</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Bellino-2007" target="_blank">Bellino 2007</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Bellino-2010" target="_blank">Bellino 2010</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Borschmann-2013" target="_blank">Borschmann 2013</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Bos-2010" target="_blank">Bos 2010</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Davidson-2006" target="_blank">Davidson 2006</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Davidson-2014" target="_blank">Davidson 2014</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Doering-2010" target="_blank">Doering 2010</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Elices-2016" target="_blank">Elices 2016</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Feigenbaum-2012" target="_blank">Feigenbaum 2012</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Giesen_x002d_Bloo-2006" target="_blank">Giesen-Bloo 2006</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Gleeson-2012" target="_blank">Gleeson 2012</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Gregory-2008b" target="_blank">Gregory 2008b</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Haeyen-2018" target="_blank">Haeyen 2018</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-J_x00f8_rgensen-2013" target="_blank">Jørgensen 2013</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Koons-2001a" target="_blank">Koons 2001a</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Kramer-2011" target="_blank">Kramer 2011</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Kramer-2014" target="_blank">Kramer 2014</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Kramer-2016" target="_blank">Kramer 2016</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Kredlow-2017a" target="_blank">Kredlow 2017a</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Kredlow-2017b" target="_blank">Kredlow 2017b</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Laurenssen-2018" target="_blank">Laurenssen 2018</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Leichsenring-2016" target="_blank">Leichsenring 2016</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Lepp_x00e4_nen-2016" target="_blank">Leppänen 2016</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Lin-2019" target="_blank">Lin 2019</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Linehan-1994" target="_blank">Linehan 1994</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Linehan-2006" target="_blank">Linehan 2006</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Linehan-2015a" target="_blank">Linehan 2015a</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Koons-2001a" target="_blank">Koons 2001a</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Morton-2012" target="_blank">Morton 2012</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Nadort-2009" target="_blank">Nadort 2009</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Pascual-2015" target="_blank">Pascual 2015</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Philips-2018" target="_blank">Philips 2018</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Priebe-2012" target="_blank">Priebe 2012</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Reneses-2013" target="_blank">Reneses 2013</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Robinson-2016" target="_blank">Robinson 2016</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Schilling-2018" target="_blank">Schilling 2018</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Soler-2009" target="_blank">Soler 2009</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Smith-2012" target="_blank">Smith 2012</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Van-den-Bosch-2005" target="_blank">Van den Bosch 2005</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Weinberg-2006" target="_blank">Weinberg 2006</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Zanarini-2018" target="_blank">Zanarini 2018</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SIDP‐IV (<a href="./references#CD012955-bbs2-0383" title="PfohlB , BlumN , ZimmermanM . Structured Interview for DSM-IV Personality (SIPD-IV). Washington (DC): American Psychiatric Press, 1997.">Pfohl 1997</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Blum-2008" target="_blank">Blum 2008</a> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="3" rowspan="1" scope="col" valign="bottom"> <p><b><i>Exclusion criteria in included studies</i> </b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants with substance abuse or dependence excluded</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Amianto-2011" target="_blank">Amianto 2011</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Andreoli-2016" target="_blank">Andreoli 2016</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Antonsen-2017" target="_blank">Antonsen 2017</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Bateman-1999" target="_blank">Bateman 1999</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Bateman-2009" target="_blank">Bateman 2009</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Bellino-2006" target="_blank">Bellino 2006</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Bellino-2007" target="_blank">Bellino 2007</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Bellino-2010" target="_blank">Bellino 2010</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Blum-2008" target="_blank">Blum 2008</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Carmona-_x00ed_-Farr_x00e9_s-2019" target="_blank">Carmona í Farrés 2019</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Cottraux-2009" target="_blank">Cottraux 2009</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Davidson-2006" target="_blank">Davidson 2006</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Doering-2010" target="_blank">Doering 2010</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Feigenbaum-2012" target="_blank">Feigenbaum 2012</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Giesen_x002d_Bloo-2006" target="_blank">Giesen-Bloo 2006</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Gratz-2006" target="_blank">Gratz 2006</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Gratz-2014" target="_blank">Gratz 2014</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-J_x00f8_rgensen-2013" target="_blank">Jørgensen 2013</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Kamalabadi-2012" target="_blank">Kamalabadi 2012</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Koons-2001a" target="_blank">Koons 2001a</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Kramer-2011" target="_blank">Kramer 2011</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Kredlow-2017a" target="_blank">Kredlow 2017a</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Laurenssen-2018" target="_blank">Laurenssen 2018</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Leichsenring-2016" target="_blank">Leichsenring 2016</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Lepp_x00e4_nen-2016" target="_blank">Leppänen 2016</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Lin-2019" target="_blank">Lin 2019</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Linehan-1991" target="_blank">Linehan 1991</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Linehan-1994" target="_blank">Linehan 1994</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-McMain-2009" target="_blank">McMain 2009</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Mohamadizadeh-2017" target="_blank">Mohamadizadeh 2017</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Morey-2010" target="_blank">Morey 2010</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Nadort-2009" target="_blank">Nadort 2009</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Pascual-2015" target="_blank">Pascual 2015</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Rossouw-2012b" target="_blank">Rossouw 2012b</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Schilling-2018" target="_blank">Schilling 2018</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Schuppert-2012" target="_blank">Schuppert 2012</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Sinnaeve-2018" target="_blank">Sinnaeve 2018</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Soler-2009" target="_blank">Soler 2009</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Stanley-2017" target="_blank">Stanley 2017</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Smith-2012" target="_blank">Smith 2012</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Weinberg-2006" target="_blank">Weinberg 2006</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Zanarini-2008" target="_blank">Zanarini 2008</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Zanarini-2018" target="_blank">Zanarini 2018</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Alcohol or substance abuse and dependence included</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Davidson-2014" target="_blank">Davidson 2014</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Gregory-2008b" target="_blank">Gregory 2008b</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Robinson-2016" target="_blank">Robinson 2016</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Santisteban-2015" target="_blank">Santisteban 2015</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antisocial features or full antisocial personality disorders excluded</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Antonsen-2017" target="_blank">Antonsen 2017</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Carter-2010" target="_blank">Carter 2010</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Cottraux-2009" target="_blank">Cottraux 2009</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Doering-2010" target="_blank">Doering 2010</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Giesen_x002d_Bloo-2006" target="_blank">Giesen-Bloo 2006</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-J_x00f8_rgensen-2013" target="_blank">Jørgensen 2013</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Kamalabadi-2012" target="_blank">Kamalabadi 2012</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Koons-2001a" target="_blank">Koons 2001a</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Nadort-2009" target="_blank">Nadort 2009</a> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="3" rowspan="1" scope="col" valign="bottom"> <p><b><i>Duration of interventions</i> </b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Less than six months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Andreoli-2016" target="_blank">Andreoli 2016</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Antonsen-2017" target="_blank">Antonsen 2017</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Blum-2008" target="_blank">Blum 2008</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Bohus-2013" target="_blank">Bohus 2013</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Borschmann-2013" target="_blank">Borschmann 2013</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Bos-2010" target="_blank">Bos 2010</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Davidson-2014" target="_blank">Davidson 2014</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Elices-2016" target="_blank">Elices 2016</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Feliu_x002d_Soler-2017" target="_blank">Feliu-Soler 2017</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Gleeson-2012" target="_blank">Gleeson 2012</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Gratz-2006" target="_blank">Gratz 2006</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Gratz-2014" target="_blank">Gratz 2014</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Haeyen-2018" target="_blank">Haeyen 2018</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Jahangard-2012" target="_blank">Jahangard 2012</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Kamalabadi-2012" target="_blank">Kamalabadi 2012</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Kramer-2011" target="_blank">Kramer 2011</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Kramer-2014" target="_blank">Kramer 2014</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Kramer-2016" target="_blank">Kramer 2016</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Kredlow-2017a" target="_blank">Kredlow 2017a</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Kredlow-2017b" target="_blank">Kredlow 2017b</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Leichsenring-2016" target="_blank">Leichsenring 2016</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Lin-2019" target="_blank">Lin 2019</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-McMain-2017" target="_blank">McMain 2017</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-McMurran-2016" target="_blank">McMurran 2016</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Mehlum-2014" target="_blank">Mehlum 2014</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Mohamadizadeh-2017" target="_blank">Mohamadizadeh 2017</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Morey-2010" target="_blank">Morey 2010</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Morton-2012" target="_blank">Morton 2012</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Pascual-2015" target="_blank">Pascual 2015</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Reneses-2013" target="_blank">Reneses 2013</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Schilling-2018" target="_blank">Schilling 2018</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Schuppert-2012" target="_blank">Schuppert 2012</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Soler-2009" target="_blank">Soler 2009</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Weinberg-2006" target="_blank">Weinberg 2006</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Zanarini-2008" target="_blank">Zanarini 2008</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Zanarini-2018" target="_blank">Zanarini 2018</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Between six months and 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Amianto-2011" target="_blank">Amianto 2011</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Bellino-2006" target="_blank">Bellino 2006</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Bellino-2007" target="_blank">Bellino 2007</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Bellino-2010" target="_blank">Bellino 2010</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Bianchini-2019" target="_blank">Bianchini 2019</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Carmona-_x00ed_-Farr_x00e9_s-2019" target="_blank">Carmona í Farrés 2019</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Carter-2010" target="_blank">Carter 2010</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Cottraux-2009" target="_blank">Cottraux 2009</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Davidson-2006" target="_blank">Davidson 2006</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Doering-2010" target="_blank">Doering 2010</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Farrell-2009" target="_blank">Farrell 2009</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Feigenbaum-2012" target="_blank">Feigenbaum 2012</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Gregory-2008b" target="_blank">Gregory 2008b</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Harned-2014" target="_blank">Harned 2014</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Jochems-2015" target="_blank">Jochems 2015</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Koons-2001a" target="_blank">Koons 2001a</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Lepp_x00e4_nen-2016" target="_blank">Leppänen 2016</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Linehan-1991" target="_blank">Linehan 1991</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Linehan-1994" target="_blank">Linehan 1994</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Linehan-2006" target="_blank">Linehan 2006</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Linehan-2015a" target="_blank">Linehan 2015a</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-McMain-2009" target="_blank">McMain 2009</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Priebe-2012" target="_blank">Priebe 2012</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Robinson-2016" target="_blank">Robinson 2016</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Rossouw-2012b" target="_blank">Rossouw 2012b</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Salzer-2014" target="_blank">Salzer 2014</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Santisteban-2015" target="_blank">Santisteban 2015</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Sinnaeve-2018" target="_blank">Sinnaeve 2018</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Stanley-2017" target="_blank">Stanley 2017</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Smith-2012" target="_blank">Smith 2012</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Turner-2000" target="_blank">Turner 2000</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Van-den-Bosch-2005" target="_blank">Van den Bosch 2005</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Longer than 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Bateman-1999" target="_blank">Bateman 1999</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Bateman-2009" target="_blank">Bateman 2009</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Giesen_x002d_Bloo-2006" target="_blank">Giesen-Bloo 2006</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-J_x00f8_rgensen-2013" target="_blank">Jørgensen 2013</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Laurenssen-2018" target="_blank">Laurenssen 2018</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Nadort-2009" target="_blank">Nadort 2009</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Philips-2018" target="_blank">Philips 2018</a> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="3" rowspan="1" scope="col" valign="bottom"> <p><b><i>Formats of interventions</i> </b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Individual treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Amianto-2011" target="_blank">Amianto 2011</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Andreoli-2016" target="_blank">Andreoli 2016</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Borschmann-2013" target="_blank">Borschmann 2013</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Bellino-2006" target="_blank">Bellino 2006</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Bellino-2007" target="_blank">Bellino 2007</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Bellino-2010" target="_blank">Bellino 2010</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Cottraux-2009" target="_blank">Cottraux 2009</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Davidson-2006" target="_blank">Davidson 2006</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Davidson-2014" target="_blank">Davidson 2014</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Doering-2010" target="_blank">Doering 2010</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Giesen_x002d_Bloo-2006" target="_blank">Giesen-Bloo 2006</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Gleeson-2012" target="_blank">Gleeson 2012</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Harned-2014" target="_blank">Harned 2014</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Jahangard-2012" target="_blank">Jahangard 2012</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Kramer-2011" target="_blank">Kramer 2011</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Kramer-2014" target="_blank">Kramer 2014</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Kredlow-2017a" target="_blank">Kredlow 2017a</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Kredlow-2017b" target="_blank">Kredlow 2017b</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Leichsenring-2016" target="_blank">Leichsenring 2016</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-McMain-2009" target="_blank">McMain 2009</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-McMurran-2016" target="_blank">McMurran 2016</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Mohamadizadeh-2017" target="_blank">Mohamadizadeh 2017</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Morey-2010" target="_blank">Morey 2010</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Nadort-2009" target="_blank">Nadort 2009</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Philips-2018" target="_blank">Philips 2018</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Priebe-2012" target="_blank">Priebe 2012</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Reneses-2013" target="_blank">Reneses 2013</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Salzer-2014" target="_blank">Salzer 2014</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Stanley-2017" target="_blank">Stanley 2017</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Smith-2012" target="_blank">Smith 2012</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Weinberg-2006" target="_blank">Weinberg 2006</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Zanarini-2008" target="_blank">Zanarini 2008</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Zanarini-2018" target="_blank">Zanarini 2018</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Antonsen-2017" target="_blank">Antonsen 2017</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Blum-2008" target="_blank">Blum 2008</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Bohus-2013" target="_blank">Bohus 2013</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Bos-2010" target="_blank">Bos 2010</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Elices-2016" target="_blank">Elices 2016</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Farrell-2009" target="_blank">Farrell 2009</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Feliu_x002d_Soler-2017" target="_blank">Feliu-Soler 2017</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Gratz-2006" target="_blank">Gratz 2006</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Gratz-2014" target="_blank">Gratz 2014</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Haeyen-2018" target="_blank">Haeyen 2018</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Jochems-2015" target="_blank">Jochems 2015</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Kamalabadi-2012" target="_blank">Kamalabadi 2012</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Kramer-2016" target="_blank">Kramer 2016</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Lepp_x00e4_nen-2016" target="_blank">Leppänen 2016</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Lin-2019" target="_blank">Lin 2019</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Linehan-2015a" target="_blank">Linehan 2015a</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-McMain-2017" target="_blank">McMain 2017</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Morton-2012" target="_blank">Morton 2012</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Pascual-2015" target="_blank">Pascual 2015</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Santisteban-2015" target="_blank">Santisteban 2015</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Schilling-2018" target="_blank">Schilling 2018</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Soler-2009" target="_blank">Soler 2009</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Combination of individual and group treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Bateman-1999" target="_blank">Bateman 1999</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Bateman-2009" target="_blank">Bateman 2009</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Bianchini-2019" target="_blank">Bianchini 2019</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Carter-2010" target="_blank">Carter 2010</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Feigenbaum-2012" target="_blank">Feigenbaum 2012</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Gregory-2008b" target="_blank">Gregory 2008b</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-J_x00f8_rgensen-2013" target="_blank">Jørgensen 2013</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Koons-2001a" target="_blank">Koons 2001a</a>; <a href="./references#CD012955-bbs2-0045" title="HoffmanRE . Impact of treatment accessibility on clinical course of parasuicidal patients. Archives of General Psychiatry1993;50(2):157-8. [DOI: 10.1001/archpsyc.1993.01820140083010] [PMID: 8427557]LindenboimN . To Know Me is to Keep Me: Self-Verification, Validation, and Therapy Dropout in the Treatment of Borderline Personality Disorder [PhD thesis]. Washington (DC): University of Washington, 2009. LinehanMM , ArmstrongHE , SuarezA , AllmonD , HeardHL . Cognitive-behavioral treatment of chronically parasuicidal borderline patients. Archives of General Psychiatry1991;48(12):1060-4. [DOI: 10.1001/archpsyc.1991.01810360024003] [PMID: 1845222]LinehanMM , HeardHL . Impact of treatment accessibility on clinical course of parasuicidal patients — reply. Archives of General Psychiatry1993;50(2):157-8. [DOI: 10.1001/archpsyc.1993.01820140083011]">Linehan 1991</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Linehan-1994" target="_blank">Linehan 1994</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Linehan-2006" target="_blank">Linehan 2006</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Laurenssen-2018" target="_blank">Laurenssen 2018</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Robinson-2016" target="_blank">Robinson 2016</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Rossouw-2012b" target="_blank">Rossouw 2012b</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Turner-2000" target="_blank">Turner 2000</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Van-den-Bosch-2005" target="_blank">Van den Bosch 2005</a> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="3" rowspan="1" scope="col" valign="bottom"> <p><b><i>Concomitant medication</i> </b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Allowed, if needed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012955-bbs2-0001" title="AmiantoF , FerreroA , PieròA , CairoE , RoccaG , SimonelliB , et al. Supervised team management, with or without structured psychotherapy, in heavy users of a mental health service with borderline personality disorder: a two-year follow-up preliminary randomized study. BMC Psychiatry2011;11:181. [DOI: 10.1186/1471-244X-11-181] [PMC3260092 ] [PMID: 22103890]NCT01356069. Efficacy of time-limited psychodynamic psychotherapy and informed clinical management in BPD high MHS users (HUMSH) [Sequential brief Adlerian psychodynamic psychotherapy in heavy users of a mental health service with borderline personality disorder: a two years follow-up preliminary randomized study]. clinicaltrials.gov/ct2/show/NCT01356069 (first received 16 May 2011). ">Amianto 2011</a>; <a href="./references#CD012955-bbs2-0002" title='AndreoliA , BurnandY , CochennecMF , MarieD , Di ClementeT , OhlendorfP . Psychoanalytic psychotherapy and venlafaxine among acutely suicidal borderline patients: a randomized clinical study. European Psychiatry2009;24(Suppl 1):S93. [DOI: 10.1016/S0924-9338(09)70326-8] [S18-03]AndreoliA , BurnandY , CochennecMF , OhlendorfP , FrambatiL , Gaudry-MaireD , et al. Disappointed love and suicide: a randomized controlled trial of "abandonment psychotherapy" among borderline patients. Journal of Personality Disorders2016;30(2):271-87. [DOI: 10.1521/pedi_2015_29_196] [PMID: 26111250]AndreoliA , BurnandY , FrambatiL , ManningD , FrancesA . Abandonment psychotherapy and psychosocial functioning among suicidal patients with borderline personality disorder: a 3-year naturalistic follow-up. Journal of Personality Disorders 2019 Feb 20 [Epub ahead of print]. [DOI: 10.1521/pedi_2019_33_423] [PMID: 30785852]AndreoliA . Re: your study in BPD - Cochrane Collaboration review [personal communication]. Email to: J Stoffers-Winterling 5 June 2018. '>Andreoli 2016</a>; <a href="./references#CD012955-bbs2-0003" title="AntonsenBT , JohansenMS , RøFG , KvarsteinEH , WilbergT . Is reflective functioning associated with clinical symptoms and long-term course in patients with personality disorders?Comprehensive Psychiatry2016;64:46-58. [DOI: 10.1016/j.comppsych.2015.05.016] [PMID: 26104432]AntonsenBT , KlungsøyrO , KampsA , HummelenB , JohansenMS , PedersenG , et al. Step-down versus outpatient psychotherapeutic treatment for personality disorders: 6-year follow-up of the Ullevål personality project. BMC Psychiatry2014;14:119. [DOI: 10.1186/1471-244X-14-119] [PMC4000615] [PMID: 24758722]AntonsenBT , KvarsteinEH , Urnes Ø, HummelenB , KarterudS , WilbergT . Favourable outcome of long-term combined psychotherapy for patients with borderline personality disorder: six-year follow-up of a randomized study. Psychotherapy Research2017;27(1):51-63. [DOI: 10.1080/10503307.2015.1072283] [PMID: 26261865]ArnevikE , WilbergT , Urnes Ø, JohansenM , MonsenJT , KarterudS . Psychotherapy for personality disorders: short-term day hospital psychotherapy versus outpatient individual therapy - a randomized controlled study. European Psychiatry2009;24(2):71-8. [DOI: 10.1016/j.eurpsy.2008.09.004] [PMID: 19097870]GullestadFS , JohansenMS , HøglendP , KarterudS , WilbergT . Mentalization as a moderator of treatment effects: findings from a randomized clinical trial for personality disorders. Psychotherapy Research2013;23(6):674-89. [DOI: 10.1080/10503307.2012.684103] [PMID: 22612470]GullestadFS . Re: questions regarding your trial on day hospital step-down program [personal communication]. Email to: E Faltinsen 4 December 2017. KvarsteinEH , ArnevikE , HalsteinliV , RøFG , KarterudS , WilbergT . Health service costs and clinical gains of psychotherapy for personality disorders: a randomized controlled trial of day-hospital-based step-down treatment versus outpatient treatment at a specialist practice. BMC Psychiatry2013;13:315. [DOI: 10.1186/1471-244X-13-315] [PMC4222503] [PMID: 24268099]">Antonsen 2017</a>; <a href="./references#CD012955-bbs2-0004" title="BatemanA , FonagyP . 8-year follow-up of patients treated for borderline personality disorder: mentalization-based treatment versus treatment as usual. American Journal of Psychiatry2008;165(5):631-8. [DOI: 10.1176/appi.ajp.2007.07040636] [PMID: 18347003]BatemanA , FonagyP . Effectiveness of partial hospitalization in the treatment of borderline personality disorder: a randomized controlled trial. American Journal of Psychiatry1999;156(10):1563-9. [DOI: 10.1176/ajp.156.10.1563] [PMID: 10518167]BatemanA , FonagyP . Health care utilization costs for borderline personality disorder patients treated with psychoanalytically oriented partial hospitalization versus general psychiatric care. American Journal of Psychiatry2003;160(1):169-71. [10.1176/appi.ajp.160.1.169] [12505818]BatemanA , FonagyP . Treatment of borderline personality disorder with psychoanalytically oriented partial hospitalization: an 18-month follow-up. American Journal of Psychiatry2001;158(1):36-42. [DOI: 10.1176/appi.ajp.158.1.36] [PMID: 11136631]BatemanA . Important: question regarding your BPD trial for systematic review in Cochrane Collaboration [personal communication]. Email to: K Lieb, J Stoffers 14 December 2010. BatemanA . Intensive outpatient and partial hospital care for BPD. In: 157th annual meeting of the American Psychiatric Association. Psychotherapy and pharmacology: dissolving the mind-brain barrier; 2004 May 1-6; New York (NY). Arlington (VA): American Psychiatric Association, 2004:102. [Symposium 100B] [www.psychiatry.org/File%20Library/Psychiatrists/Directories/Library-and-Archive/conference_publications/am_program_2004.pdf]BatemanAW , FonagyP . Drs Bateman and Fonagy reply [to Stern R. Partial hospitalization for borderline personality disorder. American Journal of Psychiatry 2001;158(11):1932-3. DOI: 10.1176/appi.ajp.158.11.1932]. American Journal of Psychiatry2001;158(11):1932-3. [DOI: 10.1176/appi.ajp.158.11.1932-a]EvansC . Treatment benefits of psychoanalytically oriented partial hospitalisation were maintained over 18 months in borderline personality disorder. Evidence-Based Mental Health2001;4(3):73. [DOI: 10.1136/ebmh.4.3.73]FonagyP , BatemanAW . Mentalizing and borderline personality disorder. Journal of Mental Health2007;16(1):83-101. [DOI: 10.1080/09638230601182045]SternR . Partial hospitalization for borderline personality disorder. American Journal of Psychiatry2001;158(11):1932-3. [DOI: 10.1176/appi.ajp.158.11.1932] [PMID: 11691712]">Bateman 1999</a>; <a href="./references#CD012955-bbs2-0005" title="BatemanA , FonagyP . Impact of clinical severity on outcomes of mentalisation-based treatment for borderline personality disorder. British Journal of Psychiatry2013;203(3):221-7. [DOI: 10.1192/bjp.bp.112.121129] [PMID: 23887998]BatemanA , FonagyP . Randomized controlled trial of outpatient mentalization-based treatment versus structured clinical management for borderline personality disorder. American Journal of Psychiatry2009;166(12):1355-64. [DOI: 10.1176/appi.ajp.2009.09040539] [PMID: 19833787]BatemanA , FonagyP . Randomized controlled trial of outpatient mentalization-based treatment versus structured clinical management for borderline personality disorder. Supplementary data. ajp.psychiatryonline.org/doi/suppl/10.1176/appi.ajp.2009.09040539/suppl_file/ajp_166_12_1355_01.pdf (accessed 27 February 2020). BatemanA , O'ConnellJ , LorenziniN , GardnerT , FonagyP . A randomised controlled trial of mentalization-based treatment versus structured clinical management for patients with comorbid borderline personality disorder and antisocial personality disorder. BMC Psychiatry2016;16:304. [DOI: 10.1186/s12888-016-1000-9] [PMC5006360] [PMID: 27577562]BatemanA . Important question regarding your BPD trial for systematic review in Cochrane Collaboration [personal communication]. Email to: K Lieb 14 December 2010. BatemanAW . Mentalization, borderline personality disorder and what works for whom? Presentation at the 11th International Congress of the International Society for the Study of Personality Disorders; 2009 Aug 21-23. www.borderlinepersonalitydisorder.com/Conferences/ISSPD/isspd_09_Bateman (accessed 21 April 2010). ISRCTN27660668. Randomised controlled trial of manualised out-patient individual and group therapy for borderline personality disorder [Effectiveness of intensive out-patient psychotherapy for treatment of borderline personality disorder: a pragmatic randomised single blind controlled study]. www.isrctn.com/ISRCTN27660668 (first received 12 October 2008). ">Bateman 2009</a>; <a href="./references#CD012955-bbs2-0010" title="BlackD . Question regarding your BPD trial [personal communication]. Email to: J Stoffers 04 January 2011. BlackDW , AllenJ , McCormickB , BlumN . Treatment received by persons with BPD participating in a randomized clinical trial of the systems training for emotional predictability and problem solving programme. Personality and Mental Health2011;5(3):159-68. [DOI: 10.1002/pmh.167]BlackDW , AllenJ , St JohnD , PfohlB , McCormickB , BlumN . Predictors of response to systems training for emotional predictability and problem solving (STEPPS) for borderline personality disorder: an exploratory study. Acta Psychiatrica Scandinavica2009;120(1):53-61. [DOI: 10.1111/j.1600-0447.2008.01340.x] [PMC3665337] [PMID: 19183126]BlackDW , BlumN , PfohlB , St JohnD . The STEPPS group treatment program for outpatients with borderline personality disorder. Journal of Contemporary Psychotherapy2004;34(3):193-210. [DOI: 10.1023/B:JOCP.0000036630.25741.83]BlackDW , PfohlBM . Randomized clinical trial of STEPPS versus treatment as usual. In: 158th annual meeting of the American Psychiatric Association. Psychosomatic medicine: integrating psychiatry &amp; medicine; 2005 May 21-26; Atlanta (GA). Arlington (VA): American Psychiatric Association, 2005:104. [No. 1B] [www.psychiatry.org/File%20Library/Psychiatrists/Directories/Library-and-Archive/syllabus/am_syllabus_2005.pdf]BlackDW , Simsek-DuranF , BlumN , McCormickB , AllenJ . Do people with borderline personality disorder complicated by antisocial personality disorder benefit from the STEPPS treatment program?Personality and Mental Health2016;10(3):205-15. [DOI: 10.1002/pmh.1326] [PMC4911327] [PMID: 26671625]BlackDW . RE: [external] questions regarding your trial on the STEPPS program for BPD [personal communication]. Email to: EG Faltinsen 27 November 2017. BlumN , AllenJ , McCormickB , BlackDW . Ms Blum and colleagues reply [to Schulte-Herbrüggen O, Koerting J, Roepke S. Effectiveness of adjunctive STEPPS group treatment in borderline personality disorder patients. American Journal of Psychiatry 2008;165(10):1354-5. DOI: 10.1176/appi.ajp.2008.08030390]. American Journal of Psychiatry2008;165(10):1354-5. [DOI: 10.1176/appi.ajp.2008.08030390r]BlumN , FranklinJ , HanselR , McCormickB , St JohnD , PfohlB , et al. Relationship of age to symptom severity, psychiatric comorbidity and health care utilization in persons with borderline personality disorder. Personality and Mental Health2008;2(1):25-43. [DOI: 10.1002/pmh.26]BlumN , St JohnD , PfohlB , StuartS , McCormickB , AllenJ , et al. Erratum. American Journal of Psychiatry2008;165(6):777. Erratum for: American Journal of Psychiatry 2008;165(4):468-78. [psycnet.apa.org/record/2008-07854-033]BlumN , St JohnD , PfohlB , StuartS , McCormickB , AllenJ , et al. Systems training for emotional predictability and problem solving (STEPPS) for outpatients with borderline personality disorder: a randomized controlled trial and 1-year follow-up. American Journal of Psychiatry2008;165(4):468-78. [DOI: 10.1176/appi.ajp.2007.07071079] [PMC3608469] [PMID: 18281407]DavidsonKM . Borderline personality disorder: STEPPS improves symptoms. Evidence-Based Mental Health2008;11(4):120. [DOI: 10.1136/ebmh.11.4.120] [PMID: 18952969]NCT00055315. Treatment for borderline personality disorder [A cognitive group treatment for borderline outpatients]. clinicaltrials.gov/ct2/show/NCT00055315 (first received 25 February 2003). ">Blum 2008</a>; <a href="./references#CD012955-bbs2-0011" title="BohusM , DyerAS , PriebeK , KrügerA , KleindienstN , SchmahlC , et al. Dialectical behaviour therapy for post-traumatic stress disorder after childhood sexual abuse in patients with and without borderline personality disorder: a randomised controlled trial. Psychotherapy and Psychosomatics2013;82(4):221-33. [DOI: 10.1159/000348451] [PMID: 23712109]BrandS . AW: questions regarding your trial on emotional intelligence training for BPD [personal communication]. Email to: EG Faltinsen 28 November 2017. DBT Working Group at the Central Institute for Mental Health, Mannheim, Germany. Requested supplementary data (as supplied 1 October 2010). Data on file. NCT00481000. Dialectical cognitive traumatherapy (DCT) on patients with severe PTSD following sexual abuse (PASA) [Dialectical cognitive traumatherapy (DCT) on patients with severe posttraumatic stress disorder following sexual abuse - a randomised controlled trial]. clinicaltrials.gov/ct2/show/NCT00481000 (first received 31 May 2007). SteilR , DyerA , PriebeK , KleindienstN , BohusM . Dialectical behavior therapy for posttraumatic stress disorder related to childhood sexual abuse: a pilot study of an intensive treatment program. Journal of Traumatic Stress2011;24(1):102-6. [DOI: 10.1002/jts.20617] [PMID: 21351167]">Bohus 2013</a>; <a href="./references#CD012955-bbs2-0012" title="BorschmannR , BarrettB , HellierJM , ByfordS , HendersonC , RoseD , et al. Joint crisis plans for people with borderline personality disorder: feasibility and outcomes in a randomised controlled trial. British Journal of Psychiatry2013;202(5):357-64. [DOI: 10.1192/bjp.bp.112.117762] [PMID: 23637110]BorschmannR . Joint crisis plans for BPD - question on publication in British Journal of Psychiatry [pers communication]. Email to: J Stoffers-Winterling 22 August 2017. BorschmannR . RE: joint crisis plans for BPD - question on publication in British Journal of Psychiatry [personal communication]. Email to: J Stoffers-Winterling 22 August 2017. BorschmannR . The development and testing of joint crisis plans for people with borderline personality disorder: a feasibility study. ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.628499 (accessed 27 January 2019). HellierJ . RE: regarding your study on on MBT for eating disorders [personal communication]. Email to: E Faltinsen 27 March 2018. HellierJ . RE: regarding your study on on MBT for eating disorders [personal communication]. Email to: E Faltinsen 3 January 2018. HellierJ . SV: regarding your study on MBT for eating disorders [personal communication]. Email to: EG Faltinsen, P Robinson 27 March 2018. ISRCTN12440268. JOSHUA: a pilot randomised controlled trial of joint crisis plans for people who self harm. www.isrctn.com/ISRCTN12440268 (first received 17 September 2009). ">Borschmann 2013</a>; <a href="./references#CD012955-bbs2-0013" title="BosEH , Van WelE , AppeloMT , VerbraakMJP . A randomized controlled trial of a Dutch version of systems training for emotional predictability and problem solving for borderline personality disorder. Journal of Nervous and Mental Disease2010;198(4):299-304. [DOI: 10.1097/NMD.0b013e3181d619cf] [PMID: 20386260]Van WelEB , BosEH , AppeloMT , BerendsenEM , WillgerothFC , VerbraakMJPM . The efficacy of the systems training for emotional predictability and problem solving (STEPPS) in the treatment of borderline personality disorder. A randomized controlled trial [De effectiviteit van de vaardigheidstraining emotieregulatiestoornis (VERS) in de behandeling van de borderlinepersoonlijkheidsstoornis: een gerandomiseerd onderzoek]. Tijdschrift voor Psychiatrie2009;51(5):291-301. [PMID: 19434566]">Bos 2010</a>; <a href="./references#CD012955-bbs2-0014" title="Carmona i FarrésC , ElicesM , SolerJ , Domínguez-ClavéE , Pomarol-ClotetE , SalvadorR , et al. Effects of mindfulness training on borderline personality disorder: impulsivity versus emotional dysregulation. Mindfulness2019;10:1243-54. [DOI: 10.1007/s12671-018-1071-4]NCT03363230. Effects of mindfulness training on emotion regulation and impulsivity. www.clinicaltrials.gov/ct2/show/NCT03363230 (first received 30 November 2017). ">Carmona í Farrés 2019</a>; <a href="./references#CD012955-bbs2-0016" title="CottrauxJ , NoteID , BoutitieF , MillieryM , GenouihlacV , YaoSN , et al. Cognitive therapy versus Rogerian supportive therapy in borderline personality disorder. Two-year follow-up of a controlled pilot study. Psychotherapy and Psychosomatics2009;78(5):307-16. [DOI: 10.1159/000229769] [PMID: 19628959]NCT00131781. Cognitive therapy versus supportive therapy in borderline personality disorder. www.clinicaltrials.gov/ct2/show/NCT00131781 (first received 18 August 2005). ">Cottraux 2009</a>; <a href="./references#CD012955-bbs2-0017" title="DavidsonK , LivingstoneS , McArthurK , DicksonL , GumleyA . An integrative complexity analysis of cognitive behaviour therapy sessions for borderline personality disorder. Psychology and Psychotherapy2007;80(Pt 4):513-23. [DOI: 10.1348/147608307X191535] [PMID: 17535542]DavidsonK , NorrieJ , TyrerP , GumleyA , TataP , MurrayH , et al. The effectiveness of cognitive behavior therapy for borderline personality disorder: results from the borderline personality disorder study of cognitive therapy (BOSCOT) trial. Journal of Personality Disorders2006;20(5):450-65. [DOI: 10.1521/pedi.2006.20.5.450] [PMC1852259] [PMID: 17032158]DavidsonK , TyrerP , GumleyA , TataP , NorrieJ , PalmerS , et al. A randomized controlled trial of cognitive behavior therapy for borderline personality disorder: rationale for trial, method, and description of sample. Journal of Personality Disorders2006;20(5):431-49. [DOI: 10.1521/pedi.2006.20.5.431] [PMC1847748] [PMID: 17032157]DavidsonKM , TyrerP , NorrieJ , PalmerSJ , TyrerH . Cognitive therapy v usual treatment for borderline personality disorder: prospective 6-year follow-up. British Journal of Psychiatry2010;197(6):456-62. [DOI: 10.1192/bjp.bp.109.074286] [PMID: 21119151]ISRCTN86177428. Borderline personality disorder study of cognitive therapy trial [A randomised controlled trial of cognitive therapy plus treatment as usual versus treatment as usual in the treatment of borderline personality disorder]. www.isrctn.com/ISRCTN86177428 (first received 22 July 2005). NCT00538135. BOSCOT: a randomised controlled trial of cognitive behavioural therapy in borderline personality disorder [BOSCOT: a randomised control trial of cognitive behavioural therapy plus treatment as usual versus treatment as usual in the treatment of borderline personality disorder]. www.clinicaltrials.gov/ct2/show/NCT00538135 (first received 29 September 2007). NorrieJ , DavidsonK , TataP , GumleyA . Influence of therapist competence and quantity of cognitive behavioural therapy on suicidal behaviour and inpatient hospitalisation in a randomised controlled trial in borderline personality disorder: further analyses of treatment effects in the BOSCOT study. Psychology and Psychotherapy2013;86(3):280-93. [DOI: 10.1111/papt.12004] [PMC4491320] [PMID: 23420622]PalmerS , DavidsonK , TyrerP , GumleyA , TataP , NorrieJ , et al. The cost-effectiveness of cognitive behavior therapy for borderline personality disorder: results from the BOSCOT trial. Journal of Personality Disorders2006;20(5):466-81. [DOI: 10.1521/pedi.2006.20.5.466] [PMC1852260] [PMID: 17032159]">Davidson 2006</a>; <a href="./references#CD012955-bbs2-0019" title="BuchheimA , Hörz-SagstetterS , DoeringS , RentropM , SchusterP , BuchheimP , et al. Change of unresolved attachment in borderline personality disorders: RCT study of transference-focused psychotherapy. Psychotherapy and Psychosomatics2017;86(5):314-6. [DOI: 10.1159/000460257] [PMID: 28903103]DiamondD , LevyKN , ClarkinJF , Fischer-KernM , CainNM , DoeringS , et al. Attachment and mentalization in female patients with comorbid narcissistic and borderline personality disorder. Personality Disorders2014;5(4):428-33. [DOI: 10.1037/per0000065] [PMID: 25314231]DiamondD , YeomansFE , SternB , LevyKN , HörzS , DoeringS , et al. Transference-focused psychotherapy for patients with comorbid narcissistic and borderline personality disorder. Psychoanalytic Inquiry2013;33(6):527-51. [DOI: 10.1080/07351690.2013.815087]DoeringS , HörzS , RentropM , Fischer-KernM , SchusterP , BeneckeC , et al. Transference-focused psychotherapy v treatment by community psychotherapists for borderline personality disorder: randomised controlled trial. British Journal of Psychiatry2010;196(5):389-95. [DOI: 10.1192/bjp.bp.109.070177] [PMID: 20435966]DoeringS . Author's reply [to Kleindienst N, Krumm B, Bohus M. Is transference-focused psychotherapy really efficacious for borderline personality disorder? British Journal of Psychiatry 2011;198(2):156-7. DOI: 10.1192/bjp.198.2.156b]. British Journal of Psychiatry2011;198(2):156-7. [DOI: 10.1192/bjp.198.2.157]DoeringS . Question regarding your BPD trial for systematic review in Cochrane Collaboration [personal communication]. Email to: K Lieb, J Stoffers 10 December 2010. Fischer-KernM , DoeringS , TaubnerS , HörzS , ZimmermannJ , RentropM , et al. Transference-focused psychotherapy for borderline personality disorder: change in reflective function. British Journal of Psychiatry2015;207(2):173-4. [DOI: 10.1192/bjp.bp.113.143842] [PMID: 25999334]KleindienstN , KrummB , BohusM . Is transference-focused psychotherapy really efficacious for borderline personality disorder?British Journal of Psychiatry2011;198(2):156-7. [DOI: 10.1192/bjp.198.2.156b] [PMID: 21282787]LevyKN , MeehanKB , YeomansFE . Transference-focused psychotherapy reduces treatment drop-out and suicide attempters compared with community psychotherapist treatment in borderline personality disorder. Evidence-based Mental Health2010;13(4):119. [DOI: 10.1136/ebmh.13.4.119] [PMID: 21036981]NCT00714311. Efficacy of transference-focused psychotherapy for borderline personality disorder [A randomized-controlled trial of transference-focused psychotherapy vs treatment by experienced community psychotherapists for borderline personality disorder]. www.clinicaltrials.gov/ct2/show/NCT00714311 (first received 9 July 2008). RentropM , MartiusP , BäumlJ , BuchheimP , DöeringS , HörzS . Patients with borderline personality disorder not participating in an RCT: are they different?Psychopathology2010;43(6):369-72. [DOI: 10.1159/000320351] [PMID: 20798576]">Doering 2010</a>; <a href="./references#CD012955-bbs2-0020" title="ElicesM , PascualJC , PortellaMJ , Feliu-SolerA , Martín-BlancoA , CarmonaC , et al. Impact of mindfulness training on borderline personality disorder: a randomized trial. Mindfulness2016;7:584-95. [DOI: 10.1007/s12671-016-0492-1]NCT02397031. Mindfulness and interpersonal effectiveness skills in borderline personality disorder [Randomized, active-controlled, clinical trial comparing effects of mindfulness and interpersonal effectiveness skills in borderline personality disorder]. www.clinicaltrials.gov/ct2/show/NCT02397031 (first received 12 March 2015). SolerJ , ElicesM , PascualJC , Martín-BlancoA , Feliu-SolerA , CarmonaC , et al. Effects of mindfulness training on different components of impulsivity in borderline personality disorder: results from a pilot randomized study. Borderline Personality Disorder and Emotion Dysregulation2016;3:1. [DOI: 10.1186/s40479-015-0035-8] [PMC4709962] [PMID: 26759718]">Elices 2016</a>; <a href="./references#CD012955-bbs2-0021" title="FarrellJM , ShawIA , WebberMA . A schema-focused approach to group psychotherapy for outpatients with borderline personality disorder: a randomized controlled trial. Journal of Behavior Therapy and Experimental Psychiatry2009;40(2):317-28 Corrigendum to: Journal of Behavior Therapy and Experimental Psychiatry 2018; 60: 111. [DOI: 10.1016/j.jbtep.2009.01.002] [PMID: 19176222]FarrellJM . Question regarding your BPD trials [personal communication]. Email to: K Lieb, J Stoffers 9 December 2010. ">Farrell 2009</a>; <a href="./references#CD012955-bbs2-0022" title="FeigenbaumJD , FonagyP , PillingS , JonesA , WildgooseA , BebbingtonPE . A real-world study of the effectiveness of DBT in the UK National Health Service. British Journal of Clinical Psychology2012;51(2):121-41. [DOI: 10.1111/j.2044-8260.2011.02017.x] [PMID: 22574799]">Feigenbaum 2012</a>; <a href="./references#CD012955-bbs2-0023" title="Feliu-SolerA , PascualJC , ElicesM , Martín-BlancoA , CarmonaC , CebollaA , et al. Fostering self-compassion and loving-kindness in patients with borderline personality disorder: a randomized pilot study. Clinical Psychology &amp; Psychotherapy2017;24(1):278-86. [DOI: 10.1002/cpp.2000] [PMID: 26818533]">Feliu‐Soler 2017</a>; <a href="./references#CD012955-bbs2-0024" title="ArntzA , Stupar-RutenfransS , BlooJ , Van DyckR , SpinhovenP . Prediction of treatment discontinuation and recovery from borderline personality disorder: results from an RCT comparing schema therapy and transference-focused psychotherapy. Behaviour Research and Therapy2015;74:60-71. [DOI: 10.1016/j.brat.2015.09.002] [PMID: 26432172]Giesen-BlooJ , ArntzA . Questions concerning the randomized trial of schema-focused therapy vs transference-focused psychotherapy—reply. Archives of General Psychiatry2007;64(5):610-1. [DOI: 10.1001/archpsyc.64.5.610]Giesen-BlooJ , Van DyckR , SpinhovenP , Van TilburgW , DirksenC , Van AsseltT , et al. Errors in table and figure in: outpatient psychotherapy for borderline personality disorder: randomized trial of schema-focused therapy vs transference-focused psychotherapy. Archives of General Psychiatry2006;63(9):1008. Erratum for: Archives of General Psychiatry 2006;63(6):649-58. [DOI: 10.1001/archpsyc.63.9.1008]Giesen-BlooJ , Van DyckR , SpinhovenP , Van TilburgW , DirksenC , Van AsseltT , et al. Outpatient psychotherapy for borderline personality disorder: randomized trial of schema-focused therapy vs transference-focused psychotherapy. Archives of General Psychiatry2006;63(6):649-58. [DOI: 10.1001/archpsyc.63.6.649] [PMID: 16754838]SpinhovenP , Giesen-BlooJ , Van DyckR , KooimanK , ArntzA . The therapeutic alliance in schema-focused therapy and transference-focused psychotherapy for borderline personality disorder. Journal of Consulting and Clinical Psychology2007;75(1):104-15. [DOI: 10.1037/0022-006X.75.1.104] [PMID: 17295569]Van AsseltADI , DirksenCD , ArntzA , Giesen-BlooJH , Van DyckR , SpinhovenP , et al. Out-patient psychotherapy for borderline personality disorder: cost-effectiveness of schema-focused therapy v transference-focused psychotherapy. British Journal of Psychiatry2008;192(6):450-7. [DOI: 10.1192/bjp.bp.106.033597] [PMID: 18515897]Van AsseltADI , DirksenCD , ArntzA , SeverensJL . Difficulties in calculating productivity costs: work disability associated with borderline personality disorder. Value in Health2008;11(4):637-44. [DOI: 10.1111/j.1524-4733.2007.00288.x]YeomansF . Questions concerning the randomized trial of schema-focused therapy vs transference-focused psychotherapy. Archives of General Psychiatry2007;64(5):609-10. [DOI: 10.1001/archpsyc.64.5.609-c] [PMID: 17485613]">Giesen‐Bloo 2006</a>; <a href="./references#CD012955-bbs2-0025" title="GleesonJF , ChanenA , CottonSM , PearceT , NewmanB , McCutcheonL . Treating co-occurring first-episode psychosis and borderline personality: a pilot randomized controlled trial. Early Intervention in Psychiatry2012;6(1):21-9. [DOI: 10.1111/j.1751-7893.2011.00306.x] [PMID: 22379625]GleesonJFM . RE: separate data [personal communication]. Email to: M Kielsholm 28 October 2016. ">Gleeson 2012</a>; <a href="./references#CD012955-bbs2-0026" title="Gratz KL. Important: question regarding your BPD trial for systematic review in Cochrane Collaboration [personal communication]. Email to: J Stoffers-Winterling 11 December 2010. GratzKL , GundersonJG . Preliminary data on an acceptance-based emotion regulation group intervention for deliberate self-harm among women with borderline personality disorder. Behavior Therapy2006;37(1):25-35. [DOI: 10.1016/j.beth.2005.03.002] [PMID: 16942958]">Gratz 2006</a>; <a href="./references#CD012955-bbs2-0027" title="GratzKL , BardeenJR , LevyR , Dixon-GordonKL , TullMT . Mechanisms of change in an emotion regulation group therapy for deliberate self-harm among women with borderline personality disorder. Behaviour Research and Therapy2015;65:29-35. [DOI: 10.1016/j.brat.2014.12.005] [PMC4306622] [PMID: 25557395]GratzKL , Dixon-GordonKL , TullMT . Predictors of treatment response to an adjunctive emotion regulation group therapy for deliberate self-harm among women with borderline personality disorder. Personality Disorders2014;5(1):97-107. [DOI: 10.1037/per0000062] [PMC4059504] [PMID: 2458806]GratzKL , TullMT , LevyR . Randomized controlled trial and uncontrolled 9-month follow-up of an adjunctive emotion regulation group therapy for deliberate self-harm among women with borderline personality disorder. Psychological Medicine2014;44(10):2099-112. [DOI: 10.1017/S0033291713002134] [PMID: 23985088]GratzKL . Question regarding your BPD trials [personal communication]. Email to: J Stoffers 11 December 2010. ">Gratz 2014</a>; <a href="./references#CD012955-bbs2-0028" title="GregoryRJ , ChlebowskiS , KangD , RemenA , SoderbergM . Psychodynamic therapy for borderline personality disorder and co-occurring alcohol use disorders: a newly designed ongoing study. Journal of the American Psychoanalytic Association2006;54(4):1331-4. [DOI: 10.1177/00030651060540040107] [PMID: 17354507]GregoryRJ , ChlebowskiS , KangD , RemenAL , SoderbergMG , StepkovitchJ , et al. A controlled trial of psychodynamic psychotherapy for co-occurring borderline personality disorder and alcohol use disorder. Psychotherapy2008;45(1):28-41. [DOI: 10.1037/0033-3204.45.1.28] [PMID: 22122363]GregoryRJ , DeLucia-DeranjaE , MogleJA . Dynamic deconstructive psychotherapy versus optimized community care for borderline personality disorder co-occuring with alcohol use disorders: a 30-month follow-up. Journal of Nervous and Mental Disease2010;198(4):292-8. [DOI: 10.1097/NMD.0b013e3181d6172d] [PMID: 20386259]GregoryRJ , RemenAL , SoderbergM , Ploutz-SnyderRJ . A controlled trial of psychodynamic psychotherapy for co-occurring borderline personality disorder and alcohol use disorder: six-month outcome. Journal of the American Psychoanalytic Association2009;57(1):199-205. [DOI: 10.1177/00030651090570011006] [PMID: 19270255]NCT00145678. Psychodynamic therapy for co-occurring borderline personality disorder and alcohol use disorder [Psychodynamic therapy for patients With borderline personality disorder and alcohol abuse]. www.clinicaltrials.gov/show/NCT00145678 (first received 1 September 2005). ">Gregory 2008b</a>; <a href="./references#CD012955-bbs2-0030" title="HarnedM . Re: SV: question regarding your trial on brief therapy for attempted suicide [personal communication]. Email to: EG Faltinsen 11 December 2018. HarnedMS , KorslundKE , LinehanMM . A pilot randomized controlled trial of dialectical behavior therapy with and without the dialectical behavior therapy prolonged exposure protocol for suicidal and self-injuring women with borderline personality disorder and PTSD. Behaviour Research and Therapy2014;55:7-17. [DOI: 10.1016/j.brat.2014.01.008] [PMC3987949] [PMID: 24562087]HarnedMS , WilksCR , SchmidtSC , CoyleTN . Improving functional outcomes in women with borderline personality disorder and PTSD by changing PTSD severity and post-traumatic cognitions. Behaviour Research and Therapy2018;103:53-61. [DOI: 10.1016/j.brat.2018.02.002] [PMC5837954] [PMID: 29448136]HarnedMS . RE: questions regarding your trial on brief therapy for attempted suicide [personal communication]. Email to: E Faltinsen 29 November 2017. ">Harned 2014</a>; <a href="./references#CD012955-bbs2-0032" title="JochemsEC , Van der Feltz-CornelisCM , Van DamA , DuivenvoordenHJ , MulderCL . The effects of motivation feedback in patients with severe mental illness: a cluster randomized controlled trial. Neuropsychiatric Disease and Treatment2015;11:3049-64. [DOI: 10.2147/NDT.S95190] [PMC4686323] [PMID: 26715847]JochemsEC . Cochrane Collaboration review on psychotherapies for borderline PD [personal communication]. Email to: EG Faltinsen 2 July 2018. JochemsEC . Re: Cochrane Collaboration review on psychotherapies for borderline PD [personal communication]. Email to: J Stoffers-Winterling 02 July 2018. ">Jochems 2015</a>; <a href="./references#CD012955-bbs2-0033" title="JørgensenCR , BøyeR , AndersenD , Døssing BlaabjergAH , FreundC , JordetH , et al. Eighteen months post-treatment naturalistic follow-up study of mentalization-based therapy and supportive group treatment of borderline personality disorder: clinical outcomes and functioning. Nordic Psychology2014;66(4):254-73. [DOI: 10.1080/19012276.2014.963649]JørgensenCR , FreundC , BøyeR , JordetH , AndersenD , KjølbyeM . Outcome of mentalization-based and supportive psychotherapy in patients with borderline personality disorder: a randomized trial. Acta Psychiatrica Scandinavica2013;127(4):305-17. [DOI: 10.1111/j.1600-0447.2012.01923.x] [PMID: 22897123]JorgensenCR . SV: questions on your trial regarding MBT for BPD patients [personal communication]. Email to: EG Faltinsen 28 November 2017. ">Jørgensen 2013</a>; <a href="./references#CD012955-bbs2-0035" title="KoonsCR , RobinsCJ , TweedJL , LynchTR , GonzalezAM , MorseJQ , et al. Efficacy of dialectical behavior therapy in women veterans with borderline personality disorder. Behavior Therapy2001;32(2):371-90. [DOI: 10.1016/S0005-7894(01)80009-5]">Koons 2001a</a>; <a href="./references#CD012955-bbs2-0036" title="KramerU , BergerT , KollyS , MarquetP , PreisigM , De RotenY , et al. Effects of motive-oriented therapeutic relationship in early-phase treatment of borderline personality disorder: a pilot study of a randomized trial. Journal of Nervous and Mental Disease2011;199(4):244-50. [DOI: 10.1097/NMD.0b013e3182125d19] [PMID: 21451348]KramerU , CasparF , DrapeauM . Change in biased thinking in a 10-session treatment for borderline personality disorder: further evidence of the motive-oriented therapeutic relationship. Psychotherapy Research2013;23(6):633-45. [DOI: 10.1080/10503307.2013.791404] [PMID: 23631622]">Kramer 2011</a>; <a href="./references#CD012955-bbs2-0037" title="BerthoudL , KramerU , CasparF , Pascual-LeoneA . Emotional processing in a ten-session general psychiatric treatment for borderline personality disorder: a case study. Personality and Mental Health2015;9(1):73-8. [DOI: 10.1002/pmh.1287] [PMID: 25711648]BerthoudL , Pascual-LeoneA , CasparF , TissotH , KellerS , RohdeKB , et al. Leaving distress behind: a randomized controlled study on change in emotional processing in borderline personality disorder. Psychiatry2017;80(2):139-54. [DOI: 10.1080/00332747.2016.1220230] [PMID: 28767333]KellerS , StelmaszczykK , KollyS , De RotenY , DesplandJN , CasparF , et al. Change in biased thinking in a treatment based on the motive-oriented therapeutic relationship for borderline personality disorder. Journal of Personality Disorders2018;32(Suppl):75-92. [DOI: 10.1521/pedi.2018.32.supp.75] [PMID: 29388899]KramerU , FlückigerC , KollyS , CasparF , MarquetP , DesplandJN , et al. Unpacking the effects of therapist responsiveness in borderline personality disorder: motive-oriented therapeutic relationship, patient in-session experience, and the therapeutic alliance. Psychotherapy and Psychosomatics2014;83(6):386-7. [DOI: 10.1159/000365400] [PMID: 25324025]KramerU , KellerS , CasparF , De RotenY , DesplandJN , KollyS . Early change in coping strategies in responsive treatments for borderline personality disorder: a mediation analysis. Journal of Consulting and Clinical Psychology2017;85(5):530-5. [DOI: 10.1037/ccp0000196] [PMID: 28425747]KramerU , KollyS , BerthoudL , KellerS , PreisigM , CasparF , et al. Effects of motive-oriented therapeutic relationship in a ten-session general psychiatric treatment of borderline personality disorder: a randomized controlled trial. Psychotherapy and Psychosomatics2014;83(3):176-86. [DOI: 10.1159/000358528] [PMID: 24752034]KramerU , StulzN , BerthoudL , CasparF , MarquetP , KollyS , et al. The shorter the better? A follow-up analysis of 10-session psychiatric treatment including the motive-oriented therapeutic relationship for borderline personality disorder. Psychotherapy Research2017;27(3):362-70. [DOI: 10.1080/10503307.2015.1110635] [PMID: 26684670]NCT01896024. Effects of motive-oriented therapeutic relationship in the early-phase treatment of borderline personality disorder (MOTR). www.clinicaltrials.gov/ct2/show/NCT01896024 (first received 5 July 2013). ">Kramer 2014</a>; <a href="./references#CD012955-bbs2-0038" title="KramerU , Pascual-LeoneA , BerthoudL , De RotenY , MarquetP , KollyS , et al. Assertive anger mediates effects of dialectical behaviour-informed skills training for borderline personality disorder: a randomized controlled trial. Clinical Psychology &amp; Psychotherapy2016;23(3):189-202. [DOI: 10.1002/cpp.1956] [PMID: 25864773]KramerU . The role of coping change in borderline personality disorder: a process-outcome analysis on dialectical-behaviour skills training. Clinical Psychology &amp; Psychotherapy2017;24(2):302-11. [DOI: 10.1002/cpp.2017] [PMID: 27098296]">Kramer 2016</a>; <a href="./references#CD012955-bbs2-0039" title="KredlowMA , SzuhanyKL , LoS , XieH , GottliebJD , RosenbergSD , et al. Cognitive behavioral therapy for posttraumatic stress disorder in individuals with severe mental illness and borderline personality disorder. Psychiatry Research2017;249:86-93. [DOI: 10.1016/j.psychres.2016.12.045] [PMC5325773] [PMID: 28086181]MueserK . Re: question regarding your trial on CBT for BPD patients [personal communication]. Email to: EG Faltinsen 28 November 2017. ">Kredlow 2017a</a>; <a href="./references#CD012955-bbs2-0040" title="KredlowMA , SzuhanyKL , LoS , XieH , GottliebJD , RosenbergSD , et al. Cognitive behavioral therapy for posttraumatic stress disorder in individuals with severe mental illness and borderline personality disorder. Psychiatry Research2017;249:86-93. [DOI: 10.1016/j.psychres.2016.12.045] [PMC5325773] [PMID: 28086181]MueserKT , GottliebJD , XieH , LuW , YanosPT , RosenbergSD , et al. Evaluation of cognitive restructuring for post-traumatic stress disorder in people with severe mental illness.. British Journal of Psychiatry2015;206(6):501-8. [DOI: 10.1192/bjp.bp.114.147926] [PMC4450219] [PMID: 25858178]MueserKT , RosenbergSD , XieH , JankowskiMK , BoltonEE , LuW , et al. A randomized controlled trial of cognitive-behavioral treatment for posttraumatic stress disorder in severe mental illness. Journal of Consulting and Clinical Psychology2008;76(2):259-71. [DOI: 10.1037/0022-006X.76.2.259] [PMC3916092] [PMID: 18377122]MueserKT . Re: question regarding your trial on CBT for PTSD participants [personal communication]. Email to: E Faltinsen 28 November 2018. ">Kredlow 2017b</a>; <a href="./references#CD012955-bbs2-0041" title="LaurenssenEM , WestraD , KikkertMJ , NoomMJ , EerenHV , Van BroekhuyzenAJ , et al. Day hospital mentalization-based treatment (MBT-DH) versus treatment as usual in the treatment of severe borderline personality disorder: protocol of a randomized controlled trial. BMC Psychiatry2014;14:149. [DOI: 10.1186/1471-244X-14-149] [PMC4045960] [PMID: 24886402]LaurenssenEMP , LuytenP , KikkertMJ , WestraD , PeenJ , SoonsMBJ , et al. Day hospital mentalization-based treatment v specialist treatment as usual in patients with borderline personality disorder: randomized controlled trial. Psychological Medicine2018;48(15):2522-9. [DOI: 10.1017/S0033291718000132] [PMID: 29478425]NL2058 (NTR2175). Mentalisation-based treatment versus care-as-usual in the treatment of severe borderline personality disorders. www.trialregister.nl/trial/2058 (first received 21 January 2010). ">Laurenssen 2018</a>; <a href="./references#CD012955-bbs2-0042" title="LeichsenringF , MasuhrO , JaegerU , RabungS , DallyA , DümpelmannM , et al. Psychoanalytic-interactional therapy versus psychodynamic therapy by experts for personality disorders: a randomized controlled efficacy-effectiveness study in cluster B personality disorders. Psychotherapy and Psychosomatics2016;85(2):71-80. [DOI: 10.1159/000441731] [PMID: 26808580]">Leichsenring 2016</a>; <a href="./references#CD012955-bbs2-0045" title="HoffmanRE . Impact of treatment accessibility on clinical course of parasuicidal patients. Archives of General Psychiatry1993;50(2):157-8. [DOI: 10.1001/archpsyc.1993.01820140083010] [PMID: 8427557]LindenboimN . To Know Me is to Keep Me: Self-Verification, Validation, and Therapy Dropout in the Treatment of Borderline Personality Disorder [PhD thesis]. Washington (DC): University of Washington, 2009. LinehanMM , ArmstrongHE , SuarezA , AllmonD , HeardHL . Cognitive-behavioral treatment of chronically parasuicidal borderline patients. Archives of General Psychiatry1991;48(12):1060-4. [DOI: 10.1001/archpsyc.1991.01810360024003] [PMID: 1845222]LinehanMM , HeardHL . Impact of treatment accessibility on clinical course of parasuicidal patients — reply. Archives of General Psychiatry1993;50(2):157-8. [DOI: 10.1001/archpsyc.1993.01820140083011]">Linehan 1991</a>; <a href="./references#CD012955-bbs2-0046" title="HeardHL . Cost-Effectiveness of Dialectical Behavior Therapy in the Treatment of Borderline Personality Disorder [PhD thesis]. Washington (DC): University of Washington, 2000. LindenboimN . To Know Me is to Keep Me: Self-Verification, Validation, and Therapy Dropout in the Treatment of Borderline Personality Disorder [PhD thesis]. Washington (DC): University of Washington, 2009. LinehanMM , HeardHL , ArmstrongHE . Naturalistic follow-up of a behavioral treatment for chronically parasuicidal borderline patients. Archives of General Psychiatry1993;50(12):971-4. [DOI: 10.1001/archpsyc.1993.01820240055007] [PMID: 8250683]LinehanMM , TutekDA , HeardHL , ArmstrongHE . Interpersonal outcome of cognitive behavioral treatment for chronically suicidal borderline patients. American Journal of Psychiatry1994;151(12):1771-6. [DOI: 10.1176/ajp.151.12.1771] [PMID: 7977884]">Linehan 1994</a>; <a href="./references#CD012955-bbs2-0047" title="BedicsJD , AtkinsDC , ComtoisKA , LinehanMM . Treatment differences in the therapeutic relationship and introject during a 2-year randomized controlled trial of dialectical behavior therapy versus nonbehavioral psychotherapy experts for borderline personality disorder. Journal of Consulting and Clinical Psychology2012;80(1):66-77. [DOI: 10.1037/a0026113] [PMC3265694] [PMID: 22061867]BedicsJD , AtkinsDC , ComtoisKA , LinehanMM . Weekly therapist ratings of the therapeutic relationship and patient introject furing the course of dialectical behavioral therapy for the treatment of borderline personality disorder. Psychotherapy2012;49(2):231-40. [DOI: 10.1037/a0028254] [PMID: 22642526]BedicsJD , AtkinsDC , HarnedMS , LinehanMM . The therapeutic alliance as a predictor of outcome in dialectical behavior therapy versus nonbehavioral psychotherapy by experts for borderline personality disorder. Psychotherapy2015;52(1):67-77. [DOI: 10.1037/a0038457] [PMID: 25751116]BrownMZ , LinehanMM , ComtoisKA , MurrayA , ChapmanAL . Shame as a prospective predictor of self-inflicted injury in borderline personality disorder: a multi-modal analysis. Behaviour Research and Therapy2009;47(10):815-22. [DOI: 10.1016/j.brat.2009.06.008] [PMC2761705] [PMID: 19596223 ]CoyleTN , ShaverJA , LinehanMM . On the potential for iatrogenic effects of psychiatric crisis services: the example of dialectical behavior therapy for adult women with borderline personality disorder. Journal of Consulting and Clinical Psychology2018;86(2):116-24. [DOI: 10.1037/ccp0000275] [PMID: 29369662]HarnedMS , ChapmanAL , Dexter-MazzaET , MurrayA , ComtoisKA , LinehanMM . Treating co-occurring Axis I disorders in recurrently suicidal women with borderline personality disorder: a 2-year randomized trial of dialectical behavior therapy versus community treatment by experts. Journal of Consulting and Clinical Psychology2008;76(6):1068-75. [DOI: 10.1037/a0014044] [PMID: 19045974]HarnedMS , ChapmanAL , Dexter-MazzaET , MurrayA , ComtoisKA , LinehanMM . Treating co-occurring Axis I disorders in recurrently suicidal women with borderline personality disorder: a 2-year randomized trial of dialectical behavior therapy versus community treatment by experts. Personality Disorders: Theory, Research, and Treatment2009;S(1):35-45. [DOI: 10.1037/1949-2715.S.1.35]HarnedMS , JacksonSC , ComtoisKA , LinehanMM . Dialectical behavior therapy as a precursor to PTSD treatment for suicidal and/or self-injuring women with bordreline personality disorder. Journal of Traumatic Stress2010;23(4):421-9. [DOI: 10.1002/jts.20553] [PMID: 20648564]LindenboimN , ComtoisKA , LinehanMM . Skills practice in dialectical behavior therapy for suicidal women meeting criteria for borderline personality disorder. Cognitive and Behavioral Practice2007;14(2):147-56. [DOI: 10.1016/j.cbpra.2006.10.004]LinehanMM , ComtoisKA , MurrayAM , BrownMZ , GallopRJ , HeardHL , et al. Two-year randomized controlled trial and follow-up of dialectical behavior therapy vs therapy by experts for suicidal behaviors and borderline personality disorder. Archives of General Psychiatry2006;63(7):757-66. [DOI: 10.1001/archpsyc.63.7.757] [PMID: 16818865]LinehanMM . Error in table in: two-year randomized controlled trial and follow-up of dialectical behavior therapy vs therapy by experts for suicidal behaviors and borderline personality disorder. Archives of General Psychiatry2007;64(12):1401. Erratum for: Archives of General Psychiatry 2007;64(12):1401. McMainS . Dialectic behaviour therapy reduces suicide attempts compared with non-behavioural psychotherapy in women with borderline personality disorder. Evidence-Based Mental Health2007;10(1):18. [DOI: 10.1136/ebmh.10.1.18] [PMID: 17255387]NeacsiuAD , LunguA , HarnedMS , RizviSL , LinehanMM . Impact of dialectical behavior therapy versus community treatment by experts on emotional experience, expression, and acceptance in borderline personality disorder. Behaviour Research and Therapy2014;53:47-54. [DOI: 10.1016/j.brat.2013.12.004] [PMC3955205] [PMID: 24418652]NeacsiuAD , RizviSL , LinehanMM . Dialectical behavior therapy skills use as a mediator and outcome of treatment for borderline personality disorder. Behaviour Research and Therapy2010;48(9):832-9. [DOI: 10.1016/j.brat.2010.05.017] [PMC2914145] [PMID: 20579633]SecristCD . The Role of Executive Functioning in the Treatment of Borderline Personality Disorder [PhD thesis]. Washington (DC): University of Washington, 2014. ">Linehan 2006</a>; <a href="./references#CD012955-bbs2-0048" title="LinehanMM , KorslundKE , HarnedMS , GallopRJ , LunguA , NeacsiuAD , et al. Dialectical behavior therapy for high suicide risk in individuals with borderline personality disorder: a randomized clinical trial and component analysis. JAMA Psychiatry2015;72(5):475-82 Erratum for: JAMA Psychiatry 2015; 72(9): 951. [DOI: 10.1001/jamapsychiatry.2014.3039] [PMID: 25806661]NCT00183651. Treatment of suicidal women with borderline personality disorder [Assessment and treatment of parasuicidal patients]. www.clinicaltrials.gov/ct2/show/NCT00183651 (first received 13 September 2005). ">Linehan 2015a</a>; <a href="./references#CD012955-bbs2-0049" title="CaseBG . Letter to the editor on 'McMain SF, Links PS, Gnam WH, Guimond T, Cardish RJ, Korman L, et al. A randomized trial of dialectical behavior therapy versus general psychiatric management for borderline personality disorder. American Journal of Psychiatry 2009;166(12):1365-74. DOI: 10.1176/appi.ajp.2009.09010039'. American Journal of Psychiatry2010;167(4):475. [DOI: 10.1176/appi.ajp.2009.09101532] [PMID: 20360332 ]ISRCTN02634417. Hope for chronically suicidal patient: evaluating the clinical and health services impact of dialectical behaviour therapy (DBT) in individuals with borderline personality disorder [Evaluating the clinical and health services impact of dialectical behaviour therapy (DBT) in individuals with borderline personality disorder: a randomised controlled trial]. www.isrctn.com/ISRCTN02634417 (first received 16 November 2005). [DOI: 10.1186/ISRCTN02634417]McMainSF , FitzpatrickS , BoritzT , BarnhartR , LinksP , StreinerDL . Outcome trajectories and prognostic factors for suicide and self-harm behaviors in patients with borderline personaliy disorder following one year of outpatient psychotherapy. Journal of Personality Disorders2018;32(4):497-512. [DOI: 10.1521/pedi_2017_31_309] [PMID: 28910214]McMainSF , LinksPS , GnamWH , GuimondT , CardishRJ , KormanL , et al. A randomized trial of dialectical behavior therapy versus general psychiatric management for borderline personality disorder. American Journal of Psychiatry2009;166(12):1365-74. [DOI: 10.1176/appi.ajp.2009.09010039] [PMID: 19755574]McMainSF . Dr McMain replies to letter to the editor on 'McMain SF, Links PS, Gnam WH, Guimond T, Cardish RJ, Korman L, et al. A randomized trial of dialectical behavior therapy versus general psychiatric management for borderline personality disorder. American Journal of Psychiatry 2009;166(12):1365-74. DOI: 10.1176/appi.ajp.2009.09010039'. American Journal of Psychiatry2010;167(4):475-6. [DOI: 10.1176/appi.ajp.2009.09101532r)]NCT00154154. Hope for the chronically suicidal patient [Hope for the chronically suicidal patient: evaluating the clinical and health services impact of dialectical behaviour therapy in individuals with borderline personality disorder]. www.clinicaltrials.gov/ct2/show/NCT00154154 (first received 7 September 2005). ">McMain 2009</a>; <a href="./references#CD012955-bbs2-0050" title="McMainSF , GuimondT , BarnhartR , HabinskiL , StreinerDL . A randomized trial of brief dialectical behaviour therapy skills training in suicidal patients suffering from borderline disorder. Acta Psychiatrica Scandinavica2017;135(2):138-48. [DOI: 10.1111/acps.12664] [PMID: 27858962]">McMain 2017</a>; <a href="./references#CD012955-bbs2-0051" title="McMurranM , CrawfordMJ , ReillyJ , DelportJ , McCroneP , WhithamD , et al. Psychoeducation with problem-solving (PEPS) therapy for adults with personality disorder: a pragmatic randomised controlled trial to determine the clinical effectiveness and cost-effectiveness of a manualised intervention to improve social functioning. Health Technology Assessment2016;20(52):1-282. [DOI: 10.3310/hta20520]McMurranM . RE: Cochrane Collaboration review - PEPS study [personal communication]. Email to: J Stoffers-Winterling 5 July 2018. McMurranM . Request for data on BPD subjects in the PEPS rcp-study for use a new Cochrane review [personal communication]. Email to: M Kongerslev 7 March 2017. ">McMurran 2016</a>; <a href="./references#CD012955-bbs2-0052" title="HagaE , AasE , GrøholtB , TørmoenAJ , MehlumL . Cost-effectiveness of dialectical behaviour therapy vs enhanced usual care in the treatment of adolescents with self-harm. Child and Adolescent Psychiatry and Mental Health2018;12:22. [DOI: 10.1186/s13034-018-0227-2] [PMC5928596] [PMID: 29743941]MehlumL , RambergM , TørmoenAJ , HagaE , DiepLM , StanleyBH , et al. Dialectical behavior therapy compared with enhanced usual care for adolescents with repeated suicidal and self-harming behavior: outcomes over a one-year follow-up. Journal of the American Academy of Child and Adolescent Psychiatry2016;55(4):295-300. [DOI: 10.1016/j.jaac.2016.01.005] [PMID: 27015720]MehlumL , TørmoenAJ , RambergM , HagaE , DiepLM , LabergS , et al. Dialectical behavior therapy for adolescents with repeated suicidal and self-harming behavior: a randomized trial. Journal of the American Academy of Child and Adolescent Psychiatry2014;53(10):1082-91. [DOI: 10.1016/j.jaac.2014.07.003] [PMID: 25245352]MehlumL . Re: regarding your study of DBT for your with suicidal behavior [personal communication] [Re: angående din studie om DBT for ungdom med selvmordsatferd [personlig kommunikation]]. Email to: E Faltinsen 5 December 2017. NCT00675129. Treatment for adolescents with deliberate self harm [A randomized controlled trial for repetitive deliberate self-harm and suicidal behaviours among Norwegian adolescents: a comparison between dialectical behaviour therapy adapted for adolescents (DBT-A) and enhanced usual care (EUC)]. www.clinicaltrials.gov/ct2/show/NCT00675129 (first received 6 May 2008). RamlethRK , GroholtB , DiepLM , WalbyFA , MehlumL . The impact of borderline personality disorder and sub-threshold borderline personality disorder on the course of self-reported and clinician-rated depression in self-harming adolescents. Borderline Personality Disorder and Emotion Dysregulation2017;4:22. [DOI: 10.1186/s40479-017-0073-5] [PMC5663078] [PMID: 29093819]">Mehlum 2014</a>; <a href="./references#CD012955-bbs2-0054" title="MoreyLC , LowmasterSE , HopwoodCJ . A pilot study of manual-assisted cognitive therapy with a therapeutic assessment augmentation for borderline personality disorder. Psychiatry Research2010;178(3):531-5. [DOI: 10.1016/j.psychres.2010.04.055] [PMID: 20537722]">Morey 2010</a>; <a href="./references#CD012955-bbs2-0055" title="MortonJ , SnowdonS , GopoldM , GuymerE . Acceptance and commitment therapy group treatment for symptoms of borderline personality disorder: a public sector pilot study. Cognitive and Behavioral Practice2012;19(4):527-44. [DOI: 10.1016/j.cbpra.2012.03.005]MortonJ . Re: SV: regarding your study on acceptance and commitment therapy for BPD [personal communication]. Email to: EG Faltinsen 22 December 2017. ">Morton 2012</a>; <a href="./references#CD012955-bbs2-0056" title="NadortM , ArntzA , SmitJH , Giesen-BlooJ , EikelenboomJ , SpinhovenP , et al. Implementation of outpatient schema therapy for borderline personality disorder with versus without crisis support by the therapist outside office hours: a randomized trial. Behaviour Research and Therapy2009;47(11):961-73. [DOI: 10.1016/j.brat.2009.07.013] [PMID: 19698939]NadortM , ArntzA , SmitJH , Giesen-BlooJ , EikelenboomM , SpinhovenP , et al. Implementation of outpatient schema therapy for borderline personality disorder: study design. BMC Psychiatry2009;9:64. [DOI: 10.1186/1471-244X-9-64] [PMC2762959] [PMID: 19807925]NL1680 (NTR1781). Implementation of out-patient schema-focused therapy for borderline personality disorder in regular mental healthcare. www.trialregister.nl/trial/1680 (first received 29 April 2009). ">Nadort 2009</a>; <a href="./references#CD012955-bbs2-0057" title="NCT02033044. Cognitive rehabilitation versus psychoeducation in psychosocial functioning of borderline personality disorder [Randomized controlled trial comparing the effects on psychosocial functioning of cognitive rehabilitation versus psychoeducation in borderline personality disorder]. www.clinicaltrials.gov/ct2/show/NCT02033044 (first received 23 December 2013). PascualJC , PalomaresN , Ibáñez Á, PortellaMJ , ArzaR , ReyesR , et al. Efficacy of cognitive rehabilitation on psychosocial functioning in borderline personality disorder: a randomized controlled trial. BMC Psychiatry2015;15:255. [DOI: 10.1186/s12888-015-0640-5] [PMC4617906] [PMID: 26487284]">Pascual 2015</a>; <a href="./references#CD012955-bbs2-0059" title="BarnicotK . Re: Regarding your study on DBT for self-harming patients [personal communication]. Email to: EG Faltinsen 28 February 2018. PriebeS , BhattiN , BarnicotK , BremnerS , GagliaA , KatsakouC , et al. Effectiveness and cost-effectiveness of dialectical behaviour therapy for self-harming patients with personality disorder: a pragmatic randomised controlled trial. Psychotherapy and Psychosomatics2012;81(6):356-65. [DOI: 10.1159/000338897] [PMID: 22964561]PriebeS . Supplemental information [personal communication]. Email to: M Kielsholm 20 May 2016. ">Priebe 2012</a>; <a href="./references#CD012955-bbs2-0060" title="RenesesB , FigueraD , SalcedoG , TrujilloM , López-IborJJ , GaliánM , et al. A controlled randomized study on the efficacy of short-term dinamic psychotherapy in borderline personality disorders (BPD). Preliminary results. European Psychiatry2011;26(Suppl 1):1040. [DOI: 10.1016/S0924-9338(11)72745-6] [P02-444]RenesesB , GaliánM , SerranoR , FigueraD , Fernandez Del MoralA , López-IborJJ , et al. A new time limited psychotherapy for BPD: preliminary results of a randomized and controlled trial. Actas Espanolas de Psiquiatria2013;41(3):139-48. [PMID: 23803797]">Reneses 2013</a>; <a href="./references#CD012955-bbs2-0062" title="ISRCTN95266816. The emergence of personality disorder traits in adolescents who deliberately self harm and the potential for using a mentalisation based treatment approach as an early intervention for such individuals: a randomised controlled trial. www.isrctn.com/ISRCTN95266816 (first received 29 October 2007). RossouwT . Mentalisation based treatment for adolescents with self harm: an RCT. European Child &amp; Adolescent Psychiatry2015;24(1 Suppl):S113. [DOI: 10.1007%2Fs00787-015-0714-4.pdf] [W1-02-02]RossouwT . Self harm in adolescence, is MBT the answer?: an RCT. Adolescent Psychiatry2012;2(1):102. [DOI: 10.2174/2210676611202010077]RossouwTI , FonagyP . Mentalization-based treatment for self-harm in adolescents: a randomized controlled trial. Journal of the American Academy of Child and Adolescent Psychiatry2012;51(12):1304-13.e3. [DOI: 10.1016/j.jaac.2012.09.018] [PMID: 23200287]">Rossouw 2012b</a>; <a href="./references#CD012955-bbs2-0063" title="SalzerS , CroppC , JaegerU , MasuhrO , Streeck-FischerA . Psychodynamic therapy for adolescents suffering from co-morbid disorders of conduct and emotions in an in-patient setting: a randomized controlled trial. Psychological Medicine2014;44(10):2213-22. [DOI: 10.1017/S003329171300278X] [PMID: 24229481]SalzerS , Streeck-FischerA . The psychoanalytic-interactional method (PiM) for adolescents with borderline personality disorder [Die psychoanalytisch-interaktionelle methode (PiM) für adoleszente mit borderline-persönlichkeitsstörung]. Personlichkeitsstorungen Theorie und Therapie2015;19(1):67-76. [elibrary.klett-cotta.de/article/99.120110/ptt-19-1-67]SalzerS . AW: Re: Cochrane Review on psychotherapies for BPD - RCT testing PiM vs WL [personal communication] [AW:Re: Cochrane Review zur Psychotherapie bei BPS - RCT zu PiM vs WL [persönliche kommunikation]]. Email to: J Stoffers-Winterling 15 July 2018. ">Salzer 2014</a>; <a href="./references#CD012955-bbs2-0065" title="SchillingL , MoritzS , KötherU , NagelM . Preliminary results on acceptance, feasibility, and subjective efficacy of the add-on group intervention metacognitive training for borderline patients. Journal of Cognitive Psychotherapy2015;29(2):153-64. [DOI: 10.1891/0889-8391.29.2.153]SchillingL , MoritzS , KristonL , KriegerM , NagelM . Efficacy of metacognitive training for patients with borderline personality disorder: preliminary results. Psychiatry Research2018;262:459-64. [DOI: 10.1016/j.psychres.2017.09.024] [PMID: 28927866]SchillingL . Re Schilling 2015/2018 - Cochrane Review of psychotherapies for BPD [personal communication] [Re Schilling 2015/2018 - Cochrane Review zur Psychotherapie bei BPS [persönliche Kommunikation]]. Email to: J Stoffers-Winterling 22 January 2019. ">Schilling 2018</a>; <a href="./references#CD012955-bbs2-0066" title="ISRCTN97589104. Evaluation of a group training for adolescents (emotion regulation training) with emotion regulation problems - a randomised controlled clinical trial. www.isrctn.com/ISRCTN97589104 (first received 23 August 2007). SchuppertHM , TimmermanME , BlooJ , Van GemertTG , WiersemaHM , MinderaaRB , et al. Emotion regulation training for adolescents with borderline personality disorder traits: a randomized controlled trial. Journal of the American Academy of Child &amp; Adolescent Psychiatry2012;51(12):1314-23. [DOI: 10.1016/j.jaac.2012.09.002] [PMID: 23200288]">Schuppert 2012</a>; <a href="./references#CD012955-bbs2-0067" title="NCT01904227. Intensified, inpatient adaptation of dialectical behavior therapy (DBT) (REDBT) [A randomized controlled study of the efficacy of an intensified, inpatient adaptation of dialectical behavior therapy (DBT) for a population of borderline patients (young adults/adults: 18-40), compared with standard outpatient DBT]. www.clinicaltrials.gov/ct2/show/NCT01904227 (first received 11 July 2013). SinnaeveR , Van den BoschLM , Van Steenbergen-WeijenburgKM . Change in interpersonal functioning during psychological interventions for borderline personality disorder — a systematic review of measures and efficacy. Personality and Mental Health2015;9(3):173-94. [DOI: 10.1002/pmh.1296] [PMID: 26058794]SinnaeveR , Van den BoschLMC , Hakkaart-van RoijenL , VansteelandtK . Effectiveness of step-down versus outpatient dialectical behaviour therapy for patients with severe levels of borderline personality disorder: a pragmatic randomized controlled trial. Borderline Personality Disorder and Emotion Dysregulation2018;5:12. [DOI: 10.1186/s40479-018-0089-5] [PMC6040072] [PMID: 30002832]SinnaeveR . Cochrane Collaboration review [personal communication]. Email to: J Stoffers-Winterling 11 June 2018. SinnaeveR . Re: BPDSI subscale data Sinnaeve et al (2018) [personal communication]. Email to: A Tadorovac 15 November 2018. SinnaeveR . RE: BPDSI subscale data Sinnaeve et al (2018) [personal communication] [RE: BPDSI subschale data Sinnaeve et al (2018) [personlig kommunikation]]. Email to: A Todorovac 15 November 2018. SinnaeveR . RE: BPDSI subscale data Sinnaeve et al (2018) [personal communication] [RE: BPDSI subschale data Sinnaeve et al (2018) [personlig kommunikation]]. Email to: A Todorovac 9 October 2018. Van den BoschLM , SinnaeveR , Hakkaart-van RoijenL , Van FurthEF . Efficacy and cost-effectiveness of an experimental short-term inpatient dialectical behavior therapy (DBT) program: study protocol for a randomized controlled trial. Trials2014;15:152. [DOI: 10.1186/1745-6215-15-152] [PMC4017823] [PMID: 24885551]Van RoijenLH , SinnaeveR , BouwmansC , Van Den BoschL . Cost-effectiveness and cost-utility of shortterm inpatient dialectical behavior therapy for chronically parasuicidal BPD (young) adults. Journal of Mental Health Policy and Economics2015;18(Suppl 1):S19-20. [www.icmpe.org/test1/journal/issues/v18s1toc.html]">Sinnaeve 2018</a>; <a href="./references#CD012955-bbs2-0068" title="SmithPN , GambleSA , CortNA , WardEA , HeH , TalbotNL . Attachment and alliance in the treatment of depressed, sexually abused women. Depression and Anxiety2012;29(2):123-30. [DOI: 10.1002/da.20913] [PMC3325338] [PMID: 22065593]SmithPN . Re: Cochrane Collaboration review of psychotherapies for BPD [personal communication]. Email to: J Stoffers-Winterling 05 July 2018. ">Smith 2012</a>; <a href="./references#CD012955-bbs2-0069" title="SolerJ , PascualJC , TianaT , CebriàA , BarrachinaJ , CampinsMJ , et al. Dialectical behaviour therapy skills training compared to standard group therapy in borderline personality disorder: a 3-month randomised controlled clinical trial. Behaviour Research and Therapy2009;47(5):353-8. [DOI: 10.1016/j.brat.2009.01.013] [PMID: 19246029]SolerJ . Question regarding your BPD trials [personal communication]. Email to: J Stoffers 15 December 2010. ">Soler 2009</a>; <a href="./references#CD012955-bbs2-0071" title="TurnerRM . Naturalistic evaluation of dialectical behavior therapy-oriented treatment for borderline personality disorder. Cognitive and Behavioral Practice2000;7(4):413-9. [DOI: 10.1016/S1077-7229(00)80052-8]">Turner 2000</a>; <a href="./references#CD012955-bbs2-0072" title="Van den BoschLM , KoeterMW , StijnenT , VerheulR , Van den BrinkW . Sustained efficacy of dialectical behaviour therapy for borderline personality disorder. Behaviour Research and Therapy2005;43(9):1231-41. [DOI: 10.1016/j.brat.2004.09.008] [PMID: 16005708]Van den BoschLM , VerheulR , SchippersGM , Van den BrinkW . Dialectical behavior therapy of borderline patients with and without substance use problems. Implementation and long-term effects. Addictive Behaviors2002;27(6):911-23. [DOI: 10.1016/s0306-4603(02)00293-9] [PMID: 12369475]Van den BoschLMC . Efficacy of dialectical behaviour therapy in the treatment of female borderline patients with and without substance abuse problems: results of a Dutch study [Dialectische gedragstherapie bij Nederlandse vrouwen met een borderline persoonlijkheidsstoornis, met en zonder verslavingsproblemen]. Tijdschrift voor Psychiatrie2005;47(3):127-37. [www.tijdschriftvoorpsychiatrie.nl/assets/articles/articles_1335pdf.pdf]VerheulR , Van den BoschLM , KoeterMW , De RidderMA , StijnenT , Van den BrinkW . Dialectical behaviour therapy for women with borderline personality disorder: 12-month, randomised clinical trial in The Netherlands. British Journal of Psychiatry2003;182:135-40. [DOI: 10.1192/bjp.182.2.135] [PMID: 12562741]">Van den Bosch 2005</a>; <a href="./references#CD012955-bbs2-0073" title="WeinbergI , GundersonJG , HennenJ , Cutter CJ Jr. Manual assisted cognitive treatment for deliberate self-harm in borderline personality disorder patients. Journal of Personality Disorders2006;20(5):482-92. [DOI: 10.1521/pedi.2006.20.5.482] [PMID: 17032160]WilbergT . SV: separate data [personal communication] [SV: separat data [personlig kommunikation]]. Email to: M Kielsholm 25 May 2016. ">Weinberg 2006</a>; <a href="./references#CD012955-bbs2-0074" title="ZanariniMC , FrankenburgFR . A preliminary, randomized trial of psychoeducation for women with borderline personality disorder. Journal of Personality Disorders2008;22(3):284-90. [DOI: 10.1521/pedi.2008.22.3.284] [PMID: 18540800]ZanariniMC , FrankenburgFR . A randomized trial of psychoeducation for patients with BPD. In: 157th annual meeting of the American Psychiatric Association. Psychotherapy and psychopharmacology: dissolving the mind-brain barrier; 2004 May 1-6; New York (NY). Arlington (VA): American Psychiatric Association, 2004:102. [Symposium 100E] [www.psychiatry.org/File%20Library/Psychiatrists/Directories/Library-and-Archive/conference_publications/am_program_2004.pdf]">Zanarini 2008</a>; <a href="./references#CD012955-bbs2-0075" title="ZanariniMC , ConkeyLC , TemesCM , FitzmauriceGM . Randomized controlled trial of web-based psychoeducation for women with borderline personality disorder. Journal of Clinical Psychiatry2018;79(3):16m11153. [DOI: 10.4088/JCP.16m11153] [PMC5764827] [PMID: 28703950]">Zanarini 2018</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All participants of each group received the same kind of concomitant medication</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Bellino-2006" target="_blank">Bellino 2006</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Bellino-2007" target="_blank">Bellino 2007</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Bellino-2010" target="_blank">Bellino 2010</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Jahangard-2012" target="_blank">Jahangard 2012</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Partly (50% of each group concomitantly received a specified, concurrent medication, 50% placebo) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Stanley-2017" target="_blank">Stanley 2017</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not allowed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Lin-2019" target="_blank">Lin 2019</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Mohamadizadeh-2017" target="_blank">Mohamadizadeh 2017</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not specified</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Bianchini-2019" target="_blank">Bianchini 2019</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Carter-2010" target="_blank">Carter 2010</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Davidson-2014" target="_blank">Davidson 2014</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Haeyen-2018" target="_blank">Haeyen 2018</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Kamalabadi-2012" target="_blank">Kamalabadi 2012</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Lepp_x00e4_nen-2016" target="_blank">Leppänen 2016</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Philips-2018" target="_blank">Philips 2018</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Robinson-2016" target="_blank">Robinson 2016</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Santisteban-2015" target="_blank">Santisteban 2015</a> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="3" rowspan="1" scope="col" valign="bottom"> <p><b><i>Control interventions</i> </b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Obligatory</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Amianto-2011" target="_blank">Amianto 2011</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Andreoli-2016" target="_blank">Andreoli 2016</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Bateman-1999" target="_blank">Bateman 1999</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Bateman-2009" target="_blank">Bateman 2009</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Bellino-2006" target="_blank">Bellino 2006</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Bellino-2010" target="_blank">Bellino 2010</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Bianchini-2019" target="_blank">Bianchini 2019</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Borschmann-2013" target="_blank">Borschmann 2013</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Bos-2010" target="_blank">Bos 2010</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Carter-2010" target="_blank">Carter 2010</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Davidson-2014" target="_blank">Davidson 2014</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Doering-2010" target="_blank">Doering 2010</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Farrell-2009" target="_blank">Farrell 2009</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Feigenbaum-2012" target="_blank">Feigenbaum 2012</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Gleeson-2012" target="_blank">Gleeson 2012</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Gratz-2006" target="_blank">Gratz 2006</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Gratz-2014" target="_blank">Gratz 2014</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Jahangard-2012" target="_blank">Jahangard 2012</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Jochems-2015" target="_blank">Jochems 2015</a>;<a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-J_x00f8_rgensen-2013" target="_blank">Jørgensen 2013</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Koons-2001a" target="_blank">Koons 2001a</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Kramer-2016" target="_blank">Kramer 2016</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Laurenssen-2018" target="_blank">Laurenssen 2018</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Leichsenring-2016" target="_blank">Leichsenring 2016</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Lepp_x00e4_nen-2016" target="_blank">Leppänen 2016</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Linehan-2006" target="_blank">Linehan 2006</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-McMurran-2016" target="_blank">McMurran 2016</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Mehlum-2014" target="_blank">Mehlum 2014</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Morton-2012" target="_blank">Morton 2012</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Mohamadizadeh-2017" target="_blank">Mohamadizadeh 2017</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Philips-2018" target="_blank">Philips 2018</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Priebe-2012" target="_blank">Priebe 2012</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Reneses-2013" target="_blank">Reneses 2013</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Robinson-2016" target="_blank">Robinson 2016</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Rossouw-2012b" target="_blank">Rossouw 2012b</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Schuppert-2012" target="_blank">Schuppert 2012</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Soler-2009" target="_blank">Soler 2009</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Stanley-2017" target="_blank">Stanley 2017</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Smith-2012" target="_blank">Smith 2012</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Van-den-Bosch-2005" target="_blank">Van den Bosch 2005</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Weinberg-2006" target="_blank">Weinberg 2006</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Zanarini-2018" target="_blank">Zanarini 2018</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Optional</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Blum-2008" target="_blank">Blum 2008</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Bohus-2013" target="_blank">Bohus 2013</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Davidson-2006" target="_blank">Davidson 2006</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Gregory-2008b" target="_blank">Gregory 2008b</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Haeyen-2018" target="_blank">Haeyen 2018</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Kamalabadi-2012" target="_blank">Kamalabadi 2012</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Kredlow-2017a" target="_blank">Kredlow 2017a</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Linehan-1991" target="_blank">Linehan 1991</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Linehan-1994" target="_blank">Linehan 1994</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-McMain-2017" target="_blank">McMain 2017</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Mohamadizadeh-2017" target="_blank">Mohamadizadeh 2017</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Salzer-2014" target="_blank">Salzer 2014</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Zanarini-2008" target="_blank">Zanarini 2008</a> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="3" rowspan="1" scope="col" valign="bottom"> <p><b><i>Funding</i> </b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Funded by grants from universities, authorities or research foundations</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012955-bbs2-0001" title="AmiantoF , FerreroA , PieròA , CairoE , RoccaG , SimonelliB , et al. Supervised team management, with or without structured psychotherapy, in heavy users of a mental health service with borderline personality disorder: a two-year follow-up preliminary randomized study. BMC Psychiatry2011;11:181. [DOI: 10.1186/1471-244X-11-181] [PMC3260092 ] [PMID: 22103890]NCT01356069. Efficacy of time-limited psychodynamic psychotherapy and informed clinical management in BPD high MHS users (HUMSH) [Sequential brief Adlerian psychodynamic psychotherapy in heavy users of a mental health service with borderline personality disorder: a two years follow-up preliminary randomized study]. clinicaltrials.gov/ct2/show/NCT01356069 (first received 16 May 2011). ">Amianto 2011</a>; <a href="./references#CD012955-bbs2-0003" title="AntonsenBT , JohansenMS , RøFG , KvarsteinEH , WilbergT . Is reflective functioning associated with clinical symptoms and long-term course in patients with personality disorders?Comprehensive Psychiatry2016;64:46-58. [DOI: 10.1016/j.comppsych.2015.05.016] [PMID: 26104432]AntonsenBT , KlungsøyrO , KampsA , HummelenB , JohansenMS , PedersenG , et al. Step-down versus outpatient psychotherapeutic treatment for personality disorders: 6-year follow-up of the Ullevål personality project. BMC Psychiatry2014;14:119. [DOI: 10.1186/1471-244X-14-119] [PMC4000615] [PMID: 24758722]AntonsenBT , KvarsteinEH , Urnes Ø, HummelenB , KarterudS , WilbergT . Favourable outcome of long-term combined psychotherapy for patients with borderline personality disorder: six-year follow-up of a randomized study. Psychotherapy Research2017;27(1):51-63. [DOI: 10.1080/10503307.2015.1072283] [PMID: 26261865]ArnevikE , WilbergT , Urnes Ø, JohansenM , MonsenJT , KarterudS . Psychotherapy for personality disorders: short-term day hospital psychotherapy versus outpatient individual therapy - a randomized controlled study. European Psychiatry2009;24(2):71-8. [DOI: 10.1016/j.eurpsy.2008.09.004] [PMID: 19097870]GullestadFS , JohansenMS , HøglendP , KarterudS , WilbergT . Mentalization as a moderator of treatment effects: findings from a randomized clinical trial for personality disorders. Psychotherapy Research2013;23(6):674-89. [DOI: 10.1080/10503307.2012.684103] [PMID: 22612470]GullestadFS . Re: questions regarding your trial on day hospital step-down program [personal communication]. Email to: E Faltinsen 4 December 2017. KvarsteinEH , ArnevikE , HalsteinliV , RøFG , KarterudS , WilbergT . Health service costs and clinical gains of psychotherapy for personality disorders: a randomized controlled trial of day-hospital-based step-down treatment versus outpatient treatment at a specialist practice. BMC Psychiatry2013;13:315. [DOI: 10.1186/1471-244X-13-315] [PMC4222503] [PMID: 24268099]">Antonsen 2017</a>; <a href="./references#CD012955-bbs2-0004" title="BatemanA , FonagyP . 8-year follow-up of patients treated for borderline personality disorder: mentalization-based treatment versus treatment as usual. American Journal of Psychiatry2008;165(5):631-8. [DOI: 10.1176/appi.ajp.2007.07040636] [PMID: 18347003]BatemanA , FonagyP . Effectiveness of partial hospitalization in the treatment of borderline personality disorder: a randomized controlled trial. American Journal of Psychiatry1999;156(10):1563-9. [DOI: 10.1176/ajp.156.10.1563] [PMID: 10518167]BatemanA , FonagyP . Health care utilization costs for borderline personality disorder patients treated with psychoanalytically oriented partial hospitalization versus general psychiatric care. American Journal of Psychiatry2003;160(1):169-71. [10.1176/appi.ajp.160.1.169] [12505818]BatemanA , FonagyP . Treatment of borderline personality disorder with psychoanalytically oriented partial hospitalization: an 18-month follow-up. American Journal of Psychiatry2001;158(1):36-42. [DOI: 10.1176/appi.ajp.158.1.36] [PMID: 11136631]BatemanA . Important: question regarding your BPD trial for systematic review in Cochrane Collaboration [personal communication]. Email to: K Lieb, J Stoffers 14 December 2010. BatemanA . Intensive outpatient and partial hospital care for BPD. In: 157th annual meeting of the American Psychiatric Association. Psychotherapy and pharmacology: dissolving the mind-brain barrier; 2004 May 1-6; New York (NY). Arlington (VA): American Psychiatric Association, 2004:102. [Symposium 100B] [www.psychiatry.org/File%20Library/Psychiatrists/Directories/Library-and-Archive/conference_publications/am_program_2004.pdf]BatemanAW , FonagyP . Drs Bateman and Fonagy reply [to Stern R. Partial hospitalization for borderline personality disorder. American Journal of Psychiatry 2001;158(11):1932-3. DOI: 10.1176/appi.ajp.158.11.1932]. American Journal of Psychiatry2001;158(11):1932-3. [DOI: 10.1176/appi.ajp.158.11.1932-a]EvansC . Treatment benefits of psychoanalytically oriented partial hospitalisation were maintained over 18 months in borderline personality disorder. Evidence-Based Mental Health2001;4(3):73. [DOI: 10.1136/ebmh.4.3.73]FonagyP , BatemanAW . Mentalizing and borderline personality disorder. Journal of Mental Health2007;16(1):83-101. [DOI: 10.1080/09638230601182045]SternR . Partial hospitalization for borderline personality disorder. American Journal of Psychiatry2001;158(11):1932-3. [DOI: 10.1176/appi.ajp.158.11.1932] [PMID: 11691712]">Bateman 1999</a>; <a href="./references#CD012955-bbs2-0005" title="BatemanA , FonagyP . Impact of clinical severity on outcomes of mentalisation-based treatment for borderline personality disorder. British Journal of Psychiatry2013;203(3):221-7. [DOI: 10.1192/bjp.bp.112.121129] [PMID: 23887998]BatemanA , FonagyP . Randomized controlled trial of outpatient mentalization-based treatment versus structured clinical management for borderline personality disorder. American Journal of Psychiatry2009;166(12):1355-64. [DOI: 10.1176/appi.ajp.2009.09040539] [PMID: 19833787]BatemanA , FonagyP . Randomized controlled trial of outpatient mentalization-based treatment versus structured clinical management for borderline personality disorder. Supplementary data. ajp.psychiatryonline.org/doi/suppl/10.1176/appi.ajp.2009.09040539/suppl_file/ajp_166_12_1355_01.pdf (accessed 27 February 2020). BatemanA , O'ConnellJ , LorenziniN , GardnerT , FonagyP . A randomised controlled trial of mentalization-based treatment versus structured clinical management for patients with comorbid borderline personality disorder and antisocial personality disorder. BMC Psychiatry2016;16:304. [DOI: 10.1186/s12888-016-1000-9] [PMC5006360] [PMID: 27577562]BatemanA . Important question regarding your BPD trial for systematic review in Cochrane Collaboration [personal communication]. Email to: K Lieb 14 December 2010. BatemanAW . Mentalization, borderline personality disorder and what works for whom? Presentation at the 11th International Congress of the International Society for the Study of Personality Disorders; 2009 Aug 21-23. www.borderlinepersonalitydisorder.com/Conferences/ISSPD/isspd_09_Bateman (accessed 21 April 2010). ISRCTN27660668. Randomised controlled trial of manualised out-patient individual and group therapy for borderline personality disorder [Effectiveness of intensive out-patient psychotherapy for treatment of borderline personality disorder: a pragmatic randomised single blind controlled study]. www.isrctn.com/ISRCTN27660668 (first received 12 October 2008). ">Bateman 2009</a>; <a href="./references#CD012955-bbs2-0010" title="BlackD . Question regarding your BPD trial [personal communication]. Email to: J Stoffers 04 January 2011. BlackDW , AllenJ , McCormickB , BlumN . Treatment received by persons with BPD participating in a randomized clinical trial of the systems training for emotional predictability and problem solving programme. Personality and Mental Health2011;5(3):159-68. [DOI: 10.1002/pmh.167]BlackDW , AllenJ , St JohnD , PfohlB , McCormickB , BlumN . Predictors of response to systems training for emotional predictability and problem solving (STEPPS) for borderline personality disorder: an exploratory study. Acta Psychiatrica Scandinavica2009;120(1):53-61. [DOI: 10.1111/j.1600-0447.2008.01340.x] [PMC3665337] [PMID: 19183126]BlackDW , BlumN , PfohlB , St JohnD . The STEPPS group treatment program for outpatients with borderline personality disorder. Journal of Contemporary Psychotherapy2004;34(3):193-210. [DOI: 10.1023/B:JOCP.0000036630.25741.83]BlackDW , PfohlBM . Randomized clinical trial of STEPPS versus treatment as usual. In: 158th annual meeting of the American Psychiatric Association. Psychosomatic medicine: integrating psychiatry &amp; medicine; 2005 May 21-26; Atlanta (GA). Arlington (VA): American Psychiatric Association, 2005:104. [No. 1B] [www.psychiatry.org/File%20Library/Psychiatrists/Directories/Library-and-Archive/syllabus/am_syllabus_2005.pdf]BlackDW , Simsek-DuranF , BlumN , McCormickB , AllenJ . Do people with borderline personality disorder complicated by antisocial personality disorder benefit from the STEPPS treatment program?Personality and Mental Health2016;10(3):205-15. [DOI: 10.1002/pmh.1326] [PMC4911327] [PMID: 26671625]BlackDW . RE: [external] questions regarding your trial on the STEPPS program for BPD [personal communication]. Email to: EG Faltinsen 27 November 2017. BlumN , AllenJ , McCormickB , BlackDW . Ms Blum and colleagues reply [to Schulte-Herbrüggen O, Koerting J, Roepke S. Effectiveness of adjunctive STEPPS group treatment in borderline personality disorder patients. American Journal of Psychiatry 2008;165(10):1354-5. DOI: 10.1176/appi.ajp.2008.08030390]. American Journal of Psychiatry2008;165(10):1354-5. [DOI: 10.1176/appi.ajp.2008.08030390r]BlumN , FranklinJ , HanselR , McCormickB , St JohnD , PfohlB , et al. Relationship of age to symptom severity, psychiatric comorbidity and health care utilization in persons with borderline personality disorder. Personality and Mental Health2008;2(1):25-43. [DOI: 10.1002/pmh.26]BlumN , St JohnD , PfohlB , StuartS , McCormickB , AllenJ , et al. Erratum. American Journal of Psychiatry2008;165(6):777. Erratum for: American Journal of Psychiatry 2008;165(4):468-78. [psycnet.apa.org/record/2008-07854-033]BlumN , St JohnD , PfohlB , StuartS , McCormickB , AllenJ , et al. Systems training for emotional predictability and problem solving (STEPPS) for outpatients with borderline personality disorder: a randomized controlled trial and 1-year follow-up. American Journal of Psychiatry2008;165(4):468-78. [DOI: 10.1176/appi.ajp.2007.07071079] [PMC3608469] [PMID: 18281407]DavidsonKM . Borderline personality disorder: STEPPS improves symptoms. Evidence-Based Mental Health2008;11(4):120. [DOI: 10.1136/ebmh.11.4.120] [PMID: 18952969]NCT00055315. Treatment for borderline personality disorder [A cognitive group treatment for borderline outpatients]. clinicaltrials.gov/ct2/show/NCT00055315 (first received 25 February 2003). ">Blum 2008</a>; <a href="./references#CD012955-bbs2-0011" title="BohusM , DyerAS , PriebeK , KrügerA , KleindienstN , SchmahlC , et al. Dialectical behaviour therapy for post-traumatic stress disorder after childhood sexual abuse in patients with and without borderline personality disorder: a randomised controlled trial. Psychotherapy and Psychosomatics2013;82(4):221-33. [DOI: 10.1159/000348451] [PMID: 23712109]BrandS . AW: questions regarding your trial on emotional intelligence training for BPD [personal communication]. Email to: EG Faltinsen 28 November 2017. DBT Working Group at the Central Institute for Mental Health, Mannheim, Germany. Requested supplementary data (as supplied 1 October 2010). Data on file. NCT00481000. Dialectical cognitive traumatherapy (DCT) on patients with severe PTSD following sexual abuse (PASA) [Dialectical cognitive traumatherapy (DCT) on patients with severe posttraumatic stress disorder following sexual abuse - a randomised controlled trial]. clinicaltrials.gov/ct2/show/NCT00481000 (first received 31 May 2007). SteilR , DyerA , PriebeK , KleindienstN , BohusM . Dialectical behavior therapy for posttraumatic stress disorder related to childhood sexual abuse: a pilot study of an intensive treatment program. Journal of Traumatic Stress2011;24(1):102-6. [DOI: 10.1002/jts.20617] [PMID: 21351167]">Bohus 2013</a>; <a href="./references#CD012955-bbs2-0012" title="BorschmannR , BarrettB , HellierJM , ByfordS , HendersonC , RoseD , et al. Joint crisis plans for people with borderline personality disorder: feasibility and outcomes in a randomised controlled trial. British Journal of Psychiatry2013;202(5):357-64. [DOI: 10.1192/bjp.bp.112.117762] [PMID: 23637110]BorschmannR . Joint crisis plans for BPD - question on publication in British Journal of Psychiatry [pers communication]. Email to: J Stoffers-Winterling 22 August 2017. BorschmannR . RE: joint crisis plans for BPD - question on publication in British Journal of Psychiatry [personal communication]. Email to: J Stoffers-Winterling 22 August 2017. BorschmannR . The development and testing of joint crisis plans for people with borderline personality disorder: a feasibility study. ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.628499 (accessed 27 January 2019). HellierJ . RE: regarding your study on on MBT for eating disorders [personal communication]. Email to: E Faltinsen 27 March 2018. HellierJ . RE: regarding your study on on MBT for eating disorders [personal communication]. Email to: E Faltinsen 3 January 2018. HellierJ . SV: regarding your study on MBT for eating disorders [personal communication]. Email to: EG Faltinsen, P Robinson 27 March 2018. ISRCTN12440268. JOSHUA: a pilot randomised controlled trial of joint crisis plans for people who self harm. www.isrctn.com/ISRCTN12440268 (first received 17 September 2009). ">Borschmann 2013</a>; <a href="./references#CD012955-bbs2-0013" title="BosEH , Van WelE , AppeloMT , VerbraakMJP . A randomized controlled trial of a Dutch version of systems training for emotional predictability and problem solving for borderline personality disorder. Journal of Nervous and Mental Disease2010;198(4):299-304. [DOI: 10.1097/NMD.0b013e3181d619cf] [PMID: 20386260]Van WelEB , BosEH , AppeloMT , BerendsenEM , WillgerothFC , VerbraakMJPM . The efficacy of the systems training for emotional predictability and problem solving (STEPPS) in the treatment of borderline personality disorder. A randomized controlled trial [De effectiviteit van de vaardigheidstraining emotieregulatiestoornis (VERS) in de behandeling van de borderlinepersoonlijkheidsstoornis: een gerandomiseerd onderzoek]. Tijdschrift voor Psychiatrie2009;51(5):291-301. [PMID: 19434566]">Bos 2010</a>; <a href="./references#CD012955-bbs2-0014" title="Carmona i FarrésC , ElicesM , SolerJ , Domínguez-ClavéE , Pomarol-ClotetE , SalvadorR , et al. Effects of mindfulness training on borderline personality disorder: impulsivity versus emotional dysregulation. Mindfulness2019;10:1243-54. [DOI: 10.1007/s12671-018-1071-4]NCT03363230. Effects of mindfulness training on emotion regulation and impulsivity. www.clinicaltrials.gov/ct2/show/NCT03363230 (first received 30 November 2017). ">Carmona í Farrés 2019</a>; <a href="./references#CD012955-bbs2-0016" title="CottrauxJ , NoteID , BoutitieF , MillieryM , GenouihlacV , YaoSN , et al. Cognitive therapy versus Rogerian supportive therapy in borderline personality disorder. Two-year follow-up of a controlled pilot study. Psychotherapy and Psychosomatics2009;78(5):307-16. [DOI: 10.1159/000229769] [PMID: 19628959]NCT00131781. Cognitive therapy versus supportive therapy in borderline personality disorder. www.clinicaltrials.gov/ct2/show/NCT00131781 (first received 18 August 2005). ">Cottraux 2009</a>; <a href="./references#CD012955-bbs2-0017" title="DavidsonK , LivingstoneS , McArthurK , DicksonL , GumleyA . An integrative complexity analysis of cognitive behaviour therapy sessions for borderline personality disorder. Psychology and Psychotherapy2007;80(Pt 4):513-23. [DOI: 10.1348/147608307X191535] [PMID: 17535542]DavidsonK , NorrieJ , TyrerP , GumleyA , TataP , MurrayH , et al. The effectiveness of cognitive behavior therapy for borderline personality disorder: results from the borderline personality disorder study of cognitive therapy (BOSCOT) trial. Journal of Personality Disorders2006;20(5):450-65. [DOI: 10.1521/pedi.2006.20.5.450] [PMC1852259] [PMID: 17032158]DavidsonK , TyrerP , GumleyA , TataP , NorrieJ , PalmerS , et al. A randomized controlled trial of cognitive behavior therapy for borderline personality disorder: rationale for trial, method, and description of sample. Journal of Personality Disorders2006;20(5):431-49. [DOI: 10.1521/pedi.2006.20.5.431] [PMC1847748] [PMID: 17032157]DavidsonKM , TyrerP , NorrieJ , PalmerSJ , TyrerH . Cognitive therapy v usual treatment for borderline personality disorder: prospective 6-year follow-up. British Journal of Psychiatry2010;197(6):456-62. [DOI: 10.1192/bjp.bp.109.074286] [PMID: 21119151]ISRCTN86177428. Borderline personality disorder study of cognitive therapy trial [A randomised controlled trial of cognitive therapy plus treatment as usual versus treatment as usual in the treatment of borderline personality disorder]. www.isrctn.com/ISRCTN86177428 (first received 22 July 2005). NCT00538135. BOSCOT: a randomised controlled trial of cognitive behavioural therapy in borderline personality disorder [BOSCOT: a randomised control trial of cognitive behavioural therapy plus treatment as usual versus treatment as usual in the treatment of borderline personality disorder]. www.clinicaltrials.gov/ct2/show/NCT00538135 (first received 29 September 2007). NorrieJ , DavidsonK , TataP , GumleyA . Influence of therapist competence and quantity of cognitive behavioural therapy on suicidal behaviour and inpatient hospitalisation in a randomised controlled trial in borderline personality disorder: further analyses of treatment effects in the BOSCOT study. Psychology and Psychotherapy2013;86(3):280-93. [DOI: 10.1111/papt.12004] [PMC4491320] [PMID: 23420622]PalmerS , DavidsonK , TyrerP , GumleyA , TataP , NorrieJ , et al. The cost-effectiveness of cognitive behavior therapy for borderline personality disorder: results from the BOSCOT trial. Journal of Personality Disorders2006;20(5):466-81. [DOI: 10.1521/pedi.2006.20.5.466] [PMC1852260] [PMID: 17032159]">Davidson 2006</a>; <a href="./references#CD012955-bbs2-0018" title="DavidsonKM , BrownTM , JamesV , KirkJ , RichardsonJ . Manual-assisted cognitive therapy for self-harm in personality disorder and substance misuse: a feasibility trial. Psychiatric Bulletin2014;38(3):108-11. [DOI: 10.1192/pb.bp.113.043109] [PMC4115373] [PMID: 25237519]DavidsonKM . Re: question regarding your trial on manual-assisted cognitive therapy [personal communication]. Email to: EG Faltinsen 28 November 2017. ">Davidson 2014</a>; <a href="./references#CD012955-bbs2-0019" title="BuchheimA , Hörz-SagstetterS , DoeringS , RentropM , SchusterP , BuchheimP , et al. Change of unresolved attachment in borderline personality disorders: RCT study of transference-focused psychotherapy. Psychotherapy and Psychosomatics2017;86(5):314-6. [DOI: 10.1159/000460257] [PMID: 28903103]DiamondD , LevyKN , ClarkinJF , Fischer-KernM , CainNM , DoeringS , et al. Attachment and mentalization in female patients with comorbid narcissistic and borderline personality disorder. Personality Disorders2014;5(4):428-33. [DOI: 10.1037/per0000065] [PMID: 25314231]DiamondD , YeomansFE , SternB , LevyKN , HörzS , DoeringS , et al. Transference-focused psychotherapy for patients with comorbid narcissistic and borderline personality disorder. Psychoanalytic Inquiry2013;33(6):527-51. [DOI: 10.1080/07351690.2013.815087]DoeringS , HörzS , RentropM , Fischer-KernM , SchusterP , BeneckeC , et al. Transference-focused psychotherapy v treatment by community psychotherapists for borderline personality disorder: randomised controlled trial. British Journal of Psychiatry2010;196(5):389-95. [DOI: 10.1192/bjp.bp.109.070177] [PMID: 20435966]DoeringS . Author's reply [to Kleindienst N, Krumm B, Bohus M. Is transference-focused psychotherapy really efficacious for borderline personality disorder? British Journal of Psychiatry 2011;198(2):156-7. DOI: 10.1192/bjp.198.2.156b]. British Journal of Psychiatry2011;198(2):156-7. [DOI: 10.1192/bjp.198.2.157]DoeringS . Question regarding your BPD trial for systematic review in Cochrane Collaboration [personal communication]. Email to: K Lieb, J Stoffers 10 December 2010. Fischer-KernM , DoeringS , TaubnerS , HörzS , ZimmermannJ , RentropM , et al. Transference-focused psychotherapy for borderline personality disorder: change in reflective function. British Journal of Psychiatry2015;207(2):173-4. [DOI: 10.1192/bjp.bp.113.143842] [PMID: 25999334]KleindienstN , KrummB , BohusM . Is transference-focused psychotherapy really efficacious for borderline personality disorder?British Journal of Psychiatry2011;198(2):156-7. [DOI: 10.1192/bjp.198.2.156b] [PMID: 21282787]LevyKN , MeehanKB , YeomansFE . Transference-focused psychotherapy reduces treatment drop-out and suicide attempters compared with community psychotherapist treatment in borderline personality disorder. Evidence-based Mental Health2010;13(4):119. [DOI: 10.1136/ebmh.13.4.119] [PMID: 21036981]NCT00714311. Efficacy of transference-focused psychotherapy for borderline personality disorder [A randomized-controlled trial of transference-focused psychotherapy vs treatment by experienced community psychotherapists for borderline personality disorder]. www.clinicaltrials.gov/ct2/show/NCT00714311 (first received 9 July 2008). RentropM , MartiusP , BäumlJ , BuchheimP , DöeringS , HörzS . Patients with borderline personality disorder not participating in an RCT: are they different?Psychopathology2010;43(6):369-72. [DOI: 10.1159/000320351] [PMID: 20798576]">Doering 2010</a>; <a href="./references#CD012955-bbs2-0020" title="ElicesM , PascualJC , PortellaMJ , Feliu-SolerA , Martín-BlancoA , CarmonaC , et al. Impact of mindfulness training on borderline personality disorder: a randomized trial. Mindfulness2016;7:584-95. [DOI: 10.1007/s12671-016-0492-1]NCT02397031. Mindfulness and interpersonal effectiveness skills in borderline personality disorder [Randomized, active-controlled, clinical trial comparing effects of mindfulness and interpersonal effectiveness skills in borderline personality disorder]. www.clinicaltrials.gov/ct2/show/NCT02397031 (first received 12 March 2015). SolerJ , ElicesM , PascualJC , Martín-BlancoA , Feliu-SolerA , CarmonaC , et al. Effects of mindfulness training on different components of impulsivity in borderline personality disorder: results from a pilot randomized study. Borderline Personality Disorder and Emotion Dysregulation2016;3:1. [DOI: 10.1186/s40479-015-0035-8] [PMC4709962] [PMID: 26759718]">Elices 2016</a>; <a href="./references#CD012955-bbs2-0021" title="FarrellJM , ShawIA , WebberMA . A schema-focused approach to group psychotherapy for outpatients with borderline personality disorder: a randomized controlled trial. Journal of Behavior Therapy and Experimental Psychiatry2009;40(2):317-28 Corrigendum to: Journal of Behavior Therapy and Experimental Psychiatry 2018; 60: 111. [DOI: 10.1016/j.jbtep.2009.01.002] [PMID: 19176222]FarrellJM . Question regarding your BPD trials [personal communication]. Email to: K Lieb, J Stoffers 9 December 2010. ">Farrell 2009</a>; <a href="./references#CD012955-bbs2-0022" title="FeigenbaumJD , FonagyP , PillingS , JonesA , WildgooseA , BebbingtonPE . A real-world study of the effectiveness of DBT in the UK National Health Service. British Journal of Clinical Psychology2012;51(2):121-41. [DOI: 10.1111/j.2044-8260.2011.02017.x] [PMID: 22574799]">Feigenbaum 2012</a>; <a href="./references#CD012955-bbs2-0023" title="Feliu-SolerA , PascualJC , ElicesM , Martín-BlancoA , CarmonaC , CebollaA , et al. Fostering self-compassion and loving-kindness in patients with borderline personality disorder: a randomized pilot study. Clinical Psychology &amp; Psychotherapy2017;24(1):278-86. [DOI: 10.1002/cpp.2000] [PMID: 26818533]">Feliu‐Soler 2017</a>; <a href="./references#CD012955-bbs2-0024" title="ArntzA , Stupar-RutenfransS , BlooJ , Van DyckR , SpinhovenP . Prediction of treatment discontinuation and recovery from borderline personality disorder: results from an RCT comparing schema therapy and transference-focused psychotherapy. Behaviour Research and Therapy2015;74:60-71. [DOI: 10.1016/j.brat.2015.09.002] [PMID: 26432172]Giesen-BlooJ , ArntzA . Questions concerning the randomized trial of schema-focused therapy vs transference-focused psychotherapy—reply. Archives of General Psychiatry2007;64(5):610-1. [DOI: 10.1001/archpsyc.64.5.610]Giesen-BlooJ , Van DyckR , SpinhovenP , Van TilburgW , DirksenC , Van AsseltT , et al. Errors in table and figure in: outpatient psychotherapy for borderline personality disorder: randomized trial of schema-focused therapy vs transference-focused psychotherapy. Archives of General Psychiatry2006;63(9):1008. Erratum for: Archives of General Psychiatry 2006;63(6):649-58. [DOI: 10.1001/archpsyc.63.9.1008]Giesen-BlooJ , Van DyckR , SpinhovenP , Van TilburgW , DirksenC , Van AsseltT , et al. Outpatient psychotherapy for borderline personality disorder: randomized trial of schema-focused therapy vs transference-focused psychotherapy. Archives of General Psychiatry2006;63(6):649-58. [DOI: 10.1001/archpsyc.63.6.649] [PMID: 16754838]SpinhovenP , Giesen-BlooJ , Van DyckR , KooimanK , ArntzA . The therapeutic alliance in schema-focused therapy and transference-focused psychotherapy for borderline personality disorder. Journal of Consulting and Clinical Psychology2007;75(1):104-15. [DOI: 10.1037/0022-006X.75.1.104] [PMID: 17295569]Van AsseltADI , DirksenCD , ArntzA , Giesen-BlooJH , Van DyckR , SpinhovenP , et al. Out-patient psychotherapy for borderline personality disorder: cost-effectiveness of schema-focused therapy v transference-focused psychotherapy. British Journal of Psychiatry2008;192(6):450-7. [DOI: 10.1192/bjp.bp.106.033597] [PMID: 18515897]Van AsseltADI , DirksenCD , ArntzA , SeverensJL . Difficulties in calculating productivity costs: work disability associated with borderline personality disorder. Value in Health2008;11(4):637-44. [DOI: 10.1111/j.1524-4733.2007.00288.x]YeomansF . Questions concerning the randomized trial of schema-focused therapy vs transference-focused psychotherapy. Archives of General Psychiatry2007;64(5):609-10. [DOI: 10.1001/archpsyc.64.5.609-c] [PMID: 17485613]">Giesen‐Bloo 2006</a>; <a href="./references#CD012955-bbs2-0025" title="GleesonJF , ChanenA , CottonSM , PearceT , NewmanB , McCutcheonL . Treating co-occurring first-episode psychosis and borderline personality: a pilot randomized controlled trial. Early Intervention in Psychiatry2012;6(1):21-9. [DOI: 10.1111/j.1751-7893.2011.00306.x] [PMID: 22379625]GleesonJFM . RE: separate data [personal communication]. Email to: M Kielsholm 28 October 2016. ">Gleeson 2012</a>; <a href="./references#CD012955-bbs2-0026" title="Gratz KL. Important: question regarding your BPD trial for systematic review in Cochrane Collaboration [personal communication]. Email to: J Stoffers-Winterling 11 December 2010. GratzKL , GundersonJG . Preliminary data on an acceptance-based emotion regulation group intervention for deliberate self-harm among women with borderline personality disorder. Behavior Therapy2006;37(1):25-35. [DOI: 10.1016/j.beth.2005.03.002] [PMID: 16942958]">Gratz 2006</a>; <a href="./references#CD012955-bbs2-0027" title="GratzKL , BardeenJR , LevyR , Dixon-GordonKL , TullMT . Mechanisms of change in an emotion regulation group therapy for deliberate self-harm among women with borderline personality disorder. Behaviour Research and Therapy2015;65:29-35. [DOI: 10.1016/j.brat.2014.12.005] [PMC4306622] [PMID: 25557395]GratzKL , Dixon-GordonKL , TullMT . Predictors of treatment response to an adjunctive emotion regulation group therapy for deliberate self-harm among women with borderline personality disorder. Personality Disorders2014;5(1):97-107. [DOI: 10.1037/per0000062] [PMC4059504] [PMID: 2458806]GratzKL , TullMT , LevyR . Randomized controlled trial and uncontrolled 9-month follow-up of an adjunctive emotion regulation group therapy for deliberate self-harm among women with borderline personality disorder. Psychological Medicine2014;44(10):2099-112. [DOI: 10.1017/S0033291713002134] [PMID: 23985088]GratzKL . Question regarding your BPD trials [personal communication]. Email to: J Stoffers 11 December 2010. ">Gratz 2014</a>; <a href="./references#CD012955-bbs2-0028" title="GregoryRJ , ChlebowskiS , KangD , RemenA , SoderbergM . Psychodynamic therapy for borderline personality disorder and co-occurring alcohol use disorders: a newly designed ongoing study. Journal of the American Psychoanalytic Association2006;54(4):1331-4. [DOI: 10.1177/00030651060540040107] [PMID: 17354507]GregoryRJ , ChlebowskiS , KangD , RemenAL , SoderbergMG , StepkovitchJ , et al. A controlled trial of psychodynamic psychotherapy for co-occurring borderline personality disorder and alcohol use disorder. Psychotherapy2008;45(1):28-41. [DOI: 10.1037/0033-3204.45.1.28] [PMID: 22122363]GregoryRJ , DeLucia-DeranjaE , MogleJA . Dynamic deconstructive psychotherapy versus optimized community care for borderline personality disorder co-occuring with alcohol use disorders: a 30-month follow-up. Journal of Nervous and Mental Disease2010;198(4):292-8. [DOI: 10.1097/NMD.0b013e3181d6172d] [PMID: 20386259]GregoryRJ , RemenAL , SoderbergM , Ploutz-SnyderRJ . A controlled trial of psychodynamic psychotherapy for co-occurring borderline personality disorder and alcohol use disorder: six-month outcome. Journal of the American Psychoanalytic Association2009;57(1):199-205. [DOI: 10.1177/00030651090570011006] [PMID: 19270255]NCT00145678. Psychodynamic therapy for co-occurring borderline personality disorder and alcohol use disorder [Psychodynamic therapy for patients With borderline personality disorder and alcohol abuse]. www.clinicaltrials.gov/show/NCT00145678 (first received 1 September 2005). ">Gregory 2008b</a>; <a href="./references#CD012955-bbs2-0029" title="HaeyenS , Van HoorenS , HutschemaekersG . Efficacy of art therapy in individuals with personality disorders cluster B/C: a randomised controlled trial. International Journal of Psychology July 2016;51:60. [DOI: 10.1521/pedi_2017_31_312] [PMID: 28926306]HaeyenS , Van HoorenS , Van der VeldW , HutschemaekersG . Efficacy of art therapy in individuals with personality disorders cluster B/C: a randomised controlled trial. Journal of Personality Disorders2018;32(4):527-42. [DOI: 10.1521/pedi_2017_31_312] [PMID: 28926306]HaeyenS . Re: Cochrane Collaboration review of psychotherapies for BPD - your RCT of art therapy [personal communication]. Email to: J Stoffers-Winterling 18 August 2018. ">Haeyen 2018</a>; <a href="./references#CD012955-bbs2-0030" title="HarnedM . Re: SV: question regarding your trial on brief therapy for attempted suicide [personal communication]. Email to: EG Faltinsen 11 December 2018. HarnedMS , KorslundKE , LinehanMM . A pilot randomized controlled trial of dialectical behavior therapy with and without the dialectical behavior therapy prolonged exposure protocol for suicidal and self-injuring women with borderline personality disorder and PTSD. Behaviour Research and Therapy2014;55:7-17. [DOI: 10.1016/j.brat.2014.01.008] [PMC3987949] [PMID: 24562087]HarnedMS , WilksCR , SchmidtSC , CoyleTN . Improving functional outcomes in women with borderline personality disorder and PTSD by changing PTSD severity and post-traumatic cognitions. Behaviour Research and Therapy2018;103:53-61. [DOI: 10.1016/j.brat.2018.02.002] [PMC5837954] [PMID: 29448136]HarnedMS . RE: questions regarding your trial on brief therapy for attempted suicide [personal communication]. Email to: E Faltinsen 29 November 2017. ">Harned 2014</a>; <a href="./references#CD012955-bbs2-0032" title="JochemsEC , Van der Feltz-CornelisCM , Van DamA , DuivenvoordenHJ , MulderCL . The effects of motivation feedback in patients with severe mental illness: a cluster randomized controlled trial. Neuropsychiatric Disease and Treatment2015;11:3049-64. [DOI: 10.2147/NDT.S95190] [PMC4686323] [PMID: 26715847]JochemsEC . Cochrane Collaboration review on psychotherapies for borderline PD [personal communication]. Email to: EG Faltinsen 2 July 2018. JochemsEC . Re: Cochrane Collaboration review on psychotherapies for borderline PD [personal communication]. Email to: J Stoffers-Winterling 02 July 2018. ">Jochems 2015</a>; <a href="./references#CD012955-bbs2-0033" title="JørgensenCR , BøyeR , AndersenD , Døssing BlaabjergAH , FreundC , JordetH , et al. Eighteen months post-treatment naturalistic follow-up study of mentalization-based therapy and supportive group treatment of borderline personality disorder: clinical outcomes and functioning. Nordic Psychology2014;66(4):254-73. [DOI: 10.1080/19012276.2014.963649]JørgensenCR , FreundC , BøyeR , JordetH , AndersenD , KjølbyeM . Outcome of mentalization-based and supportive psychotherapy in patients with borderline personality disorder: a randomized trial. Acta Psychiatrica Scandinavica2013;127(4):305-17. [DOI: 10.1111/j.1600-0447.2012.01923.x] [PMID: 22897123]JorgensenCR . SV: questions on your trial regarding MBT for BPD patients [personal communication]. Email to: EG Faltinsen 28 November 2017. ">Jørgensen 2013</a>; <a href="./references#CD012955-bbs2-0036" title="KramerU , BergerT , KollyS , MarquetP , PreisigM , De RotenY , et al. Effects of motive-oriented therapeutic relationship in early-phase treatment of borderline personality disorder: a pilot study of a randomized trial. Journal of Nervous and Mental Disease2011;199(4):244-50. [DOI: 10.1097/NMD.0b013e3182125d19] [PMID: 21451348]KramerU , CasparF , DrapeauM . Change in biased thinking in a 10-session treatment for borderline personality disorder: further evidence of the motive-oriented therapeutic relationship. Psychotherapy Research2013;23(6):633-45. [DOI: 10.1080/10503307.2013.791404] [PMID: 23631622]">Kramer 2011</a>; <a href="./references#CD012955-bbs2-0037" title="BerthoudL , KramerU , CasparF , Pascual-LeoneA . Emotional processing in a ten-session general psychiatric treatment for borderline personality disorder: a case study. Personality and Mental Health2015;9(1):73-8. [DOI: 10.1002/pmh.1287] [PMID: 25711648]BerthoudL , Pascual-LeoneA , CasparF , TissotH , KellerS , RohdeKB , et al. Leaving distress behind: a randomized controlled study on change in emotional processing in borderline personality disorder. Psychiatry2017;80(2):139-54. [DOI: 10.1080/00332747.2016.1220230] [PMID: 28767333]KellerS , StelmaszczykK , KollyS , De RotenY , DesplandJN , CasparF , et al. Change in biased thinking in a treatment based on the motive-oriented therapeutic relationship for borderline personality disorder. Journal of Personality Disorders2018;32(Suppl):75-92. [DOI: 10.1521/pedi.2018.32.supp.75] [PMID: 29388899]KramerU , FlückigerC , KollyS , CasparF , MarquetP , DesplandJN , et al. Unpacking the effects of therapist responsiveness in borderline personality disorder: motive-oriented therapeutic relationship, patient in-session experience, and the therapeutic alliance. Psychotherapy and Psychosomatics2014;83(6):386-7. [DOI: 10.1159/000365400] [PMID: 25324025]KramerU , KellerS , CasparF , De RotenY , DesplandJN , KollyS . Early change in coping strategies in responsive treatments for borderline personality disorder: a mediation analysis. Journal of Consulting and Clinical Psychology2017;85(5):530-5. [DOI: 10.1037/ccp0000196] [PMID: 28425747]KramerU , KollyS , BerthoudL , KellerS , PreisigM , CasparF , et al. Effects of motive-oriented therapeutic relationship in a ten-session general psychiatric treatment of borderline personality disorder: a randomized controlled trial. Psychotherapy and Psychosomatics2014;83(3):176-86. [DOI: 10.1159/000358528] [PMID: 24752034]KramerU , StulzN , BerthoudL , CasparF , MarquetP , KollyS , et al. The shorter the better? A follow-up analysis of 10-session psychiatric treatment including the motive-oriented therapeutic relationship for borderline personality disorder. Psychotherapy Research2017;27(3):362-70. [DOI: 10.1080/10503307.2015.1110635] [PMID: 26684670]NCT01896024. Effects of motive-oriented therapeutic relationship in the early-phase treatment of borderline personality disorder (MOTR). www.clinicaltrials.gov/ct2/show/NCT01896024 (first received 5 July 2013). ">Kramer 2014</a>; <a href="./references#CD012955-bbs2-0038" title="KramerU , Pascual-LeoneA , BerthoudL , De RotenY , MarquetP , KollyS , et al. Assertive anger mediates effects of dialectical behaviour-informed skills training for borderline personality disorder: a randomized controlled trial. Clinical Psychology &amp; Psychotherapy2016;23(3):189-202. [DOI: 10.1002/cpp.1956] [PMID: 25864773]KramerU . The role of coping change in borderline personality disorder: a process-outcome analysis on dialectical-behaviour skills training. Clinical Psychology &amp; Psychotherapy2017;24(2):302-11. [DOI: 10.1002/cpp.2017] [PMID: 27098296]">Kramer 2016</a>; <a href="./references#CD012955-bbs2-0039" title="KredlowMA , SzuhanyKL , LoS , XieH , GottliebJD , RosenbergSD , et al. Cognitive behavioral therapy for posttraumatic stress disorder in individuals with severe mental illness and borderline personality disorder. Psychiatry Research2017;249:86-93. [DOI: 10.1016/j.psychres.2016.12.045] [PMC5325773] [PMID: 28086181]MueserK . Re: question regarding your trial on CBT for BPD patients [personal communication]. Email to: EG Faltinsen 28 November 2017. ">Kredlow 2017a</a>; <a href="./references#CD012955-bbs2-0040" title="KredlowMA , SzuhanyKL , LoS , XieH , GottliebJD , RosenbergSD , et al. Cognitive behavioral therapy for posttraumatic stress disorder in individuals with severe mental illness and borderline personality disorder. Psychiatry Research2017;249:86-93. [DOI: 10.1016/j.psychres.2016.12.045] [PMC5325773] [PMID: 28086181]MueserKT , GottliebJD , XieH , LuW , YanosPT , RosenbergSD , et al. Evaluation of cognitive restructuring for post-traumatic stress disorder in people with severe mental illness.. British Journal of Psychiatry2015;206(6):501-8. [DOI: 10.1192/bjp.bp.114.147926] [PMC4450219] [PMID: 25858178]MueserKT , RosenbergSD , XieH , JankowskiMK , BoltonEE , LuW , et al. A randomized controlled trial of cognitive-behavioral treatment for posttraumatic stress disorder in severe mental illness. Journal of Consulting and Clinical Psychology2008;76(2):259-71. [DOI: 10.1037/0022-006X.76.2.259] [PMC3916092] [PMID: 18377122]MueserKT . Re: question regarding your trial on CBT for PTSD participants [personal communication]. Email to: E Faltinsen 28 November 2018. ">Kredlow 2017b</a>; <a href="./references#CD012955-bbs2-0041" title="LaurenssenEM , WestraD , KikkertMJ , NoomMJ , EerenHV , Van BroekhuyzenAJ , et al. Day hospital mentalization-based treatment (MBT-DH) versus treatment as usual in the treatment of severe borderline personality disorder: protocol of a randomized controlled trial. BMC Psychiatry2014;14:149. [DOI: 10.1186/1471-244X-14-149] [PMC4045960] [PMID: 24886402]LaurenssenEMP , LuytenP , KikkertMJ , WestraD , PeenJ , SoonsMBJ , et al. Day hospital mentalization-based treatment v specialist treatment as usual in patients with borderline personality disorder: randomized controlled trial. Psychological Medicine2018;48(15):2522-9. [DOI: 10.1017/S0033291718000132] [PMID: 29478425]NL2058 (NTR2175). Mentalisation-based treatment versus care-as-usual in the treatment of severe borderline personality disorders. www.trialregister.nl/trial/2058 (first received 21 January 2010). ">Laurenssen 2018</a>; <a href="./references#CD012955-bbs2-0042" title="LeichsenringF , MasuhrO , JaegerU , RabungS , DallyA , DümpelmannM , et al. Psychoanalytic-interactional therapy versus psychodynamic therapy by experts for personality disorders: a randomized controlled efficacy-effectiveness study in cluster B personality disorders. Psychotherapy and Psychosomatics2016;85(2):71-80. [DOI: 10.1159/000441731] [PMID: 26808580]">Leichsenring 2016</a>; <a href="./references#CD012955-bbs2-0044" title="Lin T-J, Ko H-C, Wu JY-W, OeiTP , Lane H-Y, Chen C-H. The effectiveness of dialectical behavior therapy skills training group vs cognitive therapy group on reducing depression and suicide attempts for borderline personality disorder in Taiwan. Archives of Suicide Research2019;23(1):82-99. [DOI: 10.1080/13811118.2018.1436104] [PMID: 29528807]">Lin 2019</a>; <a href="./references#CD012955-bbs2-0045" title="HoffmanRE . Impact of treatment accessibility on clinical course of parasuicidal patients. Archives of General Psychiatry1993;50(2):157-8. [DOI: 10.1001/archpsyc.1993.01820140083010] [PMID: 8427557]LindenboimN . To Know Me is to Keep Me: Self-Verification, Validation, and Therapy Dropout in the Treatment of Borderline Personality Disorder [PhD thesis]. Washington (DC): University of Washington, 2009. LinehanMM , ArmstrongHE , SuarezA , AllmonD , HeardHL . Cognitive-behavioral treatment of chronically parasuicidal borderline patients. Archives of General Psychiatry1991;48(12):1060-4. [DOI: 10.1001/archpsyc.1991.01810360024003] [PMID: 1845222]LinehanMM , HeardHL . Impact of treatment accessibility on clinical course of parasuicidal patients — reply. Archives of General Psychiatry1993;50(2):157-8. [DOI: 10.1001/archpsyc.1993.01820140083011]">Linehan 1991</a>; <a href="./references#CD012955-bbs2-0046" title="HeardHL . Cost-Effectiveness of Dialectical Behavior Therapy in the Treatment of Borderline Personality Disorder [PhD thesis]. Washington (DC): University of Washington, 2000. LindenboimN . To Know Me is to Keep Me: Self-Verification, Validation, and Therapy Dropout in the Treatment of Borderline Personality Disorder [PhD thesis]. Washington (DC): University of Washington, 2009. LinehanMM , HeardHL , ArmstrongHE . Naturalistic follow-up of a behavioral treatment for chronically parasuicidal borderline patients. Archives of General Psychiatry1993;50(12):971-4. [DOI: 10.1001/archpsyc.1993.01820240055007] [PMID: 8250683]LinehanMM , TutekDA , HeardHL , ArmstrongHE . Interpersonal outcome of cognitive behavioral treatment for chronically suicidal borderline patients. American Journal of Psychiatry1994;151(12):1771-6. [DOI: 10.1176/ajp.151.12.1771] [PMID: 7977884]">Linehan 1994</a>; <a href="./references#CD012955-bbs2-0047" title="BedicsJD , AtkinsDC , ComtoisKA , LinehanMM . Treatment differences in the therapeutic relationship and introject during a 2-year randomized controlled trial of dialectical behavior therapy versus nonbehavioral psychotherapy experts for borderline personality disorder. Journal of Consulting and Clinical Psychology2012;80(1):66-77. [DOI: 10.1037/a0026113] [PMC3265694] [PMID: 22061867]BedicsJD , AtkinsDC , ComtoisKA , LinehanMM . Weekly therapist ratings of the therapeutic relationship and patient introject furing the course of dialectical behavioral therapy for the treatment of borderline personality disorder. Psychotherapy2012;49(2):231-40. [DOI: 10.1037/a0028254] [PMID: 22642526]BedicsJD , AtkinsDC , HarnedMS , LinehanMM . The therapeutic alliance as a predictor of outcome in dialectical behavior therapy versus nonbehavioral psychotherapy by experts for borderline personality disorder. Psychotherapy2015;52(1):67-77. [DOI: 10.1037/a0038457] [PMID: 25751116]BrownMZ , LinehanMM , ComtoisKA , MurrayA , ChapmanAL . Shame as a prospective predictor of self-inflicted injury in borderline personality disorder: a multi-modal analysis. Behaviour Research and Therapy2009;47(10):815-22. [DOI: 10.1016/j.brat.2009.06.008] [PMC2761705] [PMID: 19596223 ]CoyleTN , ShaverJA , LinehanMM . On the potential for iatrogenic effects of psychiatric crisis services: the example of dialectical behavior therapy for adult women with borderline personality disorder. Journal of Consulting and Clinical Psychology2018;86(2):116-24. [DOI: 10.1037/ccp0000275] [PMID: 29369662]HarnedMS , ChapmanAL , Dexter-MazzaET , MurrayA , ComtoisKA , LinehanMM . Treating co-occurring Axis I disorders in recurrently suicidal women with borderline personality disorder: a 2-year randomized trial of dialectical behavior therapy versus community treatment by experts. Journal of Consulting and Clinical Psychology2008;76(6):1068-75. [DOI: 10.1037/a0014044] [PMID: 19045974]HarnedMS , ChapmanAL , Dexter-MazzaET , MurrayA , ComtoisKA , LinehanMM . Treating co-occurring Axis I disorders in recurrently suicidal women with borderline personality disorder: a 2-year randomized trial of dialectical behavior therapy versus community treatment by experts. Personality Disorders: Theory, Research, and Treatment2009;S(1):35-45. [DOI: 10.1037/1949-2715.S.1.35]HarnedMS , JacksonSC , ComtoisKA , LinehanMM . Dialectical behavior therapy as a precursor to PTSD treatment for suicidal and/or self-injuring women with bordreline personality disorder. Journal of Traumatic Stress2010;23(4):421-9. [DOI: 10.1002/jts.20553] [PMID: 20648564]LindenboimN , ComtoisKA , LinehanMM . Skills practice in dialectical behavior therapy for suicidal women meeting criteria for borderline personality disorder. Cognitive and Behavioral Practice2007;14(2):147-56. [DOI: 10.1016/j.cbpra.2006.10.004]LinehanMM , ComtoisKA , MurrayAM , BrownMZ , GallopRJ , HeardHL , et al. Two-year randomized controlled trial and follow-up of dialectical behavior therapy vs therapy by experts for suicidal behaviors and borderline personality disorder. Archives of General Psychiatry2006;63(7):757-66. [DOI: 10.1001/archpsyc.63.7.757] [PMID: 16818865]LinehanMM . Error in table in: two-year randomized controlled trial and follow-up of dialectical behavior therapy vs therapy by experts for suicidal behaviors and borderline personality disorder. Archives of General Psychiatry2007;64(12):1401. Erratum for: Archives of General Psychiatry 2007;64(12):1401. McMainS . Dialectic behaviour therapy reduces suicide attempts compared with non-behavioural psychotherapy in women with borderline personality disorder. Evidence-Based Mental Health2007;10(1):18. [DOI: 10.1136/ebmh.10.1.18] [PMID: 17255387]NeacsiuAD , LunguA , HarnedMS , RizviSL , LinehanMM . Impact of dialectical behavior therapy versus community treatment by experts on emotional experience, expression, and acceptance in borderline personality disorder. Behaviour Research and Therapy2014;53:47-54. [DOI: 10.1016/j.brat.2013.12.004] [PMC3955205] [PMID: 24418652]NeacsiuAD , RizviSL , LinehanMM . Dialectical behavior therapy skills use as a mediator and outcome of treatment for borderline personality disorder. Behaviour Research and Therapy2010;48(9):832-9. [DOI: 10.1016/j.brat.2010.05.017] [PMC2914145] [PMID: 20579633]SecristCD . The Role of Executive Functioning in the Treatment of Borderline Personality Disorder [PhD thesis]. Washington (DC): University of Washington, 2014. ">Linehan 2006</a>; <a href="./references#CD012955-bbs2-0048" title="LinehanMM , KorslundKE , HarnedMS , GallopRJ , LunguA , NeacsiuAD , et al. Dialectical behavior therapy for high suicide risk in individuals with borderline personality disorder: a randomized clinical trial and component analysis. JAMA Psychiatry2015;72(5):475-82 Erratum for: JAMA Psychiatry 2015; 72(9): 951. [DOI: 10.1001/jamapsychiatry.2014.3039] [PMID: 25806661]NCT00183651. Treatment of suicidal women with borderline personality disorder [Assessment and treatment of parasuicidal patients]. www.clinicaltrials.gov/ct2/show/NCT00183651 (first received 13 September 2005). ">Linehan 2015a</a>; <a href="./references#CD012955-bbs2-0049" title="CaseBG . Letter to the editor on 'McMain SF, Links PS, Gnam WH, Guimond T, Cardish RJ, Korman L, et al. A randomized trial of dialectical behavior therapy versus general psychiatric management for borderline personality disorder. American Journal of Psychiatry 2009;166(12):1365-74. DOI: 10.1176/appi.ajp.2009.09010039'. American Journal of Psychiatry2010;167(4):475. [DOI: 10.1176/appi.ajp.2009.09101532] [PMID: 20360332 ]ISRCTN02634417. Hope for chronically suicidal patient: evaluating the clinical and health services impact of dialectical behaviour therapy (DBT) in individuals with borderline personality disorder [Evaluating the clinical and health services impact of dialectical behaviour therapy (DBT) in individuals with borderline personality disorder: a randomised controlled trial]. www.isrctn.com/ISRCTN02634417 (first received 16 November 2005). [DOI: 10.1186/ISRCTN02634417]McMainSF , FitzpatrickS , BoritzT , BarnhartR , LinksP , StreinerDL . Outcome trajectories and prognostic factors for suicide and self-harm behaviors in patients with borderline personaliy disorder following one year of outpatient psychotherapy. Journal of Personality Disorders2018;32(4):497-512. [DOI: 10.1521/pedi_2017_31_309] [PMID: 28910214]McMainSF , LinksPS , GnamWH , GuimondT , CardishRJ , KormanL , et al. A randomized trial of dialectical behavior therapy versus general psychiatric management for borderline personality disorder. American Journal of Psychiatry2009;166(12):1365-74. [DOI: 10.1176/appi.ajp.2009.09010039] [PMID: 19755574]McMainSF . Dr McMain replies to letter to the editor on 'McMain SF, Links PS, Gnam WH, Guimond T, Cardish RJ, Korman L, et al. A randomized trial of dialectical behavior therapy versus general psychiatric management for borderline personality disorder. American Journal of Psychiatry 2009;166(12):1365-74. DOI: 10.1176/appi.ajp.2009.09010039'. American Journal of Psychiatry2010;167(4):475-6. [DOI: 10.1176/appi.ajp.2009.09101532r)]NCT00154154. Hope for the chronically suicidal patient [Hope for the chronically suicidal patient: evaluating the clinical and health services impact of dialectical behaviour therapy in individuals with borderline personality disorder]. www.clinicaltrials.gov/ct2/show/NCT00154154 (first received 7 September 2005). ">McMain 2009</a>; <a href="./references#CD012955-bbs2-0050" title="McMainSF , GuimondT , BarnhartR , HabinskiL , StreinerDL . A randomized trial of brief dialectical behaviour therapy skills training in suicidal patients suffering from borderline disorder. Acta Psychiatrica Scandinavica2017;135(2):138-48. [DOI: 10.1111/acps.12664] [PMID: 27858962]">McMain 2017</a>; <a href="./references#CD012955-bbs2-0051" title="McMurranM , CrawfordMJ , ReillyJ , DelportJ , McCroneP , WhithamD , et al. Psychoeducation with problem-solving (PEPS) therapy for adults with personality disorder: a pragmatic randomised controlled trial to determine the clinical effectiveness and cost-effectiveness of a manualised intervention to improve social functioning. Health Technology Assessment2016;20(52):1-282. [DOI: 10.3310/hta20520]McMurranM . RE: Cochrane Collaboration review - PEPS study [personal communication]. Email to: J Stoffers-Winterling 5 July 2018. McMurranM . Request for data on BPD subjects in the PEPS rcp-study for use a new Cochrane review [personal communication]. Email to: M Kongerslev 7 March 2017. ">McMurran 2016</a>; <a href="./references#CD012955-bbs2-0052" title="HagaE , AasE , GrøholtB , TørmoenAJ , MehlumL . Cost-effectiveness of dialectical behaviour therapy vs enhanced usual care in the treatment of adolescents with self-harm. Child and Adolescent Psychiatry and Mental Health2018;12:22. [DOI: 10.1186/s13034-018-0227-2] [PMC5928596] [PMID: 29743941]MehlumL , RambergM , TørmoenAJ , HagaE , DiepLM , StanleyBH , et al. Dialectical behavior therapy compared with enhanced usual care for adolescents with repeated suicidal and self-harming behavior: outcomes over a one-year follow-up. Journal of the American Academy of Child and Adolescent Psychiatry2016;55(4):295-300. [DOI: 10.1016/j.jaac.2016.01.005] [PMID: 27015720]MehlumL , TørmoenAJ , RambergM , HagaE , DiepLM , LabergS , et al. Dialectical behavior therapy for adolescents with repeated suicidal and self-harming behavior: a randomized trial. Journal of the American Academy of Child and Adolescent Psychiatry2014;53(10):1082-91. [DOI: 10.1016/j.jaac.2014.07.003] [PMID: 25245352]MehlumL . Re: regarding your study of DBT for your with suicidal behavior [personal communication] [Re: angående din studie om DBT for ungdom med selvmordsatferd [personlig kommunikation]]. Email to: E Faltinsen 5 December 2017. NCT00675129. Treatment for adolescents with deliberate self harm [A randomized controlled trial for repetitive deliberate self-harm and suicidal behaviours among Norwegian adolescents: a comparison between dialectical behaviour therapy adapted for adolescents (DBT-A) and enhanced usual care (EUC)]. www.clinicaltrials.gov/ct2/show/NCT00675129 (first received 6 May 2008). RamlethRK , GroholtB , DiepLM , WalbyFA , MehlumL . The impact of borderline personality disorder and sub-threshold borderline personality disorder on the course of self-reported and clinician-rated depression in self-harming adolescents. Borderline Personality Disorder and Emotion Dysregulation2017;4:22. [DOI: 10.1186/s40479-017-0073-5] [PMC5663078] [PMID: 29093819]">Mehlum 2014</a>; <a href="./references#CD012955-bbs2-0054" title="MoreyLC , LowmasterSE , HopwoodCJ . A pilot study of manual-assisted cognitive therapy with a therapeutic assessment augmentation for borderline personality disorder. Psychiatry Research2010;178(3):531-5. [DOI: 10.1016/j.psychres.2010.04.055] [PMID: 20537722]">Morey 2010</a>; <a href="./references#CD012955-bbs2-0056" title="NadortM , ArntzA , SmitJH , Giesen-BlooJ , EikelenboomJ , SpinhovenP , et al. Implementation of outpatient schema therapy for borderline personality disorder with versus without crisis support by the therapist outside office hours: a randomized trial. Behaviour Research and Therapy2009;47(11):961-73. [DOI: 10.1016/j.brat.2009.07.013] [PMID: 19698939]NadortM , ArntzA , SmitJH , Giesen-BlooJ , EikelenboomM , SpinhovenP , et al. Implementation of outpatient schema therapy for borderline personality disorder: study design. BMC Psychiatry2009;9:64. [DOI: 10.1186/1471-244X-9-64] [PMC2762959] [PMID: 19807925]NL1680 (NTR1781). Implementation of out-patient schema-focused therapy for borderline personality disorder in regular mental healthcare. www.trialregister.nl/trial/1680 (first received 29 April 2009). ">Nadort 2009</a>; <a href="./references#CD012955-bbs2-0057" title="NCT02033044. Cognitive rehabilitation versus psychoeducation in psychosocial functioning of borderline personality disorder [Randomized controlled trial comparing the effects on psychosocial functioning of cognitive rehabilitation versus psychoeducation in borderline personality disorder]. www.clinicaltrials.gov/ct2/show/NCT02033044 (first received 23 December 2013). PascualJC , PalomaresN , Ibáñez Á, PortellaMJ , ArzaR , ReyesR , et al. Efficacy of cognitive rehabilitation on psychosocial functioning in borderline personality disorder: a randomized controlled trial. BMC Psychiatry2015;15:255. [DOI: 10.1186/s12888-015-0640-5] [PMC4617906] [PMID: 26487284]">Pascual 2015</a>; <a href="./references#CD012955-bbs2-0058" title="PhilipsB , WennebergP , KonradssonP , FranckJ . Mentalization-based treatment for concurrent borderline personality disorder and substance use disorder: a randomized controlled feasibility study. European Addiction Research2018;24(1):1-8. [DOI: 10.1159/000485564] [PMC5969093] [PMID: 294028]">Philips 2018</a>; <a href="./references#CD012955-bbs2-0059" title="BarnicotK . Re: Regarding your study on DBT for self-harming patients [personal communication]. Email to: EG Faltinsen 28 February 2018. PriebeS , BhattiN , BarnicotK , BremnerS , GagliaA , KatsakouC , et al. Effectiveness and cost-effectiveness of dialectical behaviour therapy for self-harming patients with personality disorder: a pragmatic randomised controlled trial. Psychotherapy and Psychosomatics2012;81(6):356-65. [DOI: 10.1159/000338897] [PMID: 22964561]PriebeS . Supplemental information [personal communication]. Email to: M Kielsholm 20 May 2016. ">Priebe 2012</a>; <a href="./references#CD012955-bbs2-0060" title="RenesesB , FigueraD , SalcedoG , TrujilloM , López-IborJJ , GaliánM , et al. A controlled randomized study on the efficacy of short-term dinamic psychotherapy in borderline personality disorders (BPD). Preliminary results. European Psychiatry2011;26(Suppl 1):1040. [DOI: 10.1016/S0924-9338(11)72745-6] [P02-444]RenesesB , GaliánM , SerranoR , FigueraD , Fernandez Del MoralA , López-IborJJ , et al. A new time limited psychotherapy for BPD: preliminary results of a randomized and controlled trial. Actas Espanolas de Psiquiatria2013;41(3):139-48. [PMID: 23803797]">Reneses 2013</a>; <a href="./references#CD012955-bbs2-0061" title="ISRCTN51304415. Nice OUtcomes for Referrals with Impulsivity, Self Harm and Eating Disorders: the NOURISHED study [A randomised controlled trial of mentalisation based therapy against specialist supportive clinical management in patients with both eating disorders and symptoms of borderline personality disorder]. www.isrctn.com/ISRCTN51304415 (first received 31 January 2011). RobinsonP , BarrettB , BatemanA , HakeemA , HellierJ , LemonskyF , et al. Study protocol for a randomized controlled trial of mentalization based therapy against specialist supportive clinical management in patients with both eating disorders and symptoms of borderline personality disorder. BMC Psychiatry2014;14:51. [DOI: 10.1186/1471-244X-14-51] [PMC3996076] [PMID: 24555511]RobinsonP , HellierJ , BarrettB , BarzdaitieneD , BatemanA , BogaardtA , et al. The NOURISHED randomised controlled trial comparing mentalisation-based treatment for eating disorders (MBT-ED) with specialist supportive clinical management (SSCM-ED) for patients with eating disorders and symptoms of borderline personality disorder. Trials2016;17(1):549. [DOI: 10.1186/s13063-016-1606-8] [PMC5114835] [PMID: 27855714]">Robinson 2016</a>; <a href="./references#CD012955-bbs2-0062" title="ISRCTN95266816. The emergence of personality disorder traits in adolescents who deliberately self harm and the potential for using a mentalisation based treatment approach as an early intervention for such individuals: a randomised controlled trial. www.isrctn.com/ISRCTN95266816 (first received 29 October 2007). RossouwT . Mentalisation based treatment for adolescents with self harm: an RCT. European Child &amp; Adolescent Psychiatry2015;24(1 Suppl):S113. [DOI: 10.1007%2Fs00787-015-0714-4.pdf] [W1-02-02]RossouwT . Self harm in adolescence, is MBT the answer?: an RCT. Adolescent Psychiatry2012;2(1):102. [DOI: 10.2174/2210676611202010077]RossouwTI , FonagyP . Mentalization-based treatment for self-harm in adolescents: a randomized controlled trial. Journal of the American Academy of Child and Adolescent Psychiatry2012;51(12):1304-13.e3. [DOI: 10.1016/j.jaac.2012.09.018] [PMID: 23200287]">Rossouw 2012b</a>; <a href="./references#CD012955-bbs2-0063" title="SalzerS , CroppC , JaegerU , MasuhrO , Streeck-FischerA . Psychodynamic therapy for adolescents suffering from co-morbid disorders of conduct and emotions in an in-patient setting: a randomized controlled trial. Psychological Medicine2014;44(10):2213-22. [DOI: 10.1017/S003329171300278X] [PMID: 24229481]SalzerS , Streeck-FischerA . The psychoanalytic-interactional method (PiM) for adolescents with borderline personality disorder [Die psychoanalytisch-interaktionelle methode (PiM) für adoleszente mit borderline-persönlichkeitsstörung]. Personlichkeitsstorungen Theorie und Therapie2015;19(1):67-76. [elibrary.klett-cotta.de/article/99.120110/ptt-19-1-67]SalzerS . AW: Re: Cochrane Review on psychotherapies for BPD - RCT testing PiM vs WL [personal communication] [AW:Re: Cochrane Review zur Psychotherapie bei BPS - RCT zu PiM vs WL [persönliche kommunikation]]. Email to: J Stoffers-Winterling 15 July 2018. ">Salzer 2014</a>; <a href="./references#CD012955-bbs2-0064" title="SantistebanDA , MenaMP , MuirJ , McCabeBE , AbaloC , CummingsAM . The efficacy of two adolescent substance abuse treatments and the impact of comorbid depression: results of a small randomized controlled trial. Psychiatric Rehabilitation Journal2015;38(1):55-64. [DOI: 10.1037/prj0000106] [PMC5021542] [PMID: 25799306]">Santisteban 2015</a>; <a href="./references#CD012955-bbs2-0065" title="SchillingL , MoritzS , KötherU , NagelM . Preliminary results on acceptance, feasibility, and subjective efficacy of the add-on group intervention metacognitive training for borderline patients. Journal of Cognitive Psychotherapy2015;29(2):153-64. [DOI: 10.1891/0889-8391.29.2.153]SchillingL , MoritzS , KristonL , KriegerM , NagelM . Efficacy of metacognitive training for patients with borderline personality disorder: preliminary results. Psychiatry Research2018;262:459-64. [DOI: 10.1016/j.psychres.2017.09.024] [PMID: 28927866]SchillingL . Re Schilling 2015/2018 - Cochrane Review of psychotherapies for BPD [personal communication] [Re Schilling 2015/2018 - Cochrane Review zur Psychotherapie bei BPS [persönliche Kommunikation]]. Email to: J Stoffers-Winterling 22 January 2019. ">Schilling 2018</a>; <a href="./references#CD012955-bbs2-0066" title="ISRCTN97589104. Evaluation of a group training for adolescents (emotion regulation training) with emotion regulation problems - a randomised controlled clinical trial. www.isrctn.com/ISRCTN97589104 (first received 23 August 2007). SchuppertHM , TimmermanME , BlooJ , Van GemertTG , WiersemaHM , MinderaaRB , et al. Emotion regulation training for adolescents with borderline personality disorder traits: a randomized controlled trial. Journal of the American Academy of Child &amp; Adolescent Psychiatry2012;51(12):1314-23. [DOI: 10.1016/j.jaac.2012.09.002] [PMID: 23200288]">Schuppert 2012</a>; <a href="./references#CD012955-bbs2-0067" title="NCT01904227. Intensified, inpatient adaptation of dialectical behavior therapy (DBT) (REDBT) [A randomized controlled study of the efficacy of an intensified, inpatient adaptation of dialectical behavior therapy (DBT) for a population of borderline patients (young adults/adults: 18-40), compared with standard outpatient DBT]. www.clinicaltrials.gov/ct2/show/NCT01904227 (first received 11 July 2013). SinnaeveR , Van den BoschLM , Van Steenbergen-WeijenburgKM . Change in interpersonal functioning during psychological interventions for borderline personality disorder — a systematic review of measures and efficacy. Personality and Mental Health2015;9(3):173-94. [DOI: 10.1002/pmh.1296] [PMID: 26058794]SinnaeveR , Van den BoschLMC , Hakkaart-van RoijenL , VansteelandtK . Effectiveness of step-down versus outpatient dialectical behaviour therapy for patients with severe levels of borderline personality disorder: a pragmatic randomized controlled trial. Borderline Personality Disorder and Emotion Dysregulation2018;5:12. [DOI: 10.1186/s40479-018-0089-5] [PMC6040072] [PMID: 30002832]SinnaeveR . Cochrane Collaboration review [personal communication]. Email to: J Stoffers-Winterling 11 June 2018. SinnaeveR . Re: BPDSI subscale data Sinnaeve et al (2018) [personal communication]. Email to: A Tadorovac 15 November 2018. SinnaeveR . RE: BPDSI subscale data Sinnaeve et al (2018) [personal communication] [RE: BPDSI subschale data Sinnaeve et al (2018) [personlig kommunikation]]. Email to: A Todorovac 15 November 2018. SinnaeveR . RE: BPDSI subscale data Sinnaeve et al (2018) [personal communication] [RE: BPDSI subschale data Sinnaeve et al (2018) [personlig kommunikation]]. Email to: A Todorovac 9 October 2018. Van den BoschLM , SinnaeveR , Hakkaart-van RoijenL , Van FurthEF . Efficacy and cost-effectiveness of an experimental short-term inpatient dialectical behavior therapy (DBT) program: study protocol for a randomized controlled trial. Trials2014;15:152. [DOI: 10.1186/1745-6215-15-152] [PMC4017823] [PMID: 24885551]Van RoijenLH , SinnaeveR , BouwmansC , Van Den BoschL . Cost-effectiveness and cost-utility of shortterm inpatient dialectical behavior therapy for chronically parasuicidal BPD (young) adults. Journal of Mental Health Policy and Economics2015;18(Suppl 1):S19-20. [www.icmpe.org/test1/journal/issues/v18s1toc.html]">Sinnaeve 2018</a>; <a href="./references#CD012955-bbs2-0068" title="SmithPN , GambleSA , CortNA , WardEA , HeH , TalbotNL . Attachment and alliance in the treatment of depressed, sexually abused women. Depression and Anxiety2012;29(2):123-30. [DOI: 10.1002/da.20913] [PMC3325338] [PMID: 22065593]SmithPN . Re: Cochrane Collaboration review of psychotherapies for BPD [personal communication]. Email to: J Stoffers-Winterling 05 July 2018. ">Smith 2012</a>; <a href="./references#CD012955-bbs2-0069" title="SolerJ , PascualJC , TianaT , CebriàA , BarrachinaJ , CampinsMJ , et al. Dialectical behaviour therapy skills training compared to standard group therapy in borderline personality disorder: a 3-month randomised controlled clinical trial. Behaviour Research and Therapy2009;47(5):353-8. [DOI: 10.1016/j.brat.2009.01.013] [PMID: 19246029]SolerJ . Question regarding your BPD trials [personal communication]. Email to: J Stoffers 15 December 2010. ">Soler 2009</a>; <a href="./references#CD012955-bbs2-0070" title="FertuckEA , KeilpJ , SongI , MorrisMC , WilsonST , BrodskyBS , et al. Higher executive control and visual memory performance predict treatment completion in borderline personality disorder. Psychotherapy and Psychosomatics2012;81(1):38-43. [DOI: 10.1159/000329700] [PMC3242704] [PMID: 22116411]NCT00533117. Treating suicidal behavior and self-mutilation in people with borderline personality disorder. www.clinicaltrials.gov/ct2/show/NCT00533117 (first received 19 September 2007). ">Stanley 2017</a>; <a href="./references#CD012955-bbs2-0072" title="Van den BoschLM , KoeterMW , StijnenT , VerheulR , Van den BrinkW . Sustained efficacy of dialectical behaviour therapy for borderline personality disorder. Behaviour Research and Therapy2005;43(9):1231-41. [DOI: 10.1016/j.brat.2004.09.008] [PMID: 16005708]Van den BoschLM , VerheulR , SchippersGM , Van den BrinkW . Dialectical behavior therapy of borderline patients with and without substance use problems. Implementation and long-term effects. Addictive Behaviors2002;27(6):911-23. [DOI: 10.1016/s0306-4603(02)00293-9] [PMID: 12369475]Van den BoschLMC . Efficacy of dialectical behaviour therapy in the treatment of female borderline patients with and without substance abuse problems: results of a Dutch study [Dialectische gedragstherapie bij Nederlandse vrouwen met een borderline persoonlijkheidsstoornis, met en zonder verslavingsproblemen]. Tijdschrift voor Psychiatrie2005;47(3):127-37. [www.tijdschriftvoorpsychiatrie.nl/assets/articles/articles_1335pdf.pdf]VerheulR , Van den BoschLM , KoeterMW , De RidderMA , StijnenT , Van den BrinkW . Dialectical behaviour therapy for women with borderline personality disorder: 12-month, randomised clinical trial in The Netherlands. British Journal of Psychiatry2003;182:135-40. [DOI: 10.1192/bjp.182.2.135] [PMID: 12562741]">Van den Bosch 2005</a>; <a href="./references#CD012955-bbs2-0073" title="WeinbergI , GundersonJG , HennenJ , Cutter CJ Jr. Manual assisted cognitive treatment for deliberate self-harm in borderline personality disorder patients. Journal of Personality Disorders2006;20(5):482-92. [DOI: 10.1521/pedi.2006.20.5.482] [PMID: 17032160]WilbergT . SV: separate data [personal communication] [SV: separat data [personlig kommunikation]]. Email to: M Kielsholm 25 May 2016. ">Weinberg 2006</a>; <a href="./references#CD012955-bbs2-0074" title="ZanariniMC , FrankenburgFR . A preliminary, randomized trial of psychoeducation for women with borderline personality disorder. Journal of Personality Disorders2008;22(3):284-90. [DOI: 10.1521/pedi.2008.22.3.284] [PMID: 18540800]ZanariniMC , FrankenburgFR . A randomized trial of psychoeducation for patients with BPD. In: 157th annual meeting of the American Psychiatric Association. Psychotherapy and psychopharmacology: dissolving the mind-brain barrier; 2004 May 1-6; New York (NY). Arlington (VA): American Psychiatric Association, 2004:102. [Symposium 100E] [www.psychiatry.org/File%20Library/Psychiatrists/Directories/Library-and-Archive/conference_publications/am_program_2004.pdf]">Zanarini 2008</a>; <a href="./references#CD012955-bbs2-0075" title="ZanariniMC , ConkeyLC , TemesCM , FitzmauriceGM . Randomized controlled trial of web-based psychoeducation for women with borderline personality disorder. Journal of Clinical Psychiatry2018;79(3):16m11153. [DOI: 10.4088/JCP.16m11153] [PMC5764827] [PMID: 28703950]">Zanarini 2018</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No funding received</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Bellino-2006" target="_blank">Bellino 2006</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Bellino-2007" target="_blank">Bellino 2007</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Bellino-2010" target="_blank">Bellino 2010</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Jahangard-2012" target="_blank">Jahangard 2012</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear funding</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Andreoli-2016" target="_blank">Andreoli 2016</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Bianchini-2019" target="_blank">Bianchini 2019</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Carter-2010" target="_blank">Carter 2010</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Kamalabadi-2012" target="_blank">Kamalabadi 2012</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Koons-2001a" target="_blank">Koons 2001a</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Lepp_x00e4_nen-2016" target="_blank">Leppänen 2016</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Mohamadizadeh-2017" target="_blank">Mohamadizadeh 2017</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Morton-2012" target="_blank">Morton 2012</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Turner-2000" target="_blank">Turner 2000</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>BPDSI‐IV:</b> Borderline Personality Disorder Severity Index; <b>BSI:</b> Borderline Syndrome Index; <b>CI‐BPD:</b> Childhood Interview for DSM‐IV Borderline Personality Disorder; <b>DIB:</b> Diagnostic Interview for Borderline Patients; <b>DIB‐R:</b> Diagnostic Interview for Borderline Patients ‐ revised version; <b>DIPD‐IV:</b> Diagnostic Interview for DSM‐IV Personality Disorders; <b>DSM‐III:</b> Diagnostic and Statistical Manual of Mental Disorders, Third Edition; <b>DSM‐III‐R:</b> Diagnostic and Statistical Manual of Mental Disorders, Third Edition, Revised; <b>DSM‐IV:</b> Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition; <b>DSM‐IV‐TR:</b> Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision; <b>ICD‐10:</b> International Classification of Diseases, Tenth Revision; <b>IPDE:</b> International Personality Disorder Examination; <b>PDE:</b> Personality Disorders Examination; <b>SCID‐II</b> : Structured Clinical Interview for DSM DSM‐IV Axis II Personality Disorders (SCID‐II); <b>SIDP‐IV:</b> Structured Interview for DSM‐IV Personality </p> </td> </tr> </tbody> </table> </div> <section id="CD012955-sec-0048"> <h5 class="title">Design</h5> <p>We included 75 randomised, parallel‐arm trials.</p> </section> <section id="CD012955-sec-0049"> <h5 class="title">Sample sizes</h5> <p>There was considerable variation in sample sizes between the trials, as the total number of participants with BPD ranged from 16 (<a href="./references#CD012955-bbs2-0025" title="GleesonJF , ChanenA , CottonSM , PearceT , NewmanB , McCutcheonL . Treating co-occurring first-episode psychosis and borderline personality: a pilot randomized controlled trial. Early Intervention in Psychiatry2012;6(1):21-9. [DOI: 10.1111/j.1751-7893.2011.00306.x] [PMID: 22379625]GleesonJFM . RE: separate data [personal communication]. Email to: M Kielsholm 28 October 2016. ">Gleeson 2012</a>) to 190 participants (<a href="./references#CD012955-bbs2-0049" title="CaseBG . Letter to the editor on 'McMain SF, Links PS, Gnam WH, Guimond T, Cardish RJ, Korman L, et al. A randomized trial of dialectical behavior therapy versus general psychiatric management for borderline personality disorder. American Journal of Psychiatry 2009;166(12):1365-74. DOI: 10.1176/appi.ajp.2009.09010039'. American Journal of Psychiatry2010;167(4):475. [DOI: 10.1176/appi.ajp.2009.09101532] [PMID: 20360332 ]ISRCTN02634417. Hope for chronically suicidal patient: evaluating the clinical and health services impact of dialectical behaviour therapy (DBT) in individuals with borderline personality disorder [Evaluating the clinical and health services impact of dialectical behaviour therapy (DBT) in individuals with borderline personality disorder: a randomised controlled trial]. www.isrctn.com/ISRCTN02634417 (first received 16 November 2005). [DOI: 10.1186/ISRCTN02634417]McMainSF , FitzpatrickS , BoritzT , BarnhartR , LinksP , StreinerDL . Outcome trajectories and prognostic factors for suicide and self-harm behaviors in patients with borderline personaliy disorder following one year of outpatient psychotherapy. Journal of Personality Disorders2018;32(4):497-512. [DOI: 10.1521/pedi_2017_31_309] [PMID: 28910214]McMainSF , LinksPS , GnamWH , GuimondT , CardishRJ , KormanL , et al. A randomized trial of dialectical behavior therapy versus general psychiatric management for borderline personality disorder. American Journal of Psychiatry2009;166(12):1365-74. [DOI: 10.1176/appi.ajp.2009.09010039] [PMID: 19755574]McMainSF . Dr McMain replies to letter to the editor on 'McMain SF, Links PS, Gnam WH, Guimond T, Cardish RJ, Korman L, et al. A randomized trial of dialectical behavior therapy versus general psychiatric management for borderline personality disorder. American Journal of Psychiatry 2009;166(12):1365-74. DOI: 10.1176/appi.ajp.2009.09010039'. American Journal of Psychiatry2010;167(4):475-6. [DOI: 10.1176/appi.ajp.2009.09101532r)]NCT00154154. Hope for the chronically suicidal patient [Hope for the chronically suicidal patient: evaluating the clinical and health services impact of dialectical behaviour therapy in individuals with borderline personality disorder]. www.clinicaltrials.gov/ct2/show/NCT00154154 (first received 7 September 2005). ">McMain 2009</a>). Five trials had a sample size of more than 100 participants (<a href="#CD012955-tbl-0005">Table 2</a>). </p> </section> <section id="CD012955-sec-0050"> <h5 class="title">Setting</h5> <p>Sixty‐three trials were conducted in outpatient settings, five in inpatient settings, and seven in both inpatient and outpatient settings (see <a href="#CD012955-tbl-0005">Table 2</a>). </p> </section> <section id="CD012955-sec-0051"> <h5 class="title">Participants</h5> <p>The 75 trials included a total of 4507 participants with BPD; the mean age ranged from 14.8 to 45.7 years. Seventeen trials included only female participants and two trials included only males (see <a href="#CD012955-tbl-0005">Table 2</a>). All remaining trials included participants of both genders, predominantly females. </p> <section id="CD012955-sec-0052"> <h6 class="title">Diagnostic criteria</h6> <p>Participants were diagnosed as having BPD according to DSM‐III, DSM‐III‐R, DSM‐IV, DSM‐IV‐TR, or ICD‐10 criteria (see <a href="#CD012955-tbl-0005">Table 2</a>). The diagnosis was confirmed by standardised means of assessment. The most frequently used assessment instruments were the Structured Clinical Interviews for DSM‐III‐R or DSM‐IV Axis II Personality Disorders (SCID‐II) (<a href="./references#CD012955-bbs2-0295" title="FirstMB , GibbonM , SpitzerRL , WilliamsJBW , BenjaminLS . Structured Clinical Interview for DSM-IV Axis II Personality Disorders (SCID-II). Washington (DC): American Psychiatric Press, 1997.">First 1997</a>; <a href="./references#CD012955-bbs2-0399" title="SpitzerRL , WilliamJBW , GibbonM , FirstMB . Structured Clinical Interview for DSM-III-R Personality Disorders (SCID-II). New York (NY): Biometrics Research Department, New York State Psychiatric Institute, 1989.">Spitzer 1989</a>) in 47 trials. Eleven trials applied the Diagnostic Interview for Borderline Personality Disorder patients (DIB; <a href="./references#CD012955-bbs2-0305" title="GundersonJG , KolbJE , AustinV . The diagnostic interview for borderline patients. American Journal of Psychiatry1981;138(7):896-903. [DOI: 10.1176/ajp.138.7.896] [PMID: 7258348]">Gunderson 1981</a>) or the Diagnostic Interview for Borderline Personality Disorder Patients ‐ revised (DIB‐R; <a href="./references#CD012955-bbs2-0430" title="ZanariniMC , GundersonJG , FrankenburgFR , ChaunceyDL . The revised Diagnostic Interview for Borderlines: discriminating BPD from other Axis II disorders. Journal of Personality Disorders1989;3(1):10-8. [DOI: 10.1521/pedi.1989.3.1.10]">Zanarini 1989</a>). Six trials made use of the International Personality Disorder Examination (IPDE; <a href="./references#CD012955-bbs2-0358" title="LorangerAW , JancaA , SartoriusN , editor(s). Assessment and Diagnosis of Personality Disorders. The ICD-10 International Personality Disorder Examination (IPDE). Cambridge (Camb): Cambridge University Press, 1995. [WHO IRIS: apps.who.int/iris/handle/10665/41912]">Loranger 1995</a>). All assessment instruments used in the included trials are listed in <a href="#CD012955-tbl-0005">Table 2</a>. </p> </section> <section id="CD012955-sec-0053"> <h6 class="title">Participants exclusion criteria of primary studies</h6> <p>In 39 trials, people with evident mental impairment, organic brain disorder and neurological conditions were not eligible for participation. In addition, with the exception of <a href="./references#CD012955-bbs2-0013" title="BosEH , Van WelE , AppeloMT , VerbraakMJP . A randomized controlled trial of a Dutch version of systems training for emotional predictability and problem solving for borderline personality disorder. Journal of Nervous and Mental Disease2010;198(4):299-304. [DOI: 10.1097/NMD.0b013e3181d619cf] [PMID: 20386260]Van WelEB , BosEH , AppeloMT , BerendsenEM , WillgerothFC , VerbraakMJPM . The efficacy of the systems training for emotional predictability and problem solving (STEPPS) in the treatment of borderline personality disorder. A randomized controlled trial [De effectiviteit van de vaardigheidstraining emotieregulatiestoornis (VERS) in de behandeling van de borderlinepersoonlijkheidsstoornis: een gerandomiseerd onderzoek]. Tijdschrift voor Psychiatrie2009;51(5):291-301. [PMID: 19434566]">Bos 2010</a> and <a href="./references#CD012955-bbs2-0039" title="KredlowMA , SzuhanyKL , LoS , XieH , GottliebJD , RosenbergSD , et al. Cognitive behavioral therapy for posttraumatic stress disorder in individuals with severe mental illness and borderline personality disorder. Psychiatry Research2017;249:86-93. [DOI: 10.1016/j.psychres.2016.12.045] [PMC5325773] [PMID: 28086181]MueserK . Re: question regarding your trial on CBT for BPD patients [personal communication]. Email to: EG Faltinsen 28 November 2017. ">Kredlow 2017a</a>, schizophrenia, schizoaffective and other psychotic disorders were reasons for exclusion in all trials. Participants with substance abuse or dependence were not eligible for inclusion in 43 trials. Four trials included participants with alcohol or substance abuse/dependence (<a href="./references#CD012955-bbs2-0018" title="DavidsonKM , BrownTM , JamesV , KirkJ , RichardsonJ . Manual-assisted cognitive therapy for self-harm in personality disorder and substance misuse: a feasibility trial. Psychiatric Bulletin2014;38(3):108-11. [DOI: 10.1192/pb.bp.113.043109] [PMC4115373] [PMID: 25237519]DavidsonKM . Re: question regarding your trial on manual-assisted cognitive therapy [personal communication]. Email to: EG Faltinsen 28 November 2017. ">Davidson 2014</a>; <a href="./references#CD012955-bbs2-0028" title="GregoryRJ , ChlebowskiS , KangD , RemenA , SoderbergM . Psychodynamic therapy for borderline personality disorder and co-occurring alcohol use disorders: a newly designed ongoing study. Journal of the American Psychoanalytic Association2006;54(4):1331-4. [DOI: 10.1177/00030651060540040107] [PMID: 17354507]GregoryRJ , ChlebowskiS , KangD , RemenAL , SoderbergMG , StepkovitchJ , et al. A controlled trial of psychodynamic psychotherapy for co-occurring borderline personality disorder and alcohol use disorder. Psychotherapy2008;45(1):28-41. [DOI: 10.1037/0033-3204.45.1.28] [PMID: 22122363]GregoryRJ , DeLucia-DeranjaE , MogleJA . Dynamic deconstructive psychotherapy versus optimized community care for borderline personality disorder co-occuring with alcohol use disorders: a 30-month follow-up. Journal of Nervous and Mental Disease2010;198(4):292-8. [DOI: 10.1097/NMD.0b013e3181d6172d] [PMID: 20386259]GregoryRJ , RemenAL , SoderbergM , Ploutz-SnyderRJ . A controlled trial of psychodynamic psychotherapy for co-occurring borderline personality disorder and alcohol use disorder: six-month outcome. Journal of the American Psychoanalytic Association2009;57(1):199-205. [DOI: 10.1177/00030651090570011006] [PMID: 19270255]NCT00145678. Psychodynamic therapy for co-occurring borderline personality disorder and alcohol use disorder [Psychodynamic therapy for patients With borderline personality disorder and alcohol abuse]. www.clinicaltrials.gov/show/NCT00145678 (first received 1 September 2005). ">Gregory 2008b</a>; <a href="./references#CD012955-bbs2-0061" title="ISRCTN51304415. Nice OUtcomes for Referrals with Impulsivity, Self Harm and Eating Disorders: the NOURISHED study [A randomised controlled trial of mentalisation based therapy against specialist supportive clinical management in patients with both eating disorders and symptoms of borderline personality disorder]. www.isrctn.com/ISRCTN51304415 (first received 31 January 2011). RobinsonP , BarrettB , BatemanA , HakeemA , HellierJ , LemonskyF , et al. Study protocol for a randomized controlled trial of mentalization based therapy against specialist supportive clinical management in patients with both eating disorders and symptoms of borderline personality disorder. BMC Psychiatry2014;14:51. [DOI: 10.1186/1471-244X-14-51] [PMC3996076] [PMID: 24555511]RobinsonP , HellierJ , BarrettB , BarzdaitieneD , BatemanA , BogaardtA , et al. The NOURISHED randomised controlled trial comparing mentalisation-based treatment for eating disorders (MBT-ED) with specialist supportive clinical management (SSCM-ED) for patients with eating disorders and symptoms of borderline personality disorder. Trials2016;17(1):549. [DOI: 10.1186/s13063-016-1606-8] [PMC5114835] [PMID: 27855714]">Robinson 2016</a>; <a href="./references#CD012955-bbs2-0064" title="SantistebanDA , MenaMP , MuirJ , McCabeBE , AbaloC , CummingsAM . The efficacy of two adolescent substance abuse treatments and the impact of comorbid depression: results of a small randomized controlled trial. Psychiatric Rehabilitation Journal2015;38(1):55-64. [DOI: 10.1037/prj0000106] [PMC5021542] [PMID: 25799306]">Santisteban 2015</a>). Comorbid personality disorders were not a reason for exclusion in 71 trials. Nine trials excluded participants with antisocial features or full antisocial personality disorders. See <a href="#CD012955-tbl-0005">Table 2</a> for a list of the trials. </p> </section> </section> <section id="CD012955-sec-0054"> <h5 class="title">Interventions</h5> <section id="CD012955-sec-0055"> <h6 class="title">Durations of interventions</h6> <p>The duration of the trials ranged from one month (<a href="./references#CD012955-bbs2-0031" title="BrandS . AW: questions regarding your trial on emotional intelligence training for BPD [personal communication]. Email to: EG Faltinsen 28 November 2017. BrandS . Questions regarding your trial on emotional intelligence training for BPD [personal communication]. Email to: EG Faltinsen 28 November 2017. JahangardL , HaghighiM , BajoghliH , AhmadpanahM , GhaleihaA , ZarrabianMK , et al. Training emotional intelligence improves both emotional intelligence and depressive symptoms in inpatients with borderline personality disorder and depression. International Journal of Psychiatry in Clinical Practice2012;16(3):197-204. [DOI: 10.3109/13651501.2012.687454] [PMID: 22873719]">Jahangard 2012</a>) to 36 months (<a href="./references#CD012955-bbs2-0024" title="ArntzA , Stupar-RutenfransS , BlooJ , Van DyckR , SpinhovenP . Prediction of treatment discontinuation and recovery from borderline personality disorder: results from an RCT comparing schema therapy and transference-focused psychotherapy. Behaviour Research and Therapy2015;74:60-71. [DOI: 10.1016/j.brat.2015.09.002] [PMID: 26432172]Giesen-BlooJ , ArntzA . Questions concerning the randomized trial of schema-focused therapy vs transference-focused psychotherapy—reply. Archives of General Psychiatry2007;64(5):610-1. [DOI: 10.1001/archpsyc.64.5.610]Giesen-BlooJ , Van DyckR , SpinhovenP , Van TilburgW , DirksenC , Van AsseltT , et al. Errors in table and figure in: outpatient psychotherapy for borderline personality disorder: randomized trial of schema-focused therapy vs transference-focused psychotherapy. Archives of General Psychiatry2006;63(9):1008. Erratum for: Archives of General Psychiatry 2006;63(6):649-58. [DOI: 10.1001/archpsyc.63.9.1008]Giesen-BlooJ , Van DyckR , SpinhovenP , Van TilburgW , DirksenC , Van AsseltT , et al. Outpatient psychotherapy for borderline personality disorder: randomized trial of schema-focused therapy vs transference-focused psychotherapy. Archives of General Psychiatry2006;63(6):649-58. [DOI: 10.1001/archpsyc.63.6.649] [PMID: 16754838]SpinhovenP , Giesen-BlooJ , Van DyckR , KooimanK , ArntzA . The therapeutic alliance in schema-focused therapy and transference-focused psychotherapy for borderline personality disorder. Journal of Consulting and Clinical Psychology2007;75(1):104-15. [DOI: 10.1037/0022-006X.75.1.104] [PMID: 17295569]Van AsseltADI , DirksenCD , ArntzA , Giesen-BlooJH , Van DyckR , SpinhovenP , et al. Out-patient psychotherapy for borderline personality disorder: cost-effectiveness of schema-focused therapy v transference-focused psychotherapy. British Journal of Psychiatry2008;192(6):450-7. [DOI: 10.1192/bjp.bp.106.033597] [PMID: 18515897]Van AsseltADI , DirksenCD , ArntzA , SeverensJL . Difficulties in calculating productivity costs: work disability associated with borderline personality disorder. Value in Health2008;11(4):637-44. [DOI: 10.1111/j.1524-4733.2007.00288.x]YeomansF . Questions concerning the randomized trial of schema-focused therapy vs transference-focused psychotherapy. Archives of General Psychiatry2007;64(5):609-10. [DOI: 10.1001/archpsyc.64.5.609-c] [PMID: 17485613]">Giesen‐Bloo 2006</a>). Thirty‐six trials had a duration of less than six months. Thirty‐two trials lasted between six months and 12 months. See <a href="#CD012955-tbl-0005">Table 2</a>. </p> </section> <section id="CD012955-sec-0056"> <h6 class="title">Formats of interventions</h6> <p>Most of the trials applied individual treatment, with a total of 33 trials investigating the effects of individual therapy. Twenty‐two trials investigated the effects of group therapy whereas 16 trials assessed a combination of individual and group therapy (see <a href="#CD012955-tbl-0005">Table 2</a>). </p> </section> <section id="CD012955-sec-0057"> <h6 class="title">Types of interventions</h6> <p>We included any defined, psychological intervention. The following provides a brief overview and description of the interventions investigated in the individual trials. For a more elaborate description, see the relevant references. </p> <p><i>Dialectical behaviour therapy (DBT) and modified DBT‐related treatments</i> (DBT; <a href="./references#CD012955-bbs2-0348" title="LinehanMM . Cognitive-Behavioral Treatment of Borderline Personality Disorder. New York (NY): Guilford Press, 1993. [ISBN 0-89862-183-6]">Linehan 1993a</a>; <a href="./references#CD012955-bbs2-0349" title="LinehanMM . Skills Training Manual for Treating Borderline Personality Disorder. New York (NY): Guilford Press, 1993.">Linehan 1993b</a>). Twenty‐four trials investigated the effect of DBT and DBT‐related treatments (<a href="./references#CD012955-bbs2-0011" title="BohusM , DyerAS , PriebeK , KrügerA , KleindienstN , SchmahlC , et al. Dialectical behaviour therapy for post-traumatic stress disorder after childhood sexual abuse in patients with and without borderline personality disorder: a randomised controlled trial. Psychotherapy and Psychosomatics2013;82(4):221-33. [DOI: 10.1159/000348451] [PMID: 23712109]BrandS . AW: questions regarding your trial on emotional intelligence training for BPD [personal communication]. Email to: EG Faltinsen 28 November 2017. DBT Working Group at the Central Institute for Mental Health, Mannheim, Germany. Requested supplementary data (as supplied 1 October 2010). Data on file. NCT00481000. Dialectical cognitive traumatherapy (DCT) on patients with severe PTSD following sexual abuse (PASA) [Dialectical cognitive traumatherapy (DCT) on patients with severe posttraumatic stress disorder following sexual abuse - a randomised controlled trial]. clinicaltrials.gov/ct2/show/NCT00481000 (first received 31 May 2007). SteilR , DyerA , PriebeK , KleindienstN , BohusM . Dialectical behavior therapy for posttraumatic stress disorder related to childhood sexual abuse: a pilot study of an intensive treatment program. Journal of Traumatic Stress2011;24(1):102-6. [DOI: 10.1002/jts.20617] [PMID: 21351167]">Bohus 2013</a>; <a href="./references#CD012955-bbs2-0009" title="BianchiniV , CofiniV , CurtoM , LagrotteriaB , ManziA , NavariS , et al. Dialectical behavior therapy (DBT) for forensic psychiatric patients: an Italian pilot study. Criminal Behavior and Mental Health2019;29(9):122-30. [DOI: 10.1002/cbm.2102] [PMID: 30648303]">Bianchini 2019</a>; <a href="./references#CD012955-bbs2-0015" title="CarterG . Question regarding your BPD trial [personal communication]. Email to: J Stoffers 21 December 2010. CarterGL , WillcoxCH , LewinTJ , ConradAM , BenditN . Hunter DBT project: randomized controlled trial of dialectical behaviour therapy in women with borderline personality disorder. Australian and New Zealand Journal of Psychiatry2010;44(2):162-73. [DOI: 10.3109/00048670903393621] [PMID: 20113305]">Carter 2010</a>;  <a href="./references#CD012955-bbs2-0020" title="ElicesM , PascualJC , PortellaMJ , Feliu-SolerA , Martín-BlancoA , CarmonaC , et al. Impact of mindfulness training on borderline personality disorder: a randomized trial. Mindfulness2016;7:584-95. [DOI: 10.1007/s12671-016-0492-1]NCT02397031. Mindfulness and interpersonal effectiveness skills in borderline personality disorder [Randomized, active-controlled, clinical trial comparing effects of mindfulness and interpersonal effectiveness skills in borderline personality disorder]. www.clinicaltrials.gov/ct2/show/NCT02397031 (first received 12 March 2015). SolerJ , ElicesM , PascualJC , Martín-BlancoA , Feliu-SolerA , CarmonaC , et al. Effects of mindfulness training on different components of impulsivity in borderline personality disorder: results from a pilot randomized study. Borderline Personality Disorder and Emotion Dysregulation2016;3:1. [DOI: 10.1186/s40479-015-0035-8] [PMC4709962] [PMID: 26759718]">Elices 2016</a>; <a href="./references#CD012955-bbs2-0022" title="FeigenbaumJD , FonagyP , PillingS , JonesA , WildgooseA , BebbingtonPE . A real-world study of the effectiveness of DBT in the UK National Health Service. British Journal of Clinical Psychology2012;51(2):121-41. [DOI: 10.1111/j.2044-8260.2011.02017.x] [PMID: 22574799]">Feigenbaum 2012</a>; <a href="./references#CD012955-bbs2-0023" title="Feliu-SolerA , PascualJC , ElicesM , Martín-BlancoA , CarmonaC , CebollaA , et al. Fostering self-compassion and loving-kindness in patients with borderline personality disorder: a randomized pilot study. Clinical Psychology &amp; Psychotherapy2017;24(1):278-86. [DOI: 10.1002/cpp.2000] [PMID: 26818533]">Feliu‐Soler 2017</a>; <a href="./references#CD012955-bbs2-0027" title="GratzKL , BardeenJR , LevyR , Dixon-GordonKL , TullMT . Mechanisms of change in an emotion regulation group therapy for deliberate self-harm among women with borderline personality disorder. Behaviour Research and Therapy2015;65:29-35. [DOI: 10.1016/j.brat.2014.12.005] [PMC4306622] [PMID: 25557395]GratzKL , Dixon-GordonKL , TullMT . Predictors of treatment response to an adjunctive emotion regulation group therapy for deliberate self-harm among women with borderline personality disorder. Personality Disorders2014;5(1):97-107. [DOI: 10.1037/per0000062] [PMC4059504] [PMID: 2458806]GratzKL , TullMT , LevyR . Randomized controlled trial and uncontrolled 9-month follow-up of an adjunctive emotion regulation group therapy for deliberate self-harm among women with borderline personality disorder. Psychological Medicine2014;44(10):2099-112. [DOI: 10.1017/S0033291713002134] [PMID: 23985088]GratzKL . Question regarding your BPD trials [personal communication]. Email to: J Stoffers 11 December 2010. ">Gratz 2014</a>; <a href="./references#CD012955-bbs2-0030" title="HarnedM . Re: SV: question regarding your trial on brief therapy for attempted suicide [personal communication]. Email to: EG Faltinsen 11 December 2018. HarnedMS , KorslundKE , LinehanMM . A pilot randomized controlled trial of dialectical behavior therapy with and without the dialectical behavior therapy prolonged exposure protocol for suicidal and self-injuring women with borderline personality disorder and PTSD. Behaviour Research and Therapy2014;55:7-17. [DOI: 10.1016/j.brat.2014.01.008] [PMC3987949] [PMID: 24562087]HarnedMS , WilksCR , SchmidtSC , CoyleTN . Improving functional outcomes in women with borderline personality disorder and PTSD by changing PTSD severity and post-traumatic cognitions. Behaviour Research and Therapy2018;103:53-61. [DOI: 10.1016/j.brat.2018.02.002] [PMC5837954] [PMID: 29448136]HarnedMS . RE: questions regarding your trial on brief therapy for attempted suicide [personal communication]. Email to: E Faltinsen 29 November 2017. ">Harned 2014</a>; <a href="./references#CD012955-bbs2-0034" title="KamalabadiMJ , AhmadiSA , EtemadiO , FatehizadehM , BahramiF , FiroozabadiA . A study of the effect of couple dialectical behavioral therapy on symptoms and quality of marital relationships and mental health of Iranian borderline personality couples: a controlled trial. Interdisciplinary Journal of Contemporary Research in Business2012;3(9):1480-7. [psycnet.apa.org/record/2012-22425-047]">Kamalabadi 2012</a>; <a href="./references#CD012955-bbs2-0035" title="KoonsCR , RobinsCJ , TweedJL , LynchTR , GonzalezAM , MorseJQ , et al. Efficacy of dialectical behavior therapy in women veterans with borderline personality disorder. Behavior Therapy2001;32(2):371-90. [DOI: 10.1016/S0005-7894(01)80009-5]">Koons 2001a</a>; <a href="./references#CD012955-bbs2-0038" title="KramerU , Pascual-LeoneA , BerthoudL , De RotenY , MarquetP , KollyS , et al. Assertive anger mediates effects of dialectical behaviour-informed skills training for borderline personality disorder: a randomized controlled trial. Clinical Psychology &amp; Psychotherapy2016;23(3):189-202. [DOI: 10.1002/cpp.1956] [PMID: 25864773]KramerU . The role of coping change in borderline personality disorder: a process-outcome analysis on dialectical-behaviour skills training. Clinical Psychology &amp; Psychotherapy2017;24(2):302-11. [DOI: 10.1002/cpp.2017] [PMID: 27098296]">Kramer 2016</a>; <a href="./references#CD012955-bbs2-0044" title="Lin T-J, Ko H-C, Wu JY-W, OeiTP , Lane H-Y, Chen C-H. The effectiveness of dialectical behavior therapy skills training group vs cognitive therapy group on reducing depression and suicide attempts for borderline personality disorder in Taiwan. Archives of Suicide Research2019;23(1):82-99. [DOI: 10.1080/13811118.2018.1436104] [PMID: 29528807]">Lin 2019</a>; <a href="./references#CD012955-bbs2-0045" title="HoffmanRE . Impact of treatment accessibility on clinical course of parasuicidal patients. Archives of General Psychiatry1993;50(2):157-8. [DOI: 10.1001/archpsyc.1993.01820140083010] [PMID: 8427557]LindenboimN . To Know Me is to Keep Me: Self-Verification, Validation, and Therapy Dropout in the Treatment of Borderline Personality Disorder [PhD thesis]. Washington (DC): University of Washington, 2009. LinehanMM , ArmstrongHE , SuarezA , AllmonD , HeardHL . Cognitive-behavioral treatment of chronically parasuicidal borderline patients. Archives of General Psychiatry1991;48(12):1060-4. [DOI: 10.1001/archpsyc.1991.01810360024003] [PMID: 1845222]LinehanMM , HeardHL . Impact of treatment accessibility on clinical course of parasuicidal patients — reply. Archives of General Psychiatry1993;50(2):157-8. [DOI: 10.1001/archpsyc.1993.01820140083011]">Linehan 1991</a>; <a href="./references#CD012955-bbs2-0046" title="HeardHL . Cost-Effectiveness of Dialectical Behavior Therapy in the Treatment of Borderline Personality Disorder [PhD thesis]. Washington (DC): University of Washington, 2000. LindenboimN . To Know Me is to Keep Me: Self-Verification, Validation, and Therapy Dropout in the Treatment of Borderline Personality Disorder [PhD thesis]. Washington (DC): University of Washington, 2009. LinehanMM , HeardHL , ArmstrongHE . Naturalistic follow-up of a behavioral treatment for chronically parasuicidal borderline patients. Archives of General Psychiatry1993;50(12):971-4. [DOI: 10.1001/archpsyc.1993.01820240055007] [PMID: 8250683]LinehanMM , TutekDA , HeardHL , ArmstrongHE . Interpersonal outcome of cognitive behavioral treatment for chronically suicidal borderline patients. American Journal of Psychiatry1994;151(12):1771-6. [DOI: 10.1176/ajp.151.12.1771] [PMID: 7977884]">Linehan 1994</a>; <a href="./references#CD012955-bbs2-0047" title="BedicsJD , AtkinsDC , ComtoisKA , LinehanMM . Treatment differences in the therapeutic relationship and introject during a 2-year randomized controlled trial of dialectical behavior therapy versus nonbehavioral psychotherapy experts for borderline personality disorder. Journal of Consulting and Clinical Psychology2012;80(1):66-77. [DOI: 10.1037/a0026113] [PMC3265694] [PMID: 22061867]BedicsJD , AtkinsDC , ComtoisKA , LinehanMM . Weekly therapist ratings of the therapeutic relationship and patient introject furing the course of dialectical behavioral therapy for the treatment of borderline personality disorder. Psychotherapy2012;49(2):231-40. [DOI: 10.1037/a0028254] [PMID: 22642526]BedicsJD , AtkinsDC , HarnedMS , LinehanMM . The therapeutic alliance as a predictor of outcome in dialectical behavior therapy versus nonbehavioral psychotherapy by experts for borderline personality disorder. Psychotherapy2015;52(1):67-77. [DOI: 10.1037/a0038457] [PMID: 25751116]BrownMZ , LinehanMM , ComtoisKA , MurrayA , ChapmanAL . Shame as a prospective predictor of self-inflicted injury in borderline personality disorder: a multi-modal analysis. Behaviour Research and Therapy2009;47(10):815-22. [DOI: 10.1016/j.brat.2009.06.008] [PMC2761705] [PMID: 19596223 ]CoyleTN , ShaverJA , LinehanMM . On the potential for iatrogenic effects of psychiatric crisis services: the example of dialectical behavior therapy for adult women with borderline personality disorder. Journal of Consulting and Clinical Psychology2018;86(2):116-24. [DOI: 10.1037/ccp0000275] [PMID: 29369662]HarnedMS , ChapmanAL , Dexter-MazzaET , MurrayA , ComtoisKA , LinehanMM . Treating co-occurring Axis I disorders in recurrently suicidal women with borderline personality disorder: a 2-year randomized trial of dialectical behavior therapy versus community treatment by experts. Journal of Consulting and Clinical Psychology2008;76(6):1068-75. [DOI: 10.1037/a0014044] [PMID: 19045974]HarnedMS , ChapmanAL , Dexter-MazzaET , MurrayA , ComtoisKA , LinehanMM . Treating co-occurring Axis I disorders in recurrently suicidal women with borderline personality disorder: a 2-year randomized trial of dialectical behavior therapy versus community treatment by experts. Personality Disorders: Theory, Research, and Treatment2009;S(1):35-45. [DOI: 10.1037/1949-2715.S.1.35]HarnedMS , JacksonSC , ComtoisKA , LinehanMM . Dialectical behavior therapy as a precursor to PTSD treatment for suicidal and/or self-injuring women with bordreline personality disorder. Journal of Traumatic Stress2010;23(4):421-9. [DOI: 10.1002/jts.20553] [PMID: 20648564]LindenboimN , ComtoisKA , LinehanMM . Skills practice in dialectical behavior therapy for suicidal women meeting criteria for borderline personality disorder. Cognitive and Behavioral Practice2007;14(2):147-56. [DOI: 10.1016/j.cbpra.2006.10.004]LinehanMM , ComtoisKA , MurrayAM , BrownMZ , GallopRJ , HeardHL , et al. Two-year randomized controlled trial and follow-up of dialectical behavior therapy vs therapy by experts for suicidal behaviors and borderline personality disorder. Archives of General Psychiatry2006;63(7):757-66. [DOI: 10.1001/archpsyc.63.7.757] [PMID: 16818865]LinehanMM . Error in table in: two-year randomized controlled trial and follow-up of dialectical behavior therapy vs therapy by experts for suicidal behaviors and borderline personality disorder. Archives of General Psychiatry2007;64(12):1401. Erratum for: Archives of General Psychiatry 2007;64(12):1401. McMainS . Dialectic behaviour therapy reduces suicide attempts compared with non-behavioural psychotherapy in women with borderline personality disorder. Evidence-Based Mental Health2007;10(1):18. [DOI: 10.1136/ebmh.10.1.18] [PMID: 17255387]NeacsiuAD , LunguA , HarnedMS , RizviSL , LinehanMM . Impact of dialectical behavior therapy versus community treatment by experts on emotional experience, expression, and acceptance in borderline personality disorder. Behaviour Research and Therapy2014;53:47-54. [DOI: 10.1016/j.brat.2013.12.004] [PMC3955205] [PMID: 24418652]NeacsiuAD , RizviSL , LinehanMM . Dialectical behavior therapy skills use as a mediator and outcome of treatment for borderline personality disorder. Behaviour Research and Therapy2010;48(9):832-9. [DOI: 10.1016/j.brat.2010.05.017] [PMC2914145] [PMID: 20579633]SecristCD . The Role of Executive Functioning in the Treatment of Borderline Personality Disorder [PhD thesis]. Washington (DC): University of Washington, 2014. ">Linehan 2006</a>; <a href="./references#CD012955-bbs2-0048" title="LinehanMM , KorslundKE , HarnedMS , GallopRJ , LunguA , NeacsiuAD , et al. Dialectical behavior therapy for high suicide risk in individuals with borderline personality disorder: a randomized clinical trial and component analysis. JAMA Psychiatry2015;72(5):475-82 Erratum for: JAMA Psychiatry 2015; 72(9): 951. [DOI: 10.1001/jamapsychiatry.2014.3039] [PMID: 25806661]NCT00183651. Treatment of suicidal women with borderline personality disorder [Assessment and treatment of parasuicidal patients]. www.clinicaltrials.gov/ct2/show/NCT00183651 (first received 13 September 2005). ">Linehan 2015a</a>; <a href="./references#CD012955-bbs2-0049" title="CaseBG . Letter to the editor on 'McMain SF, Links PS, Gnam WH, Guimond T, Cardish RJ, Korman L, et al. A randomized trial of dialectical behavior therapy versus general psychiatric management for borderline personality disorder. American Journal of Psychiatry 2009;166(12):1365-74. DOI: 10.1176/appi.ajp.2009.09010039'. American Journal of Psychiatry2010;167(4):475. [DOI: 10.1176/appi.ajp.2009.09101532] [PMID: 20360332 ]ISRCTN02634417. Hope for chronically suicidal patient: evaluating the clinical and health services impact of dialectical behaviour therapy (DBT) in individuals with borderline personality disorder [Evaluating the clinical and health services impact of dialectical behaviour therapy (DBT) in individuals with borderline personality disorder: a randomised controlled trial]. www.isrctn.com/ISRCTN02634417 (first received 16 November 2005). [DOI: 10.1186/ISRCTN02634417]McMainSF , FitzpatrickS , BoritzT , BarnhartR , LinksP , StreinerDL . Outcome trajectories and prognostic factors for suicide and self-harm behaviors in patients with borderline personaliy disorder following one year of outpatient psychotherapy. Journal of Personality Disorders2018;32(4):497-512. [DOI: 10.1521/pedi_2017_31_309] [PMID: 28910214]McMainSF , LinksPS , GnamWH , GuimondT , CardishRJ , KormanL , et al. A randomized trial of dialectical behavior therapy versus general psychiatric management for borderline personality disorder. American Journal of Psychiatry2009;166(12):1365-74. [DOI: 10.1176/appi.ajp.2009.09010039] [PMID: 19755574]McMainSF . Dr McMain replies to letter to the editor on 'McMain SF, Links PS, Gnam WH, Guimond T, Cardish RJ, Korman L, et al. A randomized trial of dialectical behavior therapy versus general psychiatric management for borderline personality disorder. American Journal of Psychiatry 2009;166(12):1365-74. DOI: 10.1176/appi.ajp.2009.09010039'. American Journal of Psychiatry2010;167(4):475-6. [DOI: 10.1176/appi.ajp.2009.09101532r)]NCT00154154. Hope for the chronically suicidal patient [Hope for the chronically suicidal patient: evaluating the clinical and health services impact of dialectical behaviour therapy in individuals with borderline personality disorder]. www.clinicaltrials.gov/ct2/show/NCT00154154 (first received 7 September 2005). ">McMain 2009</a>; <a href="./references#CD012955-bbs2-0050" title="McMainSF , GuimondT , BarnhartR , HabinskiL , StreinerDL . A randomized trial of brief dialectical behaviour therapy skills training in suicidal patients suffering from borderline disorder. Acta Psychiatrica Scandinavica2017;135(2):138-48. [DOI: 10.1111/acps.12664] [PMID: 27858962]">McMain 2017</a>; <a href="./references#CD012955-bbs2-0053" title="MohamadizadehL , MakvandiB , PashaR , BakhtiarpourS , HafeziF . Comparing of the effect of dialectical behavior therapy (DBT) and schema therapy (ST) on reducing mood activity and suicidal thoughts in patients with borderline personality disorder. Acta Medica Mediterranea2017;33:1025-31. [DOI: 10.19193/0393-6384_2017_6_162] [www.actamedicamediterranea.com/archive/2017/medica-6/comparing-of-the-effect-of-dialectical-behavior-therapy-dbt-and-schema-therapy-st-on-reducing-mood-activity-and-suicidal-thoughts-in-patients-with-borderline-personality-disorder/pdf]">Mohamadizadeh 2017</a>; <a href="./references#CD012955-bbs2-0059" title="BarnicotK . Re: Regarding your study on DBT for self-harming patients [personal communication]. Email to: EG Faltinsen 28 February 2018. PriebeS , BhattiN , BarnicotK , BremnerS , GagliaA , KatsakouC , et al. Effectiveness and cost-effectiveness of dialectical behaviour therapy for self-harming patients with personality disorder: a pragmatic randomised controlled trial. Psychotherapy and Psychosomatics2012;81(6):356-65. [DOI: 10.1159/000338897] [PMID: 22964561]PriebeS . Supplemental information [personal communication]. Email to: M Kielsholm 20 May 2016. ">Priebe 2012</a>; <a href="./references#CD012955-bbs2-0069" title="SolerJ , PascualJC , TianaT , CebriàA , BarrachinaJ , CampinsMJ , et al. Dialectical behaviour therapy skills training compared to standard group therapy in borderline personality disorder: a 3-month randomised controlled clinical trial. Behaviour Research and Therapy2009;47(5):353-8. [DOI: 10.1016/j.brat.2009.01.013] [PMID: 19246029]SolerJ . Question regarding your BPD trials [personal communication]. Email to: J Stoffers 15 December 2010. ">Soler 2009</a>; <a href="./references#CD012955-bbs2-0070" title="FertuckEA , KeilpJ , SongI , MorrisMC , WilsonST , BrodskyBS , et al. Higher executive control and visual memory performance predict treatment completion in borderline personality disorder. Psychotherapy and Psychosomatics2012;81(1):38-43. [DOI: 10.1159/000329700] [PMC3242704] [PMID: 22116411]NCT00533117. Treating suicidal behavior and self-mutilation in people with borderline personality disorder. www.clinicaltrials.gov/ct2/show/NCT00533117 (first received 19 September 2007). ">Stanley 2017</a>; <a href="./references#CD012955-bbs2-0071" title="TurnerRM . Naturalistic evaluation of dialectical behavior therapy-oriented treatment for borderline personality disorder. Cognitive and Behavioral Practice2000;7(4):413-9. [DOI: 10.1016/S1077-7229(00)80052-8]">Turner 2000</a>; <a href="./references#CD012955-bbs2-0072" title="Van den BoschLM , KoeterMW , StijnenT , VerheulR , Van den BrinkW . Sustained efficacy of dialectical behaviour therapy for borderline personality disorder. Behaviour Research and Therapy2005;43(9):1231-41. [DOI: 10.1016/j.brat.2004.09.008] [PMID: 16005708]Van den BoschLM , VerheulR , SchippersGM , Van den BrinkW . Dialectical behavior therapy of borderline patients with and without substance use problems. Implementation and long-term effects. Addictive Behaviors2002;27(6):911-23. [DOI: 10.1016/s0306-4603(02)00293-9] [PMID: 12369475]Van den BoschLMC . Efficacy of dialectical behaviour therapy in the treatment of female borderline patients with and without substance abuse problems: results of a Dutch study [Dialectische gedragstherapie bij Nederlandse vrouwen met een borderline persoonlijkheidsstoornis, met en zonder verslavingsproblemen]. Tijdschrift voor Psychiatrie2005;47(3):127-37. [www.tijdschriftvoorpsychiatrie.nl/assets/articles/articles_1335pdf.pdf]VerheulR , Van den BoschLM , KoeterMW , De RidderMA , StijnenT , Van den BrinkW . Dialectical behaviour therapy for women with borderline personality disorder: 12-month, randomised clinical trial in The Netherlands. British Journal of Psychiatry2003;182:135-40. [DOI: 10.1192/bjp.182.2.135] [PMID: 12562741]">Van den Bosch 2005</a>).  </p> <p><i>Cognitive behavioural therapy (CBT) and CBT‐ related treatments.</i> Eleven trials investigated the effect of CBT and CBT‐related treatments (<a href="./references#CD012955-bbs2-0007" title="BellinoS , ZizzaM , RinaldiC , BogettoF . Combined therapy of major depression with concomitant borderline personality disorder: comparison of interpersonal and cognitive psychotherapy. Canadian Journal of Psychiatry2007;52(11):718-25. [DOI: 10.1177/070674370705201106] [PMID: 18399039]">Bellino 2007</a>; <a href="./references#CD012955-bbs2-0016" title="CottrauxJ , NoteID , BoutitieF , MillieryM , GenouihlacV , YaoSN , et al. Cognitive therapy versus Rogerian supportive therapy in borderline personality disorder. Two-year follow-up of a controlled pilot study. Psychotherapy and Psychosomatics2009;78(5):307-16. [DOI: 10.1159/000229769] [PMID: 19628959]NCT00131781. Cognitive therapy versus supportive therapy in borderline personality disorder. www.clinicaltrials.gov/ct2/show/NCT00131781 (first received 18 August 2005). ">Cottraux 2009</a>; <a href="./references#CD012955-bbs2-0017" title="DavidsonK , LivingstoneS , McArthurK , DicksonL , GumleyA . An integrative complexity analysis of cognitive behaviour therapy sessions for borderline personality disorder. Psychology and Psychotherapy2007;80(Pt 4):513-23. [DOI: 10.1348/147608307X191535] [PMID: 17535542]DavidsonK , NorrieJ , TyrerP , GumleyA , TataP , MurrayH , et al. The effectiveness of cognitive behavior therapy for borderline personality disorder: results from the borderline personality disorder study of cognitive therapy (BOSCOT) trial. Journal of Personality Disorders2006;20(5):450-65. [DOI: 10.1521/pedi.2006.20.5.450] [PMC1852259] [PMID: 17032158]DavidsonK , TyrerP , GumleyA , TataP , NorrieJ , PalmerS , et al. A randomized controlled trial of cognitive behavior therapy for borderline personality disorder: rationale for trial, method, and description of sample. Journal of Personality Disorders2006;20(5):431-49. [DOI: 10.1521/pedi.2006.20.5.431] [PMC1847748] [PMID: 17032157]DavidsonKM , TyrerP , NorrieJ , PalmerSJ , TyrerH . Cognitive therapy v usual treatment for borderline personality disorder: prospective 6-year follow-up. British Journal of Psychiatry2010;197(6):456-62. [DOI: 10.1192/bjp.bp.109.074286] [PMID: 21119151]ISRCTN86177428. Borderline personality disorder study of cognitive therapy trial [A randomised controlled trial of cognitive therapy plus treatment as usual versus treatment as usual in the treatment of borderline personality disorder]. www.isrctn.com/ISRCTN86177428 (first received 22 July 2005). NCT00538135. BOSCOT: a randomised controlled trial of cognitive behavioural therapy in borderline personality disorder [BOSCOT: a randomised control trial of cognitive behavioural therapy plus treatment as usual versus treatment as usual in the treatment of borderline personality disorder]. www.clinicaltrials.gov/ct2/show/NCT00538135 (first received 29 September 2007). NorrieJ , DavidsonK , TataP , GumleyA . Influence of therapist competence and quantity of cognitive behavioural therapy on suicidal behaviour and inpatient hospitalisation in a randomised controlled trial in borderline personality disorder: further analyses of treatment effects in the BOSCOT study. Psychology and Psychotherapy2013;86(3):280-93. [DOI: 10.1111/papt.12004] [PMC4491320] [PMID: 23420622]PalmerS , DavidsonK , TyrerP , GumleyA , TataP , NorrieJ , et al. The cost-effectiveness of cognitive behavior therapy for borderline personality disorder: results from the BOSCOT trial. Journal of Personality Disorders2006;20(5):466-81. [DOI: 10.1521/pedi.2006.20.5.466] [PMC1852260] [PMID: 17032159]">Davidson 2006</a>; <a href="./references#CD012955-bbs2-0018" title="DavidsonKM , BrownTM , JamesV , KirkJ , RichardsonJ . Manual-assisted cognitive therapy for self-harm in personality disorder and substance misuse: a feasibility trial. Psychiatric Bulletin2014;38(3):108-11. [DOI: 10.1192/pb.bp.113.043109] [PMC4115373] [PMID: 25237519]DavidsonKM . Re: question regarding your trial on manual-assisted cognitive therapy [personal communication]. Email to: EG Faltinsen 28 November 2017. ">Davidson 2014</a>; <a href="./references#CD012955-bbs2-0031" title="BrandS . AW: questions regarding your trial on emotional intelligence training for BPD [personal communication]. Email to: EG Faltinsen 28 November 2017. BrandS . Questions regarding your trial on emotional intelligence training for BPD [personal communication]. Email to: EG Faltinsen 28 November 2017. JahangardL , HaghighiM , BajoghliH , AhmadpanahM , GhaleihaA , ZarrabianMK , et al. Training emotional intelligence improves both emotional intelligence and depressive symptoms in inpatients with borderline personality disorder and depression. International Journal of Psychiatry in Clinical Practice2012;16(3):197-204. [DOI: 10.3109/13651501.2012.687454] [PMID: 22873719]">Jahangard 2012</a>; <a href="./references#CD012955-bbs2-0036" title="KramerU , BergerT , KollyS , MarquetP , PreisigM , De RotenY , et al. Effects of motive-oriented therapeutic relationship in early-phase treatment of borderline personality disorder: a pilot study of a randomized trial. Journal of Nervous and Mental Disease2011;199(4):244-50. [DOI: 10.1097/NMD.0b013e3182125d19] [PMID: 21451348]KramerU , CasparF , DrapeauM . Change in biased thinking in a 10-session treatment for borderline personality disorder: further evidence of the motive-oriented therapeutic relationship. Psychotherapy Research2013;23(6):633-45. [DOI: 10.1080/10503307.2013.791404] [PMID: 23631622]">Kramer 2011</a>; <a href="./references#CD012955-bbs2-0037" title="BerthoudL , KramerU , CasparF , Pascual-LeoneA . Emotional processing in a ten-session general psychiatric treatment for borderline personality disorder: a case study. Personality and Mental Health2015;9(1):73-8. [DOI: 10.1002/pmh.1287] [PMID: 25711648]BerthoudL , Pascual-LeoneA , CasparF , TissotH , KellerS , RohdeKB , et al. Leaving distress behind: a randomized controlled study on change in emotional processing in borderline personality disorder. Psychiatry2017;80(2):139-54. [DOI: 10.1080/00332747.2016.1220230] [PMID: 28767333]KellerS , StelmaszczykK , KollyS , De RotenY , DesplandJN , CasparF , et al. Change in biased thinking in a treatment based on the motive-oriented therapeutic relationship for borderline personality disorder. Journal of Personality Disorders2018;32(Suppl):75-92. [DOI: 10.1521/pedi.2018.32.supp.75] [PMID: 29388899]KramerU , FlückigerC , KollyS , CasparF , MarquetP , DesplandJN , et al. Unpacking the effects of therapist responsiveness in borderline personality disorder: motive-oriented therapeutic relationship, patient in-session experience, and the therapeutic alliance. Psychotherapy and Psychosomatics2014;83(6):386-7. [DOI: 10.1159/000365400] [PMID: 25324025]KramerU , KellerS , CasparF , De RotenY , DesplandJN , KollyS . Early change in coping strategies in responsive treatments for borderline personality disorder: a mediation analysis. Journal of Consulting and Clinical Psychology2017;85(5):530-5. [DOI: 10.1037/ccp0000196] [PMID: 28425747]KramerU , KollyS , BerthoudL , KellerS , PreisigM , CasparF , et al. Effects of motive-oriented therapeutic relationship in a ten-session general psychiatric treatment of borderline personality disorder: a randomized controlled trial. Psychotherapy and Psychosomatics2014;83(3):176-86. [DOI: 10.1159/000358528] [PMID: 24752034]KramerU , StulzN , BerthoudL , CasparF , MarquetP , KollyS , et al. The shorter the better? A follow-up analysis of 10-session psychiatric treatment including the motive-oriented therapeutic relationship for borderline personality disorder. Psychotherapy Research2017;27(3):362-70. [DOI: 10.1080/10503307.2015.1110635] [PMID: 26684670]NCT01896024. Effects of motive-oriented therapeutic relationship in the early-phase treatment of borderline personality disorder (MOTR). www.clinicaltrials.gov/ct2/show/NCT01896024 (first received 5 July 2013). ">Kramer 2014</a>; <a href="./references#CD012955-bbs2-0039" title="KredlowMA , SzuhanyKL , LoS , XieH , GottliebJD , RosenbergSD , et al. Cognitive behavioral therapy for posttraumatic stress disorder in individuals with severe mental illness and borderline personality disorder. Psychiatry Research2017;249:86-93. [DOI: 10.1016/j.psychres.2016.12.045] [PMC5325773] [PMID: 28086181]MueserK . Re: question regarding your trial on CBT for BPD patients [personal communication]. Email to: EG Faltinsen 28 November 2017. ">Kredlow 2017a</a>; <a href="./references#CD012955-bbs2-0040" title="KredlowMA , SzuhanyKL , LoS , XieH , GottliebJD , RosenbergSD , et al. Cognitive behavioral therapy for posttraumatic stress disorder in individuals with severe mental illness and borderline personality disorder. Psychiatry Research2017;249:86-93. [DOI: 10.1016/j.psychres.2016.12.045] [PMC5325773] [PMID: 28086181]MueserKT , GottliebJD , XieH , LuW , YanosPT , RosenbergSD , et al. Evaluation of cognitive restructuring for post-traumatic stress disorder in people with severe mental illness.. British Journal of Psychiatry2015;206(6):501-8. [DOI: 10.1192/bjp.bp.114.147926] [PMC4450219] [PMID: 25858178]MueserKT , RosenbergSD , XieH , JankowskiMK , BoltonEE , LuW , et al. A randomized controlled trial of cognitive-behavioral treatment for posttraumatic stress disorder in severe mental illness. Journal of Consulting and Clinical Psychology2008;76(2):259-71. [DOI: 10.1037/0022-006X.76.2.259] [PMC3916092] [PMID: 18377122]MueserKT . Re: question regarding your trial on CBT for PTSD participants [personal communication]. Email to: E Faltinsen 28 November 2018. ">Kredlow 2017b</a>; <a href="./references#CD012955-bbs2-0051" title="McMurranM , CrawfordMJ , ReillyJ , DelportJ , McCroneP , WhithamD , et al. Psychoeducation with problem-solving (PEPS) therapy for adults with personality disorder: a pragmatic randomised controlled trial to determine the clinical effectiveness and cost-effectiveness of a manualised intervention to improve social functioning. Health Technology Assessment2016;20(52):1-282. [DOI: 10.3310/hta20520]McMurranM . RE: Cochrane Collaboration review - PEPS study [personal communication]. Email to: J Stoffers-Winterling 5 July 2018. McMurranM . Request for data on BPD subjects in the PEPS rcp-study for use a new Cochrane review [personal communication]. Email to: M Kongerslev 7 March 2017. ">McMurran 2016</a>; <a href="./references#CD012955-bbs2-0065" title="SchillingL , MoritzS , KötherU , NagelM . Preliminary results on acceptance, feasibility, and subjective efficacy of the add-on group intervention metacognitive training for borderline patients. Journal of Cognitive Psychotherapy2015;29(2):153-64. [DOI: 10.1891/0889-8391.29.2.153]SchillingL , MoritzS , KristonL , KriegerM , NagelM . Efficacy of metacognitive training for patients with borderline personality disorder: preliminary results. Psychiatry Research2018;262:459-64. [DOI: 10.1016/j.psychres.2017.09.024] [PMID: 28927866]SchillingL . Re Schilling 2015/2018 - Cochrane Review of psychotherapies for BPD [personal communication] [Re Schilling 2015/2018 - Cochrane Review zur Psychotherapie bei BPS [persönliche Kommunikation]]. Email to: J Stoffers-Winterling 22 January 2019. ">Schilling 2018</a>). </p> <p><i>Psychoeducation.</i> One trial investigated a generic form of psychoeducation in which the first step (awareness of BPD) of the STEPPS programme was taught (<a href="./references#CD012955-bbs2-0057" title="NCT02033044. Cognitive rehabilitation versus psychoeducation in psychosocial functioning of borderline personality disorder [Randomized controlled trial comparing the effects on psychosocial functioning of cognitive rehabilitation versus psychoeducation in borderline personality disorder]. www.clinicaltrials.gov/ct2/show/NCT02033044 (first received 23 December 2013). PascualJC , PalomaresN , Ibáñez Á, PortellaMJ , ArzaR , ReyesR , et al. Efficacy of cognitive rehabilitation on psychosocial functioning in borderline personality disorder: a randomized controlled trial. BMC Psychiatry2015;15:255. [DOI: 10.1186/s12888-015-0640-5] [PMC4617906] [PMID: 26487284]">Pascual 2015</a>), and one trial included a once‐only workshop (<a href="./references#CD012955-bbs2-0074" title="ZanariniMC , FrankenburgFR . A preliminary, randomized trial of psychoeducation for women with borderline personality disorder. Journal of Personality Disorders2008;22(3):284-90. [DOI: 10.1521/pedi.2008.22.3.284] [PMID: 18540800]ZanariniMC , FrankenburgFR . A randomized trial of psychoeducation for patients with BPD. In: 157th annual meeting of the American Psychiatric Association. Psychotherapy and psychopharmacology: dissolving the mind-brain barrier; 2004 May 1-6; New York (NY). Arlington (VA): American Psychiatric Association, 2004:102. [Symposium 100E] [www.psychiatry.org/File%20Library/Psychiatrists/Directories/Library-and-Archive/conference_publications/am_program_2004.pdf]">Zanarini 2008</a>). </p> <p><i>Cognitive analytic therapy (CAT) and CAT‐related treatments.</i> One trial investigated the effect of CAT (<a href="./references#CD012955-bbs2-0025" title="GleesonJF , ChanenA , CottonSM , PearceT , NewmanB , McCutcheonL . Treating co-occurring first-episode psychosis and borderline personality: a pilot randomized controlled trial. Early Intervention in Psychiatry2012;6(1):21-9. [DOI: 10.1111/j.1751-7893.2011.00306.x] [PMID: 22379625]GleesonJFM . RE: separate data [personal communication]. Email to: M Kielsholm 28 October 2016. ">Gleeson 2012</a>). </p> <p><i>Psychodynamic psychotherapy and related treatments </i>were investigated by three trials: psychic representation‐focused psychotherapy in <a href="./references#CD012955-bbs2-0060" title="RenesesB , FigueraD , SalcedoG , TrujilloM , López-IborJJ , GaliánM , et al. A controlled randomized study on the efficacy of short-term dinamic psychotherapy in borderline personality disorders (BPD). Preliminary results. European Psychiatry2011;26(Suppl 1):1040. [DOI: 10.1016/S0924-9338(11)72745-6] [P02-444]RenesesB , GaliánM , SerranoR , FigueraD , Fernandez Del MoralA , López-IborJJ , et al. A new time limited psychotherapy for BPD: preliminary results of a randomized and controlled trial. Actas Espanolas de Psiquiatria2013;41(3):139-48. [PMID: 23803797]">Reneses 2013</a>; psychoanalytic‐interactional therapy in <a href="./references#CD012955-bbs2-0042" title="LeichsenringF , MasuhrO , JaegerU , RabungS , DallyA , DümpelmannM , et al. Psychoanalytic-interactional therapy versus psychodynamic therapy by experts for personality disorders: a randomized controlled efficacy-effectiveness study in cluster B personality disorders. Psychotherapy and Psychosomatics2016;85(2):71-80. [DOI: 10.1159/000441731] [PMID: 26808580]">Leichsenring 2016</a>; and sequential brief Adlerian psychodynamic psychotherapy in <a href="./references#CD012955-bbs2-0001" title="AmiantoF , FerreroA , PieròA , CairoE , RoccaG , SimonelliB , et al. Supervised team management, with or without structured psychotherapy, in heavy users of a mental health service with borderline personality disorder: a two-year follow-up preliminary randomized study. BMC Psychiatry2011;11:181. [DOI: 10.1186/1471-244X-11-181] [PMC3260092 ] [PMID: 22103890]NCT01356069. Efficacy of time-limited psychodynamic psychotherapy and informed clinical management in BPD high MHS users (HUMSH) [Sequential brief Adlerian psychodynamic psychotherapy in heavy users of a mental health service with borderline personality disorder: a two years follow-up preliminary randomized study]. clinicaltrials.gov/ct2/show/NCT01356069 (first received 16 May 2011). ">Amianto 2011</a>. </p> <p><i>Dynamic deconstructive psychotherapy (DDP</i>). One trial investigated the effect of DDP (<a href="./references#CD012955-bbs2-0028" title="GregoryRJ , ChlebowskiS , KangD , RemenA , SoderbergM . Psychodynamic therapy for borderline personality disorder and co-occurring alcohol use disorders: a newly designed ongoing study. Journal of the American Psychoanalytic Association2006;54(4):1331-4. [DOI: 10.1177/00030651060540040107] [PMID: 17354507]GregoryRJ , ChlebowskiS , KangD , RemenAL , SoderbergMG , StepkovitchJ , et al. A controlled trial of psychodynamic psychotherapy for co-occurring borderline personality disorder and alcohol use disorder. Psychotherapy2008;45(1):28-41. [DOI: 10.1037/0033-3204.45.1.28] [PMID: 22122363]GregoryRJ , DeLucia-DeranjaE , MogleJA . Dynamic deconstructive psychotherapy versus optimized community care for borderline personality disorder co-occuring with alcohol use disorders: a 30-month follow-up. Journal of Nervous and Mental Disease2010;198(4):292-8. [DOI: 10.1097/NMD.0b013e3181d6172d] [PMID: 20386259]GregoryRJ , RemenAL , SoderbergM , Ploutz-SnyderRJ . A controlled trial of psychodynamic psychotherapy for co-occurring borderline personality disorder and alcohol use disorder: six-month outcome. Journal of the American Psychoanalytic Association2009;57(1):199-205. [DOI: 10.1177/00030651090570011006] [PMID: 19270255]NCT00145678. Psychodynamic therapy for co-occurring borderline personality disorder and alcohol use disorder [Psychodynamic therapy for patients With borderline personality disorder and alcohol abuse]. www.clinicaltrials.gov/show/NCT00145678 (first received 1 September 2005). ">Gregory 2008b</a>). </p> <p><i>Schema‐focused therapy (SFT) and SFT‐related treatments</i>. Four trials investigated the effect of SFT and SFT‐related treatment (<a href="./references#CD012955-bbs2-0021" title="FarrellJM , ShawIA , WebberMA . A schema-focused approach to group psychotherapy for outpatients with borderline personality disorder: a randomized controlled trial. Journal of Behavior Therapy and Experimental Psychiatry2009;40(2):317-28 Corrigendum to: Journal of Behavior Therapy and Experimental Psychiatry 2018; 60: 111. [DOI: 10.1016/j.jbtep.2009.01.002] [PMID: 19176222]FarrellJM . Question regarding your BPD trials [personal communication]. Email to: K Lieb, J Stoffers 9 December 2010. ">Farrell 2009</a>; <a href="./references#CD012955-bbs2-0024" title="ArntzA , Stupar-RutenfransS , BlooJ , Van DyckR , SpinhovenP . Prediction of treatment discontinuation and recovery from borderline personality disorder: results from an RCT comparing schema therapy and transference-focused psychotherapy. Behaviour Research and Therapy2015;74:60-71. [DOI: 10.1016/j.brat.2015.09.002] [PMID: 26432172]Giesen-BlooJ , ArntzA . Questions concerning the randomized trial of schema-focused therapy vs transference-focused psychotherapy—reply. Archives of General Psychiatry2007;64(5):610-1. [DOI: 10.1001/archpsyc.64.5.610]Giesen-BlooJ , Van DyckR , SpinhovenP , Van TilburgW , DirksenC , Van AsseltT , et al. Errors in table and figure in: outpatient psychotherapy for borderline personality disorder: randomized trial of schema-focused therapy vs transference-focused psychotherapy. Archives of General Psychiatry2006;63(9):1008. Erratum for: Archives of General Psychiatry 2006;63(6):649-58. [DOI: 10.1001/archpsyc.63.9.1008]Giesen-BlooJ , Van DyckR , SpinhovenP , Van TilburgW , DirksenC , Van AsseltT , et al. Outpatient psychotherapy for borderline personality disorder: randomized trial of schema-focused therapy vs transference-focused psychotherapy. Archives of General Psychiatry2006;63(6):649-58. [DOI: 10.1001/archpsyc.63.6.649] [PMID: 16754838]SpinhovenP , Giesen-BlooJ , Van DyckR , KooimanK , ArntzA . The therapeutic alliance in schema-focused therapy and transference-focused psychotherapy for borderline personality disorder. Journal of Consulting and Clinical Psychology2007;75(1):104-15. [DOI: 10.1037/0022-006X.75.1.104] [PMID: 17295569]Van AsseltADI , DirksenCD , ArntzA , Giesen-BlooJH , Van DyckR , SpinhovenP , et al. Out-patient psychotherapy for borderline personality disorder: cost-effectiveness of schema-focused therapy v transference-focused psychotherapy. British Journal of Psychiatry2008;192(6):450-7. [DOI: 10.1192/bjp.bp.106.033597] [PMID: 18515897]Van AsseltADI , DirksenCD , ArntzA , SeverensJL . Difficulties in calculating productivity costs: work disability associated with borderline personality disorder. Value in Health2008;11(4):637-44. [DOI: 10.1111/j.1524-4733.2007.00288.x]YeomansF . Questions concerning the randomized trial of schema-focused therapy vs transference-focused psychotherapy. Archives of General Psychiatry2007;64(5):609-10. [DOI: 10.1001/archpsyc.64.5.609-c] [PMID: 17485613]">Giesen‐Bloo 2006</a>; <a href="./references#CD012955-bbs2-0053" title="MohamadizadehL , MakvandiB , PashaR , BakhtiarpourS , HafeziF . Comparing of the effect of dialectical behavior therapy (DBT) and schema therapy (ST) on reducing mood activity and suicidal thoughts in patients with borderline personality disorder. Acta Medica Mediterranea2017;33:1025-31. [DOI: 10.19193/0393-6384_2017_6_162] [www.actamedicamediterranea.com/archive/2017/medica-6/comparing-of-the-effect-of-dialectical-behavior-therapy-dbt-and-schema-therapy-st-on-reducing-mood-activity-and-suicidal-thoughts-in-patients-with-borderline-personality-disorder/pdf]">Mohamadizadeh 2017</a>; <a href="./references#CD012955-bbs2-0056" title="NadortM , ArntzA , SmitJH , Giesen-BlooJ , EikelenboomJ , SpinhovenP , et al. Implementation of outpatient schema therapy for borderline personality disorder with versus without crisis support by the therapist outside office hours: a randomized trial. Behaviour Research and Therapy2009;47(11):961-73. [DOI: 10.1016/j.brat.2009.07.013] [PMID: 19698939]NadortM , ArntzA , SmitJH , Giesen-BlooJ , EikelenboomM , SpinhovenP , et al. Implementation of outpatient schema therapy for borderline personality disorder: study design. BMC Psychiatry2009;9:64. [DOI: 10.1186/1471-244X-9-64] [PMC2762959] [PMID: 19807925]NL1680 (NTR1781). Implementation of out-patient schema-focused therapy for borderline personality disorder in regular mental healthcare. www.trialregister.nl/trial/1680 (first received 29 April 2009). ">Nadort 2009</a>). </p> <p><i>Acceptance and commitment therapy (ACT)</i> employs mindfulness and acceptance strategies. One trial investigated the effect of ACT (<a href="./references#CD012955-bbs2-0055" title="MortonJ , SnowdonS , GopoldM , GuymerE . Acceptance and commitment therapy group treatment for symptoms of borderline personality disorder: a public sector pilot study. Cognitive and Behavioral Practice2012;19(4):527-44. [DOI: 10.1016/j.cbpra.2012.03.005]MortonJ . Re: SV: regarding your study on acceptance and commitment therapy for BPD [personal communication]. Email to: EG Faltinsen 22 December 2017. ">Morton 2012</a>). </p> <p><i>Mentalisation‐based treatment (MBT) and MBT‐related treatments.</i> Six trials investigated the effect of MBT and MBT‐related treatments (<a href="./references#CD012955-bbs2-0004" title="BatemanA , FonagyP . 8-year follow-up of patients treated for borderline personality disorder: mentalization-based treatment versus treatment as usual. American Journal of Psychiatry2008;165(5):631-8. [DOI: 10.1176/appi.ajp.2007.07040636] [PMID: 18347003]BatemanA , FonagyP . Effectiveness of partial hospitalization in the treatment of borderline personality disorder: a randomized controlled trial. American Journal of Psychiatry1999;156(10):1563-9. [DOI: 10.1176/ajp.156.10.1563] [PMID: 10518167]BatemanA , FonagyP . Health care utilization costs for borderline personality disorder patients treated with psychoanalytically oriented partial hospitalization versus general psychiatric care. American Journal of Psychiatry2003;160(1):169-71. [10.1176/appi.ajp.160.1.169] [12505818]BatemanA , FonagyP . Treatment of borderline personality disorder with psychoanalytically oriented partial hospitalization: an 18-month follow-up. American Journal of Psychiatry2001;158(1):36-42. [DOI: 10.1176/appi.ajp.158.1.36] [PMID: 11136631]BatemanA . Important: question regarding your BPD trial for systematic review in Cochrane Collaboration [personal communication]. Email to: K Lieb, J Stoffers 14 December 2010. BatemanA . Intensive outpatient and partial hospital care for BPD. In: 157th annual meeting of the American Psychiatric Association. Psychotherapy and pharmacology: dissolving the mind-brain barrier; 2004 May 1-6; New York (NY). Arlington (VA): American Psychiatric Association, 2004:102. [Symposium 100B] [www.psychiatry.org/File%20Library/Psychiatrists/Directories/Library-and-Archive/conference_publications/am_program_2004.pdf]BatemanAW , FonagyP . Drs Bateman and Fonagy reply [to Stern R. Partial hospitalization for borderline personality disorder. American Journal of Psychiatry 2001;158(11):1932-3. DOI: 10.1176/appi.ajp.158.11.1932]. American Journal of Psychiatry2001;158(11):1932-3. [DOI: 10.1176/appi.ajp.158.11.1932-a]EvansC . Treatment benefits of psychoanalytically oriented partial hospitalisation were maintained over 18 months in borderline personality disorder. Evidence-Based Mental Health2001;4(3):73. [DOI: 10.1136/ebmh.4.3.73]FonagyP , BatemanAW . Mentalizing and borderline personality disorder. Journal of Mental Health2007;16(1):83-101. [DOI: 10.1080/09638230601182045]SternR . Partial hospitalization for borderline personality disorder. American Journal of Psychiatry2001;158(11):1932-3. [DOI: 10.1176/appi.ajp.158.11.1932] [PMID: 11691712]">Bateman 1999</a>; <a href="./references#CD012955-bbs2-0005" title="BatemanA , FonagyP . Impact of clinical severity on outcomes of mentalisation-based treatment for borderline personality disorder. British Journal of Psychiatry2013;203(3):221-7. [DOI: 10.1192/bjp.bp.112.121129] [PMID: 23887998]BatemanA , FonagyP . Randomized controlled trial of outpatient mentalization-based treatment versus structured clinical management for borderline personality disorder. American Journal of Psychiatry2009;166(12):1355-64. [DOI: 10.1176/appi.ajp.2009.09040539] [PMID: 19833787]BatemanA , FonagyP . Randomized controlled trial of outpatient mentalization-based treatment versus structured clinical management for borderline personality disorder. Supplementary data. ajp.psychiatryonline.org/doi/suppl/10.1176/appi.ajp.2009.09040539/suppl_file/ajp_166_12_1355_01.pdf (accessed 27 February 2020). BatemanA , O'ConnellJ , LorenziniN , GardnerT , FonagyP . A randomised controlled trial of mentalization-based treatment versus structured clinical management for patients with comorbid borderline personality disorder and antisocial personality disorder. BMC Psychiatry2016;16:304. [DOI: 10.1186/s12888-016-1000-9] [PMC5006360] [PMID: 27577562]BatemanA . Important question regarding your BPD trial for systematic review in Cochrane Collaboration [personal communication]. Email to: K Lieb 14 December 2010. BatemanAW . Mentalization, borderline personality disorder and what works for whom? Presentation at the 11th International Congress of the International Society for the Study of Personality Disorders; 2009 Aug 21-23. www.borderlinepersonalitydisorder.com/Conferences/ISSPD/isspd_09_Bateman (accessed 21 April 2010). ISRCTN27660668. Randomised controlled trial of manualised out-patient individual and group therapy for borderline personality disorder [Effectiveness of intensive out-patient psychotherapy for treatment of borderline personality disorder: a pragmatic randomised single blind controlled study]. www.isrctn.com/ISRCTN27660668 (first received 12 October 2008). ">Bateman 2009</a>; <a href="./references#CD012955-bbs2-0033" title="JørgensenCR , BøyeR , AndersenD , Døssing BlaabjergAH , FreundC , JordetH , et al. Eighteen months post-treatment naturalistic follow-up study of mentalization-based therapy and supportive group treatment of borderline personality disorder: clinical outcomes and functioning. Nordic Psychology2014;66(4):254-73. [DOI: 10.1080/19012276.2014.963649]JørgensenCR , FreundC , BøyeR , JordetH , AndersenD , KjølbyeM . Outcome of mentalization-based and supportive psychotherapy in patients with borderline personality disorder: a randomized trial. Acta Psychiatrica Scandinavica2013;127(4):305-17. [DOI: 10.1111/j.1600-0447.2012.01923.x] [PMID: 22897123]JorgensenCR . SV: questions on your trial regarding MBT for BPD patients [personal communication]. Email to: EG Faltinsen 28 November 2017. ">Jørgensen 2013</a>; <a href="./references#CD012955-bbs2-0058" title="PhilipsB , WennebergP , KonradssonP , FranckJ . Mentalization-based treatment for concurrent borderline personality disorder and substance use disorder: a randomized controlled feasibility study. European Addiction Research2018;24(1):1-8. [DOI: 10.1159/000485564] [PMC5969093] [PMID: 294028]">Philips 2018</a>; <a href="./references#CD012955-bbs2-0061" title="ISRCTN51304415. Nice OUtcomes for Referrals with Impulsivity, Self Harm and Eating Disorders: the NOURISHED study [A randomised controlled trial of mentalisation based therapy against specialist supportive clinical management in patients with both eating disorders and symptoms of borderline personality disorder]. www.isrctn.com/ISRCTN51304415 (first received 31 January 2011). RobinsonP , BarrettB , BatemanA , HakeemA , HellierJ , LemonskyF , et al. Study protocol for a randomized controlled trial of mentalization based therapy against specialist supportive clinical management in patients with both eating disorders and symptoms of borderline personality disorder. BMC Psychiatry2014;14:51. [DOI: 10.1186/1471-244X-14-51] [PMC3996076] [PMID: 24555511]RobinsonP , HellierJ , BarrettB , BarzdaitieneD , BatemanA , BogaardtA , et al. The NOURISHED randomised controlled trial comparing mentalisation-based treatment for eating disorders (MBT-ED) with specialist supportive clinical management (SSCM-ED) for patients with eating disorders and symptoms of borderline personality disorder. Trials2016;17(1):549. [DOI: 10.1186/s13063-016-1606-8] [PMC5114835] [PMID: 27855714]">Robinson 2016</a>; <a href="./references#CD012955-bbs2-0062" title="ISRCTN95266816. The emergence of personality disorder traits in adolescents who deliberately self harm and the potential for using a mentalisation based treatment approach as an early intervention for such individuals: a randomised controlled trial. www.isrctn.com/ISRCTN95266816 (first received 29 October 2007). RossouwT . Mentalisation based treatment for adolescents with self harm: an RCT. European Child &amp; Adolescent Psychiatry2015;24(1 Suppl):S113. [DOI: 10.1007%2Fs00787-015-0714-4.pdf] [W1-02-02]RossouwT . Self harm in adolescence, is MBT the answer?: an RCT. Adolescent Psychiatry2012;2(1):102. [DOI: 10.2174/2210676611202010077]RossouwTI , FonagyP . Mentalization-based treatment for self-harm in adolescents: a randomized controlled trial. Journal of the American Academy of Child and Adolescent Psychiatry2012;51(12):1304-13.e3. [DOI: 10.1016/j.jaac.2012.09.018] [PMID: 23200287]">Rossouw 2012b</a>). </p> <p><i>Interpersonal psychotherapy (IPT) and IPT‐related treatments.</i> Four trials investigated the effect of IPT (<a href="./references#CD012955-bbs2-0006" title="BellinoS , ParadisoE , ZizzaM , Di LorenzoR , BogettoF . Combined therapy with interpersonal psychotherapy of major depressed patients with borderline personality disorder: a comparison with pharmacotherapy [Terapia combinata con psicoterapia interpersonale di pazienti depressi maggiori con disturbo borderline di personalità: confronto con la farmacoterapia]. Journal of Psychopathology2005;11(1):34-42. [bit.ly/2rZUh5h]BellinoS , ZizzaM , RinaldiC , BogettoF . Combined treatment of major depression in patients with borderline personality disorder: a comparison with pharmacotherapy. Canadian Journal of Psychiatry2006;51(7):453-60. [DOI: 10.1177/070674370605100707] [PMID: 16838827]">Bellino 2006</a>; <a href="./references#CD012955-bbs2-0007" title="BellinoS , ZizzaM , RinaldiC , BogettoF . Combined therapy of major depression with concomitant borderline personality disorder: comparison of interpersonal and cognitive psychotherapy. Canadian Journal of Psychiatry2007;52(11):718-25. [DOI: 10.1177/070674370705201106] [PMID: 18399039]">Bellino 2007</a>; <a href="./references#CD012955-bbs2-0008" title="BellinoS , BozzatelloP , BogettoF . Combined treatment of borderline personality disorder with interpersonal psychotherapy and pharmacotherapy: predictors of response. Psychiatry Research2015;226(1):284-8. [DOI: 10.1016/j.psychres.2014.12.064] [isiarticles.com/bundles/Article/pre/pdf/34125.pdf]BellinoS , RinaldiC , BogettoF . Adaptation of interpersonal psychotherapy to borderline personality disorder: a comparison of combined therapy and single pharmacotherapy. Canadian Journal of Psychiatry2010;55(2):74-81. [DOI: 10.1177/070674371005500203] [PMID: 20181302]BellinoS . Question regarding your BPD trials for inclusion in Cochrane Collaboration review [personal communication]. Email to: J Stoffers-Winterling 19 December 2010. BellinoS . Re: question regarding your BPD trials [personal communication]. Email to: J Stoffers 16 December 2010. BozzatelloP , BellinoS . Combined therapy with interpersonal psychotherapy adapted for borderline personality disorder: a two-years follow-up. Psychiatry Research2016;240:151-6. [DOI: 10.1016/j.psychres.2016.04.014] [www.sciencedirect.com/science/article/pii/S0165178115302389]ZizzaM , FenocchioM , RinaldiC , BellinoS . Combined treatment of borderline personality disorder: a trial of modified interpersonal therapy. World Psychiatry2009;8(Suppl 1):234. ">Bellino 2010</a>; <a href="./references#CD012955-bbs2-0068" title="SmithPN , GambleSA , CortNA , WardEA , HeH , TalbotNL . Attachment and alliance in the treatment of depressed, sexually abused women. Depression and Anxiety2012;29(2):123-30. [DOI: 10.1002/da.20913] [PMC3325338] [PMID: 22065593]SmithPN . Re: Cochrane Collaboration review of psychotherapies for BPD [personal communication]. Email to: J Stoffers-Winterling 05 July 2018. ">Smith 2012</a>). </p> <p><i>Client‐centred therapy (CCT) and related treatments </i>aim to encourage the patient to find solutions to their own problems and to help them decide how they need to change. Two trials investigated the effect of CCT (<a href="./references#CD012955-bbs2-0016" title="CottrauxJ , NoteID , BoutitieF , MillieryM , GenouihlacV , YaoSN , et al. Cognitive therapy versus Rogerian supportive therapy in borderline personality disorder. Two-year follow-up of a controlled pilot study. Psychotherapy and Psychosomatics2009;78(5):307-16. [DOI: 10.1159/000229769] [PMID: 19628959]NCT00131781. Cognitive therapy versus supportive therapy in borderline personality disorder. www.clinicaltrials.gov/ct2/show/NCT00131781 (first received 18 August 2005). ">Cottraux 2009</a>; <a href="./references#CD012955-bbs2-0071" title="TurnerRM . Naturalistic evaluation of dialectical behavior therapy-oriented treatment for borderline personality disorder. Cognitive and Behavioral Practice2000;7(4):413-9. [DOI: 10.1016/S1077-7229(00)80052-8]">Turner 2000</a>). </p> <p><i>Manual‐assisted cognitive treatment (MACT</i>) is used to treat people who are acutely self‐harming. The treatment is structured around a self‐help book. Two trials investigated the effect of MACT (<a href="./references#CD012955-bbs2-0054" title="MoreyLC , LowmasterSE , HopwoodCJ . A pilot study of manual-assisted cognitive therapy with a therapeutic assessment augmentation for borderline personality disorder. Psychiatry Research2010;178(3):531-5. [DOI: 10.1016/j.psychres.2010.04.055] [PMID: 20537722]">Morey 2010</a>; <a href="./references#CD012955-bbs2-0073" title="WeinbergI , GundersonJG , HennenJ , Cutter CJ Jr. Manual assisted cognitive treatment for deliberate self-harm in borderline personality disorder patients. Journal of Personality Disorders2006;20(5):482-92. [DOI: 10.1521/pedi.2006.20.5.482] [PMID: 17032160]WilbergT . SV: separate data [personal communication] [SV: separat data [personlig kommunikation]]. Email to: M Kielsholm 25 May 2016. ">Weinberg 2006</a>). </p> <p><i>Systems training for emotional predictability and problem‐solving for borderline personality disorder (STEPPS)</i> is a seminar‐like, group treatment programme that combines cognitive‐behavioural elements and skills training. Two trials investigated the effect of STEPPS (<a href="./references#CD012955-bbs2-0010" title="BlackD . Question regarding your BPD trial [personal communication]. Email to: J Stoffers 04 January 2011. BlackDW , AllenJ , McCormickB , BlumN . Treatment received by persons with BPD participating in a randomized clinical trial of the systems training for emotional predictability and problem solving programme. Personality and Mental Health2011;5(3):159-68. [DOI: 10.1002/pmh.167]BlackDW , AllenJ , St JohnD , PfohlB , McCormickB , BlumN . Predictors of response to systems training for emotional predictability and problem solving (STEPPS) for borderline personality disorder: an exploratory study. Acta Psychiatrica Scandinavica2009;120(1):53-61. [DOI: 10.1111/j.1600-0447.2008.01340.x] [PMC3665337] [PMID: 19183126]BlackDW , BlumN , PfohlB , St JohnD . The STEPPS group treatment program for outpatients with borderline personality disorder. Journal of Contemporary Psychotherapy2004;34(3):193-210. [DOI: 10.1023/B:JOCP.0000036630.25741.83]BlackDW , PfohlBM . Randomized clinical trial of STEPPS versus treatment as usual. In: 158th annual meeting of the American Psychiatric Association. Psychosomatic medicine: integrating psychiatry &amp; medicine; 2005 May 21-26; Atlanta (GA). Arlington (VA): American Psychiatric Association, 2005:104. [No. 1B] [www.psychiatry.org/File%20Library/Psychiatrists/Directories/Library-and-Archive/syllabus/am_syllabus_2005.pdf]BlackDW , Simsek-DuranF , BlumN , McCormickB , AllenJ . Do people with borderline personality disorder complicated by antisocial personality disorder benefit from the STEPPS treatment program?Personality and Mental Health2016;10(3):205-15. [DOI: 10.1002/pmh.1326] [PMC4911327] [PMID: 26671625]BlackDW . RE: [external] questions regarding your trial on the STEPPS program for BPD [personal communication]. Email to: EG Faltinsen 27 November 2017. BlumN , AllenJ , McCormickB , BlackDW . Ms Blum and colleagues reply [to Schulte-Herbrüggen O, Koerting J, Roepke S. Effectiveness of adjunctive STEPPS group treatment in borderline personality disorder patients. American Journal of Psychiatry 2008;165(10):1354-5. DOI: 10.1176/appi.ajp.2008.08030390]. American Journal of Psychiatry2008;165(10):1354-5. [DOI: 10.1176/appi.ajp.2008.08030390r]BlumN , FranklinJ , HanselR , McCormickB , St JohnD , PfohlB , et al. Relationship of age to symptom severity, psychiatric comorbidity and health care utilization in persons with borderline personality disorder. Personality and Mental Health2008;2(1):25-43. [DOI: 10.1002/pmh.26]BlumN , St JohnD , PfohlB , StuartS , McCormickB , AllenJ , et al. Erratum. American Journal of Psychiatry2008;165(6):777. Erratum for: American Journal of Psychiatry 2008;165(4):468-78. [psycnet.apa.org/record/2008-07854-033]BlumN , St JohnD , PfohlB , StuartS , McCormickB , AllenJ , et al. Systems training for emotional predictability and problem solving (STEPPS) for outpatients with borderline personality disorder: a randomized controlled trial and 1-year follow-up. American Journal of Psychiatry2008;165(4):468-78. [DOI: 10.1176/appi.ajp.2007.07071079] [PMC3608469] [PMID: 18281407]DavidsonKM . Borderline personality disorder: STEPPS improves symptoms. Evidence-Based Mental Health2008;11(4):120. [DOI: 10.1136/ebmh.11.4.120] [PMID: 18952969]NCT00055315. Treatment for borderline personality disorder [A cognitive group treatment for borderline outpatients]. clinicaltrials.gov/ct2/show/NCT00055315 (first received 25 February 2003). ">Blum 2008</a>; <a href="./references#CD012955-bbs2-0013" title="BosEH , Van WelE , AppeloMT , VerbraakMJP . A randomized controlled trial of a Dutch version of systems training for emotional predictability and problem solving for borderline personality disorder. Journal of Nervous and Mental Disease2010;198(4):299-304. [DOI: 10.1097/NMD.0b013e3181d619cf] [PMID: 20386260]Van WelEB , BosEH , AppeloMT , BerendsenEM , WillgerothFC , VerbraakMJPM . The efficacy of the systems training for emotional predictability and problem solving (STEPPS) in the treatment of borderline personality disorder. A randomized controlled trial [De effectiviteit van de vaardigheidstraining emotieregulatiestoornis (VERS) in de behandeling van de borderlinepersoonlijkheidsstoornis: een gerandomiseerd onderzoek]. Tijdschrift voor Psychiatrie2009;51(5):291-301. [PMID: 19434566]">Bos 2010</a>). </p> <p><i>Eclectic treatments</i> included art therapy (<a href="./references#CD012955-bbs2-0029" title="HaeyenS , Van HoorenS , HutschemaekersG . Efficacy of art therapy in individuals with personality disorders cluster B/C: a randomised controlled trial. International Journal of Psychology July 2016;51:60. [DOI: 10.1521/pedi_2017_31_312] [PMID: 28926306]HaeyenS , Van HoorenS , Van der VeldW , HutschemaekersG . Efficacy of art therapy in individuals with personality disorders cluster B/C: a randomised controlled trial. Journal of Personality Disorders2018;32(4):527-42. [DOI: 10.1521/pedi_2017_31_312] [PMID: 28926306]HaeyenS . Re: Cochrane Collaboration review of psychotherapies for BPD - your RCT of art therapy [personal communication]. Email to: J Stoffers-Winterling 18 August 2018. ">Haeyen 2018</a>), abandonment psychotherapy and intensive community treatment (<a href="./references#CD012955-bbs2-0002" title='AndreoliA , BurnandY , CochennecMF , MarieD , Di ClementeT , OhlendorfP . Psychoanalytic psychotherapy and venlafaxine among acutely suicidal borderline patients: a randomized clinical study. European Psychiatry2009;24(Suppl 1):S93. [DOI: 10.1016/S0924-9338(09)70326-8] [S18-03]AndreoliA , BurnandY , CochennecMF , OhlendorfP , FrambatiL , Gaudry-MaireD , et al. Disappointed love and suicide: a randomized controlled trial of "abandonment psychotherapy" among borderline patients. Journal of Personality Disorders2016;30(2):271-87. [DOI: 10.1521/pedi_2015_29_196] [PMID: 26111250]AndreoliA , BurnandY , FrambatiL , ManningD , FrancesA . Abandonment psychotherapy and psychosocial functioning among suicidal patients with borderline personality disorder: a 3-year naturalistic follow-up. Journal of Personality Disorders 2019 Feb 20 [Epub ahead of print]. [DOI: 10.1521/pedi_2019_33_423] [PMID: 30785852]AndreoliA . Re: your study in BPD - Cochrane Collaboration review [personal communication]. Email to: J Stoffers-Winterling 5 June 2018. '>Andreoli 2016</a>), a combination of individual SFT and group DBT (<a href="./references#CD012955-bbs2-0043" title="LeppänenV , HakkoH , SintonenH , LindemanS . Comparing effectiveness of treatments for borderline personality disorder in communal mental health care: the Oulu BPD study. Community Mental Health Journal2016;52(2):216-27. [DOI: 10.1007/s10597-015-9866-4] [PMID: 25824852]LeppänenV . Re: questions regarding the Oulu BPD study [personal communication]. Email to: E Faltinsen 20 December 2017. LeppänenV . Re: SV: question regarding the Oulu BPD study [personal communication]. Email to: EG Faltinsen 22 December 2017. ">Leppänen 2016</a>), combined inpatient and outpatient psychotherapy (<a href="./references#CD012955-bbs2-0003" title="AntonsenBT , JohansenMS , RøFG , KvarsteinEH , WilbergT . Is reflective functioning associated with clinical symptoms and long-term course in patients with personality disorders?Comprehensive Psychiatry2016;64:46-58. [DOI: 10.1016/j.comppsych.2015.05.016] [PMID: 26104432]AntonsenBT , KlungsøyrO , KampsA , HummelenB , JohansenMS , PedersenG , et al. Step-down versus outpatient psychotherapeutic treatment for personality disorders: 6-year follow-up of the Ullevål personality project. BMC Psychiatry2014;14:119. [DOI: 10.1186/1471-244X-14-119] [PMC4000615] [PMID: 24758722]AntonsenBT , KvarsteinEH , Urnes Ø, HummelenB , KarterudS , WilbergT . Favourable outcome of long-term combined psychotherapy for patients with borderline personality disorder: six-year follow-up of a randomized study. Psychotherapy Research2017;27(1):51-63. [DOI: 10.1080/10503307.2015.1072283] [PMID: 26261865]ArnevikE , WilbergT , Urnes Ø, JohansenM , MonsenJT , KarterudS . Psychotherapy for personality disorders: short-term day hospital psychotherapy versus outpatient individual therapy - a randomized controlled study. European Psychiatry2009;24(2):71-8. [DOI: 10.1016/j.eurpsy.2008.09.004] [PMID: 19097870]GullestadFS , JohansenMS , HøglendP , KarterudS , WilbergT . Mentalization as a moderator of treatment effects: findings from a randomized clinical trial for personality disorders. Psychotherapy Research2013;23(6):674-89. [DOI: 10.1080/10503307.2012.684103] [PMID: 22612470]GullestadFS . Re: questions regarding your trial on day hospital step-down program [personal communication]. Email to: E Faltinsen 4 December 2017. KvarsteinEH , ArnevikE , HalsteinliV , RøFG , KarterudS , WilbergT . Health service costs and clinical gains of psychotherapy for personality disorders: a randomized controlled trial of day-hospital-based step-down treatment versus outpatient treatment at a specialist practice. BMC Psychiatry2013;13:315. [DOI: 10.1186/1471-244X-13-315] [PMC4222503] [PMID: 24268099]">Antonsen 2017</a>), integrative BPD‐oriented adolescent family therapy (<a href="./references#CD012955-bbs2-0064" title="SantistebanDA , MenaMP , MuirJ , McCabeBE , AbaloC , CummingsAM . The efficacy of two adolescent substance abuse treatments and the impact of comorbid depression: results of a small randomized controlled trial. Psychiatric Rehabilitation Journal2015;38(1):55-64. [DOI: 10.1037/prj0000106] [PMC5021542] [PMID: 25799306]">Santisteban 2015</a>), joint crises plan (<a href="./references#CD012955-bbs2-0012" title="BorschmannR , BarrettB , HellierJM , ByfordS , HendersonC , RoseD , et al. Joint crisis plans for people with borderline personality disorder: feasibility and outcomes in a randomised controlled trial. British Journal of Psychiatry2013;202(5):357-64. [DOI: 10.1192/bjp.bp.112.117762] [PMID: 23637110]BorschmannR . Joint crisis plans for BPD - question on publication in British Journal of Psychiatry [pers communication]. Email to: J Stoffers-Winterling 22 August 2017. BorschmannR . RE: joint crisis plans for BPD - question on publication in British Journal of Psychiatry [personal communication]. Email to: J Stoffers-Winterling 22 August 2017. BorschmannR . The development and testing of joint crisis plans for people with borderline personality disorder: a feasibility study. ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.628499 (accessed 27 January 2019). HellierJ . RE: regarding your study on on MBT for eating disorders [personal communication]. Email to: E Faltinsen 27 March 2018. HellierJ . RE: regarding your study on on MBT for eating disorders [personal communication]. Email to: E Faltinsen 3 January 2018. HellierJ . SV: regarding your study on MBT for eating disorders [personal communication]. Email to: EG Faltinsen, P Robinson 27 March 2018. ISRCTN12440268. JOSHUA: a pilot randomised controlled trial of joint crisis plans for people who self harm. www.isrctn.com/ISRCTN12440268 (first received 17 September 2009). ">Borschmann 2013</a>), web‐based psychoeducation (<a href="./references#CD012955-bbs2-0075" title="ZanariniMC , ConkeyLC , TemesCM , FitzmauriceGM . Randomized controlled trial of web-based psychoeducation for women with borderline personality disorder. Journal of Clinical Psychiatry2018;79(3):16m11153. [DOI: 10.4088/JCP.16m11153] [PMC5764827] [PMID: 28703950]">Zanarini 2018</a>), and motivation feedback (<a href="./references#CD012955-bbs2-0032" title="JochemsEC , Van der Feltz-CornelisCM , Van DamA , DuivenvoordenHJ , MulderCL . The effects of motivation feedback in patients with severe mental illness: a cluster randomized controlled trial. Neuropsychiatric Disease and Treatment2015;11:3049-64. [DOI: 10.2147/NDT.S95190] [PMC4686323] [PMID: 26715847]JochemsEC . Cochrane Collaboration review on psychotherapies for borderline PD [personal communication]. Email to: EG Faltinsen 2 July 2018. JochemsEC . Re: Cochrane Collaboration review on psychotherapies for borderline PD [personal communication]. Email to: J Stoffers-Winterling 02 July 2018. ">Jochems 2015</a>). Eight trials investigated eclectic treatments.  </p> </section> <section id="CD012955-sec-0058"> <h6 class="title">Concomitant treatment</h6> <p>Medication use was not allowed in three trials (<a href="./references#CD012955-bbs2-0044" title="Lin T-J, Ko H-C, Wu JY-W, OeiTP , Lane H-Y, Chen C-H. The effectiveness of dialectical behavior therapy skills training group vs cognitive therapy group on reducing depression and suicide attempts for borderline personality disorder in Taiwan. Archives of Suicide Research2019;23(1):82-99. [DOI: 10.1080/13811118.2018.1436104] [PMID: 29528807]">Lin 2019</a>; <a href="./references#CD012955-bbs2-0053" title="MohamadizadehL , MakvandiB , PashaR , BakhtiarpourS , HafeziF . Comparing of the effect of dialectical behavior therapy (DBT) and schema therapy (ST) on reducing mood activity and suicidal thoughts in patients with borderline personality disorder. Acta Medica Mediterranea2017;33:1025-31. [DOI: 10.19193/0393-6384_2017_6_162] [www.actamedicamediterranea.com/archive/2017/medica-6/comparing-of-the-effect-of-dialectical-behavior-therapy-dbt-and-schema-therapy-st-on-reducing-mood-activity-and-suicidal-thoughts-in-patients-with-borderline-personality-disorder/pdf]">Mohamadizadeh 2017</a>; <a href="./references#CD012955-bbs2-0075" title="ZanariniMC , ConkeyLC , TemesCM , FitzmauriceGM . Randomized controlled trial of web-based psychoeducation for women with borderline personality disorder. Journal of Clinical Psychiatry2018;79(3):16m11153. [DOI: 10.4088/JCP.16m11153] [PMC5764827] [PMID: 28703950]">Zanarini 2018</a>). The majority of trials allowed participants to continue their respective drug treatments if initiated before the start of the trial (59 trials). Only four out of 75 RCTs gave the same medication to all participants (fluoxetine in the first three trials, selective serotonin reuptake inhibitors not further specified in the latter) (<a href="./references#CD012955-bbs2-0006" title="BellinoS , ParadisoE , ZizzaM , Di LorenzoR , BogettoF . Combined therapy with interpersonal psychotherapy of major depressed patients with borderline personality disorder: a comparison with pharmacotherapy [Terapia combinata con psicoterapia interpersonale di pazienti depressi maggiori con disturbo borderline di personalità: confronto con la farmacoterapia]. Journal of Psychopathology2005;11(1):34-42. [bit.ly/2rZUh5h]BellinoS , ZizzaM , RinaldiC , BogettoF . Combined treatment of major depression in patients with borderline personality disorder: a comparison with pharmacotherapy. Canadian Journal of Psychiatry2006;51(7):453-60. [DOI: 10.1177/070674370605100707] [PMID: 16838827]">Bellino 2006</a>; <a href="./references#CD012955-bbs2-0007" title="BellinoS , ZizzaM , RinaldiC , BogettoF . Combined therapy of major depression with concomitant borderline personality disorder: comparison of interpersonal and cognitive psychotherapy. Canadian Journal of Psychiatry2007;52(11):718-25. [DOI: 10.1177/070674370705201106] [PMID: 18399039]">Bellino 2007</a>; <a href="./references#CD012955-bbs2-0008" title="BellinoS , BozzatelloP , BogettoF . Combined treatment of borderline personality disorder with interpersonal psychotherapy and pharmacotherapy: predictors of response. Psychiatry Research2015;226(1):284-8. [DOI: 10.1016/j.psychres.2014.12.064] [isiarticles.com/bundles/Article/pre/pdf/34125.pdf]BellinoS , RinaldiC , BogettoF . Adaptation of interpersonal psychotherapy to borderline personality disorder: a comparison of combined therapy and single pharmacotherapy. Canadian Journal of Psychiatry2010;55(2):74-81. [DOI: 10.1177/070674371005500203] [PMID: 20181302]BellinoS . Question regarding your BPD trials for inclusion in Cochrane Collaboration review [personal communication]. Email to: J Stoffers-Winterling 19 December 2010. BellinoS . Re: question regarding your BPD trials [personal communication]. Email to: J Stoffers 16 December 2010. BozzatelloP , BellinoS . Combined therapy with interpersonal psychotherapy adapted for borderline personality disorder: a two-years follow-up. Psychiatry Research2016;240:151-6. [DOI: 10.1016/j.psychres.2016.04.014] [www.sciencedirect.com/science/article/pii/S0165178115302389]ZizzaM , FenocchioM , RinaldiC , BellinoS . Combined treatment of borderline personality disorder: a trial of modified interpersonal therapy. World Psychiatry2009;8(Suppl 1):234. ">Bellino 2010</a>; <a href="./references#CD012955-bbs2-0031" title="BrandS . AW: questions regarding your trial on emotional intelligence training for BPD [personal communication]. Email to: EG Faltinsen 28 November 2017. BrandS . Questions regarding your trial on emotional intelligence training for BPD [personal communication]. Email to: EG Faltinsen 28 November 2017. JahangardL , HaghighiM , BajoghliH , AhmadpanahM , GhaleihaA , ZarrabianMK , et al. Training emotional intelligence improves both emotional intelligence and depressive symptoms in inpatients with borderline personality disorder and depression. International Journal of Psychiatry in Clinical Practice2012;16(3):197-204. [DOI: 10.3109/13651501.2012.687454] [PMID: 22873719]">Jahangard 2012</a>). One trial, <a href="./references#CD012955-bbs2-0070" title="FertuckEA , KeilpJ , SongI , MorrisMC , WilsonST , BrodskyBS , et al. Higher executive control and visual memory performance predict treatment completion in borderline personality disorder. Psychotherapy and Psychosomatics2012;81(1):38-43. [DOI: 10.1159/000329700] [PMC3242704] [PMID: 22116411]NCT00533117. Treating suicidal behavior and self-mutilation in people with borderline personality disorder. www.clinicaltrials.gov/ct2/show/NCT00533117 (first received 19 September 2007). ">Stanley 2017</a>, included four treatment groups, which we integrated into two groups of DBT and supportive treatment. Fifty percent of each of these two groups additionally received either fluoxetine or placebo. Concomitant drug use was not specified in nine trials (<a href="./references#CD012955-bbs2-0009" title="BianchiniV , CofiniV , CurtoM , LagrotteriaB , ManziA , NavariS , et al. Dialectical behavior therapy (DBT) for forensic psychiatric patients: an Italian pilot study. Criminal Behavior and Mental Health2019;29(9):122-30. [DOI: 10.1002/cbm.2102] [PMID: 30648303]">Bianchini 2019</a>; <a href="./references#CD012955-bbs2-0015" title="CarterG . Question regarding your BPD trial [personal communication]. Email to: J Stoffers 21 December 2010. CarterGL , WillcoxCH , LewinTJ , ConradAM , BenditN . Hunter DBT project: randomized controlled trial of dialectical behaviour therapy in women with borderline personality disorder. Australian and New Zealand Journal of Psychiatry2010;44(2):162-73. [DOI: 10.3109/00048670903393621] [PMID: 20113305]">Carter 2010</a>; <a href="./references#CD012955-bbs2-0018" title="DavidsonKM , BrownTM , JamesV , KirkJ , RichardsonJ . Manual-assisted cognitive therapy for self-harm in personality disorder and substance misuse: a feasibility trial. Psychiatric Bulletin2014;38(3):108-11. [DOI: 10.1192/pb.bp.113.043109] [PMC4115373] [PMID: 25237519]DavidsonKM . Re: question regarding your trial on manual-assisted cognitive therapy [personal communication]. Email to: EG Faltinsen 28 November 2017. ">Davidson 2014</a>; <a href="./references#CD012955-bbs2-0029" title="HaeyenS , Van HoorenS , HutschemaekersG . Efficacy of art therapy in individuals with personality disorders cluster B/C: a randomised controlled trial. International Journal of Psychology July 2016;51:60. [DOI: 10.1521/pedi_2017_31_312] [PMID: 28926306]HaeyenS , Van HoorenS , Van der VeldW , HutschemaekersG . Efficacy of art therapy in individuals with personality disorders cluster B/C: a randomised controlled trial. Journal of Personality Disorders2018;32(4):527-42. [DOI: 10.1521/pedi_2017_31_312] [PMID: 28926306]HaeyenS . Re: Cochrane Collaboration review of psychotherapies for BPD - your RCT of art therapy [personal communication]. Email to: J Stoffers-Winterling 18 August 2018. ">Haeyen 2018</a>; <a href="./references#CD012955-bbs2-0034" title="KamalabadiMJ , AhmadiSA , EtemadiO , FatehizadehM , BahramiF , FiroozabadiA . A study of the effect of couple dialectical behavioral therapy on symptoms and quality of marital relationships and mental health of Iranian borderline personality couples: a controlled trial. Interdisciplinary Journal of Contemporary Research in Business2012;3(9):1480-7. [psycnet.apa.org/record/2012-22425-047]">Kamalabadi 2012</a>; <a href="./references#CD012955-bbs2-0043" title="LeppänenV , HakkoH , SintonenH , LindemanS . Comparing effectiveness of treatments for borderline personality disorder in communal mental health care: the Oulu BPD study. Community Mental Health Journal2016;52(2):216-27. [DOI: 10.1007/s10597-015-9866-4] [PMID: 25824852]LeppänenV . Re: questions regarding the Oulu BPD study [personal communication]. Email to: E Faltinsen 20 December 2017. LeppänenV . Re: SV: question regarding the Oulu BPD study [personal communication]. Email to: EG Faltinsen 22 December 2017. ">Leppänen 2016</a>; <a href="./references#CD012955-bbs2-0058" title="PhilipsB , WennebergP , KonradssonP , FranckJ . Mentalization-based treatment for concurrent borderline personality disorder and substance use disorder: a randomized controlled feasibility study. European Addiction Research2018;24(1):1-8. [DOI: 10.1159/000485564] [PMC5969093] [PMID: 294028]">Philips 2018</a>; <a href="./references#CD012955-bbs2-0061" title="ISRCTN51304415. Nice OUtcomes for Referrals with Impulsivity, Self Harm and Eating Disorders: the NOURISHED study [A randomised controlled trial of mentalisation based therapy against specialist supportive clinical management in patients with both eating disorders and symptoms of borderline personality disorder]. www.isrctn.com/ISRCTN51304415 (first received 31 January 2011). RobinsonP , BarrettB , BatemanA , HakeemA , HellierJ , LemonskyF , et al. Study protocol for a randomized controlled trial of mentalization based therapy against specialist supportive clinical management in patients with both eating disorders and symptoms of borderline personality disorder. BMC Psychiatry2014;14:51. [DOI: 10.1186/1471-244X-14-51] [PMC3996076] [PMID: 24555511]RobinsonP , HellierJ , BarrettB , BarzdaitieneD , BatemanA , BogaardtA , et al. The NOURISHED randomised controlled trial comparing mentalisation-based treatment for eating disorders (MBT-ED) with specialist supportive clinical management (SSCM-ED) for patients with eating disorders and symptoms of borderline personality disorder. Trials2016;17(1):549. [DOI: 10.1186/s13063-016-1606-8] [PMC5114835] [PMID: 27855714]">Robinson 2016</a>; <a href="./references#CD012955-bbs2-0064" title="SantistebanDA , MenaMP , MuirJ , McCabeBE , AbaloC , CummingsAM . The efficacy of two adolescent substance abuse treatments and the impact of comorbid depression: results of a small randomized controlled trial. Psychiatric Rehabilitation Journal2015;38(1):55-64. [DOI: 10.1037/prj0000106] [PMC5021542] [PMID: 25799306]">Santisteban 2015</a>). Two trials included medication‐free participants only (<a href="./references#CD012955-bbs2-0044" title="Lin T-J, Ko H-C, Wu JY-W, OeiTP , Lane H-Y, Chen C-H. The effectiveness of dialectical behavior therapy skills training group vs cognitive therapy group on reducing depression and suicide attempts for borderline personality disorder in Taiwan. Archives of Suicide Research2019;23(1):82-99. [DOI: 10.1080/13811118.2018.1436104] [PMID: 29528807]">Lin 2019</a>; <a href="./references#CD012955-bbs2-0053" title="MohamadizadehL , MakvandiB , PashaR , BakhtiarpourS , HafeziF . Comparing of the effect of dialectical behavior therapy (DBT) and schema therapy (ST) on reducing mood activity and suicidal thoughts in patients with borderline personality disorder. Acta Medica Mediterranea2017;33:1025-31. [DOI: 10.19193/0393-6384_2017_6_162] [www.actamedicamediterranea.com/archive/2017/medica-6/comparing-of-the-effect-of-dialectical-behavior-therapy-dbt-and-schema-therapy-st-on-reducing-mood-activity-and-suicidal-thoughts-in-patients-with-borderline-personality-disorder/pdf]">Mohamadizadeh 2017</a>; see <a href="#CD012955-tbl-0005">Table 2</a>). </p> </section> </section> <section id="CD012955-sec-0059"> <h5 class="title">Comparisons</h5> <p>The review includes 25 different comparisons.</p> <section id="CD012955-sec-0060"> <h6 class="title">Control interventions</h6> <p>The kinds of control interventions varied widely and included, for example, treatment‐as‐usual (TAU), waiting list, no treatment or an active treatment. The composition of the control interventions used in the individual trials differed as to whether TAU was obligatory or optional. </p> <p>The majority of trials (42 trials) included a control intervention with an obligatory TAU. Thirteen trials included a control intervention with optional TAU. See <a href="#CD012955-tbl-0005">Table 2</a>. </p> </section> <section id="CD012955-sec-0061"> <h6 class="title">Active treatment</h6> <p>Twenty‐two trials included an active head‐to‐head comparison.</p> <p> <ol id="CD012955-list-0013"> <li> <p><a href="./references#CD012955-bbs2-0003" title="AntonsenBT , JohansenMS , RøFG , KvarsteinEH , WilbergT . Is reflective functioning associated with clinical symptoms and long-term course in patients with personality disorders?Comprehensive Psychiatry2016;64:46-58. [DOI: 10.1016/j.comppsych.2015.05.016] [PMID: 26104432]AntonsenBT , KlungsøyrO , KampsA , HummelenB , JohansenMS , PedersenG , et al. Step-down versus outpatient psychotherapeutic treatment for personality disorders: 6-year follow-up of the Ullevål personality project. BMC Psychiatry2014;14:119. [DOI: 10.1186/1471-244X-14-119] [PMC4000615] [PMID: 24758722]AntonsenBT , KvarsteinEH , Urnes Ø, HummelenB , KarterudS , WilbergT . Favourable outcome of long-term combined psychotherapy for patients with borderline personality disorder: six-year follow-up of a randomized study. Psychotherapy Research2017;27(1):51-63. [DOI: 10.1080/10503307.2015.1072283] [PMID: 26261865]ArnevikE , WilbergT , Urnes Ø, JohansenM , MonsenJT , KarterudS . Psychotherapy for personality disorders: short-term day hospital psychotherapy versus outpatient individual therapy - a randomized controlled study. European Psychiatry2009;24(2):71-8. [DOI: 10.1016/j.eurpsy.2008.09.004] [PMID: 19097870]GullestadFS , JohansenMS , HøglendP , KarterudS , WilbergT . Mentalization as a moderator of treatment effects: findings from a randomized clinical trial for personality disorders. Psychotherapy Research2013;23(6):674-89. [DOI: 10.1080/10503307.2012.684103] [PMID: 22612470]GullestadFS . Re: questions regarding your trial on day hospital step-down program [personal communication]. Email to: E Faltinsen 4 December 2017. KvarsteinEH , ArnevikE , HalsteinliV , RøFG , KarterudS , WilbergT . Health service costs and clinical gains of psychotherapy for personality disorders: a randomized controlled trial of day-hospital-based step-down treatment versus outpatient treatment at a specialist practice. BMC Psychiatry2013;13:315. [DOI: 10.1186/1471-244X-13-315] [PMC4222503] [PMID: 24268099]">Antonsen 2017</a>: inpatient plus outpatient psychotherapy versus outpatient psychotherapy </p> </li> <li> <p><a href="./references#CD012955-bbs2-0007" title="BellinoS , ZizzaM , RinaldiC , BogettoF . Combined therapy of major depression with concomitant borderline personality disorder: comparison of interpersonal and cognitive psychotherapy. Canadian Journal of Psychiatry2007;52(11):718-25. [DOI: 10.1177/070674370705201106] [PMID: 18399039]">Bellino 2007</a>: cognitive therapy versus interpersonal therapy </p> </li> <li> <p><a href="./references#CD012955-bbs2-0014" title="Carmona i FarrésC , ElicesM , SolerJ , Domínguez-ClavéE , Pomarol-ClotetE , SalvadorR , et al. Effects of mindfulness training on borderline personality disorder: impulsivity versus emotional dysregulation. Mindfulness2019;10:1243-54. [DOI: 10.1007/s12671-018-1071-4]NCT03363230. Effects of mindfulness training on emotion regulation and impulsivity. www.clinicaltrials.gov/ct2/show/NCT03363230 (first received 30 November 2017). ">Carmona í Farrés 2019</a>: dialectical behaviour therapy <i>(</i>DBT) mindfulness versus DBT interpersonal effectiveness </p> </li> <li> <p><a href="./references#CD012955-bbs2-0016" title="CottrauxJ , NoteID , BoutitieF , MillieryM , GenouihlacV , YaoSN , et al. Cognitive therapy versus Rogerian supportive therapy in borderline personality disorder. Two-year follow-up of a controlled pilot study. Psychotherapy and Psychosomatics2009;78(5):307-16. [DOI: 10.1159/000229769] [PMID: 19628959]NCT00131781. Cognitive therapy versus supportive therapy in borderline personality disorder. www.clinicaltrials.gov/ct2/show/NCT00131781 (first received 18 August 2005). ">Cottraux 2009</a>: cognitive therapy versus client‐centred therapy (CCT) </p> </li> <li> <p><a href="./references#CD012955-bbs2-0020" title="ElicesM , PascualJC , PortellaMJ , Feliu-SolerA , Martín-BlancoA , CarmonaC , et al. Impact of mindfulness training on borderline personality disorder: a randomized trial. Mindfulness2016;7:584-95. [DOI: 10.1007/s12671-016-0492-1]NCT02397031. Mindfulness and interpersonal effectiveness skills in borderline personality disorder [Randomized, active-controlled, clinical trial comparing effects of mindfulness and interpersonal effectiveness skills in borderline personality disorder]. www.clinicaltrials.gov/ct2/show/NCT02397031 (first received 12 March 2015). SolerJ , ElicesM , PascualJC , Martín-BlancoA , Feliu-SolerA , CarmonaC , et al. Effects of mindfulness training on different components of impulsivity in borderline personality disorder: results from a pilot randomized study. Borderline Personality Disorder and Emotion Dysregulation2016;3:1. [DOI: 10.1186/s40479-015-0035-8] [PMC4709962] [PMID: 26759718]">Elices 2016</a>: DBT mindfulness versus DBT interpersonal effectiveness </p> </li> <li> <p><a href="./references#CD012955-bbs2-0023" title="Feliu-SolerA , PascualJC , ElicesM , Martín-BlancoA , CarmonaC , CebollaA , et al. Fostering self-compassion and loving-kindness in patients with borderline personality disorder: a randomized pilot study. Clinical Psychology &amp; Psychotherapy2017;24(1):278-86. [DOI: 10.1002/cpp.2000] [PMID: 26818533]">Feliu‐Soler 2017</a>: DBT mindfulness versus loving‐kindness and compassion meditation </p> </li> <li> <p><a href="./references#CD012955-bbs2-0024" title="ArntzA , Stupar-RutenfransS , BlooJ , Van DyckR , SpinhovenP . Prediction of treatment discontinuation and recovery from borderline personality disorder: results from an RCT comparing schema therapy and transference-focused psychotherapy. Behaviour Research and Therapy2015;74:60-71. [DOI: 10.1016/j.brat.2015.09.002] [PMID: 26432172]Giesen-BlooJ , ArntzA . Questions concerning the randomized trial of schema-focused therapy vs transference-focused psychotherapy—reply. Archives of General Psychiatry2007;64(5):610-1. [DOI: 10.1001/archpsyc.64.5.610]Giesen-BlooJ , Van DyckR , SpinhovenP , Van TilburgW , DirksenC , Van AsseltT , et al. Errors in table and figure in: outpatient psychotherapy for borderline personality disorder: randomized trial of schema-focused therapy vs transference-focused psychotherapy. Archives of General Psychiatry2006;63(9):1008. Erratum for: Archives of General Psychiatry 2006;63(6):649-58. [DOI: 10.1001/archpsyc.63.9.1008]Giesen-BlooJ , Van DyckR , SpinhovenP , Van TilburgW , DirksenC , Van AsseltT , et al. Outpatient psychotherapy for borderline personality disorder: randomized trial of schema-focused therapy vs transference-focused psychotherapy. Archives of General Psychiatry2006;63(6):649-58. [DOI: 10.1001/archpsyc.63.6.649] [PMID: 16754838]SpinhovenP , Giesen-BlooJ , Van DyckR , KooimanK , ArntzA . The therapeutic alliance in schema-focused therapy and transference-focused psychotherapy for borderline personality disorder. Journal of Consulting and Clinical Psychology2007;75(1):104-15. [DOI: 10.1037/0022-006X.75.1.104] [PMID: 17295569]Van AsseltADI , DirksenCD , ArntzA , Giesen-BlooJH , Van DyckR , SpinhovenP , et al. Out-patient psychotherapy for borderline personality disorder: cost-effectiveness of schema-focused therapy v transference-focused psychotherapy. British Journal of Psychiatry2008;192(6):450-7. [DOI: 10.1192/bjp.bp.106.033597] [PMID: 18515897]Van AsseltADI , DirksenCD , ArntzA , SeverensJL . Difficulties in calculating productivity costs: work disability associated with borderline personality disorder. Value in Health2008;11(4):637-44. [DOI: 10.1111/j.1524-4733.2007.00288.x]YeomansF . Questions concerning the randomized trial of schema-focused therapy vs transference-focused psychotherapy. Archives of General Psychiatry2007;64(5):609-10. [DOI: 10.1001/archpsyc.64.5.609-c] [PMID: 17485613]">Giesen‐Bloo 2006</a>: schema‐focused therapy (SFT) versus transference‐focused therapy </p> </li> <li> <p><a href="./references#CD012955-bbs2-0030" title="HarnedM . Re: SV: question regarding your trial on brief therapy for attempted suicide [personal communication]. Email to: EG Faltinsen 11 December 2018. HarnedMS , KorslundKE , LinehanMM . A pilot randomized controlled trial of dialectical behavior therapy with and without the dialectical behavior therapy prolonged exposure protocol for suicidal and self-injuring women with borderline personality disorder and PTSD. Behaviour Research and Therapy2014;55:7-17. [DOI: 10.1016/j.brat.2014.01.008] [PMC3987949] [PMID: 24562087]HarnedMS , WilksCR , SchmidtSC , CoyleTN . Improving functional outcomes in women with borderline personality disorder and PTSD by changing PTSD severity and post-traumatic cognitions. Behaviour Research and Therapy2018;103:53-61. [DOI: 10.1016/j.brat.2018.02.002] [PMC5837954] [PMID: 29448136]HarnedMS . RE: questions regarding your trial on brief therapy for attempted suicide [personal communication]. Email to: E Faltinsen 29 November 2017. ">Harned 2014</a>: standard DBT versus DBT prolonged exposure (PE) </p> </li> <li> <p><a href="./references#CD012955-bbs2-0036" title="KramerU , BergerT , KollyS , MarquetP , PreisigM , De RotenY , et al. Effects of motive-oriented therapeutic relationship in early-phase treatment of borderline personality disorder: a pilot study of a randomized trial. Journal of Nervous and Mental Disease2011;199(4):244-50. [DOI: 10.1097/NMD.0b013e3182125d19] [PMID: 21451348]KramerU , CasparF , DrapeauM . Change in biased thinking in a 10-session treatment for borderline personality disorder: further evidence of the motive-oriented therapeutic relationship. Psychotherapy Research2013;23(6):633-45. [DOI: 10.1080/10503307.2013.791404] [PMID: 23631622]">Kramer 2011</a> and <a href="./references#CD012955-bbs2-0037" title="BerthoudL , KramerU , CasparF , Pascual-LeoneA . Emotional processing in a ten-session general psychiatric treatment for borderline personality disorder: a case study. Personality and Mental Health2015;9(1):73-8. [DOI: 10.1002/pmh.1287] [PMID: 25711648]BerthoudL , Pascual-LeoneA , CasparF , TissotH , KellerS , RohdeKB , et al. Leaving distress behind: a randomized controlled study on change in emotional processing in borderline personality disorder. Psychiatry2017;80(2):139-54. [DOI: 10.1080/00332747.2016.1220230] [PMID: 28767333]KellerS , StelmaszczykK , KollyS , De RotenY , DesplandJN , CasparF , et al. Change in biased thinking in a treatment based on the motive-oriented therapeutic relationship for borderline personality disorder. Journal of Personality Disorders2018;32(Suppl):75-92. [DOI: 10.1521/pedi.2018.32.supp.75] [PMID: 29388899]KramerU , FlückigerC , KollyS , CasparF , MarquetP , DesplandJN , et al. Unpacking the effects of therapist responsiveness in borderline personality disorder: motive-oriented therapeutic relationship, patient in-session experience, and the therapeutic alliance. Psychotherapy and Psychosomatics2014;83(6):386-7. [DOI: 10.1159/000365400] [PMID: 25324025]KramerU , KellerS , CasparF , De RotenY , DesplandJN , KollyS . Early change in coping strategies in responsive treatments for borderline personality disorder: a mediation analysis. Journal of Consulting and Clinical Psychology2017;85(5):530-5. [DOI: 10.1037/ccp0000196] [PMID: 28425747]KramerU , KollyS , BerthoudL , KellerS , PreisigM , CasparF , et al. Effects of motive-oriented therapeutic relationship in a ten-session general psychiatric treatment of borderline personality disorder: a randomized controlled trial. Psychotherapy and Psychosomatics2014;83(3):176-86. [DOI: 10.1159/000358528] [PMID: 24752034]KramerU , StulzN , BerthoudL , CasparF , MarquetP , KollyS , et al. The shorter the better? A follow-up analysis of 10-session psychiatric treatment including the motive-oriented therapeutic relationship for borderline personality disorder. Psychotherapy Research2017;27(3):362-70. [DOI: 10.1080/10503307.2015.1110635] [PMID: 26684670]NCT01896024. Effects of motive-oriented therapeutic relationship in the early-phase treatment of borderline personality disorder (MOTR). www.clinicaltrials.gov/ct2/show/NCT01896024 (first received 5 July 2013). ">Kramer 2014</a>: motive‐oriented therapeutic relationship (MOTR) versus general psychiatric management (GPM) </p> </li> <li> <p><a href="./references#CD012955-bbs2-0040" title="KredlowMA , SzuhanyKL , LoS , XieH , GottliebJD , RosenbergSD , et al. Cognitive behavioral therapy for posttraumatic stress disorder in individuals with severe mental illness and borderline personality disorder. Psychiatry Research2017;249:86-93. [DOI: 10.1016/j.psychres.2016.12.045] [PMC5325773] [PMID: 28086181]MueserKT , GottliebJD , XieH , LuW , YanosPT , RosenbergSD , et al. Evaluation of cognitive restructuring for post-traumatic stress disorder in people with severe mental illness.. British Journal of Psychiatry2015;206(6):501-8. [DOI: 10.1192/bjp.bp.114.147926] [PMC4450219] [PMID: 25858178]MueserKT , RosenbergSD , XieH , JankowskiMK , BoltonEE , LuW , et al. A randomized controlled trial of cognitive-behavioral treatment for posttraumatic stress disorder in severe mental illness. Journal of Consulting and Clinical Psychology2008;76(2):259-71. [DOI: 10.1037/0022-006X.76.2.259] [PMC3916092] [PMID: 18377122]MueserKT . Re: question regarding your trial on CBT for PTSD participants [personal communication]. Email to: E Faltinsen 28 November 2018. ">Kredlow 2017b</a>: cognitive behavioural therapy <i>(</i>CBT) versus trauma‐related plus anxiety‐related psychoeducation </p> </li> <li> <p><a href="./references#CD012955-bbs2-0044" title="Lin T-J, Ko H-C, Wu JY-W, OeiTP , Lane H-Y, Chen C-H. The effectiveness of dialectical behavior therapy skills training group vs cognitive therapy group on reducing depression and suicide attempts for borderline personality disorder in Taiwan. Archives of Suicide Research2019;23(1):82-99. [DOI: 10.1080/13811118.2018.1436104] [PMID: 29528807]">Lin 2019</a>: DBT skills training versus cognitive therapy </p> </li> <li> <p><a href="./references#CD012955-bbs2-0048" title="LinehanMM , KorslundKE , HarnedMS , GallopRJ , LunguA , NeacsiuAD , et al. Dialectical behavior therapy for high suicide risk in individuals with borderline personality disorder: a randomized clinical trial and component analysis. JAMA Psychiatry2015;72(5):475-82 Erratum for: JAMA Psychiatry 2015; 72(9): 951. [DOI: 10.1001/jamapsychiatry.2014.3039] [PMID: 25806661]NCT00183651. Treatment of suicidal women with borderline personality disorder [Assessment and treatment of parasuicidal patients]. www.clinicaltrials.gov/ct2/show/NCT00183651 (first received 13 September 2005). ">Linehan 2015a</a>: standard DBT versus DBT skills plus case management versus DBT individual therapy plus activity </p> </li> <li> <p><a href="./references#CD012955-bbs2-0049" title="CaseBG . Letter to the editor on 'McMain SF, Links PS, Gnam WH, Guimond T, Cardish RJ, Korman L, et al. A randomized trial of dialectical behavior therapy versus general psychiatric management for borderline personality disorder. American Journal of Psychiatry 2009;166(12):1365-74. DOI: 10.1176/appi.ajp.2009.09010039'. American Journal of Psychiatry2010;167(4):475. [DOI: 10.1176/appi.ajp.2009.09101532] [PMID: 20360332 ]ISRCTN02634417. Hope for chronically suicidal patient: evaluating the clinical and health services impact of dialectical behaviour therapy (DBT) in individuals with borderline personality disorder [Evaluating the clinical and health services impact of dialectical behaviour therapy (DBT) in individuals with borderline personality disorder: a randomised controlled trial]. www.isrctn.com/ISRCTN02634417 (first received 16 November 2005). [DOI: 10.1186/ISRCTN02634417]McMainSF , FitzpatrickS , BoritzT , BarnhartR , LinksP , StreinerDL . Outcome trajectories and prognostic factors for suicide and self-harm behaviors in patients with borderline personaliy disorder following one year of outpatient psychotherapy. Journal of Personality Disorders2018;32(4):497-512. [DOI: 10.1521/pedi_2017_31_309] [PMID: 28910214]McMainSF , LinksPS , GnamWH , GuimondT , CardishRJ , KormanL , et al. A randomized trial of dialectical behavior therapy versus general psychiatric management for borderline personality disorder. American Journal of Psychiatry2009;166(12):1365-74. [DOI: 10.1176/appi.ajp.2009.09010039] [PMID: 19755574]McMainSF . Dr McMain replies to letter to the editor on 'McMain SF, Links PS, Gnam WH, Guimond T, Cardish RJ, Korman L, et al. A randomized trial of dialectical behavior therapy versus general psychiatric management for borderline personality disorder. American Journal of Psychiatry 2009;166(12):1365-74. DOI: 10.1176/appi.ajp.2009.09010039'. American Journal of Psychiatry2010;167(4):475-6. [DOI: 10.1176/appi.ajp.2009.09101532r)]NCT00154154. Hope for the chronically suicidal patient [Hope for the chronically suicidal patient: evaluating the clinical and health services impact of dialectical behaviour therapy in individuals with borderline personality disorder]. www.clinicaltrials.gov/ct2/show/NCT00154154 (first received 7 September 2005). ">McMain 2009</a>: DBT versus general psychiatric management (GPM) </p> </li> <li> <p><a href="./references#CD012955-bbs2-0053" title="MohamadizadehL , MakvandiB , PashaR , BakhtiarpourS , HafeziF . Comparing of the effect of dialectical behavior therapy (DBT) and schema therapy (ST) on reducing mood activity and suicidal thoughts in patients with borderline personality disorder. Acta Medica Mediterranea2017;33:1025-31. [DOI: 10.19193/0393-6384_2017_6_162] [www.actamedicamediterranea.com/archive/2017/medica-6/comparing-of-the-effect-of-dialectical-behavior-therapy-dbt-and-schema-therapy-st-on-reducing-mood-activity-and-suicidal-thoughts-in-patients-with-borderline-personality-disorder/pdf]">Mohamadizadeh 2017</a>: DBT versus SFT </p> </li> <li> <p><a href="./references#CD012955-bbs2-0054" title="MoreyLC , LowmasterSE , HopwoodCJ . A pilot study of manual-assisted cognitive therapy with a therapeutic assessment augmentation for borderline personality disorder. Psychiatry Research2010;178(3):531-5. [DOI: 10.1016/j.psychres.2010.04.055] [PMID: 20537722]">Morey 2010</a>: manual‐assisted cognitive therapy (MACT) versus MACT plus therapeutic assessment (TA) </p> </li> <li> <p><a href="./references#CD012955-bbs2-0056" title="NadortM , ArntzA , SmitJH , Giesen-BlooJ , EikelenboomJ , SpinhovenP , et al. Implementation of outpatient schema therapy for borderline personality disorder with versus without crisis support by the therapist outside office hours: a randomized trial. Behaviour Research and Therapy2009;47(11):961-73. [DOI: 10.1016/j.brat.2009.07.013] [PMID: 19698939]NadortM , ArntzA , SmitJH , Giesen-BlooJ , EikelenboomM , SpinhovenP , et al. Implementation of outpatient schema therapy for borderline personality disorder: study design. BMC Psychiatry2009;9:64. [DOI: 10.1186/1471-244X-9-64] [PMC2762959] [PMID: 19807925]NL1680 (NTR1781). Implementation of out-patient schema-focused therapy for borderline personality disorder in regular mental healthcare. www.trialregister.nl/trial/1680 (first received 29 April 2009). ">Nadort 2009</a>: SFT versus SFT plus therapist telephone crisis support outside office hours </p> </li> <li> <p><a href="./references#CD012955-bbs2-0057" title="NCT02033044. Cognitive rehabilitation versus psychoeducation in psychosocial functioning of borderline personality disorder [Randomized controlled trial comparing the effects on psychosocial functioning of cognitive rehabilitation versus psychoeducation in borderline personality disorder]. www.clinicaltrials.gov/ct2/show/NCT02033044 (first received 23 December 2013). PascualJC , PalomaresN , Ibáñez Á, PortellaMJ , ArzaR , ReyesR , et al. Efficacy of cognitive rehabilitation on psychosocial functioning in borderline personality disorder: a randomized controlled trial. BMC Psychiatry2015;15:255. [DOI: 10.1186/s12888-015-0640-5] [PMC4617906] [PMID: 26487284]">Pascual 2015</a>: pseudoeducation versus neurocognitive rehabilitation group </p> </li> <li> <p><a href="./references#CD012955-bbs2-0064" title="SantistebanDA , MenaMP , MuirJ , McCabeBE , AbaloC , CummingsAM . The efficacy of two adolescent substance abuse treatments and the impact of comorbid depression: results of a small randomized controlled trial. Psychiatric Rehabilitation Journal2015;38(1):55-64. [DOI: 10.1037/prj0000106] [PMC5021542] [PMID: 25799306]">Santisteban 2015</a>: BPD‐oriented adolescent family therapy versus individual drug counselling </p> </li> <li> <p><a href="./references#CD012955-bbs2-0065" title="SchillingL , MoritzS , KötherU , NagelM . Preliminary results on acceptance, feasibility, and subjective efficacy of the add-on group intervention metacognitive training for borderline patients. Journal of Cognitive Psychotherapy2015;29(2):153-64. [DOI: 10.1891/0889-8391.29.2.153]SchillingL , MoritzS , KristonL , KriegerM , NagelM . Efficacy of metacognitive training for patients with borderline personality disorder: preliminary results. Psychiatry Research2018;262:459-64. [DOI: 10.1016/j.psychres.2017.09.024] [PMID: 28927866]SchillingL . Re Schilling 2015/2018 - Cochrane Review of psychotherapies for BPD [personal communication] [Re Schilling 2015/2018 - Cochrane Review zur Psychotherapie bei BPS [persönliche Kommunikation]]. Email to: J Stoffers-Winterling 22 January 2019. ">Schilling 2018</a>: meta‐cognitive training for borderline personality disorder (B‐MCT) versus progressive muscle relaxation training (PMR) </p> </li> <li> <p><a href="./references#CD012955-bbs2-0067" title="NCT01904227. Intensified, inpatient adaptation of dialectical behavior therapy (DBT) (REDBT) [A randomized controlled study of the efficacy of an intensified, inpatient adaptation of dialectical behavior therapy (DBT) for a population of borderline patients (young adults/adults: 18-40), compared with standard outpatient DBT]. www.clinicaltrials.gov/ct2/show/NCT01904227 (first received 11 July 2013). SinnaeveR , Van den BoschLM , Van Steenbergen-WeijenburgKM . Change in interpersonal functioning during psychological interventions for borderline personality disorder — a systematic review of measures and efficacy. Personality and Mental Health2015;9(3):173-94. [DOI: 10.1002/pmh.1296] [PMID: 26058794]SinnaeveR , Van den BoschLMC , Hakkaart-van RoijenL , VansteelandtK . Effectiveness of step-down versus outpatient dialectical behaviour therapy for patients with severe levels of borderline personality disorder: a pragmatic randomized controlled trial. Borderline Personality Disorder and Emotion Dysregulation2018;5:12. [DOI: 10.1186/s40479-018-0089-5] [PMC6040072] [PMID: 30002832]SinnaeveR . Cochrane Collaboration review [personal communication]. Email to: J Stoffers-Winterling 11 June 2018. SinnaeveR . Re: BPDSI subscale data Sinnaeve et al (2018) [personal communication]. Email to: A Tadorovac 15 November 2018. SinnaeveR . RE: BPDSI subscale data Sinnaeve et al (2018) [personal communication] [RE: BPDSI subschale data Sinnaeve et al (2018) [personlig kommunikation]]. Email to: A Todorovac 15 November 2018. SinnaeveR . RE: BPDSI subscale data Sinnaeve et al (2018) [personal communication] [RE: BPDSI subschale data Sinnaeve et al (2018) [personlig kommunikation]]. Email to: A Todorovac 9 October 2018. Van den BoschLM , SinnaeveR , Hakkaart-van RoijenL , Van FurthEF . Efficacy and cost-effectiveness of an experimental short-term inpatient dialectical behavior therapy (DBT) program: study protocol for a randomized controlled trial. Trials2014;15:152. [DOI: 10.1186/1745-6215-15-152] [PMC4017823] [PMID: 24885551]Van RoijenLH , SinnaeveR , BouwmansC , Van Den BoschL . Cost-effectiveness and cost-utility of shortterm inpatient dialectical behavior therapy for chronically parasuicidal BPD (young) adults. Journal of Mental Health Policy and Economics2015;18(Suppl 1):S19-20. [www.icmpe.org/test1/journal/issues/v18s1toc.html]">Sinnaeve 2018</a>: standard DBT (outpatient) versus step‐down DBT (combined inpatient and outpatient DBT) </p> </li> <li> <p><a href="./references#CD012955-bbs2-0071" title="TurnerRM . Naturalistic evaluation of dialectical behavior therapy-oriented treatment for borderline personality disorder. Cognitive and Behavioral Practice2000;7(4):413-9. [DOI: 10.1016/S1077-7229(00)80052-8]">Turner 2000</a>: DBT versus CCT </p> </li> <li> <p><a href="./references#CD012955-bbs2-0038" title="KramerU , Pascual-LeoneA , BerthoudL , De RotenY , MarquetP , KollyS , et al. Assertive anger mediates effects of dialectical behaviour-informed skills training for borderline personality disorder: a randomized controlled trial. Clinical Psychology &amp; Psychotherapy2016;23(3):189-202. [DOI: 10.1002/cpp.1956] [PMID: 25864773]KramerU . The role of coping change in borderline personality disorder: a process-outcome analysis on dialectical-behaviour skills training. Clinical Psychology &amp; Psychotherapy2017;24(2):302-11. [DOI: 10.1002/cpp.2017] [PMID: 27098296]">Kramer 2016</a>: DBT informed and individual treatment versus TAU </p> </li> </ol> </p> </section> </section> <section id="CD012955-sec-0062"> <h5 class="title">Outcomes</h5> <p>When several measures were available for the same outcome, we chose the measure that was used most often, in order to reduce heterogeneity of outcomes in form and content. Outcomes could be either self‐reported by people treated or observer‐rated by clinicians, with clinician‐rated outcomes being preferred. We included outcomes reported at the end of treatment and at ≥ six months follow‐up. trials used a variety of scales to assess both primary and secondary outcomes. The table of outcomes in <a href="./appendices#CD012955-sec-0574">Appendix 4</a> presents the list of scales used to assess the outcomes in the individual trials. The list refers to the measurement scales described in the original reports. </p> <section id="CD012955-sec-0063"> <h6 class="title">Adverse effects</h6> <p>Data on adverse effects were available from five trials (<a href="./references#CD012955-bbs2-0002" title='AndreoliA , BurnandY , CochennecMF , MarieD , Di ClementeT , OhlendorfP . Psychoanalytic psychotherapy and venlafaxine among acutely suicidal borderline patients: a randomized clinical study. European Psychiatry2009;24(Suppl 1):S93. [DOI: 10.1016/S0924-9338(09)70326-8] [S18-03]AndreoliA , BurnandY , CochennecMF , OhlendorfP , FrambatiL , Gaudry-MaireD , et al. Disappointed love and suicide: a randomized controlled trial of "abandonment psychotherapy" among borderline patients. Journal of Personality Disorders2016;30(2):271-87. [DOI: 10.1521/pedi_2015_29_196] [PMID: 26111250]AndreoliA , BurnandY , FrambatiL , ManningD , FrancesA . Abandonment psychotherapy and psychosocial functioning among suicidal patients with borderline personality disorder: a 3-year naturalistic follow-up. Journal of Personality Disorders 2019 Feb 20 [Epub ahead of print]. [DOI: 10.1521/pedi_2019_33_423] [PMID: 30785852]AndreoliA . Re: your study in BPD - Cochrane Collaboration review [personal communication]. Email to: J Stoffers-Winterling 5 June 2018. '>Andreoli 2016</a>; <a href="./references#CD012955-bbs2-0018" title="DavidsonKM , BrownTM , JamesV , KirkJ , RichardsonJ . Manual-assisted cognitive therapy for self-harm in personality disorder and substance misuse: a feasibility trial. Psychiatric Bulletin2014;38(3):108-11. [DOI: 10.1192/pb.bp.113.043109] [PMC4115373] [PMID: 25237519]DavidsonKM . Re: question regarding your trial on manual-assisted cognitive therapy [personal communication]. Email to: EG Faltinsen 28 November 2017. ">Davidson 2014</a>; <a href="./references#CD012955-bbs2-0051" title="McMurranM , CrawfordMJ , ReillyJ , DelportJ , McCroneP , WhithamD , et al. Psychoeducation with problem-solving (PEPS) therapy for adults with personality disorder: a pragmatic randomised controlled trial to determine the clinical effectiveness and cost-effectiveness of a manualised intervention to improve social functioning. Health Technology Assessment2016;20(52):1-282. [DOI: 10.3310/hta20520]McMurranM . RE: Cochrane Collaboration review - PEPS study [personal communication]. Email to: J Stoffers-Winterling 5 July 2018. McMurranM . Request for data on BPD subjects in the PEPS rcp-study for use a new Cochrane review [personal communication]. Email to: M Kongerslev 7 March 2017. ">McMurran 2016</a>; <a href="./references#CD012955-bbs2-0061" title="ISRCTN51304415. Nice OUtcomes for Referrals with Impulsivity, Self Harm and Eating Disorders: the NOURISHED study [A randomised controlled trial of mentalisation based therapy against specialist supportive clinical management in patients with both eating disorders and symptoms of borderline personality disorder]. www.isrctn.com/ISRCTN51304415 (first received 31 January 2011). RobinsonP , BarrettB , BatemanA , HakeemA , HellierJ , LemonskyF , et al. Study protocol for a randomized controlled trial of mentalization based therapy against specialist supportive clinical management in patients with both eating disorders and symptoms of borderline personality disorder. BMC Psychiatry2014;14:51. [DOI: 10.1186/1471-244X-14-51] [PMC3996076] [PMID: 24555511]RobinsonP , HellierJ , BarrettB , BarzdaitieneD , BatemanA , BogaardtA , et al. The NOURISHED randomised controlled trial comparing mentalisation-based treatment for eating disorders (MBT-ED) with specialist supportive clinical management (SSCM-ED) for patients with eating disorders and symptoms of borderline personality disorder. Trials2016;17(1):549. [DOI: 10.1186/s13063-016-1606-8] [PMC5114835] [PMID: 27855714]">Robinson 2016</a>; <a href="./references#CD012955-bbs2-0070" title="FertuckEA , KeilpJ , SongI , MorrisMC , WilsonST , BrodskyBS , et al. Higher executive control and visual memory performance predict treatment completion in borderline personality disorder. Psychotherapy and Psychosomatics2012;81(1):38-43. [DOI: 10.1159/000329700] [PMC3242704] [PMID: 22116411]NCT00533117. Treating suicidal behavior and self-mutilation in people with borderline personality disorder. www.clinicaltrials.gov/ct2/show/NCT00533117 (first received 19 September 2007). ">Stanley 2017</a>). Two more trials reported to have recorded adverse effects, but we could not use the data for effect size calculation, either because the final results were not reported (<a href="./references#CD012955-bbs2-0057" title="NCT02033044. Cognitive rehabilitation versus psychoeducation in psychosocial functioning of borderline personality disorder [Randomized controlled trial comparing the effects on psychosocial functioning of cognitive rehabilitation versus psychoeducation in borderline personality disorder]. www.clinicaltrials.gov/ct2/show/NCT02033044 (first received 23 December 2013). PascualJC , PalomaresN , Ibáñez Á, PortellaMJ , ArzaR , ReyesR , et al. Efficacy of cognitive rehabilitation on psychosocial functioning in borderline personality disorder: a randomized controlled trial. BMC Psychiatry2015;15:255. [DOI: 10.1186/s12888-015-0640-5] [PMC4617906] [PMID: 26487284]">Pascual 2015</a>) or it was unclear in which treatment group the events occurred (<a href="./references#CD012955-bbs2-0042" title="LeichsenringF , MasuhrO , JaegerU , RabungS , DallyA , DümpelmannM , et al. Psychoanalytic-interactional therapy versus psychodynamic therapy by experts for personality disorders: a randomized controlled efficacy-effectiveness study in cluster B personality disorders. Psychotherapy and Psychosomatics2016;85(2):71-80. [DOI: 10.1159/000441731] [PMID: 26808580]">Leichsenring 2016</a>). Adverse effects were either recorded as and when people reported them, or the exact method of assessment was not specified.  </p> <p>We categorised adverse effects as serious (life‐threatening, resulting in death or requiring inpatient hospitalisation; available from <a href="./references#CD012955-bbs2-0002" title='AndreoliA , BurnandY , CochennecMF , MarieD , Di ClementeT , OhlendorfP . Psychoanalytic psychotherapy and venlafaxine among acutely suicidal borderline patients: a randomized clinical study. European Psychiatry2009;24(Suppl 1):S93. [DOI: 10.1016/S0924-9338(09)70326-8] [S18-03]AndreoliA , BurnandY , CochennecMF , OhlendorfP , FrambatiL , Gaudry-MaireD , et al. Disappointed love and suicide: a randomized controlled trial of "abandonment psychotherapy" among borderline patients. Journal of Personality Disorders2016;30(2):271-87. [DOI: 10.1521/pedi_2015_29_196] [PMID: 26111250]AndreoliA , BurnandY , FrambatiL , ManningD , FrancesA . Abandonment psychotherapy and psychosocial functioning among suicidal patients with borderline personality disorder: a 3-year naturalistic follow-up. Journal of Personality Disorders 2019 Feb 20 [Epub ahead of print]. [DOI: 10.1521/pedi_2019_33_423] [PMID: 30785852]AndreoliA . Re: your study in BPD - Cochrane Collaboration review [personal communication]. Email to: J Stoffers-Winterling 5 June 2018. '>Andreoli 2016</a>; <a href="./references#CD012955-bbs2-0018" title="DavidsonKM , BrownTM , JamesV , KirkJ , RichardsonJ . Manual-assisted cognitive therapy for self-harm in personality disorder and substance misuse: a feasibility trial. Psychiatric Bulletin2014;38(3):108-11. [DOI: 10.1192/pb.bp.113.043109] [PMC4115373] [PMID: 25237519]DavidsonKM . Re: question regarding your trial on manual-assisted cognitive therapy [personal communication]. Email to: EG Faltinsen 28 November 2017. ">Davidson 2014</a>; <a href="./references#CD012955-bbs2-0051" title="McMurranM , CrawfordMJ , ReillyJ , DelportJ , McCroneP , WhithamD , et al. Psychoeducation with problem-solving (PEPS) therapy for adults with personality disorder: a pragmatic randomised controlled trial to determine the clinical effectiveness and cost-effectiveness of a manualised intervention to improve social functioning. Health Technology Assessment2016;20(52):1-282. [DOI: 10.3310/hta20520]McMurranM . RE: Cochrane Collaboration review - PEPS study [personal communication]. Email to: J Stoffers-Winterling 5 July 2018. McMurranM . Request for data on BPD subjects in the PEPS rcp-study for use a new Cochrane review [personal communication]. Email to: M Kongerslev 7 March 2017. ">McMurran 2016</a>; <a href="./references#CD012955-bbs2-0061" title="ISRCTN51304415. Nice OUtcomes for Referrals with Impulsivity, Self Harm and Eating Disorders: the NOURISHED study [A randomised controlled trial of mentalisation based therapy against specialist supportive clinical management in patients with both eating disorders and symptoms of borderline personality disorder]. www.isrctn.com/ISRCTN51304415 (first received 31 January 2011). RobinsonP , BarrettB , BatemanA , HakeemA , HellierJ , LemonskyF , et al. Study protocol for a randomized controlled trial of mentalization based therapy against specialist supportive clinical management in patients with both eating disorders and symptoms of borderline personality disorder. BMC Psychiatry2014;14:51. [DOI: 10.1186/1471-244X-14-51] [PMC3996076] [PMID: 24555511]RobinsonP , HellierJ , BarrettB , BarzdaitieneD , BatemanA , BogaardtA , et al. The NOURISHED randomised controlled trial comparing mentalisation-based treatment for eating disorders (MBT-ED) with specialist supportive clinical management (SSCM-ED) for patients with eating disorders and symptoms of borderline personality disorder. Trials2016;17(1):549. [DOI: 10.1186/s13063-016-1606-8] [PMC5114835] [PMID: 27855714]">Robinson 2016</a>; <a href="./references#CD012955-bbs2-0070" title="FertuckEA , KeilpJ , SongI , MorrisMC , WilsonST , BrodskyBS , et al. Higher executive control and visual memory performance predict treatment completion in borderline personality disorder. Psychotherapy and Psychosomatics2012;81(1):38-43. [DOI: 10.1159/000329700] [PMC3242704] [PMID: 22116411]NCT00533117. Treating suicidal behavior and self-mutilation in people with borderline personality disorder. www.clinicaltrials.gov/ct2/show/NCT00533117 (first received 19 September 2007). ">Stanley 2017</a>) or non‐serious (any other adverse effects; available from <a href="./references#CD012955-bbs2-0051" title="McMurranM , CrawfordMJ , ReillyJ , DelportJ , McCroneP , WhithamD , et al. Psychoeducation with problem-solving (PEPS) therapy for adults with personality disorder: a pragmatic randomised controlled trial to determine the clinical effectiveness and cost-effectiveness of a manualised intervention to improve social functioning. Health Technology Assessment2016;20(52):1-282. [DOI: 10.3310/hta20520]McMurranM . RE: Cochrane Collaboration review - PEPS study [personal communication]. Email to: J Stoffers-Winterling 5 July 2018. McMurranM . Request for data on BPD subjects in the PEPS rcp-study for use a new Cochrane review [personal communication]. Email to: M Kongerslev 7 March 2017. ">McMurran 2016</a>; <a href="./references#CD012955-bbs2-0070" title="FertuckEA , KeilpJ , SongI , MorrisMC , WilsonST , BrodskyBS , et al. Higher executive control and visual memory performance predict treatment completion in borderline personality disorder. Psychotherapy and Psychosomatics2012;81(1):38-43. [DOI: 10.1159/000329700] [PMC3242704] [PMID: 22116411]NCT00533117. Treating suicidal behavior and self-mutilation in people with borderline personality disorder. www.clinicaltrials.gov/ct2/show/NCT00533117 (first received 19 September 2007). ">Stanley 2017</a>). </p> </section> </section> <section id="CD012955-sec-0064"> <h5 class="title">Funding source</h5> <p>The majority of trials (k = 62) were funded by grants from universities, authorities or research foundations (see <a href="#CD012955-tbl-0005">Table 2</a>). Four trials reported that no funding was received (<a href="./references#CD012955-bbs2-0006" title="BellinoS , ParadisoE , ZizzaM , Di LorenzoR , BogettoF . Combined therapy with interpersonal psychotherapy of major depressed patients with borderline personality disorder: a comparison with pharmacotherapy [Terapia combinata con psicoterapia interpersonale di pazienti depressi maggiori con disturbo borderline di personalità: confronto con la farmacoterapia]. Journal of Psychopathology2005;11(1):34-42. [bit.ly/2rZUh5h]BellinoS , ZizzaM , RinaldiC , BogettoF . Combined treatment of major depression in patients with borderline personality disorder: a comparison with pharmacotherapy. Canadian Journal of Psychiatry2006;51(7):453-60. [DOI: 10.1177/070674370605100707] [PMID: 16838827]">Bellino 2006</a>; <a href="./references#CD012955-bbs2-0007" title="BellinoS , ZizzaM , RinaldiC , BogettoF . Combined therapy of major depression with concomitant borderline personality disorder: comparison of interpersonal and cognitive psychotherapy. Canadian Journal of Psychiatry2007;52(11):718-25. [DOI: 10.1177/070674370705201106] [PMID: 18399039]">Bellino 2007</a>; <a href="./references#CD012955-bbs2-0008" title="BellinoS , BozzatelloP , BogettoF . Combined treatment of borderline personality disorder with interpersonal psychotherapy and pharmacotherapy: predictors of response. Psychiatry Research2015;226(1):284-8. [DOI: 10.1016/j.psychres.2014.12.064] [isiarticles.com/bundles/Article/pre/pdf/34125.pdf]BellinoS , RinaldiC , BogettoF . Adaptation of interpersonal psychotherapy to borderline personality disorder: a comparison of combined therapy and single pharmacotherapy. Canadian Journal of Psychiatry2010;55(2):74-81. [DOI: 10.1177/070674371005500203] [PMID: 20181302]BellinoS . Question regarding your BPD trials for inclusion in Cochrane Collaboration review [personal communication]. Email to: J Stoffers-Winterling 19 December 2010. BellinoS . Re: question regarding your BPD trials [personal communication]. Email to: J Stoffers 16 December 2010. BozzatelloP , BellinoS . Combined therapy with interpersonal psychotherapy adapted for borderline personality disorder: a two-years follow-up. Psychiatry Research2016;240:151-6. [DOI: 10.1016/j.psychres.2016.04.014] [www.sciencedirect.com/science/article/pii/S0165178115302389]ZizzaM , FenocchioM , RinaldiC , BellinoS . Combined treatment of borderline personality disorder: a trial of modified interpersonal therapy. World Psychiatry2009;8(Suppl 1):234. ">Bellino 2010</a>; <a href="./references#CD012955-bbs2-0031" title="BrandS . AW: questions regarding your trial on emotional intelligence training for BPD [personal communication]. Email to: EG Faltinsen 28 November 2017. BrandS . Questions regarding your trial on emotional intelligence training for BPD [personal communication]. Email to: EG Faltinsen 28 November 2017. JahangardL , HaghighiM , BajoghliH , AhmadpanahM , GhaleihaA , ZarrabianMK , et al. Training emotional intelligence improves both emotional intelligence and depressive symptoms in inpatients with borderline personality disorder and depression. International Journal of Psychiatry in Clinical Practice2012;16(3):197-204. [DOI: 10.3109/13651501.2012.687454] [PMID: 22873719]">Jahangard 2012</a>). The nine remaining trials did not specify funding (<a href="./references#CD012955-bbs2-0002" title='AndreoliA , BurnandY , CochennecMF , MarieD , Di ClementeT , OhlendorfP . Psychoanalytic psychotherapy and venlafaxine among acutely suicidal borderline patients: a randomized clinical study. European Psychiatry2009;24(Suppl 1):S93. [DOI: 10.1016/S0924-9338(09)70326-8] [S18-03]AndreoliA , BurnandY , CochennecMF , OhlendorfP , FrambatiL , Gaudry-MaireD , et al. Disappointed love and suicide: a randomized controlled trial of "abandonment psychotherapy" among borderline patients. Journal of Personality Disorders2016;30(2):271-87. [DOI: 10.1521/pedi_2015_29_196] [PMID: 26111250]AndreoliA , BurnandY , FrambatiL , ManningD , FrancesA . Abandonment psychotherapy and psychosocial functioning among suicidal patients with borderline personality disorder: a 3-year naturalistic follow-up. Journal of Personality Disorders 2019 Feb 20 [Epub ahead of print]. [DOI: 10.1521/pedi_2019_33_423] [PMID: 30785852]AndreoliA . Re: your study in BPD - Cochrane Collaboration review [personal communication]. Email to: J Stoffers-Winterling 5 June 2018. '>Andreoli 2016</a>; <a href="./references#CD012955-bbs2-0009" title="BianchiniV , CofiniV , CurtoM , LagrotteriaB , ManziA , NavariS , et al. Dialectical behavior therapy (DBT) for forensic psychiatric patients: an Italian pilot study. Criminal Behavior and Mental Health2019;29(9):122-30. [DOI: 10.1002/cbm.2102] [PMID: 30648303]">Bianchini 2019</a>; <a href="./references#CD012955-bbs2-0015" title="CarterG . Question regarding your BPD trial [personal communication]. Email to: J Stoffers 21 December 2010. CarterGL , WillcoxCH , LewinTJ , ConradAM , BenditN . Hunter DBT project: randomized controlled trial of dialectical behaviour therapy in women with borderline personality disorder. Australian and New Zealand Journal of Psychiatry2010;44(2):162-73. [DOI: 10.3109/00048670903393621] [PMID: 20113305]">Carter 2010</a>; <a href="./references#CD012955-bbs2-0034" title="KamalabadiMJ , AhmadiSA , EtemadiO , FatehizadehM , BahramiF , FiroozabadiA . A study of the effect of couple dialectical behavioral therapy on symptoms and quality of marital relationships and mental health of Iranian borderline personality couples: a controlled trial. Interdisciplinary Journal of Contemporary Research in Business2012;3(9):1480-7. [psycnet.apa.org/record/2012-22425-047]">Kamalabadi 2012</a>; <a href="./references#CD012955-bbs2-0035" title="KoonsCR , RobinsCJ , TweedJL , LynchTR , GonzalezAM , MorseJQ , et al. Efficacy of dialectical behavior therapy in women veterans with borderline personality disorder. Behavior Therapy2001;32(2):371-90. [DOI: 10.1016/S0005-7894(01)80009-5]">Koons 2001a</a>; <a href="./references#CD012955-bbs2-0043" title="LeppänenV , HakkoH , SintonenH , LindemanS . Comparing effectiveness of treatments for borderline personality disorder in communal mental health care: the Oulu BPD study. Community Mental Health Journal2016;52(2):216-27. [DOI: 10.1007/s10597-015-9866-4] [PMID: 25824852]LeppänenV . Re: questions regarding the Oulu BPD study [personal communication]. Email to: E Faltinsen 20 December 2017. LeppänenV . Re: SV: question regarding the Oulu BPD study [personal communication]. Email to: EG Faltinsen 22 December 2017. ">Leppänen 2016</a>; <a href="./references#CD012955-bbs2-0053" title="MohamadizadehL , MakvandiB , PashaR , BakhtiarpourS , HafeziF . Comparing of the effect of dialectical behavior therapy (DBT) and schema therapy (ST) on reducing mood activity and suicidal thoughts in patients with borderline personality disorder. Acta Medica Mediterranea2017;33:1025-31. [DOI: 10.19193/0393-6384_2017_6_162] [www.actamedicamediterranea.com/archive/2017/medica-6/comparing-of-the-effect-of-dialectical-behavior-therapy-dbt-and-schema-therapy-st-on-reducing-mood-activity-and-suicidal-thoughts-in-patients-with-borderline-personality-disorder/pdf]">Mohamadizadeh 2017</a>; <a href="./references#CD012955-bbs2-0055" title="MortonJ , SnowdonS , GopoldM , GuymerE . Acceptance and commitment therapy group treatment for symptoms of borderline personality disorder: a public sector pilot study. Cognitive and Behavioral Practice2012;19(4):527-44. [DOI: 10.1016/j.cbpra.2012.03.005]MortonJ . Re: SV: regarding your study on acceptance and commitment therapy for BPD [personal communication]. Email to: EG Faltinsen 22 December 2017. ">Morton 2012</a>; <a href="./references#CD012955-bbs2-0071" title="TurnerRM . Naturalistic evaluation of dialectical behavior therapy-oriented treatment for borderline personality disorder. Cognitive and Behavioral Practice2000;7(4):413-9. [DOI: 10.1016/S1077-7229(00)80052-8]">Turner 2000</a>). </p> </section> </section> <section id="CD012955-sec-0065"> <h4 class="title">Excluded studies</h4> <p>In total, we excluded 105 trials from 118 full‐text reports (see <a href="./references#CD012955-sec-0638" title="">Characteristics of excluded studies</a> tables). Of these, 70 trials included an ineligible patient population, 28 assessed ineligible interventions, 1 included an ineligible comparator, 2 had unclear numbers of participants with BPD included (we were unable to retrieve information), and 4 did not include any relevant outcomes (see <a href="#CD012955-fig-0001">Figure 1</a>). </p> <section id="CD012955-sec-0066"> <h5 class="title">Studies awaiting classification</h5> <p>We included 11 trials as awaiting classification, of which we were unable to retrieve four trials, two of the trials were conference abstracts, two of the trials need to be translated, and three trials did not provide subsample data for people affected by BPD (see <a href="./references#CD012955-sec-0639" title="">Characteristics of studies awaiting classification</a> tables for an elaborated description). All trials investigated different types of psychotherapeutic treatments for people affected by BPD or individuals with PTSD or suicidal behaviour. </p> <p>Three trials involved CBT treatments for BPD (<a href="./references#CD012955-bbs2-0181" title="AkbariJ , AghamohammadianHR , GhanbariBA . Effectiveness of CBT, pharmacotherapy and combined approach in improvement of symptoms depression anger in borderline personality disorder. Journal of Psychology2009;13(3):342-59. ">Akbari 2009</a>; <a href="./references#CD012955-bbs2-0183" title="DorrepaalE , ThomaesK , SmitJH , Van BalkomAJ , VeltmanDJ , HoogendoornAW , et al. Stabilizing group treatment for complex posttraumatic stress disorder related to child abuse based on psychoeducation and cognitive behavioural therapy: a multisite randomized controlled trial. Psychotherapy and Psychosomatics2012;81(4):217-25. [DOI: 10.1159/000335044] [PMID: 22585094]">Dorrepaal 2012</a>; <a href="./references#CD012955-bbs2-0187" title="JohnsonR . Cognitive Analytic Therapy (CAT) for Borderline Personality Disorder : Is CAT effective, and what influences the delivery of this therapy? [DClinPsy thesis]. Sheffield (UK): University of Sheffield, 2017. [WHITE ROSE ETHESES ONLINE: etheses.whiterose.ac.uk/18158/]">Johnson 2017</a>) and five trials involved DBT treatments (<a href="./references#CD012955-bbs2-0180" title="AbdelkarimA , Nagui RizkD , EsmaielM , HelalH . Social media group parallel to dialectical behavior therapy skills training group, the pros and cons. European Psychiatry2016;33 Suppl:S556. [DOI: 10.1016/j.eurpsy.2016.01.2054]">Abdelkarim 2016</a>; <a href="./references#CD012955-bbs2-0182" title="CowperthwaitCM . Outpatient Dialectical Behavior Therapy for Adolescents: Treatment Outcomes and Comparison of Treatment Effects in Two Skills Training Group Formats [PhD thesis]. Atlanta (GA): Emroy University, 2016. [EMORY UNIVERSITY: etd.library.emory.edu/concern/etds/0p0967135?locale=es]">Cowperthwait 2017</a>; <a href="./references#CD012955-bbs2-0188" title="McCauleyE , BerkMS , AsarnowJR , AdrianM , CohenJ , KorslundK , et al. Efficacy of dialectical behavior therapy for adolescents at high risk for suicide: a randomized clinical trial. JAMA Psychiatry2018;75(8):777-85. [DOI: 10.1001/jamapsychiatry.2018.1109] [PMCID: PMC6584278] [PMID: 29926087]NCT01528020. Collaborative adolescent research on emotions and suicide (CARES) [Treatment of suicidal and self-injurious adolescents with emotional dysregulation]. clinicaltrials.gov/ct2/show/NCT01528020 (first received 2 February 2012). ">McCauley 2018</a>; <a href="./references#CD012955-bbs2-0189" title="OstermeierR . Adapting Dialectic Behavioral Therapy Skills Group Based on the Severity Level of Borderline Personality Disorder [PsyD thesis). Eagan (MN): Minnesota School of Professional Psychology, 2014. ">Ostermeier 2017</a>; <a href="./references#CD012955-bbs2-0190" title="SantamarinaP , BlancoIM , PicadoM , FontE , MorenoE , MartínezE , et al. Dialectical behavior therapy versus supportive therapy for adolescents with suicidal behavior: a randomized controlled trial. Journal of the American Academy of Child and Adolescent Psychiatry2017;56(10 Suppl):S226-7. [DOI: 10.1016/j.jaac.2017.09.213] [POSTER NUMBER: 3.65]">Santamarina 2017</a>). One trial apiece investigated ACT (<a href="./references#CD012955-bbs2-0184" title="DucasseD , JaussentI , Arpon-BrandV , VienotM , LaglaouiC ,  BéziatS , et al. Acceptance and commitment therapy for the management of suicidal patients: a randomized controlled trial. Psychotherapy and Psychosomatics2018;87(4):211-22. [DOI: 10.1159/000488715] [PMID: 29874680]">Ducasse 2018</a>), MBT (<a href="./references#CD012955-bbs2-0185" title="EinyS , NarimaniM , AtadokhtA , BasharpoorS , FaribaSM . Effectiveness of mentalization based therapy and cognitive-analytical therapy on improved object relationship of people with borderline personality disorder: a comparison. Payesh2018;17(3):275-87. [SCIENTIFIC INFORMATION DATABASE: www.sid.ir/en/journal/ViewPaper.aspx?ID=576872]">Einy 2018</a>) and the STEPPS programme (<a href="./references#CD012955-bbs2-0186" title="IsaiaNC . Effective Therapeutic Components in Systems Training for Emotional Predictability and Problem Solving (STEPPS) for Borderline Personality Disorder [PhD thesis]. Guildford (UK): University of Surrey, 2017. [SURREY RESEARCH INSIGHT: epubs.surrey.ac.uk/842255/]">Isaia 2017</a>). </p> <p>Three trials involved adolescents (<a href="./references#CD012955-bbs2-0182" title="CowperthwaitCM . Outpatient Dialectical Behavior Therapy for Adolescents: Treatment Outcomes and Comparison of Treatment Effects in Two Skills Training Group Formats [PhD thesis]. Atlanta (GA): Emroy University, 2016. [EMORY UNIVERSITY: etd.library.emory.edu/concern/etds/0p0967135?locale=es]">Cowperthwait 2017</a>; <a href="./references#CD012955-bbs2-0188" title="McCauleyE , BerkMS , AsarnowJR , AdrianM , CohenJ , KorslundK , et al. Efficacy of dialectical behavior therapy for adolescents at high risk for suicide: a randomized clinical trial. JAMA Psychiatry2018;75(8):777-85. [DOI: 10.1001/jamapsychiatry.2018.1109] [PMCID: PMC6584278] [PMID: 29926087]NCT01528020. Collaborative adolescent research on emotions and suicide (CARES) [Treatment of suicidal and self-injurious adolescents with emotional dysregulation]. clinicaltrials.gov/ct2/show/NCT01528020 (first received 2 February 2012). ">McCauley 2018</a>; <a href="./references#CD012955-bbs2-0190" title="SantamarinaP , BlancoIM , PicadoM , FontE , MorenoE , MartínezE , et al. Dialectical behavior therapy versus supportive therapy for adolescents with suicidal behavior: a randomized controlled trial. Journal of the American Academy of Child and Adolescent Psychiatry2017;56(10 Suppl):S226-7. [DOI: 10.1016/j.jaac.2017.09.213] [POSTER NUMBER: 3.65]">Santamarina 2017</a>), whereas the rest involved adults. </p> </section> <section id="CD012955-sec-0067"> <h5 class="title">Ongoing studies</h5> <p>We included 33 ongoing trials assessing different types of psychological interventions for the treatment of BPD, for which the outcome data are not yet available (see <a href="./references#CD012955-sec-0640" title="">Characteristics of ongoing studies</a> tables). </p> <p>The majority of trials investigated the effect of CBT, DBT or related treatment for individuals with BPD displaying self‐harm or suicidal behaviour. More specifically, nine trials investigated DBT (<a href="./references#CD012955-bbs2-0193" title="ACTRN12612001187831. Exploring dialectical behaviour therapy vs conversational model in the treatment of borderline personality disorder: a randomised clinical trial [Randomised clinical trial of dialectical behaviour therapy compared to conversational model in the treatment of borderline personality disorder in reducing parasuicidal behaviour and depression]. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=363251 (first received 8 November 2012). ">ACTRN12612001187831</a>; <a href="./references#CD012955-bbs2-0194" title="ACTRN12616000236493. Effectiveness of dialectical behaviour therapy (DBT) group skills training for borderline personality disorder (BPD) in community mental health. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=370119 (first received 15 February 2016). ">ACTRN12616000236493</a>; <a href="./references#CD012955-bbs2-0204" title="NCT02134223. Methylation status of BDNF gene after dialectical behavior therapy in BPD [Changes in methylation status of BDNF gene after receiving dialectical behavior therapy in patients with borderline personality disorder]. clinicaltrials.gov/ct2/show/NCT02134223 (first received 6 May 2014). ">NCT02134223</a>; <a href="./references#CD012955-bbs2-0205" title="McMainSF , ChapmanAL , KuoJR , GuimondT , StreinerDL , Dixon-GordonKL , et al. The effectiveness of 6 versus 12 months of dialectical behaviour therapy for borderline personality disorder: the feasibility of a shorter treatment and evaluating responses (FASTER) trial protocol. BMC Psychiatry2018;18(1):230. [DOI: 10.1186/s12888-018-1802-z] [PMCID: PMC6050694] [PMID: 30016935]NCT02387736. DBT for chronically self-harming Individuals with BPD: evaluating the clinical &amp; cost effectiveness of a 6 mo. treatment (FASTER-DBT) [Dialectical behaviour therapy for chronically self-harming individuals with BPD: evaluating the clinical and cost effectiveness of a 6-month treatment]. clinicaltrials.gov/ct2/show/NCT02387736 (first received 20 February 2015). ">NCT02387736</a>; <a href="./references#CD012955-bbs2-0206" title="NCT02517723. Narrative exposure therapy in women with borderline personality disorder and posttraumatic stress disorder [A randomized controlled clinical trial (RCCT) to test the effectiveness of narrative exposure therapy (NET) versus dialectical-behavioral therapy in reducing trauma related symptoms in women suffering from borderline personality disorder (BPD) and posttraumatic stress disorder (PTSD)]. clinicaltrials.gov/ct2/show/NCT02517723 (first received 6 January 2014). SteuweC , RullkötterN , ErtlV , BergM , NeunerF , BebloT , et al. Effectiveness and feasibility of narrative exposure therapy (NET) in patients with borderline personality disorder and posttraumatic stress disorder – a pilot study. BMC Psychiatry2016;16:254. [DOI: 10.1186/s12888-016-0969-4] [PMCID: PMC4955150] [PMID: 27439618]">NCT02517723</a>; <a href="./references#CD012955-bbs2-0210" title="NCT02991586. Effectiveness study of a dialectical behavioral treatment for families of adolescents with emotional instability (FAL). clinicaltrials.gov/show/nct02991586 (first received 10 June 2016). ">NCT02991586</a>; <a href="./references#CD012955-bbs2-0214" title="NCT03191565. Using smartphones for self-monitoring of skill-use in dialectical behavior therapy (mDIARY) [The mDIARY study: using smartphones for daily self-monitoring of skill use and outcome in dialectical behavior therapy with borderline personality disorder: a combined RCT and time series study]. clinicaltrials.gov/ct2/show/NCT03191565 (first received 24 March 2017). ">NCT03191565</a>; <a href="./references#CD012955-bbs2-0215" title="NCT03297840. Change in mindfulness in borderline personality disorder [Change in mindfulness in borderline personality disorder after dialectic-behavioural therapy (DBT): a pre-post-comparison]. clinicaltrials.gov/ct2/show/NCT03297840 (first received 9 May 2017). ">NCT03297840</a>; <a href="./references#CD012955-bbs2-0219" title="NCT03833453. Effectiveness of PTSD-treatment compared to integrated PTSD-PD-treatment in adult patients with comorbid PTSD and BPD [Prediction and outcome study in PTSD and (borderline) personality disorders]. clinicaltrials.gov/ct2/show/NCT03833453 (first received 24 January 2019). ">NCT03833453</a>), five trials investigated MBT (<a href="./references#CD012955-bbs2-0192" title="ACTRN12612000951853. A clinical trial of mentalization based therapy treatment for borderline personality disorder [Outcome effects of a mentalization based treatment service (Mindsight) for people with borderline personality disorder in urban Christchurch: a clinical trial and evaluative study]. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=362981 (first received 4 September 2012). ">ACTRN12612000951853</a>; <a href="./references#CD012955-bbs2-0201" title="BeckE , BoS , GondanM , PoulsenS , PedersenL , PedersenJ , et al. Mentalization-based treatment in groups for adolescents with borderline personality disorder (BPD) or subthreshold BPD versus treatment as usual (M-GAB): study protocol for a randomized controlled trial. Trials2016;17(1):314. [DOI: 10.1186/s13063-016-1431-0] [PMCID: PMC4942923] [PMID: 27405522]NCT02068326. MBT in groups for adolescents with BPD or subthreshold BPD versus TAU - the M-GAB randomized controlled trial (M-GAB) [Mentalization-based treatment in groups for adolescents with borderline personality disorder (BPD) or subthreshold BPD versus treatment as usual - the M-GAB randomized controlled trial]. clinicaltrials.gov/ct2/show/NCT02068326 (first received 19 February 2014). ">NCT02068326</a>; <a href="./references#CD012955-bbs2-0208" title="NCT02771691. Mentalization-based group therapy for adolescents [Efficacy of mentalization-based group therapy for adolescents: a pilot randomised controlled trial]. clinicaltrials.gov/show/nct02771691 (first received 25 April 2016). ">NCT02771691</a>; <a href="./references#CD012955-bbs2-0218" title="NCT03677037. The short-term MBT project (MBT-RCT) [Short-term versus long-term mentalization-based therapy for outpatients with subthreshold or diagnosed borderline personality disorder: a randomized clinical trial]. clinicaltrials.gov/ct2/show/NCT03677037 (first received 14 September 2018). ">NCT03677037</a>; <a href="./references#CD012955-bbs2-0221" title="LaurenssenEM , SmitsML , BalesDL , FeenstraDJ , EerenHV , NoomMJ , et al. Day hospital mentalization-based treatment versus intensive outpatient mentalization-based treatment for patients with severe borderline personality disorder: protocol of a multicentre randomized clinical trial. BMC Psychiatry2014;14:301. [DOI: 10.1186/s12888-014-0301-0] [PMCID: PMC4240895] [PMID: 25403144]NL2168/NTR2292. Dosage-trial mentalisation-based treatment (MBT): intensive outpatient MBT versus day hospital MBT [Intensive outpatient mentalisation-based treatment versus day hospital mentalisation-based treatment: a randomised controlled trial]. www.trialregister.nl/trial/2168 (first received 16 April 2010). ">NL2168/NTR2292</a>), three trials investigated cognitive behavioural treatments (<a href="./references#CD012955-bbs2-0195" title="DRKS00003605. Short term therapy in adolescents with self-destructive and risk-taking behaviours. www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&amp;TRIAL_ID=DRKS00003605 (first received 10 July 2012). FischerG , BrunnerR , ParzerP , ReschF , KaessM . Short-term psychotherapeutic treatment in adolescents engaging in non-suicidal self-injury: a randomized controlled trial. Trials2013;14:294. [DOI: 10.1186/1745-6215-14-294] [PMCID:: PMC3848593] [PMID: 24034810]">DRKS00003605</a>; <a href="./references#CD012955-bbs2-0197" title="ISRCTN21802136. Coping with unusual experiences for 12-18 (CUES+) [Coping with unusual experiences for 12-18 year olds (CUES+): a transdiagnostic randomised controlled trial of the effectiveness of cognitive therapy in reducing distress associated with unusual experiences in adolescent mental health services]. www.isrctn.com/ISRCTN21802136 (first received 8 January 2015). JolleyS , BrowningS , CorrigallR , LaurensKR , HirschC , BracegirdleK , et al. Coping with unusual experiences for 12-18 year olds (CUES+): a transdiagnostic randomised controlled trial of the effectiveness of cognitive therapy in reducing distress associated with unusual experiences in adolescent mental health services: study protocol for a randomised controlled trial. Trials2017;18(1):586. [DOI: 10.1186/s13063-017-2326-4] [PMCID: PMC5716372] [PMID: 29202862]">ISRCTN21802136</a>; <a href="./references#CD012955-bbs2-0199" title="NCT01531634. Promoting recovery processes in women with borderline personality disorder using a dynamic cognitive intervention. clinicaltrials.gov/ct2/show/NCT01531634 (first received 3 February 2012). ">NCT01531634</a>), three trials investigated SFT (<a href="./references#CD012955-bbs2-0196" title="DRKS00011534. PRO*BPD: effectiveness of outpatient treatment programmes for borderline personality disorder: a comparison of schema therapy and dialectical behaviour therapy. www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&amp;TRIAL_ID=DRKS00011534 (first received 11 January 2017). Fassbinder E, AssmannN , SchaichA , HeineckeK , WagnerT , SiposV , et al. PRO*BPD: effectiveness of outpatient treatment programs for borderline personality disorder: a comparison of schema therapy and dialectical behavior therapy: study protocol for a randomized trial. BMC Psychiatry2018;18(1):341. [DOI: 10.1186/s12888-018-1905-6] [PMCID: PMC6194626] [PMID: 30340474]">DRKS00011534</a>; <a href="./references#CD012955-bbs2-0220" title="NL1144/NTR1186. SFT for forensic PD patients [Efficacy of schema-focused therapy versus usual treatment in forensic patients with personality disorders: a three-year randomized clinical trial]. www.trialregister.nl/trial/1144 (first received 16 January 2008). ">NL1144/NTR1186</a>; <a href="./references#CD012955-bbs2-0222" title="NL2266/NTR2392. Group schema therapy for borderline personality disorder [Multi-site RCT of group schema therapy for borderline personality disorder]. www.trialregister.nl/trial/2266 (first received 25 June 2010). WetzelaerP , FarrellJ , EversSM , JacobGA , LeeCW , BrandO , et al. Design of an international multicentre RCT on group schema therapy for borderline personality disorder. BMC Psychiatry2014;14:319. [DOI: 10.1186/s12888-014-0319-3]">NL2266/NTR2392</a>), two trials investigated STEPPS programmes (<a href="./references#CD012955-bbs2-0212" title="NCT03092271. Randomized trial of stepped care for suicide prevention in teens and young adults (Step2Health) [Randomized trial of stepped care for suicide prevention in teens and young adults]. clinicaltrials.gov/ct2/show/NCT03092271 (first received 21 March 2017). ">NCT03092271</a>; <a href="./references#CD012955-bbs2-0223" title="NL3856/NTR4016. The addition of STEPPS in the treatment of patients with bipolar disorder and comorbid borderline personality features: a randomized controlled trial [Toetsing van een geïntegreerd behandelprotocol voor patiënten met een bipolaire stoornis en een comorbide borderline persoonlijkheidskenmerken. Een randomized clinical trial]. www.trialregister.nl/trial/3856 (first received 28 May 2013). RiemannG , WeisscherN , GoossensPJJ , DraijerN , Apenhorst-HolM , KupkaRW . The addition of STEPPS in the treatment of patients with bipolar disorder and comorbid borderline personality features: a protocol for a randomized controlled trial. BMC Psychiatry2014;14:172. [DOI: 10.1186/1471-244X-14-172] [PMCID: PMC4065586] [PMID: 24912456]">NL3856/NTR4016</a>), two trials investigated self‐help or psychoeducation interventions (<a href="./references#CD012955-bbs2-0213" title="NCT03185026. Psychoeducation for suicidal behavior (PEPSUI) [Effectiveness of the first French psychoeducational program for suicidal behavior: a randomized controlled trial]. clinicaltrials.gov/ct2/show/NCT03185026 (first received 11 May 2017). ">NCT03185026</a>; <a href="./references#CD012955-bbs2-0216" title="NCT03376113. The effect of a brief psychological intervention on reducing self-harm repetition: feasibility study. clinicaltrials.gov/ct2/show/NCT03376113 (first received 2 November 2017). ">NCT03376113</a>), one investigated a meditation‐based treatment (<a href="./references#CD012955-bbs2-0202" title="NCT02125942. Central meditation and imagery therapy for augmentation of borderline personality disorder treatment [Pilot study of central meditation and imagery therapy for borderline personality disorder]. clinicaltrials.gov/ct2/show/NCT02125942 (first received 26 April 2014). ">NCT02125942</a>), one investigated internet‐based treatment (<a href="./references#CD012955-bbs2-0217" title="KleinJP , HauerA , BergerT , FassbinderE , SchweigerU , JacobG . Protocol for the REVISIT-BPD trial, a randomized controlled trial testing the effectiveness of an internet-based self-management intervention in the treatment of borderline personality disorder (BPD). Frontiers in Psychiatry2018;9:439. [DOI: 10.3389/fpsyt.2018.00439] [PMCID: PMC6160537] [PMID: 3029802]NCT03418142. Evaluating an internet-based self-management intervention for borderline (REVISIT) [Research evaluating the effectiveness of adding an internet-based self-management intervention to usual care in the treatment of borderline personality disorder - REVISIT BPD]. clinicaltrials.gov/ct2/show/NCT03418142 (first received 23 January 2018). ">NCT03418142</a>), and one an emotional regulation treatment (<a href="./references#CD012955-bbs2-0211" title="Hurtado-SantiagoS , Guzmán-ParraJ ,  BersabéRM , MayoralF . Effectiveness of iconic therapy for the reduction of borderline personality disorder symptoms among suicidal youth: study protocol for a randomised controlled trial. BMC Psychiatry2018;18(1):277. [DOI: 10.1186/s12888-018-1857-x] [PMCID: PMC6122595] [PMID: 30176878]NCT03011190. Effectiveness of the iconic therapy for borderline personality disorder symptoms [Effectiveness of the iconic therapy in youth with suicidal ideation/self-injuring behavior and borderline personality traits: study protocol for a randomized controlled trial]. clinicaltrials.gov/ct2/show/NCT03011190 (first received 28 December 2016). ">NCT03011190</a>). Five trials investigated other interventions like early interventions and general care (<a href="./references#CD012955-bbs2-0191" title="ACTRN12610000100099. A randomised controlled trial of three forms of psychosocial early intervention for borderline personality disorder in youth [MOBY: a randomised controlled trial of specialised early intervention with individual Cognitive Analytic Therapy, specialised early intervention without individual psychotherapy, and standard youth mental health care for first-presentation borderline personality disorder in youth]. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12610000100099 (first received 21 December 2009). ChanenA , JacksonH , CottonS , GleesonJ , DaveyC , BettsJ , et al. Comparing three forms of early intervention for youth with borderline personality disorder (the MOBY study). Early Intervention in Psychiatry2018;12(Supp 1):201. [POSTER NUMBER: C30]ChanenA , JacksonH , CottonSM , GleesonJ , DaveyCG , BettsJ , et al. Comparing three forms of early intervention for youth with borderline personality disorder (the MOBY study): study protocol for a randomised controlled trial. Trials2015;16:476. [DOI: 10.1186/s13063-015-1001-x] [PMCID: PMC4618920] [PMID: 26489661]">ACTRN12610000100099</a>; <a href="./references#CD012955-bbs2-0198" title="NCT00603421. Effectiveness of a 24 hour phone line on the rate of suicide attempts in borderline patients. clinicaltrials.gov/ct2/show/NCT00603421 (first received 16 January 2008). ">NCT00603421</a>; <a href="./references#CD012955-bbs2-0200" title="AgyapongV , BehreT , JuhasM , GreenshawA . Preventing self-harm and reducing suicidal ideation through an expedited regular supportive psychotherapy and assertive case management-protocol for a three-arm partial randomised controlled trial. European Psychiatry2016;33 Suppl:S440. [DOI: 10.1016/j.eurpsy.2016.01.1599]NCT01823120. Text message intervention to reduce repeat self-harm [Text message intervention to reduce repeat self-harm in patients presenting to the emergency department]. clinicaltrials.gov/ct2/show/NCT01823120 (first received 26 March 2013). ">NCT01823120</a>; <a href="./references#CD012955-bbs2-0207" title="NCT02685943. A randomized trial for suicidal patients [Collaborative assessment and management of suicidality (CAMS) in comparison to treatment as usual (TAU) for suicidal patients: a randomized controlled trial]. clinicaltrials.gov/ct2/show/NCT02685943 (first received 8 February 2016). RybergW , FossseR , ZahlPH , BorsonI ,  MøllerP ,  LandrøNI ,  et al. Collaborative assessment and management of suicidality (CAMS) compared to treatment as usual (TAU) for suicidal patients: study protocol for a randomized controlled trial. Trials2016;17(1):481. [DOI: 10.1186/s13063-016-1602-z] [PMCID: PMC5048411] [PMID: 27716298]">NCT02685943</a>; <a href="./references#CD012955-bbs2-0209" title="LiljedahlSI , HellemanM , DaukantaitéD , WestrinA , WestlingS . A standardized crisis management model for self-harming and suicidal individuals with three or more diagnostic criteria of borderline personality disorder: the Brief Admission Skane randomized controlled trial protocol (BASRCT). BMC Psychiatry2017;17(1):220. [DOI: 10.1186/s12888-017-1371-6] [PMCID: PMC5472925] [PMID: 28619050]NCT02985047. Brief Admission Skane: replacing general admission for individuals with self-harm and acute risk of suicide (BAS) [Brief Admission Skane: can brief admission replace general admission for individuals with self-harm and acute risk of suicide]. clinicaltrials.gov/ct2/show/NCT02985047 (first received 25 November 2016). ">NCT02985047</a>). </p> <p>One trial investigated adolescents (<a href="./references#CD012955-bbs2-0208" title="NCT02771691. Mentalization-based group therapy for adolescents [Efficacy of mentalization-based group therapy for adolescents: a pilot randomised controlled trial]. clinicaltrials.gov/show/nct02771691 (first received 25 April 2016). ">NCT02771691</a>) whereas the other trials investigated adults. </p> </section> </section> </section> <section id="CD012955-sec-0068"> <h3 class="title">Risk of bias in included studies</h3> <p><a href="#CD012955-fig-0002">Figure 2</a> and <a href="#CD012955-fig-0003">Figure 3</a> shows the review authors´ judgements concerning the risk of bias across the included trials and for each individual trial, respectively. Further information for the individual trials can be found in <a href="./references#CD012955-sec-0637" title="">Characteristics of included studies</a> tables. </p> <div class="figure" id="CD012955-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD012955-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD012955-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD012955-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD012955-sec-0069"> <h4 class="title">Allocation</h4> <section id="CD012955-sec-0070"> <h5 class="title">Sequence generation</h5> <p>There is evidence that poor reporting of randomisation increases the odds of presenting significant outcomes (<a href="./references#CD012955-bbs2-0264" title="ChalmersTC , CelanoP , SacksHS , Smith H Jr. Bias in treatment assignment in controlled clinical trials. New England Journal of Medicine1983;309(22):1358-61. [DOI: 10.1056/NEJM198312013092204] [PMID: 6633598]">Chalmers 1983</a>; <a href="./references#CD012955-bbs2-0391" title="SchulzKF , ChalmersI , HayesRJ , AltmanDG . Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA1995;273(5):408-12. [PMID: 7823387]">Schulz 1995</a>). The trials provided further information on how the randomisation sequence had been achieved, or that a stratification was used. We judged 56 trials, where a randomisation method was reported, as having low risk of bias (<a href="./references#CD012955-bbs2-0001" title="AmiantoF , FerreroA , PieròA , CairoE , RoccaG , SimonelliB , et al. Supervised team management, with or without structured psychotherapy, in heavy users of a mental health service with borderline personality disorder: a two-year follow-up preliminary randomized study. BMC Psychiatry2011;11:181. [DOI: 10.1186/1471-244X-11-181] [PMC3260092 ] [PMID: 22103890]NCT01356069. Efficacy of time-limited psychodynamic psychotherapy and informed clinical management in BPD high MHS users (HUMSH) [Sequential brief Adlerian psychodynamic psychotherapy in heavy users of a mental health service with borderline personality disorder: a two years follow-up preliminary randomized study]. clinicaltrials.gov/ct2/show/NCT01356069 (first received 16 May 2011). ">Amianto 2011</a>; <a href="./references#CD012955-bbs2-0002" title='AndreoliA , BurnandY , CochennecMF , MarieD , Di ClementeT , OhlendorfP . Psychoanalytic psychotherapy and venlafaxine among acutely suicidal borderline patients: a randomized clinical study. European Psychiatry2009;24(Suppl 1):S93. [DOI: 10.1016/S0924-9338(09)70326-8] [S18-03]AndreoliA , BurnandY , CochennecMF , OhlendorfP , FrambatiL , Gaudry-MaireD , et al. Disappointed love and suicide: a randomized controlled trial of "abandonment psychotherapy" among borderline patients. Journal of Personality Disorders2016;30(2):271-87. [DOI: 10.1521/pedi_2015_29_196] [PMID: 26111250]AndreoliA , BurnandY , FrambatiL , ManningD , FrancesA . Abandonment psychotherapy and psychosocial functioning among suicidal patients with borderline personality disorder: a 3-year naturalistic follow-up. Journal of Personality Disorders 2019 Feb 20 [Epub ahead of print]. [DOI: 10.1521/pedi_2019_33_423] [PMID: 30785852]AndreoliA . Re: your study in BPD - Cochrane Collaboration review [personal communication]. Email to: J Stoffers-Winterling 5 June 2018. '>Andreoli 2016</a>; <a href="./references#CD012955-bbs2-0005" title="BatemanA , FonagyP . Impact of clinical severity on outcomes of mentalisation-based treatment for borderline personality disorder. British Journal of Psychiatry2013;203(3):221-7. [DOI: 10.1192/bjp.bp.112.121129] [PMID: 23887998]BatemanA , FonagyP . Randomized controlled trial of outpatient mentalization-based treatment versus structured clinical management for borderline personality disorder. American Journal of Psychiatry2009;166(12):1355-64. [DOI: 10.1176/appi.ajp.2009.09040539] [PMID: 19833787]BatemanA , FonagyP . Randomized controlled trial of outpatient mentalization-based treatment versus structured clinical management for borderline personality disorder. Supplementary data. ajp.psychiatryonline.org/doi/suppl/10.1176/appi.ajp.2009.09040539/suppl_file/ajp_166_12_1355_01.pdf (accessed 27 February 2020). BatemanA , O'ConnellJ , LorenziniN , GardnerT , FonagyP . A randomised controlled trial of mentalization-based treatment versus structured clinical management for patients with comorbid borderline personality disorder and antisocial personality disorder. BMC Psychiatry2016;16:304. [DOI: 10.1186/s12888-016-1000-9] [PMC5006360] [PMID: 27577562]BatemanA . Important question regarding your BPD trial for systematic review in Cochrane Collaboration [personal communication]. Email to: K Lieb 14 December 2010. BatemanAW . Mentalization, borderline personality disorder and what works for whom? Presentation at the 11th International Congress of the International Society for the Study of Personality Disorders; 2009 Aug 21-23. www.borderlinepersonalitydisorder.com/Conferences/ISSPD/isspd_09_Bateman (accessed 21 April 2010). ISRCTN27660668. Randomised controlled trial of manualised out-patient individual and group therapy for borderline personality disorder [Effectiveness of intensive out-patient psychotherapy for treatment of borderline personality disorder: a pragmatic randomised single blind controlled study]. www.isrctn.com/ISRCTN27660668 (first received 12 October 2008). ">Bateman 2009</a>; <a href="./references#CD012955-bbs2-0006" title="BellinoS , ParadisoE , ZizzaM , Di LorenzoR , BogettoF . Combined therapy with interpersonal psychotherapy of major depressed patients with borderline personality disorder: a comparison with pharmacotherapy [Terapia combinata con psicoterapia interpersonale di pazienti depressi maggiori con disturbo borderline di personalità: confronto con la farmacoterapia]. Journal of Psychopathology2005;11(1):34-42. [bit.ly/2rZUh5h]BellinoS , ZizzaM , RinaldiC , BogettoF . Combined treatment of major depression in patients with borderline personality disorder: a comparison with pharmacotherapy. Canadian Journal of Psychiatry2006;51(7):453-60. [DOI: 10.1177/070674370605100707] [PMID: 16838827]">Bellino 2006</a>; <a href="./references#CD012955-bbs2-0007" title="BellinoS , ZizzaM , RinaldiC , BogettoF . Combined therapy of major depression with concomitant borderline personality disorder: comparison of interpersonal and cognitive psychotherapy. Canadian Journal of Psychiatry2007;52(11):718-25. [DOI: 10.1177/070674370705201106] [PMID: 18399039]">Bellino 2007</a>; <a href="./references#CD012955-bbs2-0008" title="BellinoS , BozzatelloP , BogettoF . Combined treatment of borderline personality disorder with interpersonal psychotherapy and pharmacotherapy: predictors of response. Psychiatry Research2015;226(1):284-8. [DOI: 10.1016/j.psychres.2014.12.064] [isiarticles.com/bundles/Article/pre/pdf/34125.pdf]BellinoS , RinaldiC , BogettoF . Adaptation of interpersonal psychotherapy to borderline personality disorder: a comparison of combined therapy and single pharmacotherapy. Canadian Journal of Psychiatry2010;55(2):74-81. [DOI: 10.1177/070674371005500203] [PMID: 20181302]BellinoS . Question regarding your BPD trials for inclusion in Cochrane Collaboration review [personal communication]. Email to: J Stoffers-Winterling 19 December 2010. BellinoS . Re: question regarding your BPD trials [personal communication]. Email to: J Stoffers 16 December 2010. BozzatelloP , BellinoS . Combined therapy with interpersonal psychotherapy adapted for borderline personality disorder: a two-years follow-up. Psychiatry Research2016;240:151-6. [DOI: 10.1016/j.psychres.2016.04.014] [www.sciencedirect.com/science/article/pii/S0165178115302389]ZizzaM , FenocchioM , RinaldiC , BellinoS . Combined treatment of borderline personality disorder: a trial of modified interpersonal therapy. World Psychiatry2009;8(Suppl 1):234. ">Bellino 2010</a>; <a href="./references#CD012955-bbs2-0010" title="BlackD . Question regarding your BPD trial [personal communication]. Email to: J Stoffers 04 January 2011. BlackDW , AllenJ , McCormickB , BlumN . Treatment received by persons with BPD participating in a randomized clinical trial of the systems training for emotional predictability and problem solving programme. Personality and Mental Health2011;5(3):159-68. [DOI: 10.1002/pmh.167]BlackDW , AllenJ , St JohnD , PfohlB , McCormickB , BlumN . Predictors of response to systems training for emotional predictability and problem solving (STEPPS) for borderline personality disorder: an exploratory study. Acta Psychiatrica Scandinavica2009;120(1):53-61. [DOI: 10.1111/j.1600-0447.2008.01340.x] [PMC3665337] [PMID: 19183126]BlackDW , BlumN , PfohlB , St JohnD . The STEPPS group treatment program for outpatients with borderline personality disorder. Journal of Contemporary Psychotherapy2004;34(3):193-210. [DOI: 10.1023/B:JOCP.0000036630.25741.83]BlackDW , PfohlBM . Randomized clinical trial of STEPPS versus treatment as usual. In: 158th annual meeting of the American Psychiatric Association. Psychosomatic medicine: integrating psychiatry &amp; medicine; 2005 May 21-26; Atlanta (GA). Arlington (VA): American Psychiatric Association, 2005:104. [No. 1B] [www.psychiatry.org/File%20Library/Psychiatrists/Directories/Library-and-Archive/syllabus/am_syllabus_2005.pdf]BlackDW , Simsek-DuranF , BlumN , McCormickB , AllenJ . Do people with borderline personality disorder complicated by antisocial personality disorder benefit from the STEPPS treatment program?Personality and Mental Health2016;10(3):205-15. [DOI: 10.1002/pmh.1326] [PMC4911327] [PMID: 26671625]BlackDW . RE: [external] questions regarding your trial on the STEPPS program for BPD [personal communication]. Email to: EG Faltinsen 27 November 2017. BlumN , AllenJ , McCormickB , BlackDW . Ms Blum and colleagues reply [to Schulte-Herbrüggen O, Koerting J, Roepke S. Effectiveness of adjunctive STEPPS group treatment in borderline personality disorder patients. American Journal of Psychiatry 2008;165(10):1354-5. DOI: 10.1176/appi.ajp.2008.08030390]. American Journal of Psychiatry2008;165(10):1354-5. [DOI: 10.1176/appi.ajp.2008.08030390r]BlumN , FranklinJ , HanselR , McCormickB , St JohnD , PfohlB , et al. Relationship of age to symptom severity, psychiatric comorbidity and health care utilization in persons with borderline personality disorder. Personality and Mental Health2008;2(1):25-43. [DOI: 10.1002/pmh.26]BlumN , St JohnD , PfohlB , StuartS , McCormickB , AllenJ , et al. Erratum. American Journal of Psychiatry2008;165(6):777. Erratum for: American Journal of Psychiatry 2008;165(4):468-78. [psycnet.apa.org/record/2008-07854-033]BlumN , St JohnD , PfohlB , StuartS , McCormickB , AllenJ , et al. Systems training for emotional predictability and problem solving (STEPPS) for outpatients with borderline personality disorder: a randomized controlled trial and 1-year follow-up. American Journal of Psychiatry2008;165(4):468-78. [DOI: 10.1176/appi.ajp.2007.07071079] [PMC3608469] [PMID: 18281407]DavidsonKM . Borderline personality disorder: STEPPS improves symptoms. Evidence-Based Mental Health2008;11(4):120. [DOI: 10.1136/ebmh.11.4.120] [PMID: 18952969]NCT00055315. Treatment for borderline personality disorder [A cognitive group treatment for borderline outpatients]. clinicaltrials.gov/ct2/show/NCT00055315 (first received 25 February 2003). ">Blum 2008</a>; <a href="./references#CD012955-bbs2-0011" title="BohusM , DyerAS , PriebeK , KrügerA , KleindienstN , SchmahlC , et al. Dialectical behaviour therapy for post-traumatic stress disorder after childhood sexual abuse in patients with and without borderline personality disorder: a randomised controlled trial. Psychotherapy and Psychosomatics2013;82(4):221-33. [DOI: 10.1159/000348451] [PMID: 23712109]BrandS . AW: questions regarding your trial on emotional intelligence training for BPD [personal communication]. Email to: EG Faltinsen 28 November 2017. DBT Working Group at the Central Institute for Mental Health, Mannheim, Germany. Requested supplementary data (as supplied 1 October 2010). Data on file. NCT00481000. Dialectical cognitive traumatherapy (DCT) on patients with severe PTSD following sexual abuse (PASA) [Dialectical cognitive traumatherapy (DCT) on patients with severe posttraumatic stress disorder following sexual abuse - a randomised controlled trial]. clinicaltrials.gov/ct2/show/NCT00481000 (first received 31 May 2007). SteilR , DyerA , PriebeK , KleindienstN , BohusM . Dialectical behavior therapy for posttraumatic stress disorder related to childhood sexual abuse: a pilot study of an intensive treatment program. Journal of Traumatic Stress2011;24(1):102-6. [DOI: 10.1002/jts.20617] [PMID: 21351167]">Bohus 2013</a>; <a href="./references#CD012955-bbs2-0012" title="BorschmannR , BarrettB , HellierJM , ByfordS , HendersonC , RoseD , et al. Joint crisis plans for people with borderline personality disorder: feasibility and outcomes in a randomised controlled trial. British Journal of Psychiatry2013;202(5):357-64. [DOI: 10.1192/bjp.bp.112.117762] [PMID: 23637110]BorschmannR . Joint crisis plans for BPD - question on publication in British Journal of Psychiatry [pers communication]. Email to: J Stoffers-Winterling 22 August 2017. BorschmannR . RE: joint crisis plans for BPD - question on publication in British Journal of Psychiatry [personal communication]. Email to: J Stoffers-Winterling 22 August 2017. BorschmannR . The development and testing of joint crisis plans for people with borderline personality disorder: a feasibility study. ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.628499 (accessed 27 January 2019). HellierJ . RE: regarding your study on on MBT for eating disorders [personal communication]. Email to: E Faltinsen 27 March 2018. HellierJ . RE: regarding your study on on MBT for eating disorders [personal communication]. Email to: E Faltinsen 3 January 2018. HellierJ . SV: regarding your study on MBT for eating disorders [personal communication]. Email to: EG Faltinsen, P Robinson 27 March 2018. ISRCTN12440268. JOSHUA: a pilot randomised controlled trial of joint crisis plans for people who self harm. www.isrctn.com/ISRCTN12440268 (first received 17 September 2009). ">Borschmann 2013</a>; <a href="./references#CD012955-bbs2-0013" title="BosEH , Van WelE , AppeloMT , VerbraakMJP . A randomized controlled trial of a Dutch version of systems training for emotional predictability and problem solving for borderline personality disorder. Journal of Nervous and Mental Disease2010;198(4):299-304. [DOI: 10.1097/NMD.0b013e3181d619cf] [PMID: 20386260]Van WelEB , BosEH , AppeloMT , BerendsenEM , WillgerothFC , VerbraakMJPM . The efficacy of the systems training for emotional predictability and problem solving (STEPPS) in the treatment of borderline personality disorder. A randomized controlled trial [De effectiviteit van de vaardigheidstraining emotieregulatiestoornis (VERS) in de behandeling van de borderlinepersoonlijkheidsstoornis: een gerandomiseerd onderzoek]. Tijdschrift voor Psychiatrie2009;51(5):291-301. [PMID: 19434566]">Bos 2010</a>; <a href="./references#CD012955-bbs2-0014" title="Carmona i FarrésC , ElicesM , SolerJ , Domínguez-ClavéE , Pomarol-ClotetE , SalvadorR , et al. Effects of mindfulness training on borderline personality disorder: impulsivity versus emotional dysregulation. Mindfulness2019;10:1243-54. [DOI: 10.1007/s12671-018-1071-4]NCT03363230. Effects of mindfulness training on emotion regulation and impulsivity. www.clinicaltrials.gov/ct2/show/NCT03363230 (first received 30 November 2017). ">Carmona í Farrés 2019</a>; <a href="./references#CD012955-bbs2-0015" title="CarterG . Question regarding your BPD trial [personal communication]. Email to: J Stoffers 21 December 2010. CarterGL , WillcoxCH , LewinTJ , ConradAM , BenditN . Hunter DBT project: randomized controlled trial of dialectical behaviour therapy in women with borderline personality disorder. Australian and New Zealand Journal of Psychiatry2010;44(2):162-73. [DOI: 10.3109/00048670903393621] [PMID: 20113305]">Carter 2010</a>; <a href="./references#CD012955-bbs2-0016" title="CottrauxJ , NoteID , BoutitieF , MillieryM , GenouihlacV , YaoSN , et al. Cognitive therapy versus Rogerian supportive therapy in borderline personality disorder. Two-year follow-up of a controlled pilot study. Psychotherapy and Psychosomatics2009;78(5):307-16. [DOI: 10.1159/000229769] [PMID: 19628959]NCT00131781. Cognitive therapy versus supportive therapy in borderline personality disorder. www.clinicaltrials.gov/ct2/show/NCT00131781 (first received 18 August 2005). ">Cottraux 2009</a>; <a href="./references#CD012955-bbs2-0017" title="DavidsonK , LivingstoneS , McArthurK , DicksonL , GumleyA . An integrative complexity analysis of cognitive behaviour therapy sessions for borderline personality disorder. Psychology and Psychotherapy2007;80(Pt 4):513-23. [DOI: 10.1348/147608307X191535] [PMID: 17535542]DavidsonK , NorrieJ , TyrerP , GumleyA , TataP , MurrayH , et al. The effectiveness of cognitive behavior therapy for borderline personality disorder: results from the borderline personality disorder study of cognitive therapy (BOSCOT) trial. Journal of Personality Disorders2006;20(5):450-65. [DOI: 10.1521/pedi.2006.20.5.450] [PMC1852259] [PMID: 17032158]DavidsonK , TyrerP , GumleyA , TataP , NorrieJ , PalmerS , et al. A randomized controlled trial of cognitive behavior therapy for borderline personality disorder: rationale for trial, method, and description of sample. Journal of Personality Disorders2006;20(5):431-49. [DOI: 10.1521/pedi.2006.20.5.431] [PMC1847748] [PMID: 17032157]DavidsonKM , TyrerP , NorrieJ , PalmerSJ , TyrerH . Cognitive therapy v usual treatment for borderline personality disorder: prospective 6-year follow-up. British Journal of Psychiatry2010;197(6):456-62. [DOI: 10.1192/bjp.bp.109.074286] [PMID: 21119151]ISRCTN86177428. Borderline personality disorder study of cognitive therapy trial [A randomised controlled trial of cognitive therapy plus treatment as usual versus treatment as usual in the treatment of borderline personality disorder]. www.isrctn.com/ISRCTN86177428 (first received 22 July 2005). NCT00538135. BOSCOT: a randomised controlled trial of cognitive behavioural therapy in borderline personality disorder [BOSCOT: a randomised control trial of cognitive behavioural therapy plus treatment as usual versus treatment as usual in the treatment of borderline personality disorder]. www.clinicaltrials.gov/ct2/show/NCT00538135 (first received 29 September 2007). NorrieJ , DavidsonK , TataP , GumleyA . Influence of therapist competence and quantity of cognitive behavioural therapy on suicidal behaviour and inpatient hospitalisation in a randomised controlled trial in borderline personality disorder: further analyses of treatment effects in the BOSCOT study. Psychology and Psychotherapy2013;86(3):280-93. [DOI: 10.1111/papt.12004] [PMC4491320] [PMID: 23420622]PalmerS , DavidsonK , TyrerP , GumleyA , TataP , NorrieJ , et al. The cost-effectiveness of cognitive behavior therapy for borderline personality disorder: results from the BOSCOT trial. Journal of Personality Disorders2006;20(5):466-81. [DOI: 10.1521/pedi.2006.20.5.466] [PMC1852260] [PMID: 17032159]">Davidson 2006</a>; <a href="./references#CD012955-bbs2-0018" title="DavidsonKM , BrownTM , JamesV , KirkJ , RichardsonJ . Manual-assisted cognitive therapy for self-harm in personality disorder and substance misuse: a feasibility trial. Psychiatric Bulletin2014;38(3):108-11. [DOI: 10.1192/pb.bp.113.043109] [PMC4115373] [PMID: 25237519]DavidsonKM . Re: question regarding your trial on manual-assisted cognitive therapy [personal communication]. Email to: EG Faltinsen 28 November 2017. ">Davidson 2014</a>; <a href="./references#CD012955-bbs2-0019" title="BuchheimA , Hörz-SagstetterS , DoeringS , RentropM , SchusterP , BuchheimP , et al. Change of unresolved attachment in borderline personality disorders: RCT study of transference-focused psychotherapy. Psychotherapy and Psychosomatics2017;86(5):314-6. [DOI: 10.1159/000460257] [PMID: 28903103]DiamondD , LevyKN , ClarkinJF , Fischer-KernM , CainNM , DoeringS , et al. Attachment and mentalization in female patients with comorbid narcissistic and borderline personality disorder. Personality Disorders2014;5(4):428-33. [DOI: 10.1037/per0000065] [PMID: 25314231]DiamondD , YeomansFE , SternB , LevyKN , HörzS , DoeringS , et al. Transference-focused psychotherapy for patients with comorbid narcissistic and borderline personality disorder. Psychoanalytic Inquiry2013;33(6):527-51. [DOI: 10.1080/07351690.2013.815087]DoeringS , HörzS , RentropM , Fischer-KernM , SchusterP , BeneckeC , et al. Transference-focused psychotherapy v treatment by community psychotherapists for borderline personality disorder: randomised controlled trial. British Journal of Psychiatry2010;196(5):389-95. [DOI: 10.1192/bjp.bp.109.070177] [PMID: 20435966]DoeringS . Author's reply [to Kleindienst N, Krumm B, Bohus M. Is transference-focused psychotherapy really efficacious for borderline personality disorder? British Journal of Psychiatry 2011;198(2):156-7. DOI: 10.1192/bjp.198.2.156b]. British Journal of Psychiatry2011;198(2):156-7. [DOI: 10.1192/bjp.198.2.157]DoeringS . Question regarding your BPD trial for systematic review in Cochrane Collaboration [personal communication]. Email to: K Lieb, J Stoffers 10 December 2010. Fischer-KernM , DoeringS , TaubnerS , HörzS , ZimmermannJ , RentropM , et al. Transference-focused psychotherapy for borderline personality disorder: change in reflective function. British Journal of Psychiatry2015;207(2):173-4. [DOI: 10.1192/bjp.bp.113.143842] [PMID: 25999334]KleindienstN , KrummB , BohusM . Is transference-focused psychotherapy really efficacious for borderline personality disorder?British Journal of Psychiatry2011;198(2):156-7. [DOI: 10.1192/bjp.198.2.156b] [PMID: 21282787]LevyKN , MeehanKB , YeomansFE . Transference-focused psychotherapy reduces treatment drop-out and suicide attempters compared with community psychotherapist treatment in borderline personality disorder. Evidence-based Mental Health2010;13(4):119. [DOI: 10.1136/ebmh.13.4.119] [PMID: 21036981]NCT00714311. Efficacy of transference-focused psychotherapy for borderline personality disorder [A randomized-controlled trial of transference-focused psychotherapy vs treatment by experienced community psychotherapists for borderline personality disorder]. www.clinicaltrials.gov/ct2/show/NCT00714311 (first received 9 July 2008). RentropM , MartiusP , BäumlJ , BuchheimP , DöeringS , HörzS . Patients with borderline personality disorder not participating in an RCT: are they different?Psychopathology2010;43(6):369-72. [DOI: 10.1159/000320351] [PMID: 20798576]">Doering 2010</a>; <a href="./references#CD012955-bbs2-0020" title="ElicesM , PascualJC , PortellaMJ , Feliu-SolerA , Martín-BlancoA , CarmonaC , et al. Impact of mindfulness training on borderline personality disorder: a randomized trial. Mindfulness2016;7:584-95. [DOI: 10.1007/s12671-016-0492-1]NCT02397031. Mindfulness and interpersonal effectiveness skills in borderline personality disorder [Randomized, active-controlled, clinical trial comparing effects of mindfulness and interpersonal effectiveness skills in borderline personality disorder]. www.clinicaltrials.gov/ct2/show/NCT02397031 (first received 12 March 2015). SolerJ , ElicesM , PascualJC , Martín-BlancoA , Feliu-SolerA , CarmonaC , et al. Effects of mindfulness training on different components of impulsivity in borderline personality disorder: results from a pilot randomized study. Borderline Personality Disorder and Emotion Dysregulation2016;3:1. [DOI: 10.1186/s40479-015-0035-8] [PMC4709962] [PMID: 26759718]">Elices 2016</a>; <a href="./references#CD012955-bbs2-0021" title="FarrellJM , ShawIA , WebberMA . A schema-focused approach to group psychotherapy for outpatients with borderline personality disorder: a randomized controlled trial. Journal of Behavior Therapy and Experimental Psychiatry2009;40(2):317-28 Corrigendum to: Journal of Behavior Therapy and Experimental Psychiatry 2018; 60: 111. [DOI: 10.1016/j.jbtep.2009.01.002] [PMID: 19176222]FarrellJM . Question regarding your BPD trials [personal communication]. Email to: K Lieb, J Stoffers 9 December 2010. ">Farrell 2009</a>; <a href="./references#CD012955-bbs2-0022" title="FeigenbaumJD , FonagyP , PillingS , JonesA , WildgooseA , BebbingtonPE . A real-world study of the effectiveness of DBT in the UK National Health Service. British Journal of Clinical Psychology2012;51(2):121-41. [DOI: 10.1111/j.2044-8260.2011.02017.x] [PMID: 22574799]">Feigenbaum 2012</a>; <a href="./references#CD012955-bbs2-0024" title="ArntzA , Stupar-RutenfransS , BlooJ , Van DyckR , SpinhovenP . Prediction of treatment discontinuation and recovery from borderline personality disorder: results from an RCT comparing schema therapy and transference-focused psychotherapy. Behaviour Research and Therapy2015;74:60-71. [DOI: 10.1016/j.brat.2015.09.002] [PMID: 26432172]Giesen-BlooJ , ArntzA . Questions concerning the randomized trial of schema-focused therapy vs transference-focused psychotherapy—reply. Archives of General Psychiatry2007;64(5):610-1. [DOI: 10.1001/archpsyc.64.5.610]Giesen-BlooJ , Van DyckR , SpinhovenP , Van TilburgW , DirksenC , Van AsseltT , et al. Errors in table and figure in: outpatient psychotherapy for borderline personality disorder: randomized trial of schema-focused therapy vs transference-focused psychotherapy. Archives of General Psychiatry2006;63(9):1008. Erratum for: Archives of General Psychiatry 2006;63(6):649-58. [DOI: 10.1001/archpsyc.63.9.1008]Giesen-BlooJ , Van DyckR , SpinhovenP , Van TilburgW , DirksenC , Van AsseltT , et al. Outpatient psychotherapy for borderline personality disorder: randomized trial of schema-focused therapy vs transference-focused psychotherapy. Archives of General Psychiatry2006;63(6):649-58. [DOI: 10.1001/archpsyc.63.6.649] [PMID: 16754838]SpinhovenP , Giesen-BlooJ , Van DyckR , KooimanK , ArntzA . The therapeutic alliance in schema-focused therapy and transference-focused psychotherapy for borderline personality disorder. Journal of Consulting and Clinical Psychology2007;75(1):104-15. [DOI: 10.1037/0022-006X.75.1.104] [PMID: 17295569]Van AsseltADI , DirksenCD , ArntzA , Giesen-BlooJH , Van DyckR , SpinhovenP , et al. Out-patient psychotherapy for borderline personality disorder: cost-effectiveness of schema-focused therapy v transference-focused psychotherapy. British Journal of Psychiatry2008;192(6):450-7. [DOI: 10.1192/bjp.bp.106.033597] [PMID: 18515897]Van AsseltADI , DirksenCD , ArntzA , SeverensJL . Difficulties in calculating productivity costs: work disability associated with borderline personality disorder. Value in Health2008;11(4):637-44. [DOI: 10.1111/j.1524-4733.2007.00288.x]YeomansF . Questions concerning the randomized trial of schema-focused therapy vs transference-focused psychotherapy. Archives of General Psychiatry2007;64(5):609-10. [DOI: 10.1001/archpsyc.64.5.609-c] [PMID: 17485613]">Giesen‐Bloo 2006</a>; <a href="./references#CD012955-bbs2-0025" title="GleesonJF , ChanenA , CottonSM , PearceT , NewmanB , McCutcheonL . Treating co-occurring first-episode psychosis and borderline personality: a pilot randomized controlled trial. Early Intervention in Psychiatry2012;6(1):21-9. [DOI: 10.1111/j.1751-7893.2011.00306.x] [PMID: 22379625]GleesonJFM . RE: separate data [personal communication]. Email to: M Kielsholm 28 October 2016. ">Gleeson 2012</a>; <a href="./references#CD012955-bbs2-0026" title="Gratz KL. Important: question regarding your BPD trial for systematic review in Cochrane Collaboration [personal communication]. Email to: J Stoffers-Winterling 11 December 2010. GratzKL , GundersonJG . Preliminary data on an acceptance-based emotion regulation group intervention for deliberate self-harm among women with borderline personality disorder. Behavior Therapy2006;37(1):25-35. [DOI: 10.1016/j.beth.2005.03.002] [PMID: 16942958]">Gratz 2006</a>; <a href="./references#CD012955-bbs2-0028" title="GregoryRJ , ChlebowskiS , KangD , RemenA , SoderbergM . Psychodynamic therapy for borderline personality disorder and co-occurring alcohol use disorders: a newly designed ongoing study. Journal of the American Psychoanalytic Association2006;54(4):1331-4. [DOI: 10.1177/00030651060540040107] [PMID: 17354507]GregoryRJ , ChlebowskiS , KangD , RemenAL , SoderbergMG , StepkovitchJ , et al. A controlled trial of psychodynamic psychotherapy for co-occurring borderline personality disorder and alcohol use disorder. Psychotherapy2008;45(1):28-41. [DOI: 10.1037/0033-3204.45.1.28] [PMID: 22122363]GregoryRJ , DeLucia-DeranjaE , MogleJA . Dynamic deconstructive psychotherapy versus optimized community care for borderline personality disorder co-occuring with alcohol use disorders: a 30-month follow-up. Journal of Nervous and Mental Disease2010;198(4):292-8. [DOI: 10.1097/NMD.0b013e3181d6172d] [PMID: 20386259]GregoryRJ , RemenAL , SoderbergM , Ploutz-SnyderRJ . A controlled trial of psychodynamic psychotherapy for co-occurring borderline personality disorder and alcohol use disorder: six-month outcome. Journal of the American Psychoanalytic Association2009;57(1):199-205. [DOI: 10.1177/00030651090570011006] [PMID: 19270255]NCT00145678. Psychodynamic therapy for co-occurring borderline personality disorder and alcohol use disorder [Psychodynamic therapy for patients With borderline personality disorder and alcohol abuse]. www.clinicaltrials.gov/show/NCT00145678 (first received 1 September 2005). ">Gregory 2008b</a>; <a href="./references#CD012955-bbs2-0030" title="HarnedM . Re: SV: question regarding your trial on brief therapy for attempted suicide [personal communication]. Email to: EG Faltinsen 11 December 2018. HarnedMS , KorslundKE , LinehanMM . A pilot randomized controlled trial of dialectical behavior therapy with and without the dialectical behavior therapy prolonged exposure protocol for suicidal and self-injuring women with borderline personality disorder and PTSD. Behaviour Research and Therapy2014;55:7-17. [DOI: 10.1016/j.brat.2014.01.008] [PMC3987949] [PMID: 24562087]HarnedMS , WilksCR , SchmidtSC , CoyleTN . Improving functional outcomes in women with borderline personality disorder and PTSD by changing PTSD severity and post-traumatic cognitions. Behaviour Research and Therapy2018;103:53-61. [DOI: 10.1016/j.brat.2018.02.002] [PMC5837954] [PMID: 29448136]HarnedMS . RE: questions regarding your trial on brief therapy for attempted suicide [personal communication]. Email to: E Faltinsen 29 November 2017. ">Harned 2014</a>; <a href="./references#CD012955-bbs2-0031" title="BrandS . AW: questions regarding your trial on emotional intelligence training for BPD [personal communication]. Email to: EG Faltinsen 28 November 2017. BrandS . Questions regarding your trial on emotional intelligence training for BPD [personal communication]. Email to: EG Faltinsen 28 November 2017. JahangardL , HaghighiM , BajoghliH , AhmadpanahM , GhaleihaA , ZarrabianMK , et al. Training emotional intelligence improves both emotional intelligence and depressive symptoms in inpatients with borderline personality disorder and depression. International Journal of Psychiatry in Clinical Practice2012;16(3):197-204. [DOI: 10.3109/13651501.2012.687454] [PMID: 22873719]">Jahangard 2012</a>; <a href="./references#CD012955-bbs2-0032" title="JochemsEC , Van der Feltz-CornelisCM , Van DamA , DuivenvoordenHJ , MulderCL . The effects of motivation feedback in patients with severe mental illness: a cluster randomized controlled trial. Neuropsychiatric Disease and Treatment2015;11:3049-64. [DOI: 10.2147/NDT.S95190] [PMC4686323] [PMID: 26715847]JochemsEC . Cochrane Collaboration review on psychotherapies for borderline PD [personal communication]. Email to: EG Faltinsen 2 July 2018. JochemsEC . Re: Cochrane Collaboration review on psychotherapies for borderline PD [personal communication]. Email to: J Stoffers-Winterling 02 July 2018. ">Jochems 2015</a>; <a href="./references#CD012955-bbs2-0036" title="KramerU , BergerT , KollyS , MarquetP , PreisigM , De RotenY , et al. Effects of motive-oriented therapeutic relationship in early-phase treatment of borderline personality disorder: a pilot study of a randomized trial. Journal of Nervous and Mental Disease2011;199(4):244-50. [DOI: 10.1097/NMD.0b013e3182125d19] [PMID: 21451348]KramerU , CasparF , DrapeauM . Change in biased thinking in a 10-session treatment for borderline personality disorder: further evidence of the motive-oriented therapeutic relationship. Psychotherapy Research2013;23(6):633-45. [DOI: 10.1080/10503307.2013.791404] [PMID: 23631622]">Kramer 2011</a>; <a href="./references#CD012955-bbs2-0037" title="BerthoudL , KramerU , CasparF , Pascual-LeoneA . Emotional processing in a ten-session general psychiatric treatment for borderline personality disorder: a case study. Personality and Mental Health2015;9(1):73-8. [DOI: 10.1002/pmh.1287] [PMID: 25711648]BerthoudL , Pascual-LeoneA , CasparF , TissotH , KellerS , RohdeKB , et al. Leaving distress behind: a randomized controlled study on change in emotional processing in borderline personality disorder. Psychiatry2017;80(2):139-54. [DOI: 10.1080/00332747.2016.1220230] [PMID: 28767333]KellerS , StelmaszczykK , KollyS , De RotenY , DesplandJN , CasparF , et al. Change in biased thinking in a treatment based on the motive-oriented therapeutic relationship for borderline personality disorder. Journal of Personality Disorders2018;32(Suppl):75-92. [DOI: 10.1521/pedi.2018.32.supp.75] [PMID: 29388899]KramerU , FlückigerC , KollyS , CasparF , MarquetP , DesplandJN , et al. Unpacking the effects of therapist responsiveness in borderline personality disorder: motive-oriented therapeutic relationship, patient in-session experience, and the therapeutic alliance. Psychotherapy and Psychosomatics2014;83(6):386-7. [DOI: 10.1159/000365400] [PMID: 25324025]KramerU , KellerS , CasparF , De RotenY , DesplandJN , KollyS . Early change in coping strategies in responsive treatments for borderline personality disorder: a mediation analysis. Journal of Consulting and Clinical Psychology2017;85(5):530-5. [DOI: 10.1037/ccp0000196] [PMID: 28425747]KramerU , KollyS , BerthoudL , KellerS , PreisigM , CasparF , et al. Effects of motive-oriented therapeutic relationship in a ten-session general psychiatric treatment of borderline personality disorder: a randomized controlled trial. Psychotherapy and Psychosomatics2014;83(3):176-86. [DOI: 10.1159/000358528] [PMID: 24752034]KramerU , StulzN , BerthoudL , CasparF , MarquetP , KollyS , et al. The shorter the better? A follow-up analysis of 10-session psychiatric treatment including the motive-oriented therapeutic relationship for borderline personality disorder. Psychotherapy Research2017;27(3):362-70. [DOI: 10.1080/10503307.2015.1110635] [PMID: 26684670]NCT01896024. Effects of motive-oriented therapeutic relationship in the early-phase treatment of borderline personality disorder (MOTR). www.clinicaltrials.gov/ct2/show/NCT01896024 (first received 5 July 2013). ">Kramer 2014</a>; <a href="./references#CD012955-bbs2-0038" title="KramerU , Pascual-LeoneA , BerthoudL , De RotenY , MarquetP , KollyS , et al. Assertive anger mediates effects of dialectical behaviour-informed skills training for borderline personality disorder: a randomized controlled trial. Clinical Psychology &amp; Psychotherapy2016;23(3):189-202. [DOI: 10.1002/cpp.1956] [PMID: 25864773]KramerU . The role of coping change in borderline personality disorder: a process-outcome analysis on dialectical-behaviour skills training. Clinical Psychology &amp; Psychotherapy2017;24(2):302-11. [DOI: 10.1002/cpp.2017] [PMID: 27098296]">Kramer 2016</a>; <a href="./references#CD012955-bbs2-0039" title="KredlowMA , SzuhanyKL , LoS , XieH , GottliebJD , RosenbergSD , et al. Cognitive behavioral therapy for posttraumatic stress disorder in individuals with severe mental illness and borderline personality disorder. Psychiatry Research2017;249:86-93. [DOI: 10.1016/j.psychres.2016.12.045] [PMC5325773] [PMID: 28086181]MueserK . Re: question regarding your trial on CBT for BPD patients [personal communication]. Email to: EG Faltinsen 28 November 2017. ">Kredlow 2017a</a>; <a href="./references#CD012955-bbs2-0040" title="KredlowMA , SzuhanyKL , LoS , XieH , GottliebJD , RosenbergSD , et al. Cognitive behavioral therapy for posttraumatic stress disorder in individuals with severe mental illness and borderline personality disorder. Psychiatry Research2017;249:86-93. [DOI: 10.1016/j.psychres.2016.12.045] [PMC5325773] [PMID: 28086181]MueserKT , GottliebJD , XieH , LuW , YanosPT , RosenbergSD , et al. Evaluation of cognitive restructuring for post-traumatic stress disorder in people with severe mental illness.. British Journal of Psychiatry2015;206(6):501-8. [DOI: 10.1192/bjp.bp.114.147926] [PMC4450219] [PMID: 25858178]MueserKT , RosenbergSD , XieH , JankowskiMK , BoltonEE , LuW , et al. A randomized controlled trial of cognitive-behavioral treatment for posttraumatic stress disorder in severe mental illness. Journal of Consulting and Clinical Psychology2008;76(2):259-71. [DOI: 10.1037/0022-006X.76.2.259] [PMC3916092] [PMID: 18377122]MueserKT . Re: question regarding your trial on CBT for PTSD participants [personal communication]. Email to: E Faltinsen 28 November 2018. ">Kredlow 2017b</a>; <a href="./references#CD012955-bbs2-0041" title="LaurenssenEM , WestraD , KikkertMJ , NoomMJ , EerenHV , Van BroekhuyzenAJ , et al. Day hospital mentalization-based treatment (MBT-DH) versus treatment as usual in the treatment of severe borderline personality disorder: protocol of a randomized controlled trial. BMC Psychiatry2014;14:149. [DOI: 10.1186/1471-244X-14-149] [PMC4045960] [PMID: 24886402]LaurenssenEMP , LuytenP , KikkertMJ , WestraD , PeenJ , SoonsMBJ , et al. Day hospital mentalization-based treatment v specialist treatment as usual in patients with borderline personality disorder: randomized controlled trial. Psychological Medicine2018;48(15):2522-9. [DOI: 10.1017/S0033291718000132] [PMID: 29478425]NL2058 (NTR2175). Mentalisation-based treatment versus care-as-usual in the treatment of severe borderline personality disorders. www.trialregister.nl/trial/2058 (first received 21 January 2010). ">Laurenssen 2018</a>; <a href="./references#CD012955-bbs2-0042" title="LeichsenringF , MasuhrO , JaegerU , RabungS , DallyA , DümpelmannM , et al. Psychoanalytic-interactional therapy versus psychodynamic therapy by experts for personality disorders: a randomized controlled efficacy-effectiveness study in cluster B personality disorders. Psychotherapy and Psychosomatics2016;85(2):71-80. [DOI: 10.1159/000441731] [PMID: 26808580]">Leichsenring 2016</a>; <a href="./references#CD012955-bbs2-0043" title="LeppänenV , HakkoH , SintonenH , LindemanS . Comparing effectiveness of treatments for borderline personality disorder in communal mental health care: the Oulu BPD study. Community Mental Health Journal2016;52(2):216-27. [DOI: 10.1007/s10597-015-9866-4] [PMID: 25824852]LeppänenV . Re: questions regarding the Oulu BPD study [personal communication]. Email to: E Faltinsen 20 December 2017. LeppänenV . Re: SV: question regarding the Oulu BPD study [personal communication]. Email to: EG Faltinsen 22 December 2017. ">Leppänen 2016</a>; <a href="./references#CD012955-bbs2-0044" title="Lin T-J, Ko H-C, Wu JY-W, OeiTP , Lane H-Y, Chen C-H. The effectiveness of dialectical behavior therapy skills training group vs cognitive therapy group on reducing depression and suicide attempts for borderline personality disorder in Taiwan. Archives of Suicide Research2019;23(1):82-99. [DOI: 10.1080/13811118.2018.1436104] [PMID: 29528807]">Lin 2019</a>; <a href="./references#CD012955-bbs2-0045" title="HoffmanRE . Impact of treatment accessibility on clinical course of parasuicidal patients. Archives of General Psychiatry1993;50(2):157-8. [DOI: 10.1001/archpsyc.1993.01820140083010] [PMID: 8427557]LindenboimN . To Know Me is to Keep Me: Self-Verification, Validation, and Therapy Dropout in the Treatment of Borderline Personality Disorder [PhD thesis]. Washington (DC): University of Washington, 2009. LinehanMM , ArmstrongHE , SuarezA , AllmonD , HeardHL . Cognitive-behavioral treatment of chronically parasuicidal borderline patients. Archives of General Psychiatry1991;48(12):1060-4. [DOI: 10.1001/archpsyc.1991.01810360024003] [PMID: 1845222]LinehanMM , HeardHL . Impact of treatment accessibility on clinical course of parasuicidal patients — reply. Archives of General Psychiatry1993;50(2):157-8. [DOI: 10.1001/archpsyc.1993.01820140083011]">Linehan 1991</a>; <a href="./references#CD012955-bbs2-0046" title="HeardHL . Cost-Effectiveness of Dialectical Behavior Therapy in the Treatment of Borderline Personality Disorder [PhD thesis]. Washington (DC): University of Washington, 2000. LindenboimN . To Know Me is to Keep Me: Self-Verification, Validation, and Therapy Dropout in the Treatment of Borderline Personality Disorder [PhD thesis]. Washington (DC): University of Washington, 2009. LinehanMM , HeardHL , ArmstrongHE . Naturalistic follow-up of a behavioral treatment for chronically parasuicidal borderline patients. Archives of General Psychiatry1993;50(12):971-4. [DOI: 10.1001/archpsyc.1993.01820240055007] [PMID: 8250683]LinehanMM , TutekDA , HeardHL , ArmstrongHE . Interpersonal outcome of cognitive behavioral treatment for chronically suicidal borderline patients. American Journal of Psychiatry1994;151(12):1771-6. [DOI: 10.1176/ajp.151.12.1771] [PMID: 7977884]">Linehan 1994</a>; <a href="./references#CD012955-bbs2-0047" title="BedicsJD , AtkinsDC , ComtoisKA , LinehanMM . Treatment differences in the therapeutic relationship and introject during a 2-year randomized controlled trial of dialectical behavior therapy versus nonbehavioral psychotherapy experts for borderline personality disorder. Journal of Consulting and Clinical Psychology2012;80(1):66-77. [DOI: 10.1037/a0026113] [PMC3265694] [PMID: 22061867]BedicsJD , AtkinsDC , ComtoisKA , LinehanMM . Weekly therapist ratings of the therapeutic relationship and patient introject furing the course of dialectical behavioral therapy for the treatment of borderline personality disorder. Psychotherapy2012;49(2):231-40. [DOI: 10.1037/a0028254] [PMID: 22642526]BedicsJD , AtkinsDC , HarnedMS , LinehanMM . The therapeutic alliance as a predictor of outcome in dialectical behavior therapy versus nonbehavioral psychotherapy by experts for borderline personality disorder. Psychotherapy2015;52(1):67-77. [DOI: 10.1037/a0038457] [PMID: 25751116]BrownMZ , LinehanMM , ComtoisKA , MurrayA , ChapmanAL . Shame as a prospective predictor of self-inflicted injury in borderline personality disorder: a multi-modal analysis. Behaviour Research and Therapy2009;47(10):815-22. [DOI: 10.1016/j.brat.2009.06.008] [PMC2761705] [PMID: 19596223 ]CoyleTN , ShaverJA , LinehanMM . On the potential for iatrogenic effects of psychiatric crisis services: the example of dialectical behavior therapy for adult women with borderline personality disorder. Journal of Consulting and Clinical Psychology2018;86(2):116-24. [DOI: 10.1037/ccp0000275] [PMID: 29369662]HarnedMS , ChapmanAL , Dexter-MazzaET , MurrayA , ComtoisKA , LinehanMM . Treating co-occurring Axis I disorders in recurrently suicidal women with borderline personality disorder: a 2-year randomized trial of dialectical behavior therapy versus community treatment by experts. Journal of Consulting and Clinical Psychology2008;76(6):1068-75. [DOI: 10.1037/a0014044] [PMID: 19045974]HarnedMS , ChapmanAL , Dexter-MazzaET , MurrayA , ComtoisKA , LinehanMM . Treating co-occurring Axis I disorders in recurrently suicidal women with borderline personality disorder: a 2-year randomized trial of dialectical behavior therapy versus community treatment by experts. Personality Disorders: Theory, Research, and Treatment2009;S(1):35-45. [DOI: 10.1037/1949-2715.S.1.35]HarnedMS , JacksonSC , ComtoisKA , LinehanMM . Dialectical behavior therapy as a precursor to PTSD treatment for suicidal and/or self-injuring women with bordreline personality disorder. Journal of Traumatic Stress2010;23(4):421-9. [DOI: 10.1002/jts.20553] [PMID: 20648564]LindenboimN , ComtoisKA , LinehanMM . Skills practice in dialectical behavior therapy for suicidal women meeting criteria for borderline personality disorder. Cognitive and Behavioral Practice2007;14(2):147-56. [DOI: 10.1016/j.cbpra.2006.10.004]LinehanMM , ComtoisKA , MurrayAM , BrownMZ , GallopRJ , HeardHL , et al. Two-year randomized controlled trial and follow-up of dialectical behavior therapy vs therapy by experts for suicidal behaviors and borderline personality disorder. Archives of General Psychiatry2006;63(7):757-66. [DOI: 10.1001/archpsyc.63.7.757] [PMID: 16818865]LinehanMM . Error in table in: two-year randomized controlled trial and follow-up of dialectical behavior therapy vs therapy by experts for suicidal behaviors and borderline personality disorder. Archives of General Psychiatry2007;64(12):1401. Erratum for: Archives of General Psychiatry 2007;64(12):1401. McMainS . Dialectic behaviour therapy reduces suicide attempts compared with non-behavioural psychotherapy in women with borderline personality disorder. Evidence-Based Mental Health2007;10(1):18. [DOI: 10.1136/ebmh.10.1.18] [PMID: 17255387]NeacsiuAD , LunguA , HarnedMS , RizviSL , LinehanMM . Impact of dialectical behavior therapy versus community treatment by experts on emotional experience, expression, and acceptance in borderline personality disorder. Behaviour Research and Therapy2014;53:47-54. [DOI: 10.1016/j.brat.2013.12.004] [PMC3955205] [PMID: 24418652]NeacsiuAD , RizviSL , LinehanMM . Dialectical behavior therapy skills use as a mediator and outcome of treatment for borderline personality disorder. Behaviour Research and Therapy2010;48(9):832-9. [DOI: 10.1016/j.brat.2010.05.017] [PMC2914145] [PMID: 20579633]SecristCD . The Role of Executive Functioning in the Treatment of Borderline Personality Disorder [PhD thesis]. Washington (DC): University of Washington, 2014. ">Linehan 2006</a>; <a href="./references#CD012955-bbs2-0048" title="LinehanMM , KorslundKE , HarnedMS , GallopRJ , LunguA , NeacsiuAD , et al. Dialectical behavior therapy for high suicide risk in individuals with borderline personality disorder: a randomized clinical trial and component analysis. JAMA Psychiatry2015;72(5):475-82 Erratum for: JAMA Psychiatry 2015; 72(9): 951. [DOI: 10.1001/jamapsychiatry.2014.3039] [PMID: 25806661]NCT00183651. Treatment of suicidal women with borderline personality disorder [Assessment and treatment of parasuicidal patients]. www.clinicaltrials.gov/ct2/show/NCT00183651 (first received 13 September 2005). ">Linehan 2015a</a>; <a href="./references#CD012955-bbs2-0049" title="CaseBG . Letter to the editor on 'McMain SF, Links PS, Gnam WH, Guimond T, Cardish RJ, Korman L, et al. A randomized trial of dialectical behavior therapy versus general psychiatric management for borderline personality disorder. American Journal of Psychiatry 2009;166(12):1365-74. DOI: 10.1176/appi.ajp.2009.09010039'. American Journal of Psychiatry2010;167(4):475. [DOI: 10.1176/appi.ajp.2009.09101532] [PMID: 20360332 ]ISRCTN02634417. Hope for chronically suicidal patient: evaluating the clinical and health services impact of dialectical behaviour therapy (DBT) in individuals with borderline personality disorder [Evaluating the clinical and health services impact of dialectical behaviour therapy (DBT) in individuals with borderline personality disorder: a randomised controlled trial]. www.isrctn.com/ISRCTN02634417 (first received 16 November 2005). [DOI: 10.1186/ISRCTN02634417]McMainSF , FitzpatrickS , BoritzT , BarnhartR , LinksP , StreinerDL . Outcome trajectories and prognostic factors for suicide and self-harm behaviors in patients with borderline personaliy disorder following one year of outpatient psychotherapy. Journal of Personality Disorders2018;32(4):497-512. [DOI: 10.1521/pedi_2017_31_309] [PMID: 28910214]McMainSF , LinksPS , GnamWH , GuimondT , CardishRJ , KormanL , et al. A randomized trial of dialectical behavior therapy versus general psychiatric management for borderline personality disorder. American Journal of Psychiatry2009;166(12):1365-74. [DOI: 10.1176/appi.ajp.2009.09010039] [PMID: 19755574]McMainSF . Dr McMain replies to letter to the editor on 'McMain SF, Links PS, Gnam WH, Guimond T, Cardish RJ, Korman L, et al. A randomized trial of dialectical behavior therapy versus general psychiatric management for borderline personality disorder. American Journal of Psychiatry 2009;166(12):1365-74. DOI: 10.1176/appi.ajp.2009.09010039'. American Journal of Psychiatry2010;167(4):475-6. [DOI: 10.1176/appi.ajp.2009.09101532r)]NCT00154154. Hope for the chronically suicidal patient [Hope for the chronically suicidal patient: evaluating the clinical and health services impact of dialectical behaviour therapy in individuals with borderline personality disorder]. www.clinicaltrials.gov/ct2/show/NCT00154154 (first received 7 September 2005). ">McMain 2009</a>; <a href="./references#CD012955-bbs2-0050" title="McMainSF , GuimondT , BarnhartR , HabinskiL , StreinerDL . A randomized trial of brief dialectical behaviour therapy skills training in suicidal patients suffering from borderline disorder. Acta Psychiatrica Scandinavica2017;135(2):138-48. [DOI: 10.1111/acps.12664] [PMID: 27858962]">McMain 2017</a>; <a href="./references#CD012955-bbs2-0051" title="McMurranM , CrawfordMJ , ReillyJ , DelportJ , McCroneP , WhithamD , et al. Psychoeducation with problem-solving (PEPS) therapy for adults with personality disorder: a pragmatic randomised controlled trial to determine the clinical effectiveness and cost-effectiveness of a manualised intervention to improve social functioning. Health Technology Assessment2016;20(52):1-282. [DOI: 10.3310/hta20520]McMurranM . RE: Cochrane Collaboration review - PEPS study [personal communication]. Email to: J Stoffers-Winterling 5 July 2018. McMurranM . Request for data on BPD subjects in the PEPS rcp-study for use a new Cochrane review [personal communication]. Email to: M Kongerslev 7 March 2017. ">McMurran 2016</a>; <a href="./references#CD012955-bbs2-0052" title="HagaE , AasE , GrøholtB , TørmoenAJ , MehlumL . Cost-effectiveness of dialectical behaviour therapy vs enhanced usual care in the treatment of adolescents with self-harm. Child and Adolescent Psychiatry and Mental Health2018;12:22. [DOI: 10.1186/s13034-018-0227-2] [PMC5928596] [PMID: 29743941]MehlumL , RambergM , TørmoenAJ , HagaE , DiepLM , StanleyBH , et al. Dialectical behavior therapy compared with enhanced usual care for adolescents with repeated suicidal and self-harming behavior: outcomes over a one-year follow-up. Journal of the American Academy of Child and Adolescent Psychiatry2016;55(4):295-300. [DOI: 10.1016/j.jaac.2016.01.005] [PMID: 27015720]MehlumL , TørmoenAJ , RambergM , HagaE , DiepLM , LabergS , et al. Dialectical behavior therapy for adolescents with repeated suicidal and self-harming behavior: a randomized trial. Journal of the American Academy of Child and Adolescent Psychiatry2014;53(10):1082-91. [DOI: 10.1016/j.jaac.2014.07.003] [PMID: 25245352]MehlumL . Re: regarding your study of DBT for your with suicidal behavior [personal communication] [Re: angående din studie om DBT for ungdom med selvmordsatferd [personlig kommunikation]]. Email to: E Faltinsen 5 December 2017. NCT00675129. Treatment for adolescents with deliberate self harm [A randomized controlled trial for repetitive deliberate self-harm and suicidal behaviours among Norwegian adolescents: a comparison between dialectical behaviour therapy adapted for adolescents (DBT-A) and enhanced usual care (EUC)]. www.clinicaltrials.gov/ct2/show/NCT00675129 (first received 6 May 2008). RamlethRK , GroholtB , DiepLM , WalbyFA , MehlumL . The impact of borderline personality disorder and sub-threshold borderline personality disorder on the course of self-reported and clinician-rated depression in self-harming adolescents. Borderline Personality Disorder and Emotion Dysregulation2017;4:22. [DOI: 10.1186/s40479-017-0073-5] [PMC5663078] [PMID: 29093819]">Mehlum 2014</a>; <a href="./references#CD012955-bbs2-0055" title="MortonJ , SnowdonS , GopoldM , GuymerE . Acceptance and commitment therapy group treatment for symptoms of borderline personality disorder: a public sector pilot study. Cognitive and Behavioral Practice2012;19(4):527-44. [DOI: 10.1016/j.cbpra.2012.03.005]MortonJ . Re: SV: regarding your study on acceptance and commitment therapy for BPD [personal communication]. Email to: EG Faltinsen 22 December 2017. ">Morton 2012</a>; <a href="./references#CD012955-bbs2-0057" title="NCT02033044. Cognitive rehabilitation versus psychoeducation in psychosocial functioning of borderline personality disorder [Randomized controlled trial comparing the effects on psychosocial functioning of cognitive rehabilitation versus psychoeducation in borderline personality disorder]. www.clinicaltrials.gov/ct2/show/NCT02033044 (first received 23 December 2013). PascualJC , PalomaresN , Ibáñez Á, PortellaMJ , ArzaR , ReyesR , et al. Efficacy of cognitive rehabilitation on psychosocial functioning in borderline personality disorder: a randomized controlled trial. BMC Psychiatry2015;15:255. [DOI: 10.1186/s12888-015-0640-5] [PMC4617906] [PMID: 26487284]">Pascual 2015</a>; <a href="./references#CD012955-bbs2-0058" title="PhilipsB , WennebergP , KonradssonP , FranckJ . Mentalization-based treatment for concurrent borderline personality disorder and substance use disorder: a randomized controlled feasibility study. European Addiction Research2018;24(1):1-8. [DOI: 10.1159/000485564] [PMC5969093] [PMID: 294028]">Philips 2018</a>; <a href="./references#CD012955-bbs2-0059" title="BarnicotK . Re: Regarding your study on DBT for self-harming patients [personal communication]. Email to: EG Faltinsen 28 February 2018. PriebeS , BhattiN , BarnicotK , BremnerS , GagliaA , KatsakouC , et al. Effectiveness and cost-effectiveness of dialectical behaviour therapy for self-harming patients with personality disorder: a pragmatic randomised controlled trial. Psychotherapy and Psychosomatics2012;81(6):356-65. [DOI: 10.1159/000338897] [PMID: 22964561]PriebeS . Supplemental information [personal communication]. Email to: M Kielsholm 20 May 2016. ">Priebe 2012</a>; <a href="./references#CD012955-bbs2-0060" title="RenesesB , FigueraD , SalcedoG , TrujilloM , López-IborJJ , GaliánM , et al. A controlled randomized study on the efficacy of short-term dinamic psychotherapy in borderline personality disorders (BPD). Preliminary results. European Psychiatry2011;26(Suppl 1):1040. [DOI: 10.1016/S0924-9338(11)72745-6] [P02-444]RenesesB , GaliánM , SerranoR , FigueraD , Fernandez Del MoralA , López-IborJJ , et al. A new time limited psychotherapy for BPD: preliminary results of a randomized and controlled trial. Actas Espanolas de Psiquiatria2013;41(3):139-48. [PMID: 23803797]">Reneses 2013</a>; <a href="./references#CD012955-bbs2-0061" title="ISRCTN51304415. Nice OUtcomes for Referrals with Impulsivity, Self Harm and Eating Disorders: the NOURISHED study [A randomised controlled trial of mentalisation based therapy against specialist supportive clinical management in patients with both eating disorders and symptoms of borderline personality disorder]. www.isrctn.com/ISRCTN51304415 (first received 31 January 2011). RobinsonP , BarrettB , BatemanA , HakeemA , HellierJ , LemonskyF , et al. Study protocol for a randomized controlled trial of mentalization based therapy against specialist supportive clinical management in patients with both eating disorders and symptoms of borderline personality disorder. BMC Psychiatry2014;14:51. [DOI: 10.1186/1471-244X-14-51] [PMC3996076] [PMID: 24555511]RobinsonP , HellierJ , BarrettB , BarzdaitieneD , BatemanA , BogaardtA , et al. The NOURISHED randomised controlled trial comparing mentalisation-based treatment for eating disorders (MBT-ED) with specialist supportive clinical management (SSCM-ED) for patients with eating disorders and symptoms of borderline personality disorder. Trials2016;17(1):549. [DOI: 10.1186/s13063-016-1606-8] [PMC5114835] [PMID: 27855714]">Robinson 2016</a>; <a href="./references#CD012955-bbs2-0062" title="ISRCTN95266816. The emergence of personality disorder traits in adolescents who deliberately self harm and the potential for using a mentalisation based treatment approach as an early intervention for such individuals: a randomised controlled trial. www.isrctn.com/ISRCTN95266816 (first received 29 October 2007). RossouwT . Mentalisation based treatment for adolescents with self harm: an RCT. European Child &amp; Adolescent Psychiatry2015;24(1 Suppl):S113. [DOI: 10.1007%2Fs00787-015-0714-4.pdf] [W1-02-02]RossouwT . Self harm in adolescence, is MBT the answer?: an RCT. Adolescent Psychiatry2012;2(1):102. [DOI: 10.2174/2210676611202010077]RossouwTI , FonagyP . Mentalization-based treatment for self-harm in adolescents: a randomized controlled trial. Journal of the American Academy of Child and Adolescent Psychiatry2012;51(12):1304-13.e3. [DOI: 10.1016/j.jaac.2012.09.018] [PMID: 23200287]">Rossouw 2012b</a>; <a href="./references#CD012955-bbs2-0064" title="SantistebanDA , MenaMP , MuirJ , McCabeBE , AbaloC , CummingsAM . The efficacy of two adolescent substance abuse treatments and the impact of comorbid depression: results of a small randomized controlled trial. Psychiatric Rehabilitation Journal2015;38(1):55-64. [DOI: 10.1037/prj0000106] [PMC5021542] [PMID: 25799306]">Santisteban 2015</a>; <a href="./references#CD012955-bbs2-0066" title="ISRCTN97589104. Evaluation of a group training for adolescents (emotion regulation training) with emotion regulation problems - a randomised controlled clinical trial. www.isrctn.com/ISRCTN97589104 (first received 23 August 2007). SchuppertHM , TimmermanME , BlooJ , Van GemertTG , WiersemaHM , MinderaaRB , et al. Emotion regulation training for adolescents with borderline personality disorder traits: a randomized controlled trial. Journal of the American Academy of Child &amp; Adolescent Psychiatry2012;51(12):1314-23. [DOI: 10.1016/j.jaac.2012.09.002] [PMID: 23200288]">Schuppert 2012</a>; <a href="./references#CD012955-bbs2-0067" title="NCT01904227. Intensified, inpatient adaptation of dialectical behavior therapy (DBT) (REDBT) [A randomized controlled study of the efficacy of an intensified, inpatient adaptation of dialectical behavior therapy (DBT) for a population of borderline patients (young adults/adults: 18-40), compared with standard outpatient DBT]. www.clinicaltrials.gov/ct2/show/NCT01904227 (first received 11 July 2013). SinnaeveR , Van den BoschLM , Van Steenbergen-WeijenburgKM . Change in interpersonal functioning during psychological interventions for borderline personality disorder — a systematic review of measures and efficacy. Personality and Mental Health2015;9(3):173-94. [DOI: 10.1002/pmh.1296] [PMID: 26058794]SinnaeveR , Van den BoschLMC , Hakkaart-van RoijenL , VansteelandtK . Effectiveness of step-down versus outpatient dialectical behaviour therapy for patients with severe levels of borderline personality disorder: a pragmatic randomized controlled trial. Borderline Personality Disorder and Emotion Dysregulation2018;5:12. [DOI: 10.1186/s40479-018-0089-5] [PMC6040072] [PMID: 30002832]SinnaeveR . Cochrane Collaboration review [personal communication]. Email to: J Stoffers-Winterling 11 June 2018. SinnaeveR . Re: BPDSI subscale data Sinnaeve et al (2018) [personal communication]. Email to: A Tadorovac 15 November 2018. SinnaeveR . RE: BPDSI subscale data Sinnaeve et al (2018) [personal communication] [RE: BPDSI subschale data Sinnaeve et al (2018) [personlig kommunikation]]. Email to: A Todorovac 15 November 2018. SinnaeveR . RE: BPDSI subscale data Sinnaeve et al (2018) [personal communication] [RE: BPDSI subschale data Sinnaeve et al (2018) [personlig kommunikation]]. Email to: A Todorovac 9 October 2018. Van den BoschLM , SinnaeveR , Hakkaart-van RoijenL , Van FurthEF . Efficacy and cost-effectiveness of an experimental short-term inpatient dialectical behavior therapy (DBT) program: study protocol for a randomized controlled trial. Trials2014;15:152. [DOI: 10.1186/1745-6215-15-152] [PMC4017823] [PMID: 24885551]Van RoijenLH , SinnaeveR , BouwmansC , Van Den BoschL . Cost-effectiveness and cost-utility of shortterm inpatient dialectical behavior therapy for chronically parasuicidal BPD (young) adults. Journal of Mental Health Policy and Economics2015;18(Suppl 1):S19-20. [www.icmpe.org/test1/journal/issues/v18s1toc.html]">Sinnaeve 2018</a>; <a href="./references#CD012955-bbs2-0069" title="SolerJ , PascualJC , TianaT , CebriàA , BarrachinaJ , CampinsMJ , et al. Dialectical behaviour therapy skills training compared to standard group therapy in borderline personality disorder: a 3-month randomised controlled clinical trial. Behaviour Research and Therapy2009;47(5):353-8. [DOI: 10.1016/j.brat.2009.01.013] [PMID: 19246029]SolerJ . Question regarding your BPD trials [personal communication]. Email to: J Stoffers 15 December 2010. ">Soler 2009</a>; <a href="./references#CD012955-bbs2-0072" title="Van den BoschLM , KoeterMW , StijnenT , VerheulR , Van den BrinkW . Sustained efficacy of dialectical behaviour therapy for borderline personality disorder. Behaviour Research and Therapy2005;43(9):1231-41. [DOI: 10.1016/j.brat.2004.09.008] [PMID: 16005708]Van den BoschLM , VerheulR , SchippersGM , Van den BrinkW . Dialectical behavior therapy of borderline patients with and without substance use problems. Implementation and long-term effects. Addictive Behaviors2002;27(6):911-23. [DOI: 10.1016/s0306-4603(02)00293-9] [PMID: 12369475]Van den BoschLMC . Efficacy of dialectical behaviour therapy in the treatment of female borderline patients with and without substance abuse problems: results of a Dutch study [Dialectische gedragstherapie bij Nederlandse vrouwen met een borderline persoonlijkheidsstoornis, met en zonder verslavingsproblemen]. Tijdschrift voor Psychiatrie2005;47(3):127-37. [www.tijdschriftvoorpsychiatrie.nl/assets/articles/articles_1335pdf.pdf]VerheulR , Van den BoschLM , KoeterMW , De RidderMA , StijnenT , Van den BrinkW . Dialectical behaviour therapy for women with borderline personality disorder: 12-month, randomised clinical trial in The Netherlands. British Journal of Psychiatry2003;182:135-40. [DOI: 10.1192/bjp.182.2.135] [PMID: 12562741]">Van den Bosch 2005</a>; <a href="./references#CD012955-bbs2-0075" title="ZanariniMC , ConkeyLC , TemesCM , FitzmauriceGM . Randomized controlled trial of web-based psychoeducation for women with borderline personality disorder. Journal of Clinical Psychiatry2018;79(3):16m11153. [DOI: 10.4088/JCP.16m11153] [PMC5764827] [PMID: 28703950]">Zanarini 2018</a>). The 19 remaining trials did not describe exactly how treatment allocation had been achieved, so we rated these trials at unclear risk of bias (<a href="./references#CD012955-bbs2-0003" title="AntonsenBT , JohansenMS , RøFG , KvarsteinEH , WilbergT . Is reflective functioning associated with clinical symptoms and long-term course in patients with personality disorders?Comprehensive Psychiatry2016;64:46-58. [DOI: 10.1016/j.comppsych.2015.05.016] [PMID: 26104432]AntonsenBT , KlungsøyrO , KampsA , HummelenB , JohansenMS , PedersenG , et al. Step-down versus outpatient psychotherapeutic treatment for personality disorders: 6-year follow-up of the Ullevål personality project. BMC Psychiatry2014;14:119. [DOI: 10.1186/1471-244X-14-119] [PMC4000615] [PMID: 24758722]AntonsenBT , KvarsteinEH , Urnes Ø, HummelenB , KarterudS , WilbergT . Favourable outcome of long-term combined psychotherapy for patients with borderline personality disorder: six-year follow-up of a randomized study. Psychotherapy Research2017;27(1):51-63. [DOI: 10.1080/10503307.2015.1072283] [PMID: 26261865]ArnevikE , WilbergT , Urnes Ø, JohansenM , MonsenJT , KarterudS . Psychotherapy for personality disorders: short-term day hospital psychotherapy versus outpatient individual therapy - a randomized controlled study. European Psychiatry2009;24(2):71-8. [DOI: 10.1016/j.eurpsy.2008.09.004] [PMID: 19097870]GullestadFS , JohansenMS , HøglendP , KarterudS , WilbergT . Mentalization as a moderator of treatment effects: findings from a randomized clinical trial for personality disorders. Psychotherapy Research2013;23(6):674-89. [DOI: 10.1080/10503307.2012.684103] [PMID: 22612470]GullestadFS . Re: questions regarding your trial on day hospital step-down program [personal communication]. Email to: E Faltinsen 4 December 2017. KvarsteinEH , ArnevikE , HalsteinliV , RøFG , KarterudS , WilbergT . Health service costs and clinical gains of psychotherapy for personality disorders: a randomized controlled trial of day-hospital-based step-down treatment versus outpatient treatment at a specialist practice. BMC Psychiatry2013;13:315. [DOI: 10.1186/1471-244X-13-315] [PMC4222503] [PMID: 24268099]">Antonsen 2017</a>; <a href="./references#CD012955-bbs2-0004" title="BatemanA , FonagyP . 8-year follow-up of patients treated for borderline personality disorder: mentalization-based treatment versus treatment as usual. American Journal of Psychiatry2008;165(5):631-8. [DOI: 10.1176/appi.ajp.2007.07040636] [PMID: 18347003]BatemanA , FonagyP . Effectiveness of partial hospitalization in the treatment of borderline personality disorder: a randomized controlled trial. American Journal of Psychiatry1999;156(10):1563-9. [DOI: 10.1176/ajp.156.10.1563] [PMID: 10518167]BatemanA , FonagyP . Health care utilization costs for borderline personality disorder patients treated with psychoanalytically oriented partial hospitalization versus general psychiatric care. American Journal of Psychiatry2003;160(1):169-71. [10.1176/appi.ajp.160.1.169] [12505818]BatemanA , FonagyP . Treatment of borderline personality disorder with psychoanalytically oriented partial hospitalization: an 18-month follow-up. American Journal of Psychiatry2001;158(1):36-42. [DOI: 10.1176/appi.ajp.158.1.36] [PMID: 11136631]BatemanA . Important: question regarding your BPD trial for systematic review in Cochrane Collaboration [personal communication]. Email to: K Lieb, J Stoffers 14 December 2010. BatemanA . Intensive outpatient and partial hospital care for BPD. In: 157th annual meeting of the American Psychiatric Association. Psychotherapy and pharmacology: dissolving the mind-brain barrier; 2004 May 1-6; New York (NY). Arlington (VA): American Psychiatric Association, 2004:102. [Symposium 100B] [www.psychiatry.org/File%20Library/Psychiatrists/Directories/Library-and-Archive/conference_publications/am_program_2004.pdf]BatemanAW , FonagyP . Drs Bateman and Fonagy reply [to Stern R. Partial hospitalization for borderline personality disorder. American Journal of Psychiatry 2001;158(11):1932-3. DOI: 10.1176/appi.ajp.158.11.1932]. American Journal of Psychiatry2001;158(11):1932-3. [DOI: 10.1176/appi.ajp.158.11.1932-a]EvansC . Treatment benefits of psychoanalytically oriented partial hospitalisation were maintained over 18 months in borderline personality disorder. Evidence-Based Mental Health2001;4(3):73. [DOI: 10.1136/ebmh.4.3.73]FonagyP , BatemanAW . Mentalizing and borderline personality disorder. Journal of Mental Health2007;16(1):83-101. [DOI: 10.1080/09638230601182045]SternR . Partial hospitalization for borderline personality disorder. American Journal of Psychiatry2001;158(11):1932-3. [DOI: 10.1176/appi.ajp.158.11.1932] [PMID: 11691712]">Bateman 1999</a>; <a href="./references#CD012955-bbs2-0009" title="BianchiniV , CofiniV , CurtoM , LagrotteriaB , ManziA , NavariS , et al. Dialectical behavior therapy (DBT) for forensic psychiatric patients: an Italian pilot study. Criminal Behavior and Mental Health2019;29(9):122-30. [DOI: 10.1002/cbm.2102] [PMID: 30648303]">Bianchini 2019</a>; <a href="./references#CD012955-bbs2-0023" title="Feliu-SolerA , PascualJC , ElicesM , Martín-BlancoA , CarmonaC , CebollaA , et al. Fostering self-compassion and loving-kindness in patients with borderline personality disorder: a randomized pilot study. Clinical Psychology &amp; Psychotherapy2017;24(1):278-86. [DOI: 10.1002/cpp.2000] [PMID: 26818533]">Feliu‐Soler 2017</a>; <a href="./references#CD012955-bbs2-0027" title="GratzKL , BardeenJR , LevyR , Dixon-GordonKL , TullMT . Mechanisms of change in an emotion regulation group therapy for deliberate self-harm among women with borderline personality disorder. Behaviour Research and Therapy2015;65:29-35. [DOI: 10.1016/j.brat.2014.12.005] [PMC4306622] [PMID: 25557395]GratzKL , Dixon-GordonKL , TullMT . Predictors of treatment response to an adjunctive emotion regulation group therapy for deliberate self-harm among women with borderline personality disorder. Personality Disorders2014;5(1):97-107. [DOI: 10.1037/per0000062] [PMC4059504] [PMID: 2458806]GratzKL , TullMT , LevyR . Randomized controlled trial and uncontrolled 9-month follow-up of an adjunctive emotion regulation group therapy for deliberate self-harm among women with borderline personality disorder. Psychological Medicine2014;44(10):2099-112. [DOI: 10.1017/S0033291713002134] [PMID: 23985088]GratzKL . Question regarding your BPD trials [personal communication]. Email to: J Stoffers 11 December 2010. ">Gratz 2014</a>; <a href="./references#CD012955-bbs2-0029" title="HaeyenS , Van HoorenS , HutschemaekersG . Efficacy of art therapy in individuals with personality disorders cluster B/C: a randomised controlled trial. International Journal of Psychology July 2016;51:60. [DOI: 10.1521/pedi_2017_31_312] [PMID: 28926306]HaeyenS , Van HoorenS , Van der VeldW , HutschemaekersG . Efficacy of art therapy in individuals with personality disorders cluster B/C: a randomised controlled trial. Journal of Personality Disorders2018;32(4):527-42. [DOI: 10.1521/pedi_2017_31_312] [PMID: 28926306]HaeyenS . Re: Cochrane Collaboration review of psychotherapies for BPD - your RCT of art therapy [personal communication]. Email to: J Stoffers-Winterling 18 August 2018. ">Haeyen 2018</a>; <a href="./references#CD012955-bbs2-0033" title="JørgensenCR , BøyeR , AndersenD , Døssing BlaabjergAH , FreundC , JordetH , et al. Eighteen months post-treatment naturalistic follow-up study of mentalization-based therapy and supportive group treatment of borderline personality disorder: clinical outcomes and functioning. Nordic Psychology2014;66(4):254-73. [DOI: 10.1080/19012276.2014.963649]JørgensenCR , FreundC , BøyeR , JordetH , AndersenD , KjølbyeM . Outcome of mentalization-based and supportive psychotherapy in patients with borderline personality disorder: a randomized trial. Acta Psychiatrica Scandinavica2013;127(4):305-17. [DOI: 10.1111/j.1600-0447.2012.01923.x] [PMID: 22897123]JorgensenCR . SV: questions on your trial regarding MBT for BPD patients [personal communication]. Email to: EG Faltinsen 28 November 2017. ">Jørgensen 2013</a>; <a href="./references#CD012955-bbs2-0034" title="KamalabadiMJ , AhmadiSA , EtemadiO , FatehizadehM , BahramiF , FiroozabadiA . A study of the effect of couple dialectical behavioral therapy on symptoms and quality of marital relationships and mental health of Iranian borderline personality couples: a controlled trial. Interdisciplinary Journal of Contemporary Research in Business2012;3(9):1480-7. [psycnet.apa.org/record/2012-22425-047]">Kamalabadi 2012</a>; <a href="./references#CD012955-bbs2-0035" title="KoonsCR , RobinsCJ , TweedJL , LynchTR , GonzalezAM , MorseJQ , et al. Efficacy of dialectical behavior therapy in women veterans with borderline personality disorder. Behavior Therapy2001;32(2):371-90. [DOI: 10.1016/S0005-7894(01)80009-5]">Koons 2001a</a>; <a href="./references#CD012955-bbs2-0053" title="MohamadizadehL , MakvandiB , PashaR , BakhtiarpourS , HafeziF . Comparing of the effect of dialectical behavior therapy (DBT) and schema therapy (ST) on reducing mood activity and suicidal thoughts in patients with borderline personality disorder. Acta Medica Mediterranea2017;33:1025-31. [DOI: 10.19193/0393-6384_2017_6_162] [www.actamedicamediterranea.com/archive/2017/medica-6/comparing-of-the-effect-of-dialectical-behavior-therapy-dbt-and-schema-therapy-st-on-reducing-mood-activity-and-suicidal-thoughts-in-patients-with-borderline-personality-disorder/pdf]">Mohamadizadeh 2017</a>; <a href="./references#CD012955-bbs2-0054" title="MoreyLC , LowmasterSE , HopwoodCJ . A pilot study of manual-assisted cognitive therapy with a therapeutic assessment augmentation for borderline personality disorder. Psychiatry Research2010;178(3):531-5. [DOI: 10.1016/j.psychres.2010.04.055] [PMID: 20537722]">Morey 2010</a>; <a href="./references#CD012955-bbs2-0056" title="NadortM , ArntzA , SmitJH , Giesen-BlooJ , EikelenboomJ , SpinhovenP , et al. Implementation of outpatient schema therapy for borderline personality disorder with versus without crisis support by the therapist outside office hours: a randomized trial. Behaviour Research and Therapy2009;47(11):961-73. [DOI: 10.1016/j.brat.2009.07.013] [PMID: 19698939]NadortM , ArntzA , SmitJH , Giesen-BlooJ , EikelenboomM , SpinhovenP , et al. Implementation of outpatient schema therapy for borderline personality disorder: study design. BMC Psychiatry2009;9:64. [DOI: 10.1186/1471-244X-9-64] [PMC2762959] [PMID: 19807925]NL1680 (NTR1781). Implementation of out-patient schema-focused therapy for borderline personality disorder in regular mental healthcare. www.trialregister.nl/trial/1680 (first received 29 April 2009). ">Nadort 2009</a>; <a href="./references#CD012955-bbs2-0063" title="SalzerS , CroppC , JaegerU , MasuhrO , Streeck-FischerA . Psychodynamic therapy for adolescents suffering from co-morbid disorders of conduct and emotions in an in-patient setting: a randomized controlled trial. Psychological Medicine2014;44(10):2213-22. [DOI: 10.1017/S003329171300278X] [PMID: 24229481]SalzerS , Streeck-FischerA . The psychoanalytic-interactional method (PiM) for adolescents with borderline personality disorder [Die psychoanalytisch-interaktionelle methode (PiM) für adoleszente mit borderline-persönlichkeitsstörung]. Personlichkeitsstorungen Theorie und Therapie2015;19(1):67-76. [elibrary.klett-cotta.de/article/99.120110/ptt-19-1-67]SalzerS . AW: Re: Cochrane Review on psychotherapies for BPD - RCT testing PiM vs WL [personal communication] [AW:Re: Cochrane Review zur Psychotherapie bei BPS - RCT zu PiM vs WL [persönliche kommunikation]]. Email to: J Stoffers-Winterling 15 July 2018. ">Salzer 2014</a>; <a href="./references#CD012955-bbs2-0065" title="SchillingL , MoritzS , KötherU , NagelM . Preliminary results on acceptance, feasibility, and subjective efficacy of the add-on group intervention metacognitive training for borderline patients. Journal of Cognitive Psychotherapy2015;29(2):153-64. [DOI: 10.1891/0889-8391.29.2.153]SchillingL , MoritzS , KristonL , KriegerM , NagelM . Efficacy of metacognitive training for patients with borderline personality disorder: preliminary results. Psychiatry Research2018;262:459-64. [DOI: 10.1016/j.psychres.2017.09.024] [PMID: 28927866]SchillingL . Re Schilling 2015/2018 - Cochrane Review of psychotherapies for BPD [personal communication] [Re Schilling 2015/2018 - Cochrane Review zur Psychotherapie bei BPS [persönliche Kommunikation]]. Email to: J Stoffers-Winterling 22 January 2019. ">Schilling 2018</a>; <a href="./references#CD012955-bbs2-0068" title="SmithPN , GambleSA , CortNA , WardEA , HeH , TalbotNL . Attachment and alliance in the treatment of depressed, sexually abused women. Depression and Anxiety2012;29(2):123-30. [DOI: 10.1002/da.20913] [PMC3325338] [PMID: 22065593]SmithPN . Re: Cochrane Collaboration review of psychotherapies for BPD [personal communication]. Email to: J Stoffers-Winterling 05 July 2018. ">Smith 2012</a>; <a href="./references#CD012955-bbs2-0070" title="FertuckEA , KeilpJ , SongI , MorrisMC , WilsonST , BrodskyBS , et al. Higher executive control and visual memory performance predict treatment completion in borderline personality disorder. Psychotherapy and Psychosomatics2012;81(1):38-43. [DOI: 10.1159/000329700] [PMC3242704] [PMID: 22116411]NCT00533117. Treating suicidal behavior and self-mutilation in people with borderline personality disorder. www.clinicaltrials.gov/ct2/show/NCT00533117 (first received 19 September 2007). ">Stanley 2017</a>; <a href="./references#CD012955-bbs2-0071" title="TurnerRM . Naturalistic evaluation of dialectical behavior therapy-oriented treatment for borderline personality disorder. Cognitive and Behavioral Practice2000;7(4):413-9. [DOI: 10.1016/S1077-7229(00)80052-8]">Turner 2000</a>; <a href="./references#CD012955-bbs2-0073" title="WeinbergI , GundersonJG , HennenJ , Cutter CJ Jr. Manual assisted cognitive treatment for deliberate self-harm in borderline personality disorder patients. Journal of Personality Disorders2006;20(5):482-92. [DOI: 10.1521/pedi.2006.20.5.482] [PMID: 17032160]WilbergT . SV: separate data [personal communication] [SV: separat data [personlig kommunikation]]. Email to: M Kielsholm 25 May 2016. ">Weinberg 2006</a>; <a href="./references#CD012955-bbs2-0074" title="ZanariniMC , FrankenburgFR . A preliminary, randomized trial of psychoeducation for women with borderline personality disorder. Journal of Personality Disorders2008;22(3):284-90. [DOI: 10.1521/pedi.2008.22.3.284] [PMID: 18540800]ZanariniMC , FrankenburgFR . A randomized trial of psychoeducation for patients with BPD. In: 157th annual meeting of the American Psychiatric Association. Psychotherapy and psychopharmacology: dissolving the mind-brain barrier; 2004 May 1-6; New York (NY). Arlington (VA): American Psychiatric Association, 2004:102. [Symposium 100E] [www.psychiatry.org/File%20Library/Psychiatrists/Directories/Library-and-Archive/conference_publications/am_program_2004.pdf]">Zanarini 2008</a>) </p> </section> <section id="CD012955-sec-0071"> <h5 class="title">Allocation concealment</h5> <p>Thirty‐seven trials, reporting off‐site randomisation or notification of assignment by research coordinators not involved in delivering the therapy, were rated as having a low risk of bias (<a href="./references#CD012955-bbs2-0001" title="AmiantoF , FerreroA , PieròA , CairoE , RoccaG , SimonelliB , et al. Supervised team management, with or without structured psychotherapy, in heavy users of a mental health service with borderline personality disorder: a two-year follow-up preliminary randomized study. BMC Psychiatry2011;11:181. [DOI: 10.1186/1471-244X-11-181] [PMC3260092 ] [PMID: 22103890]NCT01356069. Efficacy of time-limited psychodynamic psychotherapy and informed clinical management in BPD high MHS users (HUMSH) [Sequential brief Adlerian psychodynamic psychotherapy in heavy users of a mental health service with borderline personality disorder: a two years follow-up preliminary randomized study]. clinicaltrials.gov/ct2/show/NCT01356069 (first received 16 May 2011). ">Amianto 2011</a>; <a href="./references#CD012955-bbs2-0002" title='AndreoliA , BurnandY , CochennecMF , MarieD , Di ClementeT , OhlendorfP . Psychoanalytic psychotherapy and venlafaxine among acutely suicidal borderline patients: a randomized clinical study. European Psychiatry2009;24(Suppl 1):S93. [DOI: 10.1016/S0924-9338(09)70326-8] [S18-03]AndreoliA , BurnandY , CochennecMF , OhlendorfP , FrambatiL , Gaudry-MaireD , et al. Disappointed love and suicide: a randomized controlled trial of "abandonment psychotherapy" among borderline patients. Journal of Personality Disorders2016;30(2):271-87. [DOI: 10.1521/pedi_2015_29_196] [PMID: 26111250]AndreoliA , BurnandY , FrambatiL , ManningD , FrancesA . Abandonment psychotherapy and psychosocial functioning among suicidal patients with borderline personality disorder: a 3-year naturalistic follow-up. Journal of Personality Disorders 2019 Feb 20 [Epub ahead of print]. [DOI: 10.1521/pedi_2019_33_423] [PMID: 30785852]AndreoliA . Re: your study in BPD - Cochrane Collaboration review [personal communication]. Email to: J Stoffers-Winterling 5 June 2018. '>Andreoli 2016</a>; <a href="./references#CD012955-bbs2-0004" title="BatemanA , FonagyP . 8-year follow-up of patients treated for borderline personality disorder: mentalization-based treatment versus treatment as usual. American Journal of Psychiatry2008;165(5):631-8. [DOI: 10.1176/appi.ajp.2007.07040636] [PMID: 18347003]BatemanA , FonagyP . Effectiveness of partial hospitalization in the treatment of borderline personality disorder: a randomized controlled trial. American Journal of Psychiatry1999;156(10):1563-9. [DOI: 10.1176/ajp.156.10.1563] [PMID: 10518167]BatemanA , FonagyP . Health care utilization costs for borderline personality disorder patients treated with psychoanalytically oriented partial hospitalization versus general psychiatric care. American Journal of Psychiatry2003;160(1):169-71. [10.1176/appi.ajp.160.1.169] [12505818]BatemanA , FonagyP . Treatment of borderline personality disorder with psychoanalytically oriented partial hospitalization: an 18-month follow-up. American Journal of Psychiatry2001;158(1):36-42. [DOI: 10.1176/appi.ajp.158.1.36] [PMID: 11136631]BatemanA . Important: question regarding your BPD trial for systematic review in Cochrane Collaboration [personal communication]. Email to: K Lieb, J Stoffers 14 December 2010. BatemanA . Intensive outpatient and partial hospital care for BPD. In: 157th annual meeting of the American Psychiatric Association. Psychotherapy and pharmacology: dissolving the mind-brain barrier; 2004 May 1-6; New York (NY). Arlington (VA): American Psychiatric Association, 2004:102. [Symposium 100B] [www.psychiatry.org/File%20Library/Psychiatrists/Directories/Library-and-Archive/conference_publications/am_program_2004.pdf]BatemanAW , FonagyP . Drs Bateman and Fonagy reply [to Stern R. Partial hospitalization for borderline personality disorder. American Journal of Psychiatry 2001;158(11):1932-3. DOI: 10.1176/appi.ajp.158.11.1932]. American Journal of Psychiatry2001;158(11):1932-3. [DOI: 10.1176/appi.ajp.158.11.1932-a]EvansC . Treatment benefits of psychoanalytically oriented partial hospitalisation were maintained over 18 months in borderline personality disorder. Evidence-Based Mental Health2001;4(3):73. [DOI: 10.1136/ebmh.4.3.73]FonagyP , BatemanAW . Mentalizing and borderline personality disorder. Journal of Mental Health2007;16(1):83-101. [DOI: 10.1080/09638230601182045]SternR . Partial hospitalization for borderline personality disorder. American Journal of Psychiatry2001;158(11):1932-3. [DOI: 10.1176/appi.ajp.158.11.1932] [PMID: 11691712]">Bateman 1999</a>; <a href="./references#CD012955-bbs2-0005" title="BatemanA , FonagyP . Impact of clinical severity on outcomes of mentalisation-based treatment for borderline personality disorder. British Journal of Psychiatry2013;203(3):221-7. [DOI: 10.1192/bjp.bp.112.121129] [PMID: 23887998]BatemanA , FonagyP . Randomized controlled trial of outpatient mentalization-based treatment versus structured clinical management for borderline personality disorder. American Journal of Psychiatry2009;166(12):1355-64. [DOI: 10.1176/appi.ajp.2009.09040539] [PMID: 19833787]BatemanA , FonagyP . Randomized controlled trial of outpatient mentalization-based treatment versus structured clinical management for borderline personality disorder. Supplementary data. ajp.psychiatryonline.org/doi/suppl/10.1176/appi.ajp.2009.09040539/suppl_file/ajp_166_12_1355_01.pdf (accessed 27 February 2020). BatemanA , O'ConnellJ , LorenziniN , GardnerT , FonagyP . A randomised controlled trial of mentalization-based treatment versus structured clinical management for patients with comorbid borderline personality disorder and antisocial personality disorder. BMC Psychiatry2016;16:304. [DOI: 10.1186/s12888-016-1000-9] [PMC5006360] [PMID: 27577562]BatemanA . Important question regarding your BPD trial for systematic review in Cochrane Collaboration [personal communication]. Email to: K Lieb 14 December 2010. BatemanAW . Mentalization, borderline personality disorder and what works for whom? Presentation at the 11th International Congress of the International Society for the Study of Personality Disorders; 2009 Aug 21-23. www.borderlinepersonalitydisorder.com/Conferences/ISSPD/isspd_09_Bateman (accessed 21 April 2010). ISRCTN27660668. Randomised controlled trial of manualised out-patient individual and group therapy for borderline personality disorder [Effectiveness of intensive out-patient psychotherapy for treatment of borderline personality disorder: a pragmatic randomised single blind controlled study]. www.isrctn.com/ISRCTN27660668 (first received 12 October 2008). ">Bateman 2009</a>; <a href="./references#CD012955-bbs2-0006" title="BellinoS , ParadisoE , ZizzaM , Di LorenzoR , BogettoF . Combined therapy with interpersonal psychotherapy of major depressed patients with borderline personality disorder: a comparison with pharmacotherapy [Terapia combinata con psicoterapia interpersonale di pazienti depressi maggiori con disturbo borderline di personalità: confronto con la farmacoterapia]. Journal of Psychopathology2005;11(1):34-42. [bit.ly/2rZUh5h]BellinoS , ZizzaM , RinaldiC , BogettoF . Combined treatment of major depression in patients with borderline personality disorder: a comparison with pharmacotherapy. Canadian Journal of Psychiatry2006;51(7):453-60. [DOI: 10.1177/070674370605100707] [PMID: 16838827]">Bellino 2006</a>; <a href="./references#CD012955-bbs2-0007" title="BellinoS , ZizzaM , RinaldiC , BogettoF . Combined therapy of major depression with concomitant borderline personality disorder: comparison of interpersonal and cognitive psychotherapy. Canadian Journal of Psychiatry2007;52(11):718-25. [DOI: 10.1177/070674370705201106] [PMID: 18399039]">Bellino 2007</a>; <a href="./references#CD012955-bbs2-0011" title="BohusM , DyerAS , PriebeK , KrügerA , KleindienstN , SchmahlC , et al. Dialectical behaviour therapy for post-traumatic stress disorder after childhood sexual abuse in patients with and without borderline personality disorder: a randomised controlled trial. Psychotherapy and Psychosomatics2013;82(4):221-33. [DOI: 10.1159/000348451] [PMID: 23712109]BrandS . AW: questions regarding your trial on emotional intelligence training for BPD [personal communication]. Email to: EG Faltinsen 28 November 2017. DBT Working Group at the Central Institute for Mental Health, Mannheim, Germany. Requested supplementary data (as supplied 1 October 2010). Data on file. NCT00481000. Dialectical cognitive traumatherapy (DCT) on patients with severe PTSD following sexual abuse (PASA) [Dialectical cognitive traumatherapy (DCT) on patients with severe posttraumatic stress disorder following sexual abuse - a randomised controlled trial]. clinicaltrials.gov/ct2/show/NCT00481000 (first received 31 May 2007). SteilR , DyerA , PriebeK , KleindienstN , BohusM . Dialectical behavior therapy for posttraumatic stress disorder related to childhood sexual abuse: a pilot study of an intensive treatment program. Journal of Traumatic Stress2011;24(1):102-6. [DOI: 10.1002/jts.20617] [PMID: 21351167]">Bohus 2013</a>; <a href="./references#CD012955-bbs2-0012" title="BorschmannR , BarrettB , HellierJM , ByfordS , HendersonC , RoseD , et al. Joint crisis plans for people with borderline personality disorder: feasibility and outcomes in a randomised controlled trial. British Journal of Psychiatry2013;202(5):357-64. [DOI: 10.1192/bjp.bp.112.117762] [PMID: 23637110]BorschmannR . Joint crisis plans for BPD - question on publication in British Journal of Psychiatry [pers communication]. Email to: J Stoffers-Winterling 22 August 2017. BorschmannR . RE: joint crisis plans for BPD - question on publication in British Journal of Psychiatry [personal communication]. Email to: J Stoffers-Winterling 22 August 2017. BorschmannR . The development and testing of joint crisis plans for people with borderline personality disorder: a feasibility study. ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.628499 (accessed 27 January 2019). HellierJ . RE: regarding your study on on MBT for eating disorders [personal communication]. Email to: E Faltinsen 27 March 2018. HellierJ . RE: regarding your study on on MBT for eating disorders [personal communication]. Email to: E Faltinsen 3 January 2018. HellierJ . SV: regarding your study on MBT for eating disorders [personal communication]. Email to: EG Faltinsen, P Robinson 27 March 2018. ISRCTN12440268. JOSHUA: a pilot randomised controlled trial of joint crisis plans for people who self harm. www.isrctn.com/ISRCTN12440268 (first received 17 September 2009). ">Borschmann 2013</a>; <a href="./references#CD012955-bbs2-0013" title="BosEH , Van WelE , AppeloMT , VerbraakMJP . A randomized controlled trial of a Dutch version of systems training for emotional predictability and problem solving for borderline personality disorder. Journal of Nervous and Mental Disease2010;198(4):299-304. [DOI: 10.1097/NMD.0b013e3181d619cf] [PMID: 20386260]Van WelEB , BosEH , AppeloMT , BerendsenEM , WillgerothFC , VerbraakMJPM . The efficacy of the systems training for emotional predictability and problem solving (STEPPS) in the treatment of borderline personality disorder. A randomized controlled trial [De effectiviteit van de vaardigheidstraining emotieregulatiestoornis (VERS) in de behandeling van de borderlinepersoonlijkheidsstoornis: een gerandomiseerd onderzoek]. Tijdschrift voor Psychiatrie2009;51(5):291-301. [PMID: 19434566]">Bos 2010</a>; <a href="./references#CD012955-bbs2-0014" title="Carmona i FarrésC , ElicesM , SolerJ , Domínguez-ClavéE , Pomarol-ClotetE , SalvadorR , et al. Effects of mindfulness training on borderline personality disorder: impulsivity versus emotional dysregulation. Mindfulness2019;10:1243-54. [DOI: 10.1007/s12671-018-1071-4]NCT03363230. Effects of mindfulness training on emotion regulation and impulsivity. www.clinicaltrials.gov/ct2/show/NCT03363230 (first received 30 November 2017). ">Carmona í Farrés 2019</a>; <a href="./references#CD012955-bbs2-0015" title="CarterG . Question regarding your BPD trial [personal communication]. Email to: J Stoffers 21 December 2010. CarterGL , WillcoxCH , LewinTJ , ConradAM , BenditN . Hunter DBT project: randomized controlled trial of dialectical behaviour therapy in women with borderline personality disorder. Australian and New Zealand Journal of Psychiatry2010;44(2):162-73. [DOI: 10.3109/00048670903393621] [PMID: 20113305]">Carter 2010</a>; <a href="./references#CD012955-bbs2-0016" title="CottrauxJ , NoteID , BoutitieF , MillieryM , GenouihlacV , YaoSN , et al. Cognitive therapy versus Rogerian supportive therapy in borderline personality disorder. Two-year follow-up of a controlled pilot study. Psychotherapy and Psychosomatics2009;78(5):307-16. [DOI: 10.1159/000229769] [PMID: 19628959]NCT00131781. Cognitive therapy versus supportive therapy in borderline personality disorder. www.clinicaltrials.gov/ct2/show/NCT00131781 (first received 18 August 2005). ">Cottraux 2009</a>; <a href="./references#CD012955-bbs2-0017" title="DavidsonK , LivingstoneS , McArthurK , DicksonL , GumleyA . An integrative complexity analysis of cognitive behaviour therapy sessions for borderline personality disorder. Psychology and Psychotherapy2007;80(Pt 4):513-23. [DOI: 10.1348/147608307X191535] [PMID: 17535542]DavidsonK , NorrieJ , TyrerP , GumleyA , TataP , MurrayH , et al. The effectiveness of cognitive behavior therapy for borderline personality disorder: results from the borderline personality disorder study of cognitive therapy (BOSCOT) trial. Journal of Personality Disorders2006;20(5):450-65. [DOI: 10.1521/pedi.2006.20.5.450] [PMC1852259] [PMID: 17032158]DavidsonK , TyrerP , GumleyA , TataP , NorrieJ , PalmerS , et al. A randomized controlled trial of cognitive behavior therapy for borderline personality disorder: rationale for trial, method, and description of sample. Journal of Personality Disorders2006;20(5):431-49. [DOI: 10.1521/pedi.2006.20.5.431] [PMC1847748] [PMID: 17032157]DavidsonKM , TyrerP , NorrieJ , PalmerSJ , TyrerH . Cognitive therapy v usual treatment for borderline personality disorder: prospective 6-year follow-up. British Journal of Psychiatry2010;197(6):456-62. [DOI: 10.1192/bjp.bp.109.074286] [PMID: 21119151]ISRCTN86177428. Borderline personality disorder study of cognitive therapy trial [A randomised controlled trial of cognitive therapy plus treatment as usual versus treatment as usual in the treatment of borderline personality disorder]. www.isrctn.com/ISRCTN86177428 (first received 22 July 2005). NCT00538135. BOSCOT: a randomised controlled trial of cognitive behavioural therapy in borderline personality disorder [BOSCOT: a randomised control trial of cognitive behavioural therapy plus treatment as usual versus treatment as usual in the treatment of borderline personality disorder]. www.clinicaltrials.gov/ct2/show/NCT00538135 (first received 29 September 2007). NorrieJ , DavidsonK , TataP , GumleyA . Influence of therapist competence and quantity of cognitive behavioural therapy on suicidal behaviour and inpatient hospitalisation in a randomised controlled trial in borderline personality disorder: further analyses of treatment effects in the BOSCOT study. Psychology and Psychotherapy2013;86(3):280-93. [DOI: 10.1111/papt.12004] [PMC4491320] [PMID: 23420622]PalmerS , DavidsonK , TyrerP , GumleyA , TataP , NorrieJ , et al. The cost-effectiveness of cognitive behavior therapy for borderline personality disorder: results from the BOSCOT trial. Journal of Personality Disorders2006;20(5):466-81. [DOI: 10.1521/pedi.2006.20.5.466] [PMC1852260] [PMID: 17032159]">Davidson 2006</a>; <a href="./references#CD012955-bbs2-0019" title="BuchheimA , Hörz-SagstetterS , DoeringS , RentropM , SchusterP , BuchheimP , et al. Change of unresolved attachment in borderline personality disorders: RCT study of transference-focused psychotherapy. Psychotherapy and Psychosomatics2017;86(5):314-6. [DOI: 10.1159/000460257] [PMID: 28903103]DiamondD , LevyKN , ClarkinJF , Fischer-KernM , CainNM , DoeringS , et al. Attachment and mentalization in female patients with comorbid narcissistic and borderline personality disorder. Personality Disorders2014;5(4):428-33. [DOI: 10.1037/per0000065] [PMID: 25314231]DiamondD , YeomansFE , SternB , LevyKN , HörzS , DoeringS , et al. Transference-focused psychotherapy for patients with comorbid narcissistic and borderline personality disorder. Psychoanalytic Inquiry2013;33(6):527-51. [DOI: 10.1080/07351690.2013.815087]DoeringS , HörzS , RentropM , Fischer-KernM , SchusterP , BeneckeC , et al. Transference-focused psychotherapy v treatment by community psychotherapists for borderline personality disorder: randomised controlled trial. British Journal of Psychiatry2010;196(5):389-95. [DOI: 10.1192/bjp.bp.109.070177] [PMID: 20435966]DoeringS . Author's reply [to Kleindienst N, Krumm B, Bohus M. Is transference-focused psychotherapy really efficacious for borderline personality disorder? British Journal of Psychiatry 2011;198(2):156-7. DOI: 10.1192/bjp.198.2.156b]. British Journal of Psychiatry2011;198(2):156-7. [DOI: 10.1192/bjp.198.2.157]DoeringS . Question regarding your BPD trial for systematic review in Cochrane Collaboration [personal communication]. Email to: K Lieb, J Stoffers 10 December 2010. Fischer-KernM , DoeringS , TaubnerS , HörzS , ZimmermannJ , RentropM , et al. Transference-focused psychotherapy for borderline personality disorder: change in reflective function. British Journal of Psychiatry2015;207(2):173-4. [DOI: 10.1192/bjp.bp.113.143842] [PMID: 25999334]KleindienstN , KrummB , BohusM . Is transference-focused psychotherapy really efficacious for borderline personality disorder?British Journal of Psychiatry2011;198(2):156-7. [DOI: 10.1192/bjp.198.2.156b] [PMID: 21282787]LevyKN , MeehanKB , YeomansFE . Transference-focused psychotherapy reduces treatment drop-out and suicide attempters compared with community psychotherapist treatment in borderline personality disorder. Evidence-based Mental Health2010;13(4):119. [DOI: 10.1136/ebmh.13.4.119] [PMID: 21036981]NCT00714311. Efficacy of transference-focused psychotherapy for borderline personality disorder [A randomized-controlled trial of transference-focused psychotherapy vs treatment by experienced community psychotherapists for borderline personality disorder]. www.clinicaltrials.gov/ct2/show/NCT00714311 (first received 9 July 2008). RentropM , MartiusP , BäumlJ , BuchheimP , DöeringS , HörzS . Patients with borderline personality disorder not participating in an RCT: are they different?Psychopathology2010;43(6):369-72. [DOI: 10.1159/000320351] [PMID: 20798576]">Doering 2010</a>, <a href="./references#CD012955-bbs2-0022" title="FeigenbaumJD , FonagyP , PillingS , JonesA , WildgooseA , BebbingtonPE . A real-world study of the effectiveness of DBT in the UK National Health Service. British Journal of Clinical Psychology2012;51(2):121-41. [DOI: 10.1111/j.2044-8260.2011.02017.x] [PMID: 22574799]">Feigenbaum 2012</a>; <a href="./references#CD012955-bbs2-0024" title="ArntzA , Stupar-RutenfransS , BlooJ , Van DyckR , SpinhovenP . Prediction of treatment discontinuation and recovery from borderline personality disorder: results from an RCT comparing schema therapy and transference-focused psychotherapy. Behaviour Research and Therapy2015;74:60-71. [DOI: 10.1016/j.brat.2015.09.002] [PMID: 26432172]Giesen-BlooJ , ArntzA . Questions concerning the randomized trial of schema-focused therapy vs transference-focused psychotherapy—reply. Archives of General Psychiatry2007;64(5):610-1. [DOI: 10.1001/archpsyc.64.5.610]Giesen-BlooJ , Van DyckR , SpinhovenP , Van TilburgW , DirksenC , Van AsseltT , et al. Errors in table and figure in: outpatient psychotherapy for borderline personality disorder: randomized trial of schema-focused therapy vs transference-focused psychotherapy. Archives of General Psychiatry2006;63(9):1008. Erratum for: Archives of General Psychiatry 2006;63(6):649-58. [DOI: 10.1001/archpsyc.63.9.1008]Giesen-BlooJ , Van DyckR , SpinhovenP , Van TilburgW , DirksenC , Van AsseltT , et al. Outpatient psychotherapy for borderline personality disorder: randomized trial of schema-focused therapy vs transference-focused psychotherapy. Archives of General Psychiatry2006;63(6):649-58. [DOI: 10.1001/archpsyc.63.6.649] [PMID: 16754838]SpinhovenP , Giesen-BlooJ , Van DyckR , KooimanK , ArntzA . The therapeutic alliance in schema-focused therapy and transference-focused psychotherapy for borderline personality disorder. Journal of Consulting and Clinical Psychology2007;75(1):104-15. [DOI: 10.1037/0022-006X.75.1.104] [PMID: 17295569]Van AsseltADI , DirksenCD , ArntzA , Giesen-BlooJH , Van DyckR , SpinhovenP , et al. Out-patient psychotherapy for borderline personality disorder: cost-effectiveness of schema-focused therapy v transference-focused psychotherapy. British Journal of Psychiatry2008;192(6):450-7. [DOI: 10.1192/bjp.bp.106.033597] [PMID: 18515897]Van AsseltADI , DirksenCD , ArntzA , SeverensJL . Difficulties in calculating productivity costs: work disability associated with borderline personality disorder. Value in Health2008;11(4):637-44. [DOI: 10.1111/j.1524-4733.2007.00288.x]YeomansF . Questions concerning the randomized trial of schema-focused therapy vs transference-focused psychotherapy. Archives of General Psychiatry2007;64(5):609-10. [DOI: 10.1001/archpsyc.64.5.609-c] [PMID: 17485613]">Giesen‐Bloo 2006</a>; <a href="./references#CD012955-bbs2-0028" title="GregoryRJ , ChlebowskiS , KangD , RemenA , SoderbergM . Psychodynamic therapy for borderline personality disorder and co-occurring alcohol use disorders: a newly designed ongoing study. Journal of the American Psychoanalytic Association2006;54(4):1331-4. [DOI: 10.1177/00030651060540040107] [PMID: 17354507]GregoryRJ , ChlebowskiS , KangD , RemenAL , SoderbergMG , StepkovitchJ , et al. A controlled trial of psychodynamic psychotherapy for co-occurring borderline personality disorder and alcohol use disorder. Psychotherapy2008;45(1):28-41. [DOI: 10.1037/0033-3204.45.1.28] [PMID: 22122363]GregoryRJ , DeLucia-DeranjaE , MogleJA . Dynamic deconstructive psychotherapy versus optimized community care for borderline personality disorder co-occuring with alcohol use disorders: a 30-month follow-up. Journal of Nervous and Mental Disease2010;198(4):292-8. [DOI: 10.1097/NMD.0b013e3181d6172d] [PMID: 20386259]GregoryRJ , RemenAL , SoderbergM , Ploutz-SnyderRJ . A controlled trial of psychodynamic psychotherapy for co-occurring borderline personality disorder and alcohol use disorder: six-month outcome. Journal of the American Psychoanalytic Association2009;57(1):199-205. [DOI: 10.1177/00030651090570011006] [PMID: 19270255]NCT00145678. Psychodynamic therapy for co-occurring borderline personality disorder and alcohol use disorder [Psychodynamic therapy for patients With borderline personality disorder and alcohol abuse]. www.clinicaltrials.gov/show/NCT00145678 (first received 1 September 2005). ">Gregory 2008b</a>; <a href="./references#CD012955-bbs2-0031" title="BrandS . AW: questions regarding your trial on emotional intelligence training for BPD [personal communication]. Email to: EG Faltinsen 28 November 2017. BrandS . Questions regarding your trial on emotional intelligence training for BPD [personal communication]. Email to: EG Faltinsen 28 November 2017. JahangardL , HaghighiM , BajoghliH , AhmadpanahM , GhaleihaA , ZarrabianMK , et al. Training emotional intelligence improves both emotional intelligence and depressive symptoms in inpatients with borderline personality disorder and depression. International Journal of Psychiatry in Clinical Practice2012;16(3):197-204. [DOI: 10.3109/13651501.2012.687454] [PMID: 22873719]">Jahangard 2012</a>; <a href="./references#CD012955-bbs2-0032" title="JochemsEC , Van der Feltz-CornelisCM , Van DamA , DuivenvoordenHJ , MulderCL . The effects of motivation feedback in patients with severe mental illness: a cluster randomized controlled trial. Neuropsychiatric Disease and Treatment2015;11:3049-64. [DOI: 10.2147/NDT.S95190] [PMC4686323] [PMID: 26715847]JochemsEC . Cochrane Collaboration review on psychotherapies for borderline PD [personal communication]. Email to: EG Faltinsen 2 July 2018. JochemsEC . Re: Cochrane Collaboration review on psychotherapies for borderline PD [personal communication]. Email to: J Stoffers-Winterling 02 July 2018. ">Jochems 2015</a>; <a href="./references#CD012955-bbs2-0036" title="KramerU , BergerT , KollyS , MarquetP , PreisigM , De RotenY , et al. Effects of motive-oriented therapeutic relationship in early-phase treatment of borderline personality disorder: a pilot study of a randomized trial. Journal of Nervous and Mental Disease2011;199(4):244-50. [DOI: 10.1097/NMD.0b013e3182125d19] [PMID: 21451348]KramerU , CasparF , DrapeauM . Change in biased thinking in a 10-session treatment for borderline personality disorder: further evidence of the motive-oriented therapeutic relationship. Psychotherapy Research2013;23(6):633-45. [DOI: 10.1080/10503307.2013.791404] [PMID: 23631622]">Kramer 2011</a>; <a href="./references#CD012955-bbs2-0037" title="BerthoudL , KramerU , CasparF , Pascual-LeoneA . Emotional processing in a ten-session general psychiatric treatment for borderline personality disorder: a case study. Personality and Mental Health2015;9(1):73-8. [DOI: 10.1002/pmh.1287] [PMID: 25711648]BerthoudL , Pascual-LeoneA , CasparF , TissotH , KellerS , RohdeKB , et al. Leaving distress behind: a randomized controlled study on change in emotional processing in borderline personality disorder. Psychiatry2017;80(2):139-54. [DOI: 10.1080/00332747.2016.1220230] [PMID: 28767333]KellerS , StelmaszczykK , KollyS , De RotenY , DesplandJN , CasparF , et al. Change in biased thinking in a treatment based on the motive-oriented therapeutic relationship for borderline personality disorder. Journal of Personality Disorders2018;32(Suppl):75-92. [DOI: 10.1521/pedi.2018.32.supp.75] [PMID: 29388899]KramerU , FlückigerC , KollyS , CasparF , MarquetP , DesplandJN , et al. Unpacking the effects of therapist responsiveness in borderline personality disorder: motive-oriented therapeutic relationship, patient in-session experience, and the therapeutic alliance. Psychotherapy and Psychosomatics2014;83(6):386-7. [DOI: 10.1159/000365400] [PMID: 25324025]KramerU , KellerS , CasparF , De RotenY , DesplandJN , KollyS . Early change in coping strategies in responsive treatments for borderline personality disorder: a mediation analysis. Journal of Consulting and Clinical Psychology2017;85(5):530-5. [DOI: 10.1037/ccp0000196] [PMID: 28425747]KramerU , KollyS , BerthoudL , KellerS , PreisigM , CasparF , et al. Effects of motive-oriented therapeutic relationship in a ten-session general psychiatric treatment of borderline personality disorder: a randomized controlled trial. Psychotherapy and Psychosomatics2014;83(3):176-86. [DOI: 10.1159/000358528] [PMID: 24752034]KramerU , StulzN , BerthoudL , CasparF , MarquetP , KollyS , et al. The shorter the better? A follow-up analysis of 10-session psychiatric treatment including the motive-oriented therapeutic relationship for borderline personality disorder. Psychotherapy Research2017;27(3):362-70. [DOI: 10.1080/10503307.2015.1110635] [PMID: 26684670]NCT01896024. Effects of motive-oriented therapeutic relationship in the early-phase treatment of borderline personality disorder (MOTR). www.clinicaltrials.gov/ct2/show/NCT01896024 (first received 5 July 2013). ">Kramer 2014</a>; <a href="./references#CD012955-bbs2-0038" title="KramerU , Pascual-LeoneA , BerthoudL , De RotenY , MarquetP , KollyS , et al. Assertive anger mediates effects of dialectical behaviour-informed skills training for borderline personality disorder: a randomized controlled trial. Clinical Psychology &amp; Psychotherapy2016;23(3):189-202. [DOI: 10.1002/cpp.1956] [PMID: 25864773]KramerU . The role of coping change in borderline personality disorder: a process-outcome analysis on dialectical-behaviour skills training. Clinical Psychology &amp; Psychotherapy2017;24(2):302-11. [DOI: 10.1002/cpp.2017] [PMID: 27098296]">Kramer 2016</a>; <a href="./references#CD012955-bbs2-0039" title="KredlowMA , SzuhanyKL , LoS , XieH , GottliebJD , RosenbergSD , et al. Cognitive behavioral therapy for posttraumatic stress disorder in individuals with severe mental illness and borderline personality disorder. Psychiatry Research2017;249:86-93. [DOI: 10.1016/j.psychres.2016.12.045] [PMC5325773] [PMID: 28086181]MueserK . Re: question regarding your trial on CBT for BPD patients [personal communication]. Email to: EG Faltinsen 28 November 2017. ">Kredlow 2017a</a>; <a href="./references#CD012955-bbs2-0040" title="KredlowMA , SzuhanyKL , LoS , XieH , GottliebJD , RosenbergSD , et al. Cognitive behavioral therapy for posttraumatic stress disorder in individuals with severe mental illness and borderline personality disorder. Psychiatry Research2017;249:86-93. [DOI: 10.1016/j.psychres.2016.12.045] [PMC5325773] [PMID: 28086181]MueserKT , GottliebJD , XieH , LuW , YanosPT , RosenbergSD , et al. Evaluation of cognitive restructuring for post-traumatic stress disorder in people with severe mental illness.. British Journal of Psychiatry2015;206(6):501-8. [DOI: 10.1192/bjp.bp.114.147926] [PMC4450219] [PMID: 25858178]MueserKT , RosenbergSD , XieH , JankowskiMK , BoltonEE , LuW , et al. A randomized controlled trial of cognitive-behavioral treatment for posttraumatic stress disorder in severe mental illness. Journal of Consulting and Clinical Psychology2008;76(2):259-71. [DOI: 10.1037/0022-006X.76.2.259] [PMC3916092] [PMID: 18377122]MueserKT . Re: question regarding your trial on CBT for PTSD participants [personal communication]. Email to: E Faltinsen 28 November 2018. ">Kredlow 2017b</a>; <a href="./references#CD012955-bbs2-0041" title="LaurenssenEM , WestraD , KikkertMJ , NoomMJ , EerenHV , Van BroekhuyzenAJ , et al. Day hospital mentalization-based treatment (MBT-DH) versus treatment as usual in the treatment of severe borderline personality disorder: protocol of a randomized controlled trial. BMC Psychiatry2014;14:149. [DOI: 10.1186/1471-244X-14-149] [PMC4045960] [PMID: 24886402]LaurenssenEMP , LuytenP , KikkertMJ , WestraD , PeenJ , SoonsMBJ , et al. Day hospital mentalization-based treatment v specialist treatment as usual in patients with borderline personality disorder: randomized controlled trial. Psychological Medicine2018;48(15):2522-9. [DOI: 10.1017/S0033291718000132] [PMID: 29478425]NL2058 (NTR2175). Mentalisation-based treatment versus care-as-usual in the treatment of severe borderline personality disorders. www.trialregister.nl/trial/2058 (first received 21 January 2010). ">Laurenssen 2018</a>; <a href="./references#CD012955-bbs2-0042" title="LeichsenringF , MasuhrO , JaegerU , RabungS , DallyA , DümpelmannM , et al. Psychoanalytic-interactional therapy versus psychodynamic therapy by experts for personality disorders: a randomized controlled efficacy-effectiveness study in cluster B personality disorders. Psychotherapy and Psychosomatics2016;85(2):71-80. [DOI: 10.1159/000441731] [PMID: 26808580]">Leichsenring 2016</a>; <a href="./references#CD012955-bbs2-0047" title="BedicsJD , AtkinsDC , ComtoisKA , LinehanMM . Treatment differences in the therapeutic relationship and introject during a 2-year randomized controlled trial of dialectical behavior therapy versus nonbehavioral psychotherapy experts for borderline personality disorder. Journal of Consulting and Clinical Psychology2012;80(1):66-77. [DOI: 10.1037/a0026113] [PMC3265694] [PMID: 22061867]BedicsJD , AtkinsDC , ComtoisKA , LinehanMM . Weekly therapist ratings of the therapeutic relationship and patient introject furing the course of dialectical behavioral therapy for the treatment of borderline personality disorder. Psychotherapy2012;49(2):231-40. [DOI: 10.1037/a0028254] [PMID: 22642526]BedicsJD , AtkinsDC , HarnedMS , LinehanMM . The therapeutic alliance as a predictor of outcome in dialectical behavior therapy versus nonbehavioral psychotherapy by experts for borderline personality disorder. Psychotherapy2015;52(1):67-77. [DOI: 10.1037/a0038457] [PMID: 25751116]BrownMZ , LinehanMM , ComtoisKA , MurrayA , ChapmanAL . Shame as a prospective predictor of self-inflicted injury in borderline personality disorder: a multi-modal analysis. Behaviour Research and Therapy2009;47(10):815-22. [DOI: 10.1016/j.brat.2009.06.008] [PMC2761705] [PMID: 19596223 ]CoyleTN , ShaverJA , LinehanMM . On the potential for iatrogenic effects of psychiatric crisis services: the example of dialectical behavior therapy for adult women with borderline personality disorder. Journal of Consulting and Clinical Psychology2018;86(2):116-24. [DOI: 10.1037/ccp0000275] [PMID: 29369662]HarnedMS , ChapmanAL , Dexter-MazzaET , MurrayA , ComtoisKA , LinehanMM . Treating co-occurring Axis I disorders in recurrently suicidal women with borderline personality disorder: a 2-year randomized trial of dialectical behavior therapy versus community treatment by experts. Journal of Consulting and Clinical Psychology2008;76(6):1068-75. [DOI: 10.1037/a0014044] [PMID: 19045974]HarnedMS , ChapmanAL , Dexter-MazzaET , MurrayA , ComtoisKA , LinehanMM . Treating co-occurring Axis I disorders in recurrently suicidal women with borderline personality disorder: a 2-year randomized trial of dialectical behavior therapy versus community treatment by experts. Personality Disorders: Theory, Research, and Treatment2009;S(1):35-45. [DOI: 10.1037/1949-2715.S.1.35]HarnedMS , JacksonSC , ComtoisKA , LinehanMM . Dialectical behavior therapy as a precursor to PTSD treatment for suicidal and/or self-injuring women with bordreline personality disorder. Journal of Traumatic Stress2010;23(4):421-9. [DOI: 10.1002/jts.20553] [PMID: 20648564]LindenboimN , ComtoisKA , LinehanMM . Skills practice in dialectical behavior therapy for suicidal women meeting criteria for borderline personality disorder. Cognitive and Behavioral Practice2007;14(2):147-56. [DOI: 10.1016/j.cbpra.2006.10.004]LinehanMM , ComtoisKA , MurrayAM , BrownMZ , GallopRJ , HeardHL , et al. Two-year randomized controlled trial and follow-up of dialectical behavior therapy vs therapy by experts for suicidal behaviors and borderline personality disorder. Archives of General Psychiatry2006;63(7):757-66. [DOI: 10.1001/archpsyc.63.7.757] [PMID: 16818865]LinehanMM . Error in table in: two-year randomized controlled trial and follow-up of dialectical behavior therapy vs therapy by experts for suicidal behaviors and borderline personality disorder. Archives of General Psychiatry2007;64(12):1401. Erratum for: Archives of General Psychiatry 2007;64(12):1401. McMainS . Dialectic behaviour therapy reduces suicide attempts compared with non-behavioural psychotherapy in women with borderline personality disorder. Evidence-Based Mental Health2007;10(1):18. [DOI: 10.1136/ebmh.10.1.18] [PMID: 17255387]NeacsiuAD , LunguA , HarnedMS , RizviSL , LinehanMM . Impact of dialectical behavior therapy versus community treatment by experts on emotional experience, expression, and acceptance in borderline personality disorder. Behaviour Research and Therapy2014;53:47-54. [DOI: 10.1016/j.brat.2013.12.004] [PMC3955205] [PMID: 24418652]NeacsiuAD , RizviSL , LinehanMM . Dialectical behavior therapy skills use as a mediator and outcome of treatment for borderline personality disorder. Behaviour Research and Therapy2010;48(9):832-9. [DOI: 10.1016/j.brat.2010.05.017] [PMC2914145] [PMID: 20579633]SecristCD . The Role of Executive Functioning in the Treatment of Borderline Personality Disorder [PhD thesis]. Washington (DC): University of Washington, 2014. ">Linehan 2006</a>; <a href="./references#CD012955-bbs2-0049" title="CaseBG . Letter to the editor on 'McMain SF, Links PS, Gnam WH, Guimond T, Cardish RJ, Korman L, et al. A randomized trial of dialectical behavior therapy versus general psychiatric management for borderline personality disorder. American Journal of Psychiatry 2009;166(12):1365-74. DOI: 10.1176/appi.ajp.2009.09010039'. American Journal of Psychiatry2010;167(4):475. [DOI: 10.1176/appi.ajp.2009.09101532] [PMID: 20360332 ]ISRCTN02634417. Hope for chronically suicidal patient: evaluating the clinical and health services impact of dialectical behaviour therapy (DBT) in individuals with borderline personality disorder [Evaluating the clinical and health services impact of dialectical behaviour therapy (DBT) in individuals with borderline personality disorder: a randomised controlled trial]. www.isrctn.com/ISRCTN02634417 (first received 16 November 2005). [DOI: 10.1186/ISRCTN02634417]McMainSF , FitzpatrickS , BoritzT , BarnhartR , LinksP , StreinerDL . Outcome trajectories and prognostic factors for suicide and self-harm behaviors in patients with borderline personaliy disorder following one year of outpatient psychotherapy. Journal of Personality Disorders2018;32(4):497-512. [DOI: 10.1521/pedi_2017_31_309] [PMID: 28910214]McMainSF , LinksPS , GnamWH , GuimondT , CardishRJ , KormanL , et al. A randomized trial of dialectical behavior therapy versus general psychiatric management for borderline personality disorder. American Journal of Psychiatry2009;166(12):1365-74. [DOI: 10.1176/appi.ajp.2009.09010039] [PMID: 19755574]McMainSF . Dr McMain replies to letter to the editor on 'McMain SF, Links PS, Gnam WH, Guimond T, Cardish RJ, Korman L, et al. A randomized trial of dialectical behavior therapy versus general psychiatric management for borderline personality disorder. American Journal of Psychiatry 2009;166(12):1365-74. DOI: 10.1176/appi.ajp.2009.09010039'. American Journal of Psychiatry2010;167(4):475-6. [DOI: 10.1176/appi.ajp.2009.09101532r)]NCT00154154. Hope for the chronically suicidal patient [Hope for the chronically suicidal patient: evaluating the clinical and health services impact of dialectical behaviour therapy in individuals with borderline personality disorder]. www.clinicaltrials.gov/ct2/show/NCT00154154 (first received 7 September 2005). ">McMain 2009</a>; <a href="./references#CD012955-bbs2-0050" title="McMainSF , GuimondT , BarnhartR , HabinskiL , StreinerDL . A randomized trial of brief dialectical behaviour therapy skills training in suicidal patients suffering from borderline disorder. Acta Psychiatrica Scandinavica2017;135(2):138-48. [DOI: 10.1111/acps.12664] [PMID: 27858962]">McMain 2017</a>; <a href="./references#CD012955-bbs2-0051" title="McMurranM , CrawfordMJ , ReillyJ , DelportJ , McCroneP , WhithamD , et al. Psychoeducation with problem-solving (PEPS) therapy for adults with personality disorder: a pragmatic randomised controlled trial to determine the clinical effectiveness and cost-effectiveness of a manualised intervention to improve social functioning. Health Technology Assessment2016;20(52):1-282. [DOI: 10.3310/hta20520]McMurranM . RE: Cochrane Collaboration review - PEPS study [personal communication]. Email to: J Stoffers-Winterling 5 July 2018. McMurranM . Request for data on BPD subjects in the PEPS rcp-study for use a new Cochrane review [personal communication]. Email to: M Kongerslev 7 March 2017. ">McMurran 2016</a>; <a href="./references#CD012955-bbs2-0052" title="HagaE , AasE , GrøholtB , TørmoenAJ , MehlumL . Cost-effectiveness of dialectical behaviour therapy vs enhanced usual care in the treatment of adolescents with self-harm. Child and Adolescent Psychiatry and Mental Health2018;12:22. [DOI: 10.1186/s13034-018-0227-2] [PMC5928596] [PMID: 29743941]MehlumL , RambergM , TørmoenAJ , HagaE , DiepLM , StanleyBH , et al. Dialectical behavior therapy compared with enhanced usual care for adolescents with repeated suicidal and self-harming behavior: outcomes over a one-year follow-up. Journal of the American Academy of Child and Adolescent Psychiatry2016;55(4):295-300. [DOI: 10.1016/j.jaac.2016.01.005] [PMID: 27015720]MehlumL , TørmoenAJ , RambergM , HagaE , DiepLM , LabergS , et al. Dialectical behavior therapy for adolescents with repeated suicidal and self-harming behavior: a randomized trial. Journal of the American Academy of Child and Adolescent Psychiatry2014;53(10):1082-91. [DOI: 10.1016/j.jaac.2014.07.003] [PMID: 25245352]MehlumL . Re: regarding your study of DBT for your with suicidal behavior [personal communication] [Re: angående din studie om DBT for ungdom med selvmordsatferd [personlig kommunikation]]. Email to: E Faltinsen 5 December 2017. NCT00675129. Treatment for adolescents with deliberate self harm [A randomized controlled trial for repetitive deliberate self-harm and suicidal behaviours among Norwegian adolescents: a comparison between dialectical behaviour therapy adapted for adolescents (DBT-A) and enhanced usual care (EUC)]. www.clinicaltrials.gov/ct2/show/NCT00675129 (first received 6 May 2008). RamlethRK , GroholtB , DiepLM , WalbyFA , MehlumL . The impact of borderline personality disorder and sub-threshold borderline personality disorder on the course of self-reported and clinician-rated depression in self-harming adolescents. Borderline Personality Disorder and Emotion Dysregulation2017;4:22. [DOI: 10.1186/s40479-017-0073-5] [PMC5663078] [PMID: 29093819]">Mehlum 2014</a>; <a href="./references#CD012955-bbs2-0056" title="NadortM , ArntzA , SmitJH , Giesen-BlooJ , EikelenboomJ , SpinhovenP , et al. Implementation of outpatient schema therapy for borderline personality disorder with versus without crisis support by the therapist outside office hours: a randomized trial. Behaviour Research and Therapy2009;47(11):961-73. [DOI: 10.1016/j.brat.2009.07.013] [PMID: 19698939]NadortM , ArntzA , SmitJH , Giesen-BlooJ , EikelenboomM , SpinhovenP , et al. Implementation of outpatient schema therapy for borderline personality disorder: study design. BMC Psychiatry2009;9:64. [DOI: 10.1186/1471-244X-9-64] [PMC2762959] [PMID: 19807925]NL1680 (NTR1781). Implementation of out-patient schema-focused therapy for borderline personality disorder in regular mental healthcare. www.trialregister.nl/trial/1680 (first received 29 April 2009). ">Nadort 2009</a>; <a href="./references#CD012955-bbs2-0058" title="PhilipsB , WennebergP , KonradssonP , FranckJ . Mentalization-based treatment for concurrent borderline personality disorder and substance use disorder: a randomized controlled feasibility study. European Addiction Research2018;24(1):1-8. [DOI: 10.1159/000485564] [PMC5969093] [PMID: 294028]">Philips 2018</a>; <a href="./references#CD012955-bbs2-0059" title="BarnicotK . Re: Regarding your study on DBT for self-harming patients [personal communication]. Email to: EG Faltinsen 28 February 2018. PriebeS , BhattiN , BarnicotK , BremnerS , GagliaA , KatsakouC , et al. Effectiveness and cost-effectiveness of dialectical behaviour therapy for self-harming patients with personality disorder: a pragmatic randomised controlled trial. Psychotherapy and Psychosomatics2012;81(6):356-65. [DOI: 10.1159/000338897] [PMID: 22964561]PriebeS . Supplemental information [personal communication]. Email to: M Kielsholm 20 May 2016. ">Priebe 2012</a>; <a href="./references#CD012955-bbs2-0062" title="ISRCTN95266816. The emergence of personality disorder traits in adolescents who deliberately self harm and the potential for using a mentalisation based treatment approach as an early intervention for such individuals: a randomised controlled trial. www.isrctn.com/ISRCTN95266816 (first received 29 October 2007). RossouwT . Mentalisation based treatment for adolescents with self harm: an RCT. European Child &amp; Adolescent Psychiatry2015;24(1 Suppl):S113. [DOI: 10.1007%2Fs00787-015-0714-4.pdf] [W1-02-02]RossouwT . Self harm in adolescence, is MBT the answer?: an RCT. Adolescent Psychiatry2012;2(1):102. [DOI: 10.2174/2210676611202010077]RossouwTI , FonagyP . Mentalization-based treatment for self-harm in adolescents: a randomized controlled trial. Journal of the American Academy of Child and Adolescent Psychiatry2012;51(12):1304-13.e3. [DOI: 10.1016/j.jaac.2012.09.018] [PMID: 23200287]">Rossouw 2012b</a>; <a href="./references#CD012955-bbs2-0066" title="ISRCTN97589104. Evaluation of a group training for adolescents (emotion regulation training) with emotion regulation problems - a randomised controlled clinical trial. www.isrctn.com/ISRCTN97589104 (first received 23 August 2007). SchuppertHM , TimmermanME , BlooJ , Van GemertTG , WiersemaHM , MinderaaRB , et al. Emotion regulation training for adolescents with borderline personality disorder traits: a randomized controlled trial. Journal of the American Academy of Child &amp; Adolescent Psychiatry2012;51(12):1314-23. [DOI: 10.1016/j.jaac.2012.09.002] [PMID: 23200288]">Schuppert 2012</a>; <a href="./references#CD012955-bbs2-0067" title="NCT01904227. Intensified, inpatient adaptation of dialectical behavior therapy (DBT) (REDBT) [A randomized controlled study of the efficacy of an intensified, inpatient adaptation of dialectical behavior therapy (DBT) for a population of borderline patients (young adults/adults: 18-40), compared with standard outpatient DBT]. www.clinicaltrials.gov/ct2/show/NCT01904227 (first received 11 July 2013). SinnaeveR , Van den BoschLM , Van Steenbergen-WeijenburgKM . Change in interpersonal functioning during psychological interventions for borderline personality disorder — a systematic review of measures and efficacy. Personality and Mental Health2015;9(3):173-94. [DOI: 10.1002/pmh.1296] [PMID: 26058794]SinnaeveR , Van den BoschLMC , Hakkaart-van RoijenL , VansteelandtK . Effectiveness of step-down versus outpatient dialectical behaviour therapy for patients with severe levels of borderline personality disorder: a pragmatic randomized controlled trial. Borderline Personality Disorder and Emotion Dysregulation2018;5:12. [DOI: 10.1186/s40479-018-0089-5] [PMC6040072] [PMID: 30002832]SinnaeveR . Cochrane Collaboration review [personal communication]. Email to: J Stoffers-Winterling 11 June 2018. SinnaeveR . Re: BPDSI subscale data Sinnaeve et al (2018) [personal communication]. Email to: A Tadorovac 15 November 2018. SinnaeveR . RE: BPDSI subscale data Sinnaeve et al (2018) [personal communication] [RE: BPDSI subschale data Sinnaeve et al (2018) [personlig kommunikation]]. Email to: A Todorovac 15 November 2018. SinnaeveR . RE: BPDSI subscale data Sinnaeve et al (2018) [personal communication] [RE: BPDSI subschale data Sinnaeve et al (2018) [personlig kommunikation]]. Email to: A Todorovac 9 October 2018. Van den BoschLM , SinnaeveR , Hakkaart-van RoijenL , Van FurthEF . Efficacy and cost-effectiveness of an experimental short-term inpatient dialectical behavior therapy (DBT) program: study protocol for a randomized controlled trial. Trials2014;15:152. [DOI: 10.1186/1745-6215-15-152] [PMC4017823] [PMID: 24885551]Van RoijenLH , SinnaeveR , BouwmansC , Van Den BoschL . Cost-effectiveness and cost-utility of shortterm inpatient dialectical behavior therapy for chronically parasuicidal BPD (young) adults. Journal of Mental Health Policy and Economics2015;18(Suppl 1):S19-20. [www.icmpe.org/test1/journal/issues/v18s1toc.html]">Sinnaeve 2018</a>). Thirty‐five trials that did not provide enough information to enable a judgement to be made about adequacy of allocation concealment were rated as having an unclear risk of bias (<a href="./references#CD012955-bbs2-0003" title="AntonsenBT , JohansenMS , RøFG , KvarsteinEH , WilbergT . Is reflective functioning associated with clinical symptoms and long-term course in patients with personality disorders?Comprehensive Psychiatry2016;64:46-58. [DOI: 10.1016/j.comppsych.2015.05.016] [PMID: 26104432]AntonsenBT , KlungsøyrO , KampsA , HummelenB , JohansenMS , PedersenG , et al. Step-down versus outpatient psychotherapeutic treatment for personality disorders: 6-year follow-up of the Ullevål personality project. BMC Psychiatry2014;14:119. [DOI: 10.1186/1471-244X-14-119] [PMC4000615] [PMID: 24758722]AntonsenBT , KvarsteinEH , Urnes Ø, HummelenB , KarterudS , WilbergT . Favourable outcome of long-term combined psychotherapy for patients with borderline personality disorder: six-year follow-up of a randomized study. Psychotherapy Research2017;27(1):51-63. [DOI: 10.1080/10503307.2015.1072283] [PMID: 26261865]ArnevikE , WilbergT , Urnes Ø, JohansenM , MonsenJT , KarterudS . Psychotherapy for personality disorders: short-term day hospital psychotherapy versus outpatient individual therapy - a randomized controlled study. European Psychiatry2009;24(2):71-8. [DOI: 10.1016/j.eurpsy.2008.09.004] [PMID: 19097870]GullestadFS , JohansenMS , HøglendP , KarterudS , WilbergT . Mentalization as a moderator of treatment effects: findings from a randomized clinical trial for personality disorders. Psychotherapy Research2013;23(6):674-89. [DOI: 10.1080/10503307.2012.684103] [PMID: 22612470]GullestadFS . Re: questions regarding your trial on day hospital step-down program [personal communication]. Email to: E Faltinsen 4 December 2017. KvarsteinEH , ArnevikE , HalsteinliV , RøFG , KarterudS , WilbergT . Health service costs and clinical gains of psychotherapy for personality disorders: a randomized controlled trial of day-hospital-based step-down treatment versus outpatient treatment at a specialist practice. BMC Psychiatry2013;13:315. [DOI: 10.1186/1471-244X-13-315] [PMC4222503] [PMID: 24268099]">Antonsen 2017</a>; <a href="./references#CD012955-bbs2-0008" title="BellinoS , BozzatelloP , BogettoF . Combined treatment of borderline personality disorder with interpersonal psychotherapy and pharmacotherapy: predictors of response. Psychiatry Research2015;226(1):284-8. [DOI: 10.1016/j.psychres.2014.12.064] [isiarticles.com/bundles/Article/pre/pdf/34125.pdf]BellinoS , RinaldiC , BogettoF . Adaptation of interpersonal psychotherapy to borderline personality disorder: a comparison of combined therapy and single pharmacotherapy. Canadian Journal of Psychiatry2010;55(2):74-81. [DOI: 10.1177/070674371005500203] [PMID: 20181302]BellinoS . Question regarding your BPD trials for inclusion in Cochrane Collaboration review [personal communication]. Email to: J Stoffers-Winterling 19 December 2010. BellinoS . Re: question regarding your BPD trials [personal communication]. Email to: J Stoffers 16 December 2010. BozzatelloP , BellinoS . Combined therapy with interpersonal psychotherapy adapted for borderline personality disorder: a two-years follow-up. Psychiatry Research2016;240:151-6. [DOI: 10.1016/j.psychres.2016.04.014] [www.sciencedirect.com/science/article/pii/S0165178115302389]ZizzaM , FenocchioM , RinaldiC , BellinoS . Combined treatment of borderline personality disorder: a trial of modified interpersonal therapy. World Psychiatry2009;8(Suppl 1):234. ">Bellino 2010</a>; <a href="./references#CD012955-bbs2-0009" title="BianchiniV , CofiniV , CurtoM , LagrotteriaB , ManziA , NavariS , et al. Dialectical behavior therapy (DBT) for forensic psychiatric patients: an Italian pilot study. Criminal Behavior and Mental Health2019;29(9):122-30. [DOI: 10.1002/cbm.2102] [PMID: 30648303]">Bianchini 2019</a>; <a href="./references#CD012955-bbs2-0010" title="BlackD . Question regarding your BPD trial [personal communication]. Email to: J Stoffers 04 January 2011. BlackDW , AllenJ , McCormickB , BlumN . Treatment received by persons with BPD participating in a randomized clinical trial of the systems training for emotional predictability and problem solving programme. Personality and Mental Health2011;5(3):159-68. [DOI: 10.1002/pmh.167]BlackDW , AllenJ , St JohnD , PfohlB , McCormickB , BlumN . Predictors of response to systems training for emotional predictability and problem solving (STEPPS) for borderline personality disorder: an exploratory study. Acta Psychiatrica Scandinavica2009;120(1):53-61. [DOI: 10.1111/j.1600-0447.2008.01340.x] [PMC3665337] [PMID: 19183126]BlackDW , BlumN , PfohlB , St JohnD . The STEPPS group treatment program for outpatients with borderline personality disorder. Journal of Contemporary Psychotherapy2004;34(3):193-210. [DOI: 10.1023/B:JOCP.0000036630.25741.83]BlackDW , PfohlBM . Randomized clinical trial of STEPPS versus treatment as usual. In: 158th annual meeting of the American Psychiatric Association. Psychosomatic medicine: integrating psychiatry &amp; medicine; 2005 May 21-26; Atlanta (GA). Arlington (VA): American Psychiatric Association, 2005:104. [No. 1B] [www.psychiatry.org/File%20Library/Psychiatrists/Directories/Library-and-Archive/syllabus/am_syllabus_2005.pdf]BlackDW , Simsek-DuranF , BlumN , McCormickB , AllenJ . Do people with borderline personality disorder complicated by antisocial personality disorder benefit from the STEPPS treatment program?Personality and Mental Health2016;10(3):205-15. [DOI: 10.1002/pmh.1326] [PMC4911327] [PMID: 26671625]BlackDW . RE: [external] questions regarding your trial on the STEPPS program for BPD [personal communication]. Email to: EG Faltinsen 27 November 2017. BlumN , AllenJ , McCormickB , BlackDW . Ms Blum and colleagues reply [to Schulte-Herbrüggen O, Koerting J, Roepke S. Effectiveness of adjunctive STEPPS group treatment in borderline personality disorder patients. American Journal of Psychiatry 2008;165(10):1354-5. DOI: 10.1176/appi.ajp.2008.08030390]. American Journal of Psychiatry2008;165(10):1354-5. [DOI: 10.1176/appi.ajp.2008.08030390r]BlumN , FranklinJ , HanselR , McCormickB , St JohnD , PfohlB , et al. Relationship of age to symptom severity, psychiatric comorbidity and health care utilization in persons with borderline personality disorder. Personality and Mental Health2008;2(1):25-43. [DOI: 10.1002/pmh.26]BlumN , St JohnD , PfohlB , StuartS , McCormickB , AllenJ , et al. Erratum. American Journal of Psychiatry2008;165(6):777. Erratum for: American Journal of Psychiatry 2008;165(4):468-78. [psycnet.apa.org/record/2008-07854-033]BlumN , St JohnD , PfohlB , StuartS , McCormickB , AllenJ , et al. Systems training for emotional predictability and problem solving (STEPPS) for outpatients with borderline personality disorder: a randomized controlled trial and 1-year follow-up. American Journal of Psychiatry2008;165(4):468-78. [DOI: 10.1176/appi.ajp.2007.07071079] [PMC3608469] [PMID: 18281407]DavidsonKM . Borderline personality disorder: STEPPS improves symptoms. Evidence-Based Mental Health2008;11(4):120. [DOI: 10.1136/ebmh.11.4.120] [PMID: 18952969]NCT00055315. Treatment for borderline personality disorder [A cognitive group treatment for borderline outpatients]. clinicaltrials.gov/ct2/show/NCT00055315 (first received 25 February 2003). ">Blum 2008</a>; <a href="./references#CD012955-bbs2-0018" title="DavidsonKM , BrownTM , JamesV , KirkJ , RichardsonJ . Manual-assisted cognitive therapy for self-harm in personality disorder and substance misuse: a feasibility trial. Psychiatric Bulletin2014;38(3):108-11. [DOI: 10.1192/pb.bp.113.043109] [PMC4115373] [PMID: 25237519]DavidsonKM . Re: question regarding your trial on manual-assisted cognitive therapy [personal communication]. Email to: EG Faltinsen 28 November 2017. ">Davidson 2014</a>; <a href="./references#CD012955-bbs2-0021" title="FarrellJM , ShawIA , WebberMA . A schema-focused approach to group psychotherapy for outpatients with borderline personality disorder: a randomized controlled trial. Journal of Behavior Therapy and Experimental Psychiatry2009;40(2):317-28 Corrigendum to: Journal of Behavior Therapy and Experimental Psychiatry 2018; 60: 111. [DOI: 10.1016/j.jbtep.2009.01.002] [PMID: 19176222]FarrellJM . Question regarding your BPD trials [personal communication]. Email to: K Lieb, J Stoffers 9 December 2010. ">Farrell 2009</a>; <a href="./references#CD012955-bbs2-0023" title="Feliu-SolerA , PascualJC , ElicesM , Martín-BlancoA , CarmonaC , CebollaA , et al. Fostering self-compassion and loving-kindness in patients with borderline personality disorder: a randomized pilot study. Clinical Psychology &amp; Psychotherapy2017;24(1):278-86. [DOI: 10.1002/cpp.2000] [PMID: 26818533]">Feliu‐Soler 2017</a>; <a href="./references#CD012955-bbs2-0026" title="Gratz KL. Important: question regarding your BPD trial for systematic review in Cochrane Collaboration [personal communication]. Email to: J Stoffers-Winterling 11 December 2010. GratzKL , GundersonJG . Preliminary data on an acceptance-based emotion regulation group intervention for deliberate self-harm among women with borderline personality disorder. Behavior Therapy2006;37(1):25-35. [DOI: 10.1016/j.beth.2005.03.002] [PMID: 16942958]">Gratz 2006</a>; <a href="./references#CD012955-bbs2-0027" title="GratzKL , BardeenJR , LevyR , Dixon-GordonKL , TullMT . Mechanisms of change in an emotion regulation group therapy for deliberate self-harm among women with borderline personality disorder. Behaviour Research and Therapy2015;65:29-35. [DOI: 10.1016/j.brat.2014.12.005] [PMC4306622] [PMID: 25557395]GratzKL , Dixon-GordonKL , TullMT . Predictors of treatment response to an adjunctive emotion regulation group therapy for deliberate self-harm among women with borderline personality disorder. Personality Disorders2014;5(1):97-107. [DOI: 10.1037/per0000062] [PMC4059504] [PMID: 2458806]GratzKL , TullMT , LevyR . Randomized controlled trial and uncontrolled 9-month follow-up of an adjunctive emotion regulation group therapy for deliberate self-harm among women with borderline personality disorder. Psychological Medicine2014;44(10):2099-112. [DOI: 10.1017/S0033291713002134] [PMID: 23985088]GratzKL . Question regarding your BPD trials [personal communication]. Email to: J Stoffers 11 December 2010. ">Gratz 2014</a>; <a href="./references#CD012955-bbs2-0029" title="HaeyenS , Van HoorenS , HutschemaekersG . Efficacy of art therapy in individuals with personality disorders cluster B/C: a randomised controlled trial. International Journal of Psychology July 2016;51:60. [DOI: 10.1521/pedi_2017_31_312] [PMID: 28926306]HaeyenS , Van HoorenS , Van der VeldW , HutschemaekersG . Efficacy of art therapy in individuals with personality disorders cluster B/C: a randomised controlled trial. Journal of Personality Disorders2018;32(4):527-42. [DOI: 10.1521/pedi_2017_31_312] [PMID: 28926306]HaeyenS . Re: Cochrane Collaboration review of psychotherapies for BPD - your RCT of art therapy [personal communication]. Email to: J Stoffers-Winterling 18 August 2018. ">Haeyen 2018</a>; <a href="./references#CD012955-bbs2-0030" title="HarnedM . Re: SV: question regarding your trial on brief therapy for attempted suicide [personal communication]. Email to: EG Faltinsen 11 December 2018. HarnedMS , KorslundKE , LinehanMM . A pilot randomized controlled trial of dialectical behavior therapy with and without the dialectical behavior therapy prolonged exposure protocol for suicidal and self-injuring women with borderline personality disorder and PTSD. Behaviour Research and Therapy2014;55:7-17. [DOI: 10.1016/j.brat.2014.01.008] [PMC3987949] [PMID: 24562087]HarnedMS , WilksCR , SchmidtSC , CoyleTN . Improving functional outcomes in women with borderline personality disorder and PTSD by changing PTSD severity and post-traumatic cognitions. Behaviour Research and Therapy2018;103:53-61. [DOI: 10.1016/j.brat.2018.02.002] [PMC5837954] [PMID: 29448136]HarnedMS . RE: questions regarding your trial on brief therapy for attempted suicide [personal communication]. Email to: E Faltinsen 29 November 2017. ">Harned 2014</a>; <a href="./references#CD012955-bbs2-0033" title="JørgensenCR , BøyeR , AndersenD , Døssing BlaabjergAH , FreundC , JordetH , et al. Eighteen months post-treatment naturalistic follow-up study of mentalization-based therapy and supportive group treatment of borderline personality disorder: clinical outcomes and functioning. Nordic Psychology2014;66(4):254-73. [DOI: 10.1080/19012276.2014.963649]JørgensenCR , FreundC , BøyeR , JordetH , AndersenD , KjølbyeM . Outcome of mentalization-based and supportive psychotherapy in patients with borderline personality disorder: a randomized trial. Acta Psychiatrica Scandinavica2013;127(4):305-17. [DOI: 10.1111/j.1600-0447.2012.01923.x] [PMID: 22897123]JorgensenCR . SV: questions on your trial regarding MBT for BPD patients [personal communication]. Email to: EG Faltinsen 28 November 2017. ">Jørgensen 2013</a>; <a href="./references#CD012955-bbs2-0034" title="KamalabadiMJ , AhmadiSA , EtemadiO , FatehizadehM , BahramiF , FiroozabadiA . A study of the effect of couple dialectical behavioral therapy on symptoms and quality of marital relationships and mental health of Iranian borderline personality couples: a controlled trial. Interdisciplinary Journal of Contemporary Research in Business2012;3(9):1480-7. [psycnet.apa.org/record/2012-22425-047]">Kamalabadi 2012</a>; <a href="./references#CD012955-bbs2-0035" title="KoonsCR , RobinsCJ , TweedJL , LynchTR , GonzalezAM , MorseJQ , et al. Efficacy of dialectical behavior therapy in women veterans with borderline personality disorder. Behavior Therapy2001;32(2):371-90. [DOI: 10.1016/S0005-7894(01)80009-5]">Koons 2001a</a>; <a href="./references#CD012955-bbs2-0043" title="LeppänenV , HakkoH , SintonenH , LindemanS . Comparing effectiveness of treatments for borderline personality disorder in communal mental health care: the Oulu BPD study. Community Mental Health Journal2016;52(2):216-27. [DOI: 10.1007/s10597-015-9866-4] [PMID: 25824852]LeppänenV . Re: questions regarding the Oulu BPD study [personal communication]. Email to: E Faltinsen 20 December 2017. LeppänenV . Re: SV: question regarding the Oulu BPD study [personal communication]. Email to: EG Faltinsen 22 December 2017. ">Leppänen 2016</a>; <a href="./references#CD012955-bbs2-0044" title="Lin T-J, Ko H-C, Wu JY-W, OeiTP , Lane H-Y, Chen C-H. The effectiveness of dialectical behavior therapy skills training group vs cognitive therapy group on reducing depression and suicide attempts for borderline personality disorder in Taiwan. Archives of Suicide Research2019;23(1):82-99. [DOI: 10.1080/13811118.2018.1436104] [PMID: 29528807]">Lin 2019</a>; <a href="./references#CD012955-bbs2-0045" title="HoffmanRE . Impact of treatment accessibility on clinical course of parasuicidal patients. Archives of General Psychiatry1993;50(2):157-8. [DOI: 10.1001/archpsyc.1993.01820140083010] [PMID: 8427557]LindenboimN . To Know Me is to Keep Me: Self-Verification, Validation, and Therapy Dropout in the Treatment of Borderline Personality Disorder [PhD thesis]. Washington (DC): University of Washington, 2009. LinehanMM , ArmstrongHE , SuarezA , AllmonD , HeardHL . Cognitive-behavioral treatment of chronically parasuicidal borderline patients. Archives of General Psychiatry1991;48(12):1060-4. [DOI: 10.1001/archpsyc.1991.01810360024003] [PMID: 1845222]LinehanMM , HeardHL . Impact of treatment accessibility on clinical course of parasuicidal patients — reply. Archives of General Psychiatry1993;50(2):157-8. [DOI: 10.1001/archpsyc.1993.01820140083011]">Linehan 1991</a>; <a href="./references#CD012955-bbs2-0046" title="HeardHL . Cost-Effectiveness of Dialectical Behavior Therapy in the Treatment of Borderline Personality Disorder [PhD thesis]. Washington (DC): University of Washington, 2000. LindenboimN . To Know Me is to Keep Me: Self-Verification, Validation, and Therapy Dropout in the Treatment of Borderline Personality Disorder [PhD thesis]. Washington (DC): University of Washington, 2009. LinehanMM , HeardHL , ArmstrongHE . Naturalistic follow-up of a behavioral treatment for chronically parasuicidal borderline patients. Archives of General Psychiatry1993;50(12):971-4. [DOI: 10.1001/archpsyc.1993.01820240055007] [PMID: 8250683]LinehanMM , TutekDA , HeardHL , ArmstrongHE . Interpersonal outcome of cognitive behavioral treatment for chronically suicidal borderline patients. American Journal of Psychiatry1994;151(12):1771-6. [DOI: 10.1176/ajp.151.12.1771] [PMID: 7977884]">Linehan 1994</a>; <a href="./references#CD012955-bbs2-0048" title="LinehanMM , KorslundKE , HarnedMS , GallopRJ , LunguA , NeacsiuAD , et al. Dialectical behavior therapy for high suicide risk in individuals with borderline personality disorder: a randomized clinical trial and component analysis. JAMA Psychiatry2015;72(5):475-82 Erratum for: JAMA Psychiatry 2015; 72(9): 951. [DOI: 10.1001/jamapsychiatry.2014.3039] [PMID: 25806661]NCT00183651. Treatment of suicidal women with borderline personality disorder [Assessment and treatment of parasuicidal patients]. www.clinicaltrials.gov/ct2/show/NCT00183651 (first received 13 September 2005). ">Linehan 2015a</a>; <a href="./references#CD012955-bbs2-0053" title="MohamadizadehL , MakvandiB , PashaR , BakhtiarpourS , HafeziF . Comparing of the effect of dialectical behavior therapy (DBT) and schema therapy (ST) on reducing mood activity and suicidal thoughts in patients with borderline personality disorder. Acta Medica Mediterranea2017;33:1025-31. [DOI: 10.19193/0393-6384_2017_6_162] [www.actamedicamediterranea.com/archive/2017/medica-6/comparing-of-the-effect-of-dialectical-behavior-therapy-dbt-and-schema-therapy-st-on-reducing-mood-activity-and-suicidal-thoughts-in-patients-with-borderline-personality-disorder/pdf]">Mohamadizadeh 2017</a>; <a href="./references#CD012955-bbs2-0054" title="MoreyLC , LowmasterSE , HopwoodCJ . A pilot study of manual-assisted cognitive therapy with a therapeutic assessment augmentation for borderline personality disorder. Psychiatry Research2010;178(3):531-5. [DOI: 10.1016/j.psychres.2010.04.055] [PMID: 20537722]">Morey 2010</a>; <a href="./references#CD012955-bbs2-0057" title="NCT02033044. Cognitive rehabilitation versus psychoeducation in psychosocial functioning of borderline personality disorder [Randomized controlled trial comparing the effects on psychosocial functioning of cognitive rehabilitation versus psychoeducation in borderline personality disorder]. www.clinicaltrials.gov/ct2/show/NCT02033044 (first received 23 December 2013). PascualJC , PalomaresN , Ibáñez Á, PortellaMJ , ArzaR , ReyesR , et al. Efficacy of cognitive rehabilitation on psychosocial functioning in borderline personality disorder: a randomized controlled trial. BMC Psychiatry2015;15:255. [DOI: 10.1186/s12888-015-0640-5] [PMC4617906] [PMID: 26487284]">Pascual 2015</a>; <a href="./references#CD012955-bbs2-0060" title="RenesesB , FigueraD , SalcedoG , TrujilloM , López-IborJJ , GaliánM , et al. A controlled randomized study on the efficacy of short-term dinamic psychotherapy in borderline personality disorders (BPD). Preliminary results. European Psychiatry2011;26(Suppl 1):1040. [DOI: 10.1016/S0924-9338(11)72745-6] [P02-444]RenesesB , GaliánM , SerranoR , FigueraD , Fernandez Del MoralA , López-IborJJ , et al. A new time limited psychotherapy for BPD: preliminary results of a randomized and controlled trial. Actas Espanolas de Psiquiatria2013;41(3):139-48. [PMID: 23803797]">Reneses 2013</a>; <a href="./references#CD012955-bbs2-0061" title="ISRCTN51304415. Nice OUtcomes for Referrals with Impulsivity, Self Harm and Eating Disorders: the NOURISHED study [A randomised controlled trial of mentalisation based therapy against specialist supportive clinical management in patients with both eating disorders and symptoms of borderline personality disorder]. www.isrctn.com/ISRCTN51304415 (first received 31 January 2011). RobinsonP , BarrettB , BatemanA , HakeemA , HellierJ , LemonskyF , et al. Study protocol for a randomized controlled trial of mentalization based therapy against specialist supportive clinical management in patients with both eating disorders and symptoms of borderline personality disorder. BMC Psychiatry2014;14:51. [DOI: 10.1186/1471-244X-14-51] [PMC3996076] [PMID: 24555511]RobinsonP , HellierJ , BarrettB , BarzdaitieneD , BatemanA , BogaardtA , et al. The NOURISHED randomised controlled trial comparing mentalisation-based treatment for eating disorders (MBT-ED) with specialist supportive clinical management (SSCM-ED) for patients with eating disorders and symptoms of borderline personality disorder. Trials2016;17(1):549. [DOI: 10.1186/s13063-016-1606-8] [PMC5114835] [PMID: 27855714]">Robinson 2016</a>; <a href="./references#CD012955-bbs2-0063" title="SalzerS , CroppC , JaegerU , MasuhrO , Streeck-FischerA . Psychodynamic therapy for adolescents suffering from co-morbid disorders of conduct and emotions in an in-patient setting: a randomized controlled trial. Psychological Medicine2014;44(10):2213-22. [DOI: 10.1017/S003329171300278X] [PMID: 24229481]SalzerS , Streeck-FischerA . The psychoanalytic-interactional method (PiM) for adolescents with borderline personality disorder [Die psychoanalytisch-interaktionelle methode (PiM) für adoleszente mit borderline-persönlichkeitsstörung]. Personlichkeitsstorungen Theorie und Therapie2015;19(1):67-76. [elibrary.klett-cotta.de/article/99.120110/ptt-19-1-67]SalzerS . AW: Re: Cochrane Review on psychotherapies for BPD - RCT testing PiM vs WL [personal communication] [AW:Re: Cochrane Review zur Psychotherapie bei BPS - RCT zu PiM vs WL [persönliche kommunikation]]. Email to: J Stoffers-Winterling 15 July 2018. ">Salzer 2014</a>; <a href="./references#CD012955-bbs2-0064" title="SantistebanDA , MenaMP , MuirJ , McCabeBE , AbaloC , CummingsAM . The efficacy of two adolescent substance abuse treatments and the impact of comorbid depression: results of a small randomized controlled trial. Psychiatric Rehabilitation Journal2015;38(1):55-64. [DOI: 10.1037/prj0000106] [PMC5021542] [PMID: 25799306]">Santisteban 2015</a>; <a href="./references#CD012955-bbs2-0065" title="SchillingL , MoritzS , KötherU , NagelM . Preliminary results on acceptance, feasibility, and subjective efficacy of the add-on group intervention metacognitive training for borderline patients. Journal of Cognitive Psychotherapy2015;29(2):153-64. [DOI: 10.1891/0889-8391.29.2.153]SchillingL , MoritzS , KristonL , KriegerM , NagelM . Efficacy of metacognitive training for patients with borderline personality disorder: preliminary results. Psychiatry Research2018;262:459-64. [DOI: 10.1016/j.psychres.2017.09.024] [PMID: 28927866]SchillingL . Re Schilling 2015/2018 - Cochrane Review of psychotherapies for BPD [personal communication] [Re Schilling 2015/2018 - Cochrane Review zur Psychotherapie bei BPS [persönliche Kommunikation]]. Email to: J Stoffers-Winterling 22 January 2019. ">Schilling 2018</a>; <a href="./references#CD012955-bbs2-0068" title="SmithPN , GambleSA , CortNA , WardEA , HeH , TalbotNL . Attachment and alliance in the treatment of depressed, sexually abused women. Depression and Anxiety2012;29(2):123-30. [DOI: 10.1002/da.20913] [PMC3325338] [PMID: 22065593]SmithPN . Re: Cochrane Collaboration review of psychotherapies for BPD [personal communication]. Email to: J Stoffers-Winterling 05 July 2018. ">Smith 2012</a>; <a href="./references#CD012955-bbs2-0069" title="SolerJ , PascualJC , TianaT , CebriàA , BarrachinaJ , CampinsMJ , et al. Dialectical behaviour therapy skills training compared to standard group therapy in borderline personality disorder: a 3-month randomised controlled clinical trial. Behaviour Research and Therapy2009;47(5):353-8. [DOI: 10.1016/j.brat.2009.01.013] [PMID: 19246029]SolerJ . Question regarding your BPD trials [personal communication]. Email to: J Stoffers 15 December 2010. ">Soler 2009</a>; <a href="./references#CD012955-bbs2-0070" title="FertuckEA , KeilpJ , SongI , MorrisMC , WilsonST , BrodskyBS , et al. Higher executive control and visual memory performance predict treatment completion in borderline personality disorder. Psychotherapy and Psychosomatics2012;81(1):38-43. [DOI: 10.1159/000329700] [PMC3242704] [PMID: 22116411]NCT00533117. Treating suicidal behavior and self-mutilation in people with borderline personality disorder. www.clinicaltrials.gov/ct2/show/NCT00533117 (first received 19 September 2007). ">Stanley 2017</a>; <a href="./references#CD012955-bbs2-0071" title="TurnerRM . Naturalistic evaluation of dialectical behavior therapy-oriented treatment for borderline personality disorder. Cognitive and Behavioral Practice2000;7(4):413-9. [DOI: 10.1016/S1077-7229(00)80052-8]">Turner 2000</a>; <a href="./references#CD012955-bbs2-0072" title="Van den BoschLM , KoeterMW , StijnenT , VerheulR , Van den BrinkW . Sustained efficacy of dialectical behaviour therapy for borderline personality disorder. Behaviour Research and Therapy2005;43(9):1231-41. [DOI: 10.1016/j.brat.2004.09.008] [PMID: 16005708]Van den BoschLM , VerheulR , SchippersGM , Van den BrinkW . Dialectical behavior therapy of borderline patients with and without substance use problems. Implementation and long-term effects. Addictive Behaviors2002;27(6):911-23. [DOI: 10.1016/s0306-4603(02)00293-9] [PMID: 12369475]Van den BoschLMC . Efficacy of dialectical behaviour therapy in the treatment of female borderline patients with and without substance abuse problems: results of a Dutch study [Dialectische gedragstherapie bij Nederlandse vrouwen met een borderline persoonlijkheidsstoornis, met en zonder verslavingsproblemen]. Tijdschrift voor Psychiatrie2005;47(3):127-37. [www.tijdschriftvoorpsychiatrie.nl/assets/articles/articles_1335pdf.pdf]VerheulR , Van den BoschLM , KoeterMW , De RidderMA , StijnenT , Van den BrinkW . Dialectical behaviour therapy for women with borderline personality disorder: 12-month, randomised clinical trial in The Netherlands. British Journal of Psychiatry2003;182:135-40. [DOI: 10.1192/bjp.182.2.135] [PMID: 12562741]">Van den Bosch 2005</a>; <a href="./references#CD012955-bbs2-0073" title="WeinbergI , GundersonJG , HennenJ , Cutter CJ Jr. Manual assisted cognitive treatment for deliberate self-harm in borderline personality disorder patients. Journal of Personality Disorders2006;20(5):482-92. [DOI: 10.1521/pedi.2006.20.5.482] [PMID: 17032160]WilbergT . SV: separate data [personal communication] [SV: separat data [personlig kommunikation]]. Email to: M Kielsholm 25 May 2016. ">Weinberg 2006</a>; <a href="./references#CD012955-bbs2-0074" title="ZanariniMC , FrankenburgFR . A preliminary, randomized trial of psychoeducation for women with borderline personality disorder. Journal of Personality Disorders2008;22(3):284-90. [DOI: 10.1521/pedi.2008.22.3.284] [PMID: 18540800]ZanariniMC , FrankenburgFR . A randomized trial of psychoeducation for patients with BPD. In: 157th annual meeting of the American Psychiatric Association. Psychotherapy and psychopharmacology: dissolving the mind-brain barrier; 2004 May 1-6; New York (NY). Arlington (VA): American Psychiatric Association, 2004:102. [Symposium 100E] [www.psychiatry.org/File%20Library/Psychiatrists/Directories/Library-and-Archive/conference_publications/am_program_2004.pdf]">Zanarini 2008</a>; <a href="./references#CD012955-bbs2-0075" title="ZanariniMC , ConkeyLC , TemesCM , FitzmauriceGM . Randomized controlled trial of web-based psychoeducation for women with borderline personality disorder. Journal of Clinical Psychiatry2018;79(3):16m11153. [DOI: 10.4088/JCP.16m11153] [PMC5764827] [PMID: 28703950]">Zanarini 2018</a>). We rated three trials as being at high risk of bias due to explicit inadequate allocation concealment (<a href="./references#CD012955-bbs2-0020" title="ElicesM , PascualJC , PortellaMJ , Feliu-SolerA , Martín-BlancoA , CarmonaC , et al. Impact of mindfulness training on borderline personality disorder: a randomized trial. Mindfulness2016;7:584-95. [DOI: 10.1007/s12671-016-0492-1]NCT02397031. Mindfulness and interpersonal effectiveness skills in borderline personality disorder [Randomized, active-controlled, clinical trial comparing effects of mindfulness and interpersonal effectiveness skills in borderline personality disorder]. www.clinicaltrials.gov/ct2/show/NCT02397031 (first received 12 March 2015). SolerJ , ElicesM , PascualJC , Martín-BlancoA , Feliu-SolerA , CarmonaC , et al. Effects of mindfulness training on different components of impulsivity in borderline personality disorder: results from a pilot randomized study. Borderline Personality Disorder and Emotion Dysregulation2016;3:1. [DOI: 10.1186/s40479-015-0035-8] [PMC4709962] [PMID: 26759718]">Elices 2016</a>; <a href="./references#CD012955-bbs2-0025" title="GleesonJF , ChanenA , CottonSM , PearceT , NewmanB , McCutcheonL . Treating co-occurring first-episode psychosis and borderline personality: a pilot randomized controlled trial. Early Intervention in Psychiatry2012;6(1):21-9. [DOI: 10.1111/j.1751-7893.2011.00306.x] [PMID: 22379625]GleesonJFM . RE: separate data [personal communication]. Email to: M Kielsholm 28 October 2016. ">Gleeson 2012</a>; <a href="./references#CD012955-bbs2-0055" title="MortonJ , SnowdonS , GopoldM , GuymerE . Acceptance and commitment therapy group treatment for symptoms of borderline personality disorder: a public sector pilot study. Cognitive and Behavioral Practice2012;19(4):527-44. [DOI: 10.1016/j.cbpra.2012.03.005]MortonJ . Re: SV: regarding your study on acceptance and commitment therapy for BPD [personal communication]. Email to: EG Faltinsen 22 December 2017. ">Morton 2012</a>). One example can be found in <a href="./references#CD012955-bbs2-0025" title="GleesonJF , ChanenA , CottonSM , PearceT , NewmanB , McCutcheonL . Treating co-occurring first-episode psychosis and borderline personality: a pilot randomized controlled trial. Early Intervention in Psychiatry2012;6(1):21-9. [DOI: 10.1111/j.1751-7893.2011.00306.x] [PMID: 22379625]GleesonJFM . RE: separate data [personal communication]. Email to: M Kielsholm 28 October 2016. ">Gleeson 2012</a>, where the following was stated: "Outcome ratings were made by the trial research assistant who was independent of the treatment, but not blind to treatment allocation because of limited resources" (quote). This could potentially have induced bias. </p> </section> </section> <section id="CD012955-sec-0072"> <h4 class="title">Blinding</h4> <p>The majority of trials (50 trials) reported that outcome assessors were kept blind to treatment allocation and, for this reason, were considered to be at low risk of bias (<a href="./references#CD012955-bbs2-0001" title="AmiantoF , FerreroA , PieròA , CairoE , RoccaG , SimonelliB , et al. Supervised team management, with or without structured psychotherapy, in heavy users of a mental health service with borderline personality disorder: a two-year follow-up preliminary randomized study. BMC Psychiatry2011;11:181. [DOI: 10.1186/1471-244X-11-181] [PMC3260092 ] [PMID: 22103890]NCT01356069. Efficacy of time-limited psychodynamic psychotherapy and informed clinical management in BPD high MHS users (HUMSH) [Sequential brief Adlerian psychodynamic psychotherapy in heavy users of a mental health service with borderline personality disorder: a two years follow-up preliminary randomized study]. clinicaltrials.gov/ct2/show/NCT01356069 (first received 16 May 2011). ">Amianto 2011</a>; <a href="./references#CD012955-bbs2-0002" title='AndreoliA , BurnandY , CochennecMF , MarieD , Di ClementeT , OhlendorfP . Psychoanalytic psychotherapy and venlafaxine among acutely suicidal borderline patients: a randomized clinical study. European Psychiatry2009;24(Suppl 1):S93. [DOI: 10.1016/S0924-9338(09)70326-8] [S18-03]AndreoliA , BurnandY , CochennecMF , OhlendorfP , FrambatiL , Gaudry-MaireD , et al. Disappointed love and suicide: a randomized controlled trial of "abandonment psychotherapy" among borderline patients. Journal of Personality Disorders2016;30(2):271-87. [DOI: 10.1521/pedi_2015_29_196] [PMID: 26111250]AndreoliA , BurnandY , FrambatiL , ManningD , FrancesA . Abandonment psychotherapy and psychosocial functioning among suicidal patients with borderline personality disorder: a 3-year naturalistic follow-up. Journal of Personality Disorders 2019 Feb 20 [Epub ahead of print]. [DOI: 10.1521/pedi_2019_33_423] [PMID: 30785852]AndreoliA . Re: your study in BPD - Cochrane Collaboration review [personal communication]. Email to: J Stoffers-Winterling 5 June 2018. '>Andreoli 2016</a>; <a href="./references#CD012955-bbs2-0004" title="BatemanA , FonagyP . 8-year follow-up of patients treated for borderline personality disorder: mentalization-based treatment versus treatment as usual. American Journal of Psychiatry2008;165(5):631-8. [DOI: 10.1176/appi.ajp.2007.07040636] [PMID: 18347003]BatemanA , FonagyP . Effectiveness of partial hospitalization in the treatment of borderline personality disorder: a randomized controlled trial. American Journal of Psychiatry1999;156(10):1563-9. [DOI: 10.1176/ajp.156.10.1563] [PMID: 10518167]BatemanA , FonagyP . Health care utilization costs for borderline personality disorder patients treated with psychoanalytically oriented partial hospitalization versus general psychiatric care. American Journal of Psychiatry2003;160(1):169-71. [10.1176/appi.ajp.160.1.169] [12505818]BatemanA , FonagyP . Treatment of borderline personality disorder with psychoanalytically oriented partial hospitalization: an 18-month follow-up. American Journal of Psychiatry2001;158(1):36-42. [DOI: 10.1176/appi.ajp.158.1.36] [PMID: 11136631]BatemanA . Important: question regarding your BPD trial for systematic review in Cochrane Collaboration [personal communication]. Email to: K Lieb, J Stoffers 14 December 2010. BatemanA . Intensive outpatient and partial hospital care for BPD. In: 157th annual meeting of the American Psychiatric Association. Psychotherapy and pharmacology: dissolving the mind-brain barrier; 2004 May 1-6; New York (NY). Arlington (VA): American Psychiatric Association, 2004:102. [Symposium 100B] [www.psychiatry.org/File%20Library/Psychiatrists/Directories/Library-and-Archive/conference_publications/am_program_2004.pdf]BatemanAW , FonagyP . Drs Bateman and Fonagy reply [to Stern R. Partial hospitalization for borderline personality disorder. American Journal of Psychiatry 2001;158(11):1932-3. DOI: 10.1176/appi.ajp.158.11.1932]. American Journal of Psychiatry2001;158(11):1932-3. [DOI: 10.1176/appi.ajp.158.11.1932-a]EvansC . Treatment benefits of psychoanalytically oriented partial hospitalisation were maintained over 18 months in borderline personality disorder. Evidence-Based Mental Health2001;4(3):73. [DOI: 10.1136/ebmh.4.3.73]FonagyP , BatemanAW . Mentalizing and borderline personality disorder. Journal of Mental Health2007;16(1):83-101. [DOI: 10.1080/09638230601182045]SternR . Partial hospitalization for borderline personality disorder. American Journal of Psychiatry2001;158(11):1932-3. [DOI: 10.1176/appi.ajp.158.11.1932] [PMID: 11691712]">Bateman 1999</a>; <a href="./references#CD012955-bbs2-0005" title="BatemanA , FonagyP . Impact of clinical severity on outcomes of mentalisation-based treatment for borderline personality disorder. British Journal of Psychiatry2013;203(3):221-7. [DOI: 10.1192/bjp.bp.112.121129] [PMID: 23887998]BatemanA , FonagyP . Randomized controlled trial of outpatient mentalization-based treatment versus structured clinical management for borderline personality disorder. American Journal of Psychiatry2009;166(12):1355-64. [DOI: 10.1176/appi.ajp.2009.09040539] [PMID: 19833787]BatemanA , FonagyP . Randomized controlled trial of outpatient mentalization-based treatment versus structured clinical management for borderline personality disorder. Supplementary data. ajp.psychiatryonline.org/doi/suppl/10.1176/appi.ajp.2009.09040539/suppl_file/ajp_166_12_1355_01.pdf (accessed 27 February 2020). BatemanA , O'ConnellJ , LorenziniN , GardnerT , FonagyP . A randomised controlled trial of mentalization-based treatment versus structured clinical management for patients with comorbid borderline personality disorder and antisocial personality disorder. BMC Psychiatry2016;16:304. [DOI: 10.1186/s12888-016-1000-9] [PMC5006360] [PMID: 27577562]BatemanA . Important question regarding your BPD trial for systematic review in Cochrane Collaboration [personal communication]. Email to: K Lieb 14 December 2010. BatemanAW . Mentalization, borderline personality disorder and what works for whom? Presentation at the 11th International Congress of the International Society for the Study of Personality Disorders; 2009 Aug 21-23. www.borderlinepersonalitydisorder.com/Conferences/ISSPD/isspd_09_Bateman (accessed 21 April 2010). ISRCTN27660668. Randomised controlled trial of manualised out-patient individual and group therapy for borderline personality disorder [Effectiveness of intensive out-patient psychotherapy for treatment of borderline personality disorder: a pragmatic randomised single blind controlled study]. www.isrctn.com/ISRCTN27660668 (first received 12 October 2008). ">Bateman 2009</a>; <a href="./references#CD012955-bbs2-0006" title="BellinoS , ParadisoE , ZizzaM , Di LorenzoR , BogettoF . Combined therapy with interpersonal psychotherapy of major depressed patients with borderline personality disorder: a comparison with pharmacotherapy [Terapia combinata con psicoterapia interpersonale di pazienti depressi maggiori con disturbo borderline di personalità: confronto con la farmacoterapia]. Journal of Psychopathology2005;11(1):34-42. [bit.ly/2rZUh5h]BellinoS , ZizzaM , RinaldiC , BogettoF . Combined treatment of major depression in patients with borderline personality disorder: a comparison with pharmacotherapy. Canadian Journal of Psychiatry2006;51(7):453-60. [DOI: 10.1177/070674370605100707] [PMID: 16838827]">Bellino 2006</a>; <a href="./references#CD012955-bbs2-0007" title="BellinoS , ZizzaM , RinaldiC , BogettoF . Combined therapy of major depression with concomitant borderline personality disorder: comparison of interpersonal and cognitive psychotherapy. Canadian Journal of Psychiatry2007;52(11):718-25. [DOI: 10.1177/070674370705201106] [PMID: 18399039]">Bellino 2007</a>; <a href="./references#CD012955-bbs2-0008" title="BellinoS , BozzatelloP , BogettoF . Combined treatment of borderline personality disorder with interpersonal psychotherapy and pharmacotherapy: predictors of response. Psychiatry Research2015;226(1):284-8. [DOI: 10.1016/j.psychres.2014.12.064] [isiarticles.com/bundles/Article/pre/pdf/34125.pdf]BellinoS , RinaldiC , BogettoF . Adaptation of interpersonal psychotherapy to borderline personality disorder: a comparison of combined therapy and single pharmacotherapy. Canadian Journal of Psychiatry2010;55(2):74-81. [DOI: 10.1177/070674371005500203] [PMID: 20181302]BellinoS . Question regarding your BPD trials for inclusion in Cochrane Collaboration review [personal communication]. Email to: J Stoffers-Winterling 19 December 2010. BellinoS . Re: question regarding your BPD trials [personal communication]. Email to: J Stoffers 16 December 2010. BozzatelloP , BellinoS . Combined therapy with interpersonal psychotherapy adapted for borderline personality disorder: a two-years follow-up. Psychiatry Research2016;240:151-6. [DOI: 10.1016/j.psychres.2016.04.014] [www.sciencedirect.com/science/article/pii/S0165178115302389]ZizzaM , FenocchioM , RinaldiC , BellinoS . Combined treatment of borderline personality disorder: a trial of modified interpersonal therapy. World Psychiatry2009;8(Suppl 1):234. ">Bellino 2010</a>; <a href="./references#CD012955-bbs2-0009" title="BianchiniV , CofiniV , CurtoM , LagrotteriaB , ManziA , NavariS , et al. Dialectical behavior therapy (DBT) for forensic psychiatric patients: an Italian pilot study. Criminal Behavior and Mental Health2019;29(9):122-30. [DOI: 10.1002/cbm.2102] [PMID: 30648303]">Bianchini 2019</a>; <a href="./references#CD012955-bbs2-0011" title="BohusM , DyerAS , PriebeK , KrügerA , KleindienstN , SchmahlC , et al. Dialectical behaviour therapy for post-traumatic stress disorder after childhood sexual abuse in patients with and without borderline personality disorder: a randomised controlled trial. Psychotherapy and Psychosomatics2013;82(4):221-33. [DOI: 10.1159/000348451] [PMID: 23712109]BrandS . AW: questions regarding your trial on emotional intelligence training for BPD [personal communication]. Email to: EG Faltinsen 28 November 2017. DBT Working Group at the Central Institute for Mental Health, Mannheim, Germany. Requested supplementary data (as supplied 1 October 2010). Data on file. NCT00481000. Dialectical cognitive traumatherapy (DCT) on patients with severe PTSD following sexual abuse (PASA) [Dialectical cognitive traumatherapy (DCT) on patients with severe posttraumatic stress disorder following sexual abuse - a randomised controlled trial]. clinicaltrials.gov/ct2/show/NCT00481000 (first received 31 May 2007). SteilR , DyerA , PriebeK , KleindienstN , BohusM . Dialectical behavior therapy for posttraumatic stress disorder related to childhood sexual abuse: a pilot study of an intensive treatment program. Journal of Traumatic Stress2011;24(1):102-6. [DOI: 10.1002/jts.20617] [PMID: 21351167]">Bohus 2013</a>; <a href="./references#CD012955-bbs2-0012" title="BorschmannR , BarrettB , HellierJM , ByfordS , HendersonC , RoseD , et al. Joint crisis plans for people with borderline personality disorder: feasibility and outcomes in a randomised controlled trial. British Journal of Psychiatry2013;202(5):357-64. [DOI: 10.1192/bjp.bp.112.117762] [PMID: 23637110]BorschmannR . Joint crisis plans for BPD - question on publication in British Journal of Psychiatry [pers communication]. Email to: J Stoffers-Winterling 22 August 2017. BorschmannR . RE: joint crisis plans for BPD - question on publication in British Journal of Psychiatry [personal communication]. Email to: J Stoffers-Winterling 22 August 2017. BorschmannR . The development and testing of joint crisis plans for people with borderline personality disorder: a feasibility study. ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.628499 (accessed 27 January 2019). HellierJ . RE: regarding your study on on MBT for eating disorders [personal communication]. Email to: E Faltinsen 27 March 2018. HellierJ . RE: regarding your study on on MBT for eating disorders [personal communication]. Email to: E Faltinsen 3 January 2018. HellierJ . SV: regarding your study on MBT for eating disorders [personal communication]. Email to: EG Faltinsen, P Robinson 27 March 2018. ISRCTN12440268. JOSHUA: a pilot randomised controlled trial of joint crisis plans for people who self harm. www.isrctn.com/ISRCTN12440268 (first received 17 September 2009). ">Borschmann 2013</a>; <a href="./references#CD012955-bbs2-0014" title="Carmona i FarrésC , ElicesM , SolerJ , Domínguez-ClavéE , Pomarol-ClotetE , SalvadorR , et al. Effects of mindfulness training on borderline personality disorder: impulsivity versus emotional dysregulation. Mindfulness2019;10:1243-54. [DOI: 10.1007/s12671-018-1071-4]NCT03363230. Effects of mindfulness training on emotion regulation and impulsivity. www.clinicaltrials.gov/ct2/show/NCT03363230 (first received 30 November 2017). ">Carmona í Farrés 2019</a>; <a href="./references#CD012955-bbs2-0015" title="CarterG . Question regarding your BPD trial [personal communication]. Email to: J Stoffers 21 December 2010. CarterGL , WillcoxCH , LewinTJ , ConradAM , BenditN . Hunter DBT project: randomized controlled trial of dialectical behaviour therapy in women with borderline personality disorder. Australian and New Zealand Journal of Psychiatry2010;44(2):162-73. [DOI: 10.3109/00048670903393621] [PMID: 20113305]">Carter 2010</a>; <a href="./references#CD012955-bbs2-0016" title="CottrauxJ , NoteID , BoutitieF , MillieryM , GenouihlacV , YaoSN , et al. Cognitive therapy versus Rogerian supportive therapy in borderline personality disorder. Two-year follow-up of a controlled pilot study. Psychotherapy and Psychosomatics2009;78(5):307-16. [DOI: 10.1159/000229769] [PMID: 19628959]NCT00131781. Cognitive therapy versus supportive therapy in borderline personality disorder. www.clinicaltrials.gov/ct2/show/NCT00131781 (first received 18 August 2005). ">Cottraux 2009</a>; <a href="./references#CD012955-bbs2-0017" title="DavidsonK , LivingstoneS , McArthurK , DicksonL , GumleyA . An integrative complexity analysis of cognitive behaviour therapy sessions for borderline personality disorder. Psychology and Psychotherapy2007;80(Pt 4):513-23. [DOI: 10.1348/147608307X191535] [PMID: 17535542]DavidsonK , NorrieJ , TyrerP , GumleyA , TataP , MurrayH , et al. The effectiveness of cognitive behavior therapy for borderline personality disorder: results from the borderline personality disorder study of cognitive therapy (BOSCOT) trial. Journal of Personality Disorders2006;20(5):450-65. [DOI: 10.1521/pedi.2006.20.5.450] [PMC1852259] [PMID: 17032158]DavidsonK , TyrerP , GumleyA , TataP , NorrieJ , PalmerS , et al. A randomized controlled trial of cognitive behavior therapy for borderline personality disorder: rationale for trial, method, and description of sample. Journal of Personality Disorders2006;20(5):431-49. [DOI: 10.1521/pedi.2006.20.5.431] [PMC1847748] [PMID: 17032157]DavidsonKM , TyrerP , NorrieJ , PalmerSJ , TyrerH . Cognitive therapy v usual treatment for borderline personality disorder: prospective 6-year follow-up. British Journal of Psychiatry2010;197(6):456-62. [DOI: 10.1192/bjp.bp.109.074286] [PMID: 21119151]ISRCTN86177428. Borderline personality disorder study of cognitive therapy trial [A randomised controlled trial of cognitive therapy plus treatment as usual versus treatment as usual in the treatment of borderline personality disorder]. www.isrctn.com/ISRCTN86177428 (first received 22 July 2005). NCT00538135. BOSCOT: a randomised controlled trial of cognitive behavioural therapy in borderline personality disorder [BOSCOT: a randomised control trial of cognitive behavioural therapy plus treatment as usual versus treatment as usual in the treatment of borderline personality disorder]. www.clinicaltrials.gov/ct2/show/NCT00538135 (first received 29 September 2007). NorrieJ , DavidsonK , TataP , GumleyA . Influence of therapist competence and quantity of cognitive behavioural therapy on suicidal behaviour and inpatient hospitalisation in a randomised controlled trial in borderline personality disorder: further analyses of treatment effects in the BOSCOT study. Psychology and Psychotherapy2013;86(3):280-93. [DOI: 10.1111/papt.12004] [PMC4491320] [PMID: 23420622]PalmerS , DavidsonK , TyrerP , GumleyA , TataP , NorrieJ , et al. The cost-effectiveness of cognitive behavior therapy for borderline personality disorder: results from the BOSCOT trial. Journal of Personality Disorders2006;20(5):466-81. [DOI: 10.1521/pedi.2006.20.5.466] [PMC1852260] [PMID: 17032159]">Davidson 2006</a>; <a href="./references#CD012955-bbs2-0018" title="DavidsonKM , BrownTM , JamesV , KirkJ , RichardsonJ . Manual-assisted cognitive therapy for self-harm in personality disorder and substance misuse: a feasibility trial. Psychiatric Bulletin2014;38(3):108-11. [DOI: 10.1192/pb.bp.113.043109] [PMC4115373] [PMID: 25237519]DavidsonKM . Re: question regarding your trial on manual-assisted cognitive therapy [personal communication]. Email to: EG Faltinsen 28 November 2017. ">Davidson 2014</a>: <a href="./references#CD012955-bbs2-0019" title="BuchheimA , Hörz-SagstetterS , DoeringS , RentropM , SchusterP , BuchheimP , et al. Change of unresolved attachment in borderline personality disorders: RCT study of transference-focused psychotherapy. Psychotherapy and Psychosomatics2017;86(5):314-6. [DOI: 10.1159/000460257] [PMID: 28903103]DiamondD , LevyKN , ClarkinJF , Fischer-KernM , CainNM , DoeringS , et al. Attachment and mentalization in female patients with comorbid narcissistic and borderline personality disorder. Personality Disorders2014;5(4):428-33. [DOI: 10.1037/per0000065] [PMID: 25314231]DiamondD , YeomansFE , SternB , LevyKN , HörzS , DoeringS , et al. Transference-focused psychotherapy for patients with comorbid narcissistic and borderline personality disorder. Psychoanalytic Inquiry2013;33(6):527-51. [DOI: 10.1080/07351690.2013.815087]DoeringS , HörzS , RentropM , Fischer-KernM , SchusterP , BeneckeC , et al. Transference-focused psychotherapy v treatment by community psychotherapists for borderline personality disorder: randomised controlled trial. British Journal of Psychiatry2010;196(5):389-95. [DOI: 10.1192/bjp.bp.109.070177] [PMID: 20435966]DoeringS . Author's reply [to Kleindienst N, Krumm B, Bohus M. Is transference-focused psychotherapy really efficacious for borderline personality disorder? British Journal of Psychiatry 2011;198(2):156-7. DOI: 10.1192/bjp.198.2.156b]. British Journal of Psychiatry2011;198(2):156-7. [DOI: 10.1192/bjp.198.2.157]DoeringS . Question regarding your BPD trial for systematic review in Cochrane Collaboration [personal communication]. Email to: K Lieb, J Stoffers 10 December 2010. Fischer-KernM , DoeringS , TaubnerS , HörzS , ZimmermannJ , RentropM , et al. Transference-focused psychotherapy for borderline personality disorder: change in reflective function. British Journal of Psychiatry2015;207(2):173-4. [DOI: 10.1192/bjp.bp.113.143842] [PMID: 25999334]KleindienstN , KrummB , BohusM . Is transference-focused psychotherapy really efficacious for borderline personality disorder?British Journal of Psychiatry2011;198(2):156-7. [DOI: 10.1192/bjp.198.2.156b] [PMID: 21282787]LevyKN , MeehanKB , YeomansFE . Transference-focused psychotherapy reduces treatment drop-out and suicide attempters compared with community psychotherapist treatment in borderline personality disorder. Evidence-based Mental Health2010;13(4):119. [DOI: 10.1136/ebmh.13.4.119] [PMID: 21036981]NCT00714311. Efficacy of transference-focused psychotherapy for borderline personality disorder [A randomized-controlled trial of transference-focused psychotherapy vs treatment by experienced community psychotherapists for borderline personality disorder]. www.clinicaltrials.gov/ct2/show/NCT00714311 (first received 9 July 2008). RentropM , MartiusP , BäumlJ , BuchheimP , DöeringS , HörzS . Patients with borderline personality disorder not participating in an RCT: are they different?Psychopathology2010;43(6):369-72. [DOI: 10.1159/000320351] [PMID: 20798576]">Doering 2010</a>; <a href="./references#CD012955-bbs2-0020" title="ElicesM , PascualJC , PortellaMJ , Feliu-SolerA , Martín-BlancoA , CarmonaC , et al. Impact of mindfulness training on borderline personality disorder: a randomized trial. Mindfulness2016;7:584-95. [DOI: 10.1007/s12671-016-0492-1]NCT02397031. Mindfulness and interpersonal effectiveness skills in borderline personality disorder [Randomized, active-controlled, clinical trial comparing effects of mindfulness and interpersonal effectiveness skills in borderline personality disorder]. www.clinicaltrials.gov/ct2/show/NCT02397031 (first received 12 March 2015). SolerJ , ElicesM , PascualJC , Martín-BlancoA , Feliu-SolerA , CarmonaC , et al. Effects of mindfulness training on different components of impulsivity in borderline personality disorder: results from a pilot randomized study. Borderline Personality Disorder and Emotion Dysregulation2016;3:1. [DOI: 10.1186/s40479-015-0035-8] [PMC4709962] [PMID: 26759718]">Elices 2016</a>; <a href="./references#CD012955-bbs2-0024" title="ArntzA , Stupar-RutenfransS , BlooJ , Van DyckR , SpinhovenP . Prediction of treatment discontinuation and recovery from borderline personality disorder: results from an RCT comparing schema therapy and transference-focused psychotherapy. Behaviour Research and Therapy2015;74:60-71. [DOI: 10.1016/j.brat.2015.09.002] [PMID: 26432172]Giesen-BlooJ , ArntzA . Questions concerning the randomized trial of schema-focused therapy vs transference-focused psychotherapy—reply. Archives of General Psychiatry2007;64(5):610-1. [DOI: 10.1001/archpsyc.64.5.610]Giesen-BlooJ , Van DyckR , SpinhovenP , Van TilburgW , DirksenC , Van AsseltT , et al. Errors in table and figure in: outpatient psychotherapy for borderline personality disorder: randomized trial of schema-focused therapy vs transference-focused psychotherapy. Archives of General Psychiatry2006;63(9):1008. Erratum for: Archives of General Psychiatry 2006;63(6):649-58. [DOI: 10.1001/archpsyc.63.9.1008]Giesen-BlooJ , Van DyckR , SpinhovenP , Van TilburgW , DirksenC , Van AsseltT , et al. Outpatient psychotherapy for borderline personality disorder: randomized trial of schema-focused therapy vs transference-focused psychotherapy. Archives of General Psychiatry2006;63(6):649-58. [DOI: 10.1001/archpsyc.63.6.649] [PMID: 16754838]SpinhovenP , Giesen-BlooJ , Van DyckR , KooimanK , ArntzA . The therapeutic alliance in schema-focused therapy and transference-focused psychotherapy for borderline personality disorder. Journal of Consulting and Clinical Psychology2007;75(1):104-15. [DOI: 10.1037/0022-006X.75.1.104] [PMID: 17295569]Van AsseltADI , DirksenCD , ArntzA , Giesen-BlooJH , Van DyckR , SpinhovenP , et al. Out-patient psychotherapy for borderline personality disorder: cost-effectiveness of schema-focused therapy v transference-focused psychotherapy. British Journal of Psychiatry2008;192(6):450-7. [DOI: 10.1192/bjp.bp.106.033597] [PMID: 18515897]Van AsseltADI , DirksenCD , ArntzA , SeverensJL . Difficulties in calculating productivity costs: work disability associated with borderline personality disorder. Value in Health2008;11(4):637-44. [DOI: 10.1111/j.1524-4733.2007.00288.x]YeomansF . Questions concerning the randomized trial of schema-focused therapy vs transference-focused psychotherapy. Archives of General Psychiatry2007;64(5):609-10. [DOI: 10.1001/archpsyc.64.5.609-c] [PMID: 17485613]">Giesen‐Bloo 2006</a>; <a href="./references#CD012955-bbs2-0025" title="GleesonJF , ChanenA , CottonSM , PearceT , NewmanB , McCutcheonL . Treating co-occurring first-episode psychosis and borderline personality: a pilot randomized controlled trial. Early Intervention in Psychiatry2012;6(1):21-9. [DOI: 10.1111/j.1751-7893.2011.00306.x] [PMID: 22379625]GleesonJFM . RE: separate data [personal communication]. Email to: M Kielsholm 28 October 2016. ">Gleeson 2012</a>; <a href="./references#CD012955-bbs2-0026" title="Gratz KL. Important: question regarding your BPD trial for systematic review in Cochrane Collaboration [personal communication]. Email to: J Stoffers-Winterling 11 December 2010. GratzKL , GundersonJG . Preliminary data on an acceptance-based emotion regulation group intervention for deliberate self-harm among women with borderline personality disorder. Behavior Therapy2006;37(1):25-35. [DOI: 10.1016/j.beth.2005.03.002] [PMID: 16942958]">Gratz 2006</a>; <a href="./references#CD012955-bbs2-0027" title="GratzKL , BardeenJR , LevyR , Dixon-GordonKL , TullMT . Mechanisms of change in an emotion regulation group therapy for deliberate self-harm among women with borderline personality disorder. Behaviour Research and Therapy2015;65:29-35. [DOI: 10.1016/j.brat.2014.12.005] [PMC4306622] [PMID: 25557395]GratzKL , Dixon-GordonKL , TullMT . Predictors of treatment response to an adjunctive emotion regulation group therapy for deliberate self-harm among women with borderline personality disorder. Personality Disorders2014;5(1):97-107. [DOI: 10.1037/per0000062] [PMC4059504] [PMID: 2458806]GratzKL , TullMT , LevyR . Randomized controlled trial and uncontrolled 9-month follow-up of an adjunctive emotion regulation group therapy for deliberate self-harm among women with borderline personality disorder. Psychological Medicine2014;44(10):2099-112. [DOI: 10.1017/S0033291713002134] [PMID: 23985088]GratzKL . Question regarding your BPD trials [personal communication]. Email to: J Stoffers 11 December 2010. ">Gratz 2014</a>; <a href="./references#CD012955-bbs2-0028" title="GregoryRJ , ChlebowskiS , KangD , RemenA , SoderbergM . Psychodynamic therapy for borderline personality disorder and co-occurring alcohol use disorders: a newly designed ongoing study. Journal of the American Psychoanalytic Association2006;54(4):1331-4. [DOI: 10.1177/00030651060540040107] [PMID: 17354507]GregoryRJ , ChlebowskiS , KangD , RemenAL , SoderbergMG , StepkovitchJ , et al. A controlled trial of psychodynamic psychotherapy for co-occurring borderline personality disorder and alcohol use disorder. Psychotherapy2008;45(1):28-41. [DOI: 10.1037/0033-3204.45.1.28] [PMID: 22122363]GregoryRJ , DeLucia-DeranjaE , MogleJA . Dynamic deconstructive psychotherapy versus optimized community care for borderline personality disorder co-occuring with alcohol use disorders: a 30-month follow-up. Journal of Nervous and Mental Disease2010;198(4):292-8. [DOI: 10.1097/NMD.0b013e3181d6172d] [PMID: 20386259]GregoryRJ , RemenAL , SoderbergM , Ploutz-SnyderRJ . A controlled trial of psychodynamic psychotherapy for co-occurring borderline personality disorder and alcohol use disorder: six-month outcome. Journal of the American Psychoanalytic Association2009;57(1):199-205. [DOI: 10.1177/00030651090570011006] [PMID: 19270255]NCT00145678. Psychodynamic therapy for co-occurring borderline personality disorder and alcohol use disorder [Psychodynamic therapy for patients With borderline personality disorder and alcohol abuse]. www.clinicaltrials.gov/show/NCT00145678 (first received 1 September 2005). ">Gregory 2008b</a>; <a href="./references#CD012955-bbs2-0030" title="HarnedM . Re: SV: question regarding your trial on brief therapy for attempted suicide [personal communication]. Email to: EG Faltinsen 11 December 2018. HarnedMS , KorslundKE , LinehanMM . A pilot randomized controlled trial of dialectical behavior therapy with and without the dialectical behavior therapy prolonged exposure protocol for suicidal and self-injuring women with borderline personality disorder and PTSD. Behaviour Research and Therapy2014;55:7-17. [DOI: 10.1016/j.brat.2014.01.008] [PMC3987949] [PMID: 24562087]HarnedMS , WilksCR , SchmidtSC , CoyleTN . Improving functional outcomes in women with borderline personality disorder and PTSD by changing PTSD severity and post-traumatic cognitions. Behaviour Research and Therapy2018;103:53-61. [DOI: 10.1016/j.brat.2018.02.002] [PMC5837954] [PMID: 29448136]HarnedMS . RE: questions regarding your trial on brief therapy for attempted suicide [personal communication]. Email to: E Faltinsen 29 November 2017. ">Harned 2014</a>; <a href="./references#CD012955-bbs2-0031" title="BrandS . AW: questions regarding your trial on emotional intelligence training for BPD [personal communication]. Email to: EG Faltinsen 28 November 2017. BrandS . Questions regarding your trial on emotional intelligence training for BPD [personal communication]. Email to: EG Faltinsen 28 November 2017. JahangardL , HaghighiM , BajoghliH , AhmadpanahM , GhaleihaA , ZarrabianMK , et al. Training emotional intelligence improves both emotional intelligence and depressive symptoms in inpatients with borderline personality disorder and depression. International Journal of Psychiatry in Clinical Practice2012;16(3):197-204. [DOI: 10.3109/13651501.2012.687454] [PMID: 22873719]">Jahangard 2012</a>; <a href="./references#CD012955-bbs2-0032" title="JochemsEC , Van der Feltz-CornelisCM , Van DamA , DuivenvoordenHJ , MulderCL . The effects of motivation feedback in patients with severe mental illness: a cluster randomized controlled trial. Neuropsychiatric Disease and Treatment2015;11:3049-64. [DOI: 10.2147/NDT.S95190] [PMC4686323] [PMID: 26715847]JochemsEC . Cochrane Collaboration review on psychotherapies for borderline PD [personal communication]. Email to: EG Faltinsen 2 July 2018. JochemsEC . Re: Cochrane Collaboration review on psychotherapies for borderline PD [personal communication]. Email to: J Stoffers-Winterling 02 July 2018. ">Jochems 2015</a>; <a href="./references#CD012955-bbs2-0035" title="KoonsCR , RobinsCJ , TweedJL , LynchTR , GonzalezAM , MorseJQ , et al. Efficacy of dialectical behavior therapy in women veterans with borderline personality disorder. Behavior Therapy2001;32(2):371-90. [DOI: 10.1016/S0005-7894(01)80009-5]">Koons 2001a</a>; <a href="./references#CD012955-bbs2-0036" title="KramerU , BergerT , KollyS , MarquetP , PreisigM , De RotenY , et al. Effects of motive-oriented therapeutic relationship in early-phase treatment of borderline personality disorder: a pilot study of a randomized trial. Journal of Nervous and Mental Disease2011;199(4):244-50. [DOI: 10.1097/NMD.0b013e3182125d19] [PMID: 21451348]KramerU , CasparF , DrapeauM . Change in biased thinking in a 10-session treatment for borderline personality disorder: further evidence of the motive-oriented therapeutic relationship. Psychotherapy Research2013;23(6):633-45. [DOI: 10.1080/10503307.2013.791404] [PMID: 23631622]">Kramer 2011</a>; <a href="./references#CD012955-bbs2-0038" title="KramerU , Pascual-LeoneA , BerthoudL , De RotenY , MarquetP , KollyS , et al. Assertive anger mediates effects of dialectical behaviour-informed skills training for borderline personality disorder: a randomized controlled trial. Clinical Psychology &amp; Psychotherapy2016;23(3):189-202. [DOI: 10.1002/cpp.1956] [PMID: 25864773]KramerU . The role of coping change in borderline personality disorder: a process-outcome analysis on dialectical-behaviour skills training. Clinical Psychology &amp; Psychotherapy2017;24(2):302-11. [DOI: 10.1002/cpp.2017] [PMID: 27098296]">Kramer 2016</a>; <a href="./references#CD012955-bbs2-0039" title="KredlowMA , SzuhanyKL , LoS , XieH , GottliebJD , RosenbergSD , et al. Cognitive behavioral therapy for posttraumatic stress disorder in individuals with severe mental illness and borderline personality disorder. Psychiatry Research2017;249:86-93. [DOI: 10.1016/j.psychres.2016.12.045] [PMC5325773] [PMID: 28086181]MueserK . Re: question regarding your trial on CBT for BPD patients [personal communication]. Email to: EG Faltinsen 28 November 2017. ">Kredlow 2017a</a>; <a href="./references#CD012955-bbs2-0040" title="KredlowMA , SzuhanyKL , LoS , XieH , GottliebJD , RosenbergSD , et al. Cognitive behavioral therapy for posttraumatic stress disorder in individuals with severe mental illness and borderline personality disorder. Psychiatry Research2017;249:86-93. [DOI: 10.1016/j.psychres.2016.12.045] [PMC5325773] [PMID: 28086181]MueserKT , GottliebJD , XieH , LuW , YanosPT , RosenbergSD , et al. Evaluation of cognitive restructuring for post-traumatic stress disorder in people with severe mental illness.. British Journal of Psychiatry2015;206(6):501-8. [DOI: 10.1192/bjp.bp.114.147926] [PMC4450219] [PMID: 25858178]MueserKT , RosenbergSD , XieH , JankowskiMK , BoltonEE , LuW , et al. A randomized controlled trial of cognitive-behavioral treatment for posttraumatic stress disorder in severe mental illness. Journal of Consulting and Clinical Psychology2008;76(2):259-71. [DOI: 10.1037/0022-006X.76.2.259] [PMC3916092] [PMID: 18377122]MueserKT . Re: question regarding your trial on CBT for PTSD participants [personal communication]. Email to: E Faltinsen 28 November 2018. ">Kredlow 2017b</a>; <a href="./references#CD012955-bbs2-0041" title="LaurenssenEM , WestraD , KikkertMJ , NoomMJ , EerenHV , Van BroekhuyzenAJ , et al. Day hospital mentalization-based treatment (MBT-DH) versus treatment as usual in the treatment of severe borderline personality disorder: protocol of a randomized controlled trial. BMC Psychiatry2014;14:149. [DOI: 10.1186/1471-244X-14-149] [PMC4045960] [PMID: 24886402]LaurenssenEMP , LuytenP , KikkertMJ , WestraD , PeenJ , SoonsMBJ , et al. Day hospital mentalization-based treatment v specialist treatment as usual in patients with borderline personality disorder: randomized controlled trial. Psychological Medicine2018;48(15):2522-9. [DOI: 10.1017/S0033291718000132] [PMID: 29478425]NL2058 (NTR2175). Mentalisation-based treatment versus care-as-usual in the treatment of severe borderline personality disorders. www.trialregister.nl/trial/2058 (first received 21 January 2010). ">Laurenssen 2018</a>; <a href="./references#CD012955-bbs2-0042" title="LeichsenringF , MasuhrO , JaegerU , RabungS , DallyA , DümpelmannM , et al. Psychoanalytic-interactional therapy versus psychodynamic therapy by experts for personality disorders: a randomized controlled efficacy-effectiveness study in cluster B personality disorders. Psychotherapy and Psychosomatics2016;85(2):71-80. [DOI: 10.1159/000441731] [PMID: 26808580]">Leichsenring 2016</a>; <a href="./references#CD012955-bbs2-0043" title="LeppänenV , HakkoH , SintonenH , LindemanS . Comparing effectiveness of treatments for borderline personality disorder in communal mental health care: the Oulu BPD study. Community Mental Health Journal2016;52(2):216-27. [DOI: 10.1007/s10597-015-9866-4] [PMID: 25824852]LeppänenV . Re: questions regarding the Oulu BPD study [personal communication]. Email to: E Faltinsen 20 December 2017. LeppänenV . Re: SV: question regarding the Oulu BPD study [personal communication]. Email to: EG Faltinsen 22 December 2017. ">Leppänen 2016</a>; <a href="./references#CD012955-bbs2-0045" title="HoffmanRE . Impact of treatment accessibility on clinical course of parasuicidal patients. Archives of General Psychiatry1993;50(2):157-8. [DOI: 10.1001/archpsyc.1993.01820140083010] [PMID: 8427557]LindenboimN . To Know Me is to Keep Me: Self-Verification, Validation, and Therapy Dropout in the Treatment of Borderline Personality Disorder [PhD thesis]. Washington (DC): University of Washington, 2009. LinehanMM , ArmstrongHE , SuarezA , AllmonD , HeardHL . Cognitive-behavioral treatment of chronically parasuicidal borderline patients. Archives of General Psychiatry1991;48(12):1060-4. [DOI: 10.1001/archpsyc.1991.01810360024003] [PMID: 1845222]LinehanMM , HeardHL . Impact of treatment accessibility on clinical course of parasuicidal patients — reply. Archives of General Psychiatry1993;50(2):157-8. [DOI: 10.1001/archpsyc.1993.01820140083011]">Linehan 1991</a>; <a href="./references#CD012955-bbs2-0046" title="HeardHL . Cost-Effectiveness of Dialectical Behavior Therapy in the Treatment of Borderline Personality Disorder [PhD thesis]. Washington (DC): University of Washington, 2000. LindenboimN . To Know Me is to Keep Me: Self-Verification, Validation, and Therapy Dropout in the Treatment of Borderline Personality Disorder [PhD thesis]. Washington (DC): University of Washington, 2009. LinehanMM , HeardHL , ArmstrongHE . Naturalistic follow-up of a behavioral treatment for chronically parasuicidal borderline patients. Archives of General Psychiatry1993;50(12):971-4. [DOI: 10.1001/archpsyc.1993.01820240055007] [PMID: 8250683]LinehanMM , TutekDA , HeardHL , ArmstrongHE . Interpersonal outcome of cognitive behavioral treatment for chronically suicidal borderline patients. American Journal of Psychiatry1994;151(12):1771-6. [DOI: 10.1176/ajp.151.12.1771] [PMID: 7977884]">Linehan 1994</a>; <a href="./references#CD012955-bbs2-0047" title="BedicsJD , AtkinsDC , ComtoisKA , LinehanMM . Treatment differences in the therapeutic relationship and introject during a 2-year randomized controlled trial of dialectical behavior therapy versus nonbehavioral psychotherapy experts for borderline personality disorder. Journal of Consulting and Clinical Psychology2012;80(1):66-77. [DOI: 10.1037/a0026113] [PMC3265694] [PMID: 22061867]BedicsJD , AtkinsDC , ComtoisKA , LinehanMM . Weekly therapist ratings of the therapeutic relationship and patient introject furing the course of dialectical behavioral therapy for the treatment of borderline personality disorder. Psychotherapy2012;49(2):231-40. [DOI: 10.1037/a0028254] [PMID: 22642526]BedicsJD , AtkinsDC , HarnedMS , LinehanMM . The therapeutic alliance as a predictor of outcome in dialectical behavior therapy versus nonbehavioral psychotherapy by experts for borderline personality disorder. Psychotherapy2015;52(1):67-77. [DOI: 10.1037/a0038457] [PMID: 25751116]BrownMZ , LinehanMM , ComtoisKA , MurrayA , ChapmanAL . Shame as a prospective predictor of self-inflicted injury in borderline personality disorder: a multi-modal analysis. Behaviour Research and Therapy2009;47(10):815-22. [DOI: 10.1016/j.brat.2009.06.008] [PMC2761705] [PMID: 19596223 ]CoyleTN , ShaverJA , LinehanMM . On the potential for iatrogenic effects of psychiatric crisis services: the example of dialectical behavior therapy for adult women with borderline personality disorder. Journal of Consulting and Clinical Psychology2018;86(2):116-24. [DOI: 10.1037/ccp0000275] [PMID: 29369662]HarnedMS , ChapmanAL , Dexter-MazzaET , MurrayA , ComtoisKA , LinehanMM . Treating co-occurring Axis I disorders in recurrently suicidal women with borderline personality disorder: a 2-year randomized trial of dialectical behavior therapy versus community treatment by experts. Journal of Consulting and Clinical Psychology2008;76(6):1068-75. [DOI: 10.1037/a0014044] [PMID: 19045974]HarnedMS , ChapmanAL , Dexter-MazzaET , MurrayA , ComtoisKA , LinehanMM . Treating co-occurring Axis I disorders in recurrently suicidal women with borderline personality disorder: a 2-year randomized trial of dialectical behavior therapy versus community treatment by experts. Personality Disorders: Theory, Research, and Treatment2009;S(1):35-45. [DOI: 10.1037/1949-2715.S.1.35]HarnedMS , JacksonSC , ComtoisKA , LinehanMM . Dialectical behavior therapy as a precursor to PTSD treatment for suicidal and/or self-injuring women with bordreline personality disorder. Journal of Traumatic Stress2010;23(4):421-9. [DOI: 10.1002/jts.20553] [PMID: 20648564]LindenboimN , ComtoisKA , LinehanMM . Skills practice in dialectical behavior therapy for suicidal women meeting criteria for borderline personality disorder. Cognitive and Behavioral Practice2007;14(2):147-56. [DOI: 10.1016/j.cbpra.2006.10.004]LinehanMM , ComtoisKA , MurrayAM , BrownMZ , GallopRJ , HeardHL , et al. Two-year randomized controlled trial and follow-up of dialectical behavior therapy vs therapy by experts for suicidal behaviors and borderline personality disorder. Archives of General Psychiatry2006;63(7):757-66. [DOI: 10.1001/archpsyc.63.7.757] [PMID: 16818865]LinehanMM . Error in table in: two-year randomized controlled trial and follow-up of dialectical behavior therapy vs therapy by experts for suicidal behaviors and borderline personality disorder. Archives of General Psychiatry2007;64(12):1401. Erratum for: Archives of General Psychiatry 2007;64(12):1401. McMainS . Dialectic behaviour therapy reduces suicide attempts compared with non-behavioural psychotherapy in women with borderline personality disorder. Evidence-Based Mental Health2007;10(1):18. [DOI: 10.1136/ebmh.10.1.18] [PMID: 17255387]NeacsiuAD , LunguA , HarnedMS , RizviSL , LinehanMM . Impact of dialectical behavior therapy versus community treatment by experts on emotional experience, expression, and acceptance in borderline personality disorder. Behaviour Research and Therapy2014;53:47-54. [DOI: 10.1016/j.brat.2013.12.004] [PMC3955205] [PMID: 24418652]NeacsiuAD , RizviSL , LinehanMM . Dialectical behavior therapy skills use as a mediator and outcome of treatment for borderline personality disorder. Behaviour Research and Therapy2010;48(9):832-9. [DOI: 10.1016/j.brat.2010.05.017] [PMC2914145] [PMID: 20579633]SecristCD . The Role of Executive Functioning in the Treatment of Borderline Personality Disorder [PhD thesis]. Washington (DC): University of Washington, 2014. ">Linehan 2006</a>; <a href="./references#CD012955-bbs2-0048" title="LinehanMM , KorslundKE , HarnedMS , GallopRJ , LunguA , NeacsiuAD , et al. Dialectical behavior therapy for high suicide risk in individuals with borderline personality disorder: a randomized clinical trial and component analysis. JAMA Psychiatry2015;72(5):475-82 Erratum for: JAMA Psychiatry 2015; 72(9): 951. [DOI: 10.1001/jamapsychiatry.2014.3039] [PMID: 25806661]NCT00183651. Treatment of suicidal women with borderline personality disorder [Assessment and treatment of parasuicidal patients]. www.clinicaltrials.gov/ct2/show/NCT00183651 (first received 13 September 2005). ">Linehan 2015a</a>; <a href="./references#CD012955-bbs2-0049" title="CaseBG . Letter to the editor on 'McMain SF, Links PS, Gnam WH, Guimond T, Cardish RJ, Korman L, et al. A randomized trial of dialectical behavior therapy versus general psychiatric management for borderline personality disorder. American Journal of Psychiatry 2009;166(12):1365-74. DOI: 10.1176/appi.ajp.2009.09010039'. American Journal of Psychiatry2010;167(4):475. [DOI: 10.1176/appi.ajp.2009.09101532] [PMID: 20360332 ]ISRCTN02634417. Hope for chronically suicidal patient: evaluating the clinical and health services impact of dialectical behaviour therapy (DBT) in individuals with borderline personality disorder [Evaluating the clinical and health services impact of dialectical behaviour therapy (DBT) in individuals with borderline personality disorder: a randomised controlled trial]. www.isrctn.com/ISRCTN02634417 (first received 16 November 2005). [DOI: 10.1186/ISRCTN02634417]McMainSF , FitzpatrickS , BoritzT , BarnhartR , LinksP , StreinerDL . Outcome trajectories and prognostic factors for suicide and self-harm behaviors in patients with borderline personaliy disorder following one year of outpatient psychotherapy. Journal of Personality Disorders2018;32(4):497-512. [DOI: 10.1521/pedi_2017_31_309] [PMID: 28910214]McMainSF , LinksPS , GnamWH , GuimondT , CardishRJ , KormanL , et al. A randomized trial of dialectical behavior therapy versus general psychiatric management for borderline personality disorder. American Journal of Psychiatry2009;166(12):1365-74. [DOI: 10.1176/appi.ajp.2009.09010039] [PMID: 19755574]McMainSF . Dr McMain replies to letter to the editor on 'McMain SF, Links PS, Gnam WH, Guimond T, Cardish RJ, Korman L, et al. A randomized trial of dialectical behavior therapy versus general psychiatric management for borderline personality disorder. American Journal of Psychiatry 2009;166(12):1365-74. DOI: 10.1176/appi.ajp.2009.09010039'. American Journal of Psychiatry2010;167(4):475-6. [DOI: 10.1176/appi.ajp.2009.09101532r)]NCT00154154. Hope for the chronically suicidal patient [Hope for the chronically suicidal patient: evaluating the clinical and health services impact of dialectical behaviour therapy in individuals with borderline personality disorder]. www.clinicaltrials.gov/ct2/show/NCT00154154 (first received 7 September 2005). ">McMain 2009</a>; <a href="./references#CD012955-bbs2-0050" title="McMainSF , GuimondT , BarnhartR , HabinskiL , StreinerDL . A randomized trial of brief dialectical behaviour therapy skills training in suicidal patients suffering from borderline disorder. Acta Psychiatrica Scandinavica2017;135(2):138-48. [DOI: 10.1111/acps.12664] [PMID: 27858962]">McMain 2017</a>; <a href="./references#CD012955-bbs2-0052" title="HagaE , AasE , GrøholtB , TørmoenAJ , MehlumL . Cost-effectiveness of dialectical behaviour therapy vs enhanced usual care in the treatment of adolescents with self-harm. Child and Adolescent Psychiatry and Mental Health2018;12:22. [DOI: 10.1186/s13034-018-0227-2] [PMC5928596] [PMID: 29743941]MehlumL , RambergM , TørmoenAJ , HagaE , DiepLM , StanleyBH , et al. Dialectical behavior therapy compared with enhanced usual care for adolescents with repeated suicidal and self-harming behavior: outcomes over a one-year follow-up. Journal of the American Academy of Child and Adolescent Psychiatry2016;55(4):295-300. [DOI: 10.1016/j.jaac.2016.01.005] [PMID: 27015720]MehlumL , TørmoenAJ , RambergM , HagaE , DiepLM , LabergS , et al. Dialectical behavior therapy for adolescents with repeated suicidal and self-harming behavior: a randomized trial. Journal of the American Academy of Child and Adolescent Psychiatry2014;53(10):1082-91. [DOI: 10.1016/j.jaac.2014.07.003] [PMID: 25245352]MehlumL . Re: regarding your study of DBT for your with suicidal behavior [personal communication] [Re: angående din studie om DBT for ungdom med selvmordsatferd [personlig kommunikation]]. Email to: E Faltinsen 5 December 2017. NCT00675129. Treatment for adolescents with deliberate self harm [A randomized controlled trial for repetitive deliberate self-harm and suicidal behaviours among Norwegian adolescents: a comparison between dialectical behaviour therapy adapted for adolescents (DBT-A) and enhanced usual care (EUC)]. www.clinicaltrials.gov/ct2/show/NCT00675129 (first received 6 May 2008). RamlethRK , GroholtB , DiepLM , WalbyFA , MehlumL . The impact of borderline personality disorder and sub-threshold borderline personality disorder on the course of self-reported and clinician-rated depression in self-harming adolescents. Borderline Personality Disorder and Emotion Dysregulation2017;4:22. [DOI: 10.1186/s40479-017-0073-5] [PMC5663078] [PMID: 29093819]">Mehlum 2014</a>; <a href="./references#CD012955-bbs2-0057" title="NCT02033044. Cognitive rehabilitation versus psychoeducation in psychosocial functioning of borderline personality disorder [Randomized controlled trial comparing the effects on psychosocial functioning of cognitive rehabilitation versus psychoeducation in borderline personality disorder]. www.clinicaltrials.gov/ct2/show/NCT02033044 (first received 23 December 2013). PascualJC , PalomaresN , Ibáñez Á, PortellaMJ , ArzaR , ReyesR , et al. Efficacy of cognitive rehabilitation on psychosocial functioning in borderline personality disorder: a randomized controlled trial. BMC Psychiatry2015;15:255. [DOI: 10.1186/s12888-015-0640-5] [PMC4617906] [PMID: 26487284]">Pascual 2015</a>; <a href="./references#CD012955-bbs2-0061" title="ISRCTN51304415. Nice OUtcomes for Referrals with Impulsivity, Self Harm and Eating Disorders: the NOURISHED study [A randomised controlled trial of mentalisation based therapy against specialist supportive clinical management in patients with both eating disorders and symptoms of borderline personality disorder]. www.isrctn.com/ISRCTN51304415 (first received 31 January 2011). RobinsonP , BarrettB , BatemanA , HakeemA , HellierJ , LemonskyF , et al. Study protocol for a randomized controlled trial of mentalization based therapy against specialist supportive clinical management in patients with both eating disorders and symptoms of borderline personality disorder. BMC Psychiatry2014;14:51. [DOI: 10.1186/1471-244X-14-51] [PMC3996076] [PMID: 24555511]RobinsonP , HellierJ , BarrettB , BarzdaitieneD , BatemanA , BogaardtA , et al. The NOURISHED randomised controlled trial comparing mentalisation-based treatment for eating disorders (MBT-ED) with specialist supportive clinical management (SSCM-ED) for patients with eating disorders and symptoms of borderline personality disorder. Trials2016;17(1):549. [DOI: 10.1186/s13063-016-1606-8] [PMC5114835] [PMID: 27855714]">Robinson 2016</a>; <a href="./references#CD012955-bbs2-0062" title="ISRCTN95266816. The emergence of personality disorder traits in adolescents who deliberately self harm and the potential for using a mentalisation based treatment approach as an early intervention for such individuals: a randomised controlled trial. www.isrctn.com/ISRCTN95266816 (first received 29 October 2007). RossouwT . Mentalisation based treatment for adolescents with self harm: an RCT. European Child &amp; Adolescent Psychiatry2015;24(1 Suppl):S113. [DOI: 10.1007%2Fs00787-015-0714-4.pdf] [W1-02-02]RossouwT . Self harm in adolescence, is MBT the answer?: an RCT. Adolescent Psychiatry2012;2(1):102. [DOI: 10.2174/2210676611202010077]RossouwTI , FonagyP . Mentalization-based treatment for self-harm in adolescents: a randomized controlled trial. Journal of the American Academy of Child and Adolescent Psychiatry2012;51(12):1304-13.e3. [DOI: 10.1016/j.jaac.2012.09.018] [PMID: 23200287]">Rossouw 2012b</a>; <a href="./references#CD012955-bbs2-0063" title="SalzerS , CroppC , JaegerU , MasuhrO , Streeck-FischerA . Psychodynamic therapy for adolescents suffering from co-morbid disorders of conduct and emotions in an in-patient setting: a randomized controlled trial. Psychological Medicine2014;44(10):2213-22. [DOI: 10.1017/S003329171300278X] [PMID: 24229481]SalzerS , Streeck-FischerA . The psychoanalytic-interactional method (PiM) for adolescents with borderline personality disorder [Die psychoanalytisch-interaktionelle methode (PiM) für adoleszente mit borderline-persönlichkeitsstörung]. Personlichkeitsstorungen Theorie und Therapie2015;19(1):67-76. [elibrary.klett-cotta.de/article/99.120110/ptt-19-1-67]SalzerS . AW: Re: Cochrane Review on psychotherapies for BPD - RCT testing PiM vs WL [personal communication] [AW:Re: Cochrane Review zur Psychotherapie bei BPS - RCT zu PiM vs WL [persönliche kommunikation]]. Email to: J Stoffers-Winterling 15 July 2018. ">Salzer 2014</a>; <a href="./references#CD012955-bbs2-0066" title="ISRCTN97589104. Evaluation of a group training for adolescents (emotion regulation training) with emotion regulation problems - a randomised controlled clinical trial. www.isrctn.com/ISRCTN97589104 (first received 23 August 2007). SchuppertHM , TimmermanME , BlooJ , Van GemertTG , WiersemaHM , MinderaaRB , et al. Emotion regulation training for adolescents with borderline personality disorder traits: a randomized controlled trial. Journal of the American Academy of Child &amp; Adolescent Psychiatry2012;51(12):1314-23. [DOI: 10.1016/j.jaac.2012.09.002] [PMID: 23200288]">Schuppert 2012</a>; <a href="./references#CD012955-bbs2-0069" title="SolerJ , PascualJC , TianaT , CebriàA , BarrachinaJ , CampinsMJ , et al. Dialectical behaviour therapy skills training compared to standard group therapy in borderline personality disorder: a 3-month randomised controlled clinical trial. Behaviour Research and Therapy2009;47(5):353-8. [DOI: 10.1016/j.brat.2009.01.013] [PMID: 19246029]SolerJ . Question regarding your BPD trials [personal communication]. Email to: J Stoffers 15 December 2010. ">Soler 2009</a>; <a href="./references#CD012955-bbs2-0070" title="FertuckEA , KeilpJ , SongI , MorrisMC , WilsonST , BrodskyBS , et al. Higher executive control and visual memory performance predict treatment completion in borderline personality disorder. Psychotherapy and Psychosomatics2012;81(1):38-43. [DOI: 10.1159/000329700] [PMC3242704] [PMID: 22116411]NCT00533117. Treating suicidal behavior and self-mutilation in people with borderline personality disorder. www.clinicaltrials.gov/ct2/show/NCT00533117 (first received 19 September 2007). ">Stanley 2017</a>; <a href="./references#CD012955-bbs2-0071" title="TurnerRM . Naturalistic evaluation of dialectical behavior therapy-oriented treatment for borderline personality disorder. Cognitive and Behavioral Practice2000;7(4):413-9. [DOI: 10.1016/S1077-7229(00)80052-8]">Turner 2000</a>; <a href="./references#CD012955-bbs2-0072" title="Van den BoschLM , KoeterMW , StijnenT , VerheulR , Van den BrinkW . Sustained efficacy of dialectical behaviour therapy for borderline personality disorder. Behaviour Research and Therapy2005;43(9):1231-41. [DOI: 10.1016/j.brat.2004.09.008] [PMID: 16005708]Van den BoschLM , VerheulR , SchippersGM , Van den BrinkW . Dialectical behavior therapy of borderline patients with and without substance use problems. Implementation and long-term effects. Addictive Behaviors2002;27(6):911-23. [DOI: 10.1016/s0306-4603(02)00293-9] [PMID: 12369475]Van den BoschLMC . Efficacy of dialectical behaviour therapy in the treatment of female borderline patients with and without substance abuse problems: results of a Dutch study [Dialectische gedragstherapie bij Nederlandse vrouwen met een borderline persoonlijkheidsstoornis, met en zonder verslavingsproblemen]. Tijdschrift voor Psychiatrie2005;47(3):127-37. [www.tijdschriftvoorpsychiatrie.nl/assets/articles/articles_1335pdf.pdf]VerheulR , Van den BoschLM , KoeterMW , De RidderMA , StijnenT , Van den BrinkW . Dialectical behaviour therapy for women with borderline personality disorder: 12-month, randomised clinical trial in The Netherlands. British Journal of Psychiatry2003;182:135-40. [DOI: 10.1192/bjp.182.2.135] [PMID: 12562741]">Van den Bosch 2005</a>; <a href="./references#CD012955-bbs2-0073" title="WeinbergI , GundersonJG , HennenJ , Cutter CJ Jr. Manual assisted cognitive treatment for deliberate self-harm in borderline personality disorder patients. Journal of Personality Disorders2006;20(5):482-92. [DOI: 10.1521/pedi.2006.20.5.482] [PMID: 17032160]WilbergT . SV: separate data [personal communication] [SV: separat data [personlig kommunikation]]. Email to: M Kielsholm 25 May 2016. ">Weinberg 2006</a>). Fourteen trials did not have an adequate description of the blinding of the outcome assessors and thus were judged to be at unclear risk of bias (<a href="./references#CD012955-bbs2-0003" title="AntonsenBT , JohansenMS , RøFG , KvarsteinEH , WilbergT . Is reflective functioning associated with clinical symptoms and long-term course in patients with personality disorders?Comprehensive Psychiatry2016;64:46-58. [DOI: 10.1016/j.comppsych.2015.05.016] [PMID: 26104432]AntonsenBT , KlungsøyrO , KampsA , HummelenB , JohansenMS , PedersenG , et al. Step-down versus outpatient psychotherapeutic treatment for personality disorders: 6-year follow-up of the Ullevål personality project. BMC Psychiatry2014;14:119. [DOI: 10.1186/1471-244X-14-119] [PMC4000615] [PMID: 24758722]AntonsenBT , KvarsteinEH , Urnes Ø, HummelenB , KarterudS , WilbergT . Favourable outcome of long-term combined psychotherapy for patients with borderline personality disorder: six-year follow-up of a randomized study. Psychotherapy Research2017;27(1):51-63. [DOI: 10.1080/10503307.2015.1072283] [PMID: 26261865]ArnevikE , WilbergT , Urnes Ø, JohansenM , MonsenJT , KarterudS . Psychotherapy for personality disorders: short-term day hospital psychotherapy versus outpatient individual therapy - a randomized controlled study. European Psychiatry2009;24(2):71-8. [DOI: 10.1016/j.eurpsy.2008.09.004] [PMID: 19097870]GullestadFS , JohansenMS , HøglendP , KarterudS , WilbergT . Mentalization as a moderator of treatment effects: findings from a randomized clinical trial for personality disorders. Psychotherapy Research2013;23(6):674-89. [DOI: 10.1080/10503307.2012.684103] [PMID: 22612470]GullestadFS . Re: questions regarding your trial on day hospital step-down program [personal communication]. Email to: E Faltinsen 4 December 2017. KvarsteinEH , ArnevikE , HalsteinliV , RøFG , KarterudS , WilbergT . Health service costs and clinical gains of psychotherapy for personality disorders: a randomized controlled trial of day-hospital-based step-down treatment versus outpatient treatment at a specialist practice. BMC Psychiatry2013;13:315. [DOI: 10.1186/1471-244X-13-315] [PMC4222503] [PMID: 24268099]">Antonsen 2017</a>; <a href="./references#CD012955-bbs2-0022" title="FeigenbaumJD , FonagyP , PillingS , JonesA , WildgooseA , BebbingtonPE . A real-world study of the effectiveness of DBT in the UK National Health Service. British Journal of Clinical Psychology2012;51(2):121-41. [DOI: 10.1111/j.2044-8260.2011.02017.x] [PMID: 22574799]">Feigenbaum 2012</a>; <a href="./references#CD012955-bbs2-0023" title="Feliu-SolerA , PascualJC , ElicesM , Martín-BlancoA , CarmonaC , CebollaA , et al. Fostering self-compassion and loving-kindness in patients with borderline personality disorder: a randomized pilot study. Clinical Psychology &amp; Psychotherapy2017;24(1):278-86. [DOI: 10.1002/cpp.2000] [PMID: 26818533]">Feliu‐Soler 2017</a>; <a href="./references#CD012955-bbs2-0034" title="KamalabadiMJ , AhmadiSA , EtemadiO , FatehizadehM , BahramiF , FiroozabadiA . A study of the effect of couple dialectical behavioral therapy on symptoms and quality of marital relationships and mental health of Iranian borderline personality couples: a controlled trial. Interdisciplinary Journal of Contemporary Research in Business2012;3(9):1480-7. [psycnet.apa.org/record/2012-22425-047]">Kamalabadi 2012</a>; <a href="./references#CD012955-bbs2-0037" title="BerthoudL , KramerU , CasparF , Pascual-LeoneA . Emotional processing in a ten-session general psychiatric treatment for borderline personality disorder: a case study. Personality and Mental Health2015;9(1):73-8. [DOI: 10.1002/pmh.1287] [PMID: 25711648]BerthoudL , Pascual-LeoneA , CasparF , TissotH , KellerS , RohdeKB , et al. Leaving distress behind: a randomized controlled study on change in emotional processing in borderline personality disorder. Psychiatry2017;80(2):139-54. [DOI: 10.1080/00332747.2016.1220230] [PMID: 28767333]KellerS , StelmaszczykK , KollyS , De RotenY , DesplandJN , CasparF , et al. Change in biased thinking in a treatment based on the motive-oriented therapeutic relationship for borderline personality disorder. Journal of Personality Disorders2018;32(Suppl):75-92. [DOI: 10.1521/pedi.2018.32.supp.75] [PMID: 29388899]KramerU , FlückigerC , KollyS , CasparF , MarquetP , DesplandJN , et al. Unpacking the effects of therapist responsiveness in borderline personality disorder: motive-oriented therapeutic relationship, patient in-session experience, and the therapeutic alliance. Psychotherapy and Psychosomatics2014;83(6):386-7. [DOI: 10.1159/000365400] [PMID: 25324025]KramerU , KellerS , CasparF , De RotenY , DesplandJN , KollyS . Early change in coping strategies in responsive treatments for borderline personality disorder: a mediation analysis. Journal of Consulting and Clinical Psychology2017;85(5):530-5. [DOI: 10.1037/ccp0000196] [PMID: 28425747]KramerU , KollyS , BerthoudL , KellerS , PreisigM , CasparF , et al. Effects of motive-oriented therapeutic relationship in a ten-session general psychiatric treatment of borderline personality disorder: a randomized controlled trial. Psychotherapy and Psychosomatics2014;83(3):176-86. [DOI: 10.1159/000358528] [PMID: 24752034]KramerU , StulzN , BerthoudL , CasparF , MarquetP , KollyS , et al. The shorter the better? A follow-up analysis of 10-session psychiatric treatment including the motive-oriented therapeutic relationship for borderline personality disorder. Psychotherapy Research2017;27(3):362-70. [DOI: 10.1080/10503307.2015.1110635] [PMID: 26684670]NCT01896024. Effects of motive-oriented therapeutic relationship in the early-phase treatment of borderline personality disorder (MOTR). www.clinicaltrials.gov/ct2/show/NCT01896024 (first received 5 July 2013). ">Kramer 2014</a>; <a href="./references#CD012955-bbs2-0044" title="Lin T-J, Ko H-C, Wu JY-W, OeiTP , Lane H-Y, Chen C-H. The effectiveness of dialectical behavior therapy skills training group vs cognitive therapy group on reducing depression and suicide attempts for borderline personality disorder in Taiwan. Archives of Suicide Research2019;23(1):82-99. [DOI: 10.1080/13811118.2018.1436104] [PMID: 29528807]">Lin 2019</a>; <a href="./references#CD012955-bbs2-0053" title="MohamadizadehL , MakvandiB , PashaR , BakhtiarpourS , HafeziF . Comparing of the effect of dialectical behavior therapy (DBT) and schema therapy (ST) on reducing mood activity and suicidal thoughts in patients with borderline personality disorder. Acta Medica Mediterranea2017;33:1025-31. [DOI: 10.19193/0393-6384_2017_6_162] [www.actamedicamediterranea.com/archive/2017/medica-6/comparing-of-the-effect-of-dialectical-behavior-therapy-dbt-and-schema-therapy-st-on-reducing-mood-activity-and-suicidal-thoughts-in-patients-with-borderline-personality-disorder/pdf]">Mohamadizadeh 2017</a>; <a href="./references#CD012955-bbs2-0054" title="MoreyLC , LowmasterSE , HopwoodCJ . A pilot study of manual-assisted cognitive therapy with a therapeutic assessment augmentation for borderline personality disorder. Psychiatry Research2010;178(3):531-5. [DOI: 10.1016/j.psychres.2010.04.055] [PMID: 20537722]">Morey 2010</a>; <a href="./references#CD012955-bbs2-0056" title="NadortM , ArntzA , SmitJH , Giesen-BlooJ , EikelenboomJ , SpinhovenP , et al. Implementation of outpatient schema therapy for borderline personality disorder with versus without crisis support by the therapist outside office hours: a randomized trial. Behaviour Research and Therapy2009;47(11):961-73. [DOI: 10.1016/j.brat.2009.07.013] [PMID: 19698939]NadortM , ArntzA , SmitJH , Giesen-BlooJ , EikelenboomM , SpinhovenP , et al. Implementation of outpatient schema therapy for borderline personality disorder: study design. BMC Psychiatry2009;9:64. [DOI: 10.1186/1471-244X-9-64] [PMC2762959] [PMID: 19807925]NL1680 (NTR1781). Implementation of out-patient schema-focused therapy for borderline personality disorder in regular mental healthcare. www.trialregister.nl/trial/1680 (first received 29 April 2009). ">Nadort 2009</a>; <a href="./references#CD012955-bbs2-0058" title="PhilipsB , WennebergP , KonradssonP , FranckJ . Mentalization-based treatment for concurrent borderline personality disorder and substance use disorder: a randomized controlled feasibility study. European Addiction Research2018;24(1):1-8. [DOI: 10.1159/000485564] [PMC5969093] [PMID: 294028]">Philips 2018</a>; <a href="./references#CD012955-bbs2-0059" title="BarnicotK . Re: Regarding your study on DBT for self-harming patients [personal communication]. Email to: EG Faltinsen 28 February 2018. PriebeS , BhattiN , BarnicotK , BremnerS , GagliaA , KatsakouC , et al. Effectiveness and cost-effectiveness of dialectical behaviour therapy for self-harming patients with personality disorder: a pragmatic randomised controlled trial. Psychotherapy and Psychosomatics2012;81(6):356-65. [DOI: 10.1159/000338897] [PMID: 22964561]PriebeS . Supplemental information [personal communication]. Email to: M Kielsholm 20 May 2016. ">Priebe 2012</a>; <a href="./references#CD012955-bbs2-0060" title="RenesesB , FigueraD , SalcedoG , TrujilloM , López-IborJJ , GaliánM , et al. A controlled randomized study on the efficacy of short-term dinamic psychotherapy in borderline personality disorders (BPD). Preliminary results. European Psychiatry2011;26(Suppl 1):1040. [DOI: 10.1016/S0924-9338(11)72745-6] [P02-444]RenesesB , GaliánM , SerranoR , FigueraD , Fernandez Del MoralA , López-IborJJ , et al. A new time limited psychotherapy for BPD: preliminary results of a randomized and controlled trial. Actas Espanolas de Psiquiatria2013;41(3):139-48. [PMID: 23803797]">Reneses 2013</a>; <a href="./references#CD012955-bbs2-0065" title="SchillingL , MoritzS , KötherU , NagelM . Preliminary results on acceptance, feasibility, and subjective efficacy of the add-on group intervention metacognitive training for borderline patients. Journal of Cognitive Psychotherapy2015;29(2):153-64. [DOI: 10.1891/0889-8391.29.2.153]SchillingL , MoritzS , KristonL , KriegerM , NagelM . Efficacy of metacognitive training for patients with borderline personality disorder: preliminary results. Psychiatry Research2018;262:459-64. [DOI: 10.1016/j.psychres.2017.09.024] [PMID: 28927866]SchillingL . Re Schilling 2015/2018 - Cochrane Review of psychotherapies for BPD [personal communication] [Re Schilling 2015/2018 - Cochrane Review zur Psychotherapie bei BPS [persönliche Kommunikation]]. Email to: J Stoffers-Winterling 22 January 2019. ">Schilling 2018</a>; <a href="./references#CD012955-bbs2-0074" title="ZanariniMC , FrankenburgFR . A preliminary, randomized trial of psychoeducation for women with borderline personality disorder. Journal of Personality Disorders2008;22(3):284-90. [DOI: 10.1521/pedi.2008.22.3.284] [PMID: 18540800]ZanariniMC , FrankenburgFR . A randomized trial of psychoeducation for patients with BPD. In: 157th annual meeting of the American Psychiatric Association. Psychotherapy and psychopharmacology: dissolving the mind-brain barrier; 2004 May 1-6; New York (NY). Arlington (VA): American Psychiatric Association, 2004:102. [Symposium 100E] [www.psychiatry.org/File%20Library/Psychiatrists/Directories/Library-and-Archive/conference_publications/am_program_2004.pdf]">Zanarini 2008</a>). Eleven trials reported inadequate blinding of outcome assessors and thus were considered to be at high risk of bias (<a href="./references#CD012955-bbs2-0010" title="BlackD . Question regarding your BPD trial [personal communication]. Email to: J Stoffers 04 January 2011. BlackDW , AllenJ , McCormickB , BlumN . Treatment received by persons with BPD participating in a randomized clinical trial of the systems training for emotional predictability and problem solving programme. Personality and Mental Health2011;5(3):159-68. [DOI: 10.1002/pmh.167]BlackDW , AllenJ , St JohnD , PfohlB , McCormickB , BlumN . Predictors of response to systems training for emotional predictability and problem solving (STEPPS) for borderline personality disorder: an exploratory study. Acta Psychiatrica Scandinavica2009;120(1):53-61. [DOI: 10.1111/j.1600-0447.2008.01340.x] [PMC3665337] [PMID: 19183126]BlackDW , BlumN , PfohlB , St JohnD . The STEPPS group treatment program for outpatients with borderline personality disorder. Journal of Contemporary Psychotherapy2004;34(3):193-210. [DOI: 10.1023/B:JOCP.0000036630.25741.83]BlackDW , PfohlBM . Randomized clinical trial of STEPPS versus treatment as usual. In: 158th annual meeting of the American Psychiatric Association. Psychosomatic medicine: integrating psychiatry &amp; medicine; 2005 May 21-26; Atlanta (GA). Arlington (VA): American Psychiatric Association, 2005:104. [No. 1B] [www.psychiatry.org/File%20Library/Psychiatrists/Directories/Library-and-Archive/syllabus/am_syllabus_2005.pdf]BlackDW , Simsek-DuranF , BlumN , McCormickB , AllenJ . Do people with borderline personality disorder complicated by antisocial personality disorder benefit from the STEPPS treatment program?Personality and Mental Health2016;10(3):205-15. [DOI: 10.1002/pmh.1326] [PMC4911327] [PMID: 26671625]BlackDW . RE: [external] questions regarding your trial on the STEPPS program for BPD [personal communication]. Email to: EG Faltinsen 27 November 2017. BlumN , AllenJ , McCormickB , BlackDW . Ms Blum and colleagues reply [to Schulte-Herbrüggen O, Koerting J, Roepke S. Effectiveness of adjunctive STEPPS group treatment in borderline personality disorder patients. American Journal of Psychiatry 2008;165(10):1354-5. DOI: 10.1176/appi.ajp.2008.08030390]. American Journal of Psychiatry2008;165(10):1354-5. [DOI: 10.1176/appi.ajp.2008.08030390r]BlumN , FranklinJ , HanselR , McCormickB , St JohnD , PfohlB , et al. Relationship of age to symptom severity, psychiatric comorbidity and health care utilization in persons with borderline personality disorder. Personality and Mental Health2008;2(1):25-43. [DOI: 10.1002/pmh.26]BlumN , St JohnD , PfohlB , StuartS , McCormickB , AllenJ , et al. Erratum. American Journal of Psychiatry2008;165(6):777. Erratum for: American Journal of Psychiatry 2008;165(4):468-78. [psycnet.apa.org/record/2008-07854-033]BlumN , St JohnD , PfohlB , StuartS , McCormickB , AllenJ , et al. Systems training for emotional predictability and problem solving (STEPPS) for outpatients with borderline personality disorder: a randomized controlled trial and 1-year follow-up. American Journal of Psychiatry2008;165(4):468-78. [DOI: 10.1176/appi.ajp.2007.07071079] [PMC3608469] [PMID: 18281407]DavidsonKM . Borderline personality disorder: STEPPS improves symptoms. Evidence-Based Mental Health2008;11(4):120. [DOI: 10.1136/ebmh.11.4.120] [PMID: 18952969]NCT00055315. Treatment for borderline personality disorder [A cognitive group treatment for borderline outpatients]. clinicaltrials.gov/ct2/show/NCT00055315 (first received 25 February 2003). ">Blum 2008</a>; <a href="./references#CD012955-bbs2-0013" title="BosEH , Van WelE , AppeloMT , VerbraakMJP . A randomized controlled trial of a Dutch version of systems training for emotional predictability and problem solving for borderline personality disorder. Journal of Nervous and Mental Disease2010;198(4):299-304. [DOI: 10.1097/NMD.0b013e3181d619cf] [PMID: 20386260]Van WelEB , BosEH , AppeloMT , BerendsenEM , WillgerothFC , VerbraakMJPM . The efficacy of the systems training for emotional predictability and problem solving (STEPPS) in the treatment of borderline personality disorder. A randomized controlled trial [De effectiviteit van de vaardigheidstraining emotieregulatiestoornis (VERS) in de behandeling van de borderlinepersoonlijkheidsstoornis: een gerandomiseerd onderzoek]. Tijdschrift voor Psychiatrie2009;51(5):291-301. [PMID: 19434566]">Bos 2010</a>; <a href="./references#CD012955-bbs2-0021" title="FarrellJM , ShawIA , WebberMA . A schema-focused approach to group psychotherapy for outpatients with borderline personality disorder: a randomized controlled trial. Journal of Behavior Therapy and Experimental Psychiatry2009;40(2):317-28 Corrigendum to: Journal of Behavior Therapy and Experimental Psychiatry 2018; 60: 111. [DOI: 10.1016/j.jbtep.2009.01.002] [PMID: 19176222]FarrellJM . Question regarding your BPD trials [personal communication]. Email to: K Lieb, J Stoffers 9 December 2010. ">Farrell 2009</a>; <a href="./references#CD012955-bbs2-0029" title="HaeyenS , Van HoorenS , HutschemaekersG . Efficacy of art therapy in individuals with personality disorders cluster B/C: a randomised controlled trial. International Journal of Psychology July 2016;51:60. [DOI: 10.1521/pedi_2017_31_312] [PMID: 28926306]HaeyenS , Van HoorenS , Van der VeldW , HutschemaekersG . Efficacy of art therapy in individuals with personality disorders cluster B/C: a randomised controlled trial. Journal of Personality Disorders2018;32(4):527-42. [DOI: 10.1521/pedi_2017_31_312] [PMID: 28926306]HaeyenS . Re: Cochrane Collaboration review of psychotherapies for BPD - your RCT of art therapy [personal communication]. Email to: J Stoffers-Winterling 18 August 2018. ">Haeyen 2018</a>; <a href="./references#CD012955-bbs2-0033" title="JørgensenCR , BøyeR , AndersenD , Døssing BlaabjergAH , FreundC , JordetH , et al. Eighteen months post-treatment naturalistic follow-up study of mentalization-based therapy and supportive group treatment of borderline personality disorder: clinical outcomes and functioning. Nordic Psychology2014;66(4):254-73. [DOI: 10.1080/19012276.2014.963649]JørgensenCR , FreundC , BøyeR , JordetH , AndersenD , KjølbyeM . Outcome of mentalization-based and supportive psychotherapy in patients with borderline personality disorder: a randomized trial. Acta Psychiatrica Scandinavica2013;127(4):305-17. [DOI: 10.1111/j.1600-0447.2012.01923.x] [PMID: 22897123]JorgensenCR . SV: questions on your trial regarding MBT for BPD patients [personal communication]. Email to: EG Faltinsen 28 November 2017. ">Jørgensen 2013</a>; <a href="./references#CD012955-bbs2-0051" title="McMurranM , CrawfordMJ , ReillyJ , DelportJ , McCroneP , WhithamD , et al. Psychoeducation with problem-solving (PEPS) therapy for adults with personality disorder: a pragmatic randomised controlled trial to determine the clinical effectiveness and cost-effectiveness of a manualised intervention to improve social functioning. Health Technology Assessment2016;20(52):1-282. [DOI: 10.3310/hta20520]McMurranM . RE: Cochrane Collaboration review - PEPS study [personal communication]. Email to: J Stoffers-Winterling 5 July 2018. McMurranM . Request for data on BPD subjects in the PEPS rcp-study for use a new Cochrane review [personal communication]. Email to: M Kongerslev 7 March 2017. ">McMurran 2016</a>; <a href="./references#CD012955-bbs2-0055" title="MortonJ , SnowdonS , GopoldM , GuymerE . Acceptance and commitment therapy group treatment for symptoms of borderline personality disorder: a public sector pilot study. Cognitive and Behavioral Practice2012;19(4):527-44. [DOI: 10.1016/j.cbpra.2012.03.005]MortonJ . Re: SV: regarding your study on acceptance and commitment therapy for BPD [personal communication]. Email to: EG Faltinsen 22 December 2017. ">Morton 2012</a>; <a href="./references#CD012955-bbs2-0064" title="SantistebanDA , MenaMP , MuirJ , McCabeBE , AbaloC , CummingsAM . The efficacy of two adolescent substance abuse treatments and the impact of comorbid depression: results of a small randomized controlled trial. Psychiatric Rehabilitation Journal2015;38(1):55-64. [DOI: 10.1037/prj0000106] [PMC5021542] [PMID: 25799306]">Santisteban 2015</a>; <a href="./references#CD012955-bbs2-0067" title="NCT01904227. Intensified, inpatient adaptation of dialectical behavior therapy (DBT) (REDBT) [A randomized controlled study of the efficacy of an intensified, inpatient adaptation of dialectical behavior therapy (DBT) for a population of borderline patients (young adults/adults: 18-40), compared with standard outpatient DBT]. www.clinicaltrials.gov/ct2/show/NCT01904227 (first received 11 July 2013). SinnaeveR , Van den BoschLM , Van Steenbergen-WeijenburgKM . Change in interpersonal functioning during psychological interventions for borderline personality disorder — a systematic review of measures and efficacy. Personality and Mental Health2015;9(3):173-94. [DOI: 10.1002/pmh.1296] [PMID: 26058794]SinnaeveR , Van den BoschLMC , Hakkaart-van RoijenL , VansteelandtK . Effectiveness of step-down versus outpatient dialectical behaviour therapy for patients with severe levels of borderline personality disorder: a pragmatic randomized controlled trial. Borderline Personality Disorder and Emotion Dysregulation2018;5:12. [DOI: 10.1186/s40479-018-0089-5] [PMC6040072] [PMID: 30002832]SinnaeveR . Cochrane Collaboration review [personal communication]. Email to: J Stoffers-Winterling 11 June 2018. SinnaeveR . Re: BPDSI subscale data Sinnaeve et al (2018) [personal communication]. Email to: A Tadorovac 15 November 2018. SinnaeveR . RE: BPDSI subscale data Sinnaeve et al (2018) [personal communication] [RE: BPDSI subschale data Sinnaeve et al (2018) [personlig kommunikation]]. Email to: A Todorovac 15 November 2018. SinnaeveR . RE: BPDSI subscale data Sinnaeve et al (2018) [personal communication] [RE: BPDSI subschale data Sinnaeve et al (2018) [personlig kommunikation]]. Email to: A Todorovac 9 October 2018. Van den BoschLM , SinnaeveR , Hakkaart-van RoijenL , Van FurthEF . Efficacy and cost-effectiveness of an experimental short-term inpatient dialectical behavior therapy (DBT) program: study protocol for a randomized controlled trial. Trials2014;15:152. [DOI: 10.1186/1745-6215-15-152] [PMC4017823] [PMID: 24885551]Van RoijenLH , SinnaeveR , BouwmansC , Van Den BoschL . Cost-effectiveness and cost-utility of shortterm inpatient dialectical behavior therapy for chronically parasuicidal BPD (young) adults. Journal of Mental Health Policy and Economics2015;18(Suppl 1):S19-20. [www.icmpe.org/test1/journal/issues/v18s1toc.html]">Sinnaeve 2018</a>; <a href="./references#CD012955-bbs2-0068" title="SmithPN , GambleSA , CortNA , WardEA , HeH , TalbotNL . Attachment and alliance in the treatment of depressed, sexually abused women. Depression and Anxiety2012;29(2):123-30. [DOI: 10.1002/da.20913] [PMC3325338] [PMID: 22065593]SmithPN . Re: Cochrane Collaboration review of psychotherapies for BPD [personal communication]. Email to: J Stoffers-Winterling 05 July 2018. ">Smith 2012</a>; <a href="./references#CD012955-bbs2-0075" title="ZanariniMC , ConkeyLC , TemesCM , FitzmauriceGM . Randomized controlled trial of web-based psychoeducation for women with borderline personality disorder. Journal of Clinical Psychiatry2018;79(3):16m11153. [DOI: 10.4088/JCP.16m11153] [PMC5764827] [PMID: 28703950]">Zanarini 2018</a>). </p> </section> <section id="CD012955-sec-0073"> <h4 class="title">Incomplete outcome data</h4> <p>The majority of trials either did not adequately describe the possible reasons for missing data, and therefore were considered to be at unclear risk of bias (30 trials: <a href="./references#CD012955-bbs2-0009" title="BianchiniV , CofiniV , CurtoM , LagrotteriaB , ManziA , NavariS , et al. Dialectical behavior therapy (DBT) for forensic psychiatric patients: an Italian pilot study. Criminal Behavior and Mental Health2019;29(9):122-30. [DOI: 10.1002/cbm.2102] [PMID: 30648303]">Bianchini 2019</a>; <a href="./references#CD012955-bbs2-0010" title="BlackD . Question regarding your BPD trial [personal communication]. Email to: J Stoffers 04 January 2011. BlackDW , AllenJ , McCormickB , BlumN . Treatment received by persons with BPD participating in a randomized clinical trial of the systems training for emotional predictability and problem solving programme. Personality and Mental Health2011;5(3):159-68. [DOI: 10.1002/pmh.167]BlackDW , AllenJ , St JohnD , PfohlB , McCormickB , BlumN . Predictors of response to systems training for emotional predictability and problem solving (STEPPS) for borderline personality disorder: an exploratory study. Acta Psychiatrica Scandinavica2009;120(1):53-61. [DOI: 10.1111/j.1600-0447.2008.01340.x] [PMC3665337] [PMID: 19183126]BlackDW , BlumN , PfohlB , St JohnD . The STEPPS group treatment program for outpatients with borderline personality disorder. Journal of Contemporary Psychotherapy2004;34(3):193-210. [DOI: 10.1023/B:JOCP.0000036630.25741.83]BlackDW , PfohlBM . Randomized clinical trial of STEPPS versus treatment as usual. In: 158th annual meeting of the American Psychiatric Association. Psychosomatic medicine: integrating psychiatry &amp; medicine; 2005 May 21-26; Atlanta (GA). Arlington (VA): American Psychiatric Association, 2005:104. [No. 1B] [www.psychiatry.org/File%20Library/Psychiatrists/Directories/Library-and-Archive/syllabus/am_syllabus_2005.pdf]BlackDW , Simsek-DuranF , BlumN , McCormickB , AllenJ . Do people with borderline personality disorder complicated by antisocial personality disorder benefit from the STEPPS treatment program?Personality and Mental Health2016;10(3):205-15. [DOI: 10.1002/pmh.1326] [PMC4911327] [PMID: 26671625]BlackDW . RE: [external] questions regarding your trial on the STEPPS program for BPD [personal communication]. Email to: EG Faltinsen 27 November 2017. BlumN , AllenJ , McCormickB , BlackDW . Ms Blum and colleagues reply [to Schulte-Herbrüggen O, Koerting J, Roepke S. Effectiveness of adjunctive STEPPS group treatment in borderline personality disorder patients. American Journal of Psychiatry 2008;165(10):1354-5. DOI: 10.1176/appi.ajp.2008.08030390]. American Journal of Psychiatry2008;165(10):1354-5. [DOI: 10.1176/appi.ajp.2008.08030390r]BlumN , FranklinJ , HanselR , McCormickB , St JohnD , PfohlB , et al. Relationship of age to symptom severity, psychiatric comorbidity and health care utilization in persons with borderline personality disorder. Personality and Mental Health2008;2(1):25-43. [DOI: 10.1002/pmh.26]BlumN , St JohnD , PfohlB , StuartS , McCormickB , AllenJ , et al. Erratum. American Journal of Psychiatry2008;165(6):777. Erratum for: American Journal of Psychiatry 2008;165(4):468-78. [psycnet.apa.org/record/2008-07854-033]BlumN , St JohnD , PfohlB , StuartS , McCormickB , AllenJ , et al. Systems training for emotional predictability and problem solving (STEPPS) for outpatients with borderline personality disorder: a randomized controlled trial and 1-year follow-up. American Journal of Psychiatry2008;165(4):468-78. [DOI: 10.1176/appi.ajp.2007.07071079] [PMC3608469] [PMID: 18281407]DavidsonKM . Borderline personality disorder: STEPPS improves symptoms. Evidence-Based Mental Health2008;11(4):120. [DOI: 10.1136/ebmh.11.4.120] [PMID: 18952969]NCT00055315. Treatment for borderline personality disorder [A cognitive group treatment for borderline outpatients]. clinicaltrials.gov/ct2/show/NCT00055315 (first received 25 February 2003). ">Blum 2008</a>; <a href="./references#CD012955-bbs2-0011" title="BohusM , DyerAS , PriebeK , KrügerA , KleindienstN , SchmahlC , et al. Dialectical behaviour therapy for post-traumatic stress disorder after childhood sexual abuse in patients with and without borderline personality disorder: a randomised controlled trial. Psychotherapy and Psychosomatics2013;82(4):221-33. [DOI: 10.1159/000348451] [PMID: 23712109]BrandS . AW: questions regarding your trial on emotional intelligence training for BPD [personal communication]. Email to: EG Faltinsen 28 November 2017. DBT Working Group at the Central Institute for Mental Health, Mannheim, Germany. Requested supplementary data (as supplied 1 October 2010). Data on file. NCT00481000. Dialectical cognitive traumatherapy (DCT) on patients with severe PTSD following sexual abuse (PASA) [Dialectical cognitive traumatherapy (DCT) on patients with severe posttraumatic stress disorder following sexual abuse - a randomised controlled trial]. clinicaltrials.gov/ct2/show/NCT00481000 (first received 31 May 2007). SteilR , DyerA , PriebeK , KleindienstN , BohusM . Dialectical behavior therapy for posttraumatic stress disorder related to childhood sexual abuse: a pilot study of an intensive treatment program. Journal of Traumatic Stress2011;24(1):102-6. [DOI: 10.1002/jts.20617] [PMID: 21351167]">Bohus 2013</a>; <a href="./references#CD012955-bbs2-0018" title="DavidsonKM , BrownTM , JamesV , KirkJ , RichardsonJ . Manual-assisted cognitive therapy for self-harm in personality disorder and substance misuse: a feasibility trial. Psychiatric Bulletin2014;38(3):108-11. [DOI: 10.1192/pb.bp.113.043109] [PMC4115373] [PMID: 25237519]DavidsonKM . Re: question regarding your trial on manual-assisted cognitive therapy [personal communication]. Email to: EG Faltinsen 28 November 2017. ">Davidson 2014</a>; <a href="./references#CD012955-bbs2-0023" title="Feliu-SolerA , PascualJC , ElicesM , Martín-BlancoA , CarmonaC , CebollaA , et al. Fostering self-compassion and loving-kindness in patients with borderline personality disorder: a randomized pilot study. Clinical Psychology &amp; Psychotherapy2017;24(1):278-86. [DOI: 10.1002/cpp.2000] [PMID: 26818533]">Feliu‐Soler 2017</a>; <a href="./references#CD012955-bbs2-0032" title="JochemsEC , Van der Feltz-CornelisCM , Van DamA , DuivenvoordenHJ , MulderCL . The effects of motivation feedback in patients with severe mental illness: a cluster randomized controlled trial. Neuropsychiatric Disease and Treatment2015;11:3049-64. [DOI: 10.2147/NDT.S95190] [PMC4686323] [PMID: 26715847]JochemsEC . Cochrane Collaboration review on psychotherapies for borderline PD [personal communication]. Email to: EG Faltinsen 2 July 2018. JochemsEC . Re: Cochrane Collaboration review on psychotherapies for borderline PD [personal communication]. Email to: J Stoffers-Winterling 02 July 2018. ">Jochems 2015</a>; <a href="./references#CD012955-bbs2-0034" title="KamalabadiMJ , AhmadiSA , EtemadiO , FatehizadehM , BahramiF , FiroozabadiA . A study of the effect of couple dialectical behavioral therapy on symptoms and quality of marital relationships and mental health of Iranian borderline personality couples: a controlled trial. Interdisciplinary Journal of Contemporary Research in Business2012;3(9):1480-7. [psycnet.apa.org/record/2012-22425-047]">Kamalabadi 2012</a>; <a href="./references#CD012955-bbs2-0038" title="KramerU , Pascual-LeoneA , BerthoudL , De RotenY , MarquetP , KollyS , et al. Assertive anger mediates effects of dialectical behaviour-informed skills training for borderline personality disorder: a randomized controlled trial. Clinical Psychology &amp; Psychotherapy2016;23(3):189-202. [DOI: 10.1002/cpp.1956] [PMID: 25864773]KramerU . The role of coping change in borderline personality disorder: a process-outcome analysis on dialectical-behaviour skills training. Clinical Psychology &amp; Psychotherapy2017;24(2):302-11. [DOI: 10.1002/cpp.2017] [PMID: 27098296]">Kramer 2016</a>; <a href="./references#CD012955-bbs2-0042" title="LeichsenringF , MasuhrO , JaegerU , RabungS , DallyA , DümpelmannM , et al. Psychoanalytic-interactional therapy versus psychodynamic therapy by experts for personality disorders: a randomized controlled efficacy-effectiveness study in cluster B personality disorders. Psychotherapy and Psychosomatics2016;85(2):71-80. [DOI: 10.1159/000441731] [PMID: 26808580]">Leichsenring 2016</a>; <a href="./references#CD012955-bbs2-0045" title="HoffmanRE . Impact of treatment accessibility on clinical course of parasuicidal patients. Archives of General Psychiatry1993;50(2):157-8. [DOI: 10.1001/archpsyc.1993.01820140083010] [PMID: 8427557]LindenboimN . To Know Me is to Keep Me: Self-Verification, Validation, and Therapy Dropout in the Treatment of Borderline Personality Disorder [PhD thesis]. Washington (DC): University of Washington, 2009. LinehanMM , ArmstrongHE , SuarezA , AllmonD , HeardHL . Cognitive-behavioral treatment of chronically parasuicidal borderline patients. Archives of General Psychiatry1991;48(12):1060-4. [DOI: 10.1001/archpsyc.1991.01810360024003] [PMID: 1845222]LinehanMM , HeardHL . Impact of treatment accessibility on clinical course of parasuicidal patients — reply. Archives of General Psychiatry1993;50(2):157-8. [DOI: 10.1001/archpsyc.1993.01820140083011]">Linehan 1991</a>; <a href="./references#CD012955-bbs2-0048" title="LinehanMM , KorslundKE , HarnedMS , GallopRJ , LunguA , NeacsiuAD , et al. Dialectical behavior therapy for high suicide risk in individuals with borderline personality disorder: a randomized clinical trial and component analysis. JAMA Psychiatry2015;72(5):475-82 Erratum for: JAMA Psychiatry 2015; 72(9): 951. [DOI: 10.1001/jamapsychiatry.2014.3039] [PMID: 25806661]NCT00183651. Treatment of suicidal women with borderline personality disorder [Assessment and treatment of parasuicidal patients]. www.clinicaltrials.gov/ct2/show/NCT00183651 (first received 13 September 2005). ">Linehan 2015a</a>; <a href="./references#CD012955-bbs2-0049" title="CaseBG . Letter to the editor on 'McMain SF, Links PS, Gnam WH, Guimond T, Cardish RJ, Korman L, et al. A randomized trial of dialectical behavior therapy versus general psychiatric management for borderline personality disorder. American Journal of Psychiatry 2009;166(12):1365-74. DOI: 10.1176/appi.ajp.2009.09010039'. American Journal of Psychiatry2010;167(4):475. [DOI: 10.1176/appi.ajp.2009.09101532] [PMID: 20360332 ]ISRCTN02634417. Hope for chronically suicidal patient: evaluating the clinical and health services impact of dialectical behaviour therapy (DBT) in individuals with borderline personality disorder [Evaluating the clinical and health services impact of dialectical behaviour therapy (DBT) in individuals with borderline personality disorder: a randomised controlled trial]. www.isrctn.com/ISRCTN02634417 (first received 16 November 2005). [DOI: 10.1186/ISRCTN02634417]McMainSF , FitzpatrickS , BoritzT , BarnhartR , LinksP , StreinerDL . Outcome trajectories and prognostic factors for suicide and self-harm behaviors in patients with borderline personaliy disorder following one year of outpatient psychotherapy. Journal of Personality Disorders2018;32(4):497-512. [DOI: 10.1521/pedi_2017_31_309] [PMID: 28910214]McMainSF , LinksPS , GnamWH , GuimondT , CardishRJ , KormanL , et al. A randomized trial of dialectical behavior therapy versus general psychiatric management for borderline personality disorder. American Journal of Psychiatry2009;166(12):1365-74. [DOI: 10.1176/appi.ajp.2009.09010039] [PMID: 19755574]McMainSF . Dr McMain replies to letter to the editor on 'McMain SF, Links PS, Gnam WH, Guimond T, Cardish RJ, Korman L, et al. A randomized trial of dialectical behavior therapy versus general psychiatric management for borderline personality disorder. American Journal of Psychiatry 2009;166(12):1365-74. DOI: 10.1176/appi.ajp.2009.09010039'. American Journal of Psychiatry2010;167(4):475-6. [DOI: 10.1176/appi.ajp.2009.09101532r)]NCT00154154. Hope for the chronically suicidal patient [Hope for the chronically suicidal patient: evaluating the clinical and health services impact of dialectical behaviour therapy in individuals with borderline personality disorder]. www.clinicaltrials.gov/ct2/show/NCT00154154 (first received 7 September 2005). ">McMain 2009</a>; <a href="./references#CD012955-bbs2-0053" title="MohamadizadehL , MakvandiB , PashaR , BakhtiarpourS , HafeziF . Comparing of the effect of dialectical behavior therapy (DBT) and schema therapy (ST) on reducing mood activity and suicidal thoughts in patients with borderline personality disorder. Acta Medica Mediterranea2017;33:1025-31. [DOI: 10.19193/0393-6384_2017_6_162] [www.actamedicamediterranea.com/archive/2017/medica-6/comparing-of-the-effect-of-dialectical-behavior-therapy-dbt-and-schema-therapy-st-on-reducing-mood-activity-and-suicidal-thoughts-in-patients-with-borderline-personality-disorder/pdf]">Mohamadizadeh 2017</a>; <a href="./references#CD012955-bbs2-0054" title="MoreyLC , LowmasterSE , HopwoodCJ . A pilot study of manual-assisted cognitive therapy with a therapeutic assessment augmentation for borderline personality disorder. Psychiatry Research2010;178(3):531-5. [DOI: 10.1016/j.psychres.2010.04.055] [PMID: 20537722]">Morey 2010</a>; <a href="./references#CD012955-bbs2-0055" title="MortonJ , SnowdonS , GopoldM , GuymerE . Acceptance and commitment therapy group treatment for symptoms of borderline personality disorder: a public sector pilot study. Cognitive and Behavioral Practice2012;19(4):527-44. [DOI: 10.1016/j.cbpra.2012.03.005]MortonJ . Re: SV: regarding your study on acceptance and commitment therapy for BPD [personal communication]. Email to: EG Faltinsen 22 December 2017. ">Morton 2012</a>; <a href="./references#CD012955-bbs2-0056" title="NadortM , ArntzA , SmitJH , Giesen-BlooJ , EikelenboomJ , SpinhovenP , et al. Implementation of outpatient schema therapy for borderline personality disorder with versus without crisis support by the therapist outside office hours: a randomized trial. Behaviour Research and Therapy2009;47(11):961-73. [DOI: 10.1016/j.brat.2009.07.013] [PMID: 19698939]NadortM , ArntzA , SmitJH , Giesen-BlooJ , EikelenboomM , SpinhovenP , et al. Implementation of outpatient schema therapy for borderline personality disorder: study design. BMC Psychiatry2009;9:64. [DOI: 10.1186/1471-244X-9-64] [PMC2762959] [PMID: 19807925]NL1680 (NTR1781). Implementation of out-patient schema-focused therapy for borderline personality disorder in regular mental healthcare. www.trialregister.nl/trial/1680 (first received 29 April 2009). ">Nadort 2009</a>; <a href="./references#CD012955-bbs2-0057" title="NCT02033044. Cognitive rehabilitation versus psychoeducation in psychosocial functioning of borderline personality disorder [Randomized controlled trial comparing the effects on psychosocial functioning of cognitive rehabilitation versus psychoeducation in borderline personality disorder]. www.clinicaltrials.gov/ct2/show/NCT02033044 (first received 23 December 2013). PascualJC , PalomaresN , Ibáñez Á, PortellaMJ , ArzaR , ReyesR , et al. Efficacy of cognitive rehabilitation on psychosocial functioning in borderline personality disorder: a randomized controlled trial. BMC Psychiatry2015;15:255. [DOI: 10.1186/s12888-015-0640-5] [PMC4617906] [PMID: 26487284]">Pascual 2015</a>; <a href="./references#CD012955-bbs2-0059" title="BarnicotK . Re: Regarding your study on DBT for self-harming patients [personal communication]. Email to: EG Faltinsen 28 February 2018. PriebeS , BhattiN , BarnicotK , BremnerS , GagliaA , KatsakouC , et al. Effectiveness and cost-effectiveness of dialectical behaviour therapy for self-harming patients with personality disorder: a pragmatic randomised controlled trial. Psychotherapy and Psychosomatics2012;81(6):356-65. [DOI: 10.1159/000338897] [PMID: 22964561]PriebeS . Supplemental information [personal communication]. Email to: M Kielsholm 20 May 2016. ">Priebe 2012</a>; <a href="./references#CD012955-bbs2-0060" title="RenesesB , FigueraD , SalcedoG , TrujilloM , López-IborJJ , GaliánM , et al. A controlled randomized study on the efficacy of short-term dinamic psychotherapy in borderline personality disorders (BPD). Preliminary results. European Psychiatry2011;26(Suppl 1):1040. [DOI: 10.1016/S0924-9338(11)72745-6] [P02-444]RenesesB , GaliánM , SerranoR , FigueraD , Fernandez Del MoralA , López-IborJJ , et al. A new time limited psychotherapy for BPD: preliminary results of a randomized and controlled trial. Actas Espanolas de Psiquiatria2013;41(3):139-48. [PMID: 23803797]">Reneses 2013</a>; <a href="./references#CD012955-bbs2-0061" title="ISRCTN51304415. Nice OUtcomes for Referrals with Impulsivity, Self Harm and Eating Disorders: the NOURISHED study [A randomised controlled trial of mentalisation based therapy against specialist supportive clinical management in patients with both eating disorders and symptoms of borderline personality disorder]. www.isrctn.com/ISRCTN51304415 (first received 31 January 2011). RobinsonP , BarrettB , BatemanA , HakeemA , HellierJ , LemonskyF , et al. Study protocol for a randomized controlled trial of mentalization based therapy against specialist supportive clinical management in patients with both eating disorders and symptoms of borderline personality disorder. BMC Psychiatry2014;14:51. [DOI: 10.1186/1471-244X-14-51] [PMC3996076] [PMID: 24555511]RobinsonP , HellierJ , BarrettB , BarzdaitieneD , BatemanA , BogaardtA , et al. The NOURISHED randomised controlled trial comparing mentalisation-based treatment for eating disorders (MBT-ED) with specialist supportive clinical management (SSCM-ED) for patients with eating disorders and symptoms of borderline personality disorder. Trials2016;17(1):549. [DOI: 10.1186/s13063-016-1606-8] [PMC5114835] [PMID: 27855714]">Robinson 2016</a>; <a href="./references#CD012955-bbs2-0064" title="SantistebanDA , MenaMP , MuirJ , McCabeBE , AbaloC , CummingsAM . The efficacy of two adolescent substance abuse treatments and the impact of comorbid depression: results of a small randomized controlled trial. Psychiatric Rehabilitation Journal2015;38(1):55-64. [DOI: 10.1037/prj0000106] [PMC5021542] [PMID: 25799306]">Santisteban 2015</a>; <a href="./references#CD012955-bbs2-0065" title="SchillingL , MoritzS , KötherU , NagelM . Preliminary results on acceptance, feasibility, and subjective efficacy of the add-on group intervention metacognitive training for borderline patients. Journal of Cognitive Psychotherapy2015;29(2):153-64. [DOI: 10.1891/0889-8391.29.2.153]SchillingL , MoritzS , KristonL , KriegerM , NagelM . Efficacy of metacognitive training for patients with borderline personality disorder: preliminary results. Psychiatry Research2018;262:459-64. [DOI: 10.1016/j.psychres.2017.09.024] [PMID: 28927866]SchillingL . Re Schilling 2015/2018 - Cochrane Review of psychotherapies for BPD [personal communication] [Re Schilling 2015/2018 - Cochrane Review zur Psychotherapie bei BPS [persönliche Kommunikation]]. Email to: J Stoffers-Winterling 22 January 2019. ">Schilling 2018</a>; <a href="./references#CD012955-bbs2-0066" title="ISRCTN97589104. Evaluation of a group training for adolescents (emotion regulation training) with emotion regulation problems - a randomised controlled clinical trial. www.isrctn.com/ISRCTN97589104 (first received 23 August 2007). SchuppertHM , TimmermanME , BlooJ , Van GemertTG , WiersemaHM , MinderaaRB , et al. Emotion regulation training for adolescents with borderline personality disorder traits: a randomized controlled trial. Journal of the American Academy of Child &amp; Adolescent Psychiatry2012;51(12):1314-23. [DOI: 10.1016/j.jaac.2012.09.002] [PMID: 23200288]">Schuppert 2012</a>; <a href="./references#CD012955-bbs2-0068" title="SmithPN , GambleSA , CortNA , WardEA , HeH , TalbotNL . Attachment and alliance in the treatment of depressed, sexually abused women. Depression and Anxiety2012;29(2):123-30. [DOI: 10.1002/da.20913] [PMC3325338] [PMID: 22065593]SmithPN . Re: Cochrane Collaboration review of psychotherapies for BPD [personal communication]. Email to: J Stoffers-Winterling 05 July 2018. ">Smith 2012</a>; <a href="./references#CD012955-bbs2-0069" title="SolerJ , PascualJC , TianaT , CebriàA , BarrachinaJ , CampinsMJ , et al. Dialectical behaviour therapy skills training compared to standard group therapy in borderline personality disorder: a 3-month randomised controlled clinical trial. Behaviour Research and Therapy2009;47(5):353-8. [DOI: 10.1016/j.brat.2009.01.013] [PMID: 19246029]SolerJ . Question regarding your BPD trials [personal communication]. Email to: J Stoffers 15 December 2010. ">Soler 2009</a>; <a href="./references#CD012955-bbs2-0070" title="FertuckEA , KeilpJ , SongI , MorrisMC , WilsonST , BrodskyBS , et al. Higher executive control and visual memory performance predict treatment completion in borderline personality disorder. Psychotherapy and Psychosomatics2012;81(1):38-43. [DOI: 10.1159/000329700] [PMC3242704] [PMID: 22116411]NCT00533117. Treating suicidal behavior and self-mutilation in people with borderline personality disorder. www.clinicaltrials.gov/ct2/show/NCT00533117 (first received 19 September 2007). ">Stanley 2017</a>; <a href="./references#CD012955-bbs2-0071" title="TurnerRM . Naturalistic evaluation of dialectical behavior therapy-oriented treatment for borderline personality disorder. Cognitive and Behavioral Practice2000;7(4):413-9. [DOI: 10.1016/S1077-7229(00)80052-8]">Turner 2000</a>; <a href="./references#CD012955-bbs2-0072" title="Van den BoschLM , KoeterMW , StijnenT , VerheulR , Van den BrinkW . Sustained efficacy of dialectical behaviour therapy for borderline personality disorder. Behaviour Research and Therapy2005;43(9):1231-41. [DOI: 10.1016/j.brat.2004.09.008] [PMID: 16005708]Van den BoschLM , VerheulR , SchippersGM , Van den BrinkW . Dialectical behavior therapy of borderline patients with and without substance use problems. Implementation and long-term effects. Addictive Behaviors2002;27(6):911-23. [DOI: 10.1016/s0306-4603(02)00293-9] [PMID: 12369475]Van den BoschLMC . Efficacy of dialectical behaviour therapy in the treatment of female borderline patients with and without substance abuse problems: results of a Dutch study [Dialectische gedragstherapie bij Nederlandse vrouwen met een borderline persoonlijkheidsstoornis, met en zonder verslavingsproblemen]. Tijdschrift voor Psychiatrie2005;47(3):127-37. [www.tijdschriftvoorpsychiatrie.nl/assets/articles/articles_1335pdf.pdf]VerheulR , Van den BoschLM , KoeterMW , De RidderMA , StijnenT , Van den BrinkW . Dialectical behaviour therapy for women with borderline personality disorder: 12-month, randomised clinical trial in The Netherlands. British Journal of Psychiatry2003;182:135-40. [DOI: 10.1192/bjp.182.2.135] [PMID: 12562741]">Van den Bosch 2005</a>; <a href="./references#CD012955-bbs2-0073" title="WeinbergI , GundersonJG , HennenJ , Cutter CJ Jr. Manual assisted cognitive treatment for deliberate self-harm in borderline personality disorder patients. Journal of Personality Disorders2006;20(5):482-92. [DOI: 10.1521/pedi.2006.20.5.482] [PMID: 17032160]WilbergT . SV: separate data [personal communication] [SV: separat data [personlig kommunikation]]. Email to: M Kielsholm 25 May 2016. ">Weinberg 2006</a>; <a href="./references#CD012955-bbs2-0074" title="ZanariniMC , FrankenburgFR . A preliminary, randomized trial of psychoeducation for women with borderline personality disorder. Journal of Personality Disorders2008;22(3):284-90. [DOI: 10.1521/pedi.2008.22.3.284] [PMID: 18540800]ZanariniMC , FrankenburgFR . A randomized trial of psychoeducation for patients with BPD. In: 157th annual meeting of the American Psychiatric Association. Psychotherapy and psychopharmacology: dissolving the mind-brain barrier; 2004 May 1-6; New York (NY). Arlington (VA): American Psychiatric Association, 2004:102. [Symposium 100E] [www.psychiatry.org/File%20Library/Psychiatrists/Directories/Library-and-Archive/conference_publications/am_program_2004.pdf]">Zanarini 2008</a>), or did not explicitly address obvious missing data and therefore were considered to be at high risk of bias (26 trials: <a href="./references#CD012955-bbs2-0002" title='AndreoliA , BurnandY , CochennecMF , MarieD , Di ClementeT , OhlendorfP . Psychoanalytic psychotherapy and venlafaxine among acutely suicidal borderline patients: a randomized clinical study. European Psychiatry2009;24(Suppl 1):S93. [DOI: 10.1016/S0924-9338(09)70326-8] [S18-03]AndreoliA , BurnandY , CochennecMF , OhlendorfP , FrambatiL , Gaudry-MaireD , et al. Disappointed love and suicide: a randomized controlled trial of "abandonment psychotherapy" among borderline patients. Journal of Personality Disorders2016;30(2):271-87. [DOI: 10.1521/pedi_2015_29_196] [PMID: 26111250]AndreoliA , BurnandY , FrambatiL , ManningD , FrancesA . Abandonment psychotherapy and psychosocial functioning among suicidal patients with borderline personality disorder: a 3-year naturalistic follow-up. Journal of Personality Disorders 2019 Feb 20 [Epub ahead of print]. [DOI: 10.1521/pedi_2019_33_423] [PMID: 30785852]AndreoliA . Re: your study in BPD - Cochrane Collaboration review [personal communication]. Email to: J Stoffers-Winterling 5 June 2018. '>Andreoli 2016</a>; <a href="./references#CD012955-bbs2-0004" title="BatemanA , FonagyP . 8-year follow-up of patients treated for borderline personality disorder: mentalization-based treatment versus treatment as usual. American Journal of Psychiatry2008;165(5):631-8. [DOI: 10.1176/appi.ajp.2007.07040636] [PMID: 18347003]BatemanA , FonagyP . Effectiveness of partial hospitalization in the treatment of borderline personality disorder: a randomized controlled trial. American Journal of Psychiatry1999;156(10):1563-9. [DOI: 10.1176/ajp.156.10.1563] [PMID: 10518167]BatemanA , FonagyP . Health care utilization costs for borderline personality disorder patients treated with psychoanalytically oriented partial hospitalization versus general psychiatric care. American Journal of Psychiatry2003;160(1):169-71. [10.1176/appi.ajp.160.1.169] [12505818]BatemanA , FonagyP . Treatment of borderline personality disorder with psychoanalytically oriented partial hospitalization: an 18-month follow-up. American Journal of Psychiatry2001;158(1):36-42. [DOI: 10.1176/appi.ajp.158.1.36] [PMID: 11136631]BatemanA . Important: question regarding your BPD trial for systematic review in Cochrane Collaboration [personal communication]. Email to: K Lieb, J Stoffers 14 December 2010. BatemanA . Intensive outpatient and partial hospital care for BPD. In: 157th annual meeting of the American Psychiatric Association. Psychotherapy and pharmacology: dissolving the mind-brain barrier; 2004 May 1-6; New York (NY). Arlington (VA): American Psychiatric Association, 2004:102. [Symposium 100B] [www.psychiatry.org/File%20Library/Psychiatrists/Directories/Library-and-Archive/conference_publications/am_program_2004.pdf]BatemanAW , FonagyP . Drs Bateman and Fonagy reply [to Stern R. Partial hospitalization for borderline personality disorder. American Journal of Psychiatry 2001;158(11):1932-3. DOI: 10.1176/appi.ajp.158.11.1932]. American Journal of Psychiatry2001;158(11):1932-3. [DOI: 10.1176/appi.ajp.158.11.1932-a]EvansC . Treatment benefits of psychoanalytically oriented partial hospitalisation were maintained over 18 months in borderline personality disorder. Evidence-Based Mental Health2001;4(3):73. [DOI: 10.1136/ebmh.4.3.73]FonagyP , BatemanAW . Mentalizing and borderline personality disorder. Journal of Mental Health2007;16(1):83-101. [DOI: 10.1080/09638230601182045]SternR . Partial hospitalization for borderline personality disorder. American Journal of Psychiatry2001;158(11):1932-3. [DOI: 10.1176/appi.ajp.158.11.1932] [PMID: 11691712]">Bateman 1999</a>; <a href="./references#CD012955-bbs2-0006" title="BellinoS , ParadisoE , ZizzaM , Di LorenzoR , BogettoF . Combined therapy with interpersonal psychotherapy of major depressed patients with borderline personality disorder: a comparison with pharmacotherapy [Terapia combinata con psicoterapia interpersonale di pazienti depressi maggiori con disturbo borderline di personalità: confronto con la farmacoterapia]. Journal of Psychopathology2005;11(1):34-42. [bit.ly/2rZUh5h]BellinoS , ZizzaM , RinaldiC , BogettoF . Combined treatment of major depression in patients with borderline personality disorder: a comparison with pharmacotherapy. Canadian Journal of Psychiatry2006;51(7):453-60. [DOI: 10.1177/070674370605100707] [PMID: 16838827]">Bellino 2006</a>; <a href="./references#CD012955-bbs2-0007" title="BellinoS , ZizzaM , RinaldiC , BogettoF . Combined therapy of major depression with concomitant borderline personality disorder: comparison of interpersonal and cognitive psychotherapy. Canadian Journal of Psychiatry2007;52(11):718-25. [DOI: 10.1177/070674370705201106] [PMID: 18399039]">Bellino 2007</a>; <a href="./references#CD012955-bbs2-0008" title="BellinoS , BozzatelloP , BogettoF . Combined treatment of borderline personality disorder with interpersonal psychotherapy and pharmacotherapy: predictors of response. Psychiatry Research2015;226(1):284-8. [DOI: 10.1016/j.psychres.2014.12.064] [isiarticles.com/bundles/Article/pre/pdf/34125.pdf]BellinoS , RinaldiC , BogettoF . Adaptation of interpersonal psychotherapy to borderline personality disorder: a comparison of combined therapy and single pharmacotherapy. Canadian Journal of Psychiatry2010;55(2):74-81. [DOI: 10.1177/070674371005500203] [PMID: 20181302]BellinoS . Question regarding your BPD trials for inclusion in Cochrane Collaboration review [personal communication]. Email to: J Stoffers-Winterling 19 December 2010. BellinoS . Re: question regarding your BPD trials [personal communication]. Email to: J Stoffers 16 December 2010. BozzatelloP , BellinoS . Combined therapy with interpersonal psychotherapy adapted for borderline personality disorder: a two-years follow-up. Psychiatry Research2016;240:151-6. [DOI: 10.1016/j.psychres.2016.04.014] [www.sciencedirect.com/science/article/pii/S0165178115302389]ZizzaM , FenocchioM , RinaldiC , BellinoS . Combined treatment of borderline personality disorder: a trial of modified interpersonal therapy. World Psychiatry2009;8(Suppl 1):234. ">Bellino 2010</a>; <a href="./references#CD012955-bbs2-0013" title="BosEH , Van WelE , AppeloMT , VerbraakMJP . A randomized controlled trial of a Dutch version of systems training for emotional predictability and problem solving for borderline personality disorder. Journal of Nervous and Mental Disease2010;198(4):299-304. [DOI: 10.1097/NMD.0b013e3181d619cf] [PMID: 20386260]Van WelEB , BosEH , AppeloMT , BerendsenEM , WillgerothFC , VerbraakMJPM . The efficacy of the systems training for emotional predictability and problem solving (STEPPS) in the treatment of borderline personality disorder. A randomized controlled trial [De effectiviteit van de vaardigheidstraining emotieregulatiestoornis (VERS) in de behandeling van de borderlinepersoonlijkheidsstoornis: een gerandomiseerd onderzoek]. Tijdschrift voor Psychiatrie2009;51(5):291-301. [PMID: 19434566]">Bos 2010</a>; <a href="./references#CD012955-bbs2-0014" title="Carmona i FarrésC , ElicesM , SolerJ , Domínguez-ClavéE , Pomarol-ClotetE , SalvadorR , et al. Effects of mindfulness training on borderline personality disorder: impulsivity versus emotional dysregulation. Mindfulness2019;10:1243-54. [DOI: 10.1007/s12671-018-1071-4]NCT03363230. Effects of mindfulness training on emotion regulation and impulsivity. www.clinicaltrials.gov/ct2/show/NCT03363230 (first received 30 November 2017). ">Carmona í Farrés 2019</a>; <a href="./references#CD012955-bbs2-0015" title="CarterG . Question regarding your BPD trial [personal communication]. Email to: J Stoffers 21 December 2010. CarterGL , WillcoxCH , LewinTJ , ConradAM , BenditN . Hunter DBT project: randomized controlled trial of dialectical behaviour therapy in women with borderline personality disorder. Australian and New Zealand Journal of Psychiatry2010;44(2):162-73. [DOI: 10.3109/00048670903393621] [PMID: 20113305]">Carter 2010</a>; <a href="./references#CD012955-bbs2-0016" title="CottrauxJ , NoteID , BoutitieF , MillieryM , GenouihlacV , YaoSN , et al. Cognitive therapy versus Rogerian supportive therapy in borderline personality disorder. Two-year follow-up of a controlled pilot study. Psychotherapy and Psychosomatics2009;78(5):307-16. [DOI: 10.1159/000229769] [PMID: 19628959]NCT00131781. Cognitive therapy versus supportive therapy in borderline personality disorder. www.clinicaltrials.gov/ct2/show/NCT00131781 (first received 18 August 2005). ">Cottraux 2009</a>; <a href="./references#CD012955-bbs2-0020" title="ElicesM , PascualJC , PortellaMJ , Feliu-SolerA , Martín-BlancoA , CarmonaC , et al. Impact of mindfulness training on borderline personality disorder: a randomized trial. Mindfulness2016;7:584-95. [DOI: 10.1007/s12671-016-0492-1]NCT02397031. Mindfulness and interpersonal effectiveness skills in borderline personality disorder [Randomized, active-controlled, clinical trial comparing effects of mindfulness and interpersonal effectiveness skills in borderline personality disorder]. www.clinicaltrials.gov/ct2/show/NCT02397031 (first received 12 March 2015). SolerJ , ElicesM , PascualJC , Martín-BlancoA , Feliu-SolerA , CarmonaC , et al. Effects of mindfulness training on different components of impulsivity in borderline personality disorder: results from a pilot randomized study. Borderline Personality Disorder and Emotion Dysregulation2016;3:1. [DOI: 10.1186/s40479-015-0035-8] [PMC4709962] [PMID: 26759718]">Elices 2016</a>; <a href="./references#CD012955-bbs2-0021" title="FarrellJM , ShawIA , WebberMA . A schema-focused approach to group psychotherapy for outpatients with borderline personality disorder: a randomized controlled trial. Journal of Behavior Therapy and Experimental Psychiatry2009;40(2):317-28 Corrigendum to: Journal of Behavior Therapy and Experimental Psychiatry 2018; 60: 111. [DOI: 10.1016/j.jbtep.2009.01.002] [PMID: 19176222]FarrellJM . Question regarding your BPD trials [personal communication]. Email to: K Lieb, J Stoffers 9 December 2010. ">Farrell 2009</a>; <a href="./references#CD012955-bbs2-0022" title="FeigenbaumJD , FonagyP , PillingS , JonesA , WildgooseA , BebbingtonPE . A real-world study of the effectiveness of DBT in the UK National Health Service. British Journal of Clinical Psychology2012;51(2):121-41. [DOI: 10.1111/j.2044-8260.2011.02017.x] [PMID: 22574799]">Feigenbaum 2012</a>; <a href="./references#CD012955-bbs2-0025" title="GleesonJF , ChanenA , CottonSM , PearceT , NewmanB , McCutcheonL . Treating co-occurring first-episode psychosis and borderline personality: a pilot randomized controlled trial. Early Intervention in Psychiatry2012;6(1):21-9. [DOI: 10.1111/j.1751-7893.2011.00306.x] [PMID: 22379625]GleesonJFM . RE: separate data [personal communication]. Email to: M Kielsholm 28 October 2016. ">Gleeson 2012</a>; <a href="./references#CD012955-bbs2-0026" title="Gratz KL. Important: question regarding your BPD trial for systematic review in Cochrane Collaboration [personal communication]. Email to: J Stoffers-Winterling 11 December 2010. GratzKL , GundersonJG . Preliminary data on an acceptance-based emotion regulation group intervention for deliberate self-harm among women with borderline personality disorder. Behavior Therapy2006;37(1):25-35. [DOI: 10.1016/j.beth.2005.03.002] [PMID: 16942958]">Gratz 2006</a>; <a href="./references#CD012955-bbs2-0028" title="GregoryRJ , ChlebowskiS , KangD , RemenA , SoderbergM . Psychodynamic therapy for borderline personality disorder and co-occurring alcohol use disorders: a newly designed ongoing study. Journal of the American Psychoanalytic Association2006;54(4):1331-4. [DOI: 10.1177/00030651060540040107] [PMID: 17354507]GregoryRJ , ChlebowskiS , KangD , RemenAL , SoderbergMG , StepkovitchJ , et al. A controlled trial of psychodynamic psychotherapy for co-occurring borderline personality disorder and alcohol use disorder. Psychotherapy2008;45(1):28-41. [DOI: 10.1037/0033-3204.45.1.28] [PMID: 22122363]GregoryRJ , DeLucia-DeranjaE , MogleJA . Dynamic deconstructive psychotherapy versus optimized community care for borderline personality disorder co-occuring with alcohol use disorders: a 30-month follow-up. Journal of Nervous and Mental Disease2010;198(4):292-8. [DOI: 10.1097/NMD.0b013e3181d6172d] [PMID: 20386259]GregoryRJ , RemenAL , SoderbergM , Ploutz-SnyderRJ . A controlled trial of psychodynamic psychotherapy for co-occurring borderline personality disorder and alcohol use disorder: six-month outcome. Journal of the American Psychoanalytic Association2009;57(1):199-205. [DOI: 10.1177/00030651090570011006] [PMID: 19270255]NCT00145678. Psychodynamic therapy for co-occurring borderline personality disorder and alcohol use disorder [Psychodynamic therapy for patients With borderline personality disorder and alcohol abuse]. www.clinicaltrials.gov/show/NCT00145678 (first received 1 September 2005). ">Gregory 2008b</a>; <a href="./references#CD012955-bbs2-0029" title="HaeyenS , Van HoorenS , HutschemaekersG . Efficacy of art therapy in individuals with personality disorders cluster B/C: a randomised controlled trial. International Journal of Psychology July 2016;51:60. [DOI: 10.1521/pedi_2017_31_312] [PMID: 28926306]HaeyenS , Van HoorenS , Van der VeldW , HutschemaekersG . Efficacy of art therapy in individuals with personality disorders cluster B/C: a randomised controlled trial. Journal of Personality Disorders2018;32(4):527-42. [DOI: 10.1521/pedi_2017_31_312] [PMID: 28926306]HaeyenS . Re: Cochrane Collaboration review of psychotherapies for BPD - your RCT of art therapy [personal communication]. Email to: J Stoffers-Winterling 18 August 2018. ">Haeyen 2018</a>; <a href="./references#CD012955-bbs2-0033" title="JørgensenCR , BøyeR , AndersenD , Døssing BlaabjergAH , FreundC , JordetH , et al. Eighteen months post-treatment naturalistic follow-up study of mentalization-based therapy and supportive group treatment of borderline personality disorder: clinical outcomes and functioning. Nordic Psychology2014;66(4):254-73. [DOI: 10.1080/19012276.2014.963649]JørgensenCR , FreundC , BøyeR , JordetH , AndersenD , KjølbyeM . Outcome of mentalization-based and supportive psychotherapy in patients with borderline personality disorder: a randomized trial. Acta Psychiatrica Scandinavica2013;127(4):305-17. [DOI: 10.1111/j.1600-0447.2012.01923.x] [PMID: 22897123]JorgensenCR . SV: questions on your trial regarding MBT for BPD patients [personal communication]. Email to: EG Faltinsen 28 November 2017. ">Jørgensen 2013</a>; <a href="./references#CD012955-bbs2-0035" title="KoonsCR , RobinsCJ , TweedJL , LynchTR , GonzalezAM , MorseJQ , et al. Efficacy of dialectical behavior therapy in women veterans with borderline personality disorder. Behavior Therapy2001;32(2):371-90. [DOI: 10.1016/S0005-7894(01)80009-5]">Koons 2001a</a>; <a href="./references#CD012955-bbs2-0036" title="KramerU , BergerT , KollyS , MarquetP , PreisigM , De RotenY , et al. Effects of motive-oriented therapeutic relationship in early-phase treatment of borderline personality disorder: a pilot study of a randomized trial. Journal of Nervous and Mental Disease2011;199(4):244-50. [DOI: 10.1097/NMD.0b013e3182125d19] [PMID: 21451348]KramerU , CasparF , DrapeauM . Change in biased thinking in a 10-session treatment for borderline personality disorder: further evidence of the motive-oriented therapeutic relationship. Psychotherapy Research2013;23(6):633-45. [DOI: 10.1080/10503307.2013.791404] [PMID: 23631622]">Kramer 2011</a>; <a href="./references#CD012955-bbs2-0037" title="BerthoudL , KramerU , CasparF , Pascual-LeoneA . Emotional processing in a ten-session general psychiatric treatment for borderline personality disorder: a case study. Personality and Mental Health2015;9(1):73-8. [DOI: 10.1002/pmh.1287] [PMID: 25711648]BerthoudL , Pascual-LeoneA , CasparF , TissotH , KellerS , RohdeKB , et al. Leaving distress behind: a randomized controlled study on change in emotional processing in borderline personality disorder. Psychiatry2017;80(2):139-54. [DOI: 10.1080/00332747.2016.1220230] [PMID: 28767333]KellerS , StelmaszczykK , KollyS , De RotenY , DesplandJN , CasparF , et al. Change in biased thinking in a treatment based on the motive-oriented therapeutic relationship for borderline personality disorder. Journal of Personality Disorders2018;32(Suppl):75-92. [DOI: 10.1521/pedi.2018.32.supp.75] [PMID: 29388899]KramerU , FlückigerC , KollyS , CasparF , MarquetP , DesplandJN , et al. Unpacking the effects of therapist responsiveness in borderline personality disorder: motive-oriented therapeutic relationship, patient in-session experience, and the therapeutic alliance. Psychotherapy and Psychosomatics2014;83(6):386-7. [DOI: 10.1159/000365400] [PMID: 25324025]KramerU , KellerS , CasparF , De RotenY , DesplandJN , KollyS . Early change in coping strategies in responsive treatments for borderline personality disorder: a mediation analysis. Journal of Consulting and Clinical Psychology2017;85(5):530-5. [DOI: 10.1037/ccp0000196] [PMID: 28425747]KramerU , KollyS , BerthoudL , KellerS , PreisigM , CasparF , et al. Effects of motive-oriented therapeutic relationship in a ten-session general psychiatric treatment of borderline personality disorder: a randomized controlled trial. Psychotherapy and Psychosomatics2014;83(3):176-86. [DOI: 10.1159/000358528] [PMID: 24752034]KramerU , StulzN , BerthoudL , CasparF , MarquetP , KollyS , et al. The shorter the better? A follow-up analysis of 10-session psychiatric treatment including the motive-oriented therapeutic relationship for borderline personality disorder. Psychotherapy Research2017;27(3):362-70. [DOI: 10.1080/10503307.2015.1110635] [PMID: 26684670]NCT01896024. Effects of motive-oriented therapeutic relationship in the early-phase treatment of borderline personality disorder (MOTR). www.clinicaltrials.gov/ct2/show/NCT01896024 (first received 5 July 2013). ">Kramer 2014</a>; <a href="./references#CD012955-bbs2-0041" title="LaurenssenEM , WestraD , KikkertMJ , NoomMJ , EerenHV , Van BroekhuyzenAJ , et al. Day hospital mentalization-based treatment (MBT-DH) versus treatment as usual in the treatment of severe borderline personality disorder: protocol of a randomized controlled trial. BMC Psychiatry2014;14:149. [DOI: 10.1186/1471-244X-14-149] [PMC4045960] [PMID: 24886402]LaurenssenEMP , LuytenP , KikkertMJ , WestraD , PeenJ , SoonsMBJ , et al. Day hospital mentalization-based treatment v specialist treatment as usual in patients with borderline personality disorder: randomized controlled trial. Psychological Medicine2018;48(15):2522-9. [DOI: 10.1017/S0033291718000132] [PMID: 29478425]NL2058 (NTR2175). Mentalisation-based treatment versus care-as-usual in the treatment of severe borderline personality disorders. www.trialregister.nl/trial/2058 (first received 21 January 2010). ">Laurenssen 2018</a>; <a href="./references#CD012955-bbs2-0043" title="LeppänenV , HakkoH , SintonenH , LindemanS . Comparing effectiveness of treatments for borderline personality disorder in communal mental health care: the Oulu BPD study. Community Mental Health Journal2016;52(2):216-27. [DOI: 10.1007/s10597-015-9866-4] [PMID: 25824852]LeppänenV . Re: questions regarding the Oulu BPD study [personal communication]. Email to: E Faltinsen 20 December 2017. LeppänenV . Re: SV: question regarding the Oulu BPD study [personal communication]. Email to: EG Faltinsen 22 December 2017. ">Leppänen 2016</a>; <a href="./references#CD012955-bbs2-0046" title="HeardHL . Cost-Effectiveness of Dialectical Behavior Therapy in the Treatment of Borderline Personality Disorder [PhD thesis]. Washington (DC): University of Washington, 2000. LindenboimN . To Know Me is to Keep Me: Self-Verification, Validation, and Therapy Dropout in the Treatment of Borderline Personality Disorder [PhD thesis]. Washington (DC): University of Washington, 2009. LinehanMM , HeardHL , ArmstrongHE . Naturalistic follow-up of a behavioral treatment for chronically parasuicidal borderline patients. Archives of General Psychiatry1993;50(12):971-4. [DOI: 10.1001/archpsyc.1993.01820240055007] [PMID: 8250683]LinehanMM , TutekDA , HeardHL , ArmstrongHE . Interpersonal outcome of cognitive behavioral treatment for chronically suicidal borderline patients. American Journal of Psychiatry1994;151(12):1771-6. [DOI: 10.1176/ajp.151.12.1771] [PMID: 7977884]">Linehan 1994</a>; <a href="./references#CD012955-bbs2-0058" title="PhilipsB , WennebergP , KonradssonP , FranckJ . Mentalization-based treatment for concurrent borderline personality disorder and substance use disorder: a randomized controlled feasibility study. European Addiction Research2018;24(1):1-8. [DOI: 10.1159/000485564] [PMC5969093] [PMID: 294028]">Philips 2018</a>; <a href="./references#CD012955-bbs2-0062" title="ISRCTN95266816. The emergence of personality disorder traits in adolescents who deliberately self harm and the potential for using a mentalisation based treatment approach as an early intervention for such individuals: a randomised controlled trial. www.isrctn.com/ISRCTN95266816 (first received 29 October 2007). RossouwT . Mentalisation based treatment for adolescents with self harm: an RCT. European Child &amp; Adolescent Psychiatry2015;24(1 Suppl):S113. [DOI: 10.1007%2Fs00787-015-0714-4.pdf] [W1-02-02]RossouwT . Self harm in adolescence, is MBT the answer?: an RCT. Adolescent Psychiatry2012;2(1):102. [DOI: 10.2174/2210676611202010077]RossouwTI , FonagyP . Mentalization-based treatment for self-harm in adolescents: a randomized controlled trial. Journal of the American Academy of Child and Adolescent Psychiatry2012;51(12):1304-13.e3. [DOI: 10.1016/j.jaac.2012.09.018] [PMID: 23200287]">Rossouw 2012b</a>; <a href="./references#CD012955-bbs2-0067" title="NCT01904227. Intensified, inpatient adaptation of dialectical behavior therapy (DBT) (REDBT) [A randomized controlled study of the efficacy of an intensified, inpatient adaptation of dialectical behavior therapy (DBT) for a population of borderline patients (young adults/adults: 18-40), compared with standard outpatient DBT]. www.clinicaltrials.gov/ct2/show/NCT01904227 (first received 11 July 2013). SinnaeveR , Van den BoschLM , Van Steenbergen-WeijenburgKM . Change in interpersonal functioning during psychological interventions for borderline personality disorder — a systematic review of measures and efficacy. Personality and Mental Health2015;9(3):173-94. [DOI: 10.1002/pmh.1296] [PMID: 26058794]SinnaeveR , Van den BoschLMC , Hakkaart-van RoijenL , VansteelandtK . Effectiveness of step-down versus outpatient dialectical behaviour therapy for patients with severe levels of borderline personality disorder: a pragmatic randomized controlled trial. Borderline Personality Disorder and Emotion Dysregulation2018;5:12. [DOI: 10.1186/s40479-018-0089-5] [PMC6040072] [PMID: 30002832]SinnaeveR . Cochrane Collaboration review [personal communication]. Email to: J Stoffers-Winterling 11 June 2018. SinnaeveR . Re: BPDSI subscale data Sinnaeve et al (2018) [personal communication]. Email to: A Tadorovac 15 November 2018. SinnaeveR . RE: BPDSI subscale data Sinnaeve et al (2018) [personal communication] [RE: BPDSI subschale data Sinnaeve et al (2018) [personlig kommunikation]]. Email to: A Todorovac 15 November 2018. SinnaeveR . RE: BPDSI subscale data Sinnaeve et al (2018) [personal communication] [RE: BPDSI subschale data Sinnaeve et al (2018) [personlig kommunikation]]. Email to: A Todorovac 9 October 2018. Van den BoschLM , SinnaeveR , Hakkaart-van RoijenL , Van FurthEF . Efficacy and cost-effectiveness of an experimental short-term inpatient dialectical behavior therapy (DBT) program: study protocol for a randomized controlled trial. Trials2014;15:152. [DOI: 10.1186/1745-6215-15-152] [PMC4017823] [PMID: 24885551]Van RoijenLH , SinnaeveR , BouwmansC , Van Den BoschL . Cost-effectiveness and cost-utility of shortterm inpatient dialectical behavior therapy for chronically parasuicidal BPD (young) adults. Journal of Mental Health Policy and Economics2015;18(Suppl 1):S19-20. [www.icmpe.org/test1/journal/issues/v18s1toc.html]">Sinnaeve 2018</a>). Nineteen trials showed no indication of incomplete outcome reporting, and thus were considered to be at low risk of bias (<a href="./references#CD012955-bbs2-0001" title="AmiantoF , FerreroA , PieròA , CairoE , RoccaG , SimonelliB , et al. Supervised team management, with or without structured psychotherapy, in heavy users of a mental health service with borderline personality disorder: a two-year follow-up preliminary randomized study. BMC Psychiatry2011;11:181. [DOI: 10.1186/1471-244X-11-181] [PMC3260092 ] [PMID: 22103890]NCT01356069. Efficacy of time-limited psychodynamic psychotherapy and informed clinical management in BPD high MHS users (HUMSH) [Sequential brief Adlerian psychodynamic psychotherapy in heavy users of a mental health service with borderline personality disorder: a two years follow-up preliminary randomized study]. clinicaltrials.gov/ct2/show/NCT01356069 (first received 16 May 2011). ">Amianto 2011</a>; <a href="./references#CD012955-bbs2-0003" title="AntonsenBT , JohansenMS , RøFG , KvarsteinEH , WilbergT . Is reflective functioning associated with clinical symptoms and long-term course in patients with personality disorders?Comprehensive Psychiatry2016;64:46-58. [DOI: 10.1016/j.comppsych.2015.05.016] [PMID: 26104432]AntonsenBT , KlungsøyrO , KampsA , HummelenB , JohansenMS , PedersenG , et al. Step-down versus outpatient psychotherapeutic treatment for personality disorders: 6-year follow-up of the Ullevål personality project. BMC Psychiatry2014;14:119. [DOI: 10.1186/1471-244X-14-119] [PMC4000615] [PMID: 24758722]AntonsenBT , KvarsteinEH , Urnes Ø, HummelenB , KarterudS , WilbergT . Favourable outcome of long-term combined psychotherapy for patients with borderline personality disorder: six-year follow-up of a randomized study. Psychotherapy Research2017;27(1):51-63. [DOI: 10.1080/10503307.2015.1072283] [PMID: 26261865]ArnevikE , WilbergT , Urnes Ø, JohansenM , MonsenJT , KarterudS . Psychotherapy for personality disorders: short-term day hospital psychotherapy versus outpatient individual therapy - a randomized controlled study. European Psychiatry2009;24(2):71-8. [DOI: 10.1016/j.eurpsy.2008.09.004] [PMID: 19097870]GullestadFS , JohansenMS , HøglendP , KarterudS , WilbergT . Mentalization as a moderator of treatment effects: findings from a randomized clinical trial for personality disorders. Psychotherapy Research2013;23(6):674-89. [DOI: 10.1080/10503307.2012.684103] [PMID: 22612470]GullestadFS . Re: questions regarding your trial on day hospital step-down program [personal communication]. Email to: E Faltinsen 4 December 2017. KvarsteinEH , ArnevikE , HalsteinliV , RøFG , KarterudS , WilbergT . Health service costs and clinical gains of psychotherapy for personality disorders: a randomized controlled trial of day-hospital-based step-down treatment versus outpatient treatment at a specialist practice. BMC Psychiatry2013;13:315. [DOI: 10.1186/1471-244X-13-315] [PMC4222503] [PMID: 24268099]">Antonsen 2017</a>; <a href="./references#CD012955-bbs2-0005" title="BatemanA , FonagyP . Impact of clinical severity on outcomes of mentalisation-based treatment for borderline personality disorder. British Journal of Psychiatry2013;203(3):221-7. [DOI: 10.1192/bjp.bp.112.121129] [PMID: 23887998]BatemanA , FonagyP . Randomized controlled trial of outpatient mentalization-based treatment versus structured clinical management for borderline personality disorder. American Journal of Psychiatry2009;166(12):1355-64. [DOI: 10.1176/appi.ajp.2009.09040539] [PMID: 19833787]BatemanA , FonagyP . Randomized controlled trial of outpatient mentalization-based treatment versus structured clinical management for borderline personality disorder. Supplementary data. ajp.psychiatryonline.org/doi/suppl/10.1176/appi.ajp.2009.09040539/suppl_file/ajp_166_12_1355_01.pdf (accessed 27 February 2020). BatemanA , O'ConnellJ , LorenziniN , GardnerT , FonagyP . A randomised controlled trial of mentalization-based treatment versus structured clinical management for patients with comorbid borderline personality disorder and antisocial personality disorder. BMC Psychiatry2016;16:304. [DOI: 10.1186/s12888-016-1000-9] [PMC5006360] [PMID: 27577562]BatemanA . Important question regarding your BPD trial for systematic review in Cochrane Collaboration [personal communication]. Email to: K Lieb 14 December 2010. BatemanAW . Mentalization, borderline personality disorder and what works for whom? Presentation at the 11th International Congress of the International Society for the Study of Personality Disorders; 2009 Aug 21-23. www.borderlinepersonalitydisorder.com/Conferences/ISSPD/isspd_09_Bateman (accessed 21 April 2010). ISRCTN27660668. Randomised controlled trial of manualised out-patient individual and group therapy for borderline personality disorder [Effectiveness of intensive out-patient psychotherapy for treatment of borderline personality disorder: a pragmatic randomised single blind controlled study]. www.isrctn.com/ISRCTN27660668 (first received 12 October 2008). ">Bateman 2009</a>; <a href="./references#CD012955-bbs2-0012" title="BorschmannR , BarrettB , HellierJM , ByfordS , HendersonC , RoseD , et al. Joint crisis plans for people with borderline personality disorder: feasibility and outcomes in a randomised controlled trial. British Journal of Psychiatry2013;202(5):357-64. [DOI: 10.1192/bjp.bp.112.117762] [PMID: 23637110]BorschmannR . Joint crisis plans for BPD - question on publication in British Journal of Psychiatry [pers communication]. Email to: J Stoffers-Winterling 22 August 2017. BorschmannR . RE: joint crisis plans for BPD - question on publication in British Journal of Psychiatry [personal communication]. Email to: J Stoffers-Winterling 22 August 2017. BorschmannR . The development and testing of joint crisis plans for people with borderline personality disorder: a feasibility study. ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.628499 (accessed 27 January 2019). HellierJ . RE: regarding your study on on MBT for eating disorders [personal communication]. Email to: E Faltinsen 27 March 2018. HellierJ . RE: regarding your study on on MBT for eating disorders [personal communication]. Email to: E Faltinsen 3 January 2018. HellierJ . SV: regarding your study on MBT for eating disorders [personal communication]. Email to: EG Faltinsen, P Robinson 27 March 2018. ISRCTN12440268. JOSHUA: a pilot randomised controlled trial of joint crisis plans for people who self harm. www.isrctn.com/ISRCTN12440268 (first received 17 September 2009). ">Borschmann 2013</a>; <a href="./references#CD012955-bbs2-0017" title="DavidsonK , LivingstoneS , McArthurK , DicksonL , GumleyA . An integrative complexity analysis of cognitive behaviour therapy sessions for borderline personality disorder. Psychology and Psychotherapy2007;80(Pt 4):513-23. [DOI: 10.1348/147608307X191535] [PMID: 17535542]DavidsonK , NorrieJ , TyrerP , GumleyA , TataP , MurrayH , et al. The effectiveness of cognitive behavior therapy for borderline personality disorder: results from the borderline personality disorder study of cognitive therapy (BOSCOT) trial. Journal of Personality Disorders2006;20(5):450-65. [DOI: 10.1521/pedi.2006.20.5.450] [PMC1852259] [PMID: 17032158]DavidsonK , TyrerP , GumleyA , TataP , NorrieJ , PalmerS , et al. A randomized controlled trial of cognitive behavior therapy for borderline personality disorder: rationale for trial, method, and description of sample. Journal of Personality Disorders2006;20(5):431-49. [DOI: 10.1521/pedi.2006.20.5.431] [PMC1847748] [PMID: 17032157]DavidsonKM , TyrerP , NorrieJ , PalmerSJ , TyrerH . Cognitive therapy v usual treatment for borderline personality disorder: prospective 6-year follow-up. British Journal of Psychiatry2010;197(6):456-62. [DOI: 10.1192/bjp.bp.109.074286] [PMID: 21119151]ISRCTN86177428. Borderline personality disorder study of cognitive therapy trial [A randomised controlled trial of cognitive therapy plus treatment as usual versus treatment as usual in the treatment of borderline personality disorder]. www.isrctn.com/ISRCTN86177428 (first received 22 July 2005). NCT00538135. BOSCOT: a randomised controlled trial of cognitive behavioural therapy in borderline personality disorder [BOSCOT: a randomised control trial of cognitive behavioural therapy plus treatment as usual versus treatment as usual in the treatment of borderline personality disorder]. www.clinicaltrials.gov/ct2/show/NCT00538135 (first received 29 September 2007). NorrieJ , DavidsonK , TataP , GumleyA . Influence of therapist competence and quantity of cognitive behavioural therapy on suicidal behaviour and inpatient hospitalisation in a randomised controlled trial in borderline personality disorder: further analyses of treatment effects in the BOSCOT study. Psychology and Psychotherapy2013;86(3):280-93. [DOI: 10.1111/papt.12004] [PMC4491320] [PMID: 23420622]PalmerS , DavidsonK , TyrerP , GumleyA , TataP , NorrieJ , et al. The cost-effectiveness of cognitive behavior therapy for borderline personality disorder: results from the BOSCOT trial. Journal of Personality Disorders2006;20(5):466-81. [DOI: 10.1521/pedi.2006.20.5.466] [PMC1852260] [PMID: 17032159]">Davidson 2006</a>; <a href="./references#CD012955-bbs2-0019" title="BuchheimA , Hörz-SagstetterS , DoeringS , RentropM , SchusterP , BuchheimP , et al. Change of unresolved attachment in borderline personality disorders: RCT study of transference-focused psychotherapy. Psychotherapy and Psychosomatics2017;86(5):314-6. [DOI: 10.1159/000460257] [PMID: 28903103]DiamondD , LevyKN , ClarkinJF , Fischer-KernM , CainNM , DoeringS , et al. Attachment and mentalization in female patients with comorbid narcissistic and borderline personality disorder. Personality Disorders2014;5(4):428-33. [DOI: 10.1037/per0000065] [PMID: 25314231]DiamondD , YeomansFE , SternB , LevyKN , HörzS , DoeringS , et al. Transference-focused psychotherapy for patients with comorbid narcissistic and borderline personality disorder. Psychoanalytic Inquiry2013;33(6):527-51. [DOI: 10.1080/07351690.2013.815087]DoeringS , HörzS , RentropM , Fischer-KernM , SchusterP , BeneckeC , et al. Transference-focused psychotherapy v treatment by community psychotherapists for borderline personality disorder: randomised controlled trial. British Journal of Psychiatry2010;196(5):389-95. [DOI: 10.1192/bjp.bp.109.070177] [PMID: 20435966]DoeringS . Author's reply [to Kleindienst N, Krumm B, Bohus M. Is transference-focused psychotherapy really efficacious for borderline personality disorder? British Journal of Psychiatry 2011;198(2):156-7. DOI: 10.1192/bjp.198.2.156b]. British Journal of Psychiatry2011;198(2):156-7. [DOI: 10.1192/bjp.198.2.157]DoeringS . Question regarding your BPD trial for systematic review in Cochrane Collaboration [personal communication]. Email to: K Lieb, J Stoffers 10 December 2010. Fischer-KernM , DoeringS , TaubnerS , HörzS , ZimmermannJ , RentropM , et al. Transference-focused psychotherapy for borderline personality disorder: change in reflective function. British Journal of Psychiatry2015;207(2):173-4. [DOI: 10.1192/bjp.bp.113.143842] [PMID: 25999334]KleindienstN , KrummB , BohusM . Is transference-focused psychotherapy really efficacious for borderline personality disorder?British Journal of Psychiatry2011;198(2):156-7. [DOI: 10.1192/bjp.198.2.156b] [PMID: 21282787]LevyKN , MeehanKB , YeomansFE . Transference-focused psychotherapy reduces treatment drop-out and suicide attempters compared with community psychotherapist treatment in borderline personality disorder. Evidence-based Mental Health2010;13(4):119. [DOI: 10.1136/ebmh.13.4.119] [PMID: 21036981]NCT00714311. Efficacy of transference-focused psychotherapy for borderline personality disorder [A randomized-controlled trial of transference-focused psychotherapy vs treatment by experienced community psychotherapists for borderline personality disorder]. www.clinicaltrials.gov/ct2/show/NCT00714311 (first received 9 July 2008). RentropM , MartiusP , BäumlJ , BuchheimP , DöeringS , HörzS . Patients with borderline personality disorder not participating in an RCT: are they different?Psychopathology2010;43(6):369-72. [DOI: 10.1159/000320351] [PMID: 20798576]">Doering 2010</a>; <a href="./references#CD012955-bbs2-0024" title="ArntzA , Stupar-RutenfransS , BlooJ , Van DyckR , SpinhovenP . Prediction of treatment discontinuation and recovery from borderline personality disorder: results from an RCT comparing schema therapy and transference-focused psychotherapy. Behaviour Research and Therapy2015;74:60-71. [DOI: 10.1016/j.brat.2015.09.002] [PMID: 26432172]Giesen-BlooJ , ArntzA . Questions concerning the randomized trial of schema-focused therapy vs transference-focused psychotherapy—reply. Archives of General Psychiatry2007;64(5):610-1. [DOI: 10.1001/archpsyc.64.5.610]Giesen-BlooJ , Van DyckR , SpinhovenP , Van TilburgW , DirksenC , Van AsseltT , et al. Errors in table and figure in: outpatient psychotherapy for borderline personality disorder: randomized trial of schema-focused therapy vs transference-focused psychotherapy. Archives of General Psychiatry2006;63(9):1008. Erratum for: Archives of General Psychiatry 2006;63(6):649-58. [DOI: 10.1001/archpsyc.63.9.1008]Giesen-BlooJ , Van DyckR , SpinhovenP , Van TilburgW , DirksenC , Van AsseltT , et al. Outpatient psychotherapy for borderline personality disorder: randomized trial of schema-focused therapy vs transference-focused psychotherapy. Archives of General Psychiatry2006;63(6):649-58. [DOI: 10.1001/archpsyc.63.6.649] [PMID: 16754838]SpinhovenP , Giesen-BlooJ , Van DyckR , KooimanK , ArntzA . The therapeutic alliance in schema-focused therapy and transference-focused psychotherapy for borderline personality disorder. Journal of Consulting and Clinical Psychology2007;75(1):104-15. [DOI: 10.1037/0022-006X.75.1.104] [PMID: 17295569]Van AsseltADI , DirksenCD , ArntzA , Giesen-BlooJH , Van DyckR , SpinhovenP , et al. Out-patient psychotherapy for borderline personality disorder: cost-effectiveness of schema-focused therapy v transference-focused psychotherapy. British Journal of Psychiatry2008;192(6):450-7. [DOI: 10.1192/bjp.bp.106.033597] [PMID: 18515897]Van AsseltADI , DirksenCD , ArntzA , SeverensJL . Difficulties in calculating productivity costs: work disability associated with borderline personality disorder. Value in Health2008;11(4):637-44. [DOI: 10.1111/j.1524-4733.2007.00288.x]YeomansF . Questions concerning the randomized trial of schema-focused therapy vs transference-focused psychotherapy. Archives of General Psychiatry2007;64(5):609-10. [DOI: 10.1001/archpsyc.64.5.609-c] [PMID: 17485613]">Giesen‐Bloo 2006</a>; <a href="./references#CD012955-bbs2-0027" title="GratzKL , BardeenJR , LevyR , Dixon-GordonKL , TullMT . Mechanisms of change in an emotion regulation group therapy for deliberate self-harm among women with borderline personality disorder. Behaviour Research and Therapy2015;65:29-35. [DOI: 10.1016/j.brat.2014.12.005] [PMC4306622] [PMID: 25557395]GratzKL , Dixon-GordonKL , TullMT . Predictors of treatment response to an adjunctive emotion regulation group therapy for deliberate self-harm among women with borderline personality disorder. Personality Disorders2014;5(1):97-107. [DOI: 10.1037/per0000062] [PMC4059504] [PMID: 2458806]GratzKL , TullMT , LevyR . Randomized controlled trial and uncontrolled 9-month follow-up of an adjunctive emotion regulation group therapy for deliberate self-harm among women with borderline personality disorder. Psychological Medicine2014;44(10):2099-112. [DOI: 10.1017/S0033291713002134] [PMID: 23985088]GratzKL . Question regarding your BPD trials [personal communication]. Email to: J Stoffers 11 December 2010. ">Gratz 2014</a>; <a href="./references#CD012955-bbs2-0030" title="HarnedM . Re: SV: question regarding your trial on brief therapy for attempted suicide [personal communication]. Email to: EG Faltinsen 11 December 2018. HarnedMS , KorslundKE , LinehanMM . A pilot randomized controlled trial of dialectical behavior therapy with and without the dialectical behavior therapy prolonged exposure protocol for suicidal and self-injuring women with borderline personality disorder and PTSD. Behaviour Research and Therapy2014;55:7-17. [DOI: 10.1016/j.brat.2014.01.008] [PMC3987949] [PMID: 24562087]HarnedMS , WilksCR , SchmidtSC , CoyleTN . Improving functional outcomes in women with borderline personality disorder and PTSD by changing PTSD severity and post-traumatic cognitions. Behaviour Research and Therapy2018;103:53-61. [DOI: 10.1016/j.brat.2018.02.002] [PMC5837954] [PMID: 29448136]HarnedMS . RE: questions regarding your trial on brief therapy for attempted suicide [personal communication]. Email to: E Faltinsen 29 November 2017. ">Harned 2014</a>; <a href="./references#CD012955-bbs2-0031" title="BrandS . AW: questions regarding your trial on emotional intelligence training for BPD [personal communication]. Email to: EG Faltinsen 28 November 2017. BrandS . Questions regarding your trial on emotional intelligence training for BPD [personal communication]. Email to: EG Faltinsen 28 November 2017. JahangardL , HaghighiM , BajoghliH , AhmadpanahM , GhaleihaA , ZarrabianMK , et al. Training emotional intelligence improves both emotional intelligence and depressive symptoms in inpatients with borderline personality disorder and depression. International Journal of Psychiatry in Clinical Practice2012;16(3):197-204. [DOI: 10.3109/13651501.2012.687454] [PMID: 22873719]">Jahangard 2012</a>; <a href="./references#CD012955-bbs2-0039" title="KredlowMA , SzuhanyKL , LoS , XieH , GottliebJD , RosenbergSD , et al. Cognitive behavioral therapy for posttraumatic stress disorder in individuals with severe mental illness and borderline personality disorder. Psychiatry Research2017;249:86-93. [DOI: 10.1016/j.psychres.2016.12.045] [PMC5325773] [PMID: 28086181]MueserK . Re: question regarding your trial on CBT for BPD patients [personal communication]. Email to: EG Faltinsen 28 November 2017. ">Kredlow 2017a</a>; <a href="./references#CD012955-bbs2-0040" title="KredlowMA , SzuhanyKL , LoS , XieH , GottliebJD , RosenbergSD , et al. Cognitive behavioral therapy for posttraumatic stress disorder in individuals with severe mental illness and borderline personality disorder. Psychiatry Research2017;249:86-93. [DOI: 10.1016/j.psychres.2016.12.045] [PMC5325773] [PMID: 28086181]MueserKT , GottliebJD , XieH , LuW , YanosPT , RosenbergSD , et al. Evaluation of cognitive restructuring for post-traumatic stress disorder in people with severe mental illness.. British Journal of Psychiatry2015;206(6):501-8. [DOI: 10.1192/bjp.bp.114.147926] [PMC4450219] [PMID: 25858178]MueserKT , RosenbergSD , XieH , JankowskiMK , BoltonEE , LuW , et al. A randomized controlled trial of cognitive-behavioral treatment for posttraumatic stress disorder in severe mental illness. Journal of Consulting and Clinical Psychology2008;76(2):259-71. [DOI: 10.1037/0022-006X.76.2.259] [PMC3916092] [PMID: 18377122]MueserKT . Re: question regarding your trial on CBT for PTSD participants [personal communication]. Email to: E Faltinsen 28 November 2018. ">Kredlow 2017b</a>; <a href="./references#CD012955-bbs2-0044" title="Lin T-J, Ko H-C, Wu JY-W, OeiTP , Lane H-Y, Chen C-H. The effectiveness of dialectical behavior therapy skills training group vs cognitive therapy group on reducing depression and suicide attempts for borderline personality disorder in Taiwan. Archives of Suicide Research2019;23(1):82-99. [DOI: 10.1080/13811118.2018.1436104] [PMID: 29528807]">Lin 2019</a>; <a href="./references#CD012955-bbs2-0047" title="BedicsJD , AtkinsDC , ComtoisKA , LinehanMM . Treatment differences in the therapeutic relationship and introject during a 2-year randomized controlled trial of dialectical behavior therapy versus nonbehavioral psychotherapy experts for borderline personality disorder. Journal of Consulting and Clinical Psychology2012;80(1):66-77. [DOI: 10.1037/a0026113] [PMC3265694] [PMID: 22061867]BedicsJD , AtkinsDC , ComtoisKA , LinehanMM . Weekly therapist ratings of the therapeutic relationship and patient introject furing the course of dialectical behavioral therapy for the treatment of borderline personality disorder. Psychotherapy2012;49(2):231-40. [DOI: 10.1037/a0028254] [PMID: 22642526]BedicsJD , AtkinsDC , HarnedMS , LinehanMM . The therapeutic alliance as a predictor of outcome in dialectical behavior therapy versus nonbehavioral psychotherapy by experts for borderline personality disorder. Psychotherapy2015;52(1):67-77. [DOI: 10.1037/a0038457] [PMID: 25751116]BrownMZ , LinehanMM , ComtoisKA , MurrayA , ChapmanAL . Shame as a prospective predictor of self-inflicted injury in borderline personality disorder: a multi-modal analysis. Behaviour Research and Therapy2009;47(10):815-22. [DOI: 10.1016/j.brat.2009.06.008] [PMC2761705] [PMID: 19596223 ]CoyleTN , ShaverJA , LinehanMM . On the potential for iatrogenic effects of psychiatric crisis services: the example of dialectical behavior therapy for adult women with borderline personality disorder. Journal of Consulting and Clinical Psychology2018;86(2):116-24. [DOI: 10.1037/ccp0000275] [PMID: 29369662]HarnedMS , ChapmanAL , Dexter-MazzaET , MurrayA , ComtoisKA , LinehanMM . Treating co-occurring Axis I disorders in recurrently suicidal women with borderline personality disorder: a 2-year randomized trial of dialectical behavior therapy versus community treatment by experts. Journal of Consulting and Clinical Psychology2008;76(6):1068-75. [DOI: 10.1037/a0014044] [PMID: 19045974]HarnedMS , ChapmanAL , Dexter-MazzaET , MurrayA , ComtoisKA , LinehanMM . Treating co-occurring Axis I disorders in recurrently suicidal women with borderline personality disorder: a 2-year randomized trial of dialectical behavior therapy versus community treatment by experts. Personality Disorders: Theory, Research, and Treatment2009;S(1):35-45. [DOI: 10.1037/1949-2715.S.1.35]HarnedMS , JacksonSC , ComtoisKA , LinehanMM . Dialectical behavior therapy as a precursor to PTSD treatment for suicidal and/or self-injuring women with bordreline personality disorder. Journal of Traumatic Stress2010;23(4):421-9. [DOI: 10.1002/jts.20553] [PMID: 20648564]LindenboimN , ComtoisKA , LinehanMM . Skills practice in dialectical behavior therapy for suicidal women meeting criteria for borderline personality disorder. Cognitive and Behavioral Practice2007;14(2):147-56. [DOI: 10.1016/j.cbpra.2006.10.004]LinehanMM , ComtoisKA , MurrayAM , BrownMZ , GallopRJ , HeardHL , et al. Two-year randomized controlled trial and follow-up of dialectical behavior therapy vs therapy by experts for suicidal behaviors and borderline personality disorder. Archives of General Psychiatry2006;63(7):757-66. [DOI: 10.1001/archpsyc.63.7.757] [PMID: 16818865]LinehanMM . Error in table in: two-year randomized controlled trial and follow-up of dialectical behavior therapy vs therapy by experts for suicidal behaviors and borderline personality disorder. Archives of General Psychiatry2007;64(12):1401. Erratum for: Archives of General Psychiatry 2007;64(12):1401. McMainS . Dialectic behaviour therapy reduces suicide attempts compared with non-behavioural psychotherapy in women with borderline personality disorder. Evidence-Based Mental Health2007;10(1):18. [DOI: 10.1136/ebmh.10.1.18] [PMID: 17255387]NeacsiuAD , LunguA , HarnedMS , RizviSL , LinehanMM . Impact of dialectical behavior therapy versus community treatment by experts on emotional experience, expression, and acceptance in borderline personality disorder. Behaviour Research and Therapy2014;53:47-54. [DOI: 10.1016/j.brat.2013.12.004] [PMC3955205] [PMID: 24418652]NeacsiuAD , RizviSL , LinehanMM . Dialectical behavior therapy skills use as a mediator and outcome of treatment for borderline personality disorder. Behaviour Research and Therapy2010;48(9):832-9. [DOI: 10.1016/j.brat.2010.05.017] [PMC2914145] [PMID: 20579633]SecristCD . The Role of Executive Functioning in the Treatment of Borderline Personality Disorder [PhD thesis]. Washington (DC): University of Washington, 2014. ">Linehan 2006</a>: <a href="./references#CD012955-bbs2-0050" title="McMainSF , GuimondT , BarnhartR , HabinskiL , StreinerDL . A randomized trial of brief dialectical behaviour therapy skills training in suicidal patients suffering from borderline disorder. Acta Psychiatrica Scandinavica2017;135(2):138-48. [DOI: 10.1111/acps.12664] [PMID: 27858962]">McMain 2017</a>; <a href="./references#CD012955-bbs2-0051" title="McMurranM , CrawfordMJ , ReillyJ , DelportJ , McCroneP , WhithamD , et al. Psychoeducation with problem-solving (PEPS) therapy for adults with personality disorder: a pragmatic randomised controlled trial to determine the clinical effectiveness and cost-effectiveness of a manualised intervention to improve social functioning. Health Technology Assessment2016;20(52):1-282. [DOI: 10.3310/hta20520]McMurranM . RE: Cochrane Collaboration review - PEPS study [personal communication]. Email to: J Stoffers-Winterling 5 July 2018. McMurranM . Request for data on BPD subjects in the PEPS rcp-study for use a new Cochrane review [personal communication]. Email to: M Kongerslev 7 March 2017. ">McMurran 2016</a>; <a href="./references#CD012955-bbs2-0052" title="HagaE , AasE , GrøholtB , TørmoenAJ , MehlumL . Cost-effectiveness of dialectical behaviour therapy vs enhanced usual care in the treatment of adolescents with self-harm. Child and Adolescent Psychiatry and Mental Health2018;12:22. [DOI: 10.1186/s13034-018-0227-2] [PMC5928596] [PMID: 29743941]MehlumL , RambergM , TørmoenAJ , HagaE , DiepLM , StanleyBH , et al. Dialectical behavior therapy compared with enhanced usual care for adolescents with repeated suicidal and self-harming behavior: outcomes over a one-year follow-up. Journal of the American Academy of Child and Adolescent Psychiatry2016;55(4):295-300. [DOI: 10.1016/j.jaac.2016.01.005] [PMID: 27015720]MehlumL , TørmoenAJ , RambergM , HagaE , DiepLM , LabergS , et al. Dialectical behavior therapy for adolescents with repeated suicidal and self-harming behavior: a randomized trial. Journal of the American Academy of Child and Adolescent Psychiatry2014;53(10):1082-91. [DOI: 10.1016/j.jaac.2014.07.003] [PMID: 25245352]MehlumL . Re: regarding your study of DBT for your with suicidal behavior [personal communication] [Re: angående din studie om DBT for ungdom med selvmordsatferd [personlig kommunikation]]. Email to: E Faltinsen 5 December 2017. NCT00675129. Treatment for adolescents with deliberate self harm [A randomized controlled trial for repetitive deliberate self-harm and suicidal behaviours among Norwegian adolescents: a comparison between dialectical behaviour therapy adapted for adolescents (DBT-A) and enhanced usual care (EUC)]. www.clinicaltrials.gov/ct2/show/NCT00675129 (first received 6 May 2008). RamlethRK , GroholtB , DiepLM , WalbyFA , MehlumL . The impact of borderline personality disorder and sub-threshold borderline personality disorder on the course of self-reported and clinician-rated depression in self-harming adolescents. Borderline Personality Disorder and Emotion Dysregulation2017;4:22. [DOI: 10.1186/s40479-017-0073-5] [PMC5663078] [PMID: 29093819]">Mehlum 2014</a>; <a href="./references#CD012955-bbs2-0063" title="SalzerS , CroppC , JaegerU , MasuhrO , Streeck-FischerA . Psychodynamic therapy for adolescents suffering from co-morbid disorders of conduct and emotions in an in-patient setting: a randomized controlled trial. Psychological Medicine2014;44(10):2213-22. [DOI: 10.1017/S003329171300278X] [PMID: 24229481]SalzerS , Streeck-FischerA . The psychoanalytic-interactional method (PiM) for adolescents with borderline personality disorder [Die psychoanalytisch-interaktionelle methode (PiM) für adoleszente mit borderline-persönlichkeitsstörung]. Personlichkeitsstorungen Theorie und Therapie2015;19(1):67-76. [elibrary.klett-cotta.de/article/99.120110/ptt-19-1-67]SalzerS . AW: Re: Cochrane Review on psychotherapies for BPD - RCT testing PiM vs WL [personal communication] [AW:Re: Cochrane Review zur Psychotherapie bei BPS - RCT zu PiM vs WL [persönliche kommunikation]]. Email to: J Stoffers-Winterling 15 July 2018. ">Salzer 2014</a>; <a href="./references#CD012955-bbs2-0075" title="ZanariniMC , ConkeyLC , TemesCM , FitzmauriceGM . Randomized controlled trial of web-based psychoeducation for women with borderline personality disorder. Journal of Clinical Psychiatry2018;79(3):16m11153. [DOI: 10.4088/JCP.16m11153] [PMC5764827] [PMID: 28703950]">Zanarini 2018</a>). </p> </section> <section id="CD012955-sec-0074"> <h4 class="title">Selective reporting</h4> <p>The majority of trials (39 trials) either did not have a published protocol prior to initiating the trials or did not provide sufficient information in the report to judge the extent of reporting bias. We considered these trials to be at unclear risk of bias (<a href="./references#CD012955-bbs2-0004" title="BatemanA , FonagyP . 8-year follow-up of patients treated for borderline personality disorder: mentalization-based treatment versus treatment as usual. American Journal of Psychiatry2008;165(5):631-8. [DOI: 10.1176/appi.ajp.2007.07040636] [PMID: 18347003]BatemanA , FonagyP . Effectiveness of partial hospitalization in the treatment of borderline personality disorder: a randomized controlled trial. American Journal of Psychiatry1999;156(10):1563-9. [DOI: 10.1176/ajp.156.10.1563] [PMID: 10518167]BatemanA , FonagyP . Health care utilization costs for borderline personality disorder patients treated with psychoanalytically oriented partial hospitalization versus general psychiatric care. American Journal of Psychiatry2003;160(1):169-71. [10.1176/appi.ajp.160.1.169] [12505818]BatemanA , FonagyP . Treatment of borderline personality disorder with psychoanalytically oriented partial hospitalization: an 18-month follow-up. American Journal of Psychiatry2001;158(1):36-42. [DOI: 10.1176/appi.ajp.158.1.36] [PMID: 11136631]BatemanA . Important: question regarding your BPD trial for systematic review in Cochrane Collaboration [personal communication]. Email to: K Lieb, J Stoffers 14 December 2010. BatemanA . Intensive outpatient and partial hospital care for BPD. In: 157th annual meeting of the American Psychiatric Association. Psychotherapy and pharmacology: dissolving the mind-brain barrier; 2004 May 1-6; New York (NY). Arlington (VA): American Psychiatric Association, 2004:102. [Symposium 100B] [www.psychiatry.org/File%20Library/Psychiatrists/Directories/Library-and-Archive/conference_publications/am_program_2004.pdf]BatemanAW , FonagyP . Drs Bateman and Fonagy reply [to Stern R. Partial hospitalization for borderline personality disorder. American Journal of Psychiatry 2001;158(11):1932-3. DOI: 10.1176/appi.ajp.158.11.1932]. American Journal of Psychiatry2001;158(11):1932-3. [DOI: 10.1176/appi.ajp.158.11.1932-a]EvansC . Treatment benefits of psychoanalytically oriented partial hospitalisation were maintained over 18 months in borderline personality disorder. Evidence-Based Mental Health2001;4(3):73. [DOI: 10.1136/ebmh.4.3.73]FonagyP , BatemanAW . Mentalizing and borderline personality disorder. Journal of Mental Health2007;16(1):83-101. [DOI: 10.1080/09638230601182045]SternR . Partial hospitalization for borderline personality disorder. American Journal of Psychiatry2001;158(11):1932-3. [DOI: 10.1176/appi.ajp.158.11.1932] [PMID: 11691712]">Bateman 1999</a>; <a href="./references#CD012955-bbs2-0006" title="BellinoS , ParadisoE , ZizzaM , Di LorenzoR , BogettoF . Combined therapy with interpersonal psychotherapy of major depressed patients with borderline personality disorder: a comparison with pharmacotherapy [Terapia combinata con psicoterapia interpersonale di pazienti depressi maggiori con disturbo borderline di personalità: confronto con la farmacoterapia]. Journal of Psychopathology2005;11(1):34-42. [bit.ly/2rZUh5h]BellinoS , ZizzaM , RinaldiC , BogettoF . Combined treatment of major depression in patients with borderline personality disorder: a comparison with pharmacotherapy. Canadian Journal of Psychiatry2006;51(7):453-60. [DOI: 10.1177/070674370605100707] [PMID: 16838827]">Bellino 2006</a>; <a href="./references#CD012955-bbs2-0007" title="BellinoS , ZizzaM , RinaldiC , BogettoF . Combined therapy of major depression with concomitant borderline personality disorder: comparison of interpersonal and cognitive psychotherapy. Canadian Journal of Psychiatry2007;52(11):718-25. [DOI: 10.1177/070674370705201106] [PMID: 18399039]">Bellino 2007</a>; <a href="./references#CD012955-bbs2-0008" title="BellinoS , BozzatelloP , BogettoF . Combined treatment of borderline personality disorder with interpersonal psychotherapy and pharmacotherapy: predictors of response. Psychiatry Research2015;226(1):284-8. [DOI: 10.1016/j.psychres.2014.12.064] [isiarticles.com/bundles/Article/pre/pdf/34125.pdf]BellinoS , RinaldiC , BogettoF . Adaptation of interpersonal psychotherapy to borderline personality disorder: a comparison of combined therapy and single pharmacotherapy. Canadian Journal of Psychiatry2010;55(2):74-81. [DOI: 10.1177/070674371005500203] [PMID: 20181302]BellinoS . Question regarding your BPD trials for inclusion in Cochrane Collaboration review [personal communication]. Email to: J Stoffers-Winterling 19 December 2010. BellinoS . Re: question regarding your BPD trials [personal communication]. Email to: J Stoffers 16 December 2010. BozzatelloP , BellinoS . Combined therapy with interpersonal psychotherapy adapted for borderline personality disorder: a two-years follow-up. Psychiatry Research2016;240:151-6. [DOI: 10.1016/j.psychres.2016.04.014] [www.sciencedirect.com/science/article/pii/S0165178115302389]ZizzaM , FenocchioM , RinaldiC , BellinoS . Combined treatment of borderline personality disorder: a trial of modified interpersonal therapy. World Psychiatry2009;8(Suppl 1):234. ">Bellino 2010</a>; <a href="./references#CD012955-bbs2-0009" title="BianchiniV , CofiniV , CurtoM , LagrotteriaB , ManziA , NavariS , et al. Dialectical behavior therapy (DBT) for forensic psychiatric patients: an Italian pilot study. Criminal Behavior and Mental Health2019;29(9):122-30. [DOI: 10.1002/cbm.2102] [PMID: 30648303]">Bianchini 2019</a>; <a href="./references#CD012955-bbs2-0013" title="BosEH , Van WelE , AppeloMT , VerbraakMJP . A randomized controlled trial of a Dutch version of systems training for emotional predictability and problem solving for borderline personality disorder. Journal of Nervous and Mental Disease2010;198(4):299-304. [DOI: 10.1097/NMD.0b013e3181d619cf] [PMID: 20386260]Van WelEB , BosEH , AppeloMT , BerendsenEM , WillgerothFC , VerbraakMJPM . The efficacy of the systems training for emotional predictability and problem solving (STEPPS) in the treatment of borderline personality disorder. A randomized controlled trial [De effectiviteit van de vaardigheidstraining emotieregulatiestoornis (VERS) in de behandeling van de borderlinepersoonlijkheidsstoornis: een gerandomiseerd onderzoek]. Tijdschrift voor Psychiatrie2009;51(5):291-301. [PMID: 19434566]">Bos 2010</a>; <a href="./references#CD012955-bbs2-0015" title="CarterG . Question regarding your BPD trial [personal communication]. Email to: J Stoffers 21 December 2010. CarterGL , WillcoxCH , LewinTJ , ConradAM , BenditN . Hunter DBT project: randomized controlled trial of dialectical behaviour therapy in women with borderline personality disorder. Australian and New Zealand Journal of Psychiatry2010;44(2):162-73. [DOI: 10.3109/00048670903393621] [PMID: 20113305]">Carter 2010</a>; <a href="./references#CD012955-bbs2-0018" title="DavidsonKM , BrownTM , JamesV , KirkJ , RichardsonJ . Manual-assisted cognitive therapy for self-harm in personality disorder and substance misuse: a feasibility trial. Psychiatric Bulletin2014;38(3):108-11. [DOI: 10.1192/pb.bp.113.043109] [PMC4115373] [PMID: 25237519]DavidsonKM . Re: question regarding your trial on manual-assisted cognitive therapy [personal communication]. Email to: EG Faltinsen 28 November 2017. ">Davidson 2014</a>; <a href="./references#CD012955-bbs2-0021" title="FarrellJM , ShawIA , WebberMA . A schema-focused approach to group psychotherapy for outpatients with borderline personality disorder: a randomized controlled trial. Journal of Behavior Therapy and Experimental Psychiatry2009;40(2):317-28 Corrigendum to: Journal of Behavior Therapy and Experimental Psychiatry 2018; 60: 111. [DOI: 10.1016/j.jbtep.2009.01.002] [PMID: 19176222]FarrellJM . Question regarding your BPD trials [personal communication]. Email to: K Lieb, J Stoffers 9 December 2010. ">Farrell 2009</a>; <a href="./references#CD012955-bbs2-0022" title="FeigenbaumJD , FonagyP , PillingS , JonesA , WildgooseA , BebbingtonPE . A real-world study of the effectiveness of DBT in the UK National Health Service. British Journal of Clinical Psychology2012;51(2):121-41. [DOI: 10.1111/j.2044-8260.2011.02017.x] [PMID: 22574799]">Feigenbaum 2012</a>; <a href="./references#CD012955-bbs2-0023" title="Feliu-SolerA , PascualJC , ElicesM , Martín-BlancoA , CarmonaC , CebollaA , et al. Fostering self-compassion and loving-kindness in patients with borderline personality disorder: a randomized pilot study. Clinical Psychology &amp; Psychotherapy2017;24(1):278-86. [DOI: 10.1002/cpp.2000] [PMID: 26818533]">Feliu‐Soler 2017</a>; <a href="./references#CD012955-bbs2-0024" title="ArntzA , Stupar-RutenfransS , BlooJ , Van DyckR , SpinhovenP . Prediction of treatment discontinuation and recovery from borderline personality disorder: results from an RCT comparing schema therapy and transference-focused psychotherapy. Behaviour Research and Therapy2015;74:60-71. [DOI: 10.1016/j.brat.2015.09.002] [PMID: 26432172]Giesen-BlooJ , ArntzA . Questions concerning the randomized trial of schema-focused therapy vs transference-focused psychotherapy—reply. Archives of General Psychiatry2007;64(5):610-1. [DOI: 10.1001/archpsyc.64.5.610]Giesen-BlooJ , Van DyckR , SpinhovenP , Van TilburgW , DirksenC , Van AsseltT , et al. Errors in table and figure in: outpatient psychotherapy for borderline personality disorder: randomized trial of schema-focused therapy vs transference-focused psychotherapy. Archives of General Psychiatry2006;63(9):1008. Erratum for: Archives of General Psychiatry 2006;63(6):649-58. [DOI: 10.1001/archpsyc.63.9.1008]Giesen-BlooJ , Van DyckR , SpinhovenP , Van TilburgW , DirksenC , Van AsseltT , et al. Outpatient psychotherapy for borderline personality disorder: randomized trial of schema-focused therapy vs transference-focused psychotherapy. Archives of General Psychiatry2006;63(6):649-58. [DOI: 10.1001/archpsyc.63.6.649] [PMID: 16754838]SpinhovenP , Giesen-BlooJ , Van DyckR , KooimanK , ArntzA . The therapeutic alliance in schema-focused therapy and transference-focused psychotherapy for borderline personality disorder. Journal of Consulting and Clinical Psychology2007;75(1):104-15. [DOI: 10.1037/0022-006X.75.1.104] [PMID: 17295569]Van AsseltADI , DirksenCD , ArntzA , Giesen-BlooJH , Van DyckR , SpinhovenP , et al. Out-patient psychotherapy for borderline personality disorder: cost-effectiveness of schema-focused therapy v transference-focused psychotherapy. British Journal of Psychiatry2008;192(6):450-7. [DOI: 10.1192/bjp.bp.106.033597] [PMID: 18515897]Van AsseltADI , DirksenCD , ArntzA , SeverensJL . Difficulties in calculating productivity costs: work disability associated with borderline personality disorder. Value in Health2008;11(4):637-44. [DOI: 10.1111/j.1524-4733.2007.00288.x]YeomansF . Questions concerning the randomized trial of schema-focused therapy vs transference-focused psychotherapy. Archives of General Psychiatry2007;64(5):609-10. [DOI: 10.1001/archpsyc.64.5.609-c] [PMID: 17485613]">Giesen‐Bloo 2006</a>; <a href="./references#CD012955-bbs2-0026" title="Gratz KL. Important: question regarding your BPD trial for systematic review in Cochrane Collaboration [personal communication]. Email to: J Stoffers-Winterling 11 December 2010. GratzKL , GundersonJG . Preliminary data on an acceptance-based emotion regulation group intervention for deliberate self-harm among women with borderline personality disorder. Behavior Therapy2006;37(1):25-35. [DOI: 10.1016/j.beth.2005.03.002] [PMID: 16942958]">Gratz 2006</a>; <a href="./references#CD012955-bbs2-0027" title="GratzKL , BardeenJR , LevyR , Dixon-GordonKL , TullMT . Mechanisms of change in an emotion regulation group therapy for deliberate self-harm among women with borderline personality disorder. Behaviour Research and Therapy2015;65:29-35. [DOI: 10.1016/j.brat.2014.12.005] [PMC4306622] [PMID: 25557395]GratzKL , Dixon-GordonKL , TullMT . Predictors of treatment response to an adjunctive emotion regulation group therapy for deliberate self-harm among women with borderline personality disorder. Personality Disorders2014;5(1):97-107. [DOI: 10.1037/per0000062] [PMC4059504] [PMID: 2458806]GratzKL , TullMT , LevyR . Randomized controlled trial and uncontrolled 9-month follow-up of an adjunctive emotion regulation group therapy for deliberate self-harm among women with borderline personality disorder. Psychological Medicine2014;44(10):2099-112. [DOI: 10.1017/S0033291713002134] [PMID: 23985088]GratzKL . Question regarding your BPD trials [personal communication]. Email to: J Stoffers 11 December 2010. ">Gratz 2014</a>; <a href="./references#CD012955-bbs2-0031" title="BrandS . AW: questions regarding your trial on emotional intelligence training for BPD [personal communication]. Email to: EG Faltinsen 28 November 2017. BrandS . Questions regarding your trial on emotional intelligence training for BPD [personal communication]. Email to: EG Faltinsen 28 November 2017. JahangardL , HaghighiM , BajoghliH , AhmadpanahM , GhaleihaA , ZarrabianMK , et al. Training emotional intelligence improves both emotional intelligence and depressive symptoms in inpatients with borderline personality disorder and depression. International Journal of Psychiatry in Clinical Practice2012;16(3):197-204. [DOI: 10.3109/13651501.2012.687454] [PMID: 22873719]">Jahangard 2012</a>; <a href="./references#CD012955-bbs2-0033" title="JørgensenCR , BøyeR , AndersenD , Døssing BlaabjergAH , FreundC , JordetH , et al. Eighteen months post-treatment naturalistic follow-up study of mentalization-based therapy and supportive group treatment of borderline personality disorder: clinical outcomes and functioning. Nordic Psychology2014;66(4):254-73. [DOI: 10.1080/19012276.2014.963649]JørgensenCR , FreundC , BøyeR , JordetH , AndersenD , KjølbyeM . Outcome of mentalization-based and supportive psychotherapy in patients with borderline personality disorder: a randomized trial. Acta Psychiatrica Scandinavica2013;127(4):305-17. [DOI: 10.1111/j.1600-0447.2012.01923.x] [PMID: 22897123]JorgensenCR . SV: questions on your trial regarding MBT for BPD patients [personal communication]. Email to: EG Faltinsen 28 November 2017. ">Jørgensen 2013</a>; <a href="./references#CD012955-bbs2-0034" title="KamalabadiMJ , AhmadiSA , EtemadiO , FatehizadehM , BahramiF , FiroozabadiA . A study of the effect of couple dialectical behavioral therapy on symptoms and quality of marital relationships and mental health of Iranian borderline personality couples: a controlled trial. Interdisciplinary Journal of Contemporary Research in Business2012;3(9):1480-7. [psycnet.apa.org/record/2012-22425-047]">Kamalabadi 2012</a>; <a href="./references#CD012955-bbs2-0035" title="KoonsCR , RobinsCJ , TweedJL , LynchTR , GonzalezAM , MorseJQ , et al. Efficacy of dialectical behavior therapy in women veterans with borderline personality disorder. Behavior Therapy2001;32(2):371-90. [DOI: 10.1016/S0005-7894(01)80009-5]">Koons 2001a</a>; <a href="./references#CD012955-bbs2-0038" title="KramerU , Pascual-LeoneA , BerthoudL , De RotenY , MarquetP , KollyS , et al. Assertive anger mediates effects of dialectical behaviour-informed skills training for borderline personality disorder: a randomized controlled trial. Clinical Psychology &amp; Psychotherapy2016;23(3):189-202. [DOI: 10.1002/cpp.1956] [PMID: 25864773]KramerU . The role of coping change in borderline personality disorder: a process-outcome analysis on dialectical-behaviour skills training. Clinical Psychology &amp; Psychotherapy2017;24(2):302-11. [DOI: 10.1002/cpp.2017] [PMID: 27098296]">Kramer 2016</a>; <a href="./references#CD012955-bbs2-0039" title="KredlowMA , SzuhanyKL , LoS , XieH , GottliebJD , RosenbergSD , et al. Cognitive behavioral therapy for posttraumatic stress disorder in individuals with severe mental illness and borderline personality disorder. Psychiatry Research2017;249:86-93. [DOI: 10.1016/j.psychres.2016.12.045] [PMC5325773] [PMID: 28086181]MueserK . Re: question regarding your trial on CBT for BPD patients [personal communication]. Email to: EG Faltinsen 28 November 2017. ">Kredlow 2017a</a>; <a href="./references#CD012955-bbs2-0040" title="KredlowMA , SzuhanyKL , LoS , XieH , GottliebJD , RosenbergSD , et al. Cognitive behavioral therapy for posttraumatic stress disorder in individuals with severe mental illness and borderline personality disorder. Psychiatry Research2017;249:86-93. [DOI: 10.1016/j.psychres.2016.12.045] [PMC5325773] [PMID: 28086181]MueserKT , GottliebJD , XieH , LuW , YanosPT , RosenbergSD , et al. Evaluation of cognitive restructuring for post-traumatic stress disorder in people with severe mental illness.. British Journal of Psychiatry2015;206(6):501-8. [DOI: 10.1192/bjp.bp.114.147926] [PMC4450219] [PMID: 25858178]MueserKT , RosenbergSD , XieH , JankowskiMK , BoltonEE , LuW , et al. A randomized controlled trial of cognitive-behavioral treatment for posttraumatic stress disorder in severe mental illness. Journal of Consulting and Clinical Psychology2008;76(2):259-71. [DOI: 10.1037/0022-006X.76.2.259] [PMC3916092] [PMID: 18377122]MueserKT . Re: question regarding your trial on CBT for PTSD participants [personal communication]. Email to: E Faltinsen 28 November 2018. ">Kredlow 2017b</a>; <a href="./references#CD012955-bbs2-0043" title="LeppänenV , HakkoH , SintonenH , LindemanS . Comparing effectiveness of treatments for borderline personality disorder in communal mental health care: the Oulu BPD study. Community Mental Health Journal2016;52(2):216-27. [DOI: 10.1007/s10597-015-9866-4] [PMID: 25824852]LeppänenV . Re: questions regarding the Oulu BPD study [personal communication]. Email to: E Faltinsen 20 December 2017. LeppänenV . Re: SV: question regarding the Oulu BPD study [personal communication]. Email to: EG Faltinsen 22 December 2017. ">Leppänen 2016</a>; <a href="./references#CD012955-bbs2-0045" title="HoffmanRE . Impact of treatment accessibility on clinical course of parasuicidal patients. Archives of General Psychiatry1993;50(2):157-8. [DOI: 10.1001/archpsyc.1993.01820140083010] [PMID: 8427557]LindenboimN . To Know Me is to Keep Me: Self-Verification, Validation, and Therapy Dropout in the Treatment of Borderline Personality Disorder [PhD thesis]. Washington (DC): University of Washington, 2009. LinehanMM , ArmstrongHE , SuarezA , AllmonD , HeardHL . Cognitive-behavioral treatment of chronically parasuicidal borderline patients. Archives of General Psychiatry1991;48(12):1060-4. [DOI: 10.1001/archpsyc.1991.01810360024003] [PMID: 1845222]LinehanMM , HeardHL . Impact of treatment accessibility on clinical course of parasuicidal patients — reply. Archives of General Psychiatry1993;50(2):157-8. [DOI: 10.1001/archpsyc.1993.01820140083011]">Linehan 1991</a>; <a href="./references#CD012955-bbs2-0046" title="HeardHL . Cost-Effectiveness of Dialectical Behavior Therapy in the Treatment of Borderline Personality Disorder [PhD thesis]. Washington (DC): University of Washington, 2000. LindenboimN . To Know Me is to Keep Me: Self-Verification, Validation, and Therapy Dropout in the Treatment of Borderline Personality Disorder [PhD thesis]. Washington (DC): University of Washington, 2009. LinehanMM , HeardHL , ArmstrongHE . Naturalistic follow-up of a behavioral treatment for chronically parasuicidal borderline patients. Archives of General Psychiatry1993;50(12):971-4. [DOI: 10.1001/archpsyc.1993.01820240055007] [PMID: 8250683]LinehanMM , TutekDA , HeardHL , ArmstrongHE . Interpersonal outcome of cognitive behavioral treatment for chronically suicidal borderline patients. American Journal of Psychiatry1994;151(12):1771-6. [DOI: 10.1176/ajp.151.12.1771] [PMID: 7977884]">Linehan 1994</a>; <a href="./references#CD012955-bbs2-0047" title="BedicsJD , AtkinsDC , ComtoisKA , LinehanMM . Treatment differences in the therapeutic relationship and introject during a 2-year randomized controlled trial of dialectical behavior therapy versus nonbehavioral psychotherapy experts for borderline personality disorder. Journal of Consulting and Clinical Psychology2012;80(1):66-77. [DOI: 10.1037/a0026113] [PMC3265694] [PMID: 22061867]BedicsJD , AtkinsDC , ComtoisKA , LinehanMM . Weekly therapist ratings of the therapeutic relationship and patient introject furing the course of dialectical behavioral therapy for the treatment of borderline personality disorder. Psychotherapy2012;49(2):231-40. [DOI: 10.1037/a0028254] [PMID: 22642526]BedicsJD , AtkinsDC , HarnedMS , LinehanMM . The therapeutic alliance as a predictor of outcome in dialectical behavior therapy versus nonbehavioral psychotherapy by experts for borderline personality disorder. Psychotherapy2015;52(1):67-77. [DOI: 10.1037/a0038457] [PMID: 25751116]BrownMZ , LinehanMM , ComtoisKA , MurrayA , ChapmanAL . Shame as a prospective predictor of self-inflicted injury in borderline personality disorder: a multi-modal analysis. Behaviour Research and Therapy2009;47(10):815-22. [DOI: 10.1016/j.brat.2009.06.008] [PMC2761705] [PMID: 19596223 ]CoyleTN , ShaverJA , LinehanMM . On the potential for iatrogenic effects of psychiatric crisis services: the example of dialectical behavior therapy for adult women with borderline personality disorder. Journal of Consulting and Clinical Psychology2018;86(2):116-24. [DOI: 10.1037/ccp0000275] [PMID: 29369662]HarnedMS , ChapmanAL , Dexter-MazzaET , MurrayA , ComtoisKA , LinehanMM . Treating co-occurring Axis I disorders in recurrently suicidal women with borderline personality disorder: a 2-year randomized trial of dialectical behavior therapy versus community treatment by experts. Journal of Consulting and Clinical Psychology2008;76(6):1068-75. [DOI: 10.1037/a0014044] [PMID: 19045974]HarnedMS , ChapmanAL , Dexter-MazzaET , MurrayA , ComtoisKA , LinehanMM . Treating co-occurring Axis I disorders in recurrently suicidal women with borderline personality disorder: a 2-year randomized trial of dialectical behavior therapy versus community treatment by experts. Personality Disorders: Theory, Research, and Treatment2009;S(1):35-45. [DOI: 10.1037/1949-2715.S.1.35]HarnedMS , JacksonSC , ComtoisKA , LinehanMM . Dialectical behavior therapy as a precursor to PTSD treatment for suicidal and/or self-injuring women with bordreline personality disorder. Journal of Traumatic Stress2010;23(4):421-9. [DOI: 10.1002/jts.20553] [PMID: 20648564]LindenboimN , ComtoisKA , LinehanMM . Skills practice in dialectical behavior therapy for suicidal women meeting criteria for borderline personality disorder. Cognitive and Behavioral Practice2007;14(2):147-56. [DOI: 10.1016/j.cbpra.2006.10.004]LinehanMM , ComtoisKA , MurrayAM , BrownMZ , GallopRJ , HeardHL , et al. Two-year randomized controlled trial and follow-up of dialectical behavior therapy vs therapy by experts for suicidal behaviors and borderline personality disorder. Archives of General Psychiatry2006;63(7):757-66. [DOI: 10.1001/archpsyc.63.7.757] [PMID: 16818865]LinehanMM . Error in table in: two-year randomized controlled trial and follow-up of dialectical behavior therapy vs therapy by experts for suicidal behaviors and borderline personality disorder. Archives of General Psychiatry2007;64(12):1401. Erratum for: Archives of General Psychiatry 2007;64(12):1401. McMainS . Dialectic behaviour therapy reduces suicide attempts compared with non-behavioural psychotherapy in women with borderline personality disorder. Evidence-Based Mental Health2007;10(1):18. [DOI: 10.1136/ebmh.10.1.18] [PMID: 17255387]NeacsiuAD , LunguA , HarnedMS , RizviSL , LinehanMM . Impact of dialectical behavior therapy versus community treatment by experts on emotional experience, expression, and acceptance in borderline personality disorder. Behaviour Research and Therapy2014;53:47-54. [DOI: 10.1016/j.brat.2013.12.004] [PMC3955205] [PMID: 24418652]NeacsiuAD , RizviSL , LinehanMM . Dialectical behavior therapy skills use as a mediator and outcome of treatment for borderline personality disorder. Behaviour Research and Therapy2010;48(9):832-9. [DOI: 10.1016/j.brat.2010.05.017] [PMC2914145] [PMID: 20579633]SecristCD . The Role of Executive Functioning in the Treatment of Borderline Personality Disorder [PhD thesis]. Washington (DC): University of Washington, 2014. ">Linehan 2006</a>; <a href="./references#CD012955-bbs2-0052" title="HagaE , AasE , GrøholtB , TørmoenAJ , MehlumL . Cost-effectiveness of dialectical behaviour therapy vs enhanced usual care in the treatment of adolescents with self-harm. Child and Adolescent Psychiatry and Mental Health2018;12:22. [DOI: 10.1186/s13034-018-0227-2] [PMC5928596] [PMID: 29743941]MehlumL , RambergM , TørmoenAJ , HagaE , DiepLM , StanleyBH , et al. Dialectical behavior therapy compared with enhanced usual care for adolescents with repeated suicidal and self-harming behavior: outcomes over a one-year follow-up. Journal of the American Academy of Child and Adolescent Psychiatry2016;55(4):295-300. [DOI: 10.1016/j.jaac.2016.01.005] [PMID: 27015720]MehlumL , TørmoenAJ , RambergM , HagaE , DiepLM , LabergS , et al. Dialectical behavior therapy for adolescents with repeated suicidal and self-harming behavior: a randomized trial. Journal of the American Academy of Child and Adolescent Psychiatry2014;53(10):1082-91. [DOI: 10.1016/j.jaac.2014.07.003] [PMID: 25245352]MehlumL . Re: regarding your study of DBT for your with suicidal behavior [personal communication] [Re: angående din studie om DBT for ungdom med selvmordsatferd [personlig kommunikation]]. Email to: E Faltinsen 5 December 2017. NCT00675129. Treatment for adolescents with deliberate self harm [A randomized controlled trial for repetitive deliberate self-harm and suicidal behaviours among Norwegian adolescents: a comparison between dialectical behaviour therapy adapted for adolescents (DBT-A) and enhanced usual care (EUC)]. www.clinicaltrials.gov/ct2/show/NCT00675129 (first received 6 May 2008). RamlethRK , GroholtB , DiepLM , WalbyFA , MehlumL . The impact of borderline personality disorder and sub-threshold borderline personality disorder on the course of self-reported and clinician-rated depression in self-harming adolescents. Borderline Personality Disorder and Emotion Dysregulation2017;4:22. [DOI: 10.1186/s40479-017-0073-5] [PMC5663078] [PMID: 29093819]">Mehlum 2014</a>; <a href="./references#CD012955-bbs2-0053" title="MohamadizadehL , MakvandiB , PashaR , BakhtiarpourS , HafeziF . Comparing of the effect of dialectical behavior therapy (DBT) and schema therapy (ST) on reducing mood activity and suicidal thoughts in patients with borderline personality disorder. Acta Medica Mediterranea2017;33:1025-31. [DOI: 10.19193/0393-6384_2017_6_162] [www.actamedicamediterranea.com/archive/2017/medica-6/comparing-of-the-effect-of-dialectical-behavior-therapy-dbt-and-schema-therapy-st-on-reducing-mood-activity-and-suicidal-thoughts-in-patients-with-borderline-personality-disorder/pdf]">Mohamadizadeh 2017</a>; <a href="./references#CD012955-bbs2-0054" title="MoreyLC , LowmasterSE , HopwoodCJ . A pilot study of manual-assisted cognitive therapy with a therapeutic assessment augmentation for borderline personality disorder. Psychiatry Research2010;178(3):531-5. [DOI: 10.1016/j.psychres.2010.04.055] [PMID: 20537722]">Morey 2010</a>; <a href="./references#CD012955-bbs2-0055" title="MortonJ , SnowdonS , GopoldM , GuymerE . Acceptance and commitment therapy group treatment for symptoms of borderline personality disorder: a public sector pilot study. Cognitive and Behavioral Practice2012;19(4):527-44. [DOI: 10.1016/j.cbpra.2012.03.005]MortonJ . Re: SV: regarding your study on acceptance and commitment therapy for BPD [personal communication]. Email to: EG Faltinsen 22 December 2017. ">Morton 2012</a>; <a href="./references#CD012955-bbs2-0057" title="NCT02033044. Cognitive rehabilitation versus psychoeducation in psychosocial functioning of borderline personality disorder [Randomized controlled trial comparing the effects on psychosocial functioning of cognitive rehabilitation versus psychoeducation in borderline personality disorder]. www.clinicaltrials.gov/ct2/show/NCT02033044 (first received 23 December 2013). PascualJC , PalomaresN , Ibáñez Á, PortellaMJ , ArzaR , ReyesR , et al. Efficacy of cognitive rehabilitation on psychosocial functioning in borderline personality disorder: a randomized controlled trial. BMC Psychiatry2015;15:255. [DOI: 10.1186/s12888-015-0640-5] [PMC4617906] [PMID: 26487284]">Pascual 2015</a>; <a href="./references#CD012955-bbs2-0059" title="BarnicotK . Re: Regarding your study on DBT for self-harming patients [personal communication]. Email to: EG Faltinsen 28 February 2018. PriebeS , BhattiN , BarnicotK , BremnerS , GagliaA , KatsakouC , et al. Effectiveness and cost-effectiveness of dialectical behaviour therapy for self-harming patients with personality disorder: a pragmatic randomised controlled trial. Psychotherapy and Psychosomatics2012;81(6):356-65. [DOI: 10.1159/000338897] [PMID: 22964561]PriebeS . Supplemental information [personal communication]. Email to: M Kielsholm 20 May 2016. ">Priebe 2012</a>; <a href="./references#CD012955-bbs2-0060" title="RenesesB , FigueraD , SalcedoG , TrujilloM , López-IborJJ , GaliánM , et al. A controlled randomized study on the efficacy of short-term dinamic psychotherapy in borderline personality disorders (BPD). Preliminary results. European Psychiatry2011;26(Suppl 1):1040. [DOI: 10.1016/S0924-9338(11)72745-6] [P02-444]RenesesB , GaliánM , SerranoR , FigueraD , Fernandez Del MoralA , López-IborJJ , et al. A new time limited psychotherapy for BPD: preliminary results of a randomized and controlled trial. Actas Espanolas de Psiquiatria2013;41(3):139-48. [PMID: 23803797]">Reneses 2013</a>; <a href="./references#CD012955-bbs2-0063" title="SalzerS , CroppC , JaegerU , MasuhrO , Streeck-FischerA . Psychodynamic therapy for adolescents suffering from co-morbid disorders of conduct and emotions in an in-patient setting: a randomized controlled trial. Psychological Medicine2014;44(10):2213-22. [DOI: 10.1017/S003329171300278X] [PMID: 24229481]SalzerS , Streeck-FischerA . The psychoanalytic-interactional method (PiM) for adolescents with borderline personality disorder [Die psychoanalytisch-interaktionelle methode (PiM) für adoleszente mit borderline-persönlichkeitsstörung]. Personlichkeitsstorungen Theorie und Therapie2015;19(1):67-76. [elibrary.klett-cotta.de/article/99.120110/ptt-19-1-67]SalzerS . AW: Re: Cochrane Review on psychotherapies for BPD - RCT testing PiM vs WL [personal communication] [AW:Re: Cochrane Review zur Psychotherapie bei BPS - RCT zu PiM vs WL [persönliche kommunikation]]. Email to: J Stoffers-Winterling 15 July 2018. ">Salzer 2014</a>; <a href="./references#CD012955-bbs2-0064" title="SantistebanDA , MenaMP , MuirJ , McCabeBE , AbaloC , CummingsAM . The efficacy of two adolescent substance abuse treatments and the impact of comorbid depression: results of a small randomized controlled trial. Psychiatric Rehabilitation Journal2015;38(1):55-64. [DOI: 10.1037/prj0000106] [PMC5021542] [PMID: 25799306]">Santisteban 2015</a>; <a href="./references#CD012955-bbs2-0065" title="SchillingL , MoritzS , KötherU , NagelM . Preliminary results on acceptance, feasibility, and subjective efficacy of the add-on group intervention metacognitive training for borderline patients. Journal of Cognitive Psychotherapy2015;29(2):153-64. [DOI: 10.1891/0889-8391.29.2.153]SchillingL , MoritzS , KristonL , KriegerM , NagelM . Efficacy of metacognitive training for patients with borderline personality disorder: preliminary results. Psychiatry Research2018;262:459-64. [DOI: 10.1016/j.psychres.2017.09.024] [PMID: 28927866]SchillingL . Re Schilling 2015/2018 - Cochrane Review of psychotherapies for BPD [personal communication] [Re Schilling 2015/2018 - Cochrane Review zur Psychotherapie bei BPS [persönliche Kommunikation]]. Email to: J Stoffers-Winterling 22 January 2019. ">Schilling 2018</a>; <a href="./references#CD012955-bbs2-0069" title="SolerJ , PascualJC , TianaT , CebriàA , BarrachinaJ , CampinsMJ , et al. Dialectical behaviour therapy skills training compared to standard group therapy in borderline personality disorder: a 3-month randomised controlled clinical trial. Behaviour Research and Therapy2009;47(5):353-8. [DOI: 10.1016/j.brat.2009.01.013] [PMID: 19246029]SolerJ . Question regarding your BPD trials [personal communication]. Email to: J Stoffers 15 December 2010. ">Soler 2009</a>; <a href="./references#CD012955-bbs2-0071" title="TurnerRM . Naturalistic evaluation of dialectical behavior therapy-oriented treatment for borderline personality disorder. Cognitive and Behavioral Practice2000;7(4):413-9. [DOI: 10.1016/S1077-7229(00)80052-8]">Turner 2000</a>; <a href="./references#CD012955-bbs2-0072" title="Van den BoschLM , KoeterMW , StijnenT , VerheulR , Van den BrinkW . Sustained efficacy of dialectical behaviour therapy for borderline personality disorder. Behaviour Research and Therapy2005;43(9):1231-41. [DOI: 10.1016/j.brat.2004.09.008] [PMID: 16005708]Van den BoschLM , VerheulR , SchippersGM , Van den BrinkW . Dialectical behavior therapy of borderline patients with and without substance use problems. Implementation and long-term effects. Addictive Behaviors2002;27(6):911-23. [DOI: 10.1016/s0306-4603(02)00293-9] [PMID: 12369475]Van den BoschLMC . Efficacy of dialectical behaviour therapy in the treatment of female borderline patients with and without substance abuse problems: results of a Dutch study [Dialectische gedragstherapie bij Nederlandse vrouwen met een borderline persoonlijkheidsstoornis, met en zonder verslavingsproblemen]. Tijdschrift voor Psychiatrie2005;47(3):127-37. [www.tijdschriftvoorpsychiatrie.nl/assets/articles/articles_1335pdf.pdf]VerheulR , Van den BoschLM , KoeterMW , De RidderMA , StijnenT , Van den BrinkW . Dialectical behaviour therapy for women with borderline personality disorder: 12-month, randomised clinical trial in The Netherlands. British Journal of Psychiatry2003;182:135-40. [DOI: 10.1192/bjp.182.2.135] [PMID: 12562741]">Van den Bosch 2005</a>; <a href="./references#CD012955-bbs2-0074" title="ZanariniMC , FrankenburgFR . A preliminary, randomized trial of psychoeducation for women with borderline personality disorder. Journal of Personality Disorders2008;22(3):284-90. [DOI: 10.1521/pedi.2008.22.3.284] [PMID: 18540800]ZanariniMC , FrankenburgFR . A randomized trial of psychoeducation for patients with BPD. In: 157th annual meeting of the American Psychiatric Association. Psychotherapy and psychopharmacology: dissolving the mind-brain barrier; 2004 May 1-6; New York (NY). Arlington (VA): American Psychiatric Association, 2004:102. [Symposium 100E] [www.psychiatry.org/File%20Library/Psychiatrists/Directories/Library-and-Archive/conference_publications/am_program_2004.pdf]">Zanarini 2008</a>). Seventeen trials did not explicitly report data for prespecified outcomes even though they initially had planned to report them. We considered these trials to be at high risk of bias (<a href="./references#CD012955-bbs2-0002" title='AndreoliA , BurnandY , CochennecMF , MarieD , Di ClementeT , OhlendorfP . Psychoanalytic psychotherapy and venlafaxine among acutely suicidal borderline patients: a randomized clinical study. European Psychiatry2009;24(Suppl 1):S93. [DOI: 10.1016/S0924-9338(09)70326-8] [S18-03]AndreoliA , BurnandY , CochennecMF , OhlendorfP , FrambatiL , Gaudry-MaireD , et al. Disappointed love and suicide: a randomized controlled trial of "abandonment psychotherapy" among borderline patients. Journal of Personality Disorders2016;30(2):271-87. [DOI: 10.1521/pedi_2015_29_196] [PMID: 26111250]AndreoliA , BurnandY , FrambatiL , ManningD , FrancesA . Abandonment psychotherapy and psychosocial functioning among suicidal patients with borderline personality disorder: a 3-year naturalistic follow-up. Journal of Personality Disorders 2019 Feb 20 [Epub ahead of print]. [DOI: 10.1521/pedi_2019_33_423] [PMID: 30785852]AndreoliA . Re: your study in BPD - Cochrane Collaboration review [personal communication]. Email to: J Stoffers-Winterling 5 June 2018. '>Andreoli 2016</a>; <a href="./references#CD012955-bbs2-0003" title="AntonsenBT , JohansenMS , RøFG , KvarsteinEH , WilbergT . Is reflective functioning associated with clinical symptoms and long-term course in patients with personality disorders?Comprehensive Psychiatry2016;64:46-58. [DOI: 10.1016/j.comppsych.2015.05.016] [PMID: 26104432]AntonsenBT , KlungsøyrO , KampsA , HummelenB , JohansenMS , PedersenG , et al. Step-down versus outpatient psychotherapeutic treatment for personality disorders: 6-year follow-up of the Ullevål personality project. BMC Psychiatry2014;14:119. [DOI: 10.1186/1471-244X-14-119] [PMC4000615] [PMID: 24758722]AntonsenBT , KvarsteinEH , Urnes Ø, HummelenB , KarterudS , WilbergT . Favourable outcome of long-term combined psychotherapy for patients with borderline personality disorder: six-year follow-up of a randomized study. Psychotherapy Research2017;27(1):51-63. [DOI: 10.1080/10503307.2015.1072283] [PMID: 26261865]ArnevikE , WilbergT , Urnes Ø, JohansenM , MonsenJT , KarterudS . Psychotherapy for personality disorders: short-term day hospital psychotherapy versus outpatient individual therapy - a randomized controlled study. European Psychiatry2009;24(2):71-8. [DOI: 10.1016/j.eurpsy.2008.09.004] [PMID: 19097870]GullestadFS , JohansenMS , HøglendP , KarterudS , WilbergT . Mentalization as a moderator of treatment effects: findings from a randomized clinical trial for personality disorders. Psychotherapy Research2013;23(6):674-89. [DOI: 10.1080/10503307.2012.684103] [PMID: 22612470]GullestadFS . Re: questions regarding your trial on day hospital step-down program [personal communication]. Email to: E Faltinsen 4 December 2017. KvarsteinEH , ArnevikE , HalsteinliV , RøFG , KarterudS , WilbergT . Health service costs and clinical gains of psychotherapy for personality disorders: a randomized controlled trial of day-hospital-based step-down treatment versus outpatient treatment at a specialist practice. BMC Psychiatry2013;13:315. [DOI: 10.1186/1471-244X-13-315] [PMC4222503] [PMID: 24268099]">Antonsen 2017</a>; <a href="./references#CD012955-bbs2-0010" title="BlackD . Question regarding your BPD trial [personal communication]. Email to: J Stoffers 04 January 2011. BlackDW , AllenJ , McCormickB , BlumN . Treatment received by persons with BPD participating in a randomized clinical trial of the systems training for emotional predictability and problem solving programme. Personality and Mental Health2011;5(3):159-68. [DOI: 10.1002/pmh.167]BlackDW , AllenJ , St JohnD , PfohlB , McCormickB , BlumN . Predictors of response to systems training for emotional predictability and problem solving (STEPPS) for borderline personality disorder: an exploratory study. Acta Psychiatrica Scandinavica2009;120(1):53-61. [DOI: 10.1111/j.1600-0447.2008.01340.x] [PMC3665337] [PMID: 19183126]BlackDW , BlumN , PfohlB , St JohnD . The STEPPS group treatment program for outpatients with borderline personality disorder. Journal of Contemporary Psychotherapy2004;34(3):193-210. [DOI: 10.1023/B:JOCP.0000036630.25741.83]BlackDW , PfohlBM . Randomized clinical trial of STEPPS versus treatment as usual. In: 158th annual meeting of the American Psychiatric Association. Psychosomatic medicine: integrating psychiatry &amp; medicine; 2005 May 21-26; Atlanta (GA). Arlington (VA): American Psychiatric Association, 2005:104. [No. 1B] [www.psychiatry.org/File%20Library/Psychiatrists/Directories/Library-and-Archive/syllabus/am_syllabus_2005.pdf]BlackDW , Simsek-DuranF , BlumN , McCormickB , AllenJ . Do people with borderline personality disorder complicated by antisocial personality disorder benefit from the STEPPS treatment program?Personality and Mental Health2016;10(3):205-15. [DOI: 10.1002/pmh.1326] [PMC4911327] [PMID: 26671625]BlackDW . RE: [external] questions regarding your trial on the STEPPS program for BPD [personal communication]. Email to: EG Faltinsen 27 November 2017. BlumN , AllenJ , McCormickB , BlackDW . Ms Blum and colleagues reply [to Schulte-Herbrüggen O, Koerting J, Roepke S. Effectiveness of adjunctive STEPPS group treatment in borderline personality disorder patients. American Journal of Psychiatry 2008;165(10):1354-5. DOI: 10.1176/appi.ajp.2008.08030390]. American Journal of Psychiatry2008;165(10):1354-5. [DOI: 10.1176/appi.ajp.2008.08030390r]BlumN , FranklinJ , HanselR , McCormickB , St JohnD , PfohlB , et al. Relationship of age to symptom severity, psychiatric comorbidity and health care utilization in persons with borderline personality disorder. Personality and Mental Health2008;2(1):25-43. [DOI: 10.1002/pmh.26]BlumN , St JohnD , PfohlB , StuartS , McCormickB , AllenJ , et al. Erratum. American Journal of Psychiatry2008;165(6):777. Erratum for: American Journal of Psychiatry 2008;165(4):468-78. [psycnet.apa.org/record/2008-07854-033]BlumN , St JohnD , PfohlB , StuartS , McCormickB , AllenJ , et al. Systems training for emotional predictability and problem solving (STEPPS) for outpatients with borderline personality disorder: a randomized controlled trial and 1-year follow-up. American Journal of Psychiatry2008;165(4):468-78. [DOI: 10.1176/appi.ajp.2007.07071079] [PMC3608469] [PMID: 18281407]DavidsonKM . Borderline personality disorder: STEPPS improves symptoms. Evidence-Based Mental Health2008;11(4):120. [DOI: 10.1136/ebmh.11.4.120] [PMID: 18952969]NCT00055315. Treatment for borderline personality disorder [A cognitive group treatment for borderline outpatients]. clinicaltrials.gov/ct2/show/NCT00055315 (first received 25 February 2003). ">Blum 2008</a>; <a href="./references#CD012955-bbs2-0025" title="GleesonJF , ChanenA , CottonSM , PearceT , NewmanB , McCutcheonL . Treating co-occurring first-episode psychosis and borderline personality: a pilot randomized controlled trial. Early Intervention in Psychiatry2012;6(1):21-9. [DOI: 10.1111/j.1751-7893.2011.00306.x] [PMID: 22379625]GleesonJFM . RE: separate data [personal communication]. Email to: M Kielsholm 28 October 2016. ">Gleeson 2012</a>; <a href="./references#CD012955-bbs2-0029" title="HaeyenS , Van HoorenS , HutschemaekersG . Efficacy of art therapy in individuals with personality disorders cluster B/C: a randomised controlled trial. International Journal of Psychology July 2016;51:60. [DOI: 10.1521/pedi_2017_31_312] [PMID: 28926306]HaeyenS , Van HoorenS , Van der VeldW , HutschemaekersG . Efficacy of art therapy in individuals with personality disorders cluster B/C: a randomised controlled trial. Journal of Personality Disorders2018;32(4):527-42. [DOI: 10.1521/pedi_2017_31_312] [PMID: 28926306]HaeyenS . Re: Cochrane Collaboration review of psychotherapies for BPD - your RCT of art therapy [personal communication]. Email to: J Stoffers-Winterling 18 August 2018. ">Haeyen 2018</a>; <a href="./references#CD012955-bbs2-0036" title="KramerU , BergerT , KollyS , MarquetP , PreisigM , De RotenY , et al. Effects of motive-oriented therapeutic relationship in early-phase treatment of borderline personality disorder: a pilot study of a randomized trial. Journal of Nervous and Mental Disease2011;199(4):244-50. [DOI: 10.1097/NMD.0b013e3182125d19] [PMID: 21451348]KramerU , CasparF , DrapeauM . Change in biased thinking in a 10-session treatment for borderline personality disorder: further evidence of the motive-oriented therapeutic relationship. Psychotherapy Research2013;23(6):633-45. [DOI: 10.1080/10503307.2013.791404] [PMID: 23631622]">Kramer 2011</a>; <a href="./references#CD012955-bbs2-0037" title="BerthoudL , KramerU , CasparF , Pascual-LeoneA . Emotional processing in a ten-session general psychiatric treatment for borderline personality disorder: a case study. Personality and Mental Health2015;9(1):73-8. [DOI: 10.1002/pmh.1287] [PMID: 25711648]BerthoudL , Pascual-LeoneA , CasparF , TissotH , KellerS , RohdeKB , et al. Leaving distress behind: a randomized controlled study on change in emotional processing in borderline personality disorder. Psychiatry2017;80(2):139-54. [DOI: 10.1080/00332747.2016.1220230] [PMID: 28767333]KellerS , StelmaszczykK , KollyS , De RotenY , DesplandJN , CasparF , et al. Change in biased thinking in a treatment based on the motive-oriented therapeutic relationship for borderline personality disorder. Journal of Personality Disorders2018;32(Suppl):75-92. [DOI: 10.1521/pedi.2018.32.supp.75] [PMID: 29388899]KramerU , FlückigerC , KollyS , CasparF , MarquetP , DesplandJN , et al. Unpacking the effects of therapist responsiveness in borderline personality disorder: motive-oriented therapeutic relationship, patient in-session experience, and the therapeutic alliance. Psychotherapy and Psychosomatics2014;83(6):386-7. [DOI: 10.1159/000365400] [PMID: 25324025]KramerU , KellerS , CasparF , De RotenY , DesplandJN , KollyS . Early change in coping strategies in responsive treatments for borderline personality disorder: a mediation analysis. Journal of Consulting and Clinical Psychology2017;85(5):530-5. [DOI: 10.1037/ccp0000196] [PMID: 28425747]KramerU , KollyS , BerthoudL , KellerS , PreisigM , CasparF , et al. Effects of motive-oriented therapeutic relationship in a ten-session general psychiatric treatment of borderline personality disorder: a randomized controlled trial. Psychotherapy and Psychosomatics2014;83(3):176-86. [DOI: 10.1159/000358528] [PMID: 24752034]KramerU , StulzN , BerthoudL , CasparF , MarquetP , KollyS , et al. The shorter the better? A follow-up analysis of 10-session psychiatric treatment including the motive-oriented therapeutic relationship for borderline personality disorder. Psychotherapy Research2017;27(3):362-70. [DOI: 10.1080/10503307.2015.1110635] [PMID: 26684670]NCT01896024. Effects of motive-oriented therapeutic relationship in the early-phase treatment of borderline personality disorder (MOTR). www.clinicaltrials.gov/ct2/show/NCT01896024 (first received 5 July 2013). ">Kramer 2014</a>; <a href="./references#CD012955-bbs2-0041" title="LaurenssenEM , WestraD , KikkertMJ , NoomMJ , EerenHV , Van BroekhuyzenAJ , et al. Day hospital mentalization-based treatment (MBT-DH) versus treatment as usual in the treatment of severe borderline personality disorder: protocol of a randomized controlled trial. BMC Psychiatry2014;14:149. [DOI: 10.1186/1471-244X-14-149] [PMC4045960] [PMID: 24886402]LaurenssenEMP , LuytenP , KikkertMJ , WestraD , PeenJ , SoonsMBJ , et al. Day hospital mentalization-based treatment v specialist treatment as usual in patients with borderline personality disorder: randomized controlled trial. Psychological Medicine2018;48(15):2522-9. [DOI: 10.1017/S0033291718000132] [PMID: 29478425]NL2058 (NTR2175). Mentalisation-based treatment versus care-as-usual in the treatment of severe borderline personality disorders. www.trialregister.nl/trial/2058 (first received 21 January 2010). ">Laurenssen 2018</a>; <a href="./references#CD012955-bbs2-0042" title="LeichsenringF , MasuhrO , JaegerU , RabungS , DallyA , DümpelmannM , et al. Psychoanalytic-interactional therapy versus psychodynamic therapy by experts for personality disorders: a randomized controlled efficacy-effectiveness study in cluster B personality disorders. Psychotherapy and Psychosomatics2016;85(2):71-80. [DOI: 10.1159/000441731] [PMID: 26808580]">Leichsenring 2016</a>; <a href="./references#CD012955-bbs2-0044" title="Lin T-J, Ko H-C, Wu JY-W, OeiTP , Lane H-Y, Chen C-H. The effectiveness of dialectical behavior therapy skills training group vs cognitive therapy group on reducing depression and suicide attempts for borderline personality disorder in Taiwan. Archives of Suicide Research2019;23(1):82-99. [DOI: 10.1080/13811118.2018.1436104] [PMID: 29528807]">Lin 2019</a>; <a href="./references#CD012955-bbs2-0048" title="LinehanMM , KorslundKE , HarnedMS , GallopRJ , LunguA , NeacsiuAD , et al. Dialectical behavior therapy for high suicide risk in individuals with borderline personality disorder: a randomized clinical trial and component analysis. JAMA Psychiatry2015;72(5):475-82 Erratum for: JAMA Psychiatry 2015; 72(9): 951. [DOI: 10.1001/jamapsychiatry.2014.3039] [PMID: 25806661]NCT00183651. Treatment of suicidal women with borderline personality disorder [Assessment and treatment of parasuicidal patients]. www.clinicaltrials.gov/ct2/show/NCT00183651 (first received 13 September 2005). ">Linehan 2015a</a>; <a href="./references#CD012955-bbs2-0058" title="PhilipsB , WennebergP , KonradssonP , FranckJ . Mentalization-based treatment for concurrent borderline personality disorder and substance use disorder: a randomized controlled feasibility study. European Addiction Research2018;24(1):1-8. [DOI: 10.1159/000485564] [PMC5969093] [PMID: 294028]">Philips 2018</a>; <a href="./references#CD012955-bbs2-0062" title="ISRCTN95266816. The emergence of personality disorder traits in adolescents who deliberately self harm and the potential for using a mentalisation based treatment approach as an early intervention for such individuals: a randomised controlled trial. www.isrctn.com/ISRCTN95266816 (first received 29 October 2007). RossouwT . Mentalisation based treatment for adolescents with self harm: an RCT. European Child &amp; Adolescent Psychiatry2015;24(1 Suppl):S113. [DOI: 10.1007%2Fs00787-015-0714-4.pdf] [W1-02-02]RossouwT . Self harm in adolescence, is MBT the answer?: an RCT. Adolescent Psychiatry2012;2(1):102. [DOI: 10.2174/2210676611202010077]RossouwTI , FonagyP . Mentalization-based treatment for self-harm in adolescents: a randomized controlled trial. Journal of the American Academy of Child and Adolescent Psychiatry2012;51(12):1304-13.e3. [DOI: 10.1016/j.jaac.2012.09.018] [PMID: 23200287]">Rossouw 2012b</a>; <a href="./references#CD012955-bbs2-0066" title="ISRCTN97589104. Evaluation of a group training for adolescents (emotion regulation training) with emotion regulation problems - a randomised controlled clinical trial. www.isrctn.com/ISRCTN97589104 (first received 23 August 2007). SchuppertHM , TimmermanME , BlooJ , Van GemertTG , WiersemaHM , MinderaaRB , et al. Emotion regulation training for adolescents with borderline personality disorder traits: a randomized controlled trial. Journal of the American Academy of Child &amp; Adolescent Psychiatry2012;51(12):1314-23. [DOI: 10.1016/j.jaac.2012.09.002] [PMID: 23200288]">Schuppert 2012</a>; <a href="./references#CD012955-bbs2-0067" title="NCT01904227. Intensified, inpatient adaptation of dialectical behavior therapy (DBT) (REDBT) [A randomized controlled study of the efficacy of an intensified, inpatient adaptation of dialectical behavior therapy (DBT) for a population of borderline patients (young adults/adults: 18-40), compared with standard outpatient DBT]. www.clinicaltrials.gov/ct2/show/NCT01904227 (first received 11 July 2013). SinnaeveR , Van den BoschLM , Van Steenbergen-WeijenburgKM . Change in interpersonal functioning during psychological interventions for borderline personality disorder — a systematic review of measures and efficacy. Personality and Mental Health2015;9(3):173-94. [DOI: 10.1002/pmh.1296] [PMID: 26058794]SinnaeveR , Van den BoschLMC , Hakkaart-van RoijenL , VansteelandtK . Effectiveness of step-down versus outpatient dialectical behaviour therapy for patients with severe levels of borderline personality disorder: a pragmatic randomized controlled trial. Borderline Personality Disorder and Emotion Dysregulation2018;5:12. [DOI: 10.1186/s40479-018-0089-5] [PMC6040072] [PMID: 30002832]SinnaeveR . Cochrane Collaboration review [personal communication]. Email to: J Stoffers-Winterling 11 June 2018. SinnaeveR . Re: BPDSI subscale data Sinnaeve et al (2018) [personal communication]. Email to: A Tadorovac 15 November 2018. SinnaeveR . RE: BPDSI subscale data Sinnaeve et al (2018) [personal communication] [RE: BPDSI subschale data Sinnaeve et al (2018) [personlig kommunikation]]. Email to: A Todorovac 15 November 2018. SinnaeveR . RE: BPDSI subscale data Sinnaeve et al (2018) [personal communication] [RE: BPDSI subschale data Sinnaeve et al (2018) [personlig kommunikation]]. Email to: A Todorovac 9 October 2018. Van den BoschLM , SinnaeveR , Hakkaart-van RoijenL , Van FurthEF . Efficacy and cost-effectiveness of an experimental short-term inpatient dialectical behavior therapy (DBT) program: study protocol for a randomized controlled trial. Trials2014;15:152. [DOI: 10.1186/1745-6215-15-152] [PMC4017823] [PMID: 24885551]Van RoijenLH , SinnaeveR , BouwmansC , Van Den BoschL . Cost-effectiveness and cost-utility of shortterm inpatient dialectical behavior therapy for chronically parasuicidal BPD (young) adults. Journal of Mental Health Policy and Economics2015;18(Suppl 1):S19-20. [www.icmpe.org/test1/journal/issues/v18s1toc.html]">Sinnaeve 2018</a>; <a href="./references#CD012955-bbs2-0068" title="SmithPN , GambleSA , CortNA , WardEA , HeH , TalbotNL . Attachment and alliance in the treatment of depressed, sexually abused women. Depression and Anxiety2012;29(2):123-30. [DOI: 10.1002/da.20913] [PMC3325338] [PMID: 22065593]SmithPN . Re: Cochrane Collaboration review of psychotherapies for BPD [personal communication]. Email to: J Stoffers-Winterling 05 July 2018. ">Smith 2012</a>; <a href="./references#CD012955-bbs2-0075" title="ZanariniMC , ConkeyLC , TemesCM , FitzmauriceGM . Randomized controlled trial of web-based psychoeducation for women with borderline personality disorder. Journal of Clinical Psychiatry2018;79(3):16m11153. [DOI: 10.4088/JCP.16m11153] [PMC5764827] [PMID: 28703950]">Zanarini 2018</a>). We rated 19 trials at low risk of bias due to the fact that they had published a protocol or registered the trial before conducting the trial, and reported all prespecified outcomes (<a href="./references#CD012955-bbs2-0001" title="AmiantoF , FerreroA , PieròA , CairoE , RoccaG , SimonelliB , et al. Supervised team management, with or without structured psychotherapy, in heavy users of a mental health service with borderline personality disorder: a two-year follow-up preliminary randomized study. BMC Psychiatry2011;11:181. [DOI: 10.1186/1471-244X-11-181] [PMC3260092 ] [PMID: 22103890]NCT01356069. Efficacy of time-limited psychodynamic psychotherapy and informed clinical management in BPD high MHS users (HUMSH) [Sequential brief Adlerian psychodynamic psychotherapy in heavy users of a mental health service with borderline personality disorder: a two years follow-up preliminary randomized study]. clinicaltrials.gov/ct2/show/NCT01356069 (first received 16 May 2011). ">Amianto 2011</a>; <a href="./references#CD012955-bbs2-0005" title="BatemanA , FonagyP . Impact of clinical severity on outcomes of mentalisation-based treatment for borderline personality disorder. British Journal of Psychiatry2013;203(3):221-7. [DOI: 10.1192/bjp.bp.112.121129] [PMID: 23887998]BatemanA , FonagyP . Randomized controlled trial of outpatient mentalization-based treatment versus structured clinical management for borderline personality disorder. American Journal of Psychiatry2009;166(12):1355-64. [DOI: 10.1176/appi.ajp.2009.09040539] [PMID: 19833787]BatemanA , FonagyP . Randomized controlled trial of outpatient mentalization-based treatment versus structured clinical management for borderline personality disorder. Supplementary data. ajp.psychiatryonline.org/doi/suppl/10.1176/appi.ajp.2009.09040539/suppl_file/ajp_166_12_1355_01.pdf (accessed 27 February 2020). BatemanA , O'ConnellJ , LorenziniN , GardnerT , FonagyP . A randomised controlled trial of mentalization-based treatment versus structured clinical management for patients with comorbid borderline personality disorder and antisocial personality disorder. BMC Psychiatry2016;16:304. [DOI: 10.1186/s12888-016-1000-9] [PMC5006360] [PMID: 27577562]BatemanA . Important question regarding your BPD trial for systematic review in Cochrane Collaboration [personal communication]. Email to: K Lieb 14 December 2010. BatemanAW . Mentalization, borderline personality disorder and what works for whom? Presentation at the 11th International Congress of the International Society for the Study of Personality Disorders; 2009 Aug 21-23. www.borderlinepersonalitydisorder.com/Conferences/ISSPD/isspd_09_Bateman (accessed 21 April 2010). ISRCTN27660668. Randomised controlled trial of manualised out-patient individual and group therapy for borderline personality disorder [Effectiveness of intensive out-patient psychotherapy for treatment of borderline personality disorder: a pragmatic randomised single blind controlled study]. www.isrctn.com/ISRCTN27660668 (first received 12 October 2008). ">Bateman 2009</a>; <a href="./references#CD012955-bbs2-0011" title="BohusM , DyerAS , PriebeK , KrügerA , KleindienstN , SchmahlC , et al. Dialectical behaviour therapy for post-traumatic stress disorder after childhood sexual abuse in patients with and without borderline personality disorder: a randomised controlled trial. Psychotherapy and Psychosomatics2013;82(4):221-33. [DOI: 10.1159/000348451] [PMID: 23712109]BrandS . AW: questions regarding your trial on emotional intelligence training for BPD [personal communication]. Email to: EG Faltinsen 28 November 2017. DBT Working Group at the Central Institute for Mental Health, Mannheim, Germany. Requested supplementary data (as supplied 1 October 2010). Data on file. NCT00481000. Dialectical cognitive traumatherapy (DCT) on patients with severe PTSD following sexual abuse (PASA) [Dialectical cognitive traumatherapy (DCT) on patients with severe posttraumatic stress disorder following sexual abuse - a randomised controlled trial]. clinicaltrials.gov/ct2/show/NCT00481000 (first received 31 May 2007). SteilR , DyerA , PriebeK , KleindienstN , BohusM . Dialectical behavior therapy for posttraumatic stress disorder related to childhood sexual abuse: a pilot study of an intensive treatment program. Journal of Traumatic Stress2011;24(1):102-6. [DOI: 10.1002/jts.20617] [PMID: 21351167]">Bohus 2013</a>; <a href="./references#CD012955-bbs2-0012" title="BorschmannR , BarrettB , HellierJM , ByfordS , HendersonC , RoseD , et al. Joint crisis plans for people with borderline personality disorder: feasibility and outcomes in a randomised controlled trial. British Journal of Psychiatry2013;202(5):357-64. [DOI: 10.1192/bjp.bp.112.117762] [PMID: 23637110]BorschmannR . Joint crisis plans for BPD - question on publication in British Journal of Psychiatry [pers communication]. Email to: J Stoffers-Winterling 22 August 2017. BorschmannR . RE: joint crisis plans for BPD - question on publication in British Journal of Psychiatry [personal communication]. Email to: J Stoffers-Winterling 22 August 2017. BorschmannR . The development and testing of joint crisis plans for people with borderline personality disorder: a feasibility study. ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.628499 (accessed 27 January 2019). HellierJ . RE: regarding your study on on MBT for eating disorders [personal communication]. Email to: E Faltinsen 27 March 2018. HellierJ . RE: regarding your study on on MBT for eating disorders [personal communication]. Email to: E Faltinsen 3 January 2018. HellierJ . SV: regarding your study on MBT for eating disorders [personal communication]. Email to: EG Faltinsen, P Robinson 27 March 2018. ISRCTN12440268. JOSHUA: a pilot randomised controlled trial of joint crisis plans for people who self harm. www.isrctn.com/ISRCTN12440268 (first received 17 September 2009). ">Borschmann 2013</a>; <a href="./references#CD012955-bbs2-0014" title="Carmona i FarrésC , ElicesM , SolerJ , Domínguez-ClavéE , Pomarol-ClotetE , SalvadorR , et al. Effects of mindfulness training on borderline personality disorder: impulsivity versus emotional dysregulation. Mindfulness2019;10:1243-54. [DOI: 10.1007/s12671-018-1071-4]NCT03363230. Effects of mindfulness training on emotion regulation and impulsivity. www.clinicaltrials.gov/ct2/show/NCT03363230 (first received 30 November 2017). ">Carmona í Farrés 2019</a>; <a href="./references#CD012955-bbs2-0016" title="CottrauxJ , NoteID , BoutitieF , MillieryM , GenouihlacV , YaoSN , et al. Cognitive therapy versus Rogerian supportive therapy in borderline personality disorder. Two-year follow-up of a controlled pilot study. Psychotherapy and Psychosomatics2009;78(5):307-16. [DOI: 10.1159/000229769] [PMID: 19628959]NCT00131781. Cognitive therapy versus supportive therapy in borderline personality disorder. www.clinicaltrials.gov/ct2/show/NCT00131781 (first received 18 August 2005). ">Cottraux 2009</a>; <a href="./references#CD012955-bbs2-0017" title="DavidsonK , LivingstoneS , McArthurK , DicksonL , GumleyA . An integrative complexity analysis of cognitive behaviour therapy sessions for borderline personality disorder. Psychology and Psychotherapy2007;80(Pt 4):513-23. [DOI: 10.1348/147608307X191535] [PMID: 17535542]DavidsonK , NorrieJ , TyrerP , GumleyA , TataP , MurrayH , et al. The effectiveness of cognitive behavior therapy for borderline personality disorder: results from the borderline personality disorder study of cognitive therapy (BOSCOT) trial. Journal of Personality Disorders2006;20(5):450-65. [DOI: 10.1521/pedi.2006.20.5.450] [PMC1852259] [PMID: 17032158]DavidsonK , TyrerP , GumleyA , TataP , NorrieJ , PalmerS , et al. A randomized controlled trial of cognitive behavior therapy for borderline personality disorder: rationale for trial, method, and description of sample. Journal of Personality Disorders2006;20(5):431-49. [DOI: 10.1521/pedi.2006.20.5.431] [PMC1847748] [PMID: 17032157]DavidsonKM , TyrerP , NorrieJ , PalmerSJ , TyrerH . Cognitive therapy v usual treatment for borderline personality disorder: prospective 6-year follow-up. British Journal of Psychiatry2010;197(6):456-62. [DOI: 10.1192/bjp.bp.109.074286] [PMID: 21119151]ISRCTN86177428. Borderline personality disorder study of cognitive therapy trial [A randomised controlled trial of cognitive therapy plus treatment as usual versus treatment as usual in the treatment of borderline personality disorder]. www.isrctn.com/ISRCTN86177428 (first received 22 July 2005). NCT00538135. BOSCOT: a randomised controlled trial of cognitive behavioural therapy in borderline personality disorder [BOSCOT: a randomised control trial of cognitive behavioural therapy plus treatment as usual versus treatment as usual in the treatment of borderline personality disorder]. www.clinicaltrials.gov/ct2/show/NCT00538135 (first received 29 September 2007). NorrieJ , DavidsonK , TataP , GumleyA . Influence of therapist competence and quantity of cognitive behavioural therapy on suicidal behaviour and inpatient hospitalisation in a randomised controlled trial in borderline personality disorder: further analyses of treatment effects in the BOSCOT study. Psychology and Psychotherapy2013;86(3):280-93. [DOI: 10.1111/papt.12004] [PMC4491320] [PMID: 23420622]PalmerS , DavidsonK , TyrerP , GumleyA , TataP , NorrieJ , et al. The cost-effectiveness of cognitive behavior therapy for borderline personality disorder: results from the BOSCOT trial. Journal of Personality Disorders2006;20(5):466-81. [DOI: 10.1521/pedi.2006.20.5.466] [PMC1852260] [PMID: 17032159]">Davidson 2006</a>; <a href="./references#CD012955-bbs2-0019" title="BuchheimA , Hörz-SagstetterS , DoeringS , RentropM , SchusterP , BuchheimP , et al. Change of unresolved attachment in borderline personality disorders: RCT study of transference-focused psychotherapy. Psychotherapy and Psychosomatics2017;86(5):314-6. [DOI: 10.1159/000460257] [PMID: 28903103]DiamondD , LevyKN , ClarkinJF , Fischer-KernM , CainNM , DoeringS , et al. Attachment and mentalization in female patients with comorbid narcissistic and borderline personality disorder. Personality Disorders2014;5(4):428-33. [DOI: 10.1037/per0000065] [PMID: 25314231]DiamondD , YeomansFE , SternB , LevyKN , HörzS , DoeringS , et al. Transference-focused psychotherapy for patients with comorbid narcissistic and borderline personality disorder. Psychoanalytic Inquiry2013;33(6):527-51. [DOI: 10.1080/07351690.2013.815087]DoeringS , HörzS , RentropM , Fischer-KernM , SchusterP , BeneckeC , et al. Transference-focused psychotherapy v treatment by community psychotherapists for borderline personality disorder: randomised controlled trial. British Journal of Psychiatry2010;196(5):389-95. [DOI: 10.1192/bjp.bp.109.070177] [PMID: 20435966]DoeringS . Author's reply [to Kleindienst N, Krumm B, Bohus M. Is transference-focused psychotherapy really efficacious for borderline personality disorder? British Journal of Psychiatry 2011;198(2):156-7. DOI: 10.1192/bjp.198.2.156b]. British Journal of Psychiatry2011;198(2):156-7. [DOI: 10.1192/bjp.198.2.157]DoeringS . Question regarding your BPD trial for systematic review in Cochrane Collaboration [personal communication]. Email to: K Lieb, J Stoffers 10 December 2010. Fischer-KernM , DoeringS , TaubnerS , HörzS , ZimmermannJ , RentropM , et al. Transference-focused psychotherapy for borderline personality disorder: change in reflective function. British Journal of Psychiatry2015;207(2):173-4. [DOI: 10.1192/bjp.bp.113.143842] [PMID: 25999334]KleindienstN , KrummB , BohusM . Is transference-focused psychotherapy really efficacious for borderline personality disorder?British Journal of Psychiatry2011;198(2):156-7. [DOI: 10.1192/bjp.198.2.156b] [PMID: 21282787]LevyKN , MeehanKB , YeomansFE . Transference-focused psychotherapy reduces treatment drop-out and suicide attempters compared with community psychotherapist treatment in borderline personality disorder. Evidence-based Mental Health2010;13(4):119. [DOI: 10.1136/ebmh.13.4.119] [PMID: 21036981]NCT00714311. Efficacy of transference-focused psychotherapy for borderline personality disorder [A randomized-controlled trial of transference-focused psychotherapy vs treatment by experienced community psychotherapists for borderline personality disorder]. www.clinicaltrials.gov/ct2/show/NCT00714311 (first received 9 July 2008). RentropM , MartiusP , BäumlJ , BuchheimP , DöeringS , HörzS . Patients with borderline personality disorder not participating in an RCT: are they different?Psychopathology2010;43(6):369-72. [DOI: 10.1159/000320351] [PMID: 20798576]">Doering 2010</a>; <a href="./references#CD012955-bbs2-0020" title="ElicesM , PascualJC , PortellaMJ , Feliu-SolerA , Martín-BlancoA , CarmonaC , et al. Impact of mindfulness training on borderline personality disorder: a randomized trial. Mindfulness2016;7:584-95. [DOI: 10.1007/s12671-016-0492-1]NCT02397031. Mindfulness and interpersonal effectiveness skills in borderline personality disorder [Randomized, active-controlled, clinical trial comparing effects of mindfulness and interpersonal effectiveness skills in borderline personality disorder]. www.clinicaltrials.gov/ct2/show/NCT02397031 (first received 12 March 2015). SolerJ , ElicesM , PascualJC , Martín-BlancoA , Feliu-SolerA , CarmonaC , et al. Effects of mindfulness training on different components of impulsivity in borderline personality disorder: results from a pilot randomized study. Borderline Personality Disorder and Emotion Dysregulation2016;3:1. [DOI: 10.1186/s40479-015-0035-8] [PMC4709962] [PMID: 26759718]">Elices 2016</a>; <a href="./references#CD012955-bbs2-0028" title="GregoryRJ , ChlebowskiS , KangD , RemenA , SoderbergM . Psychodynamic therapy for borderline personality disorder and co-occurring alcohol use disorders: a newly designed ongoing study. Journal of the American Psychoanalytic Association2006;54(4):1331-4. [DOI: 10.1177/00030651060540040107] [PMID: 17354507]GregoryRJ , ChlebowskiS , KangD , RemenAL , SoderbergMG , StepkovitchJ , et al. A controlled trial of psychodynamic psychotherapy for co-occurring borderline personality disorder and alcohol use disorder. Psychotherapy2008;45(1):28-41. [DOI: 10.1037/0033-3204.45.1.28] [PMID: 22122363]GregoryRJ , DeLucia-DeranjaE , MogleJA . Dynamic deconstructive psychotherapy versus optimized community care for borderline personality disorder co-occuring with alcohol use disorders: a 30-month follow-up. Journal of Nervous and Mental Disease2010;198(4):292-8. [DOI: 10.1097/NMD.0b013e3181d6172d] [PMID: 20386259]GregoryRJ , RemenAL , SoderbergM , Ploutz-SnyderRJ . A controlled trial of psychodynamic psychotherapy for co-occurring borderline personality disorder and alcohol use disorder: six-month outcome. Journal of the American Psychoanalytic Association2009;57(1):199-205. [DOI: 10.1177/00030651090570011006] [PMID: 19270255]NCT00145678. Psychodynamic therapy for co-occurring borderline personality disorder and alcohol use disorder [Psychodynamic therapy for patients With borderline personality disorder and alcohol abuse]. www.clinicaltrials.gov/show/NCT00145678 (first received 1 September 2005). ">Gregory 2008b</a>; <a href="./references#CD012955-bbs2-0030" title="HarnedM . Re: SV: question regarding your trial on brief therapy for attempted suicide [personal communication]. Email to: EG Faltinsen 11 December 2018. HarnedMS , KorslundKE , LinehanMM . A pilot randomized controlled trial of dialectical behavior therapy with and without the dialectical behavior therapy prolonged exposure protocol for suicidal and self-injuring women with borderline personality disorder and PTSD. Behaviour Research and Therapy2014;55:7-17. [DOI: 10.1016/j.brat.2014.01.008] [PMC3987949] [PMID: 24562087]HarnedMS , WilksCR , SchmidtSC , CoyleTN . Improving functional outcomes in women with borderline personality disorder and PTSD by changing PTSD severity and post-traumatic cognitions. Behaviour Research and Therapy2018;103:53-61. [DOI: 10.1016/j.brat.2018.02.002] [PMC5837954] [PMID: 29448136]HarnedMS . RE: questions regarding your trial on brief therapy for attempted suicide [personal communication]. Email to: E Faltinsen 29 November 2017. ">Harned 2014</a>; <a href="./references#CD012955-bbs2-0032" title="JochemsEC , Van der Feltz-CornelisCM , Van DamA , DuivenvoordenHJ , MulderCL . The effects of motivation feedback in patients with severe mental illness: a cluster randomized controlled trial. Neuropsychiatric Disease and Treatment2015;11:3049-64. [DOI: 10.2147/NDT.S95190] [PMC4686323] [PMID: 26715847]JochemsEC . Cochrane Collaboration review on psychotherapies for borderline PD [personal communication]. Email to: EG Faltinsen 2 July 2018. JochemsEC . Re: Cochrane Collaboration review on psychotherapies for borderline PD [personal communication]. Email to: J Stoffers-Winterling 02 July 2018. ">Jochems 2015</a>; <a href="./references#CD012955-bbs2-0049" title="CaseBG . Letter to the editor on 'McMain SF, Links PS, Gnam WH, Guimond T, Cardish RJ, Korman L, et al. A randomized trial of dialectical behavior therapy versus general psychiatric management for borderline personality disorder. American Journal of Psychiatry 2009;166(12):1365-74. DOI: 10.1176/appi.ajp.2009.09010039'. American Journal of Psychiatry2010;167(4):475. [DOI: 10.1176/appi.ajp.2009.09101532] [PMID: 20360332 ]ISRCTN02634417. Hope for chronically suicidal patient: evaluating the clinical and health services impact of dialectical behaviour therapy (DBT) in individuals with borderline personality disorder [Evaluating the clinical and health services impact of dialectical behaviour therapy (DBT) in individuals with borderline personality disorder: a randomised controlled trial]. www.isrctn.com/ISRCTN02634417 (first received 16 November 2005). [DOI: 10.1186/ISRCTN02634417]McMainSF , FitzpatrickS , BoritzT , BarnhartR , LinksP , StreinerDL . Outcome trajectories and prognostic factors for suicide and self-harm behaviors in patients with borderline personaliy disorder following one year of outpatient psychotherapy. Journal of Personality Disorders2018;32(4):497-512. [DOI: 10.1521/pedi_2017_31_309] [PMID: 28910214]McMainSF , LinksPS , GnamWH , GuimondT , CardishRJ , KormanL , et al. A randomized trial of dialectical behavior therapy versus general psychiatric management for borderline personality disorder. American Journal of Psychiatry2009;166(12):1365-74. [DOI: 10.1176/appi.ajp.2009.09010039] [PMID: 19755574]McMainSF . Dr McMain replies to letter to the editor on 'McMain SF, Links PS, Gnam WH, Guimond T, Cardish RJ, Korman L, et al. A randomized trial of dialectical behavior therapy versus general psychiatric management for borderline personality disorder. American Journal of Psychiatry 2009;166(12):1365-74. DOI: 10.1176/appi.ajp.2009.09010039'. American Journal of Psychiatry2010;167(4):475-6. [DOI: 10.1176/appi.ajp.2009.09101532r)]NCT00154154. Hope for the chronically suicidal patient [Hope for the chronically suicidal patient: evaluating the clinical and health services impact of dialectical behaviour therapy in individuals with borderline personality disorder]. www.clinicaltrials.gov/ct2/show/NCT00154154 (first received 7 September 2005). ">McMain 2009</a>; <a href="./references#CD012955-bbs2-0050" title="McMainSF , GuimondT , BarnhartR , HabinskiL , StreinerDL . A randomized trial of brief dialectical behaviour therapy skills training in suicidal patients suffering from borderline disorder. Acta Psychiatrica Scandinavica2017;135(2):138-48. [DOI: 10.1111/acps.12664] [PMID: 27858962]">McMain 2017</a>; <a href="./references#CD012955-bbs2-0051" title="McMurranM , CrawfordMJ , ReillyJ , DelportJ , McCroneP , WhithamD , et al. Psychoeducation with problem-solving (PEPS) therapy for adults with personality disorder: a pragmatic randomised controlled trial to determine the clinical effectiveness and cost-effectiveness of a manualised intervention to improve social functioning. Health Technology Assessment2016;20(52):1-282. [DOI: 10.3310/hta20520]McMurranM . RE: Cochrane Collaboration review - PEPS study [personal communication]. Email to: J Stoffers-Winterling 5 July 2018. McMurranM . Request for data on BPD subjects in the PEPS rcp-study for use a new Cochrane review [personal communication]. Email to: M Kongerslev 7 March 2017. ">McMurran 2016</a>; <a href="./references#CD012955-bbs2-0056" title="NadortM , ArntzA , SmitJH , Giesen-BlooJ , EikelenboomJ , SpinhovenP , et al. Implementation of outpatient schema therapy for borderline personality disorder with versus without crisis support by the therapist outside office hours: a randomized trial. Behaviour Research and Therapy2009;47(11):961-73. [DOI: 10.1016/j.brat.2009.07.013] [PMID: 19698939]NadortM , ArntzA , SmitJH , Giesen-BlooJ , EikelenboomM , SpinhovenP , et al. Implementation of outpatient schema therapy for borderline personality disorder: study design. BMC Psychiatry2009;9:64. [DOI: 10.1186/1471-244X-9-64] [PMC2762959] [PMID: 19807925]NL1680 (NTR1781). Implementation of out-patient schema-focused therapy for borderline personality disorder in regular mental healthcare. www.trialregister.nl/trial/1680 (first received 29 April 2009). ">Nadort 2009</a>; <a href="./references#CD012955-bbs2-0061" title="ISRCTN51304415. Nice OUtcomes for Referrals with Impulsivity, Self Harm and Eating Disorders: the NOURISHED study [A randomised controlled trial of mentalisation based therapy against specialist supportive clinical management in patients with both eating disorders and symptoms of borderline personality disorder]. www.isrctn.com/ISRCTN51304415 (first received 31 January 2011). RobinsonP , BarrettB , BatemanA , HakeemA , HellierJ , LemonskyF , et al. Study protocol for a randomized controlled trial of mentalization based therapy against specialist supportive clinical management in patients with both eating disorders and symptoms of borderline personality disorder. BMC Psychiatry2014;14:51. [DOI: 10.1186/1471-244X-14-51] [PMC3996076] [PMID: 24555511]RobinsonP , HellierJ , BarrettB , BarzdaitieneD , BatemanA , BogaardtA , et al. The NOURISHED randomised controlled trial comparing mentalisation-based treatment for eating disorders (MBT-ED) with specialist supportive clinical management (SSCM-ED) for patients with eating disorders and symptoms of borderline personality disorder. Trials2016;17(1):549. [DOI: 10.1186/s13063-016-1606-8] [PMC5114835] [PMID: 27855714]">Robinson 2016</a>; <a href="./references#CD012955-bbs2-0070" title="FertuckEA , KeilpJ , SongI , MorrisMC , WilsonST , BrodskyBS , et al. Higher executive control and visual memory performance predict treatment completion in borderline personality disorder. Psychotherapy and Psychosomatics2012;81(1):38-43. [DOI: 10.1159/000329700] [PMC3242704] [PMID: 22116411]NCT00533117. Treating suicidal behavior and self-mutilation in people with borderline personality disorder. www.clinicaltrials.gov/ct2/show/NCT00533117 (first received 19 September 2007). ">Stanley 2017</a>; <a href="./references#CD012955-bbs2-0073" title="WeinbergI , GundersonJG , HennenJ , Cutter CJ Jr. Manual assisted cognitive treatment for deliberate self-harm in borderline personality disorder patients. Journal of Personality Disorders2006;20(5):482-92. [DOI: 10.1521/pedi.2006.20.5.482] [PMID: 17032160]WilbergT . SV: separate data [personal communication] [SV: separat data [personlig kommunikation]]. Email to: M Kielsholm 25 May 2016. ">Weinberg 2006</a>). </p> </section> <section id="CD012955-sec-0075"> <h4 class="title">Other potential sources of bias</h4> <p>Other sources of bias included insufficient treatment adherence, allegiance bias and attention bias. The total score for this outcome was based on the highest score of bias. A detailed description of which domains are critical for the individual trials can be found in the <a href="./references#CD012955-sec-0637" title="">Characteristics of included studies</a> tables. </p> <p>Most trials (48 trials) exhibited high risk of bias in one or more of the assessed domains (<a href="./references#CD012955-bbs2-0001" title="AmiantoF , FerreroA , PieròA , CairoE , RoccaG , SimonelliB , et al. Supervised team management, with or without structured psychotherapy, in heavy users of a mental health service with borderline personality disorder: a two-year follow-up preliminary randomized study. BMC Psychiatry2011;11:181. [DOI: 10.1186/1471-244X-11-181] [PMC3260092 ] [PMID: 22103890]NCT01356069. Efficacy of time-limited psychodynamic psychotherapy and informed clinical management in BPD high MHS users (HUMSH) [Sequential brief Adlerian psychodynamic psychotherapy in heavy users of a mental health service with borderline personality disorder: a two years follow-up preliminary randomized study]. clinicaltrials.gov/ct2/show/NCT01356069 (first received 16 May 2011). ">Amianto 2011</a>; <a href="./references#CD012955-bbs2-0002" title='AndreoliA , BurnandY , CochennecMF , MarieD , Di ClementeT , OhlendorfP . Psychoanalytic psychotherapy and venlafaxine among acutely suicidal borderline patients: a randomized clinical study. European Psychiatry2009;24(Suppl 1):S93. [DOI: 10.1016/S0924-9338(09)70326-8] [S18-03]AndreoliA , BurnandY , CochennecMF , OhlendorfP , FrambatiL , Gaudry-MaireD , et al. Disappointed love and suicide: a randomized controlled trial of "abandonment psychotherapy" among borderline patients. Journal of Personality Disorders2016;30(2):271-87. [DOI: 10.1521/pedi_2015_29_196] [PMID: 26111250]AndreoliA , BurnandY , FrambatiL , ManningD , FrancesA . Abandonment psychotherapy and psychosocial functioning among suicidal patients with borderline personality disorder: a 3-year naturalistic follow-up. Journal of Personality Disorders 2019 Feb 20 [Epub ahead of print]. [DOI: 10.1521/pedi_2019_33_423] [PMID: 30785852]AndreoliA . Re: your study in BPD - Cochrane Collaboration review [personal communication]. Email to: J Stoffers-Winterling 5 June 2018. '>Andreoli 2016</a>; <a href="./references#CD012955-bbs2-0003" title="AntonsenBT , JohansenMS , RøFG , KvarsteinEH , WilbergT . Is reflective functioning associated with clinical symptoms and long-term course in patients with personality disorders?Comprehensive Psychiatry2016;64:46-58. [DOI: 10.1016/j.comppsych.2015.05.016] [PMID: 26104432]AntonsenBT , KlungsøyrO , KampsA , HummelenB , JohansenMS , PedersenG , et al. Step-down versus outpatient psychotherapeutic treatment for personality disorders: 6-year follow-up of the Ullevål personality project. BMC Psychiatry2014;14:119. [DOI: 10.1186/1471-244X-14-119] [PMC4000615] [PMID: 24758722]AntonsenBT , KvarsteinEH , Urnes Ø, HummelenB , KarterudS , WilbergT . Favourable outcome of long-term combined psychotherapy for patients with borderline personality disorder: six-year follow-up of a randomized study. Psychotherapy Research2017;27(1):51-63. [DOI: 10.1080/10503307.2015.1072283] [PMID: 26261865]ArnevikE , WilbergT , Urnes Ø, JohansenM , MonsenJT , KarterudS . Psychotherapy for personality disorders: short-term day hospital psychotherapy versus outpatient individual therapy - a randomized controlled study. European Psychiatry2009;24(2):71-8. [DOI: 10.1016/j.eurpsy.2008.09.004] [PMID: 19097870]GullestadFS , JohansenMS , HøglendP , KarterudS , WilbergT . Mentalization as a moderator of treatment effects: findings from a randomized clinical trial for personality disorders. Psychotherapy Research2013;23(6):674-89. [DOI: 10.1080/10503307.2012.684103] [PMID: 22612470]GullestadFS . Re: questions regarding your trial on day hospital step-down program [personal communication]. Email to: E Faltinsen 4 December 2017. KvarsteinEH , ArnevikE , HalsteinliV , RøFG , KarterudS , WilbergT . Health service costs and clinical gains of psychotherapy for personality disorders: a randomized controlled trial of day-hospital-based step-down treatment versus outpatient treatment at a specialist practice. BMC Psychiatry2013;13:315. [DOI: 10.1186/1471-244X-13-315] [PMC4222503] [PMID: 24268099]">Antonsen 2017</a>; <a href="./references#CD012955-bbs2-0004" title="BatemanA , FonagyP . 8-year follow-up of patients treated for borderline personality disorder: mentalization-based treatment versus treatment as usual. American Journal of Psychiatry2008;165(5):631-8. [DOI: 10.1176/appi.ajp.2007.07040636] [PMID: 18347003]BatemanA , FonagyP . Effectiveness of partial hospitalization in the treatment of borderline personality disorder: a randomized controlled trial. American Journal of Psychiatry1999;156(10):1563-9. [DOI: 10.1176/ajp.156.10.1563] [PMID: 10518167]BatemanA , FonagyP . Health care utilization costs for borderline personality disorder patients treated with psychoanalytically oriented partial hospitalization versus general psychiatric care. American Journal of Psychiatry2003;160(1):169-71. [10.1176/appi.ajp.160.1.169] [12505818]BatemanA , FonagyP . Treatment of borderline personality disorder with psychoanalytically oriented partial hospitalization: an 18-month follow-up. American Journal of Psychiatry2001;158(1):36-42. [DOI: 10.1176/appi.ajp.158.1.36] [PMID: 11136631]BatemanA . Important: question regarding your BPD trial for systematic review in Cochrane Collaboration [personal communication]. Email to: K Lieb, J Stoffers 14 December 2010. BatemanA . Intensive outpatient and partial hospital care for BPD. In: 157th annual meeting of the American Psychiatric Association. Psychotherapy and pharmacology: dissolving the mind-brain barrier; 2004 May 1-6; New York (NY). Arlington (VA): American Psychiatric Association, 2004:102. [Symposium 100B] [www.psychiatry.org/File%20Library/Psychiatrists/Directories/Library-and-Archive/conference_publications/am_program_2004.pdf]BatemanAW , FonagyP . Drs Bateman and Fonagy reply [to Stern R. Partial hospitalization for borderline personality disorder. American Journal of Psychiatry 2001;158(11):1932-3. DOI: 10.1176/appi.ajp.158.11.1932]. American Journal of Psychiatry2001;158(11):1932-3. [DOI: 10.1176/appi.ajp.158.11.1932-a]EvansC . Treatment benefits of psychoanalytically oriented partial hospitalisation were maintained over 18 months in borderline personality disorder. Evidence-Based Mental Health2001;4(3):73. [DOI: 10.1136/ebmh.4.3.73]FonagyP , BatemanAW . Mentalizing and borderline personality disorder. Journal of Mental Health2007;16(1):83-101. [DOI: 10.1080/09638230601182045]SternR . Partial hospitalization for borderline personality disorder. American Journal of Psychiatry2001;158(11):1932-3. [DOI: 10.1176/appi.ajp.158.11.1932] [PMID: 11691712]">Bateman 1999</a>; <a href="./references#CD012955-bbs2-0005" title="BatemanA , FonagyP . Impact of clinical severity on outcomes of mentalisation-based treatment for borderline personality disorder. British Journal of Psychiatry2013;203(3):221-7. [DOI: 10.1192/bjp.bp.112.121129] [PMID: 23887998]BatemanA , FonagyP . Randomized controlled trial of outpatient mentalization-based treatment versus structured clinical management for borderline personality disorder. American Journal of Psychiatry2009;166(12):1355-64. [DOI: 10.1176/appi.ajp.2009.09040539] [PMID: 19833787]BatemanA , FonagyP . Randomized controlled trial of outpatient mentalization-based treatment versus structured clinical management for borderline personality disorder. Supplementary data. ajp.psychiatryonline.org/doi/suppl/10.1176/appi.ajp.2009.09040539/suppl_file/ajp_166_12_1355_01.pdf (accessed 27 February 2020). BatemanA , O'ConnellJ , LorenziniN , GardnerT , FonagyP . A randomised controlled trial of mentalization-based treatment versus structured clinical management for patients with comorbid borderline personality disorder and antisocial personality disorder. BMC Psychiatry2016;16:304. [DOI: 10.1186/s12888-016-1000-9] [PMC5006360] [PMID: 27577562]BatemanA . Important question regarding your BPD trial for systematic review in Cochrane Collaboration [personal communication]. Email to: K Lieb 14 December 2010. BatemanAW . Mentalization, borderline personality disorder and what works for whom? Presentation at the 11th International Congress of the International Society for the Study of Personality Disorders; 2009 Aug 21-23. www.borderlinepersonalitydisorder.com/Conferences/ISSPD/isspd_09_Bateman (accessed 21 April 2010). ISRCTN27660668. Randomised controlled trial of manualised out-patient individual and group therapy for borderline personality disorder [Effectiveness of intensive out-patient psychotherapy for treatment of borderline personality disorder: a pragmatic randomised single blind controlled study]. www.isrctn.com/ISRCTN27660668 (first received 12 October 2008). ">Bateman 2009</a>; <a href="./references#CD012955-bbs2-0006" title="BellinoS , ParadisoE , ZizzaM , Di LorenzoR , BogettoF . Combined therapy with interpersonal psychotherapy of major depressed patients with borderline personality disorder: a comparison with pharmacotherapy [Terapia combinata con psicoterapia interpersonale di pazienti depressi maggiori con disturbo borderline di personalità: confronto con la farmacoterapia]. Journal of Psychopathology2005;11(1):34-42. [bit.ly/2rZUh5h]BellinoS , ZizzaM , RinaldiC , BogettoF . Combined treatment of major depression in patients with borderline personality disorder: a comparison with pharmacotherapy. Canadian Journal of Psychiatry2006;51(7):453-60. [DOI: 10.1177/070674370605100707] [PMID: 16838827]">Bellino 2006</a>; <a href="./references#CD012955-bbs2-0008" title="BellinoS , BozzatelloP , BogettoF . Combined treatment of borderline personality disorder with interpersonal psychotherapy and pharmacotherapy: predictors of response. Psychiatry Research2015;226(1):284-8. [DOI: 10.1016/j.psychres.2014.12.064] [isiarticles.com/bundles/Article/pre/pdf/34125.pdf]BellinoS , RinaldiC , BogettoF . Adaptation of interpersonal psychotherapy to borderline personality disorder: a comparison of combined therapy and single pharmacotherapy. Canadian Journal of Psychiatry2010;55(2):74-81. [DOI: 10.1177/070674371005500203] [PMID: 20181302]BellinoS . Question regarding your BPD trials for inclusion in Cochrane Collaboration review [personal communication]. Email to: J Stoffers-Winterling 19 December 2010. BellinoS . Re: question regarding your BPD trials [personal communication]. Email to: J Stoffers 16 December 2010. BozzatelloP , BellinoS . Combined therapy with interpersonal psychotherapy adapted for borderline personality disorder: a two-years follow-up. Psychiatry Research2016;240:151-6. [DOI: 10.1016/j.psychres.2016.04.014] [www.sciencedirect.com/science/article/pii/S0165178115302389]ZizzaM , FenocchioM , RinaldiC , BellinoS . Combined treatment of borderline personality disorder: a trial of modified interpersonal therapy. World Psychiatry2009;8(Suppl 1):234. ">Bellino 2010</a>; <a href="./references#CD012955-bbs2-0009" title="BianchiniV , CofiniV , CurtoM , LagrotteriaB , ManziA , NavariS , et al. Dialectical behavior therapy (DBT) for forensic psychiatric patients: an Italian pilot study. Criminal Behavior and Mental Health2019;29(9):122-30. [DOI: 10.1002/cbm.2102] [PMID: 30648303]">Bianchini 2019</a>; <a href="./references#CD012955-bbs2-0010" title="BlackD . Question regarding your BPD trial [personal communication]. Email to: J Stoffers 04 January 2011. BlackDW , AllenJ , McCormickB , BlumN . Treatment received by persons with BPD participating in a randomized clinical trial of the systems training for emotional predictability and problem solving programme. Personality and Mental Health2011;5(3):159-68. [DOI: 10.1002/pmh.167]BlackDW , AllenJ , St JohnD , PfohlB , McCormickB , BlumN . Predictors of response to systems training for emotional predictability and problem solving (STEPPS) for borderline personality disorder: an exploratory study. Acta Psychiatrica Scandinavica2009;120(1):53-61. [DOI: 10.1111/j.1600-0447.2008.01340.x] [PMC3665337] [PMID: 19183126]BlackDW , BlumN , PfohlB , St JohnD . The STEPPS group treatment program for outpatients with borderline personality disorder. Journal of Contemporary Psychotherapy2004;34(3):193-210. [DOI: 10.1023/B:JOCP.0000036630.25741.83]BlackDW , PfohlBM . Randomized clinical trial of STEPPS versus treatment as usual. In: 158th annual meeting of the American Psychiatric Association. Psychosomatic medicine: integrating psychiatry &amp; medicine; 2005 May 21-26; Atlanta (GA). Arlington (VA): American Psychiatric Association, 2005:104. [No. 1B] [www.psychiatry.org/File%20Library/Psychiatrists/Directories/Library-and-Archive/syllabus/am_syllabus_2005.pdf]BlackDW , Simsek-DuranF , BlumN , McCormickB , AllenJ . Do people with borderline personality disorder complicated by antisocial personality disorder benefit from the STEPPS treatment program?Personality and Mental Health2016;10(3):205-15. [DOI: 10.1002/pmh.1326] [PMC4911327] [PMID: 26671625]BlackDW . RE: [external] questions regarding your trial on the STEPPS program for BPD [personal communication]. Email to: EG Faltinsen 27 November 2017. BlumN , AllenJ , McCormickB , BlackDW . Ms Blum and colleagues reply [to Schulte-Herbrüggen O, Koerting J, Roepke S. Effectiveness of adjunctive STEPPS group treatment in borderline personality disorder patients. American Journal of Psychiatry 2008;165(10):1354-5. DOI: 10.1176/appi.ajp.2008.08030390]. American Journal of Psychiatry2008;165(10):1354-5. [DOI: 10.1176/appi.ajp.2008.08030390r]BlumN , FranklinJ , HanselR , McCormickB , St JohnD , PfohlB , et al. Relationship of age to symptom severity, psychiatric comorbidity and health care utilization in persons with borderline personality disorder. Personality and Mental Health2008;2(1):25-43. [DOI: 10.1002/pmh.26]BlumN , St JohnD , PfohlB , StuartS , McCormickB , AllenJ , et al. Erratum. American Journal of Psychiatry2008;165(6):777. Erratum for: American Journal of Psychiatry 2008;165(4):468-78. [psycnet.apa.org/record/2008-07854-033]BlumN , St JohnD , PfohlB , StuartS , McCormickB , AllenJ , et al. Systems training for emotional predictability and problem solving (STEPPS) for outpatients with borderline personality disorder: a randomized controlled trial and 1-year follow-up. American Journal of Psychiatry2008;165(4):468-78. [DOI: 10.1176/appi.ajp.2007.07071079] [PMC3608469] [PMID: 18281407]DavidsonKM . Borderline personality disorder: STEPPS improves symptoms. Evidence-Based Mental Health2008;11(4):120. [DOI: 10.1136/ebmh.11.4.120] [PMID: 18952969]NCT00055315. Treatment for borderline personality disorder [A cognitive group treatment for borderline outpatients]. clinicaltrials.gov/ct2/show/NCT00055315 (first received 25 February 2003). ">Blum 2008</a>; <a href="./references#CD012955-bbs2-0012" title="BorschmannR , BarrettB , HellierJM , ByfordS , HendersonC , RoseD , et al. Joint crisis plans for people with borderline personality disorder: feasibility and outcomes in a randomised controlled trial. British Journal of Psychiatry2013;202(5):357-64. [DOI: 10.1192/bjp.bp.112.117762] [PMID: 23637110]BorschmannR . Joint crisis plans for BPD - question on publication in British Journal of Psychiatry [pers communication]. Email to: J Stoffers-Winterling 22 August 2017. BorschmannR . RE: joint crisis plans for BPD - question on publication in British Journal of Psychiatry [personal communication]. Email to: J Stoffers-Winterling 22 August 2017. BorschmannR . The development and testing of joint crisis plans for people with borderline personality disorder: a feasibility study. ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.628499 (accessed 27 January 2019). HellierJ . RE: regarding your study on on MBT for eating disorders [personal communication]. Email to: E Faltinsen 27 March 2018. HellierJ . RE: regarding your study on on MBT for eating disorders [personal communication]. Email to: E Faltinsen 3 January 2018. HellierJ . SV: regarding your study on MBT for eating disorders [personal communication]. Email to: EG Faltinsen, P Robinson 27 March 2018. ISRCTN12440268. JOSHUA: a pilot randomised controlled trial of joint crisis plans for people who self harm. www.isrctn.com/ISRCTN12440268 (first received 17 September 2009). ">Borschmann 2013</a>; <a href="./references#CD012955-bbs2-0011" title="BohusM , DyerAS , PriebeK , KrügerA , KleindienstN , SchmahlC , et al. Dialectical behaviour therapy for post-traumatic stress disorder after childhood sexual abuse in patients with and without borderline personality disorder: a randomised controlled trial. Psychotherapy and Psychosomatics2013;82(4):221-33. [DOI: 10.1159/000348451] [PMID: 23712109]BrandS . AW: questions regarding your trial on emotional intelligence training for BPD [personal communication]. Email to: EG Faltinsen 28 November 2017. DBT Working Group at the Central Institute for Mental Health, Mannheim, Germany. Requested supplementary data (as supplied 1 October 2010). Data on file. NCT00481000. Dialectical cognitive traumatherapy (DCT) on patients with severe PTSD following sexual abuse (PASA) [Dialectical cognitive traumatherapy (DCT) on patients with severe posttraumatic stress disorder following sexual abuse - a randomised controlled trial]. clinicaltrials.gov/ct2/show/NCT00481000 (first received 31 May 2007). SteilR , DyerA , PriebeK , KleindienstN , BohusM . Dialectical behavior therapy for posttraumatic stress disorder related to childhood sexual abuse: a pilot study of an intensive treatment program. Journal of Traumatic Stress2011;24(1):102-6. [DOI: 10.1002/jts.20617] [PMID: 21351167]">Bohus 2013</a>; <a href="./references#CD012955-bbs2-0013" title="BosEH , Van WelE , AppeloMT , VerbraakMJP . A randomized controlled trial of a Dutch version of systems training for emotional predictability and problem solving for borderline personality disorder. Journal of Nervous and Mental Disease2010;198(4):299-304. [DOI: 10.1097/NMD.0b013e3181d619cf] [PMID: 20386260]Van WelEB , BosEH , AppeloMT , BerendsenEM , WillgerothFC , VerbraakMJPM . The efficacy of the systems training for emotional predictability and problem solving (STEPPS) in the treatment of borderline personality disorder. A randomized controlled trial [De effectiviteit van de vaardigheidstraining emotieregulatiestoornis (VERS) in de behandeling van de borderlinepersoonlijkheidsstoornis: een gerandomiseerd onderzoek]. Tijdschrift voor Psychiatrie2009;51(5):291-301. [PMID: 19434566]">Bos 2010</a>; <a href="./references#CD012955-bbs2-0015" title="CarterG . Question regarding your BPD trial [personal communication]. Email to: J Stoffers 21 December 2010. CarterGL , WillcoxCH , LewinTJ , ConradAM , BenditN . Hunter DBT project: randomized controlled trial of dialectical behaviour therapy in women with borderline personality disorder. Australian and New Zealand Journal of Psychiatry2010;44(2):162-73. [DOI: 10.3109/00048670903393621] [PMID: 20113305]">Carter 2010</a>; <a href="./references#CD012955-bbs2-0017" title="DavidsonK , LivingstoneS , McArthurK , DicksonL , GumleyA . An integrative complexity analysis of cognitive behaviour therapy sessions for borderline personality disorder. Psychology and Psychotherapy2007;80(Pt 4):513-23. [DOI: 10.1348/147608307X191535] [PMID: 17535542]DavidsonK , NorrieJ , TyrerP , GumleyA , TataP , MurrayH , et al. The effectiveness of cognitive behavior therapy for borderline personality disorder: results from the borderline personality disorder study of cognitive therapy (BOSCOT) trial. Journal of Personality Disorders2006;20(5):450-65. [DOI: 10.1521/pedi.2006.20.5.450] [PMC1852259] [PMID: 17032158]DavidsonK , TyrerP , GumleyA , TataP , NorrieJ , PalmerS , et al. A randomized controlled trial of cognitive behavior therapy for borderline personality disorder: rationale for trial, method, and description of sample. Journal of Personality Disorders2006;20(5):431-49. [DOI: 10.1521/pedi.2006.20.5.431] [PMC1847748] [PMID: 17032157]DavidsonKM , TyrerP , NorrieJ , PalmerSJ , TyrerH . Cognitive therapy v usual treatment for borderline personality disorder: prospective 6-year follow-up. British Journal of Psychiatry2010;197(6):456-62. [DOI: 10.1192/bjp.bp.109.074286] [PMID: 21119151]ISRCTN86177428. Borderline personality disorder study of cognitive therapy trial [A randomised controlled trial of cognitive therapy plus treatment as usual versus treatment as usual in the treatment of borderline personality disorder]. www.isrctn.com/ISRCTN86177428 (first received 22 July 2005). NCT00538135. BOSCOT: a randomised controlled trial of cognitive behavioural therapy in borderline personality disorder [BOSCOT: a randomised control trial of cognitive behavioural therapy plus treatment as usual versus treatment as usual in the treatment of borderline personality disorder]. www.clinicaltrials.gov/ct2/show/NCT00538135 (first received 29 September 2007). NorrieJ , DavidsonK , TataP , GumleyA . Influence of therapist competence and quantity of cognitive behavioural therapy on suicidal behaviour and inpatient hospitalisation in a randomised controlled trial in borderline personality disorder: further analyses of treatment effects in the BOSCOT study. Psychology and Psychotherapy2013;86(3):280-93. [DOI: 10.1111/papt.12004] [PMC4491320] [PMID: 23420622]PalmerS , DavidsonK , TyrerP , GumleyA , TataP , NorrieJ , et al. The cost-effectiveness of cognitive behavior therapy for borderline personality disorder: results from the BOSCOT trial. Journal of Personality Disorders2006;20(5):466-81. [DOI: 10.1521/pedi.2006.20.5.466] [PMC1852260] [PMID: 17032159]">Davidson 2006</a>; <a href="./references#CD012955-bbs2-0018" title="DavidsonKM , BrownTM , JamesV , KirkJ , RichardsonJ . Manual-assisted cognitive therapy for self-harm in personality disorder and substance misuse: a feasibility trial. Psychiatric Bulletin2014;38(3):108-11. [DOI: 10.1192/pb.bp.113.043109] [PMC4115373] [PMID: 25237519]DavidsonKM . Re: question regarding your trial on manual-assisted cognitive therapy [personal communication]. Email to: EG Faltinsen 28 November 2017. ">Davidson 2014</a>; <a href="./references#CD012955-bbs2-0021" title="FarrellJM , ShawIA , WebberMA . A schema-focused approach to group psychotherapy for outpatients with borderline personality disorder: a randomized controlled trial. Journal of Behavior Therapy and Experimental Psychiatry2009;40(2):317-28 Corrigendum to: Journal of Behavior Therapy and Experimental Psychiatry 2018; 60: 111. [DOI: 10.1016/j.jbtep.2009.01.002] [PMID: 19176222]FarrellJM . Question regarding your BPD trials [personal communication]. Email to: K Lieb, J Stoffers 9 December 2010. ">Farrell 2009</a>; <a href="./references#CD012955-bbs2-0023" title="Feliu-SolerA , PascualJC , ElicesM , Martín-BlancoA , CarmonaC , CebollaA , et al. Fostering self-compassion and loving-kindness in patients with borderline personality disorder: a randomized pilot study. Clinical Psychology &amp; Psychotherapy2017;24(1):278-86. [DOI: 10.1002/cpp.2000] [PMID: 26818533]">Feliu‐Soler 2017</a>; <a href="./references#CD012955-bbs2-0026" title="Gratz KL. Important: question regarding your BPD trial for systematic review in Cochrane Collaboration [personal communication]. Email to: J Stoffers-Winterling 11 December 2010. GratzKL , GundersonJG . Preliminary data on an acceptance-based emotion regulation group intervention for deliberate self-harm among women with borderline personality disorder. Behavior Therapy2006;37(1):25-35. [DOI: 10.1016/j.beth.2005.03.002] [PMID: 16942958]">Gratz 2006</a>; <a href="./references#CD012955-bbs2-0027" title="GratzKL , BardeenJR , LevyR , Dixon-GordonKL , TullMT . Mechanisms of change in an emotion regulation group therapy for deliberate self-harm among women with borderline personality disorder. Behaviour Research and Therapy2015;65:29-35. [DOI: 10.1016/j.brat.2014.12.005] [PMC4306622] [PMID: 25557395]GratzKL , Dixon-GordonKL , TullMT . Predictors of treatment response to an adjunctive emotion regulation group therapy for deliberate self-harm among women with borderline personality disorder. Personality Disorders2014;5(1):97-107. [DOI: 10.1037/per0000062] [PMC4059504] [PMID: 2458806]GratzKL , TullMT , LevyR . Randomized controlled trial and uncontrolled 9-month follow-up of an adjunctive emotion regulation group therapy for deliberate self-harm among women with borderline personality disorder. Psychological Medicine2014;44(10):2099-112. [DOI: 10.1017/S0033291713002134] [PMID: 23985088]GratzKL . Question regarding your BPD trials [personal communication]. Email to: J Stoffers 11 December 2010. ">Gratz 2014</a>; <a href="./references#CD012955-bbs2-0028" title="GregoryRJ , ChlebowskiS , KangD , RemenA , SoderbergM . Psychodynamic therapy for borderline personality disorder and co-occurring alcohol use disorders: a newly designed ongoing study. Journal of the American Psychoanalytic Association2006;54(4):1331-4. [DOI: 10.1177/00030651060540040107] [PMID: 17354507]GregoryRJ , ChlebowskiS , KangD , RemenAL , SoderbergMG , StepkovitchJ , et al. A controlled trial of psychodynamic psychotherapy for co-occurring borderline personality disorder and alcohol use disorder. Psychotherapy2008;45(1):28-41. [DOI: 10.1037/0033-3204.45.1.28] [PMID: 22122363]GregoryRJ , DeLucia-DeranjaE , MogleJA . Dynamic deconstructive psychotherapy versus optimized community care for borderline personality disorder co-occuring with alcohol use disorders: a 30-month follow-up. Journal of Nervous and Mental Disease2010;198(4):292-8. [DOI: 10.1097/NMD.0b013e3181d6172d] [PMID: 20386259]GregoryRJ , RemenAL , SoderbergM , Ploutz-SnyderRJ . A controlled trial of psychodynamic psychotherapy for co-occurring borderline personality disorder and alcohol use disorder: six-month outcome. Journal of the American Psychoanalytic Association2009;57(1):199-205. [DOI: 10.1177/00030651090570011006] [PMID: 19270255]NCT00145678. Psychodynamic therapy for co-occurring borderline personality disorder and alcohol use disorder [Psychodynamic therapy for patients With borderline personality disorder and alcohol abuse]. www.clinicaltrials.gov/show/NCT00145678 (first received 1 September 2005). ">Gregory 2008b</a>; <a href="./references#CD012955-bbs2-0029" title="HaeyenS , Van HoorenS , HutschemaekersG . Efficacy of art therapy in individuals with personality disorders cluster B/C: a randomised controlled trial. International Journal of Psychology July 2016;51:60. [DOI: 10.1521/pedi_2017_31_312] [PMID: 28926306]HaeyenS , Van HoorenS , Van der VeldW , HutschemaekersG . Efficacy of art therapy in individuals with personality disorders cluster B/C: a randomised controlled trial. Journal of Personality Disorders2018;32(4):527-42. [DOI: 10.1521/pedi_2017_31_312] [PMID: 28926306]HaeyenS . Re: Cochrane Collaboration review of psychotherapies for BPD - your RCT of art therapy [personal communication]. Email to: J Stoffers-Winterling 18 August 2018. ">Haeyen 2018</a>; <a href="./references#CD012955-bbs2-0030" title="HarnedM . Re: SV: question regarding your trial on brief therapy for attempted suicide [personal communication]. Email to: EG Faltinsen 11 December 2018. HarnedMS , KorslundKE , LinehanMM . A pilot randomized controlled trial of dialectical behavior therapy with and without the dialectical behavior therapy prolonged exposure protocol for suicidal and self-injuring women with borderline personality disorder and PTSD. Behaviour Research and Therapy2014;55:7-17. [DOI: 10.1016/j.brat.2014.01.008] [PMC3987949] [PMID: 24562087]HarnedMS , WilksCR , SchmidtSC , CoyleTN . Improving functional outcomes in women with borderline personality disorder and PTSD by changing PTSD severity and post-traumatic cognitions. Behaviour Research and Therapy2018;103:53-61. [DOI: 10.1016/j.brat.2018.02.002] [PMC5837954] [PMID: 29448136]HarnedMS . RE: questions regarding your trial on brief therapy for attempted suicide [personal communication]. Email to: E Faltinsen 29 November 2017. ">Harned 2014</a>; <a href="./references#CD012955-bbs2-0033" title="JørgensenCR , BøyeR , AndersenD , Døssing BlaabjergAH , FreundC , JordetH , et al. Eighteen months post-treatment naturalistic follow-up study of mentalization-based therapy and supportive group treatment of borderline personality disorder: clinical outcomes and functioning. Nordic Psychology2014;66(4):254-73. [DOI: 10.1080/19012276.2014.963649]JørgensenCR , FreundC , BøyeR , JordetH , AndersenD , KjølbyeM . Outcome of mentalization-based and supportive psychotherapy in patients with borderline personality disorder: a randomized trial. Acta Psychiatrica Scandinavica2013;127(4):305-17. [DOI: 10.1111/j.1600-0447.2012.01923.x] [PMID: 22897123]JorgensenCR . SV: questions on your trial regarding MBT for BPD patients [personal communication]. Email to: EG Faltinsen 28 November 2017. ">Jørgensen 2013</a>; <a href="./references#CD012955-bbs2-0034" title="KamalabadiMJ , AhmadiSA , EtemadiO , FatehizadehM , BahramiF , FiroozabadiA . A study of the effect of couple dialectical behavioral therapy on symptoms and quality of marital relationships and mental health of Iranian borderline personality couples: a controlled trial. Interdisciplinary Journal of Contemporary Research in Business2012;3(9):1480-7. [psycnet.apa.org/record/2012-22425-047]">Kamalabadi 2012</a>; <a href="./references#CD012955-bbs2-0036" title="KramerU , BergerT , KollyS , MarquetP , PreisigM , De RotenY , et al. Effects of motive-oriented therapeutic relationship in early-phase treatment of borderline personality disorder: a pilot study of a randomized trial. Journal of Nervous and Mental Disease2011;199(4):244-50. [DOI: 10.1097/NMD.0b013e3182125d19] [PMID: 21451348]KramerU , CasparF , DrapeauM . Change in biased thinking in a 10-session treatment for borderline personality disorder: further evidence of the motive-oriented therapeutic relationship. Psychotherapy Research2013;23(6):633-45. [DOI: 10.1080/10503307.2013.791404] [PMID: 23631622]">Kramer 2011</a>; <a href="./references#CD012955-bbs2-0037" title="BerthoudL , KramerU , CasparF , Pascual-LeoneA . Emotional processing in a ten-session general psychiatric treatment for borderline personality disorder: a case study. Personality and Mental Health2015;9(1):73-8. [DOI: 10.1002/pmh.1287] [PMID: 25711648]BerthoudL , Pascual-LeoneA , CasparF , TissotH , KellerS , RohdeKB , et al. Leaving distress behind: a randomized controlled study on change in emotional processing in borderline personality disorder. Psychiatry2017;80(2):139-54. [DOI: 10.1080/00332747.2016.1220230] [PMID: 28767333]KellerS , StelmaszczykK , KollyS , De RotenY , DesplandJN , CasparF , et al. Change in biased thinking in a treatment based on the motive-oriented therapeutic relationship for borderline personality disorder. Journal of Personality Disorders2018;32(Suppl):75-92. [DOI: 10.1521/pedi.2018.32.supp.75] [PMID: 29388899]KramerU , FlückigerC , KollyS , CasparF , MarquetP , DesplandJN , et al. Unpacking the effects of therapist responsiveness in borderline personality disorder: motive-oriented therapeutic relationship, patient in-session experience, and the therapeutic alliance. Psychotherapy and Psychosomatics2014;83(6):386-7. [DOI: 10.1159/000365400] [PMID: 25324025]KramerU , KellerS , CasparF , De RotenY , DesplandJN , KollyS . Early change in coping strategies in responsive treatments for borderline personality disorder: a mediation analysis. Journal of Consulting and Clinical Psychology2017;85(5):530-5. [DOI: 10.1037/ccp0000196] [PMID: 28425747]KramerU , KollyS , BerthoudL , KellerS , PreisigM , CasparF , et al. Effects of motive-oriented therapeutic relationship in a ten-session general psychiatric treatment of borderline personality disorder: a randomized controlled trial. Psychotherapy and Psychosomatics2014;83(3):176-86. [DOI: 10.1159/000358528] [PMID: 24752034]KramerU , StulzN , BerthoudL , CasparF , MarquetP , KollyS , et al. The shorter the better? A follow-up analysis of 10-session psychiatric treatment including the motive-oriented therapeutic relationship for borderline personality disorder. Psychotherapy Research2017;27(3):362-70. [DOI: 10.1080/10503307.2015.1110635] [PMID: 26684670]NCT01896024. Effects of motive-oriented therapeutic relationship in the early-phase treatment of borderline personality disorder (MOTR). www.clinicaltrials.gov/ct2/show/NCT01896024 (first received 5 July 2013). ">Kramer 2014</a>; <a href="./references#CD012955-bbs2-0039" title="KredlowMA , SzuhanyKL , LoS , XieH , GottliebJD , RosenbergSD , et al. Cognitive behavioral therapy for posttraumatic stress disorder in individuals with severe mental illness and borderline personality disorder. Psychiatry Research2017;249:86-93. [DOI: 10.1016/j.psychres.2016.12.045] [PMC5325773] [PMID: 28086181]MueserK . Re: question regarding your trial on CBT for BPD patients [personal communication]. Email to: EG Faltinsen 28 November 2017. ">Kredlow 2017a</a>; <a href="./references#CD012955-bbs2-0040" title="KredlowMA , SzuhanyKL , LoS , XieH , GottliebJD , RosenbergSD , et al. Cognitive behavioral therapy for posttraumatic stress disorder in individuals with severe mental illness and borderline personality disorder. Psychiatry Research2017;249:86-93. [DOI: 10.1016/j.psychres.2016.12.045] [PMC5325773] [PMID: 28086181]MueserKT , GottliebJD , XieH , LuW , YanosPT , RosenbergSD , et al. Evaluation of cognitive restructuring for post-traumatic stress disorder in people with severe mental illness.. British Journal of Psychiatry2015;206(6):501-8. [DOI: 10.1192/bjp.bp.114.147926] [PMC4450219] [PMID: 25858178]MueserKT , RosenbergSD , XieH , JankowskiMK , BoltonEE , LuW , et al. A randomized controlled trial of cognitive-behavioral treatment for posttraumatic stress disorder in severe mental illness. Journal of Consulting and Clinical Psychology2008;76(2):259-71. [DOI: 10.1037/0022-006X.76.2.259] [PMC3916092] [PMID: 18377122]MueserKT . Re: question regarding your trial on CBT for PTSD participants [personal communication]. Email to: E Faltinsen 28 November 2018. ">Kredlow 2017b</a>; <a href="./references#CD012955-bbs2-0041" title="LaurenssenEM , WestraD , KikkertMJ , NoomMJ , EerenHV , Van BroekhuyzenAJ , et al. Day hospital mentalization-based treatment (MBT-DH) versus treatment as usual in the treatment of severe borderline personality disorder: protocol of a randomized controlled trial. BMC Psychiatry2014;14:149. [DOI: 10.1186/1471-244X-14-149] [PMC4045960] [PMID: 24886402]LaurenssenEMP , LuytenP , KikkertMJ , WestraD , PeenJ , SoonsMBJ , et al. Day hospital mentalization-based treatment v specialist treatment as usual in patients with borderline personality disorder: randomized controlled trial. Psychological Medicine2018;48(15):2522-9. [DOI: 10.1017/S0033291718000132] [PMID: 29478425]NL2058 (NTR2175). Mentalisation-based treatment versus care-as-usual in the treatment of severe borderline personality disorders. www.trialregister.nl/trial/2058 (first received 21 January 2010). ">Laurenssen 2018</a>; <a href="./references#CD012955-bbs2-0042" title="LeichsenringF , MasuhrO , JaegerU , RabungS , DallyA , DümpelmannM , et al. Psychoanalytic-interactional therapy versus psychodynamic therapy by experts for personality disorders: a randomized controlled efficacy-effectiveness study in cluster B personality disorders. Psychotherapy and Psychosomatics2016;85(2):71-80. [DOI: 10.1159/000441731] [PMID: 26808580]">Leichsenring 2016</a><a href="./references#CD012955-bbs2-0043" title="LeppänenV , HakkoH , SintonenH , LindemanS . Comparing effectiveness of treatments for borderline personality disorder in communal mental health care: the Oulu BPD study. Community Mental Health Journal2016;52(2):216-27. [DOI: 10.1007/s10597-015-9866-4] [PMID: 25824852]LeppänenV . Re: questions regarding the Oulu BPD study [personal communication]. Email to: E Faltinsen 20 December 2017. LeppänenV . Re: SV: question regarding the Oulu BPD study [personal communication]. Email to: EG Faltinsen 22 December 2017. ">Leppänen 2016</a>; <a href="./references#CD012955-bbs2-0046" title="HeardHL . Cost-Effectiveness of Dialectical Behavior Therapy in the Treatment of Borderline Personality Disorder [PhD thesis]. Washington (DC): University of Washington, 2000. LindenboimN . To Know Me is to Keep Me: Self-Verification, Validation, and Therapy Dropout in the Treatment of Borderline Personality Disorder [PhD thesis]. Washington (DC): University of Washington, 2009. LinehanMM , HeardHL , ArmstrongHE . Naturalistic follow-up of a behavioral treatment for chronically parasuicidal borderline patients. Archives of General Psychiatry1993;50(12):971-4. [DOI: 10.1001/archpsyc.1993.01820240055007] [PMID: 8250683]LinehanMM , TutekDA , HeardHL , ArmstrongHE . Interpersonal outcome of cognitive behavioral treatment for chronically suicidal borderline patients. American Journal of Psychiatry1994;151(12):1771-6. [DOI: 10.1176/ajp.151.12.1771] [PMID: 7977884]">Linehan 1994</a>; <a href="./references#CD012955-bbs2-0047" title="BedicsJD , AtkinsDC , ComtoisKA , LinehanMM . Treatment differences in the therapeutic relationship and introject during a 2-year randomized controlled trial of dialectical behavior therapy versus nonbehavioral psychotherapy experts for borderline personality disorder. Journal of Consulting and Clinical Psychology2012;80(1):66-77. [DOI: 10.1037/a0026113] [PMC3265694] [PMID: 22061867]BedicsJD , AtkinsDC , ComtoisKA , LinehanMM . Weekly therapist ratings of the therapeutic relationship and patient introject furing the course of dialectical behavioral therapy for the treatment of borderline personality disorder. Psychotherapy2012;49(2):231-40. [DOI: 10.1037/a0028254] [PMID: 22642526]BedicsJD , AtkinsDC , HarnedMS , LinehanMM . The therapeutic alliance as a predictor of outcome in dialectical behavior therapy versus nonbehavioral psychotherapy by experts for borderline personality disorder. Psychotherapy2015;52(1):67-77. [DOI: 10.1037/a0038457] [PMID: 25751116]BrownMZ , LinehanMM , ComtoisKA , MurrayA , ChapmanAL . Shame as a prospective predictor of self-inflicted injury in borderline personality disorder: a multi-modal analysis. Behaviour Research and Therapy2009;47(10):815-22. [DOI: 10.1016/j.brat.2009.06.008] [PMC2761705] [PMID: 19596223 ]CoyleTN , ShaverJA , LinehanMM . On the potential for iatrogenic effects of psychiatric crisis services: the example of dialectical behavior therapy for adult women with borderline personality disorder. Journal of Consulting and Clinical Psychology2018;86(2):116-24. [DOI: 10.1037/ccp0000275] [PMID: 29369662]HarnedMS , ChapmanAL , Dexter-MazzaET , MurrayA , ComtoisKA , LinehanMM . Treating co-occurring Axis I disorders in recurrently suicidal women with borderline personality disorder: a 2-year randomized trial of dialectical behavior therapy versus community treatment by experts. Journal of Consulting and Clinical Psychology2008;76(6):1068-75. [DOI: 10.1037/a0014044] [PMID: 19045974]HarnedMS , ChapmanAL , Dexter-MazzaET , MurrayA , ComtoisKA , LinehanMM . Treating co-occurring Axis I disorders in recurrently suicidal women with borderline personality disorder: a 2-year randomized trial of dialectical behavior therapy versus community treatment by experts. Personality Disorders: Theory, Research, and Treatment2009;S(1):35-45. [DOI: 10.1037/1949-2715.S.1.35]HarnedMS , JacksonSC , ComtoisKA , LinehanMM . Dialectical behavior therapy as a precursor to PTSD treatment for suicidal and/or self-injuring women with bordreline personality disorder. Journal of Traumatic Stress2010;23(4):421-9. [DOI: 10.1002/jts.20553] [PMID: 20648564]LindenboimN , ComtoisKA , LinehanMM . Skills practice in dialectical behavior therapy for suicidal women meeting criteria for borderline personality disorder. Cognitive and Behavioral Practice2007;14(2):147-56. [DOI: 10.1016/j.cbpra.2006.10.004]LinehanMM , ComtoisKA , MurrayAM , BrownMZ , GallopRJ , HeardHL , et al. Two-year randomized controlled trial and follow-up of dialectical behavior therapy vs therapy by experts for suicidal behaviors and borderline personality disorder. Archives of General Psychiatry2006;63(7):757-66. [DOI: 10.1001/archpsyc.63.7.757] [PMID: 16818865]LinehanMM . Error in table in: two-year randomized controlled trial and follow-up of dialectical behavior therapy vs therapy by experts for suicidal behaviors and borderline personality disorder. Archives of General Psychiatry2007;64(12):1401. Erratum for: Archives of General Psychiatry 2007;64(12):1401. McMainS . Dialectic behaviour therapy reduces suicide attempts compared with non-behavioural psychotherapy in women with borderline personality disorder. Evidence-Based Mental Health2007;10(1):18. [DOI: 10.1136/ebmh.10.1.18] [PMID: 17255387]NeacsiuAD , LunguA , HarnedMS , RizviSL , LinehanMM . Impact of dialectical behavior therapy versus community treatment by experts on emotional experience, expression, and acceptance in borderline personality disorder. Behaviour Research and Therapy2014;53:47-54. [DOI: 10.1016/j.brat.2013.12.004] [PMC3955205] [PMID: 24418652]NeacsiuAD , RizviSL , LinehanMM . Dialectical behavior therapy skills use as a mediator and outcome of treatment for borderline personality disorder. Behaviour Research and Therapy2010;48(9):832-9. [DOI: 10.1016/j.brat.2010.05.017] [PMC2914145] [PMID: 20579633]SecristCD . The Role of Executive Functioning in the Treatment of Borderline Personality Disorder [PhD thesis]. Washington (DC): University of Washington, 2014. ">Linehan 2006</a>; <a href="./references#CD012955-bbs2-0048" title="LinehanMM , KorslundKE , HarnedMS , GallopRJ , LunguA , NeacsiuAD , et al. Dialectical behavior therapy for high suicide risk in individuals with borderline personality disorder: a randomized clinical trial and component analysis. JAMA Psychiatry2015;72(5):475-82 Erratum for: JAMA Psychiatry 2015; 72(9): 951. [DOI: 10.1001/jamapsychiatry.2014.3039] [PMID: 25806661]NCT00183651. Treatment of suicidal women with borderline personality disorder [Assessment and treatment of parasuicidal patients]. www.clinicaltrials.gov/ct2/show/NCT00183651 (first received 13 September 2005). ">Linehan 2015a</a>; <a href="./references#CD012955-bbs2-0051" title="McMurranM , CrawfordMJ , ReillyJ , DelportJ , McCroneP , WhithamD , et al. Psychoeducation with problem-solving (PEPS) therapy for adults with personality disorder: a pragmatic randomised controlled trial to determine the clinical effectiveness and cost-effectiveness of a manualised intervention to improve social functioning. Health Technology Assessment2016;20(52):1-282. [DOI: 10.3310/hta20520]McMurranM . RE: Cochrane Collaboration review - PEPS study [personal communication]. Email to: J Stoffers-Winterling 5 July 2018. McMurranM . Request for data on BPD subjects in the PEPS rcp-study for use a new Cochrane review [personal communication]. Email to: M Kongerslev 7 March 2017. ">McMurran 2016</a>; <a href="./references#CD012955-bbs2-0052" title="HagaE , AasE , GrøholtB , TørmoenAJ , MehlumL . Cost-effectiveness of dialectical behaviour therapy vs enhanced usual care in the treatment of adolescents with self-harm. Child and Adolescent Psychiatry and Mental Health2018;12:22. [DOI: 10.1186/s13034-018-0227-2] [PMC5928596] [PMID: 29743941]MehlumL , RambergM , TørmoenAJ , HagaE , DiepLM , StanleyBH , et al. Dialectical behavior therapy compared with enhanced usual care for adolescents with repeated suicidal and self-harming behavior: outcomes over a one-year follow-up. Journal of the American Academy of Child and Adolescent Psychiatry2016;55(4):295-300. [DOI: 10.1016/j.jaac.2016.01.005] [PMID: 27015720]MehlumL , TørmoenAJ , RambergM , HagaE , DiepLM , LabergS , et al. Dialectical behavior therapy for adolescents with repeated suicidal and self-harming behavior: a randomized trial. Journal of the American Academy of Child and Adolescent Psychiatry2014;53(10):1082-91. [DOI: 10.1016/j.jaac.2014.07.003] [PMID: 25245352]MehlumL . Re: regarding your study of DBT for your with suicidal behavior [personal communication] [Re: angående din studie om DBT for ungdom med selvmordsatferd [personlig kommunikation]]. Email to: E Faltinsen 5 December 2017. NCT00675129. Treatment for adolescents with deliberate self harm [A randomized controlled trial for repetitive deliberate self-harm and suicidal behaviours among Norwegian adolescents: a comparison between dialectical behaviour therapy adapted for adolescents (DBT-A) and enhanced usual care (EUC)]. www.clinicaltrials.gov/ct2/show/NCT00675129 (first received 6 May 2008). RamlethRK , GroholtB , DiepLM , WalbyFA , MehlumL . The impact of borderline personality disorder and sub-threshold borderline personality disorder on the course of self-reported and clinician-rated depression in self-harming adolescents. Borderline Personality Disorder and Emotion Dysregulation2017;4:22. [DOI: 10.1186/s40479-017-0073-5] [PMC5663078] [PMID: 29093819]">Mehlum 2014</a>; <a href="./references#CD012955-bbs2-0055" title="MortonJ , SnowdonS , GopoldM , GuymerE . Acceptance and commitment therapy group treatment for symptoms of borderline personality disorder: a public sector pilot study. Cognitive and Behavioral Practice2012;19(4):527-44. [DOI: 10.1016/j.cbpra.2012.03.005]MortonJ . Re: SV: regarding your study on acceptance and commitment therapy for BPD [personal communication]. Email to: EG Faltinsen 22 December 2017. ">Morton 2012</a>; <a href="./references#CD012955-bbs2-0057" title="NCT02033044. Cognitive rehabilitation versus psychoeducation in psychosocial functioning of borderline personality disorder [Randomized controlled trial comparing the effects on psychosocial functioning of cognitive rehabilitation versus psychoeducation in borderline personality disorder]. www.clinicaltrials.gov/ct2/show/NCT02033044 (first received 23 December 2013). PascualJC , PalomaresN , Ibáñez Á, PortellaMJ , ArzaR , ReyesR , et al. Efficacy of cognitive rehabilitation on psychosocial functioning in borderline personality disorder: a randomized controlled trial. BMC Psychiatry2015;15:255. [DOI: 10.1186/s12888-015-0640-5] [PMC4617906] [PMID: 26487284]">Pascual 2015</a>; <a href="./references#CD012955-bbs2-0058" title="PhilipsB , WennebergP , KonradssonP , FranckJ . Mentalization-based treatment for concurrent borderline personality disorder and substance use disorder: a randomized controlled feasibility study. European Addiction Research2018;24(1):1-8. [DOI: 10.1159/000485564] [PMC5969093] [PMID: 294028]">Philips 2018</a>; <a href="./references#CD012955-bbs2-0060" title="RenesesB , FigueraD , SalcedoG , TrujilloM , López-IborJJ , GaliánM , et al. A controlled randomized study on the efficacy of short-term dinamic psychotherapy in borderline personality disorders (BPD). Preliminary results. European Psychiatry2011;26(Suppl 1):1040. [DOI: 10.1016/S0924-9338(11)72745-6] [P02-444]RenesesB , GaliánM , SerranoR , FigueraD , Fernandez Del MoralA , López-IborJJ , et al. A new time limited psychotherapy for BPD: preliminary results of a randomized and controlled trial. Actas Espanolas de Psiquiatria2013;41(3):139-48. [PMID: 23803797]">Reneses 2013</a>; <a href="./references#CD012955-bbs2-0061" title="ISRCTN51304415. Nice OUtcomes for Referrals with Impulsivity, Self Harm and Eating Disorders: the NOURISHED study [A randomised controlled trial of mentalisation based therapy against specialist supportive clinical management in patients with both eating disorders and symptoms of borderline personality disorder]. www.isrctn.com/ISRCTN51304415 (first received 31 January 2011). RobinsonP , BarrettB , BatemanA , HakeemA , HellierJ , LemonskyF , et al. Study protocol for a randomized controlled trial of mentalization based therapy against specialist supportive clinical management in patients with both eating disorders and symptoms of borderline personality disorder. BMC Psychiatry2014;14:51. [DOI: 10.1186/1471-244X-14-51] [PMC3996076] [PMID: 24555511]RobinsonP , HellierJ , BarrettB , BarzdaitieneD , BatemanA , BogaardtA , et al. The NOURISHED randomised controlled trial comparing mentalisation-based treatment for eating disorders (MBT-ED) with specialist supportive clinical management (SSCM-ED) for patients with eating disorders and symptoms of borderline personality disorder. Trials2016;17(1):549. [DOI: 10.1186/s13063-016-1606-8] [PMC5114835] [PMID: 27855714]">Robinson 2016</a>; <a href="./references#CD012955-bbs2-0062" title="ISRCTN95266816. The emergence of personality disorder traits in adolescents who deliberately self harm and the potential for using a mentalisation based treatment approach as an early intervention for such individuals: a randomised controlled trial. www.isrctn.com/ISRCTN95266816 (first received 29 October 2007). RossouwT . Mentalisation based treatment for adolescents with self harm: an RCT. European Child &amp; Adolescent Psychiatry2015;24(1 Suppl):S113. [DOI: 10.1007%2Fs00787-015-0714-4.pdf] [W1-02-02]RossouwT . Self harm in adolescence, is MBT the answer?: an RCT. Adolescent Psychiatry2012;2(1):102. [DOI: 10.2174/2210676611202010077]RossouwTI , FonagyP . Mentalization-based treatment for self-harm in adolescents: a randomized controlled trial. Journal of the American Academy of Child and Adolescent Psychiatry2012;51(12):1304-13.e3. [DOI: 10.1016/j.jaac.2012.09.018] [PMID: 23200287]">Rossouw 2012b</a>; <a href="./references#CD012955-bbs2-0063" title="SalzerS , CroppC , JaegerU , MasuhrO , Streeck-FischerA . Psychodynamic therapy for adolescents suffering from co-morbid disorders of conduct and emotions in an in-patient setting: a randomized controlled trial. Psychological Medicine2014;44(10):2213-22. [DOI: 10.1017/S003329171300278X] [PMID: 24229481]SalzerS , Streeck-FischerA . The psychoanalytic-interactional method (PiM) for adolescents with borderline personality disorder [Die psychoanalytisch-interaktionelle methode (PiM) für adoleszente mit borderline-persönlichkeitsstörung]. Personlichkeitsstorungen Theorie und Therapie2015;19(1):67-76. [elibrary.klett-cotta.de/article/99.120110/ptt-19-1-67]SalzerS . AW: Re: Cochrane Review on psychotherapies for BPD - RCT testing PiM vs WL [personal communication] [AW:Re: Cochrane Review zur Psychotherapie bei BPS - RCT zu PiM vs WL [persönliche kommunikation]]. Email to: J Stoffers-Winterling 15 July 2018. ">Salzer 2014</a>; <a href="./references#CD012955-bbs2-0064" title="SantistebanDA , MenaMP , MuirJ , McCabeBE , AbaloC , CummingsAM . The efficacy of two adolescent substance abuse treatments and the impact of comorbid depression: results of a small randomized controlled trial. Psychiatric Rehabilitation Journal2015;38(1):55-64. [DOI: 10.1037/prj0000106] [PMC5021542] [PMID: 25799306]">Santisteban 2015</a>; <a href="./references#CD012955-bbs2-0065" title="SchillingL , MoritzS , KötherU , NagelM . Preliminary results on acceptance, feasibility, and subjective efficacy of the add-on group intervention metacognitive training for borderline patients. Journal of Cognitive Psychotherapy2015;29(2):153-64. [DOI: 10.1891/0889-8391.29.2.153]SchillingL , MoritzS , KristonL , KriegerM , NagelM . Efficacy of metacognitive training for patients with borderline personality disorder: preliminary results. Psychiatry Research2018;262:459-64. [DOI: 10.1016/j.psychres.2017.09.024] [PMID: 28927866]SchillingL . Re Schilling 2015/2018 - Cochrane Review of psychotherapies for BPD [personal communication] [Re Schilling 2015/2018 - Cochrane Review zur Psychotherapie bei BPS [persönliche Kommunikation]]. Email to: J Stoffers-Winterling 22 January 2019. ">Schilling 2018</a>; <a href="./references#CD012955-bbs2-0066" title="ISRCTN97589104. Evaluation of a group training for adolescents (emotion regulation training) with emotion regulation problems - a randomised controlled clinical trial. www.isrctn.com/ISRCTN97589104 (first received 23 August 2007). SchuppertHM , TimmermanME , BlooJ , Van GemertTG , WiersemaHM , MinderaaRB , et al. Emotion regulation training for adolescents with borderline personality disorder traits: a randomized controlled trial. Journal of the American Academy of Child &amp; Adolescent Psychiatry2012;51(12):1314-23. [DOI: 10.1016/j.jaac.2012.09.002] [PMID: 23200288]">Schuppert 2012</a>; <a href="./references#CD012955-bbs2-0067" title="NCT01904227. Intensified, inpatient adaptation of dialectical behavior therapy (DBT) (REDBT) [A randomized controlled study of the efficacy of an intensified, inpatient adaptation of dialectical behavior therapy (DBT) for a population of borderline patients (young adults/adults: 18-40), compared with standard outpatient DBT]. www.clinicaltrials.gov/ct2/show/NCT01904227 (first received 11 July 2013). SinnaeveR , Van den BoschLM , Van Steenbergen-WeijenburgKM . Change in interpersonal functioning during psychological interventions for borderline personality disorder — a systematic review of measures and efficacy. Personality and Mental Health2015;9(3):173-94. [DOI: 10.1002/pmh.1296] [PMID: 26058794]SinnaeveR , Van den BoschLMC , Hakkaart-van RoijenL , VansteelandtK . Effectiveness of step-down versus outpatient dialectical behaviour therapy for patients with severe levels of borderline personality disorder: a pragmatic randomized controlled trial. Borderline Personality Disorder and Emotion Dysregulation2018;5:12. [DOI: 10.1186/s40479-018-0089-5] [PMC6040072] [PMID: 30002832]SinnaeveR . Cochrane Collaboration review [personal communication]. Email to: J Stoffers-Winterling 11 June 2018. SinnaeveR . Re: BPDSI subscale data Sinnaeve et al (2018) [personal communication]. Email to: A Tadorovac 15 November 2018. SinnaeveR . RE: BPDSI subscale data Sinnaeve et al (2018) [personal communication] [RE: BPDSI subschale data Sinnaeve et al (2018) [personlig kommunikation]]. Email to: A Todorovac 15 November 2018. SinnaeveR . RE: BPDSI subscale data Sinnaeve et al (2018) [personal communication] [RE: BPDSI subschale data Sinnaeve et al (2018) [personlig kommunikation]]. Email to: A Todorovac 9 October 2018. Van den BoschLM , SinnaeveR , Hakkaart-van RoijenL , Van FurthEF . Efficacy and cost-effectiveness of an experimental short-term inpatient dialectical behavior therapy (DBT) program: study protocol for a randomized controlled trial. Trials2014;15:152. [DOI: 10.1186/1745-6215-15-152] [PMC4017823] [PMID: 24885551]Van RoijenLH , SinnaeveR , BouwmansC , Van Den BoschL . Cost-effectiveness and cost-utility of shortterm inpatient dialectical behavior therapy for chronically parasuicidal BPD (young) adults. Journal of Mental Health Policy and Economics2015;18(Suppl 1):S19-20. [www.icmpe.org/test1/journal/issues/v18s1toc.html]">Sinnaeve 2018</a>; <a href="./references#CD012955-bbs2-0068" title="SmithPN , GambleSA , CortNA , WardEA , HeH , TalbotNL . Attachment and alliance in the treatment of depressed, sexually abused women. Depression and Anxiety2012;29(2):123-30. [DOI: 10.1002/da.20913] [PMC3325338] [PMID: 22065593]SmithPN . Re: Cochrane Collaboration review of psychotherapies for BPD [personal communication]. Email to: J Stoffers-Winterling 05 July 2018. ">Smith 2012</a>). Twenty‐two trials had at least one domain that was not adequately described in the trials and therefore were considered to be at unclear risk of bias (<a href="./references#CD012955-bbs2-0019" title="BuchheimA , Hörz-SagstetterS , DoeringS , RentropM , SchusterP , BuchheimP , et al. Change of unresolved attachment in borderline personality disorders: RCT study of transference-focused psychotherapy. Psychotherapy and Psychosomatics2017;86(5):314-6. [DOI: 10.1159/000460257] [PMID: 28903103]DiamondD , LevyKN , ClarkinJF , Fischer-KernM , CainNM , DoeringS , et al. Attachment and mentalization in female patients with comorbid narcissistic and borderline personality disorder. Personality Disorders2014;5(4):428-33. [DOI: 10.1037/per0000065] [PMID: 25314231]DiamondD , YeomansFE , SternB , LevyKN , HörzS , DoeringS , et al. Transference-focused psychotherapy for patients with comorbid narcissistic and borderline personality disorder. Psychoanalytic Inquiry2013;33(6):527-51. [DOI: 10.1080/07351690.2013.815087]DoeringS , HörzS , RentropM , Fischer-KernM , SchusterP , BeneckeC , et al. Transference-focused psychotherapy v treatment by community psychotherapists for borderline personality disorder: randomised controlled trial. British Journal of Psychiatry2010;196(5):389-95. [DOI: 10.1192/bjp.bp.109.070177] [PMID: 20435966]DoeringS . Author's reply [to Kleindienst N, Krumm B, Bohus M. Is transference-focused psychotherapy really efficacious for borderline personality disorder? British Journal of Psychiatry 2011;198(2):156-7. DOI: 10.1192/bjp.198.2.156b]. British Journal of Psychiatry2011;198(2):156-7. [DOI: 10.1192/bjp.198.2.157]DoeringS . Question regarding your BPD trial for systematic review in Cochrane Collaboration [personal communication]. Email to: K Lieb, J Stoffers 10 December 2010. Fischer-KernM , DoeringS , TaubnerS , HörzS , ZimmermannJ , RentropM , et al. Transference-focused psychotherapy for borderline personality disorder: change in reflective function. British Journal of Psychiatry2015;207(2):173-4. [DOI: 10.1192/bjp.bp.113.143842] [PMID: 25999334]KleindienstN , KrummB , BohusM . Is transference-focused psychotherapy really efficacious for borderline personality disorder?British Journal of Psychiatry2011;198(2):156-7. [DOI: 10.1192/bjp.198.2.156b] [PMID: 21282787]LevyKN , MeehanKB , YeomansFE . Transference-focused psychotherapy reduces treatment drop-out and suicide attempters compared with community psychotherapist treatment in borderline personality disorder. Evidence-based Mental Health2010;13(4):119. [DOI: 10.1136/ebmh.13.4.119] [PMID: 21036981]NCT00714311. Efficacy of transference-focused psychotherapy for borderline personality disorder [A randomized-controlled trial of transference-focused psychotherapy vs treatment by experienced community psychotherapists for borderline personality disorder]. www.clinicaltrials.gov/ct2/show/NCT00714311 (first received 9 July 2008). RentropM , MartiusP , BäumlJ , BuchheimP , DöeringS , HörzS . Patients with borderline personality disorder not participating in an RCT: are they different?Psychopathology2010;43(6):369-72. [DOI: 10.1159/000320351] [PMID: 20798576]">Doering 2010</a>; <a href="./references#CD012955-bbs2-0020" title="ElicesM , PascualJC , PortellaMJ , Feliu-SolerA , Martín-BlancoA , CarmonaC , et al. Impact of mindfulness training on borderline personality disorder: a randomized trial. Mindfulness2016;7:584-95. [DOI: 10.1007/s12671-016-0492-1]NCT02397031. Mindfulness and interpersonal effectiveness skills in borderline personality disorder [Randomized, active-controlled, clinical trial comparing effects of mindfulness and interpersonal effectiveness skills in borderline personality disorder]. www.clinicaltrials.gov/ct2/show/NCT02397031 (first received 12 March 2015). SolerJ , ElicesM , PascualJC , Martín-BlancoA , Feliu-SolerA , CarmonaC , et al. Effects of mindfulness training on different components of impulsivity in borderline personality disorder: results from a pilot randomized study. Borderline Personality Disorder and Emotion Dysregulation2016;3:1. [DOI: 10.1186/s40479-015-0035-8] [PMC4709962] [PMID: 26759718]">Elices 2016</a>; <a href="./references#CD012955-bbs2-0022" title="FeigenbaumJD , FonagyP , PillingS , JonesA , WildgooseA , BebbingtonPE . A real-world study of the effectiveness of DBT in the UK National Health Service. British Journal of Clinical Psychology2012;51(2):121-41. [DOI: 10.1111/j.2044-8260.2011.02017.x] [PMID: 22574799]">Feigenbaum 2012</a>; <a href="./references#CD012955-bbs2-0024" title="ArntzA , Stupar-RutenfransS , BlooJ , Van DyckR , SpinhovenP . Prediction of treatment discontinuation and recovery from borderline personality disorder: results from an RCT comparing schema therapy and transference-focused psychotherapy. Behaviour Research and Therapy2015;74:60-71. [DOI: 10.1016/j.brat.2015.09.002] [PMID: 26432172]Giesen-BlooJ , ArntzA . Questions concerning the randomized trial of schema-focused therapy vs transference-focused psychotherapy—reply. Archives of General Psychiatry2007;64(5):610-1. [DOI: 10.1001/archpsyc.64.5.610]Giesen-BlooJ , Van DyckR , SpinhovenP , Van TilburgW , DirksenC , Van AsseltT , et al. Errors in table and figure in: outpatient psychotherapy for borderline personality disorder: randomized trial of schema-focused therapy vs transference-focused psychotherapy. Archives of General Psychiatry2006;63(9):1008. Erratum for: Archives of General Psychiatry 2006;63(6):649-58. [DOI: 10.1001/archpsyc.63.9.1008]Giesen-BlooJ , Van DyckR , SpinhovenP , Van TilburgW , DirksenC , Van AsseltT , et al. Outpatient psychotherapy for borderline personality disorder: randomized trial of schema-focused therapy vs transference-focused psychotherapy. Archives of General Psychiatry2006;63(6):649-58. [DOI: 10.1001/archpsyc.63.6.649] [PMID: 16754838]SpinhovenP , Giesen-BlooJ , Van DyckR , KooimanK , ArntzA . The therapeutic alliance in schema-focused therapy and transference-focused psychotherapy for borderline personality disorder. Journal of Consulting and Clinical Psychology2007;75(1):104-15. [DOI: 10.1037/0022-006X.75.1.104] [PMID: 17295569]Van AsseltADI , DirksenCD , ArntzA , Giesen-BlooJH , Van DyckR , SpinhovenP , et al. Out-patient psychotherapy for borderline personality disorder: cost-effectiveness of schema-focused therapy v transference-focused psychotherapy. British Journal of Psychiatry2008;192(6):450-7. [DOI: 10.1192/bjp.bp.106.033597] [PMID: 18515897]Van AsseltADI , DirksenCD , ArntzA , SeverensJL . Difficulties in calculating productivity costs: work disability associated with borderline personality disorder. Value in Health2008;11(4):637-44. [DOI: 10.1111/j.1524-4733.2007.00288.x]YeomansF . Questions concerning the randomized trial of schema-focused therapy vs transference-focused psychotherapy. Archives of General Psychiatry2007;64(5):609-10. [DOI: 10.1001/archpsyc.64.5.609-c] [PMID: 17485613]">Giesen‐Bloo 2006</a>; <a href="./references#CD012955-bbs2-0025" title="GleesonJF , ChanenA , CottonSM , PearceT , NewmanB , McCutcheonL . Treating co-occurring first-episode psychosis and borderline personality: a pilot randomized controlled trial. Early Intervention in Psychiatry2012;6(1):21-9. [DOI: 10.1111/j.1751-7893.2011.00306.x] [PMID: 22379625]GleesonJFM . RE: separate data [personal communication]. Email to: M Kielsholm 28 October 2016. ">Gleeson 2012</a>; <a href="./references#CD012955-bbs2-0031" title="BrandS . AW: questions regarding your trial on emotional intelligence training for BPD [personal communication]. Email to: EG Faltinsen 28 November 2017. BrandS . Questions regarding your trial on emotional intelligence training for BPD [personal communication]. Email to: EG Faltinsen 28 November 2017. JahangardL , HaghighiM , BajoghliH , AhmadpanahM , GhaleihaA , ZarrabianMK , et al. Training emotional intelligence improves both emotional intelligence and depressive symptoms in inpatients with borderline personality disorder and depression. International Journal of Psychiatry in Clinical Practice2012;16(3):197-204. [DOI: 10.3109/13651501.2012.687454] [PMID: 22873719]">Jahangard 2012</a>; <a href="./references#CD012955-bbs2-0032" title="JochemsEC , Van der Feltz-CornelisCM , Van DamA , DuivenvoordenHJ , MulderCL . The effects of motivation feedback in patients with severe mental illness: a cluster randomized controlled trial. Neuropsychiatric Disease and Treatment2015;11:3049-64. [DOI: 10.2147/NDT.S95190] [PMC4686323] [PMID: 26715847]JochemsEC . Cochrane Collaboration review on psychotherapies for borderline PD [personal communication]. Email to: EG Faltinsen 2 July 2018. JochemsEC . Re: Cochrane Collaboration review on psychotherapies for borderline PD [personal communication]. Email to: J Stoffers-Winterling 02 July 2018. ">Jochems 2015</a>; <a href="./references#CD012955-bbs2-0038" title="KramerU , Pascual-LeoneA , BerthoudL , De RotenY , MarquetP , KollyS , et al. Assertive anger mediates effects of dialectical behaviour-informed skills training for borderline personality disorder: a randomized controlled trial. Clinical Psychology &amp; Psychotherapy2016;23(3):189-202. [DOI: 10.1002/cpp.1956] [PMID: 25864773]KramerU . The role of coping change in borderline personality disorder: a process-outcome analysis on dialectical-behaviour skills training. Clinical Psychology &amp; Psychotherapy2017;24(2):302-11. [DOI: 10.1002/cpp.2017] [PMID: 27098296]">Kramer 2016</a>; <a href="./references#CD012955-bbs2-0044" title="Lin T-J, Ko H-C, Wu JY-W, OeiTP , Lane H-Y, Chen C-H. The effectiveness of dialectical behavior therapy skills training group vs cognitive therapy group on reducing depression and suicide attempts for borderline personality disorder in Taiwan. Archives of Suicide Research2019;23(1):82-99. [DOI: 10.1080/13811118.2018.1436104] [PMID: 29528807]">Lin 2019</a>; <a href="./references#CD012955-bbs2-0045" title="HoffmanRE . Impact of treatment accessibility on clinical course of parasuicidal patients. Archives of General Psychiatry1993;50(2):157-8. [DOI: 10.1001/archpsyc.1993.01820140083010] [PMID: 8427557]LindenboimN . To Know Me is to Keep Me: Self-Verification, Validation, and Therapy Dropout in the Treatment of Borderline Personality Disorder [PhD thesis]. Washington (DC): University of Washington, 2009. LinehanMM , ArmstrongHE , SuarezA , AllmonD , HeardHL . Cognitive-behavioral treatment of chronically parasuicidal borderline patients. Archives of General Psychiatry1991;48(12):1060-4. [DOI: 10.1001/archpsyc.1991.01810360024003] [PMID: 1845222]LinehanMM , HeardHL . Impact of treatment accessibility on clinical course of parasuicidal patients — reply. Archives of General Psychiatry1993;50(2):157-8. [DOI: 10.1001/archpsyc.1993.01820140083011]">Linehan 1991</a>; <a href="./references#CD012955-bbs2-0049" title="CaseBG . Letter to the editor on 'McMain SF, Links PS, Gnam WH, Guimond T, Cardish RJ, Korman L, et al. A randomized trial of dialectical behavior therapy versus general psychiatric management for borderline personality disorder. American Journal of Psychiatry 2009;166(12):1365-74. DOI: 10.1176/appi.ajp.2009.09010039'. American Journal of Psychiatry2010;167(4):475. [DOI: 10.1176/appi.ajp.2009.09101532] [PMID: 20360332 ]ISRCTN02634417. Hope for chronically suicidal patient: evaluating the clinical and health services impact of dialectical behaviour therapy (DBT) in individuals with borderline personality disorder [Evaluating the clinical and health services impact of dialectical behaviour therapy (DBT) in individuals with borderline personality disorder: a randomised controlled trial]. www.isrctn.com/ISRCTN02634417 (first received 16 November 2005). [DOI: 10.1186/ISRCTN02634417]McMainSF , FitzpatrickS , BoritzT , BarnhartR , LinksP , StreinerDL . Outcome trajectories and prognostic factors for suicide and self-harm behaviors in patients with borderline personaliy disorder following one year of outpatient psychotherapy. Journal of Personality Disorders2018;32(4):497-512. [DOI: 10.1521/pedi_2017_31_309] [PMID: 28910214]McMainSF , LinksPS , GnamWH , GuimondT , CardishRJ , KormanL , et al. A randomized trial of dialectical behavior therapy versus general psychiatric management for borderline personality disorder. American Journal of Psychiatry2009;166(12):1365-74. [DOI: 10.1176/appi.ajp.2009.09010039] [PMID: 19755574]McMainSF . Dr McMain replies to letter to the editor on 'McMain SF, Links PS, Gnam WH, Guimond T, Cardish RJ, Korman L, et al. A randomized trial of dialectical behavior therapy versus general psychiatric management for borderline personality disorder. American Journal of Psychiatry 2009;166(12):1365-74. DOI: 10.1176/appi.ajp.2009.09010039'. American Journal of Psychiatry2010;167(4):475-6. [DOI: 10.1176/appi.ajp.2009.09101532r)]NCT00154154. Hope for the chronically suicidal patient [Hope for the chronically suicidal patient: evaluating the clinical and health services impact of dialectical behaviour therapy in individuals with borderline personality disorder]. www.clinicaltrials.gov/ct2/show/NCT00154154 (first received 7 September 2005). ">McMain 2009</a>; <a href="./references#CD012955-bbs2-0050" title="McMainSF , GuimondT , BarnhartR , HabinskiL , StreinerDL . A randomized trial of brief dialectical behaviour therapy skills training in suicidal patients suffering from borderline disorder. Acta Psychiatrica Scandinavica2017;135(2):138-48. [DOI: 10.1111/acps.12664] [PMID: 27858962]">McMain 2017</a>; <a href="./references#CD012955-bbs2-0053" title="MohamadizadehL , MakvandiB , PashaR , BakhtiarpourS , HafeziF . Comparing of the effect of dialectical behavior therapy (DBT) and schema therapy (ST) on reducing mood activity and suicidal thoughts in patients with borderline personality disorder. Acta Medica Mediterranea2017;33:1025-31. [DOI: 10.19193/0393-6384_2017_6_162] [www.actamedicamediterranea.com/archive/2017/medica-6/comparing-of-the-effect-of-dialectical-behavior-therapy-dbt-and-schema-therapy-st-on-reducing-mood-activity-and-suicidal-thoughts-in-patients-with-borderline-personality-disorder/pdf]">Mohamadizadeh 2017</a>; <a href="./references#CD012955-bbs2-0056" title="NadortM , ArntzA , SmitJH , Giesen-BlooJ , EikelenboomJ , SpinhovenP , et al. Implementation of outpatient schema therapy for borderline personality disorder with versus without crisis support by the therapist outside office hours: a randomized trial. Behaviour Research and Therapy2009;47(11):961-73. [DOI: 10.1016/j.brat.2009.07.013] [PMID: 19698939]NadortM , ArntzA , SmitJH , Giesen-BlooJ , EikelenboomM , SpinhovenP , et al. Implementation of outpatient schema therapy for borderline personality disorder: study design. BMC Psychiatry2009;9:64. [DOI: 10.1186/1471-244X-9-64] [PMC2762959] [PMID: 19807925]NL1680 (NTR1781). Implementation of out-patient schema-focused therapy for borderline personality disorder in regular mental healthcare. www.trialregister.nl/trial/1680 (first received 29 April 2009). ">Nadort 2009</a>; <a href="./references#CD012955-bbs2-0059" title="BarnicotK . Re: Regarding your study on DBT for self-harming patients [personal communication]. Email to: EG Faltinsen 28 February 2018. PriebeS , BhattiN , BarnicotK , BremnerS , GagliaA , KatsakouC , et al. Effectiveness and cost-effectiveness of dialectical behaviour therapy for self-harming patients with personality disorder: a pragmatic randomised controlled trial. Psychotherapy and Psychosomatics2012;81(6):356-65. [DOI: 10.1159/000338897] [PMID: 22964561]PriebeS . Supplemental information [personal communication]. Email to: M Kielsholm 20 May 2016. ">Priebe 2012</a>; <a href="./references#CD012955-bbs2-0069" title="SolerJ , PascualJC , TianaT , CebriàA , BarrachinaJ , CampinsMJ , et al. Dialectical behaviour therapy skills training compared to standard group therapy in borderline personality disorder: a 3-month randomised controlled clinical trial. Behaviour Research and Therapy2009;47(5):353-8. [DOI: 10.1016/j.brat.2009.01.013] [PMID: 19246029]SolerJ . Question regarding your BPD trials [personal communication]. Email to: J Stoffers 15 December 2010. ">Soler 2009</a>; <a href="./references#CD012955-bbs2-0070" title="FertuckEA , KeilpJ , SongI , MorrisMC , WilsonST , BrodskyBS , et al. Higher executive control and visual memory performance predict treatment completion in borderline personality disorder. Psychotherapy and Psychosomatics2012;81(1):38-43. [DOI: 10.1159/000329700] [PMC3242704] [PMID: 22116411]NCT00533117. Treating suicidal behavior and self-mutilation in people with borderline personality disorder. www.clinicaltrials.gov/ct2/show/NCT00533117 (first received 19 September 2007). ">Stanley 2017</a>; <a href="./references#CD012955-bbs2-0071" title="TurnerRM . Naturalistic evaluation of dialectical behavior therapy-oriented treatment for borderline personality disorder. Cognitive and Behavioral Practice2000;7(4):413-9. [DOI: 10.1016/S1077-7229(00)80052-8]">Turner 2000</a>; <a href="./references#CD012955-bbs2-0072" title="Van den BoschLM , KoeterMW , StijnenT , VerheulR , Van den BrinkW . Sustained efficacy of dialectical behaviour therapy for borderline personality disorder. Behaviour Research and Therapy2005;43(9):1231-41. [DOI: 10.1016/j.brat.2004.09.008] [PMID: 16005708]Van den BoschLM , VerheulR , SchippersGM , Van den BrinkW . Dialectical behavior therapy of borderline patients with and without substance use problems. Implementation and long-term effects. Addictive Behaviors2002;27(6):911-23. [DOI: 10.1016/s0306-4603(02)00293-9] [PMID: 12369475]Van den BoschLMC . Efficacy of dialectical behaviour therapy in the treatment of female borderline patients with and without substance abuse problems: results of a Dutch study [Dialectische gedragstherapie bij Nederlandse vrouwen met een borderline persoonlijkheidsstoornis, met en zonder verslavingsproblemen]. Tijdschrift voor Psychiatrie2005;47(3):127-37. [www.tijdschriftvoorpsychiatrie.nl/assets/articles/articles_1335pdf.pdf]VerheulR , Van den BoschLM , KoeterMW , De RidderMA , StijnenT , Van den BrinkW . Dialectical behaviour therapy for women with borderline personality disorder: 12-month, randomised clinical trial in The Netherlands. British Journal of Psychiatry2003;182:135-40. [DOI: 10.1192/bjp.182.2.135] [PMID: 12562741]">Van den Bosch 2005</a>; <a href="./references#CD012955-bbs2-0073" title="WeinbergI , GundersonJG , HennenJ , Cutter CJ Jr. Manual assisted cognitive treatment for deliberate self-harm in borderline personality disorder patients. Journal of Personality Disorders2006;20(5):482-92. [DOI: 10.1521/pedi.2006.20.5.482] [PMID: 17032160]WilbergT . SV: separate data [personal communication] [SV: separat data [personlig kommunikation]]. Email to: M Kielsholm 25 May 2016. ">Weinberg 2006</a>; <a href="./references#CD012955-bbs2-0074" title="ZanariniMC , FrankenburgFR . A preliminary, randomized trial of psychoeducation for women with borderline personality disorder. Journal of Personality Disorders2008;22(3):284-90. [DOI: 10.1521/pedi.2008.22.3.284] [PMID: 18540800]ZanariniMC , FrankenburgFR . A randomized trial of psychoeducation for patients with BPD. In: 157th annual meeting of the American Psychiatric Association. Psychotherapy and psychopharmacology: dissolving the mind-brain barrier; 2004 May 1-6; New York (NY). Arlington (VA): American Psychiatric Association, 2004:102. [Symposium 100E] [www.psychiatry.org/File%20Library/Psychiatrists/Directories/Library-and-Archive/conference_publications/am_program_2004.pdf]">Zanarini 2008</a>; <a href="./references#CD012955-bbs2-0075" title="ZanariniMC , ConkeyLC , TemesCM , FitzmauriceGM . Randomized controlled trial of web-based psychoeducation for women with borderline personality disorder. Journal of Clinical Psychiatry2018;79(3):16m11153. [DOI: 10.4088/JCP.16m11153] [PMC5764827] [PMID: 28703950]">Zanarini 2018</a>). Only five trials had an overall low risk of bias for all the domains assessed as other potential sources of bias (<a href="./references#CD012955-bbs2-0007" title="BellinoS , ZizzaM , RinaldiC , BogettoF . Combined therapy of major depression with concomitant borderline personality disorder: comparison of interpersonal and cognitive psychotherapy. Canadian Journal of Psychiatry2007;52(11):718-25. [DOI: 10.1177/070674370705201106] [PMID: 18399039]">Bellino 2007</a>; <a href="./references#CD012955-bbs2-0014" title="Carmona i FarrésC , ElicesM , SolerJ , Domínguez-ClavéE , Pomarol-ClotetE , SalvadorR , et al. Effects of mindfulness training on borderline personality disorder: impulsivity versus emotional dysregulation. Mindfulness2019;10:1243-54. [DOI: 10.1007/s12671-018-1071-4]NCT03363230. Effects of mindfulness training on emotion regulation and impulsivity. www.clinicaltrials.gov/ct2/show/NCT03363230 (first received 30 November 2017). ">Carmona í Farrés 2019</a>; <a href="./references#CD012955-bbs2-0016" title="CottrauxJ , NoteID , BoutitieF , MillieryM , GenouihlacV , YaoSN , et al. Cognitive therapy versus Rogerian supportive therapy in borderline personality disorder. Two-year follow-up of a controlled pilot study. Psychotherapy and Psychosomatics2009;78(5):307-16. [DOI: 10.1159/000229769] [PMID: 19628959]NCT00131781. Cognitive therapy versus supportive therapy in borderline personality disorder. www.clinicaltrials.gov/ct2/show/NCT00131781 (first received 18 August 2005). ">Cottraux 2009</a>; <a href="./references#CD012955-bbs2-0035" title="KoonsCR , RobinsCJ , TweedJL , LynchTR , GonzalezAM , MorseJQ , et al. Efficacy of dialectical behavior therapy in women veterans with borderline personality disorder. Behavior Therapy2001;32(2):371-90. [DOI: 10.1016/S0005-7894(01)80009-5]">Koons 2001a</a>; <a href="./references#CD012955-bbs2-0054" title="MoreyLC , LowmasterSE , HopwoodCJ . A pilot study of manual-assisted cognitive therapy with a therapeutic assessment augmentation for borderline personality disorder. Psychiatry Research2010;178(3):531-5. [DOI: 10.1016/j.psychres.2010.04.055] [PMID: 20537722]">Morey 2010</a>). </p> </section> </section> <section id="CD012955-sec-0076"> <h3 class="title" id="CD012955-sec-0076">Effects of interventions</h3> <p>See: <a href="./full#CD012955-tbl-0001"><b>Summary of findings 1</b> Psychotherapy versus treatment‐as‐usual</a>; <a href="./full#CD012955-tbl-0002"><b>Summary of findings 2</b> Psychotherapy versus waiting list or no treatment</a>; <a href="./full#CD012955-tbl-0003"><b>Summary of findings 3</b> Dialectical behavioural therapy or mentalisation‐based therapy versus treatment‐as‐usual</a> </p> <p>We present the results for each of the primary and secondary outcomes connected to the 25 comparisons below. Where a meta‐analysis involved two or more different instruments to measure the same construct, we reported effect sizes as SMD, otherwise we reported the MD. To identify the MIREDIF, we transformed the SMD to MD for the scale with best validity and reliability for that outcome. For the analyses of the four primary outcomes in the comparison of psychotherapy versus TAU, we transformed the SMD into MD on the following scales, to assess whether results exceeded the minimum clinically important difference: ZAN BPD Scale, DSHI, Suicidal Attempt Self Injury Interview, GAF scale, and the Hamilton Depression scale. </p> <p>We contacted the authors of 44 trials with unclear or missing data and requested the necessary information. Twenty‐four trial authors replied with answers (<a href="./references#CD012955-bbs2-0001" title="AmiantoF , FerreroA , PieròA , CairoE , RoccaG , SimonelliB , et al. Supervised team management, with or without structured psychotherapy, in heavy users of a mental health service with borderline personality disorder: a two-year follow-up preliminary randomized study. BMC Psychiatry2011;11:181. [DOI: 10.1186/1471-244X-11-181] [PMC3260092 ] [PMID: 22103890]NCT01356069. Efficacy of time-limited psychodynamic psychotherapy and informed clinical management in BPD high MHS users (HUMSH) [Sequential brief Adlerian psychodynamic psychotherapy in heavy users of a mental health service with borderline personality disorder: a two years follow-up preliminary randomized study]. clinicaltrials.gov/ct2/show/NCT01356069 (first received 16 May 2011). ">Amianto 2011</a>; <a href="./references#CD012955-bbs2-0004" title="BatemanA , FonagyP . 8-year follow-up of patients treated for borderline personality disorder: mentalization-based treatment versus treatment as usual. American Journal of Psychiatry2008;165(5):631-8. [DOI: 10.1176/appi.ajp.2007.07040636] [PMID: 18347003]BatemanA , FonagyP . Effectiveness of partial hospitalization in the treatment of borderline personality disorder: a randomized controlled trial. American Journal of Psychiatry1999;156(10):1563-9. [DOI: 10.1176/ajp.156.10.1563] [PMID: 10518167]BatemanA , FonagyP . Health care utilization costs for borderline personality disorder patients treated with psychoanalytically oriented partial hospitalization versus general psychiatric care. American Journal of Psychiatry2003;160(1):169-71. [10.1176/appi.ajp.160.1.169] [12505818]BatemanA , FonagyP . Treatment of borderline personality disorder with psychoanalytically oriented partial hospitalization: an 18-month follow-up. American Journal of Psychiatry2001;158(1):36-42. [DOI: 10.1176/appi.ajp.158.1.36] [PMID: 11136631]BatemanA . Important: question regarding your BPD trial for systematic review in Cochrane Collaboration [personal communication]. Email to: K Lieb, J Stoffers 14 December 2010. BatemanA . Intensive outpatient and partial hospital care for BPD. In: 157th annual meeting of the American Psychiatric Association. Psychotherapy and pharmacology: dissolving the mind-brain barrier; 2004 May 1-6; New York (NY). Arlington (VA): American Psychiatric Association, 2004:102. [Symposium 100B] [www.psychiatry.org/File%20Library/Psychiatrists/Directories/Library-and-Archive/conference_publications/am_program_2004.pdf]BatemanAW , FonagyP . Drs Bateman and Fonagy reply [to Stern R. Partial hospitalization for borderline personality disorder. American Journal of Psychiatry 2001;158(11):1932-3. DOI: 10.1176/appi.ajp.158.11.1932]. American Journal of Psychiatry2001;158(11):1932-3. [DOI: 10.1176/appi.ajp.158.11.1932-a]EvansC . Treatment benefits of psychoanalytically oriented partial hospitalisation were maintained over 18 months in borderline personality disorder. Evidence-Based Mental Health2001;4(3):73. [DOI: 10.1136/ebmh.4.3.73]FonagyP , BatemanAW . Mentalizing and borderline personality disorder. Journal of Mental Health2007;16(1):83-101. [DOI: 10.1080/09638230601182045]SternR . Partial hospitalization for borderline personality disorder. American Journal of Psychiatry2001;158(11):1932-3. [DOI: 10.1176/appi.ajp.158.11.1932] [PMID: 11691712]">Bateman 1999</a>; <a href="./references#CD012955-bbs2-0006" title="BellinoS , ParadisoE , ZizzaM , Di LorenzoR , BogettoF . Combined therapy with interpersonal psychotherapy of major depressed patients with borderline personality disorder: a comparison with pharmacotherapy [Terapia combinata con psicoterapia interpersonale di pazienti depressi maggiori con disturbo borderline di personalità: confronto con la farmacoterapia]. Journal of Psychopathology2005;11(1):34-42. [bit.ly/2rZUh5h]BellinoS , ZizzaM , RinaldiC , BogettoF . Combined treatment of major depression in patients with borderline personality disorder: a comparison with pharmacotherapy. Canadian Journal of Psychiatry2006;51(7):453-60. [DOI: 10.1177/070674370605100707] [PMID: 16838827]">Bellino 2006</a>; <a href="./references#CD012955-bbs2-0010" title="BlackD . Question regarding your BPD trial [personal communication]. Email to: J Stoffers 04 January 2011. BlackDW , AllenJ , McCormickB , BlumN . Treatment received by persons with BPD participating in a randomized clinical trial of the systems training for emotional predictability and problem solving programme. Personality and Mental Health2011;5(3):159-68. [DOI: 10.1002/pmh.167]BlackDW , AllenJ , St JohnD , PfohlB , McCormickB , BlumN . Predictors of response to systems training for emotional predictability and problem solving (STEPPS) for borderline personality disorder: an exploratory study. Acta Psychiatrica Scandinavica2009;120(1):53-61. [DOI: 10.1111/j.1600-0447.2008.01340.x] [PMC3665337] [PMID: 19183126]BlackDW , BlumN , PfohlB , St JohnD . The STEPPS group treatment program for outpatients with borderline personality disorder. Journal of Contemporary Psychotherapy2004;34(3):193-210. [DOI: 10.1023/B:JOCP.0000036630.25741.83]BlackDW , PfohlBM . Randomized clinical trial of STEPPS versus treatment as usual. In: 158th annual meeting of the American Psychiatric Association. Psychosomatic medicine: integrating psychiatry &amp; medicine; 2005 May 21-26; Atlanta (GA). Arlington (VA): American Psychiatric Association, 2005:104. [No. 1B] [www.psychiatry.org/File%20Library/Psychiatrists/Directories/Library-and-Archive/syllabus/am_syllabus_2005.pdf]BlackDW , Simsek-DuranF , BlumN , McCormickB , AllenJ . Do people with borderline personality disorder complicated by antisocial personality disorder benefit from the STEPPS treatment program?Personality and Mental Health2016;10(3):205-15. [DOI: 10.1002/pmh.1326] [PMC4911327] [PMID: 26671625]BlackDW . RE: [external] questions regarding your trial on the STEPPS program for BPD [personal communication]. Email to: EG Faltinsen 27 November 2017. BlumN , AllenJ , McCormickB , BlackDW . Ms Blum and colleagues reply [to Schulte-Herbrüggen O, Koerting J, Roepke S. Effectiveness of adjunctive STEPPS group treatment in borderline personality disorder patients. American Journal of Psychiatry 2008;165(10):1354-5. DOI: 10.1176/appi.ajp.2008.08030390]. American Journal of Psychiatry2008;165(10):1354-5. [DOI: 10.1176/appi.ajp.2008.08030390r]BlumN , FranklinJ , HanselR , McCormickB , St JohnD , PfohlB , et al. Relationship of age to symptom severity, psychiatric comorbidity and health care utilization in persons with borderline personality disorder. Personality and Mental Health2008;2(1):25-43. [DOI: 10.1002/pmh.26]BlumN , St JohnD , PfohlB , StuartS , McCormickB , AllenJ , et al. Erratum. American Journal of Psychiatry2008;165(6):777. Erratum for: American Journal of Psychiatry 2008;165(4):468-78. [psycnet.apa.org/record/2008-07854-033]BlumN , St JohnD , PfohlB , StuartS , McCormickB , AllenJ , et al. Systems training for emotional predictability and problem solving (STEPPS) for outpatients with borderline personality disorder: a randomized controlled trial and 1-year follow-up. American Journal of Psychiatry2008;165(4):468-78. [DOI: 10.1176/appi.ajp.2007.07071079] [PMC3608469] [PMID: 18281407]DavidsonKM . Borderline personality disorder: STEPPS improves symptoms. Evidence-Based Mental Health2008;11(4):120. [DOI: 10.1136/ebmh.11.4.120] [PMID: 18952969]NCT00055315. Treatment for borderline personality disorder [A cognitive group treatment for borderline outpatients]. clinicaltrials.gov/ct2/show/NCT00055315 (first received 25 February 2003). ">Blum 2008</a>; <a href="./references#CD012955-bbs2-0012" title="BorschmannR , BarrettB , HellierJM , ByfordS , HendersonC , RoseD , et al. Joint crisis plans for people with borderline personality disorder: feasibility and outcomes in a randomised controlled trial. British Journal of Psychiatry2013;202(5):357-64. [DOI: 10.1192/bjp.bp.112.117762] [PMID: 23637110]BorschmannR . Joint crisis plans for BPD - question on publication in British Journal of Psychiatry [pers communication]. Email to: J Stoffers-Winterling 22 August 2017. BorschmannR . RE: joint crisis plans for BPD - question on publication in British Journal of Psychiatry [personal communication]. Email to: J Stoffers-Winterling 22 August 2017. BorschmannR . The development and testing of joint crisis plans for people with borderline personality disorder: a feasibility study. ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.628499 (accessed 27 January 2019). HellierJ . RE: regarding your study on on MBT for eating disorders [personal communication]. Email to: E Faltinsen 27 March 2018. HellierJ . RE: regarding your study on on MBT for eating disorders [personal communication]. Email to: E Faltinsen 3 January 2018. HellierJ . SV: regarding your study on MBT for eating disorders [personal communication]. Email to: EG Faltinsen, P Robinson 27 March 2018. ISRCTN12440268. JOSHUA: a pilot randomised controlled trial of joint crisis plans for people who self harm. www.isrctn.com/ISRCTN12440268 (first received 17 September 2009). ">Borschmann 2013</a>; <a href="./references#CD012955-bbs2-0014" title="Carmona i FarrésC , ElicesM , SolerJ , Domínguez-ClavéE , Pomarol-ClotetE , SalvadorR , et al. Effects of mindfulness training on borderline personality disorder: impulsivity versus emotional dysregulation. Mindfulness2019;10:1243-54. [DOI: 10.1007/s12671-018-1071-4]NCT03363230. Effects of mindfulness training on emotion regulation and impulsivity. www.clinicaltrials.gov/ct2/show/NCT03363230 (first received 30 November 2017). ">Carmona í Farrés 2019</a>; <a href="./references#CD012955-bbs2-0015" title="CarterG . Question regarding your BPD trial [personal communication]. Email to: J Stoffers 21 December 2010. CarterGL , WillcoxCH , LewinTJ , ConradAM , BenditN . Hunter DBT project: randomized controlled trial of dialectical behaviour therapy in women with borderline personality disorder. Australian and New Zealand Journal of Psychiatry2010;44(2):162-73. [DOI: 10.3109/00048670903393621] [PMID: 20113305]">Carter 2010</a>; <a href="./references#CD012955-bbs2-0019" title="BuchheimA , Hörz-SagstetterS , DoeringS , RentropM , SchusterP , BuchheimP , et al. Change of unresolved attachment in borderline personality disorders: RCT study of transference-focused psychotherapy. Psychotherapy and Psychosomatics2017;86(5):314-6. [DOI: 10.1159/000460257] [PMID: 28903103]DiamondD , LevyKN , ClarkinJF , Fischer-KernM , CainNM , DoeringS , et al. Attachment and mentalization in female patients with comorbid narcissistic and borderline personality disorder. Personality Disorders2014;5(4):428-33. [DOI: 10.1037/per0000065] [PMID: 25314231]DiamondD , YeomansFE , SternB , LevyKN , HörzS , DoeringS , et al. Transference-focused psychotherapy for patients with comorbid narcissistic and borderline personality disorder. Psychoanalytic Inquiry2013;33(6):527-51. [DOI: 10.1080/07351690.2013.815087]DoeringS , HörzS , RentropM , Fischer-KernM , SchusterP , BeneckeC , et al. Transference-focused psychotherapy v treatment by community psychotherapists for borderline personality disorder: randomised controlled trial. British Journal of Psychiatry2010;196(5):389-95. [DOI: 10.1192/bjp.bp.109.070177] [PMID: 20435966]DoeringS . Author's reply [to Kleindienst N, Krumm B, Bohus M. Is transference-focused psychotherapy really efficacious for borderline personality disorder? British Journal of Psychiatry 2011;198(2):156-7. DOI: 10.1192/bjp.198.2.156b]. British Journal of Psychiatry2011;198(2):156-7. [DOI: 10.1192/bjp.198.2.157]DoeringS . Question regarding your BPD trial for systematic review in Cochrane Collaboration [personal communication]. Email to: K Lieb, J Stoffers 10 December 2010. Fischer-KernM , DoeringS , TaubnerS , HörzS , ZimmermannJ , RentropM , et al. Transference-focused psychotherapy for borderline personality disorder: change in reflective function. British Journal of Psychiatry2015;207(2):173-4. [DOI: 10.1192/bjp.bp.113.143842] [PMID: 25999334]KleindienstN , KrummB , BohusM . Is transference-focused psychotherapy really efficacious for borderline personality disorder?British Journal of Psychiatry2011;198(2):156-7. [DOI: 10.1192/bjp.198.2.156b] [PMID: 21282787]LevyKN , MeehanKB , YeomansFE . Transference-focused psychotherapy reduces treatment drop-out and suicide attempters compared with community psychotherapist treatment in borderline personality disorder. Evidence-based Mental Health2010;13(4):119. [DOI: 10.1136/ebmh.13.4.119] [PMID: 21036981]NCT00714311. Efficacy of transference-focused psychotherapy for borderline personality disorder [A randomized-controlled trial of transference-focused psychotherapy vs treatment by experienced community psychotherapists for borderline personality disorder]. www.clinicaltrials.gov/ct2/show/NCT00714311 (first received 9 July 2008). RentropM , MartiusP , BäumlJ , BuchheimP , DöeringS , HörzS . Patients with borderline personality disorder not participating in an RCT: are they different?Psychopathology2010;43(6):369-72. [DOI: 10.1159/000320351] [PMID: 20798576]">Doering 2010</a>; <a href="./references#CD012955-bbs2-0020" title="ElicesM , PascualJC , PortellaMJ , Feliu-SolerA , Martín-BlancoA , CarmonaC , et al. Impact of mindfulness training on borderline personality disorder: a randomized trial. Mindfulness2016;7:584-95. [DOI: 10.1007/s12671-016-0492-1]NCT02397031. Mindfulness and interpersonal effectiveness skills in borderline personality disorder [Randomized, active-controlled, clinical trial comparing effects of mindfulness and interpersonal effectiveness skills in borderline personality disorder]. www.clinicaltrials.gov/ct2/show/NCT02397031 (first received 12 March 2015). SolerJ , ElicesM , PascualJC , Martín-BlancoA , Feliu-SolerA , CarmonaC , et al. Effects of mindfulness training on different components of impulsivity in borderline personality disorder: results from a pilot randomized study. Borderline Personality Disorder and Emotion Dysregulation2016;3:1. [DOI: 10.1186/s40479-015-0035-8] [PMC4709962] [PMID: 26759718]">Elices 2016</a>; <a href="./references#CD012955-bbs2-0021" title="FarrellJM , ShawIA , WebberMA . A schema-focused approach to group psychotherapy for outpatients with borderline personality disorder: a randomized controlled trial. Journal of Behavior Therapy and Experimental Psychiatry2009;40(2):317-28 Corrigendum to: Journal of Behavior Therapy and Experimental Psychiatry 2018; 60: 111. [DOI: 10.1016/j.jbtep.2009.01.002] [PMID: 19176222]FarrellJM . Question regarding your BPD trials [personal communication]. Email to: K Lieb, J Stoffers 9 December 2010. ">Farrell 2009</a>; <a href="./references#CD012955-bbs2-0025" title="GleesonJF , ChanenA , CottonSM , PearceT , NewmanB , McCutcheonL . Treating co-occurring first-episode psychosis and borderline personality: a pilot randomized controlled trial. Early Intervention in Psychiatry2012;6(1):21-9. [DOI: 10.1111/j.1751-7893.2011.00306.x] [PMID: 22379625]GleesonJFM . RE: separate data [personal communication]. Email to: M Kielsholm 28 October 2016. ">Gleeson 2012</a>; <a href="./references#CD012955-bbs2-0026" title="Gratz KL. Important: question regarding your BPD trial for systematic review in Cochrane Collaboration [personal communication]. Email to: J Stoffers-Winterling 11 December 2010. GratzKL , GundersonJG . Preliminary data on an acceptance-based emotion regulation group intervention for deliberate self-harm among women with borderline personality disorder. Behavior Therapy2006;37(1):25-35. [DOI: 10.1016/j.beth.2005.03.002] [PMID: 16942958]">Gratz 2006</a>; <a href="./references#CD012955-bbs2-0039" title="KredlowMA , SzuhanyKL , LoS , XieH , GottliebJD , RosenbergSD , et al. Cognitive behavioral therapy for posttraumatic stress disorder in individuals with severe mental illness and borderline personality disorder. Psychiatry Research2017;249:86-93. [DOI: 10.1016/j.psychres.2016.12.045] [PMC5325773] [PMID: 28086181]MueserK . Re: question regarding your trial on CBT for BPD patients [personal communication]. Email to: EG Faltinsen 28 November 2017. ">Kredlow 2017a</a>; <a href="./references#CD012955-bbs2-0040" title="KredlowMA , SzuhanyKL , LoS , XieH , GottliebJD , RosenbergSD , et al. Cognitive behavioral therapy for posttraumatic stress disorder in individuals with severe mental illness and borderline personality disorder. Psychiatry Research2017;249:86-93. [DOI: 10.1016/j.psychres.2016.12.045] [PMC5325773] [PMID: 28086181]MueserKT , GottliebJD , XieH , LuW , YanosPT , RosenbergSD , et al. Evaluation of cognitive restructuring for post-traumatic stress disorder in people with severe mental illness.. British Journal of Psychiatry2015;206(6):501-8. [DOI: 10.1192/bjp.bp.114.147926] [PMC4450219] [PMID: 25858178]MueserKT , RosenbergSD , XieH , JankowskiMK , BoltonEE , LuW , et al. A randomized controlled trial of cognitive-behavioral treatment for posttraumatic stress disorder in severe mental illness. Journal of Consulting and Clinical Psychology2008;76(2):259-71. [DOI: 10.1037/0022-006X.76.2.259] [PMC3916092] [PMID: 18377122]MueserKT . Re: question regarding your trial on CBT for PTSD participants [personal communication]. Email to: E Faltinsen 28 November 2018. ">Kredlow 2017b</a>; <a href="./references#CD012955-bbs2-0043" title="LeppänenV , HakkoH , SintonenH , LindemanS . Comparing effectiveness of treatments for borderline personality disorder in communal mental health care: the Oulu BPD study. Community Mental Health Journal2016;52(2):216-27. [DOI: 10.1007/s10597-015-9866-4] [PMID: 25824852]LeppänenV . Re: questions regarding the Oulu BPD study [personal communication]. Email to: E Faltinsen 20 December 2017. LeppänenV . Re: SV: question regarding the Oulu BPD study [personal communication]. Email to: EG Faltinsen 22 December 2017. ">Leppänen 2016</a>; <a href="./references#CD012955-bbs2-0052" title="HagaE , AasE , GrøholtB , TørmoenAJ , MehlumL . Cost-effectiveness of dialectical behaviour therapy vs enhanced usual care in the treatment of adolescents with self-harm. Child and Adolescent Psychiatry and Mental Health2018;12:22. [DOI: 10.1186/s13034-018-0227-2] [PMC5928596] [PMID: 29743941]MehlumL , RambergM , TørmoenAJ , HagaE , DiepLM , StanleyBH , et al. Dialectical behavior therapy compared with enhanced usual care for adolescents with repeated suicidal and self-harming behavior: outcomes over a one-year follow-up. Journal of the American Academy of Child and Adolescent Psychiatry2016;55(4):295-300. [DOI: 10.1016/j.jaac.2016.01.005] [PMID: 27015720]MehlumL , TørmoenAJ , RambergM , HagaE , DiepLM , LabergS , et al. Dialectical behavior therapy for adolescents with repeated suicidal and self-harming behavior: a randomized trial. Journal of the American Academy of Child and Adolescent Psychiatry2014;53(10):1082-91. [DOI: 10.1016/j.jaac.2014.07.003] [PMID: 25245352]MehlumL . Re: regarding your study of DBT for your with suicidal behavior [personal communication] [Re: angående din studie om DBT for ungdom med selvmordsatferd [personlig kommunikation]]. Email to: E Faltinsen 5 December 2017. NCT00675129. Treatment for adolescents with deliberate self harm [A randomized controlled trial for repetitive deliberate self-harm and suicidal behaviours among Norwegian adolescents: a comparison between dialectical behaviour therapy adapted for adolescents (DBT-A) and enhanced usual care (EUC)]. www.clinicaltrials.gov/ct2/show/NCT00675129 (first received 6 May 2008). RamlethRK , GroholtB , DiepLM , WalbyFA , MehlumL . The impact of borderline personality disorder and sub-threshold borderline personality disorder on the course of self-reported and clinician-rated depression in self-harming adolescents. Borderline Personality Disorder and Emotion Dysregulation2017;4:22. [DOI: 10.1186/s40479-017-0073-5] [PMC5663078] [PMID: 29093819]">Mehlum 2014</a>; <a href="./references#CD012955-bbs2-0055" title="MortonJ , SnowdonS , GopoldM , GuymerE . Acceptance and commitment therapy group treatment for symptoms of borderline personality disorder: a public sector pilot study. Cognitive and Behavioral Practice2012;19(4):527-44. [DOI: 10.1016/j.cbpra.2012.03.005]MortonJ . Re: SV: regarding your study on acceptance and commitment therapy for BPD [personal communication]. Email to: EG Faltinsen 22 December 2017. ">Morton 2012</a>; <a href="./references#CD012955-bbs2-0059" title="BarnicotK . Re: Regarding your study on DBT for self-harming patients [personal communication]. Email to: EG Faltinsen 28 February 2018. PriebeS , BhattiN , BarnicotK , BremnerS , GagliaA , KatsakouC , et al. Effectiveness and cost-effectiveness of dialectical behaviour therapy for self-harming patients with personality disorder: a pragmatic randomised controlled trial. Psychotherapy and Psychosomatics2012;81(6):356-65. [DOI: 10.1159/000338897] [PMID: 22964561]PriebeS . Supplemental information [personal communication]. Email to: M Kielsholm 20 May 2016. ">Priebe 2012</a>; <a href="./references#CD012955-bbs2-0061" title="ISRCTN51304415. Nice OUtcomes for Referrals with Impulsivity, Self Harm and Eating Disorders: the NOURISHED study [A randomised controlled trial of mentalisation based therapy against specialist supportive clinical management in patients with both eating disorders and symptoms of borderline personality disorder]. www.isrctn.com/ISRCTN51304415 (first received 31 January 2011). RobinsonP , BarrettB , BatemanA , HakeemA , HellierJ , LemonskyF , et al. Study protocol for a randomized controlled trial of mentalization based therapy against specialist supportive clinical management in patients with both eating disorders and symptoms of borderline personality disorder. BMC Psychiatry2014;14:51. [DOI: 10.1186/1471-244X-14-51] [PMC3996076] [PMID: 24555511]RobinsonP , HellierJ , BarrettB , BarzdaitieneD , BatemanA , BogaardtA , et al. The NOURISHED randomised controlled trial comparing mentalisation-based treatment for eating disorders (MBT-ED) with specialist supportive clinical management (SSCM-ED) for patients with eating disorders and symptoms of borderline personality disorder. Trials2016;17(1):549. [DOI: 10.1186/s13063-016-1606-8] [PMC5114835] [PMID: 27855714]">Robinson 2016</a>; <a href="./references#CD012955-bbs2-0063" title="SalzerS , CroppC , JaegerU , MasuhrO , Streeck-FischerA . Psychodynamic therapy for adolescents suffering from co-morbid disorders of conduct and emotions in an in-patient setting: a randomized controlled trial. Psychological Medicine2014;44(10):2213-22. [DOI: 10.1017/S003329171300278X] [PMID: 24229481]SalzerS , Streeck-FischerA . The psychoanalytic-interactional method (PiM) for adolescents with borderline personality disorder [Die psychoanalytisch-interaktionelle methode (PiM) für adoleszente mit borderline-persönlichkeitsstörung]. Personlichkeitsstorungen Theorie und Therapie2015;19(1):67-76. [elibrary.klett-cotta.de/article/99.120110/ptt-19-1-67]SalzerS . AW: Re: Cochrane Review on psychotherapies for BPD - RCT testing PiM vs WL [personal communication] [AW:Re: Cochrane Review zur Psychotherapie bei BPS - RCT zu PiM vs WL [persönliche kommunikation]]. Email to: J Stoffers-Winterling 15 July 2018. ">Salzer 2014</a>; <a href="./references#CD012955-bbs2-0065" title="SchillingL , MoritzS , KötherU , NagelM . Preliminary results on acceptance, feasibility, and subjective efficacy of the add-on group intervention metacognitive training for borderline patients. Journal of Cognitive Psychotherapy2015;29(2):153-64. [DOI: 10.1891/0889-8391.29.2.153]SchillingL , MoritzS , KristonL , KriegerM , NagelM . Efficacy of metacognitive training for patients with borderline personality disorder: preliminary results. Psychiatry Research2018;262:459-64. [DOI: 10.1016/j.psychres.2017.09.024] [PMID: 28927866]SchillingL . Re Schilling 2015/2018 - Cochrane Review of psychotherapies for BPD [personal communication] [Re Schilling 2015/2018 - Cochrane Review zur Psychotherapie bei BPS [persönliche Kommunikation]]. Email to: J Stoffers-Winterling 22 January 2019. ">Schilling 2018</a>; <a href="./references#CD012955-bbs2-0067" title="NCT01904227. Intensified, inpatient adaptation of dialectical behavior therapy (DBT) (REDBT) [A randomized controlled study of the efficacy of an intensified, inpatient adaptation of dialectical behavior therapy (DBT) for a population of borderline patients (young adults/adults: 18-40), compared with standard outpatient DBT]. www.clinicaltrials.gov/ct2/show/NCT01904227 (first received 11 July 2013). SinnaeveR , Van den BoschLM , Van Steenbergen-WeijenburgKM . Change in interpersonal functioning during psychological interventions for borderline personality disorder — a systematic review of measures and efficacy. Personality and Mental Health2015;9(3):173-94. [DOI: 10.1002/pmh.1296] [PMID: 26058794]SinnaeveR , Van den BoschLMC , Hakkaart-van RoijenL , VansteelandtK . Effectiveness of step-down versus outpatient dialectical behaviour therapy for patients with severe levels of borderline personality disorder: a pragmatic randomized controlled trial. Borderline Personality Disorder and Emotion Dysregulation2018;5:12. [DOI: 10.1186/s40479-018-0089-5] [PMC6040072] [PMID: 30002832]SinnaeveR . Cochrane Collaboration review [personal communication]. Email to: J Stoffers-Winterling 11 June 2018. SinnaeveR . Re: BPDSI subscale data Sinnaeve et al (2018) [personal communication]. Email to: A Tadorovac 15 November 2018. SinnaeveR . RE: BPDSI subscale data Sinnaeve et al (2018) [personal communication] [RE: BPDSI subschale data Sinnaeve et al (2018) [personlig kommunikation]]. Email to: A Todorovac 15 November 2018. SinnaeveR . RE: BPDSI subscale data Sinnaeve et al (2018) [personal communication] [RE: BPDSI subschale data Sinnaeve et al (2018) [personlig kommunikation]]. Email to: A Todorovac 9 October 2018. Van den BoschLM , SinnaeveR , Hakkaart-van RoijenL , Van FurthEF . Efficacy and cost-effectiveness of an experimental short-term inpatient dialectical behavior therapy (DBT) program: study protocol for a randomized controlled trial. Trials2014;15:152. [DOI: 10.1186/1745-6215-15-152] [PMC4017823] [PMID: 24885551]Van RoijenLH , SinnaeveR , BouwmansC , Van Den BoschL . Cost-effectiveness and cost-utility of shortterm inpatient dialectical behavior therapy for chronically parasuicidal BPD (young) adults. Journal of Mental Health Policy and Economics2015;18(Suppl 1):S19-20. [www.icmpe.org/test1/journal/issues/v18s1toc.html]">Sinnaeve 2018</a>; <a href="./references#CD012955-bbs2-0068" title="SmithPN , GambleSA , CortNA , WardEA , HeH , TalbotNL . Attachment and alliance in the treatment of depressed, sexually abused women. Depression and Anxiety2012;29(2):123-30. [DOI: 10.1002/da.20913] [PMC3325338] [PMID: 22065593]SmithPN . Re: Cochrane Collaboration review of psychotherapies for BPD [personal communication]. Email to: J Stoffers-Winterling 05 July 2018. ">Smith 2012</a>; <a href="./references#CD012955-bbs2-0069" title="SolerJ , PascualJC , TianaT , CebriàA , BarrachinaJ , CampinsMJ , et al. Dialectical behaviour therapy skills training compared to standard group therapy in borderline personality disorder: a 3-month randomised controlled clinical trial. Behaviour Research and Therapy2009;47(5):353-8. [DOI: 10.1016/j.brat.2009.01.013] [PMID: 19246029]SolerJ . Question regarding your BPD trials [personal communication]. Email to: J Stoffers 15 December 2010. ">Soler 2009</a>). </p> <p>We performed TSA on all primary outcomes and for the secondary outcome depression.at end of treatment for the main comparison versus TSA in our 'Summary of findings' tables, adjusting for multiplicity and sparse data. </p> <p>We considered all trials as being at high risk of bias overall. However, we used all eligible trials in the meta‐analyses, as the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> recommends doing so when all trials are assigned the same risk of bias. We took account of our 'Risk of bias' assessment when considering the quality of the evidence using the GRADE approach, to ensure that judgements about risk of bias and other factors affecting the quality of the evidence were taken into account when interpreting the results of the review (<a href="./references#CD012955-bbs2-0324" title="HigginsJPT , DeeksJJ , AltmanDG , editor(s), Cochrane Statistical Methods Group. Chapter 16: Special topics in statistics. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011</a>; <a href="./references#CD012955-bbs2-0325" title="HigginsJPT , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al (editors). Cochrane Handbook for Systematic Reviews of Interventions. 2nd edition. Chichester (UK): John Wiley &amp; Sons, 2019. [Available from: www.training.cochrane.org/handbook]">Higgins 2019</a>). </p> <section id="CD012955-sec-0077"> <h4 class="title">1. Psychotherapy versus treatment‐as‐usual (TAU)</h4> <section id="CD012955-sec-0078"> <h5 class="title">Primary outcomes</h5> <section id="CD012955-sec-0079"> <h6 class="title">1.1 BPD symptom severity (continuous)</h6> <p>Twenty‐three trials reported continuous data on BPD symptom severity (in total for all time points) (<a href="./references#CD012955-bbs2-0001" title="AmiantoF , FerreroA , PieròA , CairoE , RoccaG , SimonelliB , et al. Supervised team management, with or without structured psychotherapy, in heavy users of a mental health service with borderline personality disorder: a two-year follow-up preliminary randomized study. BMC Psychiatry2011;11:181. [DOI: 10.1186/1471-244X-11-181] [PMC3260092 ] [PMID: 22103890]NCT01356069. Efficacy of time-limited psychodynamic psychotherapy and informed clinical management in BPD high MHS users (HUMSH) [Sequential brief Adlerian psychodynamic psychotherapy in heavy users of a mental health service with borderline personality disorder: a two years follow-up preliminary randomized study]. clinicaltrials.gov/ct2/show/NCT01356069 (first received 16 May 2011). ">Amianto 2011</a>; <a href="./references#CD012955-bbs2-0010" title="BlackD . Question regarding your BPD trial [personal communication]. Email to: J Stoffers 04 January 2011. BlackDW , AllenJ , McCormickB , BlumN . Treatment received by persons with BPD participating in a randomized clinical trial of the systems training for emotional predictability and problem solving programme. Personality and Mental Health2011;5(3):159-68. [DOI: 10.1002/pmh.167]BlackDW , AllenJ , St JohnD , PfohlB , McCormickB , BlumN . Predictors of response to systems training for emotional predictability and problem solving (STEPPS) for borderline personality disorder: an exploratory study. Acta Psychiatrica Scandinavica2009;120(1):53-61. [DOI: 10.1111/j.1600-0447.2008.01340.x] [PMC3665337] [PMID: 19183126]BlackDW , BlumN , PfohlB , St JohnD . The STEPPS group treatment program for outpatients with borderline personality disorder. Journal of Contemporary Psychotherapy2004;34(3):193-210. [DOI: 10.1023/B:JOCP.0000036630.25741.83]BlackDW , PfohlBM . Randomized clinical trial of STEPPS versus treatment as usual. In: 158th annual meeting of the American Psychiatric Association. Psychosomatic medicine: integrating psychiatry &amp; medicine; 2005 May 21-26; Atlanta (GA). Arlington (VA): American Psychiatric Association, 2005:104. [No. 1B] [www.psychiatry.org/File%20Library/Psychiatrists/Directories/Library-and-Archive/syllabus/am_syllabus_2005.pdf]BlackDW , Simsek-DuranF , BlumN , McCormickB , AllenJ . Do people with borderline personality disorder complicated by antisocial personality disorder benefit from the STEPPS treatment program?Personality and Mental Health2016;10(3):205-15. [DOI: 10.1002/pmh.1326] [PMC4911327] [PMID: 26671625]BlackDW . RE: [external] questions regarding your trial on the STEPPS program for BPD [personal communication]. Email to: EG Faltinsen 27 November 2017. BlumN , AllenJ , McCormickB , BlackDW . Ms Blum and colleagues reply [to Schulte-Herbrüggen O, Koerting J, Roepke S. Effectiveness of adjunctive STEPPS group treatment in borderline personality disorder patients. American Journal of Psychiatry 2008;165(10):1354-5. DOI: 10.1176/appi.ajp.2008.08030390]. American Journal of Psychiatry2008;165(10):1354-5. [DOI: 10.1176/appi.ajp.2008.08030390r]BlumN , FranklinJ , HanselR , McCormickB , St JohnD , PfohlB , et al. Relationship of age to symptom severity, psychiatric comorbidity and health care utilization in persons with borderline personality disorder. Personality and Mental Health2008;2(1):25-43. [DOI: 10.1002/pmh.26]BlumN , St JohnD , PfohlB , StuartS , McCormickB , AllenJ , et al. Erratum. American Journal of Psychiatry2008;165(6):777. Erratum for: American Journal of Psychiatry 2008;165(4):468-78. [psycnet.apa.org/record/2008-07854-033]BlumN , St JohnD , PfohlB , StuartS , McCormickB , AllenJ , et al. Systems training for emotional predictability and problem solving (STEPPS) for outpatients with borderline personality disorder: a randomized controlled trial and 1-year follow-up. American Journal of Psychiatry2008;165(4):468-78. [DOI: 10.1176/appi.ajp.2007.07071079] [PMC3608469] [PMID: 18281407]DavidsonKM . Borderline personality disorder: STEPPS improves symptoms. Evidence-Based Mental Health2008;11(4):120. [DOI: 10.1136/ebmh.11.4.120] [PMID: 18952969]NCT00055315. Treatment for borderline personality disorder [A cognitive group treatment for borderline outpatients]. clinicaltrials.gov/ct2/show/NCT00055315 (first received 25 February 2003). ">Blum 2008</a>; <a href="./references#CD012955-bbs2-0004" title="BatemanA , FonagyP . 8-year follow-up of patients treated for borderline personality disorder: mentalization-based treatment versus treatment as usual. American Journal of Psychiatry2008;165(5):631-8. [DOI: 10.1176/appi.ajp.2007.07040636] [PMID: 18347003]BatemanA , FonagyP . Effectiveness of partial hospitalization in the treatment of borderline personality disorder: a randomized controlled trial. American Journal of Psychiatry1999;156(10):1563-9. [DOI: 10.1176/ajp.156.10.1563] [PMID: 10518167]BatemanA , FonagyP . Health care utilization costs for borderline personality disorder patients treated with psychoanalytically oriented partial hospitalization versus general psychiatric care. American Journal of Psychiatry2003;160(1):169-71. [10.1176/appi.ajp.160.1.169] [12505818]BatemanA , FonagyP . Treatment of borderline personality disorder with psychoanalytically oriented partial hospitalization: an 18-month follow-up. American Journal of Psychiatry2001;158(1):36-42. [DOI: 10.1176/appi.ajp.158.1.36] [PMID: 11136631]BatemanA . Important: question regarding your BPD trial for systematic review in Cochrane Collaboration [personal communication]. Email to: K Lieb, J Stoffers 14 December 2010. BatemanA . Intensive outpatient and partial hospital care for BPD. In: 157th annual meeting of the American Psychiatric Association. Psychotherapy and pharmacology: dissolving the mind-brain barrier; 2004 May 1-6; New York (NY). Arlington (VA): American Psychiatric Association, 2004:102. [Symposium 100B] [www.psychiatry.org/File%20Library/Psychiatrists/Directories/Library-and-Archive/conference_publications/am_program_2004.pdf]BatemanAW , FonagyP . Drs Bateman and Fonagy reply [to Stern R. Partial hospitalization for borderline personality disorder. American Journal of Psychiatry 2001;158(11):1932-3. DOI: 10.1176/appi.ajp.158.11.1932]. American Journal of Psychiatry2001;158(11):1932-3. [DOI: 10.1176/appi.ajp.158.11.1932-a]EvansC . Treatment benefits of psychoanalytically oriented partial hospitalisation were maintained over 18 months in borderline personality disorder. Evidence-Based Mental Health2001;4(3):73. [DOI: 10.1136/ebmh.4.3.73]FonagyP , BatemanAW . Mentalizing and borderline personality disorder. Journal of Mental Health2007;16(1):83-101. [DOI: 10.1080/09638230601182045]SternR . Partial hospitalization for borderline personality disorder. American Journal of Psychiatry2001;158(11):1932-3. [DOI: 10.1176/appi.ajp.158.11.1932] [PMID: 11691712]">Bateman 1999</a>; <a href="./references#CD012955-bbs2-0013" title="BosEH , Van WelE , AppeloMT , VerbraakMJP . A randomized controlled trial of a Dutch version of systems training for emotional predictability and problem solving for borderline personality disorder. Journal of Nervous and Mental Disease2010;198(4):299-304. [DOI: 10.1097/NMD.0b013e3181d619cf] [PMID: 20386260]Van WelEB , BosEH , AppeloMT , BerendsenEM , WillgerothFC , VerbraakMJPM . The efficacy of the systems training for emotional predictability and problem solving (STEPPS) in the treatment of borderline personality disorder. A randomized controlled trial [De effectiviteit van de vaardigheidstraining emotieregulatiestoornis (VERS) in de behandeling van de borderlinepersoonlijkheidsstoornis: een gerandomiseerd onderzoek]. Tijdschrift voor Psychiatrie2009;51(5):291-301. [PMID: 19434566]">Bos 2010</a>; <a href="./references#CD012955-bbs2-0019" title="BuchheimA , Hörz-SagstetterS , DoeringS , RentropM , SchusterP , BuchheimP , et al. Change of unresolved attachment in borderline personality disorders: RCT study of transference-focused psychotherapy. Psychotherapy and Psychosomatics2017;86(5):314-6. [DOI: 10.1159/000460257] [PMID: 28903103]DiamondD , LevyKN , ClarkinJF , Fischer-KernM , CainNM , DoeringS , et al. Attachment and mentalization in female patients with comorbid narcissistic and borderline personality disorder. Personality Disorders2014;5(4):428-33. [DOI: 10.1037/per0000065] [PMID: 25314231]DiamondD , YeomansFE , SternB , LevyKN , HörzS , DoeringS , et al. Transference-focused psychotherapy for patients with comorbid narcissistic and borderline personality disorder. Psychoanalytic Inquiry2013;33(6):527-51. [DOI: 10.1080/07351690.2013.815087]DoeringS , HörzS , RentropM , Fischer-KernM , SchusterP , BeneckeC , et al. Transference-focused psychotherapy v treatment by community psychotherapists for borderline personality disorder: randomised controlled trial. British Journal of Psychiatry2010;196(5):389-95. [DOI: 10.1192/bjp.bp.109.070177] [PMID: 20435966]DoeringS . Author's reply [to Kleindienst N, Krumm B, Bohus M. Is transference-focused psychotherapy really efficacious for borderline personality disorder? British Journal of Psychiatry 2011;198(2):156-7. DOI: 10.1192/bjp.198.2.156b]. British Journal of Psychiatry2011;198(2):156-7. [DOI: 10.1192/bjp.198.2.157]DoeringS . Question regarding your BPD trial for systematic review in Cochrane Collaboration [personal communication]. Email to: K Lieb, J Stoffers 10 December 2010. Fischer-KernM , DoeringS , TaubnerS , HörzS , ZimmermannJ , RentropM , et al. Transference-focused psychotherapy for borderline personality disorder: change in reflective function. British Journal of Psychiatry2015;207(2):173-4. [DOI: 10.1192/bjp.bp.113.143842] [PMID: 25999334]KleindienstN , KrummB , BohusM . Is transference-focused psychotherapy really efficacious for borderline personality disorder?British Journal of Psychiatry2011;198(2):156-7. [DOI: 10.1192/bjp.198.2.156b] [PMID: 21282787]LevyKN , MeehanKB , YeomansFE . Transference-focused psychotherapy reduces treatment drop-out and suicide attempters compared with community psychotherapist treatment in borderline personality disorder. Evidence-based Mental Health2010;13(4):119. [DOI: 10.1136/ebmh.13.4.119] [PMID: 21036981]NCT00714311. Efficacy of transference-focused psychotherapy for borderline personality disorder [A randomized-controlled trial of transference-focused psychotherapy vs treatment by experienced community psychotherapists for borderline personality disorder]. www.clinicaltrials.gov/ct2/show/NCT00714311 (first received 9 July 2008). RentropM , MartiusP , BäumlJ , BuchheimP , DöeringS , HörzS . Patients with borderline personality disorder not participating in an RCT: are they different?Psychopathology2010;43(6):369-72. [DOI: 10.1159/000320351] [PMID: 20798576]">Doering 2010</a>; <a href="./references#CD012955-bbs2-0021" title="FarrellJM , ShawIA , WebberMA . A schema-focused approach to group psychotherapy for outpatients with borderline personality disorder: a randomized controlled trial. Journal of Behavior Therapy and Experimental Psychiatry2009;40(2):317-28 Corrigendum to: Journal of Behavior Therapy and Experimental Psychiatry 2018; 60: 111. [DOI: 10.1016/j.jbtep.2009.01.002] [PMID: 19176222]FarrellJM . Question regarding your BPD trials [personal communication]. Email to: K Lieb, J Stoffers 9 December 2010. ">Farrell 2009</a>; <a href="./references#CD012955-bbs2-0026" title="Gratz KL. Important: question regarding your BPD trial for systematic review in Cochrane Collaboration [personal communication]. Email to: J Stoffers-Winterling 11 December 2010. GratzKL , GundersonJG . Preliminary data on an acceptance-based emotion regulation group intervention for deliberate self-harm among women with borderline personality disorder. Behavior Therapy2006;37(1):25-35. [DOI: 10.1016/j.beth.2005.03.002] [PMID: 16942958]">Gratz 2006</a>; <a href="./references#CD012955-bbs2-0027" title="GratzKL , BardeenJR , LevyR , Dixon-GordonKL , TullMT . Mechanisms of change in an emotion regulation group therapy for deliberate self-harm among women with borderline personality disorder. Behaviour Research and Therapy2015;65:29-35. [DOI: 10.1016/j.brat.2014.12.005] [PMC4306622] [PMID: 25557395]GratzKL , Dixon-GordonKL , TullMT . Predictors of treatment response to an adjunctive emotion regulation group therapy for deliberate self-harm among women with borderline personality disorder. Personality Disorders2014;5(1):97-107. [DOI: 10.1037/per0000062] [PMC4059504] [PMID: 2458806]GratzKL , TullMT , LevyR . Randomized controlled trial and uncontrolled 9-month follow-up of an adjunctive emotion regulation group therapy for deliberate self-harm among women with borderline personality disorder. Psychological Medicine2014;44(10):2099-112. [DOI: 10.1017/S0033291713002134] [PMID: 23985088]GratzKL . Question regarding your BPD trials [personal communication]. Email to: J Stoffers 11 December 2010. ">Gratz 2014</a>; <a href="./references#CD012955-bbs2-0028" title="GregoryRJ , ChlebowskiS , KangD , RemenA , SoderbergM . Psychodynamic therapy for borderline personality disorder and co-occurring alcohol use disorders: a newly designed ongoing study. Journal of the American Psychoanalytic Association2006;54(4):1331-4. [DOI: 10.1177/00030651060540040107] [PMID: 17354507]GregoryRJ , ChlebowskiS , KangD , RemenAL , SoderbergMG , StepkovitchJ , et al. A controlled trial of psychodynamic psychotherapy for co-occurring borderline personality disorder and alcohol use disorder. Psychotherapy2008;45(1):28-41. [DOI: 10.1037/0033-3204.45.1.28] [PMID: 22122363]GregoryRJ , DeLucia-DeranjaE , MogleJA . Dynamic deconstructive psychotherapy versus optimized community care for borderline personality disorder co-occuring with alcohol use disorders: a 30-month follow-up. Journal of Nervous and Mental Disease2010;198(4):292-8. [DOI: 10.1097/NMD.0b013e3181d6172d] [PMID: 20386259]GregoryRJ , RemenAL , SoderbergM , Ploutz-SnyderRJ . A controlled trial of psychodynamic psychotherapy for co-occurring borderline personality disorder and alcohol use disorder: six-month outcome. Journal of the American Psychoanalytic Association2009;57(1):199-205. [DOI: 10.1177/00030651090570011006] [PMID: 19270255]NCT00145678. Psychodynamic therapy for co-occurring borderline personality disorder and alcohol use disorder [Psychodynamic therapy for patients With borderline personality disorder and alcohol abuse]. www.clinicaltrials.gov/show/NCT00145678 (first received 1 September 2005). ">Gregory 2008b</a>; <a href="./references#CD012955-bbs2-0033" title="JørgensenCR , BøyeR , AndersenD , Døssing BlaabjergAH , FreundC , JordetH , et al. Eighteen months post-treatment naturalistic follow-up study of mentalization-based therapy and supportive group treatment of borderline personality disorder: clinical outcomes and functioning. Nordic Psychology2014;66(4):254-73. [DOI: 10.1080/19012276.2014.963649]JørgensenCR , FreundC , BøyeR , JordetH , AndersenD , KjølbyeM . Outcome of mentalization-based and supportive psychotherapy in patients with borderline personality disorder: a randomized trial. Acta Psychiatrica Scandinavica2013;127(4):305-17. [DOI: 10.1111/j.1600-0447.2012.01923.x] [PMID: 22897123]JorgensenCR . SV: questions on your trial regarding MBT for BPD patients [personal communication]. Email to: EG Faltinsen 28 November 2017. ">Jørgensen 2013</a>; <a href="./references#CD012955-bbs2-0035" title="KoonsCR , RobinsCJ , TweedJL , LynchTR , GonzalezAM , MorseJQ , et al. Efficacy of dialectical behavior therapy in women veterans with borderline personality disorder. Behavior Therapy2001;32(2):371-90. [DOI: 10.1016/S0005-7894(01)80009-5]">Koons 2001a</a>; <a href="./references#CD012955-bbs2-0039" title="KredlowMA , SzuhanyKL , LoS , XieH , GottliebJD , RosenbergSD , et al. Cognitive behavioral therapy for posttraumatic stress disorder in individuals with severe mental illness and borderline personality disorder. Psychiatry Research2017;249:86-93. [DOI: 10.1016/j.psychres.2016.12.045] [PMC5325773] [PMID: 28086181]MueserK . Re: question regarding your trial on CBT for BPD patients [personal communication]. Email to: EG Faltinsen 28 November 2017. ">Kredlow 2017a</a>; <a href="./references#CD012955-bbs2-0041" title="LaurenssenEM , WestraD , KikkertMJ , NoomMJ , EerenHV , Van BroekhuyzenAJ , et al. Day hospital mentalization-based treatment (MBT-DH) versus treatment as usual in the treatment of severe borderline personality disorder: protocol of a randomized controlled trial. BMC Psychiatry2014;14:149. [DOI: 10.1186/1471-244X-14-149] [PMC4045960] [PMID: 24886402]LaurenssenEMP , LuytenP , KikkertMJ , WestraD , PeenJ , SoonsMBJ , et al. Day hospital mentalization-based treatment v specialist treatment as usual in patients with borderline personality disorder: randomized controlled trial. Psychological Medicine2018;48(15):2522-9. [DOI: 10.1017/S0033291718000132] [PMID: 29478425]NL2058 (NTR2175). Mentalisation-based treatment versus care-as-usual in the treatment of severe borderline personality disorders. www.trialregister.nl/trial/2058 (first received 21 January 2010). ">Laurenssen 2018</a>; <a href="./references#CD012955-bbs2-0042" title="LeichsenringF , MasuhrO , JaegerU , RabungS , DallyA , DümpelmannM , et al. Psychoanalytic-interactional therapy versus psychodynamic therapy by experts for personality disorders: a randomized controlled efficacy-effectiveness study in cluster B personality disorders. Psychotherapy and Psychosomatics2016;85(2):71-80. [DOI: 10.1159/000441731] [PMID: 26808580]">Leichsenring 2016</a>; <a href="./references#CD012955-bbs2-0043" title="LeppänenV , HakkoH , SintonenH , LindemanS . Comparing effectiveness of treatments for borderline personality disorder in communal mental health care: the Oulu BPD study. Community Mental Health Journal2016;52(2):216-27. [DOI: 10.1007/s10597-015-9866-4] [PMID: 25824852]LeppänenV . Re: questions regarding the Oulu BPD study [personal communication]. Email to: E Faltinsen 20 December 2017. LeppänenV . Re: SV: question regarding the Oulu BPD study [personal communication]. Email to: EG Faltinsen 22 December 2017. ">Leppänen 2016</a>; <a href="./references#CD012955-bbs2-0055" title="MortonJ , SnowdonS , GopoldM , GuymerE . Acceptance and commitment therapy group treatment for symptoms of borderline personality disorder: a public sector pilot study. Cognitive and Behavioral Practice2012;19(4):527-44. [DOI: 10.1016/j.cbpra.2012.03.005]MortonJ . Re: SV: regarding your study on acceptance and commitment therapy for BPD [personal communication]. Email to: EG Faltinsen 22 December 2017. ">Morton 2012</a>; <a href="./references#CD012955-bbs2-0058" title="PhilipsB , WennebergP , KonradssonP , FranckJ . Mentalization-based treatment for concurrent borderline personality disorder and substance use disorder: a randomized controlled feasibility study. European Addiction Research2018;24(1):1-8. [DOI: 10.1159/000485564] [PMC5969093] [PMID: 294028]">Philips 2018</a>; <a href="./references#CD012955-bbs2-0059" title="BarnicotK . Re: Regarding your study on DBT for self-harming patients [personal communication]. Email to: EG Faltinsen 28 February 2018. PriebeS , BhattiN , BarnicotK , BremnerS , GagliaA , KatsakouC , et al. Effectiveness and cost-effectiveness of dialectical behaviour therapy for self-harming patients with personality disorder: a pragmatic randomised controlled trial. Psychotherapy and Psychosomatics2012;81(6):356-65. [DOI: 10.1159/000338897] [PMID: 22964561]PriebeS . Supplemental information [personal communication]. Email to: M Kielsholm 20 May 2016. ">Priebe 2012</a>; <a href="./references#CD012955-bbs2-0060" title="RenesesB , FigueraD , SalcedoG , TrujilloM , López-IborJJ , GaliánM , et al. A controlled randomized study on the efficacy of short-term dinamic psychotherapy in borderline personality disorders (BPD). Preliminary results. European Psychiatry2011;26(Suppl 1):1040. [DOI: 10.1016/S0924-9338(11)72745-6] [P02-444]RenesesB , GaliánM , SerranoR , FigueraD , Fernandez Del MoralA , López-IborJJ , et al. A new time limited psychotherapy for BPD: preliminary results of a randomized and controlled trial. Actas Espanolas de Psiquiatria2013;41(3):139-48. [PMID: 23803797]">Reneses 2013</a>; <a href="./references#CD012955-bbs2-0061" title="ISRCTN51304415. Nice OUtcomes for Referrals with Impulsivity, Self Harm and Eating Disorders: the NOURISHED study [A randomised controlled trial of mentalisation based therapy against specialist supportive clinical management in patients with both eating disorders and symptoms of borderline personality disorder]. www.isrctn.com/ISRCTN51304415 (first received 31 January 2011). RobinsonP , BarrettB , BatemanA , HakeemA , HellierJ , LemonskyF , et al. Study protocol for a randomized controlled trial of mentalization based therapy against specialist supportive clinical management in patients with both eating disorders and symptoms of borderline personality disorder. BMC Psychiatry2014;14:51. [DOI: 10.1186/1471-244X-14-51] [PMC3996076] [PMID: 24555511]RobinsonP , HellierJ , BarrettB , BarzdaitieneD , BatemanA , BogaardtA , et al. The NOURISHED randomised controlled trial comparing mentalisation-based treatment for eating disorders (MBT-ED) with specialist supportive clinical management (SSCM-ED) for patients with eating disorders and symptoms of borderline personality disorder. Trials2016;17(1):549. [DOI: 10.1186/s13063-016-1606-8] [PMC5114835] [PMID: 27855714]">Robinson 2016</a>; <a href="./references#CD012955-bbs2-0062" title="ISRCTN95266816. The emergence of personality disorder traits in adolescents who deliberately self harm and the potential for using a mentalisation based treatment approach as an early intervention for such individuals: a randomised controlled trial. www.isrctn.com/ISRCTN95266816 (first received 29 October 2007). RossouwT . Mentalisation based treatment for adolescents with self harm: an RCT. European Child &amp; Adolescent Psychiatry2015;24(1 Suppl):S113. [DOI: 10.1007%2Fs00787-015-0714-4.pdf] [W1-02-02]RossouwT . Self harm in adolescence, is MBT the answer?: an RCT. Adolescent Psychiatry2012;2(1):102. [DOI: 10.2174/2210676611202010077]RossouwTI , FonagyP . Mentalization-based treatment for self-harm in adolescents: a randomized controlled trial. Journal of the American Academy of Child and Adolescent Psychiatry2012;51(12):1304-13.e3. [DOI: 10.1016/j.jaac.2012.09.018] [PMID: 23200287]">Rossouw 2012b</a>; <a href="./references#CD012955-bbs2-0066" title="ISRCTN97589104. Evaluation of a group training for adolescents (emotion regulation training) with emotion regulation problems - a randomised controlled clinical trial. www.isrctn.com/ISRCTN97589104 (first received 23 August 2007). SchuppertHM , TimmermanME , BlooJ , Van GemertTG , WiersemaHM , MinderaaRB , et al. Emotion regulation training for adolescents with borderline personality disorder traits: a randomized controlled trial. Journal of the American Academy of Child &amp; Adolescent Psychiatry2012;51(12):1314-23. [DOI: 10.1016/j.jaac.2012.09.002] [PMID: 23200288]">Schuppert 2012</a>; <a href="./references#CD012955-bbs2-0069" title="SolerJ , PascualJC , TianaT , CebriàA , BarrachinaJ , CampinsMJ , et al. Dialectical behaviour therapy skills training compared to standard group therapy in borderline personality disorder: a 3-month randomised controlled clinical trial. Behaviour Research and Therapy2009;47(5):353-8. [DOI: 10.1016/j.brat.2009.01.013] [PMID: 19246029]SolerJ . Question regarding your BPD trials [personal communication]. Email to: J Stoffers 15 December 2010. ">Soler 2009</a>). </p> <p>Generally, psychotherapy improved BPD symptom severity at end of treatment compared with TAU (SMD −0.52, 95% CI −0.70 to −0.33; 22 trials, 1244 participants; I<sup>2</sup> = 57%; P &lt; 0.001; <a href="./references#CD012955-fig-0004" title="">Analysis 1.1</a>.1; moderate‐quality evidence, <a href="./full#CD012955-tbl-0001">summary of findings Table 1</a>). This corresponds to a MD of −3.6 (95% CI −4.4 to ‐2.08) on the ZAN‐BPD scale, which ranges from 0 to 36. This represents a clinical relevant improvement in BPD symptoms. The MIREDIF on this scale is −3.0 points (<a href="./references#CD012955-bbs2-0279" title="CrawfordMJ ,  SanatiniaR ,  BarrettB , CunninghamG , DaleO ,  GanguliP , et al. The clinical effectiveness and cost-effectiveness of lamotrigine in borderline personality disorder: a randomized placebo-controlled trial. American Journal of Psychiatry2018;175(8):756-64. [DOI: 10.1176/appi.ajp.2018.17091006] [PMID: 29621901]">Crawford 2018a</a>). The TSA analysis showed that the RIS was reached (n = 907), and that there was no risk of type 1 error (TSA adjusted confidence interval −5.49 to −1.90) (see figure 4 in <a href="./appendices#CD012955-sec-0603">Appendix 6</a>). </p> <p>Inspection of the funnel plot (see figure 5 in <a href="./appendices#CD012955-sec-0603">Appendix 6</a>) suggested potential bias (very small asymmetry), and we found evidence of possible significant publication bias: Egger’s regression intercept (bias) 2.234 (two tailed, P = 0.043). Analysis 1.1.1. might be more difficult to understand as we found asymmetry in the funnel plot and also a significant Egger's test. All effect estimates spread unequivocally at the left‐hand side of the zero line, clearly favouring experimental treatments over controls. However, identifying smaller sample size trials with insignificant results would be unlikely to change our pooled estimate substantially because these smaller trials would only contribute lesser weights to the pooled estimates. Hence, we concluded that our findings were not essentially influenced by publication bias. </p> <p>Generally, psychotherapy did not reduce BPD symptom severity at zero to six months follow‐up compared with TAU (SMD −0.59, 95% CI −1.23 to 0.05; 2 trials, 41 participants; I<sup>2</sup> = 0%; P = 0.17; <a href="./references#CD012955-fig-0004" title="">Analysis 1.1</a>.2). </p> <p>Generally, psychotherapy did not reduce BPD symptom severity at six to 12 months follow‐up compared with TAU (SMD −0.04, 95% CI −0.36 to 0.27; 2 trials, 157 participants; I<sup>2</sup> = 0%; P = 0.79; <a href="./references#CD012955-fig-0004" title="">Analysis 1.1</a>.3). </p> <p>Generally, psychotherapy did not reduce BPD symptom severity at above 12 months follow‐up compared with TAU (SMD −0.94, 95% CI −2.58 to 0.70; 2 trials, 97 participants; I<sup>2</sup> = 92%; P = 0.26; <a href="./references#CD012955-fig-0004" title="">Analysis 1.1</a>.4). </p> </section> <section id="CD012955-sec-0080"> <h6 class="title">1.2 BPD symptom severity (dichotomous)</h6> <p>One trial reported dichotomous data on BPD symptom severity (<a href="./references#CD012955-bbs2-0017" title="DavidsonK , LivingstoneS , McArthurK , DicksonL , GumleyA . An integrative complexity analysis of cognitive behaviour therapy sessions for borderline personality disorder. Psychology and Psychotherapy2007;80(Pt 4):513-23. [DOI: 10.1348/147608307X191535] [PMID: 17535542]DavidsonK , NorrieJ , TyrerP , GumleyA , TataP , MurrayH , et al. The effectiveness of cognitive behavior therapy for borderline personality disorder: results from the borderline personality disorder study of cognitive therapy (BOSCOT) trial. Journal of Personality Disorders2006;20(5):450-65. [DOI: 10.1521/pedi.2006.20.5.450] [PMC1852259] [PMID: 17032158]DavidsonK , TyrerP , GumleyA , TataP , NorrieJ , PalmerS , et al. A randomized controlled trial of cognitive behavior therapy for borderline personality disorder: rationale for trial, method, and description of sample. Journal of Personality Disorders2006;20(5):431-49. [DOI: 10.1521/pedi.2006.20.5.431] [PMC1847748] [PMID: 17032157]DavidsonKM , TyrerP , NorrieJ , PalmerSJ , TyrerH . Cognitive therapy v usual treatment for borderline personality disorder: prospective 6-year follow-up. British Journal of Psychiatry2010;197(6):456-62. [DOI: 10.1192/bjp.bp.109.074286] [PMID: 21119151]ISRCTN86177428. Borderline personality disorder study of cognitive therapy trial [A randomised controlled trial of cognitive therapy plus treatment as usual versus treatment as usual in the treatment of borderline personality disorder]. www.isrctn.com/ISRCTN86177428 (first received 22 July 2005). NCT00538135. BOSCOT: a randomised controlled trial of cognitive behavioural therapy in borderline personality disorder [BOSCOT: a randomised control trial of cognitive behavioural therapy plus treatment as usual versus treatment as usual in the treatment of borderline personality disorder]. www.clinicaltrials.gov/ct2/show/NCT00538135 (first received 29 September 2007). NorrieJ , DavidsonK , TataP , GumleyA . Influence of therapist competence and quantity of cognitive behavioural therapy on suicidal behaviour and inpatient hospitalisation in a randomised controlled trial in borderline personality disorder: further analyses of treatment effects in the BOSCOT study. Psychology and Psychotherapy2013;86(3):280-93. [DOI: 10.1111/papt.12004] [PMC4491320] [PMID: 23420622]PalmerS , DavidsonK , TyrerP , GumleyA , TataP , NorrieJ , et al. The cost-effectiveness of cognitive behavior therapy for borderline personality disorder: results from the BOSCOT trial. Journal of Personality Disorders2006;20(5):466-81. [DOI: 10.1521/pedi.2006.20.5.466] [PMC1852260] [PMID: 17032159]">Davidson 2006</a>). </p> <p>Generally, psychotherapy did not reduce BPD symptom severity at above 12 months follow‐up compared with TAU (RR 0.91, 95% CI 0.56 to 1.48; 1 trial, 76 participants; P = 0.71; <a href="./references#CD012955-fig-0005" title="">Analysis 1.2</a>). </p> <p>No data were available for end of treatment, zero to six months and six to 12 months follow‐up. </p> </section> <section id="CD012955-sec-0081"> <h6 class="title">1.3 Self‐harm (continuous)</h6> <p>Thirteen trials reported continuous data on self‐harm (<a href="./references#CD012955-bbs2-0001" title="AmiantoF , FerreroA , PieròA , CairoE , RoccaG , SimonelliB , et al. Supervised team management, with or without structured psychotherapy, in heavy users of a mental health service with borderline personality disorder: a two-year follow-up preliminary randomized study. BMC Psychiatry2011;11:181. [DOI: 10.1186/1471-244X-11-181] [PMC3260092 ] [PMID: 22103890]NCT01356069. Efficacy of time-limited psychodynamic psychotherapy and informed clinical management in BPD high MHS users (HUMSH) [Sequential brief Adlerian psychodynamic psychotherapy in heavy users of a mental health service with borderline personality disorder: a two years follow-up preliminary randomized study]. clinicaltrials.gov/ct2/show/NCT01356069 (first received 16 May 2011). ">Amianto 2011</a>; <a href="./references#CD012955-bbs2-0012" title="BorschmannR , BarrettB , HellierJM , ByfordS , HendersonC , RoseD , et al. Joint crisis plans for people with borderline personality disorder: feasibility and outcomes in a randomised controlled trial. British Journal of Psychiatry2013;202(5):357-64. [DOI: 10.1192/bjp.bp.112.117762] [PMID: 23637110]BorschmannR . Joint crisis plans for BPD - question on publication in British Journal of Psychiatry [pers communication]. Email to: J Stoffers-Winterling 22 August 2017. BorschmannR . RE: joint crisis plans for BPD - question on publication in British Journal of Psychiatry [personal communication]. Email to: J Stoffers-Winterling 22 August 2017. BorschmannR . The development and testing of joint crisis plans for people with borderline personality disorder: a feasibility study. ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.628499 (accessed 27 January 2019). HellierJ . RE: regarding your study on on MBT for eating disorders [personal communication]. Email to: E Faltinsen 27 March 2018. HellierJ . RE: regarding your study on on MBT for eating disorders [personal communication]. Email to: E Faltinsen 3 January 2018. HellierJ . SV: regarding your study on MBT for eating disorders [personal communication]. Email to: EG Faltinsen, P Robinson 27 March 2018. ISRCTN12440268. JOSHUA: a pilot randomised controlled trial of joint crisis plans for people who self harm. www.isrctn.com/ISRCTN12440268 (first received 17 September 2009). ">Borschmann 2013</a>; <a href="./references#CD012955-bbs2-0015" title="CarterG . Question regarding your BPD trial [personal communication]. Email to: J Stoffers 21 December 2010. CarterGL , WillcoxCH , LewinTJ , ConradAM , BenditN . Hunter DBT project: randomized controlled trial of dialectical behaviour therapy in women with borderline personality disorder. Australian and New Zealand Journal of Psychiatry2010;44(2):162-73. [DOI: 10.3109/00048670903393621] [PMID: 20113305]">Carter 2010</a>; <a href="./references#CD012955-bbs2-0022" title="FeigenbaumJD , FonagyP , PillingS , JonesA , WildgooseA , BebbingtonPE . A real-world study of the effectiveness of DBT in the UK National Health Service. British Journal of Clinical Psychology2012;51(2):121-41. [DOI: 10.1111/j.2044-8260.2011.02017.x] [PMID: 22574799]">Feigenbaum 2012</a>; <a href="./references#CD012955-bbs2-0026" title="Gratz KL. Important: question regarding your BPD trial for systematic review in Cochrane Collaboration [personal communication]. Email to: J Stoffers-Winterling 11 December 2010. GratzKL , GundersonJG . Preliminary data on an acceptance-based emotion regulation group intervention for deliberate self-harm among women with borderline personality disorder. Behavior Therapy2006;37(1):25-35. [DOI: 10.1016/j.beth.2005.03.002] [PMID: 16942958]">Gratz 2006</a>; <a href="./references#CD012955-bbs2-0027" title="GratzKL , BardeenJR , LevyR , Dixon-GordonKL , TullMT . Mechanisms of change in an emotion regulation group therapy for deliberate self-harm among women with borderline personality disorder. Behaviour Research and Therapy2015;65:29-35. [DOI: 10.1016/j.brat.2014.12.005] [PMC4306622] [PMID: 25557395]GratzKL , Dixon-GordonKL , TullMT . Predictors of treatment response to an adjunctive emotion regulation group therapy for deliberate self-harm among women with borderline personality disorder. Personality Disorders2014;5(1):97-107. [DOI: 10.1037/per0000062] [PMC4059504] [PMID: 2458806]GratzKL , TullMT , LevyR . Randomized controlled trial and uncontrolled 9-month follow-up of an adjunctive emotion regulation group therapy for deliberate self-harm among women with borderline personality disorder. Psychological Medicine2014;44(10):2099-112. [DOI: 10.1017/S0033291713002134] [PMID: 23985088]GratzKL . Question regarding your BPD trials [personal communication]. Email to: J Stoffers 11 December 2010. ">Gratz 2014</a>; <a href="./references#CD012955-bbs2-0035" title="KoonsCR , RobinsCJ , TweedJL , LynchTR , GonzalezAM , MorseJQ , et al. Efficacy of dialectical behavior therapy in women veterans with borderline personality disorder. Behavior Therapy2001;32(2):371-90. [DOI: 10.1016/S0005-7894(01)80009-5]">Koons 2001a</a>; <a href="./references#CD012955-bbs2-0045" title="HoffmanRE . Impact of treatment accessibility on clinical course of parasuicidal patients. Archives of General Psychiatry1993;50(2):157-8. [DOI: 10.1001/archpsyc.1993.01820140083010] [PMID: 8427557]LindenboimN . To Know Me is to Keep Me: Self-Verification, Validation, and Therapy Dropout in the Treatment of Borderline Personality Disorder [PhD thesis]. Washington (DC): University of Washington, 2009. LinehanMM , ArmstrongHE , SuarezA , AllmonD , HeardHL . Cognitive-behavioral treatment of chronically parasuicidal borderline patients. Archives of General Psychiatry1991;48(12):1060-4. [DOI: 10.1001/archpsyc.1991.01810360024003] [PMID: 1845222]LinehanMM , HeardHL . Impact of treatment accessibility on clinical course of parasuicidal patients — reply. Archives of General Psychiatry1993;50(2):157-8. [DOI: 10.1001/archpsyc.1993.01820140083011]">Linehan 1991</a>; <a href="./references#CD012955-bbs2-0047" title="BedicsJD , AtkinsDC , ComtoisKA , LinehanMM . Treatment differences in the therapeutic relationship and introject during a 2-year randomized controlled trial of dialectical behavior therapy versus nonbehavioral psychotherapy experts for borderline personality disorder. Journal of Consulting and Clinical Psychology2012;80(1):66-77. [DOI: 10.1037/a0026113] [PMC3265694] [PMID: 22061867]BedicsJD , AtkinsDC , ComtoisKA , LinehanMM . Weekly therapist ratings of the therapeutic relationship and patient introject furing the course of dialectical behavioral therapy for the treatment of borderline personality disorder. Psychotherapy2012;49(2):231-40. [DOI: 10.1037/a0028254] [PMID: 22642526]BedicsJD , AtkinsDC , HarnedMS , LinehanMM . The therapeutic alliance as a predictor of outcome in dialectical behavior therapy versus nonbehavioral psychotherapy by experts for borderline personality disorder. Psychotherapy2015;52(1):67-77. [DOI: 10.1037/a0038457] [PMID: 25751116]BrownMZ , LinehanMM , ComtoisKA , MurrayA , ChapmanAL . Shame as a prospective predictor of self-inflicted injury in borderline personality disorder: a multi-modal analysis. Behaviour Research and Therapy2009;47(10):815-22. [DOI: 10.1016/j.brat.2009.06.008] [PMC2761705] [PMID: 19596223 ]CoyleTN , ShaverJA , LinehanMM . On the potential for iatrogenic effects of psychiatric crisis services: the example of dialectical behavior therapy for adult women with borderline personality disorder. Journal of Consulting and Clinical Psychology2018;86(2):116-24. [DOI: 10.1037/ccp0000275] [PMID: 29369662]HarnedMS , ChapmanAL , Dexter-MazzaET , MurrayA , ComtoisKA , LinehanMM . Treating co-occurring Axis I disorders in recurrently suicidal women with borderline personality disorder: a 2-year randomized trial of dialectical behavior therapy versus community treatment by experts. Journal of Consulting and Clinical Psychology2008;76(6):1068-75. [DOI: 10.1037/a0014044] [PMID: 19045974]HarnedMS , ChapmanAL , Dexter-MazzaET , MurrayA , ComtoisKA , LinehanMM . Treating co-occurring Axis I disorders in recurrently suicidal women with borderline personality disorder: a 2-year randomized trial of dialectical behavior therapy versus community treatment by experts. Personality Disorders: Theory, Research, and Treatment2009;S(1):35-45. [DOI: 10.1037/1949-2715.S.1.35]HarnedMS , JacksonSC , ComtoisKA , LinehanMM . Dialectical behavior therapy as a precursor to PTSD treatment for suicidal and/or self-injuring women with bordreline personality disorder. Journal of Traumatic Stress2010;23(4):421-9. [DOI: 10.1002/jts.20553] [PMID: 20648564]LindenboimN , ComtoisKA , LinehanMM . Skills practice in dialectical behavior therapy for suicidal women meeting criteria for borderline personality disorder. Cognitive and Behavioral Practice2007;14(2):147-56. [DOI: 10.1016/j.cbpra.2006.10.004]LinehanMM , ComtoisKA , MurrayAM , BrownMZ , GallopRJ , HeardHL , et al. Two-year randomized controlled trial and follow-up of dialectical behavior therapy vs therapy by experts for suicidal behaviors and borderline personality disorder. Archives of General Psychiatry2006;63(7):757-66. [DOI: 10.1001/archpsyc.63.7.757] [PMID: 16818865]LinehanMM . Error in table in: two-year randomized controlled trial and follow-up of dialectical behavior therapy vs therapy by experts for suicidal behaviors and borderline personality disorder. Archives of General Psychiatry2007;64(12):1401. Erratum for: Archives of General Psychiatry 2007;64(12):1401. McMainS . Dialectic behaviour therapy reduces suicide attempts compared with non-behavioural psychotherapy in women with borderline personality disorder. Evidence-Based Mental Health2007;10(1):18. [DOI: 10.1136/ebmh.10.1.18] [PMID: 17255387]NeacsiuAD , LunguA , HarnedMS , RizviSL , LinehanMM . Impact of dialectical behavior therapy versus community treatment by experts on emotional experience, expression, and acceptance in borderline personality disorder. Behaviour Research and Therapy2014;53:47-54. [DOI: 10.1016/j.brat.2013.12.004] [PMC3955205] [PMID: 24418652]NeacsiuAD , RizviSL , LinehanMM . Dialectical behavior therapy skills use as a mediator and outcome of treatment for borderline personality disorder. Behaviour Research and Therapy2010;48(9):832-9. [DOI: 10.1016/j.brat.2010.05.017] [PMC2914145] [PMID: 20579633]SecristCD . The Role of Executive Functioning in the Treatment of Borderline Personality Disorder [PhD thesis]. Washington (DC): University of Washington, 2014. ">Linehan 2006</a>; <a href="./references#CD012955-bbs2-0058" title="PhilipsB , WennebergP , KonradssonP , FranckJ . Mentalization-based treatment for concurrent borderline personality disorder and substance use disorder: a randomized controlled feasibility study. European Addiction Research2018;24(1):1-8. [DOI: 10.1159/000485564] [PMC5969093] [PMID: 294028]">Philips 2018</a>; <a href="./references#CD012955-bbs2-0059" title="BarnicotK . Re: Regarding your study on DBT for self-harming patients [personal communication]. Email to: EG Faltinsen 28 February 2018. PriebeS , BhattiN , BarnicotK , BremnerS , GagliaA , KatsakouC , et al. Effectiveness and cost-effectiveness of dialectical behaviour therapy for self-harming patients with personality disorder: a pragmatic randomised controlled trial. Psychotherapy and Psychosomatics2012;81(6):356-65. [DOI: 10.1159/000338897] [PMID: 22964561]PriebeS . Supplemental information [personal communication]. Email to: M Kielsholm 20 May 2016. ">Priebe 2012</a>; <a href="./references#CD012955-bbs2-0072" title="Van den BoschLM , KoeterMW , StijnenT , VerheulR , Van den BrinkW . Sustained efficacy of dialectical behaviour therapy for borderline personality disorder. Behaviour Research and Therapy2005;43(9):1231-41. [DOI: 10.1016/j.brat.2004.09.008] [PMID: 16005708]Van den BoschLM , VerheulR , SchippersGM , Van den BrinkW . Dialectical behavior therapy of borderline patients with and without substance use problems. Implementation and long-term effects. Addictive Behaviors2002;27(6):911-23. [DOI: 10.1016/s0306-4603(02)00293-9] [PMID: 12369475]Van den BoschLMC . Efficacy of dialectical behaviour therapy in the treatment of female borderline patients with and without substance abuse problems: results of a Dutch study [Dialectische gedragstherapie bij Nederlandse vrouwen met een borderline persoonlijkheidsstoornis, met en zonder verslavingsproblemen]. Tijdschrift voor Psychiatrie2005;47(3):127-37. [www.tijdschriftvoorpsychiatrie.nl/assets/articles/articles_1335pdf.pdf]VerheulR , Van den BoschLM , KoeterMW , De RidderMA , StijnenT , Van den BrinkW . Dialectical behaviour therapy for women with borderline personality disorder: 12-month, randomised clinical trial in The Netherlands. British Journal of Psychiatry2003;182:135-40. [DOI: 10.1192/bjp.182.2.135] [PMID: 12562741]">Van den Bosch 2005</a>; <a href="./references#CD012955-bbs2-0073" title="WeinbergI , GundersonJG , HennenJ , Cutter CJ Jr. Manual assisted cognitive treatment for deliberate self-harm in borderline personality disorder patients. Journal of Personality Disorders2006;20(5):482-92. [DOI: 10.1521/pedi.2006.20.5.482] [PMID: 17032160]WilbergT . SV: separate data [personal communication] [SV: separat data [personlig kommunikation]]. Email to: M Kielsholm 25 May 2016. ">Weinberg 2006</a>). </p> <p>Generally, psychotherapy improved self‐harm at end of treatment compared with TAU (SMD −0.32, 95% CI −0.49 to −0.14; 13 trials, 616 participants; I<sup>2</sup> = 16%; P = 0.0004; low‐quality evidence, <a href="./full#CD012955-tbl-0001">summary of findings Table 1</a>). This corresponds to a MD of −0.82 (95% CI −1.25 to 0.35), on the DSHI, which ranges from 0 to 34. The MIREDIF on this scale is −1.25 points, which corresponds to ½ SD (<a href="./references#CD012955-bbs2-0293" title="FarivarSS , LiuH ,  HaysRD . Half standard deviation estimate of the minimally important difference in HRQOL scores?Expert Review of Pharmacoeconomics &amp; Outcomes Research2004;4(5):515-23. [DOI: 10.1586/14737167.4.5.515] [PMID: 19807545]">Farivar 2004</a>). Clinically, this represents no clinically important reduction in self‐harm for people with BPD. The TSA analysis showed that the RIS was reached (n = 97). However, we cannot exclude the potential risk of type 1 error (TSA adjusted confidence interval −0.59 to −0.08) (see figure 6 in <a href="./appendices#CD012955-sec-0603">Appendix 6</a>). </p> <p>Inspection of the funnel plot (see figure 7 in <a href="./appendices#CD012955-sec-0603">Appendix 6</a>) suggested no potential bias (asymmetry), and we found no evidence of possible significant publication bias: Egger’s regression intercept (bias) 1.524 (two tailed, P = 0.237). </p> <p>Generally, psychotherapy did not reduce self‐harm at zero to six months follow‐up compared with TAU (SMD −0.52, 95% CI −1.28 to 0.23; 1 trial, 28 participants; P = 0.18; <a href="./references#CD012955-fig-0006" title="">Analysis 1.3</a>.2); MD −4.71, 95% CI −11.60 to 2.18; 1 trial, 28 participants; P = 0.18; <a href="./references#CD012955-fig-0006" title="">Analysis 1.3</a>.2). </p> <p>Generally, psychotherapy did not reduce self‐harm at six to 12 months follow‐up compared with TAU (SMD −0.18, 95% CI −0.48 to 0.12; 3 trials, 174 participants; I<sup>2</sup> = 0%; P = 0.64; <a href="./references#CD012955-fig-0006" title="">Analysis 1.3</a>.3). </p> <p>No data were available for 12 months and over follow‐up.</p> </section> <section id="CD012955-sec-0082"> <h6 class="title">1.4 Self‐harm (dichotomous)</h6> <p>Six trials reported dichotomous data on self‐harm (<a href="./references#CD012955-bbs2-0004" title="BatemanA , FonagyP . 8-year follow-up of patients treated for borderline personality disorder: mentalization-based treatment versus treatment as usual. American Journal of Psychiatry2008;165(5):631-8. [DOI: 10.1176/appi.ajp.2007.07040636] [PMID: 18347003]BatemanA , FonagyP . Effectiveness of partial hospitalization in the treatment of borderline personality disorder: a randomized controlled trial. American Journal of Psychiatry1999;156(10):1563-9. [DOI: 10.1176/ajp.156.10.1563] [PMID: 10518167]BatemanA , FonagyP . Health care utilization costs for borderline personality disorder patients treated with psychoanalytically oriented partial hospitalization versus general psychiatric care. American Journal of Psychiatry2003;160(1):169-71. [10.1176/appi.ajp.160.1.169] [12505818]BatemanA , FonagyP . Treatment of borderline personality disorder with psychoanalytically oriented partial hospitalization: an 18-month follow-up. American Journal of Psychiatry2001;158(1):36-42. [DOI: 10.1176/appi.ajp.158.1.36] [PMID: 11136631]BatemanA . Important: question regarding your BPD trial for systematic review in Cochrane Collaboration [personal communication]. Email to: K Lieb, J Stoffers 14 December 2010. BatemanA . Intensive outpatient and partial hospital care for BPD. In: 157th annual meeting of the American Psychiatric Association. Psychotherapy and pharmacology: dissolving the mind-brain barrier; 2004 May 1-6; New York (NY). Arlington (VA): American Psychiatric Association, 2004:102. [Symposium 100B] [www.psychiatry.org/File%20Library/Psychiatrists/Directories/Library-and-Archive/conference_publications/am_program_2004.pdf]BatemanAW , FonagyP . Drs Bateman and Fonagy reply [to Stern R. Partial hospitalization for borderline personality disorder. American Journal of Psychiatry 2001;158(11):1932-3. DOI: 10.1176/appi.ajp.158.11.1932]. American Journal of Psychiatry2001;158(11):1932-3. [DOI: 10.1176/appi.ajp.158.11.1932-a]EvansC . Treatment benefits of psychoanalytically oriented partial hospitalisation were maintained over 18 months in borderline personality disorder. Evidence-Based Mental Health2001;4(3):73. [DOI: 10.1136/ebmh.4.3.73]FonagyP , BatemanAW . Mentalizing and borderline personality disorder. Journal of Mental Health2007;16(1):83-101. [DOI: 10.1080/09638230601182045]SternR . Partial hospitalization for borderline personality disorder. American Journal of Psychiatry2001;158(11):1932-3. [DOI: 10.1176/appi.ajp.158.11.1932] [PMID: 11691712]">Bateman 1999</a>; <a href="./references#CD012955-bbs2-0005" title="BatemanA , FonagyP . Impact of clinical severity on outcomes of mentalisation-based treatment for borderline personality disorder. British Journal of Psychiatry2013;203(3):221-7. [DOI: 10.1192/bjp.bp.112.121129] [PMID: 23887998]BatemanA , FonagyP . Randomized controlled trial of outpatient mentalization-based treatment versus structured clinical management for borderline personality disorder. American Journal of Psychiatry2009;166(12):1355-64. [DOI: 10.1176/appi.ajp.2009.09040539] [PMID: 19833787]BatemanA , FonagyP . Randomized controlled trial of outpatient mentalization-based treatment versus structured clinical management for borderline personality disorder. Supplementary data. ajp.psychiatryonline.org/doi/suppl/10.1176/appi.ajp.2009.09040539/suppl_file/ajp_166_12_1355_01.pdf (accessed 27 February 2020). BatemanA , O'ConnellJ , LorenziniN , GardnerT , FonagyP . A randomised controlled trial of mentalization-based treatment versus structured clinical management for patients with comorbid borderline personality disorder and antisocial personality disorder. BMC Psychiatry2016;16:304. [DOI: 10.1186/s12888-016-1000-9] [PMC5006360] [PMID: 27577562]BatemanA . Important question regarding your BPD trial for systematic review in Cochrane Collaboration [personal communication]. Email to: K Lieb 14 December 2010. BatemanAW . Mentalization, borderline personality disorder and what works for whom? Presentation at the 11th International Congress of the International Society for the Study of Personality Disorders; 2009 Aug 21-23. www.borderlinepersonalitydisorder.com/Conferences/ISSPD/isspd_09_Bateman (accessed 21 April 2010). ISRCTN27660668. Randomised controlled trial of manualised out-patient individual and group therapy for borderline personality disorder [Effectiveness of intensive out-patient psychotherapy for treatment of borderline personality disorder: a pragmatic randomised single blind controlled study]. www.isrctn.com/ISRCTN27660668 (first received 12 October 2008). ">Bateman 2009</a>; <a href="./references#CD012955-bbs2-0013" title="BosEH , Van WelE , AppeloMT , VerbraakMJP . A randomized controlled trial of a Dutch version of systems training for emotional predictability and problem solving for borderline personality disorder. Journal of Nervous and Mental Disease2010;198(4):299-304. [DOI: 10.1097/NMD.0b013e3181d619cf] [PMID: 20386260]Van WelEB , BosEH , AppeloMT , BerendsenEM , WillgerothFC , VerbraakMJPM . The efficacy of the systems training for emotional predictability and problem solving (STEPPS) in the treatment of borderline personality disorder. A randomized controlled trial [De effectiviteit van de vaardigheidstraining emotieregulatiestoornis (VERS) in de behandeling van de borderlinepersoonlijkheidsstoornis: een gerandomiseerd onderzoek]. Tijdschrift voor Psychiatrie2009;51(5):291-301. [PMID: 19434566]">Bos 2010</a>; <a href="./references#CD012955-bbs2-0017" title="DavidsonK , LivingstoneS , McArthurK , DicksonL , GumleyA . An integrative complexity analysis of cognitive behaviour therapy sessions for borderline personality disorder. Psychology and Psychotherapy2007;80(Pt 4):513-23. [DOI: 10.1348/147608307X191535] [PMID: 17535542]DavidsonK , NorrieJ , TyrerP , GumleyA , TataP , MurrayH , et al. The effectiveness of cognitive behavior therapy for borderline personality disorder: results from the borderline personality disorder study of cognitive therapy (BOSCOT) trial. Journal of Personality Disorders2006;20(5):450-65. [DOI: 10.1521/pedi.2006.20.5.450] [PMC1852259] [PMID: 17032158]DavidsonK , TyrerP , GumleyA , TataP , NorrieJ , PalmerS , et al. A randomized controlled trial of cognitive behavior therapy for borderline personality disorder: rationale for trial, method, and description of sample. Journal of Personality Disorders2006;20(5):431-49. [DOI: 10.1521/pedi.2006.20.5.431] [PMC1847748] [PMID: 17032157]DavidsonKM , TyrerP , NorrieJ , PalmerSJ , TyrerH . Cognitive therapy v usual treatment for borderline personality disorder: prospective 6-year follow-up. British Journal of Psychiatry2010;197(6):456-62. [DOI: 10.1192/bjp.bp.109.074286] [PMID: 21119151]ISRCTN86177428. Borderline personality disorder study of cognitive therapy trial [A randomised controlled trial of cognitive therapy plus treatment as usual versus treatment as usual in the treatment of borderline personality disorder]. www.isrctn.com/ISRCTN86177428 (first received 22 July 2005). NCT00538135. BOSCOT: a randomised controlled trial of cognitive behavioural therapy in borderline personality disorder [BOSCOT: a randomised control trial of cognitive behavioural therapy plus treatment as usual versus treatment as usual in the treatment of borderline personality disorder]. www.clinicaltrials.gov/ct2/show/NCT00538135 (first received 29 September 2007). NorrieJ , DavidsonK , TataP , GumleyA . Influence of therapist competence and quantity of cognitive behavioural therapy on suicidal behaviour and inpatient hospitalisation in a randomised controlled trial in borderline personality disorder: further analyses of treatment effects in the BOSCOT study. Psychology and Psychotherapy2013;86(3):280-93. [DOI: 10.1111/papt.12004] [PMC4491320] [PMID: 23420622]PalmerS , DavidsonK , TyrerP , GumleyA , TataP , NorrieJ , et al. The cost-effectiveness of cognitive behavior therapy for borderline personality disorder: results from the BOSCOT trial. Journal of Personality Disorders2006;20(5):466-81. [DOI: 10.1521/pedi.2006.20.5.466] [PMC1852260] [PMID: 17032159]">Davidson 2006</a>; <a href="./references#CD012955-bbs2-0019" title="BuchheimA , Hörz-SagstetterS , DoeringS , RentropM , SchusterP , BuchheimP , et al. Change of unresolved attachment in borderline personality disorders: RCT study of transference-focused psychotherapy. Psychotherapy and Psychosomatics2017;86(5):314-6. [DOI: 10.1159/000460257] [PMID: 28903103]DiamondD , LevyKN , ClarkinJF , Fischer-KernM , CainNM , DoeringS , et al. Attachment and mentalization in female patients with comorbid narcissistic and borderline personality disorder. Personality Disorders2014;5(4):428-33. [DOI: 10.1037/per0000065] [PMID: 25314231]DiamondD , YeomansFE , SternB , LevyKN , HörzS , DoeringS , et al. Transference-focused psychotherapy for patients with comorbid narcissistic and borderline personality disorder. Psychoanalytic Inquiry2013;33(6):527-51. [DOI: 10.1080/07351690.2013.815087]DoeringS , HörzS , RentropM , Fischer-KernM , SchusterP , BeneckeC , et al. Transference-focused psychotherapy v treatment by community psychotherapists for borderline personality disorder: randomised controlled trial. British Journal of Psychiatry2010;196(5):389-95. [DOI: 10.1192/bjp.bp.109.070177] [PMID: 20435966]DoeringS . Author's reply [to Kleindienst N, Krumm B, Bohus M. Is transference-focused psychotherapy really efficacious for borderline personality disorder? British Journal of Psychiatry 2011;198(2):156-7. DOI: 10.1192/bjp.198.2.156b]. British Journal of Psychiatry2011;198(2):156-7. [DOI: 10.1192/bjp.198.2.157]DoeringS . Question regarding your BPD trial for systematic review in Cochrane Collaboration [personal communication]. Email to: K Lieb, J Stoffers 10 December 2010. Fischer-KernM , DoeringS , TaubnerS , HörzS , ZimmermannJ , RentropM , et al. Transference-focused psychotherapy for borderline personality disorder: change in reflective function. British Journal of Psychiatry2015;207(2):173-4. [DOI: 10.1192/bjp.bp.113.143842] [PMID: 25999334]KleindienstN , KrummB , BohusM . Is transference-focused psychotherapy really efficacious for borderline personality disorder?British Journal of Psychiatry2011;198(2):156-7. [DOI: 10.1192/bjp.198.2.156b] [PMID: 21282787]LevyKN , MeehanKB , YeomansFE . Transference-focused psychotherapy reduces treatment drop-out and suicide attempters compared with community psychotherapist treatment in borderline personality disorder. Evidence-based Mental Health2010;13(4):119. [DOI: 10.1136/ebmh.13.4.119] [PMID: 21036981]NCT00714311. Efficacy of transference-focused psychotherapy for borderline personality disorder [A randomized-controlled trial of transference-focused psychotherapy vs treatment by experienced community psychotherapists for borderline personality disorder]. www.clinicaltrials.gov/ct2/show/NCT00714311 (first received 9 July 2008). RentropM , MartiusP , BäumlJ , BuchheimP , DöeringS , HörzS . Patients with borderline personality disorder not participating in an RCT: are they different?Psychopathology2010;43(6):369-72. [DOI: 10.1159/000320351] [PMID: 20798576]">Doering 2010</a>; <a href="./references#CD012955-bbs2-0062" title="ISRCTN95266816. The emergence of personality disorder traits in adolescents who deliberately self harm and the potential for using a mentalisation based treatment approach as an early intervention for such individuals: a randomised controlled trial. www.isrctn.com/ISRCTN95266816 (first received 29 October 2007). RossouwT . Mentalisation based treatment for adolescents with self harm: an RCT. European Child &amp; Adolescent Psychiatry2015;24(1 Suppl):S113. [DOI: 10.1007%2Fs00787-015-0714-4.pdf] [W1-02-02]RossouwT . Self harm in adolescence, is MBT the answer?: an RCT. Adolescent Psychiatry2012;2(1):102. [DOI: 10.2174/2210676611202010077]RossouwTI , FonagyP . Mentalization-based treatment for self-harm in adolescents: a randomized controlled trial. Journal of the American Academy of Child and Adolescent Psychiatry2012;51(12):1304-13.e3. [DOI: 10.1016/j.jaac.2012.09.018] [PMID: 23200287]">Rossouw 2012b</a>). </p> <p>Generally, psychotherapy did not reduce self‐harm at end of treatment compared with TAU (RR 0.85, 95% CI 0.63 to 1.14; 6 trials, 513 participants; I<sup>2</sup> = 73%; P = 0.28; <a href="./references#CD012955-fig-0007" title="">Analysis 1.4</a>.1). </p> <p>Generally, psychotherapy reduced self‐harm at zero to six months follow‐up compared with TAU (RR 0.14, 95% CI 0.04 to 0.56; 1 trial; P = 0.005; <a href="./references#CD012955-fig-0007" title="">Analysis 1.4</a>.2). </p> <p>Generally, psychotherapy reduced self‐harm at six to 12 months follow‐up compared with TAU (RR 0.27, 95% CI 0.10 to 0.68; 1 trial; P = 0.006; <a href="./references#CD012955-fig-0007" title="">Analysis 1.4</a>.3). </p> <p>Generally, psychotherapy reduced self‐harm at above 12 months follow‐up compared with TAU (RR 0.33, 95% CI 0.15 to 0.76; 1 trial, 41 participants; P = 0.009; <a href="./references#CD012955-fig-0007" title="">Analysis 1.4</a>.4). </p> </section> <section id="CD012955-sec-0083"> <h6 class="title">1.5 Suicide‐related outcomes (continuous)</h6> <p>Thirteen trials reported continuous data on suicide‐related outcomes (<a href="./references#CD012955-bbs2-0001" title="AmiantoF , FerreroA , PieròA , CairoE , RoccaG , SimonelliB , et al. Supervised team management, with or without structured psychotherapy, in heavy users of a mental health service with borderline personality disorder: a two-year follow-up preliminary randomized study. BMC Psychiatry2011;11:181. [DOI: 10.1186/1471-244X-11-181] [PMC3260092 ] [PMID: 22103890]NCT01356069. Efficacy of time-limited psychodynamic psychotherapy and informed clinical management in BPD high MHS users (HUMSH) [Sequential brief Adlerian psychodynamic psychotherapy in heavy users of a mental health service with borderline personality disorder: a two years follow-up preliminary randomized study]. clinicaltrials.gov/ct2/show/NCT01356069 (first received 16 May 2011). ">Amianto 2011</a>; <a href="./references#CD012955-bbs2-0002" title='AndreoliA , BurnandY , CochennecMF , MarieD , Di ClementeT , OhlendorfP . Psychoanalytic psychotherapy and venlafaxine among acutely suicidal borderline patients: a randomized clinical study. European Psychiatry2009;24(Suppl 1):S93. [DOI: 10.1016/S0924-9338(09)70326-8] [S18-03]AndreoliA , BurnandY , CochennecMF , OhlendorfP , FrambatiL , Gaudry-MaireD , et al. Disappointed love and suicide: a randomized controlled trial of "abandonment psychotherapy" among borderline patients. Journal of Personality Disorders2016;30(2):271-87. [DOI: 10.1521/pedi_2015_29_196] [PMID: 26111250]AndreoliA , BurnandY , FrambatiL , ManningD , FrancesA . Abandonment psychotherapy and psychosocial functioning among suicidal patients with borderline personality disorder: a 3-year naturalistic follow-up. Journal of Personality Disorders 2019 Feb 20 [Epub ahead of print]. [DOI: 10.1521/pedi_2019_33_423] [PMID: 30785852]AndreoliA . Re: your study in BPD - Cochrane Collaboration review [personal communication]. Email to: J Stoffers-Winterling 5 June 2018. '>Andreoli 2016</a>; <a href="./references#CD012955-bbs2-0017" title="DavidsonK , LivingstoneS , McArthurK , DicksonL , GumleyA . An integrative complexity analysis of cognitive behaviour therapy sessions for borderline personality disorder. Psychology and Psychotherapy2007;80(Pt 4):513-23. [DOI: 10.1348/147608307X191535] [PMID: 17535542]DavidsonK , NorrieJ , TyrerP , GumleyA , TataP , MurrayH , et al. The effectiveness of cognitive behavior therapy for borderline personality disorder: results from the borderline personality disorder study of cognitive therapy (BOSCOT) trial. Journal of Personality Disorders2006;20(5):450-65. [DOI: 10.1521/pedi.2006.20.5.450] [PMC1852259] [PMID: 17032158]DavidsonK , TyrerP , GumleyA , TataP , NorrieJ , PalmerS , et al. A randomized controlled trial of cognitive behavior therapy for borderline personality disorder: rationale for trial, method, and description of sample. Journal of Personality Disorders2006;20(5):431-49. [DOI: 10.1521/pedi.2006.20.5.431] [PMC1847748] [PMID: 17032157]DavidsonKM , TyrerP , NorrieJ , PalmerSJ , TyrerH . Cognitive therapy v usual treatment for borderline personality disorder: prospective 6-year follow-up. British Journal of Psychiatry2010;197(6):456-62. [DOI: 10.1192/bjp.bp.109.074286] [PMID: 21119151]ISRCTN86177428. Borderline personality disorder study of cognitive therapy trial [A randomised controlled trial of cognitive therapy plus treatment as usual versus treatment as usual in the treatment of borderline personality disorder]. www.isrctn.com/ISRCTN86177428 (first received 22 July 2005). NCT00538135. BOSCOT: a randomised controlled trial of cognitive behavioural therapy in borderline personality disorder [BOSCOT: a randomised control trial of cognitive behavioural therapy plus treatment as usual versus treatment as usual in the treatment of borderline personality disorder]. www.clinicaltrials.gov/ct2/show/NCT00538135 (first received 29 September 2007). NorrieJ , DavidsonK , TataP , GumleyA . Influence of therapist competence and quantity of cognitive behavioural therapy on suicidal behaviour and inpatient hospitalisation in a randomised controlled trial in borderline personality disorder: further analyses of treatment effects in the BOSCOT study. Psychology and Psychotherapy2013;86(3):280-93. [DOI: 10.1111/papt.12004] [PMC4491320] [PMID: 23420622]PalmerS , DavidsonK , TyrerP , GumleyA , TataP , NorrieJ , et al. The cost-effectiveness of cognitive behavior therapy for borderline personality disorder: results from the BOSCOT trial. Journal of Personality Disorders2006;20(5):466-81. [DOI: 10.1521/pedi.2006.20.5.466] [PMC1852260] [PMID: 17032159]">Davidson 2006</a>; <a href="./references#CD012955-bbs2-0022" title="FeigenbaumJD , FonagyP , PillingS , JonesA , WildgooseA , BebbingtonPE . A real-world study of the effectiveness of DBT in the UK National Health Service. British Journal of Clinical Psychology2012;51(2):121-41. [DOI: 10.1111/j.2044-8260.2011.02017.x] [PMID: 22574799]">Feigenbaum 2012</a>; <a href="./references#CD012955-bbs2-0025" title="GleesonJF , ChanenA , CottonSM , PearceT , NewmanB , McCutcheonL . Treating co-occurring first-episode psychosis and borderline personality: a pilot randomized controlled trial. Early Intervention in Psychiatry2012;6(1):21-9. [DOI: 10.1111/j.1751-7893.2011.00306.x] [PMID: 22379625]GleesonJFM . RE: separate data [personal communication]. Email to: M Kielsholm 28 October 2016. ">Gleeson 2012</a>; <a href="./references#CD012955-bbs2-0028" title="GregoryRJ , ChlebowskiS , KangD , RemenA , SoderbergM . Psychodynamic therapy for borderline personality disorder and co-occurring alcohol use disorders: a newly designed ongoing study. Journal of the American Psychoanalytic Association2006;54(4):1331-4. [DOI: 10.1177/00030651060540040107] [PMID: 17354507]GregoryRJ , ChlebowskiS , KangD , RemenAL , SoderbergMG , StepkovitchJ , et al. A controlled trial of psychodynamic psychotherapy for co-occurring borderline personality disorder and alcohol use disorder. Psychotherapy2008;45(1):28-41. [DOI: 10.1037/0033-3204.45.1.28] [PMID: 22122363]GregoryRJ , DeLucia-DeranjaE , MogleJA . Dynamic deconstructive psychotherapy versus optimized community care for borderline personality disorder co-occuring with alcohol use disorders: a 30-month follow-up. Journal of Nervous and Mental Disease2010;198(4):292-8. [DOI: 10.1097/NMD.0b013e3181d6172d] [PMID: 20386259]GregoryRJ , RemenAL , SoderbergM , Ploutz-SnyderRJ . A controlled trial of psychodynamic psychotherapy for co-occurring borderline personality disorder and alcohol use disorder: six-month outcome. Journal of the American Psychoanalytic Association2009;57(1):199-205. [DOI: 10.1177/00030651090570011006] [PMID: 19270255]NCT00145678. Psychodynamic therapy for co-occurring borderline personality disorder and alcohol use disorder [Psychodynamic therapy for patients With borderline personality disorder and alcohol abuse]. www.clinicaltrials.gov/show/NCT00145678 (first received 1 September 2005). ">Gregory 2008b</a>; <a href="./references#CD012955-bbs2-0035" title="KoonsCR , RobinsCJ , TweedJL , LynchTR , GonzalezAM , MorseJQ , et al. Efficacy of dialectical behavior therapy in women veterans with borderline personality disorder. Behavior Therapy2001;32(2):371-90. [DOI: 10.1016/S0005-7894(01)80009-5]">Koons 2001a</a>; <a href="./references#CD012955-bbs2-0043" title="LeppänenV , HakkoH , SintonenH , LindemanS . Comparing effectiveness of treatments for borderline personality disorder in communal mental health care: the Oulu BPD study. Community Mental Health Journal2016;52(2):216-27. [DOI: 10.1007/s10597-015-9866-4] [PMID: 25824852]LeppänenV . Re: questions regarding the Oulu BPD study [personal communication]. Email to: E Faltinsen 20 December 2017. LeppänenV . Re: SV: question regarding the Oulu BPD study [personal communication]. Email to: EG Faltinsen 22 December 2017. ">Leppänen 2016</a>; <a href="./references#CD012955-bbs2-0047" title="BedicsJD , AtkinsDC , ComtoisKA , LinehanMM . Treatment differences in the therapeutic relationship and introject during a 2-year randomized controlled trial of dialectical behavior therapy versus nonbehavioral psychotherapy experts for borderline personality disorder. Journal of Consulting and Clinical Psychology2012;80(1):66-77. [DOI: 10.1037/a0026113] [PMC3265694] [PMID: 22061867]BedicsJD , AtkinsDC , ComtoisKA , LinehanMM . Weekly therapist ratings of the therapeutic relationship and patient introject furing the course of dialectical behavioral therapy for the treatment of borderline personality disorder. Psychotherapy2012;49(2):231-40. [DOI: 10.1037/a0028254] [PMID: 22642526]BedicsJD , AtkinsDC , HarnedMS , LinehanMM . The therapeutic alliance as a predictor of outcome in dialectical behavior therapy versus nonbehavioral psychotherapy by experts for borderline personality disorder. Psychotherapy2015;52(1):67-77. [DOI: 10.1037/a0038457] [PMID: 25751116]BrownMZ , LinehanMM , ComtoisKA , MurrayA , ChapmanAL . Shame as a prospective predictor of self-inflicted injury in borderline personality disorder: a multi-modal analysis. Behaviour Research and Therapy2009;47(10):815-22. [DOI: 10.1016/j.brat.2009.06.008] [PMC2761705] [PMID: 19596223 ]CoyleTN , ShaverJA , LinehanMM . On the potential for iatrogenic effects of psychiatric crisis services: the example of dialectical behavior therapy for adult women with borderline personality disorder. Journal of Consulting and Clinical Psychology2018;86(2):116-24. [DOI: 10.1037/ccp0000275] [PMID: 29369662]HarnedMS , ChapmanAL , Dexter-MazzaET , MurrayA , ComtoisKA , LinehanMM . Treating co-occurring Axis I disorders in recurrently suicidal women with borderline personality disorder: a 2-year randomized trial of dialectical behavior therapy versus community treatment by experts. Journal of Consulting and Clinical Psychology2008;76(6):1068-75. [DOI: 10.1037/a0014044] [PMID: 19045974]HarnedMS , ChapmanAL , Dexter-MazzaET , MurrayA , ComtoisKA , LinehanMM . Treating co-occurring Axis I disorders in recurrently suicidal women with borderline personality disorder: a 2-year randomized trial of dialectical behavior therapy versus community treatment by experts. Personality Disorders: Theory, Research, and Treatment2009;S(1):35-45. [DOI: 10.1037/1949-2715.S.1.35]HarnedMS , JacksonSC , ComtoisKA , LinehanMM . Dialectical behavior therapy as a precursor to PTSD treatment for suicidal and/or self-injuring women with bordreline personality disorder. Journal of Traumatic Stress2010;23(4):421-9. [DOI: 10.1002/jts.20553] [PMID: 20648564]LindenboimN , ComtoisKA , LinehanMM . Skills practice in dialectical behavior therapy for suicidal women meeting criteria for borderline personality disorder. Cognitive and Behavioral Practice2007;14(2):147-56. [DOI: 10.1016/j.cbpra.2006.10.004]LinehanMM , ComtoisKA , MurrayAM , BrownMZ , GallopRJ , HeardHL , et al. Two-year randomized controlled trial and follow-up of dialectical behavior therapy vs therapy by experts for suicidal behaviors and borderline personality disorder. Archives of General Psychiatry2006;63(7):757-66. [DOI: 10.1001/archpsyc.63.7.757] [PMID: 16818865]LinehanMM . Error in table in: two-year randomized controlled trial and follow-up of dialectical behavior therapy vs therapy by experts for suicidal behaviors and borderline personality disorder. Archives of General Psychiatry2007;64(12):1401. Erratum for: Archives of General Psychiatry 2007;64(12):1401. McMainS . Dialectic behaviour therapy reduces suicide attempts compared with non-behavioural psychotherapy in women with borderline personality disorder. Evidence-Based Mental Health2007;10(1):18. [DOI: 10.1136/ebmh.10.1.18] [PMID: 17255387]NeacsiuAD , LunguA , HarnedMS , RizviSL , LinehanMM . Impact of dialectical behavior therapy versus community treatment by experts on emotional experience, expression, and acceptance in borderline personality disorder. Behaviour Research and Therapy2014;53:47-54. [DOI: 10.1016/j.brat.2013.12.004] [PMC3955205] [PMID: 24418652]NeacsiuAD , RizviSL , LinehanMM . Dialectical behavior therapy skills use as a mediator and outcome of treatment for borderline personality disorder. Behaviour Research and Therapy2010;48(9):832-9. [DOI: 10.1016/j.brat.2010.05.017] [PMC2914145] [PMID: 20579633]SecristCD . The Role of Executive Functioning in the Treatment of Borderline Personality Disorder [PhD thesis]. Washington (DC): University of Washington, 2014. ">Linehan 2006</a>; <a href="./references#CD012955-bbs2-0052" title="HagaE , AasE , GrøholtB , TørmoenAJ , MehlumL . Cost-effectiveness of dialectical behaviour therapy vs enhanced usual care in the treatment of adolescents with self-harm. Child and Adolescent Psychiatry and Mental Health2018;12:22. [DOI: 10.1186/s13034-018-0227-2] [PMC5928596] [PMID: 29743941]MehlumL , RambergM , TørmoenAJ , HagaE , DiepLM , StanleyBH , et al. Dialectical behavior therapy compared with enhanced usual care for adolescents with repeated suicidal and self-harming behavior: outcomes over a one-year follow-up. Journal of the American Academy of Child and Adolescent Psychiatry2016;55(4):295-300. [DOI: 10.1016/j.jaac.2016.01.005] [PMID: 27015720]MehlumL , TørmoenAJ , RambergM , HagaE , DiepLM , LabergS , et al. Dialectical behavior therapy for adolescents with repeated suicidal and self-harming behavior: a randomized trial. Journal of the American Academy of Child and Adolescent Psychiatry2014;53(10):1082-91. [DOI: 10.1016/j.jaac.2014.07.003] [PMID: 25245352]MehlumL . Re: regarding your study of DBT for your with suicidal behavior [personal communication] [Re: angående din studie om DBT for ungdom med selvmordsatferd [personlig kommunikation]]. Email to: E Faltinsen 5 December 2017. NCT00675129. Treatment for adolescents with deliberate self harm [A randomized controlled trial for repetitive deliberate self-harm and suicidal behaviours among Norwegian adolescents: a comparison between dialectical behaviour therapy adapted for adolescents (DBT-A) and enhanced usual care (EUC)]. www.clinicaltrials.gov/ct2/show/NCT00675129 (first received 6 May 2008). RamlethRK , GroholtB , DiepLM , WalbyFA , MehlumL . The impact of borderline personality disorder and sub-threshold borderline personality disorder on the course of self-reported and clinician-rated depression in self-harming adolescents. Borderline Personality Disorder and Emotion Dysregulation2017;4:22. [DOI: 10.1186/s40479-017-0073-5] [PMC5663078] [PMID: 29093819]">Mehlum 2014</a>; <a href="./references#CD012955-bbs2-0060" title="RenesesB , FigueraD , SalcedoG , TrujilloM , López-IborJJ , GaliánM , et al. A controlled randomized study on the efficacy of short-term dinamic psychotherapy in borderline personality disorders (BPD). Preliminary results. European Psychiatry2011;26(Suppl 1):1040. [DOI: 10.1016/S0924-9338(11)72745-6] [P02-444]RenesesB , GaliánM , SerranoR , FigueraD , Fernandez Del MoralA , López-IborJJ , et al. A new time limited psychotherapy for BPD: preliminary results of a randomized and controlled trial. Actas Espanolas de Psiquiatria2013;41(3):139-48. [PMID: 23803797]">Reneses 2013</a>; <a href="./references#CD012955-bbs2-0069" title="SolerJ , PascualJC , TianaT , CebriàA , BarrachinaJ , CampinsMJ , et al. Dialectical behaviour therapy skills training compared to standard group therapy in borderline personality disorder: a 3-month randomised controlled clinical trial. Behaviour Research and Therapy2009;47(5):353-8. [DOI: 10.1016/j.brat.2009.01.013] [PMID: 19246029]SolerJ . Question regarding your BPD trials [personal communication]. Email to: J Stoffers 15 December 2010. ">Soler 2009</a>; <a href="./references#CD012955-bbs2-0073" title="WeinbergI , GundersonJG , HennenJ , Cutter CJ Jr. Manual assisted cognitive treatment for deliberate self-harm in borderline personality disorder patients. Journal of Personality Disorders2006;20(5):482-92. [DOI: 10.1521/pedi.2006.20.5.482] [PMID: 17032160]WilbergT . SV: separate data [personal communication] [SV: separat data [personlig kommunikation]]. Email to: M Kielsholm 25 May 2016. ">Weinberg 2006</a>). </p> <p>Generally, psychotherapy reduced suicide‐related outcomes at end of treatment compared with TAU (SMD −0.34, 95% CI −0.57 to −0.11; 13 trials, 666 participants; I<sup>2</sup> = 43%; P = 0.004; <a href="./references#CD012955-fig-0008" title="">Analysis 1.5</a>.1; low‐quality evidence, <a href="./full#CD012955-tbl-0001">summary of findings Table 1</a>). The improvement corresponded to a clinical effect MD of −0.11 (95% CI −0.19 to −0.034), on the Suicidal Attempt Self Injury Interview. The MIREDIF on this scale is −0.17 points, which corresponds to ½ SD (<a href="./references#CD012955-bbs2-0293" title="FarivarSS , LiuH ,  HaysRD . Half standard deviation estimate of the minimally important difference in HRQOL scores?Expert Review of Pharmacoeconomics &amp; Outcomes Research2004;4(5):515-23. [DOI: 10.1586/14737167.4.5.515] [PMID: 19807545]">Farivar 2004</a>). Clinically, this represents no reduction in suicide‐related outcomes for people with BPD. The TSA analysis showed that the required information size was reached (n = 253). However, we cannot exclude the potential risk of type 1 error, and that there was no risk of type 1 error (TSA adjusted confidence interval −0.18 to −0.04) (see figure 8 in <a href="./appendices#CD012955-sec-0603">Appendix 6</a>). </p> <p>Inspection of the funnel plot (see figure 9 in <a href="./appendices#CD012955-sec-0603">Appendix 6</a>) suggested potential bias (asymmetry), and we found no evidence of possible significant publication bias: Egger’s regression intercept (bias) 0.405 (two tailed, P = 0.735). </p> <p>Generally, psychotherapy did not reduce suicide‐related outcomes at zero to six months follow‐up compared with TAU (SMD −0.43, 95% CI −1.10 to 0.23; 2 trials, 36 participants; I<sup>2</sup> = 0%; P = 0.20; <a href="./references#CD012955-fig-0008" title="">Analysis 1.5</a>.2). </p> <p>Generally, psychotherapy reduced suicide‐related outcomes at six to 12 months follow‐up compared with TAU (SMD −0.42, 95% CI −0.80 to −0.04; 2 trials, 109 participants; I<sup>2</sup> = 0%; P = 0.03; <a href="./references#CD012955-fig-0008" title="">Analysis 1.5</a>.3). </p> <p>Generally, psychotherapy did not reduce suicide‐related outcomes at above 12 months follow‐up compared with TAU (SMD −0.31, 95% CI −0.77 to 0.14; 1 trial, 76 participants; P = 0.18; MD −1.15, 95% CI −2.86 to 0.56; 1 trial, 76 participants; P = 0.19; <a href="./references#CD012955-fig-0008" title="">Analysis 1.5</a>.4). </p> </section> <section id="CD012955-sec-0084"> <h6 class="title">1.6 Suicide‐related outcomes (dichotomous)</h6> <p>Five trials reported dichotomous data on suicide‐related outcomes (<a href="./references#CD012955-bbs2-0004" title="BatemanA , FonagyP . 8-year follow-up of patients treated for borderline personality disorder: mentalization-based treatment versus treatment as usual. American Journal of Psychiatry2008;165(5):631-8. [DOI: 10.1176/appi.ajp.2007.07040636] [PMID: 18347003]BatemanA , FonagyP . Effectiveness of partial hospitalization in the treatment of borderline personality disorder: a randomized controlled trial. American Journal of Psychiatry1999;156(10):1563-9. [DOI: 10.1176/ajp.156.10.1563] [PMID: 10518167]BatemanA , FonagyP . Health care utilization costs for borderline personality disorder patients treated with psychoanalytically oriented partial hospitalization versus general psychiatric care. American Journal of Psychiatry2003;160(1):169-71. [10.1176/appi.ajp.160.1.169] [12505818]BatemanA , FonagyP . Treatment of borderline personality disorder with psychoanalytically oriented partial hospitalization: an 18-month follow-up. American Journal of Psychiatry2001;158(1):36-42. [DOI: 10.1176/appi.ajp.158.1.36] [PMID: 11136631]BatemanA . Important: question regarding your BPD trial for systematic review in Cochrane Collaboration [personal communication]. Email to: K Lieb, J Stoffers 14 December 2010. BatemanA . Intensive outpatient and partial hospital care for BPD. In: 157th annual meeting of the American Psychiatric Association. Psychotherapy and pharmacology: dissolving the mind-brain barrier; 2004 May 1-6; New York (NY). Arlington (VA): American Psychiatric Association, 2004:102. [Symposium 100B] [www.psychiatry.org/File%20Library/Psychiatrists/Directories/Library-and-Archive/conference_publications/am_program_2004.pdf]BatemanAW , FonagyP . Drs Bateman and Fonagy reply [to Stern R. Partial hospitalization for borderline personality disorder. American Journal of Psychiatry 2001;158(11):1932-3. DOI: 10.1176/appi.ajp.158.11.1932]. American Journal of Psychiatry2001;158(11):1932-3. [DOI: 10.1176/appi.ajp.158.11.1932-a]EvansC . Treatment benefits of psychoanalytically oriented partial hospitalisation were maintained over 18 months in borderline personality disorder. Evidence-Based Mental Health2001;4(3):73. [DOI: 10.1136/ebmh.4.3.73]FonagyP , BatemanAW . Mentalizing and borderline personality disorder. Journal of Mental Health2007;16(1):83-101. [DOI: 10.1080/09638230601182045]SternR . Partial hospitalization for borderline personality disorder. American Journal of Psychiatry2001;158(11):1932-3. [DOI: 10.1176/appi.ajp.158.11.1932] [PMID: 11691712]">Bateman 1999</a>; <a href="./references#CD012955-bbs2-0005" title="BatemanA , FonagyP . Impact of clinical severity on outcomes of mentalisation-based treatment for borderline personality disorder. British Journal of Psychiatry2013;203(3):221-7. [DOI: 10.1192/bjp.bp.112.121129] [PMID: 23887998]BatemanA , FonagyP . Randomized controlled trial of outpatient mentalization-based treatment versus structured clinical management for borderline personality disorder. American Journal of Psychiatry2009;166(12):1355-64. [DOI: 10.1176/appi.ajp.2009.09040539] [PMID: 19833787]BatemanA , FonagyP . Randomized controlled trial of outpatient mentalization-based treatment versus structured clinical management for borderline personality disorder. Supplementary data. ajp.psychiatryonline.org/doi/suppl/10.1176/appi.ajp.2009.09040539/suppl_file/ajp_166_12_1355_01.pdf (accessed 27 February 2020). BatemanA , O'ConnellJ , LorenziniN , GardnerT , FonagyP . A randomised controlled trial of mentalization-based treatment versus structured clinical management for patients with comorbid borderline personality disorder and antisocial personality disorder. BMC Psychiatry2016;16:304. [DOI: 10.1186/s12888-016-1000-9] [PMC5006360] [PMID: 27577562]BatemanA . Important question regarding your BPD trial for systematic review in Cochrane Collaboration [personal communication]. Email to: K Lieb 14 December 2010. BatemanAW . Mentalization, borderline personality disorder and what works for whom? Presentation at the 11th International Congress of the International Society for the Study of Personality Disorders; 2009 Aug 21-23. www.borderlinepersonalitydisorder.com/Conferences/ISSPD/isspd_09_Bateman (accessed 21 April 2010). ISRCTN27660668. Randomised controlled trial of manualised out-patient individual and group therapy for borderline personality disorder [Effectiveness of intensive out-patient psychotherapy for treatment of borderline personality disorder: a pragmatic randomised single blind controlled study]. www.isrctn.com/ISRCTN27660668 (first received 12 October 2008). ">Bateman 2009</a>; <a href="./references#CD012955-bbs2-0019" title="BuchheimA , Hörz-SagstetterS , DoeringS , RentropM , SchusterP , BuchheimP , et al. Change of unresolved attachment in borderline personality disorders: RCT study of transference-focused psychotherapy. Psychotherapy and Psychosomatics2017;86(5):314-6. [DOI: 10.1159/000460257] [PMID: 28903103]DiamondD , LevyKN , ClarkinJF , Fischer-KernM , CainNM , DoeringS , et al. Attachment and mentalization in female patients with comorbid narcissistic and borderline personality disorder. Personality Disorders2014;5(4):428-33. [DOI: 10.1037/per0000065] [PMID: 25314231]DiamondD , YeomansFE , SternB , LevyKN , HörzS , DoeringS , et al. Transference-focused psychotherapy for patients with comorbid narcissistic and borderline personality disorder. Psychoanalytic Inquiry2013;33(6):527-51. [DOI: 10.1080/07351690.2013.815087]DoeringS , HörzS , RentropM , Fischer-KernM , SchusterP , BeneckeC , et al. Transference-focused psychotherapy v treatment by community psychotherapists for borderline personality disorder: randomised controlled trial. British Journal of Psychiatry2010;196(5):389-95. [DOI: 10.1192/bjp.bp.109.070177] [PMID: 20435966]DoeringS . Author's reply [to Kleindienst N, Krumm B, Bohus M. Is transference-focused psychotherapy really efficacious for borderline personality disorder? British Journal of Psychiatry 2011;198(2):156-7. DOI: 10.1192/bjp.198.2.156b]. British Journal of Psychiatry2011;198(2):156-7. [DOI: 10.1192/bjp.198.2.157]DoeringS . Question regarding your BPD trial for systematic review in Cochrane Collaboration [personal communication]. Email to: K Lieb, J Stoffers 10 December 2010. Fischer-KernM , DoeringS , TaubnerS , HörzS , ZimmermannJ , RentropM , et al. Transference-focused psychotherapy for borderline personality disorder: change in reflective function. British Journal of Psychiatry2015;207(2):173-4. [DOI: 10.1192/bjp.bp.113.143842] [PMID: 25999334]KleindienstN , KrummB , BohusM . Is transference-focused psychotherapy really efficacious for borderline personality disorder?British Journal of Psychiatry2011;198(2):156-7. [DOI: 10.1192/bjp.198.2.156b] [PMID: 21282787]LevyKN , MeehanKB , YeomansFE . Transference-focused psychotherapy reduces treatment drop-out and suicide attempters compared with community psychotherapist treatment in borderline personality disorder. Evidence-based Mental Health2010;13(4):119. [DOI: 10.1136/ebmh.13.4.119] [PMID: 21036981]NCT00714311. Efficacy of transference-focused psychotherapy for borderline personality disorder [A randomized-controlled trial of transference-focused psychotherapy vs treatment by experienced community psychotherapists for borderline personality disorder]. www.clinicaltrials.gov/ct2/show/NCT00714311 (first received 9 July 2008). RentropM , MartiusP , BäumlJ , BuchheimP , DöeringS , HörzS . Patients with borderline personality disorder not participating in an RCT: are they different?Psychopathology2010;43(6):369-72. [DOI: 10.1159/000320351] [PMID: 20798576]">Doering 2010</a>; <a href="./references#CD012955-bbs2-0058" title="PhilipsB , WennebergP , KonradssonP , FranckJ . Mentalization-based treatment for concurrent borderline personality disorder and substance use disorder: a randomized controlled feasibility study. European Addiction Research2018;24(1):1-8. [DOI: 10.1159/000485564] [PMC5969093] [PMID: 294028]">Philips 2018</a>; <a href="./references#CD012955-bbs2-0070" title="FertuckEA , KeilpJ , SongI , MorrisMC , WilsonST , BrodskyBS , et al. Higher executive control and visual memory performance predict treatment completion in borderline personality disorder. Psychotherapy and Psychosomatics2012;81(1):38-43. [DOI: 10.1159/000329700] [PMC3242704] [PMID: 22116411]NCT00533117. Treating suicidal behavior and self-mutilation in people with borderline personality disorder. www.clinicaltrials.gov/ct2/show/NCT00533117 (first received 19 September 2007). ">Stanley 2017</a>). </p> <p>Generally, psychotherapy reduced suicide‐related outcomes at end of treatment compared with TAU (RR 0.27, 95% CI 0.11 to 0.67; 5 trials, 396 participants; I<sup>2</sup> = 45%; P = 0.005; <a href="./references#CD012955-fig-0009" title="">Analysis 1.6</a>.1). </p> <p>Generally, psychotherapy did not reduce suicide‐related outcomes at zero to six months follow‐up compared with TAU (RR 0.25, 95% CI 0.06 to 1.05; 1 trial, 41 participants; P = 0.06; <a href="./references#CD012955-fig-0009" title="">Analysis 1.6</a>.2). </p> <p>Generally, psychotherapy reduced suicide‐related outcomes at above 12 months follow‐up compared with TAU (RR 0.29, 95% CI 0.11 to 0.74; 1 trial, 41 participants; P = 0.01; <a href="./references#CD012955-fig-0009" title="">Analysis 1.6</a>.3). </p> <p>No data were available for six to 12 months follow‐up.</p> </section> <section id="CD012955-sec-0085"> <h6 class="title">1.7 Psychosocial functioning</h6> <p>Twenty‐two trials reported continuous data on psychosocial functioning (<a href="./references#CD012955-bbs2-0001" title="AmiantoF , FerreroA , PieròA , CairoE , RoccaG , SimonelliB , et al. Supervised team management, with or without structured psychotherapy, in heavy users of a mental health service with borderline personality disorder: a two-year follow-up preliminary randomized study. BMC Psychiatry2011;11:181. [DOI: 10.1186/1471-244X-11-181] [PMC3260092 ] [PMID: 22103890]NCT01356069. Efficacy of time-limited psychodynamic psychotherapy and informed clinical management in BPD high MHS users (HUMSH) [Sequential brief Adlerian psychodynamic psychotherapy in heavy users of a mental health service with borderline personality disorder: a two years follow-up preliminary randomized study]. clinicaltrials.gov/ct2/show/NCT01356069 (first received 16 May 2011). ">Amianto 2011</a>; <a href="./references#CD012955-bbs2-0002" title='AndreoliA , BurnandY , CochennecMF , MarieD , Di ClementeT , OhlendorfP . Psychoanalytic psychotherapy and venlafaxine among acutely suicidal borderline patients: a randomized clinical study. European Psychiatry2009;24(Suppl 1):S93. [DOI: 10.1016/S0924-9338(09)70326-8] [S18-03]AndreoliA , BurnandY , CochennecMF , OhlendorfP , FrambatiL , Gaudry-MaireD , et al. Disappointed love and suicide: a randomized controlled trial of "abandonment psychotherapy" among borderline patients. Journal of Personality Disorders2016;30(2):271-87. [DOI: 10.1521/pedi_2015_29_196] [PMID: 26111250]AndreoliA , BurnandY , FrambatiL , ManningD , FrancesA . Abandonment psychotherapy and psychosocial functioning among suicidal patients with borderline personality disorder: a 3-year naturalistic follow-up. Journal of Personality Disorders 2019 Feb 20 [Epub ahead of print]. [DOI: 10.1521/pedi_2019_33_423] [PMID: 30785852]AndreoliA . Re: your study in BPD - Cochrane Collaboration review [personal communication]. Email to: J Stoffers-Winterling 5 June 2018. '>Andreoli 2016</a>; <a href="./references#CD012955-bbs2-0004" title="BatemanA , FonagyP . 8-year follow-up of patients treated for borderline personality disorder: mentalization-based treatment versus treatment as usual. American Journal of Psychiatry2008;165(5):631-8. [DOI: 10.1176/appi.ajp.2007.07040636] [PMID: 18347003]BatemanA , FonagyP . Effectiveness of partial hospitalization in the treatment of borderline personality disorder: a randomized controlled trial. American Journal of Psychiatry1999;156(10):1563-9. [DOI: 10.1176/ajp.156.10.1563] [PMID: 10518167]BatemanA , FonagyP . Health care utilization costs for borderline personality disorder patients treated with psychoanalytically oriented partial hospitalization versus general psychiatric care. American Journal of Psychiatry2003;160(1):169-71. [10.1176/appi.ajp.160.1.169] [12505818]BatemanA , FonagyP . Treatment of borderline personality disorder with psychoanalytically oriented partial hospitalization: an 18-month follow-up. American Journal of Psychiatry2001;158(1):36-42. [DOI: 10.1176/appi.ajp.158.1.36] [PMID: 11136631]BatemanA . Important: question regarding your BPD trial for systematic review in Cochrane Collaboration [personal communication]. Email to: K Lieb, J Stoffers 14 December 2010. BatemanA . Intensive outpatient and partial hospital care for BPD. In: 157th annual meeting of the American Psychiatric Association. Psychotherapy and pharmacology: dissolving the mind-brain barrier; 2004 May 1-6; New York (NY). Arlington (VA): American Psychiatric Association, 2004:102. [Symposium 100B] [www.psychiatry.org/File%20Library/Psychiatrists/Directories/Library-and-Archive/conference_publications/am_program_2004.pdf]BatemanAW , FonagyP . Drs Bateman and Fonagy reply [to Stern R. Partial hospitalization for borderline personality disorder. American Journal of Psychiatry 2001;158(11):1932-3. DOI: 10.1176/appi.ajp.158.11.1932]. American Journal of Psychiatry2001;158(11):1932-3. [DOI: 10.1176/appi.ajp.158.11.1932-a]EvansC . Treatment benefits of psychoanalytically oriented partial hospitalisation were maintained over 18 months in borderline personality disorder. Evidence-Based Mental Health2001;4(3):73. [DOI: 10.1136/ebmh.4.3.73]FonagyP , BatemanAW . Mentalizing and borderline personality disorder. Journal of Mental Health2007;16(1):83-101. [DOI: 10.1080/09638230601182045]SternR . Partial hospitalization for borderline personality disorder. American Journal of Psychiatry2001;158(11):1932-3. [DOI: 10.1176/appi.ajp.158.11.1932] [PMID: 11691712]">Bateman 1999</a>; <a href="./references#CD012955-bbs2-0005" title="BatemanA , FonagyP . Impact of clinical severity on outcomes of mentalisation-based treatment for borderline personality disorder. British Journal of Psychiatry2013;203(3):221-7. [DOI: 10.1192/bjp.bp.112.121129] [PMID: 23887998]BatemanA , FonagyP . Randomized controlled trial of outpatient mentalization-based treatment versus structured clinical management for borderline personality disorder. American Journal of Psychiatry2009;166(12):1355-64. [DOI: 10.1176/appi.ajp.2009.09040539] [PMID: 19833787]BatemanA , FonagyP . Randomized controlled trial of outpatient mentalization-based treatment versus structured clinical management for borderline personality disorder. Supplementary data. ajp.psychiatryonline.org/doi/suppl/10.1176/appi.ajp.2009.09040539/suppl_file/ajp_166_12_1355_01.pdf (accessed 27 February 2020). BatemanA , O'ConnellJ , LorenziniN , GardnerT , FonagyP . A randomised controlled trial of mentalization-based treatment versus structured clinical management for patients with comorbid borderline personality disorder and antisocial personality disorder. BMC Psychiatry2016;16:304. [DOI: 10.1186/s12888-016-1000-9] [PMC5006360] [PMID: 27577562]BatemanA . Important question regarding your BPD trial for systematic review in Cochrane Collaboration [personal communication]. Email to: K Lieb 14 December 2010. BatemanAW . Mentalization, borderline personality disorder and what works for whom? Presentation at the 11th International Congress of the International Society for the Study of Personality Disorders; 2009 Aug 21-23. www.borderlinepersonalitydisorder.com/Conferences/ISSPD/isspd_09_Bateman (accessed 21 April 2010). ISRCTN27660668. Randomised controlled trial of manualised out-patient individual and group therapy for borderline personality disorder [Effectiveness of intensive out-patient psychotherapy for treatment of borderline personality disorder: a pragmatic randomised single blind controlled study]. www.isrctn.com/ISRCTN27660668 (first received 12 October 2008). ">Bateman 2009</a>; <a href="./references#CD012955-bbs2-0010" title="BlackD . Question regarding your BPD trial [personal communication]. Email to: J Stoffers 04 January 2011. BlackDW , AllenJ , McCormickB , BlumN . Treatment received by persons with BPD participating in a randomized clinical trial of the systems training for emotional predictability and problem solving programme. Personality and Mental Health2011;5(3):159-68. [DOI: 10.1002/pmh.167]BlackDW , AllenJ , St JohnD , PfohlB , McCormickB , BlumN . Predictors of response to systems training for emotional predictability and problem solving (STEPPS) for borderline personality disorder: an exploratory study. Acta Psychiatrica Scandinavica2009;120(1):53-61. [DOI: 10.1111/j.1600-0447.2008.01340.x] [PMC3665337] [PMID: 19183126]BlackDW , BlumN , PfohlB , St JohnD . The STEPPS group treatment program for outpatients with borderline personality disorder. Journal of Contemporary Psychotherapy2004;34(3):193-210. [DOI: 10.1023/B:JOCP.0000036630.25741.83]BlackDW , PfohlBM . Randomized clinical trial of STEPPS versus treatment as usual. In: 158th annual meeting of the American Psychiatric Association. Psychosomatic medicine: integrating psychiatry &amp; medicine; 2005 May 21-26; Atlanta (GA). Arlington (VA): American Psychiatric Association, 2005:104. [No. 1B] [www.psychiatry.org/File%20Library/Psychiatrists/Directories/Library-and-Archive/syllabus/am_syllabus_2005.pdf]BlackDW , Simsek-DuranF , BlumN , McCormickB , AllenJ . Do people with borderline personality disorder complicated by antisocial personality disorder benefit from the STEPPS treatment program?Personality and Mental Health2016;10(3):205-15. [DOI: 10.1002/pmh.1326] [PMC4911327] [PMID: 26671625]BlackDW . RE: [external] questions regarding your trial on the STEPPS program for BPD [personal communication]. Email to: EG Faltinsen 27 November 2017. BlumN , AllenJ , McCormickB , BlackDW . Ms Blum and colleagues reply [to Schulte-Herbrüggen O, Koerting J, Roepke S. Effectiveness of adjunctive STEPPS group treatment in borderline personality disorder patients. American Journal of Psychiatry 2008;165(10):1354-5. DOI: 10.1176/appi.ajp.2008.08030390]. American Journal of Psychiatry2008;165(10):1354-5. [DOI: 10.1176/appi.ajp.2008.08030390r]BlumN , FranklinJ , HanselR , McCormickB , St JohnD , PfohlB , et al. Relationship of age to symptom severity, psychiatric comorbidity and health care utilization in persons with borderline personality disorder. Personality and Mental Health2008;2(1):25-43. [DOI: 10.1002/pmh.26]BlumN , St JohnD , PfohlB , StuartS , McCormickB , AllenJ , et al. Erratum. American Journal of Psychiatry2008;165(6):777. Erratum for: American Journal of Psychiatry 2008;165(4):468-78. [psycnet.apa.org/record/2008-07854-033]BlumN , St JohnD , PfohlB , StuartS , McCormickB , AllenJ , et al. Systems training for emotional predictability and problem solving (STEPPS) for outpatients with borderline personality disorder: a randomized controlled trial and 1-year follow-up. American Journal of Psychiatry2008;165(4):468-78. [DOI: 10.1176/appi.ajp.2007.07071079] [PMC3608469] [PMID: 18281407]DavidsonKM . Borderline personality disorder: STEPPS improves symptoms. Evidence-Based Mental Health2008;11(4):120. [DOI: 10.1136/ebmh.11.4.120] [PMID: 18952969]NCT00055315. Treatment for borderline personality disorder [A cognitive group treatment for borderline outpatients]. clinicaltrials.gov/ct2/show/NCT00055315 (first received 25 February 2003). ">Blum 2008</a>; <a href="./references#CD012955-bbs2-0012" title="BorschmannR , BarrettB , HellierJM , ByfordS , HendersonC , RoseD , et al. Joint crisis plans for people with borderline personality disorder: feasibility and outcomes in a randomised controlled trial. British Journal of Psychiatry2013;202(5):357-64. [DOI: 10.1192/bjp.bp.112.117762] [PMID: 23637110]BorschmannR . Joint crisis plans for BPD - question on publication in British Journal of Psychiatry [pers communication]. Email to: J Stoffers-Winterling 22 August 2017. BorschmannR . RE: joint crisis plans for BPD - question on publication in British Journal of Psychiatry [personal communication]. Email to: J Stoffers-Winterling 22 August 2017. BorschmannR . The development and testing of joint crisis plans for people with borderline personality disorder: a feasibility study. ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.628499 (accessed 27 January 2019). HellierJ . RE: regarding your study on on MBT for eating disorders [personal communication]. Email to: E Faltinsen 27 March 2018. HellierJ . RE: regarding your study on on MBT for eating disorders [personal communication]. Email to: E Faltinsen 3 January 2018. HellierJ . SV: regarding your study on MBT for eating disorders [personal communication]. Email to: EG Faltinsen, P Robinson 27 March 2018. ISRCTN12440268. JOSHUA: a pilot randomised controlled trial of joint crisis plans for people who self harm. www.isrctn.com/ISRCTN12440268 (first received 17 September 2009). ">Borschmann 2013</a>; <a href="./references#CD012955-bbs2-0015" title="CarterG . Question regarding your BPD trial [personal communication]. Email to: J Stoffers 21 December 2010. CarterGL , WillcoxCH , LewinTJ , ConradAM , BenditN . Hunter DBT project: randomized controlled trial of dialectical behaviour therapy in women with borderline personality disorder. Australian and New Zealand Journal of Psychiatry2010;44(2):162-73. [DOI: 10.3109/00048670903393621] [PMID: 20113305]">Carter 2010</a>; <a href="./references#CD012955-bbs2-0017" title="DavidsonK , LivingstoneS , McArthurK , DicksonL , GumleyA . An integrative complexity analysis of cognitive behaviour therapy sessions for borderline personality disorder. Psychology and Psychotherapy2007;80(Pt 4):513-23. [DOI: 10.1348/147608307X191535] [PMID: 17535542]DavidsonK , NorrieJ , TyrerP , GumleyA , TataP , MurrayH , et al. The effectiveness of cognitive behavior therapy for borderline personality disorder: results from the borderline personality disorder study of cognitive therapy (BOSCOT) trial. Journal of Personality Disorders2006;20(5):450-65. [DOI: 10.1521/pedi.2006.20.5.450] [PMC1852259] [PMID: 17032158]DavidsonK , TyrerP , GumleyA , TataP , NorrieJ , PalmerS , et al. A randomized controlled trial of cognitive behavior therapy for borderline personality disorder: rationale for trial, method, and description of sample. Journal of Personality Disorders2006;20(5):431-49. [DOI: 10.1521/pedi.2006.20.5.431] [PMC1847748] [PMID: 17032157]DavidsonKM , TyrerP , NorrieJ , PalmerSJ , TyrerH . Cognitive therapy v usual treatment for borderline personality disorder: prospective 6-year follow-up. British Journal of Psychiatry2010;197(6):456-62. [DOI: 10.1192/bjp.bp.109.074286] [PMID: 21119151]ISRCTN86177428. Borderline personality disorder study of cognitive therapy trial [A randomised controlled trial of cognitive therapy plus treatment as usual versus treatment as usual in the treatment of borderline personality disorder]. www.isrctn.com/ISRCTN86177428 (first received 22 July 2005). NCT00538135. BOSCOT: a randomised controlled trial of cognitive behavioural therapy in borderline personality disorder [BOSCOT: a randomised control trial of cognitive behavioural therapy plus treatment as usual versus treatment as usual in the treatment of borderline personality disorder]. www.clinicaltrials.gov/ct2/show/NCT00538135 (first received 29 September 2007). NorrieJ , DavidsonK , TataP , GumleyA . Influence of therapist competence and quantity of cognitive behavioural therapy on suicidal behaviour and inpatient hospitalisation in a randomised controlled trial in borderline personality disorder: further analyses of treatment effects in the BOSCOT study. Psychology and Psychotherapy2013;86(3):280-93. [DOI: 10.1111/papt.12004] [PMC4491320] [PMID: 23420622]PalmerS , DavidsonK , TyrerP , GumleyA , TataP , NorrieJ , et al. The cost-effectiveness of cognitive behavior therapy for borderline personality disorder: results from the BOSCOT trial. Journal of Personality Disorders2006;20(5):466-81. [DOI: 10.1521/pedi.2006.20.5.466] [PMC1852260] [PMID: 17032159]">Davidson 2006</a>; <a href="./references#CD012955-bbs2-0019" title="BuchheimA , Hörz-SagstetterS , DoeringS , RentropM , SchusterP , BuchheimP , et al. Change of unresolved attachment in borderline personality disorders: RCT study of transference-focused psychotherapy. Psychotherapy and Psychosomatics2017;86(5):314-6. [DOI: 10.1159/000460257] [PMID: 28903103]DiamondD , LevyKN , ClarkinJF , Fischer-KernM , CainNM , DoeringS , et al. Attachment and mentalization in female patients with comorbid narcissistic and borderline personality disorder. Personality Disorders2014;5(4):428-33. [DOI: 10.1037/per0000065] [PMID: 25314231]DiamondD , YeomansFE , SternB , LevyKN , HörzS , DoeringS , et al. Transference-focused psychotherapy for patients with comorbid narcissistic and borderline personality disorder. Psychoanalytic Inquiry2013;33(6):527-51. [DOI: 10.1080/07351690.2013.815087]DoeringS , HörzS , RentropM , Fischer-KernM , SchusterP , BeneckeC , et al. Transference-focused psychotherapy v treatment by community psychotherapists for borderline personality disorder: randomised controlled trial. British Journal of Psychiatry2010;196(5):389-95. [DOI: 10.1192/bjp.bp.109.070177] [PMID: 20435966]DoeringS . Author's reply [to Kleindienst N, Krumm B, Bohus M. Is transference-focused psychotherapy really efficacious for borderline personality disorder? British Journal of Psychiatry 2011;198(2):156-7. DOI: 10.1192/bjp.198.2.156b]. British Journal of Psychiatry2011;198(2):156-7. [DOI: 10.1192/bjp.198.2.157]DoeringS . Question regarding your BPD trial for systematic review in Cochrane Collaboration [personal communication]. Email to: K Lieb, J Stoffers 10 December 2010. Fischer-KernM , DoeringS , TaubnerS , HörzS , ZimmermannJ , RentropM , et al. Transference-focused psychotherapy for borderline personality disorder: change in reflective function. British Journal of Psychiatry2015;207(2):173-4. [DOI: 10.1192/bjp.bp.113.143842] [PMID: 25999334]KleindienstN , KrummB , BohusM . Is transference-focused psychotherapy really efficacious for borderline personality disorder?British Journal of Psychiatry2011;198(2):156-7. [DOI: 10.1192/bjp.198.2.156b] [PMID: 21282787]LevyKN , MeehanKB , YeomansFE . Transference-focused psychotherapy reduces treatment drop-out and suicide attempters compared with community psychotherapist treatment in borderline personality disorder. Evidence-based Mental Health2010;13(4):119. [DOI: 10.1136/ebmh.13.4.119] [PMID: 21036981]NCT00714311. Efficacy of transference-focused psychotherapy for borderline personality disorder [A randomized-controlled trial of transference-focused psychotherapy vs treatment by experienced community psychotherapists for borderline personality disorder]. www.clinicaltrials.gov/ct2/show/NCT00714311 (first received 9 July 2008). RentropM , MartiusP , BäumlJ , BuchheimP , DöeringS , HörzS . Patients with borderline personality disorder not participating in an RCT: are they different?Psychopathology2010;43(6):369-72. [DOI: 10.1159/000320351] [PMID: 20798576]">Doering 2010</a>; <a href="./references#CD012955-bbs2-0021" title="FarrellJM , ShawIA , WebberMA . A schema-focused approach to group psychotherapy for outpatients with borderline personality disorder: a randomized controlled trial. Journal of Behavior Therapy and Experimental Psychiatry2009;40(2):317-28 Corrigendum to: Journal of Behavior Therapy and Experimental Psychiatry 2018; 60: 111. [DOI: 10.1016/j.jbtep.2009.01.002] [PMID: 19176222]FarrellJM . Question regarding your BPD trials [personal communication]. Email to: K Lieb, J Stoffers 9 December 2010. ">Farrell 2009</a>; <a href="./references#CD012955-bbs2-0022" title="FeigenbaumJD , FonagyP , PillingS , JonesA , WildgooseA , BebbingtonPE . A real-world study of the effectiveness of DBT in the UK National Health Service. British Journal of Clinical Psychology2012;51(2):121-41. [DOI: 10.1111/j.2044-8260.2011.02017.x] [PMID: 22574799]">Feigenbaum 2012</a>; <a href="./references#CD012955-bbs2-0025" title="GleesonJF , ChanenA , CottonSM , PearceT , NewmanB , McCutcheonL . Treating co-occurring first-episode psychosis and borderline personality: a pilot randomized controlled trial. Early Intervention in Psychiatry2012;6(1):21-9. [DOI: 10.1111/j.1751-7893.2011.00306.x] [PMID: 22379625]GleesonJFM . RE: separate data [personal communication]. Email to: M Kielsholm 28 October 2016. ">Gleeson 2012</a>; <a href="./references#CD012955-bbs2-0027" title="GratzKL , BardeenJR , LevyR , Dixon-GordonKL , TullMT . Mechanisms of change in an emotion regulation group therapy for deliberate self-harm among women with borderline personality disorder. Behaviour Research and Therapy2015;65:29-35. [DOI: 10.1016/j.brat.2014.12.005] [PMC4306622] [PMID: 25557395]GratzKL , Dixon-GordonKL , TullMT . Predictors of treatment response to an adjunctive emotion regulation group therapy for deliberate self-harm among women with borderline personality disorder. Personality Disorders2014;5(1):97-107. [DOI: 10.1037/per0000062] [PMC4059504] [PMID: 2458806]GratzKL , TullMT , LevyR . Randomized controlled trial and uncontrolled 9-month follow-up of an adjunctive emotion regulation group therapy for deliberate self-harm among women with borderline personality disorder. Psychological Medicine2014;44(10):2099-112. [DOI: 10.1017/S0033291713002134] [PMID: 23985088]GratzKL . Question regarding your BPD trials [personal communication]. Email to: J Stoffers 11 December 2010. ">Gratz 2014</a>; <a href="./references#CD012955-bbs2-0028" title="GregoryRJ , ChlebowskiS , KangD , RemenA , SoderbergM . Psychodynamic therapy for borderline personality disorder and co-occurring alcohol use disorders: a newly designed ongoing study. Journal of the American Psychoanalytic Association2006;54(4):1331-4. [DOI: 10.1177/00030651060540040107] [PMID: 17354507]GregoryRJ , ChlebowskiS , KangD , RemenAL , SoderbergMG , StepkovitchJ , et al. A controlled trial of psychodynamic psychotherapy for co-occurring borderline personality disorder and alcohol use disorder. Psychotherapy2008;45(1):28-41. [DOI: 10.1037/0033-3204.45.1.28] [PMID: 22122363]GregoryRJ , DeLucia-DeranjaE , MogleJA . Dynamic deconstructive psychotherapy versus optimized community care for borderline personality disorder co-occuring with alcohol use disorders: a 30-month follow-up. Journal of Nervous and Mental Disease2010;198(4):292-8. [DOI: 10.1097/NMD.0b013e3181d6172d] [PMID: 20386259]GregoryRJ , RemenAL , SoderbergM , Ploutz-SnyderRJ . A controlled trial of psychodynamic psychotherapy for co-occurring borderline personality disorder and alcohol use disorder: six-month outcome. Journal of the American Psychoanalytic Association2009;57(1):199-205. [DOI: 10.1177/00030651090570011006] [PMID: 19270255]NCT00145678. Psychodynamic therapy for co-occurring borderline personality disorder and alcohol use disorder [Psychodynamic therapy for patients With borderline personality disorder and alcohol abuse]. www.clinicaltrials.gov/show/NCT00145678 (first received 1 September 2005). ">Gregory 2008b</a>; <a href="./references#CD012955-bbs2-0032" title="JochemsEC , Van der Feltz-CornelisCM , Van DamA , DuivenvoordenHJ , MulderCL . The effects of motivation feedback in patients with severe mental illness: a cluster randomized controlled trial. Neuropsychiatric Disease and Treatment2015;11:3049-64. [DOI: 10.2147/NDT.S95190] [PMC4686323] [PMID: 26715847]JochemsEC . Cochrane Collaboration review on psychotherapies for borderline PD [personal communication]. Email to: EG Faltinsen 2 July 2018. JochemsEC . Re: Cochrane Collaboration review on psychotherapies for borderline PD [personal communication]. Email to: J Stoffers-Winterling 02 July 2018. ">Jochems 2015</a>; <a href="./references#CD012955-bbs2-0033" title="JørgensenCR , BøyeR , AndersenD , Døssing BlaabjergAH , FreundC , JordetH , et al. Eighteen months post-treatment naturalistic follow-up study of mentalization-based therapy and supportive group treatment of borderline personality disorder: clinical outcomes and functioning. Nordic Psychology2014;66(4):254-73. [DOI: 10.1080/19012276.2014.963649]JørgensenCR , FreundC , BøyeR , JordetH , AndersenD , KjølbyeM . Outcome of mentalization-based and supportive psychotherapy in patients with borderline personality disorder: a randomized trial. Acta Psychiatrica Scandinavica2013;127(4):305-17. [DOI: 10.1111/j.1600-0447.2012.01923.x] [PMID: 22897123]JorgensenCR . SV: questions on your trial regarding MBT for BPD patients [personal communication]. Email to: EG Faltinsen 28 November 2017. ">Jørgensen 2013</a>; <a href="./references#CD012955-bbs2-0038" title="KramerU , Pascual-LeoneA , BerthoudL , De RotenY , MarquetP , KollyS , et al. Assertive anger mediates effects of dialectical behaviour-informed skills training for borderline personality disorder: a randomized controlled trial. Clinical Psychology &amp; Psychotherapy2016;23(3):189-202. [DOI: 10.1002/cpp.1956] [PMID: 25864773]KramerU . The role of coping change in borderline personality disorder: a process-outcome analysis on dialectical-behaviour skills training. Clinical Psychology &amp; Psychotherapy2017;24(2):302-11. [DOI: 10.1002/cpp.2017] [PMID: 27098296]">Kramer 2016</a>; <a href="./references#CD012955-bbs2-0046" title="HeardHL . Cost-Effectiveness of Dialectical Behavior Therapy in the Treatment of Borderline Personality Disorder [PhD thesis]. Washington (DC): University of Washington, 2000. LindenboimN . To Know Me is to Keep Me: Self-Verification, Validation, and Therapy Dropout in the Treatment of Borderline Personality Disorder [PhD thesis]. Washington (DC): University of Washington, 2009. LinehanMM , HeardHL , ArmstrongHE . Naturalistic follow-up of a behavioral treatment for chronically parasuicidal borderline patients. Archives of General Psychiatry1993;50(12):971-4. [DOI: 10.1001/archpsyc.1993.01820240055007] [PMID: 8250683]LinehanMM , TutekDA , HeardHL , ArmstrongHE . Interpersonal outcome of cognitive behavioral treatment for chronically suicidal borderline patients. American Journal of Psychiatry1994;151(12):1771-6. [DOI: 10.1176/ajp.151.12.1771] [PMID: 7977884]">Linehan 1994</a>; <a href="./references#CD012955-bbs2-0052" title="HagaE , AasE , GrøholtB , TørmoenAJ , MehlumL . Cost-effectiveness of dialectical behaviour therapy vs enhanced usual care in the treatment of adolescents with self-harm. Child and Adolescent Psychiatry and Mental Health2018;12:22. [DOI: 10.1186/s13034-018-0227-2] [PMC5928596] [PMID: 29743941]MehlumL , RambergM , TørmoenAJ , HagaE , DiepLM , StanleyBH , et al. Dialectical behavior therapy compared with enhanced usual care for adolescents with repeated suicidal and self-harming behavior: outcomes over a one-year follow-up. Journal of the American Academy of Child and Adolescent Psychiatry2016;55(4):295-300. [DOI: 10.1016/j.jaac.2016.01.005] [PMID: 27015720]MehlumL , TørmoenAJ , RambergM , HagaE , DiepLM , LabergS , et al. Dialectical behavior therapy for adolescents with repeated suicidal and self-harming behavior: a randomized trial. Journal of the American Academy of Child and Adolescent Psychiatry2014;53(10):1082-91. [DOI: 10.1016/j.jaac.2014.07.003] [PMID: 25245352]MehlumL . Re: regarding your study of DBT for your with suicidal behavior [personal communication] [Re: angående din studie om DBT for ungdom med selvmordsatferd [personlig kommunikation]]. Email to: E Faltinsen 5 December 2017. NCT00675129. Treatment for adolescents with deliberate self harm [A randomized controlled trial for repetitive deliberate self-harm and suicidal behaviours among Norwegian adolescents: a comparison between dialectical behaviour therapy adapted for adolescents (DBT-A) and enhanced usual care (EUC)]. www.clinicaltrials.gov/ct2/show/NCT00675129 (first received 6 May 2008). RamlethRK , GroholtB , DiepLM , WalbyFA , MehlumL . The impact of borderline personality disorder and sub-threshold borderline personality disorder on the course of self-reported and clinician-rated depression in self-harming adolescents. Borderline Personality Disorder and Emotion Dysregulation2017;4:22. [DOI: 10.1186/s40479-017-0073-5] [PMC5663078] [PMID: 29093819]">Mehlum 2014</a>; <a href="./references#CD012955-bbs2-0060" title="RenesesB , FigueraD , SalcedoG , TrujilloM , López-IborJJ , GaliánM , et al. A controlled randomized study on the efficacy of short-term dinamic psychotherapy in borderline personality disorders (BPD). Preliminary results. European Psychiatry2011;26(Suppl 1):1040. [DOI: 10.1016/S0924-9338(11)72745-6] [P02-444]RenesesB , GaliánM , SerranoR , FigueraD , Fernandez Del MoralA , López-IborJJ , et al. A new time limited psychotherapy for BPD: preliminary results of a randomized and controlled trial. Actas Espanolas de Psiquiatria2013;41(3):139-48. [PMID: 23803797]">Reneses 2013</a>; <a href="./references#CD012955-bbs2-0063" title="SalzerS , CroppC , JaegerU , MasuhrO , Streeck-FischerA . Psychodynamic therapy for adolescents suffering from co-morbid disorders of conduct and emotions in an in-patient setting: a randomized controlled trial. Psychological Medicine2014;44(10):2213-22. [DOI: 10.1017/S003329171300278X] [PMID: 24229481]SalzerS , Streeck-FischerA . The psychoanalytic-interactional method (PiM) for adolescents with borderline personality disorder [Die psychoanalytisch-interaktionelle methode (PiM) für adoleszente mit borderline-persönlichkeitsstörung]. Personlichkeitsstorungen Theorie und Therapie2015;19(1):67-76. [elibrary.klett-cotta.de/article/99.120110/ptt-19-1-67]SalzerS . AW: Re: Cochrane Review on psychotherapies for BPD - RCT testing PiM vs WL [personal communication] [AW:Re: Cochrane Review zur Psychotherapie bei BPS - RCT zu PiM vs WL [persönliche kommunikation]]. Email to: J Stoffers-Winterling 15 July 2018. ">Salzer 2014</a>; <a href="./references#CD012955-bbs2-0069" title="SolerJ , PascualJC , TianaT , CebriàA , BarrachinaJ , CampinsMJ , et al. Dialectical behaviour therapy skills training compared to standard group therapy in borderline personality disorder: a 3-month randomised controlled clinical trial. Behaviour Research and Therapy2009;47(5):353-8. [DOI: 10.1016/j.brat.2009.01.013] [PMID: 19246029]SolerJ . Question regarding your BPD trials [personal communication]. Email to: J Stoffers 15 December 2010. ">Soler 2009</a>). </p> <p>Generally, psychotherapy improved psychosocial functioning at end of treatment compared with TAU (SMD −0.45, 95% CI −0.68 to −0.22; 22 trials, 1314 participants; I<sup>2</sup> = 72%; P = 0.0001; <a href="./references#CD012955-fig-0010" title="">Analysis 1.7</a>.1; low‐quality evidence, <a href="./full#CD012955-tbl-0001">summary of findings Table 1</a>). This corresponds to a MD of −2.8 (95% CI −4.25 to −1.38), on the GAF scale, which ranges from 0 to 100. The MIREDIF on this scale is −4.0 points (<a href="./references#CD012955-bbs2-0224" title="AmriA , MillierM , ToumiM . Minimum clinically important difference in the global assessment functioning in patients with schizophrenia. Value in Health2014;17(7):A765-6. [DOI: 10.1016/j.jval.2014.08.285] [Abstract #PMH2] [PMID: 27202809]">Amri 2014</a>). This finding does not represent a clinically important improvement in psychosocial functioning for people with BPD. The TSA analysis showed that the RIS was reached (n = 947), and that there was no risk of type 1 error (TSA adjusted confidence interval −3.97 to −1.94) (see figure 10 in <a href="./appendices#CD012955-sec-0603">Appendix 6</a>). </p> <p>Inspection of the funnel plot in (see figure 11 in <a href="./appendices#CD012955-sec-0603">Appendix 6</a>) suggested potential bias (asymmetry), and we found no evidence of possible significant publication bias: Egger’s regression intercept (bias) 1.50 (two tailed, P = 0.241). </p> <p>Generally, psychotherapy did not improve psychosocial functioning at zero to six months follow‐up compared with TAU (SMD −1.23, 95% CI −2.74 to 0.29; 1 trial, 9 participants; P = 0.11; MD −15.80, 95% CI −2.74 to 0.29; 1 trial, 9 participants; P = 0.11; <a href="./references#CD012955-fig-0010" title="">Analysis 1.7</a>.2). </p> <p>Generally, psychotherapy did not improve psychosocial functioning at six to 12 months follow‐up compared with TAU (SMD −0.09, 95% CI −0.40 to 0.23; 3 trials, 247 participants; I<sup>2</sup> = 30%; P = 0.59; <a href="./references#CD012955-fig-0010" title="">Analysis 1.7</a>.3). </p> <p>Generally, psychotherapy did not improve psychosocial functioning at above 12 months follow‐up compared with TAU (SMD −0.27, 95% CI −0.60 to 0.05; 6 trials, 499 participants; I<sup>2</sup> = 60%; P = 0.10; <a href="./references#CD012955-fig-0010" title="">Analysis 1.7</a>.4). </p> </section> </section> <section id="CD012955-sec-0086"> <h5 class="title">Secondary outcomes</h5> <section id="CD012955-sec-0087"> <h6 class="title">1.8 Anger</h6> <p>Eight trials reported continuous data on anger (<a href="./references#CD012955-bbs2-0001" title="AmiantoF , FerreroA , PieròA , CairoE , RoccaG , SimonelliB , et al. Supervised team management, with or without structured psychotherapy, in heavy users of a mental health service with borderline personality disorder: a two-year follow-up preliminary randomized study. BMC Psychiatry2011;11:181. [DOI: 10.1186/1471-244X-11-181] [PMC3260092 ] [PMID: 22103890]NCT01356069. Efficacy of time-limited psychodynamic psychotherapy and informed clinical management in BPD high MHS users (HUMSH) [Sequential brief Adlerian psychodynamic psychotherapy in heavy users of a mental health service with borderline personality disorder: a two years follow-up preliminary randomized study]. clinicaltrials.gov/ct2/show/NCT01356069 (first received 16 May 2011). ">Amianto 2011</a>; <a href="./references#CD012955-bbs2-0022" title="FeigenbaumJD , FonagyP , PillingS , JonesA , WildgooseA , BebbingtonPE . A real-world study of the effectiveness of DBT in the UK National Health Service. British Journal of Clinical Psychology2012;51(2):121-41. [DOI: 10.1111/j.2044-8260.2011.02017.x] [PMID: 22574799]">Feigenbaum 2012</a>; <a href="./references#CD012955-bbs2-0025" title="GleesonJF , ChanenA , CottonSM , PearceT , NewmanB , McCutcheonL . Treating co-occurring first-episode psychosis and borderline personality: a pilot randomized controlled trial. Early Intervention in Psychiatry2012;6(1):21-9. [DOI: 10.1111/j.1751-7893.2011.00306.x] [PMID: 22379625]GleesonJFM . RE: separate data [personal communication]. Email to: M Kielsholm 28 October 2016. ">Gleeson 2012</a>; <a href="./references#CD012955-bbs2-0035" title="KoonsCR , RobinsCJ , TweedJL , LynchTR , GonzalezAM , MorseJQ , et al. Efficacy of dialectical behavior therapy in women veterans with borderline personality disorder. Behavior Therapy2001;32(2):371-90. [DOI: 10.1016/S0005-7894(01)80009-5]">Koons 2001a</a>; <a href="./references#CD012955-bbs2-0043" title="LeppänenV , HakkoH , SintonenH , LindemanS . Comparing effectiveness of treatments for borderline personality disorder in communal mental health care: the Oulu BPD study. Community Mental Health Journal2016;52(2):216-27. [DOI: 10.1007/s10597-015-9866-4] [PMID: 25824852]LeppänenV . Re: questions regarding the Oulu BPD study [personal communication]. Email to: E Faltinsen 20 December 2017. LeppänenV . Re: SV: question regarding the Oulu BPD study [personal communication]. Email to: EG Faltinsen 22 December 2017. ">Leppänen 2016</a>; <a href="./references#CD012955-bbs2-0046" title="HeardHL . Cost-Effectiveness of Dialectical Behavior Therapy in the Treatment of Borderline Personality Disorder [PhD thesis]. Washington (DC): University of Washington, 2000. LindenboimN . To Know Me is to Keep Me: Self-Verification, Validation, and Therapy Dropout in the Treatment of Borderline Personality Disorder [PhD thesis]. Washington (DC): University of Washington, 2009. LinehanMM , HeardHL , ArmstrongHE . Naturalistic follow-up of a behavioral treatment for chronically parasuicidal borderline patients. Archives of General Psychiatry1993;50(12):971-4. [DOI: 10.1001/archpsyc.1993.01820240055007] [PMID: 8250683]LinehanMM , TutekDA , HeardHL , ArmstrongHE . Interpersonal outcome of cognitive behavioral treatment for chronically suicidal borderline patients. American Journal of Psychiatry1994;151(12):1771-6. [DOI: 10.1176/ajp.151.12.1771] [PMID: 7977884]">Linehan 1994</a>; <a href="./references#CD012955-bbs2-0047" title="BedicsJD , AtkinsDC , ComtoisKA , LinehanMM . Treatment differences in the therapeutic relationship and introject during a 2-year randomized controlled trial of dialectical behavior therapy versus nonbehavioral psychotherapy experts for borderline personality disorder. Journal of Consulting and Clinical Psychology2012;80(1):66-77. [DOI: 10.1037/a0026113] [PMC3265694] [PMID: 22061867]BedicsJD , AtkinsDC , ComtoisKA , LinehanMM . Weekly therapist ratings of the therapeutic relationship and patient introject furing the course of dialectical behavioral therapy for the treatment of borderline personality disorder. Psychotherapy2012;49(2):231-40. [DOI: 10.1037/a0028254] [PMID: 22642526]BedicsJD , AtkinsDC , HarnedMS , LinehanMM . The therapeutic alliance as a predictor of outcome in dialectical behavior therapy versus nonbehavioral psychotherapy by experts for borderline personality disorder. Psychotherapy2015;52(1):67-77. [DOI: 10.1037/a0038457] [PMID: 25751116]BrownMZ , LinehanMM , ComtoisKA , MurrayA , ChapmanAL . Shame as a prospective predictor of self-inflicted injury in borderline personality disorder: a multi-modal analysis. Behaviour Research and Therapy2009;47(10):815-22. [DOI: 10.1016/j.brat.2009.06.008] [PMC2761705] [PMID: 19596223 ]CoyleTN , ShaverJA , LinehanMM . On the potential for iatrogenic effects of psychiatric crisis services: the example of dialectical behavior therapy for adult women with borderline personality disorder. Journal of Consulting and Clinical Psychology2018;86(2):116-24. [DOI: 10.1037/ccp0000275] [PMID: 29369662]HarnedMS , ChapmanAL , Dexter-MazzaET , MurrayA , ComtoisKA , LinehanMM . Treating co-occurring Axis I disorders in recurrently suicidal women with borderline personality disorder: a 2-year randomized trial of dialectical behavior therapy versus community treatment by experts. Journal of Consulting and Clinical Psychology2008;76(6):1068-75. [DOI: 10.1037/a0014044] [PMID: 19045974]HarnedMS , ChapmanAL , Dexter-MazzaET , MurrayA , ComtoisKA , LinehanMM . Treating co-occurring Axis I disorders in recurrently suicidal women with borderline personality disorder: a 2-year randomized trial of dialectical behavior therapy versus community treatment by experts. Personality Disorders: Theory, Research, and Treatment2009;S(1):35-45. [DOI: 10.1037/1949-2715.S.1.35]HarnedMS , JacksonSC , ComtoisKA , LinehanMM . Dialectical behavior therapy as a precursor to PTSD treatment for suicidal and/or self-injuring women with bordreline personality disorder. Journal of Traumatic Stress2010;23(4):421-9. [DOI: 10.1002/jts.20553] [PMID: 20648564]LindenboimN , ComtoisKA , LinehanMM . Skills practice in dialectical behavior therapy for suicidal women meeting criteria for borderline personality disorder. Cognitive and Behavioral Practice2007;14(2):147-56. [DOI: 10.1016/j.cbpra.2006.10.004]LinehanMM , ComtoisKA , MurrayAM , BrownMZ , GallopRJ , HeardHL , et al. Two-year randomized controlled trial and follow-up of dialectical behavior therapy vs therapy by experts for suicidal behaviors and borderline personality disorder. Archives of General Psychiatry2006;63(7):757-66. [DOI: 10.1001/archpsyc.63.7.757] [PMID: 16818865]LinehanMM . Error in table in: two-year randomized controlled trial and follow-up of dialectical behavior therapy vs therapy by experts for suicidal behaviors and borderline personality disorder. Archives of General Psychiatry2007;64(12):1401. Erratum for: Archives of General Psychiatry 2007;64(12):1401. McMainS . Dialectic behaviour therapy reduces suicide attempts compared with non-behavioural psychotherapy in women with borderline personality disorder. Evidence-Based Mental Health2007;10(1):18. [DOI: 10.1136/ebmh.10.1.18] [PMID: 17255387]NeacsiuAD , LunguA , HarnedMS , RizviSL , LinehanMM . Impact of dialectical behavior therapy versus community treatment by experts on emotional experience, expression, and acceptance in borderline personality disorder. Behaviour Research and Therapy2014;53:47-54. [DOI: 10.1016/j.brat.2013.12.004] [PMC3955205] [PMID: 24418652]NeacsiuAD , RizviSL , LinehanMM . Dialectical behavior therapy skills use as a mediator and outcome of treatment for borderline personality disorder. Behaviour Research and Therapy2010;48(9):832-9. [DOI: 10.1016/j.brat.2010.05.017] [PMC2914145] [PMID: 20579633]SecristCD . The Role of Executive Functioning in the Treatment of Borderline Personality Disorder [PhD thesis]. Washington (DC): University of Washington, 2014. ">Linehan 2006</a>; <a href="./references#CD012955-bbs2-0069" title="SolerJ , PascualJC , TianaT , CebriàA , BarrachinaJ , CampinsMJ , et al. Dialectical behaviour therapy skills training compared to standard group therapy in borderline personality disorder: a 3-month randomised controlled clinical trial. Behaviour Research and Therapy2009;47(5):353-8. [DOI: 10.1016/j.brat.2009.01.013] [PMID: 19246029]SolerJ . Question regarding your BPD trials [personal communication]. Email to: J Stoffers 15 December 2010. ">Soler 2009</a>) </p> <p>Generally, psychotherapy reduced anger at end of treatment compared with TAU (SMD −0.38, 95% CI −0.64 to −0.12; 8 trials, 323 participants; I<sup>2</sup> = 21%; P = 0.005; <a href="./references#CD012955-fig-0011" title="">Analysis 1.8</a>.1). </p> <p>Generally, psychotherapy did not reduce anger at zero to six months follow‐up compared with TAU (SMD −1.20, 95% CI −2.82 to 0.41; 1 trial, 8 participants; P = 0.14; MD −4.50, 95% CI −9.01 to 0.01; 1 trial, 8 participants; P = 0.05; <a href="./references#CD012955-fig-0011" title="">Analysis 1.8</a>.2). </p> <p>Generally, psychotherapy did not reduce anger at six to 12 months follow‐up compared with TAU (SMD −0.12, 95% CI −0.50 to 0.25; 2 trials, 111 participants; I<sup>2</sup> = 0%; P = 0.52; <a href="./references#CD012955-fig-0011" title="">Analysis 1.8</a>.3). </p> <p>Generally, psychotherapy did not reduce anger at above 12 months follow‐up compared with TAU (SMD 0.02, 95% CI −0.42 to 0.46; 1 trial, 80 participants; P = 0.93; MD 0.01, 95% CI −0.20 to 0.22; 1 trial, 80 participants; P = 0.93; <a href="./references#CD012955-fig-0011" title="">Analysis 1.8</a>.4). </p> </section> <section id="CD012955-sec-0088"> <h6 class="title">1.9 Affective instability</h6> <p>Twelve trials reported continuous data on affective instability (<a href="./references#CD012955-bbs2-0001" title="AmiantoF , FerreroA , PieròA , CairoE , RoccaG , SimonelliB , et al. Supervised team management, with or without structured psychotherapy, in heavy users of a mental health service with borderline personality disorder: a two-year follow-up preliminary randomized study. BMC Psychiatry2011;11:181. [DOI: 10.1186/1471-244X-11-181] [PMC3260092 ] [PMID: 22103890]NCT01356069. Efficacy of time-limited psychodynamic psychotherapy and informed clinical management in BPD high MHS users (HUMSH) [Sequential brief Adlerian psychodynamic psychotherapy in heavy users of a mental health service with borderline personality disorder: a two years follow-up preliminary randomized study]. clinicaltrials.gov/ct2/show/NCT01356069 (first received 16 May 2011). ">Amianto 2011</a>; <a href="./references#CD012955-bbs2-0009" title="BianchiniV , CofiniV , CurtoM , LagrotteriaB , ManziA , NavariS , et al. Dialectical behavior therapy (DBT) for forensic psychiatric patients: an Italian pilot study. Criminal Behavior and Mental Health2019;29(9):122-30. [DOI: 10.1002/cbm.2102] [PMID: 30648303]">Bianchini 2019</a>; <a href="./references#CD012955-bbs2-0010" title="BlackD . Question regarding your BPD trial [personal communication]. Email to: J Stoffers 04 January 2011. BlackDW , AllenJ , McCormickB , BlumN . Treatment received by persons with BPD participating in a randomized clinical trial of the systems training for emotional predictability and problem solving programme. Personality and Mental Health2011;5(3):159-68. [DOI: 10.1002/pmh.167]BlackDW , AllenJ , St JohnD , PfohlB , McCormickB , BlumN . Predictors of response to systems training for emotional predictability and problem solving (STEPPS) for borderline personality disorder: an exploratory study. Acta Psychiatrica Scandinavica2009;120(1):53-61. [DOI: 10.1111/j.1600-0447.2008.01340.x] [PMC3665337] [PMID: 19183126]BlackDW , BlumN , PfohlB , St JohnD . The STEPPS group treatment program for outpatients with borderline personality disorder. Journal of Contemporary Psychotherapy2004;34(3):193-210. [DOI: 10.1023/B:JOCP.0000036630.25741.83]BlackDW , PfohlBM . Randomized clinical trial of STEPPS versus treatment as usual. In: 158th annual meeting of the American Psychiatric Association. Psychosomatic medicine: integrating psychiatry &amp; medicine; 2005 May 21-26; Atlanta (GA). Arlington (VA): American Psychiatric Association, 2005:104. [No. 1B] [www.psychiatry.org/File%20Library/Psychiatrists/Directories/Library-and-Archive/syllabus/am_syllabus_2005.pdf]BlackDW , Simsek-DuranF , BlumN , McCormickB , AllenJ . Do people with borderline personality disorder complicated by antisocial personality disorder benefit from the STEPPS treatment program?Personality and Mental Health2016;10(3):205-15. [DOI: 10.1002/pmh.1326] [PMC4911327] [PMID: 26671625]BlackDW . RE: [external] questions regarding your trial on the STEPPS program for BPD [personal communication]. Email to: EG Faltinsen 27 November 2017. BlumN , AllenJ , McCormickB , BlackDW . Ms Blum and colleagues reply [to Schulte-Herbrüggen O, Koerting J, Roepke S. Effectiveness of adjunctive STEPPS group treatment in borderline personality disorder patients. American Journal of Psychiatry 2008;165(10):1354-5. DOI: 10.1176/appi.ajp.2008.08030390]. American Journal of Psychiatry2008;165(10):1354-5. [DOI: 10.1176/appi.ajp.2008.08030390r]BlumN , FranklinJ , HanselR , McCormickB , St JohnD , PfohlB , et al. Relationship of age to symptom severity, psychiatric comorbidity and health care utilization in persons with borderline personality disorder. Personality and Mental Health2008;2(1):25-43. [DOI: 10.1002/pmh.26]BlumN , St JohnD , PfohlB , StuartS , McCormickB , AllenJ , et al. Erratum. American Journal of Psychiatry2008;165(6):777. Erratum for: American Journal of Psychiatry 2008;165(4):468-78. [psycnet.apa.org/record/2008-07854-033]BlumN , St JohnD , PfohlB , StuartS , McCormickB , AllenJ , et al. Systems training for emotional predictability and problem solving (STEPPS) for outpatients with borderline personality disorder: a randomized controlled trial and 1-year follow-up. American Journal of Psychiatry2008;165(4):468-78. [DOI: 10.1176/appi.ajp.2007.07071079] [PMC3608469] [PMID: 18281407]DavidsonKM . Borderline personality disorder: STEPPS improves symptoms. Evidence-Based Mental Health2008;11(4):120. [DOI: 10.1136/ebmh.11.4.120] [PMID: 18952969]NCT00055315. Treatment for borderline personality disorder [A cognitive group treatment for borderline outpatients]. clinicaltrials.gov/ct2/show/NCT00055315 (first received 25 February 2003). ">Blum 2008</a>; <a href="./references#CD012955-bbs2-0021" title="FarrellJM , ShawIA , WebberMA . A schema-focused approach to group psychotherapy for outpatients with borderline personality disorder: a randomized controlled trial. Journal of Behavior Therapy and Experimental Psychiatry2009;40(2):317-28 Corrigendum to: Journal of Behavior Therapy and Experimental Psychiatry 2018; 60: 111. [DOI: 10.1016/j.jbtep.2009.01.002] [PMID: 19176222]FarrellJM . Question regarding your BPD trials [personal communication]. Email to: K Lieb, J Stoffers 9 December 2010. ">Farrell 2009</a>; <a href="./references#CD012955-bbs2-0026" title="Gratz KL. Important: question regarding your BPD trial for systematic review in Cochrane Collaboration [personal communication]. Email to: J Stoffers-Winterling 11 December 2010. GratzKL , GundersonJG . Preliminary data on an acceptance-based emotion regulation group intervention for deliberate self-harm among women with borderline personality disorder. Behavior Therapy2006;37(1):25-35. [DOI: 10.1016/j.beth.2005.03.002] [PMID: 16942958]">Gratz 2006</a>; <a href="./references#CD012955-bbs2-0027" title="GratzKL , BardeenJR , LevyR , Dixon-GordonKL , TullMT . Mechanisms of change in an emotion regulation group therapy for deliberate self-harm among women with borderline personality disorder. Behaviour Research and Therapy2015;65:29-35. [DOI: 10.1016/j.brat.2014.12.005] [PMC4306622] [PMID: 25557395]GratzKL , Dixon-GordonKL , TullMT . Predictors of treatment response to an adjunctive emotion regulation group therapy for deliberate self-harm among women with borderline personality disorder. Personality Disorders2014;5(1):97-107. [DOI: 10.1037/per0000062] [PMC4059504] [PMID: 2458806]GratzKL , TullMT , LevyR . Randomized controlled trial and uncontrolled 9-month follow-up of an adjunctive emotion regulation group therapy for deliberate self-harm among women with borderline personality disorder. Psychological Medicine2014;44(10):2099-112. [DOI: 10.1017/S0033291713002134] [PMID: 23985088]GratzKL . Question regarding your BPD trials [personal communication]. Email to: J Stoffers 11 December 2010. ">Gratz 2014</a>; <a href="./references#CD012955-bbs2-0043" title="LeppänenV , HakkoH , SintonenH , LindemanS . Comparing effectiveness of treatments for borderline personality disorder in communal mental health care: the Oulu BPD study. Community Mental Health Journal2016;52(2):216-27. [DOI: 10.1007/s10597-015-9866-4] [PMID: 25824852]LeppänenV . Re: questions regarding the Oulu BPD study [personal communication]. Email to: E Faltinsen 20 December 2017. LeppänenV . Re: SV: question regarding the Oulu BPD study [personal communication]. Email to: EG Faltinsen 22 December 2017. ">Leppänen 2016</a>; <a href="./references#CD012955-bbs2-0055" title="MortonJ , SnowdonS , GopoldM , GuymerE . Acceptance and commitment therapy group treatment for symptoms of borderline personality disorder: a public sector pilot study. Cognitive and Behavioral Practice2012;19(4):527-44. [DOI: 10.1016/j.cbpra.2012.03.005]MortonJ . Re: SV: regarding your study on acceptance and commitment therapy for BPD [personal communication]. Email to: EG Faltinsen 22 December 2017. ">Morton 2012</a>; <a href="./references#CD012955-bbs2-0060" title="RenesesB , FigueraD , SalcedoG , TrujilloM , López-IborJJ , GaliánM , et al. A controlled randomized study on the efficacy of short-term dinamic psychotherapy in borderline personality disorders (BPD). Preliminary results. European Psychiatry2011;26(Suppl 1):1040. [DOI: 10.1016/S0924-9338(11)72745-6] [P02-444]RenesesB , GaliánM , SerranoR , FigueraD , Fernandez Del MoralA , López-IborJJ , et al. A new time limited psychotherapy for BPD: preliminary results of a randomized and controlled trial. Actas Espanolas de Psiquiatria2013;41(3):139-48. [PMID: 23803797]">Reneses 2013</a>; <a href="./references#CD012955-bbs2-0063" title="SalzerS , CroppC , JaegerU , MasuhrO , Streeck-FischerA . Psychodynamic therapy for adolescents suffering from co-morbid disorders of conduct and emotions in an in-patient setting: a randomized controlled trial. Psychological Medicine2014;44(10):2213-22. [DOI: 10.1017/S003329171300278X] [PMID: 24229481]SalzerS , Streeck-FischerA . The psychoanalytic-interactional method (PiM) for adolescents with borderline personality disorder [Die psychoanalytisch-interaktionelle methode (PiM) für adoleszente mit borderline-persönlichkeitsstörung]. Personlichkeitsstorungen Theorie und Therapie2015;19(1):67-76. [elibrary.klett-cotta.de/article/99.120110/ptt-19-1-67]SalzerS . AW: Re: Cochrane Review on psychotherapies for BPD - RCT testing PiM vs WL [personal communication] [AW:Re: Cochrane Review zur Psychotherapie bei BPS - RCT zu PiM vs WL [persönliche kommunikation]]. Email to: J Stoffers-Winterling 15 July 2018. ">Salzer 2014</a>; <a href="./references#CD012955-bbs2-0066" title="ISRCTN97589104. Evaluation of a group training for adolescents (emotion regulation training) with emotion regulation problems - a randomised controlled clinical trial. www.isrctn.com/ISRCTN97589104 (first received 23 August 2007). SchuppertHM , TimmermanME , BlooJ , Van GemertTG , WiersemaHM , MinderaaRB , et al. Emotion regulation training for adolescents with borderline personality disorder traits: a randomized controlled trial. Journal of the American Academy of Child &amp; Adolescent Psychiatry2012;51(12):1314-23. [DOI: 10.1016/j.jaac.2012.09.002] [PMID: 23200288]">Schuppert 2012</a>; <a href="./references#CD012955-bbs2-0069" title="SolerJ , PascualJC , TianaT , CebriàA , BarrachinaJ , CampinsMJ , et al. Dialectical behaviour therapy skills training compared to standard group therapy in borderline personality disorder: a 3-month randomised controlled clinical trial. Behaviour Research and Therapy2009;47(5):353-8. [DOI: 10.1016/j.brat.2009.01.013] [PMID: 19246029]SolerJ . Question regarding your BPD trials [personal communication]. Email to: J Stoffers 15 December 2010. ">Soler 2009</a>). </p> <p>Generally, psychotherapy improved affective instability at end of treatment compared with TAU (SMD −0.68, 95% CI −0.98 to −0.39; 12 trials, 620 participants; I<sup>2</sup> = 65%; P &lt; 0.001; (<a href="./references#CD012955-fig-0012" title="">Analysis 1.9</a>.1). </p> <p>Generally, psychotherapy did not improve affective instability at six to 12 months follow‐up compared with TAU (SMD −0.52, 95% CI −1.21 to 0.18; 1 trial, 33 participants; P = 0.15; MD −0.70, 95% CI −1.59 to 0.19; 1 trial, 33 participants; P = 0.12; <a href="./references#CD012955-fig-0012" title="">Analysis 1.9</a>.2). </p> <p>No data were available for zero to six months and above 12 months follow‐up.</p> </section> <section id="CD012955-sec-0089"> <h6 class="title">1.10 Chronic feelings of emptiness</h6> <p>Four trials reported continuous data on chronic feelings of emptiness (<a href="./references#CD012955-bbs2-0001" title="AmiantoF , FerreroA , PieròA , CairoE , RoccaG , SimonelliB , et al. Supervised team management, with or without structured psychotherapy, in heavy users of a mental health service with borderline personality disorder: a two-year follow-up preliminary randomized study. BMC Psychiatry2011;11:181. [DOI: 10.1186/1471-244X-11-181] [PMC3260092 ] [PMID: 22103890]NCT01356069. Efficacy of time-limited psychodynamic psychotherapy and informed clinical management in BPD high MHS users (HUMSH) [Sequential brief Adlerian psychodynamic psychotherapy in heavy users of a mental health service with borderline personality disorder: a two years follow-up preliminary randomized study]. clinicaltrials.gov/ct2/show/NCT01356069 (first received 16 May 2011). ">Amianto 2011</a>; <a href="./references#CD012955-bbs2-0043" title="LeppänenV , HakkoH , SintonenH , LindemanS . Comparing effectiveness of treatments for borderline personality disorder in communal mental health care: the Oulu BPD study. Community Mental Health Journal2016;52(2):216-27. [DOI: 10.1007/s10597-015-9866-4] [PMID: 25824852]LeppänenV . Re: questions regarding the Oulu BPD study [personal communication]. Email to: E Faltinsen 20 December 2017. LeppänenV . Re: SV: question regarding the Oulu BPD study [personal communication]. Email to: EG Faltinsen 22 December 2017. ">Leppänen 2016</a>; <a href="./references#CD012955-bbs2-0060" title="RenesesB , FigueraD , SalcedoG , TrujilloM , López-IborJJ , GaliánM , et al. A controlled randomized study on the efficacy of short-term dinamic psychotherapy in borderline personality disorders (BPD). Preliminary results. European Psychiatry2011;26(Suppl 1):1040. [DOI: 10.1016/S0924-9338(11)72745-6] [P02-444]RenesesB , GaliánM , SerranoR , FigueraD , Fernandez Del MoralA , López-IborJJ , et al. A new time limited psychotherapy for BPD: preliminary results of a randomized and controlled trial. Actas Espanolas de Psiquiatria2013;41(3):139-48. [PMID: 23803797]">Reneses 2013</a>; <a href="./references#CD012955-bbs2-0069" title="SolerJ , PascualJC , TianaT , CebriàA , BarrachinaJ , CampinsMJ , et al. Dialectical behaviour therapy skills training compared to standard group therapy in borderline personality disorder: a 3-month randomised controlled clinical trial. Behaviour Research and Therapy2009;47(5):353-8. [DOI: 10.1016/j.brat.2009.01.013] [PMID: 19246029]SolerJ . Question regarding your BPD trials [personal communication]. Email to: J Stoffers 15 December 2010. ">Soler 2009</a>). </p> <p>Generally, psychotherapy improved chronic feelings of emptiness at end of treatment compared with TAU (SMD −0.39, 95% CI −0.69 to −0.10; 4 trials, 187 participants; I<sup>2</sup> = 0%; P = 0.009; <a href="./references#CD012955-fig-0013" title="">Analysis 1.10</a>.1). </p> <p>Generally, psychotherapy did not improve chronic feelings of emptiness at six to 12 months follow‐up compared with TAU (SMD −0.58, 95% CI −1.28 to 0.11; 1 trial, 37 participants; P = 0.10; MD −0.60, 95% CI −1.39 to 0.09; 1 trial, 33 participants; P = 0.09; <a href="./references#CD012955-fig-0013" title="">Analysis 1.10</a>.2). </p> <p>No data were available for zero to six months and above 12 months follow‐up.</p> </section> <section id="CD012955-sec-0090"> <h6 class="title">1.11 Impulsivity (continuous)</h6> <p>Ten studiies reported continuous data on impulsivity (<a href="./references#CD012955-bbs2-0001" title="AmiantoF , FerreroA , PieròA , CairoE , RoccaG , SimonelliB , et al. Supervised team management, with or without structured psychotherapy, in heavy users of a mental health service with borderline personality disorder: a two-year follow-up preliminary randomized study. BMC Psychiatry2011;11:181. [DOI: 10.1186/1471-244X-11-181] [PMC3260092 ] [PMID: 22103890]NCT01356069. Efficacy of time-limited psychodynamic psychotherapy and informed clinical management in BPD high MHS users (HUMSH) [Sequential brief Adlerian psychodynamic psychotherapy in heavy users of a mental health service with borderline personality disorder: a two years follow-up preliminary randomized study]. clinicaltrials.gov/ct2/show/NCT01356069 (first received 16 May 2011). ">Amianto 2011</a>; <a href="./references#CD012955-bbs2-0009" title="BianchiniV , CofiniV , CurtoM , LagrotteriaB , ManziA , NavariS , et al. Dialectical behavior therapy (DBT) for forensic psychiatric patients: an Italian pilot study. Criminal Behavior and Mental Health2019;29(9):122-30. [DOI: 10.1002/cbm.2102] [PMID: 30648303]">Bianchini 2019</a>; <a href="./references#CD012955-bbs2-0010" title="BlackD . Question regarding your BPD trial [personal communication]. Email to: J Stoffers 04 January 2011. BlackDW , AllenJ , McCormickB , BlumN . Treatment received by persons with BPD participating in a randomized clinical trial of the systems training for emotional predictability and problem solving programme. Personality and Mental Health2011;5(3):159-68. [DOI: 10.1002/pmh.167]BlackDW , AllenJ , St JohnD , PfohlB , McCormickB , BlumN . Predictors of response to systems training for emotional predictability and problem solving (STEPPS) for borderline personality disorder: an exploratory study. Acta Psychiatrica Scandinavica2009;120(1):53-61. [DOI: 10.1111/j.1600-0447.2008.01340.x] [PMC3665337] [PMID: 19183126]BlackDW , BlumN , PfohlB , St JohnD . The STEPPS group treatment program for outpatients with borderline personality disorder. Journal of Contemporary Psychotherapy2004;34(3):193-210. [DOI: 10.1023/B:JOCP.0000036630.25741.83]BlackDW , PfohlBM . Randomized clinical trial of STEPPS versus treatment as usual. In: 158th annual meeting of the American Psychiatric Association. Psychosomatic medicine: integrating psychiatry &amp; medicine; 2005 May 21-26; Atlanta (GA). Arlington (VA): American Psychiatric Association, 2005:104. [No. 1B] [www.psychiatry.org/File%20Library/Psychiatrists/Directories/Library-and-Archive/syllabus/am_syllabus_2005.pdf]BlackDW , Simsek-DuranF , BlumN , McCormickB , AllenJ . Do people with borderline personality disorder complicated by antisocial personality disorder benefit from the STEPPS treatment program?Personality and Mental Health2016;10(3):205-15. [DOI: 10.1002/pmh.1326] [PMC4911327] [PMID: 26671625]BlackDW . RE: [external] questions regarding your trial on the STEPPS program for BPD [personal communication]. Email to: EG Faltinsen 27 November 2017. BlumN , AllenJ , McCormickB , BlackDW . Ms Blum and colleagues reply [to Schulte-Herbrüggen O, Koerting J, Roepke S. Effectiveness of adjunctive STEPPS group treatment in borderline personality disorder patients. American Journal of Psychiatry 2008;165(10):1354-5. DOI: 10.1176/appi.ajp.2008.08030390]. American Journal of Psychiatry2008;165(10):1354-5. [DOI: 10.1176/appi.ajp.2008.08030390r]BlumN , FranklinJ , HanselR , McCormickB , St JohnD , PfohlB , et al. Relationship of age to symptom severity, psychiatric comorbidity and health care utilization in persons with borderline personality disorder. Personality and Mental Health2008;2(1):25-43. [DOI: 10.1002/pmh.26]BlumN , St JohnD , PfohlB , StuartS , McCormickB , AllenJ , et al. Erratum. American Journal of Psychiatry2008;165(6):777. Erratum for: American Journal of Psychiatry 2008;165(4):468-78. [psycnet.apa.org/record/2008-07854-033]BlumN , St JohnD , PfohlB , StuartS , McCormickB , AllenJ , et al. Systems training for emotional predictability and problem solving (STEPPS) for outpatients with borderline personality disorder: a randomized controlled trial and 1-year follow-up. American Journal of Psychiatry2008;165(4):468-78. [DOI: 10.1176/appi.ajp.2007.07071079] [PMC3608469] [PMID: 18281407]DavidsonKM . Borderline personality disorder: STEPPS improves symptoms. Evidence-Based Mental Health2008;11(4):120. [DOI: 10.1136/ebmh.11.4.120] [PMID: 18952969]NCT00055315. Treatment for borderline personality disorder [A cognitive group treatment for borderline outpatients]. clinicaltrials.gov/ct2/show/NCT00055315 (first received 25 February 2003). ">Blum 2008</a>; <a href="./references#CD012955-bbs2-0021" title="FarrellJM , ShawIA , WebberMA . A schema-focused approach to group psychotherapy for outpatients with borderline personality disorder: a randomized controlled trial. Journal of Behavior Therapy and Experimental Psychiatry2009;40(2):317-28 Corrigendum to: Journal of Behavior Therapy and Experimental Psychiatry 2018; 60: 111. [DOI: 10.1016/j.jbtep.2009.01.002] [PMID: 19176222]FarrellJM . Question regarding your BPD trials [personal communication]. Email to: K Lieb, J Stoffers 9 December 2010. ">Farrell 2009</a>; <a href="./references#CD012955-bbs2-0026" title="Gratz KL. Important: question regarding your BPD trial for systematic review in Cochrane Collaboration [personal communication]. Email to: J Stoffers-Winterling 11 December 2010. GratzKL , GundersonJG . Preliminary data on an acceptance-based emotion regulation group intervention for deliberate self-harm among women with borderline personality disorder. Behavior Therapy2006;37(1):25-35. [DOI: 10.1016/j.beth.2005.03.002] [PMID: 16942958]">Gratz 2006</a>; <a href="./references#CD012955-bbs2-0027" title="GratzKL , BardeenJR , LevyR , Dixon-GordonKL , TullMT . Mechanisms of change in an emotion regulation group therapy for deliberate self-harm among women with borderline personality disorder. Behaviour Research and Therapy2015;65:29-35. [DOI: 10.1016/j.brat.2014.12.005] [PMC4306622] [PMID: 25557395]GratzKL , Dixon-GordonKL , TullMT . Predictors of treatment response to an adjunctive emotion regulation group therapy for deliberate self-harm among women with borderline personality disorder. Personality Disorders2014;5(1):97-107. [DOI: 10.1037/per0000062] [PMC4059504] [PMID: 2458806]GratzKL , TullMT , LevyR . Randomized controlled trial and uncontrolled 9-month follow-up of an adjunctive emotion regulation group therapy for deliberate self-harm among women with borderline personality disorder. Psychological Medicine2014;44(10):2099-112. [DOI: 10.1017/S0033291713002134] [PMID: 23985088]GratzKL . Question regarding your BPD trials [personal communication]. Email to: J Stoffers 11 December 2010. ">Gratz 2014</a>; <a href="./references#CD012955-bbs2-0043" title="LeppänenV , HakkoH , SintonenH , LindemanS . Comparing effectiveness of treatments for borderline personality disorder in communal mental health care: the Oulu BPD study. Community Mental Health Journal2016;52(2):216-27. [DOI: 10.1007/s10597-015-9866-4] [PMID: 25824852]LeppänenV . Re: questions regarding the Oulu BPD study [personal communication]. Email to: E Faltinsen 20 December 2017. LeppänenV . Re: SV: question regarding the Oulu BPD study [personal communication]. Email to: EG Faltinsen 22 December 2017. ">Leppänen 2016</a>; <a href="./references#CD012955-bbs2-0060" title="RenesesB , FigueraD , SalcedoG , TrujilloM , López-IborJJ , GaliánM , et al. A controlled randomized study on the efficacy of short-term dinamic psychotherapy in borderline personality disorders (BPD). Preliminary results. European Psychiatry2011;26(Suppl 1):1040. [DOI: 10.1016/S0924-9338(11)72745-6] [P02-444]RenesesB , GaliánM , SerranoR , FigueraD , Fernandez Del MoralA , López-IborJJ , et al. A new time limited psychotherapy for BPD: preliminary results of a randomized and controlled trial. Actas Espanolas de Psiquiatria2013;41(3):139-48. [PMID: 23803797]">Reneses 2013</a>; <a href="./references#CD012955-bbs2-0069" title="SolerJ , PascualJC , TianaT , CebriàA , BarrachinaJ , CampinsMJ , et al. Dialectical behaviour therapy skills training compared to standard group therapy in borderline personality disorder: a 3-month randomised controlled clinical trial. Behaviour Research and Therapy2009;47(5):353-8. [DOI: 10.1016/j.brat.2009.01.013] [PMID: 19246029]SolerJ . Question regarding your BPD trials [personal communication]. Email to: J Stoffers 15 December 2010. ">Soler 2009</a>; <a href="./references#CD012955-bbs2-0072" title="Van den BoschLM , KoeterMW , StijnenT , VerheulR , Van den BrinkW . Sustained efficacy of dialectical behaviour therapy for borderline personality disorder. Behaviour Research and Therapy2005;43(9):1231-41. [DOI: 10.1016/j.brat.2004.09.008] [PMID: 16005708]Van den BoschLM , VerheulR , SchippersGM , Van den BrinkW . Dialectical behavior therapy of borderline patients with and without substance use problems. Implementation and long-term effects. Addictive Behaviors2002;27(6):911-23. [DOI: 10.1016/s0306-4603(02)00293-9] [PMID: 12369475]Van den BoschLMC . Efficacy of dialectical behaviour therapy in the treatment of female borderline patients with and without substance abuse problems: results of a Dutch study [Dialectische gedragstherapie bij Nederlandse vrouwen met een borderline persoonlijkheidsstoornis, met en zonder verslavingsproblemen]. Tijdschrift voor Psychiatrie2005;47(3):127-37. [www.tijdschriftvoorpsychiatrie.nl/assets/articles/articles_1335pdf.pdf]VerheulR , Van den BoschLM , KoeterMW , De RidderMA , StijnenT , Van den BrinkW . Dialectical behaviour therapy for women with borderline personality disorder: 12-month, randomised clinical trial in The Netherlands. British Journal of Psychiatry2003;182:135-40. [DOI: 10.1192/bjp.182.2.135] [PMID: 12562741]">Van den Bosch 2005</a>). </p> <p>Generally, psychotherapy improved impulsivity at end of treatment compared with TAU (SMD −0.54, 95% CI −0.84 to −0.25; 10 trials, 491 participants; I<sup>2</sup> = 58%; P = 0.0003; <a href="./references#CD012955-fig-0014" title="">Analysis 1.11</a>.1). </p> <p>Generally, psychotherapy did not improve impulsivity at six to 12 months follow‐up compared with TAU (SMD 0.32, 95% CI −0.13 to 0.77; 2 trials, 77 participants; I<sup>2</sup> = 0%; P = 0.16; <a href="./references#CD012955-fig-0014" title="">Analysis 1.11</a>.2). </p> <p>No data were available for zero to six months and above 12 months follow‐up.</p> </section> <section id="CD012955-sec-0091"> <h6 class="title">1.12 Impulsivity (dichotomous)</h6> <p>One trial reported dichotomous data on impulsivity (<a href="./references#CD012955-bbs2-0013" title="BosEH , Van WelE , AppeloMT , VerbraakMJP . A randomized controlled trial of a Dutch version of systems training for emotional predictability and problem solving for borderline personality disorder. Journal of Nervous and Mental Disease2010;198(4):299-304. [DOI: 10.1097/NMD.0b013e3181d619cf] [PMID: 20386260]Van WelEB , BosEH , AppeloMT , BerendsenEM , WillgerothFC , VerbraakMJPM . The efficacy of the systems training for emotional predictability and problem solving (STEPPS) in the treatment of borderline personality disorder. A randomized controlled trial [De effectiviteit van de vaardigheidstraining emotieregulatiestoornis (VERS) in de behandeling van de borderlinepersoonlijkheidsstoornis: een gerandomiseerd onderzoek]. Tijdschrift voor Psychiatrie2009;51(5):291-301. [PMID: 19434566]">Bos 2010</a>). </p> <p>Generally, psychotherapy did not improve impulsivity at end of treatment compared with TAU (RR 0.93, 95% CI 0.66 to 1.29; 1 trial, 58 participants; P = 0.65; <a href="./references#CD012955-fig-0015" title="">Analysis 1.12</a>). </p> <p>No data were available for zero to six months, six to 12 months, and above 12 months follow‐up. </p> </section> <section id="CD012955-sec-0092"> <h6 class="title">1.13 Interpersonal problems</h6> <p>Eighteen trials reported continuous data on interpersonal problems (<a href="./references#CD012955-bbs2-0001" title="AmiantoF , FerreroA , PieròA , CairoE , RoccaG , SimonelliB , et al. Supervised team management, with or without structured psychotherapy, in heavy users of a mental health service with borderline personality disorder: a two-year follow-up preliminary randomized study. BMC Psychiatry2011;11:181. [DOI: 10.1186/1471-244X-11-181] [PMC3260092 ] [PMID: 22103890]NCT01356069. Efficacy of time-limited psychodynamic psychotherapy and informed clinical management in BPD high MHS users (HUMSH) [Sequential brief Adlerian psychodynamic psychotherapy in heavy users of a mental health service with borderline personality disorder: a two years follow-up preliminary randomized study]. clinicaltrials.gov/ct2/show/NCT01356069 (first received 16 May 2011). ">Amianto 2011</a>; <a href="./references#CD012955-bbs2-0004" title="BatemanA , FonagyP . 8-year follow-up of patients treated for borderline personality disorder: mentalization-based treatment versus treatment as usual. American Journal of Psychiatry2008;165(5):631-8. [DOI: 10.1176/appi.ajp.2007.07040636] [PMID: 18347003]BatemanA , FonagyP . Effectiveness of partial hospitalization in the treatment of borderline personality disorder: a randomized controlled trial. American Journal of Psychiatry1999;156(10):1563-9. [DOI: 10.1176/ajp.156.10.1563] [PMID: 10518167]BatemanA , FonagyP . Health care utilization costs for borderline personality disorder patients treated with psychoanalytically oriented partial hospitalization versus general psychiatric care. American Journal of Psychiatry2003;160(1):169-71. [10.1176/appi.ajp.160.1.169] [12505818]BatemanA , FonagyP . Treatment of borderline personality disorder with psychoanalytically oriented partial hospitalization: an 18-month follow-up. American Journal of Psychiatry2001;158(1):36-42. [DOI: 10.1176/appi.ajp.158.1.36] [PMID: 11136631]BatemanA . Important: question regarding your BPD trial for systematic review in Cochrane Collaboration [personal communication]. Email to: K Lieb, J Stoffers 14 December 2010. BatemanA . Intensive outpatient and partial hospital care for BPD. In: 157th annual meeting of the American Psychiatric Association. Psychotherapy and pharmacology: dissolving the mind-brain barrier; 2004 May 1-6; New York (NY). Arlington (VA): American Psychiatric Association, 2004:102. [Symposium 100B] [www.psychiatry.org/File%20Library/Psychiatrists/Directories/Library-and-Archive/conference_publications/am_program_2004.pdf]BatemanAW , FonagyP . Drs Bateman and Fonagy reply [to Stern R. Partial hospitalization for borderline personality disorder. American Journal of Psychiatry 2001;158(11):1932-3. DOI: 10.1176/appi.ajp.158.11.1932]. American Journal of Psychiatry2001;158(11):1932-3. [DOI: 10.1176/appi.ajp.158.11.1932-a]EvansC . Treatment benefits of psychoanalytically oriented partial hospitalisation were maintained over 18 months in borderline personality disorder. Evidence-Based Mental Health2001;4(3):73. [DOI: 10.1136/ebmh.4.3.73]FonagyP , BatemanAW . Mentalizing and borderline personality disorder. Journal of Mental Health2007;16(1):83-101. [DOI: 10.1080/09638230601182045]SternR . Partial hospitalization for borderline personality disorder. American Journal of Psychiatry2001;158(11):1932-3. [DOI: 10.1176/appi.ajp.158.11.1932] [PMID: 11691712]">Bateman 1999</a>; <a href="./references#CD012955-bbs2-0005" title="BatemanA , FonagyP . Impact of clinical severity on outcomes of mentalisation-based treatment for borderline personality disorder. British Journal of Psychiatry2013;203(3):221-7. [DOI: 10.1192/bjp.bp.112.121129] [PMID: 23887998]BatemanA , FonagyP . Randomized controlled trial of outpatient mentalization-based treatment versus structured clinical management for borderline personality disorder. American Journal of Psychiatry2009;166(12):1355-64. [DOI: 10.1176/appi.ajp.2009.09040539] [PMID: 19833787]BatemanA , FonagyP . Randomized controlled trial of outpatient mentalization-based treatment versus structured clinical management for borderline personality disorder. Supplementary data. ajp.psychiatryonline.org/doi/suppl/10.1176/appi.ajp.2009.09040539/suppl_file/ajp_166_12_1355_01.pdf (accessed 27 February 2020). BatemanA , O'ConnellJ , LorenziniN , GardnerT , FonagyP . A randomised controlled trial of mentalization-based treatment versus structured clinical management for patients with comorbid borderline personality disorder and antisocial personality disorder. BMC Psychiatry2016;16:304. [DOI: 10.1186/s12888-016-1000-9] [PMC5006360] [PMID: 27577562]BatemanA . Important question regarding your BPD trial for systematic review in Cochrane Collaboration [personal communication]. Email to: K Lieb 14 December 2010. BatemanAW . Mentalization, borderline personality disorder and what works for whom? Presentation at the 11th International Congress of the International Society for the Study of Personality Disorders; 2009 Aug 21-23. www.borderlinepersonalitydisorder.com/Conferences/ISSPD/isspd_09_Bateman (accessed 21 April 2010). ISRCTN27660668. Randomised controlled trial of manualised out-patient individual and group therapy for borderline personality disorder [Effectiveness of intensive out-patient psychotherapy for treatment of borderline personality disorder: a pragmatic randomised single blind controlled study]. www.isrctn.com/ISRCTN27660668 (first received 12 October 2008). ">Bateman 2009</a>; <a href="./references#CD012955-bbs2-0010" title="BlackD . Question regarding your BPD trial [personal communication]. Email to: J Stoffers 04 January 2011. BlackDW , AllenJ , McCormickB , BlumN . Treatment received by persons with BPD participating in a randomized clinical trial of the systems training for emotional predictability and problem solving programme. Personality and Mental Health2011;5(3):159-68. [DOI: 10.1002/pmh.167]BlackDW , AllenJ , St JohnD , PfohlB , McCormickB , BlumN . Predictors of response to systems training for emotional predictability and problem solving (STEPPS) for borderline personality disorder: an exploratory study. Acta Psychiatrica Scandinavica2009;120(1):53-61. [DOI: 10.1111/j.1600-0447.2008.01340.x] [PMC3665337] [PMID: 19183126]BlackDW , BlumN , PfohlB , St JohnD . The STEPPS group treatment program for outpatients with borderline personality disorder. Journal of Contemporary Psychotherapy2004;34(3):193-210. [DOI: 10.1023/B:JOCP.0000036630.25741.83]BlackDW , PfohlBM . Randomized clinical trial of STEPPS versus treatment as usual. In: 158th annual meeting of the American Psychiatric Association. Psychosomatic medicine: integrating psychiatry &amp; medicine; 2005 May 21-26; Atlanta (GA). Arlington (VA): American Psychiatric Association, 2005:104. [No. 1B] [www.psychiatry.org/File%20Library/Psychiatrists/Directories/Library-and-Archive/syllabus/am_syllabus_2005.pdf]BlackDW , Simsek-DuranF , BlumN , McCormickB , AllenJ . Do people with borderline personality disorder complicated by antisocial personality disorder benefit from the STEPPS treatment program?Personality and Mental Health2016;10(3):205-15. [DOI: 10.1002/pmh.1326] [PMC4911327] [PMID: 26671625]BlackDW . RE: [external] questions regarding your trial on the STEPPS program for BPD [personal communication]. Email to: EG Faltinsen 27 November 2017. BlumN , AllenJ , McCormickB , BlackDW . Ms Blum and colleagues reply [to Schulte-Herbrüggen O, Koerting J, Roepke S. Effectiveness of adjunctive STEPPS group treatment in borderline personality disorder patients. American Journal of Psychiatry 2008;165(10):1354-5. DOI: 10.1176/appi.ajp.2008.08030390]. American Journal of Psychiatry2008;165(10):1354-5. [DOI: 10.1176/appi.ajp.2008.08030390r]BlumN , FranklinJ , HanselR , McCormickB , St JohnD , PfohlB , et al. Relationship of age to symptom severity, psychiatric comorbidity and health care utilization in persons with borderline personality disorder. Personality and Mental Health2008;2(1):25-43. [DOI: 10.1002/pmh.26]BlumN , St JohnD , PfohlB , StuartS , McCormickB , AllenJ , et al. Erratum. American Journal of Psychiatry2008;165(6):777. Erratum for: American Journal of Psychiatry 2008;165(4):468-78. [psycnet.apa.org/record/2008-07854-033]BlumN , St JohnD , PfohlB , StuartS , McCormickB , AllenJ , et al. Systems training for emotional predictability and problem solving (STEPPS) for outpatients with borderline personality disorder: a randomized controlled trial and 1-year follow-up. American Journal of Psychiatry2008;165(4):468-78. [DOI: 10.1176/appi.ajp.2007.07071079] [PMC3608469] [PMID: 18281407]DavidsonKM . Borderline personality disorder: STEPPS improves symptoms. Evidence-Based Mental Health2008;11(4):120. [DOI: 10.1136/ebmh.11.4.120] [PMID: 18952969]NCT00055315. Treatment for borderline personality disorder [A cognitive group treatment for borderline outpatients]. clinicaltrials.gov/ct2/show/NCT00055315 (first received 25 February 2003). ">Blum 2008</a>; <a href="./references#CD012955-bbs2-0013" title="BosEH , Van WelE , AppeloMT , VerbraakMJP . A randomized controlled trial of a Dutch version of systems training for emotional predictability and problem solving for borderline personality disorder. Journal of Nervous and Mental Disease2010;198(4):299-304. [DOI: 10.1097/NMD.0b013e3181d619cf] [PMID: 20386260]Van WelEB , BosEH , AppeloMT , BerendsenEM , WillgerothFC , VerbraakMJPM . The efficacy of the systems training for emotional predictability and problem solving (STEPPS) in the treatment of borderline personality disorder. A randomized controlled trial [De effectiviteit van de vaardigheidstraining emotieregulatiestoornis (VERS) in de behandeling van de borderlinepersoonlijkheidsstoornis: een gerandomiseerd onderzoek]. Tijdschrift voor Psychiatrie2009;51(5):291-301. [PMID: 19434566]">Bos 2010</a>; <a href="./references#CD012955-bbs2-0015" title="CarterG . Question regarding your BPD trial [personal communication]. Email to: J Stoffers 21 December 2010. CarterGL , WillcoxCH , LewinTJ , ConradAM , BenditN . Hunter DBT project: randomized controlled trial of dialectical behaviour therapy in women with borderline personality disorder. Australian and New Zealand Journal of Psychiatry2010;44(2):162-73. [DOI: 10.3109/00048670903393621] [PMID: 20113305]">Carter 2010</a>; <a href="./references#CD012955-bbs2-0017" title="DavidsonK , LivingstoneS , McArthurK , DicksonL , GumleyA . An integrative complexity analysis of cognitive behaviour therapy sessions for borderline personality disorder. Psychology and Psychotherapy2007;80(Pt 4):513-23. [DOI: 10.1348/147608307X191535] [PMID: 17535542]DavidsonK , NorrieJ , TyrerP , GumleyA , TataP , MurrayH , et al. The effectiveness of cognitive behavior therapy for borderline personality disorder: results from the borderline personality disorder study of cognitive therapy (BOSCOT) trial. Journal of Personality Disorders2006;20(5):450-65. [DOI: 10.1521/pedi.2006.20.5.450] [PMC1852259] [PMID: 17032158]DavidsonK , TyrerP , GumleyA , TataP , NorrieJ , PalmerS , et al. A randomized controlled trial of cognitive behavior therapy for borderline personality disorder: rationale for trial, method, and description of sample. Journal of Personality Disorders2006;20(5):431-49. [DOI: 10.1521/pedi.2006.20.5.431] [PMC1847748] [PMID: 17032157]DavidsonKM , TyrerP , NorrieJ , PalmerSJ , TyrerH . Cognitive therapy v usual treatment for borderline personality disorder: prospective 6-year follow-up. British Journal of Psychiatry2010;197(6):456-62. [DOI: 10.1192/bjp.bp.109.074286] [PMID: 21119151]ISRCTN86177428. Borderline personality disorder study of cognitive therapy trial [A randomised controlled trial of cognitive therapy plus treatment as usual versus treatment as usual in the treatment of borderline personality disorder]. www.isrctn.com/ISRCTN86177428 (first received 22 July 2005). NCT00538135. BOSCOT: a randomised controlled trial of cognitive behavioural therapy in borderline personality disorder [BOSCOT: a randomised control trial of cognitive behavioural therapy plus treatment as usual versus treatment as usual in the treatment of borderline personality disorder]. www.clinicaltrials.gov/ct2/show/NCT00538135 (first received 29 September 2007). NorrieJ , DavidsonK , TataP , GumleyA . Influence of therapist competence and quantity of cognitive behavioural therapy on suicidal behaviour and inpatient hospitalisation in a randomised controlled trial in borderline personality disorder: further analyses of treatment effects in the BOSCOT study. Psychology and Psychotherapy2013;86(3):280-93. [DOI: 10.1111/papt.12004] [PMC4491320] [PMID: 23420622]PalmerS , DavidsonK , TyrerP , GumleyA , TataP , NorrieJ , et al. The cost-effectiveness of cognitive behavior therapy for borderline personality disorder: results from the BOSCOT trial. Journal of Personality Disorders2006;20(5):466-81. [DOI: 10.1521/pedi.2006.20.5.466] [PMC1852260] [PMID: 17032159]">Davidson 2006</a>; <a href="./references#CD012955-bbs2-0021" title="FarrellJM , ShawIA , WebberMA . A schema-focused approach to group psychotherapy for outpatients with borderline personality disorder: a randomized controlled trial. Journal of Behavior Therapy and Experimental Psychiatry2009;40(2):317-28 Corrigendum to: Journal of Behavior Therapy and Experimental Psychiatry 2018; 60: 111. [DOI: 10.1016/j.jbtep.2009.01.002] [PMID: 19176222]FarrellJM . Question regarding your BPD trials [personal communication]. Email to: K Lieb, J Stoffers 9 December 2010. ">Farrell 2009</a>; <a href="./references#CD012955-bbs2-0027" title="GratzKL , BardeenJR , LevyR , Dixon-GordonKL , TullMT . Mechanisms of change in an emotion regulation group therapy for deliberate self-harm among women with borderline personality disorder. Behaviour Research and Therapy2015;65:29-35. [DOI: 10.1016/j.brat.2014.12.005] [PMC4306622] [PMID: 25557395]GratzKL , Dixon-GordonKL , TullMT . Predictors of treatment response to an adjunctive emotion regulation group therapy for deliberate self-harm among women with borderline personality disorder. Personality Disorders2014;5(1):97-107. [DOI: 10.1037/per0000062] [PMC4059504] [PMID: 2458806]GratzKL , TullMT , LevyR . Randomized controlled trial and uncontrolled 9-month follow-up of an adjunctive emotion regulation group therapy for deliberate self-harm among women with borderline personality disorder. Psychological Medicine2014;44(10):2099-112. [DOI: 10.1017/S0033291713002134] [PMID: 23985088]GratzKL . Question regarding your BPD trials [personal communication]. Email to: J Stoffers 11 December 2010. ">Gratz 2014</a>; <a href="./references#CD012955-bbs2-0033" title="JørgensenCR , BøyeR , AndersenD , Døssing BlaabjergAH , FreundC , JordetH , et al. Eighteen months post-treatment naturalistic follow-up study of mentalization-based therapy and supportive group treatment of borderline personality disorder: clinical outcomes and functioning. Nordic Psychology2014;66(4):254-73. [DOI: 10.1080/19012276.2014.963649]JørgensenCR , FreundC , BøyeR , JordetH , AndersenD , KjølbyeM . Outcome of mentalization-based and supportive psychotherapy in patients with borderline personality disorder: a randomized trial. Acta Psychiatrica Scandinavica2013;127(4):305-17. [DOI: 10.1111/j.1600-0447.2012.01923.x] [PMID: 22897123]JorgensenCR . SV: questions on your trial regarding MBT for BPD patients [personal communication]. Email to: EG Faltinsen 28 November 2017. ">Jørgensen 2013</a>; <a href="./references#CD012955-bbs2-0038" title="KramerU , Pascual-LeoneA , BerthoudL , De RotenY , MarquetP , KollyS , et al. Assertive anger mediates effects of dialectical behaviour-informed skills training for borderline personality disorder: a randomized controlled trial. Clinical Psychology &amp; Psychotherapy2016;23(3):189-202. [DOI: 10.1002/cpp.1956] [PMID: 25864773]KramerU . The role of coping change in borderline personality disorder: a process-outcome analysis on dialectical-behaviour skills training. Clinical Psychology &amp; Psychotherapy2017;24(2):302-11. [DOI: 10.1002/cpp.2017] [PMID: 27098296]">Kramer 2016</a>; <a href="./references#CD012955-bbs2-0041" title="LaurenssenEM , WestraD , KikkertMJ , NoomMJ , EerenHV , Van BroekhuyzenAJ , et al. Day hospital mentalization-based treatment (MBT-DH) versus treatment as usual in the treatment of severe borderline personality disorder: protocol of a randomized controlled trial. BMC Psychiatry2014;14:149. [DOI: 10.1186/1471-244X-14-149] [PMC4045960] [PMID: 24886402]LaurenssenEMP , LuytenP , KikkertMJ , WestraD , PeenJ , SoonsMBJ , et al. Day hospital mentalization-based treatment v specialist treatment as usual in patients with borderline personality disorder: randomized controlled trial. Psychological Medicine2018;48(15):2522-9. [DOI: 10.1017/S0033291718000132] [PMID: 29478425]NL2058 (NTR2175). Mentalisation-based treatment versus care-as-usual in the treatment of severe borderline personality disorders. www.trialregister.nl/trial/2058 (first received 21 January 2010). ">Laurenssen 2018</a>; <a href="./references#CD012955-bbs2-0042" title="LeichsenringF , MasuhrO , JaegerU , RabungS , DallyA , DümpelmannM , et al. Psychoanalytic-interactional therapy versus psychodynamic therapy by experts for personality disorders: a randomized controlled efficacy-effectiveness study in cluster B personality disorders. Psychotherapy and Psychosomatics2016;85(2):71-80. [DOI: 10.1159/000441731] [PMID: 26808580]">Leichsenring 2016</a>; <a href="./references#CD012955-bbs2-0043" title="LeppänenV , HakkoH , SintonenH , LindemanS . Comparing effectiveness of treatments for borderline personality disorder in communal mental health care: the Oulu BPD study. Community Mental Health Journal2016;52(2):216-27. [DOI: 10.1007/s10597-015-9866-4] [PMID: 25824852]LeppänenV . Re: questions regarding the Oulu BPD study [personal communication]. Email to: E Faltinsen 20 December 2017. LeppänenV . Re: SV: question regarding the Oulu BPD study [personal communication]. Email to: EG Faltinsen 22 December 2017. ">Leppänen 2016</a>; <a href="./references#CD012955-bbs2-0058" title="PhilipsB , WennebergP , KonradssonP , FranckJ . Mentalization-based treatment for concurrent borderline personality disorder and substance use disorder: a randomized controlled feasibility study. European Addiction Research2018;24(1):1-8. [DOI: 10.1159/000485564] [PMC5969093] [PMID: 294028]">Philips 2018</a>; <a href="./references#CD012955-bbs2-0060" title="RenesesB , FigueraD , SalcedoG , TrujilloM , López-IborJJ , GaliánM , et al. A controlled randomized study on the efficacy of short-term dinamic psychotherapy in borderline personality disorders (BPD). Preliminary results. European Psychiatry2011;26(Suppl 1):1040. [DOI: 10.1016/S0924-9338(11)72745-6] [P02-444]RenesesB , GaliánM , SerranoR , FigueraD , Fernandez Del MoralA , López-IborJJ , et al. A new time limited psychotherapy for BPD: preliminary results of a randomized and controlled trial. Actas Espanolas de Psiquiatria2013;41(3):139-48. [PMID: 23803797]">Reneses 2013</a>; <a href="./references#CD012955-bbs2-0063" title="SalzerS , CroppC , JaegerU , MasuhrO , Streeck-FischerA . Psychodynamic therapy for adolescents suffering from co-morbid disorders of conduct and emotions in an in-patient setting: a randomized controlled trial. Psychological Medicine2014;44(10):2213-22. [DOI: 10.1017/S003329171300278X] [PMID: 24229481]SalzerS , Streeck-FischerA . The psychoanalytic-interactional method (PiM) for adolescents with borderline personality disorder [Die psychoanalytisch-interaktionelle methode (PiM) für adoleszente mit borderline-persönlichkeitsstörung]. Personlichkeitsstorungen Theorie und Therapie2015;19(1):67-76. [elibrary.klett-cotta.de/article/99.120110/ptt-19-1-67]SalzerS . AW: Re: Cochrane Review on psychotherapies for BPD - RCT testing PiM vs WL [personal communication] [AW:Re: Cochrane Review zur Psychotherapie bei BPS - RCT zu PiM vs WL [persönliche kommunikation]]. Email to: J Stoffers-Winterling 15 July 2018. ">Salzer 2014</a>; <a href="./references#CD012955-bbs2-0069" title="SolerJ , PascualJC , TianaT , CebriàA , BarrachinaJ , CampinsMJ , et al. Dialectical behaviour therapy skills training compared to standard group therapy in borderline personality disorder: a 3-month randomised controlled clinical trial. Behaviour Research and Therapy2009;47(5):353-8. [DOI: 10.1016/j.brat.2009.01.013] [PMID: 19246029]SolerJ . Question regarding your BPD trials [personal communication]. Email to: J Stoffers 15 December 2010. ">Soler 2009</a>). </p> <p>Generally, psychotherapy improved interpersonal problems at end of treatment compared with TAU (SMD −0.42, 95% CI −0.68 to −0.16; 18 trials, 1159 participants; I<sup>2</sup> = 77%; P = 0.002; <a href="./references#CD012955-fig-0016" title="">Analysis 1.13</a>.1). </p> <p>Generally, psychotherapy did not improve interpersonal problems at zero to six months follow‐up compared with TAU (SMD −0.41, 95% CI −1.01 to 0.20; 1 trial, 53 participants; P = 0.19; MD −0.30, 95% CI −0.76 to 0.16; 1 trial, 53 participants; P = 0.20; <a href="./references#CD012955-fig-0016" title="">Analysis 1.13</a>.2). </p> <p>Generally, psychotherapy did not improve interpersonal problems at six to 12 months follow‐up compared with TAU (SMD −0.17, 95% CI −0.65 to 0.32; 1 trial, 132 participants; I<sup>2</sup> = 39%; P = 0.50; <a href="./references#CD012955-fig-0016" title="">Analysis 1.13</a>.3). </p> <p>Generally, psychotherapy did not improve interpersonal problems at above 12 months follow‐up compared with TAU (SMD 0.00, 95% CI −0.54 to 0.54; 2 trials, 172 participants; I<sup>2</sup> = 65%; P = 1.00; <a href="./references#CD012955-fig-0016" title="">Analysis 1.13</a>.4). </p> </section> <section id="CD012955-sec-0093"> <h6 class="title">1.14 Abandonment</h6> <p>Two trials reported continuous data on abandonment (<a href="./references#CD012955-bbs2-0001" title="AmiantoF , FerreroA , PieròA , CairoE , RoccaG , SimonelliB , et al. Supervised team management, with or without structured psychotherapy, in heavy users of a mental health service with borderline personality disorder: a two-year follow-up preliminary randomized study. BMC Psychiatry2011;11:181. [DOI: 10.1186/1471-244X-11-181] [PMC3260092 ] [PMID: 22103890]NCT01356069. Efficacy of time-limited psychodynamic psychotherapy and informed clinical management in BPD high MHS users (HUMSH) [Sequential brief Adlerian psychodynamic psychotherapy in heavy users of a mental health service with borderline personality disorder: a two years follow-up preliminary randomized study]. clinicaltrials.gov/ct2/show/NCT01356069 (first received 16 May 2011). ">Amianto 2011</a>; <a href="./references#CD012955-bbs2-0043" title="LeppänenV , HakkoH , SintonenH , LindemanS . Comparing effectiveness of treatments for borderline personality disorder in communal mental health care: the Oulu BPD study. Community Mental Health Journal2016;52(2):216-27. [DOI: 10.1007/s10597-015-9866-4] [PMID: 25824852]LeppänenV . Re: questions regarding the Oulu BPD study [personal communication]. Email to: E Faltinsen 20 December 2017. LeppänenV . Re: SV: question regarding the Oulu BPD study [personal communication]. Email to: EG Faltinsen 22 December 2017. ">Leppänen 2016</a>). </p> <p>Generally, psychotherapy did not improve abandonment at end of treatment compared with TAU (SMD −0.22, 95% CI −0.66 to 0.21; 2 trials, 84 participants; I<sup>2</sup> = 0%; P = 0.32; <a href="./references#CD012955-fig-0017" title="">Analysis 1.14</a>.1). </p> <p>Generally, psychotherapy did not improve abandonment at six to 12 months follow‐up compared with TAU (SMD −0.39, 95% CI −1.08 to 0.30; 1 trial, 33 participants; P = 0.27; MD ‐−0.39, 95% CI −1.08 to 0.30; 1 trial, 33 participants; P = 0.25; <a href="./references#CD012955-fig-0017" title="">Analysis 1.14</a>.2). </p> <p>No data were available for zero to six months and above 12 months follow‐up.</p> </section> <section id="CD012955-sec-0094"> <h6 class="title">1.15 Identity disturbance</h6> <p>Four trials reported continuous data on identity disturbance (<a href="./references#CD012955-bbs2-0001" title="AmiantoF , FerreroA , PieròA , CairoE , RoccaG , SimonelliB , et al. Supervised team management, with or without structured psychotherapy, in heavy users of a mental health service with borderline personality disorder: a two-year follow-up preliminary randomized study. BMC Psychiatry2011;11:181. [DOI: 10.1186/1471-244X-11-181] [PMC3260092 ] [PMID: 22103890]NCT01356069. Efficacy of time-limited psychodynamic psychotherapy and informed clinical management in BPD high MHS users (HUMSH) [Sequential brief Adlerian psychodynamic psychotherapy in heavy users of a mental health service with borderline personality disorder: a two years follow-up preliminary randomized study]. clinicaltrials.gov/ct2/show/NCT01356069 (first received 16 May 2011). ">Amianto 2011</a>; <a href="./references#CD012955-bbs2-0042" title="LeichsenringF , MasuhrO , JaegerU , RabungS , DallyA , DümpelmannM , et al. Psychoanalytic-interactional therapy versus psychodynamic therapy by experts for personality disorders: a randomized controlled efficacy-effectiveness study in cluster B personality disorders. Psychotherapy and Psychosomatics2016;85(2):71-80. [DOI: 10.1159/000441731] [PMID: 26808580]">Leichsenring 2016</a>; <a href="./references#CD012955-bbs2-0043" title="LeppänenV , HakkoH , SintonenH , LindemanS . Comparing effectiveness of treatments for borderline personality disorder in communal mental health care: the Oulu BPD study. Community Mental Health Journal2016;52(2):216-27. [DOI: 10.1007/s10597-015-9866-4] [PMID: 25824852]LeppänenV . Re: questions regarding the Oulu BPD study [personal communication]. Email to: E Faltinsen 20 December 2017. LeppänenV . Re: SV: question regarding the Oulu BPD study [personal communication]. Email to: EG Faltinsen 22 December 2017. ">Leppänen 2016</a>; <a href="./references#CD012955-bbs2-0060" title="RenesesB , FigueraD , SalcedoG , TrujilloM , López-IborJJ , GaliánM , et al. A controlled randomized study on the efficacy of short-term dinamic psychotherapy in borderline personality disorders (BPD). Preliminary results. European Psychiatry2011;26(Suppl 1):1040. [DOI: 10.1016/S0924-9338(11)72745-6] [P02-444]RenesesB , GaliánM , SerranoR , FigueraD , Fernandez Del MoralA , López-IborJJ , et al. A new time limited psychotherapy for BPD: preliminary results of a randomized and controlled trial. Actas Espanolas de Psiquiatria2013;41(3):139-48. [PMID: 23803797]">Reneses 2013</a>). </p> <p>Generally, psychotherapy did not improve identity disturbance at end of treatment compared with TAU (SMD −0.37, 95% CI −0.84 to 0.10; 4 trials, 250 participants; I<sup>2</sup> = 65%; P = 0.12; <a href="./references#CD012955-fig-0018" title="">Analysis 1.15</a>.1). </p> <p>Generally, psychotherapy improved identity disturbance at six to 12 months follow‐up compared with TAU (SMD −1.09, 95% CI −1.83 to −0.35; 1 trial, 33 participants; P = 0.004; MD −1.40, 95% CI −2.25 to −0.55; 1 trial, 33 participants; P = 0.001; <a href="./references#CD012955-fig-0018" title="">Analysis 1.15</a>.2). </p> <p>No data were available for zero to six months and above 12 months follow‐up.</p> </section> <section id="CD012955-sec-0095"> <h6 class="title">1.16 Dissociation and psychotic‐like symptoms</h6> <p>Six trials reported continuous data on dissociation and psychotic‐like symptoms (<a href="./references#CD012955-bbs2-0001" title="AmiantoF , FerreroA , PieròA , CairoE , RoccaG , SimonelliB , et al. Supervised team management, with or without structured psychotherapy, in heavy users of a mental health service with borderline personality disorder: a two-year follow-up preliminary randomized study. BMC Psychiatry2011;11:181. [DOI: 10.1186/1471-244X-11-181] [PMC3260092 ] [PMID: 22103890]NCT01356069. Efficacy of time-limited psychodynamic psychotherapy and informed clinical management in BPD high MHS users (HUMSH) [Sequential brief Adlerian psychodynamic psychotherapy in heavy users of a mental health service with borderline personality disorder: a two years follow-up preliminary randomized study]. clinicaltrials.gov/ct2/show/NCT01356069 (first received 16 May 2011). ">Amianto 2011</a>; <a href="./references#CD012955-bbs2-0010" title="BlackD . Question regarding your BPD trial [personal communication]. Email to: J Stoffers 04 January 2011. BlackDW , AllenJ , McCormickB , BlumN . Treatment received by persons with BPD participating in a randomized clinical trial of the systems training for emotional predictability and problem solving programme. Personality and Mental Health2011;5(3):159-68. [DOI: 10.1002/pmh.167]BlackDW , AllenJ , St JohnD , PfohlB , McCormickB , BlumN . Predictors of response to systems training for emotional predictability and problem solving (STEPPS) for borderline personality disorder: an exploratory study. Acta Psychiatrica Scandinavica2009;120(1):53-61. [DOI: 10.1111/j.1600-0447.2008.01340.x] [PMC3665337] [PMID: 19183126]BlackDW , BlumN , PfohlB , St JohnD . The STEPPS group treatment program for outpatients with borderline personality disorder. Journal of Contemporary Psychotherapy2004;34(3):193-210. [DOI: 10.1023/B:JOCP.0000036630.25741.83]BlackDW , PfohlBM . Randomized clinical trial of STEPPS versus treatment as usual. In: 158th annual meeting of the American Psychiatric Association. Psychosomatic medicine: integrating psychiatry &amp; medicine; 2005 May 21-26; Atlanta (GA). Arlington (VA): American Psychiatric Association, 2005:104. [No. 1B] [www.psychiatry.org/File%20Library/Psychiatrists/Directories/Library-and-Archive/syllabus/am_syllabus_2005.pdf]BlackDW , Simsek-DuranF , BlumN , McCormickB , AllenJ . Do people with borderline personality disorder complicated by antisocial personality disorder benefit from the STEPPS treatment program?Personality and Mental Health2016;10(3):205-15. [DOI: 10.1002/pmh.1326] [PMC4911327] [PMID: 26671625]BlackDW . RE: [external] questions regarding your trial on the STEPPS program for BPD [personal communication]. Email to: EG Faltinsen 27 November 2017. BlumN , AllenJ , McCormickB , BlackDW . Ms Blum and colleagues reply [to Schulte-Herbrüggen O, Koerting J, Roepke S. Effectiveness of adjunctive STEPPS group treatment in borderline personality disorder patients. American Journal of Psychiatry 2008;165(10):1354-5. DOI: 10.1176/appi.ajp.2008.08030390]. American Journal of Psychiatry2008;165(10):1354-5. [DOI: 10.1176/appi.ajp.2008.08030390r]BlumN , FranklinJ , HanselR , McCormickB , St JohnD , PfohlB , et al. Relationship of age to symptom severity, psychiatric comorbidity and health care utilization in persons with borderline personality disorder. Personality and Mental Health2008;2(1):25-43. [DOI: 10.1002/pmh.26]BlumN , St JohnD , PfohlB , StuartS , McCormickB , AllenJ , et al. Erratum. American Journal of Psychiatry2008;165(6):777. Erratum for: American Journal of Psychiatry 2008;165(4):468-78. [psycnet.apa.org/record/2008-07854-033]BlumN , St JohnD , PfohlB , StuartS , McCormickB , AllenJ , et al. Systems training for emotional predictability and problem solving (STEPPS) for outpatients with borderline personality disorder: a randomized controlled trial and 1-year follow-up. American Journal of Psychiatry2008;165(4):468-78. [DOI: 10.1176/appi.ajp.2007.07071079] [PMC3608469] [PMID: 18281407]DavidsonKM . Borderline personality disorder: STEPPS improves symptoms. Evidence-Based Mental Health2008;11(4):120. [DOI: 10.1136/ebmh.11.4.120] [PMID: 18952969]NCT00055315. Treatment for borderline personality disorder [A cognitive group treatment for borderline outpatients]. clinicaltrials.gov/ct2/show/NCT00055315 (first received 25 February 2003). ">Blum 2008</a>; <a href="./references#CD012955-bbs2-0021" title="FarrellJM , ShawIA , WebberMA . A schema-focused approach to group psychotherapy for outpatients with borderline personality disorder: a randomized controlled trial. Journal of Behavior Therapy and Experimental Psychiatry2009;40(2):317-28 Corrigendum to: Journal of Behavior Therapy and Experimental Psychiatry 2018; 60: 111. [DOI: 10.1016/j.jbtep.2009.01.002] [PMID: 19176222]FarrellJM . Question regarding your BPD trials [personal communication]. Email to: K Lieb, J Stoffers 9 December 2010. ">Farrell 2009</a>; <a href="./references#CD012955-bbs2-0025" title="GleesonJF , ChanenA , CottonSM , PearceT , NewmanB , McCutcheonL . Treating co-occurring first-episode psychosis and borderline personality: a pilot randomized controlled trial. Early Intervention in Psychiatry2012;6(1):21-9. [DOI: 10.1111/j.1751-7893.2011.00306.x] [PMID: 22379625]GleesonJFM . RE: separate data [personal communication]. Email to: M Kielsholm 28 October 2016. ">Gleeson 2012</a>; <a href="./references#CD012955-bbs2-0028" title="GregoryRJ , ChlebowskiS , KangD , RemenA , SoderbergM . Psychodynamic therapy for borderline personality disorder and co-occurring alcohol use disorders: a newly designed ongoing study. Journal of the American Psychoanalytic Association2006;54(4):1331-4. [DOI: 10.1177/00030651060540040107] [PMID: 17354507]GregoryRJ , ChlebowskiS , KangD , RemenAL , SoderbergMG , StepkovitchJ , et al. A controlled trial of psychodynamic psychotherapy for co-occurring borderline personality disorder and alcohol use disorder. Psychotherapy2008;45(1):28-41. [DOI: 10.1037/0033-3204.45.1.28] [PMID: 22122363]GregoryRJ , DeLucia-DeranjaE , MogleJA . Dynamic deconstructive psychotherapy versus optimized community care for borderline personality disorder co-occuring with alcohol use disorders: a 30-month follow-up. Journal of Nervous and Mental Disease2010;198(4):292-8. [DOI: 10.1097/NMD.0b013e3181d6172d] [PMID: 20386259]GregoryRJ , RemenAL , SoderbergM , Ploutz-SnyderRJ . A controlled trial of psychodynamic psychotherapy for co-occurring borderline personality disorder and alcohol use disorder: six-month outcome. Journal of the American Psychoanalytic Association2009;57(1):199-205. [DOI: 10.1177/00030651090570011006] [PMID: 19270255]NCT00145678. Psychodynamic therapy for co-occurring borderline personality disorder and alcohol use disorder [Psychodynamic therapy for patients With borderline personality disorder and alcohol abuse]. www.clinicaltrials.gov/show/NCT00145678 (first received 1 September 2005). ">Gregory 2008b</a>; <a href="./references#CD012955-bbs2-0039" title="KredlowMA , SzuhanyKL , LoS , XieH , GottliebJD , RosenbergSD , et al. Cognitive behavioral therapy for posttraumatic stress disorder in individuals with severe mental illness and borderline personality disorder. Psychiatry Research2017;249:86-93. [DOI: 10.1016/j.psychres.2016.12.045] [PMC5325773] [PMID: 28086181]MueserK . Re: question regarding your trial on CBT for BPD patients [personal communication]. Email to: EG Faltinsen 28 November 2017. ">Kredlow 2017a</a>). </p> <p>Generally, psychotherapy improved dissociation and psychotic‐like symptoms at end of treatment compared with TAU (SMD −0.47, 95% CI −0.85 to −0.10; 6 trials, 244 participants; I<sup>2</sup> = 38%; P = 0.01; <a href="./references#CD012955-fig-0019" title="">Analysis 1.16</a>.1). </p> <p>Generally, psychotherapy improved dissociation and psychotic‐like symptoms at zero to six months follow‐up compared with TAU (SMD 0.97, 95% CI −1.69 to −0.26; 2 trials, 35 participants; I<sup>2</sup> = 0%; P = 0.008; <a href="./references#CD012955-fig-0019" title="">Analysis 1.16</a>.2). </p> <p>Generally, psychotherapy did not improve dissociation and psychotic‐like symptoms at six to 12 months follow‐up compared with TAU (SMD −0.59, 95% CI −1.29 to 0.11; 1 trial, 33 participants; P = 0.10; MD −0.70, 95% CI −1.59 to 0.09; 1 trial, 33 participants; P = 0.08; <a href="./references#CD012955-fig-0019" title="">Analysis 1.16</a>.3). </p> <p>Generally, psychotherapy did not improve dissociation and psychotic‐like symptoms at above 12 months follow‐up compared with TAU (SMD −0.01, 95% CI −0.81 to 0.79; 1 trial, 24 participants; P = 0.98; MD ‐−0.20, 95% CI −20.07 to 19.67; 1 trial, 24 participants; P = 0.98; <a href="./references#CD012955-fig-0019" title="">Analysis 1.16</a>.4). </p> </section> <section id="CD012955-sec-0096"> <h6 class="title">1.17 Depression (continuous)</h6> <p>Twenty‐two trials reported continuous data on depression (<a href="./references#CD012955-bbs2-0002" title='AndreoliA , BurnandY , CochennecMF , MarieD , Di ClementeT , OhlendorfP . Psychoanalytic psychotherapy and venlafaxine among acutely suicidal borderline patients: a randomized clinical study. European Psychiatry2009;24(Suppl 1):S93. [DOI: 10.1016/S0924-9338(09)70326-8] [S18-03]AndreoliA , BurnandY , CochennecMF , OhlendorfP , FrambatiL , Gaudry-MaireD , et al. Disappointed love and suicide: a randomized controlled trial of "abandonment psychotherapy" among borderline patients. Journal of Personality Disorders2016;30(2):271-87. [DOI: 10.1521/pedi_2015_29_196] [PMID: 26111250]AndreoliA , BurnandY , FrambatiL , ManningD , FrancesA . Abandonment psychotherapy and psychosocial functioning among suicidal patients with borderline personality disorder: a 3-year naturalistic follow-up. Journal of Personality Disorders 2019 Feb 20 [Epub ahead of print]. [DOI: 10.1521/pedi_2019_33_423] [PMID: 30785852]AndreoliA . Re: your study in BPD - Cochrane Collaboration review [personal communication]. Email to: J Stoffers-Winterling 5 June 2018. '>Andreoli 2016</a>; <a href="./references#CD012955-bbs2-0004" title="BatemanA , FonagyP . 8-year follow-up of patients treated for borderline personality disorder: mentalization-based treatment versus treatment as usual. American Journal of Psychiatry2008;165(5):631-8. [DOI: 10.1176/appi.ajp.2007.07040636] [PMID: 18347003]BatemanA , FonagyP . Effectiveness of partial hospitalization in the treatment of borderline personality disorder: a randomized controlled trial. American Journal of Psychiatry1999;156(10):1563-9. [DOI: 10.1176/ajp.156.10.1563] [PMID: 10518167]BatemanA , FonagyP . Health care utilization costs for borderline personality disorder patients treated with psychoanalytically oriented partial hospitalization versus general psychiatric care. American Journal of Psychiatry2003;160(1):169-71. [10.1176/appi.ajp.160.1.169] [12505818]BatemanA , FonagyP . Treatment of borderline personality disorder with psychoanalytically oriented partial hospitalization: an 18-month follow-up. American Journal of Psychiatry2001;158(1):36-42. [DOI: 10.1176/appi.ajp.158.1.36] [PMID: 11136631]BatemanA . Important: question regarding your BPD trial for systematic review in Cochrane Collaboration [personal communication]. Email to: K Lieb, J Stoffers 14 December 2010. BatemanA . Intensive outpatient and partial hospital care for BPD. In: 157th annual meeting of the American Psychiatric Association. Psychotherapy and pharmacology: dissolving the mind-brain barrier; 2004 May 1-6; New York (NY). Arlington (VA): American Psychiatric Association, 2004:102. [Symposium 100B] [www.psychiatry.org/File%20Library/Psychiatrists/Directories/Library-and-Archive/conference_publications/am_program_2004.pdf]BatemanAW , FonagyP . Drs Bateman and Fonagy reply [to Stern R. Partial hospitalization for borderline personality disorder. American Journal of Psychiatry 2001;158(11):1932-3. DOI: 10.1176/appi.ajp.158.11.1932]. American Journal of Psychiatry2001;158(11):1932-3. [DOI: 10.1176/appi.ajp.158.11.1932-a]EvansC . Treatment benefits of psychoanalytically oriented partial hospitalisation were maintained over 18 months in borderline personality disorder. Evidence-Based Mental Health2001;4(3):73. [DOI: 10.1136/ebmh.4.3.73]FonagyP , BatemanAW . Mentalizing and borderline personality disorder. Journal of Mental Health2007;16(1):83-101. [DOI: 10.1080/09638230601182045]SternR . Partial hospitalization for borderline personality disorder. American Journal of Psychiatry2001;158(11):1932-3. [DOI: 10.1176/appi.ajp.158.11.1932] [PMID: 11691712]">Bateman 1999</a>; <a href="./references#CD012955-bbs2-0005" title="BatemanA , FonagyP . Impact of clinical severity on outcomes of mentalisation-based treatment for borderline personality disorder. British Journal of Psychiatry2013;203(3):221-7. [DOI: 10.1192/bjp.bp.112.121129] [PMID: 23887998]BatemanA , FonagyP . Randomized controlled trial of outpatient mentalization-based treatment versus structured clinical management for borderline personality disorder. American Journal of Psychiatry2009;166(12):1355-64. [DOI: 10.1176/appi.ajp.2009.09040539] [PMID: 19833787]BatemanA , FonagyP . Randomized controlled trial of outpatient mentalization-based treatment versus structured clinical management for borderline personality disorder. Supplementary data. ajp.psychiatryonline.org/doi/suppl/10.1176/appi.ajp.2009.09040539/suppl_file/ajp_166_12_1355_01.pdf (accessed 27 February 2020). BatemanA , O'ConnellJ , LorenziniN , GardnerT , FonagyP . A randomised controlled trial of mentalization-based treatment versus structured clinical management for patients with comorbid borderline personality disorder and antisocial personality disorder. BMC Psychiatry2016;16:304. [DOI: 10.1186/s12888-016-1000-9] [PMC5006360] [PMID: 27577562]BatemanA . Important question regarding your BPD trial for systematic review in Cochrane Collaboration [personal communication]. Email to: K Lieb 14 December 2010. BatemanAW . Mentalization, borderline personality disorder and what works for whom? Presentation at the 11th International Congress of the International Society for the Study of Personality Disorders; 2009 Aug 21-23. www.borderlinepersonalitydisorder.com/Conferences/ISSPD/isspd_09_Bateman (accessed 21 April 2010). ISRCTN27660668. Randomised controlled trial of manualised out-patient individual and group therapy for borderline personality disorder [Effectiveness of intensive out-patient psychotherapy for treatment of borderline personality disorder: a pragmatic randomised single blind controlled study]. www.isrctn.com/ISRCTN27660668 (first received 12 October 2008). ">Bateman 2009</a>; <a href="./references#CD012955-bbs2-0010" title="BlackD . Question regarding your BPD trial [personal communication]. Email to: J Stoffers 04 January 2011. BlackDW , AllenJ , McCormickB , BlumN . Treatment received by persons with BPD participating in a randomized clinical trial of the systems training for emotional predictability and problem solving programme. Personality and Mental Health2011;5(3):159-68. [DOI: 10.1002/pmh.167]BlackDW , AllenJ , St JohnD , PfohlB , McCormickB , BlumN . Predictors of response to systems training for emotional predictability and problem solving (STEPPS) for borderline personality disorder: an exploratory study. Acta Psychiatrica Scandinavica2009;120(1):53-61. [DOI: 10.1111/j.1600-0447.2008.01340.x] [PMC3665337] [PMID: 19183126]BlackDW , BlumN , PfohlB , St JohnD . The STEPPS group treatment program for outpatients with borderline personality disorder. Journal of Contemporary Psychotherapy2004;34(3):193-210. [DOI: 10.1023/B:JOCP.0000036630.25741.83]BlackDW , PfohlBM . Randomized clinical trial of STEPPS versus treatment as usual. In: 158th annual meeting of the American Psychiatric Association. Psychosomatic medicine: integrating psychiatry &amp; medicine; 2005 May 21-26; Atlanta (GA). Arlington (VA): American Psychiatric Association, 2005:104. [No. 1B] [www.psychiatry.org/File%20Library/Psychiatrists/Directories/Library-and-Archive/syllabus/am_syllabus_2005.pdf]BlackDW , Simsek-DuranF , BlumN , McCormickB , AllenJ . Do people with borderline personality disorder complicated by antisocial personality disorder benefit from the STEPPS treatment program?Personality and Mental Health2016;10(3):205-15. [DOI: 10.1002/pmh.1326] [PMC4911327] [PMID: 26671625]BlackDW . RE: [external] questions regarding your trial on the STEPPS program for BPD [personal communication]. Email to: EG Faltinsen 27 November 2017. BlumN , AllenJ , McCormickB , BlackDW . Ms Blum and colleagues reply [to Schulte-Herbrüggen O, Koerting J, Roepke S. Effectiveness of adjunctive STEPPS group treatment in borderline personality disorder patients. American Journal of Psychiatry 2008;165(10):1354-5. DOI: 10.1176/appi.ajp.2008.08030390]. American Journal of Psychiatry2008;165(10):1354-5. [DOI: 10.1176/appi.ajp.2008.08030390r]BlumN , FranklinJ , HanselR , McCormickB , St JohnD , PfohlB , et al. Relationship of age to symptom severity, psychiatric comorbidity and health care utilization in persons with borderline personality disorder. Personality and Mental Health2008;2(1):25-43. [DOI: 10.1002/pmh.26]BlumN , St JohnD , PfohlB , StuartS , McCormickB , AllenJ , et al. Erratum. American Journal of Psychiatry2008;165(6):777. Erratum for: American Journal of Psychiatry 2008;165(4):468-78. [psycnet.apa.org/record/2008-07854-033]BlumN , St JohnD , PfohlB , StuartS , McCormickB , AllenJ , et al. Systems training for emotional predictability and problem solving (STEPPS) for outpatients with borderline personality disorder: a randomized controlled trial and 1-year follow-up. American Journal of Psychiatry2008;165(4):468-78. [DOI: 10.1176/appi.ajp.2007.07071079] [PMC3608469] [PMID: 18281407]DavidsonKM . Borderline personality disorder: STEPPS improves symptoms. Evidence-Based Mental Health2008;11(4):120. [DOI: 10.1136/ebmh.11.4.120] [PMID: 18952969]NCT00055315. Treatment for borderline personality disorder [A cognitive group treatment for borderline outpatients]. clinicaltrials.gov/ct2/show/NCT00055315 (first received 25 February 2003). ">Blum 2008</a>; <a href="./references#CD012955-bbs2-0012" title="BorschmannR , BarrettB , HellierJM , ByfordS , HendersonC , RoseD , et al. Joint crisis plans for people with borderline personality disorder: feasibility and outcomes in a randomised controlled trial. British Journal of Psychiatry2013;202(5):357-64. [DOI: 10.1192/bjp.bp.112.117762] [PMID: 23637110]BorschmannR . Joint crisis plans for BPD - question on publication in British Journal of Psychiatry [pers communication]. Email to: J Stoffers-Winterling 22 August 2017. BorschmannR . RE: joint crisis plans for BPD - question on publication in British Journal of Psychiatry [personal communication]. Email to: J Stoffers-Winterling 22 August 2017. BorschmannR . The development and testing of joint crisis plans for people with borderline personality disorder: a feasibility study. ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.628499 (accessed 27 January 2019). HellierJ . RE: regarding your study on on MBT for eating disorders [personal communication]. Email to: E Faltinsen 27 March 2018. HellierJ . RE: regarding your study on on MBT for eating disorders [personal communication]. Email to: E Faltinsen 3 January 2018. HellierJ . SV: regarding your study on MBT for eating disorders [personal communication]. Email to: EG Faltinsen, P Robinson 27 March 2018. ISRCTN12440268. JOSHUA: a pilot randomised controlled trial of joint crisis plans for people who self harm. www.isrctn.com/ISRCTN12440268 (first received 17 September 2009). ">Borschmann 2013</a>; <a href="./references#CD012955-bbs2-0017" title="DavidsonK , LivingstoneS , McArthurK , DicksonL , GumleyA . An integrative complexity analysis of cognitive behaviour therapy sessions for borderline personality disorder. Psychology and Psychotherapy2007;80(Pt 4):513-23. [DOI: 10.1348/147608307X191535] [PMID: 17535542]DavidsonK , NorrieJ , TyrerP , GumleyA , TataP , MurrayH , et al. The effectiveness of cognitive behavior therapy for borderline personality disorder: results from the borderline personality disorder study of cognitive therapy (BOSCOT) trial. Journal of Personality Disorders2006;20(5):450-65. [DOI: 10.1521/pedi.2006.20.5.450] [PMC1852259] [PMID: 17032158]DavidsonK , TyrerP , GumleyA , TataP , NorrieJ , PalmerS , et al. A randomized controlled trial of cognitive behavior therapy for borderline personality disorder: rationale for trial, method, and description of sample. Journal of Personality Disorders2006;20(5):431-49. [DOI: 10.1521/pedi.2006.20.5.431] [PMC1847748] [PMID: 17032157]DavidsonKM , TyrerP , NorrieJ , PalmerSJ , TyrerH . Cognitive therapy v usual treatment for borderline personality disorder: prospective 6-year follow-up. British Journal of Psychiatry2010;197(6):456-62. [DOI: 10.1192/bjp.bp.109.074286] [PMID: 21119151]ISRCTN86177428. Borderline personality disorder study of cognitive therapy trial [A randomised controlled trial of cognitive therapy plus treatment as usual versus treatment as usual in the treatment of borderline personality disorder]. www.isrctn.com/ISRCTN86177428 (first received 22 July 2005). NCT00538135. BOSCOT: a randomised controlled trial of cognitive behavioural therapy in borderline personality disorder [BOSCOT: a randomised control trial of cognitive behavioural therapy plus treatment as usual versus treatment as usual in the treatment of borderline personality disorder]. www.clinicaltrials.gov/ct2/show/NCT00538135 (first received 29 September 2007). NorrieJ , DavidsonK , TataP , GumleyA . Influence of therapist competence and quantity of cognitive behavioural therapy on suicidal behaviour and inpatient hospitalisation in a randomised controlled trial in borderline personality disorder: further analyses of treatment effects in the BOSCOT study. Psychology and Psychotherapy2013;86(3):280-93. [DOI: 10.1111/papt.12004] [PMC4491320] [PMID: 23420622]PalmerS , DavidsonK , TyrerP , GumleyA , TataP , NorrieJ , et al. The cost-effectiveness of cognitive behavior therapy for borderline personality disorder: results from the BOSCOT trial. Journal of Personality Disorders2006;20(5):466-81. [DOI: 10.1521/pedi.2006.20.5.466] [PMC1852260] [PMID: 17032159]">Davidson 2006</a>; <a href="./references#CD012955-bbs2-0018" title="DavidsonKM , BrownTM , JamesV , KirkJ , RichardsonJ . Manual-assisted cognitive therapy for self-harm in personality disorder and substance misuse: a feasibility trial. Psychiatric Bulletin2014;38(3):108-11. [DOI: 10.1192/pb.bp.113.043109] [PMC4115373] [PMID: 25237519]DavidsonKM . Re: question regarding your trial on manual-assisted cognitive therapy [personal communication]. Email to: EG Faltinsen 28 November 2017. ">Davidson 2014</a>; <a href="./references#CD012955-bbs2-0019" title="BuchheimA , Hörz-SagstetterS , DoeringS , RentropM , SchusterP , BuchheimP , et al. Change of unresolved attachment in borderline personality disorders: RCT study of transference-focused psychotherapy. Psychotherapy and Psychosomatics2017;86(5):314-6. [DOI: 10.1159/000460257] [PMID: 28903103]DiamondD , LevyKN , ClarkinJF , Fischer-KernM , CainNM , DoeringS , et al. Attachment and mentalization in female patients with comorbid narcissistic and borderline personality disorder. Personality Disorders2014;5(4):428-33. [DOI: 10.1037/per0000065] [PMID: 25314231]DiamondD , YeomansFE , SternB , LevyKN , HörzS , DoeringS , et al. Transference-focused psychotherapy for patients with comorbid narcissistic and borderline personality disorder. Psychoanalytic Inquiry2013;33(6):527-51. [DOI: 10.1080/07351690.2013.815087]DoeringS , HörzS , RentropM , Fischer-KernM , SchusterP , BeneckeC , et al. Transference-focused psychotherapy v treatment by community psychotherapists for borderline personality disorder: randomised controlled trial. British Journal of Psychiatry2010;196(5):389-95. [DOI: 10.1192/bjp.bp.109.070177] [PMID: 20435966]DoeringS . Author's reply [to Kleindienst N, Krumm B, Bohus M. Is transference-focused psychotherapy really efficacious for borderline personality disorder? British Journal of Psychiatry 2011;198(2):156-7. DOI: 10.1192/bjp.198.2.156b]. British Journal of Psychiatry2011;198(2):156-7. [DOI: 10.1192/bjp.198.2.157]DoeringS . Question regarding your BPD trial for systematic review in Cochrane Collaboration [personal communication]. Email to: K Lieb, J Stoffers 10 December 2010. Fischer-KernM , DoeringS , TaubnerS , HörzS , ZimmermannJ , RentropM , et al. Transference-focused psychotherapy for borderline personality disorder: change in reflective function. British Journal of Psychiatry2015;207(2):173-4. [DOI: 10.1192/bjp.bp.113.143842] [PMID: 25999334]KleindienstN , KrummB , BohusM . Is transference-focused psychotherapy really efficacious for borderline personality disorder?British Journal of Psychiatry2011;198(2):156-7. [DOI: 10.1192/bjp.198.2.156b] [PMID: 21282787]LevyKN , MeehanKB , YeomansFE . Transference-focused psychotherapy reduces treatment drop-out and suicide attempters compared with community psychotherapist treatment in borderline personality disorder. Evidence-based Mental Health2010;13(4):119. [DOI: 10.1136/ebmh.13.4.119] [PMID: 21036981]NCT00714311. Efficacy of transference-focused psychotherapy for borderline personality disorder [A randomized-controlled trial of transference-focused psychotherapy vs treatment by experienced community psychotherapists for borderline personality disorder]. www.clinicaltrials.gov/ct2/show/NCT00714311 (first received 9 July 2008). RentropM , MartiusP , BäumlJ , BuchheimP , DöeringS , HörzS . Patients with borderline personality disorder not participating in an RCT: are they different?Psychopathology2010;43(6):369-72. [DOI: 10.1159/000320351] [PMID: 20798576]">Doering 2010</a>; <a href="./references#CD012955-bbs2-0025" title="GleesonJF , ChanenA , CottonSM , PearceT , NewmanB , McCutcheonL . Treating co-occurring first-episode psychosis and borderline personality: a pilot randomized controlled trial. Early Intervention in Psychiatry2012;6(1):21-9. [DOI: 10.1111/j.1751-7893.2011.00306.x] [PMID: 22379625]GleesonJFM . RE: separate data [personal communication]. Email to: M Kielsholm 28 October 2016. ">Gleeson 2012</a>; <a href="./references#CD012955-bbs2-0026" title="Gratz KL. Important: question regarding your BPD trial for systematic review in Cochrane Collaboration [personal communication]. Email to: J Stoffers-Winterling 11 December 2010. GratzKL , GundersonJG . Preliminary data on an acceptance-based emotion regulation group intervention for deliberate self-harm among women with borderline personality disorder. Behavior Therapy2006;37(1):25-35. [DOI: 10.1016/j.beth.2005.03.002] [PMID: 16942958]">Gratz 2006</a>; <a href="./references#CD012955-bbs2-0027" title="GratzKL , BardeenJR , LevyR , Dixon-GordonKL , TullMT . Mechanisms of change in an emotion regulation group therapy for deliberate self-harm among women with borderline personality disorder. Behaviour Research and Therapy2015;65:29-35. [DOI: 10.1016/j.brat.2014.12.005] [PMC4306622] [PMID: 25557395]GratzKL , Dixon-GordonKL , TullMT . Predictors of treatment response to an adjunctive emotion regulation group therapy for deliberate self-harm among women with borderline personality disorder. Personality Disorders2014;5(1):97-107. [DOI: 10.1037/per0000062] [PMC4059504] [PMID: 2458806]GratzKL , TullMT , LevyR . Randomized controlled trial and uncontrolled 9-month follow-up of an adjunctive emotion regulation group therapy for deliberate self-harm among women with borderline personality disorder. Psychological Medicine2014;44(10):2099-112. [DOI: 10.1017/S0033291713002134] [PMID: 23985088]GratzKL . Question regarding your BPD trials [personal communication]. Email to: J Stoffers 11 December 2010. ">Gratz 2014</a>; <a href="./references#CD012955-bbs2-0028" title="GregoryRJ , ChlebowskiS , KangD , RemenA , SoderbergM . Psychodynamic therapy for borderline personality disorder and co-occurring alcohol use disorders: a newly designed ongoing study. Journal of the American Psychoanalytic Association2006;54(4):1331-4. [DOI: 10.1177/00030651060540040107] [PMID: 17354507]GregoryRJ , ChlebowskiS , KangD , RemenAL , SoderbergMG , StepkovitchJ , et al. A controlled trial of psychodynamic psychotherapy for co-occurring borderline personality disorder and alcohol use disorder. Psychotherapy2008;45(1):28-41. [DOI: 10.1037/0033-3204.45.1.28] [PMID: 22122363]GregoryRJ , DeLucia-DeranjaE , MogleJA . Dynamic deconstructive psychotherapy versus optimized community care for borderline personality disorder co-occuring with alcohol use disorders: a 30-month follow-up. Journal of Nervous and Mental Disease2010;198(4):292-8. [DOI: 10.1097/NMD.0b013e3181d6172d] [PMID: 20386259]GregoryRJ , RemenAL , SoderbergM , Ploutz-SnyderRJ . A controlled trial of psychodynamic psychotherapy for co-occurring borderline personality disorder and alcohol use disorder: six-month outcome. Journal of the American Psychoanalytic Association2009;57(1):199-205. [DOI: 10.1177/00030651090570011006] [PMID: 19270255]NCT00145678. Psychodynamic therapy for co-occurring borderline personality disorder and alcohol use disorder [Psychodynamic therapy for patients With borderline personality disorder and alcohol abuse]. www.clinicaltrials.gov/show/NCT00145678 (first received 1 September 2005). ">Gregory 2008b</a>; <a href="./references#CD012955-bbs2-0031" title="BrandS . AW: questions regarding your trial on emotional intelligence training for BPD [personal communication]. Email to: EG Faltinsen 28 November 2017. BrandS . Questions regarding your trial on emotional intelligence training for BPD [personal communication]. Email to: EG Faltinsen 28 November 2017. JahangardL , HaghighiM , BajoghliH , AhmadpanahM , GhaleihaA , ZarrabianMK , et al. Training emotional intelligence improves both emotional intelligence and depressive symptoms in inpatients with borderline personality disorder and depression. International Journal of Psychiatry in Clinical Practice2012;16(3):197-204. [DOI: 10.3109/13651501.2012.687454] [PMID: 22873719]">Jahangard 2012</a>; <a href="./references#CD012955-bbs2-0033" title="JørgensenCR , BøyeR , AndersenD , Døssing BlaabjergAH , FreundC , JordetH , et al. Eighteen months post-treatment naturalistic follow-up study of mentalization-based therapy and supportive group treatment of borderline personality disorder: clinical outcomes and functioning. Nordic Psychology2014;66(4):254-73. [DOI: 10.1080/19012276.2014.963649]JørgensenCR , FreundC , BøyeR , JordetH , AndersenD , KjølbyeM . Outcome of mentalization-based and supportive psychotherapy in patients with borderline personality disorder: a randomized trial. Acta Psychiatrica Scandinavica2013;127(4):305-17. [DOI: 10.1111/j.1600-0447.2012.01923.x] [PMID: 22897123]JorgensenCR . SV: questions on your trial regarding MBT for BPD patients [personal communication]. Email to: EG Faltinsen 28 November 2017. ">Jørgensen 2013</a>; <a href="./references#CD012955-bbs2-0039" title="KredlowMA , SzuhanyKL , LoS , XieH , GottliebJD , RosenbergSD , et al. Cognitive behavioral therapy for posttraumatic stress disorder in individuals with severe mental illness and borderline personality disorder. Psychiatry Research2017;249:86-93. [DOI: 10.1016/j.psychres.2016.12.045] [PMC5325773] [PMID: 28086181]MueserK . Re: question regarding your trial on CBT for BPD patients [personal communication]. Email to: EG Faltinsen 28 November 2017. ">Kredlow 2017a</a>; <a href="./references#CD012955-bbs2-0041" title="LaurenssenEM , WestraD , KikkertMJ , NoomMJ , EerenHV , Van BroekhuyzenAJ , et al. Day hospital mentalization-based treatment (MBT-DH) versus treatment as usual in the treatment of severe borderline personality disorder: protocol of a randomized controlled trial. BMC Psychiatry2014;14:149. [DOI: 10.1186/1471-244X-14-149] [PMC4045960] [PMID: 24886402]LaurenssenEMP , LuytenP , KikkertMJ , WestraD , PeenJ , SoonsMBJ , et al. Day hospital mentalization-based treatment v specialist treatment as usual in patients with borderline personality disorder: randomized controlled trial. Psychological Medicine2018;48(15):2522-9. [DOI: 10.1017/S0033291718000132] [PMID: 29478425]NL2058 (NTR2175). Mentalisation-based treatment versus care-as-usual in the treatment of severe borderline personality disorders. www.trialregister.nl/trial/2058 (first received 21 January 2010). ">Laurenssen 2018</a>; <a href="./references#CD012955-bbs2-0042" title="LeichsenringF , MasuhrO , JaegerU , RabungS , DallyA , DümpelmannM , et al. Psychoanalytic-interactional therapy versus psychodynamic therapy by experts for personality disorders: a randomized controlled efficacy-effectiveness study in cluster B personality disorders. Psychotherapy and Psychosomatics2016;85(2):71-80. [DOI: 10.1159/000441731] [PMID: 26808580]">Leichsenring 2016</a>; <a href="./references#CD012955-bbs2-0043" title="LeppänenV , HakkoH , SintonenH , LindemanS . Comparing effectiveness of treatments for borderline personality disorder in communal mental health care: the Oulu BPD study. Community Mental Health Journal2016;52(2):216-27. [DOI: 10.1007/s10597-015-9866-4] [PMID: 25824852]LeppänenV . Re: questions regarding the Oulu BPD study [personal communication]. Email to: E Faltinsen 20 December 2017. LeppänenV . Re: SV: question regarding the Oulu BPD study [personal communication]. Email to: EG Faltinsen 22 December 2017. ">Leppänen 2016</a>; <a href="./references#CD012955-bbs2-0051" title="McMurranM , CrawfordMJ , ReillyJ , DelportJ , McCroneP , WhithamD , et al. Psychoeducation with problem-solving (PEPS) therapy for adults with personality disorder: a pragmatic randomised controlled trial to determine the clinical effectiveness and cost-effectiveness of a manualised intervention to improve social functioning. Health Technology Assessment2016;20(52):1-282. [DOI: 10.3310/hta20520]McMurranM . RE: Cochrane Collaboration review - PEPS study [personal communication]. Email to: J Stoffers-Winterling 5 July 2018. McMurranM . Request for data on BPD subjects in the PEPS rcp-study for use a new Cochrane review [personal communication]. Email to: M Kongerslev 7 March 2017. ">McMurran 2016</a>; <a href="./references#CD012955-bbs2-0055" title="MortonJ , SnowdonS , GopoldM , GuymerE . Acceptance and commitment therapy group treatment for symptoms of borderline personality disorder: a public sector pilot study. Cognitive and Behavioral Practice2012;19(4):527-44. [DOI: 10.1016/j.cbpra.2012.03.005]MortonJ . Re: SV: regarding your study on acceptance and commitment therapy for BPD [personal communication]. Email to: EG Faltinsen 22 December 2017. ">Morton 2012</a>; <a href="./references#CD012955-bbs2-0060" title="RenesesB , FigueraD , SalcedoG , TrujilloM , López-IborJJ , GaliánM , et al. A controlled randomized study on the efficacy of short-term dinamic psychotherapy in borderline personality disorders (BPD). Preliminary results. European Psychiatry2011;26(Suppl 1):1040. [DOI: 10.1016/S0924-9338(11)72745-6] [P02-444]RenesesB , GaliánM , SerranoR , FigueraD , Fernandez Del MoralA , López-IborJJ , et al. A new time limited psychotherapy for BPD: preliminary results of a randomized and controlled trial. Actas Espanolas de Psiquiatria2013;41(3):139-48. [PMID: 23803797]">Reneses 2013</a>; <a href="./references#CD012955-bbs2-0075" title="ZanariniMC , ConkeyLC , TemesCM , FitzmauriceGM . Randomized controlled trial of web-based psychoeducation for women with borderline personality disorder. Journal of Clinical Psychiatry2018;79(3):16m11153. [DOI: 10.4088/JCP.16m11153] [PMC5764827] [PMID: 28703950]">Zanarini 2018</a>). </p> <p>Generally, psychotherapy improved depression at end of treatment compared to TAU (SMD −0.39, 95% CI −0.61 to −0.17; 22 trials, 1568 participants; I<sup>2</sup> = 75%; P = 0.0006; <a href="./references#CD012955-fig-0020" title="">Analysis 1.17</a>.1; very low‐quality evidence, <a href="./full#CD012955-tbl-0001">summary of findings Table 1</a>). This corresponds to −2.45 on the Hamilton Depression Scale. The MIREDIF on this scale is 3.0 points (<a href="./references#CD012955-bbs2-0370" title="National Institute for Health and Care Excellence. Depression in adults: recognition and management. Cinical guideline (CG90). www.nice.org.uk/guidance/cg90 (accessed prior to 16 March 2020).">NICE CG90</a>). However, the TSA analysis showed that the RIS was not reached (n = 2274), and that there was a potential risk of type 1 error (TSA adjusted confidence interval −3.34 to −1.72) (see figure 12 in <a href="./appendices#CD012955-sec-0603">Appendix 6</a>). </p> <p>Generally, psychotherapy improved depression at zero to six months follow‐up compared with TAU (SMD −0.80, 95% CI −1.26 to −0.34; 4 trials, 125 participants; I<sup>2</sup> = 23%; P = 0.0006; <a href="./references#CD012955-fig-0020" title="">Analysis 1.17</a>.2). </p> <p>Generally, psychotherapy did not improve depression at six to 12 months follow‐up compared with TAU (SMD −0.40, 95% CI −0.95 to 0.16; 3 trials, 260 participants; I<sup>2</sup> = 77%; P = 0.16; <a href="./references#CD012955-fig-0020" title="">Analysis 1.17</a>.3). </p> <p>Generally, psychotherapy improved depression at above 12 months follow‐up compared with TAU (SMD −0.40, 95% CI ‐0.74 to −0.06; 5 trials, 311 participants; I<sup>2</sup> = 47%; P = 0.02; <a href="./references#CD012955-fig-0020" title="">Analysis 1.17</a>.4). </p> </section> <section id="CD012955-sec-0097"> <h6 class="title">1.18 Depression (dichotomous)</h6> <p>One trial reported dichotomous data on depression (<a href="./references#CD012955-bbs2-0062" title="ISRCTN95266816. The emergence of personality disorder traits in adolescents who deliberately self harm and the potential for using a mentalisation based treatment approach as an early intervention for such individuals: a randomised controlled trial. www.isrctn.com/ISRCTN95266816 (first received 29 October 2007). RossouwT . Mentalisation based treatment for adolescents with self harm: an RCT. European Child &amp; Adolescent Psychiatry2015;24(1 Suppl):S113. [DOI: 10.1007%2Fs00787-015-0714-4.pdf] [W1-02-02]RossouwT . Self harm in adolescence, is MBT the answer?: an RCT. Adolescent Psychiatry2012;2(1):102. [DOI: 10.2174/2210676611202010077]RossouwTI , FonagyP . Mentalization-based treatment for self-harm in adolescents: a randomized controlled trial. Journal of the American Academy of Child and Adolescent Psychiatry2012;51(12):1304-13.e3. [DOI: 10.1016/j.jaac.2012.09.018] [PMID: 23200287]">Rossouw 2012b</a>). </p> <p>Generally, psychotherapy did not improve depression at end of treatment compared with TAU (RR 0.71, 95% CI 0.49 to 1.03; 1 trial, 80 participants; P = 0.08; <a href="./references#CD012955-fig-0021" title="">Analysis 1.18</a>). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> </section> <section id="CD012955-sec-0098"> <h6 class="title">1.19 Attrition</h6> <p>Thirty‐two trials reported dichotomous data on attrition (<a href="./references#CD012955-bbs2-0001" title="AmiantoF , FerreroA , PieròA , CairoE , RoccaG , SimonelliB , et al. Supervised team management, with or without structured psychotherapy, in heavy users of a mental health service with borderline personality disorder: a two-year follow-up preliminary randomized study. BMC Psychiatry2011;11:181. [DOI: 10.1186/1471-244X-11-181] [PMC3260092 ] [PMID: 22103890]NCT01356069. Efficacy of time-limited psychodynamic psychotherapy and informed clinical management in BPD high MHS users (HUMSH) [Sequential brief Adlerian psychodynamic psychotherapy in heavy users of a mental health service with borderline personality disorder: a two years follow-up preliminary randomized study]. clinicaltrials.gov/ct2/show/NCT01356069 (first received 16 May 2011). ">Amianto 2011</a>; <a href="./references#CD012955-bbs2-0002" title='AndreoliA , BurnandY , CochennecMF , MarieD , Di ClementeT , OhlendorfP . Psychoanalytic psychotherapy and venlafaxine among acutely suicidal borderline patients: a randomized clinical study. European Psychiatry2009;24(Suppl 1):S93. [DOI: 10.1016/S0924-9338(09)70326-8] [S18-03]AndreoliA , BurnandY , CochennecMF , OhlendorfP , FrambatiL , Gaudry-MaireD , et al. Disappointed love and suicide: a randomized controlled trial of "abandonment psychotherapy" among borderline patients. Journal of Personality Disorders2016;30(2):271-87. [DOI: 10.1521/pedi_2015_29_196] [PMID: 26111250]AndreoliA , BurnandY , FrambatiL , ManningD , FrancesA . Abandonment psychotherapy and psychosocial functioning among suicidal patients with borderline personality disorder: a 3-year naturalistic follow-up. Journal of Personality Disorders 2019 Feb 20 [Epub ahead of print]. [DOI: 10.1521/pedi_2019_33_423] [PMID: 30785852]AndreoliA . Re: your study in BPD - Cochrane Collaboration review [personal communication]. Email to: J Stoffers-Winterling 5 June 2018. '>Andreoli 2016</a>; <a href="./references#CD012955-bbs2-0004" title="BatemanA , FonagyP . 8-year follow-up of patients treated for borderline personality disorder: mentalization-based treatment versus treatment as usual. American Journal of Psychiatry2008;165(5):631-8. [DOI: 10.1176/appi.ajp.2007.07040636] [PMID: 18347003]BatemanA , FonagyP . Effectiveness of partial hospitalization in the treatment of borderline personality disorder: a randomized controlled trial. American Journal of Psychiatry1999;156(10):1563-9. [DOI: 10.1176/ajp.156.10.1563] [PMID: 10518167]BatemanA , FonagyP . Health care utilization costs for borderline personality disorder patients treated with psychoanalytically oriented partial hospitalization versus general psychiatric care. American Journal of Psychiatry2003;160(1):169-71. [10.1176/appi.ajp.160.1.169] [12505818]BatemanA , FonagyP . Treatment of borderline personality disorder with psychoanalytically oriented partial hospitalization: an 18-month follow-up. American Journal of Psychiatry2001;158(1):36-42. [DOI: 10.1176/appi.ajp.158.1.36] [PMID: 11136631]BatemanA . Important: question regarding your BPD trial for systematic review in Cochrane Collaboration [personal communication]. Email to: K Lieb, J Stoffers 14 December 2010. BatemanA . Intensive outpatient and partial hospital care for BPD. In: 157th annual meeting of the American Psychiatric Association. Psychotherapy and pharmacology: dissolving the mind-brain barrier; 2004 May 1-6; New York (NY). Arlington (VA): American Psychiatric Association, 2004:102. [Symposium 100B] [www.psychiatry.org/File%20Library/Psychiatrists/Directories/Library-and-Archive/conference_publications/am_program_2004.pdf]BatemanAW , FonagyP . Drs Bateman and Fonagy reply [to Stern R. Partial hospitalization for borderline personality disorder. American Journal of Psychiatry 2001;158(11):1932-3. DOI: 10.1176/appi.ajp.158.11.1932]. American Journal of Psychiatry2001;158(11):1932-3. [DOI: 10.1176/appi.ajp.158.11.1932-a]EvansC . Treatment benefits of psychoanalytically oriented partial hospitalisation were maintained over 18 months in borderline personality disorder. Evidence-Based Mental Health2001;4(3):73. [DOI: 10.1136/ebmh.4.3.73]FonagyP , BatemanAW . Mentalizing and borderline personality disorder. Journal of Mental Health2007;16(1):83-101. [DOI: 10.1080/09638230601182045]SternR . Partial hospitalization for borderline personality disorder. American Journal of Psychiatry2001;158(11):1932-3. [DOI: 10.1176/appi.ajp.158.11.1932] [PMID: 11691712]">Bateman 1999</a>; <a href="./references#CD012955-bbs2-0005" title="BatemanA , FonagyP . Impact of clinical severity on outcomes of mentalisation-based treatment for borderline personality disorder. British Journal of Psychiatry2013;203(3):221-7. [DOI: 10.1192/bjp.bp.112.121129] [PMID: 23887998]BatemanA , FonagyP . Randomized controlled trial of outpatient mentalization-based treatment versus structured clinical management for borderline personality disorder. American Journal of Psychiatry2009;166(12):1355-64. [DOI: 10.1176/appi.ajp.2009.09040539] [PMID: 19833787]BatemanA , FonagyP . Randomized controlled trial of outpatient mentalization-based treatment versus structured clinical management for borderline personality disorder. Supplementary data. ajp.psychiatryonline.org/doi/suppl/10.1176/appi.ajp.2009.09040539/suppl_file/ajp_166_12_1355_01.pdf (accessed 27 February 2020). BatemanA , O'ConnellJ , LorenziniN , GardnerT , FonagyP . A randomised controlled trial of mentalization-based treatment versus structured clinical management for patients with comorbid borderline personality disorder and antisocial personality disorder. BMC Psychiatry2016;16:304. [DOI: 10.1186/s12888-016-1000-9] [PMC5006360] [PMID: 27577562]BatemanA . Important question regarding your BPD trial for systematic review in Cochrane Collaboration [personal communication]. Email to: K Lieb 14 December 2010. BatemanAW . Mentalization, borderline personality disorder and what works for whom? Presentation at the 11th International Congress of the International Society for the Study of Personality Disorders; 2009 Aug 21-23. www.borderlinepersonalitydisorder.com/Conferences/ISSPD/isspd_09_Bateman (accessed 21 April 2010). ISRCTN27660668. Randomised controlled trial of manualised out-patient individual and group therapy for borderline personality disorder [Effectiveness of intensive out-patient psychotherapy for treatment of borderline personality disorder: a pragmatic randomised single blind controlled study]. www.isrctn.com/ISRCTN27660668 (first received 12 October 2008). ">Bateman 2009</a>; <a href="./references#CD012955-bbs2-0012" title="BorschmannR , BarrettB , HellierJM , ByfordS , HendersonC , RoseD , et al. Joint crisis plans for people with borderline personality disorder: feasibility and outcomes in a randomised controlled trial. British Journal of Psychiatry2013;202(5):357-64. [DOI: 10.1192/bjp.bp.112.117762] [PMID: 23637110]BorschmannR . Joint crisis plans for BPD - question on publication in British Journal of Psychiatry [pers communication]. Email to: J Stoffers-Winterling 22 August 2017. BorschmannR . RE: joint crisis plans for BPD - question on publication in British Journal of Psychiatry [personal communication]. Email to: J Stoffers-Winterling 22 August 2017. BorschmannR . The development and testing of joint crisis plans for people with borderline personality disorder: a feasibility study. ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.628499 (accessed 27 January 2019). HellierJ . RE: regarding your study on on MBT for eating disorders [personal communication]. Email to: E Faltinsen 27 March 2018. HellierJ . RE: regarding your study on on MBT for eating disorders [personal communication]. Email to: E Faltinsen 3 January 2018. HellierJ . SV: regarding your study on MBT for eating disorders [personal communication]. Email to: EG Faltinsen, P Robinson 27 March 2018. ISRCTN12440268. JOSHUA: a pilot randomised controlled trial of joint crisis plans for people who self harm. www.isrctn.com/ISRCTN12440268 (first received 17 September 2009). ">Borschmann 2013</a>; <a href="./references#CD012955-bbs2-0013" title="BosEH , Van WelE , AppeloMT , VerbraakMJP . A randomized controlled trial of a Dutch version of systems training for emotional predictability and problem solving for borderline personality disorder. Journal of Nervous and Mental Disease2010;198(4):299-304. [DOI: 10.1097/NMD.0b013e3181d619cf] [PMID: 20386260]Van WelEB , BosEH , AppeloMT , BerendsenEM , WillgerothFC , VerbraakMJPM . The efficacy of the systems training for emotional predictability and problem solving (STEPPS) in the treatment of borderline personality disorder. A randomized controlled trial [De effectiviteit van de vaardigheidstraining emotieregulatiestoornis (VERS) in de behandeling van de borderlinepersoonlijkheidsstoornis: een gerandomiseerd onderzoek]. Tijdschrift voor Psychiatrie2009;51(5):291-301. [PMID: 19434566]">Bos 2010</a>; <a href="./references#CD012955-bbs2-0015" title="CarterG . Question regarding your BPD trial [personal communication]. Email to: J Stoffers 21 December 2010. CarterGL , WillcoxCH , LewinTJ , ConradAM , BenditN . Hunter DBT project: randomized controlled trial of dialectical behaviour therapy in women with borderline personality disorder. Australian and New Zealand Journal of Psychiatry2010;44(2):162-73. [DOI: 10.3109/00048670903393621] [PMID: 20113305]">Carter 2010</a>; <a href="./references#CD012955-bbs2-0017" title="DavidsonK , LivingstoneS , McArthurK , DicksonL , GumleyA . An integrative complexity analysis of cognitive behaviour therapy sessions for borderline personality disorder. Psychology and Psychotherapy2007;80(Pt 4):513-23. [DOI: 10.1348/147608307X191535] [PMID: 17535542]DavidsonK , NorrieJ , TyrerP , GumleyA , TataP , MurrayH , et al. The effectiveness of cognitive behavior therapy for borderline personality disorder: results from the borderline personality disorder study of cognitive therapy (BOSCOT) trial. Journal of Personality Disorders2006;20(5):450-65. [DOI: 10.1521/pedi.2006.20.5.450] [PMC1852259] [PMID: 17032158]DavidsonK , TyrerP , GumleyA , TataP , NorrieJ , PalmerS , et al. A randomized controlled trial of cognitive behavior therapy for borderline personality disorder: rationale for trial, method, and description of sample. Journal of Personality Disorders2006;20(5):431-49. [DOI: 10.1521/pedi.2006.20.5.431] [PMC1847748] [PMID: 17032157]DavidsonKM , TyrerP , NorrieJ , PalmerSJ , TyrerH . Cognitive therapy v usual treatment for borderline personality disorder: prospective 6-year follow-up. British Journal of Psychiatry2010;197(6):456-62. [DOI: 10.1192/bjp.bp.109.074286] [PMID: 21119151]ISRCTN86177428. Borderline personality disorder study of cognitive therapy trial [A randomised controlled trial of cognitive therapy plus treatment as usual versus treatment as usual in the treatment of borderline personality disorder]. www.isrctn.com/ISRCTN86177428 (first received 22 July 2005). NCT00538135. BOSCOT: a randomised controlled trial of cognitive behavioural therapy in borderline personality disorder [BOSCOT: a randomised control trial of cognitive behavioural therapy plus treatment as usual versus treatment as usual in the treatment of borderline personality disorder]. www.clinicaltrials.gov/ct2/show/NCT00538135 (first received 29 September 2007). NorrieJ , DavidsonK , TataP , GumleyA . Influence of therapist competence and quantity of cognitive behavioural therapy on suicidal behaviour and inpatient hospitalisation in a randomised controlled trial in borderline personality disorder: further analyses of treatment effects in the BOSCOT study. Psychology and Psychotherapy2013;86(3):280-93. [DOI: 10.1111/papt.12004] [PMC4491320] [PMID: 23420622]PalmerS , DavidsonK , TyrerP , GumleyA , TataP , NorrieJ , et al. The cost-effectiveness of cognitive behavior therapy for borderline personality disorder: results from the BOSCOT trial. Journal of Personality Disorders2006;20(5):466-81. [DOI: 10.1521/pedi.2006.20.5.466] [PMC1852260] [PMID: 17032159]">Davidson 2006</a>; <a href="./references#CD012955-bbs2-0019" title="BuchheimA , Hörz-SagstetterS , DoeringS , RentropM , SchusterP , BuchheimP , et al. Change of unresolved attachment in borderline personality disorders: RCT study of transference-focused psychotherapy. Psychotherapy and Psychosomatics2017;86(5):314-6. [DOI: 10.1159/000460257] [PMID: 28903103]DiamondD , LevyKN , ClarkinJF , Fischer-KernM , CainNM , DoeringS , et al. Attachment and mentalization in female patients with comorbid narcissistic and borderline personality disorder. Personality Disorders2014;5(4):428-33. [DOI: 10.1037/per0000065] [PMID: 25314231]DiamondD , YeomansFE , SternB , LevyKN , HörzS , DoeringS , et al. Transference-focused psychotherapy for patients with comorbid narcissistic and borderline personality disorder. Psychoanalytic Inquiry2013;33(6):527-51. [DOI: 10.1080/07351690.2013.815087]DoeringS , HörzS , RentropM , Fischer-KernM , SchusterP , BeneckeC , et al. Transference-focused psychotherapy v treatment by community psychotherapists for borderline personality disorder: randomised controlled trial. British Journal of Psychiatry2010;196(5):389-95. [DOI: 10.1192/bjp.bp.109.070177] [PMID: 20435966]DoeringS . Author's reply [to Kleindienst N, Krumm B, Bohus M. Is transference-focused psychotherapy really efficacious for borderline personality disorder? British Journal of Psychiatry 2011;198(2):156-7. DOI: 10.1192/bjp.198.2.156b]. British Journal of Psychiatry2011;198(2):156-7. [DOI: 10.1192/bjp.198.2.157]DoeringS . Question regarding your BPD trial for systematic review in Cochrane Collaboration [personal communication]. Email to: K Lieb, J Stoffers 10 December 2010. Fischer-KernM , DoeringS , TaubnerS , HörzS , ZimmermannJ , RentropM , et al. Transference-focused psychotherapy for borderline personality disorder: change in reflective function. British Journal of Psychiatry2015;207(2):173-4. [DOI: 10.1192/bjp.bp.113.143842] [PMID: 25999334]KleindienstN , KrummB , BohusM . Is transference-focused psychotherapy really efficacious for borderline personality disorder?British Journal of Psychiatry2011;198(2):156-7. [DOI: 10.1192/bjp.198.2.156b] [PMID: 21282787]LevyKN , MeehanKB , YeomansFE . Transference-focused psychotherapy reduces treatment drop-out and suicide attempters compared with community psychotherapist treatment in borderline personality disorder. Evidence-based Mental Health2010;13(4):119. [DOI: 10.1136/ebmh.13.4.119] [PMID: 21036981]NCT00714311. Efficacy of transference-focused psychotherapy for borderline personality disorder [A randomized-controlled trial of transference-focused psychotherapy vs treatment by experienced community psychotherapists for borderline personality disorder]. www.clinicaltrials.gov/ct2/show/NCT00714311 (first received 9 July 2008). RentropM , MartiusP , BäumlJ , BuchheimP , DöeringS , HörzS . Patients with borderline personality disorder not participating in an RCT: are they different?Psychopathology2010;43(6):369-72. [DOI: 10.1159/000320351] [PMID: 20798576]">Doering 2010</a>; <a href="./references#CD012955-bbs2-0021" title="FarrellJM , ShawIA , WebberMA . A schema-focused approach to group psychotherapy for outpatients with borderline personality disorder: a randomized controlled trial. Journal of Behavior Therapy and Experimental Psychiatry2009;40(2):317-28 Corrigendum to: Journal of Behavior Therapy and Experimental Psychiatry 2018; 60: 111. [DOI: 10.1016/j.jbtep.2009.01.002] [PMID: 19176222]FarrellJM . Question regarding your BPD trials [personal communication]. Email to: K Lieb, J Stoffers 9 December 2010. ">Farrell 2009</a>; <a href="./references#CD012955-bbs2-0022" title="FeigenbaumJD , FonagyP , PillingS , JonesA , WildgooseA , BebbingtonPE . A real-world study of the effectiveness of DBT in the UK National Health Service. British Journal of Clinical Psychology2012;51(2):121-41. [DOI: 10.1111/j.2044-8260.2011.02017.x] [PMID: 22574799]">Feigenbaum 2012</a>; <a href="./references#CD012955-bbs2-0025" title="GleesonJF , ChanenA , CottonSM , PearceT , NewmanB , McCutcheonL . Treating co-occurring first-episode psychosis and borderline personality: a pilot randomized controlled trial. Early Intervention in Psychiatry2012;6(1):21-9. [DOI: 10.1111/j.1751-7893.2011.00306.x] [PMID: 22379625]GleesonJFM . RE: separate data [personal communication]. Email to: M Kielsholm 28 October 2016. ">Gleeson 2012</a>; <a href="./references#CD012955-bbs2-0026" title="Gratz KL. Important: question regarding your BPD trial for systematic review in Cochrane Collaboration [personal communication]. Email to: J Stoffers-Winterling 11 December 2010. GratzKL , GundersonJG . Preliminary data on an acceptance-based emotion regulation group intervention for deliberate self-harm among women with borderline personality disorder. Behavior Therapy2006;37(1):25-35. [DOI: 10.1016/j.beth.2005.03.002] [PMID: 16942958]">Gratz 2006</a>; <a href="./references#CD012955-bbs2-0027" title="GratzKL , BardeenJR , LevyR , Dixon-GordonKL , TullMT . Mechanisms of change in an emotion regulation group therapy for deliberate self-harm among women with borderline personality disorder. Behaviour Research and Therapy2015;65:29-35. [DOI: 10.1016/j.brat.2014.12.005] [PMC4306622] [PMID: 25557395]GratzKL , Dixon-GordonKL , TullMT . Predictors of treatment response to an adjunctive emotion regulation group therapy for deliberate self-harm among women with borderline personality disorder. Personality Disorders2014;5(1):97-107. [DOI: 10.1037/per0000062] [PMC4059504] [PMID: 2458806]GratzKL , TullMT , LevyR . Randomized controlled trial and uncontrolled 9-month follow-up of an adjunctive emotion regulation group therapy for deliberate self-harm among women with borderline personality disorder. Psychological Medicine2014;44(10):2099-112. [DOI: 10.1017/S0033291713002134] [PMID: 23985088]GratzKL . Question regarding your BPD trials [personal communication]. Email to: J Stoffers 11 December 2010. ">Gratz 2014</a>; <a href="./references#CD012955-bbs2-0033" title="JørgensenCR , BøyeR , AndersenD , Døssing BlaabjergAH , FreundC , JordetH , et al. Eighteen months post-treatment naturalistic follow-up study of mentalization-based therapy and supportive group treatment of borderline personality disorder: clinical outcomes and functioning. Nordic Psychology2014;66(4):254-73. [DOI: 10.1080/19012276.2014.963649]JørgensenCR , FreundC , BøyeR , JordetH , AndersenD , KjølbyeM . Outcome of mentalization-based and supportive psychotherapy in patients with borderline personality disorder: a randomized trial. Acta Psychiatrica Scandinavica2013;127(4):305-17. [DOI: 10.1111/j.1600-0447.2012.01923.x] [PMID: 22897123]JorgensenCR . SV: questions on your trial regarding MBT for BPD patients [personal communication]. Email to: EG Faltinsen 28 November 2017. ">Jørgensen 2013</a>; <a href="./references#CD012955-bbs2-0035" title="KoonsCR , RobinsCJ , TweedJL , LynchTR , GonzalezAM , MorseJQ , et al. Efficacy of dialectical behavior therapy in women veterans with borderline personality disorder. Behavior Therapy2001;32(2):371-90. [DOI: 10.1016/S0005-7894(01)80009-5]">Koons 2001a</a>; <a href="./references#CD012955-bbs2-0038" title="KramerU , Pascual-LeoneA , BerthoudL , De RotenY , MarquetP , KollyS , et al. Assertive anger mediates effects of dialectical behaviour-informed skills training for borderline personality disorder: a randomized controlled trial. Clinical Psychology &amp; Psychotherapy2016;23(3):189-202. [DOI: 10.1002/cpp.1956] [PMID: 25864773]KramerU . The role of coping change in borderline personality disorder: a process-outcome analysis on dialectical-behaviour skills training. Clinical Psychology &amp; Psychotherapy2017;24(2):302-11. [DOI: 10.1002/cpp.2017] [PMID: 27098296]">Kramer 2016</a>; <a href="./references#CD012955-bbs2-0041" title="LaurenssenEM , WestraD , KikkertMJ , NoomMJ , EerenHV , Van BroekhuyzenAJ , et al. Day hospital mentalization-based treatment (MBT-DH) versus treatment as usual in the treatment of severe borderline personality disorder: protocol of a randomized controlled trial. BMC Psychiatry2014;14:149. [DOI: 10.1186/1471-244X-14-149] [PMC4045960] [PMID: 24886402]LaurenssenEMP , LuytenP , KikkertMJ , WestraD , PeenJ , SoonsMBJ , et al. Day hospital mentalization-based treatment v specialist treatment as usual in patients with borderline personality disorder: randomized controlled trial. Psychological Medicine2018;48(15):2522-9. [DOI: 10.1017/S0033291718000132] [PMID: 29478425]NL2058 (NTR2175). Mentalisation-based treatment versus care-as-usual in the treatment of severe borderline personality disorders. www.trialregister.nl/trial/2058 (first received 21 January 2010). ">Laurenssen 2018</a>; <a href="./references#CD012955-bbs2-0042" title="LeichsenringF , MasuhrO , JaegerU , RabungS , DallyA , DümpelmannM , et al. Psychoanalytic-interactional therapy versus psychodynamic therapy by experts for personality disorders: a randomized controlled efficacy-effectiveness study in cluster B personality disorders. Psychotherapy and Psychosomatics2016;85(2):71-80. [DOI: 10.1159/000441731] [PMID: 26808580]">Leichsenring 2016</a>; <a href="./references#CD012955-bbs2-0043" title="LeppänenV , HakkoH , SintonenH , LindemanS . Comparing effectiveness of treatments for borderline personality disorder in communal mental health care: the Oulu BPD study. Community Mental Health Journal2016;52(2):216-27. [DOI: 10.1007/s10597-015-9866-4] [PMID: 25824852]LeppänenV . Re: questions regarding the Oulu BPD study [personal communication]. Email to: E Faltinsen 20 December 2017. LeppänenV . Re: SV: question regarding the Oulu BPD study [personal communication]. Email to: EG Faltinsen 22 December 2017. ">Leppänen 2016</a>; <a href="./references#CD012955-bbs2-0045" title="HoffmanRE . Impact of treatment accessibility on clinical course of parasuicidal patients. Archives of General Psychiatry1993;50(2):157-8. [DOI: 10.1001/archpsyc.1993.01820140083010] [PMID: 8427557]LindenboimN . To Know Me is to Keep Me: Self-Verification, Validation, and Therapy Dropout in the Treatment of Borderline Personality Disorder [PhD thesis]. Washington (DC): University of Washington, 2009. LinehanMM , ArmstrongHE , SuarezA , AllmonD , HeardHL . Cognitive-behavioral treatment of chronically parasuicidal borderline patients. Archives of General Psychiatry1991;48(12):1060-4. [DOI: 10.1001/archpsyc.1991.01810360024003] [PMID: 1845222]LinehanMM , HeardHL . Impact of treatment accessibility on clinical course of parasuicidal patients — reply. Archives of General Psychiatry1993;50(2):157-8. [DOI: 10.1001/archpsyc.1993.01820140083011]">Linehan 1991</a>; <a href="./references#CD012955-bbs2-0046" title="HeardHL . Cost-Effectiveness of Dialectical Behavior Therapy in the Treatment of Borderline Personality Disorder [PhD thesis]. Washington (DC): University of Washington, 2000. LindenboimN . To Know Me is to Keep Me: Self-Verification, Validation, and Therapy Dropout in the Treatment of Borderline Personality Disorder [PhD thesis]. Washington (DC): University of Washington, 2009. LinehanMM , HeardHL , ArmstrongHE . Naturalistic follow-up of a behavioral treatment for chronically parasuicidal borderline patients. Archives of General Psychiatry1993;50(12):971-4. [DOI: 10.1001/archpsyc.1993.01820240055007] [PMID: 8250683]LinehanMM , TutekDA , HeardHL , ArmstrongHE . Interpersonal outcome of cognitive behavioral treatment for chronically suicidal borderline patients. American Journal of Psychiatry1994;151(12):1771-6. [DOI: 10.1176/ajp.151.12.1771] [PMID: 7977884]">Linehan 1994</a>; <a href="./references#CD012955-bbs2-0047" title="BedicsJD , AtkinsDC , ComtoisKA , LinehanMM . Treatment differences in the therapeutic relationship and introject during a 2-year randomized controlled trial of dialectical behavior therapy versus nonbehavioral psychotherapy experts for borderline personality disorder. Journal of Consulting and Clinical Psychology2012;80(1):66-77. [DOI: 10.1037/a0026113] [PMC3265694] [PMID: 22061867]BedicsJD , AtkinsDC , ComtoisKA , LinehanMM . Weekly therapist ratings of the therapeutic relationship and patient introject furing the course of dialectical behavioral therapy for the treatment of borderline personality disorder. Psychotherapy2012;49(2):231-40. [DOI: 10.1037/a0028254] [PMID: 22642526]BedicsJD , AtkinsDC , HarnedMS , LinehanMM . The therapeutic alliance as a predictor of outcome in dialectical behavior therapy versus nonbehavioral psychotherapy by experts for borderline personality disorder. Psychotherapy2015;52(1):67-77. [DOI: 10.1037/a0038457] [PMID: 25751116]BrownMZ , LinehanMM , ComtoisKA , MurrayA , ChapmanAL . Shame as a prospective predictor of self-inflicted injury in borderline personality disorder: a multi-modal analysis. Behaviour Research and Therapy2009;47(10):815-22. [DOI: 10.1016/j.brat.2009.06.008] [PMC2761705] [PMID: 19596223 ]CoyleTN , ShaverJA , LinehanMM . On the potential for iatrogenic effects of psychiatric crisis services: the example of dialectical behavior therapy for adult women with borderline personality disorder. Journal of Consulting and Clinical Psychology2018;86(2):116-24. [DOI: 10.1037/ccp0000275] [PMID: 29369662]HarnedMS , ChapmanAL , Dexter-MazzaET , MurrayA , ComtoisKA , LinehanMM . Treating co-occurring Axis I disorders in recurrently suicidal women with borderline personality disorder: a 2-year randomized trial of dialectical behavior therapy versus community treatment by experts. Journal of Consulting and Clinical Psychology2008;76(6):1068-75. [DOI: 10.1037/a0014044] [PMID: 19045974]HarnedMS , ChapmanAL , Dexter-MazzaET , MurrayA , ComtoisKA , LinehanMM . Treating co-occurring Axis I disorders in recurrently suicidal women with borderline personality disorder: a 2-year randomized trial of dialectical behavior therapy versus community treatment by experts. Personality Disorders: Theory, Research, and Treatment2009;S(1):35-45. [DOI: 10.1037/1949-2715.S.1.35]HarnedMS , JacksonSC , ComtoisKA , LinehanMM . Dialectical behavior therapy as a precursor to PTSD treatment for suicidal and/or self-injuring women with bordreline personality disorder. Journal of Traumatic Stress2010;23(4):421-9. [DOI: 10.1002/jts.20553] [PMID: 20648564]LindenboimN , ComtoisKA , LinehanMM . Skills practice in dialectical behavior therapy for suicidal women meeting criteria for borderline personality disorder. Cognitive and Behavioral Practice2007;14(2):147-56. [DOI: 10.1016/j.cbpra.2006.10.004]LinehanMM , ComtoisKA , MurrayAM , BrownMZ , GallopRJ , HeardHL , et al. Two-year randomized controlled trial and follow-up of dialectical behavior therapy vs therapy by experts for suicidal behaviors and borderline personality disorder. Archives of General Psychiatry2006;63(7):757-66. [DOI: 10.1001/archpsyc.63.7.757] [PMID: 16818865]LinehanMM . Error in table in: two-year randomized controlled trial and follow-up of dialectical behavior therapy vs therapy by experts for suicidal behaviors and borderline personality disorder. Archives of General Psychiatry2007;64(12):1401. Erratum for: Archives of General Psychiatry 2007;64(12):1401. McMainS . Dialectic behaviour therapy reduces suicide attempts compared with non-behavioural psychotherapy in women with borderline personality disorder. Evidence-Based Mental Health2007;10(1):18. [DOI: 10.1136/ebmh.10.1.18] [PMID: 17255387]NeacsiuAD , LunguA , HarnedMS , RizviSL , LinehanMM . Impact of dialectical behavior therapy versus community treatment by experts on emotional experience, expression, and acceptance in borderline personality disorder. Behaviour Research and Therapy2014;53:47-54. [DOI: 10.1016/j.brat.2013.12.004] [PMC3955205] [PMID: 24418652]NeacsiuAD , RizviSL , LinehanMM . Dialectical behavior therapy skills use as a mediator and outcome of treatment for borderline personality disorder. Behaviour Research and Therapy2010;48(9):832-9. [DOI: 10.1016/j.brat.2010.05.017] [PMC2914145] [PMID: 20579633]SecristCD . The Role of Executive Functioning in the Treatment of Borderline Personality Disorder [PhD thesis]. Washington (DC): University of Washington, 2014. ">Linehan 2006</a>; <a href="./references#CD012955-bbs2-0055" title="MortonJ , SnowdonS , GopoldM , GuymerE . Acceptance and commitment therapy group treatment for symptoms of borderline personality disorder: a public sector pilot study. Cognitive and Behavioral Practice2012;19(4):527-44. [DOI: 10.1016/j.cbpra.2012.03.005]MortonJ . Re: SV: regarding your study on acceptance and commitment therapy for BPD [personal communication]. Email to: EG Faltinsen 22 December 2017. ">Morton 2012</a>; <a href="./references#CD012955-bbs2-0058" title="PhilipsB , WennebergP , KonradssonP , FranckJ . Mentalization-based treatment for concurrent borderline personality disorder and substance use disorder: a randomized controlled feasibility study. European Addiction Research2018;24(1):1-8. [DOI: 10.1159/000485564] [PMC5969093] [PMID: 294028]">Philips 2018</a>; <a href="./references#CD012955-bbs2-0059" title="BarnicotK . Re: Regarding your study on DBT for self-harming patients [personal communication]. Email to: EG Faltinsen 28 February 2018. PriebeS , BhattiN , BarnicotK , BremnerS , GagliaA , KatsakouC , et al. Effectiveness and cost-effectiveness of dialectical behaviour therapy for self-harming patients with personality disorder: a pragmatic randomised controlled trial. Psychotherapy and Psychosomatics2012;81(6):356-65. [DOI: 10.1159/000338897] [PMID: 22964561]PriebeS . Supplemental information [personal communication]. Email to: M Kielsholm 20 May 2016. ">Priebe 2012</a>; <a href="./references#CD012955-bbs2-0060" title="RenesesB , FigueraD , SalcedoG , TrujilloM , López-IborJJ , GaliánM , et al. A controlled randomized study on the efficacy of short-term dinamic psychotherapy in borderline personality disorders (BPD). Preliminary results. European Psychiatry2011;26(Suppl 1):1040. [DOI: 10.1016/S0924-9338(11)72745-6] [P02-444]RenesesB , GaliánM , SerranoR , FigueraD , Fernandez Del MoralA , López-IborJJ , et al. A new time limited psychotherapy for BPD: preliminary results of a randomized and controlled trial. Actas Espanolas de Psiquiatria2013;41(3):139-48. [PMID: 23803797]">Reneses 2013</a>; <a href="./references#CD012955-bbs2-0061" title="ISRCTN51304415. Nice OUtcomes for Referrals with Impulsivity, Self Harm and Eating Disorders: the NOURISHED study [A randomised controlled trial of mentalisation based therapy against specialist supportive clinical management in patients with both eating disorders and symptoms of borderline personality disorder]. www.isrctn.com/ISRCTN51304415 (first received 31 January 2011). RobinsonP , BarrettB , BatemanA , HakeemA , HellierJ , LemonskyF , et al. Study protocol for a randomized controlled trial of mentalization based therapy against specialist supportive clinical management in patients with both eating disorders and symptoms of borderline personality disorder. BMC Psychiatry2014;14:51. [DOI: 10.1186/1471-244X-14-51] [PMC3996076] [PMID: 24555511]RobinsonP , HellierJ , BarrettB , BarzdaitieneD , BatemanA , BogaardtA , et al. The NOURISHED randomised controlled trial comparing mentalisation-based treatment for eating disorders (MBT-ED) with specialist supportive clinical management (SSCM-ED) for patients with eating disorders and symptoms of borderline personality disorder. Trials2016;17(1):549. [DOI: 10.1186/s13063-016-1606-8] [PMC5114835] [PMID: 27855714]">Robinson 2016</a>; <a href="./references#CD012955-bbs2-0062" title="ISRCTN95266816. The emergence of personality disorder traits in adolescents who deliberately self harm and the potential for using a mentalisation based treatment approach as an early intervention for such individuals: a randomised controlled trial. www.isrctn.com/ISRCTN95266816 (first received 29 October 2007). RossouwT . Mentalisation based treatment for adolescents with self harm: an RCT. European Child &amp; Adolescent Psychiatry2015;24(1 Suppl):S113. [DOI: 10.1007%2Fs00787-015-0714-4.pdf] [W1-02-02]RossouwT . Self harm in adolescence, is MBT the answer?: an RCT. Adolescent Psychiatry2012;2(1):102. [DOI: 10.2174/2210676611202010077]RossouwTI , FonagyP . Mentalization-based treatment for self-harm in adolescents: a randomized controlled trial. Journal of the American Academy of Child and Adolescent Psychiatry2012;51(12):1304-13.e3. [DOI: 10.1016/j.jaac.2012.09.018] [PMID: 23200287]">Rossouw 2012b</a>; <a href="./references#CD012955-bbs2-0070" title="FertuckEA , KeilpJ , SongI , MorrisMC , WilsonST , BrodskyBS , et al. Higher executive control and visual memory performance predict treatment completion in borderline personality disorder. Psychotherapy and Psychosomatics2012;81(1):38-43. [DOI: 10.1159/000329700] [PMC3242704] [PMID: 22116411]NCT00533117. Treating suicidal behavior and self-mutilation in people with borderline personality disorder. www.clinicaltrials.gov/ct2/show/NCT00533117 (first received 19 September 2007). ">Stanley 2017</a>; <a href="./references#CD012955-bbs2-0072" title="Van den BoschLM , KoeterMW , StijnenT , VerheulR , Van den BrinkW . Sustained efficacy of dialectical behaviour therapy for borderline personality disorder. Behaviour Research and Therapy2005;43(9):1231-41. [DOI: 10.1016/j.brat.2004.09.008] [PMID: 16005708]Van den BoschLM , VerheulR , SchippersGM , Van den BrinkW . Dialectical behavior therapy of borderline patients with and without substance use problems. Implementation and long-term effects. Addictive Behaviors2002;27(6):911-23. [DOI: 10.1016/s0306-4603(02)00293-9] [PMID: 12369475]Van den BoschLMC . Efficacy of dialectical behaviour therapy in the treatment of female borderline patients with and without substance abuse problems: results of a Dutch study [Dialectische gedragstherapie bij Nederlandse vrouwen met een borderline persoonlijkheidsstoornis, met en zonder verslavingsproblemen]. Tijdschrift voor Psychiatrie2005;47(3):127-37. [www.tijdschriftvoorpsychiatrie.nl/assets/articles/articles_1335pdf.pdf]VerheulR , Van den BoschLM , KoeterMW , De RidderMA , StijnenT , Van den BrinkW . Dialectical behaviour therapy for women with borderline personality disorder: 12-month, randomised clinical trial in The Netherlands. British Journal of Psychiatry2003;182:135-40. [DOI: 10.1192/bjp.182.2.135] [PMID: 12562741]">Van den Bosch 2005</a>; <a href="./references#CD012955-bbs2-0075" title="ZanariniMC , ConkeyLC , TemesCM , FitzmauriceGM . Randomized controlled trial of web-based psychoeducation for women with borderline personality disorder. Journal of Clinical Psychiatry2018;79(3):16m11153. [DOI: 10.4088/JCP.16m11153] [PMC5764827] [PMID: 28703950]">Zanarini 2018</a>). </p> <p>Generally, psychotherapy did not reduce attrition at end of treatment compared with TAU (RR 1.00, 95% CI 0.83 to 1.20; 32 trials, 2225 participants; I<sup>2</sup> = 50%; P = 0.98; <a href="./references#CD012955-fig-0022" title="">Analysis 1.19</a>.1; low‐quality evidence, <a href="./full#CD012955-tbl-0001">summary of findings Table 1</a>). </p> <p>Generally, psychotherapy reduced attrition at zero to six months follow‐up compared with TAU (RR 0.58, 95% CI 0.34 to 1.00; 1 trial, 60 participants; P = 0.05; <a href="./references#CD012955-fig-0170" title="">Analysis 19.2</a>.2). </p> <p>No data were available for six to 12 months and above 12 months follow‐up.</p> </section> <section id="CD012955-sec-0099"> <h6 class="title">1.20 Non‐serious adverse effects</h6> <p>Two trials reported dichotomous data on non‐adverse effects (<a href="./references#CD012955-bbs2-0051" title="McMurranM , CrawfordMJ , ReillyJ , DelportJ , McCroneP , WhithamD , et al. Psychoeducation with problem-solving (PEPS) therapy for adults with personality disorder: a pragmatic randomised controlled trial to determine the clinical effectiveness and cost-effectiveness of a manualised intervention to improve social functioning. Health Technology Assessment2016;20(52):1-282. [DOI: 10.3310/hta20520]McMurranM . RE: Cochrane Collaboration review - PEPS study [personal communication]. Email to: J Stoffers-Winterling 5 July 2018. McMurranM . Request for data on BPD subjects in the PEPS rcp-study for use a new Cochrane review [personal communication]. Email to: M Kongerslev 7 March 2017. ">McMurran 2016</a>; <a href="./references#CD012955-bbs2-0070" title="FertuckEA , KeilpJ , SongI , MorrisMC , WilsonST , BrodskyBS , et al. Higher executive control and visual memory performance predict treatment completion in borderline personality disorder. Psychotherapy and Psychosomatics2012;81(1):38-43. [DOI: 10.1159/000329700] [PMC3242704] [PMID: 22116411]NCT00533117. Treating suicidal behavior and self-mutilation in people with borderline personality disorder. www.clinicaltrials.gov/ct2/show/NCT00533117 (first received 19 September 2007). ">Stanley 2017</a>). </p> <p>There was no clear difference in the number of serious adverse effects between psychotherapy and TAU at end of treatment (RR 0.92, 95% CI 0.45 to 1.88; 2 trials, 381 participants, P = 0.81; <a href="./references#CD012955-fig-0023" title="">Analysis 1.20</a>.1; low‐quality evidence, <a href="./full#CD012955-tbl-0001">summary of findings Table 1</a>). </p> <p>There was no clear difference in the number of adverse effects between psychotherapy and TAU at zero to six months follow‐up (RR 1.40, 95% CI 0.06 to 30.23; 1 trial, 20 participants; P = 0.83; <a href="./references#CD012955-fig-0023" title="">Analysis 1.20</a>.2). </p> <p>TAU reduced adverse effects compared with psychotherapy at above 12 months follow‐up (RR 1.68, 95% CI 1.34 to 2.10; 1 trial, 183 participants; P &lt; 0.001; <a href="./references#CD012955-fig-0023" title="">Analysis 1.20</a>.3). </p> <p>No data were available for six to 12 months follow‐up.</p> </section> <section id="CD012955-sec-0100"> <h6 class="title">1.21 Serious adverse effects</h6> <p>Five trials reported dichotomous data on serious adverse effects (<a href="./references#CD012955-bbs2-0002" title='AndreoliA , BurnandY , CochennecMF , MarieD , Di ClementeT , OhlendorfP . Psychoanalytic psychotherapy and venlafaxine among acutely suicidal borderline patients: a randomized clinical study. European Psychiatry2009;24(Suppl 1):S93. [DOI: 10.1016/S0924-9338(09)70326-8] [S18-03]AndreoliA , BurnandY , CochennecMF , OhlendorfP , FrambatiL , Gaudry-MaireD , et al. Disappointed love and suicide: a randomized controlled trial of "abandonment psychotherapy" among borderline patients. Journal of Personality Disorders2016;30(2):271-87. [DOI: 10.1521/pedi_2015_29_196] [PMID: 26111250]AndreoliA , BurnandY , FrambatiL , ManningD , FrancesA . Abandonment psychotherapy and psychosocial functioning among suicidal patients with borderline personality disorder: a 3-year naturalistic follow-up. Journal of Personality Disorders 2019 Feb 20 [Epub ahead of print]. [DOI: 10.1521/pedi_2019_33_423] [PMID: 30785852]AndreoliA . Re: your study in BPD - Cochrane Collaboration review [personal communication]. Email to: J Stoffers-Winterling 5 June 2018. '>Andreoli 2016</a>; <a href="./references#CD012955-bbs2-0018" title="DavidsonKM , BrownTM , JamesV , KirkJ , RichardsonJ . Manual-assisted cognitive therapy for self-harm in personality disorder and substance misuse: a feasibility trial. Psychiatric Bulletin2014;38(3):108-11. [DOI: 10.1192/pb.bp.113.043109] [PMC4115373] [PMID: 25237519]DavidsonKM . Re: question regarding your trial on manual-assisted cognitive therapy [personal communication]. Email to: EG Faltinsen 28 November 2017. ">Davidson 2014</a>; <a href="./references#CD012955-bbs2-0051" title="McMurranM , CrawfordMJ , ReillyJ , DelportJ , McCroneP , WhithamD , et al. Psychoeducation with problem-solving (PEPS) therapy for adults with personality disorder: a pragmatic randomised controlled trial to determine the clinical effectiveness and cost-effectiveness of a manualised intervention to improve social functioning. Health Technology Assessment2016;20(52):1-282. [DOI: 10.3310/hta20520]McMurranM . RE: Cochrane Collaboration review - PEPS study [personal communication]. Email to: J Stoffers-Winterling 5 July 2018. McMurranM . Request for data on BPD subjects in the PEPS rcp-study for use a new Cochrane review [personal communication]. Email to: M Kongerslev 7 March 2017. ">McMurran 2016</a>; <a href="./references#CD012955-bbs2-0061" title="ISRCTN51304415. Nice OUtcomes for Referrals with Impulsivity, Self Harm and Eating Disorders: the NOURISHED study [A randomised controlled trial of mentalisation based therapy against specialist supportive clinical management in patients with both eating disorders and symptoms of borderline personality disorder]. www.isrctn.com/ISRCTN51304415 (first received 31 January 2011). RobinsonP , BarrettB , BatemanA , HakeemA , HellierJ , LemonskyF , et al. Study protocol for a randomized controlled trial of mentalization based therapy against specialist supportive clinical management in patients with both eating disorders and symptoms of borderline personality disorder. BMC Psychiatry2014;14:51. [DOI: 10.1186/1471-244X-14-51] [PMC3996076] [PMID: 24555511]RobinsonP , HellierJ , BarrettB , BarzdaitieneD , BatemanA , BogaardtA , et al. The NOURISHED randomised controlled trial comparing mentalisation-based treatment for eating disorders (MBT-ED) with specialist supportive clinical management (SSCM-ED) for patients with eating disorders and symptoms of borderline personality disorder. Trials2016;17(1):549. [DOI: 10.1186/s13063-016-1606-8] [PMC5114835] [PMID: 27855714]">Robinson 2016</a>; <a href="./references#CD012955-bbs2-0070" title="FertuckEA , KeilpJ , SongI , MorrisMC , WilsonST , BrodskyBS , et al. Higher executive control and visual memory performance predict treatment completion in borderline personality disorder. Psychotherapy and Psychosomatics2012;81(1):38-43. [DOI: 10.1159/000329700] [PMC3242704] [PMID: 22116411]NCT00533117. Treating suicidal behavior and self-mutilation in people with borderline personality disorder. www.clinicaltrials.gov/ct2/show/NCT00533117 (first received 19 September 2007). ">Stanley 2017</a>). </p> <p>There was no clear difference in the number of serious adverse effects between psychotherapy and TAU at end of treatment ( RR 0.86, 95% CI 0.14 to 5.09; 4 trials, 571 participants, I<sup>2</sup> = 46%, P = 0.86; <a href="./references#CD012955-fig-0024" title="">Analysis 1.21</a>). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months.</p> </section> </section> </section> <section id="CD012955-sec-0101"> <h4 class="title">2. Acceptance and commitment therapy (ACT) versus treatment‐as‐usual (TAU)</h4> <section id="CD012955-sec-0102"> <h5 class="title">2.1 Primary outcome: BPD symptom severity</h5> <p>One trial reported continuous data on BPD symptom severity (<a href="./references#CD012955-bbs2-0055" title="MortonJ , SnowdonS , GopoldM , GuymerE . Acceptance and commitment therapy group treatment for symptoms of borderline personality disorder: a public sector pilot study. Cognitive and Behavioral Practice2012;19(4):527-44. [DOI: 10.1016/j.cbpra.2012.03.005]MortonJ . Re: SV: regarding your study on acceptance and commitment therapy for BPD [personal communication]. Email to: EG Faltinsen 22 December 2017. ">Morton 2012</a>). </p> <p>ACT reduced BPD symptom severity at end of treatment compared with TAU (MD −14.66, 95% CI −21.85 to −7.47; 1 trial, 41 participants; P &lt; 0.001; <a href="./references#CD012955-fig-0025" title="">Analysis 2.1</a>). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> <p>No data were available at any time point for self‐harm, suicide‐related outcomes, and psychosocial functioning. </p> </section> <section id="CD012955-sec-0103"> <h5 class="title">Secondary outcomes</h5> <section id="CD012955-sec-0104"> <h6 class="title">2.2 Affective instability</h6> <p>One trial reported continuous data on affective instability (<a href="./references#CD012955-bbs2-0055" title="MortonJ , SnowdonS , GopoldM , GuymerE . Acceptance and commitment therapy group treatment for symptoms of borderline personality disorder: a public sector pilot study. Cognitive and Behavioral Practice2012;19(4):527-44. [DOI: 10.1016/j.cbpra.2012.03.005]MortonJ . Re: SV: regarding your study on acceptance and commitment therapy for BPD [personal communication]. Email to: EG Faltinsen 22 December 2017. ">Morton 2012</a>). </p> <p>ACT reduced affective instability at end of treatment compared with TAU (MD −27.00, 95% CI −38.86 to −15.14; 1 trial, 41 participants; P &lt; 0.001; <a href="./references#CD012955-fig-0026" title="">Analysis 2.2</a>). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> </section> <section id="CD012955-sec-0105"> <h6 class="title">2.3 Depression</h6> <p>One trial reported continuous data on depression (<a href="./references#CD012955-bbs2-0055" title="MortonJ , SnowdonS , GopoldM , GuymerE . Acceptance and commitment therapy group treatment for symptoms of borderline personality disorder: a public sector pilot study. Cognitive and Behavioral Practice2012;19(4):527-44. [DOI: 10.1016/j.cbpra.2012.03.005]MortonJ . Re: SV: regarding your study on acceptance and commitment therapy for BPD [personal communication]. Email to: EG Faltinsen 22 December 2017. ">Morton 2012</a>). </p> <p>ACT reduced depression at end of treatment compared with TAU (MD −8.33, 95% CI −15.65 to −1.01; 1 trial, 41 participants; P = 0.03; <a href="./references#CD012955-fig-0027" title="">Analysis 2.3</a>). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> </section> <section id="CD012955-sec-0106"> <h6 class="title">2.4 Attrition</h6> <p>One trial reported dichotomous data on attrition (<a href="./references#CD012955-bbs2-0055" title="MortonJ , SnowdonS , GopoldM , GuymerE . Acceptance and commitment therapy group treatment for symptoms of borderline personality disorder: a public sector pilot study. Cognitive and Behavioral Practice2012;19(4):527-44. [DOI: 10.1016/j.cbpra.2012.03.005]MortonJ . Re: SV: regarding your study on acceptance and commitment therapy for BPD [personal communication]. Email to: EG Faltinsen 22 December 2017. ">Morton 2012</a>). </p> <p>ACT did not reduce attrition at end of treatment compared with TAU (RR 1.11, 95% CI 0.45 to 2.74; 1 trial, 41 participants; P = 0.82; <a href="./references#CD012955-fig-0028" title="">Analysis 2.4</a>). </p> <p>No data were available for zero to months, six to 12 months and above 12 months follow‐up.</p> <p>No data were available on any time point for anger, chronic feelings of emptiness, impulsivity, interpersonal problems, identity disturbance, dissociation and psychotic‐like symptoms and adverse effects. </p> </section> </section> </section> <section id="CD012955-sec-0107"> <h4 class="title">3. Dialectical behaviour therapy (DBT) versus treatment‐as‐usual (TAU)</h4> <section id="CD012955-sec-0108"> <h5 class="title">Primary outcomes</h5> <section id="CD012955-sec-0109"> <h6 class="title">3.1 BPD symptom severity</h6> <p>Three trials reported continuous data on BPD symptom severity (<a href="./references#CD012955-bbs2-0035" title="KoonsCR , RobinsCJ , TweedJL , LynchTR , GonzalezAM , MorseJQ , et al. Efficacy of dialectical behavior therapy in women veterans with borderline personality disorder. Behavior Therapy2001;32(2):371-90. [DOI: 10.1016/S0005-7894(01)80009-5]">Koons 2001a</a>; <a href="./references#CD012955-bbs2-0059" title="BarnicotK . Re: Regarding your study on DBT for self-harming patients [personal communication]. Email to: EG Faltinsen 28 February 2018. PriebeS , BhattiN , BarnicotK , BremnerS , GagliaA , KatsakouC , et al. Effectiveness and cost-effectiveness of dialectical behaviour therapy for self-harming patients with personality disorder: a pragmatic randomised controlled trial. Psychotherapy and Psychosomatics2012;81(6):356-65. [DOI: 10.1159/000338897] [PMID: 22964561]PriebeS . Supplemental information [personal communication]. Email to: M Kielsholm 20 May 2016. ">Priebe 2012</a>; <a href="./references#CD012955-bbs2-0069" title="SolerJ , PascualJC , TianaT , CebriàA , BarrachinaJ , CampinsMJ , et al. Dialectical behaviour therapy skills training compared to standard group therapy in borderline personality disorder: a 3-month randomised controlled clinical trial. Behaviour Research and Therapy2009;47(5):353-8. [DOI: 10.1016/j.brat.2009.01.013] [PMID: 19246029]SolerJ . Question regarding your BPD trials [personal communication]. Email to: J Stoffers 15 December 2010. ">Soler 2009</a>). </p> <p>DBT reduced BPD symptom severity at end of treatment compared with TAU (SMD −0.60, 95% CI −1.05 to −0.14; 3 trials, 149 participants; I<sup>2</sup> = 42%; P = 0.01; <a href="./references#CD012955-fig-0029" title="">Analysis 3.1</a>; low‐quality evidence, <a href="./full#CD012955-tbl-0003">summary of findings Table 3</a>). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> </section> <section id="CD012955-sec-0110"> <h6 class="title">3.2 Self‐harm</h6> <p>Seven trials reported continuous data on self‐harm (<a href="./references#CD012955-bbs2-0015" title="CarterG . Question regarding your BPD trial [personal communication]. Email to: J Stoffers 21 December 2010. CarterGL , WillcoxCH , LewinTJ , ConradAM , BenditN . Hunter DBT project: randomized controlled trial of dialectical behaviour therapy in women with borderline personality disorder. Australian and New Zealand Journal of Psychiatry2010;44(2):162-73. [DOI: 10.3109/00048670903393621] [PMID: 20113305]">Carter 2010</a>; <a href="./references#CD012955-bbs2-0022" title="FeigenbaumJD , FonagyP , PillingS , JonesA , WildgooseA , BebbingtonPE . A real-world study of the effectiveness of DBT in the UK National Health Service. British Journal of Clinical Psychology2012;51(2):121-41. [DOI: 10.1111/j.2044-8260.2011.02017.x] [PMID: 22574799]">Feigenbaum 2012</a>; <a href="./references#CD012955-bbs2-0035" title="KoonsCR , RobinsCJ , TweedJL , LynchTR , GonzalezAM , MorseJQ , et al. Efficacy of dialectical behavior therapy in women veterans with borderline personality disorder. Behavior Therapy2001;32(2):371-90. [DOI: 10.1016/S0005-7894(01)80009-5]">Koons 2001a</a>; <a href="./references#CD012955-bbs2-0045" title="HoffmanRE . Impact of treatment accessibility on clinical course of parasuicidal patients. Archives of General Psychiatry1993;50(2):157-8. [DOI: 10.1001/archpsyc.1993.01820140083010] [PMID: 8427557]LindenboimN . To Know Me is to Keep Me: Self-Verification, Validation, and Therapy Dropout in the Treatment of Borderline Personality Disorder [PhD thesis]. Washington (DC): University of Washington, 2009. LinehanMM , ArmstrongHE , SuarezA , AllmonD , HeardHL . Cognitive-behavioral treatment of chronically parasuicidal borderline patients. Archives of General Psychiatry1991;48(12):1060-4. [DOI: 10.1001/archpsyc.1991.01810360024003] [PMID: 1845222]LinehanMM , HeardHL . Impact of treatment accessibility on clinical course of parasuicidal patients — reply. Archives of General Psychiatry1993;50(2):157-8. [DOI: 10.1001/archpsyc.1993.01820140083011]">Linehan 1991</a>; <a href="./references#CD012955-bbs2-0047" title="BedicsJD , AtkinsDC , ComtoisKA , LinehanMM . Treatment differences in the therapeutic relationship and introject during a 2-year randomized controlled trial of dialectical behavior therapy versus nonbehavioral psychotherapy experts for borderline personality disorder. Journal of Consulting and Clinical Psychology2012;80(1):66-77. [DOI: 10.1037/a0026113] [PMC3265694] [PMID: 22061867]BedicsJD , AtkinsDC , ComtoisKA , LinehanMM . Weekly therapist ratings of the therapeutic relationship and patient introject furing the course of dialectical behavioral therapy for the treatment of borderline personality disorder. Psychotherapy2012;49(2):231-40. [DOI: 10.1037/a0028254] [PMID: 22642526]BedicsJD , AtkinsDC , HarnedMS , LinehanMM . The therapeutic alliance as a predictor of outcome in dialectical behavior therapy versus nonbehavioral psychotherapy by experts for borderline personality disorder. Psychotherapy2015;52(1):67-77. [DOI: 10.1037/a0038457] [PMID: 25751116]BrownMZ , LinehanMM , ComtoisKA , MurrayA , ChapmanAL . Shame as a prospective predictor of self-inflicted injury in borderline personality disorder: a multi-modal analysis. Behaviour Research and Therapy2009;47(10):815-22. [DOI: 10.1016/j.brat.2009.06.008] [PMC2761705] [PMID: 19596223 ]CoyleTN , ShaverJA , LinehanMM . On the potential for iatrogenic effects of psychiatric crisis services: the example of dialectical behavior therapy for adult women with borderline personality disorder. Journal of Consulting and Clinical Psychology2018;86(2):116-24. [DOI: 10.1037/ccp0000275] [PMID: 29369662]HarnedMS , ChapmanAL , Dexter-MazzaET , MurrayA , ComtoisKA , LinehanMM . Treating co-occurring Axis I disorders in recurrently suicidal women with borderline personality disorder: a 2-year randomized trial of dialectical behavior therapy versus community treatment by experts. Journal of Consulting and Clinical Psychology2008;76(6):1068-75. [DOI: 10.1037/a0014044] [PMID: 19045974]HarnedMS , ChapmanAL , Dexter-MazzaET , MurrayA , ComtoisKA , LinehanMM . Treating co-occurring Axis I disorders in recurrently suicidal women with borderline personality disorder: a 2-year randomized trial of dialectical behavior therapy versus community treatment by experts. Personality Disorders: Theory, Research, and Treatment2009;S(1):35-45. [DOI: 10.1037/1949-2715.S.1.35]HarnedMS , JacksonSC , ComtoisKA , LinehanMM . Dialectical behavior therapy as a precursor to PTSD treatment for suicidal and/or self-injuring women with bordreline personality disorder. Journal of Traumatic Stress2010;23(4):421-9. [DOI: 10.1002/jts.20553] [PMID: 20648564]LindenboimN , ComtoisKA , LinehanMM . Skills practice in dialectical behavior therapy for suicidal women meeting criteria for borderline personality disorder. Cognitive and Behavioral Practice2007;14(2):147-56. [DOI: 10.1016/j.cbpra.2006.10.004]LinehanMM , ComtoisKA , MurrayAM , BrownMZ , GallopRJ , HeardHL , et al. Two-year randomized controlled trial and follow-up of dialectical behavior therapy vs therapy by experts for suicidal behaviors and borderline personality disorder. Archives of General Psychiatry2006;63(7):757-66. [DOI: 10.1001/archpsyc.63.7.757] [PMID: 16818865]LinehanMM . Error in table in: two-year randomized controlled trial and follow-up of dialectical behavior therapy vs therapy by experts for suicidal behaviors and borderline personality disorder. Archives of General Psychiatry2007;64(12):1401. Erratum for: Archives of General Psychiatry 2007;64(12):1401. McMainS . Dialectic behaviour therapy reduces suicide attempts compared with non-behavioural psychotherapy in women with borderline personality disorder. Evidence-Based Mental Health2007;10(1):18. [DOI: 10.1136/ebmh.10.1.18] [PMID: 17255387]NeacsiuAD , LunguA , HarnedMS , RizviSL , LinehanMM . Impact of dialectical behavior therapy versus community treatment by experts on emotional experience, expression, and acceptance in borderline personality disorder. Behaviour Research and Therapy2014;53:47-54. [DOI: 10.1016/j.brat.2013.12.004] [PMC3955205] [PMID: 24418652]NeacsiuAD , RizviSL , LinehanMM . Dialectical behavior therapy skills use as a mediator and outcome of treatment for borderline personality disorder. Behaviour Research and Therapy2010;48(9):832-9. [DOI: 10.1016/j.brat.2010.05.017] [PMC2914145] [PMID: 20579633]SecristCD . The Role of Executive Functioning in the Treatment of Borderline Personality Disorder [PhD thesis]. Washington (DC): University of Washington, 2014. ">Linehan 2006</a>; <a href="./references#CD012955-bbs2-0059" title="BarnicotK . Re: Regarding your study on DBT for self-harming patients [personal communication]. Email to: EG Faltinsen 28 February 2018. PriebeS , BhattiN , BarnicotK , BremnerS , GagliaA , KatsakouC , et al. Effectiveness and cost-effectiveness of dialectical behaviour therapy for self-harming patients with personality disorder: a pragmatic randomised controlled trial. Psychotherapy and Psychosomatics2012;81(6):356-65. [DOI: 10.1159/000338897] [PMID: 22964561]PriebeS . Supplemental information [personal communication]. Email to: M Kielsholm 20 May 2016. ">Priebe 2012</a>; <a href="./references#CD012955-bbs2-0072" title="Van den BoschLM , KoeterMW , StijnenT , VerheulR , Van den BrinkW . Sustained efficacy of dialectical behaviour therapy for borderline personality disorder. Behaviour Research and Therapy2005;43(9):1231-41. [DOI: 10.1016/j.brat.2004.09.008] [PMID: 16005708]Van den BoschLM , VerheulR , SchippersGM , Van den BrinkW . Dialectical behavior therapy of borderline patients with and without substance use problems. Implementation and long-term effects. Addictive Behaviors2002;27(6):911-23. [DOI: 10.1016/s0306-4603(02)00293-9] [PMID: 12369475]Van den BoschLMC . Efficacy of dialectical behaviour therapy in the treatment of female borderline patients with and without substance abuse problems: results of a Dutch study [Dialectische gedragstherapie bij Nederlandse vrouwen met een borderline persoonlijkheidsstoornis, met en zonder verslavingsproblemen]. Tijdschrift voor Psychiatrie2005;47(3):127-37. [www.tijdschriftvoorpsychiatrie.nl/assets/articles/articles_1335pdf.pdf]VerheulR , Van den BoschLM , KoeterMW , De RidderMA , StijnenT , Van den BrinkW . Dialectical behaviour therapy for women with borderline personality disorder: 12-month, randomised clinical trial in The Netherlands. British Journal of Psychiatry2003;182:135-40. [DOI: 10.1192/bjp.182.2.135] [PMID: 12562741]">Van den Bosch 2005</a>). </p> <p>DBT reduced self‐harm at end of treatment compared with TAU (SMD −0.28, 95% CI −0.48 to −0.07; 7 trials, 376 participants; I<sup>2</sup> = 0%; P = 0.008; <a href="./references#CD012955-fig-0030" title="">Analysis 3.2</a>.1; low‐quality evidence, <a href="./full#CD012955-tbl-0003">summary of findings Table 3</a>). </p> <p>DBT did not reduce self‐harm at six to 12 months follow‐up compared with TAU (SMD −0.26, 95% CI −0.59 to 0.07; 2 trials, 141 participants; I<sup>2</sup> = 0%; P = 0.13; <a href="./references#CD012955-fig-0030" title="">Analysis 3.2</a>.2). </p> <p>No data were available for zero to six months and above 12 months follow‐up.</p> </section> <section id="CD012955-sec-0111"> <h6 class="title">3.3 Suicide‐related outcomes</h6> <p>Five trials reported continuous data on suicide‐related outcomes (<a href="./references#CD012955-bbs2-0022" title="FeigenbaumJD , FonagyP , PillingS , JonesA , WildgooseA , BebbingtonPE . A real-world study of the effectiveness of DBT in the UK National Health Service. British Journal of Clinical Psychology2012;51(2):121-41. [DOI: 10.1111/j.2044-8260.2011.02017.x] [PMID: 22574799]">Feigenbaum 2012</a>; <a href="./references#CD012955-bbs2-0035" title="KoonsCR , RobinsCJ , TweedJL , LynchTR , GonzalezAM , MorseJQ , et al. Efficacy of dialectical behavior therapy in women veterans with borderline personality disorder. Behavior Therapy2001;32(2):371-90. [DOI: 10.1016/S0005-7894(01)80009-5]">Koons 2001a</a>; <a href="./references#CD012955-bbs2-0047" title="BedicsJD , AtkinsDC , ComtoisKA , LinehanMM . Treatment differences in the therapeutic relationship and introject during a 2-year randomized controlled trial of dialectical behavior therapy versus nonbehavioral psychotherapy experts for borderline personality disorder. Journal of Consulting and Clinical Psychology2012;80(1):66-77. [DOI: 10.1037/a0026113] [PMC3265694] [PMID: 22061867]BedicsJD , AtkinsDC , ComtoisKA , LinehanMM . Weekly therapist ratings of the therapeutic relationship and patient introject furing the course of dialectical behavioral therapy for the treatment of borderline personality disorder. Psychotherapy2012;49(2):231-40. [DOI: 10.1037/a0028254] [PMID: 22642526]BedicsJD , AtkinsDC , HarnedMS , LinehanMM . The therapeutic alliance as a predictor of outcome in dialectical behavior therapy versus nonbehavioral psychotherapy by experts for borderline personality disorder. Psychotherapy2015;52(1):67-77. [DOI: 10.1037/a0038457] [PMID: 25751116]BrownMZ , LinehanMM , ComtoisKA , MurrayA , ChapmanAL . Shame as a prospective predictor of self-inflicted injury in borderline personality disorder: a multi-modal analysis. Behaviour Research and Therapy2009;47(10):815-22. [DOI: 10.1016/j.brat.2009.06.008] [PMC2761705] [PMID: 19596223 ]CoyleTN , ShaverJA , LinehanMM . On the potential for iatrogenic effects of psychiatric crisis services: the example of dialectical behavior therapy for adult women with borderline personality disorder. Journal of Consulting and Clinical Psychology2018;86(2):116-24. [DOI: 10.1037/ccp0000275] [PMID: 29369662]HarnedMS , ChapmanAL , Dexter-MazzaET , MurrayA , ComtoisKA , LinehanMM . Treating co-occurring Axis I disorders in recurrently suicidal women with borderline personality disorder: a 2-year randomized trial of dialectical behavior therapy versus community treatment by experts. Journal of Consulting and Clinical Psychology2008;76(6):1068-75. [DOI: 10.1037/a0014044] [PMID: 19045974]HarnedMS , ChapmanAL , Dexter-MazzaET , MurrayA , ComtoisKA , LinehanMM . Treating co-occurring Axis I disorders in recurrently suicidal women with borderline personality disorder: a 2-year randomized trial of dialectical behavior therapy versus community treatment by experts. Personality Disorders: Theory, Research, and Treatment2009;S(1):35-45. [DOI: 10.1037/1949-2715.S.1.35]HarnedMS , JacksonSC , ComtoisKA , LinehanMM . Dialectical behavior therapy as a precursor to PTSD treatment for suicidal and/or self-injuring women with bordreline personality disorder. Journal of Traumatic Stress2010;23(4):421-9. [DOI: 10.1002/jts.20553] [PMID: 20648564]LindenboimN , ComtoisKA , LinehanMM . Skills practice in dialectical behavior therapy for suicidal women meeting criteria for borderline personality disorder. Cognitive and Behavioral Practice2007;14(2):147-56. [DOI: 10.1016/j.cbpra.2006.10.004]LinehanMM , ComtoisKA , MurrayAM , BrownMZ , GallopRJ , HeardHL , et al. Two-year randomized controlled trial and follow-up of dialectical behavior therapy vs therapy by experts for suicidal behaviors and borderline personality disorder. Archives of General Psychiatry2006;63(7):757-66. [DOI: 10.1001/archpsyc.63.7.757] [PMID: 16818865]LinehanMM . Error in table in: two-year randomized controlled trial and follow-up of dialectical behavior therapy vs therapy by experts for suicidal behaviors and borderline personality disorder. Archives of General Psychiatry2007;64(12):1401. Erratum for: Archives of General Psychiatry 2007;64(12):1401. McMainS . Dialectic behaviour therapy reduces suicide attempts compared with non-behavioural psychotherapy in women with borderline personality disorder. Evidence-Based Mental Health2007;10(1):18. [DOI: 10.1136/ebmh.10.1.18] [PMID: 17255387]NeacsiuAD , LunguA , HarnedMS , RizviSL , LinehanMM . Impact of dialectical behavior therapy versus community treatment by experts on emotional experience, expression, and acceptance in borderline personality disorder. Behaviour Research and Therapy2014;53:47-54. [DOI: 10.1016/j.brat.2013.12.004] [PMC3955205] [PMID: 24418652]NeacsiuAD , RizviSL , LinehanMM . Dialectical behavior therapy skills use as a mediator and outcome of treatment for borderline personality disorder. Behaviour Research and Therapy2010;48(9):832-9. [DOI: 10.1016/j.brat.2010.05.017] [PMC2914145] [PMID: 20579633]SecristCD . The Role of Executive Functioning in the Treatment of Borderline Personality Disorder [PhD thesis]. Washington (DC): University of Washington, 2014. ">Linehan 2006</a>; <a href="./references#CD012955-bbs2-0052" title="HagaE , AasE , GrøholtB , TørmoenAJ , MehlumL . Cost-effectiveness of dialectical behaviour therapy vs enhanced usual care in the treatment of adolescents with self-harm. Child and Adolescent Psychiatry and Mental Health2018;12:22. [DOI: 10.1186/s13034-018-0227-2] [PMC5928596] [PMID: 29743941]MehlumL , RambergM , TørmoenAJ , HagaE , DiepLM , StanleyBH , et al. Dialectical behavior therapy compared with enhanced usual care for adolescents with repeated suicidal and self-harming behavior: outcomes over a one-year follow-up. Journal of the American Academy of Child and Adolescent Psychiatry2016;55(4):295-300. [DOI: 10.1016/j.jaac.2016.01.005] [PMID: 27015720]MehlumL , TørmoenAJ , RambergM , HagaE , DiepLM , LabergS , et al. Dialectical behavior therapy for adolescents with repeated suicidal and self-harming behavior: a randomized trial. Journal of the American Academy of Child and Adolescent Psychiatry2014;53(10):1082-91. [DOI: 10.1016/j.jaac.2014.07.003] [PMID: 25245352]MehlumL . Re: regarding your study of DBT for your with suicidal behavior [personal communication] [Re: angående din studie om DBT for ungdom med selvmordsatferd [personlig kommunikation]]. Email to: E Faltinsen 5 December 2017. NCT00675129. Treatment for adolescents with deliberate self harm [A randomized controlled trial for repetitive deliberate self-harm and suicidal behaviours among Norwegian adolescents: a comparison between dialectical behaviour therapy adapted for adolescents (DBT-A) and enhanced usual care (EUC)]. www.clinicaltrials.gov/ct2/show/NCT00675129 (first received 6 May 2008). RamlethRK , GroholtB , DiepLM , WalbyFA , MehlumL . The impact of borderline personality disorder and sub-threshold borderline personality disorder on the course of self-reported and clinician-rated depression in self-harming adolescents. Borderline Personality Disorder and Emotion Dysregulation2017;4:22. [DOI: 10.1186/s40479-017-0073-5] [PMC5663078] [PMID: 29093819]">Mehlum 2014</a>; <a href="./references#CD012955-bbs2-0069" title="SolerJ , PascualJC , TianaT , CebriàA , BarrachinaJ , CampinsMJ , et al. Dialectical behaviour therapy skills training compared to standard group therapy in borderline personality disorder: a 3-month randomised controlled clinical trial. Behaviour Research and Therapy2009;47(5):353-8. [DOI: 10.1016/j.brat.2009.01.013] [PMID: 19246029]SolerJ . Question regarding your BPD trials [personal communication]. Email to: J Stoffers 15 December 2010. ">Soler 2009</a>). </p> <p>DBT did not reduce suicide‐related outcomes at end of treatment compared with TAU (SMD −0.23, 95% CI −0.68 to 0.23; 5 trials, 231 participants; I<sup>2</sup> = 58%; P = 0.33; <a href="./references#CD012955-fig-0031" title="">Analysis 3.3</a>). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> </section> <section id="CD012955-sec-0112"> <h6 class="title">3.4 Suicide‐related outcomes, attempts</h6> <p>One trial reported dichotomous data on suicide‐related outcomes (<a href="./references#CD012955-bbs2-0070" title="FertuckEA , KeilpJ , SongI , MorrisMC , WilsonST , BrodskyBS , et al. Higher executive control and visual memory performance predict treatment completion in borderline personality disorder. Psychotherapy and Psychosomatics2012;81(1):38-43. [DOI: 10.1159/000329700] [PMC3242704] [PMID: 22116411]NCT00533117. Treating suicidal behavior and self-mutilation in people with borderline personality disorder. www.clinicaltrials.gov/ct2/show/NCT00533117 (first received 19 September 2007). ">Stanley 2017</a>). </p> <p>DBT did not reduce suicide‐related outcomes at end of treatment compared with TAU (RR 0.51, 95% CI 0.14 to 1.90; 1 trial, 75 participants; P = 0.32; <a href="./references#CD012955-fig-0032" title="">Analysis 3.4</a>). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> </section> <section id="CD012955-sec-0113"> <h6 class="title">3.5 Psychosocial functioning</h6> <p>Six trials reported continuous data on psychosocial functioning (<a href="./references#CD012955-bbs2-0015" title="CarterG . Question regarding your BPD trial [personal communication]. Email to: J Stoffers 21 December 2010. CarterGL , WillcoxCH , LewinTJ , ConradAM , BenditN . Hunter DBT project: randomized controlled trial of dialectical behaviour therapy in women with borderline personality disorder. Australian and New Zealand Journal of Psychiatry2010;44(2):162-73. [DOI: 10.3109/00048670903393621] [PMID: 20113305]">Carter 2010</a>; <a href="./references#CD012955-bbs2-0022" title="FeigenbaumJD , FonagyP , PillingS , JonesA , WildgooseA , BebbingtonPE . A real-world study of the effectiveness of DBT in the UK National Health Service. British Journal of Clinical Psychology2012;51(2):121-41. [DOI: 10.1111/j.2044-8260.2011.02017.x] [PMID: 22574799]">Feigenbaum 2012</a>; <a href="./references#CD012955-bbs2-0038" title="KramerU , Pascual-LeoneA , BerthoudL , De RotenY , MarquetP , KollyS , et al. Assertive anger mediates effects of dialectical behaviour-informed skills training for borderline personality disorder: a randomized controlled trial. Clinical Psychology &amp; Psychotherapy2016;23(3):189-202. [DOI: 10.1002/cpp.1956] [PMID: 25864773]KramerU . The role of coping change in borderline personality disorder: a process-outcome analysis on dialectical-behaviour skills training. Clinical Psychology &amp; Psychotherapy2017;24(2):302-11. [DOI: 10.1002/cpp.2017] [PMID: 27098296]">Kramer 2016</a>; <a href="./references#CD012955-bbs2-0046" title="HeardHL . Cost-Effectiveness of Dialectical Behavior Therapy in the Treatment of Borderline Personality Disorder [PhD thesis]. Washington (DC): University of Washington, 2000. LindenboimN . To Know Me is to Keep Me: Self-Verification, Validation, and Therapy Dropout in the Treatment of Borderline Personality Disorder [PhD thesis]. Washington (DC): University of Washington, 2009. LinehanMM , HeardHL , ArmstrongHE . Naturalistic follow-up of a behavioral treatment for chronically parasuicidal borderline patients. Archives of General Psychiatry1993;50(12):971-4. [DOI: 10.1001/archpsyc.1993.01820240055007] [PMID: 8250683]LinehanMM , TutekDA , HeardHL , ArmstrongHE . Interpersonal outcome of cognitive behavioral treatment for chronically suicidal borderline patients. American Journal of Psychiatry1994;151(12):1771-6. [DOI: 10.1176/ajp.151.12.1771] [PMID: 7977884]">Linehan 1994</a>; <a href="./references#CD012955-bbs2-0052" title="HagaE , AasE , GrøholtB , TørmoenAJ , MehlumL . Cost-effectiveness of dialectical behaviour therapy vs enhanced usual care in the treatment of adolescents with self-harm. Child and Adolescent Psychiatry and Mental Health2018;12:22. [DOI: 10.1186/s13034-018-0227-2] [PMC5928596] [PMID: 29743941]MehlumL , RambergM , TørmoenAJ , HagaE , DiepLM , StanleyBH , et al. Dialectical behavior therapy compared with enhanced usual care for adolescents with repeated suicidal and self-harming behavior: outcomes over a one-year follow-up. Journal of the American Academy of Child and Adolescent Psychiatry2016;55(4):295-300. [DOI: 10.1016/j.jaac.2016.01.005] [PMID: 27015720]MehlumL , TørmoenAJ , RambergM , HagaE , DiepLM , LabergS , et al. Dialectical behavior therapy for adolescents with repeated suicidal and self-harming behavior: a randomized trial. Journal of the American Academy of Child and Adolescent Psychiatry2014;53(10):1082-91. [DOI: 10.1016/j.jaac.2014.07.003] [PMID: 25245352]MehlumL . Re: regarding your study of DBT for your with suicidal behavior [personal communication] [Re: angående din studie om DBT for ungdom med selvmordsatferd [personlig kommunikation]]. Email to: E Faltinsen 5 December 2017. NCT00675129. Treatment for adolescents with deliberate self harm [A randomized controlled trial for repetitive deliberate self-harm and suicidal behaviours among Norwegian adolescents: a comparison between dialectical behaviour therapy adapted for adolescents (DBT-A) and enhanced usual care (EUC)]. www.clinicaltrials.gov/ct2/show/NCT00675129 (first received 6 May 2008). RamlethRK , GroholtB , DiepLM , WalbyFA , MehlumL . The impact of borderline personality disorder and sub-threshold borderline personality disorder on the course of self-reported and clinician-rated depression in self-harming adolescents. Borderline Personality Disorder and Emotion Dysregulation2017;4:22. [DOI: 10.1186/s40479-017-0073-5] [PMC5663078] [PMID: 29093819]">Mehlum 2014</a>; <a href="./references#CD012955-bbs2-0069" title="SolerJ , PascualJC , TianaT , CebriàA , BarrachinaJ , CampinsMJ , et al. Dialectical behaviour therapy skills training compared to standard group therapy in borderline personality disorder: a 3-month randomised controlled clinical trial. Behaviour Research and Therapy2009;47(5):353-8. [DOI: 10.1016/j.brat.2009.01.013] [PMID: 19246029]SolerJ . Question regarding your BPD trials [personal communication]. Email to: J Stoffers 15 December 2010. ">Soler 2009</a>). </p> <p>DBT improved psychosocial functioning at end of treatment compared with TAU (SMD −0.36, 95% CI −0.69 to −0.03; 6 trials, 225 participants; I<sup>2</sup> = 31%; P = 0.03; <a href="./references#CD012955-fig-0033" title="">Analysis 3.5</a>; low‐quality evidence, <a href="./full#CD012955-tbl-0003">summary of findings Table 3</a>). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> </section> </section> <section id="CD012955-sec-0114"> <h5 class="title">Secondary outcomes</h5> <section id="CD012955-sec-0115"> <h6 class="title">3.6 Anger</h6> <p>Five trials reported continuous data on anger (<a href="./references#CD012955-bbs2-0022" title="FeigenbaumJD , FonagyP , PillingS , JonesA , WildgooseA , BebbingtonPE . A real-world study of the effectiveness of DBT in the UK National Health Service. British Journal of Clinical Psychology2012;51(2):121-41. [DOI: 10.1111/j.2044-8260.2011.02017.x] [PMID: 22574799]">Feigenbaum 2012</a>; <a href="./references#CD012955-bbs2-0035" title="KoonsCR , RobinsCJ , TweedJL , LynchTR , GonzalezAM , MorseJQ , et al. Efficacy of dialectical behavior therapy in women veterans with borderline personality disorder. Behavior Therapy2001;32(2):371-90. [DOI: 10.1016/S0005-7894(01)80009-5]">Koons 2001a</a>; <a href="./references#CD012955-bbs2-0046" title="HeardHL . Cost-Effectiveness of Dialectical Behavior Therapy in the Treatment of Borderline Personality Disorder [PhD thesis]. Washington (DC): University of Washington, 2000. LindenboimN . To Know Me is to Keep Me: Self-Verification, Validation, and Therapy Dropout in the Treatment of Borderline Personality Disorder [PhD thesis]. Washington (DC): University of Washington, 2009. LinehanMM , HeardHL , ArmstrongHE . Naturalistic follow-up of a behavioral treatment for chronically parasuicidal borderline patients. Archives of General Psychiatry1993;50(12):971-4. [DOI: 10.1001/archpsyc.1993.01820240055007] [PMID: 8250683]LinehanMM , TutekDA , HeardHL , ArmstrongHE . Interpersonal outcome of cognitive behavioral treatment for chronically suicidal borderline patients. American Journal of Psychiatry1994;151(12):1771-6. [DOI: 10.1176/ajp.151.12.1771] [PMID: 7977884]">Linehan 1994</a>; <a href="./references#CD012955-bbs2-0047" title="BedicsJD , AtkinsDC , ComtoisKA , LinehanMM . Treatment differences in the therapeutic relationship and introject during a 2-year randomized controlled trial of dialectical behavior therapy versus nonbehavioral psychotherapy experts for borderline personality disorder. Journal of Consulting and Clinical Psychology2012;80(1):66-77. [DOI: 10.1037/a0026113] [PMC3265694] [PMID: 22061867]BedicsJD , AtkinsDC , ComtoisKA , LinehanMM . Weekly therapist ratings of the therapeutic relationship and patient introject furing the course of dialectical behavioral therapy for the treatment of borderline personality disorder. Psychotherapy2012;49(2):231-40. [DOI: 10.1037/a0028254] [PMID: 22642526]BedicsJD , AtkinsDC , HarnedMS , LinehanMM . The therapeutic alliance as a predictor of outcome in dialectical behavior therapy versus nonbehavioral psychotherapy by experts for borderline personality disorder. Psychotherapy2015;52(1):67-77. [DOI: 10.1037/a0038457] [PMID: 25751116]BrownMZ , LinehanMM , ComtoisKA , MurrayA , ChapmanAL . Shame as a prospective predictor of self-inflicted injury in borderline personality disorder: a multi-modal analysis. Behaviour Research and Therapy2009;47(10):815-22. [DOI: 10.1016/j.brat.2009.06.008] [PMC2761705] [PMID: 19596223 ]CoyleTN , ShaverJA , LinehanMM . On the potential for iatrogenic effects of psychiatric crisis services: the example of dialectical behavior therapy for adult women with borderline personality disorder. Journal of Consulting and Clinical Psychology2018;86(2):116-24. [DOI: 10.1037/ccp0000275] [PMID: 29369662]HarnedMS , ChapmanAL , Dexter-MazzaET , MurrayA , ComtoisKA , LinehanMM . Treating co-occurring Axis I disorders in recurrently suicidal women with borderline personality disorder: a 2-year randomized trial of dialectical behavior therapy versus community treatment by experts. Journal of Consulting and Clinical Psychology2008;76(6):1068-75. [DOI: 10.1037/a0014044] [PMID: 19045974]HarnedMS , ChapmanAL , Dexter-MazzaET , MurrayA , ComtoisKA , LinehanMM . Treating co-occurring Axis I disorders in recurrently suicidal women with borderline personality disorder: a 2-year randomized trial of dialectical behavior therapy versus community treatment by experts. Personality Disorders: Theory, Research, and Treatment2009;S(1):35-45. [DOI: 10.1037/1949-2715.S.1.35]HarnedMS , JacksonSC , ComtoisKA , LinehanMM . Dialectical behavior therapy as a precursor to PTSD treatment for suicidal and/or self-injuring women with bordreline personality disorder. Journal of Traumatic Stress2010;23(4):421-9. [DOI: 10.1002/jts.20553] [PMID: 20648564]LindenboimN , ComtoisKA , LinehanMM . Skills practice in dialectical behavior therapy for suicidal women meeting criteria for borderline personality disorder. Cognitive and Behavioral Practice2007;14(2):147-56. [DOI: 10.1016/j.cbpra.2006.10.004]LinehanMM , ComtoisKA , MurrayAM , BrownMZ , GallopRJ , HeardHL , et al. Two-year randomized controlled trial and follow-up of dialectical behavior therapy vs therapy by experts for suicidal behaviors and borderline personality disorder. Archives of General Psychiatry2006;63(7):757-66. [DOI: 10.1001/archpsyc.63.7.757] [PMID: 16818865]LinehanMM . Error in table in: two-year randomized controlled trial and follow-up of dialectical behavior therapy vs therapy by experts for suicidal behaviors and borderline personality disorder. Archives of General Psychiatry2007;64(12):1401. Erratum for: Archives of General Psychiatry 2007;64(12):1401. McMainS . Dialectic behaviour therapy reduces suicide attempts compared with non-behavioural psychotherapy in women with borderline personality disorder. Evidence-Based Mental Health2007;10(1):18. [DOI: 10.1136/ebmh.10.1.18] [PMID: 17255387]NeacsiuAD , LunguA , HarnedMS , RizviSL , LinehanMM . Impact of dialectical behavior therapy versus community treatment by experts on emotional experience, expression, and acceptance in borderline personality disorder. Behaviour Research and Therapy2014;53:47-54. [DOI: 10.1016/j.brat.2013.12.004] [PMC3955205] [PMID: 24418652]NeacsiuAD , RizviSL , LinehanMM . Dialectical behavior therapy skills use as a mediator and outcome of treatment for borderline personality disorder. Behaviour Research and Therapy2010;48(9):832-9. [DOI: 10.1016/j.brat.2010.05.017] [PMC2914145] [PMID: 20579633]SecristCD . The Role of Executive Functioning in the Treatment of Borderline Personality Disorder [PhD thesis]. Washington (DC): University of Washington, 2014. ">Linehan 2006</a>; <a href="./references#CD012955-bbs2-0069" title="SolerJ , PascualJC , TianaT , CebriàA , BarrachinaJ , CampinsMJ , et al. Dialectical behaviour therapy skills training compared to standard group therapy in borderline personality disorder: a 3-month randomised controlled clinical trial. Behaviour Research and Therapy2009;47(5):353-8. [DOI: 10.1016/j.brat.2009.01.013] [PMID: 19246029]SolerJ . Question regarding your BPD trials [personal communication]. Email to: J Stoffers 15 December 2010. ">Soler 2009</a>). </p> <p>DBT reduced anger at end of treatment compared with TAU (SMD −0.47, 95% CI −0.86 to −0.09; 5 trials, 230 participants; I<sup>2</sup> = 46%; P = 0.02; <a href="./references#CD012955-fig-0034" title="">Analysis 3.6</a>.1). </p> <p>DBT did not reduce anger at six to 12 months follow‐up compared with TAU (SMD −0.17, 95% CI −0.62 to 0.27; 1 trial, 78 participants; P = 0.44; MD −0.10, 95% CI −0.36 to 0.16; 1 trial, 78 participants; P = 0.45; <a href="./references#CD012955-fig-0034" title="">Analysis 3.6</a>.2). </p> <p>DBT did not reduce anger at above 12 months follow‐up compared with TAU (SMD 0.02, 95% CI −0.42 to 0.46; 1 trial, 80 participants; P = 0.93; MD 0.01, 95% CI −0.20 to 0.22; 1 trial, 79 participants; P = 0.93; <a href="./references#CD012955-fig-0034" title="">Analysis 3.6</a>.3). </p> <p>No data were available for zero to six months follow‐up.</p> </section> <section id="CD012955-sec-0116"> <h6 class="title">3.7 Affective instability</h6> <p>Two trials reported continuous data on affective instability (<a href="./references#CD012955-bbs2-0009" title="BianchiniV , CofiniV , CurtoM , LagrotteriaB , ManziA , NavariS , et al. Dialectical behavior therapy (DBT) for forensic psychiatric patients: an Italian pilot study. Criminal Behavior and Mental Health2019;29(9):122-30. [DOI: 10.1002/cbm.2102] [PMID: 30648303]">Bianchini 2019</a>; <a href="./references#CD012955-bbs2-0069" title="SolerJ , PascualJC , TianaT , CebriàA , BarrachinaJ , CampinsMJ , et al. Dialectical behaviour therapy skills training compared to standard group therapy in borderline personality disorder: a 3-month randomised controlled clinical trial. Behaviour Research and Therapy2009;47(5):353-8. [DOI: 10.1016/j.brat.2009.01.013] [PMID: 19246029]SolerJ . Question regarding your BPD trials [personal communication]. Email to: J Stoffers 15 December 2010. ">Soler 2009</a>). </p> <p>DBT did not reduce affective instability at end of treatment compared with TAU (SMD −0.57, 95% CI −1.64 to 0.51; 2 trials, 80 participants; I<sup>2</sup> = 78%; P = 0.30; <a href="./references#CD012955-fig-0035" title="">Analysis 3.7</a>; random‐effects model). </p> <p>DBT reduced affective instability at end of treatment compared with TAU (SMD ‐0.75, 95% CI−1.21 to −0.28; 2 trials, 80 participants; I<sup>2</sup> = 78%; P = 0.002; analysis not shown; fixed‐effect model). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> </section> <section id="CD012955-sec-0117"> <h6 class="title">3.8 Chronic feelings of emptiness</h6> <p>One trial reported continuous data on chronic feelings of emptiness (<a href="./references#CD012955-bbs2-0069" title="SolerJ , PascualJC , TianaT , CebriàA , BarrachinaJ , CampinsMJ , et al. Dialectical behaviour therapy skills training compared to standard group therapy in borderline personality disorder: a 3-month randomised controlled clinical trial. Behaviour Research and Therapy2009;47(5):353-8. [DOI: 10.1016/j.brat.2009.01.013] [PMID: 19246029]SolerJ . Question regarding your BPD trials [personal communication]. Email to: J Stoffers 15 December 2010. ">Soler 2009</a>). </p> <p>DBT did not reduce chronic feelings of emptiness at end of treatment compared with TAU (MD −0.67, 95% CI −1.45 to 0.11; 1 trial, 59 participants; P = 0.09; <a href="./references#CD012955-fig-0036" title="">Analysis 3.8</a>). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> </section> <section id="CD012955-sec-0118"> <h6 class="title">3.9 Impulsivity</h6> <p>Three trials reported continuous data on impulsivity (<a href="./references#CD012955-bbs2-0009" title="BianchiniV , CofiniV , CurtoM , LagrotteriaB , ManziA , NavariS , et al. Dialectical behavior therapy (DBT) for forensic psychiatric patients: an Italian pilot study. Criminal Behavior and Mental Health2019;29(9):122-30. [DOI: 10.1002/cbm.2102] [PMID: 30648303]">Bianchini 2019</a>; <a href="./references#CD012955-bbs2-0069" title="SolerJ , PascualJC , TianaT , CebriàA , BarrachinaJ , CampinsMJ , et al. Dialectical behaviour therapy skills training compared to standard group therapy in borderline personality disorder: a 3-month randomised controlled clinical trial. Behaviour Research and Therapy2009;47(5):353-8. [DOI: 10.1016/j.brat.2009.01.013] [PMID: 19246029]SolerJ . Question regarding your BPD trials [personal communication]. Email to: J Stoffers 15 December 2010. ">Soler 2009</a>; <a href="./references#CD012955-bbs2-0072" title="Van den BoschLM , KoeterMW , StijnenT , VerheulR , Van den BrinkW . Sustained efficacy of dialectical behaviour therapy for borderline personality disorder. Behaviour Research and Therapy2005;43(9):1231-41. [DOI: 10.1016/j.brat.2004.09.008] [PMID: 16005708]Van den BoschLM , VerheulR , SchippersGM , Van den BrinkW . Dialectical behavior therapy of borderline patients with and without substance use problems. Implementation and long-term effects. Addictive Behaviors2002;27(6):911-23. [DOI: 10.1016/s0306-4603(02)00293-9] [PMID: 12369475]Van den BoschLMC . Efficacy of dialectical behaviour therapy in the treatment of female borderline patients with and without substance abuse problems: results of a Dutch study [Dialectische gedragstherapie bij Nederlandse vrouwen met een borderline persoonlijkheidsstoornis, met en zonder verslavingsproblemen]. Tijdschrift voor Psychiatrie2005;47(3):127-37. [www.tijdschriftvoorpsychiatrie.nl/assets/articles/articles_1335pdf.pdf]VerheulR , Van den BoschLM , KoeterMW , De RidderMA , StijnenT , Van den BrinkW . Dialectical behaviour therapy for women with borderline personality disorder: 12-month, randomised clinical trial in The Netherlands. British Journal of Psychiatry2003;182:135-40. [DOI: 10.1192/bjp.182.2.135] [PMID: 12562741]">Van den Bosch 2005</a>). </p> <p>DBT reduced impulsivity at end of treatment compared with TAU (SMD −0.35, 95% CI −0.71 to −0.00; 3 trials, 128 participants; I<sup>2</sup> = 0%; P = 0.05; <a href="./references#CD012955-fig-0037" title="">Analysis 3.9</a>.1). </p> <p>DBT did not reduce impulsivity at six to 12 months follow‐up compared with TAU (SMD 0.30, 95% CI −0.30 to 0.90; 1 trial, 44 participants; P = 0.33; MD 0.23, 95% CI −0.24 to 0.70; 1 trial, 454 participants; P = 0.33; <a href="./references#CD012955-bbs2-0072" title="Van den BoschLM , KoeterMW , StijnenT , VerheulR , Van den BrinkW . Sustained efficacy of dialectical behaviour therapy for borderline personality disorder. Behaviour Research and Therapy2005;43(9):1231-41. [DOI: 10.1016/j.brat.2004.09.008] [PMID: 16005708]Van den BoschLM , VerheulR , SchippersGM , Van den BrinkW . Dialectical behavior therapy of borderline patients with and without substance use problems. Implementation and long-term effects. Addictive Behaviors2002;27(6):911-23. [DOI: 10.1016/s0306-4603(02)00293-9] [PMID: 12369475]Van den BoschLMC . Efficacy of dialectical behaviour therapy in the treatment of female borderline patients with and without substance abuse problems: results of a Dutch study [Dialectische gedragstherapie bij Nederlandse vrouwen met een borderline persoonlijkheidsstoornis, met en zonder verslavingsproblemen]. Tijdschrift voor Psychiatrie2005;47(3):127-37. [www.tijdschriftvoorpsychiatrie.nl/assets/articles/articles_1335pdf.pdf]VerheulR , Van den BoschLM , KoeterMW , De RidderMA , StijnenT , Van den BrinkW . Dialectical behaviour therapy for women with borderline personality disorder: 12-month, randomised clinical trial in The Netherlands. British Journal of Psychiatry2003;182:135-40. [DOI: 10.1192/bjp.182.2.135] [PMID: 12562741]">Van den Bosch 2005</a>; <a href="./references#CD012955-fig-0037" title="">Analysis 3.9</a>.2). </p> <p>No data were available for zero to six months and above 12 months follow‐up.</p> </section> <section id="CD012955-sec-0119"> <h6 class="title">3.10 Interpersonal problems</h6> <p>Three trials reported continuous data on interpersonal problems (<a href="./references#CD012955-bbs2-0015" title="CarterG . Question regarding your BPD trial [personal communication]. Email to: J Stoffers 21 December 2010. CarterGL , WillcoxCH , LewinTJ , ConradAM , BenditN . Hunter DBT project: randomized controlled trial of dialectical behaviour therapy in women with borderline personality disorder. Australian and New Zealand Journal of Psychiatry2010;44(2):162-73. [DOI: 10.3109/00048670903393621] [PMID: 20113305]">Carter 2010</a>; <a href="./references#CD012955-bbs2-0038" title="KramerU , Pascual-LeoneA , BerthoudL , De RotenY , MarquetP , KollyS , et al. Assertive anger mediates effects of dialectical behaviour-informed skills training for borderline personality disorder: a randomized controlled trial. Clinical Psychology &amp; Psychotherapy2016;23(3):189-202. [DOI: 10.1002/cpp.1956] [PMID: 25864773]KramerU . The role of coping change in borderline personality disorder: a process-outcome analysis on dialectical-behaviour skills training. Clinical Psychology &amp; Psychotherapy2017;24(2):302-11. [DOI: 10.1002/cpp.2017] [PMID: 27098296]">Kramer 2016</a>; <a href="./references#CD012955-bbs2-0069" title="SolerJ , PascualJC , TianaT , CebriàA , BarrachinaJ , CampinsMJ , et al. Dialectical behaviour therapy skills training compared to standard group therapy in borderline personality disorder: a 3-month randomised controlled clinical trial. Behaviour Research and Therapy2009;47(5):353-8. [DOI: 10.1016/j.brat.2009.01.013] [PMID: 19246029]SolerJ . Question regarding your BPD trials [personal communication]. Email to: J Stoffers 15 December 2010. ">Soler 2009</a>). </p> <p>DBT did not reduce interpersonal problems at end of treatment compared with TAU (SMD −0.12, 95% CI −0.45 to 0.20; 3 trials, 148 participants; I<sup>2</sup> = 0%; P = 0.45; <a href="./references#CD012955-fig-0038" title="">Analysis 3.10</a>). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> </section> <section id="CD012955-sec-0120"> <h6 class="title">3.11 Dissociation and psychotic‐like symptoms</h6> <p>Four trials reported continuous data on dissociation and psychotic‐like symptoms (<a href="./references#CD012955-bbs2-0022" title="FeigenbaumJD , FonagyP , PillingS , JonesA , WildgooseA , BebbingtonPE . A real-world study of the effectiveness of DBT in the UK National Health Service. British Journal of Clinical Psychology2012;51(2):121-41. [DOI: 10.1111/j.2044-8260.2011.02017.x] [PMID: 22574799]">Feigenbaum 2012</a>; <a href="./references#CD012955-bbs2-0035" title="KoonsCR , RobinsCJ , TweedJL , LynchTR , GonzalezAM , MorseJQ , et al. Efficacy of dialectical behavior therapy in women veterans with borderline personality disorder. Behavior Therapy2001;32(2):371-90. [DOI: 10.1016/S0005-7894(01)80009-5]">Koons 2001a</a>; <a href="./references#CD012955-bbs2-0059" title="BarnicotK . Re: Regarding your study on DBT for self-harming patients [personal communication]. Email to: EG Faltinsen 28 February 2018. PriebeS , BhattiN , BarnicotK , BremnerS , GagliaA , KatsakouC , et al. Effectiveness and cost-effectiveness of dialectical behaviour therapy for self-harming patients with personality disorder: a pragmatic randomised controlled trial. Psychotherapy and Psychosomatics2012;81(6):356-65. [DOI: 10.1159/000338897] [PMID: 22964561]PriebeS . Supplemental information [personal communication]. Email to: M Kielsholm 20 May 2016. ">Priebe 2012</a>; <a href="./references#CD012955-bbs2-0069" title="SolerJ , PascualJC , TianaT , CebriàA , BarrachinaJ , CampinsMJ , et al. Dialectical behaviour therapy skills training compared to standard group therapy in borderline personality disorder: a 3-month randomised controlled clinical trial. Behaviour Research and Therapy2009;47(5):353-8. [DOI: 10.1016/j.brat.2009.01.013] [PMID: 19246029]SolerJ . Question regarding your BPD trials [personal communication]. Email to: J Stoffers 15 December 2010. ">Soler 2009</a>). </p> <p>DBT reduced dissociation and psychotic‐like symptoms at end of treatment compared with TAU (SMD −0.45, 95% CI −0.73 to −0.16; 4 trials, 194 participants; I<sup>2</sup> = 0%; P = 0.002; <a href="./references#CD012955-fig-0039" title="">Analysis 3.11</a>). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> </section> <section id="CD012955-sec-0121"> <h6 class="title">3.12 Depression</h6> <p>Five trials reported continuous data on depression (<a href="./references#CD012955-bbs2-0022" title="FeigenbaumJD , FonagyP , PillingS , JonesA , WildgooseA , BebbingtonPE . A real-world study of the effectiveness of DBT in the UK National Health Service. British Journal of Clinical Psychology2012;51(2):121-41. [DOI: 10.1111/j.2044-8260.2011.02017.x] [PMID: 22574799]">Feigenbaum 2012</a>; <a href="./references#CD012955-bbs2-0035" title="KoonsCR , RobinsCJ , TweedJL , LynchTR , GonzalezAM , MorseJQ , et al. Efficacy of dialectical behavior therapy in women veterans with borderline personality disorder. Behavior Therapy2001;32(2):371-90. [DOI: 10.1016/S0005-7894(01)80009-5]">Koons 2001a</a>; <a href="./references#CD012955-bbs2-0047" title="BedicsJD , AtkinsDC , ComtoisKA , LinehanMM . Treatment differences in the therapeutic relationship and introject during a 2-year randomized controlled trial of dialectical behavior therapy versus nonbehavioral psychotherapy experts for borderline personality disorder. Journal of Consulting and Clinical Psychology2012;80(1):66-77. [DOI: 10.1037/a0026113] [PMC3265694] [PMID: 22061867]BedicsJD , AtkinsDC , ComtoisKA , LinehanMM . Weekly therapist ratings of the therapeutic relationship and patient introject furing the course of dialectical behavioral therapy for the treatment of borderline personality disorder. Psychotherapy2012;49(2):231-40. [DOI: 10.1037/a0028254] [PMID: 22642526]BedicsJD , AtkinsDC , HarnedMS , LinehanMM . The therapeutic alliance as a predictor of outcome in dialectical behavior therapy versus nonbehavioral psychotherapy by experts for borderline personality disorder. Psychotherapy2015;52(1):67-77. [DOI: 10.1037/a0038457] [PMID: 25751116]BrownMZ , LinehanMM , ComtoisKA , MurrayA , ChapmanAL . Shame as a prospective predictor of self-inflicted injury in borderline personality disorder: a multi-modal analysis. Behaviour Research and Therapy2009;47(10):815-22. [DOI: 10.1016/j.brat.2009.06.008] [PMC2761705] [PMID: 19596223 ]CoyleTN , ShaverJA , LinehanMM . On the potential for iatrogenic effects of psychiatric crisis services: the example of dialectical behavior therapy for adult women with borderline personality disorder. Journal of Consulting and Clinical Psychology2018;86(2):116-24. [DOI: 10.1037/ccp0000275] [PMID: 29369662]HarnedMS , ChapmanAL , Dexter-MazzaET , MurrayA , ComtoisKA , LinehanMM . Treating co-occurring Axis I disorders in recurrently suicidal women with borderline personality disorder: a 2-year randomized trial of dialectical behavior therapy versus community treatment by experts. Journal of Consulting and Clinical Psychology2008;76(6):1068-75. [DOI: 10.1037/a0014044] [PMID: 19045974]HarnedMS , ChapmanAL , Dexter-MazzaET , MurrayA , ComtoisKA , LinehanMM . Treating co-occurring Axis I disorders in recurrently suicidal women with borderline personality disorder: a 2-year randomized trial of dialectical behavior therapy versus community treatment by experts. Personality Disorders: Theory, Research, and Treatment2009;S(1):35-45. [DOI: 10.1037/1949-2715.S.1.35]HarnedMS , JacksonSC , ComtoisKA , LinehanMM . Dialectical behavior therapy as a precursor to PTSD treatment for suicidal and/or self-injuring women with bordreline personality disorder. Journal of Traumatic Stress2010;23(4):421-9. [DOI: 10.1002/jts.20553] [PMID: 20648564]LindenboimN , ComtoisKA , LinehanMM . Skills practice in dialectical behavior therapy for suicidal women meeting criteria for borderline personality disorder. Cognitive and Behavioral Practice2007;14(2):147-56. [DOI: 10.1016/j.cbpra.2006.10.004]LinehanMM , ComtoisKA , MurrayAM , BrownMZ , GallopRJ , HeardHL , et al. Two-year randomized controlled trial and follow-up of dialectical behavior therapy vs therapy by experts for suicidal behaviors and borderline personality disorder. Archives of General Psychiatry2006;63(7):757-66. [DOI: 10.1001/archpsyc.63.7.757] [PMID: 16818865]LinehanMM . Error in table in: two-year randomized controlled trial and follow-up of dialectical behavior therapy vs therapy by experts for suicidal behaviors and borderline personality disorder. Archives of General Psychiatry2007;64(12):1401. Erratum for: Archives of General Psychiatry 2007;64(12):1401. McMainS . Dialectic behaviour therapy reduces suicide attempts compared with non-behavioural psychotherapy in women with borderline personality disorder. Evidence-Based Mental Health2007;10(1):18. [DOI: 10.1136/ebmh.10.1.18] [PMID: 17255387]NeacsiuAD , LunguA , HarnedMS , RizviSL , LinehanMM . Impact of dialectical behavior therapy versus community treatment by experts on emotional experience, expression, and acceptance in borderline personality disorder. Behaviour Research and Therapy2014;53:47-54. [DOI: 10.1016/j.brat.2013.12.004] [PMC3955205] [PMID: 24418652]NeacsiuAD , RizviSL , LinehanMM . Dialectical behavior therapy skills use as a mediator and outcome of treatment for borderline personality disorder. Behaviour Research and Therapy2010;48(9):832-9. [DOI: 10.1016/j.brat.2010.05.017] [PMC2914145] [PMID: 20579633]SecristCD . The Role of Executive Functioning in the Treatment of Borderline Personality Disorder [PhD thesis]. Washington (DC): University of Washington, 2014. ">Linehan 2006</a>; <a href="./references#CD012955-bbs2-0052" title="HagaE , AasE , GrøholtB , TørmoenAJ , MehlumL . Cost-effectiveness of dialectical behaviour therapy vs enhanced usual care in the treatment of adolescents with self-harm. Child and Adolescent Psychiatry and Mental Health2018;12:22. [DOI: 10.1186/s13034-018-0227-2] [PMC5928596] [PMID: 29743941]MehlumL , RambergM , TørmoenAJ , HagaE , DiepLM , StanleyBH , et al. Dialectical behavior therapy compared with enhanced usual care for adolescents with repeated suicidal and self-harming behavior: outcomes over a one-year follow-up. Journal of the American Academy of Child and Adolescent Psychiatry2016;55(4):295-300. [DOI: 10.1016/j.jaac.2016.01.005] [PMID: 27015720]MehlumL , TørmoenAJ , RambergM , HagaE , DiepLM , LabergS , et al. Dialectical behavior therapy for adolescents with repeated suicidal and self-harming behavior: a randomized trial. Journal of the American Academy of Child and Adolescent Psychiatry2014;53(10):1082-91. [DOI: 10.1016/j.jaac.2014.07.003] [PMID: 25245352]MehlumL . Re: regarding your study of DBT for your with suicidal behavior [personal communication] [Re: angående din studie om DBT for ungdom med selvmordsatferd [personlig kommunikation]]. Email to: E Faltinsen 5 December 2017. NCT00675129. Treatment for adolescents with deliberate self harm [A randomized controlled trial for repetitive deliberate self-harm and suicidal behaviours among Norwegian adolescents: a comparison between dialectical behaviour therapy adapted for adolescents (DBT-A) and enhanced usual care (EUC)]. www.clinicaltrials.gov/ct2/show/NCT00675129 (first received 6 May 2008). RamlethRK , GroholtB , DiepLM , WalbyFA , MehlumL . The impact of borderline personality disorder and sub-threshold borderline personality disorder on the course of self-reported and clinician-rated depression in self-harming adolescents. Borderline Personality Disorder and Emotion Dysregulation2017;4:22. [DOI: 10.1186/s40479-017-0073-5] [PMC5663078] [PMID: 29093819]">Mehlum 2014</a>; <a href="./references#CD012955-bbs2-0069" title="SolerJ , PascualJC , TianaT , CebriàA , BarrachinaJ , CampinsMJ , et al. Dialectical behaviour therapy skills training compared to standard group therapy in borderline personality disorder: a 3-month randomised controlled clinical trial. Behaviour Research and Therapy2009;47(5):353-8. [DOI: 10.1016/j.brat.2009.01.013] [PMID: 19246029]SolerJ . Question regarding your BPD trials [personal communication]. Email to: J Stoffers 15 December 2010. ">Soler 2009</a>). </p> <p>DBT did not reduce depression at end of treatment compared with TAU (SMD −0.47, 95% CI −0.98 to 0.03; 5 trials, 219 participants; I<sup>2</sup> = 64%; P = 0.07; <a href="./references#CD012955-fig-0040" title="">Analysis 3.12</a>.1; random‐effects model). </p> <p>DBT reduced depression at end of treatment compared with TAU (SMD −0.46, 95% CI −0.73 to −0.18; 5 trials, 219 participants; I<sup>2</sup> = 64%; P = 0.001; analysis not shown; fixed‐effect model). </p> <p>DBT did not reduce depression at six to 12 months follow‐up compared with TAU (SMD −0.23, 95% CI −0.67 to 0.21; 1 trial, 81 participants; P = 0.31; MD −1.80, 95% CI −5.40 to 1.80; 1 trial, 81 participants; P = 0.33; <a href="./references#CD012955-fig-0040" title="">Analysis 3.12</a>.2). </p> <p>No data were available for zero to six months and above 12 months follow‐up.</p> </section> <section id="CD012955-sec-0122"> <h6 class="title">3.13 Attrition</h6> <p>Eleven trials reported dichotomous data on attrition (<a href="./references#CD012955-bbs2-0015" title="CarterG . Question regarding your BPD trial [personal communication]. Email to: J Stoffers 21 December 2010. CarterGL , WillcoxCH , LewinTJ , ConradAM , BenditN . Hunter DBT project: randomized controlled trial of dialectical behaviour therapy in women with borderline personality disorder. Australian and New Zealand Journal of Psychiatry2010;44(2):162-73. [DOI: 10.3109/00048670903393621] [PMID: 20113305]">Carter 2010</a>; <a href="./references#CD012955-bbs2-0022" title="FeigenbaumJD , FonagyP , PillingS , JonesA , WildgooseA , BebbingtonPE . A real-world study of the effectiveness of DBT in the UK National Health Service. British Journal of Clinical Psychology2012;51(2):121-41. [DOI: 10.1111/j.2044-8260.2011.02017.x] [PMID: 22574799]">Feigenbaum 2012</a>; <a href="./references#CD012955-bbs2-0035" title="KoonsCR , RobinsCJ , TweedJL , LynchTR , GonzalezAM , MorseJQ , et al. Efficacy of dialectical behavior therapy in women veterans with borderline personality disorder. Behavior Therapy2001;32(2):371-90. [DOI: 10.1016/S0005-7894(01)80009-5]">Koons 2001a</a>; <a href="./references#CD012955-bbs2-0038" title="KramerU , Pascual-LeoneA , BerthoudL , De RotenY , MarquetP , KollyS , et al. Assertive anger mediates effects of dialectical behaviour-informed skills training for borderline personality disorder: a randomized controlled trial. Clinical Psychology &amp; Psychotherapy2016;23(3):189-202. [DOI: 10.1002/cpp.1956] [PMID: 25864773]KramerU . The role of coping change in borderline personality disorder: a process-outcome analysis on dialectical-behaviour skills training. Clinical Psychology &amp; Psychotherapy2017;24(2):302-11. [DOI: 10.1002/cpp.2017] [PMID: 27098296]">Kramer 2016</a>; <a href="./references#CD012955-bbs2-0045" title="HoffmanRE . Impact of treatment accessibility on clinical course of parasuicidal patients. Archives of General Psychiatry1993;50(2):157-8. [DOI: 10.1001/archpsyc.1993.01820140083010] [PMID: 8427557]LindenboimN . To Know Me is to Keep Me: Self-Verification, Validation, and Therapy Dropout in the Treatment of Borderline Personality Disorder [PhD thesis]. Washington (DC): University of Washington, 2009. LinehanMM , ArmstrongHE , SuarezA , AllmonD , HeardHL . Cognitive-behavioral treatment of chronically parasuicidal borderline patients. Archives of General Psychiatry1991;48(12):1060-4. [DOI: 10.1001/archpsyc.1991.01810360024003] [PMID: 1845222]LinehanMM , HeardHL . Impact of treatment accessibility on clinical course of parasuicidal patients — reply. Archives of General Psychiatry1993;50(2):157-8. [DOI: 10.1001/archpsyc.1993.01820140083011]">Linehan 1991</a>; <a href="./references#CD012955-bbs2-0046" title="HeardHL . Cost-Effectiveness of Dialectical Behavior Therapy in the Treatment of Borderline Personality Disorder [PhD thesis]. Washington (DC): University of Washington, 2000. LindenboimN . To Know Me is to Keep Me: Self-Verification, Validation, and Therapy Dropout in the Treatment of Borderline Personality Disorder [PhD thesis]. Washington (DC): University of Washington, 2009. LinehanMM , HeardHL , ArmstrongHE . Naturalistic follow-up of a behavioral treatment for chronically parasuicidal borderline patients. Archives of General Psychiatry1993;50(12):971-4. [DOI: 10.1001/archpsyc.1993.01820240055007] [PMID: 8250683]LinehanMM , TutekDA , HeardHL , ArmstrongHE . Interpersonal outcome of cognitive behavioral treatment for chronically suicidal borderline patients. American Journal of Psychiatry1994;151(12):1771-6. [DOI: 10.1176/ajp.151.12.1771] [PMID: 7977884]">Linehan 1994</a>; <a href="./references#CD012955-bbs2-0047" title="BedicsJD , AtkinsDC , ComtoisKA , LinehanMM . Treatment differences in the therapeutic relationship and introject during a 2-year randomized controlled trial of dialectical behavior therapy versus nonbehavioral psychotherapy experts for borderline personality disorder. Journal of Consulting and Clinical Psychology2012;80(1):66-77. [DOI: 10.1037/a0026113] [PMC3265694] [PMID: 22061867]BedicsJD , AtkinsDC , ComtoisKA , LinehanMM . Weekly therapist ratings of the therapeutic relationship and patient introject furing the course of dialectical behavioral therapy for the treatment of borderline personality disorder. Psychotherapy2012;49(2):231-40. [DOI: 10.1037/a0028254] [PMID: 22642526]BedicsJD , AtkinsDC , HarnedMS , LinehanMM . The therapeutic alliance as a predictor of outcome in dialectical behavior therapy versus nonbehavioral psychotherapy by experts for borderline personality disorder. Psychotherapy2015;52(1):67-77. [DOI: 10.1037/a0038457] [PMID: 25751116]BrownMZ , LinehanMM , ComtoisKA , MurrayA , ChapmanAL . Shame as a prospective predictor of self-inflicted injury in borderline personality disorder: a multi-modal analysis. Behaviour Research and Therapy2009;47(10):815-22. [DOI: 10.1016/j.brat.2009.06.008] [PMC2761705] [PMID: 19596223 ]CoyleTN , ShaverJA , LinehanMM . On the potential for iatrogenic effects of psychiatric crisis services: the example of dialectical behavior therapy for adult women with borderline personality disorder. Journal of Consulting and Clinical Psychology2018;86(2):116-24. [DOI: 10.1037/ccp0000275] [PMID: 29369662]HarnedMS , ChapmanAL , Dexter-MazzaET , MurrayA , ComtoisKA , LinehanMM . Treating co-occurring Axis I disorders in recurrently suicidal women with borderline personality disorder: a 2-year randomized trial of dialectical behavior therapy versus community treatment by experts. Journal of Consulting and Clinical Psychology2008;76(6):1068-75. [DOI: 10.1037/a0014044] [PMID: 19045974]HarnedMS , ChapmanAL , Dexter-MazzaET , MurrayA , ComtoisKA , LinehanMM . Treating co-occurring Axis I disorders in recurrently suicidal women with borderline personality disorder: a 2-year randomized trial of dialectical behavior therapy versus community treatment by experts. Personality Disorders: Theory, Research, and Treatment2009;S(1):35-45. [DOI: 10.1037/1949-2715.S.1.35]HarnedMS , JacksonSC , ComtoisKA , LinehanMM . Dialectical behavior therapy as a precursor to PTSD treatment for suicidal and/or self-injuring women with bordreline personality disorder. Journal of Traumatic Stress2010;23(4):421-9. [DOI: 10.1002/jts.20553] [PMID: 20648564]LindenboimN , ComtoisKA , LinehanMM . Skills practice in dialectical behavior therapy for suicidal women meeting criteria for borderline personality disorder. Cognitive and Behavioral Practice2007;14(2):147-56. [DOI: 10.1016/j.cbpra.2006.10.004]LinehanMM , ComtoisKA , MurrayAM , BrownMZ , GallopRJ , HeardHL , et al. Two-year randomized controlled trial and follow-up of dialectical behavior therapy vs therapy by experts for suicidal behaviors and borderline personality disorder. Archives of General Psychiatry2006;63(7):757-66. [DOI: 10.1001/archpsyc.63.7.757] [PMID: 16818865]LinehanMM . Error in table in: two-year randomized controlled trial and follow-up of dialectical behavior therapy vs therapy by experts for suicidal behaviors and borderline personality disorder. Archives of General Psychiatry2007;64(12):1401. Erratum for: Archives of General Psychiatry 2007;64(12):1401. McMainS . Dialectic behaviour therapy reduces suicide attempts compared with non-behavioural psychotherapy in women with borderline personality disorder. Evidence-Based Mental Health2007;10(1):18. [DOI: 10.1136/ebmh.10.1.18] [PMID: 17255387]NeacsiuAD , LunguA , HarnedMS , RizviSL , LinehanMM . Impact of dialectical behavior therapy versus community treatment by experts on emotional experience, expression, and acceptance in borderline personality disorder. Behaviour Research and Therapy2014;53:47-54. [DOI: 10.1016/j.brat.2013.12.004] [PMC3955205] [PMID: 24418652]NeacsiuAD , RizviSL , LinehanMM . Dialectical behavior therapy skills use as a mediator and outcome of treatment for borderline personality disorder. Behaviour Research and Therapy2010;48(9):832-9. [DOI: 10.1016/j.brat.2010.05.017] [PMC2914145] [PMID: 20579633]SecristCD . The Role of Executive Functioning in the Treatment of Borderline Personality Disorder [PhD thesis]. Washington (DC): University of Washington, 2014. ">Linehan 2006</a>; <a href="./references#CD012955-bbs2-0059" title="BarnicotK . Re: Regarding your study on DBT for self-harming patients [personal communication]. Email to: EG Faltinsen 28 February 2018. PriebeS , BhattiN , BarnicotK , BremnerS , GagliaA , KatsakouC , et al. Effectiveness and cost-effectiveness of dialectical behaviour therapy for self-harming patients with personality disorder: a pragmatic randomised controlled trial. Psychotherapy and Psychosomatics2012;81(6):356-65. [DOI: 10.1159/000338897] [PMID: 22964561]PriebeS . Supplemental information [personal communication]. Email to: M Kielsholm 20 May 2016. ">Priebe 2012</a>; <a href="./references#CD012955-bbs2-0069" title="SolerJ , PascualJC , TianaT , CebriàA , BarrachinaJ , CampinsMJ , et al. Dialectical behaviour therapy skills training compared to standard group therapy in borderline personality disorder: a 3-month randomised controlled clinical trial. Behaviour Research and Therapy2009;47(5):353-8. [DOI: 10.1016/j.brat.2009.01.013] [PMID: 19246029]SolerJ . Question regarding your BPD trials [personal communication]. Email to: J Stoffers 15 December 2010. ">Soler 2009</a>; <a href="./references#CD012955-bbs2-0070" title="FertuckEA , KeilpJ , SongI , MorrisMC , WilsonST , BrodskyBS , et al. Higher executive control and visual memory performance predict treatment completion in borderline personality disorder. Psychotherapy and Psychosomatics2012;81(1):38-43. [DOI: 10.1159/000329700] [PMC3242704] [PMID: 22116411]NCT00533117. Treating suicidal behavior and self-mutilation in people with borderline personality disorder. www.clinicaltrials.gov/ct2/show/NCT00533117 (first received 19 September 2007). ">Stanley 2017</a>; <a href="./references#CD012955-bbs2-0072" title="Van den BoschLM , KoeterMW , StijnenT , VerheulR , Van den BrinkW . Sustained efficacy of dialectical behaviour therapy for borderline personality disorder. Behaviour Research and Therapy2005;43(9):1231-41. [DOI: 10.1016/j.brat.2004.09.008] [PMID: 16005708]Van den BoschLM , VerheulR , SchippersGM , Van den BrinkW . Dialectical behavior therapy of borderline patients with and without substance use problems. Implementation and long-term effects. Addictive Behaviors2002;27(6):911-23. [DOI: 10.1016/s0306-4603(02)00293-9] [PMID: 12369475]Van den BoschLMC . Efficacy of dialectical behaviour therapy in the treatment of female borderline patients with and without substance abuse problems: results of a Dutch study [Dialectische gedragstherapie bij Nederlandse vrouwen met een borderline persoonlijkheidsstoornis, met en zonder verslavingsproblemen]. Tijdschrift voor Psychiatrie2005;47(3):127-37. [www.tijdschriftvoorpsychiatrie.nl/assets/articles/articles_1335pdf.pdf]VerheulR , Van den BoschLM , KoeterMW , De RidderMA , StijnenT , Van den BrinkW . Dialectical behaviour therapy for women with borderline personality disorder: 12-month, randomised clinical trial in The Netherlands. British Journal of Psychiatry2003;182:135-40. [DOI: 10.1192/bjp.182.2.135] [PMID: 12562741]">Van den Bosch 2005</a>). </p> <p>DBT did not reduce attrition at end of treatment compared with TAU (RR 1.27, 95% CI 0.70 to 2.31; 10 trials, 217 participants; I<sup>2</sup> = 81%; P = 0.42; <a href="./references#CD012955-fig-0041" title="">Analysis 3.13</a>.1). </p> <p>DBT reduced attrition at zero to six months follow‐up compared with TAU (RR 0.58, 95% CI 0.34 to 1.00; 1 trial, 60 participants; P = 0.05; <a href="./references#CD012955-fig-0041" title="">Analysis 3.13</a>.2). </p> <p>No data were available for six to 12 months and above 12 months follow‐up.</p> </section> <section id="CD012955-sec-0123"> <h6 class="title">3.14 Adverse effects</h6> <p>One trial reported dichotomous data on adverse effects (<a href="./references#CD012955-bbs2-0070" title="FertuckEA , KeilpJ , SongI , MorrisMC , WilsonST , BrodskyBS , et al. Higher executive control and visual memory performance predict treatment completion in borderline personality disorder. Psychotherapy and Psychosomatics2012;81(1):38-43. [DOI: 10.1159/000329700] [PMC3242704] [PMID: 22116411]NCT00533117. Treating suicidal behavior and self-mutilation in people with borderline personality disorder. www.clinicaltrials.gov/ct2/show/NCT00533117 (first received 19 September 2007). ">Stanley 2017</a>). </p> <p>There were no adverse effects at end of treatment in any of the groups (effect not estimable; 1 trial, 75 participants; <a href="./references#CD012955-fig-0042" title="">Analysis 3.14</a>). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> </section> <section id="CD012955-sec-0124"> <h6 class="title">3.15 Serious adverse effects</h6> <p>One trial reported dichotomous data on serious adverse effects (<a href="./references#CD012955-bbs2-0070" title="FertuckEA , KeilpJ , SongI , MorrisMC , WilsonST , BrodskyBS , et al. Higher executive control and visual memory performance predict treatment completion in borderline personality disorder. Psychotherapy and Psychosomatics2012;81(1):38-43. [DOI: 10.1159/000329700] [PMC3242704] [PMID: 22116411]NCT00533117. Treating suicidal behavior and self-mutilation in people with borderline personality disorder. www.clinicaltrials.gov/ct2/show/NCT00533117 (first received 19 September 2007). ">Stanley 2017</a>). </p> <p>There was no clear difference in the number of serious adverse effects at end of treatment (RR 0.51, 95% CI 0.05 to 5.42; 1 trial, 75 participants; P = 0.58; <a href="./references#CD012955-fig-0043" title="">Analysis 3.15</a>). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> <p>No data were available on any time point for abandonment and identity disturbance.</p> </section> </section> </section> <section id="CD012955-sec-0125"> <h4 class="title">4. Mentalisation‐based therapy (MBT) versus treatment‐as‐usual (TAU)</h4> <section id="CD012955-sec-0126"> <h5 class="title">Primary outcomes</h5> <section id="CD012955-sec-0127"> <h6 class="title">4.1 BPD symptom severity</h6> <p>Six trials reported continuous data on BPD symptom severity (<a href="./references#CD012955-bbs2-0004" title="BatemanA , FonagyP . 8-year follow-up of patients treated for borderline personality disorder: mentalization-based treatment versus treatment as usual. American Journal of Psychiatry2008;165(5):631-8. [DOI: 10.1176/appi.ajp.2007.07040636] [PMID: 18347003]BatemanA , FonagyP . Effectiveness of partial hospitalization in the treatment of borderline personality disorder: a randomized controlled trial. American Journal of Psychiatry1999;156(10):1563-9. [DOI: 10.1176/ajp.156.10.1563] [PMID: 10518167]BatemanA , FonagyP . Health care utilization costs for borderline personality disorder patients treated with psychoanalytically oriented partial hospitalization versus general psychiatric care. American Journal of Psychiatry2003;160(1):169-71. [10.1176/appi.ajp.160.1.169] [12505818]BatemanA , FonagyP . Treatment of borderline personality disorder with psychoanalytically oriented partial hospitalization: an 18-month follow-up. American Journal of Psychiatry2001;158(1):36-42. [DOI: 10.1176/appi.ajp.158.1.36] [PMID: 11136631]BatemanA . Important: question regarding your BPD trial for systematic review in Cochrane Collaboration [personal communication]. Email to: K Lieb, J Stoffers 14 December 2010. BatemanA . Intensive outpatient and partial hospital care for BPD. In: 157th annual meeting of the American Psychiatric Association. Psychotherapy and pharmacology: dissolving the mind-brain barrier; 2004 May 1-6; New York (NY). Arlington (VA): American Psychiatric Association, 2004:102. [Symposium 100B] [www.psychiatry.org/File%20Library/Psychiatrists/Directories/Library-and-Archive/conference_publications/am_program_2004.pdf]BatemanAW , FonagyP . Drs Bateman and Fonagy reply [to Stern R. Partial hospitalization for borderline personality disorder. American Journal of Psychiatry 2001;158(11):1932-3. DOI: 10.1176/appi.ajp.158.11.1932]. American Journal of Psychiatry2001;158(11):1932-3. [DOI: 10.1176/appi.ajp.158.11.1932-a]EvansC . Treatment benefits of psychoanalytically oriented partial hospitalisation were maintained over 18 months in borderline personality disorder. Evidence-Based Mental Health2001;4(3):73. [DOI: 10.1136/ebmh.4.3.73]FonagyP , BatemanAW . Mentalizing and borderline personality disorder. Journal of Mental Health2007;16(1):83-101. [DOI: 10.1080/09638230601182045]SternR . Partial hospitalization for borderline personality disorder. American Journal of Psychiatry2001;158(11):1932-3. [DOI: 10.1176/appi.ajp.158.11.1932] [PMID: 11691712]">Bateman 1999</a>; <a href="./references#CD012955-bbs2-0033" title="JørgensenCR , BøyeR , AndersenD , Døssing BlaabjergAH , FreundC , JordetH , et al. Eighteen months post-treatment naturalistic follow-up study of mentalization-based therapy and supportive group treatment of borderline personality disorder: clinical outcomes and functioning. Nordic Psychology2014;66(4):254-73. [DOI: 10.1080/19012276.2014.963649]JørgensenCR , FreundC , BøyeR , JordetH , AndersenD , KjølbyeM . Outcome of mentalization-based and supportive psychotherapy in patients with borderline personality disorder: a randomized trial. Acta Psychiatrica Scandinavica2013;127(4):305-17. [DOI: 10.1111/j.1600-0447.2012.01923.x] [PMID: 22897123]JorgensenCR . SV: questions on your trial regarding MBT for BPD patients [personal communication]. Email to: EG Faltinsen 28 November 2017. ">Jørgensen 2013</a>; <a href="./references#CD012955-bbs2-0041" title="LaurenssenEM , WestraD , KikkertMJ , NoomMJ , EerenHV , Van BroekhuyzenAJ , et al. Day hospital mentalization-based treatment (MBT-DH) versus treatment as usual in the treatment of severe borderline personality disorder: protocol of a randomized controlled trial. BMC Psychiatry2014;14:149. [DOI: 10.1186/1471-244X-14-149] [PMC4045960] [PMID: 24886402]LaurenssenEMP , LuytenP , KikkertMJ , WestraD , PeenJ , SoonsMBJ , et al. Day hospital mentalization-based treatment v specialist treatment as usual in patients with borderline personality disorder: randomized controlled trial. Psychological Medicine2018;48(15):2522-9. [DOI: 10.1017/S0033291718000132] [PMID: 29478425]NL2058 (NTR2175). Mentalisation-based treatment versus care-as-usual in the treatment of severe borderline personality disorders. www.trialregister.nl/trial/2058 (first received 21 January 2010). ">Laurenssen 2018</a>; <a href="./references#CD012955-bbs2-0058" title="PhilipsB , WennebergP , KonradssonP , FranckJ . Mentalization-based treatment for concurrent borderline personality disorder and substance use disorder: a randomized controlled feasibility study. European Addiction Research2018;24(1):1-8. [DOI: 10.1159/000485564] [PMC5969093] [PMID: 294028]">Philips 2018</a>; <a href="./references#CD012955-bbs2-0061" title="ISRCTN51304415. Nice OUtcomes for Referrals with Impulsivity, Self Harm and Eating Disorders: the NOURISHED study [A randomised controlled trial of mentalisation based therapy against specialist supportive clinical management in patients with both eating disorders and symptoms of borderline personality disorder]. www.isrctn.com/ISRCTN51304415 (first received 31 January 2011). RobinsonP , BarrettB , BatemanA , HakeemA , HellierJ , LemonskyF , et al. Study protocol for a randomized controlled trial of mentalization based therapy against specialist supportive clinical management in patients with both eating disorders and symptoms of borderline personality disorder. BMC Psychiatry2014;14:51. [DOI: 10.1186/1471-244X-14-51] [PMC3996076] [PMID: 24555511]RobinsonP , HellierJ , BarrettB , BarzdaitieneD , BatemanA , BogaardtA , et al. The NOURISHED randomised controlled trial comparing mentalisation-based treatment for eating disorders (MBT-ED) with specialist supportive clinical management (SSCM-ED) for patients with eating disorders and symptoms of borderline personality disorder. Trials2016;17(1):549. [DOI: 10.1186/s13063-016-1606-8] [PMC5114835] [PMID: 27855714]">Robinson 2016</a>; <a href="./references#CD012955-bbs2-0062" title="ISRCTN95266816. The emergence of personality disorder traits in adolescents who deliberately self harm and the potential for using a mentalisation based treatment approach as an early intervention for such individuals: a randomised controlled trial. www.isrctn.com/ISRCTN95266816 (first received 29 October 2007). RossouwT . Mentalisation based treatment for adolescents with self harm: an RCT. European Child &amp; Adolescent Psychiatry2015;24(1 Suppl):S113. [DOI: 10.1007%2Fs00787-015-0714-4.pdf] [W1-02-02]RossouwT . Self harm in adolescence, is MBT the answer?: an RCT. Adolescent Psychiatry2012;2(1):102. [DOI: 10.2174/2210676611202010077]RossouwTI , FonagyP . Mentalization-based treatment for self-harm in adolescents: a randomized controlled trial. Journal of the American Academy of Child and Adolescent Psychiatry2012;51(12):1304-13.e3. [DOI: 10.1016/j.jaac.2012.09.018] [PMID: 23200287]">Rossouw 2012b</a>). </p> <p>MBT did not reduce BPD symptom severity at end of treatment compared with TAU (SMD −0.13, 95% CI −0.38 to 0.11; 5 trials, 267 participants; I<sup>2</sup> = 0%; P = 0.28; <a href="./references#CD012955-fig-0044" title="">Analysis 4.1</a>.1). </p> <p>MBT did not reduce BPD symptom severity at zero to six months follow‐up compared with TAU (SMD −0.40, 95% CI −1.49 to 0.68; 1 trial, 15 participants; P = 0.47; MD −2.90, 95% CI −10.87 to 5.07; 1 trial, 15 participants; P = 0.48; <a href="./references#CD012955-fig-0044" title="">Analysis 4.1</a>.2). </p> <p>Above 12 months follow‐up: MBT did not reduce BPD symptom severity at above 12 months follow‐up compared with TAU (SMD −0.94, 95% CI −2.58 to 0.70; 2 trials, 97 participants; I<sup>2</sup> = 92%; P = 0.26; <a href="./references#CD012955-fig-0044" title="">Analysis 4.1</a>.3; random‐effects model). </p> <p>Above 12 months follow‐up: MBT reduced BPD symptom severity at above 12 months follow‐up compared with TAU (SMD −0.76, 95% CI −1.22 to −0.30; 2 trials, 97 participants; I<sup>2</sup> = 92%; P = 0.001; analysis not shown; fixed‐effect model). </p> <p>No data were available for six to 12 months follow‐up.</p> </section> <section id="CD012955-sec-0128"> <h6 class="title">4.2 Self‐harm (continuous)</h6> <p>One trial reported continuous data on self‐harm (<a href="./references#CD012955-bbs2-0058" title="PhilipsB , WennebergP , KonradssonP , FranckJ . Mentalization-based treatment for concurrent borderline personality disorder and substance use disorder: a randomized controlled feasibility study. European Addiction Research2018;24(1):1-8. [DOI: 10.1159/000485564] [PMC5969093] [PMID: 294028]">Philips 2018</a>). </p> <p>MBT did not reduce self‐harm at end of treatment compared with TAU (MD 0.10, 95% CI −4.02 to 4.22; 1 trial, 24 participants; P = 0.96; <a href="./references#CD012955-fig-0045" title="">Analysis 4.2</a>.1). </p> </section> <section id="CD012955-sec-0129"> <h6 class="title">4.3 Self‐harm (dichotomous)</h6> <p>Three trials reported dichotomous data on self‐harm (<a href="./references#CD012955-bbs2-0004" title="BatemanA , FonagyP . 8-year follow-up of patients treated for borderline personality disorder: mentalization-based treatment versus treatment as usual. American Journal of Psychiatry2008;165(5):631-8. [DOI: 10.1176/appi.ajp.2007.07040636] [PMID: 18347003]BatemanA , FonagyP . Effectiveness of partial hospitalization in the treatment of borderline personality disorder: a randomized controlled trial. American Journal of Psychiatry1999;156(10):1563-9. [DOI: 10.1176/ajp.156.10.1563] [PMID: 10518167]BatemanA , FonagyP . Health care utilization costs for borderline personality disorder patients treated with psychoanalytically oriented partial hospitalization versus general psychiatric care. American Journal of Psychiatry2003;160(1):169-71. [10.1176/appi.ajp.160.1.169] [12505818]BatemanA , FonagyP . Treatment of borderline personality disorder with psychoanalytically oriented partial hospitalization: an 18-month follow-up. American Journal of Psychiatry2001;158(1):36-42. [DOI: 10.1176/appi.ajp.158.1.36] [PMID: 11136631]BatemanA . Important: question regarding your BPD trial for systematic review in Cochrane Collaboration [personal communication]. Email to: K Lieb, J Stoffers 14 December 2010. BatemanA . Intensive outpatient and partial hospital care for BPD. In: 157th annual meeting of the American Psychiatric Association. Psychotherapy and pharmacology: dissolving the mind-brain barrier; 2004 May 1-6; New York (NY). Arlington (VA): American Psychiatric Association, 2004:102. [Symposium 100B] [www.psychiatry.org/File%20Library/Psychiatrists/Directories/Library-and-Archive/conference_publications/am_program_2004.pdf]BatemanAW , FonagyP . Drs Bateman and Fonagy reply [to Stern R. Partial hospitalization for borderline personality disorder. American Journal of Psychiatry 2001;158(11):1932-3. DOI: 10.1176/appi.ajp.158.11.1932]. American Journal of Psychiatry2001;158(11):1932-3. [DOI: 10.1176/appi.ajp.158.11.1932-a]EvansC . Treatment benefits of psychoanalytically oriented partial hospitalisation were maintained over 18 months in borderline personality disorder. Evidence-Based Mental Health2001;4(3):73. [DOI: 10.1136/ebmh.4.3.73]FonagyP , BatemanAW . Mentalizing and borderline personality disorder. Journal of Mental Health2007;16(1):83-101. [DOI: 10.1080/09638230601182045]SternR . Partial hospitalization for borderline personality disorder. American Journal of Psychiatry2001;158(11):1932-3. [DOI: 10.1176/appi.ajp.158.11.1932] [PMID: 11691712]">Bateman 1999</a>; <a href="./references#CD012955-bbs2-0005" title="BatemanA , FonagyP . Impact of clinical severity on outcomes of mentalisation-based treatment for borderline personality disorder. British Journal of Psychiatry2013;203(3):221-7. [DOI: 10.1192/bjp.bp.112.121129] [PMID: 23887998]BatemanA , FonagyP . Randomized controlled trial of outpatient mentalization-based treatment versus structured clinical management for borderline personality disorder. American Journal of Psychiatry2009;166(12):1355-64. [DOI: 10.1176/appi.ajp.2009.09040539] [PMID: 19833787]BatemanA , FonagyP . Randomized controlled trial of outpatient mentalization-based treatment versus structured clinical management for borderline personality disorder. Supplementary data. ajp.psychiatryonline.org/doi/suppl/10.1176/appi.ajp.2009.09040539/suppl_file/ajp_166_12_1355_01.pdf (accessed 27 February 2020). BatemanA , O'ConnellJ , LorenziniN , GardnerT , FonagyP . A randomised controlled trial of mentalization-based treatment versus structured clinical management for patients with comorbid borderline personality disorder and antisocial personality disorder. BMC Psychiatry2016;16:304. [DOI: 10.1186/s12888-016-1000-9] [PMC5006360] [PMID: 27577562]BatemanA . Important question regarding your BPD trial for systematic review in Cochrane Collaboration [personal communication]. Email to: K Lieb 14 December 2010. BatemanAW . Mentalization, borderline personality disorder and what works for whom? Presentation at the 11th International Congress of the International Society for the Study of Personality Disorders; 2009 Aug 21-23. www.borderlinepersonalitydisorder.com/Conferences/ISSPD/isspd_09_Bateman (accessed 21 April 2010). ISRCTN27660668. Randomised controlled trial of manualised out-patient individual and group therapy for borderline personality disorder [Effectiveness of intensive out-patient psychotherapy for treatment of borderline personality disorder: a pragmatic randomised single blind controlled study]. www.isrctn.com/ISRCTN27660668 (first received 12 October 2008). ">Bateman 2009</a>; <a href="./references#CD012955-bbs2-0062" title="ISRCTN95266816. The emergence of personality disorder traits in adolescents who deliberately self harm and the potential for using a mentalisation based treatment approach as an early intervention for such individuals: a randomised controlled trial. www.isrctn.com/ISRCTN95266816 (first received 29 October 2007). RossouwT . Mentalisation based treatment for adolescents with self harm: an RCT. European Child &amp; Adolescent Psychiatry2015;24(1 Suppl):S113. [DOI: 10.1007%2Fs00787-015-0714-4.pdf] [W1-02-02]RossouwT . Self harm in adolescence, is MBT the answer?: an RCT. Adolescent Psychiatry2012;2(1):102. [DOI: 10.2174/2210676611202010077]RossouwTI , FonagyP . Mentalization-based treatment for self-harm in adolescents: a randomized controlled trial. Journal of the American Academy of Child and Adolescent Psychiatry2012;51(12):1304-13.e3. [DOI: 10.1016/j.jaac.2012.09.018] [PMID: 23200287]">Rossouw 2012b</a>). </p> <p>MBT reduced self‐harm at end of treatment compared with TAU (RR 0.62, 95% CI 0.49 to 0.80; 3 trials, 252 participants; I<sup>2</sup> = 7%; P = 0.0002; <a href="./references#CD012955-fig-0046" title="">Analysis 4.3</a>.1; low‐quality evidence, <a href="./full#CD012955-tbl-0003">summary of findings Table 3</a>). </p> <p>MBT reduced self‐harm at zero to six months follow‐up compared with TAU (RR 0.14, 95% CI 0.04 to 0.56; 1 trial, 41 participants; P = 0.005; <a href="./references#CD012955-fig-0046" title="">Analysis 4.3</a>.2). </p> <p>MBT reduced self‐harm at six to 12 months follow‐up compared with TAU (RR 0.27, 95% CI 0.10 to 0.68; 1 trial, 41 participants; P = 0.006; <a href="./references#CD012955-fig-0046" title="">Analysis 4.3</a>.3). </p> <p>MBT reduced self‐harm at above 12 months follow‐up compared with TAU (RR 0.33, 95% CI 0.15 to 0.76; 1 trial, 41 participants; P = 0.009; <a href="./references#CD012955-fig-0046" title="">Analysis 4.3</a>.4). </p> </section> <section id="CD012955-sec-0130"> <h6 class="title">4.4 Suicide‐related outcomes</h6> <p>Three trials reported dichotomous data on suicide‐related outcomes (<a href="./references#CD012955-bbs2-0004" title="BatemanA , FonagyP . 8-year follow-up of patients treated for borderline personality disorder: mentalization-based treatment versus treatment as usual. American Journal of Psychiatry2008;165(5):631-8. [DOI: 10.1176/appi.ajp.2007.07040636] [PMID: 18347003]BatemanA , FonagyP . Effectiveness of partial hospitalization in the treatment of borderline personality disorder: a randomized controlled trial. American Journal of Psychiatry1999;156(10):1563-9. [DOI: 10.1176/ajp.156.10.1563] [PMID: 10518167]BatemanA , FonagyP . Health care utilization costs for borderline personality disorder patients treated with psychoanalytically oriented partial hospitalization versus general psychiatric care. American Journal of Psychiatry2003;160(1):169-71. [10.1176/appi.ajp.160.1.169] [12505818]BatemanA , FonagyP . Treatment of borderline personality disorder with psychoanalytically oriented partial hospitalization: an 18-month follow-up. American Journal of Psychiatry2001;158(1):36-42. [DOI: 10.1176/appi.ajp.158.1.36] [PMID: 11136631]BatemanA . Important: question regarding your BPD trial for systematic review in Cochrane Collaboration [personal communication]. Email to: K Lieb, J Stoffers 14 December 2010. BatemanA . Intensive outpatient and partial hospital care for BPD. In: 157th annual meeting of the American Psychiatric Association. Psychotherapy and pharmacology: dissolving the mind-brain barrier; 2004 May 1-6; New York (NY). Arlington (VA): American Psychiatric Association, 2004:102. [Symposium 100B] [www.psychiatry.org/File%20Library/Psychiatrists/Directories/Library-and-Archive/conference_publications/am_program_2004.pdf]BatemanAW , FonagyP . Drs Bateman and Fonagy reply [to Stern R. Partial hospitalization for borderline personality disorder. American Journal of Psychiatry 2001;158(11):1932-3. DOI: 10.1176/appi.ajp.158.11.1932]. American Journal of Psychiatry2001;158(11):1932-3. [DOI: 10.1176/appi.ajp.158.11.1932-a]EvansC . Treatment benefits of psychoanalytically oriented partial hospitalisation were maintained over 18 months in borderline personality disorder. Evidence-Based Mental Health2001;4(3):73. [DOI: 10.1136/ebmh.4.3.73]FonagyP , BatemanAW . Mentalizing and borderline personality disorder. Journal of Mental Health2007;16(1):83-101. [DOI: 10.1080/09638230601182045]SternR . Partial hospitalization for borderline personality disorder. American Journal of Psychiatry2001;158(11):1932-3. [DOI: 10.1176/appi.ajp.158.11.1932] [PMID: 11691712]">Bateman 1999</a>; <a href="./references#CD012955-bbs2-0005" title="BatemanA , FonagyP . Impact of clinical severity on outcomes of mentalisation-based treatment for borderline personality disorder. British Journal of Psychiatry2013;203(3):221-7. [DOI: 10.1192/bjp.bp.112.121129] [PMID: 23887998]BatemanA , FonagyP . Randomized controlled trial of outpatient mentalization-based treatment versus structured clinical management for borderline personality disorder. American Journal of Psychiatry2009;166(12):1355-64. [DOI: 10.1176/appi.ajp.2009.09040539] [PMID: 19833787]BatemanA , FonagyP . Randomized controlled trial of outpatient mentalization-based treatment versus structured clinical management for borderline personality disorder. Supplementary data. ajp.psychiatryonline.org/doi/suppl/10.1176/appi.ajp.2009.09040539/suppl_file/ajp_166_12_1355_01.pdf (accessed 27 February 2020). BatemanA , O'ConnellJ , LorenziniN , GardnerT , FonagyP . A randomised controlled trial of mentalization-based treatment versus structured clinical management for patients with comorbid borderline personality disorder and antisocial personality disorder. BMC Psychiatry2016;16:304. [DOI: 10.1186/s12888-016-1000-9] [PMC5006360] [PMID: 27577562]BatemanA . Important question regarding your BPD trial for systematic review in Cochrane Collaboration [personal communication]. Email to: K Lieb 14 December 2010. BatemanAW . Mentalization, borderline personality disorder and what works for whom? Presentation at the 11th International Congress of the International Society for the Study of Personality Disorders; 2009 Aug 21-23. www.borderlinepersonalitydisorder.com/Conferences/ISSPD/isspd_09_Bateman (accessed 21 April 2010). ISRCTN27660668. Randomised controlled trial of manualised out-patient individual and group therapy for borderline personality disorder [Effectiveness of intensive out-patient psychotherapy for treatment of borderline personality disorder: a pragmatic randomised single blind controlled study]. www.isrctn.com/ISRCTN27660668 (first received 12 October 2008). ">Bateman 2009</a>; <a href="./references#CD012955-bbs2-0058" title="PhilipsB , WennebergP , KonradssonP , FranckJ . Mentalization-based treatment for concurrent borderline personality disorder and substance use disorder: a randomized controlled feasibility study. European Addiction Research2018;24(1):1-8. [DOI: 10.1159/000485564] [PMC5969093] [PMID: 294028]">Philips 2018</a>). </p> <p>MBT reduced suicide‐related outcomes at end of treatment compared with TAU (RR 0.10, 95% CI 0.04 to 0.30; 3 trials, 218 participants; I<sup>2</sup> = 0%; P &lt; 0.001; <a href="./references#CD012955-fig-0047" title="">Analysis 4.4</a>.1; low‐quality evidence, <a href="./full#CD012955-tbl-0003">summary of findings Table 3</a>). </p> <p>MBT did not reduce suicide‐related outcomes at zero to six months follow‐up compared with TAU (RR 0.25, 95% CI 0.06 to 1.05; 1 trial, 41 participants; P = 0.06; <a href="./references#CD012955-fig-0047" title="">Analysis 4.4</a>.2). </p> <p>MBT reduced suicide‐related outcomes at above 12 months follow‐up compared with TAU (RR 0.29, 95% CI 0.11 to 0.74; 1 trial, 41 participants; P &lt; 0.001; <a href="./references#CD012955-fig-0047" title="">Analysis 4.4</a>.3). </p> <p>No data were available for six to 12 months follow‐up.</p> </section> <section id="CD012955-sec-0131"> <h6 class="title">4.5 Psychosocial functioning</h6> <p>Three trials reported continuous data on psychosocial functioning (<a href="./references#CD012955-bbs2-0004" title="BatemanA , FonagyP . 8-year follow-up of patients treated for borderline personality disorder: mentalization-based treatment versus treatment as usual. American Journal of Psychiatry2008;165(5):631-8. [DOI: 10.1176/appi.ajp.2007.07040636] [PMID: 18347003]BatemanA , FonagyP . Effectiveness of partial hospitalization in the treatment of borderline personality disorder: a randomized controlled trial. American Journal of Psychiatry1999;156(10):1563-9. [DOI: 10.1176/ajp.156.10.1563] [PMID: 10518167]BatemanA , FonagyP . Health care utilization costs for borderline personality disorder patients treated with psychoanalytically oriented partial hospitalization versus general psychiatric care. American Journal of Psychiatry2003;160(1):169-71. [10.1176/appi.ajp.160.1.169] [12505818]BatemanA , FonagyP . Treatment of borderline personality disorder with psychoanalytically oriented partial hospitalization: an 18-month follow-up. American Journal of Psychiatry2001;158(1):36-42. [DOI: 10.1176/appi.ajp.158.1.36] [PMID: 11136631]BatemanA . Important: question regarding your BPD trial for systematic review in Cochrane Collaboration [personal communication]. Email to: K Lieb, J Stoffers 14 December 2010. BatemanA . Intensive outpatient and partial hospital care for BPD. In: 157th annual meeting of the American Psychiatric Association. Psychotherapy and pharmacology: dissolving the mind-brain barrier; 2004 May 1-6; New York (NY). Arlington (VA): American Psychiatric Association, 2004:102. [Symposium 100B] [www.psychiatry.org/File%20Library/Psychiatrists/Directories/Library-and-Archive/conference_publications/am_program_2004.pdf]BatemanAW , FonagyP . Drs Bateman and Fonagy reply [to Stern R. Partial hospitalization for borderline personality disorder. American Journal of Psychiatry 2001;158(11):1932-3. DOI: 10.1176/appi.ajp.158.11.1932]. American Journal of Psychiatry2001;158(11):1932-3. [DOI: 10.1176/appi.ajp.158.11.1932-a]EvansC . Treatment benefits of psychoanalytically oriented partial hospitalisation were maintained over 18 months in borderline personality disorder. Evidence-Based Mental Health2001;4(3):73. [DOI: 10.1136/ebmh.4.3.73]FonagyP , BatemanAW . Mentalizing and borderline personality disorder. Journal of Mental Health2007;16(1):83-101. [DOI: 10.1080/09638230601182045]SternR . Partial hospitalization for borderline personality disorder. American Journal of Psychiatry2001;158(11):1932-3. [DOI: 10.1176/appi.ajp.158.11.1932] [PMID: 11691712]">Bateman 1999</a>; <a href="./references#CD012955-bbs2-0005" title="BatemanA , FonagyP . Impact of clinical severity on outcomes of mentalisation-based treatment for borderline personality disorder. British Journal of Psychiatry2013;203(3):221-7. [DOI: 10.1192/bjp.bp.112.121129] [PMID: 23887998]BatemanA , FonagyP . Randomized controlled trial of outpatient mentalization-based treatment versus structured clinical management for borderline personality disorder. American Journal of Psychiatry2009;166(12):1355-64. [DOI: 10.1176/appi.ajp.2009.09040539] [PMID: 19833787]BatemanA , FonagyP . Randomized controlled trial of outpatient mentalization-based treatment versus structured clinical management for borderline personality disorder. Supplementary data. ajp.psychiatryonline.org/doi/suppl/10.1176/appi.ajp.2009.09040539/suppl_file/ajp_166_12_1355_01.pdf (accessed 27 February 2020). BatemanA , O'ConnellJ , LorenziniN , GardnerT , FonagyP . A randomised controlled trial of mentalization-based treatment versus structured clinical management for patients with comorbid borderline personality disorder and antisocial personality disorder. BMC Psychiatry2016;16:304. [DOI: 10.1186/s12888-016-1000-9] [PMC5006360] [PMID: 27577562]BatemanA . Important question regarding your BPD trial for systematic review in Cochrane Collaboration [personal communication]. Email to: K Lieb 14 December 2010. BatemanAW . Mentalization, borderline personality disorder and what works for whom? Presentation at the 11th International Congress of the International Society for the Study of Personality Disorders; 2009 Aug 21-23. www.borderlinepersonalitydisorder.com/Conferences/ISSPD/isspd_09_Bateman (accessed 21 April 2010). ISRCTN27660668. Randomised controlled trial of manualised out-patient individual and group therapy for borderline personality disorder [Effectiveness of intensive out-patient psychotherapy for treatment of borderline personality disorder: a pragmatic randomised single blind controlled study]. www.isrctn.com/ISRCTN27660668 (first received 12 October 2008). ">Bateman 2009</a>; <a href="./references#CD012955-bbs2-0033" title="JørgensenCR , BøyeR , AndersenD , Døssing BlaabjergAH , FreundC , JordetH , et al. Eighteen months post-treatment naturalistic follow-up study of mentalization-based therapy and supportive group treatment of borderline personality disorder: clinical outcomes and functioning. Nordic Psychology2014;66(4):254-73. [DOI: 10.1080/19012276.2014.963649]JørgensenCR , FreundC , BøyeR , JordetH , AndersenD , KjølbyeM . Outcome of mentalization-based and supportive psychotherapy in patients with borderline personality disorder: a randomized trial. Acta Psychiatrica Scandinavica2013;127(4):305-17. [DOI: 10.1111/j.1600-0447.2012.01923.x] [PMID: 22897123]JorgensenCR . SV: questions on your trial regarding MBT for BPD patients [personal communication]. Email to: EG Faltinsen 28 November 2017. ">Jørgensen 2013</a>). </p> <p>MBT did not improve psychosocial functioning at end of treatment compared with TAU (SMD −0.54, 95% CI −1.24 to 0.16; 3 trials, 239 participants; I<sup>2</sup> = 83%; P = 0.13; <a href="./references#CD012955-fig-0048" title="">Analysis 4.5</a>.1; random‐effects model). </p> <p>MBT improved psychosocial functioning at end of treatment compared with TAU (SMD −0.53, 95% CI −0.79 to −0.27; 3 trials, 239 participants; I<sup>2</sup> = 83%; P &lt; 0.0001; analysis not shown; fixed‐effect model). </p> <p>MBT did not improve psychosocial functioning at above 12 months follow‐up compared with TAU (SMD −0.41, 95% CI −0.97 to 0.15; 2 trials, 104 participants; I<sup>2</sup> = 47%; P = 0.1507; <a href="./references#CD012955-fig-0048" title="">Analysis 4.5</a>.2). </p> <p>No data were available for zero to six months and six to 12 months follow‐up.</p> </section> </section> <section id="CD012955-sec-0132"> <h5 class="title">Secondary outcomes</h5> <section id="CD012955-sec-0133"> <h6 class="title">4.6 Interpersonal problems</h6> <p>Five trials reported continuous data on interpersonal problems (<a href="./references#CD012955-bbs2-0004" title="BatemanA , FonagyP . 8-year follow-up of patients treated for borderline personality disorder: mentalization-based treatment versus treatment as usual. American Journal of Psychiatry2008;165(5):631-8. [DOI: 10.1176/appi.ajp.2007.07040636] [PMID: 18347003]BatemanA , FonagyP . Effectiveness of partial hospitalization in the treatment of borderline personality disorder: a randomized controlled trial. American Journal of Psychiatry1999;156(10):1563-9. [DOI: 10.1176/ajp.156.10.1563] [PMID: 10518167]BatemanA , FonagyP . Health care utilization costs for borderline personality disorder patients treated with psychoanalytically oriented partial hospitalization versus general psychiatric care. American Journal of Psychiatry2003;160(1):169-71. [10.1176/appi.ajp.160.1.169] [12505818]BatemanA , FonagyP . Treatment of borderline personality disorder with psychoanalytically oriented partial hospitalization: an 18-month follow-up. American Journal of Psychiatry2001;158(1):36-42. [DOI: 10.1176/appi.ajp.158.1.36] [PMID: 11136631]BatemanA . Important: question regarding your BPD trial for systematic review in Cochrane Collaboration [personal communication]. Email to: K Lieb, J Stoffers 14 December 2010. BatemanA . Intensive outpatient and partial hospital care for BPD. In: 157th annual meeting of the American Psychiatric Association. Psychotherapy and pharmacology: dissolving the mind-brain barrier; 2004 May 1-6; New York (NY). Arlington (VA): American Psychiatric Association, 2004:102. [Symposium 100B] [www.psychiatry.org/File%20Library/Psychiatrists/Directories/Library-and-Archive/conference_publications/am_program_2004.pdf]BatemanAW , FonagyP . Drs Bateman and Fonagy reply [to Stern R. Partial hospitalization for borderline personality disorder. American Journal of Psychiatry 2001;158(11):1932-3. DOI: 10.1176/appi.ajp.158.11.1932]. American Journal of Psychiatry2001;158(11):1932-3. [DOI: 10.1176/appi.ajp.158.11.1932-a]EvansC . Treatment benefits of psychoanalytically oriented partial hospitalisation were maintained over 18 months in borderline personality disorder. Evidence-Based Mental Health2001;4(3):73. [DOI: 10.1136/ebmh.4.3.73]FonagyP , BatemanAW . Mentalizing and borderline personality disorder. Journal of Mental Health2007;16(1):83-101. [DOI: 10.1080/09638230601182045]SternR . Partial hospitalization for borderline personality disorder. American Journal of Psychiatry2001;158(11):1932-3. [DOI: 10.1176/appi.ajp.158.11.1932] [PMID: 11691712]">Bateman 1999</a>; <a href="./references#CD012955-bbs2-0005" title="BatemanA , FonagyP . Impact of clinical severity on outcomes of mentalisation-based treatment for borderline personality disorder. British Journal of Psychiatry2013;203(3):221-7. [DOI: 10.1192/bjp.bp.112.121129] [PMID: 23887998]BatemanA , FonagyP . Randomized controlled trial of outpatient mentalization-based treatment versus structured clinical management for borderline personality disorder. American Journal of Psychiatry2009;166(12):1355-64. [DOI: 10.1176/appi.ajp.2009.09040539] [PMID: 19833787]BatemanA , FonagyP . Randomized controlled trial of outpatient mentalization-based treatment versus structured clinical management for borderline personality disorder. Supplementary data. ajp.psychiatryonline.org/doi/suppl/10.1176/appi.ajp.2009.09040539/suppl_file/ajp_166_12_1355_01.pdf (accessed 27 February 2020). BatemanA , O'ConnellJ , LorenziniN , GardnerT , FonagyP . A randomised controlled trial of mentalization-based treatment versus structured clinical management for patients with comorbid borderline personality disorder and antisocial personality disorder. BMC Psychiatry2016;16:304. [DOI: 10.1186/s12888-016-1000-9] [PMC5006360] [PMID: 27577562]BatemanA . Important question regarding your BPD trial for systematic review in Cochrane Collaboration [personal communication]. Email to: K Lieb 14 December 2010. BatemanAW . Mentalization, borderline personality disorder and what works for whom? Presentation at the 11th International Congress of the International Society for the Study of Personality Disorders; 2009 Aug 21-23. www.borderlinepersonalitydisorder.com/Conferences/ISSPD/isspd_09_Bateman (accessed 21 April 2010). ISRCTN27660668. Randomised controlled trial of manualised out-patient individual and group therapy for borderline personality disorder [Effectiveness of intensive out-patient psychotherapy for treatment of borderline personality disorder: a pragmatic randomised single blind controlled study]. www.isrctn.com/ISRCTN27660668 (first received 12 October 2008). ">Bateman 2009</a>; <a href="./references#CD012955-bbs2-0033" title="JørgensenCR , BøyeR , AndersenD , Døssing BlaabjergAH , FreundC , JordetH , et al. Eighteen months post-treatment naturalistic follow-up study of mentalization-based therapy and supportive group treatment of borderline personality disorder: clinical outcomes and functioning. Nordic Psychology2014;66(4):254-73. [DOI: 10.1080/19012276.2014.963649]JørgensenCR , FreundC , BøyeR , JordetH , AndersenD , KjølbyeM . Outcome of mentalization-based and supportive psychotherapy in patients with borderline personality disorder: a randomized trial. Acta Psychiatrica Scandinavica2013;127(4):305-17. [DOI: 10.1111/j.1600-0447.2012.01923.x] [PMID: 22897123]JorgensenCR . SV: questions on your trial regarding MBT for BPD patients [personal communication]. Email to: EG Faltinsen 28 November 2017. ">Jørgensen 2013</a>; <a href="./references#CD012955-bbs2-0033" title="JørgensenCR , BøyeR , AndersenD , Døssing BlaabjergAH , FreundC , JordetH , et al. Eighteen months post-treatment naturalistic follow-up study of mentalization-based therapy and supportive group treatment of borderline personality disorder: clinical outcomes and functioning. Nordic Psychology2014;66(4):254-73. [DOI: 10.1080/19012276.2014.963649]JørgensenCR , FreundC , BøyeR , JordetH , AndersenD , KjølbyeM . Outcome of mentalization-based and supportive psychotherapy in patients with borderline personality disorder: a randomized trial. Acta Psychiatrica Scandinavica2013;127(4):305-17. [DOI: 10.1111/j.1600-0447.2012.01923.x] [PMID: 22897123]JorgensenCR . SV: questions on your trial regarding MBT for BPD patients [personal communication]. Email to: EG Faltinsen 28 November 2017. ">Jørgensen 2013</a>; <a href="./references#CD012955-bbs2-0058" title="PhilipsB , WennebergP , KonradssonP , FranckJ . Mentalization-based treatment for concurrent borderline personality disorder and substance use disorder: a randomized controlled feasibility study. European Addiction Research2018;24(1):1-8. [DOI: 10.1159/000485564] [PMC5969093] [PMID: 294028]">Philips 2018</a>). </p> <p>MBT reduced interpersonal problems at end of treatment compared with TAU (SMD −0.68, 95% CI −1.33 to −0.02; 5 trials, 357 participants; I<sup>2</sup> = 87%; P = 0.04; <a href="./references#CD012955-fig-0049" title="">Analysis 4.6</a>.1). </p> <p>MBT did not reduce interpersonal problems at zero to six months follow‐up compared with TAU (SMD −0.41, 95% CI −1.01 to 0.20; 1 trial, 53 participants; P = 0.19; MD −0.30, 95% CI −0.76 to 0.16; 1 trial, 53 participants; P = 0.20; <a href="./references#CD012955-fig-0049" title="">Analysis 4.6</a>.2). </p> <p>MBT did not reduce interpersonal problems at above 12 months follow‐up compared with TAU (SMD −0.28, 95% CI −0.71 to 0.14; 2 trials, 96 participants; I<sup>2</sup> = 0%; P = 0.19; <a href="./references#CD012955-fig-0049" title="">Analysis 4.6</a>.3). </p> <p>No data were available for six to 12 months follow‐up.</p> </section> <section id="CD012955-sec-0134"> <h6 class="title">4.7 Depression (continuous)</h6> <p>Four trials reported continuous data on depression (<a href="./references#CD012955-bbs2-0004" title="BatemanA , FonagyP . 8-year follow-up of patients treated for borderline personality disorder: mentalization-based treatment versus treatment as usual. American Journal of Psychiatry2008;165(5):631-8. [DOI: 10.1176/appi.ajp.2007.07040636] [PMID: 18347003]BatemanA , FonagyP . Effectiveness of partial hospitalization in the treatment of borderline personality disorder: a randomized controlled trial. American Journal of Psychiatry1999;156(10):1563-9. [DOI: 10.1176/ajp.156.10.1563] [PMID: 10518167]BatemanA , FonagyP . Health care utilization costs for borderline personality disorder patients treated with psychoanalytically oriented partial hospitalization versus general psychiatric care. American Journal of Psychiatry2003;160(1):169-71. [10.1176/appi.ajp.160.1.169] [12505818]BatemanA , FonagyP . Treatment of borderline personality disorder with psychoanalytically oriented partial hospitalization: an 18-month follow-up. American Journal of Psychiatry2001;158(1):36-42. [DOI: 10.1176/appi.ajp.158.1.36] [PMID: 11136631]BatemanA . Important: question regarding your BPD trial for systematic review in Cochrane Collaboration [personal communication]. Email to: K Lieb, J Stoffers 14 December 2010. BatemanA . Intensive outpatient and partial hospital care for BPD. In: 157th annual meeting of the American Psychiatric Association. Psychotherapy and pharmacology: dissolving the mind-brain barrier; 2004 May 1-6; New York (NY). Arlington (VA): American Psychiatric Association, 2004:102. [Symposium 100B] [www.psychiatry.org/File%20Library/Psychiatrists/Directories/Library-and-Archive/conference_publications/am_program_2004.pdf]BatemanAW , FonagyP . Drs Bateman and Fonagy reply [to Stern R. Partial hospitalization for borderline personality disorder. American Journal of Psychiatry 2001;158(11):1932-3. DOI: 10.1176/appi.ajp.158.11.1932]. American Journal of Psychiatry2001;158(11):1932-3. [DOI: 10.1176/appi.ajp.158.11.1932-a]EvansC . Treatment benefits of psychoanalytically oriented partial hospitalisation were maintained over 18 months in borderline personality disorder. Evidence-Based Mental Health2001;4(3):73. [DOI: 10.1136/ebmh.4.3.73]FonagyP , BatemanAW . Mentalizing and borderline personality disorder. Journal of Mental Health2007;16(1):83-101. [DOI: 10.1080/09638230601182045]SternR . Partial hospitalization for borderline personality disorder. American Journal of Psychiatry2001;158(11):1932-3. [DOI: 10.1176/appi.ajp.158.11.1932] [PMID: 11691712]">Bateman 1999</a>; <a href="./references#CD012955-bbs2-0005" title="BatemanA , FonagyP . Impact of clinical severity on outcomes of mentalisation-based treatment for borderline personality disorder. British Journal of Psychiatry2013;203(3):221-7. [DOI: 10.1192/bjp.bp.112.121129] [PMID: 23887998]BatemanA , FonagyP . Randomized controlled trial of outpatient mentalization-based treatment versus structured clinical management for borderline personality disorder. American Journal of Psychiatry2009;166(12):1355-64. [DOI: 10.1176/appi.ajp.2009.09040539] [PMID: 19833787]BatemanA , FonagyP . Randomized controlled trial of outpatient mentalization-based treatment versus structured clinical management for borderline personality disorder. Supplementary data. ajp.psychiatryonline.org/doi/suppl/10.1176/appi.ajp.2009.09040539/suppl_file/ajp_166_12_1355_01.pdf (accessed 27 February 2020). BatemanA , O'ConnellJ , LorenziniN , GardnerT , FonagyP . A randomised controlled trial of mentalization-based treatment versus structured clinical management for patients with comorbid borderline personality disorder and antisocial personality disorder. BMC Psychiatry2016;16:304. [DOI: 10.1186/s12888-016-1000-9] [PMC5006360] [PMID: 27577562]BatemanA . Important question regarding your BPD trial for systematic review in Cochrane Collaboration [personal communication]. Email to: K Lieb 14 December 2010. BatemanAW . Mentalization, borderline personality disorder and what works for whom? Presentation at the 11th International Congress of the International Society for the Study of Personality Disorders; 2009 Aug 21-23. www.borderlinepersonalitydisorder.com/Conferences/ISSPD/isspd_09_Bateman (accessed 21 April 2010). ISRCTN27660668. Randomised controlled trial of manualised out-patient individual and group therapy for borderline personality disorder [Effectiveness of intensive out-patient psychotherapy for treatment of borderline personality disorder: a pragmatic randomised single blind controlled study]. www.isrctn.com/ISRCTN27660668 (first received 12 October 2008). ">Bateman 2009</a>; <a href="./references#CD012955-bbs2-0033" title="JørgensenCR , BøyeR , AndersenD , Døssing BlaabjergAH , FreundC , JordetH , et al. Eighteen months post-treatment naturalistic follow-up study of mentalization-based therapy and supportive group treatment of borderline personality disorder: clinical outcomes and functioning. Nordic Psychology2014;66(4):254-73. [DOI: 10.1080/19012276.2014.963649]JørgensenCR , FreundC , BøyeR , JordetH , AndersenD , KjølbyeM . Outcome of mentalization-based and supportive psychotherapy in patients with borderline personality disorder: a randomized trial. Acta Psychiatrica Scandinavica2013;127(4):305-17. [DOI: 10.1111/j.1600-0447.2012.01923.x] [PMID: 22897123]JorgensenCR . SV: questions on your trial regarding MBT for BPD patients [personal communication]. Email to: EG Faltinsen 28 November 2017. ">Jørgensen 2013</a>; <a href="./references#CD012955-bbs2-0041" title="LaurenssenEM , WestraD , KikkertMJ , NoomMJ , EerenHV , Van BroekhuyzenAJ , et al. Day hospital mentalization-based treatment (MBT-DH) versus treatment as usual in the treatment of severe borderline personality disorder: protocol of a randomized controlled trial. BMC Psychiatry2014;14:149. [DOI: 10.1186/1471-244X-14-149] [PMC4045960] [PMID: 24886402]LaurenssenEMP , LuytenP , KikkertMJ , WestraD , PeenJ , SoonsMBJ , et al. Day hospital mentalization-based treatment v specialist treatment as usual in patients with borderline personality disorder: randomized controlled trial. Psychological Medicine2018;48(15):2522-9. [DOI: 10.1017/S0033291718000132] [PMID: 29478425]NL2058 (NTR2175). Mentalisation-based treatment versus care-as-usual in the treatment of severe borderline personality disorders. www.trialregister.nl/trial/2058 (first received 21 January 2010). ">Laurenssen 2018</a>). </p> <p>MBT did not reduce depression at end of treatment compared with TAU (SMD −0.58, 95% CI −1.22 to 0.05; 4 trials, 333 participants; I<sup>2</sup> = 86%; P = 0.07; <a href="./references#CD012955-fig-0050" title="">Analysis 4.7</a>.1; random‐effects model). </p> <p>MBT reduced depression at end of treatment compared with TAU (SMD −0.38, 95% CI − 0.60 to −0.16; 4 trials, 333 participants; I<sup>2</sup> = 86%; P = 0.0009; analysis not shown; fixed‐effect model). </p> <p>MBT did not reduce depression at zero to six months follow‐up compared with TAU (SMD −0.81, 95% CI −1.69 to 0.07; 2 trials, 91 participants; I<sup>2</sup> = 72%; P = 0.07; <a href="./references#CD012955-fig-0050" title="">Analysis 4.7</a>.2; random‐effects model). </p> <p>MBT reduced depression at zero to six months follow‐up compared with TAU (SMD −0.76, 95% CI −1.22 to − 0.30; 2 trials, 91 participants; I<sup>2</sup> = 72%; P = 0.001; analysis not shown; fixed‐effect model). </p> <p>MBT reduced depression at six to 12 months follow‐up compared with TAU (SMD −1.17, 95% CI −1.88 to −0.45; 1 trial, 37 participants; P = 0.001; MD −8.20, 95% CI ‐12.96 to −3.44; 1 trial, 37 participants; P = 0.0007; <a href="./references#CD012955-fig-0050" title="">Analysis 4.7</a>.3). </p> <p>MBT did not reduce depression at above 12 months follow‐up compared with TAU (SMD −0.72, 95% CI −1.55 to 0.10; 2 trials, 90 participants; I<sup>2</sup> = 68%; P = 0.08; <a href="./references#CD012955-fig-0050" title="">Analysis 4.7</a>.4; random‐effects model). </p> <p>MBT reduced depression at above 12 months follow‐up compared with TAU (SMD −0.68, 95% CI −1.14 to − 0.22; 2 trials, 90 participants; I<sup>2</sup> = 68%; P = 0.004; analysis not shown; fixed‐effect model). </p> </section> <section id="CD012955-sec-0135"> <h6 class="title">4.8 Depression (dichotomous)</h6> <p>One trial reported dichotomous data on depression (<a href="./references#CD012955-bbs2-0062" title="ISRCTN95266816. The emergence of personality disorder traits in adolescents who deliberately self harm and the potential for using a mentalisation based treatment approach as an early intervention for such individuals: a randomised controlled trial. www.isrctn.com/ISRCTN95266816 (first received 29 October 2007). RossouwT . Mentalisation based treatment for adolescents with self harm: an RCT. European Child &amp; Adolescent Psychiatry2015;24(1 Suppl):S113. [DOI: 10.1007%2Fs00787-015-0714-4.pdf] [W1-02-02]RossouwT . Self harm in adolescence, is MBT the answer?: an RCT. Adolescent Psychiatry2012;2(1):102. [DOI: 10.2174/2210676611202010077]RossouwTI , FonagyP . Mentalization-based treatment for self-harm in adolescents: a randomized controlled trial. Journal of the American Academy of Child and Adolescent Psychiatry2012;51(12):1304-13.e3. [DOI: 10.1016/j.jaac.2012.09.018] [PMID: 23200287]">Rossouw 2012b</a>). </p> <p>MBT did not reduce depression at end of treatment compared with TAU (RR 0.71, 95% CI 0.49 to 1.03; 1 trial, 80 participants; P = 0.08; <a href="./references#CD012955-fig-0051" title="">Analysis 4.8</a>.1). </p> <p>No data were available for zero to six months, six to 12 months, and above 12 months follow‐up. </p> </section> <section id="CD012955-sec-0136"> <h6 class="title">4.9 Attrition</h6> <p>Seven trials reported dichotomous data on attrition (<a href="./references#CD012955-bbs2-0004" title="BatemanA , FonagyP . 8-year follow-up of patients treated for borderline personality disorder: mentalization-based treatment versus treatment as usual. American Journal of Psychiatry2008;165(5):631-8. [DOI: 10.1176/appi.ajp.2007.07040636] [PMID: 18347003]BatemanA , FonagyP . Effectiveness of partial hospitalization in the treatment of borderline personality disorder: a randomized controlled trial. American Journal of Psychiatry1999;156(10):1563-9. [DOI: 10.1176/ajp.156.10.1563] [PMID: 10518167]BatemanA , FonagyP . Health care utilization costs for borderline personality disorder patients treated with psychoanalytically oriented partial hospitalization versus general psychiatric care. American Journal of Psychiatry2003;160(1):169-71. [10.1176/appi.ajp.160.1.169] [12505818]BatemanA , FonagyP . Treatment of borderline personality disorder with psychoanalytically oriented partial hospitalization: an 18-month follow-up. American Journal of Psychiatry2001;158(1):36-42. [DOI: 10.1176/appi.ajp.158.1.36] [PMID: 11136631]BatemanA . Important: question regarding your BPD trial for systematic review in Cochrane Collaboration [personal communication]. Email to: K Lieb, J Stoffers 14 December 2010. BatemanA . Intensive outpatient and partial hospital care for BPD. In: 157th annual meeting of the American Psychiatric Association. Psychotherapy and pharmacology: dissolving the mind-brain barrier; 2004 May 1-6; New York (NY). Arlington (VA): American Psychiatric Association, 2004:102. [Symposium 100B] [www.psychiatry.org/File%20Library/Psychiatrists/Directories/Library-and-Archive/conference_publications/am_program_2004.pdf]BatemanAW , FonagyP . Drs Bateman and Fonagy reply [to Stern R. Partial hospitalization for borderline personality disorder. American Journal of Psychiatry 2001;158(11):1932-3. DOI: 10.1176/appi.ajp.158.11.1932]. American Journal of Psychiatry2001;158(11):1932-3. [DOI: 10.1176/appi.ajp.158.11.1932-a]EvansC . Treatment benefits of psychoanalytically oriented partial hospitalisation were maintained over 18 months in borderline personality disorder. Evidence-Based Mental Health2001;4(3):73. [DOI: 10.1136/ebmh.4.3.73]FonagyP , BatemanAW . Mentalizing and borderline personality disorder. Journal of Mental Health2007;16(1):83-101. [DOI: 10.1080/09638230601182045]SternR . Partial hospitalization for borderline personality disorder. American Journal of Psychiatry2001;158(11):1932-3. [DOI: 10.1176/appi.ajp.158.11.1932] [PMID: 11691712]">Bateman 1999</a>; <a href="./references#CD012955-bbs2-0005" title="BatemanA , FonagyP . Impact of clinical severity on outcomes of mentalisation-based treatment for borderline personality disorder. British Journal of Psychiatry2013;203(3):221-7. [DOI: 10.1192/bjp.bp.112.121129] [PMID: 23887998]BatemanA , FonagyP . Randomized controlled trial of outpatient mentalization-based treatment versus structured clinical management for borderline personality disorder. American Journal of Psychiatry2009;166(12):1355-64. [DOI: 10.1176/appi.ajp.2009.09040539] [PMID: 19833787]BatemanA , FonagyP . Randomized controlled trial of outpatient mentalization-based treatment versus structured clinical management for borderline personality disorder. Supplementary data. ajp.psychiatryonline.org/doi/suppl/10.1176/appi.ajp.2009.09040539/suppl_file/ajp_166_12_1355_01.pdf (accessed 27 February 2020). BatemanA , O'ConnellJ , LorenziniN , GardnerT , FonagyP . A randomised controlled trial of mentalization-based treatment versus structured clinical management for patients with comorbid borderline personality disorder and antisocial personality disorder. BMC Psychiatry2016;16:304. [DOI: 10.1186/s12888-016-1000-9] [PMC5006360] [PMID: 27577562]BatemanA . Important question regarding your BPD trial for systematic review in Cochrane Collaboration [personal communication]. Email to: K Lieb 14 December 2010. BatemanAW . Mentalization, borderline personality disorder and what works for whom? Presentation at the 11th International Congress of the International Society for the Study of Personality Disorders; 2009 Aug 21-23. www.borderlinepersonalitydisorder.com/Conferences/ISSPD/isspd_09_Bateman (accessed 21 April 2010). ISRCTN27660668. Randomised controlled trial of manualised out-patient individual and group therapy for borderline personality disorder [Effectiveness of intensive out-patient psychotherapy for treatment of borderline personality disorder: a pragmatic randomised single blind controlled study]. www.isrctn.com/ISRCTN27660668 (first received 12 October 2008). ">Bateman 2009</a>; <a href="./references#CD012955-bbs2-0033" title="JørgensenCR , BøyeR , AndersenD , Døssing BlaabjergAH , FreundC , JordetH , et al. Eighteen months post-treatment naturalistic follow-up study of mentalization-based therapy and supportive group treatment of borderline personality disorder: clinical outcomes and functioning. Nordic Psychology2014;66(4):254-73. [DOI: 10.1080/19012276.2014.963649]JørgensenCR , FreundC , BøyeR , JordetH , AndersenD , KjølbyeM . Outcome of mentalization-based and supportive psychotherapy in patients with borderline personality disorder: a randomized trial. Acta Psychiatrica Scandinavica2013;127(4):305-17. [DOI: 10.1111/j.1600-0447.2012.01923.x] [PMID: 22897123]JorgensenCR . SV: questions on your trial regarding MBT for BPD patients [personal communication]. Email to: EG Faltinsen 28 November 2017. ">Jørgensen 2013</a>; <a href="./references#CD012955-bbs2-0041" title="LaurenssenEM , WestraD , KikkertMJ , NoomMJ , EerenHV , Van BroekhuyzenAJ , et al. Day hospital mentalization-based treatment (MBT-DH) versus treatment as usual in the treatment of severe borderline personality disorder: protocol of a randomized controlled trial. BMC Psychiatry2014;14:149. [DOI: 10.1186/1471-244X-14-149] [PMC4045960] [PMID: 24886402]LaurenssenEMP , LuytenP , KikkertMJ , WestraD , PeenJ , SoonsMBJ , et al. Day hospital mentalization-based treatment v specialist treatment as usual in patients with borderline personality disorder: randomized controlled trial. Psychological Medicine2018;48(15):2522-9. [DOI: 10.1017/S0033291718000132] [PMID: 29478425]NL2058 (NTR2175). Mentalisation-based treatment versus care-as-usual in the treatment of severe borderline personality disorders. www.trialregister.nl/trial/2058 (first received 21 January 2010). ">Laurenssen 2018</a>; <a href="./references#CD012955-bbs2-0058" title="PhilipsB , WennebergP , KonradssonP , FranckJ . Mentalization-based treatment for concurrent borderline personality disorder and substance use disorder: a randomized controlled feasibility study. European Addiction Research2018;24(1):1-8. [DOI: 10.1159/000485564] [PMC5969093] [PMID: 294028]">Philips 2018</a>; <a href="./references#CD012955-bbs2-0061" title="ISRCTN51304415. Nice OUtcomes for Referrals with Impulsivity, Self Harm and Eating Disorders: the NOURISHED study [A randomised controlled trial of mentalisation based therapy against specialist supportive clinical management in patients with both eating disorders and symptoms of borderline personality disorder]. www.isrctn.com/ISRCTN51304415 (first received 31 January 2011). RobinsonP , BarrettB , BatemanA , HakeemA , HellierJ , LemonskyF , et al. Study protocol for a randomized controlled trial of mentalization based therapy against specialist supportive clinical management in patients with both eating disorders and symptoms of borderline personality disorder. BMC Psychiatry2014;14:51. [DOI: 10.1186/1471-244X-14-51] [PMC3996076] [PMID: 24555511]RobinsonP , HellierJ , BarrettB , BarzdaitieneD , BatemanA , BogaardtA , et al. The NOURISHED randomised controlled trial comparing mentalisation-based treatment for eating disorders (MBT-ED) with specialist supportive clinical management (SSCM-ED) for patients with eating disorders and symptoms of borderline personality disorder. Trials2016;17(1):549. [DOI: 10.1186/s13063-016-1606-8] [PMC5114835] [PMID: 27855714]">Robinson 2016</a>; <a href="./references#CD012955-bbs2-0062" title="ISRCTN95266816. The emergence of personality disorder traits in adolescents who deliberately self harm and the potential for using a mentalisation based treatment approach as an early intervention for such individuals: a randomised controlled trial. www.isrctn.com/ISRCTN95266816 (first received 29 October 2007). RossouwT . Mentalisation based treatment for adolescents with self harm: an RCT. European Child &amp; Adolescent Psychiatry2015;24(1 Suppl):S113. [DOI: 10.1007%2Fs00787-015-0714-4.pdf] [W1-02-02]RossouwT . Self harm in adolescence, is MBT the answer?: an RCT. Adolescent Psychiatry2012;2(1):102. [DOI: 10.2174/2210676611202010077]RossouwTI , FonagyP . Mentalization-based treatment for self-harm in adolescents: a randomized controlled trial. Journal of the American Academy of Child and Adolescent Psychiatry2012;51(12):1304-13.e3. [DOI: 10.1016/j.jaac.2012.09.018] [PMID: 23200287]">Rossouw 2012b</a>). </p> <p>MBT did not reduce attrition at end of treatment compared with TAU (RR 0.99, 95% CI 0.79 to 1.25; 7 trials, 552 participants; I<sup>2</sup> = 0%; P = 0.96; <a href="./references#CD012955-fig-0052" title="">Analysis 4.9</a>.1). </p> <p>No data were available for zero to six months, six to 12 months, and above 12 months follow‐up. </p> </section> <section id="CD012955-sec-0137"> <h6 class="title">4.10 Adverse effects</h6> <p>One trial reported dichotomous data on serious adverse effects (<a href="./references#CD012955-bbs2-0061" title="ISRCTN51304415. Nice OUtcomes for Referrals with Impulsivity, Self Harm and Eating Disorders: the NOURISHED study [A randomised controlled trial of mentalisation based therapy against specialist supportive clinical management in patients with both eating disorders and symptoms of borderline personality disorder]. www.isrctn.com/ISRCTN51304415 (first received 31 January 2011). RobinsonP , BarrettB , BatemanA , HakeemA , HellierJ , LemonskyF , et al. Study protocol for a randomized controlled trial of mentalization based therapy against specialist supportive clinical management in patients with both eating disorders and symptoms of borderline personality disorder. BMC Psychiatry2014;14:51. [DOI: 10.1186/1471-244X-14-51] [PMC3996076] [PMID: 24555511]RobinsonP , HellierJ , BarrettB , BarzdaitieneD , BatemanA , BogaardtA , et al. The NOURISHED randomised controlled trial comparing mentalisation-based treatment for eating disorders (MBT-ED) with specialist supportive clinical management (SSCM-ED) for patients with eating disorders and symptoms of borderline personality disorder. Trials2016;17(1):549. [DOI: 10.1186/s13063-016-1606-8] [PMC5114835] [PMID: 27855714]">Robinson 2016</a>). </p> <p>There was no clear difference in terms of severe adverse effects at end of treatment (RR 3.00, 95% CI 0.13 to 71.15; 1 trial, P = 0.50; <a href="./references#CD012955-fig-0053" title="">Analysis 4.10</a>). </p> <p>No data were available for zero to six months, six to 12 months, and above 12 months follow‐up. </p> <p>* No data were available on any time point for anger, affective instability, chronic feelings of emptiness, impulsivity, abandonment, identity disturbance, dissociation and psychotic‐like symptoms. </p> </section> </section> <section id="CD012955-sec-0138"> <h5 class="title">4.11 Mentalisation‐based treatment for eating disorders (MBT‐ED) versus specialist supportive clinical management (SSCM‐ED) (generic inverse variance) </h5> <section id="CD012955-sec-0139"> <h6 class="title">Primary outcome: psychosocial functioning</h6> <p>One trial reported continuous data on psychosocial functioning (<a href="./references#CD012955-bbs2-0061" title="ISRCTN51304415. Nice OUtcomes for Referrals with Impulsivity, Self Harm and Eating Disorders: the NOURISHED study [A randomised controlled trial of mentalisation based therapy against specialist supportive clinical management in patients with both eating disorders and symptoms of borderline personality disorder]. www.isrctn.com/ISRCTN51304415 (first received 31 January 2011). RobinsonP , BarrettB , BatemanA , HakeemA , HellierJ , LemonskyF , et al. Study protocol for a randomized controlled trial of mentalization based therapy against specialist supportive clinical management in patients with both eating disorders and symptoms of borderline personality disorder. BMC Psychiatry2014;14:51. [DOI: 10.1186/1471-244X-14-51] [PMC3996076] [PMID: 24555511]RobinsonP , HellierJ , BarrettB , BarzdaitieneD , BatemanA , BogaardtA , et al. The NOURISHED randomised controlled trial comparing mentalisation-based treatment for eating disorders (MBT-ED) with specialist supportive clinical management (SSCM-ED) for patients with eating disorders and symptoms of borderline personality disorder. Trials2016;17(1):549. [DOI: 10.1186/s13063-016-1606-8] [PMC5114835] [PMID: 27855714]">Robinson 2016</a>). </p> <p>MBT‐ED did not improve psychosocial functioning at end of treatment compared with SSCM‐ED (MD −0.07, 95% CI −0.86 to 0.72; 1 trial, 23 participants; P = 0.86; <a href="./references#CD012955-fig-0054" title="">Analysis 4.11</a>.1). </p> <p>MBT‐ED did not improve psychosocial functioning at zero to six months follow‐up compared with SSCM‐ED (MD −0.44, 95% CI −1.52 to 0.64; 1 trial, 15 participants; P = 0.42 <a href="./references#CD012955-fig-0054" title="">Analysis 4.11</a>.2). </p> <p>No data were available for six to 12 months and above 12 months follow‐up.</p> <p>No data were available on any time point for BPD symptom severity, self‐harm and suicide‐related outcomes. </p> </section> <section id="CD012955-sec-0140"> <h6 class="title">Secondary outcomes</h6> <section id="CD012955-sec-0141"> <p><b>Interpersonal problems</b></p> <p>One trial reported continuous data on interpersonal problems (<a href="./references#CD012955-bbs2-0061" title="ISRCTN51304415. Nice OUtcomes for Referrals with Impulsivity, Self Harm and Eating Disorders: the NOURISHED study [A randomised controlled trial of mentalisation based therapy against specialist supportive clinical management in patients with both eating disorders and symptoms of borderline personality disorder]. www.isrctn.com/ISRCTN51304415 (first received 31 January 2011). RobinsonP , BarrettB , BatemanA , HakeemA , HellierJ , LemonskyF , et al. Study protocol for a randomized controlled trial of mentalization based therapy against specialist supportive clinical management in patients with both eating disorders and symptoms of borderline personality disorder. BMC Psychiatry2014;14:51. [DOI: 10.1186/1471-244X-14-51] [PMC3996076] [PMID: 24555511]RobinsonP , HellierJ , BarrettB , BarzdaitieneD , BatemanA , BogaardtA , et al. The NOURISHED randomised controlled trial comparing mentalisation-based treatment for eating disorders (MBT-ED) with specialist supportive clinical management (SSCM-ED) for patients with eating disorders and symptoms of borderline personality disorder. Trials2016;17(1):549. [DOI: 10.1186/s13063-016-1606-8] [PMC5114835] [PMID: 27855714]">Robinson 2016</a>). </p> <p>MBT‐ED did not reduce interpersonal problems at end of treatment compared with SSCM‐ED (MD −0.10, 95% CI −0.89 to 0.69; 1 trial, 23 participants; P = 0.80; <a href="./references#CD012955-fig-0054" title="">Analysis 4.11</a>.3). </p> <p>MBT‐ED did not reduce interpersonal problems at zero to six months follow‐up compared with SSCM‐ED (MD −0.06, 95% CI −1.15 to 1.03; 1 trial, 15 participants; P = 0.91; <a href="./references#CD012955-fig-0054" title="">Analysis 4.11</a>.4). </p> <p>No data were available for six to 12 months and above 12 months follow‐up.</p> </section> <section id="CD012955-sec-0142"> <p><b>Depression</b></p> <p>One trial reported continuous data on depression (<a href="./references#CD012955-bbs2-0061" title="ISRCTN51304415. Nice OUtcomes for Referrals with Impulsivity, Self Harm and Eating Disorders: the NOURISHED study [A randomised controlled trial of mentalisation based therapy against specialist supportive clinical management in patients with both eating disorders and symptoms of borderline personality disorder]. www.isrctn.com/ISRCTN51304415 (first received 31 January 2011). RobinsonP , BarrettB , BatemanA , HakeemA , HellierJ , LemonskyF , et al. Study protocol for a randomized controlled trial of mentalization based therapy against specialist supportive clinical management in patients with both eating disorders and symptoms of borderline personality disorder. BMC Psychiatry2014;14:51. [DOI: 10.1186/1471-244X-14-51] [PMC3996076] [PMID: 24555511]RobinsonP , HellierJ , BarrettB , BarzdaitieneD , BatemanA , BogaardtA , et al. The NOURISHED randomised controlled trial comparing mentalisation-based treatment for eating disorders (MBT-ED) with specialist supportive clinical management (SSCM-ED) for patients with eating disorders and symptoms of borderline personality disorder. Trials2016;17(1):549. [DOI: 10.1186/s13063-016-1606-8] [PMC5114835] [PMID: 27855714]">Robinson 2016</a>). </p> <p>MBT‐ED did not reduce depression at end of treatment compared with SSCM‐ED (MD 0.19, 95% CI −0.60 to 0.98; 1 trial, 23 participants; P = 0.64; <a href="./references#CD012955-fig-0054" title="">Analysis 4.11</a>.5). </p> <p>MBT‐ED did not reduce depression at zero to six months follow‐up compared with SSCM‐ED (MD 0.51, 95% CI −0.62 to 1.64; 1 trial, 15 participants; P = 0.38; <a href="./references#CD012955-fig-0054" title="">Analysis 4.11</a>.6). </p> <p>No data were available for six to 12 months and above 12 months follow‐up.</p> <p>No data were available on any time point for anger, affective instability, chronic feelings of emptiness, impulsivity, abandonment, identity disturbance, dissociation and psychotic‐like symptoms, attrition and adverse effects. </p> </section> </section> </section> </section> <section id="CD012955-sec-0143"> <h4 class="title">5. Cognitive behaviour therapy (CBT) versus treatment‐as‐usual (TAU)</h4> <section id="CD012955-sec-0144"> <h5 class="title">Primary outcomes</h5> <section id="CD012955-sec-0145"> <h6 class="title">5.1 BPD symptom severity (continuous)</h6> <p>One trial reported continuous data on BPD symptom severity (<a href="./references#CD012955-bbs2-0039" title="KredlowMA , SzuhanyKL , LoS , XieH , GottliebJD , RosenbergSD , et al. Cognitive behavioral therapy for posttraumatic stress disorder in individuals with severe mental illness and borderline personality disorder. Psychiatry Research2017;249:86-93. [DOI: 10.1016/j.psychres.2016.12.045] [PMC5325773] [PMID: 28086181]MueserK . Re: question regarding your trial on CBT for BPD patients [personal communication]. Email to: EG Faltinsen 28 November 2017. ">Kredlow 2017a</a>). </p> <p>CBT reduced BPD symptom severity at end of treatment compared with TAU (MD −3.08, 95% CI −4.99 to −1.17; 1 trial, 26 participants; P = 0.002; <a href="./references#CD012955-fig-0055" title="">Analysis 5.1</a>.1) (random‐effects model analysis). </p> <p>CBT did not reduce BPD symptom severity at zero to six months follow‐up compared with TAU (MD −2.02, 95% CI −4.23 to 0.19; 1 trial, 26 participants; P = 0.07; <a href="./references#CD012955-fig-0055" title="">Analysis 5.1</a>.2) (fixed‐effect model analysis). </p> <p>No data were available for six to 12 months and above 12 months follow‐up.</p> </section> <section id="CD012955-sec-0146"> <h6 class="title">5.2 BPD symptom severity (dichotomous)</h6> <p>One trial reported dichotomous data on BPD symptom severity (<a href="./references#CD012955-bbs2-0017" title="DavidsonK , LivingstoneS , McArthurK , DicksonL , GumleyA . An integrative complexity analysis of cognitive behaviour therapy sessions for borderline personality disorder. Psychology and Psychotherapy2007;80(Pt 4):513-23. [DOI: 10.1348/147608307X191535] [PMID: 17535542]DavidsonK , NorrieJ , TyrerP , GumleyA , TataP , MurrayH , et al. The effectiveness of cognitive behavior therapy for borderline personality disorder: results from the borderline personality disorder study of cognitive therapy (BOSCOT) trial. Journal of Personality Disorders2006;20(5):450-65. [DOI: 10.1521/pedi.2006.20.5.450] [PMC1852259] [PMID: 17032158]DavidsonK , TyrerP , GumleyA , TataP , NorrieJ , PalmerS , et al. A randomized controlled trial of cognitive behavior therapy for borderline personality disorder: rationale for trial, method, and description of sample. Journal of Personality Disorders2006;20(5):431-49. [DOI: 10.1521/pedi.2006.20.5.431] [PMC1847748] [PMID: 17032157]DavidsonKM , TyrerP , NorrieJ , PalmerSJ , TyrerH . Cognitive therapy v usual treatment for borderline personality disorder: prospective 6-year follow-up. British Journal of Psychiatry2010;197(6):456-62. [DOI: 10.1192/bjp.bp.109.074286] [PMID: 21119151]ISRCTN86177428. Borderline personality disorder study of cognitive therapy trial [A randomised controlled trial of cognitive therapy plus treatment as usual versus treatment as usual in the treatment of borderline personality disorder]. www.isrctn.com/ISRCTN86177428 (first received 22 July 2005). NCT00538135. BOSCOT: a randomised controlled trial of cognitive behavioural therapy in borderline personality disorder [BOSCOT: a randomised control trial of cognitive behavioural therapy plus treatment as usual versus treatment as usual in the treatment of borderline personality disorder]. www.clinicaltrials.gov/ct2/show/NCT00538135 (first received 29 September 2007). NorrieJ , DavidsonK , TataP , GumleyA . Influence of therapist competence and quantity of cognitive behavioural therapy on suicidal behaviour and inpatient hospitalisation in a randomised controlled trial in borderline personality disorder: further analyses of treatment effects in the BOSCOT study. Psychology and Psychotherapy2013;86(3):280-93. [DOI: 10.1111/papt.12004] [PMC4491320] [PMID: 23420622]PalmerS , DavidsonK , TyrerP , GumleyA , TataP , NorrieJ , et al. The cost-effectiveness of cognitive behavior therapy for borderline personality disorder: results from the BOSCOT trial. Journal of Personality Disorders2006;20(5):466-81. [DOI: 10.1521/pedi.2006.20.5.466] [PMC1852260] [PMID: 17032159]">Davidson 2006</a>). </p> <p>CBT did not reduce BPD symptom severity at above 12 months follow‐up compared with TAU (RR 0.91, 95% CI 0.56 to 1.48; 1 trial, 76 participants; P = 0.71; <a href="./references#CD012955-fig-0056" title="">Analysis 5.2</a>). </p> <p>No data were available for end of treatment, zero to six months and six to 12 months follow‐up. </p> </section> <section id="CD012955-sec-0147"> <h6 class="title">5.3 Self‐harm (continuous)</h6> <p>One trial reported continuous data on self‐harm (<a href="./references#CD012955-bbs2-0073" title="WeinbergI , GundersonJG , HennenJ , Cutter CJ Jr. Manual assisted cognitive treatment for deliberate self-harm in borderline personality disorder patients. Journal of Personality Disorders2006;20(5):482-92. [DOI: 10.1521/pedi.2006.20.5.482] [PMID: 17032160]WilbergT . SV: separate data [personal communication] [SV: separat data [personlig kommunikation]]. Email to: M Kielsholm 25 May 2016. ">Weinberg 2006</a>). </p> <p>CBT reduced self‐harm at end of treatment compared with TAU (MD −3.03, 95% CI −5.68 to −0.38; 1 trial, 28 participants; P = 0.03; <a href="./references#CD012955-fig-0057" title="">Analysis 5.3</a>.1). </p> <p>CBT did not reduce self‐harm at zero to six months follow‐up compared with TAU (MD −4.71, 95% CI −11.60 to 2.18; 1 trial, 28 participants; P = 0.18; <a href="./references#CD012955-fig-0057" title="">Analysis 5.3</a>.2). </p> <p>No data were available for six to 12 months and above 12 months follow‐up.</p> </section> <section id="CD012955-sec-0148"> <h6 class="title">5.4 Self‐harm (dichotomous)</h6> <p>One trial reported dichotomous data on self‐harm (<a href="./references#CD012955-bbs2-0017" title="DavidsonK , LivingstoneS , McArthurK , DicksonL , GumleyA . An integrative complexity analysis of cognitive behaviour therapy sessions for borderline personality disorder. Psychology and Psychotherapy2007;80(Pt 4):513-23. [DOI: 10.1348/147608307X191535] [PMID: 17535542]DavidsonK , NorrieJ , TyrerP , GumleyA , TataP , MurrayH , et al. The effectiveness of cognitive behavior therapy for borderline personality disorder: results from the borderline personality disorder study of cognitive therapy (BOSCOT) trial. Journal of Personality Disorders2006;20(5):450-65. [DOI: 10.1521/pedi.2006.20.5.450] [PMC1852259] [PMID: 17032158]DavidsonK , TyrerP , GumleyA , TataP , NorrieJ , PalmerS , et al. A randomized controlled trial of cognitive behavior therapy for borderline personality disorder: rationale for trial, method, and description of sample. Journal of Personality Disorders2006;20(5):431-49. [DOI: 10.1521/pedi.2006.20.5.431] [PMC1847748] [PMID: 17032157]DavidsonKM , TyrerP , NorrieJ , PalmerSJ , TyrerH . Cognitive therapy v usual treatment for borderline personality disorder: prospective 6-year follow-up. British Journal of Psychiatry2010;197(6):456-62. [DOI: 10.1192/bjp.bp.109.074286] [PMID: 21119151]ISRCTN86177428. Borderline personality disorder study of cognitive therapy trial [A randomised controlled trial of cognitive therapy plus treatment as usual versus treatment as usual in the treatment of borderline personality disorder]. www.isrctn.com/ISRCTN86177428 (first received 22 July 2005). NCT00538135. BOSCOT: a randomised controlled trial of cognitive behavioural therapy in borderline personality disorder [BOSCOT: a randomised control trial of cognitive behavioural therapy plus treatment as usual versus treatment as usual in the treatment of borderline personality disorder]. www.clinicaltrials.gov/ct2/show/NCT00538135 (first received 29 September 2007). NorrieJ , DavidsonK , TataP , GumleyA . Influence of therapist competence and quantity of cognitive behavioural therapy on suicidal behaviour and inpatient hospitalisation in a randomised controlled trial in borderline personality disorder: further analyses of treatment effects in the BOSCOT study. Psychology and Psychotherapy2013;86(3):280-93. [DOI: 10.1111/papt.12004] [PMC4491320] [PMID: 23420622]PalmerS , DavidsonK , TyrerP , GumleyA , TataP , NorrieJ , et al. The cost-effectiveness of cognitive behavior therapy for borderline personality disorder: results from the BOSCOT trial. Journal of Personality Disorders2006;20(5):466-81. [DOI: 10.1521/pedi.2006.20.5.466] [PMC1852260] [PMID: 17032159]">Davidson 2006</a>). </p> <p>CBT did not reduce self‐harm at end of treatment compared with TAU (RR 1.17, 95% CI 0.86 to 1.60; 1 trial, 99 participants; P = 0.32; <a href="./references#CD012955-fig-0058" title="">Analysis 5.4</a>). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> </section> <section id="CD012955-sec-0149"> <h6 class="title">5.5 Suicide‐related outcomes</h6> <p>Two trials reported continuous data on suicide‐related outcomes (<a href="./references#CD012955-bbs2-0017" title="DavidsonK , LivingstoneS , McArthurK , DicksonL , GumleyA . An integrative complexity analysis of cognitive behaviour therapy sessions for borderline personality disorder. Psychology and Psychotherapy2007;80(Pt 4):513-23. [DOI: 10.1348/147608307X191535] [PMID: 17535542]DavidsonK , NorrieJ , TyrerP , GumleyA , TataP , MurrayH , et al. The effectiveness of cognitive behavior therapy for borderline personality disorder: results from the borderline personality disorder study of cognitive therapy (BOSCOT) trial. Journal of Personality Disorders2006;20(5):450-65. [DOI: 10.1521/pedi.2006.20.5.450] [PMC1852259] [PMID: 17032158]DavidsonK , TyrerP , GumleyA , TataP , NorrieJ , PalmerS , et al. A randomized controlled trial of cognitive behavior therapy for borderline personality disorder: rationale for trial, method, and description of sample. Journal of Personality Disorders2006;20(5):431-49. [DOI: 10.1521/pedi.2006.20.5.431] [PMC1847748] [PMID: 17032157]DavidsonKM , TyrerP , NorrieJ , PalmerSJ , TyrerH . Cognitive therapy v usual treatment for borderline personality disorder: prospective 6-year follow-up. British Journal of Psychiatry2010;197(6):456-62. [DOI: 10.1192/bjp.bp.109.074286] [PMID: 21119151]ISRCTN86177428. Borderline personality disorder study of cognitive therapy trial [A randomised controlled trial of cognitive therapy plus treatment as usual versus treatment as usual in the treatment of borderline personality disorder]. www.isrctn.com/ISRCTN86177428 (first received 22 July 2005). NCT00538135. BOSCOT: a randomised controlled trial of cognitive behavioural therapy in borderline personality disorder [BOSCOT: a randomised control trial of cognitive behavioural therapy plus treatment as usual versus treatment as usual in the treatment of borderline personality disorder]. www.clinicaltrials.gov/ct2/show/NCT00538135 (first received 29 September 2007). NorrieJ , DavidsonK , TataP , GumleyA . Influence of therapist competence and quantity of cognitive behavioural therapy on suicidal behaviour and inpatient hospitalisation in a randomised controlled trial in borderline personality disorder: further analyses of treatment effects in the BOSCOT study. Psychology and Psychotherapy2013;86(3):280-93. [DOI: 10.1111/papt.12004] [PMC4491320] [PMID: 23420622]PalmerS , DavidsonK , TyrerP , GumleyA , TataP , NorrieJ , et al. The cost-effectiveness of cognitive behavior therapy for borderline personality disorder: results from the BOSCOT trial. Journal of Personality Disorders2006;20(5):466-81. [DOI: 10.1521/pedi.2006.20.5.466] [PMC1852260] [PMID: 17032159]">Davidson 2006</a>; <a href="./references#CD012955-bbs2-0073" title="WeinbergI , GundersonJG , HennenJ , Cutter CJ Jr. Manual assisted cognitive treatment for deliberate self-harm in borderline personality disorder patients. Journal of Personality Disorders2006;20(5):482-92. [DOI: 10.1521/pedi.2006.20.5.482] [PMID: 17032160]WilbergT . SV: separate data [personal communication] [SV: separat data [personlig kommunikation]]. Email to: M Kielsholm 25 May 2016. ">Weinberg 2006</a>). </p> <p>CBT did not reduce suicide‐related outcomes at end of treatment compared with TAU (SMD −0.47, 95% CI −1.02 to 0.08; 2 trials, 104 participants; P = 0.09; <a href="./references#CD012955-fig-0059" title="">Analysis 5.5</a>.1; random‐effects model). </p> <p>CBT reduced suicide‐related outcomes at end of treatment compared with TAU (SMD −0.42, 95% −0.81, −0.02; 2 trials, 104 participants; P = 0.04; analysis not shown; fixed‐effect model). </p> <p>CBT did not reduce suicide‐related outcomes at zero to six months follow‐up compared with TAU (SMD −0.45, 95% CI −1.20 to 0.31; 1 trial, 28 participants; P = 0.25; MD −7.73, 95% CI −20.00 to 4.54; 1 trial, 28 participants; P = 0.22; <a href="./references#CD012955-fig-0059" title="">Analysis 5.5</a>.2). </p> <p>CBT did not reduce suicide‐related outcomes at six to 12 months follow‐up compared with TAU (SMD −0.44, 95% CI −0.89 to 0.02; 1 trial, 76 participants; P = 0.06; MD −1.16, 95% CI −2.47 to 0.15; 1 trial, 76 participants; P = 0.08; <a href="./references#CD012955-fig-0059" title="">Analysis 5.5</a>.3). </p> <p>CBT did not reduce suicide‐related outcomes at above 12 months follow‐up compared with TAU (SMD −0.31, 95% CI −0.77 to 0.14; 1 trial, 76 participants; P = 0.18; MD −1.15, 95% CI −2.86 to 0.07; 1 trial, 76 participants; P = 0.19; <a href="./references#CD012955-fig-0059" title="">Analysis 5.5</a>.4). </p> </section> <section id="CD012955-sec-0150"> <h6 class="title">5.6 Psychosocial functioning</h6> <p>Two trials reported continuous data on psychosocial functioning (<a href="./references#CD012955-bbs2-0017" title="DavidsonK , LivingstoneS , McArthurK , DicksonL , GumleyA . An integrative complexity analysis of cognitive behaviour therapy sessions for borderline personality disorder. Psychology and Psychotherapy2007;80(Pt 4):513-23. [DOI: 10.1348/147608307X191535] [PMID: 17535542]DavidsonK , NorrieJ , TyrerP , GumleyA , TataP , MurrayH , et al. The effectiveness of cognitive behavior therapy for borderline personality disorder: results from the borderline personality disorder study of cognitive therapy (BOSCOT) trial. Journal of Personality Disorders2006;20(5):450-65. [DOI: 10.1521/pedi.2006.20.5.450] [PMC1852259] [PMID: 17032158]DavidsonK , TyrerP , GumleyA , TataP , NorrieJ , PalmerS , et al. A randomized controlled trial of cognitive behavior therapy for borderline personality disorder: rationale for trial, method, and description of sample. Journal of Personality Disorders2006;20(5):431-49. [DOI: 10.1521/pedi.2006.20.5.431] [PMC1847748] [PMID: 17032157]DavidsonKM , TyrerP , NorrieJ , PalmerSJ , TyrerH . Cognitive therapy v usual treatment for borderline personality disorder: prospective 6-year follow-up. British Journal of Psychiatry2010;197(6):456-62. [DOI: 10.1192/bjp.bp.109.074286] [PMID: 21119151]ISRCTN86177428. Borderline personality disorder study of cognitive therapy trial [A randomised controlled trial of cognitive therapy plus treatment as usual versus treatment as usual in the treatment of borderline personality disorder]. www.isrctn.com/ISRCTN86177428 (first received 22 July 2005). NCT00538135. BOSCOT: a randomised controlled trial of cognitive behavioural therapy in borderline personality disorder [BOSCOT: a randomised control trial of cognitive behavioural therapy plus treatment as usual versus treatment as usual in the treatment of borderline personality disorder]. www.clinicaltrials.gov/ct2/show/NCT00538135 (first received 29 September 2007). NorrieJ , DavidsonK , TataP , GumleyA . Influence of therapist competence and quantity of cognitive behavioural therapy on suicidal behaviour and inpatient hospitalisation in a randomised controlled trial in borderline personality disorder: further analyses of treatment effects in the BOSCOT study. Psychology and Psychotherapy2013;86(3):280-93. [DOI: 10.1111/papt.12004] [PMC4491320] [PMID: 23420622]PalmerS , DavidsonK , TyrerP , GumleyA , TataP , NorrieJ , et al. The cost-effectiveness of cognitive behavior therapy for borderline personality disorder: results from the BOSCOT trial. Journal of Personality Disorders2006;20(5):466-81. [DOI: 10.1521/pedi.2006.20.5.466] [PMC1852260] [PMID: 17032159]">Davidson 2006</a>; <a href="./references#CD012955-bbs2-0051" title="McMurranM , CrawfordMJ , ReillyJ , DelportJ , McCroneP , WhithamD , et al. Psychoeducation with problem-solving (PEPS) therapy for adults with personality disorder: a pragmatic randomised controlled trial to determine the clinical effectiveness and cost-effectiveness of a manualised intervention to improve social functioning. Health Technology Assessment2016;20(52):1-282. [DOI: 10.3310/hta20520]McMurranM . RE: Cochrane Collaboration review - PEPS study [personal communication]. Email to: J Stoffers-Winterling 5 July 2018. McMurranM . Request for data on BPD subjects in the PEPS rcp-study for use a new Cochrane review [personal communication]. Email to: M Kongerslev 7 March 2017. ">McMurran 2016</a>). </p> <p>CBT did not improve psychosocial functioning at end of treatment compared with TAU (SMD 0.00, 95% CI −0.39 to 0.39; 1 trial, 99 participants; P = 1.00; MD 0.00, 95% CI −1.78 to 1.78; 1 trial, 99 participants; P = 1.00; <a href="./references#CD012955-fig-0060" title="">Analysis 5.6</a>.1). </p> <p>CBT did not improve psychosocial functioning at six to 12 months follow‐up compared with TAU (SMD 0.13, 95% CI −0.28 to 0.55; 1 trial, 90 participants; P = 0.52; MD 0.70, 95% CI −1.43 to 2.83; 1 trial, 90 participants; P = 0.52; <a href="./references#CD012955-fig-0060" title="">Analysis 5.6</a>.2). </p> <p>CBT did not improve psychosocial functioning at above 12 months follow‐up compared with TAU (SMD 0.04, 95% CI −0.36 to 0.43; 2 trials, 209 participants; I<sup>2</sup> = 51%; P = 0.86; <a href="./references#CD012955-fig-0060" title="">Analysis 5.6</a>.3. </p> <p>No data were available for zero to six months follow‐up.</p> </section> </section> <section id="CD012955-sec-0151"> <h5 class="title">Secondary outcomes</h5> <section id="CD012955-sec-0152"> <h6 class="title">5.7 Interpersonal problems</h6> <p>One trial reported continuous data on interpersonal problems (<a href="./references#CD012955-bbs2-0017" title="DavidsonK , LivingstoneS , McArthurK , DicksonL , GumleyA . An integrative complexity analysis of cognitive behaviour therapy sessions for borderline personality disorder. Psychology and Psychotherapy2007;80(Pt 4):513-23. [DOI: 10.1348/147608307X191535] [PMID: 17535542]DavidsonK , NorrieJ , TyrerP , GumleyA , TataP , MurrayH , et al. The effectiveness of cognitive behavior therapy for borderline personality disorder: results from the borderline personality disorder study of cognitive therapy (BOSCOT) trial. Journal of Personality Disorders2006;20(5):450-65. [DOI: 10.1521/pedi.2006.20.5.450] [PMC1852259] [PMID: 17032158]DavidsonK , TyrerP , GumleyA , TataP , NorrieJ , PalmerS , et al. A randomized controlled trial of cognitive behavior therapy for borderline personality disorder: rationale for trial, method, and description of sample. Journal of Personality Disorders2006;20(5):431-49. [DOI: 10.1521/pedi.2006.20.5.431] [PMC1847748] [PMID: 17032157]DavidsonKM , TyrerP , NorrieJ , PalmerSJ , TyrerH . Cognitive therapy v usual treatment for borderline personality disorder: prospective 6-year follow-up. British Journal of Psychiatry2010;197(6):456-62. [DOI: 10.1192/bjp.bp.109.074286] [PMID: 21119151]ISRCTN86177428. Borderline personality disorder study of cognitive therapy trial [A randomised controlled trial of cognitive therapy plus treatment as usual versus treatment as usual in the treatment of borderline personality disorder]. www.isrctn.com/ISRCTN86177428 (first received 22 July 2005). NCT00538135. BOSCOT: a randomised controlled trial of cognitive behavioural therapy in borderline personality disorder [BOSCOT: a randomised control trial of cognitive behavioural therapy plus treatment as usual versus treatment as usual in the treatment of borderline personality disorder]. www.clinicaltrials.gov/ct2/show/NCT00538135 (first received 29 September 2007). NorrieJ , DavidsonK , TataP , GumleyA . Influence of therapist competence and quantity of cognitive behavioural therapy on suicidal behaviour and inpatient hospitalisation in a randomised controlled trial in borderline personality disorder: further analyses of treatment effects in the BOSCOT study. Psychology and Psychotherapy2013;86(3):280-93. [DOI: 10.1111/papt.12004] [PMC4491320] [PMID: 23420622]PalmerS , DavidsonK , TyrerP , GumleyA , TataP , NorrieJ , et al. The cost-effectiveness of cognitive behavior therapy for borderline personality disorder: results from the BOSCOT trial. Journal of Personality Disorders2006;20(5):466-81. [DOI: 10.1521/pedi.2006.20.5.466] [PMC1852260] [PMID: 17032159]">Davidson 2006</a>). </p> <p>CBT did not reduce interpersonal problems at end of treatment compared with TAU (MD 5.40, 95% CI −3.70 to 14.50; 1 trial, 99 participants; P = 0.24; <a href="./references#CD012955-fig-0061" title="">Analysis 5.7</a>.1). </p> <p>CBT did not reduce interpersonal problems at six to 12 months follow‐up compared with TAU (MD 0.30, 95% CI −9.17 to 9.77; 1 trial, 99 participants; P = 0.95; <a href="./references#CD012955-fig-0061" title="">Analysis 5.7</a>.2). </p> <p>TAU reduced interpersonal problems at above 12 months follow‐up compared with CBT (MD 11.70, 95% CI 0.72 to 22.68; 1 trial, 76 participants; P = 0.04; <a href="./references#CD012955-fig-0061" title="">Analysis 5.7</a>.3). </p> <p>No data were available for zero to six months follow‐up.</p> </section> <section id="CD012955-sec-0153"> <h6 class="title">5.8 Dissociation and psychotic‐like symptoms</h6> <p>One trial reported continuous data on dissociation and psychotic‐like symptoms (<a href="./references#CD012955-bbs2-0039" title="KredlowMA , SzuhanyKL , LoS , XieH , GottliebJD , RosenbergSD , et al. Cognitive behavioral therapy for posttraumatic stress disorder in individuals with severe mental illness and borderline personality disorder. Psychiatry Research2017;249:86-93. [DOI: 10.1016/j.psychres.2016.12.045] [PMC5325773] [PMID: 28086181]MueserK . Re: question regarding your trial on CBT for BPD patients [personal communication]. Email to: EG Faltinsen 28 November 2017. ">Kredlow 2017a</a>). </p> <p>CBT did not reduce dissociation and psychotic‐like symptoms at end of treatment compared with TAU (MD −2.30, 95% CI −8.84 to 4.24; 1 trial, 26 participants; P = 0.49; <a href="./references#CD012955-fig-0062" title="">Analysis 5.8</a>.1). </p> <p>CBT reduced dissociation and psychotic‐like symptoms at zero to six months follow‐up compared with TAU (MD −13.40, 95% CI −24.49 to −2.31; 1 trial, 26 participants; P = 0.02; <a href="./references#CD012955-fig-0062" title="">Analysis 5.8</a>.2). </p> <p>No data were available for six to 12 months and above 12 months follow‐up.</p> </section> <section id="CD012955-sec-0154"> <h6 class="title">5.9 Depression</h6> <p>Five trials reported continuous data on depression (<a href="./references#CD012955-bbs2-0017" title="DavidsonK , LivingstoneS , McArthurK , DicksonL , GumleyA . An integrative complexity analysis of cognitive behaviour therapy sessions for borderline personality disorder. Psychology and Psychotherapy2007;80(Pt 4):513-23. [DOI: 10.1348/147608307X191535] [PMID: 17535542]DavidsonK , NorrieJ , TyrerP , GumleyA , TataP , MurrayH , et al. The effectiveness of cognitive behavior therapy for borderline personality disorder: results from the borderline personality disorder study of cognitive therapy (BOSCOT) trial. Journal of Personality Disorders2006;20(5):450-65. [DOI: 10.1521/pedi.2006.20.5.450] [PMC1852259] [PMID: 17032158]DavidsonK , TyrerP , GumleyA , TataP , NorrieJ , PalmerS , et al. A randomized controlled trial of cognitive behavior therapy for borderline personality disorder: rationale for trial, method, and description of sample. Journal of Personality Disorders2006;20(5):431-49. [DOI: 10.1521/pedi.2006.20.5.431] [PMC1847748] [PMID: 17032157]DavidsonKM , TyrerP , NorrieJ , PalmerSJ , TyrerH . Cognitive therapy v usual treatment for borderline personality disorder: prospective 6-year follow-up. British Journal of Psychiatry2010;197(6):456-62. [DOI: 10.1192/bjp.bp.109.074286] [PMID: 21119151]ISRCTN86177428. Borderline personality disorder study of cognitive therapy trial [A randomised controlled trial of cognitive therapy plus treatment as usual versus treatment as usual in the treatment of borderline personality disorder]. www.isrctn.com/ISRCTN86177428 (first received 22 July 2005). NCT00538135. BOSCOT: a randomised controlled trial of cognitive behavioural therapy in borderline personality disorder [BOSCOT: a randomised control trial of cognitive behavioural therapy plus treatment as usual versus treatment as usual in the treatment of borderline personality disorder]. www.clinicaltrials.gov/ct2/show/NCT00538135 (first received 29 September 2007). NorrieJ , DavidsonK , TataP , GumleyA . Influence of therapist competence and quantity of cognitive behavioural therapy on suicidal behaviour and inpatient hospitalisation in a randomised controlled trial in borderline personality disorder: further analyses of treatment effects in the BOSCOT study. Psychology and Psychotherapy2013;86(3):280-93. [DOI: 10.1111/papt.12004] [PMC4491320] [PMID: 23420622]PalmerS , DavidsonK , TyrerP , GumleyA , TataP , NorrieJ , et al. The cost-effectiveness of cognitive behavior therapy for borderline personality disorder: results from the BOSCOT trial. Journal of Personality Disorders2006;20(5):466-81. [DOI: 10.1521/pedi.2006.20.5.466] [PMC1852260] [PMID: 17032159]">Davidson 2006</a>; <a href="./references#CD012955-bbs2-0018" title="DavidsonKM , BrownTM , JamesV , KirkJ , RichardsonJ . Manual-assisted cognitive therapy for self-harm in personality disorder and substance misuse: a feasibility trial. Psychiatric Bulletin2014;38(3):108-11. [DOI: 10.1192/pb.bp.113.043109] [PMC4115373] [PMID: 25237519]DavidsonKM . Re: question regarding your trial on manual-assisted cognitive therapy [personal communication]. Email to: EG Faltinsen 28 November 2017. ">Davidson 2014</a>; <a href="./references#CD012955-bbs2-0031" title="BrandS . AW: questions regarding your trial on emotional intelligence training for BPD [personal communication]. Email to: EG Faltinsen 28 November 2017. BrandS . Questions regarding your trial on emotional intelligence training for BPD [personal communication]. Email to: EG Faltinsen 28 November 2017. JahangardL , HaghighiM , BajoghliH , AhmadpanahM , GhaleihaA , ZarrabianMK , et al. Training emotional intelligence improves both emotional intelligence and depressive symptoms in inpatients with borderline personality disorder and depression. International Journal of Psychiatry in Clinical Practice2012;16(3):197-204. [DOI: 10.3109/13651501.2012.687454] [PMID: 22873719]">Jahangard 2012</a>; <a href="./references#CD012955-bbs2-0039" title="KredlowMA , SzuhanyKL , LoS , XieH , GottliebJD , RosenbergSD , et al. Cognitive behavioral therapy for posttraumatic stress disorder in individuals with severe mental illness and borderline personality disorder. Psychiatry Research2017;249:86-93. [DOI: 10.1016/j.psychres.2016.12.045] [PMC5325773] [PMID: 28086181]MueserK . Re: question regarding your trial on CBT for BPD patients [personal communication]. Email to: EG Faltinsen 28 November 2017. ">Kredlow 2017a</a>; <a href="./references#CD012955-bbs2-0051" title="McMurranM , CrawfordMJ , ReillyJ , DelportJ , McCroneP , WhithamD , et al. Psychoeducation with problem-solving (PEPS) therapy for adults with personality disorder: a pragmatic randomised controlled trial to determine the clinical effectiveness and cost-effectiveness of a manualised intervention to improve social functioning. Health Technology Assessment2016;20(52):1-282. [DOI: 10.3310/hta20520]McMurranM . RE: Cochrane Collaboration review - PEPS study [personal communication]. Email to: J Stoffers-Winterling 5 July 2018. McMurranM . Request for data on BPD subjects in the PEPS rcp-study for use a new Cochrane review [personal communication]. Email to: M Kongerslev 7 March 2017. ">McMurran 2016</a>). </p> <p>CBT did not reduce depression at end of treatment compared with TAU (SMD −0.21, 95% CI −0.77 to 0.35; 5 trials, 314 participants; I<sup>2</sup> = 77%; P = 0.47; <a href="./references#CD012955-fig-0063" title="">Analysis 5.9</a>.1). </p> <p>CBT reduced depression at zero to six months follow‐up compared with TAU (SMD −0.96, 95% CI −1.78 to −0.14; 1 trial, 26 participants; P = 0.02; MD −12.70, 95% CI −22.62 to −2.78; 1 trial, 26 participants; P = 0.01; <a href="./references#CD012955-fig-0063" title="">Analysis 5.9</a>.2). </p> <p>CBT did not reduce depression at six to 12 months follow‐up compared with TAU (SMD −0.29, 95% CI −0.69 to 0.11; 1 trial, 99 participants; P = 0.15; MD −4.60, 95% CI −10.82 to 1.62; 1 trial, 99 participants; P = 0.15; <a href="./references#CD012955-fig-0063" title="">Analysis 5.9</a>.3). </p> <p>CBT did not reduce depression at above 12 months follow‐up compared with TAU (SMD −0.15, 95% CI −0.43 to 0.13; 2 trials, 197 participants; I<sup>2</sup> = 0%; P = 0.30; <a href="./references#CD012955-fig-0063" title="">Analysis 5.9</a>.4). </p> </section> <section id="CD012955-sec-0155"> <h6 class="title">5.10 Attrition</h6> <p>One trial reported dichotomous data on attrition (<a href="./references#CD012955-bbs2-0017" title="DavidsonK , LivingstoneS , McArthurK , DicksonL , GumleyA . An integrative complexity analysis of cognitive behaviour therapy sessions for borderline personality disorder. Psychology and Psychotherapy2007;80(Pt 4):513-23. [DOI: 10.1348/147608307X191535] [PMID: 17535542]DavidsonK , NorrieJ , TyrerP , GumleyA , TataP , MurrayH , et al. The effectiveness of cognitive behavior therapy for borderline personality disorder: results from the borderline personality disorder study of cognitive therapy (BOSCOT) trial. Journal of Personality Disorders2006;20(5):450-65. [DOI: 10.1521/pedi.2006.20.5.450] [PMC1852259] [PMID: 17032158]DavidsonK , TyrerP , GumleyA , TataP , NorrieJ , PalmerS , et al. A randomized controlled trial of cognitive behavior therapy for borderline personality disorder: rationale for trial, method, and description of sample. Journal of Personality Disorders2006;20(5):431-49. [DOI: 10.1521/pedi.2006.20.5.431] [PMC1847748] [PMID: 17032157]DavidsonKM , TyrerP , NorrieJ , PalmerSJ , TyrerH . Cognitive therapy v usual treatment for borderline personality disorder: prospective 6-year follow-up. British Journal of Psychiatry2010;197(6):456-62. [DOI: 10.1192/bjp.bp.109.074286] [PMID: 21119151]ISRCTN86177428. Borderline personality disorder study of cognitive therapy trial [A randomised controlled trial of cognitive therapy plus treatment as usual versus treatment as usual in the treatment of borderline personality disorder]. www.isrctn.com/ISRCTN86177428 (first received 22 July 2005). NCT00538135. BOSCOT: a randomised controlled trial of cognitive behavioural therapy in borderline personality disorder [BOSCOT: a randomised control trial of cognitive behavioural therapy plus treatment as usual versus treatment as usual in the treatment of borderline personality disorder]. www.clinicaltrials.gov/ct2/show/NCT00538135 (first received 29 September 2007). NorrieJ , DavidsonK , TataP , GumleyA . Influence of therapist competence and quantity of cognitive behavioural therapy on suicidal behaviour and inpatient hospitalisation in a randomised controlled trial in borderline personality disorder: further analyses of treatment effects in the BOSCOT study. Psychology and Psychotherapy2013;86(3):280-93. [DOI: 10.1111/papt.12004] [PMC4491320] [PMID: 23420622]PalmerS , DavidsonK , TyrerP , GumleyA , TataP , NorrieJ , et al. The cost-effectiveness of cognitive behavior therapy for borderline personality disorder: results from the BOSCOT trial. Journal of Personality Disorders2006;20(5):466-81. [DOI: 10.1521/pedi.2006.20.5.466] [PMC1852260] [PMID: 17032159]">Davidson 2006</a>). </p> <p>CBT did not reduce attrition at end of treatment compared with TAU (RR 0.48, 95% CI 0.09 to 2.52; 1 trial, 106 participants; P = 0.39; <a href="./references#CD012955-fig-0064" title="">Analysis 5.10</a>). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> </section> <section id="CD012955-sec-0156"> <h6 class="title">5.11 Adverse effects</h6> <p>Two trials reported dichotomous data on non‐serious and serious adverse effects (<a href="./references#CD012955-bbs2-0018" title="DavidsonKM , BrownTM , JamesV , KirkJ , RichardsonJ . Manual-assisted cognitive therapy for self-harm in personality disorder and substance misuse: a feasibility trial. Psychiatric Bulletin2014;38(3):108-11. [DOI: 10.1192/pb.bp.113.043109] [PMC4115373] [PMID: 25237519]DavidsonKM . Re: question regarding your trial on manual-assisted cognitive therapy [personal communication]. Email to: EG Faltinsen 28 November 2017. ">Davidson 2014</a><a href="./references#CD012955-bbs2-0051" title="McMurranM , CrawfordMJ , ReillyJ , DelportJ , McCroneP , WhithamD , et al. Psychoeducation with problem-solving (PEPS) therapy for adults with personality disorder: a pragmatic randomised controlled trial to determine the clinical effectiveness and cost-effectiveness of a manualised intervention to improve social functioning. Health Technology Assessment2016;20(52):1-282. [DOI: 10.3310/hta20520]McMurranM . RE: Cochrane Collaboration review - PEPS study [personal communication]. Email to: J Stoffers-Winterling 5 July 2018. McMurranM . Request for data on BPD subjects in the PEPS rcp-study for use a new Cochrane review [personal communication]. Email to: M Kongerslev 7 March 2017. ">McMurran 2016</a>). </p> <p>There was no clear difference in the number of non‐serious adverse effects at end of treatment (RR 0.92, 95% CI 0.45 to 1.88; 1 trial, 306 participants; P = 0.81; <a href="./references#CD012955-fig-0065" title="">Analysis 5.11</a>.1). </p> <p>There was no clear difference in the number of serious adverse effects at end of treatment (RR 2.65, 95% CI 0.31 to 22.93; 2 trials, 326 participants; I<sup>2</sup>= 0%, P = 0.56; <a href="./references#CD012955-fig-0065" title="">Analysis 5.11</a>.2). </p> <p>No data were available on any time point for anger, affective instability, chronic feelings of emptiness, impulsivity, abandonment and identity disturbance. </p> </section> </section> </section> <section id="CD012955-sec-0157"> <h4 class="title">6. Psychodynamic psychotherapy versus treatment‐as‐usual (TAU)</h4> <section id="CD012955-sec-0158"> <h5 class="title">Primary outcomes</h5> <section id="CD012955-sec-0159"> <h6 class="title">6.1 BPD symptom severity</h6> <p>Four trials reported continuous data on BPD symptom severity (<a href="./references#CD012955-bbs2-0001" title="AmiantoF , FerreroA , PieròA , CairoE , RoccaG , SimonelliB , et al. Supervised team management, with or without structured psychotherapy, in heavy users of a mental health service with borderline personality disorder: a two-year follow-up preliminary randomized study. BMC Psychiatry2011;11:181. [DOI: 10.1186/1471-244X-11-181] [PMC3260092 ] [PMID: 22103890]NCT01356069. Efficacy of time-limited psychodynamic psychotherapy and informed clinical management in BPD high MHS users (HUMSH) [Sequential brief Adlerian psychodynamic psychotherapy in heavy users of a mental health service with borderline personality disorder: a two years follow-up preliminary randomized study]. clinicaltrials.gov/ct2/show/NCT01356069 (first received 16 May 2011). ">Amianto 2011</a>; <a href="./references#CD012955-bbs2-0028" title="GregoryRJ , ChlebowskiS , KangD , RemenA , SoderbergM . Psychodynamic therapy for borderline personality disorder and co-occurring alcohol use disorders: a newly designed ongoing study. Journal of the American Psychoanalytic Association2006;54(4):1331-4. [DOI: 10.1177/00030651060540040107] [PMID: 17354507]GregoryRJ , ChlebowskiS , KangD , RemenAL , SoderbergMG , StepkovitchJ , et al. A controlled trial of psychodynamic psychotherapy for co-occurring borderline personality disorder and alcohol use disorder. Psychotherapy2008;45(1):28-41. [DOI: 10.1037/0033-3204.45.1.28] [PMID: 22122363]GregoryRJ , DeLucia-DeranjaE , MogleJA . Dynamic deconstructive psychotherapy versus optimized community care for borderline personality disorder co-occuring with alcohol use disorders: a 30-month follow-up. Journal of Nervous and Mental Disease2010;198(4):292-8. [DOI: 10.1097/NMD.0b013e3181d6172d] [PMID: 20386259]GregoryRJ , RemenAL , SoderbergM , Ploutz-SnyderRJ . A controlled trial of psychodynamic psychotherapy for co-occurring borderline personality disorder and alcohol use disorder: six-month outcome. Journal of the American Psychoanalytic Association2009;57(1):199-205. [DOI: 10.1177/00030651090570011006] [PMID: 19270255]NCT00145678. Psychodynamic therapy for co-occurring borderline personality disorder and alcohol use disorder [Psychodynamic therapy for patients With borderline personality disorder and alcohol abuse]. www.clinicaltrials.gov/show/NCT00145678 (first received 1 September 2005). ">Gregory 2008b</a>; <a href="./references#CD012955-bbs2-0042" title="LeichsenringF , MasuhrO , JaegerU , RabungS , DallyA , DümpelmannM , et al. Psychoanalytic-interactional therapy versus psychodynamic therapy by experts for personality disorders: a randomized controlled efficacy-effectiveness study in cluster B personality disorders. Psychotherapy and Psychosomatics2016;85(2):71-80. [DOI: 10.1159/000441731] [PMID: 26808580]">Leichsenring 2016</a>; <a href="./references#CD012955-bbs2-0060" title="RenesesB , FigueraD , SalcedoG , TrujilloM , López-IborJJ , GaliánM , et al. A controlled randomized study on the efficacy of short-term dinamic psychotherapy in borderline personality disorders (BPD). Preliminary results. European Psychiatry2011;26(Suppl 1):1040. [DOI: 10.1016/S0924-9338(11)72745-6] [P02-444]RenesesB , GaliánM , SerranoR , FigueraD , Fernandez Del MoralA , López-IborJJ , et al. A new time limited psychotherapy for BPD: preliminary results of a randomized and controlled trial. Actas Espanolas de Psiquiatria2013;41(3):139-48. [PMID: 23803797]">Reneses 2013</a>). </p> <p>Psychodynamic psychotherapy did not reduce BPD symptom severity at end of treatment compared with TAU (SMD −0.29, 95% CI −0.66 to 0.09; 4 trials, 222 participants; I<sup>2</sup> = 38%; P = 0.13; <a href="./references#CD012955-fig-0066" title="">Analysis 6.1</a>.1). </p> <p>Psychodynamic psychotherapy did not reduce BPD symptom severity at six to 12 months follow‐up compared with TAU (SMD −0.31, 95% CI −1.00 to 0.38; 1 trial, 33 participants; P = 0.38; MD −0.30, 95% CI −0.95 to 0.35; 1 trial, 33 participants; P = 0.37; <a href="./references#CD012955-fig-0066" title="">Analysis 6.1</a>.2). </p> <p>No data were available for zero to six months and above 12 months follow‐up.</p> </section> <section id="CD012955-sec-0160"> <h6 class="title">6.2 Self‐harm</h6> <p>Two trials reported continuous data on self‐harm (<a href="./references#CD012955-bbs2-0001" title="AmiantoF , FerreroA , PieròA , CairoE , RoccaG , SimonelliB , et al. Supervised team management, with or without structured psychotherapy, in heavy users of a mental health service with borderline personality disorder: a two-year follow-up preliminary randomized study. BMC Psychiatry2011;11:181. [DOI: 10.1186/1471-244X-11-181] [PMC3260092 ] [PMID: 22103890]NCT01356069. Efficacy of time-limited psychodynamic psychotherapy and informed clinical management in BPD high MHS users (HUMSH) [Sequential brief Adlerian psychodynamic psychotherapy in heavy users of a mental health service with borderline personality disorder: a two years follow-up preliminary randomized study]. clinicaltrials.gov/ct2/show/NCT01356069 (first received 16 May 2011). ">Amianto 2011</a>; <a href="./references#CD012955-bbs2-0028" title="GregoryRJ , ChlebowskiS , KangD , RemenA , SoderbergM . Psychodynamic therapy for borderline personality disorder and co-occurring alcohol use disorders: a newly designed ongoing study. Journal of the American Psychoanalytic Association2006;54(4):1331-4. [DOI: 10.1177/00030651060540040107] [PMID: 17354507]GregoryRJ , ChlebowskiS , KangD , RemenAL , SoderbergMG , StepkovitchJ , et al. A controlled trial of psychodynamic psychotherapy for co-occurring borderline personality disorder and alcohol use disorder. Psychotherapy2008;45(1):28-41. [DOI: 10.1037/0033-3204.45.1.28] [PMID: 22122363]GregoryRJ , DeLucia-DeranjaE , MogleJA . Dynamic deconstructive psychotherapy versus optimized community care for borderline personality disorder co-occuring with alcohol use disorders: a 30-month follow-up. Journal of Nervous and Mental Disease2010;198(4):292-8. [DOI: 10.1097/NMD.0b013e3181d6172d] [PMID: 20386259]GregoryRJ , RemenAL , SoderbergM , Ploutz-SnyderRJ . A controlled trial of psychodynamic psychotherapy for co-occurring borderline personality disorder and alcohol use disorder: six-month outcome. Journal of the American Psychoanalytic Association2009;57(1):199-205. [DOI: 10.1177/00030651090570011006] [PMID: 19270255]NCT00145678. Psychodynamic therapy for co-occurring borderline personality disorder and alcohol use disorder [Psychodynamic therapy for patients With borderline personality disorder and alcohol abuse]. www.clinicaltrials.gov/show/NCT00145678 (first received 1 September 2005). ">Gregory 2008b</a>). </p> <p>Psychodynamic psychotherapy did not reduce self‐harm at end of treatment compared with TAU (MD 0.12, 95% CI −0.56 to 0.80; 1 trial, 33 participants; P = 0.73; <a href="./references#CD012955-fig-0067" title="">Analysis 6.2</a>.1). </p> <p>Psychodynamic psychotherapy did not reduce self‐harm at six to 12 months follow‐up compared with TAU (MD 0.14, 95% CI −0.55 to 0.82; 1 trial, 33 participants; P = 0.69; <a href="./references#CD012955-fig-0067" title="">Analysis 6.2</a>.2). </p> <p>No data were available for zero to six months and above 12 months follow‐up.</p> </section> <section id="CD012955-sec-0161"> <h6 class="title">6.3 Suicide‐related outcomes</h6> <p>Three trials reported continuous data on suicide‐related outcomes (<a href="./references#CD012955-bbs2-0001" title="AmiantoF , FerreroA , PieròA , CairoE , RoccaG , SimonelliB , et al. Supervised team management, with or without structured psychotherapy, in heavy users of a mental health service with borderline personality disorder: a two-year follow-up preliminary randomized study. BMC Psychiatry2011;11:181. [DOI: 10.1186/1471-244X-11-181] [PMC3260092 ] [PMID: 22103890]NCT01356069. Efficacy of time-limited psychodynamic psychotherapy and informed clinical management in BPD high MHS users (HUMSH) [Sequential brief Adlerian psychodynamic psychotherapy in heavy users of a mental health service with borderline personality disorder: a two years follow-up preliminary randomized study]. clinicaltrials.gov/ct2/show/NCT01356069 (first received 16 May 2011). ">Amianto 2011</a>; <a href="./references#CD012955-bbs2-0028" title="GregoryRJ , ChlebowskiS , KangD , RemenA , SoderbergM . Psychodynamic therapy for borderline personality disorder and co-occurring alcohol use disorders: a newly designed ongoing study. Journal of the American Psychoanalytic Association2006;54(4):1331-4. [DOI: 10.1177/00030651060540040107] [PMID: 17354507]GregoryRJ , ChlebowskiS , KangD , RemenAL , SoderbergMG , StepkovitchJ , et al. A controlled trial of psychodynamic psychotherapy for co-occurring borderline personality disorder and alcohol use disorder. Psychotherapy2008;45(1):28-41. [DOI: 10.1037/0033-3204.45.1.28] [PMID: 22122363]GregoryRJ , DeLucia-DeranjaE , MogleJA . Dynamic deconstructive psychotherapy versus optimized community care for borderline personality disorder co-occuring with alcohol use disorders: a 30-month follow-up. Journal of Nervous and Mental Disease2010;198(4):292-8. [DOI: 10.1097/NMD.0b013e3181d6172d] [PMID: 20386259]GregoryRJ , RemenAL , SoderbergM , Ploutz-SnyderRJ . A controlled trial of psychodynamic psychotherapy for co-occurring borderline personality disorder and alcohol use disorder: six-month outcome. Journal of the American Psychoanalytic Association2009;57(1):199-205. [DOI: 10.1177/00030651090570011006] [PMID: 19270255]NCT00145678. Psychodynamic therapy for co-occurring borderline personality disorder and alcohol use disorder [Psychodynamic therapy for patients With borderline personality disorder and alcohol abuse]. www.clinicaltrials.gov/show/NCT00145678 (first received 1 September 2005). ">Gregory 2008b</a>; <a href="./references#CD012955-bbs2-0060" title="RenesesB , FigueraD , SalcedoG , TrujilloM , López-IborJJ , GaliánM , et al. A controlled randomized study on the efficacy of short-term dinamic psychotherapy in borderline personality disorders (BPD). Preliminary results. European Psychiatry2011;26(Suppl 1):1040. [DOI: 10.1016/S0924-9338(11)72745-6] [P02-444]RenesesB , GaliánM , SerranoR , FigueraD , Fernandez Del MoralA , López-IborJJ , et al. A new time limited psychotherapy for BPD: preliminary results of a randomized and controlled trial. Actas Espanolas de Psiquiatria2013;41(3):139-48. [PMID: 23803797]">Reneses 2013</a>). </p> <p>Psychodynamic psychotherapy did not reduce suicide‐related outcomes at end of treatment compared with TAU (SMD −0.22, 95% CI −0.62 to 0.17; 3 trials, 101 participants; I<sup>2</sup> = 27%; P = 0.27; <a href="./references#CD012955-fig-0068" title="">Analysis 6.3</a>.1). </p> <p>Psychodynamic psychotherapy did not reduce suicide‐related outcomes at six to 12 months follow‐up compared with TAU (SMD −0.38, 95% CI −1.07 to 0.31; 1 trial, 33 participants; P = 0.28; MD −0.30, 95% CI −0.82 to 0.2; 1 trial, 33 participants; P = 0.26; <a href="./references#CD012955-fig-0068" title="">Analysis 6.3</a>.2). </p> <p>No data were available for zero to six months and above 12 months follow‐up.</p> </section> <section id="CD012955-sec-0162"> <h6 class="title">6.4 Psychosocial functioning</h6> <p>Four trials reported continuous data on psychosocial functioning (<a href="./references#CD012955-bbs2-0001" title="AmiantoF , FerreroA , PieròA , CairoE , RoccaG , SimonelliB , et al. Supervised team management, with or without structured psychotherapy, in heavy users of a mental health service with borderline personality disorder: a two-year follow-up preliminary randomized study. BMC Psychiatry2011;11:181. [DOI: 10.1186/1471-244X-11-181] [PMC3260092 ] [PMID: 22103890]NCT01356069. Efficacy of time-limited psychodynamic psychotherapy and informed clinical management in BPD high MHS users (HUMSH) [Sequential brief Adlerian psychodynamic psychotherapy in heavy users of a mental health service with borderline personality disorder: a two years follow-up preliminary randomized study]. clinicaltrials.gov/ct2/show/NCT01356069 (first received 16 May 2011). ">Amianto 2011</a>; <a href="./references#CD012955-bbs2-0028" title="GregoryRJ , ChlebowskiS , KangD , RemenA , SoderbergM . Psychodynamic therapy for borderline personality disorder and co-occurring alcohol use disorders: a newly designed ongoing study. Journal of the American Psychoanalytic Association2006;54(4):1331-4. [DOI: 10.1177/00030651060540040107] [PMID: 17354507]GregoryRJ , ChlebowskiS , KangD , RemenAL , SoderbergMG , StepkovitchJ , et al. A controlled trial of psychodynamic psychotherapy for co-occurring borderline personality disorder and alcohol use disorder. Psychotherapy2008;45(1):28-41. [DOI: 10.1037/0033-3204.45.1.28] [PMID: 22122363]GregoryRJ , DeLucia-DeranjaE , MogleJA . Dynamic deconstructive psychotherapy versus optimized community care for borderline personality disorder co-occuring with alcohol use disorders: a 30-month follow-up. Journal of Nervous and Mental Disease2010;198(4):292-8. [DOI: 10.1097/NMD.0b013e3181d6172d] [PMID: 20386259]GregoryRJ , RemenAL , SoderbergM , Ploutz-SnyderRJ . A controlled trial of psychodynamic psychotherapy for co-occurring borderline personality disorder and alcohol use disorder: six-month outcome. Journal of the American Psychoanalytic Association2009;57(1):199-205. [DOI: 10.1177/00030651090570011006] [PMID: 19270255]NCT00145678. Psychodynamic therapy for co-occurring borderline personality disorder and alcohol use disorder [Psychodynamic therapy for patients With borderline personality disorder and alcohol abuse]. www.clinicaltrials.gov/show/NCT00145678 (first received 1 September 2005). ">Gregory 2008b</a>; <a href="./references#CD012955-bbs2-0060" title="RenesesB , FigueraD , SalcedoG , TrujilloM , López-IborJJ , GaliánM , et al. A controlled randomized study on the efficacy of short-term dinamic psychotherapy in borderline personality disorders (BPD). Preliminary results. European Psychiatry2011;26(Suppl 1):1040. [DOI: 10.1016/S0924-9338(11)72745-6] [P02-444]RenesesB , GaliánM , SerranoR , FigueraD , Fernandez Del MoralA , López-IborJJ , et al. A new time limited psychotherapy for BPD: preliminary results of a randomized and controlled trial. Actas Espanolas de Psiquiatria2013;41(3):139-48. [PMID: 23803797]">Reneses 2013</a>; <a href="./references#CD012955-bbs2-0063" title="SalzerS , CroppC , JaegerU , MasuhrO , Streeck-FischerA . Psychodynamic therapy for adolescents suffering from co-morbid disorders of conduct and emotions in an in-patient setting: a randomized controlled trial. Psychological Medicine2014;44(10):2213-22. [DOI: 10.1017/S003329171300278X] [PMID: 24229481]SalzerS , Streeck-FischerA . The psychoanalytic-interactional method (PiM) for adolescents with borderline personality disorder [Die psychoanalytisch-interaktionelle methode (PiM) für adoleszente mit borderline-persönlichkeitsstörung]. Personlichkeitsstorungen Theorie und Therapie2015;19(1):67-76. [elibrary.klett-cotta.de/article/99.120110/ptt-19-1-67]SalzerS . AW: Re: Cochrane Review on psychotherapies for BPD - RCT testing PiM vs WL [personal communication] [AW:Re: Cochrane Review zur Psychotherapie bei BPS - RCT zu PiM vs WL [persönliche kommunikation]]. Email to: J Stoffers-Winterling 15 July 2018. ">Salzer 2014</a>). </p> <p>Psychodynamic psychotherapy did not improve psychosocial functioning at end of treatment compared with TAU (SMD −0.69, 95% CI −1.98 to 0.59; 4 trials, 140 participants; I<sup>2</sup> = 92%; P = 0.29; <a href="./references#CD012955-fig-0069" title="">Analysis 6.4</a>.1; random‐effects model). </p> <p>Psychodynamic psychotherapy improved psychosocial functioning at end of treatment compared with TAU (SMD −0.38, 95% CI −0.75 to −0.02; 4 trials, 140 participants; I<sup>2</sup> = 92%; P = 0.04; analysis not shown; fixed‐effect model). </p> <p>Psychodynamic psychotherapy did not improve psychosocial functioning at six to 12 months follow‐up compared with TAU (SMD 0.05, 95% CI −0.64 to 0.73; 1 trial, 33 participants; P = 0.89; MD 0.60, 95% CI −8.07 to 9.27; 1 trial, 33 participants; P = 0.89; <a href="./references#CD012955-fig-0069" title="">Analysis 6.4</a>.2). </p> <p>Psychodynamic psychotherapy did not improve psychosocial functioning at above 12 months follow‐up compared with TAU (SMD −0.40, 95% CI −1.39 to 0.60; 1 trial, 16 participants; P = 0.44; MD −3.70, 95% CI −12.37 to 4.97; 1 trial, 16 participants; P = 0.40; <a href="./references#CD012955-fig-0069" title="">Analysis 6.4</a>.3). </p> <p>No data were available for zero to six months.</p> </section> </section> <section id="CD012955-sec-0163"> <h5 class="title">Secondary outcomes</h5> <section id="CD012955-sec-0164"> <h6 class="title">6.5 Anger</h6> <p>One trial reported continuous data on anger (<a href="./references#CD012955-bbs2-0001" title="AmiantoF , FerreroA , PieròA , CairoE , RoccaG , SimonelliB , et al. Supervised team management, with or without structured psychotherapy, in heavy users of a mental health service with borderline personality disorder: a two-year follow-up preliminary randomized study. BMC Psychiatry2011;11:181. [DOI: 10.1186/1471-244X-11-181] [PMC3260092 ] [PMID: 22103890]NCT01356069. Efficacy of time-limited psychodynamic psychotherapy and informed clinical management in BPD high MHS users (HUMSH) [Sequential brief Adlerian psychodynamic psychotherapy in heavy users of a mental health service with borderline personality disorder: a two years follow-up preliminary randomized study]. clinicaltrials.gov/ct2/show/NCT01356069 (first received 16 May 2011). ">Amianto 2011</a>). </p> <p>Psychodynamic psychotherapy did not reduce anger at end of treatment compared with TAU (MD 0.00, 95% CI −0.86 to 0.86; 1 trial, 33 participants; P = 1.00; <a href="./references#CD012955-fig-0070" title="">Analysis 6.5</a>.1). </p> <p>Psychodynamic psychotherapy did not reduce anger at six to 12 months follow‐up compared with TAU (MD 0.00, 95% CI −0.89 to 0.89; 1 trial, 33 participants; P = 1.00; <a href="./references#CD012955-fig-0070" title="">Analysis 6.5</a>.2). </p> <p>No data were available for zero to six months and above 12 months follow‐up.</p> </section> <section id="CD012955-sec-0165"> <h6 class="title">6.6 Affective instability</h6> <p>Three trials reported continuous data on affective instability (<a href="./references#CD012955-bbs2-0001" title="AmiantoF , FerreroA , PieròA , CairoE , RoccaG , SimonelliB , et al. Supervised team management, with or without structured psychotherapy, in heavy users of a mental health service with borderline personality disorder: a two-year follow-up preliminary randomized study. BMC Psychiatry2011;11:181. [DOI: 10.1186/1471-244X-11-181] [PMC3260092 ] [PMID: 22103890]NCT01356069. Efficacy of time-limited psychodynamic psychotherapy and informed clinical management in BPD high MHS users (HUMSH) [Sequential brief Adlerian psychodynamic psychotherapy in heavy users of a mental health service with borderline personality disorder: a two years follow-up preliminary randomized study]. clinicaltrials.gov/ct2/show/NCT01356069 (first received 16 May 2011). ">Amianto 2011</a>; <a href="./references#CD012955-bbs2-0060" title="RenesesB , FigueraD , SalcedoG , TrujilloM , López-IborJJ , GaliánM , et al. A controlled randomized study on the efficacy of short-term dinamic psychotherapy in borderline personality disorders (BPD). Preliminary results. European Psychiatry2011;26(Suppl 1):1040. [DOI: 10.1016/S0924-9338(11)72745-6] [P02-444]RenesesB , GaliánM , SerranoR , FigueraD , Fernandez Del MoralA , López-IborJJ , et al. A new time limited psychotherapy for BPD: preliminary results of a randomized and controlled trial. Actas Espanolas de Psiquiatria2013;41(3):139-48. [PMID: 23803797]">Reneses 2013</a>; <a href="./references#CD012955-bbs2-0063" title="SalzerS , CroppC , JaegerU , MasuhrO , Streeck-FischerA . Psychodynamic therapy for adolescents suffering from co-morbid disorders of conduct and emotions in an in-patient setting: a randomized controlled trial. Psychological Medicine2014;44(10):2213-22. [DOI: 10.1017/S003329171300278X] [PMID: 24229481]SalzerS , Streeck-FischerA . The psychoanalytic-interactional method (PiM) for adolescents with borderline personality disorder [Die psychoanalytisch-interaktionelle methode (PiM) für adoleszente mit borderline-persönlichkeitsstörung]. Personlichkeitsstorungen Theorie und Therapie2015;19(1):67-76. [elibrary.klett-cotta.de/article/99.120110/ptt-19-1-67]SalzerS . AW: Re: Cochrane Review on psychotherapies for BPD - RCT testing PiM vs WL [personal communication] [AW:Re: Cochrane Review zur Psychotherapie bei BPS - RCT zu PiM vs WL [persönliche kommunikation]]. Email to: J Stoffers-Winterling 15 July 2018. ">Salzer 2014</a>). </p> <p>Psychodynamic psychotherapy reduced affective instability at end of treatment compared with TAU (SMD −0.50, 95% CI −0.87 to −0.13; 3 trials, 116 participants; I<sup>2</sup> = 0%; P = 0.009; <a href="./references#CD012955-fig-0071" title="">Analysis 6.6</a>.1). </p> <p>Psychodynamic psychotherapy did not reduce affective instability at six to 12 months follow‐up compared with TAU (SMD −0.52, 95% CI −1.21 to 0.18; 1 trial, 33 participants; P = 0.15; MD −0.70, 95% CI −1.59 to 0.19; 1 trial, 33 participants; P = 0.12; <a href="./references#CD012955-fig-0071" title="">Analysis 6.6</a>.2). </p> <p>No data were available for zero to six months and above 12 months follow‐up.</p> </section> <section id="CD012955-sec-0166"> <h6 class="title">6.7 Chronic feelings of emptiness</h6> <p>Two trials reported continuous data on chronic feelings of emptiness (<a href="./references#CD012955-bbs2-0001" title="AmiantoF , FerreroA , PieròA , CairoE , RoccaG , SimonelliB , et al. Supervised team management, with or without structured psychotherapy, in heavy users of a mental health service with borderline personality disorder: a two-year follow-up preliminary randomized study. BMC Psychiatry2011;11:181. [DOI: 10.1186/1471-244X-11-181] [PMC3260092 ] [PMID: 22103890]NCT01356069. Efficacy of time-limited psychodynamic psychotherapy and informed clinical management in BPD high MHS users (HUMSH) [Sequential brief Adlerian psychodynamic psychotherapy in heavy users of a mental health service with borderline personality disorder: a two years follow-up preliminary randomized study]. clinicaltrials.gov/ct2/show/NCT01356069 (first received 16 May 2011). ">Amianto 2011</a>; <a href="./references#CD012955-bbs2-0060" title="RenesesB , FigueraD , SalcedoG , TrujilloM , López-IborJJ , GaliánM , et al. A controlled randomized study on the efficacy of short-term dinamic psychotherapy in borderline personality disorders (BPD). Preliminary results. European Psychiatry2011;26(Suppl 1):1040. [DOI: 10.1016/S0924-9338(11)72745-6] [P02-444]RenesesB , GaliánM , SerranoR , FigueraD , Fernandez Del MoralA , López-IborJJ , et al. A new time limited psychotherapy for BPD: preliminary results of a randomized and controlled trial. Actas Espanolas de Psiquiatria2013;41(3):139-48. [PMID: 23803797]">Reneses 2013</a>). </p> <p>Psychodynamic psychotherapy did not reduce chronic feelings of emptiness at end of treatment compared with TAU (SMD −0.49, 95% CI −1.02 to 0.04; 2 trials, 77 participants; I<sup>2</sup> = 24%; P = 0.07; <a href="./references#CD012955-fig-0072" title="">Analysis 6.7</a>.1; random‐effects model). </p> <p>Psychodynamic psychotherapy reduced chronic feelings of emptiness at end of treatment compared with TAU (SMD −0.50, 95% CI −0.96 to −0.04; 2 trials, 77 participants; I<sup>2</sup> = 24%; P = 0.03; analysis not shown; fixed‐effect model). </p> <p>Psychodynamic psychotherapy did not reduce chronic feelings of emptiness at six to 12 months follow‐up compared with TAU (SMD −0.58, 95% CI −1.28 to 0.11; 1 trial, 33 participants; P = 0.10; MD −0.60, 95% CI −1.29 to 0.09; 1 trial, 33 participants; P = 0.09; <a href="./references#CD012955-fig-0072" title="">Analysis 6.7</a>.2). </p> <p>No data were available for six to 12 months and above 12 months follow‐up.</p> </section> <section id="CD012955-sec-0167"> <h6 class="title">6.8 Impulsivity</h6> <p>Two trials reported continuous data on impulsivity (<a href="./references#CD012955-bbs2-0001" title="AmiantoF , FerreroA , PieròA , CairoE , RoccaG , SimonelliB , et al. Supervised team management, with or without structured psychotherapy, in heavy users of a mental health service with borderline personality disorder: a two-year follow-up preliminary randomized study. BMC Psychiatry2011;11:181. [DOI: 10.1186/1471-244X-11-181] [PMC3260092 ] [PMID: 22103890]NCT01356069. Efficacy of time-limited psychodynamic psychotherapy and informed clinical management in BPD high MHS users (HUMSH) [Sequential brief Adlerian psychodynamic psychotherapy in heavy users of a mental health service with borderline personality disorder: a two years follow-up preliminary randomized study]. clinicaltrials.gov/ct2/show/NCT01356069 (first received 16 May 2011). ">Amianto 2011</a>; <a href="./references#CD012955-bbs2-0060" title="RenesesB , FigueraD , SalcedoG , TrujilloM , López-IborJJ , GaliánM , et al. A controlled randomized study on the efficacy of short-term dinamic psychotherapy in borderline personality disorders (BPD). Preliminary results. European Psychiatry2011;26(Suppl 1):1040. [DOI: 10.1016/S0924-9338(11)72745-6] [P02-444]RenesesB , GaliánM , SerranoR , FigueraD , Fernandez Del MoralA , López-IborJJ , et al. A new time limited psychotherapy for BPD: preliminary results of a randomized and controlled trial. Actas Espanolas de Psiquiatria2013;41(3):139-48. [PMID: 23803797]">Reneses 2013</a>). </p> <p>Psychodynamic psychotherapy did not reduce impulsivity at end of treatment compared with TAU (SMD −0.39, 95% CI −0.85 to 0.07; 2 trials, 77 participants; I<sup>2</sup> = 0%; P = 0.09; <a href="./references#CD012955-fig-0073" title="">Analysis 6.8</a>.1). </p> <p>Psychodynamic psychotherapy did not reduce impulsivity at six to 12 months follow‐up compared with TAU (SMD 0.35, 95% CI −0.34 to 1.04; 1 trial, 33 participants; P = 0.32; MD 0.20, 95% CI −0.18 to 0.58; 1 trial, 33 participants; P = 0.30; <a href="./references#CD012955-fig-0073" title="">Analysis 6.8</a>.2). </p> <p>No data were available for zero to six months and above 12 months follow‐up.</p> </section> <section id="CD012955-sec-0168"> <h6 class="title">6.9 Interpersonal problems</h6> <p>Four trials reported continuous data on interpersonal problems (<a href="./references#CD012955-bbs2-0001" title="AmiantoF , FerreroA , PieròA , CairoE , RoccaG , SimonelliB , et al. Supervised team management, with or without structured psychotherapy, in heavy users of a mental health service with borderline personality disorder: a two-year follow-up preliminary randomized study. BMC Psychiatry2011;11:181. [DOI: 10.1186/1471-244X-11-181] [PMC3260092 ] [PMID: 22103890]NCT01356069. Efficacy of time-limited psychodynamic psychotherapy and informed clinical management in BPD high MHS users (HUMSH) [Sequential brief Adlerian psychodynamic psychotherapy in heavy users of a mental health service with borderline personality disorder: a two years follow-up preliminary randomized study]. clinicaltrials.gov/ct2/show/NCT01356069 (first received 16 May 2011). ">Amianto 2011</a>; <a href="./references#CD012955-bbs2-0042" title="LeichsenringF , MasuhrO , JaegerU , RabungS , DallyA , DümpelmannM , et al. Psychoanalytic-interactional therapy versus psychodynamic therapy by experts for personality disorders: a randomized controlled efficacy-effectiveness study in cluster B personality disorders. Psychotherapy and Psychosomatics2016;85(2):71-80. [DOI: 10.1159/000441731] [PMID: 26808580]">Leichsenring 2016</a>; <a href="./references#CD012955-bbs2-0060" title="RenesesB , FigueraD , SalcedoG , TrujilloM , López-IborJJ , GaliánM , et al. A controlled randomized study on the efficacy of short-term dinamic psychotherapy in borderline personality disorders (BPD). Preliminary results. European Psychiatry2011;26(Suppl 1):1040. [DOI: 10.1016/S0924-9338(11)72745-6] [P02-444]RenesesB , GaliánM , SerranoR , FigueraD , Fernandez Del MoralA , López-IborJJ , et al. A new time limited psychotherapy for BPD: preliminary results of a randomized and controlled trial. Actas Espanolas de Psiquiatria2013;41(3):139-48. [PMID: 23803797]">Reneses 2013</a>; <a href="./references#CD012955-bbs2-0063" title="SalzerS , CroppC , JaegerU , MasuhrO , Streeck-FischerA . Psychodynamic therapy for adolescents suffering from co-morbid disorders of conduct and emotions in an in-patient setting: a randomized controlled trial. Psychological Medicine2014;44(10):2213-22. [DOI: 10.1017/S003329171300278X] [PMID: 24229481]SalzerS , Streeck-FischerA . The psychoanalytic-interactional method (PiM) for adolescents with borderline personality disorder [Die psychoanalytisch-interaktionelle methode (PiM) für adoleszente mit borderline-persönlichkeitsstörung]. Personlichkeitsstorungen Theorie und Therapie2015;19(1):67-76. [elibrary.klett-cotta.de/article/99.120110/ptt-19-1-67]SalzerS . AW: Re: Cochrane Review on psychotherapies for BPD - RCT testing PiM vs WL [personal communication] [AW:Re: Cochrane Review zur Psychotherapie bei BPS - RCT zu PiM vs WL [persönliche kommunikation]]. Email to: J Stoffers-Winterling 15 July 2018. ">Salzer 2014</a>). </p> <p>Psychodynamic psychotherapy did not reduce interpersonal problems at end of treatment compared with TAU (SMD −0.21, 95% CI −0.71 to 0.29; 4 trials, 238 participants; I<sup>2</sup> = 68%; P = 0.41; <a href="./references#CD012955-fig-0074" title="">Analysis 6.9</a>.1). </p> <p>Psychodynamic psychotherapy did not reduce interpersonal problems at six to 12 months follow‐up compared with TAU (SMD −0.51, 95% CI −1.20 to 0.19; 1 trial, 33 participants; P = 0.15; MD −0.60, 95% CI −1.38 to 0.18; 1 trial, 33 participants; P = 0.13; <a href="./references#CD012955-fig-0074" title="">Analysis 6.9</a>.2). </p> <p>No data were available for zero to six months and above 12 months follow‐up.</p> </section> <section id="CD012955-sec-0169"> <h6 class="title">6.10 Abandonment</h6> <p>One trial reported continuous data on abandonment (<a href="./references#CD012955-bbs2-0001" title="AmiantoF , FerreroA , PieròA , CairoE , RoccaG , SimonelliB , et al. Supervised team management, with or without structured psychotherapy, in heavy users of a mental health service with borderline personality disorder: a two-year follow-up preliminary randomized study. BMC Psychiatry2011;11:181. [DOI: 10.1186/1471-244X-11-181] [PMC3260092 ] [PMID: 22103890]NCT01356069. Efficacy of time-limited psychodynamic psychotherapy and informed clinical management in BPD high MHS users (HUMSH) [Sequential brief Adlerian psychodynamic psychotherapy in heavy users of a mental health service with borderline personality disorder: a two years follow-up preliminary randomized study]. clinicaltrials.gov/ct2/show/NCT01356069 (first received 16 May 2011). ">Amianto 2011</a>). </p> <p>Psychodynamic psychotherapy did not reduce abandonment at end of treatment compared with TAU (MD −0.20, 95% CI −0.95 to 0.55; 1 trial, 33 participants; P = 0.60; <a href="./references#CD012955-fig-0075" title="">Analysis 6.10</a>.1). </p> <p>Psychodynamic psychotherapy did not reduce abandonment at six to 12 months follow‐up compared with TAU (MD −0.40, 95% CI −1.08 to 0.28; 1 trial, 33 participants; P = 0.25; <a href="./references#CD012955-fig-0075" title="">Analysis 6.10</a>.2). </p> <p>No data were available for zero to six months and above 12 months follow‐up.</p> </section> <section id="CD012955-sec-0170"> <h6 class="title">6.11 Identity disturbance</h6> <p>Three trials reported continuous data on identity disturbance (<a href="./references#CD012955-bbs2-0001" title="AmiantoF , FerreroA , PieròA , CairoE , RoccaG , SimonelliB , et al. Supervised team management, with or without structured psychotherapy, in heavy users of a mental health service with borderline personality disorder: a two-year follow-up preliminary randomized study. BMC Psychiatry2011;11:181. [DOI: 10.1186/1471-244X-11-181] [PMC3260092 ] [PMID: 22103890]NCT01356069. Efficacy of time-limited psychodynamic psychotherapy and informed clinical management in BPD high MHS users (HUMSH) [Sequential brief Adlerian psychodynamic psychotherapy in heavy users of a mental health service with borderline personality disorder: a two years follow-up preliminary randomized study]. clinicaltrials.gov/ct2/show/NCT01356069 (first received 16 May 2011). ">Amianto 2011</a>; <a href="./references#CD012955-bbs2-0042" title="LeichsenringF , MasuhrO , JaegerU , RabungS , DallyA , DümpelmannM , et al. Psychoanalytic-interactional therapy versus psychodynamic therapy by experts for personality disorders: a randomized controlled efficacy-effectiveness study in cluster B personality disorders. Psychotherapy and Psychosomatics2016;85(2):71-80. [DOI: 10.1159/000441731] [PMID: 26808580]">Leichsenring 2016</a>; <a href="./references#CD012955-bbs2-0060" title="RenesesB , FigueraD , SalcedoG , TrujilloM , López-IborJJ , GaliánM , et al. A controlled randomized study on the efficacy of short-term dinamic psychotherapy in borderline personality disorders (BPD). Preliminary results. European Psychiatry2011;26(Suppl 1):1040. [DOI: 10.1016/S0924-9338(11)72745-6] [P02-444]RenesesB , GaliánM , SerranoR , FigueraD , Fernandez Del MoralA , López-IborJJ , et al. A new time limited psychotherapy for BPD: preliminary results of a randomized and controlled trial. Actas Espanolas de Psiquiatria2013;41(3):139-48. [PMID: 23803797]">Reneses 2013</a>). </p> <p>Psychodynamic psychotherapy did not reduce identity disturbance at end of treatment compared with TAU (SMD −0.38, 95% CI −1.02 to 0.27; 3 trials, 199 participants; I<sup>2</sup> = 75%; P = 0.25; <a href="./references#CD012955-fig-0076" title="">Analysis 6.11</a>.1). </p> <p>Psychodynamic psychotherapy reduced identity disturbance at six to 12 months follow‐up compared with TAU (SMD −1.09, 95% CI −1.83 to −0.35; 1 trial, 33 participants; P = 0.004; MD −1.40, 95% CI −2.25 to −0.55; 1 trial, 33 participants; P = 0.001; <a href="./references#CD012955-fig-0076" title="">Analysis 6.11</a>.2). </p> <p>No data were available for zero to six months and above 12 months follow‐up.</p> </section> <section id="CD012955-sec-0171"> <h6 class="title">6.12 Dissociation and psychotic‐like symptoms</h6> <p>Two trials reported continuous data on dissociation and psychotic‐like symptoms (<a href="./references#CD012955-bbs2-0001" title="AmiantoF , FerreroA , PieròA , CairoE , RoccaG , SimonelliB , et al. Supervised team management, with or without structured psychotherapy, in heavy users of a mental health service with borderline personality disorder: a two-year follow-up preliminary randomized study. BMC Psychiatry2011;11:181. [DOI: 10.1186/1471-244X-11-181] [PMC3260092 ] [PMID: 22103890]NCT01356069. Efficacy of time-limited psychodynamic psychotherapy and informed clinical management in BPD high MHS users (HUMSH) [Sequential brief Adlerian psychodynamic psychotherapy in heavy users of a mental health service with borderline personality disorder: a two years follow-up preliminary randomized study]. clinicaltrials.gov/ct2/show/NCT01356069 (first received 16 May 2011). ">Amianto 2011</a>; <a href="./references#CD012955-bbs2-0028" title="GregoryRJ , ChlebowskiS , KangD , RemenA , SoderbergM . Psychodynamic therapy for borderline personality disorder and co-occurring alcohol use disorders: a newly designed ongoing study. Journal of the American Psychoanalytic Association2006;54(4):1331-4. [DOI: 10.1177/00030651060540040107] [PMID: 17354507]GregoryRJ , ChlebowskiS , KangD , RemenAL , SoderbergMG , StepkovitchJ , et al. A controlled trial of psychodynamic psychotherapy for co-occurring borderline personality disorder and alcohol use disorder. Psychotherapy2008;45(1):28-41. [DOI: 10.1037/0033-3204.45.1.28] [PMID: 22122363]GregoryRJ , DeLucia-DeranjaE , MogleJA . Dynamic deconstructive psychotherapy versus optimized community care for borderline personality disorder co-occuring with alcohol use disorders: a 30-month follow-up. Journal of Nervous and Mental Disease2010;198(4):292-8. [DOI: 10.1097/NMD.0b013e3181d6172d] [PMID: 20386259]GregoryRJ , RemenAL , SoderbergM , Ploutz-SnyderRJ . A controlled trial of psychodynamic psychotherapy for co-occurring borderline personality disorder and alcohol use disorder: six-month outcome. Journal of the American Psychoanalytic Association2009;57(1):199-205. [DOI: 10.1177/00030651090570011006] [PMID: 19270255]NCT00145678. Psychodynamic therapy for co-occurring borderline personality disorder and alcohol use disorder [Psychodynamic therapy for patients With borderline personality disorder and alcohol abuse]. www.clinicaltrials.gov/show/NCT00145678 (first received 1 September 2005). ">Gregory 2008b</a>). </p> <p>Psychodynamic psychotherapy did not reduce dissociation and psychotic‐like symptoms at end of treatment compared with TAU (SMD −0.18, 95% CI −0.96 to 0.60; 2 trials, 57 participants; I<sup>2</sup> = 53%; P = 0.66; <a href="./references#CD012955-fig-0077" title="">Analysis 6.12</a>.1). </p> <p>Psychodynamic psychotherapy did not reduce dissociation and psychotic‐like symptoms at six to 12 months follow‐up compared with TAU (SMD −0.59, 95% CI −1.29 to 0.11; 1 trial, 33 participants; P = 0.10; MD −0.70, 95% CI −1.49 to 0.09; 1 trial, 33 participants; P = 0.08; <a href="./references#CD012955-fig-0077" title="">Analysis 6.12</a>.2). </p> <p>Psychodynamic psychotherapy did not reduce dissociation and psychotic‐like symptoms at above 12 months follow‐up compared with TAU (SMD −0.01, 95% CI −0.81 to 0.79; 1 trial, 24 participants; P = 0.98; MD −0.20, 95% CI −20.07 to 19.67; 1 trial, 24 participants; P = 0.98; <a href="./references#CD012955-fig-0077" title="">Analysis 6.12</a>.3). </p> <p>No data were available for zero to six months follow‐up.</p> </section> <section id="CD012955-sec-0172"> <h6 class="title">6.13 Depression</h6> <p>Three trials reported continuous data on depression (<a href="./references#CD012955-bbs2-0001" title="AmiantoF , FerreroA , PieròA , CairoE , RoccaG , SimonelliB , et al. Supervised team management, with or without structured psychotherapy, in heavy users of a mental health service with borderline personality disorder: a two-year follow-up preliminary randomized study. BMC Psychiatry2011;11:181. [DOI: 10.1186/1471-244X-11-181] [PMC3260092 ] [PMID: 22103890]NCT01356069. Efficacy of time-limited psychodynamic psychotherapy and informed clinical management in BPD high MHS users (HUMSH) [Sequential brief Adlerian psychodynamic psychotherapy in heavy users of a mental health service with borderline personality disorder: a two years follow-up preliminary randomized study]. clinicaltrials.gov/ct2/show/NCT01356069 (first received 16 May 2011). ">Amianto 2011</a>; <a href="./references#CD012955-bbs2-0042" title="LeichsenringF , MasuhrO , JaegerU , RabungS , DallyA , DümpelmannM , et al. Psychoanalytic-interactional therapy versus psychodynamic therapy by experts for personality disorders: a randomized controlled efficacy-effectiveness study in cluster B personality disorders. Psychotherapy and Psychosomatics2016;85(2):71-80. [DOI: 10.1159/000441731] [PMID: 26808580]">Leichsenring 2016</a>; <a href="./references#CD012955-bbs2-0060" title="RenesesB , FigueraD , SalcedoG , TrujilloM , López-IborJJ , GaliánM , et al. A controlled randomized study on the efficacy of short-term dinamic psychotherapy in borderline personality disorders (BPD). Preliminary results. European Psychiatry2011;26(Suppl 1):1040. [DOI: 10.1016/S0924-9338(11)72745-6] [P02-444]RenesesB , GaliánM , SerranoR , FigueraD , Fernandez Del MoralA , López-IborJJ , et al. A new time limited psychotherapy for BPD: preliminary results of a randomized and controlled trial. Actas Espanolas de Psiquiatria2013;41(3):139-48. [PMID: 23803797]">Reneses 2013</a>). </p> <p>Psychodynamic psychotherapy did not reduce depression at end of treatment compared with TAU (SMD −0.17, 95% CI −0.81 to 0.47; 3 trials, 190 participants; I<sup>2</sup> = 73%; P = 0.61; <a href="./references#CD012955-fig-0078" title="">Analysis 6.13</a>.1). </p> <p>Psychodynamic psychotherapy did not reduce depression at above 12 months follow‐up compared with TAU (SMD −0.68, 95% CI −1.51 to 0.15; 1 trial, 24 participants; P = 0.11; MD −7.80, 95% CI −16.71 to 1.11; 1 trial, 24 participants; P = 0.09; <a href="./references#CD012955-fig-0078" title="">Analysis 6.13</a>.2). </p> <p>No data were available for zero to six months and six to 12 months follow‐up.</p> </section> <section id="CD012955-sec-0173"> <h6 class="title">6.14 Attrition</h6> <p>Three trials reported dichotomous data on attrition (<a href="./references#CD012955-bbs2-0001" title="AmiantoF , FerreroA , PieròA , CairoE , RoccaG , SimonelliB , et al. Supervised team management, with or without structured psychotherapy, in heavy users of a mental health service with borderline personality disorder: a two-year follow-up preliminary randomized study. BMC Psychiatry2011;11:181. [DOI: 10.1186/1471-244X-11-181] [PMC3260092 ] [PMID: 22103890]NCT01356069. Efficacy of time-limited psychodynamic psychotherapy and informed clinical management in BPD high MHS users (HUMSH) [Sequential brief Adlerian psychodynamic psychotherapy in heavy users of a mental health service with borderline personality disorder: a two years follow-up preliminary randomized study]. clinicaltrials.gov/ct2/show/NCT01356069 (first received 16 May 2011). ">Amianto 2011</a>; <a href="./references#CD012955-bbs2-0042" title="LeichsenringF , MasuhrO , JaegerU , RabungS , DallyA , DümpelmannM , et al. Psychoanalytic-interactional therapy versus psychodynamic therapy by experts for personality disorders: a randomized controlled efficacy-effectiveness study in cluster B personality disorders. Psychotherapy and Psychosomatics2016;85(2):71-80. [DOI: 10.1159/000441731] [PMID: 26808580]">Leichsenring 2016</a>; <a href="./references#CD012955-bbs2-0060" title="RenesesB , FigueraD , SalcedoG , TrujilloM , López-IborJJ , GaliánM , et al. A controlled randomized study on the efficacy of short-term dinamic psychotherapy in borderline personality disorders (BPD). Preliminary results. European Psychiatry2011;26(Suppl 1):1040. [DOI: 10.1016/S0924-9338(11)72745-6] [P02-444]RenesesB , GaliánM , SerranoR , FigueraD , Fernandez Del MoralA , López-IborJJ , et al. A new time limited psychotherapy for BPD: preliminary results of a randomized and controlled trial. Actas Espanolas de Psiquiatria2013;41(3):139-48. [PMID: 23803797]">Reneses 2013</a>). </p> <p>Psychodynamic psychotherapy did not reduce attrition at end of treatment compared with TAU (RR 0.90, 95% CI 0.56 to 1.47; 3 trials, 210 participants; I<sup>2</sup> = 0%; P = 0.68; <a href="./references#CD012955-fig-0079" title="">Analysis 6.14</a>). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> <p>No data were available on any time point for adverse effects.</p> </section> </section> </section> <section id="CD012955-sec-0174"> <h4 class="title">7. Schema‐focused therapy (SFT) versus treatment‐as‐usual (TAU)</h4> <section id="CD012955-sec-0175"> <h5 class="title">Primary outcomes</h5> <section id="CD012955-sec-0176"> <h6 class="title">7.1 BPD symptom severity</h6> <p>One trial reported continuous data on BPD symptom severity (<a href="./references#CD012955-bbs2-0021" title="FarrellJM , ShawIA , WebberMA . A schema-focused approach to group psychotherapy for outpatients with borderline personality disorder: a randomized controlled trial. Journal of Behavior Therapy and Experimental Psychiatry2009;40(2):317-28 Corrigendum to: Journal of Behavior Therapy and Experimental Psychiatry 2018; 60: 111. [DOI: 10.1016/j.jbtep.2009.01.002] [PMID: 19176222]FarrellJM . Question regarding your BPD trials [personal communication]. Email to: K Lieb, J Stoffers 9 December 2010. ">Farrell 2009</a>). </p> <p>SFT reduced BPD symptom severity at end of treatment compared with TAU (MD −13.94, 95% CI −19.66 to −8.22; 1 trial, 28 participants; P &lt; 0.001; <a href="./references#CD012955-fig-0080" title="">Analysis 7.1</a>). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> </section> <section id="CD012955-sec-0177"> <h6 class="title">7.2 Psychosocial functioning</h6> <p>One trial reported continuous data on psychosocial functioning (<a href="./references#CD012955-bbs2-0021" title="FarrellJM , ShawIA , WebberMA . A schema-focused approach to group psychotherapy for outpatients with borderline personality disorder: a randomized controlled trial. Journal of Behavior Therapy and Experimental Psychiatry2009;40(2):317-28 Corrigendum to: Journal of Behavior Therapy and Experimental Psychiatry 2018; 60: 111. [DOI: 10.1016/j.jbtep.2009.01.002] [PMID: 19176222]FarrellJM . Question regarding your BPD trials [personal communication]. Email to: K Lieb, J Stoffers 9 December 2010. ">Farrell 2009</a>). </p> <p>SFT improved psychosocial functioning at end of treatment compared with TAU (MD −10.42, 95% CI −16.17 to −4.67; 1 trial, 28 participants; P &lt; 0.001; <a href="./references#CD012955-fig-0081" title="">Analysis 7.2</a>). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> <p>No data were available on any time point for self‐harm and suicide‐related outcomes.</p> </section> </section> <section id="CD012955-sec-0178"> <h5 class="title">Secondary outcomes</h5> <section id="CD012955-sec-0179"> <h6 class="title">7.3 Affective instability</h6> <p>One trial reported continuous data on affective instability (<a href="./references#CD012955-bbs2-0021" title="FarrellJM , ShawIA , WebberMA . A schema-focused approach to group psychotherapy for outpatients with borderline personality disorder: a randomized controlled trial. Journal of Behavior Therapy and Experimental Psychiatry2009;40(2):317-28 Corrigendum to: Journal of Behavior Therapy and Experimental Psychiatry 2018; 60: 111. [DOI: 10.1016/j.jbtep.2009.01.002] [PMID: 19176222]FarrellJM . Question regarding your BPD trials [personal communication]. Email to: K Lieb, J Stoffers 9 December 2010. ">Farrell 2009</a>). </p> <p>SFT reduced affective instability at end of treatment compared with TAU (MD −3.95, 95% CI −5.75 to −2.15; 1 trial, 28 participants; P &lt; 0.001; <a href="./references#CD012955-fig-0082" title="">Analysis 7.3</a>). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> </section> <section id="CD012955-sec-0180"> <h6 class="title">7.4 Impulsivity</h6> <p>One trial reported continuous data on impulsivity (<a href="./references#CD012955-bbs2-0021" title="FarrellJM , ShawIA , WebberMA . A schema-focused approach to group psychotherapy for outpatients with borderline personality disorder: a randomized controlled trial. Journal of Behavior Therapy and Experimental Psychiatry2009;40(2):317-28 Corrigendum to: Journal of Behavior Therapy and Experimental Psychiatry 2018; 60: 111. [DOI: 10.1016/j.jbtep.2009.01.002] [PMID: 19176222]FarrellJM . Question regarding your BPD trials [personal communication]. Email to: K Lieb, J Stoffers 9 December 2010. ">Farrell 2009</a>). </p> <p>SFT reduced impulsivity at end of treatment compared with TAU (MD −4.02, 95% CI −5.68 to −2.36; 1 trial, 28 participants; P &lt; 0.001; <a href="./references#CD012955-fig-0083" title="">Analysis 7.4</a>). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> </section> <section id="CD012955-sec-0181"> <h6 class="title">7.5 Interpersonal problems</h6> <p>One trial reported continuous data on interpersonal problems (<a href="./references#CD012955-bbs2-0021" title="FarrellJM , ShawIA , WebberMA . A schema-focused approach to group psychotherapy for outpatients with borderline personality disorder: a randomized controlled trial. Journal of Behavior Therapy and Experimental Psychiatry2009;40(2):317-28 Corrigendum to: Journal of Behavior Therapy and Experimental Psychiatry 2018; 60: 111. [DOI: 10.1016/j.jbtep.2009.01.002] [PMID: 19176222]FarrellJM . Question regarding your BPD trials [personal communication]. Email to: K Lieb, J Stoffers 9 December 2010. ">Farrell 2009</a>). </p> <p>SFT reduced interpersonal problems at end of treatment compared with TAU (MD −7.12, 95% CI −9.65 to −4.59; 1 trial, 28 participants; P &lt; 0.001; <a href="./references#CD012955-fig-0084" title="">Analysis 7.5</a>). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> </section> <section id="CD012955-sec-0182"> <h6 class="title">7.6 Dissociation and psychotic‐like symptoms</h6> <p>One trial reported continuous data on dissociation and psychotic‐like symptoms (<a href="./references#CD012955-bbs2-0021" title="FarrellJM , ShawIA , WebberMA . A schema-focused approach to group psychotherapy for outpatients with borderline personality disorder: a randomized controlled trial. Journal of Behavior Therapy and Experimental Psychiatry2009;40(2):317-28 Corrigendum to: Journal of Behavior Therapy and Experimental Psychiatry 2018; 60: 111. [DOI: 10.1016/j.jbtep.2009.01.002] [PMID: 19176222]FarrellJM . Question regarding your BPD trials [personal communication]. Email to: K Lieb, J Stoffers 9 December 2010. ">Farrell 2009</a>). </p> <p>SFT reduced dissociation and psychotic‐like symptoms at end of treatment compared with TAU (MD −2.56, 95% CI −3.86 to −1.26; 1 trial, 28 participants; P &lt; 0.001; <a href="./references#CD012955-fig-0085" title="">Analysis 7.6</a>). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up.. </p> </section> <section id="CD012955-sec-0183"> <h6 class="title">7.7 Attrition</h6> <p>One trial reported dichotomous data on attrition (<a href="./references#CD012955-bbs2-0021" title="FarrellJM , ShawIA , WebberMA . A schema-focused approach to group psychotherapy for outpatients with borderline personality disorder: a randomized controlled trial. Journal of Behavior Therapy and Experimental Psychiatry2009;40(2):317-28 Corrigendum to: Journal of Behavior Therapy and Experimental Psychiatry 2018; 60: 111. [DOI: 10.1016/j.jbtep.2009.01.002] [PMID: 19176222]FarrellJM . Question regarding your BPD trials [personal communication]. Email to: K Lieb, J Stoffers 9 December 2010. ">Farrell 2009</a>). </p> <p>SFT did not reduce attrition at end of treatment compared with TAU (RR 0.11, 95% CI 0.01 to 1.91; 1 trial, 32 participants; P = 0.13; <a href="./references#CD012955-fig-0086" title="">Analysis 7.7</a>). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> <p>* No data were available on any time point for anger, chronic feelings of emptiness, abandonment, identity disturbance, depression, and adverse effects </p> </section> </section> </section> <section id="CD012955-sec-0184"> <h4 class="title">8. Systems training for emotional predictability and problem solving (STEPPS) versus treatment‐as‐usual (TAU) </h4> <section id="CD012955-sec-0185"> <h5 class="title">Primary outcomes</h5> <section id="CD012955-sec-0186"> <h6 class="title">8.1 BPD symptom severity</h6> <p>Three trials reported continuous data on BPD symptom severity (<a href="./references#CD012955-bbs2-0010" title="BlackD . Question regarding your BPD trial [personal communication]. Email to: J Stoffers 04 January 2011. BlackDW , AllenJ , McCormickB , BlumN . Treatment received by persons with BPD participating in a randomized clinical trial of the systems training for emotional predictability and problem solving programme. Personality and Mental Health2011;5(3):159-68. [DOI: 10.1002/pmh.167]BlackDW , AllenJ , St JohnD , PfohlB , McCormickB , BlumN . Predictors of response to systems training for emotional predictability and problem solving (STEPPS) for borderline personality disorder: an exploratory study. Acta Psychiatrica Scandinavica2009;120(1):53-61. [DOI: 10.1111/j.1600-0447.2008.01340.x] [PMC3665337] [PMID: 19183126]BlackDW , BlumN , PfohlB , St JohnD . The STEPPS group treatment program for outpatients with borderline personality disorder. Journal of Contemporary Psychotherapy2004;34(3):193-210. [DOI: 10.1023/B:JOCP.0000036630.25741.83]BlackDW , PfohlBM . Randomized clinical trial of STEPPS versus treatment as usual. In: 158th annual meeting of the American Psychiatric Association. Psychosomatic medicine: integrating psychiatry &amp; medicine; 2005 May 21-26; Atlanta (GA). Arlington (VA): American Psychiatric Association, 2005:104. [No. 1B] [www.psychiatry.org/File%20Library/Psychiatrists/Directories/Library-and-Archive/syllabus/am_syllabus_2005.pdf]BlackDW , Simsek-DuranF , BlumN , McCormickB , AllenJ . Do people with borderline personality disorder complicated by antisocial personality disorder benefit from the STEPPS treatment program?Personality and Mental Health2016;10(3):205-15. [DOI: 10.1002/pmh.1326] [PMC4911327] [PMID: 26671625]BlackDW . RE: [external] questions regarding your trial on the STEPPS program for BPD [personal communication]. Email to: EG Faltinsen 27 November 2017. BlumN , AllenJ , McCormickB , BlackDW . Ms Blum and colleagues reply [to Schulte-Herbrüggen O, Koerting J, Roepke S. Effectiveness of adjunctive STEPPS group treatment in borderline personality disorder patients. American Journal of Psychiatry 2008;165(10):1354-5. DOI: 10.1176/appi.ajp.2008.08030390]. American Journal of Psychiatry2008;165(10):1354-5. [DOI: 10.1176/appi.ajp.2008.08030390r]BlumN , FranklinJ , HanselR , McCormickB , St JohnD , PfohlB , et al. Relationship of age to symptom severity, psychiatric comorbidity and health care utilization in persons with borderline personality disorder. Personality and Mental Health2008;2(1):25-43. [DOI: 10.1002/pmh.26]BlumN , St JohnD , PfohlB , StuartS , McCormickB , AllenJ , et al. Erratum. American Journal of Psychiatry2008;165(6):777. Erratum for: American Journal of Psychiatry 2008;165(4):468-78. [psycnet.apa.org/record/2008-07854-033]BlumN , St JohnD , PfohlB , StuartS , McCormickB , AllenJ , et al. Systems training for emotional predictability and problem solving (STEPPS) for outpatients with borderline personality disorder: a randomized controlled trial and 1-year follow-up. American Journal of Psychiatry2008;165(4):468-78. [DOI: 10.1176/appi.ajp.2007.07071079] [PMC3608469] [PMID: 18281407]DavidsonKM . Borderline personality disorder: STEPPS improves symptoms. Evidence-Based Mental Health2008;11(4):120. [DOI: 10.1136/ebmh.11.4.120] [PMID: 18952969]NCT00055315. Treatment for borderline personality disorder [A cognitive group treatment for borderline outpatients]. clinicaltrials.gov/ct2/show/NCT00055315 (first received 25 February 2003). ">Blum 2008</a>; <a href="./references#CD012955-bbs2-0013" title="BosEH , Van WelE , AppeloMT , VerbraakMJP . A randomized controlled trial of a Dutch version of systems training for emotional predictability and problem solving for borderline personality disorder. Journal of Nervous and Mental Disease2010;198(4):299-304. [DOI: 10.1097/NMD.0b013e3181d619cf] [PMID: 20386260]Van WelEB , BosEH , AppeloMT , BerendsenEM , WillgerothFC , VerbraakMJPM . The efficacy of the systems training for emotional predictability and problem solving (STEPPS) in the treatment of borderline personality disorder. A randomized controlled trial [De effectiviteit van de vaardigheidstraining emotieregulatiestoornis (VERS) in de behandeling van de borderlinepersoonlijkheidsstoornis: een gerandomiseerd onderzoek]. Tijdschrift voor Psychiatrie2009;51(5):291-301. [PMID: 19434566]">Bos 2010</a>; <a href="./references#CD012955-bbs2-0066" title="ISRCTN97589104. Evaluation of a group training for adolescents (emotion regulation training) with emotion regulation problems - a randomised controlled clinical trial. www.isrctn.com/ISRCTN97589104 (first received 23 August 2007). SchuppertHM , TimmermanME , BlooJ , Van GemertTG , WiersemaHM , MinderaaRB , et al. Emotion regulation training for adolescents with borderline personality disorder traits: a randomized controlled trial. Journal of the American Academy of Child &amp; Adolescent Psychiatry2012;51(12):1314-23. [DOI: 10.1016/j.jaac.2012.09.002] [PMID: 23200288]">Schuppert 2012</a>). </p> <p>STEPPS reduced BPD symptom severity at end of treatment compared with TAU (SMD −0.39, 95% CI −0.63 to −0.15; 3 trials, 273 participants; I<sup>2</sup> = 0%; P = 0.001; <a href="./references#CD012955-fig-0087" title="">Analysis 8.1</a>.1). </p> <p>STEPPS did not reduce BPD symptom severity at six to 12 months follow‐up compared with TAU (SMD 0.03, 95% CI −0.33 to 0.38; 1 trial, 124 participants; P = 0.88; MD 0.60, 95% CI −7.45 to 8.65; 1 trial, 124 participants; P = 0.88; <a href="./references#CD012955-fig-0087" title="">Analysis 8.1</a>.2). </p> <p>No data were available for zero to six months and above 12 months follow‐up.</p> </section> <section id="CD012955-sec-0187"> <h6 class="title">8.2 Self‐harm</h6> <p>One trial reported dichotomous data on self‐harm (<a href="./references#CD012955-bbs2-0013" title="BosEH , Van WelE , AppeloMT , VerbraakMJP . A randomized controlled trial of a Dutch version of systems training for emotional predictability and problem solving for borderline personality disorder. Journal of Nervous and Mental Disease2010;198(4):299-304. [DOI: 10.1097/NMD.0b013e3181d619cf] [PMID: 20386260]Van WelEB , BosEH , AppeloMT , BerendsenEM , WillgerothFC , VerbraakMJPM . The efficacy of the systems training for emotional predictability and problem solving (STEPPS) in the treatment of borderline personality disorder. A randomized controlled trial [De effectiviteit van de vaardigheidstraining emotieregulatiestoornis (VERS) in de behandeling van de borderlinepersoonlijkheidsstoornis: een gerandomiseerd onderzoek]. Tijdschrift voor Psychiatrie2009;51(5):291-301. [PMID: 19434566]">Bos 2010</a>). </p> <p>STEPPS did not reduce self‐harm at end of treatment compared with TAU (RR 1.32, 95% CI 0.78 to 2.22; 1 trial, 58 participants; P = 0.30; <a href="./references#CD012955-fig-0088" title="">Analysis 8.2</a>). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> </section> <section id="CD012955-sec-0188"> <h6 class="title">8.3 Psychosocial functioning</h6> <p>One trial reported continuous data on psychosocial functioning (<a href="./references#CD012955-bbs2-0010" title="BlackD . Question regarding your BPD trial [personal communication]. Email to: J Stoffers 04 January 2011. BlackDW , AllenJ , McCormickB , BlumN . Treatment received by persons with BPD participating in a randomized clinical trial of the systems training for emotional predictability and problem solving programme. Personality and Mental Health2011;5(3):159-68. [DOI: 10.1002/pmh.167]BlackDW , AllenJ , St JohnD , PfohlB , McCormickB , BlumN . Predictors of response to systems training for emotional predictability and problem solving (STEPPS) for borderline personality disorder: an exploratory study. Acta Psychiatrica Scandinavica2009;120(1):53-61. [DOI: 10.1111/j.1600-0447.2008.01340.x] [PMC3665337] [PMID: 19183126]BlackDW , BlumN , PfohlB , St JohnD . The STEPPS group treatment program for outpatients with borderline personality disorder. Journal of Contemporary Psychotherapy2004;34(3):193-210. [DOI: 10.1023/B:JOCP.0000036630.25741.83]BlackDW , PfohlBM . Randomized clinical trial of STEPPS versus treatment as usual. In: 158th annual meeting of the American Psychiatric Association. Psychosomatic medicine: integrating psychiatry &amp; medicine; 2005 May 21-26; Atlanta (GA). Arlington (VA): American Psychiatric Association, 2005:104. [No. 1B] [www.psychiatry.org/File%20Library/Psychiatrists/Directories/Library-and-Archive/syllabus/am_syllabus_2005.pdf]BlackDW , Simsek-DuranF , BlumN , McCormickB , AllenJ . Do people with borderline personality disorder complicated by antisocial personality disorder benefit from the STEPPS treatment program?Personality and Mental Health2016;10(3):205-15. [DOI: 10.1002/pmh.1326] [PMC4911327] [PMID: 26671625]BlackDW . RE: [external] questions regarding your trial on the STEPPS program for BPD [personal communication]. Email to: EG Faltinsen 27 November 2017. BlumN , AllenJ , McCormickB , BlackDW . Ms Blum and colleagues reply [to Schulte-Herbrüggen O, Koerting J, Roepke S. Effectiveness of adjunctive STEPPS group treatment in borderline personality disorder patients. American Journal of Psychiatry 2008;165(10):1354-5. DOI: 10.1176/appi.ajp.2008.08030390]. American Journal of Psychiatry2008;165(10):1354-5. [DOI: 10.1176/appi.ajp.2008.08030390r]BlumN , FranklinJ , HanselR , McCormickB , St JohnD , PfohlB , et al. Relationship of age to symptom severity, psychiatric comorbidity and health care utilization in persons with borderline personality disorder. Personality and Mental Health2008;2(1):25-43. [DOI: 10.1002/pmh.26]BlumN , St JohnD , PfohlB , StuartS , McCormickB , AllenJ , et al. Erratum. American Journal of Psychiatry2008;165(6):777. Erratum for: American Journal of Psychiatry 2008;165(4):468-78. [psycnet.apa.org/record/2008-07854-033]BlumN , St JohnD , PfohlB , StuartS , McCormickB , AllenJ , et al. Systems training for emotional predictability and problem solving (STEPPS) for outpatients with borderline personality disorder: a randomized controlled trial and 1-year follow-up. American Journal of Psychiatry2008;165(4):468-78. [DOI: 10.1176/appi.ajp.2007.07071079] [PMC3608469] [PMID: 18281407]DavidsonKM . Borderline personality disorder: STEPPS improves symptoms. Evidence-Based Mental Health2008;11(4):120. [DOI: 10.1136/ebmh.11.4.120] [PMID: 18952969]NCT00055315. Treatment for borderline personality disorder [A cognitive group treatment for borderline outpatients]. clinicaltrials.gov/ct2/show/NCT00055315 (first received 25 February 2003). ">Blum 2008</a>). </p> <p>STEPPS improved psychosocial functioning at end of treatment compared with TAU (MD −7.00, 95% CI −11.43 to −2.57; 1 trial, 124 participants; P = 0.002; <a href="./references#CD012955-fig-0089" title="">Analysis 8.3</a>.1). </p> <p>STEPPS did not improve psychosocial functioning at six to 12 months follow‐up compared with TAU (MD −5.90, 95% CI −12.49 to 0.69; 1 trial, 124 participants; P = 0.08; <a href="./references#CD012955-fig-0089" title="">Analysis 8.3</a>.2). </p> <p>No data were available for zero to six months and above 12 months follow‐up.</p> <p>No data were available on any time point for suicide‐related outcomes.</p> </section> </section> <section id="CD012955-sec-0189"> <h5 class="title">Secondary outcomes</h5> <section id="CD012955-sec-0190"> <h6 class="title">8.4 Affective instability</h6> <p>Two trials reported continuous data on affective instability (<a href="./references#CD012955-bbs2-0010" title="BlackD . Question regarding your BPD trial [personal communication]. Email to: J Stoffers 04 January 2011. BlackDW , AllenJ , McCormickB , BlumN . Treatment received by persons with BPD participating in a randomized clinical trial of the systems training for emotional predictability and problem solving programme. Personality and Mental Health2011;5(3):159-68. [DOI: 10.1002/pmh.167]BlackDW , AllenJ , St JohnD , PfohlB , McCormickB , BlumN . Predictors of response to systems training for emotional predictability and problem solving (STEPPS) for borderline personality disorder: an exploratory study. Acta Psychiatrica Scandinavica2009;120(1):53-61. [DOI: 10.1111/j.1600-0447.2008.01340.x] [PMC3665337] [PMID: 19183126]BlackDW , BlumN , PfohlB , St JohnD . The STEPPS group treatment program for outpatients with borderline personality disorder. Journal of Contemporary Psychotherapy2004;34(3):193-210. [DOI: 10.1023/B:JOCP.0000036630.25741.83]BlackDW , PfohlBM . Randomized clinical trial of STEPPS versus treatment as usual. In: 158th annual meeting of the American Psychiatric Association. Psychosomatic medicine: integrating psychiatry &amp; medicine; 2005 May 21-26; Atlanta (GA). Arlington (VA): American Psychiatric Association, 2005:104. [No. 1B] [www.psychiatry.org/File%20Library/Psychiatrists/Directories/Library-and-Archive/syllabus/am_syllabus_2005.pdf]BlackDW , Simsek-DuranF , BlumN , McCormickB , AllenJ . Do people with borderline personality disorder complicated by antisocial personality disorder benefit from the STEPPS treatment program?Personality and Mental Health2016;10(3):205-15. [DOI: 10.1002/pmh.1326] [PMC4911327] [PMID: 26671625]BlackDW . RE: [external] questions regarding your trial on the STEPPS program for BPD [personal communication]. Email to: EG Faltinsen 27 November 2017. BlumN , AllenJ , McCormickB , BlackDW . Ms Blum and colleagues reply [to Schulte-Herbrüggen O, Koerting J, Roepke S. Effectiveness of adjunctive STEPPS group treatment in borderline personality disorder patients. American Journal of Psychiatry 2008;165(10):1354-5. DOI: 10.1176/appi.ajp.2008.08030390]. American Journal of Psychiatry2008;165(10):1354-5. [DOI: 10.1176/appi.ajp.2008.08030390r]BlumN , FranklinJ , HanselR , McCormickB , St JohnD , PfohlB , et al. Relationship of age to symptom severity, psychiatric comorbidity and health care utilization in persons with borderline personality disorder. Personality and Mental Health2008;2(1):25-43. [DOI: 10.1002/pmh.26]BlumN , St JohnD , PfohlB , StuartS , McCormickB , AllenJ , et al. Erratum. American Journal of Psychiatry2008;165(6):777. Erratum for: American Journal of Psychiatry 2008;165(4):468-78. [psycnet.apa.org/record/2008-07854-033]BlumN , St JohnD , PfohlB , StuartS , McCormickB , AllenJ , et al. Systems training for emotional predictability and problem solving (STEPPS) for outpatients with borderline personality disorder: a randomized controlled trial and 1-year follow-up. American Journal of Psychiatry2008;165(4):468-78. [DOI: 10.1176/appi.ajp.2007.07071079] [PMC3608469] [PMID: 18281407]DavidsonKM . Borderline personality disorder: STEPPS improves symptoms. Evidence-Based Mental Health2008;11(4):120. [DOI: 10.1136/ebmh.11.4.120] [PMID: 18952969]NCT00055315. Treatment for borderline personality disorder [A cognitive group treatment for borderline outpatients]. clinicaltrials.gov/ct2/show/NCT00055315 (first received 25 February 2003). ">Blum 2008</a>; <a href="./references#CD012955-bbs2-0066" title="ISRCTN97589104. Evaluation of a group training for adolescents (emotion regulation training) with emotion regulation problems - a randomised controlled clinical trial. www.isrctn.com/ISRCTN97589104 (first received 23 August 2007). SchuppertHM , TimmermanME , BlooJ , Van GemertTG , WiersemaHM , MinderaaRB , et al. Emotion regulation training for adolescents with borderline personality disorder traits: a randomized controlled trial. Journal of the American Academy of Child &amp; Adolescent Psychiatry2012;51(12):1314-23. [DOI: 10.1016/j.jaac.2012.09.002] [PMID: 23200288]">Schuppert 2012</a>). </p> <p>STEPPS did not reduce affective instability at end of treatment compared with TAU (SMD −0.25, 95% CI −0.52 to 0.02; 2 trials, 221 participants; P = 0.06; <a href="./references#CD012955-fig-0090" title="">Analysis 8.4</a>). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> </section> <section id="CD012955-sec-0191"> <h6 class="title">8.5 Impulsivity (continuous)</h6> <p>One trial reported continuous data on impulsivity (<a href="./references#CD012955-bbs2-0010" title="BlackD . Question regarding your BPD trial [personal communication]. Email to: J Stoffers 04 January 2011. BlackDW , AllenJ , McCormickB , BlumN . Treatment received by persons with BPD participating in a randomized clinical trial of the systems training for emotional predictability and problem solving programme. Personality and Mental Health2011;5(3):159-68. [DOI: 10.1002/pmh.167]BlackDW , AllenJ , St JohnD , PfohlB , McCormickB , BlumN . Predictors of response to systems training for emotional predictability and problem solving (STEPPS) for borderline personality disorder: an exploratory study. Acta Psychiatrica Scandinavica2009;120(1):53-61. [DOI: 10.1111/j.1600-0447.2008.01340.x] [PMC3665337] [PMID: 19183126]BlackDW , BlumN , PfohlB , St JohnD . The STEPPS group treatment program for outpatients with borderline personality disorder. Journal of Contemporary Psychotherapy2004;34(3):193-210. [DOI: 10.1023/B:JOCP.0000036630.25741.83]BlackDW , PfohlBM . Randomized clinical trial of STEPPS versus treatment as usual. In: 158th annual meeting of the American Psychiatric Association. Psychosomatic medicine: integrating psychiatry &amp; medicine; 2005 May 21-26; Atlanta (GA). Arlington (VA): American Psychiatric Association, 2005:104. [No. 1B] [www.psychiatry.org/File%20Library/Psychiatrists/Directories/Library-and-Archive/syllabus/am_syllabus_2005.pdf]BlackDW , Simsek-DuranF , BlumN , McCormickB , AllenJ . Do people with borderline personality disorder complicated by antisocial personality disorder benefit from the STEPPS treatment program?Personality and Mental Health2016;10(3):205-15. [DOI: 10.1002/pmh.1326] [PMC4911327] [PMID: 26671625]BlackDW . RE: [external] questions regarding your trial on the STEPPS program for BPD [personal communication]. Email to: EG Faltinsen 27 November 2017. BlumN , AllenJ , McCormickB , BlackDW . Ms Blum and colleagues reply [to Schulte-Herbrüggen O, Koerting J, Roepke S. Effectiveness of adjunctive STEPPS group treatment in borderline personality disorder patients. American Journal of Psychiatry 2008;165(10):1354-5. DOI: 10.1176/appi.ajp.2008.08030390]. American Journal of Psychiatry2008;165(10):1354-5. [DOI: 10.1176/appi.ajp.2008.08030390r]BlumN , FranklinJ , HanselR , McCormickB , St JohnD , PfohlB , et al. Relationship of age to symptom severity, psychiatric comorbidity and health care utilization in persons with borderline personality disorder. Personality and Mental Health2008;2(1):25-43. [DOI: 10.1002/pmh.26]BlumN , St JohnD , PfohlB , StuartS , McCormickB , AllenJ , et al. Erratum. American Journal of Psychiatry2008;165(6):777. Erratum for: American Journal of Psychiatry 2008;165(4):468-78. [psycnet.apa.org/record/2008-07854-033]BlumN , St JohnD , PfohlB , StuartS , McCormickB , AllenJ , et al. Systems training for emotional predictability and problem solving (STEPPS) for outpatients with borderline personality disorder: a randomized controlled trial and 1-year follow-up. American Journal of Psychiatry2008;165(4):468-78. [DOI: 10.1176/appi.ajp.2007.07071079] [PMC3608469] [PMID: 18281407]DavidsonKM . Borderline personality disorder: STEPPS improves symptoms. Evidence-Based Mental Health2008;11(4):120. [DOI: 10.1136/ebmh.11.4.120] [PMID: 18952969]NCT00055315. Treatment for borderline personality disorder [A cognitive group treatment for borderline outpatients]. clinicaltrials.gov/ct2/show/NCT00055315 (first received 25 February 2003). ">Blum 2008</a>). </p> <p>STEPPS did not reduce impulsivity at end of treatment compared with TAU (MD −0.40, 95% CI −1.23 to 0.43; 1 trial, 124 participants; P = 0.35; <a href="./references#CD012955-fig-0091" title="">Analysis 8.5</a>). </p> </section> <section id="CD012955-sec-0192"> <h6 class="title">8.6 Impulsivity (dichotomous)</h6> <p>One trial reported dichotomous data on impulsivity (<a href="./references#CD012955-bbs2-0013" title="BosEH , Van WelE , AppeloMT , VerbraakMJP . A randomized controlled trial of a Dutch version of systems training for emotional predictability and problem solving for borderline personality disorder. Journal of Nervous and Mental Disease2010;198(4):299-304. [DOI: 10.1097/NMD.0b013e3181d619cf] [PMID: 20386260]Van WelEB , BosEH , AppeloMT , BerendsenEM , WillgerothFC , VerbraakMJPM . The efficacy of the systems training for emotional predictability and problem solving (STEPPS) in the treatment of borderline personality disorder. A randomized controlled trial [De effectiviteit van de vaardigheidstraining emotieregulatiestoornis (VERS) in de behandeling van de borderlinepersoonlijkheidsstoornis: een gerandomiseerd onderzoek]. Tijdschrift voor Psychiatrie2009;51(5):291-301. [PMID: 19434566]">Bos 2010</a>). </p> <p>STEPPS did not reduce impulsivity at end of treatment compared with TAU (RR 0.93, 95% CI 0.66 to 1.29; 1 trial, 58 participants; P = 0.65; <a href="./references#CD012955-fig-0092" title="">Analysis 8.6</a>). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> </section> <section id="CD012955-sec-0193"> <h6 class="title">8.7 Interpersonal problems</h6> <p>Two trials reported continuous data on interpersonal problems (<a href="./references#CD012955-bbs2-0010" title="BlackD . Question regarding your BPD trial [personal communication]. Email to: J Stoffers 04 January 2011. BlackDW , AllenJ , McCormickB , BlumN . Treatment received by persons with BPD participating in a randomized clinical trial of the systems training for emotional predictability and problem solving programme. Personality and Mental Health2011;5(3):159-68. [DOI: 10.1002/pmh.167]BlackDW , AllenJ , St JohnD , PfohlB , McCormickB , BlumN . Predictors of response to systems training for emotional predictability and problem solving (STEPPS) for borderline personality disorder: an exploratory study. Acta Psychiatrica Scandinavica2009;120(1):53-61. [DOI: 10.1111/j.1600-0447.2008.01340.x] [PMC3665337] [PMID: 19183126]BlackDW , BlumN , PfohlB , St JohnD . The STEPPS group treatment program for outpatients with borderline personality disorder. Journal of Contemporary Psychotherapy2004;34(3):193-210. [DOI: 10.1023/B:JOCP.0000036630.25741.83]BlackDW , PfohlBM . Randomized clinical trial of STEPPS versus treatment as usual. In: 158th annual meeting of the American Psychiatric Association. Psychosomatic medicine: integrating psychiatry &amp; medicine; 2005 May 21-26; Atlanta (GA). Arlington (VA): American Psychiatric Association, 2005:104. [No. 1B] [www.psychiatry.org/File%20Library/Psychiatrists/Directories/Library-and-Archive/syllabus/am_syllabus_2005.pdf]BlackDW , Simsek-DuranF , BlumN , McCormickB , AllenJ . Do people with borderline personality disorder complicated by antisocial personality disorder benefit from the STEPPS treatment program?Personality and Mental Health2016;10(3):205-15. [DOI: 10.1002/pmh.1326] [PMC4911327] [PMID: 26671625]BlackDW . RE: [external] questions regarding your trial on the STEPPS program for BPD [personal communication]. Email to: EG Faltinsen 27 November 2017. BlumN , AllenJ , McCormickB , BlackDW . Ms Blum and colleagues reply [to Schulte-Herbrüggen O, Koerting J, Roepke S. Effectiveness of adjunctive STEPPS group treatment in borderline personality disorder patients. American Journal of Psychiatry 2008;165(10):1354-5. DOI: 10.1176/appi.ajp.2008.08030390]. American Journal of Psychiatry2008;165(10):1354-5. [DOI: 10.1176/appi.ajp.2008.08030390r]BlumN , FranklinJ , HanselR , McCormickB , St JohnD , PfohlB , et al. Relationship of age to symptom severity, psychiatric comorbidity and health care utilization in persons with borderline personality disorder. Personality and Mental Health2008;2(1):25-43. [DOI: 10.1002/pmh.26]BlumN , St JohnD , PfohlB , StuartS , McCormickB , AllenJ , et al. Erratum. American Journal of Psychiatry2008;165(6):777. Erratum for: American Journal of Psychiatry 2008;165(4):468-78. [psycnet.apa.org/record/2008-07854-033]BlumN , St JohnD , PfohlB , StuartS , McCormickB , AllenJ , et al. Systems training for emotional predictability and problem solving (STEPPS) for outpatients with borderline personality disorder: a randomized controlled trial and 1-year follow-up. American Journal of Psychiatry2008;165(4):468-78. [DOI: 10.1176/appi.ajp.2007.07071079] [PMC3608469] [PMID: 18281407]DavidsonKM . Borderline personality disorder: STEPPS improves symptoms. Evidence-Based Mental Health2008;11(4):120. [DOI: 10.1136/ebmh.11.4.120] [PMID: 18952969]NCT00055315. Treatment for borderline personality disorder [A cognitive group treatment for borderline outpatients]. clinicaltrials.gov/ct2/show/NCT00055315 (first received 25 February 2003). ">Blum 2008</a>; <a href="./references#CD012955-bbs2-0013" title="BosEH , Van WelE , AppeloMT , VerbraakMJP . A randomized controlled trial of a Dutch version of systems training for emotional predictability and problem solving for borderline personality disorder. Journal of Nervous and Mental Disease2010;198(4):299-304. [DOI: 10.1097/NMD.0b013e3181d619cf] [PMID: 20386260]Van WelEB , BosEH , AppeloMT , BerendsenEM , WillgerothFC , VerbraakMJPM . The efficacy of the systems training for emotional predictability and problem solving (STEPPS) in the treatment of borderline personality disorder. A randomized controlled trial [De effectiviteit van de vaardigheidstraining emotieregulatiestoornis (VERS) in de behandeling van de borderlinepersoonlijkheidsstoornis: een gerandomiseerd onderzoek]. Tijdschrift voor Psychiatrie2009;51(5):291-301. [PMID: 19434566]">Bos 2010</a>). </p> <p>STEPPS reduced interpersonal problems at end of treatment compared with TAU (SMD −0.38, 95% CI −0.67 to −0.08; 2 trials, 177 participants; I<sup>2</sup> = 0%; P = 0.01; <a href="./references#CD012955-fig-0093" title="">Analysis 8.7</a>). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> </section> <section id="CD012955-sec-0194"> <h6 class="title">8.8 Dissociation and psychotic‐like symptoms</h6> <p>One trial reported continuous data on dissociation and psychotic‐like symptoms (<a href="./references#CD012955-bbs2-0010" title="BlackD . Question regarding your BPD trial [personal communication]. Email to: J Stoffers 04 January 2011. BlackDW , AllenJ , McCormickB , BlumN . Treatment received by persons with BPD participating in a randomized clinical trial of the systems training for emotional predictability and problem solving programme. Personality and Mental Health2011;5(3):159-68. [DOI: 10.1002/pmh.167]BlackDW , AllenJ , St JohnD , PfohlB , McCormickB , BlumN . Predictors of response to systems training for emotional predictability and problem solving (STEPPS) for borderline personality disorder: an exploratory study. Acta Psychiatrica Scandinavica2009;120(1):53-61. [DOI: 10.1111/j.1600-0447.2008.01340.x] [PMC3665337] [PMID: 19183126]BlackDW , BlumN , PfohlB , St JohnD . The STEPPS group treatment program for outpatients with borderline personality disorder. Journal of Contemporary Psychotherapy2004;34(3):193-210. [DOI: 10.1023/B:JOCP.0000036630.25741.83]BlackDW , PfohlBM . Randomized clinical trial of STEPPS versus treatment as usual. In: 158th annual meeting of the American Psychiatric Association. Psychosomatic medicine: integrating psychiatry &amp; medicine; 2005 May 21-26; Atlanta (GA). Arlington (VA): American Psychiatric Association, 2005:104. [No. 1B] [www.psychiatry.org/File%20Library/Psychiatrists/Directories/Library-and-Archive/syllabus/am_syllabus_2005.pdf]BlackDW , Simsek-DuranF , BlumN , McCormickB , AllenJ . Do people with borderline personality disorder complicated by antisocial personality disorder benefit from the STEPPS treatment program?Personality and Mental Health2016;10(3):205-15. [DOI: 10.1002/pmh.1326] [PMC4911327] [PMID: 26671625]BlackDW . RE: [external] questions regarding your trial on the STEPPS program for BPD [personal communication]. Email to: EG Faltinsen 27 November 2017. BlumN , AllenJ , McCormickB , BlackDW . Ms Blum and colleagues reply [to Schulte-Herbrüggen O, Koerting J, Roepke S. Effectiveness of adjunctive STEPPS group treatment in borderline personality disorder patients. American Journal of Psychiatry 2008;165(10):1354-5. DOI: 10.1176/appi.ajp.2008.08030390]. American Journal of Psychiatry2008;165(10):1354-5. [DOI: 10.1176/appi.ajp.2008.08030390r]BlumN , FranklinJ , HanselR , McCormickB , St JohnD , PfohlB , et al. Relationship of age to symptom severity, psychiatric comorbidity and health care utilization in persons with borderline personality disorder. Personality and Mental Health2008;2(1):25-43. [DOI: 10.1002/pmh.26]BlumN , St JohnD , PfohlB , StuartS , McCormickB , AllenJ , et al. Erratum. American Journal of Psychiatry2008;165(6):777. Erratum for: American Journal of Psychiatry 2008;165(4):468-78. [psycnet.apa.org/record/2008-07854-033]BlumN , St JohnD , PfohlB , StuartS , McCormickB , AllenJ , et al. Systems training for emotional predictability and problem solving (STEPPS) for outpatients with borderline personality disorder: a randomized controlled trial and 1-year follow-up. American Journal of Psychiatry2008;165(4):468-78. [DOI: 10.1176/appi.ajp.2007.07071079] [PMC3608469] [PMID: 18281407]DavidsonKM . Borderline personality disorder: STEPPS improves symptoms. Evidence-Based Mental Health2008;11(4):120. [DOI: 10.1136/ebmh.11.4.120] [PMID: 18952969]NCT00055315. Treatment for borderline personality disorder [A cognitive group treatment for borderline outpatients]. clinicaltrials.gov/ct2/show/NCT00055315 (first received 25 February 2003). ">Blum 2008</a>). </p> <p>STEPPS reduced dissociation and psychotic‐like symptoms at end of treatment compared with TAU (MD −1.00, 95% CI −1.83 to −0.17; 1 trial, 124 participants; P = 0.02; <a href="./references#CD012955-fig-0094" title="">Analysis 8.8</a>). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> </section> <section id="CD012955-sec-0195"> <h6 class="title">8.9 Depression</h6> <p>One trial reported continuous data on depression (<a href="./references#CD012955-bbs2-0010" title="BlackD . Question regarding your BPD trial [personal communication]. Email to: J Stoffers 04 January 2011. BlackDW , AllenJ , McCormickB , BlumN . Treatment received by persons with BPD participating in a randomized clinical trial of the systems training for emotional predictability and problem solving programme. Personality and Mental Health2011;5(3):159-68. [DOI: 10.1002/pmh.167]BlackDW , AllenJ , St JohnD , PfohlB , McCormickB , BlumN . Predictors of response to systems training for emotional predictability and problem solving (STEPPS) for borderline personality disorder: an exploratory study. Acta Psychiatrica Scandinavica2009;120(1):53-61. [DOI: 10.1111/j.1600-0447.2008.01340.x] [PMC3665337] [PMID: 19183126]BlackDW , BlumN , PfohlB , St JohnD . The STEPPS group treatment program for outpatients with borderline personality disorder. Journal of Contemporary Psychotherapy2004;34(3):193-210. [DOI: 10.1023/B:JOCP.0000036630.25741.83]BlackDW , PfohlBM . Randomized clinical trial of STEPPS versus treatment as usual. In: 158th annual meeting of the American Psychiatric Association. Psychosomatic medicine: integrating psychiatry &amp; medicine; 2005 May 21-26; Atlanta (GA). Arlington (VA): American Psychiatric Association, 2005:104. [No. 1B] [www.psychiatry.org/File%20Library/Psychiatrists/Directories/Library-and-Archive/syllabus/am_syllabus_2005.pdf]BlackDW , Simsek-DuranF , BlumN , McCormickB , AllenJ . Do people with borderline personality disorder complicated by antisocial personality disorder benefit from the STEPPS treatment program?Personality and Mental Health2016;10(3):205-15. [DOI: 10.1002/pmh.1326] [PMC4911327] [PMID: 26671625]BlackDW . RE: [external] questions regarding your trial on the STEPPS program for BPD [personal communication]. Email to: EG Faltinsen 27 November 2017. BlumN , AllenJ , McCormickB , BlackDW . Ms Blum and colleagues reply [to Schulte-Herbrüggen O, Koerting J, Roepke S. Effectiveness of adjunctive STEPPS group treatment in borderline personality disorder patients. American Journal of Psychiatry 2008;165(10):1354-5. DOI: 10.1176/appi.ajp.2008.08030390]. American Journal of Psychiatry2008;165(10):1354-5. [DOI: 10.1176/appi.ajp.2008.08030390r]BlumN , FranklinJ , HanselR , McCormickB , St JohnD , PfohlB , et al. Relationship of age to symptom severity, psychiatric comorbidity and health care utilization in persons with borderline personality disorder. Personality and Mental Health2008;2(1):25-43. [DOI: 10.1002/pmh.26]BlumN , St JohnD , PfohlB , StuartS , McCormickB , AllenJ , et al. Erratum. American Journal of Psychiatry2008;165(6):777. Erratum for: American Journal of Psychiatry 2008;165(4):468-78. [psycnet.apa.org/record/2008-07854-033]BlumN , St JohnD , PfohlB , StuartS , McCormickB , AllenJ , et al. Systems training for emotional predictability and problem solving (STEPPS) for outpatients with borderline personality disorder: a randomized controlled trial and 1-year follow-up. American Journal of Psychiatry2008;165(4):468-78. [DOI: 10.1176/appi.ajp.2007.07071079] [PMC3608469] [PMID: 18281407]DavidsonKM . Borderline personality disorder: STEPPS improves symptoms. Evidence-Based Mental Health2008;11(4):120. [DOI: 10.1136/ebmh.11.4.120] [PMID: 18952969]NCT00055315. Treatment for borderline personality disorder [A cognitive group treatment for borderline outpatients]. clinicaltrials.gov/ct2/show/NCT00055315 (first received 25 February 2003). ">Blum 2008</a>). </p> <p>STEPPS did not reduce depression at end of treatment compared with TAU (MD −3.80, 95% CI −9.34 to 1.74; 1 trial, 124 participants; P = 0.18; <a href="./references#CD012955-fig-0095" title="">Analysis 8.9</a>.1). </p> <p>STEPPS did not reduce depression at six to 12 months follow‐up compared with TAU (MD −0.60, 95% CI −8.42 to 9.62; 1 trial, 124 participants; P = 0.90; <a href="./references#CD012955-fig-0095" title="">Analysis 8.9</a>.2). </p> <p>No data were available for zero to six months and above 12 months follow‐up.</p> </section> <section id="CD012955-sec-0196"> <h6 class="title">8.10 Attrition</h6> <p>One trial reported dichotomous data on attrition (<a href="./references#CD012955-bbs2-0013" title="BosEH , Van WelE , AppeloMT , VerbraakMJP . A randomized controlled trial of a Dutch version of systems training for emotional predictability and problem solving for borderline personality disorder. Journal of Nervous and Mental Disease2010;198(4):299-304. [DOI: 10.1097/NMD.0b013e3181d619cf] [PMID: 20386260]Van WelEB , BosEH , AppeloMT , BerendsenEM , WillgerothFC , VerbraakMJPM . The efficacy of the systems training for emotional predictability and problem solving (STEPPS) in the treatment of borderline personality disorder. A randomized controlled trial [De effectiviteit van de vaardigheidstraining emotieregulatiestoornis (VERS) in de behandeling van de borderlinepersoonlijkheidsstoornis: een gerandomiseerd onderzoek]. Tijdschrift voor Psychiatrie2009;51(5):291-301. [PMID: 19434566]">Bos 2010</a>). </p> <p>STEPPS did not reduce attrition at end of treatment compared with TAU (RR 1.47, 95% CI 0.59 to 3.65; 1 trial, 79 participants; P = 0.41; <a href="./references#CD012955-fig-0096" title="">Analysis 8.10</a>). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> <p>No data were available on any time point for anger, chronic feelings of emptiness, abandonment, identity disturbance, and adverse effects. </p> </section> </section> </section> <section id="CD012955-sec-0197"> <h4 class="title">9. Cognitive analytic therapy (CAT) versus treatment‐as‐usual (TAU)</h4> <section id="CD012955-sec-0198"> <h5 class="title">Primary outcomes</h5> <section id="CD012955-sec-0199"> <h6 class="title">9.1 Suicide‐related outcomes</h6> <p>One trial reported continuous data on suicide‐related outcomes (<a href="./references#CD012955-bbs2-0025" title="GleesonJF , ChanenA , CottonSM , PearceT , NewmanB , McCutcheonL . Treating co-occurring first-episode psychosis and borderline personality: a pilot randomized controlled trial. Early Intervention in Psychiatry2012;6(1):21-9. [DOI: 10.1111/j.1751-7893.2011.00306.x] [PMID: 22379625]GleesonJFM . RE: separate data [personal communication]. Email to: M Kielsholm 28 October 2016. ">Gleeson 2012</a>). </p> <p>CAT did not reduce suicide‐related outcomes at end of treatment compared with TAU (MD −1.40, 95% CI −4.21 to 1.41; 1 trial, 9 participants; P = 0.33; <a href="./references#CD012955-fig-0097" title="">Analysis 9.1</a>.1). </p> <p>CAT did not reduce suicide‐related outcomes at zero to six months follow‐up compared with TAU (MD −0.50, 95% CI −2.05 to 1.05; 1 trial, 8 participants; P = 0.53; <a href="./references#CD012955-fig-0097" title="">Analysis 9.1</a>.2). </p> <p>No data were available for six to 12 months and above 12 months follow‐up.</p> </section> <section id="CD012955-sec-0200"> <h6 class="title">9.2 Psychosocial functioning</h6> <p>One trial reported continuous data on psychosocial functioning (<a href="./references#CD012955-bbs2-0025" title="GleesonJF , ChanenA , CottonSM , PearceT , NewmanB , McCutcheonL . Treating co-occurring first-episode psychosis and borderline personality: a pilot randomized controlled trial. Early Intervention in Psychiatry2012;6(1):21-9. [DOI: 10.1111/j.1751-7893.2011.00306.x] [PMID: 22379625]GleesonJFM . RE: separate data [personal communication]. Email to: M Kielsholm 28 October 2016. ">Gleeson 2012</a>). </p> <p>CAT improved psychosocial functioning at end of treatment compared with TAU (MD −16.40, 95% CI −31.20 to −1.60; 1 trial, 9 participants; P = 0.03; <a href="./references#CD012955-fig-0098" title="">Analysis 9.2</a>.1). </p> <p>CAT improved psychosocial functioning at zero to six months follow‐up compared with TAU (MD −15.80, 95% CI −29.36 to −2.24; 1 trial, 9 participants; P = 0.02; <a href="./references#CD012955-fig-0098" title="">Analysis 9.2</a>.2). </p> <p>No data were available for six to 12 months and above 12 months follow‐up.</p> <p>No data were available on any time point for BPD symptom severity, and self‐harm.</p> </section> </section> <section id="CD012955-sec-0201"> <h5 class="title">Secondary outcomes</h5> <section id="CD012955-sec-0202"> <h6 class="title">9.3 Anger</h6> <p>One trial reported continuous data on anger (<a href="./references#CD012955-bbs2-0025" title="GleesonJF , ChanenA , CottonSM , PearceT , NewmanB , McCutcheonL . Treating co-occurring first-episode psychosis and borderline personality: a pilot randomized controlled trial. Early Intervention in Psychiatry2012;6(1):21-9. [DOI: 10.1111/j.1751-7893.2011.00306.x] [PMID: 22379625]GleesonJFM . RE: separate data [personal communication]. Email to: M Kielsholm 28 October 2016. ">Gleeson 2012</a>). </p> <p>CAT did not reduce anger at end of treatment compared with TAU (MD −1.90, 95% CI −7.97 to 4.17; 1 trial, 9 participants; P = 0.54; <a href="./references#CD012955-fig-0099" title="">Analysis 9.3</a>.1). </p> <p>CAT did not reduce anger at zero to six months follow‐up compared with TAU (MD −4.50, 95% CI −9.01 to 0.01; 1 trial, 8 participants; P = 0.05; <a href="./references#CD012955-fig-0099" title="">Analysis 9.3</a>.2). </p> <p>No data were available for six to 12 months and above 12 months follow‐up.</p> </section> <section id="CD012955-sec-0203"> <h6 class="title">9.4 Dissociation and psychotic‐like symptoms</h6> <p>One trial reported continuous data on dissociation and psychotic‐like symptoms (<a href="./references#CD012955-bbs2-0025" title="GleesonJF , ChanenA , CottonSM , PearceT , NewmanB , McCutcheonL . Treating co-occurring first-episode psychosis and borderline personality: a pilot randomized controlled trial. Early Intervention in Psychiatry2012;6(1):21-9. [DOI: 10.1111/j.1751-7893.2011.00306.x] [PMID: 22379625]GleesonJFM . RE: separate data [personal communication]. Email to: M Kielsholm 28 October 2016. ">Gleeson 2012</a>). </p> <p>CAT did not reduce dissociation and psychotic‐like symptoms at end of treatment compared with TAU (MD −6.10, 95% CI −15.01 to 2.81; 1 trial, 9 participants; P = 0.18; <a href="./references#CD012955-fig-0100" title="">Analysis 9.4</a>.1). </p> <p>CAT did not reduce dissociation and psychotic‐like symptoms at zero to six months follow‐up compared with TAU (MD −11.70, 95% CI −24.02 to 0.62; 1 trial, 8 participants; P = 0.06; <a href="./references#CD012955-fig-0100" title="">Analysis 9.4</a>.2). </p> <p>No data were available for six to 12 months and above 12 months follow‐up.</p> </section> <section id="CD012955-sec-0204"> <h6 class="title">9.5 Depression</h6> <p>One trial reported continuous data on depression (<a href="./references#CD012955-bbs2-0025" title="GleesonJF , ChanenA , CottonSM , PearceT , NewmanB , McCutcheonL . Treating co-occurring first-episode psychosis and borderline personality: a pilot randomized controlled trial. Early Intervention in Psychiatry2012;6(1):21-9. [DOI: 10.1111/j.1751-7893.2011.00306.x] [PMID: 22379625]GleesonJFM . RE: separate data [personal communication]. Email to: M Kielsholm 28 October 2016. ">Gleeson 2012</a>). </p> <p>CAT did not reduce depression at end of treatment compared with TAU (MD −9.70, 95% CI −20.10 to 0.70; 1 trial, 9 participants; P = 0.07; <a href="./references#CD012955-fig-0101" title="">Analysis 9.5</a>.1). </p> <p>CAT did not reduce depression at zero to six months follow‐up compared with TAU (MD −3.70, 95% CI −11.99 to 4.59; 1 trial, 8 participants; P = 0.38; <a href="./references#CD012955-fig-0101" title="">Analysis 9.5</a>.2). </p> <p>No data were available for six to 12 months and above 12 months follow‐up.</p> </section> <section id="CD012955-sec-0205"> <h6 class="title">9.6 Attrition</h6> <p>One trial reported dichotomous data on attrition (<a href="./references#CD012955-bbs2-0025" title="GleesonJF , ChanenA , CottonSM , PearceT , NewmanB , McCutcheonL . Treating co-occurring first-episode psychosis and borderline personality: a pilot randomized controlled trial. Early Intervention in Psychiatry2012;6(1):21-9. [DOI: 10.1111/j.1751-7893.2011.00306.x] [PMID: 22379625]GleesonJFM . RE: separate data [personal communication]. Email to: M Kielsholm 28 October 2016. ">Gleeson 2012</a>). </p> <p>CAT did not reduce attrition at end of treatment compared with TAU (RR 1.33, 95% CI 0.43 to 4.13; 1 trial, 16 participants; P = 0.62; <a href="./references#CD012955-fig-0102" title="">Analysis 9.6</a>). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> <p>No data were available on any time point for affective instability, chronic feelings of emptiness, impulsivity, interpersonal problems, abandonment, identity disturbance, and adverse effects. </p> </section> </section> </section> <section id="CD012955-sec-0206"> <h4 class="title">10. Motivation feedback (MF) versus treatment‐as‐usual (TAU)</h4> <section id="CD012955-sec-0207"> <h5 class="title">10.1 Primary outcome: psychosocial functioning</h5> <p>One trial reported continuous data on psychosocial functioning (<a href="./references#CD012955-bbs2-0032" title="JochemsEC , Van der Feltz-CornelisCM , Van DamA , DuivenvoordenHJ , MulderCL . The effects of motivation feedback in patients with severe mental illness: a cluster randomized controlled trial. Neuropsychiatric Disease and Treatment2015;11:3049-64. [DOI: 10.2147/NDT.S95190] [PMC4686323] [PMID: 26715847]JochemsEC . Cochrane Collaboration review on psychotherapies for borderline PD [personal communication]. Email to: EG Faltinsen 2 July 2018. JochemsEC . Re: Cochrane Collaboration review on psychotherapies for borderline PD [personal communication]. Email to: J Stoffers-Winterling 02 July 2018. ">Jochems 2015</a>). </p> <p>MF did not improve psychosocial functioning at end of treatment compared with TAU (MD −0.42, 95% CI −4.23 to 3.39; 1 trial, 43 participants; P = 0.83; <a href="./references#CD012955-fig-0103" title="">Analysis 10.1</a>). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> <p>No data were available on any time point for BPD symptom severity, self‐harm, and suicide‐related outcomes. </p> </section> <section id="CD012955-sec-0208"> <h5 class="title">Secondary outcomes</h5> <p>No data were available on any time point for anger, affective instability, chronic feelings of emptiness, impulsivity, interpersonal problems, abandonment, identity disturbance, dissociation and psychotic‐like symptoms, depression, attrition and adverse effects </p> </section> </section> <section id="CD012955-sec-0209"> <h4 class="title">11. Psychoeducation versus treatment‐as‐usual (TAU)</h4> <section id="CD012955-sec-0210"> <h5 class="title">Primary outcomes</h5> <p>No data were available on any time point for BPD symptom severity, self‐harm, suicide‐related outcomes, and psychosocial functioning. </p> </section> <section id="CD012955-sec-0211"> <h5 class="title">Secondary outcomes</h5> <section id="CD012955-sec-0212"> <h6 class="title">11.1 Depression</h6> <p>One trial reported continuous data on depression (<a href="./references#CD012955-bbs2-0075" title="ZanariniMC , ConkeyLC , TemesCM , FitzmauriceGM . Randomized controlled trial of web-based psychoeducation for women with borderline personality disorder. Journal of Clinical Psychiatry2018;79(3):16m11153. [DOI: 10.4088/JCP.16m11153] [PMC5764827] [PMID: 28703950]">Zanarini 2018</a>). </p> <p>Psychoeducation did not reduce depression at end of treatment compared with TAU (MD −7.03, 95% CI −14.35 to 0.29; 1 trial, 77 participants; P = 0.06; <a href="./references#CD012955-fig-0104" title="">Analysis 11.1</a>). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> </section> <section id="CD012955-sec-0213"> <h6 class="title">11.2 Attrition</h6> <p>One trial reported continuous data on attrition (<a href="./references#CD012955-bbs2-0075" title="ZanariniMC , ConkeyLC , TemesCM , FitzmauriceGM . Randomized controlled trial of web-based psychoeducation for women with borderline personality disorder. Journal of Clinical Psychiatry2018;79(3):16m11153. [DOI: 10.4088/JCP.16m11153] [PMC5764827] [PMID: 28703950]">Zanarini 2018</a>). </p> <p>Psychoeducation did not reduce attrition at end of treatment compared with TAU (RR 0.49, 95% CI 0.04 to 5.60; 1 trial, 80 participants; P = 0.56; <a href="./references#CD012955-fig-0105" title="">Analysis 11.2</a>). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> <p>No data were available on any time point for anger, affective instability, chronic feelings of emptiness, impulsivity, interpersonal problems, abandonment, identity disturbance, dissociation and psychotic‐like symptoms, and adverse effects </p> </section> </section> </section> <section id="CD012955-sec-0214"> <h4 class="title">12. Transference‐focused psychotherapy (TFP) versus treatment‐as‐usual (TAU)</h4> <section id="CD012955-sec-0215"> <h5 class="title">Primary outcomes</h5> <section id="CD012955-sec-0216"> <h6 class="title">12.1 BPD symptom severity</h6> <p>One trial reported continuous data on BPD symptom severity (<a href="./references#CD012955-bbs2-0019" title="BuchheimA , Hörz-SagstetterS , DoeringS , RentropM , SchusterP , BuchheimP , et al. Change of unresolved attachment in borderline personality disorders: RCT study of transference-focused psychotherapy. Psychotherapy and Psychosomatics2017;86(5):314-6. [DOI: 10.1159/000460257] [PMID: 28903103]DiamondD , LevyKN , ClarkinJF , Fischer-KernM , CainNM , DoeringS , et al. Attachment and mentalization in female patients with comorbid narcissistic and borderline personality disorder. Personality Disorders2014;5(4):428-33. [DOI: 10.1037/per0000065] [PMID: 25314231]DiamondD , YeomansFE , SternB , LevyKN , HörzS , DoeringS , et al. Transference-focused psychotherapy for patients with comorbid narcissistic and borderline personality disorder. Psychoanalytic Inquiry2013;33(6):527-51. [DOI: 10.1080/07351690.2013.815087]DoeringS , HörzS , RentropM , Fischer-KernM , SchusterP , BeneckeC , et al. Transference-focused psychotherapy v treatment by community psychotherapists for borderline personality disorder: randomised controlled trial. British Journal of Psychiatry2010;196(5):389-95. [DOI: 10.1192/bjp.bp.109.070177] [PMID: 20435966]DoeringS . Author's reply [to Kleindienst N, Krumm B, Bohus M. Is transference-focused psychotherapy really efficacious for borderline personality disorder? British Journal of Psychiatry 2011;198(2):156-7. DOI: 10.1192/bjp.198.2.156b]. British Journal of Psychiatry2011;198(2):156-7. [DOI: 10.1192/bjp.198.2.157]DoeringS . Question regarding your BPD trial for systematic review in Cochrane Collaboration [personal communication]. Email to: K Lieb, J Stoffers 10 December 2010. Fischer-KernM , DoeringS , TaubnerS , HörzS , ZimmermannJ , RentropM , et al. Transference-focused psychotherapy for borderline personality disorder: change in reflective function. British Journal of Psychiatry2015;207(2):173-4. [DOI: 10.1192/bjp.bp.113.143842] [PMID: 25999334]KleindienstN , KrummB , BohusM . Is transference-focused psychotherapy really efficacious for borderline personality disorder?British Journal of Psychiatry2011;198(2):156-7. [DOI: 10.1192/bjp.198.2.156b] [PMID: 21282787]LevyKN , MeehanKB , YeomansFE . Transference-focused psychotherapy reduces treatment drop-out and suicide attempters compared with community psychotherapist treatment in borderline personality disorder. Evidence-based Mental Health2010;13(4):119. [DOI: 10.1136/ebmh.13.4.119] [PMID: 21036981]NCT00714311. Efficacy of transference-focused psychotherapy for borderline personality disorder [A randomized-controlled trial of transference-focused psychotherapy vs treatment by experienced community psychotherapists for borderline personality disorder]. www.clinicaltrials.gov/ct2/show/NCT00714311 (first received 9 July 2008). RentropM , MartiusP , BäumlJ , BuchheimP , DöeringS , HörzS . Patients with borderline personality disorder not participating in an RCT: are they different?Psychopathology2010;43(6):369-72. [DOI: 10.1159/000320351] [PMID: 20798576]">Doering 2010</a>). </p> <p>TFP reduced BPD symptom severity at end of treatment compared with TAU (MD −0.84, 95% CI −1.42 to −0.26; 1 trial, 104 participants; P = 0.004; <a href="./references#CD012955-fig-0106" title="">Analysis 12.1</a>). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> </section> <section id="CD012955-sec-0217"> <h6 class="title">12.2 Self‐harm</h6> <p>One trial reported dichotomous data on self‐harm (<a href="./references#CD012955-bbs2-0019" title="BuchheimA , Hörz-SagstetterS , DoeringS , RentropM , SchusterP , BuchheimP , et al. Change of unresolved attachment in borderline personality disorders: RCT study of transference-focused psychotherapy. Psychotherapy and Psychosomatics2017;86(5):314-6. [DOI: 10.1159/000460257] [PMID: 28903103]DiamondD , LevyKN , ClarkinJF , Fischer-KernM , CainNM , DoeringS , et al. Attachment and mentalization in female patients with comorbid narcissistic and borderline personality disorder. Personality Disorders2014;5(4):428-33. [DOI: 10.1037/per0000065] [PMID: 25314231]DiamondD , YeomansFE , SternB , LevyKN , HörzS , DoeringS , et al. Transference-focused psychotherapy for patients with comorbid narcissistic and borderline personality disorder. Psychoanalytic Inquiry2013;33(6):527-51. [DOI: 10.1080/07351690.2013.815087]DoeringS , HörzS , RentropM , Fischer-KernM , SchusterP , BeneckeC , et al. Transference-focused psychotherapy v treatment by community psychotherapists for borderline personality disorder: randomised controlled trial. British Journal of Psychiatry2010;196(5):389-95. [DOI: 10.1192/bjp.bp.109.070177] [PMID: 20435966]DoeringS . Author's reply [to Kleindienst N, Krumm B, Bohus M. Is transference-focused psychotherapy really efficacious for borderline personality disorder? British Journal of Psychiatry 2011;198(2):156-7. DOI: 10.1192/bjp.198.2.156b]. British Journal of Psychiatry2011;198(2):156-7. [DOI: 10.1192/bjp.198.2.157]DoeringS . Question regarding your BPD trial for systematic review in Cochrane Collaboration [personal communication]. Email to: K Lieb, J Stoffers 10 December 2010. Fischer-KernM , DoeringS , TaubnerS , HörzS , ZimmermannJ , RentropM , et al. Transference-focused psychotherapy for borderline personality disorder: change in reflective function. British Journal of Psychiatry2015;207(2):173-4. [DOI: 10.1192/bjp.bp.113.143842] [PMID: 25999334]KleindienstN , KrummB , BohusM . Is transference-focused psychotherapy really efficacious for borderline personality disorder?British Journal of Psychiatry2011;198(2):156-7. [DOI: 10.1192/bjp.198.2.156b] [PMID: 21282787]LevyKN , MeehanKB , YeomansFE . Transference-focused psychotherapy reduces treatment drop-out and suicide attempters compared with community psychotherapist treatment in borderline personality disorder. Evidence-based Mental Health2010;13(4):119. [DOI: 10.1136/ebmh.13.4.119] [PMID: 21036981]NCT00714311. Efficacy of transference-focused psychotherapy for borderline personality disorder [A randomized-controlled trial of transference-focused psychotherapy vs treatment by experienced community psychotherapists for borderline personality disorder]. www.clinicaltrials.gov/ct2/show/NCT00714311 (first received 9 July 2008). RentropM , MartiusP , BäumlJ , BuchheimP , DöeringS , HörzS . Patients with borderline personality disorder not participating in an RCT: are they different?Psychopathology2010;43(6):369-72. [DOI: 10.1159/000320351] [PMID: 20798576]">Doering 2010</a>). </p> <p>TFP did not reduce self‐harm at end of treatment compared with TAU (RR 1.09, 95% CI 0.84 to 1.40; 1 trial, 104 participants; P = 0.52; <a href="./references#CD012955-fig-0107" title="">Analysis 12.2</a>). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> </section> <section id="CD012955-sec-0218"> <h6 class="title">12.3 Suicide‐related outcomes</h6> <p>One trial reported dichotomous data on suicide‐related outcomes (<a href="./references#CD012955-bbs2-0019" title="BuchheimA , Hörz-SagstetterS , DoeringS , RentropM , SchusterP , BuchheimP , et al. Change of unresolved attachment in borderline personality disorders: RCT study of transference-focused psychotherapy. Psychotherapy and Psychosomatics2017;86(5):314-6. [DOI: 10.1159/000460257] [PMID: 28903103]DiamondD , LevyKN , ClarkinJF , Fischer-KernM , CainNM , DoeringS , et al. Attachment and mentalization in female patients with comorbid narcissistic and borderline personality disorder. Personality Disorders2014;5(4):428-33. [DOI: 10.1037/per0000065] [PMID: 25314231]DiamondD , YeomansFE , SternB , LevyKN , HörzS , DoeringS , et al. Transference-focused psychotherapy for patients with comorbid narcissistic and borderline personality disorder. Psychoanalytic Inquiry2013;33(6):527-51. [DOI: 10.1080/07351690.2013.815087]DoeringS , HörzS , RentropM , Fischer-KernM , SchusterP , BeneckeC , et al. Transference-focused psychotherapy v treatment by community psychotherapists for borderline personality disorder: randomised controlled trial. British Journal of Psychiatry2010;196(5):389-95. [DOI: 10.1192/bjp.bp.109.070177] [PMID: 20435966]DoeringS . Author's reply [to Kleindienst N, Krumm B, Bohus M. Is transference-focused psychotherapy really efficacious for borderline personality disorder? British Journal of Psychiatry 2011;198(2):156-7. DOI: 10.1192/bjp.198.2.156b]. British Journal of Psychiatry2011;198(2):156-7. [DOI: 10.1192/bjp.198.2.157]DoeringS . Question regarding your BPD trial for systematic review in Cochrane Collaboration [personal communication]. Email to: K Lieb, J Stoffers 10 December 2010. Fischer-KernM , DoeringS , TaubnerS , HörzS , ZimmermannJ , RentropM , et al. Transference-focused psychotherapy for borderline personality disorder: change in reflective function. British Journal of Psychiatry2015;207(2):173-4. [DOI: 10.1192/bjp.bp.113.143842] [PMID: 25999334]KleindienstN , KrummB , BohusM . Is transference-focused psychotherapy really efficacious for borderline personality disorder?British Journal of Psychiatry2011;198(2):156-7. [DOI: 10.1192/bjp.198.2.156b] [PMID: 21282787]LevyKN , MeehanKB , YeomansFE . Transference-focused psychotherapy reduces treatment drop-out and suicide attempters compared with community psychotherapist treatment in borderline personality disorder. Evidence-based Mental Health2010;13(4):119. [DOI: 10.1136/ebmh.13.4.119] [PMID: 21036981]NCT00714311. Efficacy of transference-focused psychotherapy for borderline personality disorder [A randomized-controlled trial of transference-focused psychotherapy vs treatment by experienced community psychotherapists for borderline personality disorder]. www.clinicaltrials.gov/ct2/show/NCT00714311 (first received 9 July 2008). RentropM , MartiusP , BäumlJ , BuchheimP , DöeringS , HörzS . Patients with borderline personality disorder not participating in an RCT: are they different?Psychopathology2010;43(6):369-72. [DOI: 10.1159/000320351] [PMID: 20798576]">Doering 2010</a>). </p> <p>TFP did not reduce suicide‐related outcomes at end of treatment compared with TAU (RR 0.65, 95% CI 0.27 to 1.54; 1 trial, 104 participants; P = 0.33; <a href="./references#CD012955-fig-0108" title="">Analysis 12.3</a>). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> </section> <section id="CD012955-sec-0219"> <h6 class="title">12.4 Psychosocial functioning</h6> <p>One trial reported continuous data on psychosocial functioning (<a href="./references#CD012955-bbs2-0019" title="BuchheimA , Hörz-SagstetterS , DoeringS , RentropM , SchusterP , BuchheimP , et al. Change of unresolved attachment in borderline personality disorders: RCT study of transference-focused psychotherapy. Psychotherapy and Psychosomatics2017;86(5):314-6. [DOI: 10.1159/000460257] [PMID: 28903103]DiamondD , LevyKN , ClarkinJF , Fischer-KernM , CainNM , DoeringS , et al. Attachment and mentalization in female patients with comorbid narcissistic and borderline personality disorder. Personality Disorders2014;5(4):428-33. [DOI: 10.1037/per0000065] [PMID: 25314231]DiamondD , YeomansFE , SternB , LevyKN , HörzS , DoeringS , et al. Transference-focused psychotherapy for patients with comorbid narcissistic and borderline personality disorder. Psychoanalytic Inquiry2013;33(6):527-51. [DOI: 10.1080/07351690.2013.815087]DoeringS , HörzS , RentropM , Fischer-KernM , SchusterP , BeneckeC , et al. Transference-focused psychotherapy v treatment by community psychotherapists for borderline personality disorder: randomised controlled trial. British Journal of Psychiatry2010;196(5):389-95. [DOI: 10.1192/bjp.bp.109.070177] [PMID: 20435966]DoeringS . Author's reply [to Kleindienst N, Krumm B, Bohus M. Is transference-focused psychotherapy really efficacious for borderline personality disorder? British Journal of Psychiatry 2011;198(2):156-7. DOI: 10.1192/bjp.198.2.156b]. British Journal of Psychiatry2011;198(2):156-7. [DOI: 10.1192/bjp.198.2.157]DoeringS . Question regarding your BPD trial for systematic review in Cochrane Collaboration [personal communication]. Email to: K Lieb, J Stoffers 10 December 2010. Fischer-KernM , DoeringS , TaubnerS , HörzS , ZimmermannJ , RentropM , et al. Transference-focused psychotherapy for borderline personality disorder: change in reflective function. British Journal of Psychiatry2015;207(2):173-4. [DOI: 10.1192/bjp.bp.113.143842] [PMID: 25999334]KleindienstN , KrummB , BohusM . Is transference-focused psychotherapy really efficacious for borderline personality disorder?British Journal of Psychiatry2011;198(2):156-7. [DOI: 10.1192/bjp.198.2.156b] [PMID: 21282787]LevyKN , MeehanKB , YeomansFE . Transference-focused psychotherapy reduces treatment drop-out and suicide attempters compared with community psychotherapist treatment in borderline personality disorder. Evidence-based Mental Health2010;13(4):119. [DOI: 10.1136/ebmh.13.4.119] [PMID: 21036981]NCT00714311. Efficacy of transference-focused psychotherapy for borderline personality disorder [A randomized-controlled trial of transference-focused psychotherapy vs treatment by experienced community psychotherapists for borderline personality disorder]. www.clinicaltrials.gov/ct2/show/NCT00714311 (first received 9 July 2008). RentropM , MartiusP , BäumlJ , BuchheimP , DöeringS , HörzS . Patients with borderline personality disorder not participating in an RCT: are they different?Psychopathology2010;43(6):369-72. [DOI: 10.1159/000320351] [PMID: 20798576]">Doering 2010</a>). </p> <p>TFP did not improve psychosocial functioning at end of treatment compared with TAU (MD −2.56, 95% CI −5.43 to 0.31; 1 trial, 104 participants; P = 0.08; <a href="./references#CD012955-fig-0109" title="">Analysis 12.4</a>). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> </section> </section> <section id="CD012955-sec-0220"> <h5 class="title">Secondary outcomes</h5> <section id="CD012955-sec-0221"> <h6 class="title">12.5 Depression</h6> <p>One trial reported continuous data on depression (<a href="./references#CD012955-bbs2-0019" title="BuchheimA , Hörz-SagstetterS , DoeringS , RentropM , SchusterP , BuchheimP , et al. Change of unresolved attachment in borderline personality disorders: RCT study of transference-focused psychotherapy. Psychotherapy and Psychosomatics2017;86(5):314-6. [DOI: 10.1159/000460257] [PMID: 28903103]DiamondD , LevyKN , ClarkinJF , Fischer-KernM , CainNM , DoeringS , et al. Attachment and mentalization in female patients with comorbid narcissistic and borderline personality disorder. Personality Disorders2014;5(4):428-33. [DOI: 10.1037/per0000065] [PMID: 25314231]DiamondD , YeomansFE , SternB , LevyKN , HörzS , DoeringS , et al. Transference-focused psychotherapy for patients with comorbid narcissistic and borderline personality disorder. Psychoanalytic Inquiry2013;33(6):527-51. [DOI: 10.1080/07351690.2013.815087]DoeringS , HörzS , RentropM , Fischer-KernM , SchusterP , BeneckeC , et al. Transference-focused psychotherapy v treatment by community psychotherapists for borderline personality disorder: randomised controlled trial. British Journal of Psychiatry2010;196(5):389-95. [DOI: 10.1192/bjp.bp.109.070177] [PMID: 20435966]DoeringS . Author's reply [to Kleindienst N, Krumm B, Bohus M. Is transference-focused psychotherapy really efficacious for borderline personality disorder? British Journal of Psychiatry 2011;198(2):156-7. DOI: 10.1192/bjp.198.2.156b]. British Journal of Psychiatry2011;198(2):156-7. [DOI: 10.1192/bjp.198.2.157]DoeringS . Question regarding your BPD trial for systematic review in Cochrane Collaboration [personal communication]. Email to: K Lieb, J Stoffers 10 December 2010. Fischer-KernM , DoeringS , TaubnerS , HörzS , ZimmermannJ , RentropM , et al. Transference-focused psychotherapy for borderline personality disorder: change in reflective function. British Journal of Psychiatry2015;207(2):173-4. [DOI: 10.1192/bjp.bp.113.143842] [PMID: 25999334]KleindienstN , KrummB , BohusM . Is transference-focused psychotherapy really efficacious for borderline personality disorder?British Journal of Psychiatry2011;198(2):156-7. [DOI: 10.1192/bjp.198.2.156b] [PMID: 21282787]LevyKN , MeehanKB , YeomansFE . Transference-focused psychotherapy reduces treatment drop-out and suicide attempters compared with community psychotherapist treatment in borderline personality disorder. Evidence-based Mental Health2010;13(4):119. [DOI: 10.1136/ebmh.13.4.119] [PMID: 21036981]NCT00714311. Efficacy of transference-focused psychotherapy for borderline personality disorder [A randomized-controlled trial of transference-focused psychotherapy vs treatment by experienced community psychotherapists for borderline personality disorder]. www.clinicaltrials.gov/ct2/show/NCT00714311 (first received 9 July 2008). RentropM , MartiusP , BäumlJ , BuchheimP , DöeringS , HörzS . Patients with borderline personality disorder not participating in an RCT: are they different?Psychopathology2010;43(6):369-72. [DOI: 10.1159/000320351] [PMID: 20798576]">Doering 2010</a>). </p> <p>TFP did not reduce depression at end of treatment compared with TAU (MD 1.65, 95% CI −3.44 to 6.74; 1 trial, 104 participants; P = 0.52; <a href="./references#CD012955-fig-0110" title="">Analysis 12.5</a>). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> </section> <section id="CD012955-sec-0222"> <h6 class="title">12.6 Attrition</h6> <p>One trial reported dichotomous data on attrition (<a href="./references#CD012955-bbs2-0019" title="BuchheimA , Hörz-SagstetterS , DoeringS , RentropM , SchusterP , BuchheimP , et al. Change of unresolved attachment in borderline personality disorders: RCT study of transference-focused psychotherapy. Psychotherapy and Psychosomatics2017;86(5):314-6. [DOI: 10.1159/000460257] [PMID: 28903103]DiamondD , LevyKN , ClarkinJF , Fischer-KernM , CainNM , DoeringS , et al. Attachment and mentalization in female patients with comorbid narcissistic and borderline personality disorder. Personality Disorders2014;5(4):428-33. [DOI: 10.1037/per0000065] [PMID: 25314231]DiamondD , YeomansFE , SternB , LevyKN , HörzS , DoeringS , et al. Transference-focused psychotherapy for patients with comorbid narcissistic and borderline personality disorder. Psychoanalytic Inquiry2013;33(6):527-51. [DOI: 10.1080/07351690.2013.815087]DoeringS , HörzS , RentropM , Fischer-KernM , SchusterP , BeneckeC , et al. Transference-focused psychotherapy v treatment by community psychotherapists for borderline personality disorder: randomised controlled trial. British Journal of Psychiatry2010;196(5):389-95. [DOI: 10.1192/bjp.bp.109.070177] [PMID: 20435966]DoeringS . Author's reply [to Kleindienst N, Krumm B, Bohus M. Is transference-focused psychotherapy really efficacious for borderline personality disorder? British Journal of Psychiatry 2011;198(2):156-7. DOI: 10.1192/bjp.198.2.156b]. British Journal of Psychiatry2011;198(2):156-7. [DOI: 10.1192/bjp.198.2.157]DoeringS . Question regarding your BPD trial for systematic review in Cochrane Collaboration [personal communication]. Email to: K Lieb, J Stoffers 10 December 2010. Fischer-KernM , DoeringS , TaubnerS , HörzS , ZimmermannJ , RentropM , et al. Transference-focused psychotherapy for borderline personality disorder: change in reflective function. British Journal of Psychiatry2015;207(2):173-4. [DOI: 10.1192/bjp.bp.113.143842] [PMID: 25999334]KleindienstN , KrummB , BohusM . Is transference-focused psychotherapy really efficacious for borderline personality disorder?British Journal of Psychiatry2011;198(2):156-7. [DOI: 10.1192/bjp.198.2.156b] [PMID: 21282787]LevyKN , MeehanKB , YeomansFE . Transference-focused psychotherapy reduces treatment drop-out and suicide attempters compared with community psychotherapist treatment in borderline personality disorder. Evidence-based Mental Health2010;13(4):119. [DOI: 10.1136/ebmh.13.4.119] [PMID: 21036981]NCT00714311. Efficacy of transference-focused psychotherapy for borderline personality disorder [A randomized-controlled trial of transference-focused psychotherapy vs treatment by experienced community psychotherapists for borderline personality disorder]. www.clinicaltrials.gov/ct2/show/NCT00714311 (first received 9 July 2008). RentropM , MartiusP , BäumlJ , BuchheimP , DöeringS , HörzS . Patients with borderline personality disorder not participating in an RCT: are they different?Psychopathology2010;43(6):369-72. [DOI: 10.1159/000320351] [PMID: 20798576]">Doering 2010</a>). </p> <p>TFP reduced attrition at end of treatment compared with TAU (RR 0.57, 95% CI 0.39 to 0.85; 1 trial, 104 participants; P = 0.005; <a href="./references#CD012955-fig-0111" title="">Analysis 12.6</a>). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> <p>No data were available on any time point for anger, affective instability, chronic feelings of emptiness, impulsivity, interpersonal problems, abandonment, identity disturbance, dissociation and psychotic‐like symptoms, and adverse effects. </p> </section> </section> </section> <section id="CD012955-sec-0223"> <h4 class="title">13. Once‐only interventions (individual setting) versus treatment‐as‐usual (TAU)</h4> <section id="CD012955-sec-0224"> <h5 class="title">Primary outcomes</h5> <section id="CD012955-sec-0225"> <h6 class="title">13.1 Self‐harm</h6> <p>One trial reported continuous data on self‐harm (<a href="./references#CD012955-bbs2-0012" title="BorschmannR , BarrettB , HellierJM , ByfordS , HendersonC , RoseD , et al. Joint crisis plans for people with borderline personality disorder: feasibility and outcomes in a randomised controlled trial. British Journal of Psychiatry2013;202(5):357-64. [DOI: 10.1192/bjp.bp.112.117762] [PMID: 23637110]BorschmannR . Joint crisis plans for BPD - question on publication in British Journal of Psychiatry [pers communication]. Email to: J Stoffers-Winterling 22 August 2017. BorschmannR . RE: joint crisis plans for BPD - question on publication in British Journal of Psychiatry [personal communication]. Email to: J Stoffers-Winterling 22 August 2017. BorschmannR . The development and testing of joint crisis plans for people with borderline personality disorder: a feasibility study. ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.628499 (accessed 27 January 2019). HellierJ . RE: regarding your study on on MBT for eating disorders [personal communication]. Email to: E Faltinsen 27 March 2018. HellierJ . RE: regarding your study on on MBT for eating disorders [personal communication]. Email to: E Faltinsen 3 January 2018. HellierJ . SV: regarding your study on MBT for eating disorders [personal communication]. Email to: EG Faltinsen, P Robinson 27 March 2018. ISRCTN12440268. JOSHUA: a pilot randomised controlled trial of joint crisis plans for people who self harm. www.isrctn.com/ISRCTN12440268 (first received 17 September 2009). ">Borschmann 2013</a>). </p> <p>Once‐only interventions did not reduce self‐harm at end of treatment compared with TAU (MD 0.60, 95% CI −33.88 to 35.08; 1 trial, 72 participants; P = 0.97; <a href="./references#CD012955-fig-0112" title="">Analysis 13.1</a>). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> </section> <section id="CD012955-sec-0226"> <h6 class="title">13.2 Psychosocial functioning</h6> <p>One trial reported continuous data on psychosocial functioning (<a href="./references#CD012955-bbs2-0012" title="BorschmannR , BarrettB , HellierJM , ByfordS , HendersonC , RoseD , et al. Joint crisis plans for people with borderline personality disorder: feasibility and outcomes in a randomised controlled trial. British Journal of Psychiatry2013;202(5):357-64. [DOI: 10.1192/bjp.bp.112.117762] [PMID: 23637110]BorschmannR . Joint crisis plans for BPD - question on publication in British Journal of Psychiatry [pers communication]. Email to: J Stoffers-Winterling 22 August 2017. BorschmannR . RE: joint crisis plans for BPD - question on publication in British Journal of Psychiatry [personal communication]. Email to: J Stoffers-Winterling 22 August 2017. BorschmannR . The development and testing of joint crisis plans for people with borderline personality disorder: a feasibility study. ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.628499 (accessed 27 January 2019). HellierJ . RE: regarding your study on on MBT for eating disorders [personal communication]. Email to: E Faltinsen 27 March 2018. HellierJ . RE: regarding your study on on MBT for eating disorders [personal communication]. Email to: E Faltinsen 3 January 2018. HellierJ . SV: regarding your study on MBT for eating disorders [personal communication]. Email to: EG Faltinsen, P Robinson 27 March 2018. ISRCTN12440268. JOSHUA: a pilot randomised controlled trial of joint crisis plans for people who self harm. www.isrctn.com/ISRCTN12440268 (first received 17 September 2009). ">Borschmann 2013</a>). </p> <p>Once‐only interventions did not improve psychosocial functioning at end of treatment compared with TAU (MD 0.25, 95% CI −3.66 to 4.16; 1 trial, 72 participants; P = 0.90; <a href="./references#CD012955-fig-0113" title="">Analysis 13.2</a>). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> <p>No data were available on any time point for BPD symptom severity, and suicide‐related outcomes. </p> </section> </section> <section id="CD012955-sec-0227"> <h5 class="title">Secondary outcomes</h5> <section id="CD012955-sec-0228"> <h6 class="title">13.3 Depression</h6> <p>One trial reported continuous data on depression (<a href="./references#CD012955-bbs2-0012" title="BorschmannR , BarrettB , HellierJM , ByfordS , HendersonC , RoseD , et al. Joint crisis plans for people with borderline personality disorder: feasibility and outcomes in a randomised controlled trial. British Journal of Psychiatry2013;202(5):357-64. [DOI: 10.1192/bjp.bp.112.117762] [PMID: 23637110]BorschmannR . Joint crisis plans for BPD - question on publication in British Journal of Psychiatry [pers communication]. Email to: J Stoffers-Winterling 22 August 2017. BorschmannR . RE: joint crisis plans for BPD - question on publication in British Journal of Psychiatry [personal communication]. Email to: J Stoffers-Winterling 22 August 2017. BorschmannR . The development and testing of joint crisis plans for people with borderline personality disorder: a feasibility study. ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.628499 (accessed 27 January 2019). HellierJ . RE: regarding your study on on MBT for eating disorders [personal communication]. Email to: E Faltinsen 27 March 2018. HellierJ . RE: regarding your study on on MBT for eating disorders [personal communication]. Email to: E Faltinsen 3 January 2018. HellierJ . SV: regarding your study on MBT for eating disorders [personal communication]. Email to: EG Faltinsen, P Robinson 27 March 2018. ISRCTN12440268. JOSHUA: a pilot randomised controlled trial of joint crisis plans for people who self harm. www.isrctn.com/ISRCTN12440268 (first received 17 September 2009). ">Borschmann 2013</a>). </p> <p>Once‐only interventions did not improve depression at end of treatment compared with TAU (MD 0.27, 95% CI −1.72 to 2.26; 1 trial, 72 participants; P = 0.79; <a href="./references#CD012955-fig-0114" title="">Analysis 13.3</a>). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> </section> <section id="CD012955-sec-0229"> <h6 class="title">13.4 Attrition</h6> <p>One trial reported dichotomous data on attrition (<a href="./references#CD012955-bbs2-0012" title="BorschmannR , BarrettB , HellierJM , ByfordS , HendersonC , RoseD , et al. Joint crisis plans for people with borderline personality disorder: feasibility and outcomes in a randomised controlled trial. British Journal of Psychiatry2013;202(5):357-64. [DOI: 10.1192/bjp.bp.112.117762] [PMID: 23637110]BorschmannR . Joint crisis plans for BPD - question on publication in British Journal of Psychiatry [pers communication]. Email to: J Stoffers-Winterling 22 August 2017. BorschmannR . RE: joint crisis plans for BPD - question on publication in British Journal of Psychiatry [personal communication]. Email to: J Stoffers-Winterling 22 August 2017. BorschmannR . The development and testing of joint crisis plans for people with borderline personality disorder: a feasibility study. ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.628499 (accessed 27 January 2019). HellierJ . RE: regarding your study on on MBT for eating disorders [personal communication]. Email to: E Faltinsen 27 March 2018. HellierJ . RE: regarding your study on on MBT for eating disorders [personal communication]. Email to: E Faltinsen 3 January 2018. HellierJ . SV: regarding your study on MBT for eating disorders [personal communication]. Email to: EG Faltinsen, P Robinson 27 March 2018. ISRCTN12440268. JOSHUA: a pilot randomised controlled trial of joint crisis plans for people who self harm. www.isrctn.com/ISRCTN12440268 (first received 17 September 2009). ">Borschmann 2013</a>). </p> <p>Once‐only interventions did not reduce attrition at end of treatment compared with TAU (RR 1.37, 95% CI 0.53 to 3.52; 1 trial, 88 participants; P = 0.51; <a href="./references#CD012955-fig-0115" title="">Analysis 13.4</a>). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> <p>No data were available on any time point for anger, affective instability, chronic feelings of emptiness, impulsivity, interpersonal problems, abandonment, identity disturbance, dissociation and psychotic‐like symptoms, and adverse effects. </p> </section> </section> </section> <section id="CD012955-sec-0230"> <h4 class="title">14. Eclectic treatments versus treatment‐as‐usual (TAU)</h4> <section id="CD012955-sec-0231"> <h5 class="title">Primary outcomes</h5> <section id="CD012955-sec-0232"> <h6 class="title">14.1 BPD symptom severity</h6> <p>Three trials reported continuous data on BPD symptom severity (<a href="./references#CD012955-bbs2-0026" title="Gratz KL. Important: question regarding your BPD trial for systematic review in Cochrane Collaboration [personal communication]. Email to: J Stoffers-Winterling 11 December 2010. GratzKL , GundersonJG . Preliminary data on an acceptance-based emotion regulation group intervention for deliberate self-harm among women with borderline personality disorder. Behavior Therapy2006;37(1):25-35. [DOI: 10.1016/j.beth.2005.03.002] [PMID: 16942958]">Gratz 2006</a>; <a href="./references#CD012955-bbs2-0027" title="GratzKL , BardeenJR , LevyR , Dixon-GordonKL , TullMT . Mechanisms of change in an emotion regulation group therapy for deliberate self-harm among women with borderline personality disorder. Behaviour Research and Therapy2015;65:29-35. [DOI: 10.1016/j.brat.2014.12.005] [PMC4306622] [PMID: 25557395]GratzKL , Dixon-GordonKL , TullMT . Predictors of treatment response to an adjunctive emotion regulation group therapy for deliberate self-harm among women with borderline personality disorder. Personality Disorders2014;5(1):97-107. [DOI: 10.1037/per0000062] [PMC4059504] [PMID: 2458806]GratzKL , TullMT , LevyR . Randomized controlled trial and uncontrolled 9-month follow-up of an adjunctive emotion regulation group therapy for deliberate self-harm among women with borderline personality disorder. Psychological Medicine2014;44(10):2099-112. [DOI: 10.1017/S0033291713002134] [PMID: 23985088]GratzKL . Question regarding your BPD trials [personal communication]. Email to: J Stoffers 11 December 2010. ">Gratz 2014</a>; <a href="./references#CD012955-bbs2-0043" title="LeppänenV , HakkoH , SintonenH , LindemanS . Comparing effectiveness of treatments for borderline personality disorder in communal mental health care: the Oulu BPD study. Community Mental Health Journal2016;52(2):216-27. [DOI: 10.1007/s10597-015-9866-4] [PMID: 25824852]LeppänenV . Re: questions regarding the Oulu BPD study [personal communication]. Email to: E Faltinsen 20 December 2017. LeppänenV . Re: SV: question regarding the Oulu BPD study [personal communication]. Email to: EG Faltinsen 22 December 2017. ">Leppänen 2016</a>). </p> <p>Eclectic treatments reduced BPD symptom severity at end of treatment compared with TAU (SMD −0.90, 95% CI −1.57 to −0.23; 3 trials, 134 participants; I<sup>2</sup> = 67%; P = 0.008; <a href="./references#CD012955-fig-0116" title="">Analysis 14.1</a>). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> </section> <section id="CD012955-sec-0233"> <h6 class="title">14.2 Self‐harm</h6> <p>Two trials reported continuous data on self‐harm (<a href="./references#CD012955-bbs2-0026" title="Gratz KL. Important: question regarding your BPD trial for systematic review in Cochrane Collaboration [personal communication]. Email to: J Stoffers-Winterling 11 December 2010. GratzKL , GundersonJG . Preliminary data on an acceptance-based emotion regulation group intervention for deliberate self-harm among women with borderline personality disorder. Behavior Therapy2006;37(1):25-35. [DOI: 10.1016/j.beth.2005.03.002] [PMID: 16942958]">Gratz 2006</a>; <a href="./references#CD012955-bbs2-0027" title="GratzKL , BardeenJR , LevyR , Dixon-GordonKL , TullMT . Mechanisms of change in an emotion regulation group therapy for deliberate self-harm among women with borderline personality disorder. Behaviour Research and Therapy2015;65:29-35. [DOI: 10.1016/j.brat.2014.12.005] [PMC4306622] [PMID: 25557395]GratzKL , Dixon-GordonKL , TullMT . Predictors of treatment response to an adjunctive emotion regulation group therapy for deliberate self-harm among women with borderline personality disorder. Personality Disorders2014;5(1):97-107. [DOI: 10.1037/per0000062] [PMC4059504] [PMID: 2458806]GratzKL , TullMT , LevyR . Randomized controlled trial and uncontrolled 9-month follow-up of an adjunctive emotion regulation group therapy for deliberate self-harm among women with borderline personality disorder. Psychological Medicine2014;44(10):2099-112. [DOI: 10.1017/S0033291713002134] [PMID: 23985088]GratzKL . Question regarding your BPD trials [personal communication]. Email to: J Stoffers 11 December 2010. ">Gratz 2014</a>). </p> <p>Eclectic treatments reduced self‐harm at end of treatment compared with TAU (SMD −0.84, 95% CI −1.29 to −0.39; 2 trials, 83 participants; I<sup>2</sup> = 0%; P = 0.0003; <a href="./references#CD012955-fig-0117" title="">Analysis 14.2</a>). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> </section> <section id="CD012955-sec-0234"> <h6 class="title">14.3 Suicide‐related outcomes</h6> <p>Two trials reported continuous data on suicide‐related outcomes (<a href="./references#CD012955-bbs2-0002" title='AndreoliA , BurnandY , CochennecMF , MarieD , Di ClementeT , OhlendorfP . Psychoanalytic psychotherapy and venlafaxine among acutely suicidal borderline patients: a randomized clinical study. European Psychiatry2009;24(Suppl 1):S93. [DOI: 10.1016/S0924-9338(09)70326-8] [S18-03]AndreoliA , BurnandY , CochennecMF , OhlendorfP , FrambatiL , Gaudry-MaireD , et al. Disappointed love and suicide: a randomized controlled trial of "abandonment psychotherapy" among borderline patients. Journal of Personality Disorders2016;30(2):271-87. [DOI: 10.1521/pedi_2015_29_196] [PMID: 26111250]AndreoliA , BurnandY , FrambatiL , ManningD , FrancesA . Abandonment psychotherapy and psychosocial functioning among suicidal patients with borderline personality disorder: a 3-year naturalistic follow-up. Journal of Personality Disorders 2019 Feb 20 [Epub ahead of print]. [DOI: 10.1521/pedi_2019_33_423] [PMID: 30785852]AndreoliA . Re: your study in BPD - Cochrane Collaboration review [personal communication]. Email to: J Stoffers-Winterling 5 June 2018. '>Andreoli 2016</a>; <a href="./references#CD012955-bbs2-0043" title="LeppänenV , HakkoH , SintonenH , LindemanS . Comparing effectiveness of treatments for borderline personality disorder in communal mental health care: the Oulu BPD study. Community Mental Health Journal2016;52(2):216-27. [DOI: 10.1007/s10597-015-9866-4] [PMID: 25824852]LeppänenV . Re: questions regarding the Oulu BPD study [personal communication]. Email to: E Faltinsen 20 December 2017. LeppänenV . Re: SV: question regarding the Oulu BPD study [personal communication]. Email to: EG Faltinsen 22 December 2017. ">Leppänen 2016</a>). </p> <p>Eclectic treatments did not reduce suicide‐related outcomes at end of treatment compared with TAU (SMD −0.55, 95% CI −1.29 to 0.19; 2 trials, 221 participants; I<sup>2</sup> = 78%; P = 0.14; <a href="./references#CD012955-fig-0118" title="">Analysis 14.3</a>; random‐effects model). </p> <p>Eclectic treatments reduced suicide‐related outcomes at end of treatment compared with TAU (SMD −0.65, 95% CI −0.98 to − 0.32; 2 trials, 221 participants; I<sup>2</sup> = 78%; P = 0.0001; analysis not shown; fixed‐effect model). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> </section> <section id="CD012955-sec-0235"> <h6 class="title">14.4 Psychosocial functioning</h6> <p>Two trials reported continuous data on psychosocial functioning (<a href="./references#CD012955-bbs2-0002" title='AndreoliA , BurnandY , CochennecMF , MarieD , Di ClementeT , OhlendorfP . Psychoanalytic psychotherapy and venlafaxine among acutely suicidal borderline patients: a randomized clinical study. European Psychiatry2009;24(Suppl 1):S93. [DOI: 10.1016/S0924-9338(09)70326-8] [S18-03]AndreoliA , BurnandY , CochennecMF , OhlendorfP , FrambatiL , Gaudry-MaireD , et al. Disappointed love and suicide: a randomized controlled trial of "abandonment psychotherapy" among borderline patients. Journal of Personality Disorders2016;30(2):271-87. [DOI: 10.1521/pedi_2015_29_196] [PMID: 26111250]AndreoliA , BurnandY , FrambatiL , ManningD , FrancesA . Abandonment psychotherapy and psychosocial functioning among suicidal patients with borderline personality disorder: a 3-year naturalistic follow-up. Journal of Personality Disorders 2019 Feb 20 [Epub ahead of print]. [DOI: 10.1521/pedi_2019_33_423] [PMID: 30785852]AndreoliA . Re: your study in BPD - Cochrane Collaboration review [personal communication]. Email to: J Stoffers-Winterling 5 June 2018. '>Andreoli 2016</a>; <a href="./references#CD012955-bbs2-0027" title="GratzKL , BardeenJR , LevyR , Dixon-GordonKL , TullMT . Mechanisms of change in an emotion regulation group therapy for deliberate self-harm among women with borderline personality disorder. Behaviour Research and Therapy2015;65:29-35. [DOI: 10.1016/j.brat.2014.12.005] [PMC4306622] [PMID: 25557395]GratzKL , Dixon-GordonKL , TullMT . Predictors of treatment response to an adjunctive emotion regulation group therapy for deliberate self-harm among women with borderline personality disorder. Personality Disorders2014;5(1):97-107. [DOI: 10.1037/per0000062] [PMC4059504] [PMID: 2458806]GratzKL , TullMT , LevyR . Randomized controlled trial and uncontrolled 9-month follow-up of an adjunctive emotion regulation group therapy for deliberate self-harm among women with borderline personality disorder. Psychological Medicine2014;44(10):2099-112. [DOI: 10.1017/S0033291713002134] [PMID: 23985088]GratzKL . Question regarding your BPD trials [personal communication]. Email to: J Stoffers 11 December 2010. ">Gratz 2014</a>). </p> <p>Eclectic treatments improved psychosocial functioning at end of treatment compared with TAU (SMD −0.57, 95% CI −1.10 to −0.04; 2 trials, 231 participants; I<sup>2</sup> = 63%; P = 0.03; <a href="./references#CD012955-fig-0119" title="">Analysis 14.4</a>.1). </p> <p>Eclectic treatments improved psychosocial functioning at above 12 months follow‐up compared with TAU (SMD −0.64, 95% CI −1.04 to −0.24; 1 trial, 170 participants; P = 0.002; MD −7.50, 95% CI −12.30 to −2.70; 1 trial, 170 participants; P = 0.002; <a href="./references#CD012955-fig-0119" title="">Analysis 14.4</a>.2). </p> <p>No data were available for zero to months and six to 12 months.</p> </section> </section> <section id="CD012955-sec-0236"> <h5 class="title">Secondary outcomes</h5> <section id="CD012955-sec-0237"> <h6 class="title">14.5 Anger</h6> <p>One trial reported continuous data on anger (<a href="./references#CD012955-bbs2-0043" title="LeppänenV , HakkoH , SintonenH , LindemanS . Comparing effectiveness of treatments for borderline personality disorder in communal mental health care: the Oulu BPD study. Community Mental Health Journal2016;52(2):216-27. [DOI: 10.1007/s10597-015-9866-4] [PMID: 25824852]LeppänenV . Re: questions regarding the Oulu BPD study [personal communication]. Email to: E Faltinsen 20 December 2017. LeppänenV . Re: SV: question regarding the Oulu BPD study [personal communication]. Email to: EG Faltinsen 22 December 2017. ">Leppänen 2016</a>). </p> <p>Eclectic treatments did not reduce anger at end of treatment compared with TAU (MD −0.47, 95% CI −1.26 to 0.32; 1 trial, 51 participants; P = 0.24; <a href="./references#CD012955-fig-0120" title="">Analysis 14.5</a>). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> </section> <section id="CD012955-sec-0238"> <h6 class="title">14.6 Affective instability</h6> <p>Three trials reported continuous data on affective instability (<a href="./references#CD012955-bbs2-0026" title="Gratz KL. Important: question regarding your BPD trial for systematic review in Cochrane Collaboration [personal communication]. Email to: J Stoffers-Winterling 11 December 2010. GratzKL , GundersonJG . Preliminary data on an acceptance-based emotion regulation group intervention for deliberate self-harm among women with borderline personality disorder. Behavior Therapy2006;37(1):25-35. [DOI: 10.1016/j.beth.2005.03.002] [PMID: 16942958]">Gratz 2006</a>; <a href="./references#CD012955-bbs2-0027" title="GratzKL , BardeenJR , LevyR , Dixon-GordonKL , TullMT . Mechanisms of change in an emotion regulation group therapy for deliberate self-harm among women with borderline personality disorder. Behaviour Research and Therapy2015;65:29-35. [DOI: 10.1016/j.brat.2014.12.005] [PMC4306622] [PMID: 25557395]GratzKL , Dixon-GordonKL , TullMT . Predictors of treatment response to an adjunctive emotion regulation group therapy for deliberate self-harm among women with borderline personality disorder. Personality Disorders2014;5(1):97-107. [DOI: 10.1037/per0000062] [PMC4059504] [PMID: 2458806]GratzKL , TullMT , LevyR . Randomized controlled trial and uncontrolled 9-month follow-up of an adjunctive emotion regulation group therapy for deliberate self-harm among women with borderline personality disorder. Psychological Medicine2014;44(10):2099-112. [DOI: 10.1017/S0033291713002134] [PMID: 23985088]GratzKL . Question regarding your BPD trials [personal communication]. Email to: J Stoffers 11 December 2010. ">Gratz 2014</a>; <a href="./references#CD012955-bbs2-0043" title="LeppänenV , HakkoH , SintonenH , LindemanS . Comparing effectiveness of treatments for borderline personality disorder in communal mental health care: the Oulu BPD study. Community Mental Health Journal2016;52(2):216-27. [DOI: 10.1007/s10597-015-9866-4] [PMID: 25824852]LeppänenV . Re: questions regarding the Oulu BPD study [personal communication]. Email to: E Faltinsen 20 December 2017. LeppänenV . Re: SV: question regarding the Oulu BPD study [personal communication]. Email to: EG Faltinsen 22 December 2017. ">Leppänen 2016</a>). </p> <p>Eclectic treatments reduced affective instability at end of treatment compared with TAU (SMD −0.95, 95% CI −1.74 to −0.15; 3 trials, 134 participants; I<sup>2</sup> = 76%; P = 0.02; <a href="./references#CD012955-fig-0121" title="">Analysis 14.6</a>). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> </section> <section id="CD012955-sec-0239"> <h6 class="title">14.7 Chronic feelings of emptiness</h6> <p>One trial reported continuous data on chronic feelings of emptiness (<a href="./references#CD012955-bbs2-0043" title="LeppänenV , HakkoH , SintonenH , LindemanS . Comparing effectiveness of treatments for borderline personality disorder in communal mental health care: the Oulu BPD study. Community Mental Health Journal2016;52(2):216-27. [DOI: 10.1007/s10597-015-9866-4] [PMID: 25824852]LeppänenV . Re: questions regarding the Oulu BPD study [personal communication]. Email to: E Faltinsen 20 December 2017. LeppänenV . Re: SV: question regarding the Oulu BPD study [personal communication]. Email to: EG Faltinsen 22 December 2017. ">Leppänen 2016</a>). </p> <p>Eclectic treatments did not reduce chronic feelings of emptiness at end of treatment compared with TAU (MD −0.59, 95% CI −2.44 to 1.26; 1 trial, 51 participants; P = 0.53; <a href="./references#CD012955-fig-0122" title="">Analysis 14.7</a>). </p> <p>No data were available for zero to months, six to 12 months and above 12 months follow‐up.</p> </section> <section id="CD012955-sec-0240"> <h6 class="title">14.8 Impulsivity</h6> <p>Three trials reported continuous data on impulsivity (<a href="./references#CD012955-bbs2-0026" title="Gratz KL. Important: question regarding your BPD trial for systematic review in Cochrane Collaboration [personal communication]. Email to: J Stoffers-Winterling 11 December 2010. GratzKL , GundersonJG . Preliminary data on an acceptance-based emotion regulation group intervention for deliberate self-harm among women with borderline personality disorder. Behavior Therapy2006;37(1):25-35. [DOI: 10.1016/j.beth.2005.03.002] [PMID: 16942958]">Gratz 2006</a>; <a href="./references#CD012955-bbs2-0027" title="GratzKL , BardeenJR , LevyR , Dixon-GordonKL , TullMT . Mechanisms of change in an emotion regulation group therapy for deliberate self-harm among women with borderline personality disorder. Behaviour Research and Therapy2015;65:29-35. [DOI: 10.1016/j.brat.2014.12.005] [PMC4306622] [PMID: 25557395]GratzKL , Dixon-GordonKL , TullMT . Predictors of treatment response to an adjunctive emotion regulation group therapy for deliberate self-harm among women with borderline personality disorder. Personality Disorders2014;5(1):97-107. [DOI: 10.1037/per0000062] [PMC4059504] [PMID: 2458806]GratzKL , TullMT , LevyR . Randomized controlled trial and uncontrolled 9-month follow-up of an adjunctive emotion regulation group therapy for deliberate self-harm among women with borderline personality disorder. Psychological Medicine2014;44(10):2099-112. [DOI: 10.1017/S0033291713002134] [PMID: 23985088]GratzKL . Question regarding your BPD trials [personal communication]. Email to: J Stoffers 11 December 2010. ">Gratz 2014</a>; <a href="./references#CD012955-bbs2-0043" title="LeppänenV , HakkoH , SintonenH , LindemanS . Comparing effectiveness of treatments for borderline personality disorder in communal mental health care: the Oulu BPD study. Community Mental Health Journal2016;52(2):216-27. [DOI: 10.1007/s10597-015-9866-4] [PMID: 25824852]LeppänenV . Re: questions regarding the Oulu BPD study [personal communication]. Email to: E Faltinsen 20 December 2017. LeppänenV . Re: SV: question regarding the Oulu BPD study [personal communication]. Email to: EG Faltinsen 22 December 2017. ">Leppänen 2016</a>). </p> <p>Eclectic treatments reduced impulsivity at end of treatment compared with TAU (SMD −0.76, 95% CI −1.30 to −0.22; 3 trials, 134 participants; I<sup>2</sup> = 52%; P = 0.006; <a href="./references#CD012955-fig-0123" title="">Analysis 14.8</a>). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> </section> <section id="CD012955-sec-0241"> <h6 class="title">14.9 Interpersonal problems</h6> <p>Two trials reported continuous data on interpersonal problems (<a href="./references#CD012955-bbs2-0027" title="GratzKL , BardeenJR , LevyR , Dixon-GordonKL , TullMT . Mechanisms of change in an emotion regulation group therapy for deliberate self-harm among women with borderline personality disorder. Behaviour Research and Therapy2015;65:29-35. [DOI: 10.1016/j.brat.2014.12.005] [PMC4306622] [PMID: 25557395]GratzKL , Dixon-GordonKL , TullMT . Predictors of treatment response to an adjunctive emotion regulation group therapy for deliberate self-harm among women with borderline personality disorder. Personality Disorders2014;5(1):97-107. [DOI: 10.1037/per0000062] [PMC4059504] [PMID: 2458806]GratzKL , TullMT , LevyR . Randomized controlled trial and uncontrolled 9-month follow-up of an adjunctive emotion regulation group therapy for deliberate self-harm among women with borderline personality disorder. Psychological Medicine2014;44(10):2099-112. [DOI: 10.1017/S0033291713002134] [PMID: 23985088]GratzKL . Question regarding your BPD trials [personal communication]. Email to: J Stoffers 11 December 2010. ">Gratz 2014</a>; <a href="./references#CD012955-bbs2-0043" title="LeppänenV , HakkoH , SintonenH , LindemanS . Comparing effectiveness of treatments for borderline personality disorder in communal mental health care: the Oulu BPD study. Community Mental Health Journal2016;52(2):216-27. [DOI: 10.1007/s10597-015-9866-4] [PMID: 25824852]LeppänenV . Re: questions regarding the Oulu BPD study [personal communication]. Email to: E Faltinsen 20 December 2017. LeppänenV . Re: SV: question regarding the Oulu BPD study [personal communication]. Email to: EG Faltinsen 22 December 2017. ">Leppänen 2016</a>). </p> <p>Eclectic treatments reduced interpersonal problems at end of treatment compared with TAU (SMD −0.62, 95% CI −1.09 to −0.15; 2 trials, 112 participants; I<sup>2</sup> = 32%; P = 0.01; <a href="./references#CD012955-fig-0124" title="">Analysis 14.9</a>). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> </section> <section id="CD012955-sec-0242"> <h6 class="title">14.10 Abandonment</h6> <p>One trial reported continuous data on abandonment (<a href="./references#CD012955-bbs2-0043" title="LeppänenV , HakkoH , SintonenH , LindemanS . Comparing effectiveness of treatments for borderline personality disorder in communal mental health care: the Oulu BPD study. Community Mental Health Journal2016;52(2):216-27. [DOI: 10.1007/s10597-015-9866-4] [PMID: 25824852]LeppänenV . Re: questions regarding the Oulu BPD study [personal communication]. Email to: E Faltinsen 20 December 2017. LeppänenV . Re: SV: question regarding the Oulu BPD study [personal communication]. Email to: EG Faltinsen 22 December 2017. ">Leppänen 2016</a>). </p> <p>Eclectic treatments did not reduce abandonment at end of treatment compared with TAU (MD −0.46, 95% CI −1.39 to 0.47; 1 trial, 51 participants; P = 0.33; <a href="./references#CD012955-fig-0125" title="">Analysis 14.10</a>). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> </section> <section id="CD012955-sec-0243"> <h6 class="title">14.11 Identity disturbance</h6> <p>One trial reported continuous data on identity disturbance (<a href="./references#CD012955-bbs2-0043" title="LeppänenV , HakkoH , SintonenH , LindemanS . Comparing effectiveness of treatments for borderline personality disorder in communal mental health care: the Oulu BPD study. Community Mental Health Journal2016;52(2):216-27. [DOI: 10.1007/s10597-015-9866-4] [PMID: 25824852]LeppänenV . Re: questions regarding the Oulu BPD study [personal communication]. Email to: E Faltinsen 20 December 2017. LeppänenV . Re: SV: question regarding the Oulu BPD study [personal communication]. Email to: EG Faltinsen 22 December 2017. ">Leppänen 2016</a>). </p> <p>Eclectic treatments did not reduce identity disturbance at end of treatment compared with TAU (MD −0.85, 95% CI −1.92 to 0.22; 1 trial, 51 participants; P = 0.12; <a href="./references#CD012955-fig-0126" title="">Analysis 14.11</a>). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> </section> <section id="CD012955-sec-0244"> <h6 class="title">14.14 Depression</h6> <p>Four trials reported continuous data on depression (<a href="./references#CD012955-bbs2-0002" title='AndreoliA , BurnandY , CochennecMF , MarieD , Di ClementeT , OhlendorfP . Psychoanalytic psychotherapy and venlafaxine among acutely suicidal borderline patients: a randomized clinical study. European Psychiatry2009;24(Suppl 1):S93. [DOI: 10.1016/S0924-9338(09)70326-8] [S18-03]AndreoliA , BurnandY , CochennecMF , OhlendorfP , FrambatiL , Gaudry-MaireD , et al. Disappointed love and suicide: a randomized controlled trial of "abandonment psychotherapy" among borderline patients. Journal of Personality Disorders2016;30(2):271-87. [DOI: 10.1521/pedi_2015_29_196] [PMID: 26111250]AndreoliA , BurnandY , FrambatiL , ManningD , FrancesA . Abandonment psychotherapy and psychosocial functioning among suicidal patients with borderline personality disorder: a 3-year naturalistic follow-up. Journal of Personality Disorders 2019 Feb 20 [Epub ahead of print]. [DOI: 10.1521/pedi_2019_33_423] [PMID: 30785852]AndreoliA . Re: your study in BPD - Cochrane Collaboration review [personal communication]. Email to: J Stoffers-Winterling 5 June 2018. '>Andreoli 2016</a>; <a href="./references#CD012955-bbs2-0026" title="Gratz KL. Important: question regarding your BPD trial for systematic review in Cochrane Collaboration [personal communication]. Email to: J Stoffers-Winterling 11 December 2010. GratzKL , GundersonJG . Preliminary data on an acceptance-based emotion regulation group intervention for deliberate self-harm among women with borderline personality disorder. Behavior Therapy2006;37(1):25-35. [DOI: 10.1016/j.beth.2005.03.002] [PMID: 16942958]">Gratz 2006</a>; <a href="./references#CD012955-bbs2-0027" title="GratzKL , BardeenJR , LevyR , Dixon-GordonKL , TullMT . Mechanisms of change in an emotion regulation group therapy for deliberate self-harm among women with borderline personality disorder. Behaviour Research and Therapy2015;65:29-35. [DOI: 10.1016/j.brat.2014.12.005] [PMC4306622] [PMID: 25557395]GratzKL , Dixon-GordonKL , TullMT . Predictors of treatment response to an adjunctive emotion regulation group therapy for deliberate self-harm among women with borderline personality disorder. Personality Disorders2014;5(1):97-107. [DOI: 10.1037/per0000062] [PMC4059504] [PMID: 2458806]GratzKL , TullMT , LevyR . Randomized controlled trial and uncontrolled 9-month follow-up of an adjunctive emotion regulation group therapy for deliberate self-harm among women with borderline personality disorder. Psychological Medicine2014;44(10):2099-112. [DOI: 10.1017/S0033291713002134] [PMID: 23985088]GratzKL . Question regarding your BPD trials [personal communication]. Email to: J Stoffers 11 December 2010. ">Gratz 2014</a>; <a href="./references#CD012955-bbs2-0043" title="LeppänenV , HakkoH , SintonenH , LindemanS . Comparing effectiveness of treatments for borderline personality disorder in communal mental health care: the Oulu BPD study. Community Mental Health Journal2016;52(2):216-27. [DOI: 10.1007/s10597-015-9866-4] [PMID: 25824852]LeppänenV . Re: questions regarding the Oulu BPD study [personal communication]. Email to: E Faltinsen 20 December 2017. LeppänenV . Re: SV: question regarding the Oulu BPD study [personal communication]. Email to: EG Faltinsen 22 December 2017. ">Leppänen 2016</a>). </p> <p>Eclectic treatments reduced depression at end of treatment compared with TAU (SMD −0.82, 95% CI −1.38 to −0.26; 4 trials, 304 participants; I<sup>2</sup> = 73%; P = 0.004; <a href="./references#CD012955-fig-0127" title="">Analysis 14.12</a>). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> </section> <section id="CD012955-sec-0245"> <h6 class="title">14.13 Attrition</h6> <p>Four trials reported dichotomous data on attrition (<a href="./references#CD012955-bbs2-0002" title='AndreoliA , BurnandY , CochennecMF , MarieD , Di ClementeT , OhlendorfP . Psychoanalytic psychotherapy and venlafaxine among acutely suicidal borderline patients: a randomized clinical study. European Psychiatry2009;24(Suppl 1):S93. [DOI: 10.1016/S0924-9338(09)70326-8] [S18-03]AndreoliA , BurnandY , CochennecMF , OhlendorfP , FrambatiL , Gaudry-MaireD , et al. Disappointed love and suicide: a randomized controlled trial of "abandonment psychotherapy" among borderline patients. Journal of Personality Disorders2016;30(2):271-87. [DOI: 10.1521/pedi_2015_29_196] [PMID: 26111250]AndreoliA , BurnandY , FrambatiL , ManningD , FrancesA . Abandonment psychotherapy and psychosocial functioning among suicidal patients with borderline personality disorder: a 3-year naturalistic follow-up. Journal of Personality Disorders 2019 Feb 20 [Epub ahead of print]. [DOI: 10.1521/pedi_2019_33_423] [PMID: 30785852]AndreoliA . Re: your study in BPD - Cochrane Collaboration review [personal communication]. Email to: J Stoffers-Winterling 5 June 2018. '>Andreoli 2016</a>; <a href="./references#CD012955-bbs2-0026" title="Gratz KL. Important: question regarding your BPD trial for systematic review in Cochrane Collaboration [personal communication]. Email to: J Stoffers-Winterling 11 December 2010. GratzKL , GundersonJG . Preliminary data on an acceptance-based emotion regulation group intervention for deliberate self-harm among women with borderline personality disorder. Behavior Therapy2006;37(1):25-35. [DOI: 10.1016/j.beth.2005.03.002] [PMID: 16942958]">Gratz 2006</a>; <a href="./references#CD012955-bbs2-0027" title="GratzKL , BardeenJR , LevyR , Dixon-GordonKL , TullMT . Mechanisms of change in an emotion regulation group therapy for deliberate self-harm among women with borderline personality disorder. Behaviour Research and Therapy2015;65:29-35. [DOI: 10.1016/j.brat.2014.12.005] [PMC4306622] [PMID: 25557395]GratzKL , Dixon-GordonKL , TullMT . Predictors of treatment response to an adjunctive emotion regulation group therapy for deliberate self-harm among women with borderline personality disorder. Personality Disorders2014;5(1):97-107. [DOI: 10.1037/per0000062] [PMC4059504] [PMID: 2458806]GratzKL , TullMT , LevyR . Randomized controlled trial and uncontrolled 9-month follow-up of an adjunctive emotion regulation group therapy for deliberate self-harm among women with borderline personality disorder. Psychological Medicine2014;44(10):2099-112. [DOI: 10.1017/S0033291713002134] [PMID: 23985088]GratzKL . Question regarding your BPD trials [personal communication]. Email to: J Stoffers 11 December 2010. ">Gratz 2014</a>; <a href="./references#CD012955-bbs2-0043" title="LeppänenV , HakkoH , SintonenH , LindemanS . Comparing effectiveness of treatments for borderline personality disorder in communal mental health care: the Oulu BPD study. Community Mental Health Journal2016;52(2):216-27. [DOI: 10.1007/s10597-015-9866-4] [PMID: 25824852]LeppänenV . Re: questions regarding the Oulu BPD study [personal communication]. Email to: E Faltinsen 20 December 2017. LeppänenV . Re: SV: question regarding the Oulu BPD study [personal communication]. Email to: EG Faltinsen 22 December 2017. ">Leppänen 2016</a>). </p> <p>Eclectic treatments did not reduce attrition at end of treatment compared with TAU (RR 1.10, 95% CI 0.91 to 1.33; 4 trials, 326 participants; I<sup>2</sup> = 25%; P = 0.31; <a href="./references#CD012955-fig-0128" title="">Analysis 14.13</a>). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> </section> <section id="CD012955-sec-0246"> <h6 class="title">14.14 Adverse effects</h6> <p>One trial reported dichotomous data on adverse effects (<a href="./references#CD012955-bbs2-0002" title='AndreoliA , BurnandY , CochennecMF , MarieD , Di ClementeT , OhlendorfP . Psychoanalytic psychotherapy and venlafaxine among acutely suicidal borderline patients: a randomized clinical study. European Psychiatry2009;24(Suppl 1):S93. [DOI: 10.1016/S0924-9338(09)70326-8] [S18-03]AndreoliA , BurnandY , CochennecMF , OhlendorfP , FrambatiL , Gaudry-MaireD , et al. Disappointed love and suicide: a randomized controlled trial of "abandonment psychotherapy" among borderline patients. Journal of Personality Disorders2016;30(2):271-87. [DOI: 10.1521/pedi_2015_29_196] [PMID: 26111250]AndreoliA , BurnandY , FrambatiL , ManningD , FrancesA . Abandonment psychotherapy and psychosocial functioning among suicidal patients with borderline personality disorder: a 3-year naturalistic follow-up. Journal of Personality Disorders 2019 Feb 20 [Epub ahead of print]. [DOI: 10.1521/pedi_2019_33_423] [PMID: 30785852]AndreoliA . Re: your study in BPD - Cochrane Collaboration review [personal communication]. Email to: J Stoffers-Winterling 5 June 2018. '>Andreoli 2016</a>). </p> <p>Eclectic treatments did not reduce adverse effects at end of treatment compared with TAU (RR 0.66, 95% CI 0.03 to 15.81; 1 trial, 170 participants; P = 0.80; <a href="./references#CD012955-fig-0129" title="">Analysis 14.14</a>). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> <p>No data were available on any time point for dissociation and psychotic‐like symptoms.</p> </section> </section> </section> <section id="CD012955-sec-0247"> <h4 class="title">15. Psychotherapy versus waiting list or no treatment</h4> <section id="CD012955-sec-0248"> <h5 class="title">Primary outcomes</h5> <section id="CD012955-sec-0249"> <h6 class="title">15.1 BPD symptom severity</h6> <p>Three trials reported continuous data on BPD symptom severity (<a href="./references#CD012955-bbs2-0008" title="BellinoS , BozzatelloP , BogettoF . Combined treatment of borderline personality disorder with interpersonal psychotherapy and pharmacotherapy: predictors of response. Psychiatry Research2015;226(1):284-8. [DOI: 10.1016/j.psychres.2014.12.064] [isiarticles.com/bundles/Article/pre/pdf/34125.pdf]BellinoS , RinaldiC , BogettoF . Adaptation of interpersonal psychotherapy to borderline personality disorder: a comparison of combined therapy and single pharmacotherapy. Canadian Journal of Psychiatry2010;55(2):74-81. [DOI: 10.1177/070674371005500203] [PMID: 20181302]BellinoS . Question regarding your BPD trials for inclusion in Cochrane Collaboration review [personal communication]. Email to: J Stoffers-Winterling 19 December 2010. BellinoS . Re: question regarding your BPD trials [personal communication]. Email to: J Stoffers 16 December 2010. BozzatelloP , BellinoS . Combined therapy with interpersonal psychotherapy adapted for borderline personality disorder: a two-years follow-up. Psychiatry Research2016;240:151-6. [DOI: 10.1016/j.psychres.2016.04.014] [www.sciencedirect.com/science/article/pii/S0165178115302389]ZizzaM , FenocchioM , RinaldiC , BellinoS . Combined treatment of borderline personality disorder: a trial of modified interpersonal therapy. World Psychiatry2009;8(Suppl 1):234. ">Bellino 2010</a>; <a href="./references#CD012955-bbs2-0011" title="BohusM , DyerAS , PriebeK , KrügerA , KleindienstN , SchmahlC , et al. Dialectical behaviour therapy for post-traumatic stress disorder after childhood sexual abuse in patients with and without borderline personality disorder: a randomised controlled trial. Psychotherapy and Psychosomatics2013;82(4):221-33. [DOI: 10.1159/000348451] [PMID: 23712109]BrandS . AW: questions regarding your trial on emotional intelligence training for BPD [personal communication]. Email to: EG Faltinsen 28 November 2017. DBT Working Group at the Central Institute for Mental Health, Mannheim, Germany. Requested supplementary data (as supplied 1 October 2010). Data on file. NCT00481000. Dialectical cognitive traumatherapy (DCT) on patients with severe PTSD following sexual abuse (PASA) [Dialectical cognitive traumatherapy (DCT) on patients with severe posttraumatic stress disorder following sexual abuse - a randomised controlled trial]. clinicaltrials.gov/ct2/show/NCT00481000 (first received 31 May 2007). SteilR , DyerA , PriebeK , KleindienstN , BohusM . Dialectical behavior therapy for posttraumatic stress disorder related to childhood sexual abuse: a pilot study of an intensive treatment program. Journal of Traumatic Stress2011;24(1):102-6. [DOI: 10.1002/jts.20617] [PMID: 21351167]">Bohus 2013</a>; <a href="./references#CD012955-bbs2-0050" title="McMainSF , GuimondT , BarnhartR , HabinskiL , StreinerDL . A randomized trial of brief dialectical behaviour therapy skills training in suicidal patients suffering from borderline disorder. Acta Psychiatrica Scandinavica2017;135(2):138-48. [DOI: 10.1111/acps.12664] [PMID: 27858962]">McMain 2017</a>). </p> <p>Psychotherapy reduced BPD symptom severity at end of treatment compared with waiting list (SMD −0.49, 95% CI −0.93 to −0.5; 3 trials, 161 participants; I<sup>2</sup> = 44%; P = 0.03; <a href="./references#CD012955-fig-0130" title="">Analysis 15.1</a>; low‐quality evidence, <a href="./full#CD012955-tbl-0002">summary of findings Table 2</a>). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> </section> <section id="CD012955-sec-0250"> <h6 class="title">15.2 Self‐harm</h6> <p>Two trials reported continuous data on self‐harm (<a href="./references#CD012955-bbs2-0008" title="BellinoS , BozzatelloP , BogettoF . Combined treatment of borderline personality disorder with interpersonal psychotherapy and pharmacotherapy: predictors of response. Psychiatry Research2015;226(1):284-8. [DOI: 10.1016/j.psychres.2014.12.064] [isiarticles.com/bundles/Article/pre/pdf/34125.pdf]BellinoS , RinaldiC , BogettoF . Adaptation of interpersonal psychotherapy to borderline personality disorder: a comparison of combined therapy and single pharmacotherapy. Canadian Journal of Psychiatry2010;55(2):74-81. [DOI: 10.1177/070674371005500203] [PMID: 20181302]BellinoS . Question regarding your BPD trials for inclusion in Cochrane Collaboration review [personal communication]. Email to: J Stoffers-Winterling 19 December 2010. BellinoS . Re: question regarding your BPD trials [personal communication]. Email to: J Stoffers 16 December 2010. BozzatelloP , BellinoS . Combined therapy with interpersonal psychotherapy adapted for borderline personality disorder: a two-years follow-up. Psychiatry Research2016;240:151-6. [DOI: 10.1016/j.psychres.2016.04.014] [www.sciencedirect.com/science/article/pii/S0165178115302389]ZizzaM , FenocchioM , RinaldiC , BellinoS . Combined treatment of borderline personality disorder: a trial of modified interpersonal therapy. World Psychiatry2009;8(Suppl 1):234. ">Bellino 2010</a>; <a href="./references#CD012955-bbs2-0050" title="McMainSF , GuimondT , BarnhartR , HabinskiL , StreinerDL . A randomized trial of brief dialectical behaviour therapy skills training in suicidal patients suffering from borderline disorder. Acta Psychiatrica Scandinavica2017;135(2):138-48. [DOI: 10.1111/acps.12664] [PMID: 27858962]">McMain 2017</a>). </p> <p>Psychotherapy did not reduce self‐harm at end of treatment compared with waiting list (SMD −0.17, 95% CI −0.52 to 0.18; 2 trials, 128 participants; I<sup>2</sup> = 0%; P = 0.34; <a href="./references#CD012955-fig-0131" title="">Analysis 15.2</a>; low‐quality evidence, <a href="./full#CD012955-tbl-0002">summary of findings Table 2</a>). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> </section> <section id="CD012955-sec-0251"> <h6 class="title">15.3 Suicide‐related outcomes</h6> <p>Two trials reported continuous data on suicide‐related outcomes (<a href="./references#CD012955-bbs2-0050" title="McMainSF , GuimondT , BarnhartR , HabinskiL , StreinerDL . A randomized trial of brief dialectical behaviour therapy skills training in suicidal patients suffering from borderline disorder. Acta Psychiatrica Scandinavica2017;135(2):138-48. [DOI: 10.1111/acps.12664] [PMID: 27858962]">McMain 2017</a>; <a href="./references#CD012955-bbs2-0053" title="MohamadizadehL , MakvandiB , PashaR , BakhtiarpourS , HafeziF . Comparing of the effect of dialectical behavior therapy (DBT) and schema therapy (ST) on reducing mood activity and suicidal thoughts in patients with borderline personality disorder. Acta Medica Mediterranea2017;33:1025-31. [DOI: 10.19193/0393-6384_2017_6_162] [www.actamedicamediterranea.com/archive/2017/medica-6/comparing-of-the-effect-of-dialectical-behavior-therapy-dbt-and-schema-therapy-st-on-reducing-mood-activity-and-suicidal-thoughts-in-patients-with-borderline-personality-disorder/pdf]">Mohamadizadeh 2017</a>). </p> <p>Psychotherapy did not reduce suicide‐related outcomes at end of treatment compared with waiting list or no treatment (SMD −5.62, 95% CI −16.39 to 5.16; 2 trials, 108 participants; I<sup>2</sup> = 97%; P = 0.31; <a href="./references#CD012955-fig-0132" title="">Analysis 15.3</a>; very low‐quality evidence, <a href="./full#CD012955-tbl-0002">summary of findings Table 2</a>). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> </section> <section id="CD012955-sec-0252"> <h6 class="title">15.4 Psychosocial functioning</h6> <p>Five trials reported continuous data on psychosocial functioning (<a href="./references#CD012955-bbs2-0006" title="BellinoS , ParadisoE , ZizzaM , Di LorenzoR , BogettoF . Combined therapy with interpersonal psychotherapy of major depressed patients with borderline personality disorder: a comparison with pharmacotherapy [Terapia combinata con psicoterapia interpersonale di pazienti depressi maggiori con disturbo borderline di personalità: confronto con la farmacoterapia]. Journal of Psychopathology2005;11(1):34-42. [bit.ly/2rZUh5h]BellinoS , ZizzaM , RinaldiC , BogettoF . Combined treatment of major depression in patients with borderline personality disorder: a comparison with pharmacotherapy. Canadian Journal of Psychiatry2006;51(7):453-60. [DOI: 10.1177/070674370605100707] [PMID: 16838827]">Bellino 2006</a>; <a href="./references#CD012955-bbs2-0007" title="BellinoS , ZizzaM , RinaldiC , BogettoF . Combined therapy of major depression with concomitant borderline personality disorder: comparison of interpersonal and cognitive psychotherapy. Canadian Journal of Psychiatry2007;52(11):718-25. [DOI: 10.1177/070674370705201106] [PMID: 18399039]">Bellino 2007</a>; <a href="./references#CD012955-bbs2-0011" title="BohusM , DyerAS , PriebeK , KrügerA , KleindienstN , SchmahlC , et al. Dialectical behaviour therapy for post-traumatic stress disorder after childhood sexual abuse in patients with and without borderline personality disorder: a randomised controlled trial. Psychotherapy and Psychosomatics2013;82(4):221-33. [DOI: 10.1159/000348451] [PMID: 23712109]BrandS . AW: questions regarding your trial on emotional intelligence training for BPD [personal communication]. Email to: EG Faltinsen 28 November 2017. DBT Working Group at the Central Institute for Mental Health, Mannheim, Germany. Requested supplementary data (as supplied 1 October 2010). Data on file. NCT00481000. Dialectical cognitive traumatherapy (DCT) on patients with severe PTSD following sexual abuse (PASA) [Dialectical cognitive traumatherapy (DCT) on patients with severe posttraumatic stress disorder following sexual abuse - a randomised controlled trial]. clinicaltrials.gov/ct2/show/NCT00481000 (first received 31 May 2007). SteilR , DyerA , PriebeK , KleindienstN , BohusM . Dialectical behavior therapy for posttraumatic stress disorder related to childhood sexual abuse: a pilot study of an intensive treatment program. Journal of Traumatic Stress2011;24(1):102-6. [DOI: 10.1002/jts.20617] [PMID: 21351167]">Bohus 2013</a>; <a href="./references#CD012955-bbs2-0029" title="HaeyenS , Van HoorenS , HutschemaekersG . Efficacy of art therapy in individuals with personality disorders cluster B/C: a randomised controlled trial. International Journal of Psychology July 2016;51:60. [DOI: 10.1521/pedi_2017_31_312] [PMID: 28926306]HaeyenS , Van HoorenS , Van der VeldW , HutschemaekersG . Efficacy of art therapy in individuals with personality disorders cluster B/C: a randomised controlled trial. Journal of Personality Disorders2018;32(4):527-42. [DOI: 10.1521/pedi_2017_31_312] [PMID: 28926306]HaeyenS . Re: Cochrane Collaboration review of psychotherapies for BPD - your RCT of art therapy [personal communication]. Email to: J Stoffers-Winterling 18 August 2018. ">Haeyen 2018</a>; <a href="./references#CD012955-bbs2-0050" title="McMainSF , GuimondT , BarnhartR , HabinskiL , StreinerDL . A randomized trial of brief dialectical behaviour therapy skills training in suicidal patients suffering from borderline disorder. Acta Psychiatrica Scandinavica2017;135(2):138-48. [DOI: 10.1111/acps.12664] [PMID: 27858962]">McMain 2017</a>). </p> <p>Psychotherapy improved psychosocial functioning at end of treatment compared with waiting list (SMD −0.56, 95% CI −1.01 to −0.11; 5 trials, 219 participants; I<sup>2</sup> = 59%; P = 0.01; <a href="./references#CD012955-fig-0133" title="">Analysis 15.4</a>.1; low‐quality evidence, <a href="./full#CD012955-tbl-0002">summary of findings Table 2</a>). </p> <p>Psychotherapy improved psychosocial functioning at zero to six months follow‐up compared with waiting list (SMD −0.89, 95% CI −1.65 to −0.13; 1 trial, 30 participants; P = 0.02; MD −12.39, 95% CI −22.00 to −2.78; 1 trial, 30 participants; P = 0.01; <a href="./references#CD012955-fig-0133" title="">Analysis 15.4</a>.2). </p> <p>Psychotherapy improved psychosocial functioning at six to 12 months follow‐up compared with waiting list (SMD −1.04, 95% CI −1.81 to −0.27; 1 trial, 30 participants; P = 0.008: MD −13.59, 95% CI −22.65 to −4.53; 1 trial, 30 participants; P = 0.003; <a href="./references#CD012955-fig-0133" title="">Analysis 15.4</a>.3). </p> <p>Psychotherapy did not improve psychosocial functioning at above 12 months follow‐up compared with waiting list (SMD −0.38, 95% CI −1.14 to 0.37; 1 trial, 28 participants; P = 0.32; MD −14.68, 95% CI −46.63 to 17.27; 1 trial, 28 participants; P = 0.37; <a href="./references#CD012955-fig-0133" title="">Analysis 15.4</a>.4). </p> </section> </section> <section id="CD012955-sec-0253"> <h5 class="title">Secondary outcomes</h5> <section id="CD012955-sec-0254"> <h6 class="title">15.5 Anger</h6> <p>Two trials reported continuous data on anger (<a href="./references#CD012955-bbs2-0008" title="BellinoS , BozzatelloP , BogettoF . Combined treatment of borderline personality disorder with interpersonal psychotherapy and pharmacotherapy: predictors of response. Psychiatry Research2015;226(1):284-8. [DOI: 10.1016/j.psychres.2014.12.064] [isiarticles.com/bundles/Article/pre/pdf/34125.pdf]BellinoS , RinaldiC , BogettoF . Adaptation of interpersonal psychotherapy to borderline personality disorder: a comparison of combined therapy and single pharmacotherapy. Canadian Journal of Psychiatry2010;55(2):74-81. [DOI: 10.1177/070674371005500203] [PMID: 20181302]BellinoS . Question regarding your BPD trials for inclusion in Cochrane Collaboration review [personal communication]. Email to: J Stoffers-Winterling 19 December 2010. BellinoS . Re: question regarding your BPD trials [personal communication]. Email to: J Stoffers 16 December 2010. BozzatelloP , BellinoS . Combined therapy with interpersonal psychotherapy adapted for borderline personality disorder: a two-years follow-up. Psychiatry Research2016;240:151-6. [DOI: 10.1016/j.psychres.2016.04.014] [www.sciencedirect.com/science/article/pii/S0165178115302389]ZizzaM , FenocchioM , RinaldiC , BellinoS . Combined treatment of borderline personality disorder: a trial of modified interpersonal therapy. World Psychiatry2009;8(Suppl 1):234. ">Bellino 2010</a>; <a href="./references#CD012955-bbs2-0050" title="McMainSF , GuimondT , BarnhartR , HabinskiL , StreinerDL . A randomized trial of brief dialectical behaviour therapy skills training in suicidal patients suffering from borderline disorder. Acta Psychiatrica Scandinavica2017;135(2):138-48. [DOI: 10.1111/acps.12664] [PMID: 27858962]">McMain 2017</a>). </p> <p>Psychotherapy did not reduce anger at end of treatment compared with waiting list (SMD −0.58, 95% CI −1.70 to 0.55; 2 trials, 128 participants; I<sup>2</sup> = 89%; P = 0.32; <a href="./references#CD012955-fig-0134" title="">Analysis 15.5</a>, random‐effects model). </p> <p>Psychotherapy reduced anger at end of treatment compared with waiting list (SMD −0.70, 95% CI −1.06 to −0.33; 2 trials, 128 participants; I<sup>2</sup> = 89%; P = 0.0002; analysis not shown; fixed‐effect model). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> </section> <section id="CD012955-sec-0255"> <h6 class="title">15.6 Affective instability</h6> <p>Two trials reported continuous data on affective instability (<a href="./references#CD012955-bbs2-0008" title="BellinoS , BozzatelloP , BogettoF . Combined treatment of borderline personality disorder with interpersonal psychotherapy and pharmacotherapy: predictors of response. Psychiatry Research2015;226(1):284-8. [DOI: 10.1016/j.psychres.2014.12.064] [isiarticles.com/bundles/Article/pre/pdf/34125.pdf]BellinoS , RinaldiC , BogettoF . Adaptation of interpersonal psychotherapy to borderline personality disorder: a comparison of combined therapy and single pharmacotherapy. Canadian Journal of Psychiatry2010;55(2):74-81. [DOI: 10.1177/070674371005500203] [PMID: 20181302]BellinoS . Question regarding your BPD trials for inclusion in Cochrane Collaboration review [personal communication]. Email to: J Stoffers-Winterling 19 December 2010. BellinoS . Re: question regarding your BPD trials [personal communication]. Email to: J Stoffers 16 December 2010. BozzatelloP , BellinoS . Combined therapy with interpersonal psychotherapy adapted for borderline personality disorder: a two-years follow-up. Psychiatry Research2016;240:151-6. [DOI: 10.1016/j.psychres.2016.04.014] [www.sciencedirect.com/science/article/pii/S0165178115302389]ZizzaM , FenocchioM , RinaldiC , BellinoS . Combined treatment of borderline personality disorder: a trial of modified interpersonal therapy. World Psychiatry2009;8(Suppl 1):234. ">Bellino 2010</a>; <a href="./references#CD012955-bbs2-0050" title="McMainSF , GuimondT , BarnhartR , HabinskiL , StreinerDL . A randomized trial of brief dialectical behaviour therapy skills training in suicidal patients suffering from borderline disorder. Acta Psychiatrica Scandinavica2017;135(2):138-48. [DOI: 10.1111/acps.12664] [PMID: 27858962]">McMain 2017</a>). </p> <p>Psychotherapy reduced affective instability at end of treatment compared with waiting list (SMD −0.99, 95% CI −1.36 to −0.62; 2 trials, 128 participants; I<sup>2</sup> = 0%; P &lt; 0.001; <a href="./references#CD012955-fig-0135" title="">Analysis 15.6</a>.1). </p> <p>Psychotherapy did not reduce affective instability at zero to six months follow‐up compared with waiting list (SMD −0.47, 95% CI −1.20 to 0.26; 1 trial, 30 participants; P = 0.21; MD −0.46, 95% CI −1.15 to 0.23; 1 trial, 30 participants; P = 0.19; <a href="./references#CD012955-fig-0135" title="">Analysis 15.6</a>.2). </p> <p>Psychotherapy did not reduce affective instability at six to 12 months follow‐up compared with waiting list (SMD −0.38, 95% CI −1.10 to 0.34; 1 trial, 30 participants; P = 0.30; MD −0.39, 95% CI −1.12 to 0.34; 1 trial, 30 participants; P = 0.29; <a href="./references#CD012955-fig-0135" title="">Analysis 15.6</a>.3). </p> <p>Psychotherapy did not reduce affective instability at above 12 months follow‐up compared with waiting list (SMD −0.28, 95% CI −1.01 to 0.44; 1 trial, 30 participants; P = 0.44; MD −0.34, 95% CI −1.17 to 0.49; 1 trial, 30 participants; P = 0.42; <a href="./references#CD012955-fig-0135" title="">Analysis 15.6</a>.4). </p> </section> <section id="CD012955-sec-0256"> <h6 class="title">15.7 Chronic feelings of emptiness</h6> <p>One trial reported continuous data on chronic feelings of emptiness (<a href="./references#CD012955-bbs2-0008" title="BellinoS , BozzatelloP , BogettoF . Combined treatment of borderline personality disorder with interpersonal psychotherapy and pharmacotherapy: predictors of response. Psychiatry Research2015;226(1):284-8. [DOI: 10.1016/j.psychres.2014.12.064] [isiarticles.com/bundles/Article/pre/pdf/34125.pdf]BellinoS , RinaldiC , BogettoF . Adaptation of interpersonal psychotherapy to borderline personality disorder: a comparison of combined therapy and single pharmacotherapy. Canadian Journal of Psychiatry2010;55(2):74-81. [DOI: 10.1177/070674371005500203] [PMID: 20181302]BellinoS . Question regarding your BPD trials for inclusion in Cochrane Collaboration review [personal communication]. Email to: J Stoffers-Winterling 19 December 2010. BellinoS . Re: question regarding your BPD trials [personal communication]. Email to: J Stoffers 16 December 2010. BozzatelloP , BellinoS . Combined therapy with interpersonal psychotherapy adapted for borderline personality disorder: a two-years follow-up. Psychiatry Research2016;240:151-6. [DOI: 10.1016/j.psychres.2016.04.014] [www.sciencedirect.com/science/article/pii/S0165178115302389]ZizzaM , FenocchioM , RinaldiC , BellinoS . Combined treatment of borderline personality disorder: a trial of modified interpersonal therapy. World Psychiatry2009;8(Suppl 1):234. ">Bellino 2010</a>). </p> <p>Psychotherapy did not reduce chronic feelings of emptiness at end of treatment compared with waiting list (MD 0.04, 95% CI −0.21 to 0.29; 1 trial, 44 participants; P = 0.75; <a href="./references#CD012955-fig-0136" title="">Analysis 15.7</a>). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> </section> <section id="CD012955-sec-0257"> <h6 class="title">15.8 Impulsivity</h6> <p>Three trials reported continuous data on impulsivity (<a href="./references#CD012955-bbs2-0008" title="BellinoS , BozzatelloP , BogettoF . Combined treatment of borderline personality disorder with interpersonal psychotherapy and pharmacotherapy: predictors of response. Psychiatry Research2015;226(1):284-8. [DOI: 10.1016/j.psychres.2014.12.064] [isiarticles.com/bundles/Article/pre/pdf/34125.pdf]BellinoS , RinaldiC , BogettoF . Adaptation of interpersonal psychotherapy to borderline personality disorder: a comparison of combined therapy and single pharmacotherapy. Canadian Journal of Psychiatry2010;55(2):74-81. [DOI: 10.1177/070674371005500203] [PMID: 20181302]BellinoS . Question regarding your BPD trials for inclusion in Cochrane Collaboration review [personal communication]. Email to: J Stoffers-Winterling 19 December 2010. BellinoS . Re: question regarding your BPD trials [personal communication]. Email to: J Stoffers 16 December 2010. BozzatelloP , BellinoS . Combined therapy with interpersonal psychotherapy adapted for borderline personality disorder: a two-years follow-up. Psychiatry Research2016;240:151-6. [DOI: 10.1016/j.psychres.2016.04.014] [www.sciencedirect.com/science/article/pii/S0165178115302389]ZizzaM , FenocchioM , RinaldiC , BellinoS . Combined treatment of borderline personality disorder: a trial of modified interpersonal therapy. World Psychiatry2009;8(Suppl 1):234. ">Bellino 2010</a>; <a href="./references#CD012955-bbs2-0050" title="McMainSF , GuimondT , BarnhartR , HabinskiL , StreinerDL . A randomized trial of brief dialectical behaviour therapy skills training in suicidal patients suffering from borderline disorder. Acta Psychiatrica Scandinavica2017;135(2):138-48. [DOI: 10.1111/acps.12664] [PMID: 27858962]">McMain 2017</a>; <a href="./references#CD012955-bbs2-0074" title="ZanariniMC , FrankenburgFR . A preliminary, randomized trial of psychoeducation for women with borderline personality disorder. Journal of Personality Disorders2008;22(3):284-90. [DOI: 10.1521/pedi.2008.22.3.284] [PMID: 18540800]ZanariniMC , FrankenburgFR . A randomized trial of psychoeducation for patients with BPD. In: 157th annual meeting of the American Psychiatric Association. Psychotherapy and psychopharmacology: dissolving the mind-brain barrier; 2004 May 1-6; New York (NY). Arlington (VA): American Psychiatric Association, 2004:102. [Symposium 100E] [www.psychiatry.org/File%20Library/Psychiatrists/Directories/Library-and-Archive/conference_publications/am_program_2004.pdf]">Zanarini 2008</a>). </p> <p>Psychotherapy reduced impulsivity at end of treatment compared with waiting list (SMD −0.52, 95% CI −0.82 to ‐0.22; 3 trials, 178 participants; I<sup>2</sup> = 0%; P = 0.0007; <a href="./references#CD012955-fig-0137" title="">Analysis 15.8</a>.1). </p> <p>Psychotherapy reduced impulsivity at zero to six months follow‐up compared with waiting list (SMD −0.90, 95% CI −1.66 to −0.14; 1 trial, 30 participants; P = 0.02; MD −1.10, 95% CI −1.95 to −0.25; 1 trial, 30 participants; P = 0.01; <a href="./references#CD012955-fig-0137" title="">Analysis 15.8</a>.2). </p> <p>Psychotherapy reduced impulsivity at six to 12 months follow‐up compared with waiting list (SMD −0.79, 95% CI −1.54 to −0.04; 1 trial, 30 participants; P = 0.04; MD −1.10, 95% CI −2.06 to −0.14; 1 trial, 30 participants; P = 0.02; <a href="./references#CD012955-fig-0137" title="">Analysis 15.8</a>.3). </p> <p>Psychotherapy reduced impulsivity at above 12 months follow‐up compared with waiting list (SMD −0.75, 95% CI −1.50 to −0.01; 1 trial, 30 participants; P = 0.05; MD −1.09, 95% CI −2.09 to ‐0.09; 1 trial, 30 participants; P = 0.03; <a href="./references#CD012955-fig-0137" title="">Analysis 15.8</a>.4). </p> </section> <section id="CD012955-sec-0258"> <h6 class="title">15.9 Interpersonal problems</h6> <p>Three trials reported continuous data on interpersonal problems (<a href="./references#CD012955-bbs2-0008" title="BellinoS , BozzatelloP , BogettoF . Combined treatment of borderline personality disorder with interpersonal psychotherapy and pharmacotherapy: predictors of response. Psychiatry Research2015;226(1):284-8. [DOI: 10.1016/j.psychres.2014.12.064] [isiarticles.com/bundles/Article/pre/pdf/34125.pdf]BellinoS , RinaldiC , BogettoF . Adaptation of interpersonal psychotherapy to borderline personality disorder: a comparison of combined therapy and single pharmacotherapy. Canadian Journal of Psychiatry2010;55(2):74-81. [DOI: 10.1177/070674371005500203] [PMID: 20181302]BellinoS . Question regarding your BPD trials for inclusion in Cochrane Collaboration review [personal communication]. Email to: J Stoffers-Winterling 19 December 2010. BellinoS . Re: question regarding your BPD trials [personal communication]. Email to: J Stoffers 16 December 2010. BozzatelloP , BellinoS . Combined therapy with interpersonal psychotherapy adapted for borderline personality disorder: a two-years follow-up. Psychiatry Research2016;240:151-6. [DOI: 10.1016/j.psychres.2016.04.014] [www.sciencedirect.com/science/article/pii/S0165178115302389]ZizzaM , FenocchioM , RinaldiC , BellinoS . Combined treatment of borderline personality disorder: a trial of modified interpersonal therapy. World Psychiatry2009;8(Suppl 1):234. ">Bellino 2010</a>; <a href="./references#CD012955-bbs2-0029" title="HaeyenS , Van HoorenS , HutschemaekersG . Efficacy of art therapy in individuals with personality disorders cluster B/C: a randomised controlled trial. International Journal of Psychology July 2016;51:60. [DOI: 10.1521/pedi_2017_31_312] [PMID: 28926306]HaeyenS , Van HoorenS , Van der VeldW , HutschemaekersG . Efficacy of art therapy in individuals with personality disorders cluster B/C: a randomised controlled trial. Journal of Personality Disorders2018;32(4):527-42. [DOI: 10.1521/pedi_2017_31_312] [PMID: 28926306]HaeyenS . Re: Cochrane Collaboration review of psychotherapies for BPD - your RCT of art therapy [personal communication]. Email to: J Stoffers-Winterling 18 August 2018. ">Haeyen 2018</a>; <a href="./references#CD012955-bbs2-0074" title="ZanariniMC , FrankenburgFR . A preliminary, randomized trial of psychoeducation for women with borderline personality disorder. Journal of Personality Disorders2008;22(3):284-90. [DOI: 10.1521/pedi.2008.22.3.284] [PMID: 18540800]ZanariniMC , FrankenburgFR . A randomized trial of psychoeducation for patients with BPD. In: 157th annual meeting of the American Psychiatric Association. Psychotherapy and psychopharmacology: dissolving the mind-brain barrier; 2004 May 1-6; New York (NY). Arlington (VA): American Psychiatric Association, 2004:102. [Symposium 100E] [www.psychiatry.org/File%20Library/Psychiatrists/Directories/Library-and-Archive/conference_publications/am_program_2004.pdf]">Zanarini 2008</a>). </p> <p>Psychotherapy reduced interpersonal problems at end of treatment compared with waiting list (SMD −0.85, 95% CI −1.23 to −0.47; 3 trials, 120 participants; I<sup>2</sup> = 0%; P &lt; 0.001; <a href="./references#CD012955-fig-0138" title="">Analysis 15.9</a>.1). </p> <p>Psychotherapy reduced interpersonal problems at zero to six months follow‐up compared with waiting list (SMD −1.40, 95% CI −2.21 to −0.59; 1 trial, 30 participants; P = 0.0007; MD −2.00, 95% CI −2.98 to −1.02; 1 trial, 30 participants; P &lt; 0.001; <a href="./references#CD012955-fig-0138" title="">Analysis 15.9</a>.2). </p> <p>Psychotherapy reduced interpersonal problems at six to 12 months follow‐up compared with waiting list (SMD −0.90, 95% CI −1.66 to −0.14; 1 trial, 30 participants; P = 0.02; MD −1.56, 95% CI −2.74 to −0.38; 1 trial, 30 participants; P = 0.009; <a href="./references#CD012955-fig-0138" title="">Analysis 15.9</a>.3). </p> <p>Psychotherapy reduced interpersonal problems at above 12 months follow‐up compared with waiting list (SMD −0.86, 95% CI −1.62 to −0.11; 1 trial, 30 participants; P = 0.02; MD −1.48, 95% CI −2.63 to −0.33; 1 trial, 30 participants; P = 0.01; <a href="./references#CD012955-fig-0138" title="">Analysis 15.9</a>.4). </p> </section> <section id="CD012955-sec-0259"> <h6 class="title">15.10 Abandonment</h6> <p>One trial reported continuous data on abandonment (<a href="./references#CD012955-bbs2-0008" title="BellinoS , BozzatelloP , BogettoF . Combined treatment of borderline personality disorder with interpersonal psychotherapy and pharmacotherapy: predictors of response. Psychiatry Research2015;226(1):284-8. [DOI: 10.1016/j.psychres.2014.12.064] [isiarticles.com/bundles/Article/pre/pdf/34125.pdf]BellinoS , RinaldiC , BogettoF . Adaptation of interpersonal psychotherapy to borderline personality disorder: a comparison of combined therapy and single pharmacotherapy. Canadian Journal of Psychiatry2010;55(2):74-81. [DOI: 10.1177/070674371005500203] [PMID: 20181302]BellinoS . Question regarding your BPD trials for inclusion in Cochrane Collaboration review [personal communication]. Email to: J Stoffers-Winterling 19 December 2010. BellinoS . Re: question regarding your BPD trials [personal communication]. Email to: J Stoffers 16 December 2010. BozzatelloP , BellinoS . Combined therapy with interpersonal psychotherapy adapted for borderline personality disorder: a two-years follow-up. Psychiatry Research2016;240:151-6. [DOI: 10.1016/j.psychres.2016.04.014] [www.sciencedirect.com/science/article/pii/S0165178115302389]ZizzaM , FenocchioM , RinaldiC , BellinoS . Combined treatment of borderline personality disorder: a trial of modified interpersonal therapy. World Psychiatry2009;8(Suppl 1):234. ">Bellino 2010</a>). </p> <p>Psychotherapy did not reduce abandonment at end of treatment compared with waiting list (MD 0.01, 95% CI −0.90 to 0.92; 1 trial, 44 participants; P = 0.98; <a href="./references#CD012955-fig-0139" title="">Analysis 15.10</a>). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> </section> <section id="CD012955-sec-0260"> <h6 class="title">15.11 Identity disturbance</h6> <p>One trial reported continuous data on identity disturbance (<a href="./references#CD012955-bbs2-0008" title="BellinoS , BozzatelloP , BogettoF . Combined treatment of borderline personality disorder with interpersonal psychotherapy and pharmacotherapy: predictors of response. Psychiatry Research2015;226(1):284-8. [DOI: 10.1016/j.psychres.2014.12.064] [isiarticles.com/bundles/Article/pre/pdf/34125.pdf]BellinoS , RinaldiC , BogettoF . Adaptation of interpersonal psychotherapy to borderline personality disorder: a comparison of combined therapy and single pharmacotherapy. Canadian Journal of Psychiatry2010;55(2):74-81. [DOI: 10.1177/070674371005500203] [PMID: 20181302]BellinoS . Question regarding your BPD trials for inclusion in Cochrane Collaboration review [personal communication]. Email to: J Stoffers-Winterling 19 December 2010. BellinoS . Re: question regarding your BPD trials [personal communication]. Email to: J Stoffers 16 December 2010. BozzatelloP , BellinoS . Combined therapy with interpersonal psychotherapy adapted for borderline personality disorder: a two-years follow-up. Psychiatry Research2016;240:151-6. [DOI: 10.1016/j.psychres.2016.04.014] [www.sciencedirect.com/science/article/pii/S0165178115302389]ZizzaM , FenocchioM , RinaldiC , BellinoS . Combined treatment of borderline personality disorder: a trial of modified interpersonal therapy. World Psychiatry2009;8(Suppl 1):234. ">Bellino 2010</a>). </p> <p>Psychotherapy did not reduce identity disturbance at end of treatment compared with waiting list (MD −0.03, 95% CI −0.56 to 0.50; 1 trial, 44 participants; P = 0.91; <a href="./references#CD012955-fig-0140" title="">Analysis 15.11</a>). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> </section> <section id="CD012955-sec-0261"> <h6 class="title">15.12 Dissociation and psychotic‐like</h6> <p>Two trials reported continuous data on dissociation and psychotic‐like symptoms (<a href="./references#CD012955-bbs2-0008" title="BellinoS , BozzatelloP , BogettoF . Combined treatment of borderline personality disorder with interpersonal psychotherapy and pharmacotherapy: predictors of response. Psychiatry Research2015;226(1):284-8. [DOI: 10.1016/j.psychres.2014.12.064] [isiarticles.com/bundles/Article/pre/pdf/34125.pdf]BellinoS , RinaldiC , BogettoF . Adaptation of interpersonal psychotherapy to borderline personality disorder: a comparison of combined therapy and single pharmacotherapy. Canadian Journal of Psychiatry2010;55(2):74-81. [DOI: 10.1177/070674371005500203] [PMID: 20181302]BellinoS . Question regarding your BPD trials for inclusion in Cochrane Collaboration review [personal communication]. Email to: J Stoffers-Winterling 19 December 2010. BellinoS . Re: question regarding your BPD trials [personal communication]. Email to: J Stoffers 16 December 2010. BozzatelloP , BellinoS . Combined therapy with interpersonal psychotherapy adapted for borderline personality disorder: a two-years follow-up. Psychiatry Research2016;240:151-6. [DOI: 10.1016/j.psychres.2016.04.014] [www.sciencedirect.com/science/article/pii/S0165178115302389]ZizzaM , FenocchioM , RinaldiC , BellinoS . Combined treatment of borderline personality disorder: a trial of modified interpersonal therapy. World Psychiatry2009;8(Suppl 1):234. ">Bellino 2010</a>; <a href="./references#CD012955-bbs2-0011" title="BohusM , DyerAS , PriebeK , KrügerA , KleindienstN , SchmahlC , et al. Dialectical behaviour therapy for post-traumatic stress disorder after childhood sexual abuse in patients with and without borderline personality disorder: a randomised controlled trial. Psychotherapy and Psychosomatics2013;82(4):221-33. [DOI: 10.1159/000348451] [PMID: 23712109]BrandS . AW: questions regarding your trial on emotional intelligence training for BPD [personal communication]. Email to: EG Faltinsen 28 November 2017. DBT Working Group at the Central Institute for Mental Health, Mannheim, Germany. Requested supplementary data (as supplied 1 October 2010). Data on file. NCT00481000. Dialectical cognitive traumatherapy (DCT) on patients with severe PTSD following sexual abuse (PASA) [Dialectical cognitive traumatherapy (DCT) on patients with severe posttraumatic stress disorder following sexual abuse - a randomised controlled trial]. clinicaltrials.gov/ct2/show/NCT00481000 (first received 31 May 2007). SteilR , DyerA , PriebeK , KleindienstN , BohusM . Dialectical behavior therapy for posttraumatic stress disorder related to childhood sexual abuse: a pilot study of an intensive treatment program. Journal of Traumatic Stress2011;24(1):102-6. [DOI: 10.1002/jts.20617] [PMID: 21351167]">Bohus 2013</a>). </p> <p>Psychotherapy did not reduce dissociation and psychotic‐like symptoms at end of treatment compared with waiting list (SMD −0.13, 95% CI −0.65 to 0.39; 2 trials, 77 participants; I<sup>2</sup> = 24%; P = 0.62; <a href="./references#CD012955-fig-0141" title="">Analysis 15.12</a>). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> </section> <section id="CD012955-sec-0262"> <h6 class="title">15.13 Depression</h6> <p>Six trials reported continuous data on depression (<a href="./references#CD012955-bbs2-0006" title="BellinoS , ParadisoE , ZizzaM , Di LorenzoR , BogettoF . Combined therapy with interpersonal psychotherapy of major depressed patients with borderline personality disorder: a comparison with pharmacotherapy [Terapia combinata con psicoterapia interpersonale di pazienti depressi maggiori con disturbo borderline di personalità: confronto con la farmacoterapia]. Journal of Psychopathology2005;11(1):34-42. [bit.ly/2rZUh5h]BellinoS , ZizzaM , RinaldiC , BogettoF . Combined treatment of major depression in patients with borderline personality disorder: a comparison with pharmacotherapy. Canadian Journal of Psychiatry2006;51(7):453-60. [DOI: 10.1177/070674370605100707] [PMID: 16838827]">Bellino 2006</a>; <a href="./references#CD012955-bbs2-0007" title="BellinoS , ZizzaM , RinaldiC , BogettoF . Combined therapy of major depression with concomitant borderline personality disorder: comparison of interpersonal and cognitive psychotherapy. Canadian Journal of Psychiatry2007;52(11):718-25. [DOI: 10.1177/070674370705201106] [PMID: 18399039]">Bellino 2007</a>; <a href="./references#CD012955-bbs2-0011" title="BohusM , DyerAS , PriebeK , KrügerA , KleindienstN , SchmahlC , et al. Dialectical behaviour therapy for post-traumatic stress disorder after childhood sexual abuse in patients with and without borderline personality disorder: a randomised controlled trial. Psychotherapy and Psychosomatics2013;82(4):221-33. [DOI: 10.1159/000348451] [PMID: 23712109]BrandS . AW: questions regarding your trial on emotional intelligence training for BPD [personal communication]. Email to: EG Faltinsen 28 November 2017. DBT Working Group at the Central Institute for Mental Health, Mannheim, Germany. Requested supplementary data (as supplied 1 October 2010). Data on file. NCT00481000. Dialectical cognitive traumatherapy (DCT) on patients with severe PTSD following sexual abuse (PASA) [Dialectical cognitive traumatherapy (DCT) on patients with severe posttraumatic stress disorder following sexual abuse - a randomised controlled trial]. clinicaltrials.gov/ct2/show/NCT00481000 (first received 31 May 2007). SteilR , DyerA , PriebeK , KleindienstN , BohusM . Dialectical behavior therapy for posttraumatic stress disorder related to childhood sexual abuse: a pilot study of an intensive treatment program. Journal of Traumatic Stress2011;24(1):102-6. [DOI: 10.1002/jts.20617] [PMID: 21351167]">Bohus 2013</a>; <a href="./references#CD012955-bbs2-0050" title="McMainSF , GuimondT , BarnhartR , HabinskiL , StreinerDL . A randomized trial of brief dialectical behaviour therapy skills training in suicidal patients suffering from borderline disorder. Acta Psychiatrica Scandinavica2017;135(2):138-48. [DOI: 10.1111/acps.12664] [PMID: 27858962]">McMain 2017</a>; <a href="./references#CD012955-bbs2-0053" title="MohamadizadehL , MakvandiB , PashaR , BakhtiarpourS , HafeziF . Comparing of the effect of dialectical behavior therapy (DBT) and schema therapy (ST) on reducing mood activity and suicidal thoughts in patients with borderline personality disorder. Acta Medica Mediterranea2017;33:1025-31. [DOI: 10.19193/0393-6384_2017_6_162] [www.actamedicamediterranea.com/archive/2017/medica-6/comparing-of-the-effect-of-dialectical-behavior-therapy-dbt-and-schema-therapy-st-on-reducing-mood-activity-and-suicidal-thoughts-in-patients-with-borderline-personality-disorder/pdf]">Mohamadizadeh 2017</a>; <a href="./references#CD012955-bbs2-0068" title="SmithPN , GambleSA , CortNA , WardEA , HeH , TalbotNL . Attachment and alliance in the treatment of depressed, sexually abused women. Depression and Anxiety2012;29(2):123-30. [DOI: 10.1002/da.20913] [PMC3325338] [PMID: 22065593]SmithPN . Re: Cochrane Collaboration review of psychotherapies for BPD [personal communication]. Email to: J Stoffers-Winterling 05 July 2018. ">Smith 2012</a>). </p> <p>Psychotherapy reduced depression at end of treatment compared with waiting list or no treatment (SMD −1.28, 95% CI −2.21 to −0.34; 6 trials, 239 participants; I<sup>2</sup> = 89%; P = 0.007; <a href="./references#CD012955-fig-0142" title="">Analysis 15.13</a>; low‐quality evidence, <a href="./full#CD012955-tbl-0002">summary of findings Table 2</a>). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> </section> <section id="CD012955-sec-0263"> <h6 class="title">15.14 Attrition</h6> <p>Three trials reported dichotomous data on attrition (<a href="./references#CD012955-bbs2-0006" title="BellinoS , ParadisoE , ZizzaM , Di LorenzoR , BogettoF . Combined therapy with interpersonal psychotherapy of major depressed patients with borderline personality disorder: a comparison with pharmacotherapy [Terapia combinata con psicoterapia interpersonale di pazienti depressi maggiori con disturbo borderline di personalità: confronto con la farmacoterapia]. Journal of Psychopathology2005;11(1):34-42. [bit.ly/2rZUh5h]BellinoS , ZizzaM , RinaldiC , BogettoF . Combined treatment of major depression in patients with borderline personality disorder: a comparison with pharmacotherapy. Canadian Journal of Psychiatry2006;51(7):453-60. [DOI: 10.1177/070674370605100707] [PMID: 16838827]">Bellino 2006</a>; <a href="./references#CD012955-bbs2-0008" title="BellinoS , BozzatelloP , BogettoF . Combined treatment of borderline personality disorder with interpersonal psychotherapy and pharmacotherapy: predictors of response. Psychiatry Research2015;226(1):284-8. [DOI: 10.1016/j.psychres.2014.12.064] [isiarticles.com/bundles/Article/pre/pdf/34125.pdf]BellinoS , RinaldiC , BogettoF . Adaptation of interpersonal psychotherapy to borderline personality disorder: a comparison of combined therapy and single pharmacotherapy. Canadian Journal of Psychiatry2010;55(2):74-81. [DOI: 10.1177/070674371005500203] [PMID: 20181302]BellinoS . Question regarding your BPD trials for inclusion in Cochrane Collaboration review [personal communication]. Email to: J Stoffers-Winterling 19 December 2010. BellinoS . Re: question regarding your BPD trials [personal communication]. Email to: J Stoffers 16 December 2010. BozzatelloP , BellinoS . Combined therapy with interpersonal psychotherapy adapted for borderline personality disorder: a two-years follow-up. Psychiatry Research2016;240:151-6. [DOI: 10.1016/j.psychres.2016.04.014] [www.sciencedirect.com/science/article/pii/S0165178115302389]ZizzaM , FenocchioM , RinaldiC , BellinoS . Combined treatment of borderline personality disorder: a trial of modified interpersonal therapy. World Psychiatry2009;8(Suppl 1):234. ">Bellino 2010</a>; <a href="./references#CD012955-bbs2-0074" title="ZanariniMC , FrankenburgFR . A preliminary, randomized trial of psychoeducation for women with borderline personality disorder. Journal of Personality Disorders2008;22(3):284-90. [DOI: 10.1521/pedi.2008.22.3.284] [PMID: 18540800]ZanariniMC , FrankenburgFR . A randomized trial of psychoeducation for patients with BPD. In: 157th annual meeting of the American Psychiatric Association. Psychotherapy and psychopharmacology: dissolving the mind-brain barrier; 2004 May 1-6; New York (NY). Arlington (VA): American Psychiatric Association, 2004:102. [Symposium 100E] [www.psychiatry.org/File%20Library/Psychiatrists/Directories/Library-and-Archive/conference_publications/am_program_2004.pdf]">Zanarini 2008</a>). </p> <p>Psychotherapy did not reduce attrition at end of treatment compared with waiting list (RR 0.55, 95% CI 0.20 to 1.50; 3 trials, 144 participants; I<sup>2</sup> = 0%; P = 0.24; <a href="./references#CD012955-fig-0143" title="">Analysis 15.14</a>; very low‐quality evidence, <a href="./full#CD012955-tbl-0002">summary of findings Table 2</a>). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> <p>No data were available on any time point for adverse effects.</p> </section> </section> </section> <section id="CD012955-sec-0264"> <h4 class="title">16. Dialectical behaviour therapy (DBT) versus waiting list or no treatment</h4> <section id="CD012955-sec-0265"> <h5 class="title">Primary outcomes</h5> <section id="CD012955-sec-0266"> <h6 class="title">16.1 BPD symptom severity</h6> <p>Two trials reported continuous data on BPD symptom severity (<a href="./references#CD012955-bbs2-0011" title="BohusM , DyerAS , PriebeK , KrügerA , KleindienstN , SchmahlC , et al. Dialectical behaviour therapy for post-traumatic stress disorder after childhood sexual abuse in patients with and without borderline personality disorder: a randomised controlled trial. Psychotherapy and Psychosomatics2013;82(4):221-33. [DOI: 10.1159/000348451] [PMID: 23712109]BrandS . AW: questions regarding your trial on emotional intelligence training for BPD [personal communication]. Email to: EG Faltinsen 28 November 2017. DBT Working Group at the Central Institute for Mental Health, Mannheim, Germany. Requested supplementary data (as supplied 1 October 2010). Data on file. NCT00481000. Dialectical cognitive traumatherapy (DCT) on patients with severe PTSD following sexual abuse (PASA) [Dialectical cognitive traumatherapy (DCT) on patients with severe posttraumatic stress disorder following sexual abuse - a randomised controlled trial]. clinicaltrials.gov/ct2/show/NCT00481000 (first received 31 May 2007). SteilR , DyerA , PriebeK , KleindienstN , BohusM . Dialectical behavior therapy for posttraumatic stress disorder related to childhood sexual abuse: a pilot study of an intensive treatment program. Journal of Traumatic Stress2011;24(1):102-6. [DOI: 10.1002/jts.20617] [PMID: 21351167]">Bohus 2013</a>; <a href="./references#CD012955-bbs2-0050" title="McMainSF , GuimondT , BarnhartR , HabinskiL , StreinerDL . A randomized trial of brief dialectical behaviour therapy skills training in suicidal patients suffering from borderline disorder. Acta Psychiatrica Scandinavica2017;135(2):138-48. [DOI: 10.1111/acps.12664] [PMID: 27858962]">McMain 2017</a>). </p> <p>DBT reduced BPD symptom severity at end of treatment compared with waiting list (SMD −0.71, 95% CI −1.08 to −0.33; 2 trials, 117 participants; I<sup>2</sup> = 0%; P = 0.0002; <a href="./references#CD012955-fig-0144" title="">Analysis 16.1</a>). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> </section> <section id="CD012955-sec-0267"> <h6 class="title">16.2 Self‐harm</h6> <p>One trial reported continuous data on self‐harm (<a href="./references#CD012955-bbs2-0050" title="McMainSF , GuimondT , BarnhartR , HabinskiL , StreinerDL . A randomized trial of brief dialectical behaviour therapy skills training in suicidal patients suffering from borderline disorder. Acta Psychiatrica Scandinavica2017;135(2):138-48. [DOI: 10.1111/acps.12664] [PMID: 27858962]">McMain 2017</a>). </p> <p>DBT did not reduce self‐harm at end of treatment compared with waiting list (MD −1.45, 95% CI −3.76 to 0.86; 1 trial, 84 participants; P = 0.22; <a href="./references#CD012955-fig-0145" title="">Analysis 16.2</a>). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> </section> <section id="CD012955-sec-0268"> <h6 class="title">16.3 Suicide‐related outcomes</h6> <p>Two trials reported continuous data on suicide‐related outcomes (<a href="./references#CD012955-bbs2-0050" title="McMainSF , GuimondT , BarnhartR , HabinskiL , StreinerDL . A randomized trial of brief dialectical behaviour therapy skills training in suicidal patients suffering from borderline disorder. Acta Psychiatrica Scandinavica2017;135(2):138-48. [DOI: 10.1111/acps.12664] [PMID: 27858962]">McMain 2017</a>; <a href="./references#CD012955-bbs2-0053" title="MohamadizadehL , MakvandiB , PashaR , BakhtiarpourS , HafeziF . Comparing of the effect of dialectical behavior therapy (DBT) and schema therapy (ST) on reducing mood activity and suicidal thoughts in patients with borderline personality disorder. Acta Medica Mediterranea2017;33:1025-31. [DOI: 10.19193/0393-6384_2017_6_162] [www.actamedicamediterranea.com/archive/2017/medica-6/comparing-of-the-effect-of-dialectical-behavior-therapy-dbt-and-schema-therapy-st-on-reducing-mood-activity-and-suicidal-thoughts-in-patients-with-borderline-personality-disorder/pdf]">Mohamadizadeh 2017</a>). </p> <p>Psychotherapy did not reduce suicide‐related outcomes at end of treatment compared with waiting list or no treatment (SMD −5.62, 95% CI −16.39 to 5.16; 2 trials, 108 participants; I<sup>2</sup> = 97%; P = 0.30; <a href="./references#CD012955-fig-0146" title="">Analysis 16.3</a>). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> </section> <section id="CD012955-sec-0269"> <h6 class="title">16.4 Psychosocial functioning</h6> <p>Two trials reported continuous data on psychosocial functioning (<a href="./references#CD012955-bbs2-0011" title="BohusM , DyerAS , PriebeK , KrügerA , KleindienstN , SchmahlC , et al. Dialectical behaviour therapy for post-traumatic stress disorder after childhood sexual abuse in patients with and without borderline personality disorder: a randomised controlled trial. Psychotherapy and Psychosomatics2013;82(4):221-33. [DOI: 10.1159/000348451] [PMID: 23712109]BrandS . AW: questions regarding your trial on emotional intelligence training for BPD [personal communication]. Email to: EG Faltinsen 28 November 2017. DBT Working Group at the Central Institute for Mental Health, Mannheim, Germany. Requested supplementary data (as supplied 1 October 2010). Data on file. NCT00481000. Dialectical cognitive traumatherapy (DCT) on patients with severe PTSD following sexual abuse (PASA) [Dialectical cognitive traumatherapy (DCT) on patients with severe posttraumatic stress disorder following sexual abuse - a randomised controlled trial]. clinicaltrials.gov/ct2/show/NCT00481000 (first received 31 May 2007). SteilR , DyerA , PriebeK , KleindienstN , BohusM . Dialectical behavior therapy for posttraumatic stress disorder related to childhood sexual abuse: a pilot study of an intensive treatment program. Journal of Traumatic Stress2011;24(1):102-6. [DOI: 10.1002/jts.20617] [PMID: 21351167]">Bohus 2013</a>; <a href="./references#CD012955-bbs2-0050" title="McMainSF , GuimondT , BarnhartR , HabinskiL , StreinerDL . A randomized trial of brief dialectical behaviour therapy skills training in suicidal patients suffering from borderline disorder. Acta Psychiatrica Scandinavica2017;135(2):138-48. [DOI: 10.1111/acps.12664] [PMID: 27858962]">McMain 2017</a>). </p> <p>DBT reduced psychosocial functioning at end of treatment compared with waiting list (SMD −0.73, 95% CI −1.11 to −0.36; 2 trials, 117 participants; I<sup>2</sup> = 0%; P = 0.0001; <a href="./references#CD012955-fig-0147" title="">Analysis 16.4</a>). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> </section> </section> <section id="CD012955-sec-0270"> <h5 class="title">Secondary outcomes</h5> <section id="CD012955-sec-0271"> <h6 class="title">16.5 Anger</h6> <p>One trial reported continuous data on anger (<a href="./references#CD012955-bbs2-0050" title="McMainSF , GuimondT , BarnhartR , HabinskiL , StreinerDL . A randomized trial of brief dialectical behaviour therapy skills training in suicidal patients suffering from borderline disorder. Acta Psychiatrica Scandinavica2017;135(2):138-48. [DOI: 10.1111/acps.12664] [PMID: 27858962]">McMain 2017</a>). </p> <p>DBT reduced anger at end of treatment compared with waiting list (MD −11.45, 95% CI −15.73 to −7.17; 1 trial, 84 participants; P &lt; 0.001; <a href="./references#CD012955-fig-0148" title="">Analysis 16.5</a>). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> </section> <section id="CD012955-sec-0272"> <h6 class="title">16.6 Affective instability</h6> <p>One trial reported continuous data on affective instability (<a href="./references#CD012955-bbs2-0050" title="McMainSF , GuimondT , BarnhartR , HabinskiL , StreinerDL . A randomized trial of brief dialectical behaviour therapy skills training in suicidal patients suffering from borderline disorder. Acta Psychiatrica Scandinavica2017;135(2):138-48. [DOI: 10.1111/acps.12664] [PMID: 27858962]">McMain 2017</a>). </p> <p>DBT reduced affective instability at end of treatment compared with waiting list (MD −20.15, 95% CI −28.49 to −11.81; 1 trial, 84 participants; P &lt; 0.001; <a href="./references#CD012955-fig-0149" title="">Analysis 16.6</a>). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> </section> <section id="CD012955-sec-0273"> <h6 class="title">16.7 Impulsivity</h6> <p>One trial reported continuous data on impulsivity (<a href="./references#CD012955-bbs2-0050" title="McMainSF , GuimondT , BarnhartR , HabinskiL , StreinerDL . A randomized trial of brief dialectical behaviour therapy skills training in suicidal patients suffering from borderline disorder. Acta Psychiatrica Scandinavica2017;135(2):138-48. [DOI: 10.1111/acps.12664] [PMID: 27858962]">McMain 2017</a>). </p> <p>DBT did not reduce impulsivity at end of treatment compared with waiting list (MD −3.41, 95% CI −7.32 to 0.50; 1 trial, 84 participants; P = 0.09; <a href="./references#CD012955-fig-0150" title="">Analysis 16.7</a>). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> </section> <section id="CD012955-sec-0274"> <h6 class="title">16.8 Dissociation and psychotic‐like symptoms</h6> <p>One trial reported continuous data on dissociation and psychotic‐like symptoms (<a href="./references#CD012955-bbs2-0011" title="BohusM , DyerAS , PriebeK , KrügerA , KleindienstN , SchmahlC , et al. Dialectical behaviour therapy for post-traumatic stress disorder after childhood sexual abuse in patients with and without borderline personality disorder: a randomised controlled trial. Psychotherapy and Psychosomatics2013;82(4):221-33. [DOI: 10.1159/000348451] [PMID: 23712109]BrandS . AW: questions regarding your trial on emotional intelligence training for BPD [personal communication]. Email to: EG Faltinsen 28 November 2017. DBT Working Group at the Central Institute for Mental Health, Mannheim, Germany. Requested supplementary data (as supplied 1 October 2010). Data on file. NCT00481000. Dialectical cognitive traumatherapy (DCT) on patients with severe PTSD following sexual abuse (PASA) [Dialectical cognitive traumatherapy (DCT) on patients with severe posttraumatic stress disorder following sexual abuse - a randomised controlled trial]. clinicaltrials.gov/ct2/show/NCT00481000 (first received 31 May 2007). SteilR , DyerA , PriebeK , KleindienstN , BohusM . Dialectical behavior therapy for posttraumatic stress disorder related to childhood sexual abuse: a pilot study of an intensive treatment program. Journal of Traumatic Stress2011;24(1):102-6. [DOI: 10.1002/jts.20617] [PMID: 21351167]">Bohus 2013</a>). </p> <p>DBT did not reduce dissociation and psychotic‐like symptoms at end of treatment compared with waiting list (MD −6.45, 95% CI −16.51 to 3.61; 1 trial, 33 participants; P = 0.21; <a href="./references#CD012955-fig-0151" title="">Analysis 16.8</a>). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> </section> <section id="CD012955-sec-0275"> <h6 class="title">16.9 Depression</h6> <p>Three trials reported continuous data on depression (<a href="./references#CD012955-bbs2-0011" title="BohusM , DyerAS , PriebeK , KrügerA , KleindienstN , SchmahlC , et al. Dialectical behaviour therapy for post-traumatic stress disorder after childhood sexual abuse in patients with and without borderline personality disorder: a randomised controlled trial. Psychotherapy and Psychosomatics2013;82(4):221-33. [DOI: 10.1159/000348451] [PMID: 23712109]BrandS . AW: questions regarding your trial on emotional intelligence training for BPD [personal communication]. Email to: EG Faltinsen 28 November 2017. DBT Working Group at the Central Institute for Mental Health, Mannheim, Germany. Requested supplementary data (as supplied 1 October 2010). Data on file. NCT00481000. Dialectical cognitive traumatherapy (DCT) on patients with severe PTSD following sexual abuse (PASA) [Dialectical cognitive traumatherapy (DCT) on patients with severe posttraumatic stress disorder following sexual abuse - a randomised controlled trial]. clinicaltrials.gov/ct2/show/NCT00481000 (first received 31 May 2007). SteilR , DyerA , PriebeK , KleindienstN , BohusM . Dialectical behavior therapy for posttraumatic stress disorder related to childhood sexual abuse: a pilot study of an intensive treatment program. Journal of Traumatic Stress2011;24(1):102-6. [DOI: 10.1002/jts.20617] [PMID: 21351167]">Bohus 2013</a>; <a href="./references#CD012955-bbs2-0050" title="McMainSF , GuimondT , BarnhartR , HabinskiL , StreinerDL . A randomized trial of brief dialectical behaviour therapy skills training in suicidal patients suffering from borderline disorder. Acta Psychiatrica Scandinavica2017;135(2):138-48. [DOI: 10.1111/acps.12664] [PMID: 27858962]">McMain 2017</a>; <a href="./references#CD012955-bbs2-0053" title="MohamadizadehL , MakvandiB , PashaR , BakhtiarpourS , HafeziF . Comparing of the effect of dialectical behavior therapy (DBT) and schema therapy (ST) on reducing mood activity and suicidal thoughts in patients with borderline personality disorder. Acta Medica Mediterranea2017;33:1025-31. [DOI: 10.19193/0393-6384_2017_6_162] [www.actamedicamediterranea.com/archive/2017/medica-6/comparing-of-the-effect-of-dialectical-behavior-therapy-dbt-and-schema-therapy-st-on-reducing-mood-activity-and-suicidal-thoughts-in-patients-with-borderline-personality-disorder/pdf]">Mohamadizadeh 2017</a>). </p> <p>DBT reduced depression at end of treatment compared with waiting list or no treatment (SMD −3.20, 95% CI −5.57 to −0.83; 3 trials, 141 participants; P = 0.008; <a href="./references#CD012955-fig-0152" title="">Analysis 16.9</a>). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> <p>No data were available on any time point for chronic feelings of emptiness, interpersonal problems, abandonment, identity disturbance, attrition and adverse effects. </p> </section> </section> <section id="CD012955-sec-0276"> <h5 class="title">16.10. DBT couple therapy (CDBT) versus waiting list (generic inverse variance)</h5> <section id="CD012955-sec-0277"> <h6 class="title">Primary outcomes</h6> <section id="CD012955-sec-0278"> <p><b>BPD symptom severity</b></p> <p>One trial reported continuous data on BPD symptom severity (<a href="./references#CD012955-bbs2-0034" title="KamalabadiMJ , AhmadiSA , EtemadiO , FatehizadehM , BahramiF , FiroozabadiA . A study of the effect of couple dialectical behavioral therapy on symptoms and quality of marital relationships and mental health of Iranian borderline personality couples: a controlled trial. Interdisciplinary Journal of Contemporary Research in Business2012;3(9):1480-7. [psycnet.apa.org/record/2012-22425-047]">Kamalabadi 2012</a>). </p> <p>End of treatment: CDBT reduced BPD symptom severity at end of treatment compared with waiting list (MD −27.15, 95% CI −31.59 to −22.71; 1 trial, 30 participants; P &lt; 0.001; <a href="./references#CD012955-fig-0153" title="">Analysis 16.10</a>.1). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> </section> <section id="CD012955-sec-0279"> <p><b>Suicide‐related outcomes</b></p> <p>One trial reported continuous data on suicide‐related outcomes (<a href="./references#CD012955-bbs2-0034" title="KamalabadiMJ , AhmadiSA , EtemadiO , FatehizadehM , BahramiF , FiroozabadiA . A study of the effect of couple dialectical behavioral therapy on symptoms and quality of marital relationships and mental health of Iranian borderline personality couples: a controlled trial. Interdisciplinary Journal of Contemporary Research in Business2012;3(9):1480-7. [psycnet.apa.org/record/2012-22425-047]">Kamalabadi 2012</a>). </p> <p>CDBT reduced suicide‐related outcomes at end of treatment compared with waiting list (MD −0.94, 95% CI −1.24 to −0.64; 1 trial, 30 participants; P &lt; 0.001; <a href="./references#CD012955-fig-0153" title="">Analysis 16.10</a>.2). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> </section> <section id="CD012955-sec-0280"> <p><b>Psychosocial functioning</b></p> <p>One trial reported continuous data on psychosocial functioning (<a href="./references#CD012955-bbs2-0034" title="KamalabadiMJ , AhmadiSA , EtemadiO , FatehizadehM , BahramiF , FiroozabadiA . A study of the effect of couple dialectical behavioral therapy on symptoms and quality of marital relationships and mental health of Iranian borderline personality couples: a controlled trial. Interdisciplinary Journal of Contemporary Research in Business2012;3(9):1480-7. [psycnet.apa.org/record/2012-22425-047]">Kamalabadi 2012</a>). </p> <p>CDBT improved psychosocial functioning at end of treatment compared with waiting list (MD −10.70, 95% CI −12.31 to −9.09; 1 trial, 30 participants; P &lt; 0.001; <a href="./references#CD012955-fig-0153" title="">Analysis 16.10</a>.3). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> <p>No data were available on any time point for self‐harm.</p> </section> </section> <section id="CD012955-sec-0281"> <h6 class="title">Secondary outcomes</h6> <section id="CD012955-sec-0282"> <p><b>Anger</b></p> <p>One trial reported continuous data on anger (<a href="./references#CD012955-bbs2-0034" title="KamalabadiMJ , AhmadiSA , EtemadiO , FatehizadehM , BahramiF , FiroozabadiA . A study of the effect of couple dialectical behavioral therapy on symptoms and quality of marital relationships and mental health of Iranian borderline personality couples: a controlled trial. Interdisciplinary Journal of Contemporary Research in Business2012;3(9):1480-7. [psycnet.apa.org/record/2012-22425-047]">Kamalabadi 2012</a>). </p> <p>CDBT reduced anger at end of treatment compared with waiting list (MD −1.42, 95% CI −1.72 to −1.12; 1 trial, 30 participants; P &lt; 0.001; <a href="./references#CD012955-fig-0153" title="">Analysis 16.10</a>.4). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> </section> <section id="CD012955-sec-0283"> <p><b>Affective instability</b></p> <p>One trial reported continuous data on affective instability (<a href="./references#CD012955-bbs2-0034" title="KamalabadiMJ , AhmadiSA , EtemadiO , FatehizadehM , BahramiF , FiroozabadiA . A study of the effect of couple dialectical behavioral therapy on symptoms and quality of marital relationships and mental health of Iranian borderline personality couples: a controlled trial. Interdisciplinary Journal of Contemporary Research in Business2012;3(9):1480-7. [psycnet.apa.org/record/2012-22425-047]">Kamalabadi 2012</a>). </p> <p>CDBT reduced affective instability at end of treatment compared with waiting list (MD −4.01, 95% CI −5.44 to −2.58; 1 trial, 30 participants; P &lt; 0.001; <a href="./references#CD012955-fig-0153" title="">Analysis 16.10</a>.5). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> </section> <section id="CD012955-sec-0284"> <p><b>Chronic feelings of emptiness</b></p> <p>One trial reported continuous data on chronic feelings of emptiness (<a href="./references#CD012955-bbs2-0034" title="KamalabadiMJ , AhmadiSA , EtemadiO , FatehizadehM , BahramiF , FiroozabadiA . A study of the effect of couple dialectical behavioral therapy on symptoms and quality of marital relationships and mental health of Iranian borderline personality couples: a controlled trial. Interdisciplinary Journal of Contemporary Research in Business2012;3(9):1480-7. [psycnet.apa.org/record/2012-22425-047]">Kamalabadi 2012</a>). </p> <p>CDBT reduced chronic feelings of emptiness at end of treatment compared with waiting list (MD −3.54, 95% CI −4.81 to −2.27; 1 trial, 30 participants; P &lt; 0.001; <a href="./references#CD012955-fig-0153" title="">Analysis 16.10</a>.6). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> </section> <section id="CD012955-sec-0285"> <p><b>Impulsivity</b></p> <p>One trial reported continuous data on impulsivity (<a href="./references#CD012955-bbs2-0034" title="KamalabadiMJ , AhmadiSA , EtemadiO , FatehizadehM , BahramiF , FiroozabadiA . A study of the effect of couple dialectical behavioral therapy on symptoms and quality of marital relationships and mental health of Iranian borderline personality couples: a controlled trial. Interdisciplinary Journal of Contemporary Research in Business2012;3(9):1480-7. [psycnet.apa.org/record/2012-22425-047]">Kamalabadi 2012</a>). </p> <p>CDBT reduced impulsivity at end of treatment compared with waiting list (MD −0.51, 95% CI −0.72 to −0.30; 1 trial, 30 participants; P &lt; 0.001; <a href="./references#CD012955-fig-0153" title="">Analysis 16.10</a>.7). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> </section> <section id="CD012955-sec-0286"> <p><b>Interpersonal problems</b></p> <p>One trial reported continuous data on interpersonal problems (<a href="./references#CD012955-bbs2-0034" title="KamalabadiMJ , AhmadiSA , EtemadiO , FatehizadehM , BahramiF , FiroozabadiA . A study of the effect of couple dialectical behavioral therapy on symptoms and quality of marital relationships and mental health of Iranian borderline personality couples: a controlled trial. Interdisciplinary Journal of Contemporary Research in Business2012;3(9):1480-7. [psycnet.apa.org/record/2012-22425-047]">Kamalabadi 2012</a>). </p> <p>CDBT reduced interpersonal problems at end of treatment compared with waiting list (MD −1.98, 95% CI −2.47 to −1.49; 1 trial, 30 participants;, P &lt; 0.001; <a href="./references#CD012955-fig-0153" title="">Analysis 16.10</a>.8). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> </section> <section id="CD012955-sec-0287"> <p><b>Abandonment</b></p> <p>One trial reported continuous data on abandonment (<a href="./references#CD012955-bbs2-0034" title="KamalabadiMJ , AhmadiSA , EtemadiO , FatehizadehM , BahramiF , FiroozabadiA . A study of the effect of couple dialectical behavioral therapy on symptoms and quality of marital relationships and mental health of Iranian borderline personality couples: a controlled trial. Interdisciplinary Journal of Contemporary Research in Business2012;3(9):1480-7. [psycnet.apa.org/record/2012-22425-047]">Kamalabadi 2012</a>). </p> <p>CDBT reduced abandonment at end of treatment compared with waiting list (MD −0.86, 95% CI −1.09 to ‐0.63; 1 trial, 30 participants; P &lt; 0.001; <a href="./references#CD012955-fig-0153" title="">Analysis 16.10</a>.9). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> </section> <section id="CD012955-sec-0288"> <p><b>Identity disturbance</b></p> <p>One trial reported continuous data on identity disturbance (<a href="./references#CD012955-bbs2-0034" title="KamalabadiMJ , AhmadiSA , EtemadiO , FatehizadehM , BahramiF , FiroozabadiA . A study of the effect of couple dialectical behavioral therapy on symptoms and quality of marital relationships and mental health of Iranian borderline personality couples: a controlled trial. Interdisciplinary Journal of Contemporary Research in Business2012;3(9):1480-7. [psycnet.apa.org/record/2012-22425-047]">Kamalabadi 2012</a>). </p> <p>CDBT reduced identity disturbance at end of treatment compared with waiting list (MD −2.44, 95% CI −2.77 to −2.11; 1 trial, 30 participants; P &lt; 0.001; <a href="./references#CD012955-fig-0153" title="">Analysis 16.10</a>.10). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> </section> <section id="CD012955-sec-0289"> <p><b>Dissociation and psychotic‐like symptoms</b></p> <p>One trial reported continuous data on dissociation and psychotic‐like symptoms (<a href="./references#CD012955-bbs2-0034" title="KamalabadiMJ , AhmadiSA , EtemadiO , FatehizadehM , BahramiF , FiroozabadiA . A study of the effect of couple dialectical behavioral therapy on symptoms and quality of marital relationships and mental health of Iranian borderline personality couples: a controlled trial. Interdisciplinary Journal of Contemporary Research in Business2012;3(9):1480-7. [psycnet.apa.org/record/2012-22425-047]">Kamalabadi 2012</a>). </p> <p>CDBT reduced dissociation or psychotic‐like symptoms at end of treatment compared with waiting list (MD −1.92, 95% CI −2.46 to −1.38; 1 trial, 30 participants; P &lt; 0.001; <a href="./references#CD012955-fig-0153" title="">Analysis 16.10</a>.11). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> </section> <section id="CD012955-sec-0290"> <p><b>Depression</b></p> <p>One trial reported continuous data on depression (<a href="./references#CD012955-bbs2-0034" title="KamalabadiMJ , AhmadiSA , EtemadiO , FatehizadehM , BahramiF , FiroozabadiA . A study of the effect of couple dialectical behavioral therapy on symptoms and quality of marital relationships and mental health of Iranian borderline personality couples: a controlled trial. Interdisciplinary Journal of Contemporary Research in Business2012;3(9):1480-7. [psycnet.apa.org/record/2012-22425-047]">Kamalabadi 2012</a>). </p> <p>CDBT reduced depression at end of treatment compared with waiting list (MD −10.43, 95% CI −11.86 to −9.00; 1 trial, number of participants = 30, P &lt; 0.001; <a href="./references#CD012955-fig-0153" title="">Analysis 16.10</a>.12). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> <p>No data were available on any time point for attrition and adverse effects.</p> </section> </section> </section> </section> <section id="CD012955-sec-0291"> <h4 class="title">17. Schema‐focused therapy (SFT) versus no treatment</h4> <section id="CD012955-sec-0292"> <h5 class="title">17.1 Primary outcome: suicide‐related outcomes</h5> <p>One trial reported continuous data on suicide‐related outcomes (<a href="./references#CD012955-bbs2-0053" title="MohamadizadehL , MakvandiB , PashaR , BakhtiarpourS , HafeziF . Comparing of the effect of dialectical behavior therapy (DBT) and schema therapy (ST) on reducing mood activity and suicidal thoughts in patients with borderline personality disorder. Acta Medica Mediterranea2017;33:1025-31. [DOI: 10.19193/0393-6384_2017_6_162] [www.actamedicamediterranea.com/archive/2017/medica-6/comparing-of-the-effect-of-dialectical-behavior-therapy-dbt-and-schema-therapy-st-on-reducing-mood-activity-and-suicidal-thoughts-in-patients-with-borderline-personality-disorder/pdf]">Mohamadizadeh 2017</a>). </p> <p>SFT reduced suicide‐related outcomes at end of treatment compared with no treatment (MD −16.67, 95% CI −17.70 to −15.64; 1 trial, 24 participants; P &lt; 0.001; <a href="./references#CD012955-fig-0154" title="">Analysis 17.1</a>). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> <p>No data were available on any time point for BPD symptom severity, self‐harm, and psychosocial functioning. </p> </section> <section id="CD012955-sec-0293"> <h5 class="title">17.2 Secondary outcome: depression</h5> <p>One trial reported continuous data on depression (<a href="./references#CD012955-bbs2-0053" title="MohamadizadehL , MakvandiB , PashaR , BakhtiarpourS , HafeziF . Comparing of the effect of dialectical behavior therapy (DBT) and schema therapy (ST) on reducing mood activity and suicidal thoughts in patients with borderline personality disorder. Acta Medica Mediterranea2017;33:1025-31. [DOI: 10.19193/0393-6384_2017_6_162] [www.actamedicamediterranea.com/archive/2017/medica-6/comparing-of-the-effect-of-dialectical-behavior-therapy-dbt-and-schema-therapy-st-on-reducing-mood-activity-and-suicidal-thoughts-in-patients-with-borderline-personality-disorder/pdf]">Mohamadizadeh 2017</a>). </p> <p>SFT reduced depression at end of treatment compared with no treatment (MD −33.92, 95% CI −35.40 to −32.44; 1 trial, 24 participants; P &lt; 0.001; <a href="./references#CD012955-fig-0155" title="">Analysis 17.2</a>). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> <p>No data were available on any time point for anger, affective instability, chronic feelings of emptiness, impulsivity, interpersonal problems, abandonment, identity disturbance, dissociation and psychotic‐like symptoms, attrition and adverse effects. </p> </section> </section> <section id="CD012955-sec-0294"> <h4 class="title">18. Interpersonal psychotherapy (IPT) versus waiting list</h4> <section id="CD012955-sec-0295"> <h5 class="title">Primary outcomes</h5> <section id="CD012955-sec-0296"> <h6 class="title">18.1 BPD symptom severity</h6> <p>One trial reported continuous data on BPD symptom severity (<a href="./references#CD012955-bbs2-0008" title="BellinoS , BozzatelloP , BogettoF . Combined treatment of borderline personality disorder with interpersonal psychotherapy and pharmacotherapy: predictors of response. Psychiatry Research2015;226(1):284-8. [DOI: 10.1016/j.psychres.2014.12.064] [isiarticles.com/bundles/Article/pre/pdf/34125.pdf]BellinoS , RinaldiC , BogettoF . Adaptation of interpersonal psychotherapy to borderline personality disorder: a comparison of combined therapy and single pharmacotherapy. Canadian Journal of Psychiatry2010;55(2):74-81. [DOI: 10.1177/070674371005500203] [PMID: 20181302]BellinoS . Question regarding your BPD trials for inclusion in Cochrane Collaboration review [personal communication]. Email to: J Stoffers-Winterling 19 December 2010. BellinoS . Re: question regarding your BPD trials [personal communication]. Email to: J Stoffers 16 December 2010. BozzatelloP , BellinoS . Combined therapy with interpersonal psychotherapy adapted for borderline personality disorder: a two-years follow-up. Psychiatry Research2016;240:151-6. [DOI: 10.1016/j.psychres.2016.04.014] [www.sciencedirect.com/science/article/pii/S0165178115302389]ZizzaM , FenocchioM , RinaldiC , BellinoS . Combined treatment of borderline personality disorder: a trial of modified interpersonal therapy. World Psychiatry2009;8(Suppl 1):234. ">Bellino 2010</a>). </p> <p>IPT did not reduce BPD symptom severity at end of treatment compared with waiting list (MD −0.19, 95% CI −3.71 to 3.33; 1 trial, 44 participants; P = 0.92; <a href="./references#CD012955-fig-0156" title="">Analysis 18.1</a>). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> </section> <section id="CD012955-sec-0297"> <h6 class="title">18.2 Self‐harm</h6> <p>One trial reported continuous data on self‐harm (<a href="./references#CD012955-bbs2-0008" title="BellinoS , BozzatelloP , BogettoF . Combined treatment of borderline personality disorder with interpersonal psychotherapy and pharmacotherapy: predictors of response. Psychiatry Research2015;226(1):284-8. [DOI: 10.1016/j.psychres.2014.12.064] [isiarticles.com/bundles/Article/pre/pdf/34125.pdf]BellinoS , RinaldiC , BogettoF . Adaptation of interpersonal psychotherapy to borderline personality disorder: a comparison of combined therapy and single pharmacotherapy. Canadian Journal of Psychiatry2010;55(2):74-81. [DOI: 10.1177/070674371005500203] [PMID: 20181302]BellinoS . Question regarding your BPD trials for inclusion in Cochrane Collaboration review [personal communication]. Email to: J Stoffers-Winterling 19 December 2010. BellinoS . Re: question regarding your BPD trials [personal communication]. Email to: J Stoffers 16 December 2010. BozzatelloP , BellinoS . Combined therapy with interpersonal psychotherapy adapted for borderline personality disorder: a two-years follow-up. Psychiatry Research2016;240:151-6. [DOI: 10.1016/j.psychres.2016.04.014] [www.sciencedirect.com/science/article/pii/S0165178115302389]ZizzaM , FenocchioM , RinaldiC , BellinoS . Combined treatment of borderline personality disorder: a trial of modified interpersonal therapy. World Psychiatry2009;8(Suppl 1):234. ">Bellino 2010</a>). </p> <p>IPT did not reduce self‐harm at end of treatment compared with waiting list (MD 0.03, 95% CI −1.09 to 1.15; 1 trial, 44 participants; P = 0.96; <a href="./references#CD012955-fig-0157" title="">Analysis 18.2</a>). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> </section> <section id="CD012955-sec-0298"> <h6 class="title">18.3 Psychosocial functioning</h6> <p>Two trials reported continuous data on psychosocial functioning (<a href="./references#CD012955-bbs2-0006" title="BellinoS , ParadisoE , ZizzaM , Di LorenzoR , BogettoF . Combined therapy with interpersonal psychotherapy of major depressed patients with borderline personality disorder: a comparison with pharmacotherapy [Terapia combinata con psicoterapia interpersonale di pazienti depressi maggiori con disturbo borderline di personalità: confronto con la farmacoterapia]. Journal of Psychopathology2005;11(1):34-42. [bit.ly/2rZUh5h]BellinoS , ZizzaM , RinaldiC , BogettoF . Combined treatment of major depression in patients with borderline personality disorder: a comparison with pharmacotherapy. Canadian Journal of Psychiatry2006;51(7):453-60. [DOI: 10.1177/070674370605100707] [PMID: 16838827]">Bellino 2006</a>; <a href="./references#CD012955-bbs2-0008" title="BellinoS , BozzatelloP , BogettoF . Combined treatment of borderline personality disorder with interpersonal psychotherapy and pharmacotherapy: predictors of response. Psychiatry Research2015;226(1):284-8. [DOI: 10.1016/j.psychres.2014.12.064] [isiarticles.com/bundles/Article/pre/pdf/34125.pdf]BellinoS , RinaldiC , BogettoF . Adaptation of interpersonal psychotherapy to borderline personality disorder: a comparison of combined therapy and single pharmacotherapy. Canadian Journal of Psychiatry2010;55(2):74-81. [DOI: 10.1177/070674371005500203] [PMID: 20181302]BellinoS . Question regarding your BPD trials for inclusion in Cochrane Collaboration review [personal communication]. Email to: J Stoffers-Winterling 19 December 2010. BellinoS . Re: question regarding your BPD trials [personal communication]. Email to: J Stoffers 16 December 2010. BozzatelloP , BellinoS . Combined therapy with interpersonal psychotherapy adapted for borderline personality disorder: a two-years follow-up. Psychiatry Research2016;240:151-6. [DOI: 10.1016/j.psychres.2016.04.014] [www.sciencedirect.com/science/article/pii/S0165178115302389]ZizzaM , FenocchioM , RinaldiC , BellinoS . Combined treatment of borderline personality disorder: a trial of modified interpersonal therapy. World Psychiatry2009;8(Suppl 1):234. ">Bellino 2010</a>). </p> <p>IPT did not improve psychosocial functioning at end of treatment compared with waiting list (SMD −0.03, 95% CI −0.48 to 0.42; 2 trials, 76 participants; I<sup>2</sup> = 0%; P = 0.91; <a href="./references#CD012955-fig-0158" title="">Analysis 18.3</a>.1). </p> <p>IPT improved psychosocial functioning at zero to six months follow‐up compared with waiting list (SMD −0.89, 95% CI −1.65 to −0.13; 1 trial, 30 participants; P = 0.02; MD −12.39, 95% CI −22.00 to −2.78; 1 trial, 30 participants; P = 0.01; <a href="./references#CD012955-fig-0158" title="">Analysis 18.3</a>.2). </p> <p>IPT improved psychosocial functioning at six to 12 months follow‐up compared with waiting list (SMD −1.04, 95% CI −1.81 to −0.27; 1 trial, 30 participants; P = 0.008; MD −13.59, 95% CI −22.65 to −4.53; 1 trial, 30 participants; P = 0.003; <a href="./references#CD012955-fig-0158" title="">Analysis 18.3</a>.3). </p> <p>IPT did not improve psychosocial functioning at above 12 months follow‐up compared with waiting list (SMD −0.38, 95% CI −1.14 to 0.37; 1 trial, 30 participants; P = 0.32; MD −14.68, 95% CI −46.63 to 17.27; 1 trial, 30 participants; P = 0.37; <a href="./references#CD012955-fig-0158" title="">Analysis 18.3</a>.4). </p> <p>No data were available on any time point for suicide‐related outcomes.</p> </section> </section> <section id="CD012955-sec-0299"> <h5 class="title">Secondary outcomes</h5> <section id="CD012955-sec-0300"> <h6 class="title">18.4 Anger</h6> <p>One trial reported continuous data on anger (<a href="./references#CD012955-bbs2-0008" title="BellinoS , BozzatelloP , BogettoF . Combined treatment of borderline personality disorder with interpersonal psychotherapy and pharmacotherapy: predictors of response. Psychiatry Research2015;226(1):284-8. [DOI: 10.1016/j.psychres.2014.12.064] [isiarticles.com/bundles/Article/pre/pdf/34125.pdf]BellinoS , RinaldiC , BogettoF . Adaptation of interpersonal psychotherapy to borderline personality disorder: a comparison of combined therapy and single pharmacotherapy. Canadian Journal of Psychiatry2010;55(2):74-81. [DOI: 10.1177/070674371005500203] [PMID: 20181302]BellinoS . Question regarding your BPD trials for inclusion in Cochrane Collaboration review [personal communication]. Email to: J Stoffers-Winterling 19 December 2010. BellinoS . Re: question regarding your BPD trials [personal communication]. Email to: J Stoffers 16 December 2010. BozzatelloP , BellinoS . Combined therapy with interpersonal psychotherapy adapted for borderline personality disorder: a two-years follow-up. Psychiatry Research2016;240:151-6. [DOI: 10.1016/j.psychres.2016.04.014] [www.sciencedirect.com/science/article/pii/S0165178115302389]ZizzaM , FenocchioM , RinaldiC , BellinoS . Combined treatment of borderline personality disorder: a trial of modified interpersonal therapy. World Psychiatry2009;8(Suppl 1):234. ">Bellino 2010</a>). </p> <p>IPT did not reduce anger at end of treatment compared with waiting list (MD 0.01, 95% CI −0.40 to 0.42; 1 trial, 44 participants; P = 0.96; <a href="./references#CD012955-fig-0159" title="">Analysis 18.4</a>). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> </section> <section id="CD012955-sec-0301"> <h6 class="title">18.5 Affective instability</h6> <p>One trial reported continuous data on affective instability (<a href="./references#CD012955-bbs2-0008" title="BellinoS , BozzatelloP , BogettoF . Combined treatment of borderline personality disorder with interpersonal psychotherapy and pharmacotherapy: predictors of response. Psychiatry Research2015;226(1):284-8. [DOI: 10.1016/j.psychres.2014.12.064] [isiarticles.com/bundles/Article/pre/pdf/34125.pdf]BellinoS , RinaldiC , BogettoF . Adaptation of interpersonal psychotherapy to borderline personality disorder: a comparison of combined therapy and single pharmacotherapy. Canadian Journal of Psychiatry2010;55(2):74-81. [DOI: 10.1177/070674371005500203] [PMID: 20181302]BellinoS . Question regarding your BPD trials for inclusion in Cochrane Collaboration review [personal communication]. Email to: J Stoffers-Winterling 19 December 2010. BellinoS . Re: question regarding your BPD trials [personal communication]. Email to: J Stoffers 16 December 2010. BozzatelloP , BellinoS . Combined therapy with interpersonal psychotherapy adapted for borderline personality disorder: a two-years follow-up. Psychiatry Research2016;240:151-6. [DOI: 10.1016/j.psychres.2016.04.014] [www.sciencedirect.com/science/article/pii/S0165178115302389]ZizzaM , FenocchioM , RinaldiC , BellinoS . Combined treatment of borderline personality disorder: a trial of modified interpersonal therapy. World Psychiatry2009;8(Suppl 1):234. ">Bellino 2010</a>). </p> <p>IPT reduced affective instability at end of treatment compared with waiting list (MD −1.02, 95% CI −1.66 to −0.38; 1 trial, 44 participants; P = 0.002; <a href="./references#CD012955-fig-0160" title="">Analysis 18.5</a>.1). </p> <p>IPT did not reduce affective instability at zero to six months follow‐up compared with waiting list (MD −0.46, 95% CI −1.15 to 0.23; 1 trial, 30 participants; P = 0.19; <a href="./references#CD012955-fig-0160" title="">Analysis 18.5</a>.2). </p> <p>IPT did not reduce affective instability at six to 12 months follow‐up compared with waiting list (MD −0.39, 95% CI −1.12 to 0.34; 1 trial, 30 participants; P = 0.29; <a href="./references#CD012955-fig-0160" title="">Analysis 18.5</a>.3). </p> <p>IPT did not reduce affective instability at above 12 months follow‐up compared with waiting list (MD −0.34, 95% CI −1.17 to 0.49; 1 trial, 30 participants; P = 0.42; <a href="./references#CD012955-fig-0160" title="">Analysis 18.5</a>.4). </p> </section> <section id="CD012955-sec-0302"> <h6 class="title">18.6 Chronic feelings of emptiness</h6> <p>One trial reported continuous data on chronic feelings of emptiness (<a href="./references#CD012955-bbs2-0008" title="BellinoS , BozzatelloP , BogettoF . Combined treatment of borderline personality disorder with interpersonal psychotherapy and pharmacotherapy: predictors of response. Psychiatry Research2015;226(1):284-8. [DOI: 10.1016/j.psychres.2014.12.064] [isiarticles.com/bundles/Article/pre/pdf/34125.pdf]BellinoS , RinaldiC , BogettoF . Adaptation of interpersonal psychotherapy to borderline personality disorder: a comparison of combined therapy and single pharmacotherapy. Canadian Journal of Psychiatry2010;55(2):74-81. [DOI: 10.1177/070674371005500203] [PMID: 20181302]BellinoS . Question regarding your BPD trials for inclusion in Cochrane Collaboration review [personal communication]. Email to: J Stoffers-Winterling 19 December 2010. BellinoS . Re: question regarding your BPD trials [personal communication]. Email to: J Stoffers 16 December 2010. BozzatelloP , BellinoS . Combined therapy with interpersonal psychotherapy adapted for borderline personality disorder: a two-years follow-up. Psychiatry Research2016;240:151-6. [DOI: 10.1016/j.psychres.2016.04.014] [www.sciencedirect.com/science/article/pii/S0165178115302389]ZizzaM , FenocchioM , RinaldiC , BellinoS . Combined treatment of borderline personality disorder: a trial of modified interpersonal therapy. World Psychiatry2009;8(Suppl 1):234. ">Bellino 2010</a>). </p> <p>IPT did not reduce chronic feelings of emptiness at end of treatment compared with waiting list (MD 0.04, 95% CI −0.21 to 0.29; 1 trial, 44 participants; P = 0.75; <a href="./references#CD012955-fig-0161" title="">Analysis 18.6</a>). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> </section> <section id="CD012955-sec-0303"> <h6 class="title">18.7 Impulsivity</h6> <p>One trial reported continuous data on impulsivity (<a href="./references#CD012955-bbs2-0008" title="BellinoS , BozzatelloP , BogettoF . Combined treatment of borderline personality disorder with interpersonal psychotherapy and pharmacotherapy: predictors of response. Psychiatry Research2015;226(1):284-8. [DOI: 10.1016/j.psychres.2014.12.064] [isiarticles.com/bundles/Article/pre/pdf/34125.pdf]BellinoS , RinaldiC , BogettoF . Adaptation of interpersonal psychotherapy to borderline personality disorder: a comparison of combined therapy and single pharmacotherapy. Canadian Journal of Psychiatry2010;55(2):74-81. [DOI: 10.1177/070674371005500203] [PMID: 20181302]BellinoS . Question regarding your BPD trials for inclusion in Cochrane Collaboration review [personal communication]. Email to: J Stoffers-Winterling 19 December 2010. BellinoS . Re: question regarding your BPD trials [personal communication]. Email to: J Stoffers 16 December 2010. BozzatelloP , BellinoS . Combined therapy with interpersonal psychotherapy adapted for borderline personality disorder: a two-years follow-up. Psychiatry Research2016;240:151-6. [DOI: 10.1016/j.psychres.2016.04.014] [www.sciencedirect.com/science/article/pii/S0165178115302389]ZizzaM , FenocchioM , RinaldiC , BellinoS . Combined treatment of borderline personality disorder: a trial of modified interpersonal therapy. World Psychiatry2009;8(Suppl 1):234. ">Bellino 2010</a>). </p> <p>IPT reduced impulsivity at end of treatment compared with waiting list (MD −1.03, 95% CI −1.69 to −0.37; 1 trial, 44 participants; P = 0.002; <a href="./references#CD012955-fig-0162" title="">Analysis 18.7</a>.1). </p> <p>IPT reduced impulsivity at zero to six months follow‐up compared with waiting list (MD −1.10, 95% CI −1.95 to −0.25; 1 trial, 30 participants; P = 0.01; <a href="./references#CD012955-fig-0162" title="">Analysis 18.7</a>.2). </p> <p>IPT reduced impulsivity at six to 12 months compared with waiting list (MD −1.10, 95% CI −2.06 to −0.14; 1 trial, 30 participants; P = 0.02; <a href="./references#CD012955-fig-0162" title="">Analysis 18.7</a>.3). </p> <p>IPT reduced impulsivity at above 12 months follow‐up compared with waiting list (MD −1.09, 95% CI −2.09 to −0.09; 1 trial, 30 participants; P = 0.03; <a href="./references#CD012955-fig-0162" title="">Analysis 18.7</a>.4). </p> </section> <section id="CD012955-sec-0304"> <h6 class="title">18.8 Interpersonal problems</h6> <p>One trial reported continuous data on interpersonal problems (<a href="./references#CD012955-bbs2-0008" title="BellinoS , BozzatelloP , BogettoF . Combined treatment of borderline personality disorder with interpersonal psychotherapy and pharmacotherapy: predictors of response. Psychiatry Research2015;226(1):284-8. [DOI: 10.1016/j.psychres.2014.12.064] [isiarticles.com/bundles/Article/pre/pdf/34125.pdf]BellinoS , RinaldiC , BogettoF . Adaptation of interpersonal psychotherapy to borderline personality disorder: a comparison of combined therapy and single pharmacotherapy. Canadian Journal of Psychiatry2010;55(2):74-81. [DOI: 10.1177/070674371005500203] [PMID: 20181302]BellinoS . Question regarding your BPD trials for inclusion in Cochrane Collaboration review [personal communication]. Email to: J Stoffers-Winterling 19 December 2010. BellinoS . Re: question regarding your BPD trials [personal communication]. Email to: J Stoffers 16 December 2010. BozzatelloP , BellinoS . Combined therapy with interpersonal psychotherapy adapted for borderline personality disorder: a two-years follow-up. Psychiatry Research2016;240:151-6. [DOI: 10.1016/j.psychres.2016.04.014] [www.sciencedirect.com/science/article/pii/S0165178115302389]ZizzaM , FenocchioM , RinaldiC , BellinoS . Combined treatment of borderline personality disorder: a trial of modified interpersonal therapy. World Psychiatry2009;8(Suppl 1):234. ">Bellino 2010</a>). </p> <p>IPT reduced interpersonal problems at end of treatment compared with waiting list (MD −1.14, 95% CI −1.94 to −0.34; 1 trial, 44 participants; P = 0.005; <a href="./references#CD012955-fig-0163" title="">Analysis 18.8</a>.1). </p> <p>IPT reduced interpersonal problems at zero to six months follow‐up compared with waiting list (MD −2.00, 95% CI −2.98 to −1.02; 1 trial, 30 participants; P &lt; 0.001; <a href="./references#CD012955-fig-0163" title="">Analysis 18.8</a>.2). </p> <p>IPT reduced interpersonal problems at six to 12 months follow‐up compared with waiting list (MD −1.56, 95% CI −2.74 to −0.38; 1 trial, 30 participants; P = 0.009; <a href="./references#CD012955-fig-0163" title="">Analysis 18.8</a>.3). </p> <p>IPT reduced interpersonal problems above 12 months follow‐up compared with waiting list (MD −1.48, 95% CI −2.63 to −0.33; 1 trial, 30 participants; P = 0.01; <a href="./references#CD012955-fig-0163" title="">Analysis 18.8</a>.4). </p> </section> <section id="CD012955-sec-0305"> <h6 class="title">18.9 Abandonment</h6> <p>One trial reported continuous data on abandonment (<a href="./references#CD012955-bbs2-0008" title="BellinoS , BozzatelloP , BogettoF . Combined treatment of borderline personality disorder with interpersonal psychotherapy and pharmacotherapy: predictors of response. Psychiatry Research2015;226(1):284-8. [DOI: 10.1016/j.psychres.2014.12.064] [isiarticles.com/bundles/Article/pre/pdf/34125.pdf]BellinoS , RinaldiC , BogettoF . Adaptation of interpersonal psychotherapy to borderline personality disorder: a comparison of combined therapy and single pharmacotherapy. Canadian Journal of Psychiatry2010;55(2):74-81. [DOI: 10.1177/070674371005500203] [PMID: 20181302]BellinoS . Question regarding your BPD trials for inclusion in Cochrane Collaboration review [personal communication]. Email to: J Stoffers-Winterling 19 December 2010. BellinoS . Re: question regarding your BPD trials [personal communication]. Email to: J Stoffers 16 December 2010. BozzatelloP , BellinoS . Combined therapy with interpersonal psychotherapy adapted for borderline personality disorder: a two-years follow-up. Psychiatry Research2016;240:151-6. [DOI: 10.1016/j.psychres.2016.04.014] [www.sciencedirect.com/science/article/pii/S0165178115302389]ZizzaM , FenocchioM , RinaldiC , BellinoS . Combined treatment of borderline personality disorder: a trial of modified interpersonal therapy. World Psychiatry2009;8(Suppl 1):234. ">Bellino 2010</a>). </p> <p>IPT did not reduce abandonment at end of treatment compared with waiting list (MD 0.01, 95% CI −0.90 to 0.92; 1 trial, 44 participants; P = 0.98; <a href="./references#CD012955-fig-0164" title="">Analysis 18.9</a>). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> </section> <section id="CD012955-sec-0306"> <h6 class="title">18.10 Identity disturbance</h6> <p>One trial reported continuous data on identity disturbance (<a href="./references#CD012955-bbs2-0008" title="BellinoS , BozzatelloP , BogettoF . Combined treatment of borderline personality disorder with interpersonal psychotherapy and pharmacotherapy: predictors of response. Psychiatry Research2015;226(1):284-8. [DOI: 10.1016/j.psychres.2014.12.064] [isiarticles.com/bundles/Article/pre/pdf/34125.pdf]BellinoS , RinaldiC , BogettoF . Adaptation of interpersonal psychotherapy to borderline personality disorder: a comparison of combined therapy and single pharmacotherapy. Canadian Journal of Psychiatry2010;55(2):74-81. [DOI: 10.1177/070674371005500203] [PMID: 20181302]BellinoS . Question regarding your BPD trials for inclusion in Cochrane Collaboration review [personal communication]. Email to: J Stoffers-Winterling 19 December 2010. BellinoS . Re: question regarding your BPD trials [personal communication]. Email to: J Stoffers 16 December 2010. BozzatelloP , BellinoS . Combined therapy with interpersonal psychotherapy adapted for borderline personality disorder: a two-years follow-up. Psychiatry Research2016;240:151-6. [DOI: 10.1016/j.psychres.2016.04.014] [www.sciencedirect.com/science/article/pii/S0165178115302389]ZizzaM , FenocchioM , RinaldiC , BellinoS . Combined treatment of borderline personality disorder: a trial of modified interpersonal therapy. World Psychiatry2009;8(Suppl 1):234. ">Bellino 2010</a>). </p> <p>IPT did not reduce identity disturbance at end of treatment compared with waiting list (MD −0.03, 95% CI −0.56 to 0.50; 1 trial, 44 participants; P = 0.91; <a href="./references#CD012955-fig-0165" title="">Analysis 18.10</a>). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> </section> <section id="CD012955-sec-0307"> <h6 class="title">18.11 Dissociation and psychotic‐like symptoms</h6> <p>One trial reported continuous data on dissociation and psychotic‐like symptoms (<a href="./references#CD012955-bbs2-0008" title="BellinoS , BozzatelloP , BogettoF . Combined treatment of borderline personality disorder with interpersonal psychotherapy and pharmacotherapy: predictors of response. Psychiatry Research2015;226(1):284-8. [DOI: 10.1016/j.psychres.2014.12.064] [isiarticles.com/bundles/Article/pre/pdf/34125.pdf]BellinoS , RinaldiC , BogettoF . Adaptation of interpersonal psychotherapy to borderline personality disorder: a comparison of combined therapy and single pharmacotherapy. Canadian Journal of Psychiatry2010;55(2):74-81. [DOI: 10.1177/070674371005500203] [PMID: 20181302]BellinoS . Question regarding your BPD trials for inclusion in Cochrane Collaboration review [personal communication]. Email to: J Stoffers-Winterling 19 December 2010. BellinoS . Re: question regarding your BPD trials [personal communication]. Email to: J Stoffers 16 December 2010. BozzatelloP , BellinoS . Combined therapy with interpersonal psychotherapy adapted for borderline personality disorder: a two-years follow-up. Psychiatry Research2016;240:151-6. [DOI: 10.1016/j.psychres.2016.04.014] [www.sciencedirect.com/science/article/pii/S0165178115302389]ZizzaM , FenocchioM , RinaldiC , BellinoS . Combined treatment of borderline personality disorder: a trial of modified interpersonal therapy. World Psychiatry2009;8(Suppl 1):234. ">Bellino 2010</a>). </p> <p>IPT did not reduce dissociation and psychotic‐like symptoms at end of treatment compared with waiting list (MD 0.23, 95% CI −1.06 to 1.52; 1 trial, 44 participants; P = 0.73; <a href="./references#CD012955-fig-0166" title="">Analysis 18.11</a>). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> </section> <section id="CD012955-sec-0308"> <h6 class="title">18.12 Depression</h6> <p>Three trials reported continuous data on depression (<a href="./references#CD012955-bbs2-0006" title="BellinoS , ParadisoE , ZizzaM , Di LorenzoR , BogettoF . Combined therapy with interpersonal psychotherapy of major depressed patients with borderline personality disorder: a comparison with pharmacotherapy [Terapia combinata con psicoterapia interpersonale di pazienti depressi maggiori con disturbo borderline di personalità: confronto con la farmacoterapia]. Journal of Psychopathology2005;11(1):34-42. [bit.ly/2rZUh5h]BellinoS , ZizzaM , RinaldiC , BogettoF . Combined treatment of major depression in patients with borderline personality disorder: a comparison with pharmacotherapy. Canadian Journal of Psychiatry2006;51(7):453-60. [DOI: 10.1177/070674370605100707] [PMID: 16838827]">Bellino 2006</a>; <a href="./references#CD012955-bbs2-0008" title="BellinoS , BozzatelloP , BogettoF . Combined treatment of borderline personality disorder with interpersonal psychotherapy and pharmacotherapy: predictors of response. Psychiatry Research2015;226(1):284-8. [DOI: 10.1016/j.psychres.2014.12.064] [isiarticles.com/bundles/Article/pre/pdf/34125.pdf]BellinoS , RinaldiC , BogettoF . Adaptation of interpersonal psychotherapy to borderline personality disorder: a comparison of combined therapy and single pharmacotherapy. Canadian Journal of Psychiatry2010;55(2):74-81. [DOI: 10.1177/070674371005500203] [PMID: 20181302]BellinoS . Question regarding your BPD trials for inclusion in Cochrane Collaboration review [personal communication]. Email to: J Stoffers-Winterling 19 December 2010. BellinoS . Re: question regarding your BPD trials [personal communication]. Email to: J Stoffers 16 December 2010. BozzatelloP , BellinoS . Combined therapy with interpersonal psychotherapy adapted for borderline personality disorder: a two-years follow-up. Psychiatry Research2016;240:151-6. [DOI: 10.1016/j.psychres.2016.04.014] [www.sciencedirect.com/science/article/pii/S0165178115302389]ZizzaM , FenocchioM , RinaldiC , BellinoS . Combined treatment of borderline personality disorder: a trial of modified interpersonal therapy. World Psychiatry2009;8(Suppl 1):234. ">Bellino 2010</a>; <a href="./references#CD012955-bbs2-0068" title="SmithPN , GambleSA , CortNA , WardEA , HeH , TalbotNL . Attachment and alliance in the treatment of depressed, sexually abused women. Depression and Anxiety2012;29(2):123-30. [DOI: 10.1002/da.20913] [PMC3325338] [PMID: 22065593]SmithPN . Re: Cochrane Collaboration review of psychotherapies for BPD [personal communication]. Email to: J Stoffers-Winterling 05 July 2018. ">Smith 2012</a>). </p> <p>IPT did not reduce depression at end of treatment compared with waiting list (SMD −0.52, 95% CI −1.11 to 0.06; 3 trials, 98 participants; P = 0.08; <a href="./references#CD012955-fig-0167" title="">Analysis 18.12</a>; random‐effects model). </p> <p>IPT reduced depression at end of treatment compared with waiting list (SMD −0.46, 95% CI − 0.88 to −0.05; 3 trials, 98 participants; P = 0.03; analysis not shown; fixed‐effect model). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> </section> <section id="CD012955-sec-0309"> <h6 class="title">18.13 Attrition</h6> <p>Two trials reported dichotomous data on attrition (<a href="./references#CD012955-bbs2-0006" title="BellinoS , ParadisoE , ZizzaM , Di LorenzoR , BogettoF . Combined therapy with interpersonal psychotherapy of major depressed patients with borderline personality disorder: a comparison with pharmacotherapy [Terapia combinata con psicoterapia interpersonale di pazienti depressi maggiori con disturbo borderline di personalità: confronto con la farmacoterapia]. Journal of Psychopathology2005;11(1):34-42. [bit.ly/2rZUh5h]BellinoS , ZizzaM , RinaldiC , BogettoF . Combined treatment of major depression in patients with borderline personality disorder: a comparison with pharmacotherapy. Canadian Journal of Psychiatry2006;51(7):453-60. [DOI: 10.1177/070674370605100707] [PMID: 16838827]">Bellino 2006</a>; <a href="./references#CD012955-bbs2-0008" title="BellinoS , BozzatelloP , BogettoF . Combined treatment of borderline personality disorder with interpersonal psychotherapy and pharmacotherapy: predictors of response. Psychiatry Research2015;226(1):284-8. [DOI: 10.1016/j.psychres.2014.12.064] [isiarticles.com/bundles/Article/pre/pdf/34125.pdf]BellinoS , RinaldiC , BogettoF . Adaptation of interpersonal psychotherapy to borderline personality disorder: a comparison of combined therapy and single pharmacotherapy. Canadian Journal of Psychiatry2010;55(2):74-81. [DOI: 10.1177/070674371005500203] [PMID: 20181302]BellinoS . Question regarding your BPD trials for inclusion in Cochrane Collaboration review [personal communication]. Email to: J Stoffers-Winterling 19 December 2010. BellinoS . Re: question regarding your BPD trials [personal communication]. Email to: J Stoffers 16 December 2010. BozzatelloP , BellinoS . Combined therapy with interpersonal psychotherapy adapted for borderline personality disorder: a two-years follow-up. Psychiatry Research2016;240:151-6. [DOI: 10.1016/j.psychres.2016.04.014] [www.sciencedirect.com/science/article/pii/S0165178115302389]ZizzaM , FenocchioM , RinaldiC , BellinoS . Combined treatment of borderline personality disorder: a trial of modified interpersonal therapy. World Psychiatry2009;8(Suppl 1):234. ">Bellino 2010</a>). </p> <p>IPT did not reduce attrition at end of treatment compared with waiting list (RR 0.55, 95% CI 0.20 to 1.50; 2 trials, 94 participants; P = 0.24; <a href="./references#CD012955-fig-0168" title="">Analysis 18.13</a>). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> <p>No data were available on any time point for adverse effects.</p> </section> </section> </section> <section id="CD012955-sec-0310"> <h4 class="title">19. Once‐only interventions (individual setting) versus waiting list</h4> <section id="CD012955-sec-0311"> <h5 class="title">Primary outcomes</h5> <p>No data were available on any time point for BPD symptom severity, self‐harm, suicide‐related outcomes and psychosocial functioning. </p> </section> <section id="CD012955-sec-0312"> <h5 class="title">Secondary outcomes</h5> <section id="CD012955-sec-0313"> <h6 class="title">19.1 Impulsivity</h6> <p>One trial reported continuous data on impulsivity (<a href="./references#CD012955-bbs2-0074" title="ZanariniMC , FrankenburgFR . A preliminary, randomized trial of psychoeducation for women with borderline personality disorder. Journal of Personality Disorders2008;22(3):284-90. [DOI: 10.1521/pedi.2008.22.3.284] [PMID: 18540800]ZanariniMC , FrankenburgFR . A randomized trial of psychoeducation for patients with BPD. In: 157th annual meeting of the American Psychiatric Association. Psychotherapy and psychopharmacology: dissolving the mind-brain barrier; 2004 May 1-6; New York (NY). Arlington (VA): American Psychiatric Association, 2004:102. [Symposium 100E] [www.psychiatry.org/File%20Library/Psychiatrists/Directories/Library-and-Archive/conference_publications/am_program_2004.pdf]">Zanarini 2008</a>). </p> <p>Once‐only interventions did not reduce impulsivity at end of treatment compared with waiting list (MD −0.48, 95% CI −1.07 to 0.11; 1 trial, 50 participants; P = 0.11; <a href="./references#CD012955-fig-0169" title="">Analysis 19.1</a>). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> </section> <section id="CD012955-sec-0314"> <h6 class="title">19.2 Interpersonal problems</h6> <p>One trial reported continuous data on interpersonal problems (<a href="./references#CD012955-bbs2-0074" title="ZanariniMC , FrankenburgFR . A preliminary, randomized trial of psychoeducation for women with borderline personality disorder. Journal of Personality Disorders2008;22(3):284-90. [DOI: 10.1521/pedi.2008.22.3.284] [PMID: 18540800]ZanariniMC , FrankenburgFR . A randomized trial of psychoeducation for patients with BPD. In: 157th annual meeting of the American Psychiatric Association. Psychotherapy and psychopharmacology: dissolving the mind-brain barrier; 2004 May 1-6; New York (NY). Arlington (VA): American Psychiatric Association, 2004:102. [Symposium 100E] [www.psychiatry.org/File%20Library/Psychiatrists/Directories/Library-and-Archive/conference_publications/am_program_2004.pdf]">Zanarini 2008</a>). </p> <p>Once‐only interventions reduced interpersonal problems at end of treatment compared with waiting list (MD −0.88, 95% CI −1.59 to −0.17; 1 trial, 50 participants; P = 0.02; <a href="./references#CD012955-fig-0170" title="">Analysis 19.2</a>). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> </section> <section id="CD012955-sec-0315"> <h6 class="title">19.3 Attrition</h6> <p>One trial reported dichotomous data on attrition (<a href="./references#CD012955-bbs2-0074" title="ZanariniMC , FrankenburgFR . A preliminary, randomized trial of psychoeducation for women with borderline personality disorder. Journal of Personality Disorders2008;22(3):284-90. [DOI: 10.1521/pedi.2008.22.3.284] [PMID: 18540800]ZanariniMC , FrankenburgFR . A randomized trial of psychoeducation for patients with BPD. In: 157th annual meeting of the American Psychiatric Association. Psychotherapy and psychopharmacology: dissolving the mind-brain barrier; 2004 May 1-6; New York (NY). Arlington (VA): American Psychiatric Association, 2004:102. [Symposium 100E] [www.psychiatry.org/File%20Library/Psychiatrists/Directories/Library-and-Archive/conference_publications/am_program_2004.pdf]">Zanarini 2008</a>). </p> <p>There was no attrition at end of treatment in any of the groups (effect not estimable; one trial, 50 participants; <a href="./references#CD012955-fig-0171" title="">Analysis 19.3</a>). </p> <p>No data were available on any time point for anger, affective instability, chronic feelings of emptiness, abandonment, identity disturbance, dissociation and psychotic‐like symptoms, depression and adverse effects. </p> </section> </section> </section> <section id="CD012955-sec-0316"> <h4 class="title">20. Eclectic treatments versus waiting list</h4> <section id="CD012955-sec-0317"> <h5 class="title">20.1 Primary outcome: psychosocial functioning</h5> <p>One trial reported continuous data on psychosocial functioning (<a href="./references#CD012955-bbs2-0029" title="HaeyenS , Van HoorenS , HutschemaekersG . Efficacy of art therapy in individuals with personality disorders cluster B/C: a randomised controlled trial. International Journal of Psychology July 2016;51:60. [DOI: 10.1521/pedi_2017_31_312] [PMID: 28926306]HaeyenS , Van HoorenS , Van der VeldW , HutschemaekersG . Efficacy of art therapy in individuals with personality disorders cluster B/C: a randomised controlled trial. Journal of Personality Disorders2018;32(4):527-42. [DOI: 10.1521/pedi_2017_31_312] [PMID: 28926306]HaeyenS . Re: Cochrane Collaboration review of psychotherapies for BPD - your RCT of art therapy [personal communication]. Email to: J Stoffers-Winterling 18 August 2018. ">Haeyen 2018</a>). </p> <p>Eclectic treatments improved psychosocial functioning at end of treatment compared with waiting list (MD −18.64, 95% CI −30.06 to −7.22; 1 trial, 16 participants; P = 0.001; <a href="./references#CD012955-fig-0172" title="">Analysis 20.1</a>). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> <p>No data were available on any time point for BPD symptom severity, self‐harm, and suicide‐related outcomes. </p> </section> <section id="CD012955-sec-0318"> <h5 class="title">20.2 Secondary outcome: interpersonal problems</h5> <p>One trial reported continuous data on interpersonal problems (<a href="./references#CD012955-bbs2-0029" title="HaeyenS , Van HoorenS , HutschemaekersG . Efficacy of art therapy in individuals with personality disorders cluster B/C: a randomised controlled trial. International Journal of Psychology July 2016;51:60. [DOI: 10.1521/pedi_2017_31_312] [PMID: 28926306]HaeyenS , Van HoorenS , Van der VeldW , HutschemaekersG . Efficacy of art therapy in individuals with personality disorders cluster B/C: a randomised controlled trial. Journal of Personality Disorders2018;32(4):527-42. [DOI: 10.1521/pedi_2017_31_312] [PMID: 28926306]HaeyenS . Re: Cochrane Collaboration review of psychotherapies for BPD - your RCT of art therapy [personal communication]. Email to: J Stoffers-Winterling 18 August 2018. ">Haeyen 2018</a>). </p> <p>Eclectic treatments reduced interpersonal problems at end of treatment compared with waiting list (MD −4.89, 95% CI −8.49 to −1.29; 1 trial, 16 participants; P = 0.008; <a href="./references#CD012955-fig-0173" title="">Analysis 20.2</a>). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> <p>No data were available on any time point for anger, affective instability, chronic feelings of emptiness, impulsivity, abandonment, identity disturbance, dissociation and psychotic‐like symptoms, depression, attrition and adverse effects. </p> </section> </section> <section id="CD012955-sec-0319"> <h4 class="title">21. Dialectical behaviour therapy (DBT) and related treatments versus active treatment</h4> <section id="CD012955-sec-0320"> <h5 class="title">21.1 Standard DBT (DBT) versus client‐centred therapy (CCT) (continuous)</h5> <section id="CD012955-sec-0321"> <h6 class="title">Primary outcomes</h6> <section id="CD012955-sec-0322"> <p><b>Self‐harm</b></p> <p>One trial reported continuous data on self‐harm (<a href="./references#CD012955-bbs2-0071" title="TurnerRM . Naturalistic evaluation of dialectical behavior therapy-oriented treatment for borderline personality disorder. Cognitive and Behavioral Practice2000;7(4):413-9. [DOI: 10.1016/S1077-7229(00)80052-8]">Turner 2000</a>). </p> <p>DBT reduced self‐harm at end of treatment compared with CCT (MD −2.75, 95% CI −4.42 to −1.08; 1 trial, 24 participants; P = 0.001; <a href="./references#CD012955-fig-0174" title="">Analysis 21.1</a>.1). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> </section> <section id="CD012955-sec-0323"> <p><b>Suicide‐related outcomes</b></p> <p>One trial reported continuous data on suicide‐related outcomes (<a href="./references#CD012955-bbs2-0071" title="TurnerRM . Naturalistic evaluation of dialectical behavior therapy-oriented treatment for borderline personality disorder. Cognitive and Behavioral Practice2000;7(4):413-9. [DOI: 10.1016/S1077-7229(00)80052-8]">Turner 2000</a>). </p> <p>DBT reduced suicide‐related outcomes at end of treatment compared with CCT (MD −7.75, 95% CI −14.66 to −0.84; 1 trial, 24 participants; P = 0.03; <a href="./references#CD012955-fig-0174" title="">Analysis 21.1</a>.2). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> <p>No data were available on any time point for BPD symptom severity and psychosocial functioning. </p> </section> </section> <section id="CD012955-sec-0324"> <h6 class="title">Secondary outcomes</h6> <section id="CD012955-sec-0325"> <p><b>Anger</b></p> <p>One trial reported continuous data on anger (<a href="./references#CD012955-bbs2-0071" title="TurnerRM . Naturalistic evaluation of dialectical behavior therapy-oriented treatment for borderline personality disorder. Cognitive and Behavioral Practice2000;7(4):413-9. [DOI: 10.1016/S1077-7229(00)80052-8]">Turner 2000</a>). </p> <p>DBT reduced anger at end of treatment compared with CCT (MD −1.00, 95% CI −1.98 to −0.02; 1 trial, 24 participants; P = 0.05, <a href="./references#CD012955-fig-0174" title="">Analysis 21.1</a>.3). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> </section> <section id="CD012955-sec-0326"> <p><b>Impulsivity</b></p> <p>One trial reported continuous data on impulsivity (<a href="./references#CD012955-bbs2-0071" title="TurnerRM . Naturalistic evaluation of dialectical behavior therapy-oriented treatment for borderline personality disorder. Cognitive and Behavioral Practice2000;7(4):413-9. [DOI: 10.1016/S1077-7229(00)80052-8]">Turner 2000</a>). </p> <p>DBT reduced impulsivity at end of treatment compared with CCT (MD −1.50, 95% CI −2.60 to −0.40; 1 trial, 24 participants; P = 0.008; <a href="./references#CD012955-fig-0174" title="">Analysis 21.1</a>.4). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> </section> <section id="CD012955-sec-0327"> <p><b>Dissociation and psychotic‐like symptoms</b></p> <p>One trial reported continuous data on dissociation and psychotic‐like symptoms (<a href="./references#CD012955-bbs2-0071" title="TurnerRM . Naturalistic evaluation of dialectical behavior therapy-oriented treatment for borderline personality disorder. Cognitive and Behavioral Practice2000;7(4):413-9. [DOI: 10.1016/S1077-7229(00)80052-8]">Turner 2000</a>). </p> <p>DBT reduced dissociation and psychotic‐like symptoms at end of treatment compared with CCT (MD −7.16, 95% CI −12.15 to −2.17; 1 trial, 24 participants; P = 0.005; <a href="./references#CD012955-fig-0174" title="">Analysis 21.1</a>.5). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> </section> <section id="CD012955-sec-0328"> <p><b>Depression</b></p> <p>One trial reported continuous data on depression (<a href="./references#CD012955-bbs2-0071" title="TurnerRM . Naturalistic evaluation of dialectical behavior therapy-oriented treatment for borderline personality disorder. Cognitive and Behavioral Practice2000;7(4):413-9. [DOI: 10.1016/S1077-7229(00)80052-8]">Turner 2000</a>). </p> <p>DBT reduced depression at end of treatment compared with CCT (MD −9.16, 95% CI −14.79 to −3.53; 1 trial, 24 participants; P = 0.001; <a href="./references#CD012955-fig-0174" title="">Analysis 21.1</a>.6). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> <p>No data were available on any time point for affective instability, chronic feelings of emptiness, interpersonal problems, abandonment, identity disturbance, attrition, and adverse effects. </p> </section> </section> </section> <section id="CD012955-sec-0329"> <h5 class="title">21.2 DBT versus CCT (dichotomous)</h5> <section id="CD012955-sec-0330"> <h6 class="title">Primary outcomes</h6> <p>No data were available on any time point for BPD symptom severity, self‐harm, suicide‐related outcomes, and psychosocial functioning. </p> </section> <section id="CD012955-sec-0331"> <h6 class="title">Secondary outcome: attrition</h6> <p>One trial reported dichotomous data on attrition (<a href="./references#CD012955-bbs2-0071" title="TurnerRM . Naturalistic evaluation of dialectical behavior therapy-oriented treatment for borderline personality disorder. Cognitive and Behavioral Practice2000;7(4):413-9. [DOI: 10.1016/S1077-7229(00)80052-8]">Turner 2000</a>). </p> <p>DBT did not reduce attrition at end of treatment compared with CCT (RR 0.50, 95% CI 0.16 to 1.55; 1 trial, 24 participants; P = 0.23; <a href="./references#CD012955-fig-0175" title="">Analysis 21.2</a>). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> <p>No data were available on any time point for anger, affective instability, chronic feelings of emptiness, impulsivity, interpersonal problems, abandonment, identity disturbance, dissociation and psychotic‐like symptoms. depression, and adverse effects. </p> </section> </section> <section id="CD012955-sec-0332"> <h5 class="title">21.3 Standard DBT (DBT) versus good psychiatric management (GPM) (continuous)</h5> <section id="CD012955-sec-0333"> <h6 class="title">Primary outcomes</h6> <section id="CD012955-sec-0334"> <p><b>BPD symptom severity</b></p> <p>One trial reported continuous data on BPD symptom severity (<a href="./references#CD012955-bbs2-0049" title="CaseBG . Letter to the editor on 'McMain SF, Links PS, Gnam WH, Guimond T, Cardish RJ, Korman L, et al. A randomized trial of dialectical behavior therapy versus general psychiatric management for borderline personality disorder. American Journal of Psychiatry 2009;166(12):1365-74. DOI: 10.1176/appi.ajp.2009.09010039'. American Journal of Psychiatry2010;167(4):475. [DOI: 10.1176/appi.ajp.2009.09101532] [PMID: 20360332 ]ISRCTN02634417. Hope for chronically suicidal patient: evaluating the clinical and health services impact of dialectical behaviour therapy (DBT) in individuals with borderline personality disorder [Evaluating the clinical and health services impact of dialectical behaviour therapy (DBT) in individuals with borderline personality disorder: a randomised controlled trial]. www.isrctn.com/ISRCTN02634417 (first received 16 November 2005). [DOI: 10.1186/ISRCTN02634417]McMainSF , FitzpatrickS , BoritzT , BarnhartR , LinksP , StreinerDL . Outcome trajectories and prognostic factors for suicide and self-harm behaviors in patients with borderline personaliy disorder following one year of outpatient psychotherapy. Journal of Personality Disorders2018;32(4):497-512. [DOI: 10.1521/pedi_2017_31_309] [PMID: 28910214]McMainSF , LinksPS , GnamWH , GuimondT , CardishRJ , KormanL , et al. A randomized trial of dialectical behavior therapy versus general psychiatric management for borderline personality disorder. American Journal of Psychiatry2009;166(12):1365-74. [DOI: 10.1176/appi.ajp.2009.09010039] [PMID: 19755574]McMainSF . Dr McMain replies to letter to the editor on 'McMain SF, Links PS, Gnam WH, Guimond T, Cardish RJ, Korman L, et al. A randomized trial of dialectical behavior therapy versus general psychiatric management for borderline personality disorder. American Journal of Psychiatry 2009;166(12):1365-74. DOI: 10.1176/appi.ajp.2009.09010039'. American Journal of Psychiatry2010;167(4):475-6. [DOI: 10.1176/appi.ajp.2009.09101532r)]NCT00154154. Hope for the chronically suicidal patient [Hope for the chronically suicidal patient: evaluating the clinical and health services impact of dialectical behaviour therapy in individuals with borderline personality disorder]. www.clinicaltrials.gov/ct2/show/NCT00154154 (first received 7 September 2005). ">McMain 2009</a>). </p> <p>DBT did not reduce BPD symptom severity at end of treatment compared with GPM (MD −0.23, 95% CI −1.97 to 1.51; 1 trial, 180 participants; P = 0.80; <a href="./references#CD012955-fig-0176" title="">Analysis 21.3</a>.1). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> </section> <section id="CD012955-sec-0335"> <p><b>Self‐harm</b></p> <p>One trial reported continuous data on self‐harm (<a href="./references#CD012955-bbs2-0049" title="CaseBG . Letter to the editor on 'McMain SF, Links PS, Gnam WH, Guimond T, Cardish RJ, Korman L, et al. A randomized trial of dialectical behavior therapy versus general psychiatric management for borderline personality disorder. American Journal of Psychiatry 2009;166(12):1365-74. DOI: 10.1176/appi.ajp.2009.09010039'. American Journal of Psychiatry2010;167(4):475. [DOI: 10.1176/appi.ajp.2009.09101532] [PMID: 20360332 ]ISRCTN02634417. Hope for chronically suicidal patient: evaluating the clinical and health services impact of dialectical behaviour therapy (DBT) in individuals with borderline personality disorder [Evaluating the clinical and health services impact of dialectical behaviour therapy (DBT) in individuals with borderline personality disorder: a randomised controlled trial]. www.isrctn.com/ISRCTN02634417 (first received 16 November 2005). [DOI: 10.1186/ISRCTN02634417]McMainSF , FitzpatrickS , BoritzT , BarnhartR , LinksP , StreinerDL . Outcome trajectories and prognostic factors for suicide and self-harm behaviors in patients with borderline personaliy disorder following one year of outpatient psychotherapy. Journal of Personality Disorders2018;32(4):497-512. [DOI: 10.1521/pedi_2017_31_309] [PMID: 28910214]McMainSF , LinksPS , GnamWH , GuimondT , CardishRJ , KormanL , et al. A randomized trial of dialectical behavior therapy versus general psychiatric management for borderline personality disorder. American Journal of Psychiatry2009;166(12):1365-74. [DOI: 10.1176/appi.ajp.2009.09010039] [PMID: 19755574]McMainSF . Dr McMain replies to letter to the editor on 'McMain SF, Links PS, Gnam WH, Guimond T, Cardish RJ, Korman L, et al. A randomized trial of dialectical behavior therapy versus general psychiatric management for borderline personality disorder. American Journal of Psychiatry 2009;166(12):1365-74. DOI: 10.1176/appi.ajp.2009.09010039'. American Journal of Psychiatry2010;167(4):475-6. [DOI: 10.1176/appi.ajp.2009.09101532r)]NCT00154154. Hope for the chronically suicidal patient [Hope for the chronically suicidal patient: evaluating the clinical and health services impact of dialectical behaviour therapy in individuals with borderline personality disorder]. www.clinicaltrials.gov/ct2/show/NCT00154154 (first received 7 September 2005). ">McMain 2009</a>). </p> <p>DBT did not reduce self‐harm at end of treatment compared with GPM (MD −8.58, 95% CI −19.38 to 2.22; 1 trial, 180 participants; P = 0.12; <a href="./references#CD012955-fig-0176" title="">Analysis 21.3</a>.2). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> <p>No data were available on any time point for suicide‐related outcomes and psychosocial functioning. </p> </section> </section> <section id="CD012955-sec-0336"> <h6 class="title">Secondary outcomes</h6> <section id="CD012955-sec-0337"> <p><b>Anger</b></p> <p>One trial reported continuous data on anger (<a href="./references#CD012955-bbs2-0049" title="CaseBG . Letter to the editor on 'McMain SF, Links PS, Gnam WH, Guimond T, Cardish RJ, Korman L, et al. A randomized trial of dialectical behavior therapy versus general psychiatric management for borderline personality disorder. American Journal of Psychiatry 2009;166(12):1365-74. DOI: 10.1176/appi.ajp.2009.09010039'. American Journal of Psychiatry2010;167(4):475. [DOI: 10.1176/appi.ajp.2009.09101532] [PMID: 20360332 ]ISRCTN02634417. Hope for chronically suicidal patient: evaluating the clinical and health services impact of dialectical behaviour therapy (DBT) in individuals with borderline personality disorder [Evaluating the clinical and health services impact of dialectical behaviour therapy (DBT) in individuals with borderline personality disorder: a randomised controlled trial]. www.isrctn.com/ISRCTN02634417 (first received 16 November 2005). [DOI: 10.1186/ISRCTN02634417]McMainSF , FitzpatrickS , BoritzT , BarnhartR , LinksP , StreinerDL . Outcome trajectories and prognostic factors for suicide and self-harm behaviors in patients with borderline personaliy disorder following one year of outpatient psychotherapy. Journal of Personality Disorders2018;32(4):497-512. [DOI: 10.1521/pedi_2017_31_309] [PMID: 28910214]McMainSF , LinksPS , GnamWH , GuimondT , CardishRJ , KormanL , et al. A randomized trial of dialectical behavior therapy versus general psychiatric management for borderline personality disorder. American Journal of Psychiatry2009;166(12):1365-74. [DOI: 10.1176/appi.ajp.2009.09010039] [PMID: 19755574]McMainSF . Dr McMain replies to letter to the editor on 'McMain SF, Links PS, Gnam WH, Guimond T, Cardish RJ, Korman L, et al. A randomized trial of dialectical behavior therapy versus general psychiatric management for borderline personality disorder. American Journal of Psychiatry 2009;166(12):1365-74. DOI: 10.1176/appi.ajp.2009.09010039'. American Journal of Psychiatry2010;167(4):475-6. [DOI: 10.1176/appi.ajp.2009.09101532r)]NCT00154154. Hope for the chronically suicidal patient [Hope for the chronically suicidal patient: evaluating the clinical and health services impact of dialectical behaviour therapy in individuals with borderline personality disorder]. www.clinicaltrials.gov/ct2/show/NCT00154154 (first received 7 September 2005). ">McMain 2009</a>). </p> <p>DBT did not reduce anger at end of treatment compared with GPM (MD −0.15, 95% CI −1.65 to 1.35; 1 trial, 180 participants; P = 0.85; <a href="./references#CD012955-fig-0176" title="">Analysis 21.3</a>.3). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> </section> <section id="CD012955-sec-0338"> <p><b>Interpersonal problems</b></p> <p>One trial reported continuous data on interpersonal problems (<a href="./references#CD012955-bbs2-0049" title="CaseBG . Letter to the editor on 'McMain SF, Links PS, Gnam WH, Guimond T, Cardish RJ, Korman L, et al. A randomized trial of dialectical behavior therapy versus general psychiatric management for borderline personality disorder. American Journal of Psychiatry 2009;166(12):1365-74. DOI: 10.1176/appi.ajp.2009.09010039'. American Journal of Psychiatry2010;167(4):475. [DOI: 10.1176/appi.ajp.2009.09101532] [PMID: 20360332 ]ISRCTN02634417. Hope for chronically suicidal patient: evaluating the clinical and health services impact of dialectical behaviour therapy (DBT) in individuals with borderline personality disorder [Evaluating the clinical and health services impact of dialectical behaviour therapy (DBT) in individuals with borderline personality disorder: a randomised controlled trial]. www.isrctn.com/ISRCTN02634417 (first received 16 November 2005). [DOI: 10.1186/ISRCTN02634417]McMainSF , FitzpatrickS , BoritzT , BarnhartR , LinksP , StreinerDL . Outcome trajectories and prognostic factors for suicide and self-harm behaviors in patients with borderline personaliy disorder following one year of outpatient psychotherapy. Journal of Personality Disorders2018;32(4):497-512. [DOI: 10.1521/pedi_2017_31_309] [PMID: 28910214]McMainSF , LinksPS , GnamWH , GuimondT , CardishRJ , KormanL , et al. A randomized trial of dialectical behavior therapy versus general psychiatric management for borderline personality disorder. American Journal of Psychiatry2009;166(12):1365-74. [DOI: 10.1176/appi.ajp.2009.09010039] [PMID: 19755574]McMainSF . Dr McMain replies to letter to the editor on 'McMain SF, Links PS, Gnam WH, Guimond T, Cardish RJ, Korman L, et al. A randomized trial of dialectical behavior therapy versus general psychiatric management for borderline personality disorder. American Journal of Psychiatry 2009;166(12):1365-74. DOI: 10.1176/appi.ajp.2009.09010039'. American Journal of Psychiatry2010;167(4):475-6. [DOI: 10.1176/appi.ajp.2009.09101532r)]NCT00154154. Hope for the chronically suicidal patient [Hope for the chronically suicidal patient: evaluating the clinical and health services impact of dialectical behaviour therapy in individuals with borderline personality disorder]. www.clinicaltrials.gov/ct2/show/NCT00154154 (first received 7 September 2005). ">McMain 2009</a>). </p> <p>DBT did not reduce interpersonal problems at end of treatment compared with GPM (MD −1.34, 95% CI −15.36 to 12.68; 1 trial, 180 participants; P = 0.85; <a href="./references#CD012955-fig-0176" title="">Analysis 21.3</a>.4). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> </section> <section id="CD012955-sec-0339"> <p><b>Depression</b></p> <p>One trial reported continuous data on depression (<a href="./references#CD012955-bbs2-0049" title="CaseBG . Letter to the editor on 'McMain SF, Links PS, Gnam WH, Guimond T, Cardish RJ, Korman L, et al. A randomized trial of dialectical behavior therapy versus general psychiatric management for borderline personality disorder. American Journal of Psychiatry 2009;166(12):1365-74. DOI: 10.1176/appi.ajp.2009.09010039'. American Journal of Psychiatry2010;167(4):475. [DOI: 10.1176/appi.ajp.2009.09101532] [PMID: 20360332 ]ISRCTN02634417. Hope for chronically suicidal patient: evaluating the clinical and health services impact of dialectical behaviour therapy (DBT) in individuals with borderline personality disorder [Evaluating the clinical and health services impact of dialectical behaviour therapy (DBT) in individuals with borderline personality disorder: a randomised controlled trial]. www.isrctn.com/ISRCTN02634417 (first received 16 November 2005). [DOI: 10.1186/ISRCTN02634417]McMainSF , FitzpatrickS , BoritzT , BarnhartR , LinksP , StreinerDL . Outcome trajectories and prognostic factors for suicide and self-harm behaviors in patients with borderline personaliy disorder following one year of outpatient psychotherapy. Journal of Personality Disorders2018;32(4):497-512. [DOI: 10.1521/pedi_2017_31_309] [PMID: 28910214]McMainSF , LinksPS , GnamWH , GuimondT , CardishRJ , KormanL , et al. A randomized trial of dialectical behavior therapy versus general psychiatric management for borderline personality disorder. American Journal of Psychiatry2009;166(12):1365-74. [DOI: 10.1176/appi.ajp.2009.09010039] [PMID: 19755574]McMainSF . Dr McMain replies to letter to the editor on 'McMain SF, Links PS, Gnam WH, Guimond T, Cardish RJ, Korman L, et al. A randomized trial of dialectical behavior therapy versus general psychiatric management for borderline personality disorder. American Journal of Psychiatry 2009;166(12):1365-74. DOI: 10.1176/appi.ajp.2009.09010039'. American Journal of Psychiatry2010;167(4):475-6. [DOI: 10.1176/appi.ajp.2009.09101532r)]NCT00154154. Hope for the chronically suicidal patient [Hope for the chronically suicidal patient: evaluating the clinical and health services impact of dialectical behaviour therapy in individuals with borderline personality disorder]. www.clinicaltrials.gov/ct2/show/NCT00154154 (first received 7 September 2005). ">McMain 2009</a>). </p> <p>DBT did not reduce depression at end of treatment compared with GPM (MD −2.65, 95% CI −7.18 to 1.88; 1 trial, 180 participants; P = 0.25; <a href="./references#CD012955-fig-0176" title="">Analysis 21.3</a>.5). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> <p>No data were available on any time point for affective instability, chronic feelings of emptiness, impulsivity, abandonment, identity disturbance, dissociation and psychotic‐like symptoms, attrition, and adverse effects. </p> </section> </section> </section> <section id="CD012955-sec-0340"> <h5 class="title">21.4 DBT versus GPM (dichotomous)</h5> <section id="CD012955-sec-0341"> <h6 class="title">Primary outcomes</h6> <p>No data were available on any time point for BPD symptom severity, self‐harm, suicide‐related outcomes, and psychosocial functioning. </p> </section> <section id="CD012955-sec-0342"> <h6 class="title">Secondary outcome: attrition</h6> <p>One trial reported dichotomous data on attrition (<a href="./references#CD012955-bbs2-0049" title="CaseBG . Letter to the editor on 'McMain SF, Links PS, Gnam WH, Guimond T, Cardish RJ, Korman L, et al. A randomized trial of dialectical behavior therapy versus general psychiatric management for borderline personality disorder. American Journal of Psychiatry 2009;166(12):1365-74. DOI: 10.1176/appi.ajp.2009.09010039'. American Journal of Psychiatry2010;167(4):475. [DOI: 10.1176/appi.ajp.2009.09101532] [PMID: 20360332 ]ISRCTN02634417. Hope for chronically suicidal patient: evaluating the clinical and health services impact of dialectical behaviour therapy (DBT) in individuals with borderline personality disorder [Evaluating the clinical and health services impact of dialectical behaviour therapy (DBT) in individuals with borderline personality disorder: a randomised controlled trial]. www.isrctn.com/ISRCTN02634417 (first received 16 November 2005). [DOI: 10.1186/ISRCTN02634417]McMainSF , FitzpatrickS , BoritzT , BarnhartR , LinksP , StreinerDL . Outcome trajectories and prognostic factors for suicide and self-harm behaviors in patients with borderline personaliy disorder following one year of outpatient psychotherapy. Journal of Personality Disorders2018;32(4):497-512. [DOI: 10.1521/pedi_2017_31_309] [PMID: 28910214]McMainSF , LinksPS , GnamWH , GuimondT , CardishRJ , KormanL , et al. A randomized trial of dialectical behavior therapy versus general psychiatric management for borderline personality disorder. American Journal of Psychiatry2009;166(12):1365-74. [DOI: 10.1176/appi.ajp.2009.09010039] [PMID: 19755574]McMainSF . Dr McMain replies to letter to the editor on 'McMain SF, Links PS, Gnam WH, Guimond T, Cardish RJ, Korman L, et al. A randomized trial of dialectical behavior therapy versus general psychiatric management for borderline personality disorder. American Journal of Psychiatry 2009;166(12):1365-74. DOI: 10.1176/appi.ajp.2009.09010039'. American Journal of Psychiatry2010;167(4):475-6. [DOI: 10.1176/appi.ajp.2009.09101532r)]NCT00154154. Hope for the chronically suicidal patient [Hope for the chronically suicidal patient: evaluating the clinical and health services impact of dialectical behaviour therapy in individuals with borderline personality disorder]. www.clinicaltrials.gov/ct2/show/NCT00154154 (first received 7 September 2005). ">McMain 2009</a>). </p> <p>DBT did not reduce attrition at end of treatment compared with GPM (RR 1.03, 95% CI 0.71 to 1.49; 1 trial, 180 participants; P = 0.88; <a href="./references#CD012955-fig-0177" title="">Analysis 21.4</a>). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> <p>No data were available on any time point for anger, affective instability, chronic feelings of emptiness, impulsivity, interpersonal problems, abandonment, identity disturbance, dissociation and psychotic‐like symptoms, depression, and adverse effects. </p> </section> </section> <section id="CD012955-sec-0343"> <h5 class="title">21.5 Standard DBT (DBT) versus individual DBT therapy + activities group (DBT‐I) (continuous)</h5> <section id="CD012955-sec-0344"> <h6 class="title">Primary outcomes</h6> <section id="CD012955-sec-0345"> <p><b>Self‐harm</b></p> <p>One trial reported continuous data on self‐harm (<a href="./references#CD012955-bbs2-0048" title="LinehanMM , KorslundKE , HarnedMS , GallopRJ , LunguA , NeacsiuAD , et al. Dialectical behavior therapy for high suicide risk in individuals with borderline personality disorder: a randomized clinical trial and component analysis. JAMA Psychiatry2015;72(5):475-82 Erratum for: JAMA Psychiatry 2015; 72(9): 951. [DOI: 10.1001/jamapsychiatry.2014.3039] [PMID: 25806661]NCT00183651. Treatment of suicidal women with borderline personality disorder [Assessment and treatment of parasuicidal patients]. www.clinicaltrials.gov/ct2/show/NCT00183651 (first received 13 September 2005). ">Linehan 2015a</a>). </p> <p>DBT did not reduce self‐harm at end of treatment compared with DBT‐I (MD −10.40, 95% CI −22.99 to 2.19; 1 trial, 66 participants; P = 0.11; <a href="./references#CD012955-fig-0178" title="">Analysis 21.5</a>.1). </p> <p>DBT did not reduce self‐harm at six to 12 months compared with DBT‐I (MD −8.10, 95% CI −19.59 to 3.39; 1 trial, 66 participants; P = 0.17; <a href="./references#CD012955-fig-0178" title="">Analysis 21.5</a>.2). </p> <p>No data were available for zero to six months and above 12 months follow‐up.</p> </section> <section id="CD012955-sec-0346"> <p><b>Suicide‐related outcomes</b></p> <p>One trial reported continuous data on suicide‐related outcomes (<a href="./references#CD012955-bbs2-0048" title="LinehanMM , KorslundKE , HarnedMS , GallopRJ , LunguA , NeacsiuAD , et al. Dialectical behavior therapy for high suicide risk in individuals with borderline personality disorder: a randomized clinical trial and component analysis. JAMA Psychiatry2015;72(5):475-82 Erratum for: JAMA Psychiatry 2015; 72(9): 951. [DOI: 10.1001/jamapsychiatry.2014.3039] [PMID: 25806661]NCT00183651. Treatment of suicidal women with borderline personality disorder [Assessment and treatment of parasuicidal patients]. www.clinicaltrials.gov/ct2/show/NCT00183651 (first received 13 September 2005). ">Linehan 2015a</a>). </p> <p>DBT did not reduce suicide‐related outcomes at end of treatment compared with DBT‐I (MD 0.50, 95% CI −1.37 to 2.37; 1 trial, 66 participants; P = 0.60; <a href="./references#CD012955-fig-0178" title="">Analysis 21.5</a>.3). </p> <p>DBT reduced suicide‐related outcomes at six to 12 months follow‐up compared with DBT‐I (MD −1.60, 95% CI −2.79 to −0.41; 1 trial, 66 participants; P = 0.009; <a href="./references#CD012955-fig-0178" title="">Analysis 21.5</a>.4). </p> <p>No data were available for zero to six months and above 12 months follow‐up.</p> <p>No data were available on any time point for BPD symptom severity and psychosocial functioning. </p> </section> </section> <section id="CD012955-sec-0347"> <h6 class="title">Secondary outcomes: depression</h6> <p>One trial reported continuous data on depression (<a href="./references#CD012955-bbs2-0048" title="LinehanMM , KorslundKE , HarnedMS , GallopRJ , LunguA , NeacsiuAD , et al. Dialectical behavior therapy for high suicide risk in individuals with borderline personality disorder: a randomized clinical trial and component analysis. JAMA Psychiatry2015;72(5):475-82 Erratum for: JAMA Psychiatry 2015; 72(9): 951. [DOI: 10.1001/jamapsychiatry.2014.3039] [PMID: 25806661]NCT00183651. Treatment of suicidal women with borderline personality disorder [Assessment and treatment of parasuicidal patients]. www.clinicaltrials.gov/ct2/show/NCT00183651 (first received 13 September 2005). ">Linehan 2015a</a>). </p> <p>DBT reduced depression at end of treatment compared with DBT‐I (MD −5.90, 95% CI −9.74 to −2.06; 1 trial, 66 participants; P = 0.003, <a href="./references#CD012955-fig-0178" title="">Analysis 21.5</a>.5). </p> <p>DBT did not reduce depression at six to 12 months follow‐up compared with DBT‐I (MD 1.30, 95% CI −3.10 to 5.70; 1 trial, 66 participants; P = 0.56; <a href="./references#CD012955-fig-0178" title="">Analysis 21.5</a>.6). </p> <p>No data were available for zero to six months and above 12 months follow‐up.</p> <p>No data were available on any time point for anger, affective instability, chronic feelings of emptiness, impulsivity, interpersonal problems, abandonment, identity disturbance, dissociation and psychotic‐like symptoms, attrition, and adverse effects. </p> </section> </section> <section id="CD012955-sec-0348"> <h5 class="title">21.6 DBT versus GPM (dichotomous)</h5> <section id="CD012955-sec-0349"> <h6 class="title">Primary outcomes</h6> <p>No data were available on any time point for BPD symptom severity, self‐harm, suicide‐related outcomes, and psychosocial functioning. </p> </section> <section id="CD012955-sec-0350"> <h6 class="title">Secondary outcome: attrition</h6> <p>One trial reported dichotomous data on attrition (<a href="./references#CD012955-bbs2-0048" title="LinehanMM , KorslundKE , HarnedMS , GallopRJ , LunguA , NeacsiuAD , et al. Dialectical behavior therapy for high suicide risk in individuals with borderline personality disorder: a randomized clinical trial and component analysis. JAMA Psychiatry2015;72(5):475-82 Erratum for: JAMA Psychiatry 2015; 72(9): 951. [DOI: 10.1001/jamapsychiatry.2014.3039] [PMID: 25806661]NCT00183651. Treatment of suicidal women with borderline personality disorder [Assessment and treatment of parasuicidal patients]. www.clinicaltrials.gov/ct2/show/NCT00183651 (first received 13 September 2005). ">Linehan 2015a</a>). </p> <p>DBT did not reduce attrition at end of treatment compared with DBT‐I (RR 0.50, 95% CI 0.25 to 1.01; 1 trial, 66 participants; P = 0.05; <a href="./references#CD012955-fig-0179" title="">Analysis 21.6</a>). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> <p>No data were available on any time point for anger, affective instability, chronic feelings of emptiness, impulsivity, interpersonal problems, abandonment, identity disturbance, dissociation and psychotic‐like symptoms, depression, and adverse effects. </p> </section> </section> <section id="CD012955-sec-0351"> <h5 class="title">21.7 Standard DBT (DBT) versus skills training group + individual case management (DBT‐S) (continuous) </h5> <section id="CD012955-sec-0352"> <h6 class="title">Primary outcomes</h6> <section id="CD012955-sec-0353"> <p><b>Self‐harm</b></p> <p>One trial reported continuous data on self‐harm (<a href="./references#CD012955-bbs2-0048" title="LinehanMM , KorslundKE , HarnedMS , GallopRJ , LunguA , NeacsiuAD , et al. Dialectical behavior therapy for high suicide risk in individuals with borderline personality disorder: a randomized clinical trial and component analysis. JAMA Psychiatry2015;72(5):475-82 Erratum for: JAMA Psychiatry 2015; 72(9): 951. [DOI: 10.1001/jamapsychiatry.2014.3039] [PMID: 25806661]NCT00183651. Treatment of suicidal women with borderline personality disorder [Assessment and treatment of parasuicidal patients]. www.clinicaltrials.gov/ct2/show/NCT00183651 (first received 13 September 2005). ">Linehan 2015a</a>). </p> <p>DBT did not reduce self‐harm at end of treatment compared with DBT‐S (MD 0.30, 95% CI −8.42 to 9.02; 1 trial, 66 participants, P = 0.95; <a href="./references#CD012955-fig-0180" title="">Analysis 21.7</a>.1). </p> <p>DBT did not reduce self‐harm at six to 12 months follow‐up compared with DBT‐S (MD −1.50, 95% CI −9.04 to 6.04, 1 trial, 66 participants; P = 0.70; <a href="./references#CD012955-fig-0180" title="">Analysis 21.7</a>.2). </p> <p>No data were available for zero to six months and above 12 months follow‐up.</p> </section> <section id="CD012955-sec-0354"> <p><b>Suicide‐related outcomes</b></p> <p>One trial reported continuous data on suicide‐related outcomes (<a href="./references#CD012955-bbs2-0048" title="LinehanMM , KorslundKE , HarnedMS , GallopRJ , LunguA , NeacsiuAD , et al. Dialectical behavior therapy for high suicide risk in individuals with borderline personality disorder: a randomized clinical trial and component analysis. JAMA Psychiatry2015;72(5):475-82 Erratum for: JAMA Psychiatry 2015; 72(9): 951. [DOI: 10.1001/jamapsychiatry.2014.3039] [PMID: 25806661]NCT00183651. Treatment of suicidal women with borderline personality disorder [Assessment and treatment of parasuicidal patients]. www.clinicaltrials.gov/ct2/show/NCT00183651 (first received 13 September 2005). ">Linehan 2015a</a>). </p> <p>DBT did not reduce suicide‐related outcomes at end of treatment compared with DBT‐S (MD 0.80, 95% CI −1.06 to 2.66; 1 trial, 66 participants; P = 0.40; <a href="./references#CD012955-fig-0180" title="">Analysis 21.7</a>.3). </p> <p>DBT reduced suicide‐related outcomes at six to 12 months follow‐up compared with DBT‐S (MD 0.50, 95% CI −0.02 to 1.02; 1 trial, 66 participants; P = 0.06; <a href="./references#CD012955-fig-0180" title="">Analysis 21.7</a>.4). </p> <p>No data were available for zero to six months and above 12 months follow‐up.</p> <p>No data were available on any time point for BPD symptom severity and psychosocial functioning. </p> </section> </section> <section id="CD012955-sec-0355"> <h6 class="title">Secondary outcomes: depression</h6> <p>One trial reported continuous data on depression (<a href="./references#CD012955-bbs2-0048" title="LinehanMM , KorslundKE , HarnedMS , GallopRJ , LunguA , NeacsiuAD , et al. Dialectical behavior therapy for high suicide risk in individuals with borderline personality disorder: a randomized clinical trial and component analysis. JAMA Psychiatry2015;72(5):475-82 Erratum for: JAMA Psychiatry 2015; 72(9): 951. [DOI: 10.1001/jamapsychiatry.2014.3039] [PMID: 25806661]NCT00183651. Treatment of suicidal women with borderline personality disorder [Assessment and treatment of parasuicidal patients]. www.clinicaltrials.gov/ct2/show/NCT00183651 (first received 13 September 2005). ">Linehan 2015a</a>). </p> <p>DBT did not reduce depression at end of treatment compared with DBT‐S (MD 1.90, 95% CI −1.60 to 5.40; 1 trial, 66 participants; P = 0.29; <a href="./references#CD012955-fig-0180" title="">Analysis 21.7</a>.5). </p> <p>DBT did not reduce depression at six to 12 months follow‐up compared with DBT‐S (MD 3.30, 95% CI −0.90 to 7.50; 1 trial, 66 participants; P = 0.12; <a href="./references#CD012955-fig-0180" title="">Analysis 21.7</a>.6). </p> <p>No data were available for zero to six months, and above 12 months follow‐up.</p> <p>No data were available on any time point for anger, affective instability, chronic feelings of emptiness, impulsivity, interpersonal problems, abandonment, identity disturbance, dissociation and psychotic‐like symptoms, attrition, and adverse effects. </p> </section> </section> <section id="CD012955-sec-0356"> <h5 class="title">21.8 DBT versus DBT‐S (dichotomous)</h5> <section id="CD012955-sec-0357"> <h6 class="title">Primary outcomes</h6> <p>No data were available on any time point for BPD symptom severity, self‐harm, suicide‐related outcomes and psychosocial functioning. </p> </section> <section id="CD012955-sec-0358"> <h6 class="title">Secondary outcome: attrition</h6> <p>One trial reported dichotomous data on attrition (<a href="./references#CD012955-bbs2-0048" title="LinehanMM , KorslundKE , HarnedMS , GallopRJ , LunguA , NeacsiuAD , et al. Dialectical behavior therapy for high suicide risk in individuals with borderline personality disorder: a randomized clinical trial and component analysis. JAMA Psychiatry2015;72(5):475-82 Erratum for: JAMA Psychiatry 2015; 72(9): 951. [DOI: 10.1001/jamapsychiatry.2014.3039] [PMID: 25806661]NCT00183651. Treatment of suicidal women with borderline personality disorder [Assessment and treatment of parasuicidal patients]. www.clinicaltrials.gov/ct2/show/NCT00183651 (first received 13 September 2005). ">Linehan 2015a</a>). </p> <p>DBT did not reduce attrition at six to 12 months follow‐up compared with DBT‐S (RR 0.62, 95% CI 0.29 to 1.29; 1 trial, 66 participants; P = 0.20; <a href="./references#CD012955-fig-0181" title="">Analysis 21.8</a>). </p> <p>No data were available for end of treatment, zero to six months and above 12 months follow‐up. </p> <p>No data were available on any time point for anger, affective instability, chronic feelings of emptiness, impulsivity, interpersonal problems, abandonment, identity disturbance, dissociation and psychotic‐like symptoms, depression, and adverse effects. </p> </section> </section> <section id="CD012955-sec-0359"> <h5 class="title">21.9 Standard DBT (DBT) versus step‐down DBT (DBT‐SD) (continuous)</h5> <section id="CD012955-sec-0360"> <h6 class="title">Primary outcomes</h6> <section id="CD012955-sec-0361"> <p><b>BPD symptom severity</b></p> <p>One trial reported continuous data on BPD symptom severity (<a href="./references#CD012955-bbs2-0067" title="NCT01904227. Intensified, inpatient adaptation of dialectical behavior therapy (DBT) (REDBT) [A randomized controlled study of the efficacy of an intensified, inpatient adaptation of dialectical behavior therapy (DBT) for a population of borderline patients (young adults/adults: 18-40), compared with standard outpatient DBT]. www.clinicaltrials.gov/ct2/show/NCT01904227 (first received 11 July 2013). SinnaeveR , Van den BoschLM , Van Steenbergen-WeijenburgKM . Change in interpersonal functioning during psychological interventions for borderline personality disorder — a systematic review of measures and efficacy. Personality and Mental Health2015;9(3):173-94. [DOI: 10.1002/pmh.1296] [PMID: 26058794]SinnaeveR , Van den BoschLMC , Hakkaart-van RoijenL , VansteelandtK . Effectiveness of step-down versus outpatient dialectical behaviour therapy for patients with severe levels of borderline personality disorder: a pragmatic randomized controlled trial. Borderline Personality Disorder and Emotion Dysregulation2018;5:12. [DOI: 10.1186/s40479-018-0089-5] [PMC6040072] [PMID: 30002832]SinnaeveR . Cochrane Collaboration review [personal communication]. Email to: J Stoffers-Winterling 11 June 2018. SinnaeveR . Re: BPDSI subscale data Sinnaeve et al (2018) [personal communication]. Email to: A Tadorovac 15 November 2018. SinnaeveR . RE: BPDSI subscale data Sinnaeve et al (2018) [personal communication] [RE: BPDSI subschale data Sinnaeve et al (2018) [personlig kommunikation]]. Email to: A Todorovac 15 November 2018. SinnaeveR . RE: BPDSI subscale data Sinnaeve et al (2018) [personal communication] [RE: BPDSI subschale data Sinnaeve et al (2018) [personlig kommunikation]]. Email to: A Todorovac 9 October 2018. Van den BoschLM , SinnaeveR , Hakkaart-van RoijenL , Van FurthEF . Efficacy and cost-effectiveness of an experimental short-term inpatient dialectical behavior therapy (DBT) program: study protocol for a randomized controlled trial. Trials2014;15:152. [DOI: 10.1186/1745-6215-15-152] [PMC4017823] [PMID: 24885551]Van RoijenLH , SinnaeveR , BouwmansC , Van Den BoschL . Cost-effectiveness and cost-utility of shortterm inpatient dialectical behavior therapy for chronically parasuicidal BPD (young) adults. Journal of Mental Health Policy and Economics2015;18(Suppl 1):S19-20. [www.icmpe.org/test1/journal/issues/v18s1toc.html]">Sinnaeve 2018</a>). </p> <p>DBT did not reduce BPD severity at end of treatment compared with DBT‐SD (MD −2.83, 95% CI −11.21 to 5.55; 1 trial, 38 participants; P = 0.51; <a href="./references#CD012955-fig-0182" title="">Analysis 21.9</a>.1). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> </section> <section id="CD012955-sec-0362"> <p><b>Self‐harm</b></p> <p>One trial reported continuous data on self‐harm (<a href="./references#CD012955-bbs2-0067" title="NCT01904227. Intensified, inpatient adaptation of dialectical behavior therapy (DBT) (REDBT) [A randomized controlled study of the efficacy of an intensified, inpatient adaptation of dialectical behavior therapy (DBT) for a population of borderline patients (young adults/adults: 18-40), compared with standard outpatient DBT]. www.clinicaltrials.gov/ct2/show/NCT01904227 (first received 11 July 2013). SinnaeveR , Van den BoschLM , Van Steenbergen-WeijenburgKM . Change in interpersonal functioning during psychological interventions for borderline personality disorder — a systematic review of measures and efficacy. Personality and Mental Health2015;9(3):173-94. [DOI: 10.1002/pmh.1296] [PMID: 26058794]SinnaeveR , Van den BoschLMC , Hakkaart-van RoijenL , VansteelandtK . Effectiveness of step-down versus outpatient dialectical behaviour therapy for patients with severe levels of borderline personality disorder: a pragmatic randomized controlled trial. Borderline Personality Disorder and Emotion Dysregulation2018;5:12. [DOI: 10.1186/s40479-018-0089-5] [PMC6040072] [PMID: 30002832]SinnaeveR . Cochrane Collaboration review [personal communication]. Email to: J Stoffers-Winterling 11 June 2018. SinnaeveR . Re: BPDSI subscale data Sinnaeve et al (2018) [personal communication]. Email to: A Tadorovac 15 November 2018. SinnaeveR . RE: BPDSI subscale data Sinnaeve et al (2018) [personal communication] [RE: BPDSI subschale data Sinnaeve et al (2018) [personlig kommunikation]]. Email to: A Todorovac 15 November 2018. SinnaeveR . RE: BPDSI subscale data Sinnaeve et al (2018) [personal communication] [RE: BPDSI subschale data Sinnaeve et al (2018) [personlig kommunikation]]. Email to: A Todorovac 9 October 2018. Van den BoschLM , SinnaeveR , Hakkaart-van RoijenL , Van FurthEF . Efficacy and cost-effectiveness of an experimental short-term inpatient dialectical behavior therapy (DBT) program: study protocol for a randomized controlled trial. Trials2014;15:152. [DOI: 10.1186/1745-6215-15-152] [PMC4017823] [PMID: 24885551]Van RoijenLH , SinnaeveR , BouwmansC , Van Den BoschL . Cost-effectiveness and cost-utility of shortterm inpatient dialectical behavior therapy for chronically parasuicidal BPD (young) adults. Journal of Mental Health Policy and Economics2015;18(Suppl 1):S19-20. [www.icmpe.org/test1/journal/issues/v18s1toc.html]">Sinnaeve 2018</a>). </p> <p>DBT did not reduce self‐harm at end of treatment compared with DBT‐SD (MD 4.10, 95% CI −4.07 to 12.27; 1 trial, 38 participants; P = 0.33; <a href="./references#CD012955-fig-0182" title="">Analysis 21.9</a>.2). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> </section> <section id="CD012955-sec-0363"> <p><b>Suicide‐related outcomes</b></p> <p>One trial reported continuous data on suicide‐related outcomes (<a href="./references#CD012955-bbs2-0067" title="NCT01904227. Intensified, inpatient adaptation of dialectical behavior therapy (DBT) (REDBT) [A randomized controlled study of the efficacy of an intensified, inpatient adaptation of dialectical behavior therapy (DBT) for a population of borderline patients (young adults/adults: 18-40), compared with standard outpatient DBT]. www.clinicaltrials.gov/ct2/show/NCT01904227 (first received 11 July 2013). SinnaeveR , Van den BoschLM , Van Steenbergen-WeijenburgKM . Change in interpersonal functioning during psychological interventions for borderline personality disorder — a systematic review of measures and efficacy. Personality and Mental Health2015;9(3):173-94. [DOI: 10.1002/pmh.1296] [PMID: 26058794]SinnaeveR , Van den BoschLMC , Hakkaart-van RoijenL , VansteelandtK . Effectiveness of step-down versus outpatient dialectical behaviour therapy for patients with severe levels of borderline personality disorder: a pragmatic randomized controlled trial. Borderline Personality Disorder and Emotion Dysregulation2018;5:12. [DOI: 10.1186/s40479-018-0089-5] [PMC6040072] [PMID: 30002832]SinnaeveR . Cochrane Collaboration review [personal communication]. Email to: J Stoffers-Winterling 11 June 2018. SinnaeveR . Re: BPDSI subscale data Sinnaeve et al (2018) [personal communication]. Email to: A Tadorovac 15 November 2018. SinnaeveR . RE: BPDSI subscale data Sinnaeve et al (2018) [personal communication] [RE: BPDSI subschale data Sinnaeve et al (2018) [personlig kommunikation]]. Email to: A Todorovac 15 November 2018. SinnaeveR . RE: BPDSI subscale data Sinnaeve et al (2018) [personal communication] [RE: BPDSI subschale data Sinnaeve et al (2018) [personlig kommunikation]]. Email to: A Todorovac 9 October 2018. Van den BoschLM , SinnaeveR , Hakkaart-van RoijenL , Van FurthEF . Efficacy and cost-effectiveness of an experimental short-term inpatient dialectical behavior therapy (DBT) program: study protocol for a randomized controlled trial. Trials2014;15:152. [DOI: 10.1186/1745-6215-15-152] [PMC4017823] [PMID: 24885551]Van RoijenLH , SinnaeveR , BouwmansC , Van Den BoschL . Cost-effectiveness and cost-utility of shortterm inpatient dialectical behavior therapy for chronically parasuicidal BPD (young) adults. Journal of Mental Health Policy and Economics2015;18(Suppl 1):S19-20. [www.icmpe.org/test1/journal/issues/v18s1toc.html]">Sinnaeve 2018</a>). </p> <p>DBT did not reduce suicide‐related outcomes at end of treatment compared with DBT‐SD (MD 0.30, 95% CI −0.73 to 1.33; 1 trial, 38 participants; P = 0.57; <a href="./references#CD012955-fig-0182" title="">Analysis 21.9</a>.3). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> <p>No data were available on any time point for psychosocial functioning.</p> </section> </section> <section id="CD012955-sec-0364"> <h6 class="title">Secondary outcomes</h6> <section id="CD012955-sec-0365"> <p><b>Anger</b></p> <p>One trial reported continuous data on anger (<a href="./references#CD012955-bbs2-0067" title="NCT01904227. Intensified, inpatient adaptation of dialectical behavior therapy (DBT) (REDBT) [A randomized controlled study of the efficacy of an intensified, inpatient adaptation of dialectical behavior therapy (DBT) for a population of borderline patients (young adults/adults: 18-40), compared with standard outpatient DBT]. www.clinicaltrials.gov/ct2/show/NCT01904227 (first received 11 July 2013). SinnaeveR , Van den BoschLM , Van Steenbergen-WeijenburgKM . Change in interpersonal functioning during psychological interventions for borderline personality disorder — a systematic review of measures and efficacy. Personality and Mental Health2015;9(3):173-94. [DOI: 10.1002/pmh.1296] [PMID: 26058794]SinnaeveR , Van den BoschLMC , Hakkaart-van RoijenL , VansteelandtK . Effectiveness of step-down versus outpatient dialectical behaviour therapy for patients with severe levels of borderline personality disorder: a pragmatic randomized controlled trial. Borderline Personality Disorder and Emotion Dysregulation2018;5:12. [DOI: 10.1186/s40479-018-0089-5] [PMC6040072] [PMID: 30002832]SinnaeveR . Cochrane Collaboration review [personal communication]. Email to: J Stoffers-Winterling 11 June 2018. SinnaeveR . Re: BPDSI subscale data Sinnaeve et al (2018) [personal communication]. Email to: A Tadorovac 15 November 2018. SinnaeveR . RE: BPDSI subscale data Sinnaeve et al (2018) [personal communication] [RE: BPDSI subschale data Sinnaeve et al (2018) [personlig kommunikation]]. Email to: A Todorovac 15 November 2018. SinnaeveR . RE: BPDSI subscale data Sinnaeve et al (2018) [personal communication] [RE: BPDSI subschale data Sinnaeve et al (2018) [personlig kommunikation]]. Email to: A Todorovac 9 October 2018. Van den BoschLM , SinnaeveR , Hakkaart-van RoijenL , Van FurthEF . Efficacy and cost-effectiveness of an experimental short-term inpatient dialectical behavior therapy (DBT) program: study protocol for a randomized controlled trial. Trials2014;15:152. [DOI: 10.1186/1745-6215-15-152] [PMC4017823] [PMID: 24885551]Van RoijenLH , SinnaeveR , BouwmansC , Van Den BoschL . Cost-effectiveness and cost-utility of shortterm inpatient dialectical behavior therapy for chronically parasuicidal BPD (young) adults. Journal of Mental Health Policy and Economics2015;18(Suppl 1):S19-20. [www.icmpe.org/test1/journal/issues/v18s1toc.html]">Sinnaeve 2018</a>). </p> <p>DBT did not reduce anger symptoms at end of treatment compared with DBT‐SD (MD −0.53, 95% CI −1.48 to 0.43; 1 trial, 41 participants; P = 0.28; <a href="./references#CD012955-fig-0182" title="">Analysis 21.9</a>.4). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> </section> <section id="CD012955-sec-0366"> <p><b>Affective instability</b></p> <p>One trial reported continuous data on affective instability (<a href="./references#CD012955-bbs2-0067" title="NCT01904227. Intensified, inpatient adaptation of dialectical behavior therapy (DBT) (REDBT) [A randomized controlled study of the efficacy of an intensified, inpatient adaptation of dialectical behavior therapy (DBT) for a population of borderline patients (young adults/adults: 18-40), compared with standard outpatient DBT]. www.clinicaltrials.gov/ct2/show/NCT01904227 (first received 11 July 2013). SinnaeveR , Van den BoschLM , Van Steenbergen-WeijenburgKM . Change in interpersonal functioning during psychological interventions for borderline personality disorder — a systematic review of measures and efficacy. Personality and Mental Health2015;9(3):173-94. [DOI: 10.1002/pmh.1296] [PMID: 26058794]SinnaeveR , Van den BoschLMC , Hakkaart-van RoijenL , VansteelandtK . Effectiveness of step-down versus outpatient dialectical behaviour therapy for patients with severe levels of borderline personality disorder: a pragmatic randomized controlled trial. Borderline Personality Disorder and Emotion Dysregulation2018;5:12. [DOI: 10.1186/s40479-018-0089-5] [PMC6040072] [PMID: 30002832]SinnaeveR . Cochrane Collaboration review [personal communication]. Email to: J Stoffers-Winterling 11 June 2018. SinnaeveR . Re: BPDSI subscale data Sinnaeve et al (2018) [personal communication]. Email to: A Tadorovac 15 November 2018. SinnaeveR . RE: BPDSI subscale data Sinnaeve et al (2018) [personal communication] [RE: BPDSI subschale data Sinnaeve et al (2018) [personlig kommunikation]]. Email to: A Todorovac 15 November 2018. SinnaeveR . RE: BPDSI subscale data Sinnaeve et al (2018) [personal communication] [RE: BPDSI subschale data Sinnaeve et al (2018) [personlig kommunikation]]. Email to: A Todorovac 9 October 2018. Van den BoschLM , SinnaeveR , Hakkaart-van RoijenL , Van FurthEF . Efficacy and cost-effectiveness of an experimental short-term inpatient dialectical behavior therapy (DBT) program: study protocol for a randomized controlled trial. Trials2014;15:152. [DOI: 10.1186/1745-6215-15-152] [PMC4017823] [PMID: 24885551]Van RoijenLH , SinnaeveR , BouwmansC , Van Den BoschL . Cost-effectiveness and cost-utility of shortterm inpatient dialectical behavior therapy for chronically parasuicidal BPD (young) adults. Journal of Mental Health Policy and Economics2015;18(Suppl 1):S19-20. [www.icmpe.org/test1/journal/issues/v18s1toc.html]">Sinnaeve 2018</a>). </p> <p>DBT did not reduce affective instability at end of treatment compared with DBT‐SD (MD −0.71, 95% CI −2.51 to 1.09; 1 trial, 41 participants; P = 0.44; <a href="./references#CD012955-fig-0182" title="">Analysis 21.9</a>.5). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> </section> <section id="CD012955-sec-0367"> <p><b>Chronic feelings of emptiness</b></p> <p>One trial reported continuous data on chronic feelings of emptiness (<a href="./references#CD012955-bbs2-0067" title="NCT01904227. Intensified, inpatient adaptation of dialectical behavior therapy (DBT) (REDBT) [A randomized controlled study of the efficacy of an intensified, inpatient adaptation of dialectical behavior therapy (DBT) for a population of borderline patients (young adults/adults: 18-40), compared with standard outpatient DBT]. www.clinicaltrials.gov/ct2/show/NCT01904227 (first received 11 July 2013). SinnaeveR , Van den BoschLM , Van Steenbergen-WeijenburgKM . Change in interpersonal functioning during psychological interventions for borderline personality disorder — a systematic review of measures and efficacy. Personality and Mental Health2015;9(3):173-94. [DOI: 10.1002/pmh.1296] [PMID: 26058794]SinnaeveR , Van den BoschLMC , Hakkaart-van RoijenL , VansteelandtK . Effectiveness of step-down versus outpatient dialectical behaviour therapy for patients with severe levels of borderline personality disorder: a pragmatic randomized controlled trial. Borderline Personality Disorder and Emotion Dysregulation2018;5:12. [DOI: 10.1186/s40479-018-0089-5] [PMC6040072] [PMID: 30002832]SinnaeveR . Cochrane Collaboration review [personal communication]. Email to: J Stoffers-Winterling 11 June 2018. SinnaeveR . Re: BPDSI subscale data Sinnaeve et al (2018) [personal communication]. Email to: A Tadorovac 15 November 2018. SinnaeveR . RE: BPDSI subscale data Sinnaeve et al (2018) [personal communication] [RE: BPDSI subschale data Sinnaeve et al (2018) [personlig kommunikation]]. Email to: A Todorovac 15 November 2018. SinnaeveR . RE: BPDSI subscale data Sinnaeve et al (2018) [personal communication] [RE: BPDSI subschale data Sinnaeve et al (2018) [personlig kommunikation]]. Email to: A Todorovac 9 October 2018. Van den BoschLM , SinnaeveR , Hakkaart-van RoijenL , Van FurthEF . Efficacy and cost-effectiveness of an experimental short-term inpatient dialectical behavior therapy (DBT) program: study protocol for a randomized controlled trial. Trials2014;15:152. [DOI: 10.1186/1745-6215-15-152] [PMC4017823] [PMID: 24885551]Van RoijenLH , SinnaeveR , BouwmansC , Van Den BoschL . Cost-effectiveness and cost-utility of shortterm inpatient dialectical behavior therapy for chronically parasuicidal BPD (young) adults. Journal of Mental Health Policy and Economics2015;18(Suppl 1):S19-20. [www.icmpe.org/test1/journal/issues/v18s1toc.html]">Sinnaeve 2018</a>). </p> <p>DBT did not reduce chronic feelings of emptiness at end of treatment compared with DBT‐SD (MD 0.18, 95% CI −1.68 to 2.04; 1 trial, 41 participants; P = 0.85; <a href="./references#CD012955-fig-0182" title="">Analysis 21.9</a>.6). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> </section> <section id="CD012955-sec-0368"> <p><b>Impulsivity</b></p> <p>One trial reported continuous data on impulsivity (<a href="./references#CD012955-bbs2-0067" title="NCT01904227. Intensified, inpatient adaptation of dialectical behavior therapy (DBT) (REDBT) [A randomized controlled study of the efficacy of an intensified, inpatient adaptation of dialectical behavior therapy (DBT) for a population of borderline patients (young adults/adults: 18-40), compared with standard outpatient DBT]. www.clinicaltrials.gov/ct2/show/NCT01904227 (first received 11 July 2013). SinnaeveR , Van den BoschLM , Van Steenbergen-WeijenburgKM . Change in interpersonal functioning during psychological interventions for borderline personality disorder — a systematic review of measures and efficacy. Personality and Mental Health2015;9(3):173-94. [DOI: 10.1002/pmh.1296] [PMID: 26058794]SinnaeveR , Van den BoschLMC , Hakkaart-van RoijenL , VansteelandtK . Effectiveness of step-down versus outpatient dialectical behaviour therapy for patients with severe levels of borderline personality disorder: a pragmatic randomized controlled trial. Borderline Personality Disorder and Emotion Dysregulation2018;5:12. [DOI: 10.1186/s40479-018-0089-5] [PMC6040072] [PMID: 30002832]SinnaeveR . Cochrane Collaboration review [personal communication]. Email to: J Stoffers-Winterling 11 June 2018. SinnaeveR . Re: BPDSI subscale data Sinnaeve et al (2018) [personal communication]. Email to: A Tadorovac 15 November 2018. SinnaeveR . RE: BPDSI subscale data Sinnaeve et al (2018) [personal communication] [RE: BPDSI subschale data Sinnaeve et al (2018) [personlig kommunikation]]. Email to: A Todorovac 15 November 2018. SinnaeveR . RE: BPDSI subscale data Sinnaeve et al (2018) [personal communication] [RE: BPDSI subschale data Sinnaeve et al (2018) [personlig kommunikation]]. Email to: A Todorovac 9 October 2018. Van den BoschLM , SinnaeveR , Hakkaart-van RoijenL , Van FurthEF . Efficacy and cost-effectiveness of an experimental short-term inpatient dialectical behavior therapy (DBT) program: study protocol for a randomized controlled trial. Trials2014;15:152. [DOI: 10.1186/1745-6215-15-152] [PMC4017823] [PMID: 24885551]Van RoijenLH , SinnaeveR , BouwmansC , Van Den BoschL . Cost-effectiveness and cost-utility of shortterm inpatient dialectical behavior therapy for chronically parasuicidal BPD (young) adults. Journal of Mental Health Policy and Economics2015;18(Suppl 1):S19-20. [www.icmpe.org/test1/journal/issues/v18s1toc.html]">Sinnaeve 2018</a>). </p> <p>DBT did not reduce impulsivity at end of treatment compared with DBT‐SD (MD 0.24, 95% CI −0.26 to 0.75; 1 trial, 41 participants; P = 0.34; <a href="./references#CD012955-fig-0182" title="">Analysis 21.9</a>.7). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> </section> <section id="CD012955-sec-0369"> <p><b>Interpersonal problems</b></p> <p>One trial reported continuous data on interpersonal problems (<a href="./references#CD012955-bbs2-0067" title="NCT01904227. Intensified, inpatient adaptation of dialectical behavior therapy (DBT) (REDBT) [A randomized controlled study of the efficacy of an intensified, inpatient adaptation of dialectical behavior therapy (DBT) for a population of borderline patients (young adults/adults: 18-40), compared with standard outpatient DBT]. www.clinicaltrials.gov/ct2/show/NCT01904227 (first received 11 July 2013). SinnaeveR , Van den BoschLM , Van Steenbergen-WeijenburgKM . Change in interpersonal functioning during psychological interventions for borderline personality disorder — a systematic review of measures and efficacy. Personality and Mental Health2015;9(3):173-94. [DOI: 10.1002/pmh.1296] [PMID: 26058794]SinnaeveR , Van den BoschLMC , Hakkaart-van RoijenL , VansteelandtK . Effectiveness of step-down versus outpatient dialectical behaviour therapy for patients with severe levels of borderline personality disorder: a pragmatic randomized controlled trial. Borderline Personality Disorder and Emotion Dysregulation2018;5:12. [DOI: 10.1186/s40479-018-0089-5] [PMC6040072] [PMID: 30002832]SinnaeveR . Cochrane Collaboration review [personal communication]. Email to: J Stoffers-Winterling 11 June 2018. SinnaeveR . Re: BPDSI subscale data Sinnaeve et al (2018) [personal communication]. Email to: A Tadorovac 15 November 2018. SinnaeveR . RE: BPDSI subscale data Sinnaeve et al (2018) [personal communication] [RE: BPDSI subschale data Sinnaeve et al (2018) [personlig kommunikation]]. Email to: A Todorovac 15 November 2018. SinnaeveR . RE: BPDSI subscale data Sinnaeve et al (2018) [personal communication] [RE: BPDSI subschale data Sinnaeve et al (2018) [personlig kommunikation]]. Email to: A Todorovac 9 October 2018. Van den BoschLM , SinnaeveR , Hakkaart-van RoijenL , Van FurthEF . Efficacy and cost-effectiveness of an experimental short-term inpatient dialectical behavior therapy (DBT) program: study protocol for a randomized controlled trial. Trials2014;15:152. [DOI: 10.1186/1745-6215-15-152] [PMC4017823] [PMID: 24885551]Van RoijenLH , SinnaeveR , BouwmansC , Van Den BoschL . Cost-effectiveness and cost-utility of shortterm inpatient dialectical behavior therapy for chronically parasuicidal BPD (young) adults. Journal of Mental Health Policy and Economics2015;18(Suppl 1):S19-20. [www.icmpe.org/test1/journal/issues/v18s1toc.html]">Sinnaeve 2018</a>). </p> <p>DBT reduced interpersonal at end of treatment problems compared with DBT‐SD (MD −1.31, 95% CI −2.05 to −0.57; 1 trial, 41 participants; P = 0.005; <a href="./references#CD012955-fig-0182" title="">Analysis 21.9</a>.8). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> </section> <section id="CD012955-sec-0370"> <p><b>Abandonment</b></p> <p>One trial reported continuous data on abandonment (<a href="./references#CD012955-bbs2-0067" title="NCT01904227. Intensified, inpatient adaptation of dialectical behavior therapy (DBT) (REDBT) [A randomized controlled study of the efficacy of an intensified, inpatient adaptation of dialectical behavior therapy (DBT) for a population of borderline patients (young adults/adults: 18-40), compared with standard outpatient DBT]. www.clinicaltrials.gov/ct2/show/NCT01904227 (first received 11 July 2013). SinnaeveR , Van den BoschLM , Van Steenbergen-WeijenburgKM . Change in interpersonal functioning during psychological interventions for borderline personality disorder — a systematic review of measures and efficacy. Personality and Mental Health2015;9(3):173-94. [DOI: 10.1002/pmh.1296] [PMID: 26058794]SinnaeveR , Van den BoschLMC , Hakkaart-van RoijenL , VansteelandtK . Effectiveness of step-down versus outpatient dialectical behaviour therapy for patients with severe levels of borderline personality disorder: a pragmatic randomized controlled trial. Borderline Personality Disorder and Emotion Dysregulation2018;5:12. [DOI: 10.1186/s40479-018-0089-5] [PMC6040072] [PMID: 30002832]SinnaeveR . Cochrane Collaboration review [personal communication]. Email to: J Stoffers-Winterling 11 June 2018. SinnaeveR . Re: BPDSI subscale data Sinnaeve et al (2018) [personal communication]. Email to: A Tadorovac 15 November 2018. SinnaeveR . RE: BPDSI subscale data Sinnaeve et al (2018) [personal communication] [RE: BPDSI subschale data Sinnaeve et al (2018) [personlig kommunikation]]. Email to: A Todorovac 15 November 2018. SinnaeveR . RE: BPDSI subscale data Sinnaeve et al (2018) [personal communication] [RE: BPDSI subschale data Sinnaeve et al (2018) [personlig kommunikation]]. Email to: A Todorovac 9 October 2018. Van den BoschLM , SinnaeveR , Hakkaart-van RoijenL , Van FurthEF . Efficacy and cost-effectiveness of an experimental short-term inpatient dialectical behavior therapy (DBT) program: study protocol for a randomized controlled trial. Trials2014;15:152. [DOI: 10.1186/1745-6215-15-152] [PMC4017823] [PMID: 24885551]Van RoijenLH , SinnaeveR , BouwmansC , Van Den BoschL . Cost-effectiveness and cost-utility of shortterm inpatient dialectical behavior therapy for chronically parasuicidal BPD (young) adults. Journal of Mental Health Policy and Economics2015;18(Suppl 1):S19-20. [www.icmpe.org/test1/journal/issues/v18s1toc.html]">Sinnaeve 2018</a>). </p> <p>DBT reduced abandonment at end of treatment compared with DBT‐SD (MD −1.11, 95% CI −2.14 to −0.08; 1 trial, 41 participants; P = 0.03; <a href="./references#CD012955-fig-0182" title="">Analysis 21.9</a>.9). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> </section> <section id="CD012955-sec-0371"> <p><b>Dissociation and psychotic‐like symptoms</b></p> <p>One trial reported continuous data on dissociation and psychotic‐like symptoms (<a href="./references#CD012955-bbs2-0067" title="NCT01904227. Intensified, inpatient adaptation of dialectical behavior therapy (DBT) (REDBT) [A randomized controlled study of the efficacy of an intensified, inpatient adaptation of dialectical behavior therapy (DBT) for a population of borderline patients (young adults/adults: 18-40), compared with standard outpatient DBT]. www.clinicaltrials.gov/ct2/show/NCT01904227 (first received 11 July 2013). SinnaeveR , Van den BoschLM , Van Steenbergen-WeijenburgKM . Change in interpersonal functioning during psychological interventions for borderline personality disorder — a systematic review of measures and efficacy. Personality and Mental Health2015;9(3):173-94. [DOI: 10.1002/pmh.1296] [PMID: 26058794]SinnaeveR , Van den BoschLMC , Hakkaart-van RoijenL , VansteelandtK . Effectiveness of step-down versus outpatient dialectical behaviour therapy for patients with severe levels of borderline personality disorder: a pragmatic randomized controlled trial. Borderline Personality Disorder and Emotion Dysregulation2018;5:12. [DOI: 10.1186/s40479-018-0089-5] [PMC6040072] [PMID: 30002832]SinnaeveR . Cochrane Collaboration review [personal communication]. Email to: J Stoffers-Winterling 11 June 2018. SinnaeveR . Re: BPDSI subscale data Sinnaeve et al (2018) [personal communication]. Email to: A Tadorovac 15 November 2018. SinnaeveR . RE: BPDSI subscale data Sinnaeve et al (2018) [personal communication] [RE: BPDSI subschale data Sinnaeve et al (2018) [personlig kommunikation]]. Email to: A Todorovac 15 November 2018. SinnaeveR . RE: BPDSI subscale data Sinnaeve et al (2018) [personal communication] [RE: BPDSI subschale data Sinnaeve et al (2018) [personlig kommunikation]]. Email to: A Todorovac 9 October 2018. Van den BoschLM , SinnaeveR , Hakkaart-van RoijenL , Van FurthEF . Efficacy and cost-effectiveness of an experimental short-term inpatient dialectical behavior therapy (DBT) program: study protocol for a randomized controlled trial. Trials2014;15:152. [DOI: 10.1186/1745-6215-15-152] [PMC4017823] [PMID: 24885551]Van RoijenLH , SinnaeveR , BouwmansC , Van Den BoschL . Cost-effectiveness and cost-utility of shortterm inpatient dialectical behavior therapy for chronically parasuicidal BPD (young) adults. Journal of Mental Health Policy and Economics2015;18(Suppl 1):S19-20. [www.icmpe.org/test1/journal/issues/v18s1toc.html]">Sinnaeve 2018</a>). </p> <p>DBT did not reduce dissociation and psychotic‐like symptoms at end of treatment compared with DBT‐SD (MD −0.44, 95% CI −1.56 to 0.68; 1 trial, 41 participants; P = 0.44; <a href="./references#CD012955-fig-0182" title="">Analysis 21.9</a>.10). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> <p>No data were available on any time point for identity disturbance, depression, attrition, and adverse effects. </p> </section> </section> </section> <section id="CD012955-sec-0372"> <h5 class="title">21.10 DBT versus DBT‐SD (dichotomous)</h5> <section id="CD012955-sec-0373"> <h6 class="title">Primary outcomes</h6> <p>No data were available on any time point for BPD symptom severity, self‐harm, suicide‐related outcomes, and psychosocial functioning. </p> </section> <section id="CD012955-sec-0374"> <h6 class="title">Secondary outcome: attrition</h6> <p>One trial reported dichotomous data on attrition (<a href="./references#CD012955-bbs2-0067" title="NCT01904227. Intensified, inpatient adaptation of dialectical behavior therapy (DBT) (REDBT) [A randomized controlled study of the efficacy of an intensified, inpatient adaptation of dialectical behavior therapy (DBT) for a population of borderline patients (young adults/adults: 18-40), compared with standard outpatient DBT]. www.clinicaltrials.gov/ct2/show/NCT01904227 (first received 11 July 2013). SinnaeveR , Van den BoschLM , Van Steenbergen-WeijenburgKM . Change in interpersonal functioning during psychological interventions for borderline personality disorder — a systematic review of measures and efficacy. Personality and Mental Health2015;9(3):173-94. [DOI: 10.1002/pmh.1296] [PMID: 26058794]SinnaeveR , Van den BoschLMC , Hakkaart-van RoijenL , VansteelandtK . Effectiveness of step-down versus outpatient dialectical behaviour therapy for patients with severe levels of borderline personality disorder: a pragmatic randomized controlled trial. Borderline Personality Disorder and Emotion Dysregulation2018;5:12. [DOI: 10.1186/s40479-018-0089-5] [PMC6040072] [PMID: 30002832]SinnaeveR . Cochrane Collaboration review [personal communication]. Email to: J Stoffers-Winterling 11 June 2018. SinnaeveR . Re: BPDSI subscale data Sinnaeve et al (2018) [personal communication]. Email to: A Tadorovac 15 November 2018. SinnaeveR . RE: BPDSI subscale data Sinnaeve et al (2018) [personal communication] [RE: BPDSI subschale data Sinnaeve et al (2018) [personlig kommunikation]]. Email to: A Todorovac 15 November 2018. SinnaeveR . RE: BPDSI subscale data Sinnaeve et al (2018) [personal communication] [RE: BPDSI subschale data Sinnaeve et al (2018) [personlig kommunikation]]. Email to: A Todorovac 9 October 2018. Van den BoschLM , SinnaeveR , Hakkaart-van RoijenL , Van FurthEF . Efficacy and cost-effectiveness of an experimental short-term inpatient dialectical behavior therapy (DBT) program: study protocol for a randomized controlled trial. Trials2014;15:152. [DOI: 10.1186/1745-6215-15-152] [PMC4017823] [PMID: 24885551]Van RoijenLH , SinnaeveR , BouwmansC , Van Den BoschL . Cost-effectiveness and cost-utility of shortterm inpatient dialectical behavior therapy for chronically parasuicidal BPD (young) adults. Journal of Mental Health Policy and Economics2015;18(Suppl 1):S19-20. [www.icmpe.org/test1/journal/issues/v18s1toc.html]">Sinnaeve 2018</a>).0.37 [0.17, 0.78] </p> <p>DBT reduced attrition at end of treatment compared with DBT‐SD (RR 0.37, 95% CI 0.17 to 0.78; 1 trial, 84 participants; P = 0.009; <a href="./references#CD012955-fig-0183" title="">Analysis 21.10</a>). </p> <p>No data were available on any time point for anger, affective instability, chronic feelings of emptiness, impulsivity, interpersonal problems, abandonment, identity disturbance, dissociation and psychotic‐like symptoms, depression, and adverse effects. </p> </section> </section> <section id="CD012955-sec-0375"> <h5 class="title">21.11 Standard DBT (DBT) versus DBT prolonged exposure (DBT‐PE) (continuous)</h5> <section id="CD012955-sec-0376"> <h6 class="title">Primary outcomes</h6> <section id="CD012955-sec-0377"> <p><b>Self‐harm</b></p> <p>One trial reported continuous data on self‐harm (<a href="./references#CD012955-bbs2-0030" title="HarnedM . Re: SV: question regarding your trial on brief therapy for attempted suicide [personal communication]. Email to: EG Faltinsen 11 December 2018. HarnedMS , KorslundKE , LinehanMM . A pilot randomized controlled trial of dialectical behavior therapy with and without the dialectical behavior therapy prolonged exposure protocol for suicidal and self-injuring women with borderline personality disorder and PTSD. Behaviour Research and Therapy2014;55:7-17. [DOI: 10.1016/j.brat.2014.01.008] [PMC3987949] [PMID: 24562087]HarnedMS , WilksCR , SchmidtSC , CoyleTN . Improving functional outcomes in women with borderline personality disorder and PTSD by changing PTSD severity and post-traumatic cognitions. Behaviour Research and Therapy2018;103:53-61. [DOI: 10.1016/j.brat.2018.02.002] [PMC5837954] [PMID: 29448136]HarnedMS . RE: questions regarding your trial on brief therapy for attempted suicide [personal communication]. Email to: E Faltinsen 29 November 2017. ">Harned 2014</a>). </p> <p>DBT did not reduce self‐harm at end of treatment compared with DBT‐PE (MD 0.10, 95% CI −1.86 to 2.06; 1 trial, 18 participants; P = 0.92; <a href="./references#CD012955-fig-0184" title="">Analysis 21.11</a>.1). </p> <p>DBT did not reduce self‐harm at zero to six months follow‐up compared with DBT‐PE (MD −0.30, 95% CI −1.09 to 0.49; 1 trial, 18 participants; P = 0.46; <a href="./references#CD012955-fig-0184" title="">Analysis 21.11</a>.2). </p> <p>No data were available for six to 12 months and above 12 months follow‐up.</p> </section> <section id="CD012955-sec-0378"> <p><b>Suicide‐related outcomes</b></p> <p>One trial reported continuous data on suicide‐related outcomes (<a href="./references#CD012955-bbs2-0030" title="HarnedM . Re: SV: question regarding your trial on brief therapy for attempted suicide [personal communication]. Email to: EG Faltinsen 11 December 2018. HarnedMS , KorslundKE , LinehanMM . A pilot randomized controlled trial of dialectical behavior therapy with and without the dialectical behavior therapy prolonged exposure protocol for suicidal and self-injuring women with borderline personality disorder and PTSD. Behaviour Research and Therapy2014;55:7-17. [DOI: 10.1016/j.brat.2014.01.008] [PMC3987949] [PMID: 24562087]HarnedMS , WilksCR , SchmidtSC , CoyleTN . Improving functional outcomes in women with borderline personality disorder and PTSD by changing PTSD severity and post-traumatic cognitions. Behaviour Research and Therapy2018;103:53-61. [DOI: 10.1016/j.brat.2018.02.002] [PMC5837954] [PMID: 29448136]HarnedMS . RE: questions regarding your trial on brief therapy for attempted suicide [personal communication]. Email to: E Faltinsen 29 November 2017. ">Harned 2014</a>). </p> <p>There were no suicide attempts in DBT‐PE group at end of treatment (effect not estimable; 1 trial, 18 participants; <a href="./references#CD012955-fig-0184" title="">Analysis 21.11</a>.3). </p> <p>There were no suicide attempts in DBT group at zero to six months follow‐up (effect not estimable; 1 trial, 18 participants; <a href="./references#CD012955-fig-0184" title="">Analysis 21.11</a>.4). </p> <p>No data were available for six to 12 months and above 12 months follow‐up.</p> </section> <section id="CD012955-sec-0379"> <p><b>Psychosocial functioning</b></p> <p>One trial reported continuous data on psychosocial functioning (<a href="./references#CD012955-bbs2-0030" title="HarnedM . Re: SV: question regarding your trial on brief therapy for attempted suicide [personal communication]. Email to: EG Faltinsen 11 December 2018. HarnedMS , KorslundKE , LinehanMM . A pilot randomized controlled trial of dialectical behavior therapy with and without the dialectical behavior therapy prolonged exposure protocol for suicidal and self-injuring women with borderline personality disorder and PTSD. Behaviour Research and Therapy2014;55:7-17. [DOI: 10.1016/j.brat.2014.01.008] [PMC3987949] [PMID: 24562087]HarnedMS , WilksCR , SchmidtSC , CoyleTN . Improving functional outcomes in women with borderline personality disorder and PTSD by changing PTSD severity and post-traumatic cognitions. Behaviour Research and Therapy2018;103:53-61. [DOI: 10.1016/j.brat.2018.02.002] [PMC5837954] [PMID: 29448136]HarnedMS . RE: questions regarding your trial on brief therapy for attempted suicide [personal communication]. Email to: E Faltinsen 29 November 2017. ">Harned 2014</a>). </p> <p>DBT did not improve psychosocial functioning at end of treatment compared with DBT‐PE (MD 5.27, 95% CI −2.06 to 12.60; 1 trial, 18 participants; P = 0.16, <a href="./references#CD012955-fig-0184" title="">Analysis 21.11</a>.5). </p> <p>DBT did not improve psychosocial functioning at zero to six months follow‐up compared with DBT‐PE (MD 2.00, 95% CI −6.27 to 10.27; 1 trial, 18 participants; P = 0.64; <a href="./references#CD012955-fig-0184" title="">Analysis 21.11</a>.6). </p> <p>No data were available for six to 12 months and above 12 months follow‐up.</p> <p>No data were available on any time point for BPD symptom severity.</p> </section> </section> <section id="CD012955-sec-0380"> <h6 class="title">Secondary outcomes</h6> <section id="CD012955-sec-0381"> <p><b>Interpersonal problems</b></p> <p>One trial reported continuous data on interpersonal problems (<a href="./references#CD012955-bbs2-0030" title="HarnedM . Re: SV: question regarding your trial on brief therapy for attempted suicide [personal communication]. Email to: EG Faltinsen 11 December 2018. HarnedMS , KorslundKE , LinehanMM . A pilot randomized controlled trial of dialectical behavior therapy with and without the dialectical behavior therapy prolonged exposure protocol for suicidal and self-injuring women with borderline personality disorder and PTSD. Behaviour Research and Therapy2014;55:7-17. [DOI: 10.1016/j.brat.2014.01.008] [PMC3987949] [PMID: 24562087]HarnedMS , WilksCR , SchmidtSC , CoyleTN . Improving functional outcomes in women with borderline personality disorder and PTSD by changing PTSD severity and post-traumatic cognitions. Behaviour Research and Therapy2018;103:53-61. [DOI: 10.1016/j.brat.2018.02.002] [PMC5837954] [PMID: 29448136]HarnedMS . RE: questions regarding your trial on brief therapy for attempted suicide [personal communication]. Email to: E Faltinsen 29 November 2017. ">Harned 2014</a>). </p> <p>DBT did not reduce interpersonal problems at end of treatment compared with DBT‐PE (MD 0.14, 95% CI −0.42 to 0.70; 1 trial, 18 participants; P = 0.62; <a href="./references#CD012955-fig-0184" title="">Analysis 21.11</a>.7). </p> <p>DBT did not reduce interpersonal problems at zero to six months follow‐up compared with DBT‐PE (MD 0.19, 95% CI −0.48 to 0.86; 1 trial, 18 participants; P = 0.58; <a href="./references#CD012955-fig-0184" title="">Analysis 21.11</a>.8). </p> <p>No data were available for six to 12 months and above 12 months follow‐up.</p> </section> <section id="CD012955-sec-0382"> <p><b>Dissociation and psychotic‐like symptoms</b></p> <p>One trial reported continuous data on dissociation and psychotic‐like symptoms (<a href="./references#CD012955-bbs2-0030" title="HarnedM . Re: SV: question regarding your trial on brief therapy for attempted suicide [personal communication]. Email to: EG Faltinsen 11 December 2018. HarnedMS , KorslundKE , LinehanMM . A pilot randomized controlled trial of dialectical behavior therapy with and without the dialectical behavior therapy prolonged exposure protocol for suicidal and self-injuring women with borderline personality disorder and PTSD. Behaviour Research and Therapy2014;55:7-17. [DOI: 10.1016/j.brat.2014.01.008] [PMC3987949] [PMID: 24562087]HarnedMS , WilksCR , SchmidtSC , CoyleTN . Improving functional outcomes in women with borderline personality disorder and PTSD by changing PTSD severity and post-traumatic cognitions. Behaviour Research and Therapy2018;103:53-61. [DOI: 10.1016/j.brat.2018.02.002] [PMC5837954] [PMID: 29448136]HarnedMS . RE: questions regarding your trial on brief therapy for attempted suicide [personal communication]. Email to: E Faltinsen 29 November 2017. ">Harned 2014</a>). </p> <p>DBT did not reduce dissociation and psychotic‐like symptoms at end of treatment compared with DBT‐PE (MD 4.60, 95% CI −9.24 to 18.44; 1 trial, 18 participants; P = 0.51; <a href="./references#CD012955-fig-0184" title="">Analysis 21.11</a>.9). </p> <p>DBT did not reduce dissociation and psychotic‐like symptoms at zero to six months follow‐up compared with DBT‐PE (MD 6.00, 95% CI −9.46 to 21.46; 1 trial, 18 participants; P = 0.45; <a href="./references#CD012955-fig-0184" title="">Analysis 21.11</a>.10). </p> <p>No data were available for six to 12 months and above 12 months follow‐up.</p> </section> <section id="CD012955-sec-0383"> <p><b>Depression</b></p> <p>One trial reported continuous data on depression (<a href="./references#CD012955-bbs2-0030" title="HarnedM . Re: SV: question regarding your trial on brief therapy for attempted suicide [personal communication]. Email to: EG Faltinsen 11 December 2018. HarnedMS , KorslundKE , LinehanMM . A pilot randomized controlled trial of dialectical behavior therapy with and without the dialectical behavior therapy prolonged exposure protocol for suicidal and self-injuring women with borderline personality disorder and PTSD. Behaviour Research and Therapy2014;55:7-17. [DOI: 10.1016/j.brat.2014.01.008] [PMC3987949] [PMID: 24562087]HarnedMS , WilksCR , SchmidtSC , CoyleTN . Improving functional outcomes in women with borderline personality disorder and PTSD by changing PTSD severity and post-traumatic cognitions. Behaviour Research and Therapy2018;103:53-61. [DOI: 10.1016/j.brat.2018.02.002] [PMC5837954] [PMID: 29448136]HarnedMS . RE: questions regarding your trial on brief therapy for attempted suicide [personal communication]. Email to: E Faltinsen 29 November 2017. ">Harned 2014</a>). </p> <p>DBT did not reduce depression at end of treatment compared with DBT‐PE (MD 3.70, 95% CI −3.19 to 10.59; 1 trial, 18 participants; P = 0.29; <a href="./references#CD012955-fig-0184" title="">Analysis 21.11</a>.11). </p> <p>DBT did not reduce depression at zero to six months follow‐up compared to DBT‐PE (MD 4.30, 95% CI −1.08 to 9.68; 1 trial, 18 participants; P = 0.12; <a href="./references#CD012955-fig-0184" title="">Analysis 21.11</a>.12). </p> <p>No data were available for six to 12 months and above 12 months follow‐up.</p> <p>No data were available on any time point for anger, affective instability, chronic feelings of emptiness, impulsivity, abandonment, identity disturbance, attrition, and adverse effects. </p> </section> </section> </section> <section id="CD012955-sec-0384"> <h5 class="title">21.12 Standard DBT (DBT) versus DBT prolonged exposure (DBT‐PE) (dichotomous)</h5> <section id="CD012955-sec-0385"> <h6 class="title">Primary outcomes</h6> <p>No data were available on any time point for BPD symptom severity, self‐harm, suicide‐related outcomes, and psychosocial functioning. </p> </section> <section id="CD012955-sec-0386"> <h6 class="title">Secondary outcome: attrition</h6> <p>One trial reported dichotomous data on attrition <a href="./references#CD012955-bbs2-0030" title="HarnedM . Re: SV: question regarding your trial on brief therapy for attempted suicide [personal communication]. Email to: EG Faltinsen 11 December 2018. HarnedMS , KorslundKE , LinehanMM . A pilot randomized controlled trial of dialectical behavior therapy with and without the dialectical behavior therapy prolonged exposure protocol for suicidal and self-injuring women with borderline personality disorder and PTSD. Behaviour Research and Therapy2014;55:7-17. [DOI: 10.1016/j.brat.2014.01.008] [PMC3987949] [PMID: 24562087]HarnedMS , WilksCR , SchmidtSC , CoyleTN . Improving functional outcomes in women with borderline personality disorder and PTSD by changing PTSD severity and post-traumatic cognitions. Behaviour Research and Therapy2018;103:53-61. [DOI: 10.1016/j.brat.2018.02.002] [PMC5837954] [PMID: 29448136]HarnedMS . RE: questions regarding your trial on brief therapy for attempted suicide [personal communication]. Email to: E Faltinsen 29 November 2017. ">Harned 2014</a>). </p> <p>DBT did not reduce attrition at zero to six months follow‐up compared with DBT‐PE (RR 0.88, 95% CI 0.27 to 2.88; 1 trial, 28 participants; P = 0.84; <a href="./references#CD012955-fig-0185" title="">Analysis 21.12</a>). </p> <p>No data were available for end of treatment, six to 12 months and above 12 months follow‐up. </p> <p>No data were available on any time point for anger, affective instability, chronic feelings of emptiness, impulsivity, interpersonal problems, abandonment, identity disturbance, dissociation and psychotic‐like symptoms, depression,and adverse effects. </p> </section> </section> <section id="CD012955-sec-0387"> <h5 class="title">21.13 DBT skills group plus case management (DBT‐S) versus DBT individual therapy plus activity group (DBT‐I) (continuous) </h5> <section id="CD012955-sec-0388"> <h6 class="title">Primary outcomes</h6> <section id="CD012955-sec-0389"> <p><b>Self‐harm</b></p> <p>One trial reported continuous data on self‐harm (<a href="./references#CD012955-bbs2-0048" title="LinehanMM , KorslundKE , HarnedMS , GallopRJ , LunguA , NeacsiuAD , et al. Dialectical behavior therapy for high suicide risk in individuals with borderline personality disorder: a randomized clinical trial and component analysis. JAMA Psychiatry2015;72(5):475-82 Erratum for: JAMA Psychiatry 2015; 72(9): 951. [DOI: 10.1001/jamapsychiatry.2014.3039] [PMID: 25806661]NCT00183651. Treatment of suicidal women with borderline personality disorder [Assessment and treatment of parasuicidal patients]. www.clinicaltrials.gov/ct2/show/NCT00183651 (first received 13 September 2005). ">Linehan 2015a</a>). </p> <p>DBT‐S did not reduce self harm at end of treatment compared with DBT‐I (MD −10.70, 95% CI −22.47 to 1.07; 1 trial, 66 participants; P = 0.07; <a href="./references#CD012955-fig-0186" title="">Analysis 21.13</a>.1). </p> <p>DBT‐S did not reduce self harm at six to 12 months follow‐up compared with DBT‐I (MD −6.60, 95% CI −19.72 to 6.52; 1 trial, 66 participants; P = 0.32; <a href="./references#CD012955-fig-0186" title="">Analysis 21.13</a>.2). </p> <p>No data were available for six to 12 months and above 12 months follow‐up.</p> </section> <section id="CD012955-sec-0390"> <p><b>Suicide‐related outcomes</b></p> <p>One trial reported continuous data on suicide‐related outcomes (<a href="./references#CD012955-bbs2-0048" title="LinehanMM , KorslundKE , HarnedMS , GallopRJ , LunguA , NeacsiuAD , et al. Dialectical behavior therapy for high suicide risk in individuals with borderline personality disorder: a randomized clinical trial and component analysis. JAMA Psychiatry2015;72(5):475-82 Erratum for: JAMA Psychiatry 2015; 72(9): 951. [DOI: 10.1001/jamapsychiatry.2014.3039] [PMID: 25806661]NCT00183651. Treatment of suicidal women with borderline personality disorder [Assessment and treatment of parasuicidal patients]. www.clinicaltrials.gov/ct2/show/NCT00183651 (first received 13 September 2005). ">Linehan 2015a</a>). </p> <p>DBT‐S did not reduce suicide‐related outcomes at end of treatment compared with DBT‐I (MD −0.30, 95% CI −1.72 to 1.12; 1 trial, 66 participants: P = 0.68; <a href="./references#CD012955-fig-0186" title="">Analysis 21.13</a>.3). </p> <p>DBT‐S reduced suicide‐related outcomes at six to 12 months follow‐up compared with DBT‐I (MD −2.10, 95% CI −3.21 to −0.99; 1 trial, 66 participants; P = 0.0002; <a href="./references#CD012955-fig-0186" title="">Analysis 21.13</a>.4). </p> <p>No data were available for six to 12 months and above 12 months follow‐up.</p> <p>No data were available on any time point for BPD symptom severity and psychosocial functioning. </p> </section> </section> <section id="CD012955-sec-0391"> <h6 class="title">Secondary outcomes: depression</h6> <p>One trial reported continuous data on depression (<a href="./references#CD012955-bbs2-0048" title="LinehanMM , KorslundKE , HarnedMS , GallopRJ , LunguA , NeacsiuAD , et al. Dialectical behavior therapy for high suicide risk in individuals with borderline personality disorder: a randomized clinical trial and component analysis. JAMA Psychiatry2015;72(5):475-82 Erratum for: JAMA Psychiatry 2015; 72(9): 951. [DOI: 10.1001/jamapsychiatry.2014.3039] [PMID: 25806661]NCT00183651. Treatment of suicidal women with borderline personality disorder [Assessment and treatment of parasuicidal patients]. www.clinicaltrials.gov/ct2/show/NCT00183651 (first received 13 September 2005). ">Linehan 2015a</a>). </p> <p>DBT‐S reduced depression at end of treatment compared with DBT‐I (MD −7.80, 95% CI −11.27 to −4.33; 1 trial, 66 participants; P &lt; 0.001; <a href="./references#CD012955-fig-0186" title="">Analysis 21.13</a>.5). </p> <p>DBT‐S did not reduce depression at six to 12 months follow‐up compared with DBT‐I (MD −2.00, 95% CI −6.44 to 2.44; 1 trial, 66 participants; P = 0.38; <a href="./references#CD012955-fig-0186" title="">Analysis 21.13</a>.6). </p> <p>No data were available for six to 12 months and above 12 months follow‐up.</p> <p>No data were available on any time point for anger, affective instability, chronic feelings of emptiness, impulsivity, interpersonal problems, abandonment, identity disturbance, dissociation and psychotic‐like symptoms, attrition, and adverse effects. </p> </section> </section> <section id="CD012955-sec-0392"> <h5 class="title">21.14 DBT‐S versus DBT‐I (dichotomous)</h5> <section id="CD012955-sec-0393"> <h6 class="title">Primary outcomes</h6> <p>No data were available on any time point for BPD symptom severity, self‐harm, suicide‐related outcomes, and psychosocial functioning. </p> </section> <section id="CD012955-sec-0394"> <h6 class="title">Secondary outcome: attrition</h6> <p>One trial reported dichotomous data on attrition (<a href="./references#CD012955-bbs2-0048" title="LinehanMM , KorslundKE , HarnedMS , GallopRJ , LunguA , NeacsiuAD , et al. Dialectical behavior therapy for high suicide risk in individuals with borderline personality disorder: a randomized clinical trial and component analysis. JAMA Psychiatry2015;72(5):475-82 Erratum for: JAMA Psychiatry 2015; 72(9): 951. [DOI: 10.1001/jamapsychiatry.2014.3039] [PMID: 25806661]NCT00183651. Treatment of suicidal women with borderline personality disorder [Assessment and treatment of parasuicidal patients]. www.clinicaltrials.gov/ct2/show/NCT00183651 (first received 13 September 2005). ">Linehan 2015a</a>). </p> <p>DBT‐S did not reduce attrition at six to 12 months follow‐up compared with DBT‐I (RR 0.81, 95% CI 0.61 to 1.09; 1 trial, 66 participants; P = 0.17; <a href="./references#CD012955-fig-0187" title="">Analysis 21.14</a>). </p> <p>No data were available for end of treatment, zero to six months and above 12 months follow‐up. </p> <p>No data were available on any time point for anger, affective instability, chronic feelings of emptiness, impulsivity, interpersonal problems, abandonment, identity disturbance, dissociation and psychotic‐like symptoms, depression, and adverse effects. </p> </section> </section> <section id="CD012955-sec-0395"> <h5 class="title">21.15 DBT skills group (DBT‐S) versus cognitive therapy group (CT‐G) (continuous)</h5> <section id="CD012955-sec-0396"> <h6 class="title">Primary outcomes</h6> <section id="CD012955-sec-0397"> <p><b>BPD symptom severity</b></p> <p>One trial reported continuous data on BPD symptom severity (<a href="./references#CD012955-bbs2-0044" title="Lin T-J, Ko H-C, Wu JY-W, OeiTP , Lane H-Y, Chen C-H. The effectiveness of dialectical behavior therapy skills training group vs cognitive therapy group on reducing depression and suicide attempts for borderline personality disorder in Taiwan. Archives of Suicide Research2019;23(1):82-99. [DOI: 10.1080/13811118.2018.1436104] [PMID: 29528807]">Lin 2019</a>). </p> <p>DBT‐S did not reduce BPD symptom severity at end of treatment compared with CT‐G (MD 0.26, 95% CI −0.13 to 0.65; 1 trial, 82 participants; P = 0.19; <a href="./references#CD012955-fig-0188" title="">Analysis 21.15</a>.1). </p> <p>DBT‐S reduced BPD symptom severity at zero to six months follow‐up compared with CT‐G (MD −0.96, 95% CI −1.15 to −0.77; 1 trial, 82 participants = 82; P &lt; 0.001; <a href="./references#CD012955-fig-0188" title="">Analysis 21.15</a>.2). </p> <p>No data were available for six to 12 months and above 12 months follow‐up.</p> </section> <section id="CD012955-sec-0398"> <p><b>Suicide‐related outcomes</b></p> <p>One trial reported continuous data on suicide‐related outcomes (<a href="./references#CD012955-bbs2-0044" title="Lin T-J, Ko H-C, Wu JY-W, OeiTP , Lane H-Y, Chen C-H. The effectiveness of dialectical behavior therapy skills training group vs cognitive therapy group on reducing depression and suicide attempts for borderline personality disorder in Taiwan. Archives of Suicide Research2019;23(1):82-99. [DOI: 10.1080/13811118.2018.1436104] [PMID: 29528807]">Lin 2019</a>). </p> <p>DBT‐S did not reduce suicide‐related outcomes at end of treatment compared with CT‐G (MD 0.46, 95% CI −2.47 to 3.39; 1 trial, 82 participants; P = 0.76; <a href="./references#CD012955-fig-0188" title="">Analysis 21.15</a>.3). </p> <p>DBT‐S reduced suicide‐related outcomes at zero to six months follow‐up compared with CT‐G (MD −2.69, 95% CI −4.89 to −0.49; 1 trial, 82 participants; P = 0.02; <a href="./references#CD012955-fig-0188" title="">Analysis 21.15</a>.4). </p> <p>No data were available for six to 12 months and above 12 months follow‐up.</p> <p>No data were available on any time point for self‐harm and psychosocial functioning.</p> </section> </section> <section id="CD012955-sec-0399"> <h6 class="title">Secondary outcomes: depression</h6> <p>One trial reported continuous data on depression (<a href="./references#CD012955-bbs2-0044" title="Lin T-J, Ko H-C, Wu JY-W, OeiTP , Lane H-Y, Chen C-H. The effectiveness of dialectical behavior therapy skills training group vs cognitive therapy group on reducing depression and suicide attempts for borderline personality disorder in Taiwan. Archives of Suicide Research2019;23(1):82-99. [DOI: 10.1080/13811118.2018.1436104] [PMID: 29528807]">Lin 2019</a>). </p> <p>DBT‐S did not reduce depression at end of treatment compared with CT‐G (MD −2.12, 95% CI −5.25 to 1.01; 1 trial, 82 participants; P = 0.18, <a href="./references#CD012955-fig-0188" title="">Analysis 21.15</a>.5). </p> <p>DBT‐S did not reduce depression at zero to six months follow‐up compared with CT‐G (MD −1.60, 95% CI −5.07 to 1.87; 1 trial, 82 participants, P = 0.37 <a href="./references#CD012955-fig-0188" title="">Analysis 21.15</a>.6). </p> <p>No data were available for six to 12 months and above 12 months follow‐up.</p> <p>No data were available on any time point for anger, affective instability, chronic feelings of emptiness, impulsivity, interpersonal problems, abandonment, identity disturbance, dissociation and psychotic‐like symptoms, attrition, and adverse effects. </p> </section> </section> <section id="CD012955-sec-0400"> <h5 class="title">21.16 DBT‐S versus CT‐G (dichotomous)</h5> <section id="CD012955-sec-0401"> <h6 class="title">Primary outcomes</h6> <p>No data were available on any time point for BPD symptom severity, self‐harm, suicide‐related outcomes, and psychosocial functioning. </p> </section> <section id="CD012955-sec-0402"> <h6 class="title">Secondary outcome: attrition</h6> <p>One trial reported dichotomous data on attrition (<a href="./references#CD012955-bbs2-0044" title="Lin T-J, Ko H-C, Wu JY-W, OeiTP , Lane H-Y, Chen C-H. The effectiveness of dialectical behavior therapy skills training group vs cognitive therapy group on reducing depression and suicide attempts for borderline personality disorder in Taiwan. Archives of Suicide Research2019;23(1):82-99. [DOI: 10.1080/13811118.2018.1436104] [PMID: 29528807]">Lin 2019</a>). </p> <p>DBT‐S did not reduce attrition at end of treatment compared with CT‐G (RR 0.71, 95% CI 0.27 to 1.88; 1 trial, 82 participants; P = 0.49; <a href="./references#CD012955-fig-0189" title="">Analysis 21.16</a>). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> <p>No data were available on any time point for anger, affective instability, chronic feelings of emptiness, impulsivity, interpersonal problems, abandonment, identity disturbance, dissociation and psychotic‐like symptoms, depression, and adverse effects. </p> </section> </section> <section id="CD012955-sec-0403"> <h5 class="title">21.17 DBT skills group (DBT‐S) versus schema‐focused therapy group (SFT‐G) (continuous)</h5> <section id="CD012955-sec-0404"> <h6 class="title">Primary outcomes: suicide‐related outcomes</h6> <p>One trial reported continuous data on suicide‐related outcomes (<a href="./references#CD012955-bbs2-0053" title="MohamadizadehL , MakvandiB , PashaR , BakhtiarpourS , HafeziF . Comparing of the effect of dialectical behavior therapy (DBT) and schema therapy (ST) on reducing mood activity and suicidal thoughts in patients with borderline personality disorder. Acta Medica Mediterranea2017;33:1025-31. [DOI: 10.19193/0393-6384_2017_6_162] [www.actamedicamediterranea.com/archive/2017/medica-6/comparing-of-the-effect-of-dialectical-behavior-therapy-dbt-and-schema-therapy-st-on-reducing-mood-activity-and-suicidal-thoughts-in-patients-with-borderline-personality-disorder/pdf]">Mohamadizadeh 2017</a>). </p> <p>DBT‐S did not reduce suicide‐related outcomes at end of treatment compared with SFT‐G (MD 0.92, 95% CI −0.36 to 2.20; 1 trial, 24 participants; P = 0.16; <a href="./references#CD012955-fig-0190" title="">Analysis 21.17</a>.1). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> <p>No data were available on any time point for BPD symptom severity, self‐harm, and psychosocial functioning. </p> </section> <section id="CD012955-sec-0405"> <h6 class="title">Secondary outcomes: depression</h6> <p>One trial reported continuous data on depression (<a href="./references#CD012955-bbs2-0053" title="MohamadizadehL , MakvandiB , PashaR , BakhtiarpourS , HafeziF . Comparing of the effect of dialectical behavior therapy (DBT) and schema therapy (ST) on reducing mood activity and suicidal thoughts in patients with borderline personality disorder. Acta Medica Mediterranea2017;33:1025-31. [DOI: 10.19193/0393-6384_2017_6_162] [www.actamedicamediterranea.com/archive/2017/medica-6/comparing-of-the-effect-of-dialectical-behavior-therapy-dbt-and-schema-therapy-st-on-reducing-mood-activity-and-suicidal-thoughts-in-patients-with-borderline-personality-disorder/pdf]">Mohamadizadeh 2017</a>). </p> <p>SFT‐G reduced depression at end of treatment compared with DBT‐S (MD 4.33, 95% CI 2.57 to 6.09; 1 trial, 24 participants; P &lt; 0.001; <a href="./references#CD012955-fig-0190" title="">Analysis 21.17</a>.2). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> <p>No data were available on any time point for anger, affective instability, chronic feelings of emptiness, impulsivity, interpersonal problems, abandonment, identity disturbance, dissociation and psychotic‐like symptoms, attrition and adverse effects. </p> </section> </section> <section id="CD012955-sec-0406"> <h5 class="title">21.18 DBT mindfulness group (DBT‐M) versus DBT interpersonal effectiveness group (DBT‐IE) (continuous) </h5> <section id="CD012955-sec-0407"> <h6 class="title">Primary outcomes: BPD symptom severity</h6> <p>Two trials reported continuous data on BPD symptom severity (<a href="./references#CD012955-bbs2-0014" title="Carmona i FarrésC , ElicesM , SolerJ , Domínguez-ClavéE , Pomarol-ClotetE , SalvadorR , et al. Effects of mindfulness training on borderline personality disorder: impulsivity versus emotional dysregulation. Mindfulness2019;10:1243-54. [DOI: 10.1007/s12671-018-1071-4]NCT03363230. Effects of mindfulness training on emotion regulation and impulsivity. www.clinicaltrials.gov/ct2/show/NCT03363230 (first received 30 November 2017). ">Carmona í Farrés 2019</a>; <a href="./references#CD012955-bbs2-0020" title="ElicesM , PascualJC , PortellaMJ , Feliu-SolerA , Martín-BlancoA , CarmonaC , et al. Impact of mindfulness training on borderline personality disorder: a randomized trial. Mindfulness2016;7:584-95. [DOI: 10.1007/s12671-016-0492-1]NCT02397031. Mindfulness and interpersonal effectiveness skills in borderline personality disorder [Randomized, active-controlled, clinical trial comparing effects of mindfulness and interpersonal effectiveness skills in borderline personality disorder]. www.clinicaltrials.gov/ct2/show/NCT02397031 (first received 12 March 2015). SolerJ , ElicesM , PascualJC , Martín-BlancoA , Feliu-SolerA , CarmonaC , et al. Effects of mindfulness training on different components of impulsivity in borderline personality disorder: results from a pilot randomized study. Borderline Personality Disorder and Emotion Dysregulation2016;3:1. [DOI: 10.1186/s40479-015-0035-8] [PMC4709962] [PMID: 26759718]">Elices 2016</a>). </p> <p>DBT‐M did not reduce BPD symptom severity at end of treatment compared with DBT‐IE (SMD −0.45, 95% CI −1.47 to 0.58, 2 trials, 113 participants; I<sup>2</sup> = 86%; P = 0.39; <a href="./references#CD012955-fig-0191" title="">Analysis 21.18</a>.1). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> <p>No data were available on any time point for self‐harm, suicide‐related outcomes and psychosocial functioning. </p> </section> <section id="CD012955-sec-0408"> <h6 class="title">Secondary outcomes: impulsivity</h6> <p>Two trials reported continuous data on impulsivity (<a href="./references#CD012955-bbs2-0014" title="Carmona i FarrésC , ElicesM , SolerJ , Domínguez-ClavéE , Pomarol-ClotetE , SalvadorR , et al. Effects of mindfulness training on borderline personality disorder: impulsivity versus emotional dysregulation. Mindfulness2019;10:1243-54. [DOI: 10.1007/s12671-018-1071-4]NCT03363230. Effects of mindfulness training on emotion regulation and impulsivity. www.clinicaltrials.gov/ct2/show/NCT03363230 (first received 30 November 2017). ">Carmona í Farrés 2019</a>; <a href="./references#CD012955-bbs2-0020" title="ElicesM , PascualJC , PortellaMJ , Feliu-SolerA , Martín-BlancoA , CarmonaC , et al. Impact of mindfulness training on borderline personality disorder: a randomized trial. Mindfulness2016;7:584-95. [DOI: 10.1007/s12671-016-0492-1]NCT02397031. Mindfulness and interpersonal effectiveness skills in borderline personality disorder [Randomized, active-controlled, clinical trial comparing effects of mindfulness and interpersonal effectiveness skills in borderline personality disorder]. www.clinicaltrials.gov/ct2/show/NCT02397031 (first received 12 March 2015). SolerJ , ElicesM , PascualJC , Martín-BlancoA , Feliu-SolerA , CarmonaC , et al. Effects of mindfulness training on different components of impulsivity in borderline personality disorder: results from a pilot randomized study. Borderline Personality Disorder and Emotion Dysregulation2016;3:1. [DOI: 10.1186/s40479-015-0035-8] [PMC4709962] [PMID: 26759718]">Elices 2016</a>). </p> <p>DBT‐M did not reduce impulsivity at end of treatment compared with DBT‐IE (SMD −0.36, 95% CI −0.77 to 0.06; 2 trials, 91 participants; I<sup>2</sup> = 0%; P = 0.09; <a href="./references#CD012955-fig-0191" title="">Analysis 21.18</a>.2). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> <p>No data were available on any time point for anger, affective instability, chronic feelings of emptiness, interpersonal problems, abandonment, identity disturbance, dissociation and psychotic‐like symptoms, depression, attrition, and adverse effects. </p> </section> </section> <section id="CD012955-sec-0409"> <h5 class="title">21.19 DBT‐M versus DBT‐IE (dichotomous)</h5> <section id="CD012955-sec-0410"> <h6 class="title">Primary outcomes</h6> <p>No data were available on any time point for BPD symptom severity, self‐harm, suicide‐related outcomes, and psychosocial functioning. </p> </section> <section id="CD012955-sec-0411"> <h6 class="title">Secondary outcome: attrition</h6> <p>Two trials reported dichotomous data on attrition (<a href="./references#CD012955-bbs2-0014" title="Carmona i FarrésC , ElicesM , SolerJ , Domínguez-ClavéE , Pomarol-ClotetE , SalvadorR , et al. Effects of mindfulness training on borderline personality disorder: impulsivity versus emotional dysregulation. Mindfulness2019;10:1243-54. [DOI: 10.1007/s12671-018-1071-4]NCT03363230. Effects of mindfulness training on emotion regulation and impulsivity. www.clinicaltrials.gov/ct2/show/NCT03363230 (first received 30 November 2017). ">Carmona í Farrés 2019</a>; <a href="./references#CD012955-bbs2-0020" title="ElicesM , PascualJC , PortellaMJ , Feliu-SolerA , Martín-BlancoA , CarmonaC , et al. Impact of mindfulness training on borderline personality disorder: a randomized trial. Mindfulness2016;7:584-95. [DOI: 10.1007/s12671-016-0492-1]NCT02397031. Mindfulness and interpersonal effectiveness skills in borderline personality disorder [Randomized, active-controlled, clinical trial comparing effects of mindfulness and interpersonal effectiveness skills in borderline personality disorder]. www.clinicaltrials.gov/ct2/show/NCT02397031 (first received 12 March 2015). SolerJ , ElicesM , PascualJC , Martín-BlancoA , Feliu-SolerA , CarmonaC , et al. Effects of mindfulness training on different components of impulsivity in borderline personality disorder: results from a pilot randomized study. Borderline Personality Disorder and Emotion Dysregulation2016;3:1. [DOI: 10.1186/s40479-015-0035-8] [PMC4709962] [PMID: 26759718]">Elices 2016</a>). </p> <p>DBT‐IE reduced attrition at end of treatment compared with DBT‐M (RR 1.86, 95% CI 1.07 to 3.23; 2 trials, 134 participants; I<sup>2</sup> = 0%; P = 0.03; <a href="./references#CD012955-fig-0192" title="">Analysis 21.19</a>). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> <p>No data were available on any time point for anger, affective instability, chronic feelings of emptiness, impulsivity, interpersonal problems, abandonment, identity disturbance, dissociation and psychotic‐like symptoms, depression, and adverse effects. </p> </section> </section> <section id="CD012955-sec-0412"> <h5 class="title">21.20 DBT mindfulness group (DBT‐M) versus loving‐kindness and compassion mediation (LKM/CM) </h5> <section id="CD012955-sec-0413"> <h6 class="title">Primary outcomes: BPD symptom severity</h6> <p>One trial reported continuous data on BPD symptom severity (<a href="./references#CD012955-bbs2-0023" title="Feliu-SolerA , PascualJC , ElicesM , Martín-BlancoA , CarmonaC , CebollaA , et al. Fostering self-compassion and loving-kindness in patients with borderline personality disorder: a randomized pilot study. Clinical Psychology &amp; Psychotherapy2017;24(1):278-86. [DOI: 10.1002/cpp.2000] [PMID: 26818533]">Feliu‐Soler 2017</a>). </p> <p>DBT‐M did not reduce BPD symptom severity at end of treatment compared with LKM/CM (MD 0.04, 95% CI −0.66 to 0.74; 1 trial, 32 participants; P = 0.91; <a href="./references#CD012955-fig-0193" title="">Analysis 21.20</a>). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> <p>No data were available on any time point for self‐harm, suicide‐related outcomes and psychosocial functioning. </p> </section> <section id="CD012955-sec-0414"> <h6 class="title">Secondary outcomes</h6> <p>No data were available on any time point for anger, affective instability, chronic feelings of emptiness, impulsivity, interpersonal problems, abandonment, identity disturbance, dissociation and psychotic‐like symptoms, depression, attrition and adverse effects. </p> </section> </section> </section> <section id="CD012955-sec-0415"> <h4 class="title">22. Cognitive behavioural therapy (CBT) and related treatments versus active treatment</h4> <section id="CD012955-sec-0416"> <h5 class="title">22.1 CBT versus brief trauma and anxiety‐related group psychoeducation (continuous)</h5> <section id="CD012955-sec-0417"> <h6 class="title">Primary outcomes</h6> <section id="CD012955-sec-0418"> <p><b>BPD symptom severity</b></p> <p>One trial reported continuous data on BPD symptom severity (<a href="./references#CD012955-bbs2-0040" title="KredlowMA , SzuhanyKL , LoS , XieH , GottliebJD , RosenbergSD , et al. Cognitive behavioral therapy for posttraumatic stress disorder in individuals with severe mental illness and borderline personality disorder. Psychiatry Research2017;249:86-93. [DOI: 10.1016/j.psychres.2016.12.045] [PMC5325773] [PMID: 28086181]MueserKT , GottliebJD , XieH , LuW , YanosPT , RosenbergSD , et al. Evaluation of cognitive restructuring for post-traumatic stress disorder in people with severe mental illness.. British Journal of Psychiatry2015;206(6):501-8. [DOI: 10.1192/bjp.bp.114.147926] [PMC4450219] [PMID: 25858178]MueserKT , RosenbergSD , XieH , JankowskiMK , BoltonEE , LuW , et al. A randomized controlled trial of cognitive-behavioral treatment for posttraumatic stress disorder in severe mental illness. Journal of Consulting and Clinical Psychology2008;76(2):259-71. [DOI: 10.1037/0022-006X.76.2.259] [PMC3916092] [PMID: 18377122]MueserKT . Re: question regarding your trial on CBT for PTSD participants [personal communication]. Email to: E Faltinsen 28 November 2018. ">Kredlow 2017b</a>). </p> <p>CBT did not reduce BPD symptom severity at end of treatment compared with brief trauma and anxiety‐related group psychoeducation (MD −0.26, 95% CI −1.46 to 0.94; 1 trial, 50 participants; P = 0.67; <a href="./references#CD012955-fig-0194" title="">Analysis 22.1</a>.1). </p> <p>CBT did not reduce BPD symptom severity at zero to six months follow‐up compared with brief trauma and anxiety‐related group psychoeducation (MD −0.39, 95% CI −1.60 to 0.82; 1 trial, 50 participants; P = 0.53; <a href="./references#CD012955-fig-0194" title="">Analysis 22.1</a>.2). </p> <p>CBT did not reduce BPD symptom severity at six to 12 months follow‐up compared to brief trauma and anxiety‐related group psychoeducation (MD 0.57, 95% CI −0.48 to 1.62; 1 trial, number of 50 participants; P = 0.29; <a href="./references#CD012955-fig-0194" title="">Analysis 22.1</a>.3). </p> <p>No data were available for above 12 months follow‐up.</p> </section> <section id="CD012955-sec-0419"> <p><b>Psychosocial functioning</b></p> <p>One trial reported continuous data on psychosocial functioning (<a href="./references#CD012955-bbs2-0040" title="KredlowMA , SzuhanyKL , LoS , XieH , GottliebJD , RosenbergSD , et al. Cognitive behavioral therapy for posttraumatic stress disorder in individuals with severe mental illness and borderline personality disorder. Psychiatry Research2017;249:86-93. [DOI: 10.1016/j.psychres.2016.12.045] [PMC5325773] [PMID: 28086181]MueserKT , GottliebJD , XieH , LuW , YanosPT , RosenbergSD , et al. Evaluation of cognitive restructuring for post-traumatic stress disorder in people with severe mental illness.. British Journal of Psychiatry2015;206(6):501-8. [DOI: 10.1192/bjp.bp.114.147926] [PMC4450219] [PMID: 25858178]MueserKT , RosenbergSD , XieH , JankowskiMK , BoltonEE , LuW , et al. A randomized controlled trial of cognitive-behavioral treatment for posttraumatic stress disorder in severe mental illness. Journal of Consulting and Clinical Psychology2008;76(2):259-71. [DOI: 10.1037/0022-006X.76.2.259] [PMC3916092] [PMID: 18377122]MueserKT . Re: question regarding your trial on CBT for PTSD participants [personal communication]. Email to: E Faltinsen 28 November 2018. ">Kredlow 2017b</a>). </p> <p>CBT did not improve psychosocial functioning at end of treatment compared with brief trauma and anxiety‐related group psychoeducation (MD −0.64, 95% CI −5.76 to 4.48; 1 trial, 50 participants; P = 0.81; <a href="./references#CD012955-fig-0194" title="">Analysis 22.1</a>.4). </p> <p>CBT did not improve psychosocial functioning at zero to six months follow‐up compared with brief trauma and anxiety‐related group psychoeducation (MD −1.23, 95% CI −6.94 to 4.48; 1 trial, 50 participants; P = 0.67; <a href="./references#CD012955-fig-0194" title="">Analysis 22.1</a>.5). </p> <p>CBT did not improve psychosocial functioning at six to 12 months follow‐up compared with brief trauma and anxiety‐related group psychoeducation (MD 0.61, 95% CI −5.00 to 6.22; 1 trial, 50 participants; P = 0.83; <a href="./references#CD012955-fig-0194" title="">Analysis 22.1</a>.6). </p> <p>No data were available for above 12 months follow‐up.</p> <p>No data were available on any time point for self‐harm and suicide‐related outcomes.</p> </section> </section> <section id="CD012955-sec-0420"> <h6 class="title">Secondary outcomes: depression</h6> <p>One trial reported continuous data on depression (<a href="./references#CD012955-bbs2-0040" title="KredlowMA , SzuhanyKL , LoS , XieH , GottliebJD , RosenbergSD , et al. Cognitive behavioral therapy for posttraumatic stress disorder in individuals with severe mental illness and borderline personality disorder. Psychiatry Research2017;249:86-93. [DOI: 10.1016/j.psychres.2016.12.045] [PMC5325773] [PMID: 28086181]MueserKT , GottliebJD , XieH , LuW , YanosPT , RosenbergSD , et al. Evaluation of cognitive restructuring for post-traumatic stress disorder in people with severe mental illness.. British Journal of Psychiatry2015;206(6):501-8. [DOI: 10.1192/bjp.bp.114.147926] [PMC4450219] [PMID: 25858178]MueserKT , RosenbergSD , XieH , JankowskiMK , BoltonEE , LuW , et al. A randomized controlled trial of cognitive-behavioral treatment for posttraumatic stress disorder in severe mental illness. Journal of Consulting and Clinical Psychology2008;76(2):259-71. [DOI: 10.1037/0022-006X.76.2.259] [PMC3916092] [PMID: 18377122]MueserKT . Re: question regarding your trial on CBT for PTSD participants [personal communication]. Email to: E Faltinsen 28 November 2018. ">Kredlow 2017b</a>). </p> <p>CBT did not reduce depression at end of treatment compared with brief trauma and anxiety‐related group psychoeducation (MD 0.76, 95% CI −8.20 to 9.72, 1 trial; 50 participants; P = 0.87; <a href="./references#CD012955-fig-0194" title="">Analysis 22.1</a>.7). </p> <p>CBT did not reduce depression at zero to six months follow‐up compared with brief trauma and anxiety‐related group psychoeducation (MD 3.13, 95% CI −4.05 to 10.31; 1 trial, 50 participants; P = 0.39; <a href="./references#CD012955-fig-0194" title="">Analysis 22.1</a>.8). </p> <p>CBT did not reduce depression at six to 12 months follow‐up compared with brief trauma and anxiety‐related group psychoeducation (MD 0.77, 95% CI −7.08 to 8.62; 1 trial; 50 participants; P = 0.85; <a href="./references#CD012955-fig-0194" title="">Analysis 22.1</a>.9). </p> <p>No data were available on any time point for anger, affective instability, chronic feelings of emptiness, impulsivity, interpersonal problems, abandonment, identity disturbance, dissociation and psychotic‐like symptoms, attrition, and adverse effects. </p> </section> </section> <section id="CD012955-sec-0421"> <h5 class="title">22.2 CBT versus brief trauma and anxiety‐related group psychoeducation (dichotomous)</h5> <section id="CD012955-sec-0422"> <h6 class="title">Primary outcomes</h6> <p>No data were available on any time point for BPD symptom severity, self‐harm, suicide‐related outcomes, and psychosocial functioning. </p> </section> <section id="CD012955-sec-0423"> <h6 class="title">Secondary outcome: attrition</h6> <p>One trial reported dichotomous data on attrition (<a href="./references#CD012955-bbs2-0040" title="KredlowMA , SzuhanyKL , LoS , XieH , GottliebJD , RosenbergSD , et al. Cognitive behavioral therapy for posttraumatic stress disorder in individuals with severe mental illness and borderline personality disorder. Psychiatry Research2017;249:86-93. [DOI: 10.1016/j.psychres.2016.12.045] [PMC5325773] [PMID: 28086181]MueserKT , GottliebJD , XieH , LuW , YanosPT , RosenbergSD , et al. Evaluation of cognitive restructuring for post-traumatic stress disorder in people with severe mental illness.. British Journal of Psychiatry2015;206(6):501-8. [DOI: 10.1192/bjp.bp.114.147926] [PMC4450219] [PMID: 25858178]MueserKT , RosenbergSD , XieH , JankowskiMK , BoltonEE , LuW , et al. A randomized controlled trial of cognitive-behavioral treatment for posttraumatic stress disorder in severe mental illness. Journal of Consulting and Clinical Psychology2008;76(2):259-71. [DOI: 10.1037/0022-006X.76.2.259] [PMC3916092] [PMID: 18377122]MueserKT . Re: question regarding your trial on CBT for PTSD participants [personal communication]. Email to: E Faltinsen 28 November 2018. ">Kredlow 2017b</a>). </p> <p>CBT did not reduce attrition at end of treatment compared with brief trauma and anxiety‐related group psychoeducation (RR 1.99, 95% CI 0.58 to 6.82, 1 trial, 50 participants, P = 0.27; <a href="./references#CD012955-fig-0195" title="">Analysis 22.2</a>). </p> <p>No data were available on any time point for anger, affective instability, chronic feelings of emptiness, impulsivity, interpersonal problems, abandonment, identity disturbance, dissociation and psychotic‐like symptoms, depression, and adverse effects. </p> </section> </section> <section id="CD012955-sec-0424"> <h5 class="title">22.3 CBT versus interpersonal therapy (IPT) (continuous)</h5> <section id="CD012955-sec-0425"> <h6 class="title">Primary outcome: psychosocial functioning</h6> <p>One trial reported continuous data on psychosocial functioning (<a href="./references#CD012955-bbs2-0007" title="BellinoS , ZizzaM , RinaldiC , BogettoF . Combined therapy of major depression with concomitant borderline personality disorder: comparison of interpersonal and cognitive psychotherapy. Canadian Journal of Psychiatry2007;52(11):718-25. [DOI: 10.1177/070674370705201106] [PMID: 18399039]">Bellino 2007</a>). </p> <p>CBT did not improve psychosocial functioning at end of treatment compared with IPT (MD −5.30, 95% CI −12.36 to 1.76; 1 trial, 26 participants; P = 0.14; <a href="./references#CD012955-fig-0196" title="">Analysis 22.3</a>.1). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> <p>No data were available on any time point for BPD symptom severity, self‐harm, and suicide‐related outcomes. </p> </section> <section id="CD012955-sec-0426"> <h6 class="title">Secondary outcomes: depression</h6> <p>One trial reported continuous data on depression (<a href="./references#CD012955-bbs2-0007" title="BellinoS , ZizzaM , RinaldiC , BogettoF . Combined therapy of major depression with concomitant borderline personality disorder: comparison of interpersonal and cognitive psychotherapy. Canadian Journal of Psychiatry2007;52(11):718-25. [DOI: 10.1177/070674370705201106] [PMID: 18399039]">Bellino 2007</a>). </p> <p>CBT did not reduce depression at end of treatment compared to IPT (MD −0.40, 95% CI −4.72 to 3.92; 1 trial, 26 participants; P = 0.86; <a href="./references#CD012955-fig-0196" title="">Analysis 22.3</a>.2). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> <p>No data were available on any time point for anger, affective instability, chronic feelings of emptiness, impulsivity, interpersonal problems, abandonment, identity disturbance, dissociation and psychotic‐like symptoms, attrition and adverse effects. </p> </section> </section> <section id="CD012955-sec-0427"> <h5 class="title">22.4 CBT versus interpersonal therapy (IPT) (dichotomous)</h5> <section id="CD012955-sec-0428"> <h6 class="title">Primary outcomes</h6> <p>No data were available on any time point for BPD symptom severity, self‐harm, suicide‐related outcomes, and psychosocial functioning. </p> </section> <section id="CD012955-sec-0429"> <h6 class="title">Secondary outcome: attrition</h6> <p>One trial reported dichotomous data on attrition (<a href="./references#CD012955-bbs2-0007" title="BellinoS , ZizzaM , RinaldiC , BogettoF . Combined therapy of major depression with concomitant borderline personality disorder: comparison of interpersonal and cognitive psychotherapy. Canadian Journal of Psychiatry2007;52(11):718-25. [DOI: 10.1177/070674370705201106] [PMID: 18399039]">Bellino 2007</a>). </p> <p>CBT did not reduce attrition at end of treatment compared with IPT (RR 2.00, 95% CI 0.42 to 9.42; 1 trial; 32 participants; P = 0.38; <a href="./references#CD012955-fig-0197" title="">Analysis 22.4</a>). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> <p>No data were available on any time point for anger, affective instability, chronic feelings of emptiness, impulsivity, interpersonal problems, abandonment, identity disturbance, dissociation and psychotic‐like symptoms, depression, and adverse effects. </p> </section> </section> <section id="CD012955-sec-0430"> <h5 class="title">22.5 CBT versus Rogerian supportive therapy (continuous)</h5> <section id="CD012955-sec-0431"> <h6 class="title">Primary outcomes</h6> <section id="CD012955-sec-0432"> <p><b>Self‐harm</b></p> <p>One trial reported continuous data on self‐harm (<a href="./references#CD012955-bbs2-0016" title="CottrauxJ , NoteID , BoutitieF , MillieryM , GenouihlacV , YaoSN , et al. Cognitive therapy versus Rogerian supportive therapy in borderline personality disorder. Two-year follow-up of a controlled pilot study. Psychotherapy and Psychosomatics2009;78(5):307-16. [DOI: 10.1159/000229769] [PMID: 19628959]NCT00131781. Cognitive therapy versus supportive therapy in borderline personality disorder. www.clinicaltrials.gov/ct2/show/NCT00131781 (first received 18 August 2005). ">Cottraux 2009</a>). </p> <p>CBT did not reduce self‐harm at end of treatment compared with Rogerian support therapy (MD 0.74, 95% CI −0.03 to 1.51; 1 trial, 38 participants; P = 0.06; <a href="./references#CD012955-fig-0198" title="">Analysis 22.5</a>.1). </p> <p>CBT did not reduce self‐harm at six to 12 months compared with Rogerian support therapy (MD ‐0.63, 95% CI −1.75 to 0.49; 1 trial, 21 participants; P = 0.27; <a href="./references#CD012955-fig-0198" title="">Analysis 22.5</a>.2). </p> <p>No data were available for zero to six months and above 12 months follow‐up.</p> </section> <section id="CD012955-sec-0433"> <p><b>Suicide‐related outcomes</b></p> <p>One trial reported continuous data on suicide‐related outcomes (<a href="./references#CD012955-bbs2-0016" title="CottrauxJ , NoteID , BoutitieF , MillieryM , GenouihlacV , YaoSN , et al. Cognitive therapy versus Rogerian supportive therapy in borderline personality disorder. Two-year follow-up of a controlled pilot study. Psychotherapy and Psychosomatics2009;78(5):307-16. [DOI: 10.1159/000229769] [PMID: 19628959]NCT00131781. Cognitive therapy versus supportive therapy in borderline personality disorder. www.clinicaltrials.gov/ct2/show/NCT00131781 (first received 18 August 2005). ">Cottraux 2009</a>). </p> <p>CBT did not reduce suicide‐related outcomes at end of treatment compared with Rogerian support therapy (MD 0.69, 95% CI −2.60 to 3.9; 1 trial, 38 participants; P = 0.68; <a href="./references#CD012955-fig-0198" title="">Analysis 22.5</a>.3). </p> <p>CBT did not reduce suicide‐related outcomes at six to 12 months compared with Rogerian support therapy (MD ‐2.43, 95% CI ‐6.14 to 1.28; 1 trial, 21 participants; P = 0.20; <a href="./references#CD012955-fig-0198" title="">Analysis 22.5</a>.4). </p> <p>No data were available for zero to six months and above 12 months follow‐up.</p> </section> <section id="CD012955-sec-0434"> <p><b>Psychosocial functioning</b></p> <p>One trial reported continuous data on psychosocial functioning (<a href="./references#CD012955-bbs2-0016" title="CottrauxJ , NoteID , BoutitieF , MillieryM , GenouihlacV , YaoSN , et al. Cognitive therapy versus Rogerian supportive therapy in borderline personality disorder. Two-year follow-up of a controlled pilot study. Psychotherapy and Psychosomatics2009;78(5):307-16. [DOI: 10.1159/000229769] [PMID: 19628959]NCT00131781. Cognitive therapy versus supportive therapy in borderline personality disorder. www.clinicaltrials.gov/ct2/show/NCT00131781 (first received 18 August 2005). ">Cottraux 2009</a>). </p> <p>CBT did not improve psychosocial functioning at end of treatment compared with Rogerian support therapy (MD −0.43, 95% CI −1.31 to 0.45; 1 trial, 38 participants; P = 0.34; <a href="./references#CD012955-fig-0198" title="">Analysis 22.5</a>.5). </p> <p>CBT did not improve psychosocial functioning at six to 12 months compared with Rogerian support therapy (MD ‐0.98, 95% CI ‐2.02 to 0.06; 1 trial, 21 participants; P = 0.07; <a href="./references#CD012955-fig-0198" title="">Analysis 22.5</a>.6). </p> <p>No data were available for zero to six months and above 12 months follow‐up.</p> <p>No data were available on any time point for BPD symptom severity.</p> </section> </section> <section id="CD012955-sec-0435"> <h6 class="title">Secondary outcomes</h6> <section id="CD012955-sec-0436"> <p><b>Impulsivity</b></p> <p>One trial reported continuous data on Impulsivity (<a href="./references#CD012955-bbs2-0016" title="CottrauxJ , NoteID , BoutitieF , MillieryM , GenouihlacV , YaoSN , et al. Cognitive therapy versus Rogerian supportive therapy in borderline personality disorder. Two-year follow-up of a controlled pilot study. Psychotherapy and Psychosomatics2009;78(5):307-16. [DOI: 10.1159/000229769] [PMID: 19628959]NCT00131781. Cognitive therapy versus supportive therapy in borderline personality disorder. www.clinicaltrials.gov/ct2/show/NCT00131781 (first received 18 August 2005). ">Cottraux 2009</a>). </p> <p>CBT did not reduce impulsivity at end of treatment compared with Rogerian support therapy (MD −1.01, 95% CI −3.85 to 1.83; 1 trial, 38 participants; P = 0.49; <a href="./references#CD012955-fig-0198" title="">Analysis 22.5</a>.7). </p> <p>CBT did not reduce impulsivity at six to 12 months compared with Rogerian support therapy (MD ‐2.18, 95% CI ‐5.91 to 1.55; 1 trial, 21 participants; P = 0.25; <a href="./references#CD012955-fig-0198" title="">Analysis 22.5</a>.8). </p> <p>No data were available for zero to six months and above 12 months follow‐up.</p> </section> <section id="CD012955-sec-0437"> <p><b>Depression</b></p> <p>One trial reported continuous data on depression (<a href="./references#CD012955-bbs2-0016" title="CottrauxJ , NoteID , BoutitieF , MillieryM , GenouihlacV , YaoSN , et al. Cognitive therapy versus Rogerian supportive therapy in borderline personality disorder. Two-year follow-up of a controlled pilot study. Psychotherapy and Psychosomatics2009;78(5):307-16. [DOI: 10.1159/000229769] [PMID: 19628959]NCT00131781. Cognitive therapy versus supportive therapy in borderline personality disorder. www.clinicaltrials.gov/ct2/show/NCT00131781 (first received 18 August 2005). ">Cottraux 2009</a>). </p> <p>CBT did not reduce depression at end of treatment compared with Rogerian support therapy (MD 1.04, 95% CI −5.59 to 7.67; 1 trial, 38 participants; P = 0.76; <a href="./references#CD012955-fig-0198" title="">Analysis 22.5</a>.9). </p> <p>CBT did reduce depression at six to 12 months compared with Rogerian support therapy (MD ‐5.15, 95% CI ‐9.38 to ‐0.92; 1 trial, 21 participants; P = 0.02; <a href="./references#CD012955-fig-0198" title="">Analysis 22.5</a>.10). </p> <p>No data were available for zero to six months and above 12 months follow‐up.</p> <p>No data were available on any time point for anger, affective instability, chronic feelings of emptiness, interpersonal problems, abandonment, identity disturbance, dissociation and psychotic‐like symptoms, attrition, and adverse effects. </p> </section> </section> </section> <section id="CD012955-sec-0438"> <h5 class="title">22.6 CBT versus Rogerian supportive therapy (dichotomous)</h5> <section id="CD012955-sec-0439"> <h6 class="title">Primary outcomes</h6> <p>No data were available on any time point for BPD symptom severity, self‐harm, suicide‐related outcomes, and psychosocial functioning. </p> </section> <section id="CD012955-sec-0440"> <h6 class="title">Secondary outcome: attrition</h6> <p>One trial reported dichotomous data on attrition (<a href="./references#CD012955-bbs2-0016" title="CottrauxJ , NoteID , BoutitieF , MillieryM , GenouihlacV , YaoSN , et al. Cognitive therapy versus Rogerian supportive therapy in borderline personality disorder. Two-year follow-up of a controlled pilot study. Psychotherapy and Psychosomatics2009;78(5):307-16. [DOI: 10.1159/000229769] [PMID: 19628959]NCT00131781. Cognitive therapy versus supportive therapy in borderline personality disorder. www.clinicaltrials.gov/ct2/show/NCT00131781 (first received 18 August 2005). ">Cottraux 2009</a>). </p> <p>CBT did not reduce attrition at end of treatment compared with Rogerian support therapy (RR 0.90, 95% CI 0.51 to 1.60; 1 trial, 38 participants; P = 0.72; <a href="./references#CD012955-fig-0199" title="">Analysis 22.6</a>). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> <p>No data were available on any time point for anger, affective instability, chronic feelings of emptiness, impulsivity, interpersonal problems, abandonment, identity disturbance, dissociation and psychotic‐like symptoms, depression, and adverse effects. </p> </section> </section> <section id="CD012955-sec-0441"> <h5 class="title">22.7 MACT (manual‐assisted cognitive therapy) versus MACT + therapeutic assessment (TA) (continuous) </h5> <section id="CD012955-sec-0442"> <h6 class="title">Primary outcomes</h6> <section id="CD012955-sec-0443"> <p><b>BPD symptom severity</b></p> <p>One trial reported continuous data on BPD symptom severity (<a href="./references#CD012955-bbs2-0054" title="MoreyLC , LowmasterSE , HopwoodCJ . A pilot study of manual-assisted cognitive therapy with a therapeutic assessment augmentation for borderline personality disorder. Psychiatry Research2010;178(3):531-5. [DOI: 10.1016/j.psychres.2010.04.055] [PMID: 20537722]">Morey 2010</a>). </p> <p>MACT did not reduce BPD symptom severity at end of treatment compared with MACT + TA (MD −3.75, 95% CI −14.17 to 6.67; 1 trial, 16 participants; P = 0.48; <a href="./references#CD012955-fig-0200" title="">Analysis 22.7</a>.1). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> </section> <section id="CD012955-sec-0444"> <p><b>Self‐harm</b></p> <p>One trial reported continuous data on self‐harm (<a href="./references#CD012955-bbs2-0054" title="MoreyLC , LowmasterSE , HopwoodCJ . A pilot study of manual-assisted cognitive therapy with a therapeutic assessment augmentation for borderline personality disorder. Psychiatry Research2010;178(3):531-5. [DOI: 10.1016/j.psychres.2010.04.055] [PMID: 20537722]">Morey 2010</a>). </p> <p>MACT did not reduce self‐harm at end of treatment compared with MACT + TA (MD 1.75, 95% CI −18.71 to 22.21; 1 trial, 16 participants; P = 0.87; <a href="./references#CD012955-fig-0200" title="">Analysis 22.7</a>.2). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> </section> <section id="CD012955-sec-0445"> <p><b>Suicide‐related outcomes</b></p> <p>One trial reported continuous data on suicide‐related outcomes (<a href="./references#CD012955-bbs2-0054" title="MoreyLC , LowmasterSE , HopwoodCJ . A pilot study of manual-assisted cognitive therapy with a therapeutic assessment augmentation for borderline personality disorder. Psychiatry Research2010;178(3):531-5. [DOI: 10.1016/j.psychres.2010.04.055] [PMID: 20537722]">Morey 2010</a>). </p> <p>MACT did not reduce suicide‐related outcomes at end of treatment compared with MACT + TA (MD −0.63, 95% CI −17.71 to 16.45; 1 trial, 16 participants; P = 0.94; <a href="./references#CD012955-fig-0200" title="">Analysis 22.7</a>.3). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> <p>No data were available on any time point for psychosocial functioning.</p> </section> </section> <section id="CD012955-sec-0446"> <h6 class="title">Secondary outcomes</h6> <section id="CD012955-sec-0447"> <p><b>Affective instability</b></p> <p>One trial reported continuous data on affective instability (<a href="./references#CD012955-bbs2-0054" title="MoreyLC , LowmasterSE , HopwoodCJ . A pilot study of manual-assisted cognitive therapy with a therapeutic assessment augmentation for borderline personality disorder. Psychiatry Research2010;178(3):531-5. [DOI: 10.1016/j.psychres.2010.04.055] [PMID: 20537722]">Morey 2010</a>). </p> <p>MACT did not reduce affective instability at end of treatment compared with MACT + TA (MD −5.25, 95% CI −12.10 to 1.60; 1 trial, 16 participants; P = 0.13; <a href="./references#CD012955-fig-0200" title="">Analysis 22.7</a>.4). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> </section> <section id="CD012955-sec-0448"> <p><b>Interpersonal problems</b></p> <p>One trial reported continuous data on interpersonal problems (<a href="./references#CD012955-bbs2-0054" title="MoreyLC , LowmasterSE , HopwoodCJ . A pilot study of manual-assisted cognitive therapy with a therapeutic assessment augmentation for borderline personality disorder. Psychiatry Research2010;178(3):531-5. [DOI: 10.1016/j.psychres.2010.04.055] [PMID: 20537722]">Morey 2010</a>). </p> <p>MACT did not interpersonal problems at end of treatment compared with MACT + TA (MD −0.50, 95% CI −11.24 to 10.24; 1 trial, 16 participants; P = 0.93; <a href="./references#CD012955-fig-0200" title="">Analysis 22.7</a>.5). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> </section> <section id="CD012955-sec-0449"> <p><b>Identity disturbance</b></p> <p>One trial reported continuous data on identity disturbance (<a href="./references#CD012955-bbs2-0054" title="MoreyLC , LowmasterSE , HopwoodCJ . A pilot study of manual-assisted cognitive therapy with a therapeutic assessment augmentation for borderline personality disorder. Psychiatry Research2010;178(3):531-5. [DOI: 10.1016/j.psychres.2010.04.055] [PMID: 20537722]">Morey 2010</a>). </p> <p>MACT did not reduce identity disturbance at end of treatment compared with MACT + TA (MD −4.88, 95% CI −14.98 to 5.22; 1 trial, 16 participants; P = 0.34; <a href="./references#CD012955-fig-0200" title="">Analysis 22.7</a>.6). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> <p>No data were available on any time point for anger, chronic feelings of emptiness, impulsivity, abandonment, dissociation and psychotic‐like symptoms, depression, attrition, and adverse effects. </p> </section> </section> </section> <section id="CD012955-sec-0450"> <h5 class="title">22.8 MACT versus MACT + TA (dichotomous)</h5> <section id="CD012955-sec-0451"> <h6 class="title">Primary outcomes</h6> <p>No data were available on any time point for BPD symptom severity, self‐harm, suicide‐related outcomes, and psychosocial functioning. </p> </section> <section id="CD012955-sec-0452"> <h6 class="title">Secondary outcome: attrition</h6> <p>One trial reported dichotomous data on attrition (<a href="./references#CD012955-bbs2-0054" title="MoreyLC , LowmasterSE , HopwoodCJ . A pilot study of manual-assisted cognitive therapy with a therapeutic assessment augmentation for borderline personality disorder. Psychiatry Research2010;178(3):531-5. [DOI: 10.1016/j.psychres.2010.04.055] [PMID: 20537722]">Morey 2010</a>). </p> <p>MACT did not reduce attrition at end of treatment compared with MACT + TA (RR 0.80, 95% CI 0.33 to 1.92; 1 trial, 16 participants; P = 0.62; <a href="./references#CD012955-fig-0201" title="">Analysis 22.8</a>). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> <p>No data were available on any time point for anger, affective instability, chronic feelings of emptiness, impulsivity, interpersonal problems, abandonment, identity disturbance, dissociation and psychotic‐like symptoms, depression, and adverse effects. </p> </section> </section> <section id="CD012955-sec-0453"> <h5 class="title">22.9 Meta‐cognitive training for BPD (B‐MCT) versus progressive muscle relaxation (PMR) (continuous) </h5> <section id="CD012955-sec-0454"> <h6 class="title">Primary outcome: BPD symptom severity</h6> <p>One trial reported continuous data on BPD symptom severity (<a href="./references#CD012955-bbs2-0065" title="SchillingL , MoritzS , KötherU , NagelM . Preliminary results on acceptance, feasibility, and subjective efficacy of the add-on group intervention metacognitive training for borderline patients. Journal of Cognitive Psychotherapy2015;29(2):153-64. [DOI: 10.1891/0889-8391.29.2.153]SchillingL , MoritzS , KristonL , KriegerM , NagelM . Efficacy of metacognitive training for patients with borderline personality disorder: preliminary results. Psychiatry Research2018;262:459-64. [DOI: 10.1016/j.psychres.2017.09.024] [PMID: 28927866]SchillingL . Re Schilling 2015/2018 - Cochrane Review of psychotherapies for BPD [personal communication] [Re Schilling 2015/2018 - Cochrane Review zur Psychotherapie bei BPS [persönliche Kommunikation]]. Email to: J Stoffers-Winterling 22 January 2019. ">Schilling 2018</a>). </p> <p>B‐MCT did not reduce BPD symptom severity at end of treatment compared PMR (MD −1.80, 95% CI −4.97 to 1.37; 1 trial, 49 participants; P = 0.27; <a href="./references#CD012955-fig-0202" title="">Analysis 22.9</a>.1). </p> <p>PMR reduced BPD symptom severity at zero to six months follow‐up compared B‐MCT (MD −3.60, 95% CI −7.16 to −0.04; 1 trial, 39 participants; P = 0.05; <a href="./references#CD012955-fig-0202" title="">Analysis 22.9</a>.2). </p> <p>No data were available for six to 12 months and above 12 months follow‐up.</p> <p>No data were available on any time point for self‐harm, suicide‐related outcomes and psychosocial functioning. </p> </section> <section id="CD012955-sec-0455"> <h6 class="title">Secondary outcomes: depression</h6> <p>One trial reported continuous data on depression (<a href="./references#CD012955-bbs2-0065" title="SchillingL , MoritzS , KötherU , NagelM . Preliminary results on acceptance, feasibility, and subjective efficacy of the add-on group intervention metacognitive training for borderline patients. Journal of Cognitive Psychotherapy2015;29(2):153-64. [DOI: 10.1891/0889-8391.29.2.153]SchillingL , MoritzS , KristonL , KriegerM , NagelM . Efficacy of metacognitive training for patients with borderline personality disorder: preliminary results. Psychiatry Research2018;262:459-64. [DOI: 10.1016/j.psychres.2017.09.024] [PMID: 28927866]SchillingL . Re Schilling 2015/2018 - Cochrane Review of psychotherapies for BPD [personal communication] [Re Schilling 2015/2018 - Cochrane Review zur Psychotherapie bei BPS [persönliche Kommunikation]]. Email to: J Stoffers-Winterling 22 January 2019. ">Schilling 2018</a>). </p> <p>B‐MCT did not reduce depression at end of treatment compared with PMR (MD −3.20, 95% CI −9.91 to 3.51; 1 trial, 54 participants; P = 0.35; <a href="./references#CD012955-fig-0202" title="">Analysis 22.9</a>.3). </p> <p>B‐MCT reduced depression at zero to six months follow‐up compared with PMR (MD 8.50, 95% CI 2.03 to 14.97; 1 trial, 47 participants, P = 0.01 <a href="./references#CD012955-fig-0202" title="">Analysis 22.9</a>.4). </p> <p>No data were available for six to 12 months and above 12 months follow‐up.</p> <p>No data were available on any time point for anger, affective instability, chronic feelings of emptiness, impulsivity, interpersonal problems, abandonment, identity disturbance, dissociation and psychotic‐like symptoms, attrition and adverse effects. </p> </section> </section> <section id="CD012955-sec-0456"> <h5 class="title">22.10 B‐MCT versus PMR (dichotomous)</h5> <section id="CD012955-sec-0457"> <h6 class="title">Primary outcomes</h6> <p>No data were available on any time point for BPD symptom severity, self‐harm, suicide‐related outcomes, and psychosocial functioning. </p> </section> <section id="CD012955-sec-0458"> <h6 class="title">Secondary outcome: attrition</h6> <p>One trial reported dichotomous data on attrition (<a href="./references#CD012955-bbs2-0065" title="SchillingL , MoritzS , KötherU , NagelM . Preliminary results on acceptance, feasibility, and subjective efficacy of the add-on group intervention metacognitive training for borderline patients. Journal of Cognitive Psychotherapy2015;29(2):153-64. [DOI: 10.1891/0889-8391.29.2.153]SchillingL , MoritzS , KristonL , KriegerM , NagelM . Efficacy of metacognitive training for patients with borderline personality disorder: preliminary results. Psychiatry Research2018;262:459-64. [DOI: 10.1016/j.psychres.2017.09.024] [PMID: 28927866]SchillingL . Re Schilling 2015/2018 - Cochrane Review of psychotherapies for BPD [personal communication] [Re Schilling 2015/2018 - Cochrane Review zur Psychotherapie bei BPS [persönliche Kommunikation]]. Email to: J Stoffers-Winterling 22 January 2019. ">Schilling 2018</a>). </p> <p>B‐MCT did not reduce attrition at end of treatment compared with PMR (RR 0.95, 95% CI 0.45 to 2.00; 1 trial, 74 participants; P = 0.89; <a href="./references#CD012955-fig-0203" title="">Analysis 22.10</a>). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> <p>No data were available on any time point for anger, affective instability, chronic feelings of emptiness, impulsivity, interpersonal problems, abandonment, identity disturbance, dissociation and psychotic‐like symptoms, depression, and adverse effects. </p> </section> </section> <section id="CD012955-sec-0459"> <h5 class="title">22.11 Motive‐oriented therapeutic relationship (MOTR) versus good psychiatric management (GPM) </h5> <section id="CD012955-sec-0460"> <h6 class="title">Primary outcomes</h6> <section id="CD012955-sec-0461"> <p><b>BPD symptom severity</b></p> <p>One trial reported continuous data on BPD symptom severity (<a href="./references#CD012955-bbs2-0037" title="BerthoudL , KramerU , CasparF , Pascual-LeoneA . Emotional processing in a ten-session general psychiatric treatment for borderline personality disorder: a case study. Personality and Mental Health2015;9(1):73-8. [DOI: 10.1002/pmh.1287] [PMID: 25711648]BerthoudL , Pascual-LeoneA , CasparF , TissotH , KellerS , RohdeKB , et al. Leaving distress behind: a randomized controlled study on change in emotional processing in borderline personality disorder. Psychiatry2017;80(2):139-54. [DOI: 10.1080/00332747.2016.1220230] [PMID: 28767333]KellerS , StelmaszczykK , KollyS , De RotenY , DesplandJN , CasparF , et al. Change in biased thinking in a treatment based on the motive-oriented therapeutic relationship for borderline personality disorder. Journal of Personality Disorders2018;32(Suppl):75-92. [DOI: 10.1521/pedi.2018.32.supp.75] [PMID: 29388899]KramerU , FlückigerC , KollyS , CasparF , MarquetP , DesplandJN , et al. Unpacking the effects of therapist responsiveness in borderline personality disorder: motive-oriented therapeutic relationship, patient in-session experience, and the therapeutic alliance. Psychotherapy and Psychosomatics2014;83(6):386-7. [DOI: 10.1159/000365400] [PMID: 25324025]KramerU , KellerS , CasparF , De RotenY , DesplandJN , KollyS . Early change in coping strategies in responsive treatments for borderline personality disorder: a mediation analysis. Journal of Consulting and Clinical Psychology2017;85(5):530-5. [DOI: 10.1037/ccp0000196] [PMID: 28425747]KramerU , KollyS , BerthoudL , KellerS , PreisigM , CasparF , et al. Effects of motive-oriented therapeutic relationship in a ten-session general psychiatric treatment of borderline personality disorder: a randomized controlled trial. Psychotherapy and Psychosomatics2014;83(3):176-86. [DOI: 10.1159/000358528] [PMID: 24752034]KramerU , StulzN , BerthoudL , CasparF , MarquetP , KollyS , et al. The shorter the better? A follow-up analysis of 10-session psychiatric treatment including the motive-oriented therapeutic relationship for borderline personality disorder. Psychotherapy Research2017;27(3):362-70. [DOI: 10.1080/10503307.2015.1110635] [PMID: 26684670]NCT01896024. Effects of motive-oriented therapeutic relationship in the early-phase treatment of borderline personality disorder (MOTR). www.clinicaltrials.gov/ct2/show/NCT01896024 (first received 5 July 2013). ">Kramer 2014</a>). </p> <p>MOTR did not reduce BPD symptom severity at end of treatment compared with GPM (MD 0.07, 95% CI −0.38 to 0.52; 1 trial, 74 participants = 74; P = 0.76; <a href="./references#CD012955-fig-0204" title="">Analysis 22.11</a>.1). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> </section> <section id="CD012955-sec-0462"> <p><b>Psychosocial functioning</b></p> <p>Two trials reported continuous data on psychosocial functioning (<a href="./references#CD012955-bbs2-0036" title="KramerU , BergerT , KollyS , MarquetP , PreisigM , De RotenY , et al. Effects of motive-oriented therapeutic relationship in early-phase treatment of borderline personality disorder: a pilot study of a randomized trial. Journal of Nervous and Mental Disease2011;199(4):244-50. [DOI: 10.1097/NMD.0b013e3182125d19] [PMID: 21451348]KramerU , CasparF , DrapeauM . Change in biased thinking in a 10-session treatment for borderline personality disorder: further evidence of the motive-oriented therapeutic relationship. Psychotherapy Research2013;23(6):633-45. [DOI: 10.1080/10503307.2013.791404] [PMID: 23631622]">Kramer 2011</a>; <a href="./references#CD012955-bbs2-0037" title="BerthoudL , KramerU , CasparF , Pascual-LeoneA . Emotional processing in a ten-session general psychiatric treatment for borderline personality disorder: a case study. Personality and Mental Health2015;9(1):73-8. [DOI: 10.1002/pmh.1287] [PMID: 25711648]BerthoudL , Pascual-LeoneA , CasparF , TissotH , KellerS , RohdeKB , et al. Leaving distress behind: a randomized controlled study on change in emotional processing in borderline personality disorder. Psychiatry2017;80(2):139-54. [DOI: 10.1080/00332747.2016.1220230] [PMID: 28767333]KellerS , StelmaszczykK , KollyS , De RotenY , DesplandJN , CasparF , et al. Change in biased thinking in a treatment based on the motive-oriented therapeutic relationship for borderline personality disorder. Journal of Personality Disorders2018;32(Suppl):75-92. [DOI: 10.1521/pedi.2018.32.supp.75] [PMID: 29388899]KramerU , FlückigerC , KollyS , CasparF , MarquetP , DesplandJN , et al. Unpacking the effects of therapist responsiveness in borderline personality disorder: motive-oriented therapeutic relationship, patient in-session experience, and the therapeutic alliance. Psychotherapy and Psychosomatics2014;83(6):386-7. [DOI: 10.1159/000365400] [PMID: 25324025]KramerU , KellerS , CasparF , De RotenY , DesplandJN , KollyS . Early change in coping strategies in responsive treatments for borderline personality disorder: a mediation analysis. Journal of Consulting and Clinical Psychology2017;85(5):530-5. [DOI: 10.1037/ccp0000196] [PMID: 28425747]KramerU , KollyS , BerthoudL , KellerS , PreisigM , CasparF , et al. Effects of motive-oriented therapeutic relationship in a ten-session general psychiatric treatment of borderline personality disorder: a randomized controlled trial. Psychotherapy and Psychosomatics2014;83(3):176-86. [DOI: 10.1159/000358528] [PMID: 24752034]KramerU , StulzN , BerthoudL , CasparF , MarquetP , KollyS , et al. The shorter the better? A follow-up analysis of 10-session psychiatric treatment including the motive-oriented therapeutic relationship for borderline personality disorder. Psychotherapy Research2017;27(3):362-70. [DOI: 10.1080/10503307.2015.1110635] [PMID: 26684670]NCT01896024. Effects of motive-oriented therapeutic relationship in the early-phase treatment of borderline personality disorder (MOTR). www.clinicaltrials.gov/ct2/show/NCT01896024 (first received 5 July 2013). ">Kramer 2014</a>). </p> <p>MOTR group improved psychosocial functioning at end of treatment compared with GPM (SMD −0.45, 95% CI −0.85 to −0.05: 2 trials, 99 participants; I<sup>2</sup> = 0%; P = 0.03; <a href="./references#CD012955-fig-0204" title="">Analysis 22.11</a>.2). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> <p>No data were available on any time point for self‐harm and suicide‐related outcomes.</p> </section> </section> <section id="CD012955-sec-0463"> <h6 class="title">Secondary outcomes: interpersonal problems</h6> <p>Two trials reported continuous data on interpersonal problems (<a href="./references#CD012955-bbs2-0036" title="KramerU , BergerT , KollyS , MarquetP , PreisigM , De RotenY , et al. Effects of motive-oriented therapeutic relationship in early-phase treatment of borderline personality disorder: a pilot study of a randomized trial. Journal of Nervous and Mental Disease2011;199(4):244-50. [DOI: 10.1097/NMD.0b013e3182125d19] [PMID: 21451348]KramerU , CasparF , DrapeauM . Change in biased thinking in a 10-session treatment for borderline personality disorder: further evidence of the motive-oriented therapeutic relationship. Psychotherapy Research2013;23(6):633-45. [DOI: 10.1080/10503307.2013.791404] [PMID: 23631622]">Kramer 2011</a>; <a href="./references#CD012955-bbs2-0037" title="BerthoudL , KramerU , CasparF , Pascual-LeoneA . Emotional processing in a ten-session general psychiatric treatment for borderline personality disorder: a case study. Personality and Mental Health2015;9(1):73-8. [DOI: 10.1002/pmh.1287] [PMID: 25711648]BerthoudL , Pascual-LeoneA , CasparF , TissotH , KellerS , RohdeKB , et al. Leaving distress behind: a randomized controlled study on change in emotional processing in borderline personality disorder. Psychiatry2017;80(2):139-54. [DOI: 10.1080/00332747.2016.1220230] [PMID: 28767333]KellerS , StelmaszczykK , KollyS , De RotenY , DesplandJN , CasparF , et al. Change in biased thinking in a treatment based on the motive-oriented therapeutic relationship for borderline personality disorder. Journal of Personality Disorders2018;32(Suppl):75-92. [DOI: 10.1521/pedi.2018.32.supp.75] [PMID: 29388899]KramerU , FlückigerC , KollyS , CasparF , MarquetP , DesplandJN , et al. Unpacking the effects of therapist responsiveness in borderline personality disorder: motive-oriented therapeutic relationship, patient in-session experience, and the therapeutic alliance. Psychotherapy and Psychosomatics2014;83(6):386-7. [DOI: 10.1159/000365400] [PMID: 25324025]KramerU , KellerS , CasparF , De RotenY , DesplandJN , KollyS . Early change in coping strategies in responsive treatments for borderline personality disorder: a mediation analysis. Journal of Consulting and Clinical Psychology2017;85(5):530-5. [DOI: 10.1037/ccp0000196] [PMID: 28425747]KramerU , KollyS , BerthoudL , KellerS , PreisigM , CasparF , et al. Effects of motive-oriented therapeutic relationship in a ten-session general psychiatric treatment of borderline personality disorder: a randomized controlled trial. Psychotherapy and Psychosomatics2014;83(3):176-86. [DOI: 10.1159/000358528] [PMID: 24752034]KramerU , StulzN , BerthoudL , CasparF , MarquetP , KollyS , et al. The shorter the better? A follow-up analysis of 10-session psychiatric treatment including the motive-oriented therapeutic relationship for borderline personality disorder. Psychotherapy Research2017;27(3):362-70. [DOI: 10.1080/10503307.2015.1110635] [PMID: 26684670]NCT01896024. Effects of motive-oriented therapeutic relationship in the early-phase treatment of borderline personality disorder (MOTR). www.clinicaltrials.gov/ct2/show/NCT01896024 (first received 5 July 2013). ">Kramer 2014</a>). </p> <p>MOTR group improved interpersonal problems at end of treatment compared with GPM (SMD −0.56, 95% CI −0.97 to −0.16: 2 trials, 99 participants; I<sup>2</sup> = 0%; P = 0.006; <a href="./references#CD012955-fig-0204" title="">Analysis 22.11</a>.3). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> <p>No data were available on any time point for anger, affective instability, chronic feelings of emptiness, impulsivity, abandonment, identity disturbance, dissociation and psychotic‐like symptoms, depression, attrition, and adverse effects. </p> </section> </section> <section id="CD012955-sec-0464"> <h5 class="title">22.12 MOTR versus GPM (dichotomous)</h5> <section id="CD012955-sec-0465"> <h6 class="title">Primary outcomes</h6> <p>No data were available on any time point for BPD symptom severity, self‐harm, suicide‐related outcomes, and psychosocial functioning. </p> </section> <section id="CD012955-sec-0466"> <h6 class="title">Secondary outcome: attrition</h6> <p>Two trials reported dichotomous data on attrition (<a href="./references#CD012955-bbs2-0036" title="KramerU , BergerT , KollyS , MarquetP , PreisigM , De RotenY , et al. Effects of motive-oriented therapeutic relationship in early-phase treatment of borderline personality disorder: a pilot study of a randomized trial. Journal of Nervous and Mental Disease2011;199(4):244-50. [DOI: 10.1097/NMD.0b013e3182125d19] [PMID: 21451348]KramerU , CasparF , DrapeauM . Change in biased thinking in a 10-session treatment for borderline personality disorder: further evidence of the motive-oriented therapeutic relationship. Psychotherapy Research2013;23(6):633-45. [DOI: 10.1080/10503307.2013.791404] [PMID: 23631622]">Kramer 2011</a>; <a href="./references#CD012955-bbs2-0037" title="BerthoudL , KramerU , CasparF , Pascual-LeoneA . Emotional processing in a ten-session general psychiatric treatment for borderline personality disorder: a case study. Personality and Mental Health2015;9(1):73-8. [DOI: 10.1002/pmh.1287] [PMID: 25711648]BerthoudL , Pascual-LeoneA , CasparF , TissotH , KellerS , RohdeKB , et al. Leaving distress behind: a randomized controlled study on change in emotional processing in borderline personality disorder. Psychiatry2017;80(2):139-54. [DOI: 10.1080/00332747.2016.1220230] [PMID: 28767333]KellerS , StelmaszczykK , KollyS , De RotenY , DesplandJN , CasparF , et al. Change in biased thinking in a treatment based on the motive-oriented therapeutic relationship for borderline personality disorder. Journal of Personality Disorders2018;32(Suppl):75-92. [DOI: 10.1521/pedi.2018.32.supp.75] [PMID: 29388899]KramerU , FlückigerC , KollyS , CasparF , MarquetP , DesplandJN , et al. Unpacking the effects of therapist responsiveness in borderline personality disorder: motive-oriented therapeutic relationship, patient in-session experience, and the therapeutic alliance. Psychotherapy and Psychosomatics2014;83(6):386-7. [DOI: 10.1159/000365400] [PMID: 25324025]KramerU , KellerS , CasparF , De RotenY , DesplandJN , KollyS . Early change in coping strategies in responsive treatments for borderline personality disorder: a mediation analysis. Journal of Consulting and Clinical Psychology2017;85(5):530-5. [DOI: 10.1037/ccp0000196] [PMID: 28425747]KramerU , KollyS , BerthoudL , KellerS , PreisigM , CasparF , et al. Effects of motive-oriented therapeutic relationship in a ten-session general psychiatric treatment of borderline personality disorder: a randomized controlled trial. Psychotherapy and Psychosomatics2014;83(3):176-86. [DOI: 10.1159/000358528] [PMID: 24752034]KramerU , StulzN , BerthoudL , CasparF , MarquetP , KollyS , et al. The shorter the better? A follow-up analysis of 10-session psychiatric treatment including the motive-oriented therapeutic relationship for borderline personality disorder. Psychotherapy Research2017;27(3):362-70. [DOI: 10.1080/10503307.2015.1110635] [PMID: 26684670]NCT01896024. Effects of motive-oriented therapeutic relationship in the early-phase treatment of borderline personality disorder (MOTR). www.clinicaltrials.gov/ct2/show/NCT01896024 (first received 5 July 2013). ">Kramer 2014</a>). </p> <p>MOTR group did not reduce attrition at end of treatment compared with GPM (RR 0.61, 95% CI 0.26 to 1.41: 2 trials, 110 participants; I<sup>2</sup> = 34%; P = 0.25; <a href="./references#CD012955-fig-0205" title="">Analysis 22.12</a>). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> <p>No data were available on any time point for anger, affective instability, chronic feelings of emptiness, impulsivity, interpersonal problems, abandonment, identity disturbance, dissociation and psychotic‐like symptoms, depression, and adverse effects. </p> </section> </section> </section> <section id="CD012955-sec-0467"> <h4 class="title">23. Schema‐focused therapy (SFT) versus active treatment</h4> <section id="CD012955-sec-0468"> <h5 class="title">23.1 SFT versus transference‐focused psychotherapy (TFP) (continuous)</h5> <section id="CD012955-sec-0469"> <h6 class="title">Primary outcome: BPD symptom severity</h6> <p>One trial reported continuous data on BPD symptom severity (<a href="./references#CD012955-bbs2-0024" title="ArntzA , Stupar-RutenfransS , BlooJ , Van DyckR , SpinhovenP . Prediction of treatment discontinuation and recovery from borderline personality disorder: results from an RCT comparing schema therapy and transference-focused psychotherapy. Behaviour Research and Therapy2015;74:60-71. [DOI: 10.1016/j.brat.2015.09.002] [PMID: 26432172]Giesen-BlooJ , ArntzA . Questions concerning the randomized trial of schema-focused therapy vs transference-focused psychotherapy—reply. Archives of General Psychiatry2007;64(5):610-1. [DOI: 10.1001/archpsyc.64.5.610]Giesen-BlooJ , Van DyckR , SpinhovenP , Van TilburgW , DirksenC , Van AsseltT , et al. Errors in table and figure in: outpatient psychotherapy for borderline personality disorder: randomized trial of schema-focused therapy vs transference-focused psychotherapy. Archives of General Psychiatry2006;63(9):1008. Erratum for: Archives of General Psychiatry 2006;63(6):649-58. [DOI: 10.1001/archpsyc.63.9.1008]Giesen-BlooJ , Van DyckR , SpinhovenP , Van TilburgW , DirksenC , Van AsseltT , et al. Outpatient psychotherapy for borderline personality disorder: randomized trial of schema-focused therapy vs transference-focused psychotherapy. Archives of General Psychiatry2006;63(6):649-58. [DOI: 10.1001/archpsyc.63.6.649] [PMID: 16754838]SpinhovenP , Giesen-BlooJ , Van DyckR , KooimanK , ArntzA . The therapeutic alliance in schema-focused therapy and transference-focused psychotherapy for borderline personality disorder. Journal of Consulting and Clinical Psychology2007;75(1):104-15. [DOI: 10.1037/0022-006X.75.1.104] [PMID: 17295569]Van AsseltADI , DirksenCD , ArntzA , Giesen-BlooJH , Van DyckR , SpinhovenP , et al. Out-patient psychotherapy for borderline personality disorder: cost-effectiveness of schema-focused therapy v transference-focused psychotherapy. British Journal of Psychiatry2008;192(6):450-7. [DOI: 10.1192/bjp.bp.106.033597] [PMID: 18515897]Van AsseltADI , DirksenCD , ArntzA , SeverensJL . Difficulties in calculating productivity costs: work disability associated with borderline personality disorder. Value in Health2008;11(4):637-44. [DOI: 10.1111/j.1524-4733.2007.00288.x]YeomansF . Questions concerning the randomized trial of schema-focused therapy vs transference-focused psychotherapy. Archives of General Psychiatry2007;64(5):609-10. [DOI: 10.1001/archpsyc.64.5.609-c] [PMID: 17485613]">Giesen‐Bloo 2006</a>). </p> <p>SFT reduced BPD symptom severity at end of treatment compared with TFP (MD −4.95, 95% CI −9.59 to −0.31; 1 trial, 86 participants; P = 0.04; <a href="./references#CD012955-fig-0206" title="">Analysis 23.1</a>). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> <p>No data were available on any time point for self‐harm, suicide‐related outcomes, and psychosocial functioning. </p> </section> <section id="CD012955-sec-0470"> <h6 class="title">Secondary outcomes</h6> <p>No data were available on any time point for anger, affective instability, chronic feelings of emptiness, impulsivity, interpersonal problems, abandonment, identity disturbance, dissociation and psychotic‐like symptoms, depression, attrition and adverse effects. </p> </section> </section> <section id="CD012955-sec-0471"> <h5 class="title">23.2 SFT versus TFP (dichotomous)</h5> <section id="CD012955-sec-0472"> <h6 class="title">Primary outcomes</h6> <p>No data were available on any time point for BPD symptom severity, self‐harm, suicide‐related outcomes, and psychosocial functioning. </p> </section> <section id="CD012955-sec-0473"> <h6 class="title">Secondary outcome: attrition</h6> <p>One trial reported dichotomous data on attrition (<a href="./references#CD012955-bbs2-0024" title="ArntzA , Stupar-RutenfransS , BlooJ , Van DyckR , SpinhovenP . Prediction of treatment discontinuation and recovery from borderline personality disorder: results from an RCT comparing schema therapy and transference-focused psychotherapy. Behaviour Research and Therapy2015;74:60-71. [DOI: 10.1016/j.brat.2015.09.002] [PMID: 26432172]Giesen-BlooJ , ArntzA . Questions concerning the randomized trial of schema-focused therapy vs transference-focused psychotherapy—reply. Archives of General Psychiatry2007;64(5):610-1. [DOI: 10.1001/archpsyc.64.5.610]Giesen-BlooJ , Van DyckR , SpinhovenP , Van TilburgW , DirksenC , Van AsseltT , et al. Errors in table and figure in: outpatient psychotherapy for borderline personality disorder: randomized trial of schema-focused therapy vs transference-focused psychotherapy. Archives of General Psychiatry2006;63(9):1008. Erratum for: Archives of General Psychiatry 2006;63(6):649-58. [DOI: 10.1001/archpsyc.63.9.1008]Giesen-BlooJ , Van DyckR , SpinhovenP , Van TilburgW , DirksenC , Van AsseltT , et al. Outpatient psychotherapy for borderline personality disorder: randomized trial of schema-focused therapy vs transference-focused psychotherapy. Archives of General Psychiatry2006;63(6):649-58. [DOI: 10.1001/archpsyc.63.6.649] [PMID: 16754838]SpinhovenP , Giesen-BlooJ , Van DyckR , KooimanK , ArntzA . The therapeutic alliance in schema-focused therapy and transference-focused psychotherapy for borderline personality disorder. Journal of Consulting and Clinical Psychology2007;75(1):104-15. [DOI: 10.1037/0022-006X.75.1.104] [PMID: 17295569]Van AsseltADI , DirksenCD , ArntzA , Giesen-BlooJH , Van DyckR , SpinhovenP , et al. Out-patient psychotherapy for borderline personality disorder: cost-effectiveness of schema-focused therapy v transference-focused psychotherapy. British Journal of Psychiatry2008;192(6):450-7. [DOI: 10.1192/bjp.bp.106.033597] [PMID: 18515897]Van AsseltADI , DirksenCD , ArntzA , SeverensJL . Difficulties in calculating productivity costs: work disability associated with borderline personality disorder. Value in Health2008;11(4):637-44. [DOI: 10.1111/j.1524-4733.2007.00288.x]YeomansF . Questions concerning the randomized trial of schema-focused therapy vs transference-focused psychotherapy. Archives of General Psychiatry2007;64(5):609-10. [DOI: 10.1001/archpsyc.64.5.609-c] [PMID: 17485613]">Giesen‐Bloo 2006</a>). </p> <p>SFT reduced attrition at zero to six months follow‐up compared with TFP (RR 0.52, 95% CI 0.30 to 0.92; 1 trial, 88 participants; P = 0.02; <a href="./references#CD012955-fig-0207" title="">Analysis 23.2</a>). </p> <p>No data were available for end of treatment, six to 12 months and above 12 months follow‐up. </p> <p>No data were available on any time point for anger, affective instability, chronic feelings of emptiness, impulsivity, interpersonal problems, abandonment, identity disturbance, dissociation and psychotic‐like symptoms, depression, and adverse effects. </p> </section> </section> <section id="CD012955-sec-0474"> <h5 class="title">23.3 SFT versus SFT + therapist availability (continuous)</h5> <section id="CD012955-sec-0475"> <h6 class="title">Primary outcome: BPD symptom severity</h6> <p>One trial reported continuous data on BPD symptom severity (<a href="./references#CD012955-bbs2-0056" title="NadortM , ArntzA , SmitJH , Giesen-BlooJ , EikelenboomJ , SpinhovenP , et al. Implementation of outpatient schema therapy for borderline personality disorder with versus without crisis support by the therapist outside office hours: a randomized trial. Behaviour Research and Therapy2009;47(11):961-73. [DOI: 10.1016/j.brat.2009.07.013] [PMID: 19698939]NadortM , ArntzA , SmitJH , Giesen-BlooJ , EikelenboomM , SpinhovenP , et al. Implementation of outpatient schema therapy for borderline personality disorder: study design. BMC Psychiatry2009;9:64. [DOI: 10.1186/1471-244X-9-64] [PMC2762959] [PMID: 19807925]NL1680 (NTR1781). Implementation of out-patient schema-focused therapy for borderline personality disorder in regular mental healthcare. www.trialregister.nl/trial/1680 (first received 29 April 2009). ">Nadort 2009</a>). </p> <p>SFT did not reduce BPD severity at end of treatment compared with TFP (MD −0.30, 95% CI −5.51 to 4.91; 1 trial, 61 participants; P = 0.91; <a href="./references#CD012955-fig-0208" title="">Analysis 23.3</a>). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> <p>No data were available on any time point for self‐harm, suicide‐related outcomes and psychosocial functioning. </p> </section> <section id="CD012955-sec-0476"> <h6 class="title">Secondary outcomes</h6> <p>No data were available on any time point for anger, affective instability, chronic feelings of emptiness, impulsivity, interpersonal problems, abandonment, identity disturbance, dissociation and psychotic‐like symptoms, depression, attrition and adverse effects. </p> </section> </section> <section id="CD012955-sec-0477"> <h5 class="title">23.4 SFT versus SFT + therapist availability (dichotomous)</h5> <section id="CD012955-sec-0478"> <h6 class="title">Primary outcomes</h6> <p>No data were available on any time point for BPD symptom severity, self‐harm, suicide‐related outcomes, and psychosocial functioning. </p> </section> <section id="CD012955-sec-0479"> <h6 class="title">Secondary outcome: attrition</h6> <p>One trial reported dichotomous data on attrition (<a href="./references#CD012955-bbs2-0056" title="NadortM , ArntzA , SmitJH , Giesen-BlooJ , EikelenboomJ , SpinhovenP , et al. Implementation of outpatient schema therapy for borderline personality disorder with versus without crisis support by the therapist outside office hours: a randomized trial. Behaviour Research and Therapy2009;47(11):961-73. [DOI: 10.1016/j.brat.2009.07.013] [PMID: 19698939]NadortM , ArntzA , SmitJH , Giesen-BlooJ , EikelenboomM , SpinhovenP , et al. Implementation of outpatient schema therapy for borderline personality disorder: study design. BMC Psychiatry2009;9:64. [DOI: 10.1186/1471-244X-9-64] [PMC2762959] [PMID: 19807925]NL1680 (NTR1781). Implementation of out-patient schema-focused therapy for borderline personality disorder in regular mental healthcare. www.trialregister.nl/trial/1680 (first received 29 April 2009). ">Nadort 2009</a>). </p> <p>SFT did not reduce attrition at zero to six months follow‐up compared with TFP (RR 0.91, 95% CI 0.35 to 2.41; 1 trial, 62 participants; P = 0.86; <a href="./references#CD012955-fig-0209" title="">Analysis 23.4</a>). </p> <p>No data were available for end of treatment, six to 12 months and above 12 months follow‐up. </p> <p>No data were available on any time point for anger, affective instability, chronic feelings of emptiness, impulsivity, interpersonal problems, abandonment, identity disturbance, dissociation and psychotic‐like symptoms, depression, and adverse effects. </p> </section> </section> </section> <section id="CD012955-sec-0480"> <h4 class="title">24. Systems training for emotional predictability and problem solving (STEPPS)‐based psychoeducation (STEPPS‐PE) versus cognitive rehabilitation (CR) </h4> <section id="CD012955-sec-0481"> <h5 class="title">24.1 STEPPS‐PE versus CR (continuous)</h5> <section id="CD012955-sec-0482"> <h6 class="title">Primary outcome: BPD symptom severity</h6> <p>One trial reported continuous data on BPD symptom severity (<a href="./references#CD012955-bbs2-0057" title="NCT02033044. Cognitive rehabilitation versus psychoeducation in psychosocial functioning of borderline personality disorder [Randomized controlled trial comparing the effects on psychosocial functioning of cognitive rehabilitation versus psychoeducation in borderline personality disorder]. www.clinicaltrials.gov/ct2/show/NCT02033044 (first received 23 December 2013). PascualJC , PalomaresN , Ibáñez Á, PortellaMJ , ArzaR , ReyesR , et al. Efficacy of cognitive rehabilitation on psychosocial functioning in borderline personality disorder: a randomized controlled trial. BMC Psychiatry2015;15:255. [DOI: 10.1186/s12888-015-0640-5] [PMC4617906] [PMID: 26487284]">Pascual 2015</a>). </p> <p>STEPPS‐PE reduced BPD symptom severity at end of treatment compared with cognitive rehabilitation (MD −3.67, 95% CI −6.52 to −0.82; 1 trial, 46 participants; P = 0.01; <a href="./references#CD012955-fig-0210" title="">Analysis 24.1</a>.1). </p> <p>Cognitive rehabilitation reduced BPD symptom severity at zero to six months follow‐up compared with STEPPS‐PE (MD 4.68, 95% CI 1.42 to 7.94; 1 trial, 42 participants; P = 0.005; <a href="./references#CD012955-fig-0210" title="">Analysis 24.1</a>.2). </p> <p>No data were available for six to 12 months and above 12 months follow‐up.</p> <p>No data were available on any time point for self‐harm, suicide‐related outcomes and psychosocial functioning. </p> </section> <section id="CD012955-sec-0483"> <h6 class="title">Secondary outcomes</h6> <section id="CD012955-sec-0484"> <p><b>Impulsivity</b></p> <p>One trial reported continuous data on impulsivity (<a href="./references#CD012955-bbs2-0057" title="NCT02033044. Cognitive rehabilitation versus psychoeducation in psychosocial functioning of borderline personality disorder [Randomized controlled trial comparing the effects on psychosocial functioning of cognitive rehabilitation versus psychoeducation in borderline personality disorder]. www.clinicaltrials.gov/ct2/show/NCT02033044 (first received 23 December 2013). PascualJC , PalomaresN , Ibáñez Á, PortellaMJ , ArzaR , ReyesR , et al. Efficacy of cognitive rehabilitation on psychosocial functioning in borderline personality disorder: a randomized controlled trial. BMC Psychiatry2015;15:255. [DOI: 10.1186/s12888-015-0640-5] [PMC4617906] [PMID: 26487284]">Pascual 2015</a>). </p> <p>Cognitive rehabilitation reduced impulsivity at end of treatment compared with STEPPS‐PE (MD 1.99, 95% CI 0.06 to 3.92; 1 trial, 46 participants; P = 0.04; <a href="./references#CD012955-fig-0210" title="">Analysis 24.1</a>.3). </p> <p>Cognitive rehabilitation reduced impulsivity at zero to six months follow‐up compared with STEPPS‐PE (MD 9.92, 95% CI 7.38 to 12.46; 1 trial, 42 participants; P &lt; 0.001; <a href="./references#CD012955-fig-0210" title="">Analysis 24.1</a>.4). </p> <p>No data were available for six to 12 months and above 12 months follow‐up.</p> </section> <section id="CD012955-sec-0485"> <p><b>Depression</b></p> <p>One trial reported continuous data on depression (<a href="./references#CD012955-bbs2-0057" title="NCT02033044. Cognitive rehabilitation versus psychoeducation in psychosocial functioning of borderline personality disorder [Randomized controlled trial comparing the effects on psychosocial functioning of cognitive rehabilitation versus psychoeducation in borderline personality disorder]. www.clinicaltrials.gov/ct2/show/NCT02033044 (first received 23 December 2013). PascualJC , PalomaresN , Ibáñez Á, PortellaMJ , ArzaR , ReyesR , et al. Efficacy of cognitive rehabilitation on psychosocial functioning in borderline personality disorder: a randomized controlled trial. BMC Psychiatry2015;15:255. [DOI: 10.1186/s12888-015-0640-5] [PMC4617906] [PMID: 26487284]">Pascual 2015</a>). </p> <p>STEPPS‐PE reduced depression at end of treatment compared with cognitive rehabilitation (MD −2.58, 95% CI −3.62 to −1.54; 1 trial, 48 participants; P &lt; 0.001; <a href="./references#CD012955-fig-0210" title="">Analysis 24.1</a>.5). </p> <p>STEPPS‐PE reduced depression at zero to six months follow‐up compared to cognitive rehabilitation (MD −10.11, 95% CI −11.35 to −8.87; 1 trial, 42 participants; P &lt; 0.001; <a href="./references#CD012955-fig-0210" title="">Analysis 24.1</a>.6). </p> <p>No data were available for six to 12 months and above 12 months follow‐up.</p> <p>No data were available on any time point for anger, affective instability, chronic feelings of emptiness, interpersonal problems, abandonment, identity disturbance, dissociation and psychotic‐like symptoms, attrition and adverse effects. </p> </section> </section> </section> <section id="CD012955-sec-0486"> <h5 class="title">24.2 STEPPS‐PE versus CR (dichotomous)</h5> <section id="CD012955-sec-0487"> <h6 class="title">Primary outcomes</h6> <p>No data were available on any time point for BPD symptom severity, self‐harm, suicide‐related outcomes, and psychosocial functioning. </p> </section> <section id="CD012955-sec-0488"> <h6 class="title">Secondary outcome: attrition</h6> <p>One trial reported dichotomous data on attrition (<a href="./references#CD012955-bbs2-0057" title="NCT02033044. Cognitive rehabilitation versus psychoeducation in psychosocial functioning of borderline personality disorder [Randomized controlled trial comparing the effects on psychosocial functioning of cognitive rehabilitation versus psychoeducation in borderline personality disorder]. www.clinicaltrials.gov/ct2/show/NCT02033044 (first received 23 December 2013). PascualJC , PalomaresN , Ibáñez Á, PortellaMJ , ArzaR , ReyesR , et al. Efficacy of cognitive rehabilitation on psychosocial functioning in borderline personality disorder: a randomized controlled trial. BMC Psychiatry2015;15:255. [DOI: 10.1186/s12888-015-0640-5] [PMC4617906] [PMID: 26487284]">Pascual 2015</a>). </p> <p>STEPPS‐PE did not reduce attrition at end of treatment compared with cognitive rehabilitation (RR 0.76, 95% CI 0.39 to 1.47; 1 trial, 70 participants; P = 0.41; <a href="./references#CD012955-fig-0211" title="">Analysis 24.2</a>). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> <p>No data were available on any time point for anger, affective instability, chronic feelings of emptiness, interpersonal problems, abandonment, identity disturbance, dissociation and psychotic‐like symptoms, and adverse effects. </p> </section> </section> </section> <section id="CD012955-sec-0489"> <h4 class="title">25. Eclectic treatments versus active treatment</h4> <section id="CD012955-sec-0490"> <h5 class="title">25.1 Combined inpatient and outpatient psychotherapy versus outpatient psychotherapy (continuous) </h5> <section id="CD012955-sec-0491"> <h6 class="title">Primary outcome: psychosocial functioning</h6> <p>One trial reported continuous data on psychosocial functioning (<a href="./references#CD012955-bbs2-0003" title="AntonsenBT , JohansenMS , RøFG , KvarsteinEH , WilbergT . Is reflective functioning associated with clinical symptoms and long-term course in patients with personality disorders?Comprehensive Psychiatry2016;64:46-58. [DOI: 10.1016/j.comppsych.2015.05.016] [PMID: 26104432]AntonsenBT , KlungsøyrO , KampsA , HummelenB , JohansenMS , PedersenG , et al. Step-down versus outpatient psychotherapeutic treatment for personality disorders: 6-year follow-up of the Ullevål personality project. BMC Psychiatry2014;14:119. [DOI: 10.1186/1471-244X-14-119] [PMC4000615] [PMID: 24758722]AntonsenBT , KvarsteinEH , Urnes Ø, HummelenB , KarterudS , WilbergT . Favourable outcome of long-term combined psychotherapy for patients with borderline personality disorder: six-year follow-up of a randomized study. Psychotherapy Research2017;27(1):51-63. [DOI: 10.1080/10503307.2015.1072283] [PMID: 26261865]ArnevikE , WilbergT , Urnes Ø, JohansenM , MonsenJT , KarterudS . Psychotherapy for personality disorders: short-term day hospital psychotherapy versus outpatient individual therapy - a randomized controlled study. European Psychiatry2009;24(2):71-8. [DOI: 10.1016/j.eurpsy.2008.09.004] [PMID: 19097870]GullestadFS , JohansenMS , HøglendP , KarterudS , WilbergT . Mentalization as a moderator of treatment effects: findings from a randomized clinical trial for personality disorders. Psychotherapy Research2013;23(6):674-89. [DOI: 10.1080/10503307.2012.684103] [PMID: 22612470]GullestadFS . Re: questions regarding your trial on day hospital step-down program [personal communication]. Email to: E Faltinsen 4 December 2017. KvarsteinEH , ArnevikE , HalsteinliV , RøFG , KarterudS , WilbergT . Health service costs and clinical gains of psychotherapy for personality disorders: a randomized controlled trial of day-hospital-based step-down treatment versus outpatient treatment at a specialist practice. BMC Psychiatry2013;13:315. [DOI: 10.1186/1471-244X-13-315] [PMC4222503] [PMID: 24268099]">Antonsen 2017</a>). </p> <p>Inpatient and outpatient psychotherapy did not improve psychosocial functioning at end of treatment compared with psychotherapy alone (MD 6.50, 95% CI −0.06 to 13.06; 1 trial, 52 participants; P = 0.05; <a href="./references#CD012955-fig-0212" title="">Analysis 25.1</a>.1). </p> <p>Inpatient and outpatient psychotherapy did not improve psychosocial functioning at above 12 months follow‐up compared with psychotherapy alone (MD −5.70, 95% CI −13.33 to 1.93; 1 trial, 52 participants; P = 0.14, <a href="./references#CD012955-fig-0212" title="">Analysis 25.1</a>.2). </p> <p>No data were available for zero to six months and six to 12 months follow‐up.</p> <p>No data were available on any time point for BPD symptom severity, self‐harm, and suicide‐related outcomes. </p> </section> <section id="CD012955-sec-0492"> <h6 class="title">Secondary outcomes</h6> <section id="CD012955-sec-0493"> <p><b>Interpersonal problems</b></p> <p>One trial reported continuous data on interpersonal problems (<a href="./references#CD012955-bbs2-0003" title="AntonsenBT , JohansenMS , RøFG , KvarsteinEH , WilbergT . Is reflective functioning associated with clinical symptoms and long-term course in patients with personality disorders?Comprehensive Psychiatry2016;64:46-58. [DOI: 10.1016/j.comppsych.2015.05.016] [PMID: 26104432]AntonsenBT , KlungsøyrO , KampsA , HummelenB , JohansenMS , PedersenG , et al. Step-down versus outpatient psychotherapeutic treatment for personality disorders: 6-year follow-up of the Ullevål personality project. BMC Psychiatry2014;14:119. [DOI: 10.1186/1471-244X-14-119] [PMC4000615] [PMID: 24758722]AntonsenBT , KvarsteinEH , Urnes Ø, HummelenB , KarterudS , WilbergT . Favourable outcome of long-term combined psychotherapy for patients with borderline personality disorder: six-year follow-up of a randomized study. Psychotherapy Research2017;27(1):51-63. [DOI: 10.1080/10503307.2015.1072283] [PMID: 26261865]ArnevikE , WilbergT , Urnes Ø, JohansenM , MonsenJT , KarterudS . Psychotherapy for personality disorders: short-term day hospital psychotherapy versus outpatient individual therapy - a randomized controlled study. European Psychiatry2009;24(2):71-8. [DOI: 10.1016/j.eurpsy.2008.09.004] [PMID: 19097870]GullestadFS , JohansenMS , HøglendP , KarterudS , WilbergT . Mentalization as a moderator of treatment effects: findings from a randomized clinical trial for personality disorders. Psychotherapy Research2013;23(6):674-89. [DOI: 10.1080/10503307.2012.684103] [PMID: 22612470]GullestadFS . Re: questions regarding your trial on day hospital step-down program [personal communication]. Email to: E Faltinsen 4 December 2017. KvarsteinEH , ArnevikE , HalsteinliV , RøFG , KarterudS , WilbergT . Health service costs and clinical gains of psychotherapy for personality disorders: a randomized controlled trial of day-hospital-based step-down treatment versus outpatient treatment at a specialist practice. BMC Psychiatry2013;13:315. [DOI: 10.1186/1471-244X-13-315] [PMC4222503] [PMID: 24268099]">Antonsen 2017</a>). </p> <p>Inpatient and outpatient psychotherapy did not reduce interpersonal problems at end of treatment (three years) compared with psychotherapy alone (MD 0.05, 95% CI −0.24 to 0.34; 1 trial, 52 participants; P = 0.74; <a href="./references#CD012955-fig-0212" title="">Analysis 25.1</a>.3). </p> <p>Participants in the inpatient and outpatient psychotherapy reported fewer interpersonal problems at above 12 months follow‐up compared with psychotherapy alone (MD −0.42, 95% CI −0.77 to −0.0; 1 trial, 52 participants; P = 0.02; <a href="./references#CD012955-fig-0212" title="">Analysis 25.1</a>.4). </p> <p>No data were available for zero to six months and six to 12 months follow‐up.</p> </section> <section id="CD012955-sec-0494"> <p><b>Identity disturbance</b></p> <p>One trial reported continuous data on identity disturbance (<a href="./references#CD012955-bbs2-0003" title="AntonsenBT , JohansenMS , RøFG , KvarsteinEH , WilbergT . Is reflective functioning associated with clinical symptoms and long-term course in patients with personality disorders?Comprehensive Psychiatry2016;64:46-58. [DOI: 10.1016/j.comppsych.2015.05.016] [PMID: 26104432]AntonsenBT , KlungsøyrO , KampsA , HummelenB , JohansenMS , PedersenG , et al. Step-down versus outpatient psychotherapeutic treatment for personality disorders: 6-year follow-up of the Ullevål personality project. BMC Psychiatry2014;14:119. [DOI: 10.1186/1471-244X-14-119] [PMC4000615] [PMID: 24758722]AntonsenBT , KvarsteinEH , Urnes Ø, HummelenB , KarterudS , WilbergT . Favourable outcome of long-term combined psychotherapy for patients with borderline personality disorder: six-year follow-up of a randomized study. Psychotherapy Research2017;27(1):51-63. [DOI: 10.1080/10503307.2015.1072283] [PMID: 26261865]ArnevikE , WilbergT , Urnes Ø, JohansenM , MonsenJT , KarterudS . Psychotherapy for personality disorders: short-term day hospital psychotherapy versus outpatient individual therapy - a randomized controlled study. European Psychiatry2009;24(2):71-8. [DOI: 10.1016/j.eurpsy.2008.09.004] [PMID: 19097870]GullestadFS , JohansenMS , HøglendP , KarterudS , WilbergT . Mentalization as a moderator of treatment effects: findings from a randomized clinical trial for personality disorders. Psychotherapy Research2013;23(6):674-89. [DOI: 10.1080/10503307.2012.684103] [PMID: 22612470]GullestadFS . Re: questions regarding your trial on day hospital step-down program [personal communication]. Email to: E Faltinsen 4 December 2017. KvarsteinEH , ArnevikE , HalsteinliV , RøFG , KarterudS , WilbergT . Health service costs and clinical gains of psychotherapy for personality disorders: a randomized controlled trial of day-hospital-based step-down treatment versus outpatient treatment at a specialist practice. BMC Psychiatry2013;13:315. [DOI: 10.1186/1471-244X-13-315] [PMC4222503] [PMID: 24268099]">Antonsen 2017</a>). </p> <p>Inpatient and outpatient psychotherapy did not reduce identity disturbance at end of treatment (three years) compared with psychotherapy alone (MD −0.25, 95% CI −0.59 to 0.09; 1 trial, 52 participants; P = 0.15; <a href="./references#CD012955-fig-0212" title="">Analysis 25.1</a>.5). </p> <p>Inpatient and outpatient psychotherapy reported less identity disturbance at above 12 months follow‐up compared with psychotherapy alone (MD −0.47, 95% CI −0.78 to −0.16; 1 trial, 52 participants; P = 0.003; <a href="./references#CD012955-fig-0212" title="">Analysis 25.1</a>.6). </p> <p>No data were available for zero to six months and six to 12 months follow‐up.</p> </section> <section id="CD012955-sec-0495"> <p><b>Depression</b></p> <p>One trial reported continuous data on depression (<a href="./references#CD012955-bbs2-0003" title="AntonsenBT , JohansenMS , RøFG , KvarsteinEH , WilbergT . Is reflective functioning associated with clinical symptoms and long-term course in patients with personality disorders?Comprehensive Psychiatry2016;64:46-58. [DOI: 10.1016/j.comppsych.2015.05.016] [PMID: 26104432]AntonsenBT , KlungsøyrO , KampsA , HummelenB , JohansenMS , PedersenG , et al. Step-down versus outpatient psychotherapeutic treatment for personality disorders: 6-year follow-up of the Ullevål personality project. BMC Psychiatry2014;14:119. [DOI: 10.1186/1471-244X-14-119] [PMC4000615] [PMID: 24758722]AntonsenBT , KvarsteinEH , Urnes Ø, HummelenB , KarterudS , WilbergT . Favourable outcome of long-term combined psychotherapy for patients with borderline personality disorder: six-year follow-up of a randomized study. Psychotherapy Research2017;27(1):51-63. [DOI: 10.1080/10503307.2015.1072283] [PMID: 26261865]ArnevikE , WilbergT , Urnes Ø, JohansenM , MonsenJT , KarterudS . Psychotherapy for personality disorders: short-term day hospital psychotherapy versus outpatient individual therapy - a randomized controlled study. European Psychiatry2009;24(2):71-8. [DOI: 10.1016/j.eurpsy.2008.09.004] [PMID: 19097870]GullestadFS , JohansenMS , HøglendP , KarterudS , WilbergT . Mentalization as a moderator of treatment effects: findings from a randomized clinical trial for personality disorders. Psychotherapy Research2013;23(6):674-89. [DOI: 10.1080/10503307.2012.684103] [PMID: 22612470]GullestadFS . Re: questions regarding your trial on day hospital step-down program [personal communication]. Email to: E Faltinsen 4 December 2017. KvarsteinEH , ArnevikE , HalsteinliV , RøFG , KarterudS , WilbergT . Health service costs and clinical gains of psychotherapy for personality disorders: a randomized controlled trial of day-hospital-based step-down treatment versus outpatient treatment at a specialist practice. BMC Psychiatry2013;13:315. [DOI: 10.1186/1471-244X-13-315] [PMC4222503] [PMID: 24268099]">Antonsen 2017</a>). </p> <p>Inpatient and outpatient psychotherapy did not reduce depression at end of treatment (three years) compared with psychotherapy alone (MD −0.40, 95% CI −6.25 to 5.45; 1 trial, 52 participants; P = 0.8; <a href="./references#CD012955-fig-0212" title="">Analysis 25.1</a>.7). </p> <p>Inpatient and outpatient psychotherapy did not reduce depression at above 12 months follow‐up compared to psychotherapy alone (MD −4.70, 95% CI −11.02 to 1.62; 1 trial, 52 participants; P = 0.14; <a href="./references#CD012955-fig-0212" title="">Analysis 25.1</a>.8). </p> <p>No data were available for zero to six months and six to 12 months follow‐up.</p> <p>No data were available on any time point for anger, affective instability, chronic feelings of emptiness, impulsivity, abandonment, dissociation and psychotic‐like symptoms, attrition and adverse effects. </p> </section> </section> </section> <section id="CD012955-sec-0496"> <h5 class="title">25.2 Combined inpatient and outpatient psychotherapy versus outpatient psychotherapy (dichotomous) </h5> <section id="CD012955-sec-0497"> <h6 class="title">Primary outcomes</h6> <p>No data were available on any time point for BPD symptom severity, self‐harm, suicide‐related outcomes, and psychosocial functioning. </p> </section> <section id="CD012955-sec-0498"> <h6 class="title">Secondary outcome: attrition</h6> <p>One trial reported dichotomous data on attrition (<a href="./references#CD012955-bbs2-0003" title="AntonsenBT , JohansenMS , RøFG , KvarsteinEH , WilbergT . Is reflective functioning associated with clinical symptoms and long-term course in patients with personality disorders?Comprehensive Psychiatry2016;64:46-58. [DOI: 10.1016/j.comppsych.2015.05.016] [PMID: 26104432]AntonsenBT , KlungsøyrO , KampsA , HummelenB , JohansenMS , PedersenG , et al. Step-down versus outpatient psychotherapeutic treatment for personality disorders: 6-year follow-up of the Ullevål personality project. BMC Psychiatry2014;14:119. [DOI: 10.1186/1471-244X-14-119] [PMC4000615] [PMID: 24758722]AntonsenBT , KvarsteinEH , Urnes Ø, HummelenB , KarterudS , WilbergT . Favourable outcome of long-term combined psychotherapy for patients with borderline personality disorder: six-year follow-up of a randomized study. Psychotherapy Research2017;27(1):51-63. [DOI: 10.1080/10503307.2015.1072283] [PMID: 26261865]ArnevikE , WilbergT , Urnes Ø, JohansenM , MonsenJT , KarterudS . Psychotherapy for personality disorders: short-term day hospital psychotherapy versus outpatient individual therapy - a randomized controlled study. European Psychiatry2009;24(2):71-8. [DOI: 10.1016/j.eurpsy.2008.09.004] [PMID: 19097870]GullestadFS , JohansenMS , HøglendP , KarterudS , WilbergT . Mentalization as a moderator of treatment effects: findings from a randomized clinical trial for personality disorders. Psychotherapy Research2013;23(6):674-89. [DOI: 10.1080/10503307.2012.684103] [PMID: 22612470]GullestadFS . Re: questions regarding your trial on day hospital step-down program [personal communication]. Email to: E Faltinsen 4 December 2017. KvarsteinEH , ArnevikE , HalsteinliV , RøFG , KarterudS , WilbergT . Health service costs and clinical gains of psychotherapy for personality disorders: a randomized controlled trial of day-hospital-based step-down treatment versus outpatient treatment at a specialist practice. BMC Psychiatry2013;13:315. [DOI: 10.1186/1471-244X-13-315] [PMC4222503] [PMID: 24268099]">Antonsen 2017</a>). </p> <p>Inpatient and outpatient psychotherapy did not reduce attrition at end of treatment (three years) compared with psychotherapy alone (RR 0.62, 95% CI 0.26 to 1.49; 1 trial, 52 participants; P = 0.28; <a href="./references#CD012955-fig-0213" title="">Analysis 25.2</a>). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> <p>No data were available on any time point for anger, affective instability, chronic feelings of emptiness, impulsivity, interpersonal problems, abandonment, identity disturbance, dissociation and psychotic‐like symptoms, depression, and adverse effects. </p> </section> </section> <section id="CD012955-sec-0499"> <h5 class="title">25.3 Integrative BPD‐oriented adolescent family therapy (I‐BAFT) versus individual drug counselling (IDC) </h5> <section id="CD012955-sec-0500"> <h6 class="title">Primary outcome: BPD symptom severity</h6> <p>One trial reported dichotomous data on BPD symptom severity (<a href="./references#CD012955-bbs2-0064" title="SantistebanDA , MenaMP , MuirJ , McCabeBE , AbaloC , CummingsAM . The efficacy of two adolescent substance abuse treatments and the impact of comorbid depression: results of a small randomized controlled trial. Psychiatric Rehabilitation Journal2015;38(1):55-64. [DOI: 10.1037/prj0000106] [PMC5021542] [PMID: 25799306]">Santisteban 2015</a>). </p> <p>Integrative BPD did not reduce BPD severity at end of treatment compared with control (RR 0.91, 95% CI 0.50 to 1.64; 1 trial, 40 participants; P = 0.75; <a href="./references#CD012955-fig-0214" title="">Analysis 25.3</a>.1). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> <p>No data were available on any time point for self‐harm, suicide‐related outcomes and psychosocial functioning. </p> </section> <section id="CD012955-sec-0501"> <h6 class="title">Secondary outcome: attrition</h6> <p>One trial reported dichotomous data on attrition (<a href="./references#CD012955-bbs2-0064" title="SantistebanDA , MenaMP , MuirJ , McCabeBE , AbaloC , CummingsAM . The efficacy of two adolescent substance abuse treatments and the impact of comorbid depression: results of a small randomized controlled trial. Psychiatric Rehabilitation Journal2015;38(1):55-64. [DOI: 10.1037/prj0000106] [PMC5021542] [PMID: 25799306]">Santisteban 2015</a>). </p> <p>Integrative BPD did not reduce attrition at end of treatment compared with control (RR 0.50, 95% CI 0.18 to 1.40; 1 trial, 40 participants; P = 0.19; <a href="./references#CD012955-fig-0214" title="">Analysis 25.3</a>.2). </p> <p>No data were available for zero to six months, six to 12 months and above 12 months follow‐up. </p> <p>No data were available on any time point for anger, affective instability, chronic feelings of emptiness, impulsivity, interpersonal problems, abandonment, identity disturbance, dissociation and psychotic‐like symptoms, depression, and adverse effects. </p> </section> </section> </section> <section id="CD012955-sec-0502"> <h4 class="title">Subgroup analyses</h4> <p>Where data permitted, we conducted our planned subgroup analyses, in addition to two post hoc subgroup analyses, for the primary outcomes of BPD symptom severity and psychosocial functioning. For the 'types of comparisons' subgroup, we also conducted analyses for self‐harm and suicide‐related outcomes. Only subgroups with two or more trials were included in the subgroup analyses. </p> <section id="CD012955-sec-0503"> <h5 class="title">26. Therapeutic approaches</h5> <section id="CD012955-sec-0504"> <h6 class="title">26.1 BPD symptom severity</h6> <p>We compared the effects of DBT versus MBT versus psychodynamic psychotherapy versus STEPPS versus eclectic treatments for the outcome of BPD symptom severity. We found no evidence of significant differences between the subgroups (test for subgroup differences: Chi<sup>2</sup> = 6.88, df = 4 (P = 0.14), I<sup>2</sup> = 41.8%): DBT SMD = −0.60 (95% CI −1.05 to −0.14; 3 trials, 149 participants; I<sup>2</sup> = 42%; P = 0.01; <a href="./references#CD012955-fig-0215" title="">Analysis 26.1</a>.1); MBT SMD = −0.13 (95% CI −0.38 to 0.11; 5 trials, 267 participants; I<sup>2</sup> = 0%; P = 0.28; <a href="./references#CD012955-fig-0215" title="">Analysis 26.1</a>.2); psychodynamic psychotherapy SMD = −0.29 (95% CI −0.66 to 0.09; 4 trials, 222 participants; I<sup>2</sup> = 38%; P = 0.13; <a href="./references#CD012955-fig-0215" title="">Analysis 26.1</a>.3); STEPPS SMD = −0.39 (95% CI −0.63 to −0.15; 3 trials, 273 participants; I<sup>2</sup> = 0%; P = 0.001; <a href="./references#CD012955-fig-0215" title="">Analysis 26.1</a>.4); and eclectic treatments SMD = −0.90 (95% CI −1.57 to −0.23; 2 trials, 134 participants; I<sup>2</sup> = 67%; P = 0.008; <a href="./references#CD012955-fig-0215" title="">Analysis 26.1</a>.5). For illustrative purposes, we present the results of other therapeutic approaches from single trials in <a href="./references#CD012955-fig-0215" title="">Analysis 26.1</a>.6 to <a href="./references#CD012955-fig-0215" title="">Analysis 26.1</a>.10. </p> </section> <section id="CD012955-sec-0505"> <h6 class="title">26.2 Psychosocial functioning</h6> <p>We compared the effects of DBT versus MBT versus psychodynamic psychotherapy versus eclectic treatments for the outcome of psychosocial functioning. We found no evidence of significant differences between the subgroups (test for subgroup differences: Chi<sup>2</sup> = 0.67, df = 3 (P = 0.88), I<sup>2</sup> = 0%): DBT SMD = −0.36 (95% CI −0.69 to −0.03; 6 trials, 225 participants; I<sup>2</sup> = 31%; P = 0.03; <a href="./references#CD012955-fig-0216" title="">Analysis 26.2</a>.1); MBT SMD = −0.54 (95% CI −1.24 to 0.16; 3 trials, 239 participants; I<sup>2</sup> = 83%; P = 0.13; <a href="./references#CD012955-fig-0216" title="">Analysis 26.2</a>.2); psychodynamic psychotherapy SMD = −0.69 (95% CI −1.98 to 0.59; 4 trials, 140 participants; I<sup>2</sup> = 92%; P = 0.29; <a href="./references#CD012955-fig-0216" title="">Analysis 26.2</a>.3); and eclectic treatments SMD = −0.57 (95% CI −1.10 to −0.04; 2 trials, 231 participants; I<sup>2</sup> = 63%; P = 0.03; <a href="./references#CD012955-fig-0216" title="">Analysis 26.2</a>.11). For illustrative purposes, we present the results of other therapeutic approaches from single trials in <a href="./references#CD012955-fig-0216" title="">Analysis 26.2</a>.5 to <a href="./references#CD012955-fig-0216" title="">Analysis 26.2</a>.11. </p> </section> </section> <section id="CD012955-sec-0506"> <h5 class="title">27. Age: BPD symptom severity</h5> <p>We compared the effects for the subgroup of 15 to 18 years of age versus above 18 years of age for the outcome of BPD symptom severity. There were significant differences between subgroups (test for subgroup differences: Chi<sup>2</sup> = 5.03, df = 1 (P = 0.02), I<sup>2</sup> = 80.1%): 15 to 18 years of age SMD = −0.14 (95% CI −0.46 to 0.17; 2 trials, 156 participants; I<sup>2</sup> = 0%; P = 0.38; <a href="./references#CD012955-fig-0217" title="">Analysis 27.1</a>.1); and above 18 years of age SMD = −0.57 (95% CI −0.76 to ‐0.37; 20 trials, 1088 participants; I<sup>2</sup> = 57%; P &lt; 0.001; <a href="./references#CD012955-fig-0217" title="">Analysis 27.1</a>.2). </p> </section> <section id="CD012955-sec-0507"> <h5 class="title">28. Duration</h5> <section id="CD012955-sec-0508"> <h6 class="title">28.1 BPD symptom severity</h6> <p>We compared the effects of less than six months versus six to 12 months versus above 12 months duration for the outcome of BPD symptom severity. We found no evidence of significant differences between the subgroups (test for subgroup differences: Chi<sup>2</sup> = 3.86, df = 2 (P = 0.15), I<sup>2</sup> = 48.2%): less than six months SMD = −0.76 (95% CI −1.10 to −0.42; 8 trials, 525 participants; I<sup>2</sup> = 69%; P &lt; 0.001; <a href="./references#CD012955-fig-0218" title="">Analysis 28.1</a>.1); six to 12 months SMD = −0.36 (95% CI −0.60 to −0.12; 11 trials, 606 participants; I<sup>2</sup> = 50%; P = 0.003; <a href="./references#CD012955-fig-0218" title="">Analysis 28.1</a>.2); and above 12 months SMD = −0.37 (95% CI −0.75 to 0.01; 3 trials, 113 participants; I<sup>2</sup> = 0%; P = 0.06; <a href="./references#CD012955-fig-0218" title="">Analysis 28.1</a>.3). </p> </section> <section id="CD012955-sec-0509"> <h6 class="title">28.2 Psychosocial functioning</h6> <p>We compared the effects of less than six months versus six to 12 months versus above 12 months durations for the outcome of psychosocial functioning. There were no significant differences between subgroups (test for subgroup differences: Chi<sup>2</sup> = 2.24, df = 2 (P = 0.33), I<sup>2</sup> = 10.9%): less than six months SMD = −0.31 (95% CI −0.73 to 0.11; 6 trials, 468 participants; I<sup>2</sup> = 73%; P = 0.14; <a href="./references#CD012955-fig-0219" title="">Analysis 28.2</a>.1); six to 12 months SMD = −0.25 (95% CI −0.49 to −0.01; 10 trials, 535 participants; I<sup>2</sup> = 45%; P = 0.04; <a href="./references#CD012955-fig-0219" title="">Analysis 28.2</a>.2); and above 12 months SMD = −0.86 (95% CI −1.62 to −0.10; 4 trials, 263 participants; I<sup>2</sup> = 86%; P = 0.03; <a href="./references#CD012955-fig-0219" title="">Analysis 28.2</a>.3). </p> </section> </section> <section id="CD012955-sec-0510"> <h5 class="title">29. Mode of therapy</h5> <section id="CD012955-sec-0511"> <h6 class="title">29.1 BPD symptom severity</h6> <p>We compared the effects of individual therapy versus group therapy versus mixed therapy for the outcome of BPD symptom severity. There were significant differences between subgroups (test for subgroup differences: Chi<sup>2</sup> = 13.23, df = 2 (P = 0.001), I<sup>2</sup> = 84.9%): individual therapy SMD = −0.39 (95% CI −0.63 to −0.16; 8 trials, 520 participants; I<sup>2</sup> = 39%; P = 0.001; <a href="./references#CD012955-fig-0220" title="">Analysis 29.1</a>.1); group therapy SMD = −0.89 (95% CI −1.21 to −0.57; 8 trials, 438 participants; I<sup>2</sup> = 57%; P &lt; 0.001; <a href="./references#CD012955-fig-0220" title="">Analysis 29.1</a>.2); and mixed therapy SMD = −0.15 (95% CI −0.38 to 0.09; 6 trials, 286 participants; I<sup>2</sup> = 0%; P = 0.22; <a href="./references#CD012955-fig-0220" title="">Analysis 29.1</a>.3). </p> </section> <section id="CD012955-sec-0512"> <h6 class="title">29.2 Psychosocial functioning</h6> <p>We compared the effects of individual therapy versus group therapy versus mixed therapy for the outcome of psychosocial functioning. There were no significant differences between subgroups (test for subgroup differences: Chi<sup>2</sup> = 0.89, df = 2 (P = 0.64), I<sup>2</sup> = 0%): individual therapy = SMD −0.31 (95% CI −0.75 to 0.12; 8 trials, 570 participants; I<sup>2</sup> = 80%; P = 0.16; <a href="./references#CD012955-fig-0221" title="">Analysis 29.2</a>.1); group therapy SMD = −0.44 (95% CI −0.65 to −0.23; 7 trials, 366 participants; I<sup>2</sup> = 0%; P &lt; 0.001; <a href="./references#CD012955-fig-0221" title="">Analysis 29.2</a>.2); and mixed therapy SMD = −0.63 (95% CI −1.14 to −0.13; 7 trials, 378 participants; I<sup>2</sup> = 80%; P = 0.01; <a href="./references#CD012955-fig-0221" title="">Analysis 29.2</a>.3). </p> </section> </section> <section id="CD012955-sec-0513"> <h5 class="title">30. Setting</h5> <section id="CD012955-sec-0514"> <h6 class="title">30.1 BPD symptom severity</h6> <p>We compared the effects of inpatient versus outpatient settings for the outcome of BPD symptom severity. There were significant differences between subgroups (test for subgroup differences: Chi<sup>2</sup> = 9.18, df = 1 (P = 0.002), I<sup>2</sup> = 89.1%): inpatient SMD = −0.07 (95% CI −0.34 to 0.20; 2 trials, 217 participants; I<sup>2</sup> = 0%; P = 0.61; <a href="./references#CD012955-fig-0222" title="">Analysis 30.1</a>.1); and outpatient SMD = −0.58 (95% CI −0.77 to −0.39; 20 trials, 1027 participants; I<sup>2</sup> = 51%; P &lt; 0.001; <a href="./references#CD012955-fig-0222" title="">Analysis 30.1</a>.2). </p> </section> <section id="CD012955-sec-0515"> <h6 class="title">30.2 Psychosocial functioning</h6> <p>We compared the effects of inpatient versus outpatient versus combined inpatient and outpatient settings for the outcome of psychosocial functioning. There were significant differences between subgroups (test for subgroup differences: Chi<sup>2</sup> = 15.99, df = 2 (P = 0.0003), I<sup>2</sup> = 87.5%): inpatient SMD = −0.85 (95% CI −1.24 to −0.46; 2 trials, 179 participants; I<sup>2</sup> = 0%; P &lt; 0.001; <a href="./references#CD012955-fig-0223" title="">Analysis 30.2</a>.1); outpatient SMD = −0.31 (95% CI −0.54 to −0.08; 18 trials, 1057 participants; I<sup>2</sup> = 67%; P = 0.008; <a href="./references#CD012955-fig-0223" title="">Analysis 30.2</a>.2); and combined inpatient and outpatient SMD = −1.34 (95% CI −1.84 to −0.84; two trials, 78 participants; I<sup>2</sup> = 0%; P &lt; 0.001; <a href="./references#CD012955-fig-0223" title="">Analysis 30.2</a>.3). </p> </section> </section> <section id="CD012955-sec-0516"> <h5 class="title">31. Type of raters</h5> <section id="CD012955-sec-0517"> <h6 class="title">31.1 BPD symptom severity</h6> <p>We compared the effects of self‐rated versus clinician‐rated for the outcome of BPD symptom severity. There were no significant differences between subgroups (test for subgroup differences: Chi<sup>2</sup> = 1.79, df = 1 (P = 0.18), I<sup>2</sup> = 44.2%): self‐rated SMD = −0.74 (95% CI −1.19 to −0.29; 8 trials, 408 participants; I<sup>2</sup> = 77%; P = 0.001; <a href="./references#CD012955-fig-0224" title="">Analysis 31.1</a>.1); and clinician‐rated SMD = −0.42 (95% CI −0.58 to −0.25; 14 trials, 836 participants; I<sup>2</sup> = 24%; P &lt; 0.001; <a href="./references#CD012955-fig-0224" title="">Analysis 31.1</a>.2). </p> </section> <section id="CD012955-sec-0518"> <h6 class="title">31.2 Psychosocial functioning</h6> <p>We compared the effects of self‐rated versus clinician‐rated for the outcome of psychosocial functioning. There were no significant differences between subgroups (test for subgroup differences: Chi<sup>2</sup> = 2.86, df = 1 (P = 0.09), I<sup>2</sup> = 65.1%): self‐rated SMD = −0.29 (95% CI −0.60 to 0.03; 12 trials, 728 participants; I<sup>2</sup> = 76%; P = 0.07; <a href="./references#CD012955-fig-0225" title="">Analysis 31.2</a>.1); and clinician‐rated SMD = −0.66 (95% CI −0.96 to −0.37; 10 trials, 586 participants; I<sup>2</sup> = 54%; P &lt; 0.001; <a href="./references#CD012955-fig-0225" title="">Analysis 31.2</a>.2). </p> </section> </section> <section id="CD012955-sec-0519"> <h5 class="title">32. Types of TAU</h5> <section id="CD012955-sec-0520"> <h6 class="title">32.1 BPD symptom severity</h6> <p>We compared the effects of obligatory TAU versus optional TAU for the outcome of BPD symptom severity. There were no significant differences between subgroups (test for subgroup differences: Chi<sup>2</sup> = 0.25, df = 1 (P = 0.61), I<sup>2</sup> = 0%): obligatory TAU SMD = −0.50 (95% CI −0.70 to −0.30; 19 trials, 1071 participants; I<sup>2</sup> = 60%; P &lt; 0.001; <a href="./references#CD012955-fig-0226" title="">Analysis 32.1</a>.1); and unspecified TAU SMD = −0.63 (95% CI −1.09 to ‐0.17; 3 trials, 173 participants; I<sup>2</sup> = 36%; P = 0.007; <a href="./references#CD012955-fig-0226" title="">Analysis 32.1</a>.2). </p> </section> <section id="CD012955-sec-0521"> <h6 class="title">32.2 Psychosocial functioning</h6> <p>We compared the effects of obligatory TAU versus optional TAU for the outcome of psychosocial functioning. There were no significant differences between subgroups (test for subgroup differences: Chi<sup>2</sup> = 3.18, df = 1 (P = 0.07), I<sup>2</sup> = 68.6%): obligatory TAU SMD = −0.32 (95% CI −0.56 to −0.09; 17 trials, 1002 participants; I<sup>2</sup> = 65%; P = 0.007; <a href="./references#CD012955-fig-0227" title="">Analysis 32.2</a>.1); and unspecified TAU SMD = −0.96 (95% CI −1.62 to −0.30; 5 trials, 312 participants; I<sup>2</sup> = 84%; P = 0.004; <a href="./references#CD012955-fig-0227" title="">Analysis 32.2</a>.2). </p> </section> </section> <section id="CD012955-sec-0522"> <h5 class="title">33. Types of comparison group</h5> <section id="CD012955-sec-0523"> <h6 class="title">33.1 BPD symptom severity</h6> <p>We compared the effects of trials with TAU versus trials with waiting list for the outcome of BPD symptom severity. There were no significant differences between subgroups (test for subgroup differences: Chi<sup>2</sup> = 0.01, df = 1 (P = 0.92), I<sup>2</sup> = 0%): trials with TAU SMD = −0.52 (95% CI −0.70 to −0.33; 22 trials, 1244 participants; I<sup>2</sup> = 57%; P &lt; 0.001; <a href="./references#CD012955-fig-0228" title="">Analysis 33.1</a>.1); and trials with waiting list (SMD −0.49, 95% CI −0.93 to −0.05; 3 trials, 161 participants; I<sup>2</sup> = 44%; P = 0.03; <a href="./references#CD012955-fig-0228" title="">Analysis 33.1</a>.2). </p> </section> <section id="CD012955-sec-0524"> <h6 class="title">33.2 Psychosocial functioning</h6> <p>We compared the effects of trials with TAU versus trials with waiting list for the outcome of psychosocial functioning. There were no significant differences between subgroups (test for subgroup differences: Chi<sup>2</sup> = 0.18, df = 1 (P = 0.67), I<sup>2</sup> = 0%): trials with TAU SMD = −0.45 (95% CI −0.68 to −0.22; 22 trials, 1314 participants; I<sup>2</sup> = 72%; P = 0.0001; <a href="./references#CD012955-fig-0229" title="">Analysis 33.2</a>.1); and trials with waiting list SMD = −0.56 (95% CI −1.01 to −0.11; 5 trials, 219 participants; I<sup>2</sup> = 59%; P = 0.01; <a href="./references#CD012955-fig-0229" title="">Analysis 33.2</a>.2). </p> </section> </section> <section id="CD012955-sec-0525"> <h5 class="title">34. Types of scales</h5> <section id="CD012955-sec-0526"> <h6 class="title">34.1 BPD symptom severity</h6> <p>We compared the effects of ZAN‐BPD versus SCID versus BEST versus BPDSI on the outcome of BPD symptom severity. There were significant differences between subgroups (test for subgroup differences: Chi<sup>2</sup> = 15.40, df = 3 (P = 0.002), I<sup>2</sup> = 80.5%): ZAN‐BPD SMD = −0.45 (95% CI −0.69 to −0.20; 4 trials, 261 participants; I<sup>2</sup> = 0%; P = 0.0004; <a href="./references#CD012955-fig-0230" title="">Analysis 34.1</a>.1); SCID SMD = −0.58 (95% CI −1.16 to −0.00; 3 trials, 112 participants; I<sup>2</sup> = 47%; P = 0.05; <a href="./references#CD012955-fig-0230" title="">Analysis 34.1</a>.2); BEST SMD = −1.10 (95% CI −1.47 to −0.72; 4 trials, 147 participants; I<sup>2</sup> = 10%; P &lt; 0.001; <a href="./references#CD012955-fig-0230" title="">Analysis 34.1</a>.3); and BPDSI SMD = −0.21 (95% CI −0.45 to 0.04; 4 trials, 267 participants; I<sup>2</sup> = 0%; P = 0.10; <a href="./references#CD012955-fig-0230" title="">Analysis 34.1</a>.4. For illustrative purposes, the results of other scales from single trials are report in <a href="./references#CD012955-fig-0230" title="">Analysis 34.1</a>.5 to <a href="./references#CD012955-fig-0230" title="">Analysis 34.1</a>.11. </p> </section> <section id="CD012955-sec-0527"> <h6 class="title">34.2 Psychosocial functioning</h6> <p>We compared the effects of the GAF versus GAS versus SAS on the outcome of psychosocial functioning. There were no significant differences between subgroups (test for subgroup differences: Chi<sup>2</sup> = 1.39, df = 2 (P = 0.50), I<sup>2</sup> = 0%): GAF SMD = −0.73 (95% CI −1.41 to −0.05; 4 trials, 204 participants; I<sup>2</sup> = 78%; P = 0.04; <a href="./references#CD012955-fig-0231" title="">Analysis 34.2</a>.1); GAS SMD = −0.71 (95% CI −0.96 to −0.46; 4 trials, 330 participants; I<sup>2</sup> = 0%; P &lt; 0.001; <a href="./references#CD012955-fig-0231" title="">Analysis 34.2</a>.2); and SAS SMD = −0.23 (95% CI −0.99 to 0.53; 4 trials, 283 participants; I<sup>2</sup> = 88%; P = 0.55; <a href="./references#CD012955-fig-0231" title="">Analysis 34.2</a>.3). For illustrative purposes, the results of other scales from single trials are reported in <a href="./references#CD012955-fig-0231" title="">Analysis 34.2</a>.4. to <a href="./references#CD012955-fig-0231" title="">Analysis 34.2</a>.13 </p> </section> </section> </section> <section id="CD012955-sec-0528"> <h4 class="title">Sensitivity analysis</h4> <p>We conducted a TSA as an sensitivity analysis on the significant findings for all primary outcomes and the secondary outcome of depression at end of treatment. The RIS was reached for BPD symptom severity, self‐harm, suicide‐related outcomes and psychosocial functioning. However, due to inconsistency for self‐harm and suicide‐related outcomes, we could only exclude the risk of a false positive finding (type 1 error) for BPD symptom severity and psychosocial functioning. The RIS was not reached for depression. </p> <p>We used both the fixed‐effect and random‐effects models in all meta‐analyses. However, when there were two or more trials included in an analysis, we chose to report the results of the random‐effects model, which gives greater weight to smaller trials; where only one trial was included in an analysis, we reported the results of the fixed‐effect model. Statistical significance changed in 13 analyses and in those cases we reported the results of both the random‐effects and fixed‐effect models (see <a href="./references#CD012955-fig-0035" title="">Analysis 3.7</a>, <a href="./references#CD012955-fig-0040" title="">Analysis 3.12</a>, <a href="./references#CD012955-fig-0044" title="">Analysis 4.1</a>.3, <a href="./references#CD012955-fig-0048" title="">Analysis 4.5</a>.1, <a href="./references#CD012955-fig-0050" title="">Analysis 4.7</a>.1, <a href="./references#CD012955-fig-0050" title="">Analysis 4.7</a>.2, <a href="./references#CD012955-fig-0050" title="">Analysis 4.7</a>.4, <a href="./references#CD012955-fig-0059" title="">Analysis 5.5</a>.1, <a href="./references#CD012955-fig-0069" title="">Analysis 6.4</a>.1, <a href="./references#CD012955-fig-0072" title="">Analysis 6.7</a>.1, <a href="./references#CD012955-fig-0118" title="">Analysis 14.3</a>, <a href="./references#CD012955-fig-0134" title="">Analysis 15.5</a>, <a href="./references#CD012955-fig-0167" title="">Analysis 18.12</a>). </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD012955-sec-0529" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD012955-sec-0529"></div> <section id="CD012955-sec-0530"> <h3 class="title" id="CD012955-sec-0530">Summary of main results</h3> <p>We considered 400 full‐text reports and, of these, we included 75 trials that randomised a total of 4507 participants. The age ranged from 14.8 to 45.7 mean years, and the majority of included persons were female. The length of the trials ranged from one to 36 months, with most of them performed in outpatient settings. We judged all included trials to be at high risk of bias. </p> <p>DBT and related treatments were the most intensively studied, with more than one‐third of all included trials comparing DBT to TAU, a waiting list or an alternate active treatment (26 RCTs). Fifteen RCTs investigated the effects of CBT and related treatments, seven of which assessed MBT or eclectic treatments, five evaluated BPD‐specific psychodynamic therapies, four investigated SFT and related treatments, and three assessed STEPPS and IPT, two investigated TFP, PE or MOTR, and one evaluated CAT, ACT, JCP or motivation feedback, respectively. </p> <p>In the following section, we summarise the main findings for the pooled analyses of psychotherapy versus TAU or waiting list for our primary outcomes (BPD symptom severity, self‐harm, suicide‐related outcomes and psychosocial functioning), and for those secondary outcomes that are not a part of the symptom characteristics of BPD (depression, attrition and adverse effects). We report end‐of‐treatment data. We advise the interested reader to explore the <a href="#CD012955-sec-0076">Effects of interventions</a> section for a more elaborated description of the effect of psychotherapy on the remaining secondary outcomes, and follow‐up data. There, they will also find a complete overview of the effects of specific kinds of psychotherapy (such as DBT, MBT, CBT, etc.). </p> <section id="CD012955-sec-0531"> <h4 class="title">Psychotherapy versus TAU</h4> <p>Comparing the effects of psychotherapy with TAU, we observed significant effects for all primary outcomes at the end of treatment (<a href="./full#CD012955-tbl-0001">summary of findings Table 1</a>). </p> <p>Psychotherapy significantly reduced BPD symptom severity (SMD −0.52, 95% CI −0.70 to −0.33; 22 trials, 1244 participants) compared with TAU. This corresponds to a MD of −3.6 (95% CI −4.4 to −2.08) on the ZAN‐BPD scale, which ranges from 0 to 36. This represents a clinically relevant improvement in BPD symptoms. The MIREDIF on this scale is −3.0 points (<a href="./references#CD012955-bbs2-0279" title="CrawfordMJ ,  SanatiniaR ,  BarrettB , CunninghamG , DaleO ,  GanguliP , et al. The clinical effectiveness and cost-effectiveness of lamotrigine in borderline personality disorder: a randomized placebo-controlled trial. American Journal of Psychiatry2018;175(8):756-64. [DOI: 10.1176/appi.ajp.2018.17091006] [PMID: 29621901]">Crawford 2018a</a>). </p> <p>Psychotherapy also showed a significant reduction in self‐harm when measured as a continuous outcome (SMD −0.32, 95% CI −0.49 to −0.14; 13 trials, 616 participants), but not a dichotomous outcome. The significant effect of continuous outcomes corresponds to a MD of −0.816 (95% CI −1.25 to 0.35) on the DSHI, which ranges from 0 to 34. The MIREDIF on this scale is −1.25 points, which corresponds to ½ SD (<a href="./references#CD012955-bbs2-0293" title="FarivarSS , LiuH ,  HaysRD . Half standard deviation estimate of the minimally important difference in HRQOL scores?Expert Review of Pharmacoeconomics &amp; Outcomes Research2004;4(5):515-23. [DOI: 10.1586/14737167.4.5.515] [PMID: 19807545]">Farivar 2004</a>). Clinically, this finding does not represent an important reduction in self‐harm for people with BPD. </p> <p>Additionally, suicide‐related outcomes were significantly reduced in both continuous (SMD −0.34, 95% CI −0.57 to −0.11; 13 trials, 616 participants) and dichotomous outcomes (RR 0.27, 95% CI 0.11 to 0.67; 5 trials, 396 participants). The improvement corresponded to a MD of −0.11 (95% CI −0.19 to −0.034) on the Suicidal Attempt Self Injury Interview. The MIREDIF on this scale is −0.17 points, which corresponds to ½ SD (<a href="./references#CD012955-bbs2-0293" title="FarivarSS , LiuH ,  HaysRD . Half standard deviation estimate of the minimally important difference in HRQOL scores?Expert Review of Pharmacoeconomics &amp; Outcomes Research2004;4(5):515-23. [DOI: 10.1586/14737167.4.5.515] [PMID: 19807545]">Farivar 2004</a>). These findings suggest that suicide‐related outcomes improved following treatment, but these improvements did not quite reach a clinically relevant level. However, when it comes to suicide or suicide attempts, any reduction is of importance. </p> <p>Psychosocial functioning improved significantly following psychotherapy compared with TAU (SMD −0.45, 95% CI −0.68 to −0.22; 22 trials, 1314 participants). This corresponds to a MD of −2.8 (95% CI −4.25 to −1.38) on the GAF Scale, which ranges from 0 to 100. The MIREDIF on this scale is −4.0 points (<a href="./references#CD012955-bbs2-0224" title="AmriA , MillierM , ToumiM . Minimum clinically important difference in the global assessment functioning in patients with schizophrenia. Value in Health2014;17(7):A765-6. [DOI: 10.1016/j.jval.2014.08.285] [Abstract #PMH2] [PMID: 27202809]">Amri 2014</a>); therefore, the improvement did not reach clinical relevance. </p> <p>Regarding our secondary outcomes, we observed a significant reduction in depression for participants receiving psychotherapy compared to TAU (SMD −0.39, 95% CI −0.61 to −0.17; 22 trials, 1570 participants). This corresponds to −2.45 on the Hamilton Depression Scale, and does not quite reach the MIREDIF on this scale, which is 3.0 points (<a href="./references#CD012955-bbs2-0370" title="National Institute for Health and Care Excellence. Depression in adults: recognition and management. Cinical guideline (CG90). www.nice.org.uk/guidance/cg90 (accessed prior to 16 March 2020).">NICE CG90</a>) . </p> <p>Sufficient data were not available for effect size calculation for the outcome of adverse effects. </p> <p>Our additional TSA on all significant findings of the primary outcomes found that the RIS was reached for all primary outcomes but not for the secondary outcome of depression. However, only for BPD symptoms severity and psychosocial functioning could we reject the possibility of type 1 error. </p> <p>Only 15 trials reported on the effect following end of treatment at zero to six months, six to 12 months and &gt; 12 months (<a href="./references#CD012955-bbs2-0001" title="AmiantoF , FerreroA , PieròA , CairoE , RoccaG , SimonelliB , et al. Supervised team management, with or without structured psychotherapy, in heavy users of a mental health service with borderline personality disorder: a two-year follow-up preliminary randomized study. BMC Psychiatry2011;11:181. [DOI: 10.1186/1471-244X-11-181] [PMC3260092 ] [PMID: 22103890]NCT01356069. Efficacy of time-limited psychodynamic psychotherapy and informed clinical management in BPD high MHS users (HUMSH) [Sequential brief Adlerian psychodynamic psychotherapy in heavy users of a mental health service with borderline personality disorder: a two years follow-up preliminary randomized study]. clinicaltrials.gov/ct2/show/NCT01356069 (first received 16 May 2011). ">Amianto 2011</a>; <a href="./references#CD012955-bbs2-0002" title='AndreoliA , BurnandY , CochennecMF , MarieD , Di ClementeT , OhlendorfP . Psychoanalytic psychotherapy and venlafaxine among acutely suicidal borderline patients: a randomized clinical study. European Psychiatry2009;24(Suppl 1):S93. [DOI: 10.1016/S0924-9338(09)70326-8] [S18-03]AndreoliA , BurnandY , CochennecMF , OhlendorfP , FrambatiL , Gaudry-MaireD , et al. Disappointed love and suicide: a randomized controlled trial of "abandonment psychotherapy" among borderline patients. Journal of Personality Disorders2016;30(2):271-87. [DOI: 10.1521/pedi_2015_29_196] [PMID: 26111250]AndreoliA , BurnandY , FrambatiL , ManningD , FrancesA . Abandonment psychotherapy and psychosocial functioning among suicidal patients with borderline personality disorder: a 3-year naturalistic follow-up. Journal of Personality Disorders 2019 Feb 20 [Epub ahead of print]. [DOI: 10.1521/pedi_2019_33_423] [PMID: 30785852]AndreoliA . Re: your study in BPD - Cochrane Collaboration review [personal communication]. Email to: J Stoffers-Winterling 5 June 2018. '>Andreoli 2016</a>; <a href="./references#CD012955-bbs2-0004" title="BatemanA , FonagyP . 8-year follow-up of patients treated for borderline personality disorder: mentalization-based treatment versus treatment as usual. American Journal of Psychiatry2008;165(5):631-8. [DOI: 10.1176/appi.ajp.2007.07040636] [PMID: 18347003]BatemanA , FonagyP . Effectiveness of partial hospitalization in the treatment of borderline personality disorder: a randomized controlled trial. American Journal of Psychiatry1999;156(10):1563-9. [DOI: 10.1176/ajp.156.10.1563] [PMID: 10518167]BatemanA , FonagyP . Health care utilization costs for borderline personality disorder patients treated with psychoanalytically oriented partial hospitalization versus general psychiatric care. American Journal of Psychiatry2003;160(1):169-71. [10.1176/appi.ajp.160.1.169] [12505818]BatemanA , FonagyP . Treatment of borderline personality disorder with psychoanalytically oriented partial hospitalization: an 18-month follow-up. American Journal of Psychiatry2001;158(1):36-42. [DOI: 10.1176/appi.ajp.158.1.36] [PMID: 11136631]BatemanA . Important: question regarding your BPD trial for systematic review in Cochrane Collaboration [personal communication]. Email to: K Lieb, J Stoffers 14 December 2010. BatemanA . Intensive outpatient and partial hospital care for BPD. In: 157th annual meeting of the American Psychiatric Association. Psychotherapy and pharmacology: dissolving the mind-brain barrier; 2004 May 1-6; New York (NY). Arlington (VA): American Psychiatric Association, 2004:102. [Symposium 100B] [www.psychiatry.org/File%20Library/Psychiatrists/Directories/Library-and-Archive/conference_publications/am_program_2004.pdf]BatemanAW , FonagyP . Drs Bateman and Fonagy reply [to Stern R. Partial hospitalization for borderline personality disorder. American Journal of Psychiatry 2001;158(11):1932-3. DOI: 10.1176/appi.ajp.158.11.1932]. American Journal of Psychiatry2001;158(11):1932-3. [DOI: 10.1176/appi.ajp.158.11.1932-a]EvansC . Treatment benefits of psychoanalytically oriented partial hospitalisation were maintained over 18 months in borderline personality disorder. Evidence-Based Mental Health2001;4(3):73. [DOI: 10.1136/ebmh.4.3.73]FonagyP , BatemanAW . Mentalizing and borderline personality disorder. Journal of Mental Health2007;16(1):83-101. [DOI: 10.1080/09638230601182045]SternR . Partial hospitalization for borderline personality disorder. American Journal of Psychiatry2001;158(11):1932-3. [DOI: 10.1176/appi.ajp.158.11.1932] [PMID: 11691712]">Bateman 1999</a>; <a href="./references#CD012955-bbs2-0010" title="BlackD . Question regarding your BPD trial [personal communication]. Email to: J Stoffers 04 January 2011. BlackDW , AllenJ , McCormickB , BlumN . Treatment received by persons with BPD participating in a randomized clinical trial of the systems training for emotional predictability and problem solving programme. Personality and Mental Health2011;5(3):159-68. [DOI: 10.1002/pmh.167]BlackDW , AllenJ , St JohnD , PfohlB , McCormickB , BlumN . Predictors of response to systems training for emotional predictability and problem solving (STEPPS) for borderline personality disorder: an exploratory study. Acta Psychiatrica Scandinavica2009;120(1):53-61. [DOI: 10.1111/j.1600-0447.2008.01340.x] [PMC3665337] [PMID: 19183126]BlackDW , BlumN , PfohlB , St JohnD . The STEPPS group treatment program for outpatients with borderline personality disorder. Journal of Contemporary Psychotherapy2004;34(3):193-210. [DOI: 10.1023/B:JOCP.0000036630.25741.83]BlackDW , PfohlBM . Randomized clinical trial of STEPPS versus treatment as usual. In: 158th annual meeting of the American Psychiatric Association. Psychosomatic medicine: integrating psychiatry &amp; medicine; 2005 May 21-26; Atlanta (GA). Arlington (VA): American Psychiatric Association, 2005:104. [No. 1B] [www.psychiatry.org/File%20Library/Psychiatrists/Directories/Library-and-Archive/syllabus/am_syllabus_2005.pdf]BlackDW , Simsek-DuranF , BlumN , McCormickB , AllenJ . Do people with borderline personality disorder complicated by antisocial personality disorder benefit from the STEPPS treatment program?Personality and Mental Health2016;10(3):205-15. [DOI: 10.1002/pmh.1326] [PMC4911327] [PMID: 26671625]BlackDW . RE: [external] questions regarding your trial on the STEPPS program for BPD [personal communication]. Email to: EG Faltinsen 27 November 2017. BlumN , AllenJ , McCormickB , BlackDW . Ms Blum and colleagues reply [to Schulte-Herbrüggen O, Koerting J, Roepke S. Effectiveness of adjunctive STEPPS group treatment in borderline personality disorder patients. American Journal of Psychiatry 2008;165(10):1354-5. DOI: 10.1176/appi.ajp.2008.08030390]. American Journal of Psychiatry2008;165(10):1354-5. [DOI: 10.1176/appi.ajp.2008.08030390r]BlumN , FranklinJ , HanselR , McCormickB , St JohnD , PfohlB , et al. Relationship of age to symptom severity, psychiatric comorbidity and health care utilization in persons with borderline personality disorder. Personality and Mental Health2008;2(1):25-43. [DOI: 10.1002/pmh.26]BlumN , St JohnD , PfohlB , StuartS , McCormickB , AllenJ , et al. Erratum. American Journal of Psychiatry2008;165(6):777. Erratum for: American Journal of Psychiatry 2008;165(4):468-78. [psycnet.apa.org/record/2008-07854-033]BlumN , St JohnD , PfohlB , StuartS , McCormickB , AllenJ , et al. Systems training for emotional predictability and problem solving (STEPPS) for outpatients with borderline personality disorder: a randomized controlled trial and 1-year follow-up. American Journal of Psychiatry2008;165(4):468-78. [DOI: 10.1176/appi.ajp.2007.07071079] [PMC3608469] [PMID: 18281407]DavidsonKM . Borderline personality disorder: STEPPS improves symptoms. Evidence-Based Mental Health2008;11(4):120. [DOI: 10.1136/ebmh.11.4.120] [PMID: 18952969]NCT00055315. Treatment for borderline personality disorder [A cognitive group treatment for borderline outpatients]. clinicaltrials.gov/ct2/show/NCT00055315 (first received 25 February 2003). ">Blum 2008</a>; <a href="./references#CD012955-bbs2-0017" title="DavidsonK , LivingstoneS , McArthurK , DicksonL , GumleyA . An integrative complexity analysis of cognitive behaviour therapy sessions for borderline personality disorder. Psychology and Psychotherapy2007;80(Pt 4):513-23. [DOI: 10.1348/147608307X191535] [PMID: 17535542]DavidsonK , NorrieJ , TyrerP , GumleyA , TataP , MurrayH , et al. The effectiveness of cognitive behavior therapy for borderline personality disorder: results from the borderline personality disorder study of cognitive therapy (BOSCOT) trial. Journal of Personality Disorders2006;20(5):450-65. [DOI: 10.1521/pedi.2006.20.5.450] [PMC1852259] [PMID: 17032158]DavidsonK , TyrerP , GumleyA , TataP , NorrieJ , PalmerS , et al. A randomized controlled trial of cognitive behavior therapy for borderline personality disorder: rationale for trial, method, and description of sample. Journal of Personality Disorders2006;20(5):431-49. [DOI: 10.1521/pedi.2006.20.5.431] [PMC1847748] [PMID: 17032157]DavidsonKM , TyrerP , NorrieJ , PalmerSJ , TyrerH . Cognitive therapy v usual treatment for borderline personality disorder: prospective 6-year follow-up. British Journal of Psychiatry2010;197(6):456-62. [DOI: 10.1192/bjp.bp.109.074286] [PMID: 21119151]ISRCTN86177428. Borderline personality disorder study of cognitive therapy trial [A randomised controlled trial of cognitive therapy plus treatment as usual versus treatment as usual in the treatment of borderline personality disorder]. www.isrctn.com/ISRCTN86177428 (first received 22 July 2005). NCT00538135. BOSCOT: a randomised controlled trial of cognitive behavioural therapy in borderline personality disorder [BOSCOT: a randomised control trial of cognitive behavioural therapy plus treatment as usual versus treatment as usual in the treatment of borderline personality disorder]. www.clinicaltrials.gov/ct2/show/NCT00538135 (first received 29 September 2007). NorrieJ , DavidsonK , TataP , GumleyA . Influence of therapist competence and quantity of cognitive behavioural therapy on suicidal behaviour and inpatient hospitalisation in a randomised controlled trial in borderline personality disorder: further analyses of treatment effects in the BOSCOT study. Psychology and Psychotherapy2013;86(3):280-93. [DOI: 10.1111/papt.12004] [PMC4491320] [PMID: 23420622]PalmerS , DavidsonK , TyrerP , GumleyA , TataP , NorrieJ , et al. The cost-effectiveness of cognitive behavior therapy for borderline personality disorder: results from the BOSCOT trial. Journal of Personality Disorders2006;20(5):466-81. [DOI: 10.1521/pedi.2006.20.5.466] [PMC1852260] [PMID: 17032159]">Davidson 2006</a>; <a href="./references#CD012955-bbs2-0025" title="GleesonJF , ChanenA , CottonSM , PearceT , NewmanB , McCutcheonL . Treating co-occurring first-episode psychosis and borderline personality: a pilot randomized controlled trial. Early Intervention in Psychiatry2012;6(1):21-9. [DOI: 10.1111/j.1751-7893.2011.00306.x] [PMID: 22379625]GleesonJFM . RE: separate data [personal communication]. Email to: M Kielsholm 28 October 2016. ">Gleeson 2012</a>; <a href="./references#CD012955-bbs2-0028" title="GregoryRJ , ChlebowskiS , KangD , RemenA , SoderbergM . Psychodynamic therapy for borderline personality disorder and co-occurring alcohol use disorders: a newly designed ongoing study. Journal of the American Psychoanalytic Association2006;54(4):1331-4. [DOI: 10.1177/00030651060540040107] [PMID: 17354507]GregoryRJ , ChlebowskiS , KangD , RemenAL , SoderbergMG , StepkovitchJ , et al. A controlled trial of psychodynamic psychotherapy for co-occurring borderline personality disorder and alcohol use disorder. Psychotherapy2008;45(1):28-41. [DOI: 10.1037/0033-3204.45.1.28] [PMID: 22122363]GregoryRJ , DeLucia-DeranjaE , MogleJA . Dynamic deconstructive psychotherapy versus optimized community care for borderline personality disorder co-occuring with alcohol use disorders: a 30-month follow-up. Journal of Nervous and Mental Disease2010;198(4):292-8. [DOI: 10.1097/NMD.0b013e3181d6172d] [PMID: 20386259]GregoryRJ , RemenAL , SoderbergM , Ploutz-SnyderRJ . A controlled trial of psychodynamic psychotherapy for co-occurring borderline personality disorder and alcohol use disorder: six-month outcome. Journal of the American Psychoanalytic Association2009;57(1):199-205. [DOI: 10.1177/00030651090570011006] [PMID: 19270255]NCT00145678. Psychodynamic therapy for co-occurring borderline personality disorder and alcohol use disorder [Psychodynamic therapy for patients With borderline personality disorder and alcohol abuse]. www.clinicaltrials.gov/show/NCT00145678 (first received 1 September 2005). ">Gregory 2008b</a>; <a href="./references#CD012955-bbs2-0033" title="JørgensenCR , BøyeR , AndersenD , Døssing BlaabjergAH , FreundC , JordetH , et al. Eighteen months post-treatment naturalistic follow-up study of mentalization-based therapy and supportive group treatment of borderline personality disorder: clinical outcomes and functioning. Nordic Psychology2014;66(4):254-73. [DOI: 10.1080/19012276.2014.963649]JørgensenCR , FreundC , BøyeR , JordetH , AndersenD , KjølbyeM . Outcome of mentalization-based and supportive psychotherapy in patients with borderline personality disorder: a randomized trial. Acta Psychiatrica Scandinavica2013;127(4):305-17. [DOI: 10.1111/j.1600-0447.2012.01923.x] [PMID: 22897123]JorgensenCR . SV: questions on your trial regarding MBT for BPD patients [personal communication]. Email to: EG Faltinsen 28 November 2017. ">Jørgensen 2013</a>; <a href="./references#CD012955-bbs2-0039" title="KredlowMA , SzuhanyKL , LoS , XieH , GottliebJD , RosenbergSD , et al. Cognitive behavioral therapy for posttraumatic stress disorder in individuals with severe mental illness and borderline personality disorder. Psychiatry Research2017;249:86-93. [DOI: 10.1016/j.psychres.2016.12.045] [PMC5325773] [PMID: 28086181]MueserK . Re: question regarding your trial on CBT for BPD patients [personal communication]. Email to: EG Faltinsen 28 November 2017. ">Kredlow 2017a</a>; <a href="./references#CD012955-bbs2-0047" title="BedicsJD , AtkinsDC , ComtoisKA , LinehanMM . Treatment differences in the therapeutic relationship and introject during a 2-year randomized controlled trial of dialectical behavior therapy versus nonbehavioral psychotherapy experts for borderline personality disorder. Journal of Consulting and Clinical Psychology2012;80(1):66-77. [DOI: 10.1037/a0026113] [PMC3265694] [PMID: 22061867]BedicsJD , AtkinsDC , ComtoisKA , LinehanMM . Weekly therapist ratings of the therapeutic relationship and patient introject furing the course of dialectical behavioral therapy for the treatment of borderline personality disorder. Psychotherapy2012;49(2):231-40. [DOI: 10.1037/a0028254] [PMID: 22642526]BedicsJD , AtkinsDC , HarnedMS , LinehanMM . The therapeutic alliance as a predictor of outcome in dialectical behavior therapy versus nonbehavioral psychotherapy by experts for borderline personality disorder. Psychotherapy2015;52(1):67-77. [DOI: 10.1037/a0038457] [PMID: 25751116]BrownMZ , LinehanMM , ComtoisKA , MurrayA , ChapmanAL . Shame as a prospective predictor of self-inflicted injury in borderline personality disorder: a multi-modal analysis. Behaviour Research and Therapy2009;47(10):815-22. [DOI: 10.1016/j.brat.2009.06.008] [PMC2761705] [PMID: 19596223 ]CoyleTN , ShaverJA , LinehanMM . On the potential for iatrogenic effects of psychiatric crisis services: the example of dialectical behavior therapy for adult women with borderline personality disorder. Journal of Consulting and Clinical Psychology2018;86(2):116-24. [DOI: 10.1037/ccp0000275] [PMID: 29369662]HarnedMS , ChapmanAL , Dexter-MazzaET , MurrayA , ComtoisKA , LinehanMM . Treating co-occurring Axis I disorders in recurrently suicidal women with borderline personality disorder: a 2-year randomized trial of dialectical behavior therapy versus community treatment by experts. Journal of Consulting and Clinical Psychology2008;76(6):1068-75. [DOI: 10.1037/a0014044] [PMID: 19045974]HarnedMS , ChapmanAL , Dexter-MazzaET , MurrayA , ComtoisKA , LinehanMM . Treating co-occurring Axis I disorders in recurrently suicidal women with borderline personality disorder: a 2-year randomized trial of dialectical behavior therapy versus community treatment by experts. Personality Disorders: Theory, Research, and Treatment2009;S(1):35-45. [DOI: 10.1037/1949-2715.S.1.35]HarnedMS , JacksonSC , ComtoisKA , LinehanMM . Dialectical behavior therapy as a precursor to PTSD treatment for suicidal and/or self-injuring women with bordreline personality disorder. Journal of Traumatic Stress2010;23(4):421-9. [DOI: 10.1002/jts.20553] [PMID: 20648564]LindenboimN , ComtoisKA , LinehanMM . Skills practice in dialectical behavior therapy for suicidal women meeting criteria for borderline personality disorder. Cognitive and Behavioral Practice2007;14(2):147-56. [DOI: 10.1016/j.cbpra.2006.10.004]LinehanMM , ComtoisKA , MurrayAM , BrownMZ , GallopRJ , HeardHL , et al. Two-year randomized controlled trial and follow-up of dialectical behavior therapy vs therapy by experts for suicidal behaviors and borderline personality disorder. Archives of General Psychiatry2006;63(7):757-66. [DOI: 10.1001/archpsyc.63.7.757] [PMID: 16818865]LinehanMM . Error in table in: two-year randomized controlled trial and follow-up of dialectical behavior therapy vs therapy by experts for suicidal behaviors and borderline personality disorder. Archives of General Psychiatry2007;64(12):1401. Erratum for: Archives of General Psychiatry 2007;64(12):1401. McMainS . Dialectic behaviour therapy reduces suicide attempts compared with non-behavioural psychotherapy in women with borderline personality disorder. Evidence-Based Mental Health2007;10(1):18. [DOI: 10.1136/ebmh.10.1.18] [PMID: 17255387]NeacsiuAD , LunguA , HarnedMS , RizviSL , LinehanMM . Impact of dialectical behavior therapy versus community treatment by experts on emotional experience, expression, and acceptance in borderline personality disorder. Behaviour Research and Therapy2014;53:47-54. [DOI: 10.1016/j.brat.2013.12.004] [PMC3955205] [PMID: 24418652]NeacsiuAD , RizviSL , LinehanMM . Dialectical behavior therapy skills use as a mediator and outcome of treatment for borderline personality disorder. Behaviour Research and Therapy2010;48(9):832-9. [DOI: 10.1016/j.brat.2010.05.017] [PMC2914145] [PMID: 20579633]SecristCD . The Role of Executive Functioning in the Treatment of Borderline Personality Disorder [PhD thesis]. Washington (DC): University of Washington, 2014. ">Linehan 2006</a>; <a href="./references#CD012955-bbs2-0051" title="McMurranM , CrawfordMJ , ReillyJ , DelportJ , McCroneP , WhithamD , et al. Psychoeducation with problem-solving (PEPS) therapy for adults with personality disorder: a pragmatic randomised controlled trial to determine the clinical effectiveness and cost-effectiveness of a manualised intervention to improve social functioning. Health Technology Assessment2016;20(52):1-282. [DOI: 10.3310/hta20520]McMurranM . RE: Cochrane Collaboration review - PEPS study [personal communication]. Email to: J Stoffers-Winterling 5 July 2018. McMurranM . Request for data on BPD subjects in the PEPS rcp-study for use a new Cochrane review [personal communication]. Email to: M Kongerslev 7 March 2017. ">McMurran 2016</a>; <a href="./references#CD012955-bbs2-0061" title="ISRCTN51304415. Nice OUtcomes for Referrals with Impulsivity, Self Harm and Eating Disorders: the NOURISHED study [A randomised controlled trial of mentalisation based therapy against specialist supportive clinical management in patients with both eating disorders and symptoms of borderline personality disorder]. www.isrctn.com/ISRCTN51304415 (first received 31 January 2011). RobinsonP , BarrettB , BatemanA , HakeemA , HellierJ , LemonskyF , et al. Study protocol for a randomized controlled trial of mentalization based therapy against specialist supportive clinical management in patients with both eating disorders and symptoms of borderline personality disorder. BMC Psychiatry2014;14:51. [DOI: 10.1186/1471-244X-14-51] [PMC3996076] [PMID: 24555511]RobinsonP , HellierJ , BarrettB , BarzdaitieneD , BatemanA , BogaardtA , et al. The NOURISHED randomised controlled trial comparing mentalisation-based treatment for eating disorders (MBT-ED) with specialist supportive clinical management (SSCM-ED) for patients with eating disorders and symptoms of borderline personality disorder. Trials2016;17(1):549. [DOI: 10.1186/s13063-016-1606-8] [PMC5114835] [PMID: 27855714]">Robinson 2016</a>; <a href="./references#CD012955-bbs2-0069" title="SolerJ , PascualJC , TianaT , CebriàA , BarrachinaJ , CampinsMJ , et al. Dialectical behaviour therapy skills training compared to standard group therapy in borderline personality disorder: a 3-month randomised controlled clinical trial. Behaviour Research and Therapy2009;47(5):353-8. [DOI: 10.1016/j.brat.2009.01.013] [PMID: 19246029]SolerJ . Question regarding your BPD trials [personal communication]. Email to: J Stoffers 15 December 2010. ">Soler 2009</a>; <a href="./references#CD012955-bbs2-0072" title="Van den BoschLM , KoeterMW , StijnenT , VerheulR , Van den BrinkW . Sustained efficacy of dialectical behaviour therapy for borderline personality disorder. Behaviour Research and Therapy2005;43(9):1231-41. [DOI: 10.1016/j.brat.2004.09.008] [PMID: 16005708]Van den BoschLM , VerheulR , SchippersGM , Van den BrinkW . Dialectical behavior therapy of borderline patients with and without substance use problems. Implementation and long-term effects. Addictive Behaviors2002;27(6):911-23. [DOI: 10.1016/s0306-4603(02)00293-9] [PMID: 12369475]Van den BoschLMC . Efficacy of dialectical behaviour therapy in the treatment of female borderline patients with and without substance abuse problems: results of a Dutch study [Dialectische gedragstherapie bij Nederlandse vrouwen met een borderline persoonlijkheidsstoornis, met en zonder verslavingsproblemen]. Tijdschrift voor Psychiatrie2005;47(3):127-37. [www.tijdschriftvoorpsychiatrie.nl/assets/articles/articles_1335pdf.pdf]VerheulR , Van den BoschLM , KoeterMW , De RidderMA , StijnenT , Van den BrinkW . Dialectical behaviour therapy for women with borderline personality disorder: 12-month, randomised clinical trial in The Netherlands. British Journal of Psychiatry2003;182:135-40. [DOI: 10.1192/bjp.182.2.135] [PMID: 12562741]">Van den Bosch 2005</a>; <a href="./references#CD012955-bbs2-0073" title="WeinbergI , GundersonJG , HennenJ , Cutter CJ Jr. Manual assisted cognitive treatment for deliberate self-harm in borderline personality disorder patients. Journal of Personality Disorders2006;20(5):482-92. [DOI: 10.1521/pedi.2006.20.5.482] [PMID: 17032160]WilbergT . SV: separate data [personal communication] [SV: separat data [personlig kommunikation]]. Email to: M Kielsholm 25 May 2016. ">Weinberg 2006</a>). There was no effect on BPD severity at follow‐up when assessed as a continuous measure; however, an improvement was observed at &gt; 12 months follow‐up in the number of people presenting with severe BPD. In addition, the number of persons with self‐harm was reduced at the zero to six months, six to 12 months and &gt; 12 months follow‐up time points. Suicide‐related behaviour was reduced at six to 12 months follow‐up, and a reduction in the number of persons with suicidal behaviour was seen at &gt; 12 months follow‐up. There was an improvement in psychosocial functioning at zero to six months follow‐up; however, this was not sustained at six to 12 months or at &gt; 12 months follow‐up time points. </p> <p>Regarding the secondary outcomes, there was an improvement in depression at zero to six months and &gt; 12 months follow‐up, as well as a reduction in adverse effects at &gt; 12 months follow‐up only. No improvement in anger, affective instability, impulsivity, emptiness, interpersonal problems or abandonment was observed at follow‐up. </p> </section> <section id="CD012955-sec-0532"> <h4 class="title">Psychotherapy versus waiting list or no treatment</h4> <p>Comparing the effects of psychotherapy with waiting list, we observed effects in favour of psychotherapy for the primary outcomes of BPD severity (SMD −0.49, 95% CI −0.93 to −0.05; 3 trials, 161 participants) and psychosocial functioning (SMD −0.56, 95% CI −1.01 to −0.11; 5 trials, 219 participants. No clear differences were found for self‐harm and suicide‐related outcomes. See <a href="./full#CD012955-tbl-0002">summary of findings Table 2</a>. </p> <p>We moreover observed a significant reduction in depression for participants receiving psychotherapy compared to waiting list or no treatment (SMD −1.28, 95% CI −2.21 to −0.34; 6 trials, 239 participants). No reductions were detected in attrition, and once again, sufficient data were not available for effect size calculation for the outcome of adverse effects. </p> <p>Only one trial, <a href="./references#CD012955-bbs2-0008" title="BellinoS , BozzatelloP , BogettoF . Combined treatment of borderline personality disorder with interpersonal psychotherapy and pharmacotherapy: predictors of response. Psychiatry Research2015;226(1):284-8. [DOI: 10.1016/j.psychres.2014.12.064] [isiarticles.com/bundles/Article/pre/pdf/34125.pdf]BellinoS , RinaldiC , BogettoF . Adaptation of interpersonal psychotherapy to borderline personality disorder: a comparison of combined therapy and single pharmacotherapy. Canadian Journal of Psychiatry2010;55(2):74-81. [DOI: 10.1177/070674371005500203] [PMID: 20181302]BellinoS . Question regarding your BPD trials for inclusion in Cochrane Collaboration review [personal communication]. Email to: J Stoffers-Winterling 19 December 2010. BellinoS . Re: question regarding your BPD trials [personal communication]. Email to: J Stoffers 16 December 2010. BozzatelloP , BellinoS . Combined therapy with interpersonal psychotherapy adapted for borderline personality disorder: a two-years follow-up. Psychiatry Research2016;240:151-6. [DOI: 10.1016/j.psychres.2016.04.014] [www.sciencedirect.com/science/article/pii/S0165178115302389]ZizzaM , FenocchioM , RinaldiC , BellinoS . Combined treatment of borderline personality disorder: a trial of modified interpersonal therapy. World Psychiatry2009;8(Suppl 1):234. ">Bellino 2010</a>, reported on the effect following end of treatment (zero to six months, six to 12 months and &gt; 12 months follow‐up periods). Follow‐up data were reported on psychosocial functioning, in which an improvement was observed at zero to six months and six to 12 months post‐treatment. There was no significant improvement observed at &gt; 12 months post‐treatment. Regarding the secondary outcomes, improvements in both impulsivity and interpersonal problems were observed at zero to six months, six to 12 months and &gt; 12 months post‐treatment. No improvement was observed in affective instability at any of the follow‐up time points. </p> </section> <section id="CD012955-sec-0533"> <h4 class="title">Individual treatment approaches</h4> <p>Among distinct BPD‐specific therapies, most findings were based on single trials. DBT and MBT had the highest numbers of primary trials, with DBT accounting for roughly one‐third of all included trials, followed by MBT with seven RCTs. </p> <p>Compared to TAU, we observed significant effects of DBT for the primary outcomes of BPD severity (SMD −0.60, 95% CI −1.05 to −0.14; 3 trials, 149 participants), self‐harm (SMD −0.28, 95% CI −0.48 to −0.07; 7 trials, 376 participants) and psychosocial functioning (SMD −0.36, 95% CI −0.69 to −0.03; 6 trials, 225 participants). MBT was found to have significant effects on self‐harm (RR 0.62, 95% CI 0.49 to 0.80; 3 trials, 252 participants) and suicidality (RR 0.10, 95% CI 0.04, 0.30, 3 trials, 218 participants). See <a href="./full#CD012955-tbl-0003">summary of findings Table 3</a>. </p> </section> <section id="CD012955-sec-0534"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We had intended to conduct several subgroup analyses, but not all were possible due to a lack of data. See <a href="#CD012955-tbl-0004">Table 1</a> for more information. </p> <p>In one subgroup analysis, we tested for differences between psychotherapeutic approaches appearing in two or more trials. We found no significant subgroup differences between the different therapeutic approaches for BPD symptom severity and psychosocial functioning. </p> <p>To test the statistical heterogeneity in our analyses of BPD symptom severity and psychosocial functioning, we added a post hoc subgroup analysis exploring the different measurement scales versus each other. We found significant differences between ZAN‐BPD, SCID, BEST and BPDSI, with BEST providing the highest effect estimate. By differentiating between scales, we found that the heterogeneity between trials was I<sup>2</sup> = 0% with ZAN‐BPD; I<sup>2</sup> = 47% with SCID; I<sup>2</sup> = 10% with BEST; and I<sup>2</sup> = 0% with BPDSI. The results suggest that much of the statistical heterogeneity found in the analysis of psychotherapy versus TAU for BPD symptom severity was due to the various scales used in trials. We found no significant differences between GAF, GAS and SAS, and no reductions in heterogeneity. </p> <p>We found significant subgroup differences for BPD symptom severity for age, where the effects of psychotherapy were higher for the subgroup 'older than 18 years of age'; 'mode of therapy', with group therapy being more effective than individual or mixed therapy; and setting, with outpatient groups being more effective than inpatient groups. Additionally, we found significant differences for psychosocial functioning for setting, with the combination of inpatient and outpatient groups and inpatient groups alone showing to be more effective than outpatient groups. We found no subgroup differences for BPD symptom severity for duration and type of raters, or for psychosocial functioning for duration, mode of therapy and types of raters. </p> <p>trials of psychotherapy versus TAU did not indicate any significant subgroup differences for BPD symptom severity and psychosocial functioning compared with trials of psychotherapy versus waiting list or no treatment. Likewise, we found no subgroup differences for the different types of TAU. Therefore, effect estimates do not seem to differ between comparisons with control groups consisting of any kind of unspecified intervention, such as TAU, standard care or regular appointments, and comparisons with waiting list or no treatment, the participants of which were not paid any special attention at all. </p> </section> <section id="CD012955-sec-0535"> <h4 class="title">Previous review</h4> <p>In contrast to the previous versions of this review (<a href="./references#CD012955-bbs2-0441" title="BinksC , FentonM , McCarthyL , LeeT , AdamsCE , DugganC . Psychological therapies for people with borderline personality disorder. Cochrane Database of Systematic Reviews2006, Issue 1. Art. No: CD005652. [DOI: 10.1002/14651858.CD005652]">Binks 2006</a>; <a href="./references#CD012955-bbs2-0442" title="Stoffers-WinterlingJM , VöllmBA , RückerG , TimmerA , HubandN , LiebK . Psychological therapies for people with borderline personality disorder. Cochrane Database of Systematic Reviews2012, Issue 8. Art. No: CD005652. [DOI: 10.1002/14651858.CD005652.pub2]">Stoffers‐Winterling 2012</a>), we broadened the scope to include the treatment of adolescents also. We were able to include only three RCTs that focused solely on adolescents: the <a href="./references#CD012955-bbs2-0052" title="HagaE , AasE , GrøholtB , TørmoenAJ , MehlumL . Cost-effectiveness of dialectical behaviour therapy vs enhanced usual care in the treatment of adolescents with self-harm. Child and Adolescent Psychiatry and Mental Health2018;12:22. [DOI: 10.1186/s13034-018-0227-2] [PMC5928596] [PMID: 29743941]MehlumL , RambergM , TørmoenAJ , HagaE , DiepLM , StanleyBH , et al. Dialectical behavior therapy compared with enhanced usual care for adolescents with repeated suicidal and self-harming behavior: outcomes over a one-year follow-up. Journal of the American Academy of Child and Adolescent Psychiatry2016;55(4):295-300. [DOI: 10.1016/j.jaac.2016.01.005] [PMID: 27015720]MehlumL , TørmoenAJ , RambergM , HagaE , DiepLM , LabergS , et al. Dialectical behavior therapy for adolescents with repeated suicidal and self-harming behavior: a randomized trial. Journal of the American Academy of Child and Adolescent Psychiatry2014;53(10):1082-91. [DOI: 10.1016/j.jaac.2014.07.003] [PMID: 25245352]MehlumL . Re: regarding your study of DBT for your with suicidal behavior [personal communication] [Re: angående din studie om DBT for ungdom med selvmordsatferd [personlig kommunikation]]. Email to: E Faltinsen 5 December 2017. NCT00675129. Treatment for adolescents with deliberate self harm [A randomized controlled trial for repetitive deliberate self-harm and suicidal behaviours among Norwegian adolescents: a comparison between dialectical behaviour therapy adapted for adolescents (DBT-A) and enhanced usual care (EUC)]. www.clinicaltrials.gov/ct2/show/NCT00675129 (first received 6 May 2008). RamlethRK , GroholtB , DiepLM , WalbyFA , MehlumL . The impact of borderline personality disorder and sub-threshold borderline personality disorder on the course of self-reported and clinician-rated depression in self-harming adolescents. Borderline Personality Disorder and Emotion Dysregulation2017;4:22. [DOI: 10.1186/s40479-017-0073-5] [PMC5663078] [PMID: 29093819]">Mehlum 2014</a> trial on DBT‐A; the <a href="./references#CD012955-bbs2-0062" title="ISRCTN95266816. The emergence of personality disorder traits in adolescents who deliberately self harm and the potential for using a mentalisation based treatment approach as an early intervention for such individuals: a randomised controlled trial. www.isrctn.com/ISRCTN95266816 (first received 29 October 2007). RossouwT . Mentalisation based treatment for adolescents with self harm: an RCT. European Child &amp; Adolescent Psychiatry2015;24(1 Suppl):S113. [DOI: 10.1007%2Fs00787-015-0714-4.pdf] [W1-02-02]RossouwT . Self harm in adolescence, is MBT the answer?: an RCT. Adolescent Psychiatry2012;2(1):102. [DOI: 10.2174/2210676611202010077]RossouwTI , FonagyP . Mentalization-based treatment for self-harm in adolescents: a randomized controlled trial. Journal of the American Academy of Child and Adolescent Psychiatry2012;51(12):1304-13.e3. [DOI: 10.1016/j.jaac.2012.09.018] [PMID: 23200287]">Rossouw 2012b</a> trial on MBT‐A; and the <a href="./references#CD012955-bbs2-0066" title="ISRCTN97589104. Evaluation of a group training for adolescents (emotion regulation training) with emotion regulation problems - a randomised controlled clinical trial. www.isrctn.com/ISRCTN97589104 (first received 23 August 2007). SchuppertHM , TimmermanME , BlooJ , Van GemertTG , WiersemaHM , MinderaaRB , et al. Emotion regulation training for adolescents with borderline personality disorder traits: a randomized controlled trial. Journal of the American Academy of Child &amp; Adolescent Psychiatry2012;51(12):1314-23. [DOI: 10.1016/j.jaac.2012.09.002] [PMID: 23200288]">Schuppert 2012</a> trial on ERT, an adaptation of STEPPS for adolescents. Another pilot RCT on HYPE + CAT + SFET included participants from ages 15 to 25 years old, with a mean age of 18.4 years (SD = 2.9) (<a href="./references#CD012955-bbs2-0025" title="GleesonJF , ChanenA , CottonSM , PearceT , NewmanB , McCutcheonL . Treating co-occurring first-episode psychosis and borderline personality: a pilot randomized controlled trial. Early Intervention in Psychiatry2012;6(1):21-9. [DOI: 10.1111/j.1751-7893.2011.00306.x] [PMID: 22379625]GleesonJFM . RE: separate data [personal communication]. Email to: M Kielsholm 28 October 2016. ">Gleeson 2012</a>). Subgroup analyses revealed that adolescents benefited less from psychotherapy than those older than 18 years of age. However, the power was much too low to detect any true effects, with sample sizes ranging from 10 participants (subsample of participants with five or more DSM‐IV BPD criteria in the <a href="./references#CD012955-bbs2-0052" title="HagaE , AasE , GrøholtB , TørmoenAJ , MehlumL . Cost-effectiveness of dialectical behaviour therapy vs enhanced usual care in the treatment of adolescents with self-harm. Child and Adolescent Psychiatry and Mental Health2018;12:22. [DOI: 10.1186/s13034-018-0227-2] [PMC5928596] [PMID: 29743941]MehlumL , RambergM , TørmoenAJ , HagaE , DiepLM , StanleyBH , et al. Dialectical behavior therapy compared with enhanced usual care for adolescents with repeated suicidal and self-harming behavior: outcomes over a one-year follow-up. Journal of the American Academy of Child and Adolescent Psychiatry2016;55(4):295-300. [DOI: 10.1016/j.jaac.2016.01.005] [PMID: 27015720]MehlumL , TørmoenAJ , RambergM , HagaE , DiepLM , LabergS , et al. Dialectical behavior therapy for adolescents with repeated suicidal and self-harming behavior: a randomized trial. Journal of the American Academy of Child and Adolescent Psychiatry2014;53(10):1082-91. [DOI: 10.1016/j.jaac.2014.07.003] [PMID: 25245352]MehlumL . Re: regarding your study of DBT for your with suicidal behavior [personal communication] [Re: angående din studie om DBT for ungdom med selvmordsatferd [personlig kommunikation]]. Email to: E Faltinsen 5 December 2017. NCT00675129. Treatment for adolescents with deliberate self harm [A randomized controlled trial for repetitive deliberate self-harm and suicidal behaviours among Norwegian adolescents: a comparison between dialectical behaviour therapy adapted for adolescents (DBT-A) and enhanced usual care (EUC)]. www.clinicaltrials.gov/ct2/show/NCT00675129 (first received 6 May 2008). RamlethRK , GroholtB , DiepLM , WalbyFA , MehlumL . The impact of borderline personality disorder and sub-threshold borderline personality disorder on the course of self-reported and clinician-rated depression in self-harming adolescents. Borderline Personality Disorder and Emotion Dysregulation2017;4:22. [DOI: 10.1186/s40479-017-0073-5] [PMC5663078] [PMID: 29093819]">Mehlum 2014</a> trial) to 97 participants (in <a href="./references#CD012955-bbs2-0066" title="ISRCTN97589104. Evaluation of a group training for adolescents (emotion regulation training) with emotion regulation problems - a randomised controlled clinical trial. www.isrctn.com/ISRCTN97589104 (first received 23 August 2007). SchuppertHM , TimmermanME , BlooJ , Van GemertTG , WiersemaHM , MinderaaRB , et al. Emotion regulation training for adolescents with borderline personality disorder traits: a randomized controlled trial. Journal of the American Academy of Child &amp; Adolescent Psychiatry2012;51(12):1314-23. [DOI: 10.1016/j.jaac.2012.09.002] [PMID: 23200288]">Schuppert 2012</a>). Notably, we only included trial samples or subsamples in which at least 70% of participants had full BPD (i.e. fulfilled a minimum of five DSM BPD criteria). Oftentimes, however, adolescents may only fulfil criteria at a subthreshold level while both their personality and BPD are still developing. Nevertheless, they might profit from BPD‐specific treatments in terms of preventing the development of full threshold BPD later in life. </p> </section> </section> <section id="CD012955-sec-0536"> <h3 class="title" id="CD012955-sec-0536">Overall completeness and applicability of evidence</h3> <p>In most cases, we were able to calculate the effect sizes from the data reported in the included trials. If information was missing, we contacted and requested the missing information from the trial authors. Therefore, there is no evident bias within this review as a consequence of inadequate inclusion of existing data. </p> <p>We rated all trials at high risk of bias, with the most prevalent risk of bias being categorised as 'other risk of bias'; that is insufficient treatment adherence, allegiance bias or attention bias, which might lead to biased data. </p> <section id="CD012955-sec-0537"> <h4 class="title">Participants</h4> <p>The majority of trials included mainly females, with only two trials solely including males (<a href="./references#CD012955-bbs2-0009" title="BianchiniV , CofiniV , CurtoM , LagrotteriaB , ManziA , NavariS , et al. Dialectical behavior therapy (DBT) for forensic psychiatric patients: an Italian pilot study. Criminal Behavior and Mental Health2019;29(9):122-30. [DOI: 10.1002/cbm.2102] [PMID: 30648303]">Bianchini 2019</a>; <a href="./references#CD012955-bbs2-0034" title="KamalabadiMJ , AhmadiSA , EtemadiO , FatehizadehM , BahramiF , FiroozabadiA . A study of the effect of couple dialectical behavioral therapy on symptoms and quality of marital relationships and mental health of Iranian borderline personality couples: a controlled trial. Interdisciplinary Journal of Contemporary Research in Business2012;3(9):1480-7. [psycnet.apa.org/record/2012-22425-047]">Kamalabadi 2012</a>). This configuration may reflect the reality of clinical settings, where approximately 75% of all BPD diagnoses are assigned to women (<a href="./references#CD012955-bbs2-0231" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR), 4th edition, text revision. Washington (DC): American Psychiatric Association, 2000. [ISBN 978-0-89042-0256]">APA 2000</a>). There are, however, contradictory findings pointing towards balanced proportions or an even higher prevalence in men (<a href="./references#CD012955-bbs2-0388" title="SansoneRA , SansoneLA . Gender patterns in borderline personality disorder. Innovations in Clinical Neuroscience2011;8(5):16-20. [PMCID:: PMC3115767] [PMID: 21686143]">Sansone 2011</a>). Men with BPD may display a different clinical picture than women, especially with antisocial features being more prevalent in men than in women with BPD (<a href="./references#CD012955-bbs2-0388" title="SansoneRA , SansoneLA . Gender patterns in borderline personality disorder. Innovations in Clinical Neuroscience2011;8(5):16-20. [PMCID:: PMC3115767] [PMID: 21686143]">Sansone 2011</a>). Clinically, this may mediate different treatment approaches or special requirements, which may not be reflected in most of the RCT evidence, which stems from either all female or predominantly female samples (see the <a href="./references#CD012955-sec-0637" title="">Characteristics of included studies</a> tables). In addition, in several of the included trials, full antisocial personality disorders or antisocial features were reasons for exclusion. As such, the extent to which the findings in this review are applicable to men with BPD may be limited. Level of functioning at baseline was not available in several of the included trials. However, trials that reported level of functioning using objective measures, such as GAS, GAF, CGI or SFQ, showed that the degree of illness ranged from moderate to severe. Regarding comorbidity, most trials excluded participants with severe mental disorders, organic brain disorders and mental impairments. In sum, the findings of this review may apply mainly to females with a moderate to severe level of illness, and without severe comorbid mental disorders. We do not know how the lack of this information has affected our findings, only that we cannot generalise the findings to men, to females with low levels of illness or to those with severe comorbid mental disorders. On the other hand, several trials concentrated on people with BPD plus distinct comorbidities (i.e. PTSD, depression, eating disorders or substance use disorders). Moreover, subgroups analyses revealed a significant difference, where the effect of psychotherapy on BPD symptom severity and psychosocial functioning seemed lower for adolescents. However, only three trials on adolescents were included in the review, and readers should exercise caution when drawing conclusions. </p> <p>Some argue that BPD treatment should start before the condition has developed fully, and stress the importance of early assessment and treatment (<a href="./references#CD012955-bbs2-0267" title="ChanenAM , McCutcheonL . Prevention and early intervention for borderline personality disorder: current status and recent evidence. British Journal of Psychiatry2013;202(54 Suppl):S24-9. [DOI: 10.1192/bjp.bp.112.119180] [PMID: 23288497]">Chanen 2013</a>; <a href="./references#CD012955-bbs2-0164" title="SharpC , VentaA , HaC , NewlinE . Oxytocin and trust in adolescents with borderline personality disorder. Biological Psychiatry2015;77(9 Suppl):30S. [DOI: 10.1016/j.biopsych.2015.03.006] [Abstract #78]">Sharp 2015</a>). Therefore, psychological interventions may also be relevant for patients who have yet to fully fulfil the DSM‐5 criteria. Nevertheless, with respect to the patient sample in this review, we only included adolescent samples if at least 70% of them fulfilled (a minimum five) DSM‐5 criteria for a diagnosis of BPD. We decided to do so in order to assure a minimum level of clinical homogeneity throughout the overall pool of trials. </p> </section> <section id="CD012955-sec-0538"> <h4 class="title">Interventions</h4> <p>The major psychotherapeutic treatments used in the treatment of BPD (DBT, MBT, SFT, TFP) have been tested in the RCTs included in this review. However, the number of available trials per intervention vary broadly, with the majority of trials investigating DBT; a very limited number of trials assessed SFT and TFP especially, which may not reflect their prevalence in clinical practice. The vast majority of primary trials were conducted in outpatient settings. However, psychotherapy may also be provided on inpatient wards (depending on the respective health system), but only limited evidence was available for this setting. Subgroups analyses showed no evidence of significant differences between psychotherapeutic approaches, indicating that all individual types of psychotherapy are effective in treating people with BPD. Most trials allowed concurrent psychotherapy and psychotropic treatments. As such, it cannot be ruled out that the concurrent treatment may have confounded the corresponding findings. However, we only included trials if possible concurrent treatments were the same for all trial groups. </p> <p>Some interesting findings revealed that group therapy might be more effective than individual or mixed therapy for reducing BPD symptom severity. However, there was no evidence of subgroup differences for psychosocial functioning. Additionally, outpatient care seemed to be more effective than inpatient care in reducing BPD symptom severity, but not in improving psychosocial functioning, where a combination of inpatient and outpatient treatment was more effective. The duration of treatment does not seem to be a factor in the improvement of BPD symptoms and psychosocial functioning. </p> </section> <section id="CD012955-sec-0539"> <h4 class="title">Comparisons</h4> <p>The treatments used in the control groups were largely heterogeneous, including TAU, which is a common label for controls. TAU itself may differ between different treatment formats, let alone between different health systems. In some trials, participants receiving TAU were free to use any kind of care, whereas other participants in receipt of TAU were required to receive a minimum standard of care whilst taking part in the trial (see <a href="#CD012955-sec-0019">Types of interventions</a>). Consequently, the components of TAU will most certainly vary between countries, as the standard of care is known to differ depending on the national healthcare system. </p> <p>The use of a control group in randomised trials provides a point of reference from which the effect of a given intervention is measured against. As such, a 'clean' control group is essential when we want to obtain insight into the magnitude of treatment effects and potential adverse effects. In psychiatric research, there is a lack of consensus on what constitutes an appropriate control intervention (<a href="./references#CD012955-bbs2-0294" title="FinchEF , IliakisEA , MaslandSR , Choi-KainLW . A meta-analysis of treatment as usual for borderline personality disorder. Personality Disorders2019;10(6):491-9. [DOI: 10.1037/per0000353] [PMID: 31414854]">Finch 2019</a>). In accordance, we found that control groups across trials were heterogeneous and included, for example, TAU, standard care or waiting list. In 72% of the included trials, either psychotherapeutic treatment was a part of the control intervention or concomitant psychotherapy was allowed while participating in the trial (for more information see <a href="./references#CD012955-sec-0637" title="">Characteristics of included studies</a> tables). As such, a majority of trials compared psychotherapeutic therapy against another intervention that included psychotherapeutic elements. The willingness to let people affected by BPD continue with different variations of psychotherapeutic therapy while included in a control group may indicate a general concern of otherwise withholding them from an important treatment. Yet a drawback of this approach is that it could potentially mask the difference in treatment effects between the control and intervention groups. Concurrently, we found that effects sizes were small, heterogeneous and largely insignificant for the majority of comparisons. There is a substantial need for larger, well‐performed randomised trials that include standardised control groups before we can make firmer conclusions about the effects of psychological therapies in BPD. </p> </section> <section id="CD012955-sec-0540"> <h4 class="title">Outcomes</h4> <p>The individual trials included a great variety of outcomes, with only minor consensus on what constituted core outcomes for BPD and how these ideally should be assessed. We identified high heterogeneity and significant differences between scales for BPD symptom severity, which might indicate that different scales may give different effect estimates. We found no significant differences between scales for psychosocial functioning, and there were no significant differences for self‐rated and clinician‐rated outcomes. In addition, core symptoms, such as fewer interpersonal conflicts or crises that both caregivers and people with BPD may consider essential when searching for helpful treatments, are sometimes neglected. The outcome of attrition must be interpreted with caution, as the likelihood of leaving a trial may depend on the specific type of control group used. For example, participants assigned to waiting lists may be more likely to leave a trial early than participants assigned to TAU or participants who are provided with regular appointments. Geographical conditions and accessibility of study centres can also play an important role, as rural regions with long distances to study centres may lead to higher dropout rates than urban settings (<a href="./references#CD012955-bbs2-0010" title="BlackD . Question regarding your BPD trial [personal communication]. Email to: J Stoffers 04 January 2011. BlackDW , AllenJ , McCormickB , BlumN . Treatment received by persons with BPD participating in a randomized clinical trial of the systems training for emotional predictability and problem solving programme. Personality and Mental Health2011;5(3):159-68. [DOI: 10.1002/pmh.167]BlackDW , AllenJ , St JohnD , PfohlB , McCormickB , BlumN . Predictors of response to systems training for emotional predictability and problem solving (STEPPS) for borderline personality disorder: an exploratory study. Acta Psychiatrica Scandinavica2009;120(1):53-61. [DOI: 10.1111/j.1600-0447.2008.01340.x] [PMC3665337] [PMID: 19183126]BlackDW , BlumN , PfohlB , St JohnD . The STEPPS group treatment program for outpatients with borderline personality disorder. Journal of Contemporary Psychotherapy2004;34(3):193-210. [DOI: 10.1023/B:JOCP.0000036630.25741.83]BlackDW , PfohlBM . Randomized clinical trial of STEPPS versus treatment as usual. In: 158th annual meeting of the American Psychiatric Association. Psychosomatic medicine: integrating psychiatry &amp; medicine; 2005 May 21-26; Atlanta (GA). Arlington (VA): American Psychiatric Association, 2005:104. [No. 1B] [www.psychiatry.org/File%20Library/Psychiatrists/Directories/Library-and-Archive/syllabus/am_syllabus_2005.pdf]BlackDW , Simsek-DuranF , BlumN , McCormickB , AllenJ . Do people with borderline personality disorder complicated by antisocial personality disorder benefit from the STEPPS treatment program?Personality and Mental Health2016;10(3):205-15. [DOI: 10.1002/pmh.1326] [PMC4911327] [PMID: 26671625]BlackDW . RE: [external] questions regarding your trial on the STEPPS program for BPD [personal communication]. Email to: EG Faltinsen 27 November 2017. BlumN , AllenJ , McCormickB , BlackDW . Ms Blum and colleagues reply [to Schulte-Herbrüggen O, Koerting J, Roepke S. Effectiveness of adjunctive STEPPS group treatment in borderline personality disorder patients. American Journal of Psychiatry 2008;165(10):1354-5. DOI: 10.1176/appi.ajp.2008.08030390]. American Journal of Psychiatry2008;165(10):1354-5. [DOI: 10.1176/appi.ajp.2008.08030390r]BlumN , FranklinJ , HanselR , McCormickB , St JohnD , PfohlB , et al. Relationship of age to symptom severity, psychiatric comorbidity and health care utilization in persons with borderline personality disorder. Personality and Mental Health2008;2(1):25-43. [DOI: 10.1002/pmh.26]BlumN , St JohnD , PfohlB , StuartS , McCormickB , AllenJ , et al. Erratum. American Journal of Psychiatry2008;165(6):777. Erratum for: American Journal of Psychiatry 2008;165(4):468-78. [psycnet.apa.org/record/2008-07854-033]BlumN , St JohnD , PfohlB , StuartS , McCormickB , AllenJ , et al. Systems training for emotional predictability and problem solving (STEPPS) for outpatients with borderline personality disorder: a randomized controlled trial and 1-year follow-up. American Journal of Psychiatry2008;165(4):468-78. [DOI: 10.1176/appi.ajp.2007.07071079] [PMC3608469] [PMID: 18281407]DavidsonKM . Borderline personality disorder: STEPPS improves symptoms. Evidence-Based Mental Health2008;11(4):120. [DOI: 10.1136/ebmh.11.4.120] [PMID: 18952969]NCT00055315. Treatment for borderline personality disorder [A cognitive group treatment for borderline outpatients]. clinicaltrials.gov/ct2/show/NCT00055315 (first received 25 February 2003). ">Blum 2008</a> trial completer analysis: high dropouts). </p> <p>Most trials did not consider adverse effects but did consider suicidal or self‐harming behaviour. These outcomes were categorised as primary outcomes in this review (see <a href="./appendices#CD012955-sec-0574">Appendix 4</a>) and are usually classified as severe adverse effects. Future randomised trials should not only concentrate on these outcomes, but also transparently report non‐serious adverse effects that occur during BPD treatment. Adverse effects of importance would include increased impulsive behaviour or substance use. Such outcomes may occur if psychotherapy induces excessive emotional arousal with which the affected person is not (yet) able to cope (<a href="./references#CD012955-bbs2-0252" title="BerkM , ParkerG . The elephant on the couch: side-effects of psychotherapy. Australian &amp; New Zealand Journal of Psychiatry2009;43(9):787-94. [DOI: doi.org/10.1080/00048670903107559] [PMID: 19670051]">Berk 2009</a>). </p> <p>For more information, see the <a href="./references#CD012955-sec-0637" title="">Characteristics of included studies</a> tables, where we describe the characteristics of each included trial in greater detail. </p> </section> </section> <section id="CD012955-sec-0541"> <h3 class="title" id="CD012955-sec-0541">Quality of the evidence</h3> <p>We rated the quality of evidence using the GRADE approach, based on the following considerations; risk of bias, inconsistency, indirectness, imprecision and publication bias. </p> <p>We assessed the risk of bias in all trials in accordance with the <i>Cochrane Handbook for Systematic Reviews of Intervention</i>s (<a href="./references#CD012955-bbs2-0325" title="HigginsJPT , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al (editors). Cochrane Handbook for Systematic Reviews of Interventions. 2nd edition. Chichester (UK): John Wiley &amp; Sons, 2019. [Available from: www.training.cochrane.org/handbook]">Higgins 2019</a>). The majority of the trials were prone to selection bias, as well as attrition and reporting bias. High risk of bias in randomised clinical trials has been shown to overestimate benefits and underestimate harms (<a href="./references#CD012955-bbs2-0338" title="KjaergardLL , VillumsenJ , GluudC . Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Annals of Internal Medicine2001;135(11):982-9. [PMID: 11730399]">Kjaergard 2001</a>; <a href="./references#CD012955-bbs2-0359" title="LundhA , SismondoS , LexchinJ , BusuiocOA , BeroL . Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews2012, Issue 12. Art. No: MR000033. [DOI: 10.1002/14651858.MR000033.pub2]">Lundh 2012</a>; <a href="./references#CD012955-bbs2-0361" title="MoherD , PhamB , JonesA , CookDJ , JadadAR , MoherM , et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analysis?Lancet1998;352(9128):609-13. [DOI: 10.1016/S0140-6736(98)01085-X] [PMID: 9746022]">Moher 1998</a>; <a href="./references#CD012955-bbs2-0389" title="SavovićJ , JonesH , AltmanD , HarrisR , JüniP , PildalJ , et al. Influence of reported study design characteristics on intervention effect estimates from randomised controlled trials: combined analysis of meta-epidemiological studies. Health Technology Assessment2012;16(35):1-82. [DOI: 10.3310/hta16350] [PMID: 22989478]">Savović 2012a</a>; <a href="./references#CD012955-bbs2-0390" title="SavovićJ , JonesHE , AltmanDG , HarrisRJ , JüniP , PildalJ , et al. Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Annals of Internal Medicine2012;157(6):429-38. [DOI: 10.7326/0003-4819-157-6-201209180-00537] [PMID: 22945832]">Savović 2012b</a>; <a href="./references#CD012955-bbs2-0391" title="SchulzKF , ChalmersI , HayesRJ , AltmanDG . Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA1995;273(5):408-12. [PMID: 7823387]">Schulz 1995</a>; <a href="./references#CD012955-bbs2-0425" title="WoodL , EggerM , GluudLL , SchulzKF , JüniP , AltmanDG , et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ2008;336(7644):601-5. [DOI: 10.1136/bmj.39465.451748.AD] [PMC2267990] [PMID: 18316340]">Wood 2008</a>). The results are based on 75 trials that involved a limited number of people (n = 4507). Most trials included small sample sizes, with the number of participants ranging from 7 to 151 in the individual trials. Heterogeneity in the reporting of outcomes and the interventions investigated in the individual trials hindered the pooling of effect estimates. Except for DBT, ERGT, MBT and MOTR, the review findings are based largely on single trial effects that could not be pooled. The small samples and inability to pool results led to imprecise effect estimates. </p> <p>The highest risk of bias we observed in the individual trials was for the category of 'other bias', covering attention, affiliation or adherence bias. We rated approximately two‐thirds of trials (49 out of 75) as having a high risk of bias, and another 21 RCTs as having an unclear risk of bias, leaving only five (i.e. 6.7%) RCTs at low risk of bias. We rated two‐thirds of trials as having either a high or an unclear risk of bias in terms of both incomplete outcome data and selective reporting (only 19 trials out of 75 had a low risk of bias in these categories). We rated half or more of the trials as having applied appropriate means of random sequence generation, allocation concealment, and blinding of outcome assessment. </p> <p>From the analyses regarding psychotherapy and DBT versus waiting list or no treatment for suicide‐related outcomes and depression, we found one trial to be an outlier (<a href="./references#CD012955-bbs2-0053" title="MohamadizadehL , MakvandiB , PashaR , BakhtiarpourS , HafeziF . Comparing of the effect of dialectical behavior therapy (DBT) and schema therapy (ST) on reducing mood activity and suicidal thoughts in patients with borderline personality disorder. Acta Medica Mediterranea2017;33:1025-31. [DOI: 10.19193/0393-6384_2017_6_162] [www.actamedicamediterranea.com/archive/2017/medica-6/comparing-of-the-effect-of-dialectical-behavior-therapy-dbt-and-schema-therapy-st-on-reducing-mood-activity-and-suicidal-thoughts-in-patients-with-borderline-personality-disorder/pdf]">Mohamadizadeh 2017</a>). The trial was rated at high risk of bias due to unclear risks of bias in all domains. To ensure transparency, we did not exclude it from the analyses. However, sensitivity analyses showed that the trial's inclusion did not change any conclusions on the aforementioned outcomes. </p> <p>Notably, there were only two RCTs out of 75 that included medication‐free patients only. The majority of trials allowed participants to continue their respective drug treatments. There were no reports of different medication rates between the groups at baseline from any trial. Apart from those trials that included medication as a compulsory part of their respective treatment regimens for both groups (<a href="./references#CD012955-bbs2-0006" title="BellinoS , ParadisoE , ZizzaM , Di LorenzoR , BogettoF . Combined therapy with interpersonal psychotherapy of major depressed patients with borderline personality disorder: a comparison with pharmacotherapy [Terapia combinata con psicoterapia interpersonale di pazienti depressi maggiori con disturbo borderline di personalità: confronto con la farmacoterapia]. Journal of Psychopathology2005;11(1):34-42. [bit.ly/2rZUh5h]BellinoS , ZizzaM , RinaldiC , BogettoF . Combined treatment of major depression in patients with borderline personality disorder: a comparison with pharmacotherapy. Canadian Journal of Psychiatry2006;51(7):453-60. [DOI: 10.1177/070674370605100707] [PMID: 16838827]">Bellino 2006</a>; <a href="./references#CD012955-bbs2-0007" title="BellinoS , ZizzaM , RinaldiC , BogettoF . Combined therapy of major depression with concomitant borderline personality disorder: comparison of interpersonal and cognitive psychotherapy. Canadian Journal of Psychiatry2007;52(11):718-25. [DOI: 10.1177/070674370705201106] [PMID: 18399039]">Bellino 2007</a>; <a href="./references#CD012955-bbs2-0008" title="BellinoS , BozzatelloP , BogettoF . Combined treatment of borderline personality disorder with interpersonal psychotherapy and pharmacotherapy: predictors of response. Psychiatry Research2015;226(1):284-8. [DOI: 10.1016/j.psychres.2014.12.064] [isiarticles.com/bundles/Article/pre/pdf/34125.pdf]BellinoS , RinaldiC , BogettoF . Adaptation of interpersonal psychotherapy to borderline personality disorder: a comparison of combined therapy and single pharmacotherapy. Canadian Journal of Psychiatry2010;55(2):74-81. [DOI: 10.1177/070674371005500203] [PMID: 20181302]BellinoS . Question regarding your BPD trials for inclusion in Cochrane Collaboration review [personal communication]. Email to: J Stoffers-Winterling 19 December 2010. BellinoS . Re: question regarding your BPD trials [personal communication]. Email to: J Stoffers 16 December 2010. BozzatelloP , BellinoS . Combined therapy with interpersonal psychotherapy adapted for borderline personality disorder: a two-years follow-up. Psychiatry Research2016;240:151-6. [DOI: 10.1016/j.psychres.2016.04.014] [www.sciencedirect.com/science/article/pii/S0165178115302389]ZizzaM , FenocchioM , RinaldiC , BellinoS . Combined treatment of borderline personality disorder: a trial of modified interpersonal therapy. World Psychiatry2009;8(Suppl 1):234. ">Bellino 2010</a>; <a href="./references#CD012955-bbs2-0031" title="BrandS . AW: questions regarding your trial on emotional intelligence training for BPD [personal communication]. Email to: EG Faltinsen 28 November 2017. BrandS . Questions regarding your trial on emotional intelligence training for BPD [personal communication]. Email to: EG Faltinsen 28 November 2017. JahangardL , HaghighiM , BajoghliH , AhmadpanahM , GhaleihaA , ZarrabianMK , et al. Training emotional intelligence improves both emotional intelligence and depressive symptoms in inpatients with borderline personality disorder and depression. International Journal of Psychiatry in Clinical Practice2012;16(3):197-204. [DOI: 10.3109/13651501.2012.687454] [PMID: 22873719]">Jahangard 2012</a>), 24 trials reported on actual medication use during the trial observation period: 17 found no difference in medication use between the groups (<a href="./references#CD012955-bbs2-0003" title="AntonsenBT , JohansenMS , RøFG , KvarsteinEH , WilbergT . Is reflective functioning associated with clinical symptoms and long-term course in patients with personality disorders?Comprehensive Psychiatry2016;64:46-58. [DOI: 10.1016/j.comppsych.2015.05.016] [PMID: 26104432]AntonsenBT , KlungsøyrO , KampsA , HummelenB , JohansenMS , PedersenG , et al. Step-down versus outpatient psychotherapeutic treatment for personality disorders: 6-year follow-up of the Ullevål personality project. BMC Psychiatry2014;14:119. [DOI: 10.1186/1471-244X-14-119] [PMC4000615] [PMID: 24758722]AntonsenBT , KvarsteinEH , Urnes Ø, HummelenB , KarterudS , WilbergT . Favourable outcome of long-term combined psychotherapy for patients with borderline personality disorder: six-year follow-up of a randomized study. Psychotherapy Research2017;27(1):51-63. [DOI: 10.1080/10503307.2015.1072283] [PMID: 26261865]ArnevikE , WilbergT , Urnes Ø, JohansenM , MonsenJT , KarterudS . Psychotherapy for personality disorders: short-term day hospital psychotherapy versus outpatient individual therapy - a randomized controlled study. European Psychiatry2009;24(2):71-8. [DOI: 10.1016/j.eurpsy.2008.09.004] [PMID: 19097870]GullestadFS , JohansenMS , HøglendP , KarterudS , WilbergT . Mentalization as a moderator of treatment effects: findings from a randomized clinical trial for personality disorders. Psychotherapy Research2013;23(6):674-89. [DOI: 10.1080/10503307.2012.684103] [PMID: 22612470]GullestadFS . Re: questions regarding your trial on day hospital step-down program [personal communication]. Email to: E Faltinsen 4 December 2017. KvarsteinEH , ArnevikE , HalsteinliV , RøFG , KarterudS , WilbergT . Health service costs and clinical gains of psychotherapy for personality disorders: a randomized controlled trial of day-hospital-based step-down treatment versus outpatient treatment at a specialist practice. BMC Psychiatry2013;13:315. [DOI: 10.1186/1471-244X-13-315] [PMC4222503] [PMID: 24268099]">Antonsen 2017</a>; <a href="./references#CD012955-bbs2-0010" title="BlackD . Question regarding your BPD trial [personal communication]. Email to: J Stoffers 04 January 2011. BlackDW , AllenJ , McCormickB , BlumN . Treatment received by persons with BPD participating in a randomized clinical trial of the systems training for emotional predictability and problem solving programme. Personality and Mental Health2011;5(3):159-68. [DOI: 10.1002/pmh.167]BlackDW , AllenJ , St JohnD , PfohlB , McCormickB , BlumN . Predictors of response to systems training for emotional predictability and problem solving (STEPPS) for borderline personality disorder: an exploratory study. Acta Psychiatrica Scandinavica2009;120(1):53-61. [DOI: 10.1111/j.1600-0447.2008.01340.x] [PMC3665337] [PMID: 19183126]BlackDW , BlumN , PfohlB , St JohnD . The STEPPS group treatment program for outpatients with borderline personality disorder. Journal of Contemporary Psychotherapy2004;34(3):193-210. [DOI: 10.1023/B:JOCP.0000036630.25741.83]BlackDW , PfohlBM . Randomized clinical trial of STEPPS versus treatment as usual. In: 158th annual meeting of the American Psychiatric Association. Psychosomatic medicine: integrating psychiatry &amp; medicine; 2005 May 21-26; Atlanta (GA). Arlington (VA): American Psychiatric Association, 2005:104. [No. 1B] [www.psychiatry.org/File%20Library/Psychiatrists/Directories/Library-and-Archive/syllabus/am_syllabus_2005.pdf]BlackDW , Simsek-DuranF , BlumN , McCormickB , AllenJ . Do people with borderline personality disorder complicated by antisocial personality disorder benefit from the STEPPS treatment program?Personality and Mental Health2016;10(3):205-15. [DOI: 10.1002/pmh.1326] [PMC4911327] [PMID: 26671625]BlackDW . RE: [external] questions regarding your trial on the STEPPS program for BPD [personal communication]. Email to: EG Faltinsen 27 November 2017. BlumN , AllenJ , McCormickB , BlackDW . Ms Blum and colleagues reply [to Schulte-Herbrüggen O, Koerting J, Roepke S. Effectiveness of adjunctive STEPPS group treatment in borderline personality disorder patients. American Journal of Psychiatry 2008;165(10):1354-5. DOI: 10.1176/appi.ajp.2008.08030390]. American Journal of Psychiatry2008;165(10):1354-5. [DOI: 10.1176/appi.ajp.2008.08030390r]BlumN , FranklinJ , HanselR , McCormickB , St JohnD , PfohlB , et al. Relationship of age to symptom severity, psychiatric comorbidity and health care utilization in persons with borderline personality disorder. Personality and Mental Health2008;2(1):25-43. [DOI: 10.1002/pmh.26]BlumN , St JohnD , PfohlB , StuartS , McCormickB , AllenJ , et al. Erratum. American Journal of Psychiatry2008;165(6):777. Erratum for: American Journal of Psychiatry 2008;165(4):468-78. [psycnet.apa.org/record/2008-07854-033]BlumN , St JohnD , PfohlB , StuartS , McCormickB , AllenJ , et al. Systems training for emotional predictability and problem solving (STEPPS) for outpatients with borderline personality disorder: a randomized controlled trial and 1-year follow-up. American Journal of Psychiatry2008;165(4):468-78. [DOI: 10.1176/appi.ajp.2007.07071079] [PMC3608469] [PMID: 18281407]DavidsonKM . Borderline personality disorder: STEPPS improves symptoms. Evidence-Based Mental Health2008;11(4):120. [DOI: 10.1136/ebmh.11.4.120] [PMID: 18952969]NCT00055315. Treatment for borderline personality disorder [A cognitive group treatment for borderline outpatients]. clinicaltrials.gov/ct2/show/NCT00055315 (first received 25 February 2003). ">Blum 2008</a>; <a href="./references#CD012955-bbs2-0011" title="BohusM , DyerAS , PriebeK , KrügerA , KleindienstN , SchmahlC , et al. Dialectical behaviour therapy for post-traumatic stress disorder after childhood sexual abuse in patients with and without borderline personality disorder: a randomised controlled trial. Psychotherapy and Psychosomatics2013;82(4):221-33. [DOI: 10.1159/000348451] [PMID: 23712109]BrandS . AW: questions regarding your trial on emotional intelligence training for BPD [personal communication]. Email to: EG Faltinsen 28 November 2017. DBT Working Group at the Central Institute for Mental Health, Mannheim, Germany. Requested supplementary data (as supplied 1 October 2010). Data on file. NCT00481000. Dialectical cognitive traumatherapy (DCT) on patients with severe PTSD following sexual abuse (PASA) [Dialectical cognitive traumatherapy (DCT) on patients with severe posttraumatic stress disorder following sexual abuse - a randomised controlled trial]. clinicaltrials.gov/ct2/show/NCT00481000 (first received 31 May 2007). SteilR , DyerA , PriebeK , KleindienstN , BohusM . Dialectical behavior therapy for posttraumatic stress disorder related to childhood sexual abuse: a pilot study of an intensive treatment program. Journal of Traumatic Stress2011;24(1):102-6. [DOI: 10.1002/jts.20617] [PMID: 21351167]">Bohus 2013</a>; <a href="./references#CD012955-bbs2-0013" title="BosEH , Van WelE , AppeloMT , VerbraakMJP . A randomized controlled trial of a Dutch version of systems training for emotional predictability and problem solving for borderline personality disorder. Journal of Nervous and Mental Disease2010;198(4):299-304. [DOI: 10.1097/NMD.0b013e3181d619cf] [PMID: 20386260]Van WelEB , BosEH , AppeloMT , BerendsenEM , WillgerothFC , VerbraakMJPM . The efficacy of the systems training for emotional predictability and problem solving (STEPPS) in the treatment of borderline personality disorder. A randomized controlled trial [De effectiviteit van de vaardigheidstraining emotieregulatiestoornis (VERS) in de behandeling van de borderlinepersoonlijkheidsstoornis: een gerandomiseerd onderzoek]. Tijdschrift voor Psychiatrie2009;51(5):291-301. [PMID: 19434566]">Bos 2010</a>; <a href="./references#CD012955-bbs2-0019" title="BuchheimA , Hörz-SagstetterS , DoeringS , RentropM , SchusterP , BuchheimP , et al. Change of unresolved attachment in borderline personality disorders: RCT study of transference-focused psychotherapy. Psychotherapy and Psychosomatics2017;86(5):314-6. [DOI: 10.1159/000460257] [PMID: 28903103]DiamondD , LevyKN , ClarkinJF , Fischer-KernM , CainNM , DoeringS , et al. Attachment and mentalization in female patients with comorbid narcissistic and borderline personality disorder. Personality Disorders2014;5(4):428-33. [DOI: 10.1037/per0000065] [PMID: 25314231]DiamondD , YeomansFE , SternB , LevyKN , HörzS , DoeringS , et al. Transference-focused psychotherapy for patients with comorbid narcissistic and borderline personality disorder. Psychoanalytic Inquiry2013;33(6):527-51. [DOI: 10.1080/07351690.2013.815087]DoeringS , HörzS , RentropM , Fischer-KernM , SchusterP , BeneckeC , et al. Transference-focused psychotherapy v treatment by community psychotherapists for borderline personality disorder: randomised controlled trial. British Journal of Psychiatry2010;196(5):389-95. [DOI: 10.1192/bjp.bp.109.070177] [PMID: 20435966]DoeringS . Author's reply [to Kleindienst N, Krumm B, Bohus M. Is transference-focused psychotherapy really efficacious for borderline personality disorder? British Journal of Psychiatry 2011;198(2):156-7. DOI: 10.1192/bjp.198.2.156b]. British Journal of Psychiatry2011;198(2):156-7. [DOI: 10.1192/bjp.198.2.157]DoeringS . Question regarding your BPD trial for systematic review in Cochrane Collaboration [personal communication]. Email to: K Lieb, J Stoffers 10 December 2010. Fischer-KernM , DoeringS , TaubnerS , HörzS , ZimmermannJ , RentropM , et al. Transference-focused psychotherapy for borderline personality disorder: change in reflective function. British Journal of Psychiatry2015;207(2):173-4. [DOI: 10.1192/bjp.bp.113.143842] [PMID: 25999334]KleindienstN , KrummB , BohusM . Is transference-focused psychotherapy really efficacious for borderline personality disorder?British Journal of Psychiatry2011;198(2):156-7. [DOI: 10.1192/bjp.198.2.156b] [PMID: 21282787]LevyKN , MeehanKB , YeomansFE . Transference-focused psychotherapy reduces treatment drop-out and suicide attempters compared with community psychotherapist treatment in borderline personality disorder. Evidence-based Mental Health2010;13(4):119. [DOI: 10.1136/ebmh.13.4.119] [PMID: 21036981]NCT00714311. Efficacy of transference-focused psychotherapy for borderline personality disorder [A randomized-controlled trial of transference-focused psychotherapy vs treatment by experienced community psychotherapists for borderline personality disorder]. www.clinicaltrials.gov/ct2/show/NCT00714311 (first received 9 July 2008). RentropM , MartiusP , BäumlJ , BuchheimP , DöeringS , HörzS . Patients with borderline personality disorder not participating in an RCT: are they different?Psychopathology2010;43(6):369-72. [DOI: 10.1159/000320351] [PMID: 20798576]">Doering 2010</a>; <a href="./references#CD012955-bbs2-0020" title="ElicesM , PascualJC , PortellaMJ , Feliu-SolerA , Martín-BlancoA , CarmonaC , et al. Impact of mindfulness training on borderline personality disorder: a randomized trial. Mindfulness2016;7:584-95. [DOI: 10.1007/s12671-016-0492-1]NCT02397031. Mindfulness and interpersonal effectiveness skills in borderline personality disorder [Randomized, active-controlled, clinical trial comparing effects of mindfulness and interpersonal effectiveness skills in borderline personality disorder]. www.clinicaltrials.gov/ct2/show/NCT02397031 (first received 12 March 2015). SolerJ , ElicesM , PascualJC , Martín-BlancoA , Feliu-SolerA , CarmonaC , et al. Effects of mindfulness training on different components of impulsivity in borderline personality disorder: results from a pilot randomized study. Borderline Personality Disorder and Emotion Dysregulation2016;3:1. [DOI: 10.1186/s40479-015-0035-8] [PMC4709962] [PMID: 26759718]">Elices 2016</a>; <a href="./references#CD012955-bbs2-0025" title="GleesonJF , ChanenA , CottonSM , PearceT , NewmanB , McCutcheonL . Treating co-occurring first-episode psychosis and borderline personality: a pilot randomized controlled trial. Early Intervention in Psychiatry2012;6(1):21-9. [DOI: 10.1111/j.1751-7893.2011.00306.x] [PMID: 22379625]GleesonJFM . RE: separate data [personal communication]. Email to: M Kielsholm 28 October 2016. ">Gleeson 2012</a>; <a href="./references#CD012955-bbs2-0042" title="LeichsenringF , MasuhrO , JaegerU , RabungS , DallyA , DümpelmannM , et al. Psychoanalytic-interactional therapy versus psychodynamic therapy by experts for personality disorders: a randomized controlled efficacy-effectiveness study in cluster B personality disorders. Psychotherapy and Psychosomatics2016;85(2):71-80. [DOI: 10.1159/000441731] [PMID: 26808580]">Leichsenring 2016</a>; <a href="./references#CD012955-bbs2-0044" title="Lin T-J, Ko H-C, Wu JY-W, OeiTP , Lane H-Y, Chen C-H. The effectiveness of dialectical behavior therapy skills training group vs cognitive therapy group on reducing depression and suicide attempts for borderline personality disorder in Taiwan. Archives of Suicide Research2019;23(1):82-99. [DOI: 10.1080/13811118.2018.1436104] [PMID: 29528807]">Lin 2019</a>; <a href="./references#CD012955-bbs2-0048" title="LinehanMM , KorslundKE , HarnedMS , GallopRJ , LunguA , NeacsiuAD , et al. Dialectical behavior therapy for high suicide risk in individuals with borderline personality disorder: a randomized clinical trial and component analysis. JAMA Psychiatry2015;72(5):475-82 Erratum for: JAMA Psychiatry 2015; 72(9): 951. [DOI: 10.1001/jamapsychiatry.2014.3039] [PMID: 25806661]NCT00183651. Treatment of suicidal women with borderline personality disorder [Assessment and treatment of parasuicidal patients]. www.clinicaltrials.gov/ct2/show/NCT00183651 (first received 13 September 2005). ">Linehan 2015a</a>; <a href="./references#CD012955-bbs2-0049" title="CaseBG . Letter to the editor on 'McMain SF, Links PS, Gnam WH, Guimond T, Cardish RJ, Korman L, et al. A randomized trial of dialectical behavior therapy versus general psychiatric management for borderline personality disorder. American Journal of Psychiatry 2009;166(12):1365-74. DOI: 10.1176/appi.ajp.2009.09010039'. American Journal of Psychiatry2010;167(4):475. [DOI: 10.1176/appi.ajp.2009.09101532] [PMID: 20360332 ]ISRCTN02634417. Hope for chronically suicidal patient: evaluating the clinical and health services impact of dialectical behaviour therapy (DBT) in individuals with borderline personality disorder [Evaluating the clinical and health services impact of dialectical behaviour therapy (DBT) in individuals with borderline personality disorder: a randomised controlled trial]. www.isrctn.com/ISRCTN02634417 (first received 16 November 2005). [DOI: 10.1186/ISRCTN02634417]McMainSF , FitzpatrickS , BoritzT , BarnhartR , LinksP , StreinerDL . Outcome trajectories and prognostic factors for suicide and self-harm behaviors in patients with borderline personaliy disorder following one year of outpatient psychotherapy. Journal of Personality Disorders2018;32(4):497-512. [DOI: 10.1521/pedi_2017_31_309] [PMID: 28910214]McMainSF , LinksPS , GnamWH , GuimondT , CardishRJ , KormanL , et al. A randomized trial of dialectical behavior therapy versus general psychiatric management for borderline personality disorder. American Journal of Psychiatry2009;166(12):1365-74. [DOI: 10.1176/appi.ajp.2009.09010039] [PMID: 19755574]McMainSF . Dr McMain replies to letter to the editor on 'McMain SF, Links PS, Gnam WH, Guimond T, Cardish RJ, Korman L, et al. A randomized trial of dialectical behavior therapy versus general psychiatric management for borderline personality disorder. American Journal of Psychiatry 2009;166(12):1365-74. DOI: 10.1176/appi.ajp.2009.09010039'. American Journal of Psychiatry2010;167(4):475-6. [DOI: 10.1176/appi.ajp.2009.09101532r)]NCT00154154. Hope for the chronically suicidal patient [Hope for the chronically suicidal patient: evaluating the clinical and health services impact of dialectical behaviour therapy in individuals with borderline personality disorder]. www.clinicaltrials.gov/ct2/show/NCT00154154 (first received 7 September 2005). ">McMain 2009</a>; <a href="./references#CD012955-bbs2-0050" title="McMainSF , GuimondT , BarnhartR , HabinskiL , StreinerDL . A randomized trial of brief dialectical behaviour therapy skills training in suicidal patients suffering from borderline disorder. Acta Psychiatrica Scandinavica2017;135(2):138-48. [DOI: 10.1111/acps.12664] [PMID: 27858962]">McMain 2017</a>; <a href="./references#CD012955-bbs2-0053" title="MohamadizadehL , MakvandiB , PashaR , BakhtiarpourS , HafeziF . Comparing of the effect of dialectical behavior therapy (DBT) and schema therapy (ST) on reducing mood activity and suicidal thoughts in patients with borderline personality disorder. Acta Medica Mediterranea2017;33:1025-31. [DOI: 10.19193/0393-6384_2017_6_162] [www.actamedicamediterranea.com/archive/2017/medica-6/comparing-of-the-effect-of-dialectical-behavior-therapy-dbt-and-schema-therapy-st-on-reducing-mood-activity-and-suicidal-thoughts-in-patients-with-borderline-personality-disorder/pdf]">Mohamadizadeh 2017</a>; <a href="./references#CD012955-bbs2-0060" title="RenesesB , FigueraD , SalcedoG , TrujilloM , López-IborJJ , GaliánM , et al. A controlled randomized study on the efficacy of short-term dinamic psychotherapy in borderline personality disorders (BPD). Preliminary results. European Psychiatry2011;26(Suppl 1):1040. [DOI: 10.1016/S0924-9338(11)72745-6] [P02-444]RenesesB , GaliánM , SerranoR , FigueraD , Fernandez Del MoralA , López-IborJJ , et al. A new time limited psychotherapy for BPD: preliminary results of a randomized and controlled trial. Actas Espanolas de Psiquiatria2013;41(3):139-48. [PMID: 23803797]">Reneses 2013</a>; <a href="./references#CD012955-bbs2-0066" title="ISRCTN97589104. Evaluation of a group training for adolescents (emotion regulation training) with emotion regulation problems - a randomised controlled clinical trial. www.isrctn.com/ISRCTN97589104 (first received 23 August 2007). SchuppertHM , TimmermanME , BlooJ , Van GemertTG , WiersemaHM , MinderaaRB , et al. Emotion regulation training for adolescents with borderline personality disorder traits: a randomized controlled trial. Journal of the American Academy of Child &amp; Adolescent Psychiatry2012;51(12):1314-23. [DOI: 10.1016/j.jaac.2012.09.002] [PMID: 23200288]">Schuppert 2012</a>; <a href="./references#CD012955-bbs2-0067" title="NCT01904227. Intensified, inpatient adaptation of dialectical behavior therapy (DBT) (REDBT) [A randomized controlled study of the efficacy of an intensified, inpatient adaptation of dialectical behavior therapy (DBT) for a population of borderline patients (young adults/adults: 18-40), compared with standard outpatient DBT]. www.clinicaltrials.gov/ct2/show/NCT01904227 (first received 11 July 2013). SinnaeveR , Van den BoschLM , Van Steenbergen-WeijenburgKM . Change in interpersonal functioning during psychological interventions for borderline personality disorder — a systematic review of measures and efficacy. Personality and Mental Health2015;9(3):173-94. [DOI: 10.1002/pmh.1296] [PMID: 26058794]SinnaeveR , Van den BoschLMC , Hakkaart-van RoijenL , VansteelandtK . Effectiveness of step-down versus outpatient dialectical behaviour therapy for patients with severe levels of borderline personality disorder: a pragmatic randomized controlled trial. Borderline Personality Disorder and Emotion Dysregulation2018;5:12. [DOI: 10.1186/s40479-018-0089-5] [PMC6040072] [PMID: 30002832]SinnaeveR . Cochrane Collaboration review [personal communication]. Email to: J Stoffers-Winterling 11 June 2018. SinnaeveR . Re: BPDSI subscale data Sinnaeve et al (2018) [personal communication]. Email to: A Tadorovac 15 November 2018. SinnaeveR . RE: BPDSI subscale data Sinnaeve et al (2018) [personal communication] [RE: BPDSI subschale data Sinnaeve et al (2018) [personlig kommunikation]]. Email to: A Todorovac 15 November 2018. SinnaeveR . RE: BPDSI subscale data Sinnaeve et al (2018) [personal communication] [RE: BPDSI subschale data Sinnaeve et al (2018) [personlig kommunikation]]. Email to: A Todorovac 9 October 2018. Van den BoschLM , SinnaeveR , Hakkaart-van RoijenL , Van FurthEF . Efficacy and cost-effectiveness of an experimental short-term inpatient dialectical behavior therapy (DBT) program: study protocol for a randomized controlled trial. Trials2014;15:152. [DOI: 10.1186/1745-6215-15-152] [PMC4017823] [PMID: 24885551]Van RoijenLH , SinnaeveR , BouwmansC , Van Den BoschL . Cost-effectiveness and cost-utility of shortterm inpatient dialectical behavior therapy for chronically parasuicidal BPD (young) adults. Journal of Mental Health Policy and Economics2015;18(Suppl 1):S19-20. [www.icmpe.org/test1/journal/issues/v18s1toc.html]">Sinnaeve 2018</a>; <a href="./references#CD012955-bbs2-0072" title="Van den BoschLM , KoeterMW , StijnenT , VerheulR , Van den BrinkW . Sustained efficacy of dialectical behaviour therapy for borderline personality disorder. Behaviour Research and Therapy2005;43(9):1231-41. [DOI: 10.1016/j.brat.2004.09.008] [PMID: 16005708]Van den BoschLM , VerheulR , SchippersGM , Van den BrinkW . Dialectical behavior therapy of borderline patients with and without substance use problems. Implementation and long-term effects. Addictive Behaviors2002;27(6):911-23. [DOI: 10.1016/s0306-4603(02)00293-9] [PMID: 12369475]Van den BoschLMC . Efficacy of dialectical behaviour therapy in the treatment of female borderline patients with and without substance abuse problems: results of a Dutch study [Dialectische gedragstherapie bij Nederlandse vrouwen met een borderline persoonlijkheidsstoornis, met en zonder verslavingsproblemen]. Tijdschrift voor Psychiatrie2005;47(3):127-37. [www.tijdschriftvoorpsychiatrie.nl/assets/articles/articles_1335pdf.pdf]VerheulR , Van den BoschLM , KoeterMW , De RidderMA , StijnenT , Van den BrinkW . Dialectical behaviour therapy for women with borderline personality disorder: 12-month, randomised clinical trial in The Netherlands. British Journal of Psychiatry2003;182:135-40. [DOI: 10.1192/bjp.182.2.135] [PMID: 12562741]">Van den Bosch 2005</a>); six reported a higher use of medications in their control groups (<a href="./references#CD012955-bbs2-0004" title="BatemanA , FonagyP . 8-year follow-up of patients treated for borderline personality disorder: mentalization-based treatment versus treatment as usual. American Journal of Psychiatry2008;165(5):631-8. [DOI: 10.1176/appi.ajp.2007.07040636] [PMID: 18347003]BatemanA , FonagyP . Effectiveness of partial hospitalization in the treatment of borderline personality disorder: a randomized controlled trial. American Journal of Psychiatry1999;156(10):1563-9. [DOI: 10.1176/ajp.156.10.1563] [PMID: 10518167]BatemanA , FonagyP . Health care utilization costs for borderline personality disorder patients treated with psychoanalytically oriented partial hospitalization versus general psychiatric care. American Journal of Psychiatry2003;160(1):169-71. [10.1176/appi.ajp.160.1.169] [12505818]BatemanA , FonagyP . Treatment of borderline personality disorder with psychoanalytically oriented partial hospitalization: an 18-month follow-up. American Journal of Psychiatry2001;158(1):36-42. [DOI: 10.1176/appi.ajp.158.1.36] [PMID: 11136631]BatemanA . Important: question regarding your BPD trial for systematic review in Cochrane Collaboration [personal communication]. Email to: K Lieb, J Stoffers 14 December 2010. BatemanA . Intensive outpatient and partial hospital care for BPD. In: 157th annual meeting of the American Psychiatric Association. Psychotherapy and pharmacology: dissolving the mind-brain barrier; 2004 May 1-6; New York (NY). Arlington (VA): American Psychiatric Association, 2004:102. [Symposium 100B] [www.psychiatry.org/File%20Library/Psychiatrists/Directories/Library-and-Archive/conference_publications/am_program_2004.pdf]BatemanAW , FonagyP . Drs Bateman and Fonagy reply [to Stern R. Partial hospitalization for borderline personality disorder. American Journal of Psychiatry 2001;158(11):1932-3. DOI: 10.1176/appi.ajp.158.11.1932]. American Journal of Psychiatry2001;158(11):1932-3. [DOI: 10.1176/appi.ajp.158.11.1932-a]EvansC . Treatment benefits of psychoanalytically oriented partial hospitalisation were maintained over 18 months in borderline personality disorder. Evidence-Based Mental Health2001;4(3):73. [DOI: 10.1136/ebmh.4.3.73]FonagyP , BatemanAW . Mentalizing and borderline personality disorder. Journal of Mental Health2007;16(1):83-101. [DOI: 10.1080/09638230601182045]SternR . Partial hospitalization for borderline personality disorder. American Journal of Psychiatry2001;158(11):1932-3. [DOI: 10.1176/appi.ajp.158.11.1932] [PMID: 11691712]">Bateman 1999</a>; <a href="./references#CD012955-bbs2-0005" title="BatemanA , FonagyP . Impact of clinical severity on outcomes of mentalisation-based treatment for borderline personality disorder. British Journal of Psychiatry2013;203(3):221-7. [DOI: 10.1192/bjp.bp.112.121129] [PMID: 23887998]BatemanA , FonagyP . Randomized controlled trial of outpatient mentalization-based treatment versus structured clinical management for borderline personality disorder. American Journal of Psychiatry2009;166(12):1355-64. [DOI: 10.1176/appi.ajp.2009.09040539] [PMID: 19833787]BatemanA , FonagyP . Randomized controlled trial of outpatient mentalization-based treatment versus structured clinical management for borderline personality disorder. Supplementary data. ajp.psychiatryonline.org/doi/suppl/10.1176/appi.ajp.2009.09040539/suppl_file/ajp_166_12_1355_01.pdf (accessed 27 February 2020). BatemanA , O'ConnellJ , LorenziniN , GardnerT , FonagyP . A randomised controlled trial of mentalization-based treatment versus structured clinical management for patients with comorbid borderline personality disorder and antisocial personality disorder. BMC Psychiatry2016;16:304. [DOI: 10.1186/s12888-016-1000-9] [PMC5006360] [PMID: 27577562]BatemanA . Important question regarding your BPD trial for systematic review in Cochrane Collaboration [personal communication]. Email to: K Lieb 14 December 2010. BatemanAW . Mentalization, borderline personality disorder and what works for whom? Presentation at the 11th International Congress of the International Society for the Study of Personality Disorders; 2009 Aug 21-23. www.borderlinepersonalitydisorder.com/Conferences/ISSPD/isspd_09_Bateman (accessed 21 April 2010). ISRCTN27660668. Randomised controlled trial of manualised out-patient individual and group therapy for borderline personality disorder [Effectiveness of intensive out-patient psychotherapy for treatment of borderline personality disorder: a pragmatic randomised single blind controlled study]. www.isrctn.com/ISRCTN27660668 (first received 12 October 2008). ">Bateman 2009</a>; <a href="./references#CD012955-bbs2-0303" title="GregoryRJ , RemenAL . A manual-based psychodynamic therapy for treatment-resistant borderline personality disorder. Psychotherapy: Theory, Research, Practice, Training2008;45:15-27.">Gregory 2008</a>; <a href="./references#CD012955-bbs2-0046" title="HeardHL . Cost-Effectiveness of Dialectical Behavior Therapy in the Treatment of Borderline Personality Disorder [PhD thesis]. Washington (DC): University of Washington, 2000. LindenboimN . To Know Me is to Keep Me: Self-Verification, Validation, and Therapy Dropout in the Treatment of Borderline Personality Disorder [PhD thesis]. Washington (DC): University of Washington, 2009. LinehanMM , HeardHL , ArmstrongHE . Naturalistic follow-up of a behavioral treatment for chronically parasuicidal borderline patients. Archives of General Psychiatry1993;50(12):971-4. [DOI: 10.1001/archpsyc.1993.01820240055007] [PMID: 8250683]LinehanMM , TutekDA , HeardHL , ArmstrongHE . Interpersonal outcome of cognitive behavioral treatment for chronically suicidal borderline patients. American Journal of Psychiatry1994;151(12):1771-6. [DOI: 10.1176/ajp.151.12.1771] [PMID: 7977884]">Linehan 1994</a>; <a href="./references#CD012955-bbs2-0047" title="BedicsJD , AtkinsDC , ComtoisKA , LinehanMM . Treatment differences in the therapeutic relationship and introject during a 2-year randomized controlled trial of dialectical behavior therapy versus nonbehavioral psychotherapy experts for borderline personality disorder. Journal of Consulting and Clinical Psychology2012;80(1):66-77. [DOI: 10.1037/a0026113] [PMC3265694] [PMID: 22061867]BedicsJD , AtkinsDC , ComtoisKA , LinehanMM . Weekly therapist ratings of the therapeutic relationship and patient introject furing the course of dialectical behavioral therapy for the treatment of borderline personality disorder. Psychotherapy2012;49(2):231-40. [DOI: 10.1037/a0028254] [PMID: 22642526]BedicsJD , AtkinsDC , HarnedMS , LinehanMM . The therapeutic alliance as a predictor of outcome in dialectical behavior therapy versus nonbehavioral psychotherapy by experts for borderline personality disorder. Psychotherapy2015;52(1):67-77. [DOI: 10.1037/a0038457] [PMID: 25751116]BrownMZ , LinehanMM , ComtoisKA , MurrayA , ChapmanAL . Shame as a prospective predictor of self-inflicted injury in borderline personality disorder: a multi-modal analysis. Behaviour Research and Therapy2009;47(10):815-22. [DOI: 10.1016/j.brat.2009.06.008] [PMC2761705] [PMID: 19596223 ]CoyleTN , ShaverJA , LinehanMM . On the potential for iatrogenic effects of psychiatric crisis services: the example of dialectical behavior therapy for adult women with borderline personality disorder. Journal of Consulting and Clinical Psychology2018;86(2):116-24. [DOI: 10.1037/ccp0000275] [PMID: 29369662]HarnedMS , ChapmanAL , Dexter-MazzaET , MurrayA , ComtoisKA , LinehanMM . Treating co-occurring Axis I disorders in recurrently suicidal women with borderline personality disorder: a 2-year randomized trial of dialectical behavior therapy versus community treatment by experts. Journal of Consulting and Clinical Psychology2008;76(6):1068-75. [DOI: 10.1037/a0014044] [PMID: 19045974]HarnedMS , ChapmanAL , Dexter-MazzaET , MurrayA , ComtoisKA , LinehanMM . Treating co-occurring Axis I disorders in recurrently suicidal women with borderline personality disorder: a 2-year randomized trial of dialectical behavior therapy versus community treatment by experts. Personality Disorders: Theory, Research, and Treatment2009;S(1):35-45. [DOI: 10.1037/1949-2715.S.1.35]HarnedMS , JacksonSC , ComtoisKA , LinehanMM . Dialectical behavior therapy as a precursor to PTSD treatment for suicidal and/or self-injuring women with bordreline personality disorder. Journal of Traumatic Stress2010;23(4):421-9. [DOI: 10.1002/jts.20553] [PMID: 20648564]LindenboimN , ComtoisKA , LinehanMM . Skills practice in dialectical behavior therapy for suicidal women meeting criteria for borderline personality disorder. Cognitive and Behavioral Practice2007;14(2):147-56. [DOI: 10.1016/j.cbpra.2006.10.004]LinehanMM , ComtoisKA , MurrayAM , BrownMZ , GallopRJ , HeardHL , et al. Two-year randomized controlled trial and follow-up of dialectical behavior therapy vs therapy by experts for suicidal behaviors and borderline personality disorder. Archives of General Psychiatry2006;63(7):757-66. [DOI: 10.1001/archpsyc.63.7.757] [PMID: 16818865]LinehanMM . Error in table in: two-year randomized controlled trial and follow-up of dialectical behavior therapy vs therapy by experts for suicidal behaviors and borderline personality disorder. Archives of General Psychiatry2007;64(12):1401. Erratum for: Archives of General Psychiatry 2007;64(12):1401. McMainS . Dialectic behaviour therapy reduces suicide attempts compared with non-behavioural psychotherapy in women with borderline personality disorder. Evidence-Based Mental Health2007;10(1):18. [DOI: 10.1136/ebmh.10.1.18] [PMID: 17255387]NeacsiuAD , LunguA , HarnedMS , RizviSL , LinehanMM . Impact of dialectical behavior therapy versus community treatment by experts on emotional experience, expression, and acceptance in borderline personality disorder. Behaviour Research and Therapy2014;53:47-54. [DOI: 10.1016/j.brat.2013.12.004] [PMC3955205] [PMID: 24418652]NeacsiuAD , RizviSL , LinehanMM . Dialectical behavior therapy skills use as a mediator and outcome of treatment for borderline personality disorder. Behaviour Research and Therapy2010;48(9):832-9. [DOI: 10.1016/j.brat.2010.05.017] [PMC2914145] [PMID: 20579633]SecristCD . The Role of Executive Functioning in the Treatment of Borderline Personality Disorder [PhD thesis]. Washington (DC): University of Washington, 2014. ">Linehan 2006</a>; <a href="./references#CD012955-bbs2-0071" title="TurnerRM . Naturalistic evaluation of dialectical behavior therapy-oriented treatment for borderline personality disorder. Cognitive and Behavioral Practice2000;7(4):413-9. [DOI: 10.1016/S1077-7229(00)80052-8]">Turner 2000</a>); and  only one found a higher rate in the active treatment group (<a href="./references#CD012955-bbs2-0002" title='AndreoliA , BurnandY , CochennecMF , MarieD , Di ClementeT , OhlendorfP . Psychoanalytic psychotherapy and venlafaxine among acutely suicidal borderline patients: a randomized clinical study. European Psychiatry2009;24(Suppl 1):S93. [DOI: 10.1016/S0924-9338(09)70326-8] [S18-03]AndreoliA , BurnandY , CochennecMF , OhlendorfP , FrambatiL , Gaudry-MaireD , et al. Disappointed love and suicide: a randomized controlled trial of "abandonment psychotherapy" among borderline patients. Journal of Personality Disorders2016;30(2):271-87. [DOI: 10.1521/pedi_2015_29_196] [PMID: 26111250]AndreoliA , BurnandY , FrambatiL , ManningD , FrancesA . Abandonment psychotherapy and psychosocial functioning among suicidal patients with borderline personality disorder: a 3-year naturalistic follow-up. Journal of Personality Disorders 2019 Feb 20 [Epub ahead of print]. [DOI: 10.1521/pedi_2019_33_423] [PMID: 30785852]AndreoliA . Re: your study in BPD - Cochrane Collaboration review [personal communication]. Email to: J Stoffers-Winterling 5 June 2018. '>Andreoli 2016</a>). Therefore, medication use as a possible confounding variable can be ruled out whenever beneficial effects for the experimental group were observed. </p> </section> <section id="CD012955-sec-0542"> <h3 class="title" id="CD012955-sec-0542">Potential biases in the review process</h3> <p>This review was designed to minimise the risk of potential biases. We developed a protocol, <a href="./references#CD012955-bbs2-0443" title="StorebøOJ , Stoffers-WinterlingJM , VöllmBA , KongerslevMT , MattiviJT , KielsholmML , et al. Psychological therapies for people with borderline personality disorder. Cochrane Database of Systematic Reviews2018, Issue 2. Art. No: CD012955. [DOI: 10.1002/14651858.CD012955]">Storebø 2018</a>, for this review in accordance with the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012955-bbs2-0325" title="HigginsJPT , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al (editors). Cochrane Handbook for Systematic Reviews of Interventions. 2nd edition. Chichester (UK): John Wiley &amp; Sons, 2019. [Available from: www.training.cochrane.org/handbook]">Higgins 2019</a>). We conducted extensive searches of relevant databases, with no restrictions in language, publication year, publication type or publication status. Two independent review authors selected appropriate trials, extracted data, assessed the risk of bias and graded the quality of the evidence. Disagreements were resolved through discussion. We conducted a TSA, to estimate the RIS needed to either detect or reject a certain intervention effect. </p> <p>With regard to our inclusion criteria (<a href="#CD012955-sec-0016">Criteria for considering studies for this review</a>), we tried to retain a homogeneous pool of primary trials. However, there were some inconsistencies between trials, particularly pertaining to psychiatric comorbidity of trial participants. For example, although the presence of a substance‐related disorder was a common exclusion criterion (see <a href="#CD012955-sec-0018">Types of participants</a>), two trials required participants to have such a disorder (<a href="./references#CD012955-bbs2-0028" title="GregoryRJ , ChlebowskiS , KangD , RemenA , SoderbergM . Psychodynamic therapy for borderline personality disorder and co-occurring alcohol use disorders: a newly designed ongoing study. Journal of the American Psychoanalytic Association2006;54(4):1331-4. [DOI: 10.1177/00030651060540040107] [PMID: 17354507]GregoryRJ , ChlebowskiS , KangD , RemenAL , SoderbergMG , StepkovitchJ , et al. A controlled trial of psychodynamic psychotherapy for co-occurring borderline personality disorder and alcohol use disorder. Psychotherapy2008;45(1):28-41. [DOI: 10.1037/0033-3204.45.1.28] [PMID: 22122363]GregoryRJ , DeLucia-DeranjaE , MogleJA . Dynamic deconstructive psychotherapy versus optimized community care for borderline personality disorder co-occuring with alcohol use disorders: a 30-month follow-up. Journal of Nervous and Mental Disease2010;198(4):292-8. [DOI: 10.1097/NMD.0b013e3181d6172d] [PMID: 20386259]GregoryRJ , RemenAL , SoderbergM , Ploutz-SnyderRJ . A controlled trial of psychodynamic psychotherapy for co-occurring borderline personality disorder and alcohol use disorder: six-month outcome. Journal of the American Psychoanalytic Association2009;57(1):199-205. [DOI: 10.1177/00030651090570011006] [PMID: 19270255]NCT00145678. Psychodynamic therapy for co-occurring borderline personality disorder and alcohol use disorder [Psychodynamic therapy for patients With borderline personality disorder and alcohol abuse]. www.clinicaltrials.gov/show/NCT00145678 (first received 1 September 2005). ">Gregory 2008b</a>; <a href="./references#CD012955-bbs2-0064" title="SantistebanDA , MenaMP , MuirJ , McCabeBE , AbaloC , CummingsAM . The efficacy of two adolescent substance abuse treatments and the impact of comorbid depression: results of a small randomized controlled trial. Psychiatric Rehabilitation Journal2015;38(1):55-64. [DOI: 10.1037/prj0000106] [PMC5021542] [PMID: 25799306]">Santisteban 2015</a>), and another trial included a mixed sample of participants with and without substance abuse problems (<a href="./references#CD012955-bbs2-0072" title="Van den BoschLM , KoeterMW , StijnenT , VerheulR , Van den BrinkW . Sustained efficacy of dialectical behaviour therapy for borderline personality disorder. Behaviour Research and Therapy2005;43(9):1231-41. [DOI: 10.1016/j.brat.2004.09.008] [PMID: 16005708]Van den BoschLM , VerheulR , SchippersGM , Van den BrinkW . Dialectical behavior therapy of borderline patients with and without substance use problems. Implementation and long-term effects. Addictive Behaviors2002;27(6):911-23. [DOI: 10.1016/s0306-4603(02)00293-9] [PMID: 12369475]Van den BoschLMC . Efficacy of dialectical behaviour therapy in the treatment of female borderline patients with and without substance abuse problems: results of a Dutch study [Dialectische gedragstherapie bij Nederlandse vrouwen met een borderline persoonlijkheidsstoornis, met en zonder verslavingsproblemen]. Tijdschrift voor Psychiatrie2005;47(3):127-37. [www.tijdschriftvoorpsychiatrie.nl/assets/articles/articles_1335pdf.pdf]VerheulR , Van den BoschLM , KoeterMW , De RidderMA , StijnenT , Van den BrinkW . Dialectical behaviour therapy for women with borderline personality disorder: 12-month, randomised clinical trial in The Netherlands. British Journal of Psychiatry2003;182:135-40. [DOI: 10.1192/bjp.182.2.135] [PMID: 12562741]">Van den Bosch 2005</a>). In addition, the severity of illness varied between trials, ranging from severe to mild. </p> <p>We also went to great effort to try and obtain unpublished data pertaining to BPD subsamples where the full sample included fewer than 70% of participants with full BPD. We were able to obtain such subsample data from some trials, but in other cases, trial authors did not respond. We do not know why they did not respond, but it is possible that the subsample data we received are biased in a positive way (i.e. being associated with desired findings). </p> </section> <section id="CD012955-sec-0543"> <h3 class="title" id="CD012955-sec-0543">Agreements and disagreements with other studies or reviews</h3> <p>This updated review has a new conclusion compared to the review published in 2012 (<a href="./references#CD012955-bbs2-0442" title="Stoffers-WinterlingJM , VöllmBA , RückerG , TimmerA , HubandN , LiebK . Psychological therapies for people with borderline personality disorder. Cochrane Database of Systematic Reviews2012, Issue 8. Art. No: CD005652. [DOI: 10.1002/14651858.CD005652.pub2]">Stoffers‐Winterling 2012</a>). The 2012 review concluded that there were indications of beneficial effects for psychological therapies for BPD core pathology and associated general psychopathology. The overall findings supported a substantial role for psychotherapy in the treatment of people with BPD. However, the authors also reported that the treatments did not have a very robust evidence base, as there were some concerns regarding the quality of individual trials, and therefore indicated a need for replication trials (<a href="./references#CD012955-bbs2-0442" title="Stoffers-WinterlingJM , VöllmBA , RückerG , TimmerA , HubandN , LiebK . Psychological therapies for people with borderline personality disorder. Cochrane Database of Systematic Reviews2012, Issue 8. Art. No: CD005652. [DOI: 10.1002/14651858.CD005652.pub2]">Stoffers‐Winterling 2012</a>). Following the update of this review, we are now able to state, for the first time, that BPD‐specific psychotherapy seem to be better than usual or control treatments for reducing BPD severity in persons affected by BPD, with effect sizes of clinical relevance. This change in conclusion may result from the following: in 2012, only 28 trials were available for inclusion, and any comparisons were done on treatment approach levels. This means that the review authors did not pool any kind of BPD‐specific treatment, only DBT, MBT and so on. This new review has used updated methods, including a broader search strategy, and thus a new protocol was published in 2018 (<a href="./references#CD012955-bbs2-0443" title="StorebøOJ , Stoffers-WinterlingJM , VöllmBA , KongerslevMT , MattiviJT , KielsholmML , et al. Psychological therapies for people with borderline personality disorder. Cochrane Database of Systematic Reviews2018, Issue 2. Art. No: CD012955. [DOI: 10.1002/14651858.CD012955]">Storebø 2018</a>). What is more, this version is the first to include the required information sizes, for at least some comparisons, on the level of BPD‐specific approaches in general (see <a href="./full#CD012955-tbl-0001">summary of findings Table 1</a>), allowing for drawing conclusions on a much more reliable basis. </p> <p>Our review is in partial agreement with the review by Cristea and colleagues who found that psychotherapy, especially DBT and psychodynamic approaches, are effective for borderline symptoms and related problems (<a href="./references#CD012955-bbs2-0280" title="CristeaIA , GentiliC , CotetCD , PalombaD , BarbuiC , CuijpersP . Efficacy of psychotherapies for borderline personality disorder: a systematic review and meta-analysis. JAMA Psychiatry2017;74(4):319-28. [DOI: doi:10.1001/jamapsychiatry.2016.4287] [PMID: 28249086]">Cristea 2017</a>). Similarly, we found that psychotherapy appears to be more effective than usual treatment at improving BPD symptoms; however, we found no clear differences between the various treatments. We agree that DBT treatments in particular, seem to have a more robust evidence base, due to more clinical trials having been conducted. This discrepancy in conclusions may be due to differences in methodological approach. The study by Cristea and colleagues searched for data in only four databases and included only one publication per trial. They also did not use subsamples of persons with BPD and did not perform an assessment of the overall quality of the evidence. Taken together these limitations suggest that their conclusions may be too optimistic (<a href="./references#CD012955-bbs2-0292" title="FaltinsenEG , KongerslevM , StorebøOJ . Reviews and meta-analyses of psychotherapy efficacy for borderline personality disorder. JAMA Psychiatry2017;74(8):853–4. [DOI: doi:10.1001/jamapsychiatry.2017.1397] [PMID: 28636688]">Faltinsen 2017</a>). </p> <p>Matthijs Oud and colleagues published a review in 2018 (<a href="./references#CD012955-bbs2-0376" title="OudM , ArntzA , HermensMLM , VerhoefR , KendallT . Specialized psychotherapies for adults with borderline personality disorder: a systematic review and meta-analysis. Australian &amp; New Zealand Journal of Psychiatry2018;52(10):949-61. [DOI: 10.1177/0004867418791257] [PMCID: PMC6151959] [PMID: 30091375]">Oud 2018</a>), which investigated the effects of specialised psychotherapy for BPD. In contrast to our review, they focused on four BPD‐specific treatments (DBT, MBT, SFT, and TFP) and only included adult samples, resulting in the inclusion of 20 trials. In line with the findings of this review, they reported moderate‐quality evidence that psychotherapy is effective in reducing overall BPD severity (SMD of −0.59 compared to our SMD of −0.52). We took a broader approach and included all types of psychotherapy conducted in participants of all ages, which resulted in a more complete picture of the area with a larger evidence base (Oud and colleagues included only 321 participants in their analysis of BPD severity compared to 1244 participants in our analysis of the same outcome). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD012955-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram" data-id="CD012955-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/full#CD012955-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD012955-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/full#CD012955-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD012955-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/full#CD012955-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0237"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-FIG-04" target="_blank"><b></b></a></p> </div><img alt="Trial Sequential Analysis on primary outcome: Psychotherapy ‐ borderline symptom severity at end of treatment" data-id="CD012955-fig-0237" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-FIG-04.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-FIG-04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Trial Sequential Analysis on primary outcome: Psychotherapy ‐ borderline symptom severity at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/appendices#CD012955-fig-0237">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-FIG-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0238"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-FIG-05" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison 1: Psychotherapy versus TAU, outcome: 1.1 Primary outcome: BPD symptom severity." data-id="CD012955-fig-0238" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-FIG-05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-FIG-05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Funnel plot of comparison 1: Psychotherapy versus TAU, outcome: 1.1 Primary outcome: BPD symptom severity. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/appendices#CD012955-fig-0238">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-FIG-05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0239"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-FIG-06" target="_blank"><b></b></a></p> </div><img alt="Trial Sequential Analysis on primary outcome: Psychotherapy ‐ self‐harm at end of treatment" data-id="CD012955-fig-0239" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-FIG-06.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-FIG-06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Trial Sequential Analysis on primary outcome: Psychotherapy ‐ self‐harm at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/appendices#CD012955-fig-0239">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-FIG-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0240"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-FIG-07" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 Psychotherapy versus TAU, outcome: 1.3 Primary outcome: self‐harm." data-id="CD012955-fig-0240" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-FIG-07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-FIG-07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 7</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Psychotherapy versus TAU, outcome: 1.3 Primary outcome: self‐harm. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/appendices#CD012955-fig-0240">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-FIG-07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0241"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-FIG-08" target="_blank"><b></b></a></p> </div><img alt="Trial Sequential Analysis on primary outcome: Psychotherapy ‐ suicide‐related outcomes at end of treatment" data-id="CD012955-fig-0241" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-FIG-08.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-FIG-08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 8</div> <div class="figure-caption"> <p>Trial Sequential Analysis on primary outcome: Psychotherapy ‐ suicide‐related outcomes at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/appendices#CD012955-fig-0241">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-FIG-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0242"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-FIG-09" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 Psychotherapy compared with TAU, outcome: 1.5 Primary outcome: suicide‐related outcomes." data-id="CD012955-fig-0242" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-FIG-09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-FIG-09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 9</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Psychotherapy compared with TAU, outcome: 1.5 Primary outcome: suicide‐related outcomes. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/appendices#CD012955-fig-0242">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-FIG-09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0243"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-FIG-10" target="_blank"><b></b></a></p> </div><img alt="Trial Sequential Analysis on primary outcome: Psychotherapy ‐ psychosocial functioning at end of treatment" data-id="CD012955-fig-0243" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-FIG-10.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-FIG-10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 10</div> <div class="figure-caption"> <p>Trial Sequential Analysis on primary outcome: Psychotherapy ‐ psychosocial functioning at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/appendices#CD012955-fig-0243">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-FIG-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0244"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-FIG-11" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 Psychotherapy compared with TAU, outcome: 1.7 Primary outcome: psychosocial functioning." data-id="CD012955-fig-0244" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-FIG-11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-FIG-11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 11</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Psychotherapy compared with TAU, outcome: 1.7 Primary outcome: psychosocial functioning. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/appendices#CD012955-fig-0244">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-FIG-11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0245"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-FIG-12" target="_blank"><b></b></a></p> </div><img alt="Trial Sequential Analysis on secondary outcome: Psychotherapy ‐ depression at end of treatment" data-id="CD012955-fig-0245" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-FIG-12.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-FIG-12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 12</div> <div class="figure-caption"> <p>Trial Sequential Analysis on secondary outcome: Psychotherapy ‐ depression at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/appendices#CD012955-fig-0245">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-FIG-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Psychotherapy vs TAU, Outcome 1: Primary: BPD symptom severity (continuous)" data-id="CD012955-fig-0004" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Psychotherapy vs TAU, Outcome 1: Primary: BPD symptom severity (continuous)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Psychotherapy vs TAU, Outcome 2: Primary: BPD symptom severity (dichotomous), at above 12 months follow‐up" data-id="CD012955-fig-0005" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Psychotherapy vs TAU, Outcome 2: Primary: BPD symptom severity (dichotomous), at above 12 months follow‐up </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Psychotherapy vs TAU, Outcome 3: Primary: self‐harm (continuous)" data-id="CD012955-fig-0006" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Psychotherapy vs TAU, Outcome 3: Primary: self‐harm (continuous)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Psychotherapy vs TAU, Outcome 4: Primary: self‐harm (dichotomous)" data-id="CD012955-fig-0007" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Psychotherapy vs TAU, Outcome 4: Primary: self‐harm (dichotomous)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Psychotherapy vs TAU, Outcome 5: Primary: suicide‐related outcomes (continuous)" data-id="CD012955-fig-0008" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Psychotherapy vs TAU, Outcome 5: Primary: suicide‐related outcomes (continuous)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Psychotherapy vs TAU, Outcome 6: Primary: suicide‐related outcomes (dichotomous)" data-id="CD012955-fig-0009" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Psychotherapy vs TAU, Outcome 6: Primary: suicide‐related outcomes (dichotomous)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Psychotherapy vs TAU, Outcome 7: Primary: psychosocial functioning (continuous)" data-id="CD012955-fig-0010" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Psychotherapy vs TAU, Outcome 7: Primary: psychosocial functioning (continuous)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-001.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Psychotherapy vs TAU, Outcome 8: Secondary: anger (continuous)" data-id="CD012955-fig-0011" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-001.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-001.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: Psychotherapy vs TAU, Outcome 8: Secondary: anger (continuous)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-001.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-001.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Psychotherapy vs TAU, Outcome 9: Secondary: affective instability (continuous)" data-id="CD012955-fig-0012" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-001.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-001.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1: Psychotherapy vs TAU, Outcome 9: Secondary: affective instability (continuous)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-001.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-001.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Psychotherapy vs TAU, Outcome 10: Secondary: chronic feelings of emptiness (continuous)" data-id="CD012955-fig-0013" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-001.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-001.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1: Psychotherapy vs TAU, Outcome 10: Secondary: chronic feelings of emptiness (continuous) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-001.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-001.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Psychotherapy vs TAU, Outcome 11: Secondary: impulsivity (continuous)" data-id="CD012955-fig-0014" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-001.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-001.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1: Psychotherapy vs TAU, Outcome 11: Secondary: impulsivity (continuous)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-001.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-001.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Psychotherapy vs TAU, Outcome 12: Secondary: impulsivity (dichotomous), at end of treatment" data-id="CD012955-fig-0015" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-001.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-001.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1: Psychotherapy vs TAU, Outcome 12: Secondary: impulsivity (dichotomous), at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-001.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-001.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Psychotherapy vs TAU, Outcome 13: Secondary: interpersonal problems (continuous)" data-id="CD012955-fig-0016" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-001.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-001.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1: Psychotherapy vs TAU, Outcome 13: Secondary: interpersonal problems (continuous) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-001.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-001.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Psychotherapy vs TAU, Outcome 14: Secondary: abandonment (continuous)" data-id="CD012955-fig-0017" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-001.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-001.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1: Psychotherapy vs TAU, Outcome 14: Secondary: abandonment (continuous)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-001.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-001.15" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Psychotherapy vs TAU, Outcome 15: Secondary: identity disturbance (continuous)" data-id="CD012955-fig-0018" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-001.15.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-001.15.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1: Psychotherapy vs TAU, Outcome 15: Secondary: identity disturbance (continuous)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-001.15.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-001.16" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Psychotherapy vs TAU, Outcome 16: Secondary: dissociation and psychotic‐like symptoms (continuous)" data-id="CD012955-fig-0019" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-001.16.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-001.16.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1: Psychotherapy vs TAU, Outcome 16: Secondary: dissociation and psychotic‐like symptoms (continuous) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-001.16.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-001.17" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Psychotherapy vs TAU, Outcome 17: Secondary: depression (continuous)" data-id="CD012955-fig-0020" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-001.17.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-001.17.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.17</div> <div class="figure-caption"> <p>Comparison 1: Psychotherapy vs TAU, Outcome 17: Secondary: depression (continuous)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-001.17.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-001.18" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Psychotherapy vs TAU, Outcome 18: Secondary: depression (dichotomous), at end of treatment" data-id="CD012955-fig-0021" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-001.18.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-001.18.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.18</div> <div class="figure-caption"> <p>Comparison 1: Psychotherapy vs TAU, Outcome 18: Secondary: depression (dichotomous), at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-001.18.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-001.19" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Psychotherapy vs TAU, Outcome 19: Secondary: attrition (dichotomous)" data-id="CD012955-fig-0022" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-001.19.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-001.19.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.19</div> <div class="figure-caption"> <p>Comparison 1: Psychotherapy vs TAU, Outcome 19: Secondary: attrition (dichotomous)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-001.19.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-001.20" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Psychotherapy vs TAU, Outcome 20: Secondary: non‐serious adverse effects (dichotomous), at end of treatment" data-id="CD012955-fig-0023" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-001.20.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-001.20.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.20</div> <div class="figure-caption"> <p>Comparison 1: Psychotherapy vs TAU, Outcome 20: Secondary: non‐serious adverse effects (dichotomous), at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-001.20.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-001.21" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Psychotherapy vs TAU, Outcome 21: Secondary: serious adverse effects (dichotomous), at end of treatment" data-id="CD012955-fig-0024" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-001.21.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-001.21.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.21</div> <div class="figure-caption"> <p>Comparison 1: Psychotherapy vs TAU, Outcome 21: Secondary: serious adverse effects (dichotomous), at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-001.21.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Acceptance and commitment therapy (ACT) vs TAU, Outcome 1: Primary: BPD symptom severity (continuous), at end of treatment" data-id="CD012955-fig-0025" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Acceptance and commitment therapy (ACT) vs TAU, Outcome 1: Primary: BPD symptom severity (continuous), at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Acceptance and commitment therapy (ACT) vs TAU, Outcome 2: Secondary: affective instability (continuous), at end of treatment" data-id="CD012955-fig-0026" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Acceptance and commitment therapy (ACT) vs TAU, Outcome 2: Secondary: affective instability (continuous), at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Acceptance and commitment therapy (ACT) vs TAU, Outcome 3: Secondary: depression (continuous), at end of treatment" data-id="CD012955-fig-0027" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Acceptance and commitment therapy (ACT) vs TAU, Outcome 3: Secondary: depression (continuous), at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Acceptance and commitment therapy (ACT) vs TAU, Outcome 4: Secondary: attrition (dichotomous), at end of treatment" data-id="CD012955-fig-0028" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: Acceptance and commitment therapy (ACT) vs TAU, Outcome 4: Secondary: attrition (dichotomous), at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Dialectical behavior therapy (DBT) vs TAU, Outcome 1: Primary: BPD symptom severity (continuous), at end of treatment" data-id="CD012955-fig-0029" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Dialectical behavior therapy (DBT) vs TAU, Outcome 1: Primary: BPD symptom severity (continuous), at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Dialectical behavior therapy (DBT) vs TAU, Outcome 2: Primary, self‐harm (continuous)" data-id="CD012955-fig-0030" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: Dialectical behavior therapy (DBT) vs TAU, Outcome 2: Primary, self‐harm (continuous) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-003.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Dialectical behavior therapy (DBT) vs TAU, Outcome 3: Primary: suicide‐related outcomes (continuous), at end of treatment" data-id="CD012955-fig-0031" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-003.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-003.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3: Dialectical behavior therapy (DBT) vs TAU, Outcome 3: Primary: suicide‐related outcomes (continuous), at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-003.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-003.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Dialectical behavior therapy (DBT) vs TAU, Outcome 4: Primary: suicide‐related outcomes, attempts (dichotomous), at end of treatment" data-id="CD012955-fig-0032" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-003.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-003.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3: Dialectical behavior therapy (DBT) vs TAU, Outcome 4: Primary: suicide‐related outcomes, attempts (dichotomous), at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-003.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-003.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Dialectical behavior therapy (DBT) vs TAU, Outcome 5: Primary: psychosocial functioning (continuous), at end of treatment" data-id="CD012955-fig-0033" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-003.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-003.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3: Dialectical behavior therapy (DBT) vs TAU, Outcome 5: Primary: psychosocial functioning (continuous), at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-003.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-003.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Dialectical behavior therapy (DBT) vs TAU, Outcome 6: Secondary: anger (continuous)" data-id="CD012955-fig-0034" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-003.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-003.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3: Dialectical behavior therapy (DBT) vs TAU, Outcome 6: Secondary: anger (continuous) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-003.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-003.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Dialectical behavior therapy (DBT) vs TAU, Outcome 7: Secondary: affective instability (continuous), at end of treatment" data-id="CD012955-fig-0035" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-003.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-003.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3: Dialectical behavior therapy (DBT) vs TAU, Outcome 7: Secondary: affective instability (continuous), at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-003.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-003.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Dialectical behavior therapy (DBT) vs TAU, Outcome 8: Secondary: chronic feelings of emptiness (continuous), at end of treatment" data-id="CD012955-fig-0036" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-003.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-003.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.8</div> <div class="figure-caption"> <p>Comparison 3: Dialectical behavior therapy (DBT) vs TAU, Outcome 8: Secondary: chronic feelings of emptiness (continuous), at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-003.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-003.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Dialectical behavior therapy (DBT) vs TAU, Outcome 9: Secondary: impulsivity (continuous)" data-id="CD012955-fig-0037" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-003.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-003.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.9</div> <div class="figure-caption"> <p>Comparison 3: Dialectical behavior therapy (DBT) vs TAU, Outcome 9: Secondary: impulsivity (continuous) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-003.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-003.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Dialectical behavior therapy (DBT) vs TAU, Outcome 10: Secondary: interpersonal problems (continuous), at end of treatment" data-id="CD012955-fig-0038" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-003.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-003.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.10</div> <div class="figure-caption"> <p>Comparison 3: Dialectical behavior therapy (DBT) vs TAU, Outcome 10: Secondary: interpersonal problems (continuous), at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-003.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-003.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Dialectical behavior therapy (DBT) vs TAU, Outcome 11: Secondary: dissociation and psychotic‐like symptoms (continuous), at end of treatment" data-id="CD012955-fig-0039" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-003.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-003.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.11</div> <div class="figure-caption"> <p>Comparison 3: Dialectical behavior therapy (DBT) vs TAU, Outcome 11: Secondary: dissociation and psychotic‐like symptoms (continuous), at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-003.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-003.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Dialectical behavior therapy (DBT) vs TAU, Outcome 12: Secondary: depression (continuous)" data-id="CD012955-fig-0040" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-003.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-003.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.12</div> <div class="figure-caption"> <p>Comparison 3: Dialectical behavior therapy (DBT) vs TAU, Outcome 12: Secondary: depression (continuous) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-003.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-003.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Dialectical behavior therapy (DBT) vs TAU, Outcome 13: Secondary: attrition (dichotomous)" data-id="CD012955-fig-0041" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-003.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-003.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.13</div> <div class="figure-caption"> <p>Comparison 3: Dialectical behavior therapy (DBT) vs TAU, Outcome 13: Secondary: attrition (dichotomous) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-003.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-003.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Dialectical behavior therapy (DBT) vs TAU, Outcome 14: Secondary: adverse effects (dichotomous), at end of treatment" data-id="CD012955-fig-0042" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-003.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-003.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.14</div> <div class="figure-caption"> <p>Comparison 3: Dialectical behavior therapy (DBT) vs TAU, Outcome 14: Secondary: adverse effects (dichotomous), at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-003.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-003.15" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Dialectical behavior therapy (DBT) vs TAU, Outcome 15: Secondary: serious adverse effects (dichotomous), at end of treatment" data-id="CD012955-fig-0043" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-003.15.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-003.15.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.15</div> <div class="figure-caption"> <p>Comparison 3: Dialectical behavior therapy (DBT) vs TAU, Outcome 15: Secondary: serious adverse effects (dichotomous), at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-003.15.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-004.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Mentalisation based therapy (MBT) vs TAU, Outcome 1: Primary: BPD symptom severity (continuous)" data-id="CD012955-fig-0044" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-004.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-004.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4: Mentalisation based therapy (MBT) vs TAU, Outcome 1: Primary: BPD symptom severity (continuous) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-004.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-004.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Mentalisation based therapy (MBT) vs TAU, Outcome 2: Primary: self‐harm (continuous), at end of treatment" data-id="CD012955-fig-0045" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-004.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-004.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4: Mentalisation based therapy (MBT) vs TAU, Outcome 2: Primary: self‐harm (continuous), at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-004.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-004.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Mentalisation based therapy (MBT) vs TAU, Outcome 3: Primary: self‐harm (dichotomous)" data-id="CD012955-fig-0046" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-004.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-004.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4: Mentalisation based therapy (MBT) vs TAU, Outcome 3: Primary: self‐harm (dichotomous) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-004.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-004.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Mentalisation based therapy (MBT) vs TAU, Outcome 4: Primary: suicide‐related outcomes (dichotomous)" data-id="CD012955-fig-0047" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-004.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-004.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4: Mentalisation based therapy (MBT) vs TAU, Outcome 4: Primary: suicide‐related outcomes (dichotomous) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-004.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-004.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Mentalisation based therapy (MBT) vs TAU, Outcome 5: Primary: psychosocial functioning (continuous)" data-id="CD012955-fig-0048" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-004.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-004.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4: Mentalisation based therapy (MBT) vs TAU, Outcome 5: Primary: psychosocial functioning (continuous) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-004.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-004.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Mentalisation based therapy (MBT) vs TAU, Outcome 6: Secondary: interpersonal problems (continuous)" data-id="CD012955-fig-0049" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-004.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-004.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.6</div> <div class="figure-caption"> <p>Comparison 4: Mentalisation based therapy (MBT) vs TAU, Outcome 6: Secondary: interpersonal problems (continuous) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-004.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-004.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Mentalisation based therapy (MBT) vs TAU, Outcome 7: Secondary: depression (continuous)" data-id="CD012955-fig-0050" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-004.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-004.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.7</div> <div class="figure-caption"> <p>Comparison 4: Mentalisation based therapy (MBT) vs TAU, Outcome 7: Secondary: depression (continuous) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-004.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-004.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Mentalisation based therapy (MBT) vs TAU, Outcome 8: Secondary: depression (dichotomous), at end of treatment" data-id="CD012955-fig-0051" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-004.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-004.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.8</div> <div class="figure-caption"> <p>Comparison 4: Mentalisation based therapy (MBT) vs TAU, Outcome 8: Secondary: depression (dichotomous), at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-004.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-004.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Mentalisation based therapy (MBT) vs TAU, Outcome 9: Secondary: attrition (dichotomous), at end of treatment" data-id="CD012955-fig-0052" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-004.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-004.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.9</div> <div class="figure-caption"> <p>Comparison 4: Mentalisation based therapy (MBT) vs TAU, Outcome 9: Secondary: attrition (dichotomous), at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-004.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0053"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-004.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Mentalisation based therapy (MBT) vs TAU, Outcome 10: Secondary: adverse effects (dichotomous), at end of treatment" data-id="CD012955-fig-0053" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-004.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-004.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.10</div> <div class="figure-caption"> <p>Comparison 4: Mentalisation based therapy (MBT) vs TAU, Outcome 10: Secondary: adverse effects (dichotomous), at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0053">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-004.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0054"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-004.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Mentalisation based therapy (MBT) vs TAU, Outcome 11: Mentalisation‐based treatment for eating disorders (MBT‐ED) versus specialist supportive clinical management (SSCM‐ED) (generic inverse variance)" data-id="CD012955-fig-0054" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-004.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-004.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.11</div> <div class="figure-caption"> <p>Comparison 4: Mentalisation based therapy (MBT) vs TAU, Outcome 11: Mentalisation‐based treatment for eating disorders (MBT‐ED) versus specialist supportive clinical management (SSCM‐ED) (generic inverse variance) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0054">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-004.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0055"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-005.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Cognitive behavioural therapy (CBT) and related treatments vs TAU, Outcome 1: Primary: BPD symptom severity (continuous)" data-id="CD012955-fig-0055" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-005.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-005.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5: Cognitive behavioural therapy (CBT) and related treatments vs TAU, Outcome 1: Primary: BPD symptom severity (continuous) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0055">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-005.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0056"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-005.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Cognitive behavioural therapy (CBT) and related treatments vs TAU, Outcome 2: Primary: BPD symptom severity (dichotomous), at above 12 months follow‐up" data-id="CD012955-fig-0056" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-005.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-005.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5: Cognitive behavioural therapy (CBT) and related treatments vs TAU, Outcome 2: Primary: BPD symptom severity (dichotomous), at above 12 months follow‐up </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0056">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-005.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0057"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-005.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Cognitive behavioural therapy (CBT) and related treatments vs TAU, Outcome 3: Primary: self‐harm (continuous)" data-id="CD012955-fig-0057" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-005.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-005.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5: Cognitive behavioural therapy (CBT) and related treatments vs TAU, Outcome 3: Primary: self‐harm (continuous) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0057">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-005.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0058"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-005.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Cognitive behavioural therapy (CBT) and related treatments vs TAU, Outcome 4: Primary: self‐harm (dichotomous), at end of treatment" data-id="CD012955-fig-0058" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-005.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-005.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5: Cognitive behavioural therapy (CBT) and related treatments vs TAU, Outcome 4: Primary: self‐harm (dichotomous), at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0058">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-005.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0059"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-005.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Cognitive behavioural therapy (CBT) and related treatments vs TAU, Outcome 5: Primary: suicide‐related outcomes (continuous)" data-id="CD012955-fig-0059" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-005.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-005.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.5</div> <div class="figure-caption"> <p>Comparison 5: Cognitive behavioural therapy (CBT) and related treatments vs TAU, Outcome 5: Primary: suicide‐related outcomes (continuous) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0059">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-005.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0060"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-005.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Cognitive behavioural therapy (CBT) and related treatments vs TAU, Outcome 6: Primary: psychosocial functioning (continuous)" data-id="CD012955-fig-0060" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-005.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-005.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.6</div> <div class="figure-caption"> <p>Comparison 5: Cognitive behavioural therapy (CBT) and related treatments vs TAU, Outcome 6: Primary: psychosocial functioning (continuous) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0060">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-005.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0061"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-005.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Cognitive behavioural therapy (CBT) and related treatments vs TAU, Outcome 7: Secondary: interpersonal problems (continuous)" data-id="CD012955-fig-0061" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-005.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-005.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.7</div> <div class="figure-caption"> <p>Comparison 5: Cognitive behavioural therapy (CBT) and related treatments vs TAU, Outcome 7: Secondary: interpersonal problems (continuous) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0061">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-005.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0062"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-005.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Cognitive behavioural therapy (CBT) and related treatments vs TAU, Outcome 8: Secondary: dissociation and psychotic‐like symptoms (continuous)" data-id="CD012955-fig-0062" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-005.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-005.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.8</div> <div class="figure-caption"> <p>Comparison 5: Cognitive behavioural therapy (CBT) and related treatments vs TAU, Outcome 8: Secondary: dissociation and psychotic‐like symptoms (continuous) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0062">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-005.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0063"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-005.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Cognitive behavioural therapy (CBT) and related treatments vs TAU, Outcome 9: Secondary: depression (continuous)" data-id="CD012955-fig-0063" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-005.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-005.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.9</div> <div class="figure-caption"> <p>Comparison 5: Cognitive behavioural therapy (CBT) and related treatments vs TAU, Outcome 9: Secondary: depression (continuous) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0063">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-005.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0064"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-005.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Cognitive behavioural therapy (CBT) and related treatments vs TAU, Outcome 10: Secondary: attrition (dichotomous), at end of treatment" data-id="CD012955-fig-0064" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-005.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-005.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.10</div> <div class="figure-caption"> <p>Comparison 5: Cognitive behavioural therapy (CBT) and related treatments vs TAU, Outcome 10: Secondary: attrition (dichotomous), at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0064">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-005.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0065"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-005.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Cognitive behavioural therapy (CBT) and related treatments vs TAU, Outcome 11: Secondary: adverse effects (dichotomous), at end of treatment" data-id="CD012955-fig-0065" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-005.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-005.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.11</div> <div class="figure-caption"> <p>Comparison 5: Cognitive behavioural therapy (CBT) and related treatments vs TAU, Outcome 11: Secondary: adverse effects (dichotomous), at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0065">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-005.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0066"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-006.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Psychodynamic psychotherapy vs TAU, Outcome 1: Primary: BPD symptom severity (continuous)" data-id="CD012955-fig-0066" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-006.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-006.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6: Psychodynamic psychotherapy vs TAU, Outcome 1: Primary: BPD symptom severity (continuous) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0066">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-006.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0067"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-006.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Psychodynamic psychotherapy vs TAU, Outcome 2: Primary: self‐harm (continuous)" data-id="CD012955-fig-0067" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-006.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-006.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6: Psychodynamic psychotherapy vs TAU, Outcome 2: Primary: self‐harm (continuous)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0067">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-006.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0068"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-006.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Psychodynamic psychotherapy vs TAU, Outcome 3: Primary: suicide‐related outcomes (continuous)" data-id="CD012955-fig-0068" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-006.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-006.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.3</div> <div class="figure-caption"> <p>Comparison 6: Psychodynamic psychotherapy vs TAU, Outcome 3: Primary: suicide‐related outcomes (continuous) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0068">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-006.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0069"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-006.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Psychodynamic psychotherapy vs TAU, Outcome 4: Primary: psychosocial functioning (continuous)" data-id="CD012955-fig-0069" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-006.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-006.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.4</div> <div class="figure-caption"> <p>Comparison 6: Psychodynamic psychotherapy vs TAU, Outcome 4: Primary: psychosocial functioning (continuous) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0069">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-006.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0070"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-006.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Psychodynamic psychotherapy vs TAU, Outcome 5: Secondary: anger (continuous)" data-id="CD012955-fig-0070" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-006.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-006.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.5</div> <div class="figure-caption"> <p>Comparison 6: Psychodynamic psychotherapy vs TAU, Outcome 5: Secondary: anger (continuous)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0070">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-006.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0071"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-006.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Psychodynamic psychotherapy vs TAU, Outcome 6: Secondary: affective instability (continuous)" data-id="CD012955-fig-0071" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-006.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-006.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.6</div> <div class="figure-caption"> <p>Comparison 6: Psychodynamic psychotherapy vs TAU, Outcome 6: Secondary: affective instability (continuous) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0071">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-006.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0072"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-006.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Psychodynamic psychotherapy vs TAU, Outcome 7: Secondary: chronic feelings of emptiness (continuous)" data-id="CD012955-fig-0072" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-006.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-006.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.7</div> <div class="figure-caption"> <p>Comparison 6: Psychodynamic psychotherapy vs TAU, Outcome 7: Secondary: chronic feelings of emptiness (continuous) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0072">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-006.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0073"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-006.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Psychodynamic psychotherapy vs TAU, Outcome 8: Secondary: impulsivity (continuous)" data-id="CD012955-fig-0073" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-006.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-006.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.8</div> <div class="figure-caption"> <p>Comparison 6: Psychodynamic psychotherapy vs TAU, Outcome 8: Secondary: impulsivity (continuous) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0073">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-006.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0074"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-006.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Psychodynamic psychotherapy vs TAU, Outcome 9: Secondary: interpersonal problems (continuous)" data-id="CD012955-fig-0074" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-006.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-006.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.9</div> <div class="figure-caption"> <p>Comparison 6: Psychodynamic psychotherapy vs TAU, Outcome 9: Secondary: interpersonal problems (continuous) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0074">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-006.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0075"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-006.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Psychodynamic psychotherapy vs TAU, Outcome 10: Secondary: abandonment (continuous)" data-id="CD012955-fig-0075" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-006.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-006.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.10</div> <div class="figure-caption"> <p>Comparison 6: Psychodynamic psychotherapy vs TAU, Outcome 10: Secondary: abandonment (continuous) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0075">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-006.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0076"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-006.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Psychodynamic psychotherapy vs TAU, Outcome 11: Secondary: identity disturbance (continuous)" data-id="CD012955-fig-0076" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-006.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-006.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.11</div> <div class="figure-caption"> <p>Comparison 6: Psychodynamic psychotherapy vs TAU, Outcome 11: Secondary: identity disturbance (continuous) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0076">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-006.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0077"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-006.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Psychodynamic psychotherapy vs TAU, Outcome 12: Secondary: dissociation and psychotic‐like symptoms (continuous)" data-id="CD012955-fig-0077" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-006.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-006.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.12</div> <div class="figure-caption"> <p>Comparison 6: Psychodynamic psychotherapy vs TAU, Outcome 12: Secondary: dissociation and psychotic‐like symptoms (continuous) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0077">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-006.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0078"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-006.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Psychodynamic psychotherapy vs TAU, Outcome 13: Secondary: depression (continuous)" data-id="CD012955-fig-0078" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-006.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-006.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.13</div> <div class="figure-caption"> <p>Comparison 6: Psychodynamic psychotherapy vs TAU, Outcome 13: Secondary: depression (continuous) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0078">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-006.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0079"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-006.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Psychodynamic psychotherapy vs TAU, Outcome 14: Secondary: attrition (dichotomous), at end of treatment" data-id="CD012955-fig-0079" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-006.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-006.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.14</div> <div class="figure-caption"> <p>Comparison 6: Psychodynamic psychotherapy vs TAU, Outcome 14: Secondary: attrition (dichotomous), at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0079">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-006.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0080"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-007.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Schema‐focused therapy (SFT) vs TAU, Outcome 1: Primary: BPD symptom severity (continuous), at end of treatment" data-id="CD012955-fig-0080" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-007.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-007.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7: Schema‐focused therapy (SFT) vs TAU, Outcome 1: Primary: BPD symptom severity (continuous), at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0080">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-007.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0081"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-007.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Schema‐focused therapy (SFT) vs TAU, Outcome 2: Primary: psychosocial functioning (continuous), at end of treatment" data-id="CD012955-fig-0081" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-007.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-007.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.2</div> <div class="figure-caption"> <p>Comparison 7: Schema‐focused therapy (SFT) vs TAU, Outcome 2: Primary: psychosocial functioning (continuous), at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0081">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-007.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0082"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-007.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Schema‐focused therapy (SFT) vs TAU, Outcome 3: Secondary: affective instability (continuous), at end of treatment" data-id="CD012955-fig-0082" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-007.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-007.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.3</div> <div class="figure-caption"> <p>Comparison 7: Schema‐focused therapy (SFT) vs TAU, Outcome 3: Secondary: affective instability (continuous), at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0082">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-007.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0083"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-007.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Schema‐focused therapy (SFT) vs TAU, Outcome 4: Secondary: impulsivity (continuous), at end of treatment" data-id="CD012955-fig-0083" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-007.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-007.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.4</div> <div class="figure-caption"> <p>Comparison 7: Schema‐focused therapy (SFT) vs TAU, Outcome 4: Secondary: impulsivity (continuous), at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0083">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-007.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0084"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-007.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Schema‐focused therapy (SFT) vs TAU, Outcome 5: Secondary: interpersonal problems (continuous), at end of treatment" data-id="CD012955-fig-0084" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-007.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-007.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.5</div> <div class="figure-caption"> <p>Comparison 7: Schema‐focused therapy (SFT) vs TAU, Outcome 5: Secondary: interpersonal problems (continuous), at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0084">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-007.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0085"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-007.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Schema‐focused therapy (SFT) vs TAU, Outcome 6: Secondary: dissociation and psychotic‐like symptoms (continuous), at end of treatment" data-id="CD012955-fig-0085" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-007.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-007.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.6</div> <div class="figure-caption"> <p>Comparison 7: Schema‐focused therapy (SFT) vs TAU, Outcome 6: Secondary: dissociation and psychotic‐like symptoms (continuous), at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0085">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-007.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0086"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-007.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Schema‐focused therapy (SFT) vs TAU, Outcome 7: Secondary: attrition (dichotomous), at end of treatment" data-id="CD012955-fig-0086" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-007.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-007.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.7</div> <div class="figure-caption"> <p>Comparison 7: Schema‐focused therapy (SFT) vs TAU, Outcome 7: Secondary: attrition (dichotomous), at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0086">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-007.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0087"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-008.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Systems training for emotional predictability and problem solving (STEPPS) vs TAU, Outcome 1: Primary: BPD symptom severity (continuous), at end of treatment" data-id="CD012955-fig-0087" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-008.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-008.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8: Systems training for emotional predictability and problem solving (STEPPS) vs TAU, Outcome 1: Primary: BPD symptom severity (continuous), at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0087">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-008.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0088"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-008.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Systems training for emotional predictability and problem solving (STEPPS) vs TAU, Outcome 2: Primary: self‐harm (dichtomous), at end of treatment" data-id="CD012955-fig-0088" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-008.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-008.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.2</div> <div class="figure-caption"> <p>Comparison 8: Systems training for emotional predictability and problem solving (STEPPS) vs TAU, Outcome 2: Primary: self‐harm (dichtomous), at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0088">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-008.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0089"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-008.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Systems training for emotional predictability and problem solving (STEPPS) vs TAU, Outcome 3: Primary: psychosocial functioning (continuous)" data-id="CD012955-fig-0089" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-008.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-008.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.3</div> <div class="figure-caption"> <p>Comparison 8: Systems training for emotional predictability and problem solving (STEPPS) vs TAU, Outcome 3: Primary: psychosocial functioning (continuous) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0089">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-008.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0090"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-008.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Systems training for emotional predictability and problem solving (STEPPS) vs TAU, Outcome 4: Secondary: affective instability (continuous), at end of treatment" data-id="CD012955-fig-0090" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-008.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-008.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.4</div> <div class="figure-caption"> <p>Comparison 8: Systems training for emotional predictability and problem solving (STEPPS) vs TAU, Outcome 4: Secondary: affective instability (continuous), at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0090">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-008.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0091"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-008.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Systems training for emotional predictability and problem solving (STEPPS) vs TAU, Outcome 5: Secondary: impulsivity (continuous), at end of treatment" data-id="CD012955-fig-0091" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-008.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-008.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.5</div> <div class="figure-caption"> <p>Comparison 8: Systems training for emotional predictability and problem solving (STEPPS) vs TAU, Outcome 5: Secondary: impulsivity (continuous), at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0091">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-008.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0092"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-008.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Systems training for emotional predictability and problem solving (STEPPS) vs TAU, Outcome 6: Secondary: impulsivity (dichotomous), at end of treatment" data-id="CD012955-fig-0092" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-008.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-008.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.6</div> <div class="figure-caption"> <p>Comparison 8: Systems training for emotional predictability and problem solving (STEPPS) vs TAU, Outcome 6: Secondary: impulsivity (dichotomous), at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0092">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-008.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0093"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-008.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Systems training for emotional predictability and problem solving (STEPPS) vs TAU, Outcome 7: Secondary: interpersonal problems (continuous), at end of treatment" data-id="CD012955-fig-0093" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-008.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-008.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.7</div> <div class="figure-caption"> <p>Comparison 8: Systems training for emotional predictability and problem solving (STEPPS) vs TAU, Outcome 7: Secondary: interpersonal problems (continuous), at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0093">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-008.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0094"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-008.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Systems training for emotional predictability and problem solving (STEPPS) vs TAU, Outcome 8: Secondary: dissociation and psychotic‐like symptoms (continuous), at end of treatment" data-id="CD012955-fig-0094" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-008.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-008.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.8</div> <div class="figure-caption"> <p>Comparison 8: Systems training for emotional predictability and problem solving (STEPPS) vs TAU, Outcome 8: Secondary: dissociation and psychotic‐like symptoms (continuous), at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0094">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-008.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0095"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-008.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Systems training for emotional predictability and problem solving (STEPPS) vs TAU, Outcome 9: Secondary: depression (continuous), at end of treatment" data-id="CD012955-fig-0095" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-008.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-008.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.9</div> <div class="figure-caption"> <p>Comparison 8: Systems training for emotional predictability and problem solving (STEPPS) vs TAU, Outcome 9: Secondary: depression (continuous), at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0095">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-008.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0096"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-008.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Systems training for emotional predictability and problem solving (STEPPS) vs TAU, Outcome 10: Secondary: attrition (dichotomous), at end of treatment" data-id="CD012955-fig-0096" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-008.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-008.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.10</div> <div class="figure-caption"> <p>Comparison 8: Systems training for emotional predictability and problem solving (STEPPS) vs TAU, Outcome 10: Secondary: attrition (dichotomous), at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0096">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-008.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0097"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-009.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Cognitive analytic therapy (CAT) vs TAU, Outcome 1: Primary: suicide‐related outcomes (continuous)" data-id="CD012955-fig-0097" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-009.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-009.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.1</div> <div class="figure-caption"> <p>Comparison 9: Cognitive analytic therapy (CAT) vs TAU, Outcome 1: Primary: suicide‐related outcomes (continuous) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0097">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-009.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0098"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-009.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Cognitive analytic therapy (CAT) vs TAU, Outcome 2: Primary: psychosocial functioning (continuous)" data-id="CD012955-fig-0098" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-009.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-009.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.2</div> <div class="figure-caption"> <p>Comparison 9: Cognitive analytic therapy (CAT) vs TAU, Outcome 2: Primary: psychosocial functioning (continuous) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0098">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-009.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0099"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-009.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Cognitive analytic therapy (CAT) vs TAU, Outcome 3: Secondary: anger (continuous)" data-id="CD012955-fig-0099" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-009.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-009.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.3</div> <div class="figure-caption"> <p>Comparison 9: Cognitive analytic therapy (CAT) vs TAU, Outcome 3: Secondary: anger (continuous) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0099">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-009.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0100"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-009.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Cognitive analytic therapy (CAT) vs TAU, Outcome 4: Secondary: dissociation and psychotic‐like symptoms (continuous)" data-id="CD012955-fig-0100" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-009.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-009.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.4</div> <div class="figure-caption"> <p>Comparison 9: Cognitive analytic therapy (CAT) vs TAU, Outcome 4: Secondary: dissociation and psychotic‐like symptoms (continuous) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0100">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-009.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0101"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-009.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Cognitive analytic therapy (CAT) vs TAU, Outcome 5: Secondary: depression (continuous)" data-id="CD012955-fig-0101" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-009.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-009.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.5</div> <div class="figure-caption"> <p>Comparison 9: Cognitive analytic therapy (CAT) vs TAU, Outcome 5: Secondary: depression (continuous) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0101">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-009.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0102"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-009.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Cognitive analytic therapy (CAT) vs TAU, Outcome 6: Secondary: attrition (dichotomous), at end of treatment" data-id="CD012955-fig-0102" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-009.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-009.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.6</div> <div class="figure-caption"> <p>Comparison 9: Cognitive analytic therapy (CAT) vs TAU, Outcome 6: Secondary: attrition (dichotomous), at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0102">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-009.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0103"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-010.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: Motivation feedback (MF) vs TAU, Outcome 1: Primary: psychosocial functioning, at end of treatment" data-id="CD012955-fig-0103" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-010.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-010.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.1</div> <div class="figure-caption"> <p>Comparison 10: Motivation feedback (MF) vs TAU, Outcome 1: Primary: psychosocial functioning, at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0103">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-010.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0104"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-011.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: Psychoeducation vs TAU, Outcome 1: Secondary: depression (continuous), at end of treatment" data-id="CD012955-fig-0104" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-011.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-011.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.1</div> <div class="figure-caption"> <p>Comparison 11: Psychoeducation vs TAU, Outcome 1: Secondary: depression (continuous), at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0104">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-011.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0105"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-011.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: Psychoeducation vs TAU, Outcome 2: Secondary: attrition (dichotomous), at end of treatment" data-id="CD012955-fig-0105" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-011.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-011.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.2</div> <div class="figure-caption"> <p>Comparison 11: Psychoeducation vs TAU, Outcome 2: Secondary: attrition (dichotomous), at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0105">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-011.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0106"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-012.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 12: Transference‐focused psychotherapy (TFP) vs TAU, Outcome 1: Primary: BPD symptom severity (continuous), at end of treatment" data-id="CD012955-fig-0106" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-012.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-012.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.1</div> <div class="figure-caption"> <p>Comparison 12: Transference‐focused psychotherapy (TFP) vs TAU, Outcome 1: Primary: BPD symptom severity (continuous), at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0106">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-012.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0107"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-012.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 12: Transference‐focused psychotherapy (TFP) vs TAU, Outcome 2: Primary: self‐harm (dichotomous), at end of treatment" data-id="CD012955-fig-0107" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-012.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-012.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.2</div> <div class="figure-caption"> <p>Comparison 12: Transference‐focused psychotherapy (TFP) vs TAU, Outcome 2: Primary: self‐harm (dichotomous), at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0107">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-012.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0108"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-012.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 12: Transference‐focused psychotherapy (TFP) vs TAU, Outcome 3: Primary: suicide‐related outcomes (dichotomous), at end of treatment" data-id="CD012955-fig-0108" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-012.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-012.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.3</div> <div class="figure-caption"> <p>Comparison 12: Transference‐focused psychotherapy (TFP) vs TAU, Outcome 3: Primary: suicide‐related outcomes (dichotomous), at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0108">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-012.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0109"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-012.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 12: Transference‐focused psychotherapy (TFP) vs TAU, Outcome 4: Primary: psychosocial functioning (continuous), at end of treatment" data-id="CD012955-fig-0109" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-012.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-012.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.4</div> <div class="figure-caption"> <p>Comparison 12: Transference‐focused psychotherapy (TFP) vs TAU, Outcome 4: Primary: psychosocial functioning (continuous), at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0109">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-012.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0110"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-012.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 12: Transference‐focused psychotherapy (TFP) vs TAU, Outcome 5: Secondary: depression (continuous), at end of treatment" data-id="CD012955-fig-0110" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-012.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-012.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.5</div> <div class="figure-caption"> <p>Comparison 12: Transference‐focused psychotherapy (TFP) vs TAU, Outcome 5: Secondary: depression (continuous), at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0110">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-012.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0111"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-012.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 12: Transference‐focused psychotherapy (TFP) vs TAU, Outcome 6: Secondary: attrition (dichotomous), at end of treatment" data-id="CD012955-fig-0111" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-012.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-012.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.6</div> <div class="figure-caption"> <p>Comparison 12: Transference‐focused psychotherapy (TFP) vs TAU, Outcome 6: Secondary: attrition (dichotomous), at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0111">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-012.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0112"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-013.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 13: Once‐only interventions (individual setting) vs TAU, Outcome 1: Primary: self‐harm (continuous), at end of treatment" data-id="CD012955-fig-0112" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-013.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-013.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.1</div> <div class="figure-caption"> <p>Comparison 13: Once‐only interventions (individual setting) vs TAU, Outcome 1: Primary: self‐harm (continuous), at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0112">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-013.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0113"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-013.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 13: Once‐only interventions (individual setting) vs TAU, Outcome 2: Primary: psychosocial functioning (continuous), at end of treatment" data-id="CD012955-fig-0113" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-013.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-013.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.2</div> <div class="figure-caption"> <p>Comparison 13: Once‐only interventions (individual setting) vs TAU, Outcome 2: Primary: psychosocial functioning (continuous), at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0113">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-013.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0114"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-013.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 13: Once‐only interventions (individual setting) vs TAU, Outcome 3: Secondary: depression (continuous), at end of treatment" data-id="CD012955-fig-0114" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-013.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-013.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.3</div> <div class="figure-caption"> <p>Comparison 13: Once‐only interventions (individual setting) vs TAU, Outcome 3: Secondary: depression (continuous), at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0114">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-013.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0115"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-013.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 13: Once‐only interventions (individual setting) vs TAU, Outcome 4: Secondary: attrition (dichotomous), at end of treatment" data-id="CD012955-fig-0115" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-013.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-013.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.4</div> <div class="figure-caption"> <p>Comparison 13: Once‐only interventions (individual setting) vs TAU, Outcome 4: Secondary: attrition (dichotomous), at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0115">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-013.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0116"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-014.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 14: Eclectic treatments vs TAU, Outcome 1: Primary: BPD symptom severity (continuous), at end of treatment" data-id="CD012955-fig-0116" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-014.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-014.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.1</div> <div class="figure-caption"> <p>Comparison 14: Eclectic treatments vs TAU, Outcome 1: Primary: BPD symptom severity (continuous), at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0116">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-014.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0117"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-014.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 14: Eclectic treatments vs TAU, Outcome 2: Primary: self‐harm (continuous), at end of treatment" data-id="CD012955-fig-0117" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-014.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-014.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.2</div> <div class="figure-caption"> <p>Comparison 14: Eclectic treatments vs TAU, Outcome 2: Primary: self‐harm (continuous), at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0117">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-014.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0118"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-014.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 14: Eclectic treatments vs TAU, Outcome 3: Primary: suicide‐related outcomes (continuous), at end of treatment" data-id="CD012955-fig-0118" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-014.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-014.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.3</div> <div class="figure-caption"> <p>Comparison 14: Eclectic treatments vs TAU, Outcome 3: Primary: suicide‐related outcomes (continuous), at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0118">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-014.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0119"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-014.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 14: Eclectic treatments vs TAU, Outcome 4: Primary: psychosocial functioning (continuous)" data-id="CD012955-fig-0119" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-014.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-014.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.4</div> <div class="figure-caption"> <p>Comparison 14: Eclectic treatments vs TAU, Outcome 4: Primary: psychosocial functioning (continuous) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0119">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-014.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0120"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-014.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 14: Eclectic treatments vs TAU, Outcome 5: Secondary: anger (continuous), at end of treatment" data-id="CD012955-fig-0120" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-014.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-014.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.5</div> <div class="figure-caption"> <p>Comparison 14: Eclectic treatments vs TAU, Outcome 5: Secondary: anger (continuous), at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0120">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-014.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0121"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-014.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 14: Eclectic treatments vs TAU, Outcome 6: Secondary: affective instability (continuous), at end of treatment" data-id="CD012955-fig-0121" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-014.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-014.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.6</div> <div class="figure-caption"> <p>Comparison 14: Eclectic treatments vs TAU, Outcome 6: Secondary: affective instability (continuous), at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0121">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-014.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0122"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-014.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 14: Eclectic treatments vs TAU, Outcome 7: Secondary: chronic feelings of emptiness (continuous), at end of treatment" data-id="CD012955-fig-0122" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-014.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-014.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.7</div> <div class="figure-caption"> <p>Comparison 14: Eclectic treatments vs TAU, Outcome 7: Secondary: chronic feelings of emptiness (continuous), at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0122">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-014.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0123"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-014.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 14: Eclectic treatments vs TAU, Outcome 8: Secondary: impulsivity (continuous), at end of treatment" data-id="CD012955-fig-0123" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-014.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-014.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.8</div> <div class="figure-caption"> <p>Comparison 14: Eclectic treatments vs TAU, Outcome 8: Secondary: impulsivity (continuous), at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0123">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-014.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0124"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-014.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 14: Eclectic treatments vs TAU, Outcome 9: Secondary: interpersonal problems (continuous), at end of treatment" data-id="CD012955-fig-0124" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-014.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-014.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.9</div> <div class="figure-caption"> <p>Comparison 14: Eclectic treatments vs TAU, Outcome 9: Secondary: interpersonal problems (continuous), at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0124">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-014.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0125"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-014.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 14: Eclectic treatments vs TAU, Outcome 10: Secondary: abandonment (continuous), at end of treatment" data-id="CD012955-fig-0125" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-014.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-014.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.10</div> <div class="figure-caption"> <p>Comparison 14: Eclectic treatments vs TAU, Outcome 10: Secondary: abandonment (continuous), at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0125">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-014.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0126"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-014.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 14: Eclectic treatments vs TAU, Outcome 11: Secondary: identity disturbance (continuous), at end of treatment" data-id="CD012955-fig-0126" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-014.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-014.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.11</div> <div class="figure-caption"> <p>Comparison 14: Eclectic treatments vs TAU, Outcome 11: Secondary: identity disturbance (continuous), at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0126">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-014.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0127"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-014.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 14: Eclectic treatments vs TAU, Outcome 12: Secondary: depression (continuous), at end of treatment" data-id="CD012955-fig-0127" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-014.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-014.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.12</div> <div class="figure-caption"> <p>Comparison 14: Eclectic treatments vs TAU, Outcome 12: Secondary: depression (continuous), at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0127">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-014.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0128"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-014.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 14: Eclectic treatments vs TAU, Outcome 13: Secondary: attrition (dichotomuous), at end of treatment" data-id="CD012955-fig-0128" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-014.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-014.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.13</div> <div class="figure-caption"> <p>Comparison 14: Eclectic treatments vs TAU, Outcome 13: Secondary: attrition (dichotomuous), at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0128">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-014.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0129"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-014.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 14: Eclectic treatments vs TAU, Outcome 14: Secondary: adverse effects (dichotomous), at end of treatment" data-id="CD012955-fig-0129" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-014.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-014.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.14</div> <div class="figure-caption"> <p>Comparison 14: Eclectic treatments vs TAU, Outcome 14: Secondary: adverse effects (dichotomous), at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0129">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-014.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0130"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-015.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 15: Psychotherapy vs waiting list or no treatment, Outcome 1: Primary: BPD symptom severity (continuous), at end of treatment" data-id="CD012955-fig-0130" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-015.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-015.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.1</div> <div class="figure-caption"> <p>Comparison 15: Psychotherapy vs waiting list or no treatment, Outcome 1: Primary: BPD symptom severity (continuous), at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0130">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-015.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0131"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-015.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 15: Psychotherapy vs waiting list or no treatment, Outcome 2: Primary: self‐harm (continuous), at end of treatment" data-id="CD012955-fig-0131" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-015.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-015.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.2</div> <div class="figure-caption"> <p>Comparison 15: Psychotherapy vs waiting list or no treatment, Outcome 2: Primary: self‐harm (continuous), at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0131">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-015.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0132"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-015.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 15: Psychotherapy vs waiting list or no treatment, Outcome 3: Primary: suicide‐related outcomes (continuous), at end of treatment" data-id="CD012955-fig-0132" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-015.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-015.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.3</div> <div class="figure-caption"> <p>Comparison 15: Psychotherapy vs waiting list or no treatment, Outcome 3: Primary: suicide‐related outcomes (continuous), at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0132">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-015.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0133"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-015.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 15: Psychotherapy vs waiting list or no treatment, Outcome 4: Primary: psychosocial functioning (continuous)" data-id="CD012955-fig-0133" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-015.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-015.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.4</div> <div class="figure-caption"> <p>Comparison 15: Psychotherapy vs waiting list or no treatment, Outcome 4: Primary: psychosocial functioning (continuous) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0133">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-015.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0134"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-015.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 15: Psychotherapy vs waiting list or no treatment, Outcome 5: Secondary: anger (continuous), at end of treatment" data-id="CD012955-fig-0134" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-015.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-015.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.5</div> <div class="figure-caption"> <p>Comparison 15: Psychotherapy vs waiting list or no treatment, Outcome 5: Secondary: anger (continuous), at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0134">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-015.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0135"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-015.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 15: Psychotherapy vs waiting list or no treatment, Outcome 6: Secondary: affective instability (continuous)" data-id="CD012955-fig-0135" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-015.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-015.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.6</div> <div class="figure-caption"> <p>Comparison 15: Psychotherapy vs waiting list or no treatment, Outcome 6: Secondary: affective instability (continuous) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0135">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-015.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0136"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-015.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 15: Psychotherapy vs waiting list or no treatment, Outcome 7: Secondary: chronic feelings of emptiness (continuous), at end of treatment" data-id="CD012955-fig-0136" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-015.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-015.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.7</div> <div class="figure-caption"> <p>Comparison 15: Psychotherapy vs waiting list or no treatment, Outcome 7: Secondary: chronic feelings of emptiness (continuous), at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0136">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-015.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0137"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-015.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 15: Psychotherapy vs waiting list or no treatment, Outcome 8: Secondary: impulsivity (continuous)" data-id="CD012955-fig-0137" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-015.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-015.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.8</div> <div class="figure-caption"> <p>Comparison 15: Psychotherapy vs waiting list or no treatment, Outcome 8: Secondary: impulsivity (continuous) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0137">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-015.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0138"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-015.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 15: Psychotherapy vs waiting list or no treatment, Outcome 9: Secondary: interpersonal problems (continuous)" data-id="CD012955-fig-0138" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-015.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-015.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.9</div> <div class="figure-caption"> <p>Comparison 15: Psychotherapy vs waiting list or no treatment, Outcome 9: Secondary: interpersonal problems (continuous) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0138">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-015.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0139"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-015.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 15: Psychotherapy vs waiting list or no treatment, Outcome 10: Secondary: abandonment (continuous), at end of treatment" data-id="CD012955-fig-0139" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-015.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-015.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.10</div> <div class="figure-caption"> <p>Comparison 15: Psychotherapy vs waiting list or no treatment, Outcome 10: Secondary: abandonment (continuous), at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0139">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-015.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0140"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-015.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 15: Psychotherapy vs waiting list or no treatment, Outcome 11: Secondary: identity disturbance (continuous), at end of treatment" data-id="CD012955-fig-0140" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-015.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-015.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.11</div> <div class="figure-caption"> <p>Comparison 15: Psychotherapy vs waiting list or no treatment, Outcome 11: Secondary: identity disturbance (continuous), at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0140">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-015.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0141"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-015.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 15: Psychotherapy vs waiting list or no treatment, Outcome 12: Secondary: dissociation and psychotic‐like symptoms (continuous), at end of treatment" data-id="CD012955-fig-0141" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-015.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-015.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.12</div> <div class="figure-caption"> <p>Comparison 15: Psychotherapy vs waiting list or no treatment, Outcome 12: Secondary: dissociation and psychotic‐like symptoms (continuous), at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0141">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-015.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0142"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-015.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 15: Psychotherapy vs waiting list or no treatment, Outcome 13: Secondary: depression (continuous), at end of treatment" data-id="CD012955-fig-0142" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-015.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-015.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.13</div> <div class="figure-caption"> <p>Comparison 15: Psychotherapy vs waiting list or no treatment, Outcome 13: Secondary: depression (continuous), at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0142">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-015.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0143"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-015.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 15: Psychotherapy vs waiting list or no treatment, Outcome 14: Secondary: attrition (dichotomous), at end of treatment" data-id="CD012955-fig-0143" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-015.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-015.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.14</div> <div class="figure-caption"> <p>Comparison 15: Psychotherapy vs waiting list or no treatment, Outcome 14: Secondary: attrition (dichotomous), at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0143">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-015.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0144"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-016.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 16: Dialectical behavior therapy (DBT) vs waiting list or no treatment, Outcome 1: Primary: BPD symptom severity (continuous), at end of treatment" data-id="CD012955-fig-0144" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-016.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-016.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.1</div> <div class="figure-caption"> <p>Comparison 16: Dialectical behavior therapy (DBT) vs waiting list or no treatment, Outcome 1: Primary: BPD symptom severity (continuous), at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0144">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-016.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0145"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-016.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 16: Dialectical behavior therapy (DBT) vs waiting list or no treatment, Outcome 2: Primary: self‐harm (continuous), at end of treatment" data-id="CD012955-fig-0145" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-016.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-016.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.2</div> <div class="figure-caption"> <p>Comparison 16: Dialectical behavior therapy (DBT) vs waiting list or no treatment, Outcome 2: Primary: self‐harm (continuous), at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0145">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-016.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0146"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-016.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 16: Dialectical behavior therapy (DBT) vs waiting list or no treatment, Outcome 3: Primary: suicide‐related outcomes (continuous), at end of treatment" data-id="CD012955-fig-0146" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-016.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-016.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.3</div> <div class="figure-caption"> <p>Comparison 16: Dialectical behavior therapy (DBT) vs waiting list or no treatment, Outcome 3: Primary: suicide‐related outcomes (continuous), at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0146">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-016.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0147"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-016.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 16: Dialectical behavior therapy (DBT) vs waiting list or no treatment, Outcome 4: Primary: psychosocial functioning (continuous), at end of treatment" data-id="CD012955-fig-0147" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-016.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-016.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.4</div> <div class="figure-caption"> <p>Comparison 16: Dialectical behavior therapy (DBT) vs waiting list or no treatment, Outcome 4: Primary: psychosocial functioning (continuous), at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0147">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-016.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0148"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-016.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 16: Dialectical behavior therapy (DBT) vs waiting list or no treatment, Outcome 5: Secondary: anger (continuous), at end of treatment" data-id="CD012955-fig-0148" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-016.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-016.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.5</div> <div class="figure-caption"> <p>Comparison 16: Dialectical behavior therapy (DBT) vs waiting list or no treatment, Outcome 5: Secondary: anger (continuous), at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0148">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-016.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0149"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-016.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 16: Dialectical behavior therapy (DBT) vs waiting list or no treatment, Outcome 6: Secondary: affective instability (continuous), at end of treatment" data-id="CD012955-fig-0149" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-016.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-016.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.6</div> <div class="figure-caption"> <p>Comparison 16: Dialectical behavior therapy (DBT) vs waiting list or no treatment, Outcome 6: Secondary: affective instability (continuous), at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0149">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-016.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0150"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-016.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 16: Dialectical behavior therapy (DBT) vs waiting list or no treatment, Outcome 7: Secondary: impulsivity (continuous), at end of treatment" data-id="CD012955-fig-0150" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-016.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-016.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.7</div> <div class="figure-caption"> <p>Comparison 16: Dialectical behavior therapy (DBT) vs waiting list or no treatment, Outcome 7: Secondary: impulsivity (continuous), at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0150">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-016.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0151"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-016.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 16: Dialectical behavior therapy (DBT) vs waiting list or no treatment, Outcome 8: Secondary: dissociation and psychotic‐like symptoms (continuous), at end of treatment" data-id="CD012955-fig-0151" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-016.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-016.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.8</div> <div class="figure-caption"> <p>Comparison 16: Dialectical behavior therapy (DBT) vs waiting list or no treatment, Outcome 8: Secondary: dissociation and psychotic‐like symptoms (continuous), at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0151">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-016.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0152"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-016.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 16: Dialectical behavior therapy (DBT) vs waiting list or no treatment, Outcome 9: Secondary: depression (continuous), at end of treatment" data-id="CD012955-fig-0152" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-016.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-016.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.9</div> <div class="figure-caption"> <p>Comparison 16: Dialectical behavior therapy (DBT) vs waiting list or no treatment, Outcome 9: Secondary: depression (continuous), at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0152">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-016.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0153"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-016.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 16: Dialectical behavior therapy (DBT) vs waiting list or no treatment, Outcome 10: DBT‐couple therapy (CDBT) vs waiting list (generic inverse variance)" data-id="CD012955-fig-0153" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-016.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-016.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.10</div> <div class="figure-caption"> <p>Comparison 16: Dialectical behavior therapy (DBT) vs waiting list or no treatment, Outcome 10: DBT‐couple therapy (CDBT) vs waiting list (generic inverse variance) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0153">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-016.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0154"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-017.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 17: Schema‐focused therapy (SFT) vs no treatment, Outcome 1: Primary: suicide‐related outcomes (continuous), at end of treatment" data-id="CD012955-fig-0154" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-017.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-017.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.1</div> <div class="figure-caption"> <p>Comparison 17: Schema‐focused therapy (SFT) vs no treatment, Outcome 1: Primary: suicide‐related outcomes (continuous), at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0154">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-017.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0155"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-017.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 17: Schema‐focused therapy (SFT) vs no treatment, Outcome 2: Secondary: depression (continuous), at end of treatment" data-id="CD012955-fig-0155" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-017.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-017.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.2</div> <div class="figure-caption"> <p>Comparison 17: Schema‐focused therapy (SFT) vs no treatment, Outcome 2: Secondary: depression (continuous), at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0155">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-017.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0156"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-018.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 18: Interpersonal psychotherapy (IPT) vs waiting list, Outcome 1: Primary: BPD symptom severity (continuous), at end of treatment" data-id="CD012955-fig-0156" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-018.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-018.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 18.1</div> <div class="figure-caption"> <p>Comparison 18: Interpersonal psychotherapy (IPT) vs waiting list, Outcome 1: Primary: BPD symptom severity (continuous), at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0156">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-018.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0157"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-018.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 18: Interpersonal psychotherapy (IPT) vs waiting list, Outcome 2: Primary: self‐harm (continuous), at end of treatment" data-id="CD012955-fig-0157" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-018.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-018.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 18.2</div> <div class="figure-caption"> <p>Comparison 18: Interpersonal psychotherapy (IPT) vs waiting list, Outcome 2: Primary: self‐harm (continuous), at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0157">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-018.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0158"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-018.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 18: Interpersonal psychotherapy (IPT) vs waiting list, Outcome 3: Primary: psychosocial functioning (continuous)" data-id="CD012955-fig-0158" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-018.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-018.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 18.3</div> <div class="figure-caption"> <p>Comparison 18: Interpersonal psychotherapy (IPT) vs waiting list, Outcome 3: Primary: psychosocial functioning (continuous) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0158">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-018.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0159"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-018.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 18: Interpersonal psychotherapy (IPT) vs waiting list, Outcome 4: Secondary: anger (continuous), at end of treatment" data-id="CD012955-fig-0159" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-018.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-018.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 18.4</div> <div class="figure-caption"> <p>Comparison 18: Interpersonal psychotherapy (IPT) vs waiting list, Outcome 4: Secondary: anger (continuous), at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0159">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-018.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0160"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-018.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 18: Interpersonal psychotherapy (IPT) vs waiting list, Outcome 5: Secondary: affective instability (continuous)" data-id="CD012955-fig-0160" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-018.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-018.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 18.5</div> <div class="figure-caption"> <p>Comparison 18: Interpersonal psychotherapy (IPT) vs waiting list, Outcome 5: Secondary: affective instability (continuous) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0160">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-018.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0161"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-018.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 18: Interpersonal psychotherapy (IPT) vs waiting list, Outcome 6: Secondary: chronic feelings of emptiness (continuous), at end of treatment" data-id="CD012955-fig-0161" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-018.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-018.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 18.6</div> <div class="figure-caption"> <p>Comparison 18: Interpersonal psychotherapy (IPT) vs waiting list, Outcome 6: Secondary: chronic feelings of emptiness (continuous), at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0161">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-018.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0162"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-018.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 18: Interpersonal psychotherapy (IPT) vs waiting list, Outcome 7: Secondary: impulsivity (continuous)" data-id="CD012955-fig-0162" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-018.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-018.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 18.7</div> <div class="figure-caption"> <p>Comparison 18: Interpersonal psychotherapy (IPT) vs waiting list, Outcome 7: Secondary: impulsivity (continuous) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0162">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-018.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0163"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-018.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 18: Interpersonal psychotherapy (IPT) vs waiting list, Outcome 8: Secondary: interpersonal problems (continuous)" data-id="CD012955-fig-0163" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-018.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-018.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 18.8</div> <div class="figure-caption"> <p>Comparison 18: Interpersonal psychotherapy (IPT) vs waiting list, Outcome 8: Secondary: interpersonal problems (continuous) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0163">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-018.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0164"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-018.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 18: Interpersonal psychotherapy (IPT) vs waiting list, Outcome 9: Secondary: abandonment (continuous), at end of treatment" data-id="CD012955-fig-0164" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-018.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-018.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 18.9</div> <div class="figure-caption"> <p>Comparison 18: Interpersonal psychotherapy (IPT) vs waiting list, Outcome 9: Secondary: abandonment (continuous), at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0164">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-018.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0165"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-018.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 18: Interpersonal psychotherapy (IPT) vs waiting list, Outcome 10: Secondary: identity disturbance (continuous), at end of treatment" data-id="CD012955-fig-0165" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-018.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-018.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 18.10</div> <div class="figure-caption"> <p>Comparison 18: Interpersonal psychotherapy (IPT) vs waiting list, Outcome 10: Secondary: identity disturbance (continuous), at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0165">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-018.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0166"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-018.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 18: Interpersonal psychotherapy (IPT) vs waiting list, Outcome 11: Secondary: dissociation and psychotic‐like symptoms (continuous), at end of treatment" data-id="CD012955-fig-0166" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-018.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-018.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 18.11</div> <div class="figure-caption"> <p>Comparison 18: Interpersonal psychotherapy (IPT) vs waiting list, Outcome 11: Secondary: dissociation and psychotic‐like symptoms (continuous), at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0166">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-018.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0167"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-018.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 18: Interpersonal psychotherapy (IPT) vs waiting list, Outcome 12: Secondary outcome: depression (continuous), at end of treatment" data-id="CD012955-fig-0167" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-018.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-018.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 18.12</div> <div class="figure-caption"> <p>Comparison 18: Interpersonal psychotherapy (IPT) vs waiting list, Outcome 12: Secondary outcome: depression (continuous), at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0167">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-018.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0168"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-018.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 18: Interpersonal psychotherapy (IPT) vs waiting list, Outcome 13: Secondary outcome: attrition (dichotomous), at end of treatment" data-id="CD012955-fig-0168" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-018.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-018.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 18.13</div> <div class="figure-caption"> <p>Comparison 18: Interpersonal psychotherapy (IPT) vs waiting list, Outcome 13: Secondary outcome: attrition (dichotomous), at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0168">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-018.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0169"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-019.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 19: Once‐only interventions (individual setting) vs waiting list, Outcome 1: Secondary: impulsivity (continuous), at end of treatment" data-id="CD012955-fig-0169" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-019.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-019.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 19.1</div> <div class="figure-caption"> <p>Comparison 19: Once‐only interventions (individual setting) vs waiting list, Outcome 1: Secondary: impulsivity (continuous), at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0169">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-019.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0170"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-019.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 19: Once‐only interventions (individual setting) vs waiting list, Outcome 2: Secondary: interpersonal problems (continuous), at end of treatment" data-id="CD012955-fig-0170" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-019.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-019.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 19.2</div> <div class="figure-caption"> <p>Comparison 19: Once‐only interventions (individual setting) vs waiting list, Outcome 2: Secondary: interpersonal problems (continuous), at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0170">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-019.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0171"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-019.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 19: Once‐only interventions (individual setting) vs waiting list, Outcome 3: Secondary: attrition (dichotomous), at end of treatment" data-id="CD012955-fig-0171" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-019.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-019.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 19.3</div> <div class="figure-caption"> <p>Comparison 19: Once‐only interventions (individual setting) vs waiting list, Outcome 3: Secondary: attrition (dichotomous), at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0171">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-019.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0172"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-020.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 20: Eclectic treatments vs waiting list, Outcome 1: Primary outcome: psychosocial functioning (continuous), at end of treatment" data-id="CD012955-fig-0172" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-020.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-020.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 20.1</div> <div class="figure-caption"> <p>Comparison 20: Eclectic treatments vs waiting list, Outcome 1: Primary outcome: psychosocial functioning (continuous), at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0172">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-020.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0173"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-020.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 20: Eclectic treatments vs waiting list, Outcome 2: Secondary outcome: interpersonal problems (continuous), at end of treatment" data-id="CD012955-fig-0173" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-020.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-020.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 20.2</div> <div class="figure-caption"> <p>Comparison 20: Eclectic treatments vs waiting list, Outcome 2: Secondary outcome: interpersonal problems (continuous), at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0173">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-020.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0174"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-021.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 21: Dialectical behavior therapy (DBT) and related treatments vs active treatment, Outcome 1: Standard DBT (DBT) vs client‐centred therapy (CCT) (continuous)" data-id="CD012955-fig-0174" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-021.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-021.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 21.1</div> <div class="figure-caption"> <p>Comparison 21: Dialectical behavior therapy (DBT) and related treatments vs active treatment, Outcome 1: Standard DBT (DBT) vs client‐centred therapy (CCT) (continuous) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0174">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-021.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0175"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-021.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 21: Dialectical behavior therapy (DBT) and related treatments vs active treatment, Outcome 2: DBT vs CCT, secondary: attrition (dichotomous), at end of treatment" data-id="CD012955-fig-0175" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-021.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-021.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 21.2</div> <div class="figure-caption"> <p>Comparison 21: Dialectical behavior therapy (DBT) and related treatments vs active treatment, Outcome 2: DBT vs CCT, secondary: attrition (dichotomous), at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0175">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-021.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0176"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-021.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 21: Dialectical behavior therapy (DBT) and related treatments vs active treatment, Outcome 3: Standard DBT (DBT) vs good psychiatric management (GPM) (continuous)" data-id="CD012955-fig-0176" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-021.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-021.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 21.3</div> <div class="figure-caption"> <p>Comparison 21: Dialectical behavior therapy (DBT) and related treatments vs active treatment, Outcome 3: Standard DBT (DBT) vs good psychiatric management (GPM) (continuous) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0176">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-021.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0177"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-021.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 21: Dialectical behavior therapy (DBT) and related treatments vs active treatment, Outcome 4: DBT vs GPM, secondary: attrition (dichotomous), at end of treatment" data-id="CD012955-fig-0177" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-021.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-021.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 21.4</div> <div class="figure-caption"> <p>Comparison 21: Dialectical behavior therapy (DBT) and related treatments vs active treatment, Outcome 4: DBT vs GPM, secondary: attrition (dichotomous), at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0177">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-021.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0178"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-021.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 21: Dialectical behavior therapy (DBT) and related treatments vs active treatment, Outcome 5: Standard DBT (DBT) vs individual DBT therapy + activities group (DBT‐I) (continuous)" data-id="CD012955-fig-0178" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-021.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-021.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 21.5</div> <div class="figure-caption"> <p>Comparison 21: Dialectical behavior therapy (DBT) and related treatments vs active treatment, Outcome 5: Standard DBT (DBT) vs individual DBT therapy + activities group (DBT‐I) (continuous) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0178">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-021.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0179"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-021.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 21: Dialectical behavior therapy (DBT) and related treatments vs active treatment, Outcome 6: DBT vs DBT‐I, secondary: attrition (dichotomous), at end of treatment" data-id="CD012955-fig-0179" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-021.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-021.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 21.6</div> <div class="figure-caption"> <p>Comparison 21: Dialectical behavior therapy (DBT) and related treatments vs active treatment, Outcome 6: DBT vs DBT‐I, secondary: attrition (dichotomous), at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0179">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-021.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0180"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-021.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 21: Dialectical behavior therapy (DBT) and related treatments vs active treatment, Outcome 7: Standard DBT (DBT) vs skills training group + individual case management (DBT‐S) (continuous)" data-id="CD012955-fig-0180" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-021.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-021.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 21.7</div> <div class="figure-caption"> <p>Comparison 21: Dialectical behavior therapy (DBT) and related treatments vs active treatment, Outcome 7: Standard DBT (DBT) vs skills training group + individual case management (DBT‐S) (continuous) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0180">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-021.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0181"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-021.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 21: Dialectical behavior therapy (DBT) and related treatments vs active treatment, Outcome 8: DBT vs DBT‐S, secondary: attrition (dichotomous), at 6‐12 months follow‐up" data-id="CD012955-fig-0181" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-021.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-021.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 21.8</div> <div class="figure-caption"> <p>Comparison 21: Dialectical behavior therapy (DBT) and related treatments vs active treatment, Outcome 8: DBT vs DBT‐S, secondary: attrition (dichotomous), at 6‐12 months follow‐up </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0181">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-021.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0182"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-021.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 21: Dialectical behavior therapy (DBT) and related treatments vs active treatment, Outcome 9: Standard DBT (DBT) vs step‐down DBT (DBT‐SD) (continuous)" data-id="CD012955-fig-0182" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-021.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-021.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 21.9</div> <div class="figure-caption"> <p>Comparison 21: Dialectical behavior therapy (DBT) and related treatments vs active treatment, Outcome 9: Standard DBT (DBT) vs step‐down DBT (DBT‐SD) (continuous) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0182">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-021.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0183"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-021.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 21: Dialectical behavior therapy (DBT) and related treatments vs active treatment, Outcome 10: DBT vs DBT‐SD, secondary: attrition (dichotomous), at end of treatment" data-id="CD012955-fig-0183" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-021.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-021.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 21.10</div> <div class="figure-caption"> <p>Comparison 21: Dialectical behavior therapy (DBT) and related treatments vs active treatment, Outcome 10: DBT vs DBT‐SD, secondary: attrition (dichotomous), at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0183">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-021.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0184"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-021.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 21: Dialectical behavior therapy (DBT) and related treatments vs active treatment, Outcome 11: Standard DBT (DBT) vs DBT Prolonged Exposure (PE) (continuous)" data-id="CD012955-fig-0184" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-021.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-021.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 21.11</div> <div class="figure-caption"> <p>Comparison 21: Dialectical behavior therapy (DBT) and related treatments vs active treatment, Outcome 11: Standard DBT (DBT) vs DBT Prolonged Exposure (PE) (continuous) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0184">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-021.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0185"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-021.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 21: Dialectical behavior therapy (DBT) and related treatments vs active treatment, Outcome 12: DBT vs DBT‐PE, secondary: attrition (dichotomous), at 0‐6 months follow‐up" data-id="CD012955-fig-0185" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-021.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-021.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 21.12</div> <div class="figure-caption"> <p>Comparison 21: Dialectical behavior therapy (DBT) and related treatments vs active treatment, Outcome 12: DBT vs DBT‐PE, secondary: attrition (dichotomous), at 0‐6 months follow‐up </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0185">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-021.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0186"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-021.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 21: Dialectical behavior therapy (DBT) and related treatments vs active treatment, Outcome 13: DBT skills group + case management (DBT‐S) vs DBT individual therapy + activity group (DBT‐I) (continuous)" data-id="CD012955-fig-0186" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-021.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-021.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 21.13</div> <div class="figure-caption"> <p>Comparison 21: Dialectical behavior therapy (DBT) and related treatments vs active treatment, Outcome 13: DBT skills group + case management (DBT‐S) vs DBT individual therapy + activity group (DBT‐I) (continuous) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0186">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-021.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0187"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-021.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 21: Dialectical behavior therapy (DBT) and related treatments vs active treatment, Outcome 14: DBT‐S vs DBT‐I, secondary: attrition (dichotomous), at 6‐12 months follow‐up" data-id="CD012955-fig-0187" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-021.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-021.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 21.14</div> <div class="figure-caption"> <p>Comparison 21: Dialectical behavior therapy (DBT) and related treatments vs active treatment, Outcome 14: DBT‐S vs DBT‐I, secondary: attrition (dichotomous), at 6‐12 months follow‐up </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0187">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-021.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0188"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-021.15" target="_blank"><b></b></a></p> </div><img alt="Comparison 21: Dialectical behavior therapy (DBT) and related treatments vs active treatment, Outcome 15: DBT skills group (DBT‐S) vs cognitive therapy group (CT‐G) (continuous)" data-id="CD012955-fig-0188" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-021.15.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-021.15.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 21.15</div> <div class="figure-caption"> <p>Comparison 21: Dialectical behavior therapy (DBT) and related treatments vs active treatment, Outcome 15: DBT skills group (DBT‐S) vs cognitive therapy group (CT‐G) (continuous) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0188">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-021.15.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0189"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-021.16" target="_blank"><b></b></a></p> </div><img alt="Comparison 21: Dialectical behavior therapy (DBT) and related treatments vs active treatment, Outcome 16: DBT‐S vs CT‐G, secondary: attrition (dichotomous), at end of treatment" data-id="CD012955-fig-0189" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-021.16.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-021.16.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 21.16</div> <div class="figure-caption"> <p>Comparison 21: Dialectical behavior therapy (DBT) and related treatments vs active treatment, Outcome 16: DBT‐S vs CT‐G, secondary: attrition (dichotomous), at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0189">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-021.16.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0190"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-021.17" target="_blank"><b></b></a></p> </div><img alt="Comparison 21: Dialectical behavior therapy (DBT) and related treatments vs active treatment, Outcome 17: DBT skills group (DBT‐S) vs schema‐focused therapy group (SFT‐G)" data-id="CD012955-fig-0190" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-021.17.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-021.17.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 21.17</div> <div class="figure-caption"> <p>Comparison 21: Dialectical behavior therapy (DBT) and related treatments vs active treatment, Outcome 17: DBT skills group (DBT‐S) vs schema‐focused therapy group (SFT‐G) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0190">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-021.17.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0191"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-021.18" target="_blank"><b></b></a></p> </div><img alt="Comparison 21: Dialectical behavior therapy (DBT) and related treatments vs active treatment, Outcome 18: DBT mindfulness group (DBT‐M) vs DBT interpersonal effectiveness group (DBT‐IE) (continuous)" data-id="CD012955-fig-0191" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-021.18.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-021.18.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 21.18</div> <div class="figure-caption"> <p>Comparison 21: Dialectical behavior therapy (DBT) and related treatments vs active treatment, Outcome 18: DBT mindfulness group (DBT‐M) vs DBT interpersonal effectiveness group (DBT‐IE) (continuous) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0191">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-021.18.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0192"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-021.19" target="_blank"><b></b></a></p> </div><img alt="Comparison 21: Dialectical behavior therapy (DBT) and related treatments vs active treatment, Outcome 19: DBT‐M vs DBT‐IE, secondary: attrition (dichotomous), at end of treatment" data-id="CD012955-fig-0192" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-021.19.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-021.19.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 21.19</div> <div class="figure-caption"> <p>Comparison 21: Dialectical behavior therapy (DBT) and related treatments vs active treatment, Outcome 19: DBT‐M vs DBT‐IE, secondary: attrition (dichotomous), at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0192">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-021.19.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0193"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-021.20" target="_blank"><b></b></a></p> </div><img alt="Comparison 21: Dialectical behavior therapy (DBT) and related treatments vs active treatment, Outcome 20: DBT mindfulness group (DBT‐M) vs loving‐kindness and compassion meditation (LK/CM), primary: BPD symptom severity (continuous), at end of treatment" data-id="CD012955-fig-0193" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-021.20.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-021.20.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 21.20</div> <div class="figure-caption"> <p>Comparison 21: Dialectical behavior therapy (DBT) and related treatments vs active treatment, Outcome 20: DBT mindfulness group (DBT‐M) vs loving‐kindness and compassion meditation (LK/CM), primary: BPD symptom severity (continuous), at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0193">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-021.20.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0194"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-022.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 22: Cognitive behavioural therapy (CBT) and related treatments vs active treatment, Outcome 1: CBT vs trauma‐ and anxiety‐related group psychoeducation (continuous)" data-id="CD012955-fig-0194" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-022.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-022.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 22.1</div> <div class="figure-caption"> <p>Comparison 22: Cognitive behavioural therapy (CBT) and related treatments vs active treatment, Outcome 1: CBT vs trauma‐ and anxiety‐related group psychoeducation (continuous) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0194">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-022.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0195"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-022.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 22: Cognitive behavioural therapy (CBT) and related treatments vs active treatment, Outcome 2: CBT vs trauma‐ and anxiety‐related group psychoeducation, secondary: attrition (dichotomous), at end of treatment" data-id="CD012955-fig-0195" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-022.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-022.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 22.2</div> <div class="figure-caption"> <p>Comparison 22: Cognitive behavioural therapy (CBT) and related treatments vs active treatment, Outcome 2: CBT vs trauma‐ and anxiety‐related group psychoeducation, secondary: attrition (dichotomous), at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0195">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-022.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0196"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-022.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 22: Cognitive behavioural therapy (CBT) and related treatments vs active treatment, Outcome 3: CBT vs interpersonal psychotherapy (IPT) (continuous)" data-id="CD012955-fig-0196" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-022.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-022.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 22.3</div> <div class="figure-caption"> <p>Comparison 22: Cognitive behavioural therapy (CBT) and related treatments vs active treatment, Outcome 3: CBT vs interpersonal psychotherapy (IPT) (continuous) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0196">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-022.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0197"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-022.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 22: Cognitive behavioural therapy (CBT) and related treatments vs active treatment, Outcome 4: CBT vs IPT, secondary: attrition (dichotomous), at end of treatment" data-id="CD012955-fig-0197" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-022.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-022.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 22.4</div> <div class="figure-caption"> <p>Comparison 22: Cognitive behavioural therapy (CBT) and related treatments vs active treatment, Outcome 4: CBT vs IPT, secondary: attrition (dichotomous), at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0197">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-022.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0198"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-022.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 22: Cognitive behavioural therapy (CBT) and related treatments vs active treatment, Outcome 5: CBT vs Rogerian supportive therapy (continuous)" data-id="CD012955-fig-0198" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-022.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-022.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 22.5</div> <div class="figure-caption"> <p>Comparison 22: Cognitive behavioural therapy (CBT) and related treatments vs active treatment, Outcome 5: CBT vs Rogerian supportive therapy (continuous) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0198">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-022.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0199"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-022.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 22: Cognitive behavioural therapy (CBT) and related treatments vs active treatment, Outcome 6: CBT vs Rogerian supportive therapy, secondary: attrition (dichotomous), end of treatment" data-id="CD012955-fig-0199" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-022.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-022.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 22.6</div> <div class="figure-caption"> <p>Comparison 22: Cognitive behavioural therapy (CBT) and related treatments vs active treatment, Outcome 6: CBT vs Rogerian supportive therapy, secondary: attrition (dichotomous), end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0199">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-022.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0200"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-022.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 22: Cognitive behavioural therapy (CBT) and related treatments vs active treatment, Outcome 7: MACT (Manual‐assisted Cognitive Therapy) vs MACT + therapeutic assessment (MACT + TA) (continuous)" data-id="CD012955-fig-0200" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-022.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-022.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 22.7</div> <div class="figure-caption"> <p>Comparison 22: Cognitive behavioural therapy (CBT) and related treatments vs active treatment, Outcome 7: MACT (Manual‐assisted Cognitive Therapy) vs MACT + therapeutic assessment (MACT + TA) (continuous) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0200">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-022.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0201"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-022.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 22: Cognitive behavioural therapy (CBT) and related treatments vs active treatment, Outcome 8: MACT vs MACT + TA, secondary: attrition (dichotomous), at end of treatment" data-id="CD012955-fig-0201" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-022.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-022.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 22.8</div> <div class="figure-caption"> <p>Comparison 22: Cognitive behavioural therapy (CBT) and related treatments vs active treatment, Outcome 8: MACT vs MACT + TA, secondary: attrition (dichotomous), at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0201">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-022.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0202"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-022.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 22: Cognitive behavioural therapy (CBT) and related treatments vs active treatment, Outcome 9: Meta‐Cognitive training for BPD (B‐MCT) vs progressive muscle relaxation training (PMR)" data-id="CD012955-fig-0202" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-022.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-022.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 22.9</div> <div class="figure-caption"> <p>Comparison 22: Cognitive behavioural therapy (CBT) and related treatments vs active treatment, Outcome 9: Meta‐Cognitive training for BPD (B‐MCT) vs progressive muscle relaxation training (PMR) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0202">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-022.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0203"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-022.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 22: Cognitive behavioural therapy (CBT) and related treatments vs active treatment, Outcome 10: B‐MCT vs progressive muscle relaxation (PMR) training + TAU (dichotomous). Secondary: attrition (dichotomous), at end of treatment" data-id="CD012955-fig-0203" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-022.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-022.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 22.10</div> <div class="figure-caption"> <p>Comparison 22: Cognitive behavioural therapy (CBT) and related treatments vs active treatment, Outcome 10: B‐MCT vs progressive muscle relaxation (PMR) training + TAU (dichotomous). Secondary: attrition (dichotomous), at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0203">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-022.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0204"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-022.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 22: Cognitive behavioural therapy (CBT) and related treatments vs active treatment, Outcome 11: MOTR (Motive‐Oriented Therapeutic Relationship) vs Good Psychiatric Management (GPM) (continuous)" data-id="CD012955-fig-0204" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-022.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-022.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 22.11</div> <div class="figure-caption"> <p>Comparison 22: Cognitive behavioural therapy (CBT) and related treatments vs active treatment, Outcome 11: MOTR (Motive‐Oriented Therapeutic Relationship) vs Good Psychiatric Management (GPM) (continuous) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0204">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-022.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0205"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-022.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 22: Cognitive behavioural therapy (CBT) and related treatments vs active treatment, Outcome 12: MOTR vs (GPM), secondary: attrition (dichotomous), at end of treatment" data-id="CD012955-fig-0205" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-022.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-022.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 22.12</div> <div class="figure-caption"> <p>Comparison 22: Cognitive behavioural therapy (CBT) and related treatments vs active treatment, Outcome 12: MOTR vs (GPM), secondary: attrition (dichotomous), at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0205">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-022.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0206"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-023.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 23: Schema‐focused therapy (SFT) vs active treatment, Outcome 1: SFT vs TFP. Primary: BPD symptom severity (continuous), at end of treatment" data-id="CD012955-fig-0206" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-023.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-023.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 23.1</div> <div class="figure-caption"> <p>Comparison 23: Schema‐focused therapy (SFT) vs active treatment, Outcome 1: SFT vs TFP. Primary: BPD symptom severity (continuous), at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0206">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-023.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0207"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-023.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 23: Schema‐focused therapy (SFT) vs active treatment, Outcome 2: SFT vs TFP. Secondary: attrition (dichotomous), at 0‐6 months follow‐up" data-id="CD012955-fig-0207" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-023.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-023.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 23.2</div> <div class="figure-caption"> <p>Comparison 23: Schema‐focused therapy (SFT) vs active treatment, Outcome 2: SFT vs TFP. Secondary: attrition (dichotomous), at 0‐6 months follow‐up </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0207">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-023.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0208"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-023.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 23: Schema‐focused therapy (SFT) vs active treatment, Outcome 3: SFT vs SFT + therapist availability (TA). Primary: BPD symptom severity (continuous), at end of treatment" data-id="CD012955-fig-0208" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-023.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-023.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 23.3</div> <div class="figure-caption"> <p>Comparison 23: Schema‐focused therapy (SFT) vs active treatment, Outcome 3: SFT vs SFT + therapist availability (TA). Primary: BPD symptom severity (continuous), at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0208">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-023.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0209"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-023.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 23: Schema‐focused therapy (SFT) vs active treatment, Outcome 4: SFT vs SFT + TA. Secondary: attrition (dichotomous), 0‐6 months follow‐up" data-id="CD012955-fig-0209" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-023.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-023.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 23.4</div> <div class="figure-caption"> <p>Comparison 23: Schema‐focused therapy (SFT) vs active treatment, Outcome 4: SFT vs SFT + TA. Secondary: attrition (dichotomous), 0‐6 months follow‐up </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0209">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-023.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0210"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-024.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 24: Systems training for emotional predictability and problem solving‐based psychoeducation (STEPPS‐PE) vs cognitive rehabilitation (CR), Outcome 1: STEPPS‐PE vs CR" data-id="CD012955-fig-0210" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-024.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-024.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 24.1</div> <div class="figure-caption"> <p>Comparison 24: Systems training for emotional predictability and problem solving‐based psychoeducation (STEPPS‐PE) vs cognitive rehabilitation (CR), Outcome 1: STEPPS‐PE vs CR </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0210">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-024.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0211"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-024.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 24: Systems training for emotional predictability and problem solving‐based psychoeducation (STEPPS‐PE) vs cognitive rehabilitation (CR), Outcome 2: STEPPS‐PE vs CR. Secondary: attrition (dichotomous), at end of treatment" data-id="CD012955-fig-0211" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-024.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-024.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 24.2</div> <div class="figure-caption"> <p>Comparison 24: Systems training for emotional predictability and problem solving‐based psychoeducation (STEPPS‐PE) vs cognitive rehabilitation (CR), Outcome 2: STEPPS‐PE vs CR. Secondary: attrition (dichotomous), at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0211">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-024.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0212"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-025.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 25: Eclectic treatments vs active treatment, Outcome 1: Combined inpatient and outpatient psychotherapy versus outpatient psychotherapy" data-id="CD012955-fig-0212" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-025.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-025.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 25.1</div> <div class="figure-caption"> <p>Comparison 25: Eclectic treatments vs active treatment, Outcome 1: Combined inpatient and outpatient psychotherapy versus outpatient psychotherapy </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0212">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-025.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0213"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-025.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 25: Eclectic treatments vs active treatment, Outcome 2: Combined inpatient and outpatient psychotherapy versus outpatient psychotherapy. Secondary: attrition (dichotomous), at end of treatment" data-id="CD012955-fig-0213" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-025.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-025.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 25.2</div> <div class="figure-caption"> <p>Comparison 25: Eclectic treatments vs active treatment, Outcome 2: Combined inpatient and outpatient psychotherapy versus outpatient psychotherapy. Secondary: attrition (dichotomous), at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0213">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-025.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0214"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-025.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 25: Eclectic treatments vs active treatment, Outcome 3: integrative BPD‐oriented adolescent family therapy (I‐BAFT) vs individual drug counselling (IDC)" data-id="CD012955-fig-0214" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-025.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-025.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 25.3</div> <div class="figure-caption"> <p>Comparison 25: Eclectic treatments vs active treatment, Outcome 3: integrative BPD‐oriented adolescent family therapy (I‐BAFT) vs individual drug counselling (IDC) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0214">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-025.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0215"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-026.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 26: Subgroup analysis: therapeutic approaches, Outcome 1: BPD symptom severity" data-id="CD012955-fig-0215" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-026.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-026.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 26.1</div> <div class="figure-caption"> <p>Comparison 26: Subgroup analysis: therapeutic approaches, Outcome 1: BPD symptom severity</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0215">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-026.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0216"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-026.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 26: Subgroup analysis: therapeutic approaches, Outcome 2: Psychosocial functioning" data-id="CD012955-fig-0216" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-026.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-026.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 26.2</div> <div class="figure-caption"> <p>Comparison 26: Subgroup analysis: therapeutic approaches, Outcome 2: Psychosocial functioning </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0216">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-026.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0217"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-027.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 27: Subgroup analysis: age, Outcome 1: BPD symptom severity" data-id="CD012955-fig-0217" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-027.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-027.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 27.1</div> <div class="figure-caption"> <p>Comparison 27: Subgroup analysis: age, Outcome 1: BPD symptom severity</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0217">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-027.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0218"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-028.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 28: Subgroup analysis: duration, Outcome 1: BPD symptom severity" data-id="CD012955-fig-0218" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-028.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-028.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 28.1</div> <div class="figure-caption"> <p>Comparison 28: Subgroup analysis: duration, Outcome 1: BPD symptom severity</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0218">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-028.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0219"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-028.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 28: Subgroup analysis: duration, Outcome 2: Psychosocial functioning" data-id="CD012955-fig-0219" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-028.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-028.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 28.2</div> <div class="figure-caption"> <p>Comparison 28: Subgroup analysis: duration, Outcome 2: Psychosocial functioning</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0219">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-028.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0220"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-029.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 29: Subgroup analysis: mode of therapy, Outcome 1: BPD symptom severity" data-id="CD012955-fig-0220" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-029.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-029.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 29.1</div> <div class="figure-caption"> <p>Comparison 29: Subgroup analysis: mode of therapy, Outcome 1: BPD symptom severity</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0220">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-029.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0221"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-029.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 29: Subgroup analysis: mode of therapy, Outcome 2: Psychosocial functioning" data-id="CD012955-fig-0221" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-029.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-029.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 29.2</div> <div class="figure-caption"> <p>Comparison 29: Subgroup analysis: mode of therapy, Outcome 2: Psychosocial functioning</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0221">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-029.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0222"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-030.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 30: Subgroup analysis: setting, Outcome 1: BPD symptom severity" data-id="CD012955-fig-0222" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-030.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-030.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 30.1</div> <div class="figure-caption"> <p>Comparison 30: Subgroup analysis: setting, Outcome 1: BPD symptom severity</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0222">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-030.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0223"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-030.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 30: Subgroup analysis: setting, Outcome 2: Psychosocial functioning" data-id="CD012955-fig-0223" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-030.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-030.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 30.2</div> <div class="figure-caption"> <p>Comparison 30: Subgroup analysis: setting, Outcome 2: Psychosocial functioning</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0223">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-030.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0224"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-031.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 31: Subgroup analysis: types of raters, Outcome 1: BPD symptom severity" data-id="CD012955-fig-0224" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-031.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-031.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 31.1</div> <div class="figure-caption"> <p>Comparison 31: Subgroup analysis: types of raters, Outcome 1: BPD symptom severity</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0224">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-031.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0225"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-031.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 31: Subgroup analysis: types of raters, Outcome 2: Psychosocial functioning" data-id="CD012955-fig-0225" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-031.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-031.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 31.2</div> <div class="figure-caption"> <p>Comparison 31: Subgroup analysis: types of raters, Outcome 2: Psychosocial functioning</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0225">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-031.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0226"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-032.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 32: Subgroup analysis: types of TAU, Outcome 1: BPD symptom severity" data-id="CD012955-fig-0226" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-032.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-032.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 32.1</div> <div class="figure-caption"> <p>Comparison 32: Subgroup analysis: types of TAU, Outcome 1: BPD symptom severity</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0226">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-032.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0227"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-032.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 32: Subgroup analysis: types of TAU, Outcome 2: Psychosocial functioning" data-id="CD012955-fig-0227" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-032.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-032.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 32.2</div> <div class="figure-caption"> <p>Comparison 32: Subgroup analysis: types of TAU, Outcome 2: Psychosocial functioning</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0227">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-032.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0228"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-033.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 33: Subgroup analysis: type of comparison group, Outcome 1: BPD symptom severity" data-id="CD012955-fig-0228" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-033.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-033.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 33.1</div> <div class="figure-caption"> <p>Comparison 33: Subgroup analysis: type of comparison group, Outcome 1: BPD symptom severity </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0228">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-033.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0229"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-033.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 33: Subgroup analysis: type of comparison group, Outcome 2: Psychosocial functioning" data-id="CD012955-fig-0229" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-033.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-033.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 33.2</div> <div class="figure-caption"> <p>Comparison 33: Subgroup analysis: type of comparison group, Outcome 2: Psychosocial functioning </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0229">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-033.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0230"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-034.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 34: Subgroup analysis: types of scales, Outcome 1: BPD symptom severity" data-id="CD012955-fig-0230" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-034.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-034.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 34.1</div> <div class="figure-caption"> <p>Comparison 34: Subgroup analysis: types of scales, Outcome 1: BPD symptom severity</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0230">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-034.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0231"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-034.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 34: Subgroup analysis: types of scales, Outcome 2: Psychosocial functioning" data-id="CD012955-fig-0231" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-034.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-034.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 34.2</div> <div class="figure-caption"> <p>Comparison 34: Subgroup analysis: types of scales, Outcome 2: Psychosocial functioning</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0231">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-034.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0232"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-035.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 35: TSA sensitivity analyses: psychotherapy versus TAU, Outcome 1: Primary: BPD symptom severity, at end of treatment" data-id="CD012955-fig-0232" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-035.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-035.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 35.1</div> <div class="figure-caption"> <p>Comparison 35: TSA sensitivity analyses: psychotherapy versus TAU, Outcome 1: Primary: BPD symptom severity, at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0232">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-035.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0233"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-035.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 35: TSA sensitivity analyses: psychotherapy versus TAU, Outcome 2: Primary: self‐harm" data-id="CD012955-fig-0233" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-035.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-035.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 35.2</div> <div class="figure-caption"> <p>Comparison 35: TSA sensitivity analyses: psychotherapy versus TAU, Outcome 2: Primary: self‐harm </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0233">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-035.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0234"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-035.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 35: TSA sensitivity analyses: psychotherapy versus TAU, Outcome 3: Primary: suicide‐related outcomes" data-id="CD012955-fig-0234" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-035.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-035.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 35.3</div> <div class="figure-caption"> <p>Comparison 35: TSA sensitivity analyses: psychotherapy versus TAU, Outcome 3: Primary: suicide‐related outcomes </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0234">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-035.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0235"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-035.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 35: TSA sensitivity analyses: psychotherapy versus TAU, Outcome 4: Primary: psychosocial functioning, at end of treatment" data-id="CD012955-fig-0235" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-035.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-035.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 35.4</div> <div class="figure-caption"> <p>Comparison 35: TSA sensitivity analyses: psychotherapy versus TAU, Outcome 4: Primary: psychosocial functioning, at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0235">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-035.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012955-fig-0236"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/urn:x-wiley:14651858:media:CD012955:CD012955-CMP-035.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 35: TSA sensitivity analyses: psychotherapy versus TAU, Outcome 5: Secondary: depression" data-id="CD012955-fig-0236" src="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-035.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_t/tCD012955-CMP-035.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 35.5</div> <div class="figure-caption"> <p>Comparison 35: TSA sensitivity analyses: psychotherapy versus TAU, Outcome 5: Secondary: depression </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-fig-0236">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/media/CDSR/CD012955/image_n/nCD012955-CMP-035.05.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD012955-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Psychotherapy versus treatment‐as‐usual</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Psychotherapy versus treatment‐as‐usual</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> borderline personality disorder </p> <p><b>Settings:</b> inpatient and outpatient </p> <p><b>Intervention:</b> psychotherapy </p> <p><b>Comparison:</b> treatment‐as‐usual (TAU) </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Number of participants</b> </p> <p><b>(RCTs)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Quality of the evidence</b> </p> <p><b>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="center" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="center" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>TAU</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Psychotherapy</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>BPD symptom severity</b> </p> <p>Measured by: clinicians and self‐rated</p> <p>Timing of outcome assessment: end of treatment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean score in the intervention groups was <b>0.52 SD lower</b> (0.70 lower to 0.33 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1244 </p> <p>(22 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>Moderate<sup>a</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The SMD of −0.52 corresponds to −3.6 on the Zanarini BPD scale. The MIREDIF on this scale is 3.0 points </p> <p>TSA adjusted Cl = −5.49 to −1.90 on the Zanarini BPD scale</p> <p>TSA RIS = 901</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Self‐harm (frequency)</b> </p> <p>Measured by: clinicians and self‐rated</p> <p>Timing of outcome assessment: end of treatment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean score in the intervention groups was <b>0.32 SD lower</b> (0.49 lower to 0.14 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>616</p> <p>(13 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low<sup>a,b</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The SMD of −0. 32 corresponds to −0.82 on the DSHI. The MIREDIF on this scale is −1.25 points (½ SD) </p> <p>TSA adjusted CI = −0.59 to −0.08 on the DSHI</p> <p>TSA RIS = 97</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Suicide‐related outcomes (suicidality)</b> </p> <p>Measured by: clinicians and self‐rated</p> <p>Timing of outcome assessment: end of treatment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean score in the intervention groups was <b>0.34 SD lower</b> (0.57 lower to 0.11 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>666</p> <p>(13 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low<sup>a,b</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The SMD of −0. 34 corresponds to −0.11 on the SASII. The MIREDIF on this scale is −0.17 points (½ SD) </p> <p>TSA adjusted CI = −0.18 to −0.04 on the SASII</p> <p>TSA RIS = 253</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Psychosocial functioning</b> </p> <p>Measured by: clinicians and self‐rated</p> <p>Timing of outcome assessment: end of treatment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean score in the intervention groups was <b>0.45 SD lower</b> (0.68 lower to 0.22 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1314</p> <p>(22 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low<sup>a,c</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The SMD of −0.45 corresponds to −2.8 on the GAF. The MIREDIF on this scale is −4.0 points </p> <p>TSA adjusted CI = −3.97 to −1.94 on the GAF</p> <p>TSA RIS = 947</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Depression</b> </p> <p>Measured by: clinicians and self‐rated</p> <p>Timing of outcome assessment: end of treatment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean score in the intervention groups was <b>0.39 SD lower</b> (0.61 lower to 0.17 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1568</p> <p>(22 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very</b> <b>low<sup>a,b,c</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The SMD of ‐0.45 corresponds to −2.45 on the Hamilton Depression Scale. The MIREDIF on this scale is 3.0 points </p> <p>TSA adjusted CI = −3.34 to −1.72 on the Hamilton Depression Scale</p> <p>TSA RIS = 2274</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Attrition</b> </p> <p>Timing of outcome assessment: end of treatment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>328 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>328 per 1000</b> (95% CI 56 fewer to 66 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.00 (95% CI 0.83 to 1.20)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2225</p> <p>(32 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low<sup>a,b</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects</b> </p> <p>Timing of outcome assessment: end of treatment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>74 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>6 per 1000</b> (95% CI 41 fewer to 65 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.92 (95% CI 0.45 to 1.88)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>381</p> <p>(2 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low<sup>a,b</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> Confidence interval; <b>DSHI:</b> Deliberate Self‐Harm Inventory; <b>GAF:</b> Global Assessment of Functioning scale; <b>MIREDIF:</b> Minimum relevant difference; <b>RCTs:</b> Randomised controlled trials; <b>RIS:</b> Required information size; <b>RR:</b> Risk Ratio; <b>SASII:</b> Suicide Attempt Self‐Injury Interview; <b>SD:</b> Standard deviation; <b>SMD:</b> Standardised mean difference; <b>TAU:</b> treatment‐as‐usual; <b>TSA:</b> Trial Sequential Analysis </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect<br/><b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate<br/><b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate<br/><b>Very low quality:</b> we are very uncertain about the estimate </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>We downgraded the quality of this evidence by one level due to risk of bias (other bias).<br/><sup>b</sup>We downgraded the quality of this evidence by one level due to imprecision.<br/><sup>c</sup>We downgraded the quality of this evidence by one level due to high heterogeneity. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Psychotherapy versus treatment‐as‐usual</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/full#CD012955-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012955-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Psychotherapy versus waiting list or no treatment</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Psychotherapy versus waiting list or no treatment</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> borderline personality disorder </p> <p><b>Settings:</b> inpatient and outpatient </p> <p><b>Intervention:</b> psychotherapy </p> <p><b>Comparison:</b> waiting list or no treatment </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Number of participants</b> </p> <p><b>(RCTs)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Quality of the evidence</b> </p> <p><b>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="center" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="center" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Waiting list or no treatment</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Psychotherapy</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>BPD symptom severity</b> </p> <p>Measured by: clinicians and self‐rated</p> <p>Timing of outcome assessment: end of treatment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean score in the intervention groups was <b>0.49 SD lower</b> (0.93 lower to 0.05 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>161</p> <p>(3 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low<sup>a,b</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>An SMD of 0.49 represents a moderate effect.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Self‐harm</b> </p> <p>Measured by: clinicians and self‐rated</p> <p>Timing of outcome assessment: end of treatment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean score in the intervention groups was<b>0.17 SD lower</b> (0.52 lower to 0.18 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>128</p> <p>(2 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low<sup>a,b</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>An SMD of 0.17 represents a small effect.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Suicide‐related outcomes</b> </p> <p>Measured by: self‐rated</p> <p>Timing of outcome assessment: end of treatment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean score in the intervention groups was <b>5.62 SD lower</b> (16.39 lower to 5.16 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>108</p> <p>(2 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very</b> <b>low<sup>a,b,c</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>An SMD of 5.62 represents a large effect.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Psychosocial functioning</b> </p> <p>Measured by: clinicians and self‐rated</p> <p>Timing of outcome assessment: end of treatment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean score in the intervention groups was <b>0.56 SD lower</b> (1.01 lower to 0.11 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>219</p> <p>(5 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low<sup>a,b</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>An SMD of 0.56 represents a moderate effect.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Depression</b> </p> <p>Measured by: clinicians and self‐rated</p> <p>Timing of outcome assessment: end of treatment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean score in the intervention groups was <b>1.28 SD lower</b> (2.21 lower to 0.34 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>239</p> <p>(6 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low<sup>a,b</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>An effect size of 1.28 represents a large effect.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Attrition</b> </p> <p>Timing of outcome assessment: end of treatment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>81 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>147 per 1000</b> (95% CI 118 fewer to 74 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.55 (95% CI 0.20 to 1.50)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>144</p> <p>(3 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very</b> <b>low<sup>a,b,c</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects (not measured</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comments</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comments</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies were found that assessed this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> Confidence interval; <b>RCTs:</b> Randomised controlled trials; <b>RR:</b> Risk ratio; <b>SMD:</b> Standardized mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect<br/><b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate<br/><b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate<br/><b>Very low quality:</b> we are very uncertain about the estimate </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>We downgraded the quality of this evidence by one level due to risk of bias.<br/><sup>b</sup>We downgraded the quality of this evidence by one level due to imprecision (there was a wide CI).<br/><sup>c</sup>We downgraded the quality of this evidence by one level due to inconsistency. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Psychotherapy versus waiting list or no treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/full#CD012955-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012955-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Dialectical behavioural therapy or mentalisation‐based therapy versus treatment‐as‐usual</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Dialectical behavioural therapy or mentalisation‐based therapy versus treatment‐as‐usual</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> borderline personality disorder </p> <p><b>Settings:</b> inpatient and outpatient </p> <p><b>Intervention:</b> dialectical behavioural therapy (DBT) or mentalisation‐based therapy (MBT) </p> <p><b>Comparison:</b> treatment‐as‐usual (TAU) </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Number of participants</b> </p> <p><b>(RCTs)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Quality of the evidence</b> </p> <p><b>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="center" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="center" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>TAU</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>DBT or MBT</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell" colspan="7" rowspan="1" scope="col" valign=""> <p><b><i>DBT</i> </b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>BPD severity</b> </p> <p>Measured by: clinicians</p> <p>Timing of outcome assessment: end of treatment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean score in the intervention groups was <b>0.60 SD lower</b> (1.05 lower to 0.14 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>149</p> <p>(3 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low<sup>a,b</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>An SMD of 0.60 represents a moderate effect.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Self‐harm</b> </p> <p>Measured by: clinicians</p> <p>Timing of outcome assessment: end of treatment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean score in the intervention groups was<br/><b>0.28 SD lower</b> (0.48 lower to 0.07 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>376</p> <p>(7 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low<sup>a,b</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>An SMD of 0.28 represents a small effect.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Psychosocial functioning</b> </p> <p>Measured by: clinicians and self‐rated</p> <p>Timing of outcome assessment: end of treatment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean score in the intervention groups was <b>0.36 SD lower</b> (0.69 lower to 0.03 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>225</p> <p>(6 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low<sup>a,b,</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>An SMD of 0.36 represents a small effect.</p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="7" rowspan="1" scope="col" valign=""> <p><b><i><b>MBT</b> </i> </b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Self‐harm</b> </p> <p>Measured by: clinicians</p> <p>Timing of outcome assessment: end of treatment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>631 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>240 per 1000</b> (95% CI 334 fewer to 126 fewer) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.62 (95% CI 0.49 to 0.80)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>252</p> <p>(3 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low<sup>a,b</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Suicide‐related outcomes</b> </p> <p>Measured by: clinicians</p> <p>Timing of outcome assessment: end of treatment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>298 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>268 per 1000</b> (95% CI 286 fewer to 209 fewer) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.10 (95% CI 0.04 to 0.30)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>218</p> <p>(3 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low<sup>a,b</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> Confidence interval; <b>DBT:</b> Dialectical behavioural therapy; <b>MBT:</b> Mentalisation‐based therapy; <b>RCTs:</b> Randomised controlled trials; <b>RR:</b> Risk ratio; <b>SMD:</b> Standardized mean difference; <b>TAU:</b> Treatment‐as‐usual </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect<br/><b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate<br/><b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate<br/><b>Very low quality:</b> we are very uncertain about the estimate </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>We downgraded the quality of this evidence by one level due to risk of bias.<br/><sup>b</sup>We downgraded the quality of this evidence by one level due to imprecision (there was a wide CI). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Dialectical behavioural therapy or mentalisation‐based therapy versus treatment‐as‐usual</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/full#CD012955-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012955-tbl-0004"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Unused methods</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Section</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Protocol (</b><a href="./references#CD012955-bbs2-0443" title="StorebøOJ , Stoffers-WinterlingJM , VöllmBA , KongerslevMT , MattiviJT , KielsholmML , et al. Psychological therapies for people with borderline personality disorder. Cochrane Database of Systematic Reviews2018, Issue 2. Art. No: CD012955. [DOI: 10.1002/14651858.CD012955]">Storebø 2018</a><b>)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Review</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Unit of analysis issues</b><br/> <br/>  </p> <p> <br/>  </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cross‐over trials</b> </p> <p>We would have included cross‐over trials. We planned to include data up to the point of first cross‐over (first period only; <a href="./references#CD012955-bbs2-0282" title="CurtinF , ElbourneD , AltmanDG . Meta-analysis combining parallel and cross-over clinical trials. III: the issue of carry-over. Statistics in Medicine2002;21(15):2161-73. [DOI: 10.1002/sim.1207] [PMID: 12210631]">Curtin 2002</a>). We did not intend to use data from subsequent periods due to the likelihood of carry‐over effects from the preceding treatment(s). We planned not to combine repeated participant interventions in one meta‐analysis. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We did not include any cross‐over trial. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cluster‐randomised trials</b> </p> <p>Had trials used cluster randomisation, we would have anticipated that investigators would have presented their results after appropriately controlling for clustering effects (robust standard errors or hierarchical linear models). If it had been unclear whether a cluster‐randomised trial had used appropriate controls for clustering, we would have contacted the investigators for further information. We would have requested and re‐analysed individual patient data using multilevel models that controlled for clustering, if appropriate controls had not been used. Following this, we would have analysed effect sizes and standard errors in RevMan 5 (<a href="./references#CD012955-bbs2-0385" title="Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">Review Manager 2014</a>), using the generic inverse method (<a href="./references#CD012955-bbs2-0324" title="HigginsJPT , DeeksJJ , AltmanDG , editor(s), Cochrane Statistical Methods Group. Chapter 16: Special topics in statistics. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011</a>). If there had been insufficient information to control for clustering, we would have entered outcome data using individuals as the units of analysis, and then conducted a sensitivity analysis to assess the potential biasing effects of inadequately controlled cluster‐randomised trials (<a href="./references#CD012955-bbs2-0289" title="DonnerA , KlarN . Issues in the meta-analysis of cluster-randomized trials. Statistics in Medicine2002;21(9):2971-80. [DOI: 10.1002/sim.1301] [PMID: 12325113]">Donner 2002</a>). If individual participant data had not been available, we would have looked for information on intra‐class correlation coefficients to adjust for the potential clustering effects.   </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We did not include any cluster‐randomised trial.<br/>  </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adjustment for multiplicity</b> </p> <p>We planned to adjust the P values and CIs for multiplicity due to the many secondary outcome comparisons following the method described by <a href="./references#CD012955-bbs2-0331" title="JakobsenJC , WetterslevJ , WinkelP , LangeT , GluudC . Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods. BMC Medical Research Methodology2014;14:120. [DOI: 10.1186/1471-2288-14-120] [PMCID: PMC4251848] [PMID: 25416419]">Jakobsen 2014</a>. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>We only adjusted the primary outcomes and one secondary outcomes for multiplicity, i.e. those outcomes presented in the SoF table. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Dealing with missing data</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Had dichotomous data not been presented on the basis of ITT data, we would have added the number of participants lost in each group to the participants with unfavourable results, acting on the assumption that most people with BPD do not get lost at random. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We were unable to perform this analysis due to insufficient information</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Subgroup analysis and investigation of heterogeneity</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We intended to conduct subgroup analyses to make hypotheses about the subgroups mentioned below. </p> <p> <ol id="CD012955-list-0006"> <li> <p>Sex (male versus female)</p> </li> <li> <p>Comorbidity (people with comorbidity versus people without comorbidity)</p> </li> <li> <p>Treatment intensity (once a week compared to more than once a week</p> </li> <li> <p>Concurrent‐drug interventions (trials with concurrent‐drug interventions compared to those without) </p> </li> </ol> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We did not conduct these preplanned analyses because of lack of data.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sensitivity analysis</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We intended to assess the impact of heterogeneity on the overall pooled effect estimate by removing studies ('outliers') that contributed to heterogeneity. We intended to remove outliers one by one and assess the impact on the overall outcome. </p> <p> <ol id="CD012955-list-0007"> <li> <p>Decisions made during the review process (our assessment of the level of clinical heterogeneity) </p> </li> <li> <p>Impact of bias (studies with low and high risk of bias)</p> </li> <li> <p>Type of data collection (for example, different ways to measure depression)</p> </li> <li> <p>Imputed data (comparing analyses with available outcome data with those using an ITT approach) </p> </li> </ol> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We were not able to perform these analyses, due to a lack of sufficient data.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>TSA</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We intended to calculate post hoc, low bias, risk diversity‐adjusted required information size TSA analyses for the primary outcomes. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We were not able to perform these analyses with low risk of bias trials.</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p><b>BPD:</b> borderline personality disorder; <b>CI:</b> confidence interval;<b>ITT:</b> intention to treat; <b>TAU:</b> treatment‐as‐usual </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Unused methods</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/full#CD012955-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012955-tbl-0005"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Key demographic characteristics of the included studies</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Category</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study frequency</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="3" rowspan="1" scope="col" valign="bottom"> <p><b><i>Sample size</i> </b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sample size above 100 participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012955-bbs2-0002" title='AndreoliA , BurnandY , CochennecMF , MarieD , Di ClementeT , OhlendorfP . Psychoanalytic psychotherapy and venlafaxine among acutely suicidal borderline patients: a randomized clinical study. European Psychiatry2009;24(Suppl 1):S93. [DOI: 10.1016/S0924-9338(09)70326-8] [S18-03]AndreoliA , BurnandY , CochennecMF , OhlendorfP , FrambatiL , Gaudry-MaireD , et al. Disappointed love and suicide: a randomized controlled trial of "abandonment psychotherapy" among borderline patients. Journal of Personality Disorders2016;30(2):271-87. [DOI: 10.1521/pedi_2015_29_196] [PMID: 26111250]AndreoliA , BurnandY , FrambatiL , ManningD , FrancesA . Abandonment psychotherapy and psychosocial functioning among suicidal patients with borderline personality disorder: a 3-year naturalistic follow-up. Journal of Personality Disorders 2019 Feb 20 [Epub ahead of print]. [DOI: 10.1521/pedi_2019_33_423] [PMID: 30785852]AndreoliA . Re: your study in BPD - Cochrane Collaboration review [personal communication]. Email to: J Stoffers-Winterling 5 June 2018. '>Andreoli 2016</a>; <a href="./references#CD012955-bbs2-0003" title="AntonsenBT , JohansenMS , RøFG , KvarsteinEH , WilbergT . Is reflective functioning associated with clinical symptoms and long-term course in patients with personality disorders?Comprehensive Psychiatry2016;64:46-58. [DOI: 10.1016/j.comppsych.2015.05.016] [PMID: 26104432]AntonsenBT , KlungsøyrO , KampsA , HummelenB , JohansenMS , PedersenG , et al. Step-down versus outpatient psychotherapeutic treatment for personality disorders: 6-year follow-up of the Ullevål personality project. BMC Psychiatry2014;14:119. [DOI: 10.1186/1471-244X-14-119] [PMC4000615] [PMID: 24758722]AntonsenBT , KvarsteinEH , Urnes Ø, HummelenB , KarterudS , WilbergT . Favourable outcome of long-term combined psychotherapy for patients with borderline personality disorder: six-year follow-up of a randomized study. Psychotherapy Research2017;27(1):51-63. [DOI: 10.1080/10503307.2015.1072283] [PMID: 26261865]ArnevikE , WilbergT , Urnes Ø, JohansenM , MonsenJT , KarterudS . Psychotherapy for personality disorders: short-term day hospital psychotherapy versus outpatient individual therapy - a randomized controlled study. European Psychiatry2009;24(2):71-8. [DOI: 10.1016/j.eurpsy.2008.09.004] [PMID: 19097870]GullestadFS , JohansenMS , HøglendP , KarterudS , WilbergT . Mentalization as a moderator of treatment effects: findings from a randomized clinical trial for personality disorders. Psychotherapy Research2013;23(6):674-89. [DOI: 10.1080/10503307.2012.684103] [PMID: 22612470]GullestadFS . Re: questions regarding your trial on day hospital step-down program [personal communication]. Email to: E Faltinsen 4 December 2017. KvarsteinEH , ArnevikE , HalsteinliV , RøFG , KarterudS , WilbergT . Health service costs and clinical gains of psychotherapy for personality disorders: a randomized controlled trial of day-hospital-based step-down treatment versus outpatient treatment at a specialist practice. BMC Psychiatry2013;13:315. [DOI: 10.1186/1471-244X-13-315] [PMC4222503] [PMID: 24268099]">Antonsen 2017</a>; <a href="./references#CD012955-bbs2-0047" title="BedicsJD , AtkinsDC , ComtoisKA , LinehanMM . Treatment differences in the therapeutic relationship and introject during a 2-year randomized controlled trial of dialectical behavior therapy versus nonbehavioral psychotherapy experts for borderline personality disorder. Journal of Consulting and Clinical Psychology2012;80(1):66-77. [DOI: 10.1037/a0026113] [PMC3265694] [PMID: 22061867]BedicsJD , AtkinsDC , ComtoisKA , LinehanMM . Weekly therapist ratings of the therapeutic relationship and patient introject furing the course of dialectical behavioral therapy for the treatment of borderline personality disorder. Psychotherapy2012;49(2):231-40. [DOI: 10.1037/a0028254] [PMID: 22642526]BedicsJD , AtkinsDC , HarnedMS , LinehanMM . The therapeutic alliance as a predictor of outcome in dialectical behavior therapy versus nonbehavioral psychotherapy by experts for borderline personality disorder. Psychotherapy2015;52(1):67-77. [DOI: 10.1037/a0038457] [PMID: 25751116]BrownMZ , LinehanMM , ComtoisKA , MurrayA , ChapmanAL . Shame as a prospective predictor of self-inflicted injury in borderline personality disorder: a multi-modal analysis. Behaviour Research and Therapy2009;47(10):815-22. [DOI: 10.1016/j.brat.2009.06.008] [PMC2761705] [PMID: 19596223 ]CoyleTN , ShaverJA , LinehanMM . On the potential for iatrogenic effects of psychiatric crisis services: the example of dialectical behavior therapy for adult women with borderline personality disorder. Journal of Consulting and Clinical Psychology2018;86(2):116-24. [DOI: 10.1037/ccp0000275] [PMID: 29369662]HarnedMS , ChapmanAL , Dexter-MazzaET , MurrayA , ComtoisKA , LinehanMM . Treating co-occurring Axis I disorders in recurrently suicidal women with borderline personality disorder: a 2-year randomized trial of dialectical behavior therapy versus community treatment by experts. Journal of Consulting and Clinical Psychology2008;76(6):1068-75. [DOI: 10.1037/a0014044] [PMID: 19045974]HarnedMS , ChapmanAL , Dexter-MazzaET , MurrayA , ComtoisKA , LinehanMM . Treating co-occurring Axis I disorders in recurrently suicidal women with borderline personality disorder: a 2-year randomized trial of dialectical behavior therapy versus community treatment by experts. Personality Disorders: Theory, Research, and Treatment2009;S(1):35-45. [DOI: 10.1037/1949-2715.S.1.35]HarnedMS , JacksonSC , ComtoisKA , LinehanMM . Dialectical behavior therapy as a precursor to PTSD treatment for suicidal and/or self-injuring women with bordreline personality disorder. Journal of Traumatic Stress2010;23(4):421-9. [DOI: 10.1002/jts.20553] [PMID: 20648564]LindenboimN , ComtoisKA , LinehanMM . Skills practice in dialectical behavior therapy for suicidal women meeting criteria for borderline personality disorder. Cognitive and Behavioral Practice2007;14(2):147-56. [DOI: 10.1016/j.cbpra.2006.10.004]LinehanMM , ComtoisKA , MurrayAM , BrownMZ , GallopRJ , HeardHL , et al. Two-year randomized controlled trial and follow-up of dialectical behavior therapy vs therapy by experts for suicidal behaviors and borderline personality disorder. Archives of General Psychiatry2006;63(7):757-66. [DOI: 10.1001/archpsyc.63.7.757] [PMID: 16818865]LinehanMM . Error in table in: two-year randomized controlled trial and follow-up of dialectical behavior therapy vs therapy by experts for suicidal behaviors and borderline personality disorder. Archives of General Psychiatry2007;64(12):1401. Erratum for: Archives of General Psychiatry 2007;64(12):1401. McMainS . Dialectic behaviour therapy reduces suicide attempts compared with non-behavioural psychotherapy in women with borderline personality disorder. Evidence-Based Mental Health2007;10(1):18. [DOI: 10.1136/ebmh.10.1.18] [PMID: 17255387]NeacsiuAD , LunguA , HarnedMS , RizviSL , LinehanMM . Impact of dialectical behavior therapy versus community treatment by experts on emotional experience, expression, and acceptance in borderline personality disorder. Behaviour Research and Therapy2014;53:47-54. [DOI: 10.1016/j.brat.2013.12.004] [PMC3955205] [PMID: 24418652]NeacsiuAD , RizviSL , LinehanMM . Dialectical behavior therapy skills use as a mediator and outcome of treatment for borderline personality disorder. Behaviour Research and Therapy2010;48(9):832-9. [DOI: 10.1016/j.brat.2010.05.017] [PMC2914145] [PMID: 20579633]SecristCD . The Role of Executive Functioning in the Treatment of Borderline Personality Disorder [PhD thesis]. Washington (DC): University of Washington, 2014. ">Linehan 2006</a>; <a href="./references#CD012955-bbs2-0049" title="CaseBG . Letter to the editor on 'McMain SF, Links PS, Gnam WH, Guimond T, Cardish RJ, Korman L, et al. A randomized trial of dialectical behavior therapy versus general psychiatric management for borderline personality disorder. American Journal of Psychiatry 2009;166(12):1365-74. DOI: 10.1176/appi.ajp.2009.09010039'. American Journal of Psychiatry2010;167(4):475. [DOI: 10.1176/appi.ajp.2009.09101532] [PMID: 20360332 ]ISRCTN02634417. Hope for chronically suicidal patient: evaluating the clinical and health services impact of dialectical behaviour therapy (DBT) in individuals with borderline personality disorder [Evaluating the clinical and health services impact of dialectical behaviour therapy (DBT) in individuals with borderline personality disorder: a randomised controlled trial]. www.isrctn.com/ISRCTN02634417 (first received 16 November 2005). [DOI: 10.1186/ISRCTN02634417]McMainSF , FitzpatrickS , BoritzT , BarnhartR , LinksP , StreinerDL . Outcome trajectories and prognostic factors for suicide and self-harm behaviors in patients with borderline personaliy disorder following one year of outpatient psychotherapy. Journal of Personality Disorders2018;32(4):497-512. [DOI: 10.1521/pedi_2017_31_309] [PMID: 28910214]McMainSF , LinksPS , GnamWH , GuimondT , CardishRJ , KormanL , et al. A randomized trial of dialectical behavior therapy versus general psychiatric management for borderline personality disorder. American Journal of Psychiatry2009;166(12):1365-74. [DOI: 10.1176/appi.ajp.2009.09010039] [PMID: 19755574]McMainSF . Dr McMain replies to letter to the editor on 'McMain SF, Links PS, Gnam WH, Guimond T, Cardish RJ, Korman L, et al. A randomized trial of dialectical behavior therapy versus general psychiatric management for borderline personality disorder. American Journal of Psychiatry 2009;166(12):1365-74. DOI: 10.1176/appi.ajp.2009.09010039'. American Journal of Psychiatry2010;167(4):475-6. [DOI: 10.1176/appi.ajp.2009.09101532r)]NCT00154154. Hope for the chronically suicidal patient [Hope for the chronically suicidal patient: evaluating the clinical and health services impact of dialectical behaviour therapy in individuals with borderline personality disorder]. www.clinicaltrials.gov/ct2/show/NCT00154154 (first received 7 September 2005). ">McMain 2009</a>; <a href="./references#CD012955-bbs2-0051" title="McMurranM , CrawfordMJ , ReillyJ , DelportJ , McCroneP , WhithamD , et al. Psychoeducation with problem-solving (PEPS) therapy for adults with personality disorder: a pragmatic randomised controlled trial to determine the clinical effectiveness and cost-effectiveness of a manualised intervention to improve social functioning. Health Technology Assessment2016;20(52):1-282. [DOI: 10.3310/hta20520]McMurranM . RE: Cochrane Collaboration review - PEPS study [personal communication]. Email to: J Stoffers-Winterling 5 July 2018. McMurranM . Request for data on BPD subjects in the PEPS rcp-study for use a new Cochrane review [personal communication]. Email to: M Kongerslev 7 March 2017. ">McMurran 2016</a> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="3" rowspan="1" scope="col" valign="bottom"> <p><b><i>Setting</i> </b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Studies with inpatient settings</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Jahangard-2012" target="_blank">Jahangard 2012</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Leichsenring-2016" target="_blank">Leichsenring 2016</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Mohamadizadeh-2017" target="_blank">Mohamadizadeh 2017</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Schilling-2018" target="_blank">Schilling 2018</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Stanley-2017" target="_blank">Stanley 2017</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Studies with both inpatient and outpatient settings</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Antonsen-2017" target="_blank">Antonsen 2017</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Bateman-1999" target="_blank">Bateman 1999</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Davidson-2014" target="_blank">Davidson 2014</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Gleeson-2012" target="_blank">Gleeson 2012</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Kredlow-2017b" target="_blank">Kredlow 2017b</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Laurenssen-2018" target="_blank">Laurenssen 2018</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Smith-2012" target="_blank">Smith 2012</a> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="3" rowspan="1" scope="col" valign="bottom"> <p><b><i>Gender</i> </b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Only females included</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Carter-2010" target="_blank">Carter 2010</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Doering-2010" target="_blank">Doering 2010</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Farrell-2009" target="_blank">Farrell 2009</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Gratz-2006" target="_blank">Gratz 2006</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Gratz-2014" target="_blank">Gratz 2014</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Harned-2014" target="_blank">Harned 2014</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Koons-2001a" target="_blank">Koons 2001a</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Linehan-1991" target="_blank">Linehan 1991</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Linehan-1994" target="_blank">Linehan 1994</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Linehan-2006" target="_blank">Linehan 2006</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Linehan-2015a" target="_blank">Linehan 2015a</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Mohamadizadeh-2017" target="_blank">Mohamadizadeh 2017</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Smith-2012" target="_blank">Smith 2012</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Van-den-Bosch-2005" target="_blank">Van den Bosch 2005</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Weinberg-2006" target="_blank">Weinberg 2006</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Zanarini-2008" target="_blank">Zanarini 2008</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Zanarini-2018" target="_blank">Zanarini 2018</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Only males included</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Bianchini-2019" target="_blank">Bianchini 2019</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Kamalabadi-2012" target="_blank">Kamalabadi 2012</a> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="3" rowspan="1" scope="col" valign="bottom"> <p><b><i>Diagnostic classification</i> </b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DSM‐III diagnosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Linehan-1991" target="_blank">Linehan 1991</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DSM‐III‐R diagnosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Bateman-1999" target="_blank">Bateman 1999</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Koons-2001a" target="_blank">Koons 2001a</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Linehan-1994" target="_blank">Linehan 1994</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Turner-2000" target="_blank">Turner 2000</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DSM‐IV diagnosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Borschmann-2013" target="_blank">Borschmann 2013</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-McMurran-2016" target="_blank">McMurran 2016</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Mohamadizadeh-2017" target="_blank">Mohamadizadeh 2017</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Priebe-2012" target="_blank">Priebe 2012</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Rossouw-2012b" target="_blank">Rossouw 2012b</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Schilling-2018" target="_blank">Schilling 2018</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DSM‐IV‐TR diagnosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Andreoli-2016" target="_blank">Andreoli 2016</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Antonsen-2017" target="_blank">Antonsen 2017</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Bateman-2009" target="_blank">Bateman 2009</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Bellino-2006" target="_blank">Bellino 2006</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Bellino-2007" target="_blank">Bellino 2007</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Bellino-2010" target="_blank">Bellino 2010</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Blum-2008" target="_blank">Blum 2008</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Bos-2010" target="_blank">Bos 2010</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Carter-2010" target="_blank">Carter 2010</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Cottraux-2009" target="_blank">Cottraux 2009</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Davidson-2006" target="_blank">Davidson 2006</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Davidson-2014" target="_blank">Davidson 2014</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Doering-2010" target="_blank">Doering 2010</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Elices-2016" target="_blank">Elices 2016</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Feigenbaum-2012" target="_blank">Feigenbaum 2012</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Feliu_x002d_Soler-2017" target="_blank">Feliu-Soler 2017</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Giesen_x002d_Bloo-2006" target="_blank">Giesen-Bloo 2006</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Gleeson-2012" target="_blank">Gleeson 2012</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Gratz-2006" target="_blank">Gratz 2006</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Gratz-2014" target="_blank">Gratz 2014</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Gregory-2008b" target="_blank">Gregory 2008b</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Haeyen-2018" target="_blank">Haeyen 2018</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Harned-2014" target="_blank">Harned 2014</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Jahangard-2012" target="_blank">Jahangard 2012</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Jochems-2015" target="_blank">Jochems 2015</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-J_x00f8_rgensen-2013" target="_blank">Jørgensen 2013</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Kamalabadi-2012" target="_blank">Kamalabadi 2012</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Kramer-2011" target="_blank">Kramer 2011</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Kramer-2014" target="_blank">Kramer 2014</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Kramer-2016" target="_blank">Kramer 2016</a>: <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Kredlow-2017a" target="_blank">Kredlow 2017a</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Kredlow-2017b" target="_blank">Kredlow 2017b</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Laurenssen-2018" target="_blank">Laurenssen 2018</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Lepp_x00e4_nen-2016" target="_blank">Leppänen 2016</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Lin-2019" target="_blank">Lin 2019</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Linehan-2006" target="_blank">Linehan 2006</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-McMain-2009" target="_blank">McMain 2009</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-McMain-2017" target="_blank">McMain 2017</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Morey-2010" target="_blank">Morey 2010</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Morton-2012" target="_blank">Morton 2012</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Nadort-2009" target="_blank">Nadort 2009</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Pascual-2015" target="_blank">Pascual 2015</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Philips-2018" target="_blank">Philips 2018</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Reneses-2013" target="_blank">Reneses 2013</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Robinson-2016" target="_blank">Robinson 2016</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Santisteban-2015" target="_blank">Santisteban 2015</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Schilling-2018" target="_blank">Schilling 2018</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Sinnaeve-2018" target="_blank">Sinnaeve 2018</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Soler-2009" target="_blank">Soler 2009</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Smith-2012" target="_blank">Smith 2012</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Van-den-Bosch-2005" target="_blank">Van den Bosch 2005</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Weinberg-2006" target="_blank">Weinberg 2006</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Zanarini-2008" target="_blank">Zanarini 2008</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Zanarini-2018" target="_blank">Zanarini 2018</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ICD‐10 diagnosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Leichsenring-2016" target="_blank">Leichsenring 2016</a> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="3" rowspan="1" scope="col" valign="bottom"> <p><b><i>Diagnostic assessment</i> </b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BPDSI‐IV (<a href="./references#CD012955-bbs2-0233" title="ArntzA , Van den HoornM , CornelisJ , VerheulR , Van den BoschW , De BieAJ . Reliability and validity of the borderline personality disorder severity index. Journal of Personality Disorders2003;17(1):45-59. [PMID: 12659546]">Arntz 2003</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Kamalabadi-2012" target="_blank">Kamalabadi 2012</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CI‐BPD (<a href="./references#CD012955-bbs2-0434" title="ZanariniMC . The Childhood Interview for DSM-IV Borderline Personality Disorder (CI-BPD). Belmont (MA): McLean Hospital and Harvard Medical School, 2003.">Zanarini 2003b</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Rossouw-2012b" target="_blank">Rossouw 2012b</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DIB (<a href="./references#CD012955-bbs2-0305" title="GundersonJG , KolbJE , AustinV . The diagnostic interview for borderline patients. American Journal of Psychiatry1981;138(7):896-903. [DOI: 10.1176/ajp.138.7.896] [PMID: 7258348]">Gunderson 1981</a>) or DIB‐R (<a href="./references#CD012955-bbs2-0430" title="ZanariniMC , GundersonJG , FrankenburgFR , ChaunceyDL . The revised Diagnostic Interview for Borderlines: discriminating BPD from other Axis II disorders. Journal of Personality Disorders1989;3(1):10-8. [DOI: 10.1521/pedi.1989.3.1.10]">Zanarini 1989</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Cottraux-2009" target="_blank">Cottraux 2009</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Feliu_x002d_Soler-2017" target="_blank">Feliu-Soler 2017</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Linehan-1991" target="_blank">Linehan 1991</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Zanarini-2008" target="_blank">Zanarini 2008</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DIB‐R (<a href="./references#CD012955-bbs2-0430" title="ZanariniMC , GundersonJG , FrankenburgFR , ChaunceyDL . The revised Diagnostic Interview for Borderlines: discriminating BPD from other Axis II disorders. Journal of Personality Disorders1989;3(1):10-8. [DOI: 10.1521/pedi.1989.3.1.10]">Zanarini 1989</a>) and the BSI (<a href="./references#CD012955-bbs2-0278" title="ConteHR , PlutchikR , KarasuTB , JerretI . A self-report borderline scale. Discriminative validity and preliminary norms. Journal of Nervous and Mental Disease1980;168(7):428-35. [DOI: 10.1097/00005053-198007000-00007] [PMID: 7400793]">Conte 1980</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Farrell-2009" target="_blank">Farrell 2009</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DIB‐R (<a href="./references#CD012955-bbs2-0430" title="ZanariniMC , GundersonJG , FrankenburgFR , ChaunceyDL . The revised Diagnostic Interview for Borderlines: discriminating BPD from other Axis II disorders. Journal of Personality Disorders1989;3(1):10-8. [DOI: 10.1521/pedi.1989.3.1.10]">Zanarini 1989</a>) plus any other DSM‐oriented diagnostic interview SCID‐II (<a href="./references#CD012955-bbs2-0295" title="FirstMB , GibbonM , SpitzerRL , WilliamsJBW , BenjaminLS . Structured Clinical Interview for DSM-IV Axis II Personality Disorders (SCID-II). Washington (DC): American Psychiatric Press, 1997.">First 1997</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Bateman-1999" target="_blank">Bateman 1999</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DIPD‐IV (<a href="./references#CD012955-bbs2-0429" title="ZanariniMC , FrankenburgFR , ChaunceyDL , GundersonJG . The Diagnostic Interview for Personality Disorders: interrater and test-retest reliability. Comprehensive Psychiatry1987;28(6):467-80. [DOI: 10.1016/0010-440x(87)90012-5] [PMID: 3691072]">Zanarini 1987</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Gratz-2006" target="_blank">Gratz 2006</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Gratz-2014" target="_blank">Gratz 2014</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Morey-2010" target="_blank">Morey 2010</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IPDE (<a href="./references#CD012955-bbs2-0358" title="LorangerAW , JancaA , SartoriusN , editor(s). Assessment and Diagnosis of Personality Disorders. The ICD-10 International Personality Disorder Examination (IPDE). Cambridge (Camb): Cambridge University Press, 1995. [WHO IRIS: apps.who.int/iris/handle/10665/41912]">Loranger 1995</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Andreoli-2016" target="_blank">Andreoli 2016</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Harned-2014" target="_blank">Harned 2014</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-McMain-2017" target="_blank">McMain 2017</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-McMurran-2016" target="_blank">McMurran 2016</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IPDE‐self‐rating screening and questionnaire, with the preliminary findings confirmed in clinical interviews by a psychiatrist </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Carter-2010" target="_blank">Carter 2010</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Millon Clinical Multiaxial Inventory, 3rd Edition (MCMI‐III)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Jahangard-2012" target="_blank">Jahangard 2012</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PDE (<a href="./references#CD012955-bbs2-0357" title="LorangerAW . Personality Disorder Examination (PDE) Manual. Yonkers (NY): DV Communications, 1988.">Loranger 1988</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Turner-2000" target="_blank">Turner 2000</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SCID‐II (<a href="./references#CD012955-bbs2-0295" title="FirstMB , GibbonM , SpitzerRL , WilliamsJBW , BenjaminLS . Structured Clinical Interview for DSM-IV Axis II Personality Disorders (SCID-II). Washington (DC): American Psychiatric Press, 1997.">First 1997</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Amianto-2011" target="_blank">Amianto 2011</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Antonsen-2017" target="_blank">Antonsen 2017</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Bateman-1999" target="_blank">Bateman 1999</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Bateman-2009" target="_blank">Bateman 2009</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Bellino-2006" target="_blank">Bellino 2006</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Bellino-2007" target="_blank">Bellino 2007</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Bellino-2010" target="_blank">Bellino 2010</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Borschmann-2013" target="_blank">Borschmann 2013</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Bos-2010" target="_blank">Bos 2010</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Davidson-2006" target="_blank">Davidson 2006</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Davidson-2014" target="_blank">Davidson 2014</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Doering-2010" target="_blank">Doering 2010</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Elices-2016" target="_blank">Elices 2016</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Feigenbaum-2012" target="_blank">Feigenbaum 2012</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Giesen_x002d_Bloo-2006" target="_blank">Giesen-Bloo 2006</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Gleeson-2012" target="_blank">Gleeson 2012</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Gregory-2008b" target="_blank">Gregory 2008b</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Haeyen-2018" target="_blank">Haeyen 2018</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-J_x00f8_rgensen-2013" target="_blank">Jørgensen 2013</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Koons-2001a" target="_blank">Koons 2001a</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Kramer-2011" target="_blank">Kramer 2011</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Kramer-2014" target="_blank">Kramer 2014</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Kramer-2016" target="_blank">Kramer 2016</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Kredlow-2017a" target="_blank">Kredlow 2017a</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Kredlow-2017b" target="_blank">Kredlow 2017b</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Laurenssen-2018" target="_blank">Laurenssen 2018</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Leichsenring-2016" target="_blank">Leichsenring 2016</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Lepp_x00e4_nen-2016" target="_blank">Leppänen 2016</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Lin-2019" target="_blank">Lin 2019</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Linehan-1994" target="_blank">Linehan 1994</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Linehan-2006" target="_blank">Linehan 2006</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Linehan-2015a" target="_blank">Linehan 2015a</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Koons-2001a" target="_blank">Koons 2001a</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Morton-2012" target="_blank">Morton 2012</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Nadort-2009" target="_blank">Nadort 2009</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Pascual-2015" target="_blank">Pascual 2015</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Philips-2018" target="_blank">Philips 2018</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Priebe-2012" target="_blank">Priebe 2012</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Reneses-2013" target="_blank">Reneses 2013</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Robinson-2016" target="_blank">Robinson 2016</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Schilling-2018" target="_blank">Schilling 2018</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Soler-2009" target="_blank">Soler 2009</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Smith-2012" target="_blank">Smith 2012</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Van-den-Bosch-2005" target="_blank">Van den Bosch 2005</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Weinberg-2006" target="_blank">Weinberg 2006</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Zanarini-2018" target="_blank">Zanarini 2018</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SIDP‐IV (<a href="./references#CD012955-bbs2-0383" title="PfohlB , BlumN , ZimmermanM . Structured Interview for DSM-IV Personality (SIPD-IV). Washington (DC): American Psychiatric Press, 1997.">Pfohl 1997</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Blum-2008" target="_blank">Blum 2008</a> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="3" rowspan="1" scope="col" valign="bottom"> <p><b><i>Exclusion criteria in included studies</i> </b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants with substance abuse or dependence excluded</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Amianto-2011" target="_blank">Amianto 2011</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Andreoli-2016" target="_blank">Andreoli 2016</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Antonsen-2017" target="_blank">Antonsen 2017</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Bateman-1999" target="_blank">Bateman 1999</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Bateman-2009" target="_blank">Bateman 2009</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Bellino-2006" target="_blank">Bellino 2006</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Bellino-2007" target="_blank">Bellino 2007</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Bellino-2010" target="_blank">Bellino 2010</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Blum-2008" target="_blank">Blum 2008</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Carmona-_x00ed_-Farr_x00e9_s-2019" target="_blank">Carmona í Farrés 2019</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Cottraux-2009" target="_blank">Cottraux 2009</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Davidson-2006" target="_blank">Davidson 2006</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Doering-2010" target="_blank">Doering 2010</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Feigenbaum-2012" target="_blank">Feigenbaum 2012</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Giesen_x002d_Bloo-2006" target="_blank">Giesen-Bloo 2006</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Gratz-2006" target="_blank">Gratz 2006</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Gratz-2014" target="_blank">Gratz 2014</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-J_x00f8_rgensen-2013" target="_blank">Jørgensen 2013</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Kamalabadi-2012" target="_blank">Kamalabadi 2012</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Koons-2001a" target="_blank">Koons 2001a</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Kramer-2011" target="_blank">Kramer 2011</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Kredlow-2017a" target="_blank">Kredlow 2017a</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Laurenssen-2018" target="_blank">Laurenssen 2018</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Leichsenring-2016" target="_blank">Leichsenring 2016</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Lepp_x00e4_nen-2016" target="_blank">Leppänen 2016</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Lin-2019" target="_blank">Lin 2019</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Linehan-1991" target="_blank">Linehan 1991</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Linehan-1994" target="_blank">Linehan 1994</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-McMain-2009" target="_blank">McMain 2009</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Mohamadizadeh-2017" target="_blank">Mohamadizadeh 2017</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Morey-2010" target="_blank">Morey 2010</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Nadort-2009" target="_blank">Nadort 2009</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Pascual-2015" target="_blank">Pascual 2015</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Rossouw-2012b" target="_blank">Rossouw 2012b</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Schilling-2018" target="_blank">Schilling 2018</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Schuppert-2012" target="_blank">Schuppert 2012</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Sinnaeve-2018" target="_blank">Sinnaeve 2018</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Soler-2009" target="_blank">Soler 2009</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Stanley-2017" target="_blank">Stanley 2017</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Smith-2012" target="_blank">Smith 2012</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Weinberg-2006" target="_blank">Weinberg 2006</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Zanarini-2008" target="_blank">Zanarini 2008</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Zanarini-2018" target="_blank">Zanarini 2018</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Alcohol or substance abuse and dependence included</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Davidson-2014" target="_blank">Davidson 2014</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Gregory-2008b" target="_blank">Gregory 2008b</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Robinson-2016" target="_blank">Robinson 2016</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Santisteban-2015" target="_blank">Santisteban 2015</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antisocial features or full antisocial personality disorders excluded</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Antonsen-2017" target="_blank">Antonsen 2017</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Carter-2010" target="_blank">Carter 2010</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Cottraux-2009" target="_blank">Cottraux 2009</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Doering-2010" target="_blank">Doering 2010</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Giesen_x002d_Bloo-2006" target="_blank">Giesen-Bloo 2006</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-J_x00f8_rgensen-2013" target="_blank">Jørgensen 2013</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Kamalabadi-2012" target="_blank">Kamalabadi 2012</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Koons-2001a" target="_blank">Koons 2001a</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Nadort-2009" target="_blank">Nadort 2009</a> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="3" rowspan="1" scope="col" valign="bottom"> <p><b><i>Duration of interventions</i> </b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Less than six months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Andreoli-2016" target="_blank">Andreoli 2016</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Antonsen-2017" target="_blank">Antonsen 2017</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Blum-2008" target="_blank">Blum 2008</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Bohus-2013" target="_blank">Bohus 2013</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Borschmann-2013" target="_blank">Borschmann 2013</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Bos-2010" target="_blank">Bos 2010</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Davidson-2014" target="_blank">Davidson 2014</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Elices-2016" target="_blank">Elices 2016</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Feliu_x002d_Soler-2017" target="_blank">Feliu-Soler 2017</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Gleeson-2012" target="_blank">Gleeson 2012</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Gratz-2006" target="_blank">Gratz 2006</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Gratz-2014" target="_blank">Gratz 2014</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Haeyen-2018" target="_blank">Haeyen 2018</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Jahangard-2012" target="_blank">Jahangard 2012</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Kamalabadi-2012" target="_blank">Kamalabadi 2012</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Kramer-2011" target="_blank">Kramer 2011</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Kramer-2014" target="_blank">Kramer 2014</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Kramer-2016" target="_blank">Kramer 2016</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Kredlow-2017a" target="_blank">Kredlow 2017a</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Kredlow-2017b" target="_blank">Kredlow 2017b</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Leichsenring-2016" target="_blank">Leichsenring 2016</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Lin-2019" target="_blank">Lin 2019</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-McMain-2017" target="_blank">McMain 2017</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-McMurran-2016" target="_blank">McMurran 2016</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Mehlum-2014" target="_blank">Mehlum 2014</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Mohamadizadeh-2017" target="_blank">Mohamadizadeh 2017</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Morey-2010" target="_blank">Morey 2010</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Morton-2012" target="_blank">Morton 2012</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Pascual-2015" target="_blank">Pascual 2015</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Reneses-2013" target="_blank">Reneses 2013</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Schilling-2018" target="_blank">Schilling 2018</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Schuppert-2012" target="_blank">Schuppert 2012</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Soler-2009" target="_blank">Soler 2009</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Weinberg-2006" target="_blank">Weinberg 2006</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Zanarini-2008" target="_blank">Zanarini 2008</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Zanarini-2018" target="_blank">Zanarini 2018</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Between six months and 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Amianto-2011" target="_blank">Amianto 2011</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Bellino-2006" target="_blank">Bellino 2006</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Bellino-2007" target="_blank">Bellino 2007</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Bellino-2010" target="_blank">Bellino 2010</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Bianchini-2019" target="_blank">Bianchini 2019</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Carmona-_x00ed_-Farr_x00e9_s-2019" target="_blank">Carmona í Farrés 2019</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Carter-2010" target="_blank">Carter 2010</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Cottraux-2009" target="_blank">Cottraux 2009</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Davidson-2006" target="_blank">Davidson 2006</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Doering-2010" target="_blank">Doering 2010</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Farrell-2009" target="_blank">Farrell 2009</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Feigenbaum-2012" target="_blank">Feigenbaum 2012</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Gregory-2008b" target="_blank">Gregory 2008b</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Harned-2014" target="_blank">Harned 2014</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Jochems-2015" target="_blank">Jochems 2015</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Koons-2001a" target="_blank">Koons 2001a</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Lepp_x00e4_nen-2016" target="_blank">Leppänen 2016</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Linehan-1991" target="_blank">Linehan 1991</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Linehan-1994" target="_blank">Linehan 1994</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Linehan-2006" target="_blank">Linehan 2006</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Linehan-2015a" target="_blank">Linehan 2015a</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-McMain-2009" target="_blank">McMain 2009</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Priebe-2012" target="_blank">Priebe 2012</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Robinson-2016" target="_blank">Robinson 2016</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Rossouw-2012b" target="_blank">Rossouw 2012b</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Salzer-2014" target="_blank">Salzer 2014</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Santisteban-2015" target="_blank">Santisteban 2015</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Sinnaeve-2018" target="_blank">Sinnaeve 2018</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Stanley-2017" target="_blank">Stanley 2017</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Smith-2012" target="_blank">Smith 2012</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Turner-2000" target="_blank">Turner 2000</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Van-den-Bosch-2005" target="_blank">Van den Bosch 2005</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Longer than 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Bateman-1999" target="_blank">Bateman 1999</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Bateman-2009" target="_blank">Bateman 2009</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Giesen_x002d_Bloo-2006" target="_blank">Giesen-Bloo 2006</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-J_x00f8_rgensen-2013" target="_blank">Jørgensen 2013</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Laurenssen-2018" target="_blank">Laurenssen 2018</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Nadort-2009" target="_blank">Nadort 2009</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Philips-2018" target="_blank">Philips 2018</a> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="3" rowspan="1" scope="col" valign="bottom"> <p><b><i>Formats of interventions</i> </b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Individual treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Amianto-2011" target="_blank">Amianto 2011</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Andreoli-2016" target="_blank">Andreoli 2016</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Borschmann-2013" target="_blank">Borschmann 2013</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Bellino-2006" target="_blank">Bellino 2006</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Bellino-2007" target="_blank">Bellino 2007</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Bellino-2010" target="_blank">Bellino 2010</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Cottraux-2009" target="_blank">Cottraux 2009</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Davidson-2006" target="_blank">Davidson 2006</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Davidson-2014" target="_blank">Davidson 2014</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Doering-2010" target="_blank">Doering 2010</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Giesen_x002d_Bloo-2006" target="_blank">Giesen-Bloo 2006</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Gleeson-2012" target="_blank">Gleeson 2012</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Harned-2014" target="_blank">Harned 2014</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Jahangard-2012" target="_blank">Jahangard 2012</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Kramer-2011" target="_blank">Kramer 2011</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Kramer-2014" target="_blank">Kramer 2014</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Kredlow-2017a" target="_blank">Kredlow 2017a</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Kredlow-2017b" target="_blank">Kredlow 2017b</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Leichsenring-2016" target="_blank">Leichsenring 2016</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-McMain-2009" target="_blank">McMain 2009</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-McMurran-2016" target="_blank">McMurran 2016</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Mohamadizadeh-2017" target="_blank">Mohamadizadeh 2017</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Morey-2010" target="_blank">Morey 2010</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Nadort-2009" target="_blank">Nadort 2009</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Philips-2018" target="_blank">Philips 2018</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Priebe-2012" target="_blank">Priebe 2012</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Reneses-2013" target="_blank">Reneses 2013</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Salzer-2014" target="_blank">Salzer 2014</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Stanley-2017" target="_blank">Stanley 2017</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Smith-2012" target="_blank">Smith 2012</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Weinberg-2006" target="_blank">Weinberg 2006</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Zanarini-2008" target="_blank">Zanarini 2008</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Zanarini-2018" target="_blank">Zanarini 2018</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Antonsen-2017" target="_blank">Antonsen 2017</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Blum-2008" target="_blank">Blum 2008</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Bohus-2013" target="_blank">Bohus 2013</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Bos-2010" target="_blank">Bos 2010</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Elices-2016" target="_blank">Elices 2016</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Farrell-2009" target="_blank">Farrell 2009</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Feliu_x002d_Soler-2017" target="_blank">Feliu-Soler 2017</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Gratz-2006" target="_blank">Gratz 2006</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Gratz-2014" target="_blank">Gratz 2014</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Haeyen-2018" target="_blank">Haeyen 2018</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Jochems-2015" target="_blank">Jochems 2015</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Kamalabadi-2012" target="_blank">Kamalabadi 2012</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Kramer-2016" target="_blank">Kramer 2016</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Lepp_x00e4_nen-2016" target="_blank">Leppänen 2016</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Lin-2019" target="_blank">Lin 2019</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Linehan-2015a" target="_blank">Linehan 2015a</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-McMain-2017" target="_blank">McMain 2017</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Morton-2012" target="_blank">Morton 2012</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Pascual-2015" target="_blank">Pascual 2015</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Santisteban-2015" target="_blank">Santisteban 2015</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Schilling-2018" target="_blank">Schilling 2018</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Soler-2009" target="_blank">Soler 2009</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Combination of individual and group treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Bateman-1999" target="_blank">Bateman 1999</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Bateman-2009" target="_blank">Bateman 2009</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Bianchini-2019" target="_blank">Bianchini 2019</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Carter-2010" target="_blank">Carter 2010</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Feigenbaum-2012" target="_blank">Feigenbaum 2012</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Gregory-2008b" target="_blank">Gregory 2008b</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-J_x00f8_rgensen-2013" target="_blank">Jørgensen 2013</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Koons-2001a" target="_blank">Koons 2001a</a>; <a href="./references#CD012955-bbs2-0045" title="HoffmanRE . Impact of treatment accessibility on clinical course of parasuicidal patients. Archives of General Psychiatry1993;50(2):157-8. [DOI: 10.1001/archpsyc.1993.01820140083010] [PMID: 8427557]LindenboimN . To Know Me is to Keep Me: Self-Verification, Validation, and Therapy Dropout in the Treatment of Borderline Personality Disorder [PhD thesis]. Washington (DC): University of Washington, 2009. LinehanMM , ArmstrongHE , SuarezA , AllmonD , HeardHL . Cognitive-behavioral treatment of chronically parasuicidal borderline patients. Archives of General Psychiatry1991;48(12):1060-4. [DOI: 10.1001/archpsyc.1991.01810360024003] [PMID: 1845222]LinehanMM , HeardHL . Impact of treatment accessibility on clinical course of parasuicidal patients — reply. Archives of General Psychiatry1993;50(2):157-8. [DOI: 10.1001/archpsyc.1993.01820140083011]">Linehan 1991</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Linehan-1994" target="_blank">Linehan 1994</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Linehan-2006" target="_blank">Linehan 2006</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Laurenssen-2018" target="_blank">Laurenssen 2018</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Robinson-2016" target="_blank">Robinson 2016</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Rossouw-2012b" target="_blank">Rossouw 2012b</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Turner-2000" target="_blank">Turner 2000</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Van-den-Bosch-2005" target="_blank">Van den Bosch 2005</a> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="3" rowspan="1" scope="col" valign="bottom"> <p><b><i>Concomitant medication</i> </b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Allowed, if needed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012955-bbs2-0001" title="AmiantoF , FerreroA , PieròA , CairoE , RoccaG , SimonelliB , et al. Supervised team management, with or without structured psychotherapy, in heavy users of a mental health service with borderline personality disorder: a two-year follow-up preliminary randomized study. BMC Psychiatry2011;11:181. [DOI: 10.1186/1471-244X-11-181] [PMC3260092 ] [PMID: 22103890]NCT01356069. Efficacy of time-limited psychodynamic psychotherapy and informed clinical management in BPD high MHS users (HUMSH) [Sequential brief Adlerian psychodynamic psychotherapy in heavy users of a mental health service with borderline personality disorder: a two years follow-up preliminary randomized study]. clinicaltrials.gov/ct2/show/NCT01356069 (first received 16 May 2011). ">Amianto 2011</a>; <a href="./references#CD012955-bbs2-0002" title='AndreoliA , BurnandY , CochennecMF , MarieD , Di ClementeT , OhlendorfP . Psychoanalytic psychotherapy and venlafaxine among acutely suicidal borderline patients: a randomized clinical study. European Psychiatry2009;24(Suppl 1):S93. [DOI: 10.1016/S0924-9338(09)70326-8] [S18-03]AndreoliA , BurnandY , CochennecMF , OhlendorfP , FrambatiL , Gaudry-MaireD , et al. Disappointed love and suicide: a randomized controlled trial of "abandonment psychotherapy" among borderline patients. Journal of Personality Disorders2016;30(2):271-87. [DOI: 10.1521/pedi_2015_29_196] [PMID: 26111250]AndreoliA , BurnandY , FrambatiL , ManningD , FrancesA . Abandonment psychotherapy and psychosocial functioning among suicidal patients with borderline personality disorder: a 3-year naturalistic follow-up. Journal of Personality Disorders 2019 Feb 20 [Epub ahead of print]. [DOI: 10.1521/pedi_2019_33_423] [PMID: 30785852]AndreoliA . Re: your study in BPD - Cochrane Collaboration review [personal communication]. Email to: J Stoffers-Winterling 5 June 2018. '>Andreoli 2016</a>; <a href="./references#CD012955-bbs2-0003" title="AntonsenBT , JohansenMS , RøFG , KvarsteinEH , WilbergT . Is reflective functioning associated with clinical symptoms and long-term course in patients with personality disorders?Comprehensive Psychiatry2016;64:46-58. [DOI: 10.1016/j.comppsych.2015.05.016] [PMID: 26104432]AntonsenBT , KlungsøyrO , KampsA , HummelenB , JohansenMS , PedersenG , et al. Step-down versus outpatient psychotherapeutic treatment for personality disorders: 6-year follow-up of the Ullevål personality project. BMC Psychiatry2014;14:119. [DOI: 10.1186/1471-244X-14-119] [PMC4000615] [PMID: 24758722]AntonsenBT , KvarsteinEH , Urnes Ø, HummelenB , KarterudS , WilbergT . Favourable outcome of long-term combined psychotherapy for patients with borderline personality disorder: six-year follow-up of a randomized study. Psychotherapy Research2017;27(1):51-63. [DOI: 10.1080/10503307.2015.1072283] [PMID: 26261865]ArnevikE , WilbergT , Urnes Ø, JohansenM , MonsenJT , KarterudS . Psychotherapy for personality disorders: short-term day hospital psychotherapy versus outpatient individual therapy - a randomized controlled study. European Psychiatry2009;24(2):71-8. [DOI: 10.1016/j.eurpsy.2008.09.004] [PMID: 19097870]GullestadFS , JohansenMS , HøglendP , KarterudS , WilbergT . Mentalization as a moderator of treatment effects: findings from a randomized clinical trial for personality disorders. Psychotherapy Research2013;23(6):674-89. [DOI: 10.1080/10503307.2012.684103] [PMID: 22612470]GullestadFS . Re: questions regarding your trial on day hospital step-down program [personal communication]. Email to: E Faltinsen 4 December 2017. KvarsteinEH , ArnevikE , HalsteinliV , RøFG , KarterudS , WilbergT . Health service costs and clinical gains of psychotherapy for personality disorders: a randomized controlled trial of day-hospital-based step-down treatment versus outpatient treatment at a specialist practice. BMC Psychiatry2013;13:315. [DOI: 10.1186/1471-244X-13-315] [PMC4222503] [PMID: 24268099]">Antonsen 2017</a>; <a href="./references#CD012955-bbs2-0004" title="BatemanA , FonagyP . 8-year follow-up of patients treated for borderline personality disorder: mentalization-based treatment versus treatment as usual. American Journal of Psychiatry2008;165(5):631-8. [DOI: 10.1176/appi.ajp.2007.07040636] [PMID: 18347003]BatemanA , FonagyP . Effectiveness of partial hospitalization in the treatment of borderline personality disorder: a randomized controlled trial. American Journal of Psychiatry1999;156(10):1563-9. [DOI: 10.1176/ajp.156.10.1563] [PMID: 10518167]BatemanA , FonagyP . Health care utilization costs for borderline personality disorder patients treated with psychoanalytically oriented partial hospitalization versus general psychiatric care. American Journal of Psychiatry2003;160(1):169-71. [10.1176/appi.ajp.160.1.169] [12505818]BatemanA , FonagyP . Treatment of borderline personality disorder with psychoanalytically oriented partial hospitalization: an 18-month follow-up. American Journal of Psychiatry2001;158(1):36-42. [DOI: 10.1176/appi.ajp.158.1.36] [PMID: 11136631]BatemanA . Important: question regarding your BPD trial for systematic review in Cochrane Collaboration [personal communication]. Email to: K Lieb, J Stoffers 14 December 2010. BatemanA . Intensive outpatient and partial hospital care for BPD. In: 157th annual meeting of the American Psychiatric Association. Psychotherapy and pharmacology: dissolving the mind-brain barrier; 2004 May 1-6; New York (NY). Arlington (VA): American Psychiatric Association, 2004:102. [Symposium 100B] [www.psychiatry.org/File%20Library/Psychiatrists/Directories/Library-and-Archive/conference_publications/am_program_2004.pdf]BatemanAW , FonagyP . Drs Bateman and Fonagy reply [to Stern R. Partial hospitalization for borderline personality disorder. American Journal of Psychiatry 2001;158(11):1932-3. DOI: 10.1176/appi.ajp.158.11.1932]. American Journal of Psychiatry2001;158(11):1932-3. [DOI: 10.1176/appi.ajp.158.11.1932-a]EvansC . Treatment benefits of psychoanalytically oriented partial hospitalisation were maintained over 18 months in borderline personality disorder. Evidence-Based Mental Health2001;4(3):73. [DOI: 10.1136/ebmh.4.3.73]FonagyP , BatemanAW . Mentalizing and borderline personality disorder. Journal of Mental Health2007;16(1):83-101. [DOI: 10.1080/09638230601182045]SternR . Partial hospitalization for borderline personality disorder. American Journal of Psychiatry2001;158(11):1932-3. [DOI: 10.1176/appi.ajp.158.11.1932] [PMID: 11691712]">Bateman 1999</a>; <a href="./references#CD012955-bbs2-0005" title="BatemanA , FonagyP . Impact of clinical severity on outcomes of mentalisation-based treatment for borderline personality disorder. British Journal of Psychiatry2013;203(3):221-7. [DOI: 10.1192/bjp.bp.112.121129] [PMID: 23887998]BatemanA , FonagyP . Randomized controlled trial of outpatient mentalization-based treatment versus structured clinical management for borderline personality disorder. American Journal of Psychiatry2009;166(12):1355-64. [DOI: 10.1176/appi.ajp.2009.09040539] [PMID: 19833787]BatemanA , FonagyP . Randomized controlled trial of outpatient mentalization-based treatment versus structured clinical management for borderline personality disorder. Supplementary data. ajp.psychiatryonline.org/doi/suppl/10.1176/appi.ajp.2009.09040539/suppl_file/ajp_166_12_1355_01.pdf (accessed 27 February 2020). BatemanA , O'ConnellJ , LorenziniN , GardnerT , FonagyP . A randomised controlled trial of mentalization-based treatment versus structured clinical management for patients with comorbid borderline personality disorder and antisocial personality disorder. BMC Psychiatry2016;16:304. [DOI: 10.1186/s12888-016-1000-9] [PMC5006360] [PMID: 27577562]BatemanA . Important question regarding your BPD trial for systematic review in Cochrane Collaboration [personal communication]. Email to: K Lieb 14 December 2010. BatemanAW . Mentalization, borderline personality disorder and what works for whom? Presentation at the 11th International Congress of the International Society for the Study of Personality Disorders; 2009 Aug 21-23. www.borderlinepersonalitydisorder.com/Conferences/ISSPD/isspd_09_Bateman (accessed 21 April 2010). ISRCTN27660668. Randomised controlled trial of manualised out-patient individual and group therapy for borderline personality disorder [Effectiveness of intensive out-patient psychotherapy for treatment of borderline personality disorder: a pragmatic randomised single blind controlled study]. www.isrctn.com/ISRCTN27660668 (first received 12 October 2008). ">Bateman 2009</a>; <a href="./references#CD012955-bbs2-0010" title="BlackD . Question regarding your BPD trial [personal communication]. Email to: J Stoffers 04 January 2011. BlackDW , AllenJ , McCormickB , BlumN . Treatment received by persons with BPD participating in a randomized clinical trial of the systems training for emotional predictability and problem solving programme. Personality and Mental Health2011;5(3):159-68. [DOI: 10.1002/pmh.167]BlackDW , AllenJ , St JohnD , PfohlB , McCormickB , BlumN . Predictors of response to systems training for emotional predictability and problem solving (STEPPS) for borderline personality disorder: an exploratory study. Acta Psychiatrica Scandinavica2009;120(1):53-61. [DOI: 10.1111/j.1600-0447.2008.01340.x] [PMC3665337] [PMID: 19183126]BlackDW , BlumN , PfohlB , St JohnD . The STEPPS group treatment program for outpatients with borderline personality disorder. Journal of Contemporary Psychotherapy2004;34(3):193-210. [DOI: 10.1023/B:JOCP.0000036630.25741.83]BlackDW , PfohlBM . Randomized clinical trial of STEPPS versus treatment as usual. In: 158th annual meeting of the American Psychiatric Association. Psychosomatic medicine: integrating psychiatry &amp; medicine; 2005 May 21-26; Atlanta (GA). Arlington (VA): American Psychiatric Association, 2005:104. [No. 1B] [www.psychiatry.org/File%20Library/Psychiatrists/Directories/Library-and-Archive/syllabus/am_syllabus_2005.pdf]BlackDW , Simsek-DuranF , BlumN , McCormickB , AllenJ . Do people with borderline personality disorder complicated by antisocial personality disorder benefit from the STEPPS treatment program?Personality and Mental Health2016;10(3):205-15. [DOI: 10.1002/pmh.1326] [PMC4911327] [PMID: 26671625]BlackDW . RE: [external] questions regarding your trial on the STEPPS program for BPD [personal communication]. Email to: EG Faltinsen 27 November 2017. BlumN , AllenJ , McCormickB , BlackDW . Ms Blum and colleagues reply [to Schulte-Herbrüggen O, Koerting J, Roepke S. Effectiveness of adjunctive STEPPS group treatment in borderline personality disorder patients. American Journal of Psychiatry 2008;165(10):1354-5. DOI: 10.1176/appi.ajp.2008.08030390]. American Journal of Psychiatry2008;165(10):1354-5. [DOI: 10.1176/appi.ajp.2008.08030390r]BlumN , FranklinJ , HanselR , McCormickB , St JohnD , PfohlB , et al. Relationship of age to symptom severity, psychiatric comorbidity and health care utilization in persons with borderline personality disorder. Personality and Mental Health2008;2(1):25-43. [DOI: 10.1002/pmh.26]BlumN , St JohnD , PfohlB , StuartS , McCormickB , AllenJ , et al. Erratum. American Journal of Psychiatry2008;165(6):777. Erratum for: American Journal of Psychiatry 2008;165(4):468-78. [psycnet.apa.org/record/2008-07854-033]BlumN , St JohnD , PfohlB , StuartS , McCormickB , AllenJ , et al. Systems training for emotional predictability and problem solving (STEPPS) for outpatients with borderline personality disorder: a randomized controlled trial and 1-year follow-up. American Journal of Psychiatry2008;165(4):468-78. [DOI: 10.1176/appi.ajp.2007.07071079] [PMC3608469] [PMID: 18281407]DavidsonKM . Borderline personality disorder: STEPPS improves symptoms. Evidence-Based Mental Health2008;11(4):120. [DOI: 10.1136/ebmh.11.4.120] [PMID: 18952969]NCT00055315. Treatment for borderline personality disorder [A cognitive group treatment for borderline outpatients]. clinicaltrials.gov/ct2/show/NCT00055315 (first received 25 February 2003). ">Blum 2008</a>; <a href="./references#CD012955-bbs2-0011" title="BohusM , DyerAS , PriebeK , KrügerA , KleindienstN , SchmahlC , et al. Dialectical behaviour therapy for post-traumatic stress disorder after childhood sexual abuse in patients with and without borderline personality disorder: a randomised controlled trial. Psychotherapy and Psychosomatics2013;82(4):221-33. [DOI: 10.1159/000348451] [PMID: 23712109]BrandS . AW: questions regarding your trial on emotional intelligence training for BPD [personal communication]. Email to: EG Faltinsen 28 November 2017. DBT Working Group at the Central Institute for Mental Health, Mannheim, Germany. Requested supplementary data (as supplied 1 October 2010). Data on file. NCT00481000. Dialectical cognitive traumatherapy (DCT) on patients with severe PTSD following sexual abuse (PASA) [Dialectical cognitive traumatherapy (DCT) on patients with severe posttraumatic stress disorder following sexual abuse - a randomised controlled trial]. clinicaltrials.gov/ct2/show/NCT00481000 (first received 31 May 2007). SteilR , DyerA , PriebeK , KleindienstN , BohusM . Dialectical behavior therapy for posttraumatic stress disorder related to childhood sexual abuse: a pilot study of an intensive treatment program. Journal of Traumatic Stress2011;24(1):102-6. [DOI: 10.1002/jts.20617] [PMID: 21351167]">Bohus 2013</a>; <a href="./references#CD012955-bbs2-0012" title="BorschmannR , BarrettB , HellierJM , ByfordS , HendersonC , RoseD , et al. Joint crisis plans for people with borderline personality disorder: feasibility and outcomes in a randomised controlled trial. British Journal of Psychiatry2013;202(5):357-64. [DOI: 10.1192/bjp.bp.112.117762] [PMID: 23637110]BorschmannR . Joint crisis plans for BPD - question on publication in British Journal of Psychiatry [pers communication]. Email to: J Stoffers-Winterling 22 August 2017. BorschmannR . RE: joint crisis plans for BPD - question on publication in British Journal of Psychiatry [personal communication]. Email to: J Stoffers-Winterling 22 August 2017. BorschmannR . The development and testing of joint crisis plans for people with borderline personality disorder: a feasibility study. ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.628499 (accessed 27 January 2019). HellierJ . RE: regarding your study on on MBT for eating disorders [personal communication]. Email to: E Faltinsen 27 March 2018. HellierJ . RE: regarding your study on on MBT for eating disorders [personal communication]. Email to: E Faltinsen 3 January 2018. HellierJ . SV: regarding your study on MBT for eating disorders [personal communication]. Email to: EG Faltinsen, P Robinson 27 March 2018. ISRCTN12440268. JOSHUA: a pilot randomised controlled trial of joint crisis plans for people who self harm. www.isrctn.com/ISRCTN12440268 (first received 17 September 2009). ">Borschmann 2013</a>; <a href="./references#CD012955-bbs2-0013" title="BosEH , Van WelE , AppeloMT , VerbraakMJP . A randomized controlled trial of a Dutch version of systems training for emotional predictability and problem solving for borderline personality disorder. Journal of Nervous and Mental Disease2010;198(4):299-304. [DOI: 10.1097/NMD.0b013e3181d619cf] [PMID: 20386260]Van WelEB , BosEH , AppeloMT , BerendsenEM , WillgerothFC , VerbraakMJPM . The efficacy of the systems training for emotional predictability and problem solving (STEPPS) in the treatment of borderline personality disorder. A randomized controlled trial [De effectiviteit van de vaardigheidstraining emotieregulatiestoornis (VERS) in de behandeling van de borderlinepersoonlijkheidsstoornis: een gerandomiseerd onderzoek]. Tijdschrift voor Psychiatrie2009;51(5):291-301. [PMID: 19434566]">Bos 2010</a>; <a href="./references#CD012955-bbs2-0014" title="Carmona i FarrésC , ElicesM , SolerJ , Domínguez-ClavéE , Pomarol-ClotetE , SalvadorR , et al. Effects of mindfulness training on borderline personality disorder: impulsivity versus emotional dysregulation. Mindfulness2019;10:1243-54. [DOI: 10.1007/s12671-018-1071-4]NCT03363230. Effects of mindfulness training on emotion regulation and impulsivity. www.clinicaltrials.gov/ct2/show/NCT03363230 (first received 30 November 2017). ">Carmona í Farrés 2019</a>; <a href="./references#CD012955-bbs2-0016" title="CottrauxJ , NoteID , BoutitieF , MillieryM , GenouihlacV , YaoSN , et al. Cognitive therapy versus Rogerian supportive therapy in borderline personality disorder. Two-year follow-up of a controlled pilot study. Psychotherapy and Psychosomatics2009;78(5):307-16. [DOI: 10.1159/000229769] [PMID: 19628959]NCT00131781. Cognitive therapy versus supportive therapy in borderline personality disorder. www.clinicaltrials.gov/ct2/show/NCT00131781 (first received 18 August 2005). ">Cottraux 2009</a>; <a href="./references#CD012955-bbs2-0017" title="DavidsonK , LivingstoneS , McArthurK , DicksonL , GumleyA . An integrative complexity analysis of cognitive behaviour therapy sessions for borderline personality disorder. Psychology and Psychotherapy2007;80(Pt 4):513-23. [DOI: 10.1348/147608307X191535] [PMID: 17535542]DavidsonK , NorrieJ , TyrerP , GumleyA , TataP , MurrayH , et al. The effectiveness of cognitive behavior therapy for borderline personality disorder: results from the borderline personality disorder study of cognitive therapy (BOSCOT) trial. Journal of Personality Disorders2006;20(5):450-65. [DOI: 10.1521/pedi.2006.20.5.450] [PMC1852259] [PMID: 17032158]DavidsonK , TyrerP , GumleyA , TataP , NorrieJ , PalmerS , et al. A randomized controlled trial of cognitive behavior therapy for borderline personality disorder: rationale for trial, method, and description of sample. Journal of Personality Disorders2006;20(5):431-49. [DOI: 10.1521/pedi.2006.20.5.431] [PMC1847748] [PMID: 17032157]DavidsonKM , TyrerP , NorrieJ , PalmerSJ , TyrerH . Cognitive therapy v usual treatment for borderline personality disorder: prospective 6-year follow-up. British Journal of Psychiatry2010;197(6):456-62. [DOI: 10.1192/bjp.bp.109.074286] [PMID: 21119151]ISRCTN86177428. Borderline personality disorder study of cognitive therapy trial [A randomised controlled trial of cognitive therapy plus treatment as usual versus treatment as usual in the treatment of borderline personality disorder]. www.isrctn.com/ISRCTN86177428 (first received 22 July 2005). NCT00538135. BOSCOT: a randomised controlled trial of cognitive behavioural therapy in borderline personality disorder [BOSCOT: a randomised control trial of cognitive behavioural therapy plus treatment as usual versus treatment as usual in the treatment of borderline personality disorder]. www.clinicaltrials.gov/ct2/show/NCT00538135 (first received 29 September 2007). NorrieJ , DavidsonK , TataP , GumleyA . Influence of therapist competence and quantity of cognitive behavioural therapy on suicidal behaviour and inpatient hospitalisation in a randomised controlled trial in borderline personality disorder: further analyses of treatment effects in the BOSCOT study. Psychology and Psychotherapy2013;86(3):280-93. [DOI: 10.1111/papt.12004] [PMC4491320] [PMID: 23420622]PalmerS , DavidsonK , TyrerP , GumleyA , TataP , NorrieJ , et al. The cost-effectiveness of cognitive behavior therapy for borderline personality disorder: results from the BOSCOT trial. Journal of Personality Disorders2006;20(5):466-81. [DOI: 10.1521/pedi.2006.20.5.466] [PMC1852260] [PMID: 17032159]">Davidson 2006</a>; <a href="./references#CD012955-bbs2-0019" title="BuchheimA , Hörz-SagstetterS , DoeringS , RentropM , SchusterP , BuchheimP , et al. Change of unresolved attachment in borderline personality disorders: RCT study of transference-focused psychotherapy. Psychotherapy and Psychosomatics2017;86(5):314-6. [DOI: 10.1159/000460257] [PMID: 28903103]DiamondD , LevyKN , ClarkinJF , Fischer-KernM , CainNM , DoeringS , et al. Attachment and mentalization in female patients with comorbid narcissistic and borderline personality disorder. Personality Disorders2014;5(4):428-33. [DOI: 10.1037/per0000065] [PMID: 25314231]DiamondD , YeomansFE , SternB , LevyKN , HörzS , DoeringS , et al. Transference-focused psychotherapy for patients with comorbid narcissistic and borderline personality disorder. Psychoanalytic Inquiry2013;33(6):527-51. [DOI: 10.1080/07351690.2013.815087]DoeringS , HörzS , RentropM , Fischer-KernM , SchusterP , BeneckeC , et al. Transference-focused psychotherapy v treatment by community psychotherapists for borderline personality disorder: randomised controlled trial. British Journal of Psychiatry2010;196(5):389-95. [DOI: 10.1192/bjp.bp.109.070177] [PMID: 20435966]DoeringS . Author's reply [to Kleindienst N, Krumm B, Bohus M. Is transference-focused psychotherapy really efficacious for borderline personality disorder? British Journal of Psychiatry 2011;198(2):156-7. DOI: 10.1192/bjp.198.2.156b]. British Journal of Psychiatry2011;198(2):156-7. [DOI: 10.1192/bjp.198.2.157]DoeringS . Question regarding your BPD trial for systematic review in Cochrane Collaboration [personal communication]. Email to: K Lieb, J Stoffers 10 December 2010. Fischer-KernM , DoeringS , TaubnerS , HörzS , ZimmermannJ , RentropM , et al. Transference-focused psychotherapy for borderline personality disorder: change in reflective function. British Journal of Psychiatry2015;207(2):173-4. [DOI: 10.1192/bjp.bp.113.143842] [PMID: 25999334]KleindienstN , KrummB , BohusM . Is transference-focused psychotherapy really efficacious for borderline personality disorder?British Journal of Psychiatry2011;198(2):156-7. [DOI: 10.1192/bjp.198.2.156b] [PMID: 21282787]LevyKN , MeehanKB , YeomansFE . Transference-focused psychotherapy reduces treatment drop-out and suicide attempters compared with community psychotherapist treatment in borderline personality disorder. Evidence-based Mental Health2010;13(4):119. [DOI: 10.1136/ebmh.13.4.119] [PMID: 21036981]NCT00714311. Efficacy of transference-focused psychotherapy for borderline personality disorder [A randomized-controlled trial of transference-focused psychotherapy vs treatment by experienced community psychotherapists for borderline personality disorder]. www.clinicaltrials.gov/ct2/show/NCT00714311 (first received 9 July 2008). RentropM , MartiusP , BäumlJ , BuchheimP , DöeringS , HörzS . Patients with borderline personality disorder not participating in an RCT: are they different?Psychopathology2010;43(6):369-72. [DOI: 10.1159/000320351] [PMID: 20798576]">Doering 2010</a>; <a href="./references#CD012955-bbs2-0020" title="ElicesM , PascualJC , PortellaMJ , Feliu-SolerA , Martín-BlancoA , CarmonaC , et al. Impact of mindfulness training on borderline personality disorder: a randomized trial. Mindfulness2016;7:584-95. [DOI: 10.1007/s12671-016-0492-1]NCT02397031. Mindfulness and interpersonal effectiveness skills in borderline personality disorder [Randomized, active-controlled, clinical trial comparing effects of mindfulness and interpersonal effectiveness skills in borderline personality disorder]. www.clinicaltrials.gov/ct2/show/NCT02397031 (first received 12 March 2015). SolerJ , ElicesM , PascualJC , Martín-BlancoA , Feliu-SolerA , CarmonaC , et al. Effects of mindfulness training on different components of impulsivity in borderline personality disorder: results from a pilot randomized study. Borderline Personality Disorder and Emotion Dysregulation2016;3:1. [DOI: 10.1186/s40479-015-0035-8] [PMC4709962] [PMID: 26759718]">Elices 2016</a>; <a href="./references#CD012955-bbs2-0021" title="FarrellJM , ShawIA , WebberMA . A schema-focused approach to group psychotherapy for outpatients with borderline personality disorder: a randomized controlled trial. Journal of Behavior Therapy and Experimental Psychiatry2009;40(2):317-28 Corrigendum to: Journal of Behavior Therapy and Experimental Psychiatry 2018; 60: 111. [DOI: 10.1016/j.jbtep.2009.01.002] [PMID: 19176222]FarrellJM . Question regarding your BPD trials [personal communication]. Email to: K Lieb, J Stoffers 9 December 2010. ">Farrell 2009</a>; <a href="./references#CD012955-bbs2-0022" title="FeigenbaumJD , FonagyP , PillingS , JonesA , WildgooseA , BebbingtonPE . A real-world study of the effectiveness of DBT in the UK National Health Service. British Journal of Clinical Psychology2012;51(2):121-41. [DOI: 10.1111/j.2044-8260.2011.02017.x] [PMID: 22574799]">Feigenbaum 2012</a>; <a href="./references#CD012955-bbs2-0023" title="Feliu-SolerA , PascualJC , ElicesM , Martín-BlancoA , CarmonaC , CebollaA , et al. Fostering self-compassion and loving-kindness in patients with borderline personality disorder: a randomized pilot study. Clinical Psychology &amp; Psychotherapy2017;24(1):278-86. [DOI: 10.1002/cpp.2000] [PMID: 26818533]">Feliu‐Soler 2017</a>; <a href="./references#CD012955-bbs2-0024" title="ArntzA , Stupar-RutenfransS , BlooJ , Van DyckR , SpinhovenP . Prediction of treatment discontinuation and recovery from borderline personality disorder: results from an RCT comparing schema therapy and transference-focused psychotherapy. Behaviour Research and Therapy2015;74:60-71. [DOI: 10.1016/j.brat.2015.09.002] [PMID: 26432172]Giesen-BlooJ , ArntzA . Questions concerning the randomized trial of schema-focused therapy vs transference-focused psychotherapy—reply. Archives of General Psychiatry2007;64(5):610-1. [DOI: 10.1001/archpsyc.64.5.610]Giesen-BlooJ , Van DyckR , SpinhovenP , Van TilburgW , DirksenC , Van AsseltT , et al. Errors in table and figure in: outpatient psychotherapy for borderline personality disorder: randomized trial of schema-focused therapy vs transference-focused psychotherapy. Archives of General Psychiatry2006;63(9):1008. Erratum for: Archives of General Psychiatry 2006;63(6):649-58. [DOI: 10.1001/archpsyc.63.9.1008]Giesen-BlooJ , Van DyckR , SpinhovenP , Van TilburgW , DirksenC , Van AsseltT , et al. Outpatient psychotherapy for borderline personality disorder: randomized trial of schema-focused therapy vs transference-focused psychotherapy. Archives of General Psychiatry2006;63(6):649-58. [DOI: 10.1001/archpsyc.63.6.649] [PMID: 16754838]SpinhovenP , Giesen-BlooJ , Van DyckR , KooimanK , ArntzA . The therapeutic alliance in schema-focused therapy and transference-focused psychotherapy for borderline personality disorder. Journal of Consulting and Clinical Psychology2007;75(1):104-15. [DOI: 10.1037/0022-006X.75.1.104] [PMID: 17295569]Van AsseltADI , DirksenCD , ArntzA , Giesen-BlooJH , Van DyckR , SpinhovenP , et al. Out-patient psychotherapy for borderline personality disorder: cost-effectiveness of schema-focused therapy v transference-focused psychotherapy. British Journal of Psychiatry2008;192(6):450-7. [DOI: 10.1192/bjp.bp.106.033597] [PMID: 18515897]Van AsseltADI , DirksenCD , ArntzA , SeverensJL . Difficulties in calculating productivity costs: work disability associated with borderline personality disorder. Value in Health2008;11(4):637-44. [DOI: 10.1111/j.1524-4733.2007.00288.x]YeomansF . Questions concerning the randomized trial of schema-focused therapy vs transference-focused psychotherapy. Archives of General Psychiatry2007;64(5):609-10. [DOI: 10.1001/archpsyc.64.5.609-c] [PMID: 17485613]">Giesen‐Bloo 2006</a>; <a href="./references#CD012955-bbs2-0025" title="GleesonJF , ChanenA , CottonSM , PearceT , NewmanB , McCutcheonL . Treating co-occurring first-episode psychosis and borderline personality: a pilot randomized controlled trial. Early Intervention in Psychiatry2012;6(1):21-9. [DOI: 10.1111/j.1751-7893.2011.00306.x] [PMID: 22379625]GleesonJFM . RE: separate data [personal communication]. Email to: M Kielsholm 28 October 2016. ">Gleeson 2012</a>; <a href="./references#CD012955-bbs2-0026" title="Gratz KL. Important: question regarding your BPD trial for systematic review in Cochrane Collaboration [personal communication]. Email to: J Stoffers-Winterling 11 December 2010. GratzKL , GundersonJG . Preliminary data on an acceptance-based emotion regulation group intervention for deliberate self-harm among women with borderline personality disorder. Behavior Therapy2006;37(1):25-35. [DOI: 10.1016/j.beth.2005.03.002] [PMID: 16942958]">Gratz 2006</a>; <a href="./references#CD012955-bbs2-0027" title="GratzKL , BardeenJR , LevyR , Dixon-GordonKL , TullMT . Mechanisms of change in an emotion regulation group therapy for deliberate self-harm among women with borderline personality disorder. Behaviour Research and Therapy2015;65:29-35. [DOI: 10.1016/j.brat.2014.12.005] [PMC4306622] [PMID: 25557395]GratzKL , Dixon-GordonKL , TullMT . Predictors of treatment response to an adjunctive emotion regulation group therapy for deliberate self-harm among women with borderline personality disorder. Personality Disorders2014;5(1):97-107. [DOI: 10.1037/per0000062] [PMC4059504] [PMID: 2458806]GratzKL , TullMT , LevyR . Randomized controlled trial and uncontrolled 9-month follow-up of an adjunctive emotion regulation group therapy for deliberate self-harm among women with borderline personality disorder. Psychological Medicine2014;44(10):2099-112. [DOI: 10.1017/S0033291713002134] [PMID: 23985088]GratzKL . Question regarding your BPD trials [personal communication]. Email to: J Stoffers 11 December 2010. ">Gratz 2014</a>; <a href="./references#CD012955-bbs2-0028" title="GregoryRJ , ChlebowskiS , KangD , RemenA , SoderbergM . Psychodynamic therapy for borderline personality disorder and co-occurring alcohol use disorders: a newly designed ongoing study. Journal of the American Psychoanalytic Association2006;54(4):1331-4. [DOI: 10.1177/00030651060540040107] [PMID: 17354507]GregoryRJ , ChlebowskiS , KangD , RemenAL , SoderbergMG , StepkovitchJ , et al. A controlled trial of psychodynamic psychotherapy for co-occurring borderline personality disorder and alcohol use disorder. Psychotherapy2008;45(1):28-41. [DOI: 10.1037/0033-3204.45.1.28] [PMID: 22122363]GregoryRJ , DeLucia-DeranjaE , MogleJA . Dynamic deconstructive psychotherapy versus optimized community care for borderline personality disorder co-occuring with alcohol use disorders: a 30-month follow-up. Journal of Nervous and Mental Disease2010;198(4):292-8. [DOI: 10.1097/NMD.0b013e3181d6172d] [PMID: 20386259]GregoryRJ , RemenAL , SoderbergM , Ploutz-SnyderRJ . A controlled trial of psychodynamic psychotherapy for co-occurring borderline personality disorder and alcohol use disorder: six-month outcome. Journal of the American Psychoanalytic Association2009;57(1):199-205. [DOI: 10.1177/00030651090570011006] [PMID: 19270255]NCT00145678. Psychodynamic therapy for co-occurring borderline personality disorder and alcohol use disorder [Psychodynamic therapy for patients With borderline personality disorder and alcohol abuse]. www.clinicaltrials.gov/show/NCT00145678 (first received 1 September 2005). ">Gregory 2008b</a>; <a href="./references#CD012955-bbs2-0030" title="HarnedM . Re: SV: question regarding your trial on brief therapy for attempted suicide [personal communication]. Email to: EG Faltinsen 11 December 2018. HarnedMS , KorslundKE , LinehanMM . A pilot randomized controlled trial of dialectical behavior therapy with and without the dialectical behavior therapy prolonged exposure protocol for suicidal and self-injuring women with borderline personality disorder and PTSD. Behaviour Research and Therapy2014;55:7-17. [DOI: 10.1016/j.brat.2014.01.008] [PMC3987949] [PMID: 24562087]HarnedMS , WilksCR , SchmidtSC , CoyleTN . Improving functional outcomes in women with borderline personality disorder and PTSD by changing PTSD severity and post-traumatic cognitions. Behaviour Research and Therapy2018;103:53-61. [DOI: 10.1016/j.brat.2018.02.002] [PMC5837954] [PMID: 29448136]HarnedMS . RE: questions regarding your trial on brief therapy for attempted suicide [personal communication]. Email to: E Faltinsen 29 November 2017. ">Harned 2014</a>; <a href="./references#CD012955-bbs2-0032" title="JochemsEC , Van der Feltz-CornelisCM , Van DamA , DuivenvoordenHJ , MulderCL . The effects of motivation feedback in patients with severe mental illness: a cluster randomized controlled trial. Neuropsychiatric Disease and Treatment2015;11:3049-64. [DOI: 10.2147/NDT.S95190] [PMC4686323] [PMID: 26715847]JochemsEC . Cochrane Collaboration review on psychotherapies for borderline PD [personal communication]. Email to: EG Faltinsen 2 July 2018. JochemsEC . Re: Cochrane Collaboration review on psychotherapies for borderline PD [personal communication]. Email to: J Stoffers-Winterling 02 July 2018. ">Jochems 2015</a>; <a href="./references#CD012955-bbs2-0033" title="JørgensenCR , BøyeR , AndersenD , Døssing BlaabjergAH , FreundC , JordetH , et al. Eighteen months post-treatment naturalistic follow-up study of mentalization-based therapy and supportive group treatment of borderline personality disorder: clinical outcomes and functioning. Nordic Psychology2014;66(4):254-73. [DOI: 10.1080/19012276.2014.963649]JørgensenCR , FreundC , BøyeR , JordetH , AndersenD , KjølbyeM . Outcome of mentalization-based and supportive psychotherapy in patients with borderline personality disorder: a randomized trial. Acta Psychiatrica Scandinavica2013;127(4):305-17. [DOI: 10.1111/j.1600-0447.2012.01923.x] [PMID: 22897123]JorgensenCR . SV: questions on your trial regarding MBT for BPD patients [personal communication]. Email to: EG Faltinsen 28 November 2017. ">Jørgensen 2013</a>; <a href="./references#CD012955-bbs2-0035" title="KoonsCR , RobinsCJ , TweedJL , LynchTR , GonzalezAM , MorseJQ , et al. Efficacy of dialectical behavior therapy in women veterans with borderline personality disorder. Behavior Therapy2001;32(2):371-90. [DOI: 10.1016/S0005-7894(01)80009-5]">Koons 2001a</a>; <a href="./references#CD012955-bbs2-0036" title="KramerU , BergerT , KollyS , MarquetP , PreisigM , De RotenY , et al. Effects of motive-oriented therapeutic relationship in early-phase treatment of borderline personality disorder: a pilot study of a randomized trial. Journal of Nervous and Mental Disease2011;199(4):244-50. [DOI: 10.1097/NMD.0b013e3182125d19] [PMID: 21451348]KramerU , CasparF , DrapeauM . Change in biased thinking in a 10-session treatment for borderline personality disorder: further evidence of the motive-oriented therapeutic relationship. Psychotherapy Research2013;23(6):633-45. [DOI: 10.1080/10503307.2013.791404] [PMID: 23631622]">Kramer 2011</a>; <a href="./references#CD012955-bbs2-0037" title="BerthoudL , KramerU , CasparF , Pascual-LeoneA . Emotional processing in a ten-session general psychiatric treatment for borderline personality disorder: a case study. Personality and Mental Health2015;9(1):73-8. [DOI: 10.1002/pmh.1287] [PMID: 25711648]BerthoudL , Pascual-LeoneA , CasparF , TissotH , KellerS , RohdeKB , et al. Leaving distress behind: a randomized controlled study on change in emotional processing in borderline personality disorder. Psychiatry2017;80(2):139-54. [DOI: 10.1080/00332747.2016.1220230] [PMID: 28767333]KellerS , StelmaszczykK , KollyS , De RotenY , DesplandJN , CasparF , et al. Change in biased thinking in a treatment based on the motive-oriented therapeutic relationship for borderline personality disorder. Journal of Personality Disorders2018;32(Suppl):75-92. [DOI: 10.1521/pedi.2018.32.supp.75] [PMID: 29388899]KramerU , FlückigerC , KollyS , CasparF , MarquetP , DesplandJN , et al. Unpacking the effects of therapist responsiveness in borderline personality disorder: motive-oriented therapeutic relationship, patient in-session experience, and the therapeutic alliance. Psychotherapy and Psychosomatics2014;83(6):386-7. [DOI: 10.1159/000365400] [PMID: 25324025]KramerU , KellerS , CasparF , De RotenY , DesplandJN , KollyS . Early change in coping strategies in responsive treatments for borderline personality disorder: a mediation analysis. Journal of Consulting and Clinical Psychology2017;85(5):530-5. [DOI: 10.1037/ccp0000196] [PMID: 28425747]KramerU , KollyS , BerthoudL , KellerS , PreisigM , CasparF , et al. Effects of motive-oriented therapeutic relationship in a ten-session general psychiatric treatment of borderline personality disorder: a randomized controlled trial. Psychotherapy and Psychosomatics2014;83(3):176-86. [DOI: 10.1159/000358528] [PMID: 24752034]KramerU , StulzN , BerthoudL , CasparF , MarquetP , KollyS , et al. The shorter the better? A follow-up analysis of 10-session psychiatric treatment including the motive-oriented therapeutic relationship for borderline personality disorder. Psychotherapy Research2017;27(3):362-70. [DOI: 10.1080/10503307.2015.1110635] [PMID: 26684670]NCT01896024. Effects of motive-oriented therapeutic relationship in the early-phase treatment of borderline personality disorder (MOTR). www.clinicaltrials.gov/ct2/show/NCT01896024 (first received 5 July 2013). ">Kramer 2014</a>; <a href="./references#CD012955-bbs2-0038" title="KramerU , Pascual-LeoneA , BerthoudL , De RotenY , MarquetP , KollyS , et al. Assertive anger mediates effects of dialectical behaviour-informed skills training for borderline personality disorder: a randomized controlled trial. Clinical Psychology &amp; Psychotherapy2016;23(3):189-202. [DOI: 10.1002/cpp.1956] [PMID: 25864773]KramerU . The role of coping change in borderline personality disorder: a process-outcome analysis on dialectical-behaviour skills training. Clinical Psychology &amp; Psychotherapy2017;24(2):302-11. [DOI: 10.1002/cpp.2017] [PMID: 27098296]">Kramer 2016</a>; <a href="./references#CD012955-bbs2-0039" title="KredlowMA , SzuhanyKL , LoS , XieH , GottliebJD , RosenbergSD , et al. Cognitive behavioral therapy for posttraumatic stress disorder in individuals with severe mental illness and borderline personality disorder. Psychiatry Research2017;249:86-93. [DOI: 10.1016/j.psychres.2016.12.045] [PMC5325773] [PMID: 28086181]MueserK . Re: question regarding your trial on CBT for BPD patients [personal communication]. Email to: EG Faltinsen 28 November 2017. ">Kredlow 2017a</a>; <a href="./references#CD012955-bbs2-0040" title="KredlowMA , SzuhanyKL , LoS , XieH , GottliebJD , RosenbergSD , et al. Cognitive behavioral therapy for posttraumatic stress disorder in individuals with severe mental illness and borderline personality disorder. Psychiatry Research2017;249:86-93. [DOI: 10.1016/j.psychres.2016.12.045] [PMC5325773] [PMID: 28086181]MueserKT , GottliebJD , XieH , LuW , YanosPT , RosenbergSD , et al. Evaluation of cognitive restructuring for post-traumatic stress disorder in people with severe mental illness.. British Journal of Psychiatry2015;206(6):501-8. [DOI: 10.1192/bjp.bp.114.147926] [PMC4450219] [PMID: 25858178]MueserKT , RosenbergSD , XieH , JankowskiMK , BoltonEE , LuW , et al. A randomized controlled trial of cognitive-behavioral treatment for posttraumatic stress disorder in severe mental illness. Journal of Consulting and Clinical Psychology2008;76(2):259-71. [DOI: 10.1037/0022-006X.76.2.259] [PMC3916092] [PMID: 18377122]MueserKT . Re: question regarding your trial on CBT for PTSD participants [personal communication]. Email to: E Faltinsen 28 November 2018. ">Kredlow 2017b</a>; <a href="./references#CD012955-bbs2-0041" title="LaurenssenEM , WestraD , KikkertMJ , NoomMJ , EerenHV , Van BroekhuyzenAJ , et al. Day hospital mentalization-based treatment (MBT-DH) versus treatment as usual in the treatment of severe borderline personality disorder: protocol of a randomized controlled trial. BMC Psychiatry2014;14:149. [DOI: 10.1186/1471-244X-14-149] [PMC4045960] [PMID: 24886402]LaurenssenEMP , LuytenP , KikkertMJ , WestraD , PeenJ , SoonsMBJ , et al. Day hospital mentalization-based treatment v specialist treatment as usual in patients with borderline personality disorder: randomized controlled trial. Psychological Medicine2018;48(15):2522-9. [DOI: 10.1017/S0033291718000132] [PMID: 29478425]NL2058 (NTR2175). Mentalisation-based treatment versus care-as-usual in the treatment of severe borderline personality disorders. www.trialregister.nl/trial/2058 (first received 21 January 2010). ">Laurenssen 2018</a>; <a href="./references#CD012955-bbs2-0042" title="LeichsenringF , MasuhrO , JaegerU , RabungS , DallyA , DümpelmannM , et al. Psychoanalytic-interactional therapy versus psychodynamic therapy by experts for personality disorders: a randomized controlled efficacy-effectiveness study in cluster B personality disorders. Psychotherapy and Psychosomatics2016;85(2):71-80. [DOI: 10.1159/000441731] [PMID: 26808580]">Leichsenring 2016</a>; <a href="./references#CD012955-bbs2-0045" title="HoffmanRE . Impact of treatment accessibility on clinical course of parasuicidal patients. Archives of General Psychiatry1993;50(2):157-8. [DOI: 10.1001/archpsyc.1993.01820140083010] [PMID: 8427557]LindenboimN . To Know Me is to Keep Me: Self-Verification, Validation, and Therapy Dropout in the Treatment of Borderline Personality Disorder [PhD thesis]. Washington (DC): University of Washington, 2009. LinehanMM , ArmstrongHE , SuarezA , AllmonD , HeardHL . Cognitive-behavioral treatment of chronically parasuicidal borderline patients. Archives of General Psychiatry1991;48(12):1060-4. [DOI: 10.1001/archpsyc.1991.01810360024003] [PMID: 1845222]LinehanMM , HeardHL . Impact of treatment accessibility on clinical course of parasuicidal patients — reply. Archives of General Psychiatry1993;50(2):157-8. [DOI: 10.1001/archpsyc.1993.01820140083011]">Linehan 1991</a>; <a href="./references#CD012955-bbs2-0046" title="HeardHL . Cost-Effectiveness of Dialectical Behavior Therapy in the Treatment of Borderline Personality Disorder [PhD thesis]. Washington (DC): University of Washington, 2000. LindenboimN . To Know Me is to Keep Me: Self-Verification, Validation, and Therapy Dropout in the Treatment of Borderline Personality Disorder [PhD thesis]. Washington (DC): University of Washington, 2009. LinehanMM , HeardHL , ArmstrongHE . Naturalistic follow-up of a behavioral treatment for chronically parasuicidal borderline patients. Archives of General Psychiatry1993;50(12):971-4. [DOI: 10.1001/archpsyc.1993.01820240055007] [PMID: 8250683]LinehanMM , TutekDA , HeardHL , ArmstrongHE . Interpersonal outcome of cognitive behavioral treatment for chronically suicidal borderline patients. American Journal of Psychiatry1994;151(12):1771-6. [DOI: 10.1176/ajp.151.12.1771] [PMID: 7977884]">Linehan 1994</a>; <a href="./references#CD012955-bbs2-0047" title="BedicsJD , AtkinsDC , ComtoisKA , LinehanMM . Treatment differences in the therapeutic relationship and introject during a 2-year randomized controlled trial of dialectical behavior therapy versus nonbehavioral psychotherapy experts for borderline personality disorder. Journal of Consulting and Clinical Psychology2012;80(1):66-77. [DOI: 10.1037/a0026113] [PMC3265694] [PMID: 22061867]BedicsJD , AtkinsDC , ComtoisKA , LinehanMM . Weekly therapist ratings of the therapeutic relationship and patient introject furing the course of dialectical behavioral therapy for the treatment of borderline personality disorder. Psychotherapy2012;49(2):231-40. [DOI: 10.1037/a0028254] [PMID: 22642526]BedicsJD , AtkinsDC , HarnedMS , LinehanMM . The therapeutic alliance as a predictor of outcome in dialectical behavior therapy versus nonbehavioral psychotherapy by experts for borderline personality disorder. Psychotherapy2015;52(1):67-77. [DOI: 10.1037/a0038457] [PMID: 25751116]BrownMZ , LinehanMM , ComtoisKA , MurrayA , ChapmanAL . Shame as a prospective predictor of self-inflicted injury in borderline personality disorder: a multi-modal analysis. Behaviour Research and Therapy2009;47(10):815-22. [DOI: 10.1016/j.brat.2009.06.008] [PMC2761705] [PMID: 19596223 ]CoyleTN , ShaverJA , LinehanMM . On the potential for iatrogenic effects of psychiatric crisis services: the example of dialectical behavior therapy for adult women with borderline personality disorder. Journal of Consulting and Clinical Psychology2018;86(2):116-24. [DOI: 10.1037/ccp0000275] [PMID: 29369662]HarnedMS , ChapmanAL , Dexter-MazzaET , MurrayA , ComtoisKA , LinehanMM . Treating co-occurring Axis I disorders in recurrently suicidal women with borderline personality disorder: a 2-year randomized trial of dialectical behavior therapy versus community treatment by experts. Journal of Consulting and Clinical Psychology2008;76(6):1068-75. [DOI: 10.1037/a0014044] [PMID: 19045974]HarnedMS , ChapmanAL , Dexter-MazzaET , MurrayA , ComtoisKA , LinehanMM . Treating co-occurring Axis I disorders in recurrently suicidal women with borderline personality disorder: a 2-year randomized trial of dialectical behavior therapy versus community treatment by experts. Personality Disorders: Theory, Research, and Treatment2009;S(1):35-45. [DOI: 10.1037/1949-2715.S.1.35]HarnedMS , JacksonSC , ComtoisKA , LinehanMM . Dialectical behavior therapy as a precursor to PTSD treatment for suicidal and/or self-injuring women with bordreline personality disorder. Journal of Traumatic Stress2010;23(4):421-9. [DOI: 10.1002/jts.20553] [PMID: 20648564]LindenboimN , ComtoisKA , LinehanMM . Skills practice in dialectical behavior therapy for suicidal women meeting criteria for borderline personality disorder. Cognitive and Behavioral Practice2007;14(2):147-56. [DOI: 10.1016/j.cbpra.2006.10.004]LinehanMM , ComtoisKA , MurrayAM , BrownMZ , GallopRJ , HeardHL , et al. Two-year randomized controlled trial and follow-up of dialectical behavior therapy vs therapy by experts for suicidal behaviors and borderline personality disorder. Archives of General Psychiatry2006;63(7):757-66. [DOI: 10.1001/archpsyc.63.7.757] [PMID: 16818865]LinehanMM . Error in table in: two-year randomized controlled trial and follow-up of dialectical behavior therapy vs therapy by experts for suicidal behaviors and borderline personality disorder. Archives of General Psychiatry2007;64(12):1401. Erratum for: Archives of General Psychiatry 2007;64(12):1401. McMainS . Dialectic behaviour therapy reduces suicide attempts compared with non-behavioural psychotherapy in women with borderline personality disorder. Evidence-Based Mental Health2007;10(1):18. [DOI: 10.1136/ebmh.10.1.18] [PMID: 17255387]NeacsiuAD , LunguA , HarnedMS , RizviSL , LinehanMM . Impact of dialectical behavior therapy versus community treatment by experts on emotional experience, expression, and acceptance in borderline personality disorder. Behaviour Research and Therapy2014;53:47-54. [DOI: 10.1016/j.brat.2013.12.004] [PMC3955205] [PMID: 24418652]NeacsiuAD , RizviSL , LinehanMM . Dialectical behavior therapy skills use as a mediator and outcome of treatment for borderline personality disorder. Behaviour Research and Therapy2010;48(9):832-9. [DOI: 10.1016/j.brat.2010.05.017] [PMC2914145] [PMID: 20579633]SecristCD . The Role of Executive Functioning in the Treatment of Borderline Personality Disorder [PhD thesis]. Washington (DC): University of Washington, 2014. ">Linehan 2006</a>; <a href="./references#CD012955-bbs2-0048" title="LinehanMM , KorslundKE , HarnedMS , GallopRJ , LunguA , NeacsiuAD , et al. Dialectical behavior therapy for high suicide risk in individuals with borderline personality disorder: a randomized clinical trial and component analysis. JAMA Psychiatry2015;72(5):475-82 Erratum for: JAMA Psychiatry 2015; 72(9): 951. [DOI: 10.1001/jamapsychiatry.2014.3039] [PMID: 25806661]NCT00183651. Treatment of suicidal women with borderline personality disorder [Assessment and treatment of parasuicidal patients]. www.clinicaltrials.gov/ct2/show/NCT00183651 (first received 13 September 2005). ">Linehan 2015a</a>; <a href="./references#CD012955-bbs2-0049" title="CaseBG . Letter to the editor on 'McMain SF, Links PS, Gnam WH, Guimond T, Cardish RJ, Korman L, et al. A randomized trial of dialectical behavior therapy versus general psychiatric management for borderline personality disorder. American Journal of Psychiatry 2009;166(12):1365-74. DOI: 10.1176/appi.ajp.2009.09010039'. American Journal of Psychiatry2010;167(4):475. [DOI: 10.1176/appi.ajp.2009.09101532] [PMID: 20360332 ]ISRCTN02634417. Hope for chronically suicidal patient: evaluating the clinical and health services impact of dialectical behaviour therapy (DBT) in individuals with borderline personality disorder [Evaluating the clinical and health services impact of dialectical behaviour therapy (DBT) in individuals with borderline personality disorder: a randomised controlled trial]. www.isrctn.com/ISRCTN02634417 (first received 16 November 2005). [DOI: 10.1186/ISRCTN02634417]McMainSF , FitzpatrickS , BoritzT , BarnhartR , LinksP , StreinerDL . Outcome trajectories and prognostic factors for suicide and self-harm behaviors in patients with borderline personaliy disorder following one year of outpatient psychotherapy. Journal of Personality Disorders2018;32(4):497-512. [DOI: 10.1521/pedi_2017_31_309] [PMID: 28910214]McMainSF , LinksPS , GnamWH , GuimondT , CardishRJ , KormanL , et al. A randomized trial of dialectical behavior therapy versus general psychiatric management for borderline personality disorder. American Journal of Psychiatry2009;166(12):1365-74. [DOI: 10.1176/appi.ajp.2009.09010039] [PMID: 19755574]McMainSF . Dr McMain replies to letter to the editor on 'McMain SF, Links PS, Gnam WH, Guimond T, Cardish RJ, Korman L, et al. A randomized trial of dialectical behavior therapy versus general psychiatric management for borderline personality disorder. American Journal of Psychiatry 2009;166(12):1365-74. DOI: 10.1176/appi.ajp.2009.09010039'. American Journal of Psychiatry2010;167(4):475-6. [DOI: 10.1176/appi.ajp.2009.09101532r)]NCT00154154. Hope for the chronically suicidal patient [Hope for the chronically suicidal patient: evaluating the clinical and health services impact of dialectical behaviour therapy in individuals with borderline personality disorder]. www.clinicaltrials.gov/ct2/show/NCT00154154 (first received 7 September 2005). ">McMain 2009</a>; <a href="./references#CD012955-bbs2-0050" title="McMainSF , GuimondT , BarnhartR , HabinskiL , StreinerDL . A randomized trial of brief dialectical behaviour therapy skills training in suicidal patients suffering from borderline disorder. Acta Psychiatrica Scandinavica2017;135(2):138-48. [DOI: 10.1111/acps.12664] [PMID: 27858962]">McMain 2017</a>; <a href="./references#CD012955-bbs2-0051" title="McMurranM , CrawfordMJ , ReillyJ , DelportJ , McCroneP , WhithamD , et al. Psychoeducation with problem-solving (PEPS) therapy for adults with personality disorder: a pragmatic randomised controlled trial to determine the clinical effectiveness and cost-effectiveness of a manualised intervention to improve social functioning. Health Technology Assessment2016;20(52):1-282. [DOI: 10.3310/hta20520]McMurranM . RE: Cochrane Collaboration review - PEPS study [personal communication]. Email to: J Stoffers-Winterling 5 July 2018. McMurranM . Request for data on BPD subjects in the PEPS rcp-study for use a new Cochrane review [personal communication]. Email to: M Kongerslev 7 March 2017. ">McMurran 2016</a>; <a href="./references#CD012955-bbs2-0052" title="HagaE , AasE , GrøholtB , TørmoenAJ , MehlumL . Cost-effectiveness of dialectical behaviour therapy vs enhanced usual care in the treatment of adolescents with self-harm. Child and Adolescent Psychiatry and Mental Health2018;12:22. [DOI: 10.1186/s13034-018-0227-2] [PMC5928596] [PMID: 29743941]MehlumL , RambergM , TørmoenAJ , HagaE , DiepLM , StanleyBH , et al. Dialectical behavior therapy compared with enhanced usual care for adolescents with repeated suicidal and self-harming behavior: outcomes over a one-year follow-up. Journal of the American Academy of Child and Adolescent Psychiatry2016;55(4):295-300. [DOI: 10.1016/j.jaac.2016.01.005] [PMID: 27015720]MehlumL , TørmoenAJ , RambergM , HagaE , DiepLM , LabergS , et al. Dialectical behavior therapy for adolescents with repeated suicidal and self-harming behavior: a randomized trial. Journal of the American Academy of Child and Adolescent Psychiatry2014;53(10):1082-91. [DOI: 10.1016/j.jaac.2014.07.003] [PMID: 25245352]MehlumL . Re: regarding your study of DBT for your with suicidal behavior [personal communication] [Re: angående din studie om DBT for ungdom med selvmordsatferd [personlig kommunikation]]. Email to: E Faltinsen 5 December 2017. NCT00675129. Treatment for adolescents with deliberate self harm [A randomized controlled trial for repetitive deliberate self-harm and suicidal behaviours among Norwegian adolescents: a comparison between dialectical behaviour therapy adapted for adolescents (DBT-A) and enhanced usual care (EUC)]. www.clinicaltrials.gov/ct2/show/NCT00675129 (first received 6 May 2008). RamlethRK , GroholtB , DiepLM , WalbyFA , MehlumL . The impact of borderline personality disorder and sub-threshold borderline personality disorder on the course of self-reported and clinician-rated depression in self-harming adolescents. Borderline Personality Disorder and Emotion Dysregulation2017;4:22. [DOI: 10.1186/s40479-017-0073-5] [PMC5663078] [PMID: 29093819]">Mehlum 2014</a>; <a href="./references#CD012955-bbs2-0054" title="MoreyLC , LowmasterSE , HopwoodCJ . A pilot study of manual-assisted cognitive therapy with a therapeutic assessment augmentation for borderline personality disorder. Psychiatry Research2010;178(3):531-5. [DOI: 10.1016/j.psychres.2010.04.055] [PMID: 20537722]">Morey 2010</a>; <a href="./references#CD012955-bbs2-0055" title="MortonJ , SnowdonS , GopoldM , GuymerE . Acceptance and commitment therapy group treatment for symptoms of borderline personality disorder: a public sector pilot study. Cognitive and Behavioral Practice2012;19(4):527-44. [DOI: 10.1016/j.cbpra.2012.03.005]MortonJ . Re: SV: regarding your study on acceptance and commitment therapy for BPD [personal communication]. Email to: EG Faltinsen 22 December 2017. ">Morton 2012</a>; <a href="./references#CD012955-bbs2-0056" title="NadortM , ArntzA , SmitJH , Giesen-BlooJ , EikelenboomJ , SpinhovenP , et al. Implementation of outpatient schema therapy for borderline personality disorder with versus without crisis support by the therapist outside office hours: a randomized trial. Behaviour Research and Therapy2009;47(11):961-73. [DOI: 10.1016/j.brat.2009.07.013] [PMID: 19698939]NadortM , ArntzA , SmitJH , Giesen-BlooJ , EikelenboomM , SpinhovenP , et al. Implementation of outpatient schema therapy for borderline personality disorder: study design. BMC Psychiatry2009;9:64. [DOI: 10.1186/1471-244X-9-64] [PMC2762959] [PMID: 19807925]NL1680 (NTR1781). Implementation of out-patient schema-focused therapy for borderline personality disorder in regular mental healthcare. www.trialregister.nl/trial/1680 (first received 29 April 2009). ">Nadort 2009</a>; <a href="./references#CD012955-bbs2-0057" title="NCT02033044. Cognitive rehabilitation versus psychoeducation in psychosocial functioning of borderline personality disorder [Randomized controlled trial comparing the effects on psychosocial functioning of cognitive rehabilitation versus psychoeducation in borderline personality disorder]. www.clinicaltrials.gov/ct2/show/NCT02033044 (first received 23 December 2013). PascualJC , PalomaresN , Ibáñez Á, PortellaMJ , ArzaR , ReyesR , et al. Efficacy of cognitive rehabilitation on psychosocial functioning in borderline personality disorder: a randomized controlled trial. BMC Psychiatry2015;15:255. [DOI: 10.1186/s12888-015-0640-5] [PMC4617906] [PMID: 26487284]">Pascual 2015</a>; <a href="./references#CD012955-bbs2-0059" title="BarnicotK . Re: Regarding your study on DBT for self-harming patients [personal communication]. Email to: EG Faltinsen 28 February 2018. PriebeS , BhattiN , BarnicotK , BremnerS , GagliaA , KatsakouC , et al. Effectiveness and cost-effectiveness of dialectical behaviour therapy for self-harming patients with personality disorder: a pragmatic randomised controlled trial. Psychotherapy and Psychosomatics2012;81(6):356-65. [DOI: 10.1159/000338897] [PMID: 22964561]PriebeS . Supplemental information [personal communication]. Email to: M Kielsholm 20 May 2016. ">Priebe 2012</a>; <a href="./references#CD012955-bbs2-0060" title="RenesesB , FigueraD , SalcedoG , TrujilloM , López-IborJJ , GaliánM , et al. A controlled randomized study on the efficacy of short-term dinamic psychotherapy in borderline personality disorders (BPD). Preliminary results. European Psychiatry2011;26(Suppl 1):1040. [DOI: 10.1016/S0924-9338(11)72745-6] [P02-444]RenesesB , GaliánM , SerranoR , FigueraD , Fernandez Del MoralA , López-IborJJ , et al. A new time limited psychotherapy for BPD: preliminary results of a randomized and controlled trial. Actas Espanolas de Psiquiatria2013;41(3):139-48. [PMID: 23803797]">Reneses 2013</a>; <a href="./references#CD012955-bbs2-0062" title="ISRCTN95266816. The emergence of personality disorder traits in adolescents who deliberately self harm and the potential for using a mentalisation based treatment approach as an early intervention for such individuals: a randomised controlled trial. www.isrctn.com/ISRCTN95266816 (first received 29 October 2007). RossouwT . Mentalisation based treatment for adolescents with self harm: an RCT. European Child &amp; Adolescent Psychiatry2015;24(1 Suppl):S113. [DOI: 10.1007%2Fs00787-015-0714-4.pdf] [W1-02-02]RossouwT . Self harm in adolescence, is MBT the answer?: an RCT. Adolescent Psychiatry2012;2(1):102. [DOI: 10.2174/2210676611202010077]RossouwTI , FonagyP . Mentalization-based treatment for self-harm in adolescents: a randomized controlled trial. Journal of the American Academy of Child and Adolescent Psychiatry2012;51(12):1304-13.e3. [DOI: 10.1016/j.jaac.2012.09.018] [PMID: 23200287]">Rossouw 2012b</a>; <a href="./references#CD012955-bbs2-0063" title="SalzerS , CroppC , JaegerU , MasuhrO , Streeck-FischerA . Psychodynamic therapy for adolescents suffering from co-morbid disorders of conduct and emotions in an in-patient setting: a randomized controlled trial. Psychological Medicine2014;44(10):2213-22. [DOI: 10.1017/S003329171300278X] [PMID: 24229481]SalzerS , Streeck-FischerA . The psychoanalytic-interactional method (PiM) for adolescents with borderline personality disorder [Die psychoanalytisch-interaktionelle methode (PiM) für adoleszente mit borderline-persönlichkeitsstörung]. Personlichkeitsstorungen Theorie und Therapie2015;19(1):67-76. [elibrary.klett-cotta.de/article/99.120110/ptt-19-1-67]SalzerS . AW: Re: Cochrane Review on psychotherapies for BPD - RCT testing PiM vs WL [personal communication] [AW:Re: Cochrane Review zur Psychotherapie bei BPS - RCT zu PiM vs WL [persönliche kommunikation]]. Email to: J Stoffers-Winterling 15 July 2018. ">Salzer 2014</a>; <a href="./references#CD012955-bbs2-0065" title="SchillingL , MoritzS , KötherU , NagelM . Preliminary results on acceptance, feasibility, and subjective efficacy of the add-on group intervention metacognitive training for borderline patients. Journal of Cognitive Psychotherapy2015;29(2):153-64. [DOI: 10.1891/0889-8391.29.2.153]SchillingL , MoritzS , KristonL , KriegerM , NagelM . Efficacy of metacognitive training for patients with borderline personality disorder: preliminary results. Psychiatry Research2018;262:459-64. [DOI: 10.1016/j.psychres.2017.09.024] [PMID: 28927866]SchillingL . Re Schilling 2015/2018 - Cochrane Review of psychotherapies for BPD [personal communication] [Re Schilling 2015/2018 - Cochrane Review zur Psychotherapie bei BPS [persönliche Kommunikation]]. Email to: J Stoffers-Winterling 22 January 2019. ">Schilling 2018</a>; <a href="./references#CD012955-bbs2-0066" title="ISRCTN97589104. Evaluation of a group training for adolescents (emotion regulation training) with emotion regulation problems - a randomised controlled clinical trial. www.isrctn.com/ISRCTN97589104 (first received 23 August 2007). SchuppertHM , TimmermanME , BlooJ , Van GemertTG , WiersemaHM , MinderaaRB , et al. Emotion regulation training for adolescents with borderline personality disorder traits: a randomized controlled trial. Journal of the American Academy of Child &amp; Adolescent Psychiatry2012;51(12):1314-23. [DOI: 10.1016/j.jaac.2012.09.002] [PMID: 23200288]">Schuppert 2012</a>; <a href="./references#CD012955-bbs2-0067" title="NCT01904227. Intensified, inpatient adaptation of dialectical behavior therapy (DBT) (REDBT) [A randomized controlled study of the efficacy of an intensified, inpatient adaptation of dialectical behavior therapy (DBT) for a population of borderline patients (young adults/adults: 18-40), compared with standard outpatient DBT]. www.clinicaltrials.gov/ct2/show/NCT01904227 (first received 11 July 2013). SinnaeveR , Van den BoschLM , Van Steenbergen-WeijenburgKM . Change in interpersonal functioning during psychological interventions for borderline personality disorder — a systematic review of measures and efficacy. Personality and Mental Health2015;9(3):173-94. [DOI: 10.1002/pmh.1296] [PMID: 26058794]SinnaeveR , Van den BoschLMC , Hakkaart-van RoijenL , VansteelandtK . Effectiveness of step-down versus outpatient dialectical behaviour therapy for patients with severe levels of borderline personality disorder: a pragmatic randomized controlled trial. Borderline Personality Disorder and Emotion Dysregulation2018;5:12. [DOI: 10.1186/s40479-018-0089-5] [PMC6040072] [PMID: 30002832]SinnaeveR . Cochrane Collaboration review [personal communication]. Email to: J Stoffers-Winterling 11 June 2018. SinnaeveR . Re: BPDSI subscale data Sinnaeve et al (2018) [personal communication]. Email to: A Tadorovac 15 November 2018. SinnaeveR . RE: BPDSI subscale data Sinnaeve et al (2018) [personal communication] [RE: BPDSI subschale data Sinnaeve et al (2018) [personlig kommunikation]]. Email to: A Todorovac 15 November 2018. SinnaeveR . RE: BPDSI subscale data Sinnaeve et al (2018) [personal communication] [RE: BPDSI subschale data Sinnaeve et al (2018) [personlig kommunikation]]. Email to: A Todorovac 9 October 2018. Van den BoschLM , SinnaeveR , Hakkaart-van RoijenL , Van FurthEF . Efficacy and cost-effectiveness of an experimental short-term inpatient dialectical behavior therapy (DBT) program: study protocol for a randomized controlled trial. Trials2014;15:152. [DOI: 10.1186/1745-6215-15-152] [PMC4017823] [PMID: 24885551]Van RoijenLH , SinnaeveR , BouwmansC , Van Den BoschL . Cost-effectiveness and cost-utility of shortterm inpatient dialectical behavior therapy for chronically parasuicidal BPD (young) adults. Journal of Mental Health Policy and Economics2015;18(Suppl 1):S19-20. [www.icmpe.org/test1/journal/issues/v18s1toc.html]">Sinnaeve 2018</a>; <a href="./references#CD012955-bbs2-0068" title="SmithPN , GambleSA , CortNA , WardEA , HeH , TalbotNL . Attachment and alliance in the treatment of depressed, sexually abused women. Depression and Anxiety2012;29(2):123-30. [DOI: 10.1002/da.20913] [PMC3325338] [PMID: 22065593]SmithPN . Re: Cochrane Collaboration review of psychotherapies for BPD [personal communication]. Email to: J Stoffers-Winterling 05 July 2018. ">Smith 2012</a>; <a href="./references#CD012955-bbs2-0069" title="SolerJ , PascualJC , TianaT , CebriàA , BarrachinaJ , CampinsMJ , et al. Dialectical behaviour therapy skills training compared to standard group therapy in borderline personality disorder: a 3-month randomised controlled clinical trial. Behaviour Research and Therapy2009;47(5):353-8. [DOI: 10.1016/j.brat.2009.01.013] [PMID: 19246029]SolerJ . Question regarding your BPD trials [personal communication]. Email to: J Stoffers 15 December 2010. ">Soler 2009</a>; <a href="./references#CD012955-bbs2-0071" title="TurnerRM . Naturalistic evaluation of dialectical behavior therapy-oriented treatment for borderline personality disorder. Cognitive and Behavioral Practice2000;7(4):413-9. [DOI: 10.1016/S1077-7229(00)80052-8]">Turner 2000</a>; <a href="./references#CD012955-bbs2-0072" title="Van den BoschLM , KoeterMW , StijnenT , VerheulR , Van den BrinkW . Sustained efficacy of dialectical behaviour therapy for borderline personality disorder. Behaviour Research and Therapy2005;43(9):1231-41. [DOI: 10.1016/j.brat.2004.09.008] [PMID: 16005708]Van den BoschLM , VerheulR , SchippersGM , Van den BrinkW . Dialectical behavior therapy of borderline patients with and without substance use problems. Implementation and long-term effects. Addictive Behaviors2002;27(6):911-23. [DOI: 10.1016/s0306-4603(02)00293-9] [PMID: 12369475]Van den BoschLMC . Efficacy of dialectical behaviour therapy in the treatment of female borderline patients with and without substance abuse problems: results of a Dutch study [Dialectische gedragstherapie bij Nederlandse vrouwen met een borderline persoonlijkheidsstoornis, met en zonder verslavingsproblemen]. Tijdschrift voor Psychiatrie2005;47(3):127-37. [www.tijdschriftvoorpsychiatrie.nl/assets/articles/articles_1335pdf.pdf]VerheulR , Van den BoschLM , KoeterMW , De RidderMA , StijnenT , Van den BrinkW . Dialectical behaviour therapy for women with borderline personality disorder: 12-month, randomised clinical trial in The Netherlands. British Journal of Psychiatry2003;182:135-40. [DOI: 10.1192/bjp.182.2.135] [PMID: 12562741]">Van den Bosch 2005</a>; <a href="./references#CD012955-bbs2-0073" title="WeinbergI , GundersonJG , HennenJ , Cutter CJ Jr. Manual assisted cognitive treatment for deliberate self-harm in borderline personality disorder patients. Journal of Personality Disorders2006;20(5):482-92. [DOI: 10.1521/pedi.2006.20.5.482] [PMID: 17032160]WilbergT . SV: separate data [personal communication] [SV: separat data [personlig kommunikation]]. Email to: M Kielsholm 25 May 2016. ">Weinberg 2006</a>; <a href="./references#CD012955-bbs2-0074" title="ZanariniMC , FrankenburgFR . A preliminary, randomized trial of psychoeducation for women with borderline personality disorder. Journal of Personality Disorders2008;22(3):284-90. [DOI: 10.1521/pedi.2008.22.3.284] [PMID: 18540800]ZanariniMC , FrankenburgFR . A randomized trial of psychoeducation for patients with BPD. In: 157th annual meeting of the American Psychiatric Association. Psychotherapy and psychopharmacology: dissolving the mind-brain barrier; 2004 May 1-6; New York (NY). Arlington (VA): American Psychiatric Association, 2004:102. [Symposium 100E] [www.psychiatry.org/File%20Library/Psychiatrists/Directories/Library-and-Archive/conference_publications/am_program_2004.pdf]">Zanarini 2008</a>; <a href="./references#CD012955-bbs2-0075" title="ZanariniMC , ConkeyLC , TemesCM , FitzmauriceGM . Randomized controlled trial of web-based psychoeducation for women with borderline personality disorder. Journal of Clinical Psychiatry2018;79(3):16m11153. [DOI: 10.4088/JCP.16m11153] [PMC5764827] [PMID: 28703950]">Zanarini 2018</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All participants of each group received the same kind of concomitant medication</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Bellino-2006" target="_blank">Bellino 2006</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Bellino-2007" target="_blank">Bellino 2007</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Bellino-2010" target="_blank">Bellino 2010</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Jahangard-2012" target="_blank">Jahangard 2012</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Partly (50% of each group concomitantly received a specified, concurrent medication, 50% placebo) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Stanley-2017" target="_blank">Stanley 2017</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not allowed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Lin-2019" target="_blank">Lin 2019</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Mohamadizadeh-2017" target="_blank">Mohamadizadeh 2017</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not specified</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Bianchini-2019" target="_blank">Bianchini 2019</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Carter-2010" target="_blank">Carter 2010</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Davidson-2014" target="_blank">Davidson 2014</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Haeyen-2018" target="_blank">Haeyen 2018</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Kamalabadi-2012" target="_blank">Kamalabadi 2012</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Lepp_x00e4_nen-2016" target="_blank">Leppänen 2016</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Philips-2018" target="_blank">Philips 2018</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Robinson-2016" target="_blank">Robinson 2016</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Santisteban-2015" target="_blank">Santisteban 2015</a> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="3" rowspan="1" scope="col" valign="bottom"> <p><b><i>Control interventions</i> </b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Obligatory</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Amianto-2011" target="_blank">Amianto 2011</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Andreoli-2016" target="_blank">Andreoli 2016</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Bateman-1999" target="_blank">Bateman 1999</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Bateman-2009" target="_blank">Bateman 2009</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Bellino-2006" target="_blank">Bellino 2006</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Bellino-2010" target="_blank">Bellino 2010</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Bianchini-2019" target="_blank">Bianchini 2019</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Borschmann-2013" target="_blank">Borschmann 2013</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Bos-2010" target="_blank">Bos 2010</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Carter-2010" target="_blank">Carter 2010</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Davidson-2014" target="_blank">Davidson 2014</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Doering-2010" target="_blank">Doering 2010</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Farrell-2009" target="_blank">Farrell 2009</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Feigenbaum-2012" target="_blank">Feigenbaum 2012</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Gleeson-2012" target="_blank">Gleeson 2012</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Gratz-2006" target="_blank">Gratz 2006</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Gratz-2014" target="_blank">Gratz 2014</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Jahangard-2012" target="_blank">Jahangard 2012</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Jochems-2015" target="_blank">Jochems 2015</a>;<a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-J_x00f8_rgensen-2013" target="_blank">Jørgensen 2013</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Koons-2001a" target="_blank">Koons 2001a</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Kramer-2016" target="_blank">Kramer 2016</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Laurenssen-2018" target="_blank">Laurenssen 2018</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Leichsenring-2016" target="_blank">Leichsenring 2016</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Lepp_x00e4_nen-2016" target="_blank">Leppänen 2016</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Linehan-2006" target="_blank">Linehan 2006</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-McMurran-2016" target="_blank">McMurran 2016</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Mehlum-2014" target="_blank">Mehlum 2014</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Morton-2012" target="_blank">Morton 2012</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Mohamadizadeh-2017" target="_blank">Mohamadizadeh 2017</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Philips-2018" target="_blank">Philips 2018</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Priebe-2012" target="_blank">Priebe 2012</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Reneses-2013" target="_blank">Reneses 2013</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Robinson-2016" target="_blank">Robinson 2016</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Rossouw-2012b" target="_blank">Rossouw 2012b</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Schuppert-2012" target="_blank">Schuppert 2012</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Soler-2009" target="_blank">Soler 2009</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Stanley-2017" target="_blank">Stanley 2017</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Smith-2012" target="_blank">Smith 2012</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Van-den-Bosch-2005" target="_blank">Van den Bosch 2005</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Weinberg-2006" target="_blank">Weinberg 2006</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Zanarini-2018" target="_blank">Zanarini 2018</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Optional</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Blum-2008" target="_blank">Blum 2008</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Bohus-2013" target="_blank">Bohus 2013</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Davidson-2006" target="_blank">Davidson 2006</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Gregory-2008b" target="_blank">Gregory 2008b</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Haeyen-2018" target="_blank">Haeyen 2018</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Kamalabadi-2012" target="_blank">Kamalabadi 2012</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Kredlow-2017a" target="_blank">Kredlow 2017a</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Linehan-1991" target="_blank">Linehan 1991</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Linehan-1994" target="_blank">Linehan 1994</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-McMain-2017" target="_blank">McMain 2017</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Mohamadizadeh-2017" target="_blank">Mohamadizadeh 2017</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Salzer-2014" target="_blank">Salzer 2014</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Zanarini-2008" target="_blank">Zanarini 2008</a> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="3" rowspan="1" scope="col" valign="bottom"> <p><b><i>Funding</i> </b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Funded by grants from universities, authorities or research foundations</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012955-bbs2-0001" title="AmiantoF , FerreroA , PieròA , CairoE , RoccaG , SimonelliB , et al. Supervised team management, with or without structured psychotherapy, in heavy users of a mental health service with borderline personality disorder: a two-year follow-up preliminary randomized study. BMC Psychiatry2011;11:181. [DOI: 10.1186/1471-244X-11-181] [PMC3260092 ] [PMID: 22103890]NCT01356069. Efficacy of time-limited psychodynamic psychotherapy and informed clinical management in BPD high MHS users (HUMSH) [Sequential brief Adlerian psychodynamic psychotherapy in heavy users of a mental health service with borderline personality disorder: a two years follow-up preliminary randomized study]. clinicaltrials.gov/ct2/show/NCT01356069 (first received 16 May 2011). ">Amianto 2011</a>; <a href="./references#CD012955-bbs2-0003" title="AntonsenBT , JohansenMS , RøFG , KvarsteinEH , WilbergT . Is reflective functioning associated with clinical symptoms and long-term course in patients with personality disorders?Comprehensive Psychiatry2016;64:46-58. [DOI: 10.1016/j.comppsych.2015.05.016] [PMID: 26104432]AntonsenBT , KlungsøyrO , KampsA , HummelenB , JohansenMS , PedersenG , et al. Step-down versus outpatient psychotherapeutic treatment for personality disorders: 6-year follow-up of the Ullevål personality project. BMC Psychiatry2014;14:119. [DOI: 10.1186/1471-244X-14-119] [PMC4000615] [PMID: 24758722]AntonsenBT , KvarsteinEH , Urnes Ø, HummelenB , KarterudS , WilbergT . Favourable outcome of long-term combined psychotherapy for patients with borderline personality disorder: six-year follow-up of a randomized study. Psychotherapy Research2017;27(1):51-63. [DOI: 10.1080/10503307.2015.1072283] [PMID: 26261865]ArnevikE , WilbergT , Urnes Ø, JohansenM , MonsenJT , KarterudS . Psychotherapy for personality disorders: short-term day hospital psychotherapy versus outpatient individual therapy - a randomized controlled study. European Psychiatry2009;24(2):71-8. [DOI: 10.1016/j.eurpsy.2008.09.004] [PMID: 19097870]GullestadFS , JohansenMS , HøglendP , KarterudS , WilbergT . Mentalization as a moderator of treatment effects: findings from a randomized clinical trial for personality disorders. Psychotherapy Research2013;23(6):674-89. [DOI: 10.1080/10503307.2012.684103] [PMID: 22612470]GullestadFS . Re: questions regarding your trial on day hospital step-down program [personal communication]. Email to: E Faltinsen 4 December 2017. KvarsteinEH , ArnevikE , HalsteinliV , RøFG , KarterudS , WilbergT . Health service costs and clinical gains of psychotherapy for personality disorders: a randomized controlled trial of day-hospital-based step-down treatment versus outpatient treatment at a specialist practice. BMC Psychiatry2013;13:315. [DOI: 10.1186/1471-244X-13-315] [PMC4222503] [PMID: 24268099]">Antonsen 2017</a>; <a href="./references#CD012955-bbs2-0004" title="BatemanA , FonagyP . 8-year follow-up of patients treated for borderline personality disorder: mentalization-based treatment versus treatment as usual. American Journal of Psychiatry2008;165(5):631-8. [DOI: 10.1176/appi.ajp.2007.07040636] [PMID: 18347003]BatemanA , FonagyP . Effectiveness of partial hospitalization in the treatment of borderline personality disorder: a randomized controlled trial. American Journal of Psychiatry1999;156(10):1563-9. [DOI: 10.1176/ajp.156.10.1563] [PMID: 10518167]BatemanA , FonagyP . Health care utilization costs for borderline personality disorder patients treated with psychoanalytically oriented partial hospitalization versus general psychiatric care. American Journal of Psychiatry2003;160(1):169-71. [10.1176/appi.ajp.160.1.169] [12505818]BatemanA , FonagyP . Treatment of borderline personality disorder with psychoanalytically oriented partial hospitalization: an 18-month follow-up. American Journal of Psychiatry2001;158(1):36-42. [DOI: 10.1176/appi.ajp.158.1.36] [PMID: 11136631]BatemanA . Important: question regarding your BPD trial for systematic review in Cochrane Collaboration [personal communication]. Email to: K Lieb, J Stoffers 14 December 2010. BatemanA . Intensive outpatient and partial hospital care for BPD. In: 157th annual meeting of the American Psychiatric Association. Psychotherapy and pharmacology: dissolving the mind-brain barrier; 2004 May 1-6; New York (NY). Arlington (VA): American Psychiatric Association, 2004:102. [Symposium 100B] [www.psychiatry.org/File%20Library/Psychiatrists/Directories/Library-and-Archive/conference_publications/am_program_2004.pdf]BatemanAW , FonagyP . Drs Bateman and Fonagy reply [to Stern R. Partial hospitalization for borderline personality disorder. American Journal of Psychiatry 2001;158(11):1932-3. DOI: 10.1176/appi.ajp.158.11.1932]. American Journal of Psychiatry2001;158(11):1932-3. [DOI: 10.1176/appi.ajp.158.11.1932-a]EvansC . Treatment benefits of psychoanalytically oriented partial hospitalisation were maintained over 18 months in borderline personality disorder. Evidence-Based Mental Health2001;4(3):73. [DOI: 10.1136/ebmh.4.3.73]FonagyP , BatemanAW . Mentalizing and borderline personality disorder. Journal of Mental Health2007;16(1):83-101. [DOI: 10.1080/09638230601182045]SternR . Partial hospitalization for borderline personality disorder. American Journal of Psychiatry2001;158(11):1932-3. [DOI: 10.1176/appi.ajp.158.11.1932] [PMID: 11691712]">Bateman 1999</a>; <a href="./references#CD012955-bbs2-0005" title="BatemanA , FonagyP . Impact of clinical severity on outcomes of mentalisation-based treatment for borderline personality disorder. British Journal of Psychiatry2013;203(3):221-7. [DOI: 10.1192/bjp.bp.112.121129] [PMID: 23887998]BatemanA , FonagyP . Randomized controlled trial of outpatient mentalization-based treatment versus structured clinical management for borderline personality disorder. American Journal of Psychiatry2009;166(12):1355-64. [DOI: 10.1176/appi.ajp.2009.09040539] [PMID: 19833787]BatemanA , FonagyP . Randomized controlled trial of outpatient mentalization-based treatment versus structured clinical management for borderline personality disorder. Supplementary data. ajp.psychiatryonline.org/doi/suppl/10.1176/appi.ajp.2009.09040539/suppl_file/ajp_166_12_1355_01.pdf (accessed 27 February 2020). BatemanA , O'ConnellJ , LorenziniN , GardnerT , FonagyP . A randomised controlled trial of mentalization-based treatment versus structured clinical management for patients with comorbid borderline personality disorder and antisocial personality disorder. BMC Psychiatry2016;16:304. [DOI: 10.1186/s12888-016-1000-9] [PMC5006360] [PMID: 27577562]BatemanA . Important question regarding your BPD trial for systematic review in Cochrane Collaboration [personal communication]. Email to: K Lieb 14 December 2010. BatemanAW . Mentalization, borderline personality disorder and what works for whom? Presentation at the 11th International Congress of the International Society for the Study of Personality Disorders; 2009 Aug 21-23. www.borderlinepersonalitydisorder.com/Conferences/ISSPD/isspd_09_Bateman (accessed 21 April 2010). ISRCTN27660668. Randomised controlled trial of manualised out-patient individual and group therapy for borderline personality disorder [Effectiveness of intensive out-patient psychotherapy for treatment of borderline personality disorder: a pragmatic randomised single blind controlled study]. www.isrctn.com/ISRCTN27660668 (first received 12 October 2008). ">Bateman 2009</a>; <a href="./references#CD012955-bbs2-0010" title="BlackD . Question regarding your BPD trial [personal communication]. Email to: J Stoffers 04 January 2011. BlackDW , AllenJ , McCormickB , BlumN . Treatment received by persons with BPD participating in a randomized clinical trial of the systems training for emotional predictability and problem solving programme. Personality and Mental Health2011;5(3):159-68. [DOI: 10.1002/pmh.167]BlackDW , AllenJ , St JohnD , PfohlB , McCormickB , BlumN . Predictors of response to systems training for emotional predictability and problem solving (STEPPS) for borderline personality disorder: an exploratory study. Acta Psychiatrica Scandinavica2009;120(1):53-61. [DOI: 10.1111/j.1600-0447.2008.01340.x] [PMC3665337] [PMID: 19183126]BlackDW , BlumN , PfohlB , St JohnD . The STEPPS group treatment program for outpatients with borderline personality disorder. Journal of Contemporary Psychotherapy2004;34(3):193-210. [DOI: 10.1023/B:JOCP.0000036630.25741.83]BlackDW , PfohlBM . Randomized clinical trial of STEPPS versus treatment as usual. In: 158th annual meeting of the American Psychiatric Association. Psychosomatic medicine: integrating psychiatry &amp; medicine; 2005 May 21-26; Atlanta (GA). Arlington (VA): American Psychiatric Association, 2005:104. [No. 1B] [www.psychiatry.org/File%20Library/Psychiatrists/Directories/Library-and-Archive/syllabus/am_syllabus_2005.pdf]BlackDW , Simsek-DuranF , BlumN , McCormickB , AllenJ . Do people with borderline personality disorder complicated by antisocial personality disorder benefit from the STEPPS treatment program?Personality and Mental Health2016;10(3):205-15. [DOI: 10.1002/pmh.1326] [PMC4911327] [PMID: 26671625]BlackDW . RE: [external] questions regarding your trial on the STEPPS program for BPD [personal communication]. Email to: EG Faltinsen 27 November 2017. BlumN , AllenJ , McCormickB , BlackDW . Ms Blum and colleagues reply [to Schulte-Herbrüggen O, Koerting J, Roepke S. Effectiveness of adjunctive STEPPS group treatment in borderline personality disorder patients. American Journal of Psychiatry 2008;165(10):1354-5. DOI: 10.1176/appi.ajp.2008.08030390]. American Journal of Psychiatry2008;165(10):1354-5. [DOI: 10.1176/appi.ajp.2008.08030390r]BlumN , FranklinJ , HanselR , McCormickB , St JohnD , PfohlB , et al. Relationship of age to symptom severity, psychiatric comorbidity and health care utilization in persons with borderline personality disorder. Personality and Mental Health2008;2(1):25-43. [DOI: 10.1002/pmh.26]BlumN , St JohnD , PfohlB , StuartS , McCormickB , AllenJ , et al. Erratum. American Journal of Psychiatry2008;165(6):777. Erratum for: American Journal of Psychiatry 2008;165(4):468-78. [psycnet.apa.org/record/2008-07854-033]BlumN , St JohnD , PfohlB , StuartS , McCormickB , AllenJ , et al. Systems training for emotional predictability and problem solving (STEPPS) for outpatients with borderline personality disorder: a randomized controlled trial and 1-year follow-up. American Journal of Psychiatry2008;165(4):468-78. [DOI: 10.1176/appi.ajp.2007.07071079] [PMC3608469] [PMID: 18281407]DavidsonKM . Borderline personality disorder: STEPPS improves symptoms. Evidence-Based Mental Health2008;11(4):120. [DOI: 10.1136/ebmh.11.4.120] [PMID: 18952969]NCT00055315. Treatment for borderline personality disorder [A cognitive group treatment for borderline outpatients]. clinicaltrials.gov/ct2/show/NCT00055315 (first received 25 February 2003). ">Blum 2008</a>; <a href="./references#CD012955-bbs2-0011" title="BohusM , DyerAS , PriebeK , KrügerA , KleindienstN , SchmahlC , et al. Dialectical behaviour therapy for post-traumatic stress disorder after childhood sexual abuse in patients with and without borderline personality disorder: a randomised controlled trial. Psychotherapy and Psychosomatics2013;82(4):221-33. [DOI: 10.1159/000348451] [PMID: 23712109]BrandS . AW: questions regarding your trial on emotional intelligence training for BPD [personal communication]. Email to: EG Faltinsen 28 November 2017. DBT Working Group at the Central Institute for Mental Health, Mannheim, Germany. Requested supplementary data (as supplied 1 October 2010). Data on file. NCT00481000. Dialectical cognitive traumatherapy (DCT) on patients with severe PTSD following sexual abuse (PASA) [Dialectical cognitive traumatherapy (DCT) on patients with severe posttraumatic stress disorder following sexual abuse - a randomised controlled trial]. clinicaltrials.gov/ct2/show/NCT00481000 (first received 31 May 2007). SteilR , DyerA , PriebeK , KleindienstN , BohusM . Dialectical behavior therapy for posttraumatic stress disorder related to childhood sexual abuse: a pilot study of an intensive treatment program. Journal of Traumatic Stress2011;24(1):102-6. [DOI: 10.1002/jts.20617] [PMID: 21351167]">Bohus 2013</a>; <a href="./references#CD012955-bbs2-0012" title="BorschmannR , BarrettB , HellierJM , ByfordS , HendersonC , RoseD , et al. Joint crisis plans for people with borderline personality disorder: feasibility and outcomes in a randomised controlled trial. British Journal of Psychiatry2013;202(5):357-64. [DOI: 10.1192/bjp.bp.112.117762] [PMID: 23637110]BorschmannR . Joint crisis plans for BPD - question on publication in British Journal of Psychiatry [pers communication]. Email to: J Stoffers-Winterling 22 August 2017. BorschmannR . RE: joint crisis plans for BPD - question on publication in British Journal of Psychiatry [personal communication]. Email to: J Stoffers-Winterling 22 August 2017. BorschmannR . The development and testing of joint crisis plans for people with borderline personality disorder: a feasibility study. ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.628499 (accessed 27 January 2019). HellierJ . RE: regarding your study on on MBT for eating disorders [personal communication]. Email to: E Faltinsen 27 March 2018. HellierJ . RE: regarding your study on on MBT for eating disorders [personal communication]. Email to: E Faltinsen 3 January 2018. HellierJ . SV: regarding your study on MBT for eating disorders [personal communication]. Email to: EG Faltinsen, P Robinson 27 March 2018. ISRCTN12440268. JOSHUA: a pilot randomised controlled trial of joint crisis plans for people who self harm. www.isrctn.com/ISRCTN12440268 (first received 17 September 2009). ">Borschmann 2013</a>; <a href="./references#CD012955-bbs2-0013" title="BosEH , Van WelE , AppeloMT , VerbraakMJP . A randomized controlled trial of a Dutch version of systems training for emotional predictability and problem solving for borderline personality disorder. Journal of Nervous and Mental Disease2010;198(4):299-304. [DOI: 10.1097/NMD.0b013e3181d619cf] [PMID: 20386260]Van WelEB , BosEH , AppeloMT , BerendsenEM , WillgerothFC , VerbraakMJPM . The efficacy of the systems training for emotional predictability and problem solving (STEPPS) in the treatment of borderline personality disorder. A randomized controlled trial [De effectiviteit van de vaardigheidstraining emotieregulatiestoornis (VERS) in de behandeling van de borderlinepersoonlijkheidsstoornis: een gerandomiseerd onderzoek]. Tijdschrift voor Psychiatrie2009;51(5):291-301. [PMID: 19434566]">Bos 2010</a>; <a href="./references#CD012955-bbs2-0014" title="Carmona i FarrésC , ElicesM , SolerJ , Domínguez-ClavéE , Pomarol-ClotetE , SalvadorR , et al. Effects of mindfulness training on borderline personality disorder: impulsivity versus emotional dysregulation. Mindfulness2019;10:1243-54. [DOI: 10.1007/s12671-018-1071-4]NCT03363230. Effects of mindfulness training on emotion regulation and impulsivity. www.clinicaltrials.gov/ct2/show/NCT03363230 (first received 30 November 2017). ">Carmona í Farrés 2019</a>; <a href="./references#CD012955-bbs2-0016" title="CottrauxJ , NoteID , BoutitieF , MillieryM , GenouihlacV , YaoSN , et al. Cognitive therapy versus Rogerian supportive therapy in borderline personality disorder. Two-year follow-up of a controlled pilot study. Psychotherapy and Psychosomatics2009;78(5):307-16. [DOI: 10.1159/000229769] [PMID: 19628959]NCT00131781. Cognitive therapy versus supportive therapy in borderline personality disorder. www.clinicaltrials.gov/ct2/show/NCT00131781 (first received 18 August 2005). ">Cottraux 2009</a>; <a href="./references#CD012955-bbs2-0017" title="DavidsonK , LivingstoneS , McArthurK , DicksonL , GumleyA . An integrative complexity analysis of cognitive behaviour therapy sessions for borderline personality disorder. Psychology and Psychotherapy2007;80(Pt 4):513-23. [DOI: 10.1348/147608307X191535] [PMID: 17535542]DavidsonK , NorrieJ , TyrerP , GumleyA , TataP , MurrayH , et al. The effectiveness of cognitive behavior therapy for borderline personality disorder: results from the borderline personality disorder study of cognitive therapy (BOSCOT) trial. Journal of Personality Disorders2006;20(5):450-65. [DOI: 10.1521/pedi.2006.20.5.450] [PMC1852259] [PMID: 17032158]DavidsonK , TyrerP , GumleyA , TataP , NorrieJ , PalmerS , et al. A randomized controlled trial of cognitive behavior therapy for borderline personality disorder: rationale for trial, method, and description of sample. Journal of Personality Disorders2006;20(5):431-49. [DOI: 10.1521/pedi.2006.20.5.431] [PMC1847748] [PMID: 17032157]DavidsonKM , TyrerP , NorrieJ , PalmerSJ , TyrerH . Cognitive therapy v usual treatment for borderline personality disorder: prospective 6-year follow-up. British Journal of Psychiatry2010;197(6):456-62. [DOI: 10.1192/bjp.bp.109.074286] [PMID: 21119151]ISRCTN86177428. Borderline personality disorder study of cognitive therapy trial [A randomised controlled trial of cognitive therapy plus treatment as usual versus treatment as usual in the treatment of borderline personality disorder]. www.isrctn.com/ISRCTN86177428 (first received 22 July 2005). NCT00538135. BOSCOT: a randomised controlled trial of cognitive behavioural therapy in borderline personality disorder [BOSCOT: a randomised control trial of cognitive behavioural therapy plus treatment as usual versus treatment as usual in the treatment of borderline personality disorder]. www.clinicaltrials.gov/ct2/show/NCT00538135 (first received 29 September 2007). NorrieJ , DavidsonK , TataP , GumleyA . Influence of therapist competence and quantity of cognitive behavioural therapy on suicidal behaviour and inpatient hospitalisation in a randomised controlled trial in borderline personality disorder: further analyses of treatment effects in the BOSCOT study. Psychology and Psychotherapy2013;86(3):280-93. [DOI: 10.1111/papt.12004] [PMC4491320] [PMID: 23420622]PalmerS , DavidsonK , TyrerP , GumleyA , TataP , NorrieJ , et al. The cost-effectiveness of cognitive behavior therapy for borderline personality disorder: results from the BOSCOT trial. Journal of Personality Disorders2006;20(5):466-81. [DOI: 10.1521/pedi.2006.20.5.466] [PMC1852260] [PMID: 17032159]">Davidson 2006</a>; <a href="./references#CD012955-bbs2-0018" title="DavidsonKM , BrownTM , JamesV , KirkJ , RichardsonJ . Manual-assisted cognitive therapy for self-harm in personality disorder and substance misuse: a feasibility trial. Psychiatric Bulletin2014;38(3):108-11. [DOI: 10.1192/pb.bp.113.043109] [PMC4115373] [PMID: 25237519]DavidsonKM . Re: question regarding your trial on manual-assisted cognitive therapy [personal communication]. Email to: EG Faltinsen 28 November 2017. ">Davidson 2014</a>; <a href="./references#CD012955-bbs2-0019" title="BuchheimA , Hörz-SagstetterS , DoeringS , RentropM , SchusterP , BuchheimP , et al. Change of unresolved attachment in borderline personality disorders: RCT study of transference-focused psychotherapy. Psychotherapy and Psychosomatics2017;86(5):314-6. [DOI: 10.1159/000460257] [PMID: 28903103]DiamondD , LevyKN , ClarkinJF , Fischer-KernM , CainNM , DoeringS , et al. Attachment and mentalization in female patients with comorbid narcissistic and borderline personality disorder. Personality Disorders2014;5(4):428-33. [DOI: 10.1037/per0000065] [PMID: 25314231]DiamondD , YeomansFE , SternB , LevyKN , HörzS , DoeringS , et al. Transference-focused psychotherapy for patients with comorbid narcissistic and borderline personality disorder. Psychoanalytic Inquiry2013;33(6):527-51. [DOI: 10.1080/07351690.2013.815087]DoeringS , HörzS , RentropM , Fischer-KernM , SchusterP , BeneckeC , et al. Transference-focused psychotherapy v treatment by community psychotherapists for borderline personality disorder: randomised controlled trial. British Journal of Psychiatry2010;196(5):389-95. [DOI: 10.1192/bjp.bp.109.070177] [PMID: 20435966]DoeringS . Author's reply [to Kleindienst N, Krumm B, Bohus M. Is transference-focused psychotherapy really efficacious for borderline personality disorder? British Journal of Psychiatry 2011;198(2):156-7. DOI: 10.1192/bjp.198.2.156b]. British Journal of Psychiatry2011;198(2):156-7. [DOI: 10.1192/bjp.198.2.157]DoeringS . Question regarding your BPD trial for systematic review in Cochrane Collaboration [personal communication]. Email to: K Lieb, J Stoffers 10 December 2010. Fischer-KernM , DoeringS , TaubnerS , HörzS , ZimmermannJ , RentropM , et al. Transference-focused psychotherapy for borderline personality disorder: change in reflective function. British Journal of Psychiatry2015;207(2):173-4. [DOI: 10.1192/bjp.bp.113.143842] [PMID: 25999334]KleindienstN , KrummB , BohusM . Is transference-focused psychotherapy really efficacious for borderline personality disorder?British Journal of Psychiatry2011;198(2):156-7. [DOI: 10.1192/bjp.198.2.156b] [PMID: 21282787]LevyKN , MeehanKB , YeomansFE . Transference-focused psychotherapy reduces treatment drop-out and suicide attempters compared with community psychotherapist treatment in borderline personality disorder. Evidence-based Mental Health2010;13(4):119. [DOI: 10.1136/ebmh.13.4.119] [PMID: 21036981]NCT00714311. Efficacy of transference-focused psychotherapy for borderline personality disorder [A randomized-controlled trial of transference-focused psychotherapy vs treatment by experienced community psychotherapists for borderline personality disorder]. www.clinicaltrials.gov/ct2/show/NCT00714311 (first received 9 July 2008). RentropM , MartiusP , BäumlJ , BuchheimP , DöeringS , HörzS . Patients with borderline personality disorder not participating in an RCT: are they different?Psychopathology2010;43(6):369-72. [DOI: 10.1159/000320351] [PMID: 20798576]">Doering 2010</a>; <a href="./references#CD012955-bbs2-0020" title="ElicesM , PascualJC , PortellaMJ , Feliu-SolerA , Martín-BlancoA , CarmonaC , et al. Impact of mindfulness training on borderline personality disorder: a randomized trial. Mindfulness2016;7:584-95. [DOI: 10.1007/s12671-016-0492-1]NCT02397031. Mindfulness and interpersonal effectiveness skills in borderline personality disorder [Randomized, active-controlled, clinical trial comparing effects of mindfulness and interpersonal effectiveness skills in borderline personality disorder]. www.clinicaltrials.gov/ct2/show/NCT02397031 (first received 12 March 2015). SolerJ , ElicesM , PascualJC , Martín-BlancoA , Feliu-SolerA , CarmonaC , et al. Effects of mindfulness training on different components of impulsivity in borderline personality disorder: results from a pilot randomized study. Borderline Personality Disorder and Emotion Dysregulation2016;3:1. [DOI: 10.1186/s40479-015-0035-8] [PMC4709962] [PMID: 26759718]">Elices 2016</a>; <a href="./references#CD012955-bbs2-0021" title="FarrellJM , ShawIA , WebberMA . A schema-focused approach to group psychotherapy for outpatients with borderline personality disorder: a randomized controlled trial. Journal of Behavior Therapy and Experimental Psychiatry2009;40(2):317-28 Corrigendum to: Journal of Behavior Therapy and Experimental Psychiatry 2018; 60: 111. [DOI: 10.1016/j.jbtep.2009.01.002] [PMID: 19176222]FarrellJM . Question regarding your BPD trials [personal communication]. Email to: K Lieb, J Stoffers 9 December 2010. ">Farrell 2009</a>; <a href="./references#CD012955-bbs2-0022" title="FeigenbaumJD , FonagyP , PillingS , JonesA , WildgooseA , BebbingtonPE . A real-world study of the effectiveness of DBT in the UK National Health Service. British Journal of Clinical Psychology2012;51(2):121-41. [DOI: 10.1111/j.2044-8260.2011.02017.x] [PMID: 22574799]">Feigenbaum 2012</a>; <a href="./references#CD012955-bbs2-0023" title="Feliu-SolerA , PascualJC , ElicesM , Martín-BlancoA , CarmonaC , CebollaA , et al. Fostering self-compassion and loving-kindness in patients with borderline personality disorder: a randomized pilot study. Clinical Psychology &amp; Psychotherapy2017;24(1):278-86. [DOI: 10.1002/cpp.2000] [PMID: 26818533]">Feliu‐Soler 2017</a>; <a href="./references#CD012955-bbs2-0024" title="ArntzA , Stupar-RutenfransS , BlooJ , Van DyckR , SpinhovenP . Prediction of treatment discontinuation and recovery from borderline personality disorder: results from an RCT comparing schema therapy and transference-focused psychotherapy. Behaviour Research and Therapy2015;74:60-71. [DOI: 10.1016/j.brat.2015.09.002] [PMID: 26432172]Giesen-BlooJ , ArntzA . Questions concerning the randomized trial of schema-focused therapy vs transference-focused psychotherapy—reply. Archives of General Psychiatry2007;64(5):610-1. [DOI: 10.1001/archpsyc.64.5.610]Giesen-BlooJ , Van DyckR , SpinhovenP , Van TilburgW , DirksenC , Van AsseltT , et al. Errors in table and figure in: outpatient psychotherapy for borderline personality disorder: randomized trial of schema-focused therapy vs transference-focused psychotherapy. Archives of General Psychiatry2006;63(9):1008. Erratum for: Archives of General Psychiatry 2006;63(6):649-58. [DOI: 10.1001/archpsyc.63.9.1008]Giesen-BlooJ , Van DyckR , SpinhovenP , Van TilburgW , DirksenC , Van AsseltT , et al. Outpatient psychotherapy for borderline personality disorder: randomized trial of schema-focused therapy vs transference-focused psychotherapy. Archives of General Psychiatry2006;63(6):649-58. [DOI: 10.1001/archpsyc.63.6.649] [PMID: 16754838]SpinhovenP , Giesen-BlooJ , Van DyckR , KooimanK , ArntzA . The therapeutic alliance in schema-focused therapy and transference-focused psychotherapy for borderline personality disorder. Journal of Consulting and Clinical Psychology2007;75(1):104-15. [DOI: 10.1037/0022-006X.75.1.104] [PMID: 17295569]Van AsseltADI , DirksenCD , ArntzA , Giesen-BlooJH , Van DyckR , SpinhovenP , et al. Out-patient psychotherapy for borderline personality disorder: cost-effectiveness of schema-focused therapy v transference-focused psychotherapy. British Journal of Psychiatry2008;192(6):450-7. [DOI: 10.1192/bjp.bp.106.033597] [PMID: 18515897]Van AsseltADI , DirksenCD , ArntzA , SeverensJL . Difficulties in calculating productivity costs: work disability associated with borderline personality disorder. Value in Health2008;11(4):637-44. [DOI: 10.1111/j.1524-4733.2007.00288.x]YeomansF . Questions concerning the randomized trial of schema-focused therapy vs transference-focused psychotherapy. Archives of General Psychiatry2007;64(5):609-10. [DOI: 10.1001/archpsyc.64.5.609-c] [PMID: 17485613]">Giesen‐Bloo 2006</a>; <a href="./references#CD012955-bbs2-0025" title="GleesonJF , ChanenA , CottonSM , PearceT , NewmanB , McCutcheonL . Treating co-occurring first-episode psychosis and borderline personality: a pilot randomized controlled trial. Early Intervention in Psychiatry2012;6(1):21-9. [DOI: 10.1111/j.1751-7893.2011.00306.x] [PMID: 22379625]GleesonJFM . RE: separate data [personal communication]. Email to: M Kielsholm 28 October 2016. ">Gleeson 2012</a>; <a href="./references#CD012955-bbs2-0026" title="Gratz KL. Important: question regarding your BPD trial for systematic review in Cochrane Collaboration [personal communication]. Email to: J Stoffers-Winterling 11 December 2010. GratzKL , GundersonJG . Preliminary data on an acceptance-based emotion regulation group intervention for deliberate self-harm among women with borderline personality disorder. Behavior Therapy2006;37(1):25-35. [DOI: 10.1016/j.beth.2005.03.002] [PMID: 16942958]">Gratz 2006</a>; <a href="./references#CD012955-bbs2-0027" title="GratzKL , BardeenJR , LevyR , Dixon-GordonKL , TullMT . Mechanisms of change in an emotion regulation group therapy for deliberate self-harm among women with borderline personality disorder. Behaviour Research and Therapy2015;65:29-35. [DOI: 10.1016/j.brat.2014.12.005] [PMC4306622] [PMID: 25557395]GratzKL , Dixon-GordonKL , TullMT . Predictors of treatment response to an adjunctive emotion regulation group therapy for deliberate self-harm among women with borderline personality disorder. Personality Disorders2014;5(1):97-107. [DOI: 10.1037/per0000062] [PMC4059504] [PMID: 2458806]GratzKL , TullMT , LevyR . Randomized controlled trial and uncontrolled 9-month follow-up of an adjunctive emotion regulation group therapy for deliberate self-harm among women with borderline personality disorder. Psychological Medicine2014;44(10):2099-112. [DOI: 10.1017/S0033291713002134] [PMID: 23985088]GratzKL . Question regarding your BPD trials [personal communication]. Email to: J Stoffers 11 December 2010. ">Gratz 2014</a>; <a href="./references#CD012955-bbs2-0028" title="GregoryRJ , ChlebowskiS , KangD , RemenA , SoderbergM . Psychodynamic therapy for borderline personality disorder and co-occurring alcohol use disorders: a newly designed ongoing study. Journal of the American Psychoanalytic Association2006;54(4):1331-4. [DOI: 10.1177/00030651060540040107] [PMID: 17354507]GregoryRJ , ChlebowskiS , KangD , RemenAL , SoderbergMG , StepkovitchJ , et al. A controlled trial of psychodynamic psychotherapy for co-occurring borderline personality disorder and alcohol use disorder. Psychotherapy2008;45(1):28-41. [DOI: 10.1037/0033-3204.45.1.28] [PMID: 22122363]GregoryRJ , DeLucia-DeranjaE , MogleJA . Dynamic deconstructive psychotherapy versus optimized community care for borderline personality disorder co-occuring with alcohol use disorders: a 30-month follow-up. Journal of Nervous and Mental Disease2010;198(4):292-8. [DOI: 10.1097/NMD.0b013e3181d6172d] [PMID: 20386259]GregoryRJ , RemenAL , SoderbergM , Ploutz-SnyderRJ . A controlled trial of psychodynamic psychotherapy for co-occurring borderline personality disorder and alcohol use disorder: six-month outcome. Journal of the American Psychoanalytic Association2009;57(1):199-205. [DOI: 10.1177/00030651090570011006] [PMID: 19270255]NCT00145678. Psychodynamic therapy for co-occurring borderline personality disorder and alcohol use disorder [Psychodynamic therapy for patients With borderline personality disorder and alcohol abuse]. www.clinicaltrials.gov/show/NCT00145678 (first received 1 September 2005). ">Gregory 2008b</a>; <a href="./references#CD012955-bbs2-0029" title="HaeyenS , Van HoorenS , HutschemaekersG . Efficacy of art therapy in individuals with personality disorders cluster B/C: a randomised controlled trial. International Journal of Psychology July 2016;51:60. [DOI: 10.1521/pedi_2017_31_312] [PMID: 28926306]HaeyenS , Van HoorenS , Van der VeldW , HutschemaekersG . Efficacy of art therapy in individuals with personality disorders cluster B/C: a randomised controlled trial. Journal of Personality Disorders2018;32(4):527-42. [DOI: 10.1521/pedi_2017_31_312] [PMID: 28926306]HaeyenS . Re: Cochrane Collaboration review of psychotherapies for BPD - your RCT of art therapy [personal communication]. Email to: J Stoffers-Winterling 18 August 2018. ">Haeyen 2018</a>; <a href="./references#CD012955-bbs2-0030" title="HarnedM . Re: SV: question regarding your trial on brief therapy for attempted suicide [personal communication]. Email to: EG Faltinsen 11 December 2018. HarnedMS , KorslundKE , LinehanMM . A pilot randomized controlled trial of dialectical behavior therapy with and without the dialectical behavior therapy prolonged exposure protocol for suicidal and self-injuring women with borderline personality disorder and PTSD. Behaviour Research and Therapy2014;55:7-17. [DOI: 10.1016/j.brat.2014.01.008] [PMC3987949] [PMID: 24562087]HarnedMS , WilksCR , SchmidtSC , CoyleTN . Improving functional outcomes in women with borderline personality disorder and PTSD by changing PTSD severity and post-traumatic cognitions. Behaviour Research and Therapy2018;103:53-61. [DOI: 10.1016/j.brat.2018.02.002] [PMC5837954] [PMID: 29448136]HarnedMS . RE: questions regarding your trial on brief therapy for attempted suicide [personal communication]. Email to: E Faltinsen 29 November 2017. ">Harned 2014</a>; <a href="./references#CD012955-bbs2-0032" title="JochemsEC , Van der Feltz-CornelisCM , Van DamA , DuivenvoordenHJ , MulderCL . The effects of motivation feedback in patients with severe mental illness: a cluster randomized controlled trial. Neuropsychiatric Disease and Treatment2015;11:3049-64. [DOI: 10.2147/NDT.S95190] [PMC4686323] [PMID: 26715847]JochemsEC . Cochrane Collaboration review on psychotherapies for borderline PD [personal communication]. Email to: EG Faltinsen 2 July 2018. JochemsEC . Re: Cochrane Collaboration review on psychotherapies for borderline PD [personal communication]. Email to: J Stoffers-Winterling 02 July 2018. ">Jochems 2015</a>; <a href="./references#CD012955-bbs2-0033" title="JørgensenCR , BøyeR , AndersenD , Døssing BlaabjergAH , FreundC , JordetH , et al. Eighteen months post-treatment naturalistic follow-up study of mentalization-based therapy and supportive group treatment of borderline personality disorder: clinical outcomes and functioning. Nordic Psychology2014;66(4):254-73. [DOI: 10.1080/19012276.2014.963649]JørgensenCR , FreundC , BøyeR , JordetH , AndersenD , KjølbyeM . Outcome of mentalization-based and supportive psychotherapy in patients with borderline personality disorder: a randomized trial. Acta Psychiatrica Scandinavica2013;127(4):305-17. [DOI: 10.1111/j.1600-0447.2012.01923.x] [PMID: 22897123]JorgensenCR . SV: questions on your trial regarding MBT for BPD patients [personal communication]. Email to: EG Faltinsen 28 November 2017. ">Jørgensen 2013</a>; <a href="./references#CD012955-bbs2-0036" title="KramerU , BergerT , KollyS , MarquetP , PreisigM , De RotenY , et al. Effects of motive-oriented therapeutic relationship in early-phase treatment of borderline personality disorder: a pilot study of a randomized trial. Journal of Nervous and Mental Disease2011;199(4):244-50. [DOI: 10.1097/NMD.0b013e3182125d19] [PMID: 21451348]KramerU , CasparF , DrapeauM . Change in biased thinking in a 10-session treatment for borderline personality disorder: further evidence of the motive-oriented therapeutic relationship. Psychotherapy Research2013;23(6):633-45. [DOI: 10.1080/10503307.2013.791404] [PMID: 23631622]">Kramer 2011</a>; <a href="./references#CD012955-bbs2-0037" title="BerthoudL , KramerU , CasparF , Pascual-LeoneA . Emotional processing in a ten-session general psychiatric treatment for borderline personality disorder: a case study. Personality and Mental Health2015;9(1):73-8. [DOI: 10.1002/pmh.1287] [PMID: 25711648]BerthoudL , Pascual-LeoneA , CasparF , TissotH , KellerS , RohdeKB , et al. Leaving distress behind: a randomized controlled study on change in emotional processing in borderline personality disorder. Psychiatry2017;80(2):139-54. [DOI: 10.1080/00332747.2016.1220230] [PMID: 28767333]KellerS , StelmaszczykK , KollyS , De RotenY , DesplandJN , CasparF , et al. Change in biased thinking in a treatment based on the motive-oriented therapeutic relationship for borderline personality disorder. Journal of Personality Disorders2018;32(Suppl):75-92. [DOI: 10.1521/pedi.2018.32.supp.75] [PMID: 29388899]KramerU , FlückigerC , KollyS , CasparF , MarquetP , DesplandJN , et al. Unpacking the effects of therapist responsiveness in borderline personality disorder: motive-oriented therapeutic relationship, patient in-session experience, and the therapeutic alliance. Psychotherapy and Psychosomatics2014;83(6):386-7. [DOI: 10.1159/000365400] [PMID: 25324025]KramerU , KellerS , CasparF , De RotenY , DesplandJN , KollyS . Early change in coping strategies in responsive treatments for borderline personality disorder: a mediation analysis. Journal of Consulting and Clinical Psychology2017;85(5):530-5. [DOI: 10.1037/ccp0000196] [PMID: 28425747]KramerU , KollyS , BerthoudL , KellerS , PreisigM , CasparF , et al. Effects of motive-oriented therapeutic relationship in a ten-session general psychiatric treatment of borderline personality disorder: a randomized controlled trial. Psychotherapy and Psychosomatics2014;83(3):176-86. [DOI: 10.1159/000358528] [PMID: 24752034]KramerU , StulzN , BerthoudL , CasparF , MarquetP , KollyS , et al. The shorter the better? A follow-up analysis of 10-session psychiatric treatment including the motive-oriented therapeutic relationship for borderline personality disorder. Psychotherapy Research2017;27(3):362-70. [DOI: 10.1080/10503307.2015.1110635] [PMID: 26684670]NCT01896024. Effects of motive-oriented therapeutic relationship in the early-phase treatment of borderline personality disorder (MOTR). www.clinicaltrials.gov/ct2/show/NCT01896024 (first received 5 July 2013). ">Kramer 2014</a>; <a href="./references#CD012955-bbs2-0038" title="KramerU , Pascual-LeoneA , BerthoudL , De RotenY , MarquetP , KollyS , et al. Assertive anger mediates effects of dialectical behaviour-informed skills training for borderline personality disorder: a randomized controlled trial. Clinical Psychology &amp; Psychotherapy2016;23(3):189-202. [DOI: 10.1002/cpp.1956] [PMID: 25864773]KramerU . The role of coping change in borderline personality disorder: a process-outcome analysis on dialectical-behaviour skills training. Clinical Psychology &amp; Psychotherapy2017;24(2):302-11. [DOI: 10.1002/cpp.2017] [PMID: 27098296]">Kramer 2016</a>; <a href="./references#CD012955-bbs2-0039" title="KredlowMA , SzuhanyKL , LoS , XieH , GottliebJD , RosenbergSD , et al. Cognitive behavioral therapy for posttraumatic stress disorder in individuals with severe mental illness and borderline personality disorder. Psychiatry Research2017;249:86-93. [DOI: 10.1016/j.psychres.2016.12.045] [PMC5325773] [PMID: 28086181]MueserK . Re: question regarding your trial on CBT for BPD patients [personal communication]. Email to: EG Faltinsen 28 November 2017. ">Kredlow 2017a</a>; <a href="./references#CD012955-bbs2-0040" title="KredlowMA , SzuhanyKL , LoS , XieH , GottliebJD , RosenbergSD , et al. Cognitive behavioral therapy for posttraumatic stress disorder in individuals with severe mental illness and borderline personality disorder. Psychiatry Research2017;249:86-93. [DOI: 10.1016/j.psychres.2016.12.045] [PMC5325773] [PMID: 28086181]MueserKT , GottliebJD , XieH , LuW , YanosPT , RosenbergSD , et al. Evaluation of cognitive restructuring for post-traumatic stress disorder in people with severe mental illness.. British Journal of Psychiatry2015;206(6):501-8. [DOI: 10.1192/bjp.bp.114.147926] [PMC4450219] [PMID: 25858178]MueserKT , RosenbergSD , XieH , JankowskiMK , BoltonEE , LuW , et al. A randomized controlled trial of cognitive-behavioral treatment for posttraumatic stress disorder in severe mental illness. Journal of Consulting and Clinical Psychology2008;76(2):259-71. [DOI: 10.1037/0022-006X.76.2.259] [PMC3916092] [PMID: 18377122]MueserKT . Re: question regarding your trial on CBT for PTSD participants [personal communication]. Email to: E Faltinsen 28 November 2018. ">Kredlow 2017b</a>; <a href="./references#CD012955-bbs2-0041" title="LaurenssenEM , WestraD , KikkertMJ , NoomMJ , EerenHV , Van BroekhuyzenAJ , et al. Day hospital mentalization-based treatment (MBT-DH) versus treatment as usual in the treatment of severe borderline personality disorder: protocol of a randomized controlled trial. BMC Psychiatry2014;14:149. [DOI: 10.1186/1471-244X-14-149] [PMC4045960] [PMID: 24886402]LaurenssenEMP , LuytenP , KikkertMJ , WestraD , PeenJ , SoonsMBJ , et al. Day hospital mentalization-based treatment v specialist treatment as usual in patients with borderline personality disorder: randomized controlled trial. Psychological Medicine2018;48(15):2522-9. [DOI: 10.1017/S0033291718000132] [PMID: 29478425]NL2058 (NTR2175). Mentalisation-based treatment versus care-as-usual in the treatment of severe borderline personality disorders. www.trialregister.nl/trial/2058 (first received 21 January 2010). ">Laurenssen 2018</a>; <a href="./references#CD012955-bbs2-0042" title="LeichsenringF , MasuhrO , JaegerU , RabungS , DallyA , DümpelmannM , et al. Psychoanalytic-interactional therapy versus psychodynamic therapy by experts for personality disorders: a randomized controlled efficacy-effectiveness study in cluster B personality disorders. Psychotherapy and Psychosomatics2016;85(2):71-80. [DOI: 10.1159/000441731] [PMID: 26808580]">Leichsenring 2016</a>; <a href="./references#CD012955-bbs2-0044" title="Lin T-J, Ko H-C, Wu JY-W, OeiTP , Lane H-Y, Chen C-H. The effectiveness of dialectical behavior therapy skills training group vs cognitive therapy group on reducing depression and suicide attempts for borderline personality disorder in Taiwan. Archives of Suicide Research2019;23(1):82-99. [DOI: 10.1080/13811118.2018.1436104] [PMID: 29528807]">Lin 2019</a>; <a href="./references#CD012955-bbs2-0045" title="HoffmanRE . Impact of treatment accessibility on clinical course of parasuicidal patients. Archives of General Psychiatry1993;50(2):157-8. [DOI: 10.1001/archpsyc.1993.01820140083010] [PMID: 8427557]LindenboimN . To Know Me is to Keep Me: Self-Verification, Validation, and Therapy Dropout in the Treatment of Borderline Personality Disorder [PhD thesis]. Washington (DC): University of Washington, 2009. LinehanMM , ArmstrongHE , SuarezA , AllmonD , HeardHL . Cognitive-behavioral treatment of chronically parasuicidal borderline patients. Archives of General Psychiatry1991;48(12):1060-4. [DOI: 10.1001/archpsyc.1991.01810360024003] [PMID: 1845222]LinehanMM , HeardHL . Impact of treatment accessibility on clinical course of parasuicidal patients — reply. Archives of General Psychiatry1993;50(2):157-8. [DOI: 10.1001/archpsyc.1993.01820140083011]">Linehan 1991</a>; <a href="./references#CD012955-bbs2-0046" title="HeardHL . Cost-Effectiveness of Dialectical Behavior Therapy in the Treatment of Borderline Personality Disorder [PhD thesis]. Washington (DC): University of Washington, 2000. LindenboimN . To Know Me is to Keep Me: Self-Verification, Validation, and Therapy Dropout in the Treatment of Borderline Personality Disorder [PhD thesis]. Washington (DC): University of Washington, 2009. LinehanMM , HeardHL , ArmstrongHE . Naturalistic follow-up of a behavioral treatment for chronically parasuicidal borderline patients. Archives of General Psychiatry1993;50(12):971-4. [DOI: 10.1001/archpsyc.1993.01820240055007] [PMID: 8250683]LinehanMM , TutekDA , HeardHL , ArmstrongHE . Interpersonal outcome of cognitive behavioral treatment for chronically suicidal borderline patients. American Journal of Psychiatry1994;151(12):1771-6. [DOI: 10.1176/ajp.151.12.1771] [PMID: 7977884]">Linehan 1994</a>; <a href="./references#CD012955-bbs2-0047" title="BedicsJD , AtkinsDC , ComtoisKA , LinehanMM . Treatment differences in the therapeutic relationship and introject during a 2-year randomized controlled trial of dialectical behavior therapy versus nonbehavioral psychotherapy experts for borderline personality disorder. Journal of Consulting and Clinical Psychology2012;80(1):66-77. [DOI: 10.1037/a0026113] [PMC3265694] [PMID: 22061867]BedicsJD , AtkinsDC , ComtoisKA , LinehanMM . Weekly therapist ratings of the therapeutic relationship and patient introject furing the course of dialectical behavioral therapy for the treatment of borderline personality disorder. Psychotherapy2012;49(2):231-40. [DOI: 10.1037/a0028254] [PMID: 22642526]BedicsJD , AtkinsDC , HarnedMS , LinehanMM . The therapeutic alliance as a predictor of outcome in dialectical behavior therapy versus nonbehavioral psychotherapy by experts for borderline personality disorder. Psychotherapy2015;52(1):67-77. [DOI: 10.1037/a0038457] [PMID: 25751116]BrownMZ , LinehanMM , ComtoisKA , MurrayA , ChapmanAL . Shame as a prospective predictor of self-inflicted injury in borderline personality disorder: a multi-modal analysis. Behaviour Research and Therapy2009;47(10):815-22. [DOI: 10.1016/j.brat.2009.06.008] [PMC2761705] [PMID: 19596223 ]CoyleTN , ShaverJA , LinehanMM . On the potential for iatrogenic effects of psychiatric crisis services: the example of dialectical behavior therapy for adult women with borderline personality disorder. Journal of Consulting and Clinical Psychology2018;86(2):116-24. [DOI: 10.1037/ccp0000275] [PMID: 29369662]HarnedMS , ChapmanAL , Dexter-MazzaET , MurrayA , ComtoisKA , LinehanMM . Treating co-occurring Axis I disorders in recurrently suicidal women with borderline personality disorder: a 2-year randomized trial of dialectical behavior therapy versus community treatment by experts. Journal of Consulting and Clinical Psychology2008;76(6):1068-75. [DOI: 10.1037/a0014044] [PMID: 19045974]HarnedMS , ChapmanAL , Dexter-MazzaET , MurrayA , ComtoisKA , LinehanMM . Treating co-occurring Axis I disorders in recurrently suicidal women with borderline personality disorder: a 2-year randomized trial of dialectical behavior therapy versus community treatment by experts. Personality Disorders: Theory, Research, and Treatment2009;S(1):35-45. [DOI: 10.1037/1949-2715.S.1.35]HarnedMS , JacksonSC , ComtoisKA , LinehanMM . Dialectical behavior therapy as a precursor to PTSD treatment for suicidal and/or self-injuring women with bordreline personality disorder. Journal of Traumatic Stress2010;23(4):421-9. [DOI: 10.1002/jts.20553] [PMID: 20648564]LindenboimN , ComtoisKA , LinehanMM . Skills practice in dialectical behavior therapy for suicidal women meeting criteria for borderline personality disorder. Cognitive and Behavioral Practice2007;14(2):147-56. [DOI: 10.1016/j.cbpra.2006.10.004]LinehanMM , ComtoisKA , MurrayAM , BrownMZ , GallopRJ , HeardHL , et al. Two-year randomized controlled trial and follow-up of dialectical behavior therapy vs therapy by experts for suicidal behaviors and borderline personality disorder. Archives of General Psychiatry2006;63(7):757-66. [DOI: 10.1001/archpsyc.63.7.757] [PMID: 16818865]LinehanMM . Error in table in: two-year randomized controlled trial and follow-up of dialectical behavior therapy vs therapy by experts for suicidal behaviors and borderline personality disorder. Archives of General Psychiatry2007;64(12):1401. Erratum for: Archives of General Psychiatry 2007;64(12):1401. McMainS . Dialectic behaviour therapy reduces suicide attempts compared with non-behavioural psychotherapy in women with borderline personality disorder. Evidence-Based Mental Health2007;10(1):18. [DOI: 10.1136/ebmh.10.1.18] [PMID: 17255387]NeacsiuAD , LunguA , HarnedMS , RizviSL , LinehanMM . Impact of dialectical behavior therapy versus community treatment by experts on emotional experience, expression, and acceptance in borderline personality disorder. Behaviour Research and Therapy2014;53:47-54. [DOI: 10.1016/j.brat.2013.12.004] [PMC3955205] [PMID: 24418652]NeacsiuAD , RizviSL , LinehanMM . Dialectical behavior therapy skills use as a mediator and outcome of treatment for borderline personality disorder. Behaviour Research and Therapy2010;48(9):832-9. [DOI: 10.1016/j.brat.2010.05.017] [PMC2914145] [PMID: 20579633]SecristCD . The Role of Executive Functioning in the Treatment of Borderline Personality Disorder [PhD thesis]. Washington (DC): University of Washington, 2014. ">Linehan 2006</a>; <a href="./references#CD012955-bbs2-0048" title="LinehanMM , KorslundKE , HarnedMS , GallopRJ , LunguA , NeacsiuAD , et al. Dialectical behavior therapy for high suicide risk in individuals with borderline personality disorder: a randomized clinical trial and component analysis. JAMA Psychiatry2015;72(5):475-82 Erratum for: JAMA Psychiatry 2015; 72(9): 951. [DOI: 10.1001/jamapsychiatry.2014.3039] [PMID: 25806661]NCT00183651. Treatment of suicidal women with borderline personality disorder [Assessment and treatment of parasuicidal patients]. www.clinicaltrials.gov/ct2/show/NCT00183651 (first received 13 September 2005). ">Linehan 2015a</a>; <a href="./references#CD012955-bbs2-0049" title="CaseBG . Letter to the editor on 'McMain SF, Links PS, Gnam WH, Guimond T, Cardish RJ, Korman L, et al. A randomized trial of dialectical behavior therapy versus general psychiatric management for borderline personality disorder. American Journal of Psychiatry 2009;166(12):1365-74. DOI: 10.1176/appi.ajp.2009.09010039'. American Journal of Psychiatry2010;167(4):475. [DOI: 10.1176/appi.ajp.2009.09101532] [PMID: 20360332 ]ISRCTN02634417. Hope for chronically suicidal patient: evaluating the clinical and health services impact of dialectical behaviour therapy (DBT) in individuals with borderline personality disorder [Evaluating the clinical and health services impact of dialectical behaviour therapy (DBT) in individuals with borderline personality disorder: a randomised controlled trial]. www.isrctn.com/ISRCTN02634417 (first received 16 November 2005). [DOI: 10.1186/ISRCTN02634417]McMainSF , FitzpatrickS , BoritzT , BarnhartR , LinksP , StreinerDL . Outcome trajectories and prognostic factors for suicide and self-harm behaviors in patients with borderline personaliy disorder following one year of outpatient psychotherapy. Journal of Personality Disorders2018;32(4):497-512. [DOI: 10.1521/pedi_2017_31_309] [PMID: 28910214]McMainSF , LinksPS , GnamWH , GuimondT , CardishRJ , KormanL , et al. A randomized trial of dialectical behavior therapy versus general psychiatric management for borderline personality disorder. American Journal of Psychiatry2009;166(12):1365-74. [DOI: 10.1176/appi.ajp.2009.09010039] [PMID: 19755574]McMainSF . Dr McMain replies to letter to the editor on 'McMain SF, Links PS, Gnam WH, Guimond T, Cardish RJ, Korman L, et al. A randomized trial of dialectical behavior therapy versus general psychiatric management for borderline personality disorder. American Journal of Psychiatry 2009;166(12):1365-74. DOI: 10.1176/appi.ajp.2009.09010039'. American Journal of Psychiatry2010;167(4):475-6. [DOI: 10.1176/appi.ajp.2009.09101532r)]NCT00154154. Hope for the chronically suicidal patient [Hope for the chronically suicidal patient: evaluating the clinical and health services impact of dialectical behaviour therapy in individuals with borderline personality disorder]. www.clinicaltrials.gov/ct2/show/NCT00154154 (first received 7 September 2005). ">McMain 2009</a>; <a href="./references#CD012955-bbs2-0050" title="McMainSF , GuimondT , BarnhartR , HabinskiL , StreinerDL . A randomized trial of brief dialectical behaviour therapy skills training in suicidal patients suffering from borderline disorder. Acta Psychiatrica Scandinavica2017;135(2):138-48. [DOI: 10.1111/acps.12664] [PMID: 27858962]">McMain 2017</a>; <a href="./references#CD012955-bbs2-0051" title="McMurranM , CrawfordMJ , ReillyJ , DelportJ , McCroneP , WhithamD , et al. Psychoeducation with problem-solving (PEPS) therapy for adults with personality disorder: a pragmatic randomised controlled trial to determine the clinical effectiveness and cost-effectiveness of a manualised intervention to improve social functioning. Health Technology Assessment2016;20(52):1-282. [DOI: 10.3310/hta20520]McMurranM . RE: Cochrane Collaboration review - PEPS study [personal communication]. Email to: J Stoffers-Winterling 5 July 2018. McMurranM . Request for data on BPD subjects in the PEPS rcp-study for use a new Cochrane review [personal communication]. Email to: M Kongerslev 7 March 2017. ">McMurran 2016</a>; <a href="./references#CD012955-bbs2-0052" title="HagaE , AasE , GrøholtB , TørmoenAJ , MehlumL . Cost-effectiveness of dialectical behaviour therapy vs enhanced usual care in the treatment of adolescents with self-harm. Child and Adolescent Psychiatry and Mental Health2018;12:22. [DOI: 10.1186/s13034-018-0227-2] [PMC5928596] [PMID: 29743941]MehlumL , RambergM , TørmoenAJ , HagaE , DiepLM , StanleyBH , et al. Dialectical behavior therapy compared with enhanced usual care for adolescents with repeated suicidal and self-harming behavior: outcomes over a one-year follow-up. Journal of the American Academy of Child and Adolescent Psychiatry2016;55(4):295-300. [DOI: 10.1016/j.jaac.2016.01.005] [PMID: 27015720]MehlumL , TørmoenAJ , RambergM , HagaE , DiepLM , LabergS , et al. Dialectical behavior therapy for adolescents with repeated suicidal and self-harming behavior: a randomized trial. Journal of the American Academy of Child and Adolescent Psychiatry2014;53(10):1082-91. [DOI: 10.1016/j.jaac.2014.07.003] [PMID: 25245352]MehlumL . Re: regarding your study of DBT for your with suicidal behavior [personal communication] [Re: angående din studie om DBT for ungdom med selvmordsatferd [personlig kommunikation]]. Email to: E Faltinsen 5 December 2017. NCT00675129. Treatment for adolescents with deliberate self harm [A randomized controlled trial for repetitive deliberate self-harm and suicidal behaviours among Norwegian adolescents: a comparison between dialectical behaviour therapy adapted for adolescents (DBT-A) and enhanced usual care (EUC)]. www.clinicaltrials.gov/ct2/show/NCT00675129 (first received 6 May 2008). RamlethRK , GroholtB , DiepLM , WalbyFA , MehlumL . The impact of borderline personality disorder and sub-threshold borderline personality disorder on the course of self-reported and clinician-rated depression in self-harming adolescents. Borderline Personality Disorder and Emotion Dysregulation2017;4:22. [DOI: 10.1186/s40479-017-0073-5] [PMC5663078] [PMID: 29093819]">Mehlum 2014</a>; <a href="./references#CD012955-bbs2-0054" title="MoreyLC , LowmasterSE , HopwoodCJ . A pilot study of manual-assisted cognitive therapy with a therapeutic assessment augmentation for borderline personality disorder. Psychiatry Research2010;178(3):531-5. [DOI: 10.1016/j.psychres.2010.04.055] [PMID: 20537722]">Morey 2010</a>; <a href="./references#CD012955-bbs2-0056" title="NadortM , ArntzA , SmitJH , Giesen-BlooJ , EikelenboomJ , SpinhovenP , et al. Implementation of outpatient schema therapy for borderline personality disorder with versus without crisis support by the therapist outside office hours: a randomized trial. Behaviour Research and Therapy2009;47(11):961-73. [DOI: 10.1016/j.brat.2009.07.013] [PMID: 19698939]NadortM , ArntzA , SmitJH , Giesen-BlooJ , EikelenboomM , SpinhovenP , et al. Implementation of outpatient schema therapy for borderline personality disorder: study design. BMC Psychiatry2009;9:64. [DOI: 10.1186/1471-244X-9-64] [PMC2762959] [PMID: 19807925]NL1680 (NTR1781). Implementation of out-patient schema-focused therapy for borderline personality disorder in regular mental healthcare. www.trialregister.nl/trial/1680 (first received 29 April 2009). ">Nadort 2009</a>; <a href="./references#CD012955-bbs2-0057" title="NCT02033044. Cognitive rehabilitation versus psychoeducation in psychosocial functioning of borderline personality disorder [Randomized controlled trial comparing the effects on psychosocial functioning of cognitive rehabilitation versus psychoeducation in borderline personality disorder]. www.clinicaltrials.gov/ct2/show/NCT02033044 (first received 23 December 2013). PascualJC , PalomaresN , Ibáñez Á, PortellaMJ , ArzaR , ReyesR , et al. Efficacy of cognitive rehabilitation on psychosocial functioning in borderline personality disorder: a randomized controlled trial. BMC Psychiatry2015;15:255. [DOI: 10.1186/s12888-015-0640-5] [PMC4617906] [PMID: 26487284]">Pascual 2015</a>; <a href="./references#CD012955-bbs2-0058" title="PhilipsB , WennebergP , KonradssonP , FranckJ . Mentalization-based treatment for concurrent borderline personality disorder and substance use disorder: a randomized controlled feasibility study. European Addiction Research2018;24(1):1-8. [DOI: 10.1159/000485564] [PMC5969093] [PMID: 294028]">Philips 2018</a>; <a href="./references#CD012955-bbs2-0059" title="BarnicotK . Re: Regarding your study on DBT for self-harming patients [personal communication]. Email to: EG Faltinsen 28 February 2018. PriebeS , BhattiN , BarnicotK , BremnerS , GagliaA , KatsakouC , et al. Effectiveness and cost-effectiveness of dialectical behaviour therapy for self-harming patients with personality disorder: a pragmatic randomised controlled trial. Psychotherapy and Psychosomatics2012;81(6):356-65. [DOI: 10.1159/000338897] [PMID: 22964561]PriebeS . Supplemental information [personal communication]. Email to: M Kielsholm 20 May 2016. ">Priebe 2012</a>; <a href="./references#CD012955-bbs2-0060" title="RenesesB , FigueraD , SalcedoG , TrujilloM , López-IborJJ , GaliánM , et al. A controlled randomized study on the efficacy of short-term dinamic psychotherapy in borderline personality disorders (BPD). Preliminary results. European Psychiatry2011;26(Suppl 1):1040. [DOI: 10.1016/S0924-9338(11)72745-6] [P02-444]RenesesB , GaliánM , SerranoR , FigueraD , Fernandez Del MoralA , López-IborJJ , et al. A new time limited psychotherapy for BPD: preliminary results of a randomized and controlled trial. Actas Espanolas de Psiquiatria2013;41(3):139-48. [PMID: 23803797]">Reneses 2013</a>; <a href="./references#CD012955-bbs2-0061" title="ISRCTN51304415. Nice OUtcomes for Referrals with Impulsivity, Self Harm and Eating Disorders: the NOURISHED study [A randomised controlled trial of mentalisation based therapy against specialist supportive clinical management in patients with both eating disorders and symptoms of borderline personality disorder]. www.isrctn.com/ISRCTN51304415 (first received 31 January 2011). RobinsonP , BarrettB , BatemanA , HakeemA , HellierJ , LemonskyF , et al. Study protocol for a randomized controlled trial of mentalization based therapy against specialist supportive clinical management in patients with both eating disorders and symptoms of borderline personality disorder. BMC Psychiatry2014;14:51. [DOI: 10.1186/1471-244X-14-51] [PMC3996076] [PMID: 24555511]RobinsonP , HellierJ , BarrettB , BarzdaitieneD , BatemanA , BogaardtA , et al. The NOURISHED randomised controlled trial comparing mentalisation-based treatment for eating disorders (MBT-ED) with specialist supportive clinical management (SSCM-ED) for patients with eating disorders and symptoms of borderline personality disorder. Trials2016;17(1):549. [DOI: 10.1186/s13063-016-1606-8] [PMC5114835] [PMID: 27855714]">Robinson 2016</a>; <a href="./references#CD012955-bbs2-0062" title="ISRCTN95266816. The emergence of personality disorder traits in adolescents who deliberately self harm and the potential for using a mentalisation based treatment approach as an early intervention for such individuals: a randomised controlled trial. www.isrctn.com/ISRCTN95266816 (first received 29 October 2007). RossouwT . Mentalisation based treatment for adolescents with self harm: an RCT. European Child &amp; Adolescent Psychiatry2015;24(1 Suppl):S113. [DOI: 10.1007%2Fs00787-015-0714-4.pdf] [W1-02-02]RossouwT . Self harm in adolescence, is MBT the answer?: an RCT. Adolescent Psychiatry2012;2(1):102. [DOI: 10.2174/2210676611202010077]RossouwTI , FonagyP . Mentalization-based treatment for self-harm in adolescents: a randomized controlled trial. Journal of the American Academy of Child and Adolescent Psychiatry2012;51(12):1304-13.e3. [DOI: 10.1016/j.jaac.2012.09.018] [PMID: 23200287]">Rossouw 2012b</a>; <a href="./references#CD012955-bbs2-0063" title="SalzerS , CroppC , JaegerU , MasuhrO , Streeck-FischerA . Psychodynamic therapy for adolescents suffering from co-morbid disorders of conduct and emotions in an in-patient setting: a randomized controlled trial. Psychological Medicine2014;44(10):2213-22. [DOI: 10.1017/S003329171300278X] [PMID: 24229481]SalzerS , Streeck-FischerA . The psychoanalytic-interactional method (PiM) for adolescents with borderline personality disorder [Die psychoanalytisch-interaktionelle methode (PiM) für adoleszente mit borderline-persönlichkeitsstörung]. Personlichkeitsstorungen Theorie und Therapie2015;19(1):67-76. [elibrary.klett-cotta.de/article/99.120110/ptt-19-1-67]SalzerS . AW: Re: Cochrane Review on psychotherapies for BPD - RCT testing PiM vs WL [personal communication] [AW:Re: Cochrane Review zur Psychotherapie bei BPS - RCT zu PiM vs WL [persönliche kommunikation]]. Email to: J Stoffers-Winterling 15 July 2018. ">Salzer 2014</a>; <a href="./references#CD012955-bbs2-0064" title="SantistebanDA , MenaMP , MuirJ , McCabeBE , AbaloC , CummingsAM . The efficacy of two adolescent substance abuse treatments and the impact of comorbid depression: results of a small randomized controlled trial. Psychiatric Rehabilitation Journal2015;38(1):55-64. [DOI: 10.1037/prj0000106] [PMC5021542] [PMID: 25799306]">Santisteban 2015</a>; <a href="./references#CD012955-bbs2-0065" title="SchillingL , MoritzS , KötherU , NagelM . Preliminary results on acceptance, feasibility, and subjective efficacy of the add-on group intervention metacognitive training for borderline patients. Journal of Cognitive Psychotherapy2015;29(2):153-64. [DOI: 10.1891/0889-8391.29.2.153]SchillingL , MoritzS , KristonL , KriegerM , NagelM . Efficacy of metacognitive training for patients with borderline personality disorder: preliminary results. Psychiatry Research2018;262:459-64. [DOI: 10.1016/j.psychres.2017.09.024] [PMID: 28927866]SchillingL . Re Schilling 2015/2018 - Cochrane Review of psychotherapies for BPD [personal communication] [Re Schilling 2015/2018 - Cochrane Review zur Psychotherapie bei BPS [persönliche Kommunikation]]. Email to: J Stoffers-Winterling 22 January 2019. ">Schilling 2018</a>; <a href="./references#CD012955-bbs2-0066" title="ISRCTN97589104. Evaluation of a group training for adolescents (emotion regulation training) with emotion regulation problems - a randomised controlled clinical trial. www.isrctn.com/ISRCTN97589104 (first received 23 August 2007). SchuppertHM , TimmermanME , BlooJ , Van GemertTG , WiersemaHM , MinderaaRB , et al. Emotion regulation training for adolescents with borderline personality disorder traits: a randomized controlled trial. Journal of the American Academy of Child &amp; Adolescent Psychiatry2012;51(12):1314-23. [DOI: 10.1016/j.jaac.2012.09.002] [PMID: 23200288]">Schuppert 2012</a>; <a href="./references#CD012955-bbs2-0067" title="NCT01904227. Intensified, inpatient adaptation of dialectical behavior therapy (DBT) (REDBT) [A randomized controlled study of the efficacy of an intensified, inpatient adaptation of dialectical behavior therapy (DBT) for a population of borderline patients (young adults/adults: 18-40), compared with standard outpatient DBT]. www.clinicaltrials.gov/ct2/show/NCT01904227 (first received 11 July 2013). SinnaeveR , Van den BoschLM , Van Steenbergen-WeijenburgKM . Change in interpersonal functioning during psychological interventions for borderline personality disorder — a systematic review of measures and efficacy. Personality and Mental Health2015;9(3):173-94. [DOI: 10.1002/pmh.1296] [PMID: 26058794]SinnaeveR , Van den BoschLMC , Hakkaart-van RoijenL , VansteelandtK . Effectiveness of step-down versus outpatient dialectical behaviour therapy for patients with severe levels of borderline personality disorder: a pragmatic randomized controlled trial. Borderline Personality Disorder and Emotion Dysregulation2018;5:12. [DOI: 10.1186/s40479-018-0089-5] [PMC6040072] [PMID: 30002832]SinnaeveR . Cochrane Collaboration review [personal communication]. Email to: J Stoffers-Winterling 11 June 2018. SinnaeveR . Re: BPDSI subscale data Sinnaeve et al (2018) [personal communication]. Email to: A Tadorovac 15 November 2018. SinnaeveR . RE: BPDSI subscale data Sinnaeve et al (2018) [personal communication] [RE: BPDSI subschale data Sinnaeve et al (2018) [personlig kommunikation]]. Email to: A Todorovac 15 November 2018. SinnaeveR . RE: BPDSI subscale data Sinnaeve et al (2018) [personal communication] [RE: BPDSI subschale data Sinnaeve et al (2018) [personlig kommunikation]]. Email to: A Todorovac 9 October 2018. Van den BoschLM , SinnaeveR , Hakkaart-van RoijenL , Van FurthEF . Efficacy and cost-effectiveness of an experimental short-term inpatient dialectical behavior therapy (DBT) program: study protocol for a randomized controlled trial. Trials2014;15:152. [DOI: 10.1186/1745-6215-15-152] [PMC4017823] [PMID: 24885551]Van RoijenLH , SinnaeveR , BouwmansC , Van Den BoschL . Cost-effectiveness and cost-utility of shortterm inpatient dialectical behavior therapy for chronically parasuicidal BPD (young) adults. Journal of Mental Health Policy and Economics2015;18(Suppl 1):S19-20. [www.icmpe.org/test1/journal/issues/v18s1toc.html]">Sinnaeve 2018</a>; <a href="./references#CD012955-bbs2-0068" title="SmithPN , GambleSA , CortNA , WardEA , HeH , TalbotNL . Attachment and alliance in the treatment of depressed, sexually abused women. Depression and Anxiety2012;29(2):123-30. [DOI: 10.1002/da.20913] [PMC3325338] [PMID: 22065593]SmithPN . Re: Cochrane Collaboration review of psychotherapies for BPD [personal communication]. Email to: J Stoffers-Winterling 05 July 2018. ">Smith 2012</a>; <a href="./references#CD012955-bbs2-0069" title="SolerJ , PascualJC , TianaT , CebriàA , BarrachinaJ , CampinsMJ , et al. Dialectical behaviour therapy skills training compared to standard group therapy in borderline personality disorder: a 3-month randomised controlled clinical trial. Behaviour Research and Therapy2009;47(5):353-8. [DOI: 10.1016/j.brat.2009.01.013] [PMID: 19246029]SolerJ . Question regarding your BPD trials [personal communication]. Email to: J Stoffers 15 December 2010. ">Soler 2009</a>; <a href="./references#CD012955-bbs2-0070" title="FertuckEA , KeilpJ , SongI , MorrisMC , WilsonST , BrodskyBS , et al. Higher executive control and visual memory performance predict treatment completion in borderline personality disorder. Psychotherapy and Psychosomatics2012;81(1):38-43. [DOI: 10.1159/000329700] [PMC3242704] [PMID: 22116411]NCT00533117. Treating suicidal behavior and self-mutilation in people with borderline personality disorder. www.clinicaltrials.gov/ct2/show/NCT00533117 (first received 19 September 2007). ">Stanley 2017</a>; <a href="./references#CD012955-bbs2-0072" title="Van den BoschLM , KoeterMW , StijnenT , VerheulR , Van den BrinkW . Sustained efficacy of dialectical behaviour therapy for borderline personality disorder. Behaviour Research and Therapy2005;43(9):1231-41. [DOI: 10.1016/j.brat.2004.09.008] [PMID: 16005708]Van den BoschLM , VerheulR , SchippersGM , Van den BrinkW . Dialectical behavior therapy of borderline patients with and without substance use problems. Implementation and long-term effects. Addictive Behaviors2002;27(6):911-23. [DOI: 10.1016/s0306-4603(02)00293-9] [PMID: 12369475]Van den BoschLMC . Efficacy of dialectical behaviour therapy in the treatment of female borderline patients with and without substance abuse problems: results of a Dutch study [Dialectische gedragstherapie bij Nederlandse vrouwen met een borderline persoonlijkheidsstoornis, met en zonder verslavingsproblemen]. Tijdschrift voor Psychiatrie2005;47(3):127-37. [www.tijdschriftvoorpsychiatrie.nl/assets/articles/articles_1335pdf.pdf]VerheulR , Van den BoschLM , KoeterMW , De RidderMA , StijnenT , Van den BrinkW . Dialectical behaviour therapy for women with borderline personality disorder: 12-month, randomised clinical trial in The Netherlands. British Journal of Psychiatry2003;182:135-40. [DOI: 10.1192/bjp.182.2.135] [PMID: 12562741]">Van den Bosch 2005</a>; <a href="./references#CD012955-bbs2-0073" title="WeinbergI , GundersonJG , HennenJ , Cutter CJ Jr. Manual assisted cognitive treatment for deliberate self-harm in borderline personality disorder patients. Journal of Personality Disorders2006;20(5):482-92. [DOI: 10.1521/pedi.2006.20.5.482] [PMID: 17032160]WilbergT . SV: separate data [personal communication] [SV: separat data [personlig kommunikation]]. Email to: M Kielsholm 25 May 2016. ">Weinberg 2006</a>; <a href="./references#CD012955-bbs2-0074" title="ZanariniMC , FrankenburgFR . A preliminary, randomized trial of psychoeducation for women with borderline personality disorder. Journal of Personality Disorders2008;22(3):284-90. [DOI: 10.1521/pedi.2008.22.3.284] [PMID: 18540800]ZanariniMC , FrankenburgFR . A randomized trial of psychoeducation for patients with BPD. In: 157th annual meeting of the American Psychiatric Association. Psychotherapy and psychopharmacology: dissolving the mind-brain barrier; 2004 May 1-6; New York (NY). Arlington (VA): American Psychiatric Association, 2004:102. [Symposium 100E] [www.psychiatry.org/File%20Library/Psychiatrists/Directories/Library-and-Archive/conference_publications/am_program_2004.pdf]">Zanarini 2008</a>; <a href="./references#CD012955-bbs2-0075" title="ZanariniMC , ConkeyLC , TemesCM , FitzmauriceGM . Randomized controlled trial of web-based psychoeducation for women with borderline personality disorder. Journal of Clinical Psychiatry2018;79(3):16m11153. [DOI: 10.4088/JCP.16m11153] [PMC5764827] [PMID: 28703950]">Zanarini 2018</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No funding received</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Bellino-2006" target="_blank">Bellino 2006</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Bellino-2007" target="_blank">Bellino 2007</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Bellino-2010" target="_blank">Bellino 2010</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Jahangard-2012" target="_blank">Jahangard 2012</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear funding</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Andreoli-2016" target="_blank">Andreoli 2016</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Bianchini-2019" target="_blank">Bianchini 2019</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Carter-2010" target="_blank">Carter 2010</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Kamalabadi-2012" target="_blank">Kamalabadi 2012</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Koons-2001a" target="_blank">Koons 2001a</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Lepp_x00e4_nen-2016" target="_blank">Leppänen 2016</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Mohamadizadeh-2017" target="_blank">Mohamadizadeh 2017</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Morton-2012" target="_blank">Morton 2012</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003131210525595826892717132089&amp;format=REVMAN&amp;showNbsp=false#STD-Turner-2000" target="_blank">Turner 2000</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>BPDSI‐IV:</b> Borderline Personality Disorder Severity Index; <b>BSI:</b> Borderline Syndrome Index; <b>CI‐BPD:</b> Childhood Interview for DSM‐IV Borderline Personality Disorder; <b>DIB:</b> Diagnostic Interview for Borderline Patients; <b>DIB‐R:</b> Diagnostic Interview for Borderline Patients ‐ revised version; <b>DIPD‐IV:</b> Diagnostic Interview for DSM‐IV Personality Disorders; <b>DSM‐III:</b> Diagnostic and Statistical Manual of Mental Disorders, Third Edition; <b>DSM‐III‐R:</b> Diagnostic and Statistical Manual of Mental Disorders, Third Edition, Revised; <b>DSM‐IV:</b> Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition; <b>DSM‐IV‐TR:</b> Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision; <b>ICD‐10:</b> International Classification of Diseases, Tenth Revision; <b>IPDE:</b> International Personality Disorder Examination; <b>PDE:</b> Personality Disorders Examination; <b>SCID‐II</b> : Structured Clinical Interview for DSM DSM‐IV Axis II Personality Disorders (SCID‐II); <b>SIDP‐IV:</b> Structured Interview for DSM‐IV Personality </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Key demographic characteristics of the included studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/full#CD012955-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012955-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Psychotherapy vs TAU</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Primary: BPD symptom severity (continuous) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.1 End of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1244</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.52 [‐0.70, ‐0.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.2 0‐6 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.59 [‐1.23, 0.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.3 6‐12 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>157</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.04 [‐0.36, 0.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.4 12 months and over follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>97</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.94 [‐2.58, 0.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Primary: BPD symptom severity (dichotomous), at above 12 months follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Primary: self‐harm (continuous) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.1 End of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>616</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.32 [‐0.49, ‐0.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.2 0‐6 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.52 [‐1.28, 0.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.3 6‐12 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>174</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.18 [‐0.48, 0.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Primary: self‐harm (dichotomous) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.1 End of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>513</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.63, 1.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.2 0‐6 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.14 [0.04, 0.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.3 6‐12 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.27 [0.10, 0.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.4 12 months and over follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.15, 0.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Primary: suicide‐related outcomes (continuous) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.1 End of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>666</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.34 [‐0.57, ‐0.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.2 0‐6 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.43 [‐1.10, 0.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.3 6‐12 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>109</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.42 [‐0.80, ‐0.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.4 Above 12 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.31 [‐0.77, 0.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Primary: suicide‐related outcomes (dichotomous) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.1 End of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>396</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.27 [0.11, 0.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.2 0‐6 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.25 [0.06, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.3 Above 12 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.29 [0.11, 0.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Primary: psychosocial functioning (continuous) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.1 End of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1314</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.45 [‐0.68, ‐0.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.2 0‐6 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.23 [‐2.74, 0.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.3 6‐12 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>247</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.09 [‐0.40, 0.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.4 Above 12 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>499</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.27 [‐0.60, 0.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 Secondary: anger (continuous) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.1 End of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>323</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.38 [‐0.64, ‐0.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.2 0‐6 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.20 [‐2.82, 0.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.3 6‐12 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>111</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.12 [‐0.50, 0.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.4 Above 12 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.02 [‐0.42, 0.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.9 Secondary: affective instability (continuous) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.1 End of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>620</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.68 [‐0.98, ‐0.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.2 6‐12 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.52 [‐1.21, 0.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.10 Secondary: chronic feelings of emptiness (continuous) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.1 End of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>187</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.39 [‐0.69, ‐0.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.2 6‐12 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.58 [‐1.28, 0.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.11 Secondary: impulsivity (continuous) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.1 End of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>491</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.54 [‐0.84, ‐0.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.2 6‐12 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [‐0.13, 0.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.12 Secondary: impulsivity (dichotomous), at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.13 Secondary: interpersonal problems (continuous) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.13.1 End of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1159</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.42 [‐0.68, ‐0.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.13.2 0‐6 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.41 [‐1.01, 0.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.13.3 6‐12 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>132</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.17 [‐0.65, 0.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.13.4 Above 12 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>172</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐0.54, 0.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.14 Secondary: abandonment (continuous) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.14.1 End of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.22 [‐0.66, 0.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.14.2 6‐12 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.39 [‐1.08, 0.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.15 Secondary: identity disturbance (continuous) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.15.1 End of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>250</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.37 [‐0.84, 0.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.15.2 6‐12 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.09 [‐1.83, ‐0.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.16 Secondary: dissociation and psychotic‐like symptoms (continuous) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.16.1 End of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>244</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.47 [‐0.85, ‐0.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.16.2 0‐6 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.97 [‐1.69, ‐0.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.16.3 6‐12 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.59 [‐1.29, 0.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.16.4 12 months and over follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.01 [‐0.81, 0.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.17 Secondary: depression (continuous) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.17.1 End of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1568</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.39 [‐0.61, ‐0.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.17.2 0‐6 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.80 [‐1.26, ‐0.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.17.3 6‐12 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>260</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.40 [‐0.95, 0.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.17.4 12 months and over follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>311</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.40 [‐0.74, ‐0.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.18 Secondary: depression (dichotomous), at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.19 Secondary: attrition (dichotomous) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.19.1 End of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2225</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.83, 1.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.19.2 0‐6 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.34, 1.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.20 Secondary: non‐serious adverse effects (dichotomous), at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>381</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.45, 1.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.21 Secondary: serious adverse effects (dichotomous), at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>571</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.14, 5.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Psychotherapy vs TAU</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012955-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Acceptance and commitment therapy (ACT) vs TAU</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Primary: BPD symptom severity (continuous), at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Secondary: affective instability (continuous), at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Secondary: depression (continuous), at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 Secondary: attrition (dichotomous), at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Acceptance and commitment therapy (ACT) vs TAU</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012955-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Dialectical behavior therapy (DBT) vs TAU</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Primary: BPD symptom severity (continuous), at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>149</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.60 [‐1.05, ‐0.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 Primary, self‐harm (continuous) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.1 End of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>376</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.28 [‐0.48, ‐0.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.2 6‐12 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>141</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.26 [‐0.59, 0.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.3 Primary: suicide‐related outcomes (continuous), at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>231</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.23 [‐0.68, 0.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.4 Primary: suicide‐related outcomes, attempts (dichotomous), at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.5 Primary: psychosocial functioning (continuous), at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>225</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.36 [‐0.69, ‐0.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.6 Secondary: anger (continuous) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6.1 End of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>230</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.47 [‐0.86, ‐0.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6.2 6‐12 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.17 [‐0.62, 0.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6.3 Above 12 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.02 [‐0.42, 0.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.7 Secondary: affective instability (continuous), at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.57 [‐1.64, 0.51]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.8 Secondary: chronic feelings of emptiness (continuous), at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.9 Secondary: impulsivity (continuous) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.9.1 End of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>128</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.35 [‐0.71, ‐0.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.9.2 6‐12 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [‐0.30, 0.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.10 Secondary: interpersonal problems (continuous), at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.12 [‐0.45, 0.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.11 Secondary: dissociation and psychotic‐like symptoms (continuous), at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>194</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.45 [‐0.73, ‐0.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.12 Secondary: depression (continuous) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.12.1 End of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>219</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.47 [‐0.98, 0.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.12.2 6‐12 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.23 [‐0.67, 0.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.13 Secondary: attrition (dichotomous) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.13.1 End of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>591</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.27 [0.70, 2.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.13.2 0‐6 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.34, 1.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.14 Secondary: adverse effects (dichotomous), at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.15 Secondary: serious adverse effects (dichotomous), at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Dialectical behavior therapy (DBT) vs TAU</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012955-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Mentalisation based therapy (MBT) vs TAU</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.1 Primary: BPD symptom severity (continuous) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.1 End of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>267</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.13 [‐0.38, 0.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.2 0‐6 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.40 [‐1.49, 0.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.3 Above 12 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>97</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.94 [‐2.58, 0.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.2 Primary: self‐harm (continuous), at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.3 Primary: self‐harm (dichotomous) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3.1 End of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>252</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.49, 0.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3.2 0‐6 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.14 [0.04, 0.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3.3 6‐12 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.27 [0.10, 0.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3.4 Above 12 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.15, 0.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.4 Primary: suicide‐related outcomes (dichotomous) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4.1 End of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>218</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [0.04, 0.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4.2 0‐6 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.25 [0.06, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4.3 Above 12 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.29 [0.11, 0.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.5 Primary: psychosocial functioning (continuous) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5.1 End of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>239</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.54 [‐1.24, 0.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5.2 Above 12 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.41 [‐0.97, 0.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.6 Secondary: interpersonal problems (continuous) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.6.1 End of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>357</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.68 [‐1.33, ‐0.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.6.2 0‐6 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.41 [‐1.01, 0.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.6.3 Above 12 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.28 [‐0.71, 0.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.7 Secondary: depression (continuous) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.7.1 End of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>333</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.58 [‐1.22, 0.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.7.2 0‐6 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.81 [‐1.69, 0.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.7.3 6‐12 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.17 [‐1.88, ‐0.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.7.4 Above 12 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.72 [‐1.55, 0.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.8 Secondary: depression (dichotomous), at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.9 Secondary: attrition (dichotomous), at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>552</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.79, 1.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.10 Secondary: adverse effects (dichotomous), at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.11 Mentalisation‐based treatment for eating disorders (MBT‐ED) versus specialist supportive clinical management (SSCM‐ED) (generic inverse variance) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.11.1 Primary: psychosocial functioning (continuous), at end of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.07 [‐0.86, 0.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.11.2 Primary: psychosocial functioning (dichotomous), at 0‐6 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.44 [‐1.52, 0.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.11.3 Secondary: interpersonal problems (continuous), at end of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.10 [‐0.89, 0.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.11.4 Secondary: interpersonal problems (continuous), at 0‐6 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.06 [‐1.15, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.11.5 Secondary: depression (continuous), at end of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.19 [‐0.60, 0.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.11.6 Secondary: depression (continuous), at 0‐6 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [‐0.62, 1.64]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Mentalisation based therapy (MBT) vs TAU</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012955-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Cognitive behavioural therapy (CBT) and related treatments vs TAU</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.1 Primary: BPD symptom severity (continuous) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1.1 End of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.08 [‐4.99, ‐1.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1.2 0‐6 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.02 [‐4.23, 0.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.2 Primary: BPD symptom severity (dichotomous), at above 12 months follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.56, 1.48]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.3 Primary: self‐harm (continuous) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3.1 End of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.03 [‐5.68, ‐0.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3.2 0‐6 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.71 [‐11.60, 2.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.4 Primary: self‐harm (dichotomous), at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.5 Primary: suicide‐related outcomes (continuous) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.5.1 End of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.47 [‐1.02, 0.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.5.2 0‐6 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.45 [‐1.20, 0.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.5.3 6‐12 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.44 [‐0.89, 0.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.5.4 Above 12 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.31 [‐0.77, 0.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.6 Primary: psychosocial functioning (continuous) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.6.1 End of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐0.39, 0.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.6.2 6‐12 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.13 [‐0.28, 0.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.6.3 Above 12 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>209</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.04 [‐0.36, 0.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.7 Secondary: interpersonal problems (continuous) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.7.1 End of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.40 [‐3.70, 14.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.7.2 6‐12 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [‐9.17, 9.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.7.3 Above 12 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>11.70 [0.72, 22.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.8 Secondary: dissociation and psychotic‐like symptoms (continuous) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.8.1 End of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.30 [‐8.84, 4.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.8.2 0‐6 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐13.40 [‐24.49, ‐2.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.9 Secondary: depression (continuous) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.9.1 End of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>314</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.21 [‐0.77, 0.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.9.2 0‐6 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.96 [‐1.78, ‐0.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.9.3 6‐12 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.29 [‐0.69, 0.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.9.4 Above 12 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>197</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.15 [‐0.43, 0.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.10 Secondary: attrition (dichotomous), at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.11 Secondary: adverse effects (dichotomous), at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.11.1 Non‐serious adverse effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>306</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.45, 1.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.11.2 Serious adverse effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>326</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.65 [0.31, 22.93]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Cognitive behavioural therapy (CBT) and related treatments vs TAU</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012955-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Psychodynamic psychotherapy vs TAU</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.1 Primary: BPD symptom severity (continuous) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1.1 End of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>222</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.29 [‐0.66, 0.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1.2 6‐12 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.31 [‐1.00, 0.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.2 Primary: self‐harm (continuous) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2.1 End of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.12 [‐0.56, 0.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2.2 6‐12 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.14 [‐0.55, 0.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.3 Primary: suicide‐related outcomes (continuous) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3.1 End of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.22 [‐0.62, 0.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3.2 6‐12 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.38 [‐1.07, 0.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.4 Primary: psychosocial functioning (continuous) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.4.1 End of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.69 [‐1.98, 0.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.4.2 6‐12 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.05 [‐0.64, 0.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.4.3 Above 12 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.40 [‐1.39, 0.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.5 Secondary: anger (continuous) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.5.1 End of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐0.86, 0.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.5.2 6‐12 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐0.89, 0.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.6 Secondary: affective instability (continuous) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.6.1 End of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>116</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.50 [‐0.87, ‐0.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.6.2 6‐12 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.52 [‐1.21, 0.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.7 Secondary: chronic feelings of emptiness (continuous) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.7.1 End of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.49 [‐1.02, 0.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.7.2 6‐12 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.58 [‐1.28, 0.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.8 Secondary: impulsivity (continuous) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.8.1 End of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.39 [‐0.85, 0.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.8.2 6‐12 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.35 [‐0.34, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.9 Secondary: interpersonal problems (continuous) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.9.1 End of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>238</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.21 [‐0.71, 0.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.9.2 6‐12 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.51 [‐1.20, 0.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.10 Secondary: abandonment (continuous) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.10.1 End of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.20 [‐0.95, 0.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.10.2 6‐12 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.40 [‐1.08, 0.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.11 Secondary: identity disturbance (continuous) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.11.1 End of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>199</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.38 [‐1.02, 0.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.11.2 6‐12 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.09 [‐1.83, ‐0.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.12 Secondary: dissociation and psychotic‐like symptoms (continuous) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.12.1 End of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.18 [‐0.96, 0.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.12.2 6‐12 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.59 [‐1.29, 0.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.12.3 Above 12 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.01 [‐0.81, 0.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.13 Secondary: depression (continuous) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.13.1 End of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>190</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.17 [‐0.81, 0.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.13.2 Above 12 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.68 [‐1.51, 0.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.14 Secondary: attrition (dichotomous), at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>210</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.56, 1.47]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Psychodynamic psychotherapy vs TAU</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012955-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Schema‐focused therapy (SFT) vs TAU</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.1 Primary: BPD symptom severity (continuous), at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.2 Primary: psychosocial functioning (continuous), at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.3 Secondary: affective instability (continuous), at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.4 Secondary: impulsivity (continuous), at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.5 Secondary: interpersonal problems (continuous), at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.6 Secondary: dissociation and psychotic‐like symptoms (continuous), at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.7 Secondary: attrition (dichotomous), at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Schema‐focused therapy (SFT) vs TAU</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012955-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Systems training for emotional predictability and problem solving (STEPPS) vs TAU</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.1 Primary: BPD symptom severity (continuous), at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1.1 End of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>273</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.39 [‐0.63, ‐0.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1.2 6‐12 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>124</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.03 [‐0.33, 0.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.2 Primary: self‐harm (dichtomous), at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.3 Primary: psychosocial functioning (continuous) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3.1 End of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>124</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐7.00 [‐11.43, ‐2.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3.2 6‐12 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>124</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.90 [‐12.49, 0.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.4 Secondary: affective instability (continuous), at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>221</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.25 [‐0.52, 0.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.5 Secondary: impulsivity (continuous), at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.6 Secondary: impulsivity (dichotomous), at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.7 Secondary: interpersonal problems (continuous), at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>177</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.38 [‐0.67, ‐0.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.8 Secondary: dissociation and psychotic‐like symptoms (continuous), at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.9 Secondary: depression (continuous), at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.9.1 End of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>124</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.80 [‐9.34, 1.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.9.2 6‐12 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>124</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [‐8.42, 9.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.10 Secondary: attrition (dichotomous), at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Systems training for emotional predictability and problem solving (STEPPS) vs TAU</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012955-tbl-0014"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Cognitive analytic therapy (CAT) vs TAU</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.1 Primary: suicide‐related outcomes (continuous) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1.1 End of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.40 [‐4.21, 1.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1.2 0‐6 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.50 [‐2.05, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.2 Primary: psychosocial functioning (continuous) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2.1 End of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐16.40 [‐31.20, ‐1.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2.2 0‐6 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐15.80 [‐29.36, ‐2.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.3 Secondary: anger (continuous) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.3.1 End of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.90 [‐7.97, 4.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.3.2 0‐6 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.50 [‐9.01, 0.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.4 Secondary: dissociation and psychotic‐like symptoms (continuous) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.4.1 End of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐6.10 [‐15.01, 2.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.4.2 0‐6 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐11.70 [‐24.02, 0.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.5 Secondary: depression (continuous) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.5.1 End of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐9.70 [‐20.10, 0.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.5.2 0‐6 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.70 [‐11.99, 4.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.6 Secondary: attrition (dichotomous), at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Cognitive analytic therapy (CAT) vs TAU</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012955-tbl-0015"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Motivation feedback (MF) vs TAU</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.1 Primary: psychosocial functioning, at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Motivation feedback (MF) vs TAU</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-tbl-0015">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012955-tbl-0016"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">Psychoeducation vs TAU</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.1 Secondary: depression (continuous), at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.2 Secondary: attrition (dichotomous), at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">Psychoeducation vs TAU</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-tbl-0016">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012955-tbl-0017"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">Transference‐focused psychotherapy (TFP) vs TAU</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12.1 Primary: BPD symptom severity (continuous), at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12.2 Primary: self‐harm (dichotomous), at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12.3 Primary: suicide‐related outcomes (dichotomous), at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12.4 Primary: psychosocial functioning (continuous), at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12.5 Secondary: depression (continuous), at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12.6 Secondary: attrition (dichotomous), at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">Transference‐focused psychotherapy (TFP) vs TAU</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-tbl-0017">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012955-tbl-0018"> <div class="table-heading"><span class="table-label">Comparison 13.</span> <span class="table-title">Once‐only interventions (individual setting) vs TAU</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13.1 Primary: self‐harm (continuous), at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13.2 Primary: psychosocial functioning (continuous), at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13.3 Secondary: depression (continuous), at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13.4 Secondary: attrition (dichotomous), at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 13.</span> <span class="table-title">Once‐only interventions (individual setting) vs TAU</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-tbl-0018">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012955-tbl-0019"> <div class="table-heading"><span class="table-label">Comparison 14.</span> <span class="table-title">Eclectic treatments vs TAU</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14.1 Primary: BPD symptom severity (continuous), at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.90 [‐1.57, ‐0.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14.2 Primary: self‐harm (continuous), at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.84 [‐1.29, ‐0.39]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14.3 Primary: suicide‐related outcomes (continuous), at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>221</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.55 [‐1.29, 0.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14.4 Primary: psychosocial functioning (continuous) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.4.1 End of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>231</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.57 [‐1.10, ‐0.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.4.2 Above 12 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>170</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.64 [‐1.04, ‐0.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14.5 Secondary: anger (continuous), at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14.6 Secondary: affective instability (continuous), at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.95 [‐1.74, ‐0.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14.7 Secondary: chronic feelings of emptiness (continuous), at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14.8 Secondary: impulsivity (continuous), at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.76 [‐1.30, ‐0.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14.9 Secondary: interpersonal problems (continuous), at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.62 [‐1.09, ‐0.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14.10 Secondary: abandonment (continuous), at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14.11 Secondary: identity disturbance (continuous), at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14.12 Secondary: depression (continuous), at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>304</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.82 [‐1.38, ‐0.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14.13 Secondary: attrition (dichotomuous), at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>326</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.85, 1.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14.14 Secondary: adverse effects (dichotomous), at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 14.</span> <span class="table-title">Eclectic treatments vs TAU</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-tbl-0019">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012955-tbl-0020"> <div class="table-heading"><span class="table-label">Comparison 15.</span> <span class="table-title">Psychotherapy vs waiting list or no treatment</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15.1 Primary: BPD symptom severity (continuous), at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>161</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.49 [‐0.93, ‐0.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15.2 Primary: self‐harm (continuous), at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>128</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.17 [‐0.52, 0.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15.3 Primary: suicide‐related outcomes (continuous), at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>108</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.62 [‐16.39, 5.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15.4 Primary: psychosocial functioning (continuous) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.4.1 End of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>219</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.56 [‐1.01, ‐0.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.4.2 0‐6 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.89 [‐1.65, ‐0.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.4.3 6‐12 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.04 [‐1.81, ‐0.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.4.4 Above 12 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.38 [‐1.14, 0.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15.5 Secondary: anger (continuous), at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>128</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.58 [‐1.70, 0.55]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15.6 Secondary: affective instability (continuous) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.6.1 End of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>128</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.99 [‐1.36, ‐0.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.6.2 0‐6 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.47 [‐1.20, 0.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.6.3 6‐12 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.38 [‐1.10, 0.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.6.4 Above 12 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.28 [‐1.01, 0.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15.7 Secondary: chronic feelings of emptiness (continuous), at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15.8 Secondary: impulsivity (continuous) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.8.1 End of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>178</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.52 [‐0.82, ‐0.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.8.2 0‐6 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.90 [‐1.66, ‐0.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.8.3 6‐12 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.79 [‐1.54, ‐0.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.8.4 Above 12 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.75 [‐1.50, ‐0.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15.9 Secondary: interpersonal problems (continuous) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.9.1 End of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.85 [‐1.23, ‐0.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.9.2 0‐6 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.40 [‐2.21, ‐0.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.9.3 6‐12 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.90 [‐1.66, ‐0.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.9.4 Above 12 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.86 [‐1.62, ‐0.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15.10 Secondary: abandonment (continuous), at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15.11 Secondary: identity disturbance (continuous), at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15.12 Secondary: dissociation and psychotic‐like symptoms (continuous), at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.13 [‐0.65, 0.39]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15.13 Secondary: depression (continuous), at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>239</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.28 [‐2.21, ‐0.34]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15.14 Secondary: attrition (dichotomous), at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>144</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.20, 1.50]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 15.</span> <span class="table-title">Psychotherapy vs waiting list or no treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-tbl-0020">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012955-tbl-0021"> <div class="table-heading"><span class="table-label">Comparison 16.</span> <span class="table-title">Dialectical behavior therapy (DBT) vs waiting list or no treatment</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16.1 Primary: BPD symptom severity (continuous), at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>117</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.71 [‐1.08, ‐0.33]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16.2 Primary: self‐harm (continuous), at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16.3 Primary: suicide‐related outcomes (continuous), at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>108</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.62 [‐16.39, 5.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16.4 Primary: psychosocial functioning (continuous), at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>117</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.73 [‐1.11, ‐0.36]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16.5 Secondary: anger (continuous), at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16.6 Secondary: affective instability (continuous), at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16.7 Secondary: impulsivity (continuous), at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16.8 Secondary: dissociation and psychotic‐like symptoms (continuous), at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16.9 Secondary: depression (continuous), at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>141</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.20 [‐5.57, ‐0.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16.10 DBT‐couple therapy (CDBT) vs waiting list (generic inverse variance) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.10.1 Primary: BPD severity (continuous), at end of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐27.15 [‐31.59, ‐22.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.10.2 Primary: suicide‐related outcomes (continuous), at end of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.94 [‐1.24, ‐0.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.10.3 Primary: psychosocial functioning (continuous), at end of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐10.70 [‐12.31, ‐9.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.10.4 Secondary: anger (continuous), at end of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.42 [‐1.72, ‐1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.10.5 Secondary: affective instability (continuous), at end of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.01 [‐5.44, ‐2.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.10.6 Secondary: chronic feelings of emptiness (continuous), at end of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.54 [‐4.81, ‐2.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.10.7 Secondary: impulsivity (continuous), at end of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.51 [‐0.72, ‐0.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.10.8 Secondary: interpersonal problems (continuous), at end of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.98 [‐2.47, ‐1.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.10.9 Secondary: abandonment (continuous), at end of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.86 [‐1.09, ‐0.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.10.10 Secondary: identity disturbance (continuous), at end of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.44 [‐2.77, ‐2.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.10.11 Secondary: dissociation or psychotic‐like symptoms (continuous), at end of treatment </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.92 [‐2.46, ‐1.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.10.12 Secondary: depression (continuous), at end of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐10.43 [‐11.86, ‐9.00]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 16.</span> <span class="table-title">Dialectical behavior therapy (DBT) vs waiting list or no treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-tbl-0021">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012955-tbl-0022"> <div class="table-heading"><span class="table-label">Comparison 17.</span> <span class="table-title">Schema‐focused therapy (SFT) vs no treatment</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17.1 Primary: suicide‐related outcomes (continuous), at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17.2 Secondary: depression (continuous), at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 17.</span> <span class="table-title">Schema‐focused therapy (SFT) vs no treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-tbl-0022">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012955-tbl-0023"> <div class="table-heading"><span class="table-label">Comparison 18.</span> <span class="table-title">Interpersonal psychotherapy (IPT) vs waiting list</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18.1 Primary: BPD symptom severity (continuous), at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18.2 Primary: self‐harm (continuous), at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18.3 Primary: psychosocial functioning (continuous) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.3.1 End of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.03 [‐0.48, 0.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.3.2 0‐6 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.89 [‐1.65, ‐0.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.3.3 6‐12 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.04 [‐1.81, ‐0.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.3.4 Above 12 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.38 [‐1.14, 0.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18.4 Secondary: anger (continuous), at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18.5 Secondary: affective instability (continuous) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.5.1 End of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.02 [‐1.66, ‐0.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.5.2 0‐6 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.46 [‐1.15, 0.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.5.3 6‐12 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.39 [‐1.12, 0.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.5.4 Above 12 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.34 [‐1.17, 0.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18.6 Secondary: chronic feelings of emptiness (continuous), at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18.7 Secondary: impulsivity (continuous) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.7.1 End of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.03 [‐1.69, ‐0.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.7.2 0‐6 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.10 [‐1.95, ‐0.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.7.3 6‐12 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.10 [‐2.06, ‐0.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.7.4 Above 12 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.09 [‐2.09, ‐0.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18.8 Secondary: interpersonal problems (continuous) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.8.1 End of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.14 [‐1.94, ‐0.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.8.2 0‐6 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.00 [‐2.98, ‐1.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.8.3 6‐12 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.56 [‐2.74, ‐0.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.8.4 Above 12 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.48 [‐2.63, ‐0.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18.9 Secondary: abandonment (continuous), at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18.10 Secondary: identity disturbance (continuous), at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18.11 Secondary: dissociation and psychotic‐like symptoms (continuous), at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18.12 Secondary outcome: depression (continuous), at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>98</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.52 [‐1.11, 0.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18.13 Secondary outcome: attrition (dichotomous), at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.20, 1.50]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 18.</span> <span class="table-title">Interpersonal psychotherapy (IPT) vs waiting list</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-tbl-0023">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012955-tbl-0024"> <div class="table-heading"><span class="table-label">Comparison 19.</span> <span class="table-title">Once‐only interventions (individual setting) vs waiting list</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19.1 Secondary: impulsivity (continuous), at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19.2 Secondary: interpersonal problems (continuous), at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19.3 Secondary: attrition (dichotomous), at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 19.</span> <span class="table-title">Once‐only interventions (individual setting) vs waiting list</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-tbl-0024">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012955-tbl-0025"> <div class="table-heading"><span class="table-label">Comparison 20.</span> <span class="table-title">Eclectic treatments vs waiting list</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20.1 Primary outcome: psychosocial functioning (continuous), at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20.2 Secondary outcome: interpersonal problems (continuous), at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 20.</span> <span class="table-title">Eclectic treatments vs waiting list</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-tbl-0025">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012955-tbl-0026"> <div class="table-heading"><span class="table-label">Comparison 21.</span> <span class="table-title">Dialectical behavior therapy (DBT) and related treatments vs active treatment</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21.1 Standard DBT (DBT) vs client‐centred therapy (CCT) (continuous) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.1.1 Primary: self‐harm (continuous), at end of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.75 [‐4.42, ‐1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.1.2 Primary: suicide‐related outcomes (continuous), at end of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐7.75 [‐14.66, ‐0.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.1.3 Secondary: anger (continuous), at end of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.00 [‐1.98, ‐0.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.1.4 Secondary: impulsivity (continuous), at end of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.50 [‐2.60, ‐0.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.1.5 Secondary: dissociation and psychotic‐like symptoms (continuous), at end of treatment </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐7.16 [‐12.15, ‐2.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.1.6 Secondary: depression (continuous), at end of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐9.16 [‐14.79, ‐3.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21.2 DBT vs CCT, secondary: attrition (dichotomous), at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21.3 Standard DBT (DBT) vs good psychiatric management (GPM) (continuous) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.3.1 Primary: BPD severity (continuous), at end of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.23 [‐1.97, 1.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.3.2 Primary: self‐harm (continuous), at end of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐8.58 [‐19.38, 2.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.3.3 Secondary: anger (continuous), at end of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.15 [‐1.65, 1.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.3.4 Secondary: interpersonal problems (continuous), at end of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.34 [‐15.36, 12.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.3.5 Secondary: depression (continuous), at end of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.65 [‐7.18, 1.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21.4 DBT vs GPM, secondary: attrition (dichotomous), at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21.5 Standard DBT (DBT) vs individual DBT therapy + activities group (DBT‐I) (continuous) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.5.1 Primary: self‐harm (continuous), at end of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐10.40 [‐22.99, 2.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.5.2 Primary: self‐harm (continuous), at 6‐12 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐8.10 [‐19.59, 3.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.5.3 Primary: suicide‐related outcomes (continuous), at end of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [‐1.37, 2.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.5.4 Primary: suicide‐related outcomes (continuous), at 6‐12 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.60 [‐2.79, ‐0.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.5.5 Secondary: depression (continuous), at end of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.90 [‐9.74, ‐2.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.5.6 Secondary: depression (continuous), at 6‐12 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.30 [‐3.10, 5.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21.6 DBT vs DBT‐I, secondary: attrition (dichotomous), at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21.7 Standard DBT (DBT) vs skills training group + individual case management (DBT‐S) (continuous) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.7.1 Primary: self‐harm (continuous), at end of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [‐8.42, 9.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.7.2 Primary: self‐harm (continuous), at 6‐12 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.50 [‐9.04, 6.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.7.3 Primary: suicide‐related outcomes (continuous), at end of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [‐1.06, 2.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.7.4 Primary: suicide‐related outcomes (continuous), at 6‐12 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [‐0.02, 1.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.7.5 Secondary: depression (continuous), at end of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.90 [‐1.60, 5.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.7.6 Secondary: depression (continuous), at 6‐12 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.30 [‐0.90, 7.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21.8 DBT vs DBT‐S, secondary: attrition (dichotomous), at 6‐12 months follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21.9 Standard DBT (DBT) vs step‐down DBT (DBT‐SD) (continuous) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.9.1 Primary: BPD symptom severity (continuous), at end of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.83 [‐11.21, 5.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.9.2 Primary: self‐harm (continuous), at end of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.10 [‐4.07, 12.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.9.3 Primary: suicide‐related outcomes (continuous), at end of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [‐0.73, 1.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.9.4 Secondary: anger (continuous), at end of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.53 [‐1.48, 0.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.9.5 Secondary: affective instability (continuous), at end of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.71 [‐2.51, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.9.6 Secondary: chronic feeling of emptiness (continuous), at end of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.18 [‐1.68, 2.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.9.7 Secondary: impulsivity (continuous), at end of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.24 [‐0.26, 0.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.9.8 Secondary: interpersonal problems (continuous), at end of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.31 [‐2.05, ‐0.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.9.9 Secondary: abandonment (continuous), at end of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.11 [‐2.14, ‐0.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.9.10 Secondary: dissociation and psychotic‐like symptoms (continuous), at end of treatment </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.44 [‐1.56, 0.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21.10 DBT vs DBT‐SD, secondary: attrition (dichotomous), at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.37 [0.17, 0.78]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21.11 Standard DBT (DBT) vs DBT Prolonged Exposure (PE) (continuous) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.11.1 Primary: self‐harm (continuous), end of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [‐1.86, 2.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.11.2 Primary: self‐harm (continuous), at 0‐6 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.30 [‐1.09, 0.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.11.3 Primary: suicide‐related outcomes (continuous), end of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.11.4 Primary: suicide‐related outcomes (continuous), at 0‐6 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.11.5 Primary: psychosocial functioning (continuous), end of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.27 [‐2.06, 12.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.11.6 Primary: psychosocial functioning (continuous), at 0‐6 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.00 [‐6.27, 10.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.11.7 Secondary: interpersonal problems (continuous), end of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.14 [‐0.42, 0.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.11.8 Secondary: interpersonal problems (continuous), at 0‐6 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.19 [‐0.48, 0.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.11.9 Secondary: dissociation or psychotic‐like symptoms (continuous), end of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.60 [‐9.24, 18.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.11.10 Secondary: dissociation or psychotic‐like symptoms (continuous), at 0‐6 months follow‐up </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.00 [‐9.46, 21.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.11.11 Secondary: depression (continuous), end of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.70 [‐3.19, 10.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.11.12 Secondary: depression (continuous), at 0‐6 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.30 [‐1.08, 9.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21.12 DBT vs DBT‐PE, secondary: attrition (dichotomous), at 0‐6 months follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21.13 DBT skills group + case management (DBT‐S) vs DBT individual therapy + activity group (DBT‐I) (continuous) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.13.1 Primary: self‐harm (continuous), at end of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐10.70 [‐22.47, 1.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.13.2 Primary: self‐harming behaviour (continuous), at 6‐12 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐6.60 [‐19.72, 6.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.13.3 Primary: suicide‐related outcomes (continuous), at end of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.30 [‐1.72, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.13.4 Primary: suicide‐related outcomes (continuous), at 6‐12 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.10 [‐3.21, ‐0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.13.5 Secondary: depression (continuous), at end of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐7.80 [‐11.27, ‐4.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.13.6 Secondary: depression (continuous), at 6‐12 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.00 [‐6.44, 2.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21.14 DBT‐S vs DBT‐I, secondary: attrition (dichotomous), at 6‐12 months follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21.15 DBT skills group (DBT‐S) vs cognitive therapy group (CT‐G) (continuous) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.15.1 Primary: BPD symptom severity (continuous), at end of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.26 [‐0.13, 0.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.15.2 Primary: BPD symptom severity (continuous), at 0‐6 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.96 [‐1.15, ‐0.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.15.3 Primary: suicide‐related outcomes (continuous), at end of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.46 [‐2.47, 3.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.15.4 Primary: suicide‐related outcomes (continuous), at 0‐6 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.69 [‐4.89, ‐0.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.15.5 Secondary: depression (continuous), at end of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.12 [‐5.25, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.15.6 Secondary: depression (continuous), at 0‐6 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.60 [‐5.07, 1.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21.16 DBT‐S vs CT‐G, secondary: attrition (dichotomous), at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21.17 DBT skills group (DBT‐S) vs schema‐focused therapy group (SFT‐G) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.17.1 Primary: suicide‐related outcomes (continuous), at end of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [‐0.36, 2.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.17.2 Secondary: depression (continuous), at end of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.33 [2.57, 6.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21.18 DBT mindfulness group (DBT‐M) vs DBT interpersonal effectiveness group (DBT‐IE) (continuous) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.18.1 Primary: BPD symptom severity (continuous), at end of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>113</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.45 [‐1.47, 0.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.18.2 Secondary: impulsivity (continuous), at end of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.36 [‐0.77, 0.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21.19 DBT‐M vs DBT‐IE, secondary: attrition (dichotomous), at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.86 [1.07, 3.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21.20 DBT mindfulness group (DBT‐M) vs loving‐kindness and compassion meditation (LK/CM), primary: BPD symptom severity (continuous), at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 21.</span> <span class="table-title">Dialectical behavior therapy (DBT) and related treatments vs active treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-tbl-0026">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012955-tbl-0027"> <div class="table-heading"><span class="table-label">Comparison 22.</span> <span class="table-title">Cognitive behavioural therapy (CBT) and related treatments vs active treatment</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">22.1 CBT vs trauma‐ and anxiety‐related group psychoeducation (continuous) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.1.1 Primary: BPD symptom severity (continuous), at end of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.26 [‐1.46, 0.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.1.2 Primary: BPD symptom severity (continuous), at 0‐6 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.39 [‐1.60, 0.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.1.3 Primary: BPD symptom severity (continuous), at 6‐12 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [‐0.48, 1.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.1.4 Primary: psychosocial functioning (continuous), at end of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.64 [‐5.76, 4.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.1.5 Primary: psychosocial functioning (continuous), at 0‐6 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.23 [‐6.94, 4.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.1.6 Primary: psychosocial functioning (continuous), at 6‐12 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [‐5.00, 6.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.1.7 Secondary: depression (continuous), at end of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [‐8.20, 9.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.1.8 Secondary: depression (continuous), at 0‐6 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.13 [‐4.05, 10.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.1.9 Secondary: depression (continuous), at 6‐12 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [‐7.08, 8.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">22.2 CBT vs trauma‐ and anxiety‐related group psychoeducation, secondary: attrition (dichotomous), at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">22.3 CBT vs interpersonal psychotherapy (IPT) (continuous) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.3.1 Primary: psychosocial functioning (continuous), at end of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.30 [‐12.36, 1.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.3.2 Secondary: depression (continuous), at end of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.40 [‐4.72, 3.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">22.4 CBT vs IPT, secondary: attrition (dichotomous), at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">22.5 CBT vs Rogerian supportive therapy (continuous) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.5.1 Primary: self‐harm (continuous), end of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [‐0.03, 1.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.5.2 Primary: self‐harm (continuous), at 6‐12 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.63 [‐1.75, 0.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.5.3 Primary: suicide‐related outcomes (continuous), at end of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [‐2.60, 3.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.5.4 Primary: suicide‐related outcomes (continuous), at 6‐12 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.43 [‐6.14, 1.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.5.5 Primary: psychosocial functioning (continuous), at end of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.43 [‐1.31, 0.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.5.6 Primary: psychosocial functioning (continuous), at 6‐12 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.98 [‐2.02, 0.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.5.7 Secondary: impulsivity (continuous), at end of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.01 [‐3.85, 1.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.5.8 Secondary: impulsivity (continuous), at 6‐12 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.18 [‐5.91, 1.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.5.9 Secondary: depression (continuous), at end of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [‐5.59, 7.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.5.10 Secondary: depression (continuous), at 6‐12 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.15 [‐9.38, ‐0.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">22.6 CBT vs Rogerian supportive therapy, secondary: attrition (dichotomous), end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">22.7 MACT (Manual‐assisted Cognitive Therapy) vs MACT + therapeutic assessment (MACT + TA) (continuous) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.7.1 Primary: BPD symptom severity (continuous), at end of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.75 [‐14.17, 6.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.7.2 Primary: self‐harm (continuous), at end of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.75 [‐18.71, 22.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.7.3 Primary: suicide‐related outcomes (continuous), at end of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.63 [‐17.71, 16.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.7.4 Secondary: affective instability (continuous), at end of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.25 [‐12.10, 1.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.7.5 Secondary: interpersonal problems (continuous), at end of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.50 [‐11.24, 10.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.7.6 Secondary: identity disturbance (continuous), at end of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.88 [‐14.98, 5.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">22.8 MACT vs MACT + TA, secondary: attrition (dichotomous), at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">22.9 Meta‐Cognitive training for BPD (B‐MCT) vs progressive muscle relaxation training (PMR) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.9.1 Primary: BPD symptom severity (continuous), at end of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.80 [‐4.97, 1.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.9.2 Primary: BPD symptom severity (continuous), at 0‐6 months follow up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.60 [‐7.16, ‐0.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.9.3 Secondary: depression (continuous), at end of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.20 [‐9.91, 3.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.9.4 Secondary: depression (continuous), at 0‐6 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.50 [2.03, 14.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">22.10 B‐MCT vs progressive muscle relaxation (PMR) training + TAU (dichotomous). Secondary: attrition (dichotomous), at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">22.11 MOTR (Motive‐Oriented Therapeutic Relationship) vs Good Psychiatric Management (GPM) (continuous) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.11.1 Primary: BPD symptom severity (continuous), at end of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.07 [‐0.39, 0.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.11.2 Primary: psychosocial functioning (continuous), at end of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.45 [‐0.85, ‐0.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.11.3 Secondary: interpersonal problems (continuous), at end of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.56 [‐0.97, ‐0.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">22.12 MOTR vs (GPM), secondary: attrition (dichotomous), at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.26, 1.41]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 22.</span> <span class="table-title">Cognitive behavioural therapy (CBT) and related treatments vs active treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-tbl-0027">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012955-tbl-0028"> <div class="table-heading"><span class="table-label">Comparison 23.</span> <span class="table-title">Schema‐focused therapy (SFT) vs active treatment</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">23.1 SFT vs TFP. Primary: BPD symptom severity (continuous), at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">23.2 SFT vs TFP. Secondary: attrition (dichotomous), at 0‐6 months follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">23.3 SFT vs SFT + therapist availability (TA). Primary: BPD symptom severity (continuous), at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">23.4 SFT vs SFT + TA. Secondary: attrition (dichotomous), 0‐6 months follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 23.</span> <span class="table-title">Schema‐focused therapy (SFT) vs active treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-tbl-0028">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012955-tbl-0029"> <div class="table-heading"><span class="table-label">Comparison 24.</span> <span class="table-title">Systems training for emotional predictability and problem solving‐based psychoeducation (STEPPS‐PE) vs cognitive rehabilitation (CR)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">24.1 STEPPS‐PE vs CR <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.1.1 Primary: BPD symptom severity (continuous), at end of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.67 [‐6.52, ‐0.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.1.2 Primary: BPD symptom severity (continuous), at 0‐6 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.68 [1.42, 7.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.1.3 Secondary: impulsivity (continuous), at end of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.99 [0.06, 3.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.1.4 Secondary: impulsivity (continuous), at 0‐6 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.92 [7.38, 12.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.1.5 Secondary: depression (continuous), at end of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.58 [‐3.62, ‐1.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.1.6 Secondary: depression (continuous), at 0‐6 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐10.11 [‐11.35, ‐8.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">24.2 STEPPS‐PE vs CR. Secondary: attrition (dichotomous), at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 24.</span> <span class="table-title">Systems training for emotional predictability and problem solving‐based psychoeducation (STEPPS‐PE) vs cognitive rehabilitation (CR)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-tbl-0029">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012955-tbl-0030"> <div class="table-heading"><span class="table-label">Comparison 25.</span> <span class="table-title">Eclectic treatments vs active treatment</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">25.1 Combined inpatient and outpatient psychotherapy versus outpatient psychotherapy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.1.1 Primary: psychosocial functioning (continuous), at end of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.50 [‐0.06, 13.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.1.2 Primary: psychosocial functioning (continuous), at above 12 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.70 [‐13.33, 1.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.1.3 Secondary: interpersonal problems (continuous), at end of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.05 [‐0.24, 0.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.1.4 Secondary: interpersonal problems (continuous), at above 12 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.42 [‐0.77, ‐0.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.1.5 Secondary: identity disturbance (continuous), at end of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.25 [‐0.59, 0.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.1.6 Secondary: identity disturbance (continuous), at above 12 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.47 [‐0.78, ‐0.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.1.7 Secondary: depression (continuous), at end of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.40 [‐6.25, 5.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.1.8 Secondary: depression (continuous), at above 12 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.70 [‐11.02, 1.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">25.2 Combined inpatient and outpatient psychotherapy versus outpatient psychotherapy. Secondary: attrition (dichotomous), at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">25.3 integrative BPD‐oriented adolescent family therapy (I‐BAFT) vs individual drug counselling (IDC) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.3.1 Primary: BPD symptom severity (dichotomous), at end of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.50, 1.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.3.2 Secondary: attrition (dichotomous), at 6‐12 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.18, 1.40]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 25.</span> <span class="table-title">Eclectic treatments vs active treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-tbl-0030">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012955-tbl-0031"> <div class="table-heading"><span class="table-label">Comparison 26.</span> <span class="table-title">Subgroup analysis: therapeutic approaches</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">26.1 BPD symptom severity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.1.1 DBT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>149</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.60 [‐1.05, ‐0.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.1.2 MBT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>267</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.13 [‐0.38, 0.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.1.3 Psychodynamic psychotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>222</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.29 [‐0.66, 0.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.1.4 STEPPS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>273</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.39 [‐0.63, ‐0.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.1.5 Eclectic treatments</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.90 [‐1.57, ‐0.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.1.6 ACT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.22 [‐1.89, ‐0.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.1.7 CBT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.28 [‐2.14, ‐0.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.1.8 SFT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.66 [‐2.54, ‐0.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.1.9 CAT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.53 [‐1.88, 0.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.1.10 Tranference‐focused psychotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.55 [‐0.95, ‐0.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">26.2 Psychosocial functioning <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.2.1 DBT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>225</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.36 [‐0.69, ‐0.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.2.2 MBT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>239</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.54 [‐1.24, 0.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.2.3 Psychodynamic psychotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.69 [‐1.98, 0.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.2.4 Eclectic treatments</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>231</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.57 [‐1.10, ‐0.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.2.5 CBT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐0.39, 0.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.2.6 SFT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.20 [‐2.03, ‐0.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.2.7 STEPPS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>124</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.55 [‐0.91, ‐0.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.2.8 CAT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.22 [‐2.73, 0.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.2.9 Motivation feedback</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.07 [‐0.69, 0.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.2.10 Tranference‐focused psychotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.34 [‐0.73, 0.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.2.11 Once‐only intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.03 [‐0.43, 0.49]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 26.</span> <span class="table-title">Subgroup analysis: therapeutic approaches</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-tbl-0031">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012955-tbl-0032"> <div class="table-heading"><span class="table-label">Comparison 27.</span> <span class="table-title">Subgroup analysis: age</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">27.1 BPD symptom severity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>27.1.1 15 to 18 years old</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>156</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.14 [‐0.46, 0.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>27.1.2 Above 18 years old</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1088</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.57 [‐0.76, ‐0.37]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 27.</span> <span class="table-title">Subgroup analysis: age</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-tbl-0032">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012955-tbl-0033"> <div class="table-heading"><span class="table-label">Comparison 28.</span> <span class="table-title">Subgroup analysis: duration</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">28.1 BPD symptom severity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>28.1.1 Less than 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>525</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.76 [‐1.10, ‐0.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>28.1.2 6 to 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>606</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.36 [‐0.60, ‐0.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>28.1.3 Above 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>113</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.37 [‐0.75, 0.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">28.2 Psychosocial functioning <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>28.2.1 Less than 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>468</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.31 [‐0.73, 0.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>28.2.2 6 to 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>535</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.25 [‐0.49, ‐0.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>28.2.3 Over 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>263</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.86 [‐1.62, ‐0.10]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 28.</span> <span class="table-title">Subgroup analysis: duration</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-tbl-0033">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012955-tbl-0034"> <div class="table-heading"><span class="table-label">Comparison 29.</span> <span class="table-title">Subgroup analysis: mode of therapy</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">29.1 BPD symptom severity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>29.1.1 Individual therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>520</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.39 [‐0.63, ‐0.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>29.1.2 Group therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>438</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.89 [‐1.21, ‐0.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>29.1.3 Mixed therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>286</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.15 [‐0.38, 0.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">29.2 Psychosocial functioning <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>29.2.1 Individual therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>570</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.31 [‐0.75, 0.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>29.2.2 Group therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>366</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.44 [‐0.65, ‐0.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>29.2.3 Mixed therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>378</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.63 [‐1.14, ‐0.13]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 29.</span> <span class="table-title">Subgroup analysis: mode of therapy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-tbl-0034">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012955-tbl-0035"> <div class="table-heading"><span class="table-label">Comparison 30.</span> <span class="table-title">Subgroup analysis: setting</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">30.1 BPD symptom severity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>30.1.1 Inpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>217</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.07 [‐0.34, 0.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>30.1.2 Outpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1027</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.58 [‐0.77, ‐0.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">30.2 Psychosocial functioning <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>30.2.1 Inpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>179</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.85 [‐1.24, ‐0.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>30.2.2 Outpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1057</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.31 [‐0.54, ‐0.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>30.2.3 Inpatient and outpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.34 [‐1.84, ‐0.84]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 30.</span> <span class="table-title">Subgroup analysis: setting</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-tbl-0035">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012955-tbl-0036"> <div class="table-heading"><span class="table-label">Comparison 31.</span> <span class="table-title">Subgroup analysis: types of raters</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">31.1 BPD symptom severity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>31.1.1 Self‐rated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>408</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.74 [‐1.19, ‐0.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>31.1.2 Clinician‐rated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>836</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.42 [‐0.58, ‐0.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">31.2 Psychosocial functioning <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>31.2.1 Self‐rated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>728</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.29 [‐0.60, 0.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>31.2.2 Clinician‐rated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>586</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.66 [‐0.96, ‐0.37]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 31.</span> <span class="table-title">Subgroup analysis: types of raters</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-tbl-0036">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012955-tbl-0037"> <div class="table-heading"><span class="table-label">Comparison 32.</span> <span class="table-title">Subgroup analysis: types of TAU</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">32.1 BPD symptom severity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>32.1.1 Obligatory TAU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1071</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.50 [‐0.70, ‐0.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>32.1.2 Optional TAU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>173</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.63 [‐1.09, ‐0.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">32.2 Psychosocial functioning <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>32.2.1 Obligatory TAU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.32 [‐0.56, ‐0.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>32.2.2 Optional TAU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>312</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.96 [‐1.62, ‐0.30]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 32.</span> <span class="table-title">Subgroup analysis: types of TAU</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-tbl-0037">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012955-tbl-0038"> <div class="table-heading"><span class="table-label">Comparison 33.</span> <span class="table-title">Subgroup analysis: type of comparison group</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">33.1 BPD symptom severity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>33.1.1 TAU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1244</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.52 [‐0.70, ‐0.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>33.1.2 Waiting list</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>161</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.49 [‐0.93, ‐0.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">33.2 Psychosocial functioning <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>33.2.1 TAU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1314</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.45 [‐0.68, ‐0.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>33.2.2 Waiting list</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>219</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.56 [‐1.01, ‐0.11]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 33.</span> <span class="table-title">Subgroup analysis: type of comparison group</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-tbl-0038">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012955-tbl-0039"> <div class="table-heading"><span class="table-label">Comparison 34.</span> <span class="table-title">Subgroup analysis: types of scales</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">34.1 BPD symptom severity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>34.1.1 ZAN‐BPD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>261</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.45 [‐0.69, ‐0.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>34.1.2 SCID</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.58 [‐1.16, ‐0.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>34.1.3 BEST</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>147</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.10 [‐1.47, ‐0.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>34.1.4 BPDSI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>267</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.21 [‐0.45, 0.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>34.1.5 BPP‐40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.55 [‐1.11, 0.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>34.1.6 CGI‐BPD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐0.68, 0.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>34.1.7 CCGI‐BPD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.01 [‐1.55, ‐0.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>34.1.8 BPT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>122</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.07 [‐0.43, 0.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>34.1.9 BPFS‐C</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.01 [‐0.52, 0.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>34.1.10 BSI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.66 [‐2.54, ‐0.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>34.1.11 Mean number of DSM‐IV symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.55 [‐0.95, ‐0.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">34.2 Psychosocial functioning <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>34.2.1 GAF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>204</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.73 [‐1.41, ‐0.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>34.2.2 GAS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>330</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.71 [‐0.96, ‐0.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>34.2.3 SAS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>283</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.23 [‐0.99, 0.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>34.2.4 SPS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.17 [‐3.22, ‐1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>34.2.5 QQ45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.47 [‐1.09, 0.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>34.2.6 WSAS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.03 [‐0.43, 0.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>34.2.7 CORE‐OM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.29 [‐0.34, 0.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>34.2.8 BDQ</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.42 [‐1.00, 0.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>34.2.9 SOFAS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.22 [‐2.73, 0.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>34.2.10 SFQ</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐0.39, 0.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>34.2.11 SDS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.28 [‐0.78, 0.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>34.2.12 CGI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.29 [‐0.80, 0.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>34.2.13 HoNOS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.07 [‐0.69, 0.55]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 34.</span> <span class="table-title">Subgroup analysis: types of scales</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-tbl-0039">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012955-tbl-0040"> <div class="table-heading"><span class="table-label">Comparison 35.</span> <span class="table-title">TSA sensitivity analyses: psychotherapy versus TAU</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">35.1 Primary: BPD symptom severity, at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1244</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.47 [‐0.63, ‐0.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">35.2 Primary: self‐harm <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>616</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.42 [‐0.69, ‐0.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">35.3 Primary: suicide‐related outcomes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>676</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.30 [‐0.47, ‐0.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">35.4 Primary: psychosocial functioning, at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1314</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.36 [‐0.55, ‐0.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">35.5 Secondary: depression <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1568</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.34 [‐0.54, ‐0.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 35.</span> <span class="table-title">TSA sensitivity analyses: psychotherapy versus TAU</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012955.pub2/references#CD012955-tbl-0040">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD012955.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD012955-note-0023">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD012955-note-0020">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD012955-note-0022">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD012955-note-0019">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ja#CD012955-note-0018">日本語</a> </li> <li class="section-language"> <a class="" href="ko#CD012955-note-0015">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD012955-note-0017">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD012955-note-0021">Polski</a> </li> <li class="section-language"> <a class="" href="pt#CD012955-note-0016">Português</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD012955-note-0013">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD012955-note-0014">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012955\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012955\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012955\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012955\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012955\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012955\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012955\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012955\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012955\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012955\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012955\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012955\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012955\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012955\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012955\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012955\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012955\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012955\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=IYhCEbRn&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012955.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012955.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD012955.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD012955.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012955.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740715060256"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012955.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740715060260"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012955.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d7dca7a2e1bde',t:'MTc0MDcxNTA2MC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 